<SEC-DOCUMENT>0001493152-24-043154.txt : 20241031
<SEC-HEADER>0001493152-24-043154.hdr.sgml : 20241031
<ACCEPTANCE-DATETIME>20241031120510
ACCESSION NUMBER:		0001493152-24-043154
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		89
FILED AS OF DATE:		20241031
DATE AS OF CHANGE:		20241031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shuttle Pharmaceuticals Holdings, Inc.
		CENTRAL INDEX KEY:			0001757499
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282231
		FILM NUMBER:		241413916

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE
		STREET 2:		SUITE 260
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		(240) 403-4212

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE
		STREET 2:		SUITE 260
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>form424b4.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:SHPH="http://shuttlepharma.com/20240630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_SHPH_shuttlepharma.com_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240101_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityRegistrantName_Shuttle Pharmaceuticals Holdings, Inc. -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DDocumentType_424B4 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001757499 -->
<!-- Field: Set; Name: xdx; ID: xdx_071_XDX_forms%2D1a.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_076_SO_forms%2D1a.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_TradingDays_0_utr%2D%2DD -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000004" name="dei:EntityRegistrantName">Shuttle Pharmaceuticals Holdings, Inc.</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000005" name="dei:DocumentType">424B4</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001757499</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-06-30" id="xdx2ixbrl0040" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0041" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_RelatedPartyMember" id="xdx2ixbrl0058" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_RelatedPartyMember" id="xdx2ixbrl0061" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-06-30_us-gaap_RelatedPartyMember" id="xdx2ixbrl0067" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0068" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2024-06-30" id="xdx2ixbrl0082" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0098" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-04-012024-06-30_us-gaap_RelatedPartyMember" id="xdx2ixbrl0191" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-06-30_us-gaap_RelatedPartyMember" id="xdx2ixbrl0193" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FinanceFee" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FinanceFee" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FinanceFee" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfAccruedInterest" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfAccruedInterest" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0592" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:InitialRecognitionOfRightOfUseAssetAndLiability" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="xdx2ixbrl0618" name="us-gaap:WarrantsAndRightsOutstandingTerm">P4Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0767" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0768" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0781" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0782" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0786" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0787" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0791" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0792" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0802" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0803" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0807" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0816" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0817" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0821" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0822" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0826" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0827" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0831" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0832" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0910" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0912" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0929" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0930" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0931" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828" id="xdx2ixbrl1123" decimals="INF" unitRef="USDPShares">23.21</ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember29544843" id="xdx2ixbrl1127" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember29544843" id="xdx2ixbrl1129" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1324" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1339" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1361" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1363" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1373" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl1382" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1388" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl1399" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl1400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1449" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1450" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1498" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FairValueAdjustmentOfWarrant" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1512" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1516" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1519" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:GainOnSettlementOfAccountsPayable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1527" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1530" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1539" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1542" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1545" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1548" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1570" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1581" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1584" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1585" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1590" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1591" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1593" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1594" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1597" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1598" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1601" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1602" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1606" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1607" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1609" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1610" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1615" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1618" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1619" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1624" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1625" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1626" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1627" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1628" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1629" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1633" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1634" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1635" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1636" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1637" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1638" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1642" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1643" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1645" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1646" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1649" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1650" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1652" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1653" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1656" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1657" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1658" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfPreferredStock" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1659" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1660" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfPreferredStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1661" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1663" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1664" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1665" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1666" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1667" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1668" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1670" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1671" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1672" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1673" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1674" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1675" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1677" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1678" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1680" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1681" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1688" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1689" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1691" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1692" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1695" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1696" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1697" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1698" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1702" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1705" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1709" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1713" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1716" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1720" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1724" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1725" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1727" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1728" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1733" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1736" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1737" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1742" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1743" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1744" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1745" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1746" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1747" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1751" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1752" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1754" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1755" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1758" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1759" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1760" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1761" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1765" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1768" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1772" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1776" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl1779" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1783" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1802" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1809" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1812" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:AccruedInterestSettledWithCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1815" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1820" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:GainOnSettlementOnAccountsPayable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1823" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1826" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1836" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1854" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1866" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1869" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1872" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1875" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1878" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1883" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1886" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ProceedsFromNotesPayableAndWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1895" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1902" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1925" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1926" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfAccruedInterestAsRestated" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1931" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1937" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1940" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1950" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:InitialRecognitionOfRightOfUseAssetAndLiability" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1954" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FinanceFee" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2066" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2070" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2078" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2090" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2094" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2098" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2118" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForCash" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2124" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantsExercisedForCash" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2128" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2136" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2138" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2158" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2170" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2182" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2186" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:GainOnInterestReliefOnConversionOfNotesPayable" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2192" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ProceedsFromNotesPayableAndWarrants" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2214" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2218" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2250" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl2328" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl2329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl2333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl2334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeLiabilityWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl2342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeLiabilityWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl2343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeLiabilityAcceleratedFeature" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl2347" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeLiabilityAcceleratedFeature" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl2348" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl2352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl2353" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="xdx2ixbrl2385" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="xdx2ixbrl2393" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="xdx2ixbrl2397" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="xdx2ixbrl2401" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilitiesIssued" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="xdx2ixbrl2471" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilitiesExercised" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="xdx2ixbrl2473" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilities" contextRef="AsOf2022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="xdx2ixbrl2479" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilities" contextRef="AsOf2021-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="xdx2ixbrl2481" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilities" contextRef="AsOf2022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="xdx2ixbrl2491" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilities" contextRef="AsOf2021-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="xdx2ixbrl2493" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilitiesExercised" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="xdx2ixbrl2497" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:WarrantLiabilities" contextRef="AsOf2022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="xdx2ixbrl2503" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2541" decimals="INF" unitRef="Integer">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="xdx2ixbrl2549" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2595" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2610" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl2612" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">P4Y11M23D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" id="xdx2ixbrl2616" decimals="INF" scale="-2" unitRef="Pure">10.46</ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember" id="xdx2ixbrl3052" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" id="xdx2ixbrl3064" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="SHPH:DerivativeLiabilityOfCarringValueMeasurementDate" contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember" id="xdx2ixbrl3262" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="xdx2ixbrl3276" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SettlementMember" id="xdx2ixbrl3296" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SettlementMember" id="xdx2ixbrl3302" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="xdx2ixbrl3308" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember" id="xdx2ixbrl3316" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="xdx2ixbrl3324" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703" id="xdx2ixbrl3356" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember" id="xdx2ixbrl3378" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="xdx2ixbrl3386" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="xdx2ixbrl3398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember" id="xdx2ixbrl3400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="xdx2ixbrl3402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="xdx2ixbrl3404" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember" id="xdx2ixbrl3406" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeSettlementsOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="xdx2ixbrl3408" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="xdx2ixbrl3410" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember" id="xdx2ixbrl3412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember" id="xdx2ixbrl3428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" id="xdx2ixbrl3430" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_NotesDerivativeMember" id="xdx2ixbrl3432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember" id="xdx2ixbrl3450" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember" id="xdx2ixbrl3452" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" id="xdx2ixbrl3454" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember" id="xdx2ixbrl3456" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember" id="xdx2ixbrl3458" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" id="xdx2ixbrl3460" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember" id="xdx2ixbrl3462" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember" id="xdx2ixbrl3464" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" id="xdx2ixbrl3466" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember" id="xdx2ixbrl3468" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember" id="xdx2ixbrl3470" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" id="xdx2ixbrl3472" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3509" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ShortfallOfStockCompensationExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3524" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl3529" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3530" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="xdx2ixbrl3537" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFairMarketValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl3559" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2023-12-31" id="xdx2ixbrl3564" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFiniteLivedAssets" contextRef="AsOf2022-12-31" id="xdx2ixbrl3568" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl3579" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl3580" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3591" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3603" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3618" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3621" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl3623" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl3624" unitRef="Pure" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="shph-20240630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-122016-08-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-12</xbrli:startDate>
        <xbrli:endDate>2016-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-062024-08-06_us-gaap_InvestorMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-06</xbrli:startDate>
        <xbrli:endDate>2024-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-132024-08-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-13</xbrli:startDate>
        <xbrli:endDate>2024-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember29538078">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-162023-02-16_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-16</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-16</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-152023-02-16_custom_NewLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-15</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16_custom_NewLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-152023-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-15</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-01_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-212021-06-21_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-21</xbrli:startDate>
        <xbrli:endDate>2021-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-11</xbrli:startDate>
        <xbrli:endDate>2023-01-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember_custom_AltoConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-092021-03-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-09</xbrli:startDate>
        <xbrli:endDate>2021-03-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-282021-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-28</xbrli:startDate>
        <xbrli:endDate>2021-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-28_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-302022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-30</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-302022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-30</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-08</xbrli:startDate>
        <xbrli:endDate>2022-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-11</xbrli:startDate>
        <xbrli:endDate>2022-03-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-082022-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-08</xbrli:startDate>
        <xbrli:endDate>2022-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-112022-03-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-11</xbrli:startDate>
        <xbrli:endDate>2022-03-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-312022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-31</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandAndTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_AltoConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-072024-02-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-07</xbrli:startDate>
        <xbrli:endDate>2024-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-072024-02-07_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-07</xbrli:startDate>
        <xbrli:endDate>2024-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember29542531">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleNoteDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleNoteDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_DecemberTwentyThousandTwentyOneNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwentyThousandTwentyOneNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:BlackScholesModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:BlackScholesModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsOfficersAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsOfficersAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember29544828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_WarrantMember29544843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_WarrantMember29544859">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:AyrtonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AugustTwoThousandTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:AugustTwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_custom_AltoWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AltoWarrantsMember_custom_MeasurementInputEstimatedFairValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AcceleratedFeatureMember29546515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AcceleratedFeatureMember29546593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_NotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:NotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember29546843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember29546859">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TCGGreenChemIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TCGGreenChemIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-062024-08-06_custom_AltoConvertibleNoteMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-06</xbrli:startDate>
        <xbrli:endDate>2024-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30_us-gaap_SubsequentEventMember_custom_AllianceGlobalPartnersMember_custom_OfferingMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AllianceGlobalPartnersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-082024-08-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-08</xbrli:startDate>
        <xbrli:endDate>2024-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-312023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-31</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-07</xbrli:startDate>
        <xbrli:endDate>2024-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-07</xbrli:startDate>
        <xbrli:endDate>2024-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-08</xbrli:startDate>
        <xbrli:endDate>2024-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-13_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06_us-gaap_SubsequentEventMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingOccurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingOccurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfQualifiedIPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfQualifiedIPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandAndTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NotesPayableRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AugustTwoThousandAndTwentyOnePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandAndTwentyOnePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotesPayableRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MeasurementInputIpoDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_IssuanceDatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_IssuanceDatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-03_custom_MeasurementInputSharePriceProbabilityOfIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_IssuanceDatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FederalTaxableIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:FederalTaxableIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StateTaxableIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:StateTaxableIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TaxYear2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TaxYear2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="TradingDays">
      <xbrli:measure>utr:D</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>SHPH:Integer</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001237" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001238" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001239" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001240" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001241" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001242" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001243" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001244" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001245" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001247" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001249" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001250" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001251" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001252" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001253" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001254" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001255" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001257" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact001259" toRefs="Footnote001260"/>
  <ix:relationship fromRefs="Fact002013" toRefs="Footnote002019"/>
  <ix:relationship fromRefs="Fact002018" toRefs="Footnote002032"/>
  <ix:relationship fromRefs="Fact002257" toRefs="Footnote002263"/>
  <ix:relationship fromRefs="Fact002262" toRefs="Footnote002270"/>
  <ix:relationship fromRefs="Fact003086" toRefs="Footnote003119"/>
  <ix:relationship fromRefs="Fact003088" toRefs="Footnote003119"/>
  <ix:relationship fromRefs="Fact003090" toRefs="Footnote003119"/>
  <ix:relationship fromRefs="Fact003223" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003224" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003225" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003226" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003227" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003228" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003229" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003230" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003231" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003233" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003235" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003237" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003239" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003240" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003241" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003242" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003243" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003244" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003245" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003247" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003249" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003251" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003253" toRefs="Footnote003254"/>
  <ix:relationship fromRefs="Fact003652" toRefs="Footnote003659"/>
  <ix:relationship fromRefs="Fact003653" toRefs="Footnote003659"/>
  <ix:relationship fromRefs="Fact003654" toRefs="Footnote003659"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    Pursuant to Rule 424(b)(4)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
    No. 333-282231</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>395,574
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2,555,246
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded Warrants to Purchase up to 2,555,246
Shares of Common Stock</b></span></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2,950,820
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Warrants to Purchase up to 2,950,820
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>2,555,246</b><b> Shares
of Common Stock Underlying the Pre-Funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2,950,820
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock Underlying the Common
Warrants</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This is a reasonable best efforts offering of (i)
395,574 shares (the &#8220;Shares&#8221;) of common stock, par value $0.00001 per share (&#8220;common stock&#8221;) and 2,555,246
pre-funded warrants to purchase up to 2,555,246 shares common stock (the &#8220;Pre-Funded Warrants&#8221;) together with
accompanying 2,950,820 common warrants to purchase up to 2,950,820 shares of common stock (the &#8220;Common Warrant&#8221;).
Each share of common stock, or a Pre-Funded Warrant in lieu thereof, is being sold together with an accompanying Common Warrant to purchase
one share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The public offering price for each share of common
stock and one accompanying Common Warrant is $1.525. The exercise price of the Common Warrants will be $1.40 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering Pre-Funded Warrants to certain purchasers whose purchase of shares of common stock in this offering would otherwise result
in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election
of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to
purchase, if any such purchaser so chooses, Pre-Funded Warrants, in lieu of shares of common stock. The public offering price of each&#160;Pre-Funded&#160;Warrant
and accompanying Common Warrant is $1.524, which equals the price at which one share of common stock and accompanying Common Warrant
is sold to the public in this offering, minus $0.001, and the exercise price of each Pre-Funded Warrant will be $0.001 per share. The
Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised
in full. The Pre-Funded Warrants and the Common Warrants are collectively referred to as the &#8220;Warrants.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock or Pre-Funded Warrants in lieu thereof and Common Warrants are immediately separable and will be issued separately
in this offering but must be purchased together in this offering.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Warrant offered hereby will be exercisable upon issuance (the &#8220;Initial Exercise Date&#8221;)</span>. The Common Warrants
will expire five (5) years from the date of issuance. The exercise price and number of shares of common stock issuable under the Common
Warrants are subject to adjustment as described in the Common Warrant. <span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> This prospectus also includes the shares of common stock issuable upon exercise
of the Pre-Funded Warrants and Warrants. See &#8220;Description of Securities We Are Offering&#8221; in this prospectus for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock trades on the Nasdaq under the symbol &#8220;SHPH.&#8221; On October 29, 2024, the last reported sale price of our
common stock was $1.80 per share. There is no established trading market for the Warrants, and we do not intend to list the Warrants
on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will
be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;), who will work in conjunction with Boustead Securities, LLC
(&#8220;Boustead&#8221;), as the placement agents (together, the &#8220;Placement Agents&#8221;) with respect to this
Offering. The Placement Agents are not purchasing or selling any shares offered hereby, nor are they required to arrange for the
purchase or sale of any specific number or dollar amount of shares, but they have agreed to use their reasonable best commercial
efforts to arrange for the sale of the securities offered by this prospectus. We have agreed to pay the Placement Agents&#8217; fees
totaling 9.0% of the aggregate gross cash proceeds actually realized by the Company from the sale of the shares being offered
hereby. Because there is no minimum amount of shares that must be sold as a condition to closing this offering, the placement agent
fees and the proceeds to us are not presently determinable and may be substantially different than the amounts set forth below,
which assume the sale of all of the shares offered hereby. See &#8220;Plan of Distribution&#8221; beginning on page 97 of this
prospectus supplement for more information regarding these arrangements. Because there is no minimum number of securities or minimum
aggregate amount of proceeds for this offering to close, we may sell fewer than all of the securities offered hereby, and investors
in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the
business goals outlined in this prospectus. Because there is no escrow account and there is no minimum offering amount, investors
could be in a position where they have invested in our Company, but we are unable to fulfill our objectives due to a lack of
interest in this offering. Also, any proceeds from the sale of securities offered by us will be available for our immediate
use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. We expect
that the closing of the offering will occur on or about October 31, 2024 but no later than one trading day after we price the
securities offered hereby. You should read this prospectus, together with additional information described under the heading
&#8220;Where You Can Find More Information,&#8221; carefully before you invest in any of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act, and we have elected to comply with certain
reduced public company reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>An
investment in our securities involves significant risks. You should carefully consider the risk factors beginning on page 13
of this prospectus before you make your decision to invest in our securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission, or the SEC, nor any state securities commission has approved or disapproved of these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share and Common Warrant</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Pre-Funded</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Public offering price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1.525</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1.524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,497,445.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent Fees<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">404,770.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Proceeds to us, before expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,092,675.18</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have agreed to pay the Placement Agents a cash fee equal to nine percent (9%) of the aggregate
                                            gross proceeds raised in this offering. In addition, we have agreed to reimburse the Placement
                                            Agents for certain offering-related expenses. We refer you to &#8220;Plan of Distribution&#8221;
                                            beginning on page 97 for additional information regarding compensation to be received by
                                            the Placement Agents.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount of offering proceeds to us presented in this table does not give effect to any exercise of the Warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
of the Shares and Warrants is expected to be made on or about October 31, 2024, subject to satisfaction of customary
closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lead
Placement Agent</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>A.G.P.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Co-
Placement Agent</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>Boustead
Securities, LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is October 29, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="margin-right: 0pt; break-before: page; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PROSPECTUS
    SUMMARY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">THE
    OFFERING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">RISK
    FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_001">SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_002">SELECTED
    FINANCIAL DATA</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_003">USE
    OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bk_002">BUSINESS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">44</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bk_003">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
    CONDITION AND RESULTS OF OPERATIONS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bk_004">MANAGEMENT</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bk_005">EXECUTIVE AND DIRECTOR COMPENSATION</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">83</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bk_006">BENEFICIAL OWNERSHIP OF SECURITIES</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">86</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bk_007">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">87</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bk_008">CAPITALIZATION</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">88</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt"><a href="#bk_009">DILUTION</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt; vertical-align: bottom; text-align: center">89</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_004">DIVIDEND
    POLICY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span>0</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_005">DESCRIPTION
    OF CAPITAL STOCK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_006">DESCRIPTION
    OF SECURITIES WE ARE OFFERING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_007">PLAN
    OF DISTRIBUTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_008">LEGAL
    MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_009">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_011">WHERE
    YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#kpa_001">INDEX TO FINANCIAL STATEMENTS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-right: 0pt; break-before: page; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration statement of which this prospectus forms a part and which we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;)
includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related
exhibits filed with the SEC, together with the additional information described under the heading &#8220;Where You Can Find More Information&#8221; before making your investment decision. You should rely only on the information
provided in this prospectus, in any prospectus supplement or in a related free writing prospectus, or
documents to which we otherwise refer you. In addition, this prospectus contains summaries of certain provisions contained in some of
the documents described herein, but reference is made to the actual documents for complete information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus includes important information about us, the securities being offered and other information you should know before investing
in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the
date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed
of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment
decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents
referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which
this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find
More Information.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not, and the Placement Agents have not, authorized anyone to provide any information or to make any representations other than those
contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which
we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that
others may give you. The information contained in this prospectus or contained in any
applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities.
Our business, financial condition, results of operations and prospects may have changed since that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States: We have not done anything that would permit a public offering of the securities or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons
outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating
to, the offering of the securities and the distribution of this prospectus outside of the United States. You are required to inform yourselves
about and to observe any restrictions relating to this offering and the distribution of this prospectus outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
should rely only on the information contained in this prospectus and in any free writing prospectus prepared
by or on behalf of us. We have not authorized anyone to provide you with information different from, or in addition to, that contained
in this prospectus or any related free writing prospectus. This prospectus is an offer to sell only the
securities offered hereby but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Our business, financial condition, results of operations
and prospects may have changed since that date.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-right: 0pt; break-before: page; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted.
We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where
action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus and any free writing prospectus related to this offering in jurisdictions outside the United States are required to inform
themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free
writing prospectus applicable to that jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, any reference to Shuttle Pharmaceuticals Holdings, Inc., or as &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;
refers to Shuttle Pharmaceuticals Holdings, Inc. and its subsidiary (&#8220;Shuttle Pharma&#8221; or the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
and Market Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate or plan to
operate, including our general expectations and market position, market opportunity and market share, is based on information from our
own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted
by third parties. Management estimates are derived from publicly available information, our knowledge of our industry, and assumptions
based on such information and knowledge which we believe to be reasonable. Our management estimates have not been verified by any independent
source, and we have not independently verified any third-party information. In addition, assumptions and estimates of our company&#8217;s
and our industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors,
including those described in the section entitled &#8220;Risk Factors&#8221; beginning on page 13. These and other factors could cause
our future performance to differ materially from our assumptions and estimates. See &#8220;Special Note Regarding Forward-Looking Statements&#8221;
on page 42 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2024, we filed a Certificate of Amendment to our certificate of incorporation with the Secretary of State of the State of
Delaware to effect a 1-for-8 reverse stock split of our issued and outstanding shares of common stock, par value $0.00001 per share
(the &#8220;2024 Reverse Stock Split&#8221;), which became effective on August 13, 2024. All historical share and per share amounts
reflected throughout this prospectus have been adjusted to reflect the 2024 Reverse Stock Split. However, our periodic and current
reports, and all other documents that were filed prior to August 13, 2024, do not
give effect to the 2024 Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-right: 0pt; break-before: page; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights information contained in greater detail elsewhere in this prospectus
from our filings with the SEC. This summary is not complete and does not contain all of the information you should consider in making
your investment decision. You should read the entire prospectus carefully before
making an investment in our securities. You should carefully consider, among other things, our financial statements and the related notes
and the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations&#8221; included elsewhere in this prospectus. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this prospectus to &#8220;Shuttle Pharma,&#8221; &#8220;Shuttle Pharmaceuticals,&#8221;
&#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refers to Shuttle Pharmaceuticals Holdings, Inc.
and its subsidiary, Shuttle Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers.
Our goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy
(&#8220;RT&#8221;) is one of the most effective modalities for treating cancers. We are developing a pipeline of products designed to
address the limitations of the current cancer therapies as well as to extend to the new applications of RT. We believe that our product
candidates will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current
standard of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate structure is based on Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq SHPH &#8211; a Delaware Company) with drug discovery and
development performed in the wholly owned Shuttle Pharmaceuticals, Inc. (a Maryland Company) and diagnostics performed in the wholly
owned Shuttle Diagnostics, Inc. (a Maryland Company). Our product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation
sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303) and two preclinical, prostate cancer-oriented diagnostics
assets &#8211; the PC-RAD Test, a blood test to predict clinical response to radiation therapy and the PSMA-B ligand for potential use
as a theranostic agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, we submitted an Investigational New Drug (&#8220;IND&#8221;) application with the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
to support the next phase of development of Ropidoxuridine. In January 2024, we received the &#8216;Safe to Proceed&#8217; letter from
the FDA for our IND application for the Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows us to commence
the Phase II study of Ropidoxuridine (IPdR). We have applied for and received FDA approval of Orphan designation for Ropidoxuridine and
RT for treating brain cancer (glioblastoma). The Phase II clinical trial was also approved by the Institutional Review Board &#8220;IRB&#8221;
on June 21, 2024. We believe our management team&#8217;s expertise in radiation therapy, combined modality cancer treatment and immuno-oncology
will help drive the development and, if approved, the commercialization of these potentially curative therapies for patients with aggressive
cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncology has gone through transformative technological innovation over the last decade to better define tumors, allow improved shaping
of radiation delivery and support dose escalation with shorter, more intensive courses of treatment. Furthermore, achieving higher dose
distributions within tumor volumes has reached a practical plateau, since cancers are frequently integrated with or surrounded by more
sensitive normal tissues and further dose escalation increases risks of tissue necrosis. To increase cancer cures at maximally tolerated
radiation doses, pharmacological and biological modifications of cells are needed to sensitize cancers, protect normal tissues, and stimulate
the immune system to react against antigens produced by irradiated, damaged cancer cells. Drugs that show sensitizing properties, or
the ability to make cancer cells more sensitive to radiation, offer a solution to this problem. Currently, such drugs are chemotherapy
agents used off-label, and many have inherent toxicities since they were designed for direct cancer treatments and not for sensitization.
However, the clinical value of using radiation sensitizing drugs in combination with RT has been accepted in a variety of cancer types,
including gynecological, gastro-intestinal, pulmonary and other malignancies. Hence, there is a critical need for new drugs that preferentially
sensitize cancer cells to radiation therapy and that stimulate the innate immune response against irradiated cancer cells. Furthermore,
to advance precision medicine in radiation oncology, there is a need for imaging and molecular diagnostic tests for determining the extent
of cancer spread in the body and for predicting clinical responses to therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our products with the goal of addressing the unmet need in cancer treatment for a commercially marketable radiation response
modifier solution that leads to greater sensitivity of cancer cells to ionizing radiation therapy. The goal of our products is to increase
the therapeutic index for patients receiving radiation and to decrease radiation-related toxicities in patients with solid tumors. Our
products operate across three areas related to the treatment of cancer with RT:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitization
    of growing cancer cells, rendering them more susceptible to the effects of radiation therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the DNA damage response pathway to kill cancer cells and protect adjacent normal cells.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the immune system to kill any remaining cells after RT.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology allows for the creation of an inventory of products for radiation sensitizing, immune modulation, and protection
of healthy tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Operations
to date have focused on continuing our research and development efforts to advance Ropidoxuridine clinical testing and improved drug
formulation, to advance HDAC6 inhibitor (SP-2-225) preclinical development and explore application of the PC-RAD Test, predictive biomarkers
of radiation response. The clinical development of Ropidoxuridine has included completion of a Phase I clinical trial to establish drug
bioavailability and a maximum tolerated dose for use in Phase II clinical trials. TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;),
with whom we have contracted for process research, development and cGMP compliant manufacture of IPdR, has manufactured the active pharmaceutical
ingredient (API) of Ropidoxuridine and the University of Iowa Pharmaceuticals has formulated the drug product for use in the Company&#8217;s
upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. The drug product (capsules) were shipped to contract
research organization (CRO) Theradex Oncology and distributed to clinical trial sites that are fully approved to enroll patients in the
trial. Shuttle received approval from the FDA to begin the clinical trial. The FDA made recommendations to expand the clinical trial
to include a randomized dose &#8220;optimization&#8221; step and we agreed with the recommendation. Meetings with engaged clinical sites
to review the protocol documents have occurred and FDA required Institutional Review Board, or IRB approvals have been received. With
FDA recommended changes incorporated into the revised protocol and the completion of site initiation visits, the Company has commenced
its Phase II clinical study. The radiation biomarker project and the health disparities project have been completed and the Company is
proceeding with plans for clinical validation and potential for commercialization of Ropidoxuridine as a radiation sensitizer. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing a pipeline of small molecule radiation sensitizers and immune response regulating drugs. Our most advanced product
candidate is Ropidoxuridine, an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties is in preclinical
studies. In addition, we have a pipeline of complimentary product candidates that we are developing to address solid tumor cancer indications
by radiation sensitization or immune modification. Our therapeutic pipeline is represented in the diagram below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_003.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timeline
for clinical phase (Ropidoxuridine) and pre-clinical phase (HDAC inhibitors) pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidates include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    (IPdR)</span></b> is our lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and
    sarcomas. Phase I clinical trial results supported by a National Institutes of Health, or NIH contract to Shuttle Pharma and
    the NCI (CTEP) were reported in the medical journal, Clinical Cancer Research, in July 2019, by our <span style="background-color: white">Small
    Business Innovation Research, or</span> SBIR, subcontractor. Eighteen patients completed dose escalations to 1,800 mg/day
    for 30 days, establishing the maximum tolerated dose (MTD) of 1,200 mg/day in combination with RT. Four partial responses, nine stable
    disease and one progressive disease in target lesions were reported. Four patients did not have measurable disease and, as a result,
    were not evaluable. These Phase I trial results demonstrate oral bioavailability and an MTD of 1,200 mg per day for 28 days for use
    in combination with radiation for Phase II clinical trials that we propose to perform in brain tumors and in sarcomas. The brain
    tumor, glioblastoma multiforme (GB) is eligible for orphan disease designations. Shuttle Pharma has advanced drug manufacture and
    formulation and prepared a clinical protocol of a &#8220;Phase 2 Single-Arm Study of IPdR as a Radiation Sensitizing Agent During
    Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype MGMT Unmethylated Glioblastoma Multiforme.&#8221; In December 2023, we
    submitted an IND application with the FDA to support the next phase of development of Ropidoxuridine. In January 2024, we received
    the &#8216;Safe to Proceed&#8217; letter from the FDA for our IND application for the Phase II study of Ropidoxuridine (IPdR) as
    a radiation sensitizing agent during radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT
    promoter. Receipt of the letter allows us to commence the Phase II study of Ropidoxuridine (IPdR). The clinical development of Ropidoxuridine
    has shown drug bioavailability and a maximum tolerated dose has been established for use in Phase II clinical trials. TCG GreenChem,
    Inc. (&#8220;TCG GreenChem&#8221;), with whom we have contracted for process research, development and cGMP compliant manufacture
    of IPdR, has successfully completed the manufacturing campaign for the active pharmaceutical ingredient (API) of Ropidoxuridine for
    use in the Company&#8217;s upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. Shuttle also worked
    with University of Iowa Pharmaceuticals to develop the formulation and produce the capsules, which have been shipped to contract
    research organization (CRO) Theradex Oncology for distribution to clinical trial sites. Both activities have now been completed.
    In addition, Shuttle received approval from the FDA to begin the clinical trial. The FDA made recommendations that led to an expanded
    clinical trial to include randomized dose optimization and we agreed with the recommendation. We met with representatives from six
    candidate clinical sites to review the protocol documents and FDA required IRB approvals have been obtained. With FDA recommended
    changes incorporated into the revised protocol, the Company has now contractually engaged five of the planned six research
    centers which will be performing clinical trials and has initiated its Phase II clinical study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Phase II clinical study is summarized below:</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_004.jpg" alt="" style="height: 336px; width: 700px"/></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: Red"></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schema
for the Phase II clinical trial. The initial cohort of 40 patients will be randomized to one of two Ropidoxuridine doses. 20 patients
will receive the 1200 mg dose and 20 patients will receive the 960 mg dose. The optimum dose will be determined by comparing drug bioavailability
and side-effects. The optimum dose will then continue to enroll 14 additional patients to provide the required 34 patients for statistical
significance in comparison to historical controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    and Tipiracil (IPdR/TPI)</span></b> is a new combination formulation demonstrating extended bioavailability after oral administration
    in an animal model system. The IPdR/TPI formulation will undergo preclinical development for use as a radiation sensitizer and represents
    a &#8220;next generation&#8221; drug product for clinical evaluation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-2-225
    </span></b>is Shuttle Pharma&#8217;s pre-clinical class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6 has been
    identified as the candidate lead molecule for development as a post-RT innate immune system activator. The macrophage is a key target
    for activating the innate immune system against cancer cells. SP-2-225 has effects on the regulation of the immune system by maintaining
    macrophage cells in an inflammatory, anti-cancer polarization. The interactions of RT with the immune response for cancer treatment
    are of great current interest, offering insight into potential mechanisms for primary site and metastatic cancer treatment. For this
    reason, Shuttle Pharma has selected SP-2-225 as the candidate lead HDAC inhibitor for preclinical development. We have contracted
    with investigators at Georgetown University to perform preclinical studies of immune activation after radiation therapy in an animal
    tumor model. These data have been published (Noonepalle SKR, Grindrod S, Aghdam N, Li X, Gracia-Hernandez M, Zevallos-Delgado C,
    Jung M, Villagra A, Dritschilo A. Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition. Mol Cancer Ther. 2023
    Dec 1;22(12):1376-1389. doi: 10.1158/1535-7163.MCT-23-0215. PMID: 37586844; PMCID: PMC10878032) and additional preclinical studies
    are in progress with our contractors. With the introduction of check-point inhibitors, CAR-T therapies and personalized medicine
    in cancer, regulation of the immune response following RT is of significant clinical and commercial interest.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-303
    </span></b>is Shuttle Pharma&#8217;s pre-clinical selective Class I HDAC inhibitor that preferentially affects histone deacetylases
    HDAC1 and HDAC3 members of the class I HDAC family of enzymes. SP-1-303 data show direct cellular toxicity in ER positive breast
    cancer cells. Furthermore, SP-1-303 increases PD-L1 expression. Completed preclinical in vitro studies have been published (Jung
    M, Nicholas N, Grindrod S, Dritschilo A. Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits
    estrogen receptor positive breast cancer cell growth. PLoS One. 2024 Jul 15;19(7):e0306168. doi: 10.1371/journal.pone.0306168. PMID:
    39008483; PMCID: PMC11249239.). We plan to seek university collaborations to complete SP-1-303 pre-clinical development in 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Approach</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have established a leadership position in radiation sensitizer and response modifier discovery and development. We have
identified a clinical phase product candidate and discovered new pre-clinical phase molecules using our proprietary platform technologies
to increase the therapeutic index for patients receiving radiation for treatment of solid tumors. Our development strategy has four key
pillars: (1) to improve the efficacy of RT by demonstrating improved disease-free survival rates in patients who undergo radiation therapy,
(2) reduce the amount of radiation needed for a favorable tumor response, thereby limiting the potential for radiation related toxicities
to healthy cells, (3) decrease the extent of surgery needed to remove cancers and improve quality of life, and (4) leverage our next
generation technologies to create drugs that regulate the immune response assisting immune checkpoint and CAR-T therapies and other personalized
medicines targeting cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to private and public investment into our candidate therapeutic technology, we have also competed for non-dilutive funding from
the NIH to support our lead sensitizer and to explore development of complimentary diagnostic products. To date, we have completed three
SBIR contracts awarded to Shuttle Pharma by the NIH to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    IPdR as a radiation sensitizer. This funding provided partial support for the Phase I clinical trial of Ropidoxuridine and RT.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    prostate cancer cell cultures from African-American men, with donor matched normal prostate cells, establishing 50 pairs for accelerating
    research to reduce prostate cancer health disparities in African-American men. This project was funded under &#8220;Moonshot&#8221;
    designation. Shuttle Pharma is eligible to apply for additional SBIR (Phase IIb) funding to commercialize these cells for research
    purposes. Currently, cells from African-American patients are distributed, on request, to investigators who are conducting health
    disparities research. We plan to test new small molecules using these cellular reagents for health disparities screening.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    a predictive biomarker for determining outcomes for prostate cancer patients following treatment with RT. This SBIR-funded project
    for blood test (PC-RAD Test) discovery and analytical validation were completed on March 15, 2022, and Shuttle Pharma intends to
    perform a clinical validation study. Shuttle Pharma has licensed the intellectual property for the prostate cancer predictive biomarker
    test from Georgetown University and will seek additional investment from the public market to advance clinical development through
    its Shuttle Diagnostics entity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
three SBIR funded projects have been completed. The Company is eligible to apply for SBIR Phase IIb funding to advance the &#8220;Moonshot&#8221;
health disparities or the predictive biomarker project. The NIH SBIR program is designed to encourage small businesses to engage in Federal
Research/Research and Development (&#8220;R/R&amp;D&#8221;) that has the potential for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma&#8217;s scientists have also developed collaborations to invent intellectual properties for prostate cancer theranostics. From
a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for diagnosis and therapy of prostate cancer.
In a discovery project to develop a novel, boron-containing PSMA ligand to enhance proton radiation therapy of prostate cancer, we discovered
PSMA-B, a molecule containing boron and demonstrating nanomolar binding activity to PSMA. Preclinical evaluations have been initiated
to explore the PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy, as well as a PET diagnostic
reagent and as a targeted prostate cancer therapeutic. By in-licensing our collaborator&#8217;s shares of the intellectual property,
Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application. Theranostic molecules
are suitable for diagnosis and therapy of cancers. The PSMA ligand is a molecule that binds to the PSMA, an enzyme that is highly expressed
in prostate cancer cells. The PSMA ligand is currently used for imaging and therapy to detect and treat prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
                                            PSMA-B as a potential diagnostic and therapeutic molecule in pre-clinical models in collaboration
                                            with academic nuclear medicine programs. Shuttle Pharma has licensed the intellectual property
                                            for the prostate cancer predictive biomarker test from inventors and will seek additional
                                            investment from NIH by applying for grant applications and from the public market to advance
                                            pre-clinical development through its Shuttle Diagnostics entity.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6
inhibitor (SP-2-225) and, if approved by the FDA, commercialize our product candidates for the treatment of cancers. While this process
may require years to complete, we believe achieving this goal could result in new radiation sensitizer and immunotherapy products. Key
elements of our strategy include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer. </b>To date, there is one drug (Cetuximab, a monoclonal
    antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine and obtaining
    FDA approval, a small molecule sensitizer would then be enabled for clinical applications for radiation sensitization indications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expand
    our leadership position within radiation sensitizers</b>. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop an innovative and well-tolerated drug for proton therapy sensitization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates</b>. We have built our current product
    pipeline through in-house discovery, development, partnerships with leading academic institutions and through in-licensing. We will
    continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other biotechnology
    companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability of clinical
    success, including programs beyond our target franchise areas and current technology footprint.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Invest
    in our HDAC platform technology and maximize its utility across cancer therapies</b>. We are initially applying the platform to develop
    drugs for cancer radiation sensitization, normal tissue radiation protection and post radiation immune stimulation. Based on the
    data we have obtained thus far, these drugs are immune regulatory. We intend to invest to develop other properties of our platform
    technology, as well.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enter
    into collaborations to realize the full potential of our platform</b>. The breadth of our HDAC technology platform enables other
    therapeutic applications, including radiation sensitization and immune therapy. We intend to seek collaborations centered on our
    platform to maximize applications for cancer treatment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Establish
    Shuttle Diagnostics, Inc. as a subsidiary of SHPH</b> to advance development of the predictive biomarker (PC-RAD Test) and the PSMA
    ligand (PSMA-B) to advance prostate cancer treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management
Team</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has significant experience in radiation oncology and in progressing products from early-stage research through clinical
trials. Our Chief Executive Officer, or CEO, Anatoly Dritschilo, M.D., is an experienced clinician and researcher who has held senior
academic and management positions including serving as Department Chairman, Hospital Medical Director and Cancer Center Director at Georgetown
University Medical Center. Prior to co-founding our Company, Dr. Dritschilo was a co-founder of Oncomed, Inc., a company that became
public as NeoPharm, Inc. (Nasdaq: NEOL). He has experience in providing care for patients undergoing treatment for cancers of the prostate,
breast, brain, lung, sarcomas and GI systems. Dr. Dritschilo has directed basic science research supported by grants from the National
Cancer Institute (&#8220;NCI&#8221;) and performed clinical trials using drugs and radiation therapy. In addition, Dr. Dritschilo served
as the principal investigator of pharmaceutical industry sponsored clinical evaluations of human interferon alpha-2 (Bristol-Myers) with
radiation therapy and antisense raf oligonucleotides, LErafAON (NeoPharm) with radiation therapy. He serves as a Radiation Biology and
Radiation Oncology expert on committees of the NIH to review Program Project (P01) grant applications, Specialized Program of Research
Excellence (SPORE) grant applications and investigator-initiated research project (R01) applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Dritschilo is supported in our clinical development effort by Tyvin Rich, MD, our Chief Clinical Officer and Medical Director. Dr. Rich
is the former Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences
Center and proton radiation therapy specialist at the Hampton Proton Therapy Center in Hampton, Virginia. Dr. Rich has served as principal
investigator on multi-modality clinical trials for the treatment of gastrointestinal (GI) cancers and helped to develop treatment with
5-fluorouracil (5-FU) as a radiation sensitizer for use with RT in the treatment of GI cancers. He has extensive cancer clinical trial
experience in developing radiation sensitizer applications through his participation in the Radiation Therapy Oncology Group (RTOG).
Dr. Rich is a co-inventor with scientists at the University of Virginia of the Proton Activated Atomic Medicine technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
administrative services are provided by Peter Dritschilo, MBA, who has served as our President and COO since 2012. Mr. Dritschilo&#8217;s
experience in hospital administration and management of medical oncology clinical services and radiation therapy facilities, including
management of day-to-day operations, human resources and financial oversight. Peter Dritschilo is the son of our Chairman and CEO, Dr.
Anatoly Dritschilo. <span style="background-color: white">Mr. Timothy J. Lorber is our Chief Financial Officer, or CFO, a position he
has served in since June 2024. Mr. Lorber is a CPA with more than 40 years of professional finance experience. We believe his extensive
experience and expertise in the financial industry supports his service as our CFO. </span>Michael Vander Hoek, our former CFO, as Vice
President for Operations and Regulatory expands our capability to provide the level of management needed for the proposed expansion of
clinical trials. Mr. Vander Hoek served as administrative director of the Lombardi Comprehensive Cancer Center (LCC) for 12 years and
has extensive experience in negotiations, management and supervision of Contract Research Organizations (CROs) and research contracts
in general. As the administrative director of the Lombardi Comprehensive Cancer Center, Mr. Vander Hoek also served as the chief financial
officer. Taken together, we believe our leadership team of highly qualified specialists will help us achieve the proposed milestones
for the development of radiation sensitizer products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Deficiency </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet Nasdaq listing rules in order to
maintain such listing, including a requirement that the Company&#8217;s stockholders equity remain at or above $2.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2024, we received a letter from The Nasdaq notifying the Company that it is no longer in compliance with the minimum stockholders&#8217;
equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain
stockholders&#8217; equity of at least $2.5 million. In the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30,
2024, the Company reported stockholders&#8217; equity of $801,434, which is below the minimum stockholders&#8217; equity required for
continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). In addition, at present, the Company does not meet the alternatives of
market value of listed securities or net income from continuing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Nasdaq notice has no immediate effect on the listing of the Company&#8217;s securities on the Nasdaq Capital Market. Nasdaq has provided
the Company with 45 calendar days, or until October 25, 2024, to submit a plan to regain compliance with the minimum stockholders&#8217;
equity standard. The Company subsequently submitted a plan of compliance to Nasdaq on October 15, 2024. If the Company&#8217;s
plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from September 10, 2024 for the Company
to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">can be no assurance that the Company&#8217;s
plan will be accepted or that, if it is, the Company will be able to regain compliance and maintain its listing on the Nasdaq Capital
Market. If the Company&#8217;s plan to regain compliance is not accepted or if Nasdaq does not grant the Company a 180-day extension
to regain compliance, or if the Company fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide
notice that the Company&#8217;s securities will become subject to delisting. In such event, the Company will have an opportunity
to appeal Nasdaq&#8217;s decision to a hearings panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2023 we received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq (the &#8220;Staff&#8221;) stating that
for the 30 consecutive business day period the Company&#8217;s common stock had failed to maintain a minimum closing bid price of $1.00
per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum
Bid Price Requirement&#8221;). In accordance with Nasdaq rules, the Company was provided with an initial period of 180 calendar days,
or until February 27, 2024, to regain compliance with the Minimum Bid Price Requirement and a second Grace Period on February 19, 2024
through August 26, 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to regain compliance with the Minimum Bid Price Requirement, on August 6, 2024, we filed an amendment to our certificate of incorporation
to effect a 1-for-8 reverse stock split of our outstanding common stock (the &#8220;2024 Reverse Stock Split&#8221;). The 2024 Reverse
Stock Split became effective on August 13, 2024, when the Company&#8217;s common stock opened for trading on Nasdaq on a post-split basis
under the Company&#8217;s existing trading symbol, &#8220;SHPH.&#8221; Subsequently, on August 27, 2024, we received notice from Nasdaq
that we regained compliance with the Minimum Bid Price Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
historical share and per share amounts reflected throughout this prospectus have been adjusted to reflect the 2024 Reverse Stock Split.
However, our periodic and current reports, and all other documents that were filed prior
to August 13, 2024 do not give effect to the 2024 Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Uncertainty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
condensed consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and had
a net loss of approximately $3.8 million and no revenues for the six months ended June 30, 2024 and had working capital of approximately
$1.1 million as of June 30, 2024. In addition, the convertible note payable outstanding at June 30, 2024 included covenants and
certain cash payment requirements. The convertible note payable outstanding at June 30, 2024, however, was paid off in full as of September 30, 2024. These conditions, and the
Company&#8217;s ability to comply with such conditions, raise substantial doubt about the Company&#8217;s ability to continue as a going
concern within one year after the date that the condensed consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company completed its initial public offering, or IPO, generating net proceeds of approximately $10.0 million. And
in January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $4.3 million (the &#8220;January 2023 Convertible Note&#8221;), along with a four-year
warrant to purchase 1,018,079 shares of common stock (127,260 shares, post Reverse Split), exercisable at $1.93 per share (post
Reverse Split, as adjusted), providing the Company with approximately $3.6 million in net proceeds. While the January 2023 Note has
been paid off in full, to date, the warrant has not yet been exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations leading up to the manufacture of drug product and FDA approval of the IND
for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the Company agreed to
an expansion of the clinical trial, necessitating additional capital to complete the trial as well as fund ongoing operations. The ability of the Company to continue as a going
concern is dependent upon its ability to successfully raise additional equity or debt financing, including through bridge financing,
to allow the Company to fund ongoing operations, conduct clinical trials and bring a drug candidate to commercialization to generate
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to obtain additional material financing in the near-term, our clinical trials and targeted FDA submission timeline could be delayed,
and we could be forced to abandon such activities entirely and cease operations, with the possible loss of such properties or assets.
If we are unable to obtain a material quantum of financing in the imminent future or unable to continue to obtain additional financing
over at least the next 12 months as we continue to generate negative cash flow, our board of directors could determine to cause the Company
to undertake a process of liquidation under Chapter 7 of applicable U.S. bankruptcy laws, or otherwise seek other protection under such
laws. <span style="background-color: white">In such event, we expect that holders of shares of our common stock would recoup little if
any material value in such process.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Financings &#8211; Our IPO and Post-2022 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 2, 2022, we closed on our IPO of 1,225,888 units (each a &#8220;IPO Unit,&#8221; and collectively, the &#8220;IPO Units&#8221;),
with each IPO Unit consisting of one share of the Company&#8217;s common stock and one warrant to purchase one share of common stock,
at a public offering price of $8.125 per IPO Unit ($65 per IPO Unit, on a post-reverse split basis). Our IPO, which was underwritten
by Boustead Securities, LLC (&#8220;Boustead&#8221;), resulted in gross proceeds of $9.96 million, before deducting underwriting discounts
and commissions. On September 29, 2022, Boustead exercised its overallotment option, purchasing an additional 183,883 IPO Units, resulting
in gross proceeds of $1.49 million, before deducting underwriter commissions and discounts. As a result, our IPO raised a total of $11.45
million, before deducting underwriting discounts, commissions and related IPO expenses. On a post Reverse Split basis, 352,443 shares
(including exercised warrants) were issued under the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, we entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master Fund, SPC &#8211;
Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), as amended on May 10, 2023 and June 4, 2023, pursuant to
which the Company sold to the Investor a $4.3 million convertible note (the &#8220;January 2023 Convertible Note&#8221;) and warrant
(the &#8220;January 2023 Warrant&#8221;) to purchase 127,260 (post Reverse Split) shares of common stock of the Company, in exchange
for gross proceeds of $4.0 million (the &#8220;Investment Amount&#8221;). The January 2023 Convertible Note amortizes on a monthly basis
and the Company can make such monthly amortization payments in cash or, subject to certain equity conditions, in registered shares of
common stock or a combination thereof. For equity repayment, the January 2023 Convertible Note is convertible into shares of common stock
at price per share equal to the lower of (i) $18.8 (post Reverse Split) (ii) 90% of the three lowest daily VWAPs of the 15 trading days
prior to the payment date or (iii) 90% of the VWAP of the trading day prior to payment date. The January 2023 Convertible Note is repayable
over 26 months and bears interest at the rate of 5% per annum. The January 2023 Warrant is exercisable for four years from the date of
closing and is exercisable at $1.93 per share (post Reverse Split, as adjusted). In the event the Investor exercises the January
2023 Warrant in full, such exercise would result in additional gross proceeds to the Company of approximately $246 thousand. As
of the date of this filing, the January 2023 Convertible Note has been paid in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 4, 2024, the Company entered into a loan agreement with our Chief Executive Officer, Dr. Anatoly Dritschilo, pursuant to which Dr. Dritschilo loaned the Company $250,000 (principal), bearing interest at the rate of 12% per annum and which is repayable in 12 substantially equal monthly installments
over a one year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2024, the Company conducted the initial closing of an up to $1.3 million 5% original issue discount (&#8220;OID&#8221;) senior secured convertible note warrant
offering, pursuant to which the Company issued a total of $600,000 notes and warrants to purchase 286,169 shares of common stock,
exercisable at $1.53 per share. The notes bear interest at the rate of 14.5% per annum, with the interest payable quarterly in cash,
mature one year after the date of issuance, are redeemable at any time by the Company at a 107% premium to the principal value of
the notes and, three months after issuance, can be converted at any time by the holder at a 110% premium to the principal value of
the note. Of the above investment amount, the Company&#8217;s CEO purchased $250,000 of notes and warrants in the October 2024
Bridge Offering. The closing of the offering is occurring on a rolling basis and the Company anticipates there may be additional
investments in the October 2024 Bridge Offering in coming days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks you should be aware of before making an investment decision. These risks are discussed more
fully in the &#8220;Risk Factors&#8221; section of this prospectus at page 13 immediately following this prospectus summary, and in Part
I, Item 1A &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as amended
on September 3, 2024, and in Part II, Item 1A &#8220;Risk Factors&#8221; of our Quarterly Report on Form 10-Q for the quarter ended June
30, 2024, which are each included in this prospectus. These risks include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to continue as a going concern in the near term is dependent upon us successfully raising additional equity or debt financing
    to fund our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success is primarily dependent on achieving the development, regulatory approval and commercialization of our product candidates,
    both of which are in the early stages of development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    approach to the discovery and development of innovative radiation oncology drugs based on our HDAC small molecule delivery platform,
    which is novel, unproven and may not result in marketable products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have no product revenue, have incurred significant losses since inception, may never become profitable and may incur substantial
    and increasing net losses for the foreseeable future as we continue the development of, and seek regulatory approvals for our product
    candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    clinical trials of our product candidates fail to demonstrate safety and efficacy, which are ongoing determinations that are solely
    within the authority of the FDA, we may be unable to obtain regulatory approvals to commercialize our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to regulatory approval processes that are lengthy, time-consuming and unpredictable. We may not obtain approval for any
    of our product candidates from the FDA or foreign regulatory authorities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval, the market may not be receptive to our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to establish collaborative partnerships with other pharmaceutical companies, through which we expect to complete
    development of, obtain marketing approval for and, if approved, manufacture and market our product candidates.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter difficulties satisfying the requirements of clinical trial protocols, including patient enrollment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may face competition from other companies in our field or claims from third parties alleging infringement of their intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to recruit or retain key employees, including our senior management team.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Any
    drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform
    initiatives, thereby harming our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a Phase I clinical stage pharmaceutical company with a limited operating history upon which you can evaluate our business and
    prospects. Specialty pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of
    risk. </span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not currently have any product candidates in advanced clinical trials or approved for sale, and we continue to incur significant
    research and development and general and administrative expenses in relation to our operations. In addition, we have not yet demonstrated
    an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
    fields, particularly in the specialty pharmaceutical industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not submitted an application or received marketing approval for any of our product candidates. Regulatory approval of our product
    candidates is not guaranteed, and the approval process is expensive and may take several years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is difficult and costly to protect our intellectual property rights.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
    we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    September 4, 2024, we restated our annual report on Form 10-K for the year ended December 31, 2023, as a result of a re-audit of
    our 2022 financial statements, and there may be some risk of regulatory, shareholder / investor or other actions or consequences
    as a result of the restatement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            future issuance of equity or of debt securities that are convertible into common stock will
                                            dilute our share capital.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
    we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being an Emerging Growth Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a smaller reporting company,
  and as a company with less than $1.235 billion in revenue during our last fiscal year, we qualify as an &#8220;emerging growth
  company&#8221; as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely
  on exemptions from specified disclosure and other requirements that are applicable to other public companies that are not emerging
  growth companies. These exemptions include:</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being permitted to provide
  only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly
  reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply
  with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with any mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional
    information about the audit and the financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of the above provisions for up to five years or until such earlier time that we are no longer an emerging growth company.
We would cease to be an emerging growth company if we have more than $1.235 billion in annual revenues, have more than $700 million
in market value of our capital stock held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year
period. We may also choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of some reduced
reporting requirements in this prospectus. Accordingly, the information contained in this prospectus may be different than the information
you receive from other public companies in which you hold stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards
until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended
transition period for adopting new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as a limited liability company in the state of Maryland in December 2012 and was converted to a C corporation in August
2016. In June 2018, Shuttle completed a share exchange with Shuttle Pharma Acquisition Corp. Inc. (&#8220;Acquisition Corp.&#8221;),
pursuant to which Shuttle Pharmaceuticals, Inc. became a subsidiary of Acquisition Corp. and we subsequently changed the name of Acquisition
Corp. to Shuttle Pharmaceuticals Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879 and our telephone number is <span style="background-color: white">(240)
430-4212</span>. Our corporate website is www.shuttlepharma.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, and all amendments to those reports, if any, are available to you free of charge through the &#8220;Investor Relations&#8221;
section of our website as soon as reasonably practicable after such materials have been electronically filed with or furnished to the
SEC. Information contained on our websites does not form a part of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>THE
OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%; vertical-align: top">Common stock we are offering:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: justify">395,574 shares of common stock based
    on a combined public offering price of $1.525 per share of common stock and accompanying Common Warrant.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
    Warrants to be offered:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We
                                            are also offering 2,555,246 Pre-Funded Warrants to purchase up to 2,555,246
                                            shares of common stock in lieu of Shares of common stock to each purchaser whose purchase
                                            of shares of common stock in this offering would otherwise result in the purchaser, together
                                            with its affiliates and certain related parties, beneficially owning more than 4.99% (or,
                                            at the election of the purchaser, 9.99%) of our outstanding common stock immediately following
                                            the consummation of this offering. The purchase price of each Pre-Funded Warrant and accompanying
                                            Common Warrant is $1.524, which equals the price at which one share of common stock
                                            and accompanying Common Warrant is sold to the public in this offering, minus $0.001,
                                            and the exercise price of each Pre-Funded Warrant will be $0.001 per share. The Pre-Funded
                                            Warrants will be exercisable immediately and may be exercised at any time until all of the
                                            Pre-Funded Warrants are exercised in full. For each Pre-Funded Warrant we sell, the number
                                            of shares of Common Stock we are offering will be decreased on a one-for-one basis.</p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The
Pre-Funded Warrants have no stand-alone rights and will not be certificated or issued as stand-alone securities. </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    prospectus also relates to the offering of our common stock issuable upon exercise of the Pre-Funded Warrants. See &#8220;<i>Description
    of Securities We Are Offering &#8211; Pre-Funded Warrants.&#8221;</i></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Warrants to be offered:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are also offering 2,950,820 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Warrants. Each share of common stock (or Pre-Funded Warrant to purchase one share of common stock in lieu thereof) sold includes one
    Common Warrant to purchase one share of common stock, exercisable at $1.40 per share. The Common Warrants will be exercisable on the Initial Exercise Date. The
    Common Warrants will expire five years from such date. See &#8220;<i>Description of the Securities We Are Offering &#8211; Common
    Warrants.</i>&#8221; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding before this offering:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,946,099
    shares of common stock<sup>(1)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding immediately after this offering:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,341,673
    shares</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> (assuming no exercise of the Pre-Funded
    Warrants or Common Warrants issued in this offering).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    policy:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have never paid cash dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future.
    See the section entitled &#8220;Dividend Policy.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that the net proceeds from this offering will be approximately $4.1 million, after deducting the cash fees to be
    paid to the Placement Agents and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise
    of the Common Warrants in this offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds from this offering to fund IND-enabling and Phase I and II clinical trials of product candidates,
    including $2.3 million in payments that will be owed to Theradex Systems, Inc., the clinical research organization (CRO) supporting
    our Phase II clinical trials for radiation sensitizer Ropidoxuridine. We anticipate that the funds raised from this offering will
    allow us to complete the Phase II clinical trial, although there is no guarantee that we will not require additional funds. See &#8220;Use
    of Proceeds&#8221; beginning on page 43  below.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    trading symbol:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is listed on Nasdaq under the symbol &#8220;SHPH.&#8221; There is no established trading market for the Common Warrants
    or Pre-Funded Warrants, and we do not expect a market to develop. In addition, we do not intend to apply for the listing of
    the Common Warrants or Pre-Funded Warrants on any national securities exchange or other trading market. Without an active trading
    market, the liquidity of the Common Warrants and Pre-Funded Warrant will be limited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
                                            &#8220;Risk Factors&#8221; beginning on page 13 of this prospectus and other information
                                            included in this prospectus for a discussion of the risk factors
                                            you should consider carefully when making an investment decision.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonable
    best efforts offering</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to offer and sell the securities offered hereby to the purchasers through the Placement Agents. The Placement Agents
    are not required to buy or sell any specific number or dollar amount of the securities offered hereby but will use their reasonable
    best efforts to solicit offers to purchase the securities offered by this prospectus. See &#8220;Plan of Distribution&#8221; on page
    97 of this prospectus.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of shares of our common stock to be outstanding before this offering is based on 2,946,099 shares of our common stock
    outstanding as of October 29, 2024, and, unless otherwise indicated, excludes, as of that date: (i) 184,000 warrants to
    purchase common stock, exercisable at an average exercise price of $11.54 per share; and (ii) the 732,134 shares issuable
    under the convertible bridge notes and warrants to purchase 329,460 shares of common stock, exercisable at a weighted
    average price of $1.42 per share, issued in the October 2024 Convertible Note Offering. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, the information in this prospectus assumes no exercise of any Warrants to be issued in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and all the other
information in this registration statement before you decide to buy our common stock. If any of the following risks related to our business
actually occurs, our business, financial condition, operating results, and prospects would be adversely affected. The market price of
our common stock could decline due to any of these risks and uncertainties related to our business, or related to an investment in our
common stock, and you may lose part or all of your investment.</i></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect
our business. Certain statements below are forward-looking statements. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to this Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of substantial amounts of our securities in the public market could depress the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for trading on the Nasdaq Capital Market. If our stockholders sell substantial amounts of our common stock in
the public market, or the market perceives that such sales may occur, the market price of our securities could fall and we may be unable
to sell our securities in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
securities may experience extreme price and volume fluctuations, which could lead to costly litigation for us and make an investment
in us less appealing.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may fluctuate substantially due to a variety of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    status and results of our clinical trials for our product candidate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to fund and complete our study and, if such study provides data supporting an FDA submission, our ability to apply for and
    obtain clearance from the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to remain a going concern;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">our ability to maintain our Nasdaq listing;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    business strategy and plans;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential market for our product candidate, if approved for sale in the U.S.;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    regulatory pronouncements and changes in regulatory guidelines and timing of regulatory approvals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    and industry-specific economic conditions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our quarterly financial and operating results, including the rate at which we incur negative cash flow in future periods;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or departures of our key personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in market valuations of other companies that operate in our business segments or in our industry;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of trading liquidity;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    our product is approved and becomes available for us to sell in the U.S., whether we ultimately achieve profitability or not;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions, economic and other external factors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market prices of the securities of early-stage companies, particularly companies like ours that are seeking to obtain regulatory approval
of their product candidate and do not yet generate operating revenue, have been highly volatile and are likely to remain highly volatile
in the future. This volatility has often been unrelated to the operating performance of particular companies. In the past, companies
that experience volatility in the market price of their securities have often faced securities class action litigation. Whether or not
meritorious, litigation brought against us could result in substantial costs, divert our management&#8217;s attention and resources and
harm our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Although
we have no preferred stock outstanding as of the date hereof and we have currently no intention to issue any preferred stock, our common
stockholders could be adversely affected by the issuance by us of preferred stock in the future, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation does not restrict our ability to offer one or more series of preferred stock, any or all of which could
rank equally with or have preferences over our common stock as to dividend payments, voting rights, rights upon liquidation or other
types of rights. Our board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock
in one or more series and to fix the rights, preferences and the number of shares constituting any series or the designation of such
series. In the case our board of directors decides to issue any preferred stock, we would have no obligation to consider the specific
interests of the holders of common stock in creating any such series of preferred stock or engaging in any such offering or transaction.
Our creation of any series of preferred stock or our engaging in any such offering or transaction could have a material adverse effect
on holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have broad discretion in how we use the net proceeds of this offering, and we may not use these proceeds effectively or in ways with
which you agree.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion as to the application of the net proceeds of this offering and could use them for purposes other
than those contemplated at the time of the offering. We currently intend to use the net proceeds from the offering to fund IND-enabling
and Phase I and II clinical trials of product candidates, including radiation sensitizer Ropidoxuridine, IPdR/TPI and the HDAC inhibitor
small molecule technology platform, potential acquisition or in-licensing activities and working capital and general corporate purposes.
Our stockholders may not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our
management may use the net proceeds for corporate purposes that may not increase the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing requirements of Nasdaq, it could result in our common stock being delisted,
which could adversely affect the market price and liquidity of our securities and could have other adverse effects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2024, we received a letter (the &#8220;Notification&#8221;) from Nasdaq notifying the Company that it is no longer in compliance
with the minimum stockholders&#8217; equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1)
requires listed companies to maintain stockholders&#8217; equity of at least $2,500,000. In the Company&#8217;s Quarterly Report on Form
10-Q for the period ended June 30, 2024, the Company reported stockholders&#8217; equity of $801,434, which is below the minimum stockholders&#8217;
equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). In addition, presently, the Company does not meet the
alternatives of market value of listed securities or net income from continuing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Notification has no immediate effect on the listing of the Company&#8217;s securities on the Nasdaq Capital Market. Nasdaq has provided
the Company with 45 calendar days, or until October 25, 2024, to submit a plan to regain compliance with the minimum stockholders&#8217;
equity standard. If the Company&#8217;s plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days
from September 10, 2024 for the Company to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is presently evaluating various courses of action to regain compliance and intends to timely submit a compliance plan to Nasdaq.
However, there can be no assurance that the Company&#8217;s plan will be accepted or that, if it is, the Company will be able to regain
compliance and maintain its listing on the Nasdaq Capital Market. If the Company&#8217;s plan to regain compliance is not accepted or
if Nasdaq does not grant an extension and the Company does not regain compliance by October 25, 2024, or if the Company fails to satisfy
another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company&#8217;s securities will become subject
to delisting. In that event, the Company will have an opportunity to appeal Nasdaq&#8217;s decision to a hearings panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we aim to regain compliance with Nasdaq&#8217;s stockholders equity requirement, we nonetheless run the risk that our stock may be delisted
if we fail to comply with Nasdaq listing requirements. In the event our common stock is delisted, we may seek to have our common stock
quoted on an over-the-counter marketplace, such as on the OTCQX. The OTCQX is not a stock exchange, and if our common stock trades on
the OTCQX rather than a securities exchange, there may be significantly less trading volume and analyst coverage of, and significantly
less investor interest in, our common stock, which may lead to lower trading prices for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
potential delisting of our common stock from the Nasdaq may have materially adverse consequences to our stockholders, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    reduced market price and liquidity with respect to our shares of common stock, which could make our ability to raise new investment
    capital more difficult;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    dissemination of market price of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    news coverage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    interest by investors in our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    of the prices of our common stock, due to low trading volume;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    common stock being considered a &#8220;penny stock,&#8221; which would result in broker-dealers participating in sales of our common
    stock being subject to the regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange Act </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    difficulty in selling our common stock in certain states due to &#8220;blue sky&#8221; restrictions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    ability to issue additional securities or to secure additional financing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
you purchase our securities in this offering, you may experience future dilution as a result of future equity offerings or other equity
issuances.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and issue additional shares of our common stock or other securities convertible into or exchangeable for our common stock in
the future. We are generally not restricted from issuing additional securities, including shares of common stock, securities that are
convertible into or exchangeable for, or that represent the right to receive, common stock or substantially similar securities. The issuance
of securities in future offerings may cause dilution to our stockholders, including investors in this offering. We cannot assure you
that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the
price per share paid by investors in this offering, and investors purchasing other securities in the future could have rights superior
to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible
into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trading
of our common stock may be limited, making it difficult for our stockholders to sell their shares, and future sales of common stock could
reduce our stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock currently trades on Nasdaq under the ticker &#8220;SHPH.&#8221; The liquidity of our common stock may be limited, including
in terms of the number of shares that can be bought and sold at a given price and reduction in security analysts&#8217; and the media&#8217;s
coverage of us, if any. These factors may result in different prices for our common stock than might otherwise be obtained in a more
liquid market and could also result in a larger spread between the bid and asked prices for our common stock. In addition, in the absence
of a large market capitalization, our common stock is less liquid than the stock of companies with broader public ownership, and, as
a result, the trading prices of our common stock may be more volatile. In the absence of an active public trading market, an investor
may be unable to liquidate his/her investment in our common stock. Trading of a relatively small volume of our common stock may have
a greater impact on the trading price of our stock. We cannot predict the prices at which our common stock will trade in the future,
if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not currently intend to pay dividends on our common stock in the foreseeable future and, consequently, your ability to achieve a return
on your investment will depend on appreciation in the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any cash dividends to holders of our common stock for the foreseeable future. Consequently, investors must rely
on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their
investments. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which our stockholders
have purchased their shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
offering price of the common stock or Pre-Funded Warrants may not be indicative of the value of our assets or the price at which securities
can be resold. The offering price of the common stock or Pre-Funded Warrants may not be an indication of our actual value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price per common stock or Pre-Funded Warrant is being determined based upon negotiations between the Company and the
Placement Agents. Factors taken into consideration include the trading volume of our common stock prior to this offering, the historical
prices at which our shares of common stock have recently traded, the history and prospects of our business, the stage of development
of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management,
general conditions of the securities markets at the time of the offering, and such other factors as we and the Placement Agents deem
relevant. No assurance can be given that our common stock can be resold at the public offering price for the shares. You may not receive
a positive return on your investment when you sell your shares of common stock and you may lose the entire amount of your investment
in the common stock, Pre-Funded Warrants, or the Common Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Common Warrants and Pre-Funded Warrants are speculative in nature.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants and Pre-Funded Warrants offered hereby do not confer any rights of common stock ownership on their holders, such as voting
rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically,
commencing on the date of issuance, holders of the Pre-Funded Warrants may acquire the common stock issuable upon exercise of such warrants
at an exercise price of $0.001 per share and holders of the Common Warrants may acquire the common stock issuable upon exercise
of such warrants at an exercise price of $1.40 per share. Moreover, following this offering, the market value of the Pre-Funded Warrants and Common Warrants will be uncertain and there
can be no assurance that the market value of such Warrants will equal or exceed their public offering price. There can be no assurance
that the market price of the common stock will ever equal or exceed the exercise price of the Common Warrants, and consequently, whether
it will ever be profitable for holders of the Common Warrants to exercise the Common Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock may depend in part on research and reports that securities or industry analysts publish about us
or our business. Securities and industry analysts do not currently, and may never, publish research on us. If securities or industry
analysts do not cover us or commence coverage of us, the trading price for our stock would likely be negatively impacted. In the event
securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate
or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of us or fails
to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FINRA
sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 30, 2020, the SEC implemented Regulation Best Interest requiring that &#8220;A broker, dealer, or a natural person who is an associated
person of a broker or dealer, when making a recommendation of any securities transaction or investment strategy involving securities
(including account recommendations) to a retail customer, shall act in the best interest of the retail customer at the time the recommendation
is made, without placing the financial or other interest of the broker, dealer, or natural person who is an associated person of a broker
or dealer making the recommendation ahead of the interest of the retail customer.&#8221; This is a significantly higher standard for
broker-dealers to recommend securities to retail customers than before under FINRA &#8220;suitability rules.&#8221; FINRA suitability
rules do still apply to institutional investors and require that in recommending an investment to a customer, a broker-dealer must have
reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending securities to their customers,
broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment
objectives and other information, and for retail customers determine the investment is in the customer&#8217;s &#8220;best interest&#8221;
and meet other SEC requirements. As a result, fewer broker-dealers may be willing to make a market in our common stock, reducing a stockholder&#8217;s
ability to resell shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>This
offering may cause the trading price of our shares of common stock to decrease.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price per common stock or Pre-Funded Warrant, may result in an immediate decrease in the market price of our shares. This decrease may
continue after the completion of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Resales
of our shares of common stock in the public market by the stockholders as a result of this offering may cause the market price of our
shares of common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Sales of substantial amounts of our shares
of common stock in the public market, or the perception that such sales might occur, could adversely affect the market price of our shares
of common stock. The issuance of new shares of common stock could result in resales of our shares of common stock by our current shareholders
concerned about the potential ownership dilution of their holdings. Furthermore, in the future, we may issue additional shares of common
stock or other equity or debt securities exercisable or convertible into shares of common stock. Any such issuance could result in substantial
dilution to our existing shareholders and could cause our stock price to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business, Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business; our ability to continue as a going concern is dependent upon our ability
to successfully conduct clinical trials, bring a drug candidate to commercialization, generate revenues, and to raise additional equity
or debt financing to fund our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and had a net loss of
approximately $6.6 million and no revenues for the year ended December 31, 2023, with working capital of approximately $4.6 million as
of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and certain cash
payment requirements. These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt about
the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements
are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company completed its initial public offering of common stock, generating net proceeds of approximately $10.0 million.
Additionally, in January 2023, the Company entered into a securities purchase agreement with an institutional investor through which
the Company sold a convertible note with a principal value of $4.3 million, along with a four-year warrant to purchase 127,260 shares
of common stock, exercisable at $18.80 per share ($1.93 post Reverse Split, as adjusted), providing the Company with approximately
$3.6 million in net proceeds. To date, the warrant has not yet been exercised. However, the Company&#8217;s existing cash resources,
marketable securities and the cash received from the Company&#8217;s initial public offering and convertible note offering are not expected
to provide sufficient funds to support the Company&#8217;s operations and clinical trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
capital raise has supported operations leading up to the manufacture of drug product and FDA approval of the IND for the Phase II clinical
trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the company agreed to an expansion of the clinical
trial, necessitating additional capital expenditures to complete the trial. Management intends to initiate a rights offering for $4.5
million and has submitted SBIR applications for non-dilutive NIH funding for our pre-clinical project. The ability of the Company to
continue as a going concern is dependent upon our ability to successfully conduct clinical trials, bring a drug candidate to commercialization,
generate revenues, and to raise additional equity or debt financing to fund our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success is primarily dependent on the successful development, regulatory approval and commercialization of our product candidates, all
of which are in the early stages of development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have one clinical stage product candidate in the early stages of development. Ropidoxuridine has undergone an SBIR funded Phase
I clinical trial at Lifespan/Rhode Island Hospital. We also have an HDAC inhibitor small molecule platform. The three lead drug candidate
molecules are in preclinical phases of development. None of our product candidates have gained marketing approval for sale in the United
States or any other country, and we cannot guarantee that we will ever have marketable products. To date, we have invested substantially
all of our efforts and financial resources in the research and development and commercial planning for our current product candidate
and our HDAC small molecule delivery platform. Our near-term prospects, including our ability to finance our Company and generate revenue,
as well as our future growth, will depend heavily on the development, marketing approval and commercialization of our product candidates.
The clinical and commercial success of product candidates will depend on a number of factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">building
    on favorable results from our Phase I clinical trial for IPdR and proceeding to Phase II and Phase III clinical trials, which may
    be slower or cost more than we currently anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate safety and efficacy of our product candidates, which are ongoing determinations that are solely within the
    authority of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if our clinical trials are completed, there can be no assurance that the FDA will agree that we have satisfactorily demonstrated
    safety or efficacy or that the FDA will not raise new issues regarding the design of our clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are required by the FDA to conduct additional clinical trials to support the approval of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance by the FDA of our proposed parameters for regulatory approval, including our proposed indication, endpoints and endpoint
    measurement tools relating to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    incidence, duration and severity of adverse side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are able to secure collaborations for completing the development and, if approved, commercialization of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our and our potential collaborators&#8217; marketing, sales and distribution strategy and operations of product
    candidates that are approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    success in educating physicians and patients about the benefits, administration and use of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our third-party manufacturers and potential collaborators to manufacture clinical trial and commercial supplies of our
    product candidates to remain in good standing with regulatory bodies, and to develop, validate and maintain commercially viable manufacturing
    processes that are compliant with current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to commercialize our product candidates, if approved for marketing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enforce our intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to avoid third-party patent interference or patent infringement claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our product candidates as safe and effective by patients and the medical community; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable quality profile of our product candidates following approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Many
of the above-listed risk factors are beyond our control. Accordingly, we cannot assure you that we will ever be able to generate revenue
through the sale of our product candidates. Any one of these factors or other factors discussed in this Annual Report could affect our
ability to commercialize product candidates, which could impact our ability to earn sufficient revenues to transition from a developmental
stage company and continue our business. If we do not obtain marketing approval of and commercialization of our product candidates, or
are significantly delayed in doing so, our business will be materially harmed. We have a limited operating history and have incurred
significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future and may never
achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company, preparing to commence Phase II clinical trials of our lead drug candidate, with a limited
operating history upon which you can evaluate our business and prospects. Specialty pharmaceutical product development is a highly speculative
undertaking and involves a substantial degree of risk. We do not currently have any product candidates in advanced clinical trials or
approved for sale, and we continue to incur significant research and development and general and administrative expenses related to our
operations. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks
and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the specialty pharmaceutical
industry. We have not generated any revenue and have incurred losses in each year since our founding in December 2012. Our accumulated
deficit as of December 31, 2023 was $25.4 million. We expect to continue to incur significant losses for the foreseeable future. Even
if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no source of product sales revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet completed clinical trials and thus do not yet have commercial sales of our products and have not yet not generated any revenues
from commercial sales of our product candidates. Our ability to generate product revenue depends upon our ability to develop and commercialize
products, including any of our current product candidates or other product candidates that we may develop, in-license or acquire in the
future. We do not anticipate generating revenue from the sale of products for the foreseeable future. Our ability to generate future
product revenue from our current or future product candidates also depends on a number of additional factors, including our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    research and clinical development of current and future product candidates, either directly or through collaborative relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of
    bulk drug substances and drug products to maintain that supply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    regulatory approval from relevant regulatory authorities in jurisdictions where we intend to market our product candidates, either
    directly or through collaborative relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch
    and commercialize future product candidates for which we obtain marketing approval, if any, through collaborative partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    coverage and adequate product reimbursement from third-party payors, including government payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
    market acceptance for our products, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish,
    maintain and protect our intellectual property rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
    hire and retain qualified personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because of the numerous risks and uncertainties associated with clinical product development, including that our product candidates
may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount
of any potential future product sales revenues. Our expenses also could increase beyond expectations if we decide to or are required
by the FDA, or comparable foreign regulatory authorities, to perform studies or trials in addition to those that we currently anticipate.
Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with
launching and commercializing these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market may not be receptive to our product candidates based on our novel therapeutic modality, and we may not generate any future revenue
from the sale or licensing of product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such
as whether the product can be sold at a competitive cost and otherwise accepted in the market. The product candidates that we are developing
are based on new delivery platform therapeutic approaches (there currently is no drug which has FDA approval for indications of radiation
sensitization). Market participants with significant influence over acceptance of new treatments, such as physicians and third-party
payors, may not accept our delivery platform, and we may not be able to convince the medical community and third-party payors to accept
and use, or to provide favorable reimbursement for, any product candidates developed by us. Market acceptance of our product candidates
will depend on, among other factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    of our receipt of any marketing and commercialization approvals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms
    of any approvals and the countries in which approvals are obtained;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    and efficacy of our product candidates, which are determinations solely within the authority of the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of any adverse side effects associated with our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warnings
    contained in any labeling approved by the FDA or other regulatory authority;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
    and ease of administration of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of our physician education programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of adequate government and third-party payor reimbursement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    of our products, particularly as compared to alternative treatments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of alternative effective products for indications our product candidates are intended to treat.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional financing in order to obtain marketing approval of our product candidates and commercialize our product
candidates; a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce
or terminate our product development, other operations or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, substantially all of our resources have been dedicated to the preclinical and clinical development of our HDAC small molecule
delivery platform and our initial product candidate, Ropidoxuridine. Our capital needs to date have been met by contributions from existing
stockholders, as well as through private offerings and IPO of our securities and our SBIR contracts. We believe that we will continue
to expend substantial resources for the foreseeable future on the completion of clinical development and regulatory preparedness of our
product candidates, preparations for a commercial launch of our product candidates, if approved, and development of any other current
or future product candidates we may choose to further develop. These expenditures will include costs associated with research and development,
conducting preclinical studies and clinical trials, obtaining marketing approvals, and, if we are not able to enter into planned collaborations,
manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may
arise. Because the outcome of any drug development process is highly uncertain, we cannot reasonably estimate the actual amounts necessary
to complete the development and commercialization of our current product candidates, if approved, or future product candidates, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the proceeds we received in our IPO and subsequent $4.0 million follow on convertible note offering, for which we received
net proceeds of $3.6 million, along with our existing capital resources, will not be sufficient to fund our operations one year after
the date that the consolidated financial statements are issued without additional capital infusion. We anticipate we will need to seek
additional funding through public or private equity or debt financings or other sources, such as through a rights offering, strategic
collaborations or grants and contracts. Such financing may result in dilution to stockholders, imposition of debt covenants and repayment
obligations, or other restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable
market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing our current product candidates, future product candidates and conducting
    preclinical and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities if our current product candidates and future product candidates are approved for sale, including
    securing collaborative ventures for completing development of, securing marketing approval for and ultimately marketing, selling
    and distributing our product candidates, if approved or building a corporate infrastructure if we have to undertake these activities
    directly;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of any additional product candidates we may develop or acquire;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    product liability or other lawsuits related to our products or commenced against us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expenses needed to attract and retain skilled personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs
    and the outcome of such litigation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and amount of sales of, or royalties on, any future approved products, if any.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us
on a timely basis, we may be required to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate preclinical studies, clinical trials or other development activities for our current product candidates
    or future product candidates, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our research and development activities; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize
    our current or future product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of public and private equity offerings, debt financings, strategic collaborations and
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive
covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual
property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional
funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
and/or unstable global market and economic conditions, including those caused by the ongoing conflict between the Ukraine and Russia
and the ongoing COVID-19 pandemic, could have serious adverse consequences on our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions as a result of the ongoing
conflict between the Ukraine and Russia and challenges arising from the ongoing COVID-19 pandemic, including severely diminished liquidity
and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in
inflation rates and uncertainty about economic stability. Our results of operations could be adversely affected by the general conditions
of the global economy and the global financial markets. In addition, any such volatility and disruptions may have adverse consequences
on us or the third parties upon whom we rely. For example, in 2008, the global financial crisis caused extreme volatility and disruptions
in the capital and credit markets and the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international
markets. Inflation rates, particularly in the United States, have increased recently to levels not seen in years. Increased inflation
may result in increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit
or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest
rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and
volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks, which may
impact our ability to raise additional capital in the future. The March 2023 failure of Silicon Valley Bank, the pressure such failure
has placed on other mid-sized banks, and its potential near- and long-term effects on the biotechnology industry and its participants
such as our vendors, suppliers and investors, may also adversely affect our operations and stock price. In addition, U.S. and global
markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict
between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length
and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including
significant volatility in commodity prices, credit and capital markets, as well as supply chain disruptions. Various of Russia&#8217;s
actions have led to sanctions and other penalties being levied by the United States, Australia, the European Union, and other countries,
as well as other public and private actors and companies, against Russia and certain other geographic areas, including agreement to remove
certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system and restrictions
on imports of Russian oil, liquified natural gas and coal. Additional potential sanctions and penalties have also been proposed and/or
threatened. Russian military actions and the resulting sanctions could disrupt or otherwise adversely impact our operations and the operations
of third parties upon which we rely, as well as the global economy and financial markets, and lead to instability and lack of liquidity
in capital markets, potentially making it more difficult for us to obtain additional funds. Related sanctions, export controls or other
actions that may be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption
of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with
which we conduct business. A severe or prolonged economic downturn, inflationary environment, rising interest rates, or political unrest
could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional
capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in
supply disruption, or cause our customers to delay making payments for our services. The extent and duration of the military action,
sanctions, and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify
the impact of other risks described in this Annual Report on Form 10-K and elsewhere herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates are in the early stages of development and may fail in development or suffer delays that materially adversely affect
their commercial viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products on the market and all of our product candidates are in the early stages of development. Our ability to achieve and sustain
profitability depends on obtaining regulatory approvals, including IRB approval, for and commercializing our product candidates, either
alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or one
of our collaborators must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of
our product candidates, the final determination of which rests solely in the authority of the FDA. Preclinical testing and clinical trials
are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of
a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial
administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of
a comparative drug or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient
enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of
a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients
who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient
enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial,
the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical
sites and the availability of effective treatments for the relevant disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product
candidates is high due to scientific feasibility, lack of quality and effectiveness, changing standards of medical care and other variables.
The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained
in later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical
trials of a product candidate at any time for various reasons, including a belief that subjects participating in such trials are being
exposed to unacceptable health risks or adverse side effects. We may not have the financial resources to continue development of, or
to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent
regulatory approval of, or our ability to commercialize, product candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading
    to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in submitting an Investigational New Drug application (&#8220;IND&#8221;) or delays or failure in obtaining the necessary approvals
    from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in enrolling research subjects in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
    drop-out rates of research subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    than anticipated clinical trial costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
    effectiveness of our product candidates during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    FDA or other regulatory agency inspection and review of a clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations
    in a timely manner, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around
    clinical testing generally or with respect to our technology in particular; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
    interpretations of data by the FDA and similar foreign regulatory agencies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third parties on which we depend to conduct our preclinical studies, or any future clinical trials, do not perform as contractually required,
fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with materially
adverse effects on our business, financial condition, results of operations and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying on third party collaborators to conduct our efficacy clinical trials for Ropidoxuridine and plan to rely on third party clinical
investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies
of our product candidates and will do the same for any clinical trials. Because we plan to largely rely on third parties and do not have
the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other
aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, and consultants
are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third
parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources
from our programs. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies
or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry
out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or
meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible
for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan
and protocols for the trial. The FDA requires clinical trials to be conducted in accordance with good clinical practices, including for
conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on
third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have a material
adverse effect on our business, financial condition, results of operations and/or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we rely on third party manufacturing and supply partners, our supply of research and development, preclinical and clinical development
materials may become limited or interrupted or may not be of satisfactory quantity or quality.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development,
preclinical and clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials.
There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials
will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at
acceptable prices. In particular, any replacement of any drug product formulation manufacturer we may use could require significant effort
and expertise in the event there are a limited number of qualified replacements for a particular product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers
must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities
in order to comply with regulatory standards, such as Current Good Manufacturing Practice (or CGMP). In the event that any of our suppliers
or manufacturers fail to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise,
or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the
materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third
party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture
our product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty, or there may be contractual
restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist.
These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have
another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required
to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations
and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product
candidates in a timely manner or within budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to rely on third party manufacturers if we receive regulatory approval for any product candidate. To the extent that
we have existing or future manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations
in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance.
If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms,
we may not be able to fully develop and commercialize our product candidates. Our or a third party&#8217;s failure to execute on our
manufacturing requirements could adversely affect our business in a number of ways, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or continue clinical trials of product candidates under development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of the cooperation of a collaborator;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    our product candidates to additional inspections by regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease distribution or to recall batches of our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unsuccessful in engaging in strategic transactions which could adversely affect our ability to develop and commercialize product
candidates, impact our cash position, increase our expense and present significant distractions to our management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and out- or
in- licensing of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter
into additional collaborations, including with major biotechnology or pharmaceutical companies to complete development and marketing
of our product candidates, if approved. The competition for collaborators is intense, and the negotiation process is time-consuming and
complex. Any proposed collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new or existing
collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not
meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require
us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation
challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including
exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage
a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances
of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs,
write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration
or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or
customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired
business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect
on our business, results of operations, financial condition and prospects. Conversely, any failure to enter into any collaboration or
other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product
candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face competition from entities that have developed or may develop product candidates for our target disease indications, including companies
developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies
or product candidates more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability
to develop and commercialize product candidates may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as with universities and other research institutions which are developing new technology.
Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates.
Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments
that enter the market. We believe that a significant number of products are currently under development, and may become commercially
available in the future, for the treatment of conditions for which we may try to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we have. If we obtain approval for any product candidate, we will face competition based on many different factors, including the
quality and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept
relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of
manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present
superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than
any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense
of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact
our level of expertise and our ability to execute our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success largely depends on the continued service of certain key management and other specialized personnel, including Anatoly Dritschilo,
M.D., our Chief Executive Officer, Mira Jung, Ph.D., our Chief Scientific Officer, Michael Vander Hoek, our Chief Financial Officer and
Vice President Operations and Regulatory, and Peter Dritschilo, our President and Chief Operating Officer. The loss of one or more members
of our management team or other key employees or advisors could delay our research and development programs and materially harm our business,
financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry
make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel
because of the highly technical nature of our product candidates and technologies and the specialized nature of the regulatory approval
process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their
employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members
or key employees. Our future success will depend in large part on our continued ability to attract and retain other highly qualified
scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental
regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions,
government entities and other organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our product candidates advance into Phase II and Phase III clinical trials, we may experience difficulties in managing our growth and
expanding our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our product candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development,
regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we
expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage
our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting
systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient
or timely manner and may discover deficiencies in existing systems and controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our product candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution
capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable
to commercialize any such future products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved, we plan
to enter into collaborations with third parties to sell, market and distribute our products. In the alternative, we would have to develop
internal sales, marketing and distribution capabilities to commercialize any approved product, which would be expensive and time-consuming,
or, as is more likely, enter into collaborations with third parties to perform these services. If we rely on third parties with sales,
marketing and distribution capabilities to market our products or decide to co-promote products with collaborators, we will need to establish
and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter
into such arrangements on acceptable terms, if, at all. In entering into third-party marketing or distribution arrangements, any revenue
we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate
sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we decide to market our
products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with
technical expertise and supporting distribution, administration and compliance capabilities. If we are not able to commercialize any
product approved in the future, either on our own or through third parties, our business, financial condition, results of operations
and prospects could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization
approvals we may receive and subject us to other penalties that could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we receive marketing and commercialization approval of a product candidate, there can be no assurance we will not be subject to future
or continuing regulatory review, including in relation to adverse patient experiences with the product and clinical results that are
reported after a product is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval.
The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and
to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of
the product from the market. The FDA also has the authority to require a risk evaluation and mitigation strategies (&#8220;REMS&#8221;)
plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturer
and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA
and other regulatory agencies, including for continued compliance with CGMP requirements. The discovery of any new or previously unknown
problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer
or facility, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will not have control over
compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to
regulatory requirements and continuing regulatory review. If we or our collaborators, manufacturers or service providers fail to comply
with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or
they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA to approve pending applications
or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit
the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material
effect on our business, financial condition, results of operations or prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products,
such claims could result in an FDA investigation of the quality and effectiveness of our products, our manufacturing processes and facilities
or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications
for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may
also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s
time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently
have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior
to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential
liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable
to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a
material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance
with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraud, other misconduct or illegal
activity. Misconduct by these parties could include intentional failures to comply with FDA regulations, provide accurate information
to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations,
report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business
arrangements in the healthcare industry are subject to extensive laws and regulations, kickbacks, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. While we make an effort to maintain strict work processes and oversight
of our employees, contractors and consultants, any misconduct could expose us to liability through the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Furthermore, it is not
always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective
in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits
stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are
not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of cyber security measures, our internal computer systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. Such events could cause interruptions of our operations. For example, the loss of preclinical data or data from any future
clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly
increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be
delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, our proprietary
business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers,
clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of
this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable
to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced
any such material security breach to date, any such breach could compromise our network, or the networks of our CROs or other third-party
service providers, and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure
or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information,
regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in our products and our ability to
conduct clinical trials, which could adversely affect our business and reputation and lead to delays in gaining regulatory approvals
for our drugs. Although we maintain business interruption insurance coverage, our insurance might not cover all losses from any future
breaches of our systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
of our information technology systems could significantly disrupt the operation of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business increasingly depends on the use of information technologies, which means that certain key areas such as research and development,
production and sales are to a large extent dependent on our information systems or those of third-party providers. Our ability to execute
our business plan and to comply with regulatory requirements with respect to data control and data integrity, depends, in part, on the
continued and uninterrupted performance of our information technology systems, or IT systems and the IT systems supplied by third-party
service providers. These systems are vulnerable to damage from a variety of sources, including telecommunications or network failures,
malicious human acts and natural disasters. Moreover, despite network security and backup measures, some of our servers are potentially
vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures
we and our third-party service providers have taken to prevent unanticipated problems that could affect our IT systems, sustained or
repeated system failures or problems arising during the upgrade of any of our IT systems that interrupt our ability to generate and maintain
data, and in particular to operate our proprietary technology platform, could adversely affect our ability to operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various
flammable and toxic chemicals in our facilities in Gaithersburg, Maryland that are required for our research, development and manufacturing
activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal
of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Gaithersburg facilities
comply with the relevant guidelines of Gaithersburg, the State of Maryland and the Occupational Safety and Health Administration of the
U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the
standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated.
If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental,
health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens
and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs
and expenses, we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide
adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may
be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and
local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and
substantial fines or penalties if we violate any of these laws or regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
information technology systems could face serious disruptions that could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection
to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of
our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners
and delays in our research and development work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change
our compensation policies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
methods and policies for pharmaceutical companies, including policies governing revenue recognition, research and development and related
expenses and accounting for stock-based compensation are subject to review, interpretation and guidance from relevant accounting authorities,
including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise
change or revise our financial statements, including those contained in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization
of our product candidates may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses
of intellectual property rights of others, for our product candidates, methods used to manufacture our product candidates and methods
for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from
infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of the date of this
registration statement, we have filed 6 patent applications with the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) with
respect to various aspects of our HDAC inhibitor small molecule delivery platforms and Ropidoxuridine, our lead product candidate. &#160;However,
we may not be able to apply for patents on certain aspects of our product candidates or delivery technologies in a timely fashion or
at all. To date, four U.S. patents and eighteen European patents have been granted. There is no guarantee that any of our pending patent
applications will result in issued or granted patents, that any of our issued, granted or licensed patents will not later be found to
be invalid or unenforceable or that any issued, granted or licensed patents will include claims that are sufficiently broad to cover
our product candidates or delivery technologies or to provide meaningful protection from our competitors. Moreover, the patent position
of specialty pharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able
to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology
and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties
disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
requirements during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors
might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent
offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding
patentable subject matter or the scope of claims allowable in pharmaceutical patents. As such, we do not know the degree of future protection
that we will have on our proprietary products and technology. While we will endeavor to try to protect our product candidates with intellectual
property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may decide for business reasons to no longer pursue or to abandon certain intellectual property rights in the U.S. or elsewhere, including
due to non-cooperation of inventors or owners of such intellectual property, prior art, or scope of protection, or for other reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or
derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which
time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted
period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the
allowed or granted claims altogether. In addition, there can be no assurance that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are
    not covered by the claims of the patents that we own or license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to make the inventions covered by each of our issued patents
    and pending patent applications that we own or license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to file patent applications covering certain aspects of
    our inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    third party may not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may develop additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others will not have an adverse effect on our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then
    use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
intend to license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain,
maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive
position and business prospects may be adversely affected. We may not be able to protect our intellectual property rights throughout
the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions
where we have not obtained patent protection, competitors may use our technology to develop their own products and further, may export
otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared
to the U.S. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents
or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities
in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce
patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biopharmaceuticals.
This could make it difficult for us to prevent the infringement of patents or marketing of competing products in violation of our proprietary
rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
cost and divert our efforts and attention from other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally file a provisional patent application first (a priority filing) at the USPTO. A U.S. utility application and international
application under the Patent Cooperation Treaty (PCT) are usually filed within twelve months after the priority filing. Based on the
PCT filing, national and regional patent applications may be filed in the European Union, Japan, Australia and Canada and other countries.
We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In
addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national
or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused
by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes
of patent protection may be granted on the same product candidate or technology. The laws of some jurisdictions do not protect intellectual
property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting
and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded
from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights
may be diminished, and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing
laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with
respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business
and results of operations may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or our licensors, or any future collaborators or a strategic partners may become subject to third party claims or litigation alleging
infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to
resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay
or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights at risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors, or any future collaborators or strategic partners may be subject to third-party claims for infringement or misappropriation
of patent or other proprietary rights. We are generally obligated under our license or collaboration agreements to indemnify and hold
harmless our licensors or collaborator for damages arising from intellectual property infringement by us. If we or our licensors, or
any future collaborators or strategic partners are found to infringe a third-party patent or other intellectual property rights, we could
be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our
licensors, collaborators or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which
may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive,
which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a
required license, we or our collaborator, or any future collaborator, may be unable to effectively market product candidates based on
our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue
sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce
our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating
to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s
attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because
they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant
could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity
or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements,
for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution.
The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to
the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose
at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology.
Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights
also will not protect our technology if competitors design around our protected technology without legally infringing our patents or
other intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could
be costly or not available on commercially reasonable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products
or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop
or commercialize products or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual
property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially
reasonable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be
able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms
acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented
from or experience substantial delays in marketing our products. If we fail in any such dispute, in addition to being forced to pay damages,
we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We
might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property
rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could
lose intellectual property rights that are necessary for developing and protecting our product candidates and delivery technologies or
we could lose certain rights to grant sublicenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding,
milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach
any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages
and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell
products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our
licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless
of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine
the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant.
The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we aim to
develop and commercialize, if any. Therefore, even if we are able to develop and commercialize products, we may be unable to achieve
or maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patent protection for certain aspects of our product candidates and delivery technologies, we also consider trade
secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets
and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have
access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,
consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with
our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not
be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret is difficult, expensive and time- consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain
foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete
with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217;
or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we
may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may
be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to
commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need
for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based
on our trademarks and trade names, we may not be able to effectively compete and our business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation and Product Approvals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development,
manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing,
marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are
required to be completed in the U.S. and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other
regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the product
candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval
by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement
of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign
counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from
preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit
or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example,
from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials
and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations,
guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular
product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations
on the approved uses for which we may market the product or the labeling or other restrictions. In addition, the FDA has the authority
to require a Risk Evaluation and Mitigation Strategy (REMS) plan as part of an NDA or biologics license application (BLA) or after approval,
which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing
to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use
criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market
for the product and affect reimbursement by third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be
subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our collaborators are subject to federal, state, and foreign healthcare laws and regulations pertaining to fraud and abuse and patients&#8217;
rights. These laws and regulations include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing
    remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing
    or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal false claims law, which prohibits, among other things, individuals or entities from knowingly presenting or causing
    to be presented, claims for payment by government funded programs such as Medicare or Medicaid that are false or fraudulent, and
    which may apply to us by virtue of statements and representations made to customers or third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal Health Insurance Portability and Accountability Act (HIPAA) and Health Information Technology for Economic and Clinical
    Health (HITECH) Act, which prohibit executing a scheme to defraud healthcare programs, impose requirements relating to the privacy,
    security, and transmission of individually identifiable health information, and require notification to affected individuals and
    regulatory authorities of certain breaches of security of individually identifiable health information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Open Payments regulations under the National Physician Payment Transparency Program have been issued under the Patient Protection
    and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, and will require that manufacturers
    of pharmaceutical and biological drugs covered by Medicare, Medicaid, and Children&#8217;s Health Insurance Programs report all consulting
    fees, travel reimbursements, research grants, and other payments or gifts with values over $10 made to physicians and teaching hospitals;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws applicable to commercial
    insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to
    patient data privacy and security.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties,
monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion
from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid,
any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and
prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected
violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of
our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations
may be costly to us in terms of money, time, and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state, or foreign laws or regulations,
we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and
could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory inspection findings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, marketing our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, importation or exportation of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    of review or refusal to approve pending applications or supplements to approved applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from participation in government-funded healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from eligibility for the award of government contracts for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    and criminal penalties and fines.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives,
thereby harming our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries
require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing
or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing
governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently
in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result,
we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial
launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any products also will depend in part on the extent to which reimbursement for these products and related treatments
will be available from government health administration authorities, private health insurers and other organizations. Even if we succeed
in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any
products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of
development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly,
the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring
that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts
reimbursed for pharmaceutical products. If the price we are able to charge for any products we develop, or the reimbursement provided
for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidates will need to be administered under the supervision of a physician on an outpatient basis. Under currently
applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under
the Medicare Part B program if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are incident to a physician&#8217;s services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to
    accepted standards of medical practice; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    have been approved by the FDA and meet other requirements of the statute.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the purposes for which
the drug is approved by the FDA. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or at
a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if
applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed
for lower- cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary
constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where
they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded
and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on
our operating results, our ability to raise capital needed to commercialize products and our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory
proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and
biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare
markets have been proposed in recent years, and such efforts have expanded substantially in recent years. These developments have included
prescription drug benefit legislation that was enacted and took effect in January 2006, healthcare reform legislation enacted by certain
states, and Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
(the &#8220;ACA&#8221;), a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending and enhance remedies against fraud and abuse. The ACA also contains provisions that will affect companies in the pharmaceutical
industry and other healthcare related industries by imposing additional costs and changes to business practices. Provisions affecting
pharmaceutical companies include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandatory
    rebates for drugs sold into the Medicaid program have been increased, and the rebate requirement has been extended to drugs used
    in risk-based Medicaid managed care plans;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    340B Drug Pricing Program under the Public Health Services Act has been extended to require mandatory discounts for drug products
    sold to certain critical access hospitals, cancer hospitals and other covered entities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly
    referred to as the &#8220;Donut Hole&#8221;; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#8217;s market share
    of prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans
    Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal
    health program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory
developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have
an adverse effect on anticipated revenues from product candidates that we may develop and for which we may obtain regulatory approval
and may affect our overall financial condition and ability to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal government agencies currently face potentially significant spending reductions. Under the Budget Control Act of 2011, the failure
of Congress to enact deficit reduction measures of at least $1.2 trillion for the years 2013 through 2021 triggered automatic cuts to
most federal programs. These cuts would include aggregate reductions to Medicare payments to providers of up to two percent per fiscal
year, starting in 2013. Under the American Taxpayer Relief Act of 2012, which was enacted on January 1, 2013, the imposition of these
automatic cuts was delayed until March 1, 2013. Certain of these automatic cuts have been implemented. The full impact on our business
of these automatic cuts is uncertain. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of
relevant agencies, such as the FDA or the NIH to continue to function at current levels. Amounts allocated to federal grants and contracts
may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research
and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may
develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product
candidate, our ability to market and derive revenue from the product candidates could be compromised.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by
one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and
materially and adversely affect our results of operations and business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval of the product or seize the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall the product or change the way the product is administered to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
    thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
financial covenants of the convertible note could result in default and could have a material adverse effect on our liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our ability to settle debt on the convertible note through cash or issuing shares of common stock, we may be required to repay the convertible
note and interest thereon in cash if we do not meet certain equity conditions, including but not limited to volume or price failure on
each trading day during the equity conditions measuring period, authorized shares failure, or occurrence of default as defined in the
note. Events that could trigger a default include failure to pay the note holder any amount, bankruptcy, insolvency, or violation of
the Cash Burn Covenant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>While
our Company&#8217;s management is working to improve our internal controls and procedures, at present management has determined that
our internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation
being disseminated to the public.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rule 13a-15(f)
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), internal control over financial reporting is
a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those
policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with
    authorizations of management and/or directors of the Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s
    assets that could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to include a report of management on the effectiveness of our internal control over financial reporting. We expect to incur
additional expenses and diversion of management&#8217;s time as a result of performing the system and process evaluation, testing and
remediation required in order to comply with the management certification requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presently,
we do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging
outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies
that we may not be able to timely remediate. If we cannot provide reliable financial reports or prevent fraud, our business and operating
results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock,
if a market ever develops, could drop significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
JOBS Act has reduced the information that we are required to disclose.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, the information that we will be required to disclose has been reduced in a number of ways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company that had gross revenues of less than $1.235 billion during the Company&#8217;s last fiscal year, the Company is an &#8220;emerging
growth company,&#8221; as defined in the JOBS Act (an &#8220;EGC&#8221;). We will retain that status until the earliest of (a)
the last day of the fiscal year which we have total annual gross revenues of $1.235 billion (as indexed for inflation in the manner
set forth in the JOBS Act) or more; (b) the last day of the fiscal year of following the fifth anniversary of the date of the
first sale of the common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;); (c) the date on which we have, during the previous three year period, issued more than $1.0 billion in non-convertible
debt; or (d) the date on which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange
Act or any successor thereto. As an EGC, the Company is relieved from the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company is excluded from Section 404(b) of Sarbanes-Oxley Act (&#8220;Sarbanes-Oxley&#8221;), which otherwise would have required
    the Company&#8217;s auditors to attest to and report on the Company&#8217;s internal control over financial reporting. The JOBS Act
    also amended Section 103(a)(3) of Sarbanes-Oxley to provide that (i) any new rules adopted by the PCAOB requiring mandatory audit
    firm rotation or changes to the auditor&#8217;s report to include auditor discussion and analysis (in the event the PCAOB adopts
    an auditor rotation requirement) will not apply to an audit of an EGC; and (ii) any other future rules adopted by the PCAOB will
    not apply to the Company&#8217;s audits unless the SEC determines otherwise.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    JOBS Act amended Section 7(a) of the Securities Act to provide that the Company need not present more than two years of audited
    financial statements in an initial public offering registration statement and in any other registration statement, need not present
    selected financial data pursuant to Item 301 of Regulation S-K for any period prior to the earliest audited period presented in connection
    with such initial public offering. In addition, the Company is not required to comply with any new or revised financial accounting
    standard until such date as a private company (i.e., a company that is not an &#8220;issuer&#8221; as defined by Section 2(a) of
    Sarbanes-Oxley) is required to comply with such new or revised accounting standard. Corresponding changes have been made to the Exchange
    Act, which relates to periodic reporting requirements, which would be applicable if the Company were required to comply with them.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    long as we are an EGC, we may comply with Item 402 of Regulation S-K, which requires extensive quantitative and qualitative disclosure
    regarding executive compensation, by disclosing the more limited information required of a &#8220;smaller reporting company.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    JOBS Act will also exempt us from the following additional compensation-related disclosure provisions that were imposed on
    U.S. public companies pursuant to the Dodd-Frank Act: (i) the advisory vote on executive compensation required by Section 14A(a)
    of the Exchange Act; (ii) the requirements of Section 14A(b) of the Exchange Act relating to stockholders advisory votes on &#8220;golden
    parachute&#8221; compensation; (iii) the requirements of Section 14(i) of the Exchange Act as to disclosure relating to the relationship
    between executive compensation and our financial performance; and (iv) the requirement of Section 953(b)(1) of the Dodd-Frank Act,
    which requires disclosure as to the relationship between the compensation of our chief executive officer and median employee pay.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price may be volatile, and purchasers of our common stock could incur substantial losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
commencement of trading on Nasdaq Stock Market LLC or Nasdaq, on August 29, 2022, our stock price has been extremely volatile, having
traded as high as $1,010.08 and as low as $1.03. As a result of this volatility, investors may not be able to sell their common
stock at or above the price when they purchased our common stock. The market price for our common stock may be influenced by many factors,
including the other risks described in this section of this Annual Report entitled &#8220;Risk Factors&#8221; and the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of preclinical and clinical studies of our product candidates, or those of our competitors, our existing collaborator or any future
    collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introductions
    and announcements of new products by us, our commercialization partners, or our competitors, and the timing of these introductions
    or announcements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our efforts to acquire or in-license additional technologies, products or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning our collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization
    partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent
    protection for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recruitment or departure of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of healthcare payment systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions in the pharmaceutical and biotechnology sectors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other
    comparable companies or our industry generally;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to
    the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the valuation of companies perceived by investors to be comparable to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
    and expectation of additional financing efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us or our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    concentrated ownership of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terrorist
    acts, acts of war or periods of widespread civil unrest;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters and other calamities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, industry and market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets in general, and the markets for pharmaceutical stocks, in particular, have experienced extreme volatility
that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm
the market price of our common stock, regardless of our operating performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements.
To the extent that additional capital is raised through the issuance of shares or other securities convertible into shares of our common
stock, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such
sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future
offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common stock or the
availability of common stock for future sales will have on the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain applicable listing requirements, Nasdaq may delist our common stock from trading, in which case the liquidity and
market price of our common stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that we will be able to meet the continued listing standards of Nasdaq in the future. If we fail to comply with the
applicable listing standards and Nasdaq delists our common stock, we and our stockholders could face significant material adverse consequences,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for shares of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity for our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is &#8220;penny stock,&#8221; which would require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for shares of
    our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news about us and analyst coverage of us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the
sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Because our common stock is listed on Nasdaq,
such securities will be deemed covered securities. Although the states will be preempted from regulating the sale of our securities,
the federal statute does allow states to investigate companies if there is a suspicion of fraud and, if there is a finding of fraudulent
activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if we were no longer listed
on Nasdaq, our securities would not be covered securities and we would be subject to regulations in each state in which we offer our
securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our management has broad discretion over the use of the net proceeds we received from our IPO and any follow-on offerings, you may not
agree with how we use them and the proceeds may not be invested successfully.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds to us from our IPO and any follow-on offerings to fund preclinical and clinical trials of product candidates,
Ropidoxuridine and new formulations of Ropidoxuridine with Tipiracil, O-18 containing molecules for proton radiation sensitization, continued
HDAC technology platform development, working capital and general corporate purposes, including the costs of operating as a public company,
as well as potential acquisition or in-licensing activities. Therefore, our management has broad discretion as to the use of the IPO
proceeds and proceeds from our subsequent private placements or follow-on offerings. Accordingly, you will be relying on the judgment
of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision,
to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not
yield a favorable, or any, return for our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion
regarding our stock, our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about
us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few
securities or industry analysts commence coverage of us, the trading price for our stock would be negatively impacted. In the event we
obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding
us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet
the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to
publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading
volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
board of directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to
holders of our common stock and such issuance could potentially adversely affect stockholders&#8217; voting power and perpetuate their
control over us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended to date, allows us to issue shares of preferred stock without any vote or further action by
our stockholders. Our board of directors has the authority to fix and determine the relative rights and preferences of any preferred
stock. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the
preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders
of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of shares of our common
stock. These rights and preferences could negatively affect the holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
ability of our executive officers and directors, who are our principal stockholders, to control our business may limit or eliminate the
ability of minority stockholders to influence corporate affairs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers and directors, who are our principal stockholders, own approximately 39.4% of our issued and outstanding common stock.
Accordingly, they may be able to effectively control the election of directors, as well as all other matters requiring stockholder approval.
The interests of our principal stockholders may differ from the interests of other stockholders with respect to the issuance of shares,
business transactions with or sales to other companies, selection of other directors and other business decisions. The minority stockholders
have no way of overriding decisions made by our principal stockholders. This level of control may also have an adverse impact on the
market value of our shares because our principal stockholders may institute or undertake transactions, policies or programs that result
in losses and may not take any steps to increase our visibility in the financial community and/or may sell sufficient numbers of shares
to significantly decrease our price per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for indemnification of officers and directors at the expense
of the Company and limit their liability that may result in a major cost to us and hurt the interests of our stockholders because corporate
resources may be expended for the benefit of officers and/or directors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for the indemnification of our officers and directors. We have
been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public
policy as expressed in the Securities Act and is therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation, as amended to date, provides that disputes must be resolved in the Court of Chancery of the State of Delaware,
except for cases brought under the Securities Act or Exchange Act.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended to date, provides that the Court of Chancery in the State of Delaware will be the exclusive
forum for dispute resolution for certain enumerated actions, excluding any actions brought under the Securities Act or Exchange Act,
or unless the Company consents in writing to an alternative jurisdiction. This exclusive forum selection clause may cause inconvenience
of our stockholders or other stakeholders, should they need to bring suit against the Company for an action other than one arising under
the Securities Act or Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to pay cash dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on our common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable
future. The future payment of dividends on our common stock directly depends upon our future earnings, capital requirements, financial
requirements and other factors that our board of directors will consider. Since we do not anticipate paying cash dividends on our common
stock, return on your investment, if any, will depend solely on an increase, if any, in the market value of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
in our amended and restated certificate of incorporation, as amended, and bylaws, as amended, as well as Delaware law, might discourage,
delay or prevent a change of control of our company or changes in our management and, therefore, depress the market price of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, each as amended to date, and bylaws contain provisions that could depress the market price of
our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the
stockholders of our company may deem advantageous. These provisions, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit
    the board of directors to establish the number of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that directors may only be removed &#8220;for cause&#8221; and only with the approval of 66 2/3 percent of our stockholders;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    super-majority voting to amend some provisions in our Certificate of Incorporation and Bylaws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights
    plan (also known as a &#8220;poison pill&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eliminate
    the ability of our stockholders to call special meetings of stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit
    stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that the board of directors is expressly authorized to make, alter or repeal our bylaws; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon
    by stockholders at annual stockholder meetings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company. Section
203 imposes certain restrictions on merger, business combinations and other transactions between us and holders of 15% or more of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
restatement of our consolidated financial statements and identification of material weaknesses in our internal controls may result in
additional risks and uncertainties, including regulatory, stockholder or other actions, loss of investor and counterparty confidence
and negative impacts on our stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2024, the Audit Committee and Company management, after consultation and discussion with our independent registered public accounting
firm, concluded that certain of our previously issued audited consolidated financial statements and unaudited consolidated financial
statements need to be restated and should no longer be relied on for the reasons described in the Current Report on Form 8-K dated July
10, 2024, and in &#8220;Explanatory Note&#8221; preceding Part I, Item 1 of this Form 10-K/A and Note 2 to the Consolidated Financial
Statements under Part II, Item 8 of this Form 10-K/A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting errors impacted the Company&#8217;s consolidated financial statements for the year ended December 31, 2022. These errors further
resulted in an impact to the Company&#8217;s consolidated balance sheet for the year ended December 31, 2023 and the unaudited condensed
consolidated balance sheet as of and for the periods ended March 31, 2023, June 30, 2023, and September 30, 2023, specific to Additional
Paid In Capital and Accumulated Deficit. Additionally, the restatement constituted an event of default under the terms of one of the
Company&#8217;s financing arrangements that was subsequently waived, but required additional cash collateral from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in connection with the restatement of the previously issued financial statements for the fiscal year ended December 31, 2023
and December 31, 2022, and fiscal quarter ended March 31, 2024 (the &#8220;Affected Periods&#8221;), management identified certain material
weaknesses in our internal control over financial reporting. Although we are taking remediation measures, including having hired a new
Chief Financial Officer during the second quarter of 2024 to bolster the Company&#8217;s internal technical accounting and financial
reporting experience and provide bandwidth for the prior CFO to focus on the Company&#8217;s expanding clinical trials, we can give no
assurance that the measures we have taken, are taking and plan to take in the future will remediate the material weaknesses identified
or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement
and maintain adequate internal control over financial reporting. In addition, even if we are successful in strengthening our controls
and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to
facilitate the fair presentation of our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the restatement and associated non-reliance on the previously issued financial statements for the Affected Periods and the
identified material weakness, we have become subject to a number of additional costs and risks, including unanticipated costs for accounting
and legal fees in connection with or related to the restatement and the ongoing process of remediating the material weaknesses. We could
also be subject to regulatory, stockholder or other actions in connection with the restatement and/or the material weaknesses, which
would, regardless of the outcome, consume management&#8217;s time and attention and may result in additional legal, accounting and other
costs. If such proceedings arise and we do not prevail in such proceedings, we could be required to pay damages or settlement costs.
In addition, the restatement and related matters could impair our reputation or could cause our stockholders or other counterparties
to lose confidence in us. Any of these occurrences could adversely affect our business, financial condition, liquidity and results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_001"></span>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and the documents included herein contain forward-looking statements that involve risks and uncertainties. All statements
other than statements of historical facts contained in this prospectus and the documents included herein are forward-looking
statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221;
&#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221;
&#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology.
These forward-looking statements include, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and INDs,
    NDAs other regulatory submissions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expected dependence on third party collaborators for developing, obtaining regulatory approval for and commercializing product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    receipt and timing of any milestone payments or royalties under any research collaboration and license agreement we enter into;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and develop product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    or a collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance of any approved products candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commercialization of any approved product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain additional collaborations and retain commercial rights for our product candidates subject to collaborations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business, technologies and product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates of our expenses, ongoing losses, future revenue and capital requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funds for our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our technologies and product candidates and our ability to operate
    our business without infringing the intellectual property rights of others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties to conduct our preclinical studies or any future clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research
    and development, preclinical and clinical trial drug supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified key management and technical personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    use of net proceeds to us from this offering;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the time during which we will be an emerging growth company under the JOBS Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors or our industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance
or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially
from current expectations include, among other things, those described in the section entitled &#8220;Risk Factors&#8221; in this prospectus
and contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as amended, our Quarterly Report on Form
10-Q for the six months ended June 30, 2024, which are included in this prospectus, together with the information included in
this prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement in this prospectus and the documents included herein reflects our current view with respect
to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations,
industry, and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except
as required by U.S. federal securities law, we assume no obligation to update or revise these forward-looking statements for any reason,
even if new information becomes available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_001"></span>MARKET
AND INDUSTRY DATA AND FORECASTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtained the industry and market data used throughout this prospectus from our own internal estimates and research, as well as from independent
market research, industry and general publications and surveys, governmental agencies, publicly available information and research, surveys
and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts
and third- party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data
and our knowledge of our industry and market, which we believe to be reliable and reasonable. In some cases, we do not expressly refer
to the sources from which this data is derived. In addition, while we believe the industry and market data included in this prospectus
is reliable and based on reasonable assumptions, such data involve material risks and other uncertainties and are subject to change based
on various factors, including those discussed in the section entitled &#8220;<span style="font-weight: normal">Risk Factors</span>&#8221;
and &#8220;Special Note Regarding Forward-Looking Statements.&#8221; These and other factors could cause results to differ materially
from those expressed in the estimates made by the independent parties or by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_002"></span>SELECTED
FINANCIAL DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following selected financial data has been derived from our audited financial statements included in our Annual Report on Form 10-K for
the year ended December 31, 2023, as amended, filed with the SEC on September 4, 2024, and our unaudited financial statements included
in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on September 4, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
historical share and per share amounts reflected throughout this prospectus have been adjusted to reflect the 2024 Reverse Stock Split.
However, our periodic and current reports, and all other documents included in this prospectus that were filed prior to August
13, 2024 do not give effect to the 2024 Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical results are not indicative of the results that may be expected in the future, and results of interim periods are not indicative
of the results for the entire year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Years Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Six Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(As Restated)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,892,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,343,826</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,867,481</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,010,411</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,892,382</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,343,826</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,867,481</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,010,411</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expense)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(700,341</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,652,243</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(894,765</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(149,057</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,592,723</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,996,069</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,762,246</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,159,468</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average common shares
    outstanding &#8211; basic and diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,886,275</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,337,742</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,090,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,742,520</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share &#8211;
    basic and diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.53</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.81</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_003"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from this offering, after deducting Placement Agents&#8217; fees and estimated offering expenses
payable by us, will be approximately $4.1 million assuming no exercise of the Common Warrants. We intend to use the net
proceeds from this offering to fund our Phase II clinical trial for our product candidate, including $2.3 million in payments that will
be owed to Theradex Systems, Inc., the clinical research organization (CRO) supporting our Phase II clinical trials for our radiation
sensitizer Ropidoxuridine, and for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which
could change in the future as our plans and business conditions evolve. While we anticipate that the majority of the net proceeds will
be used to support our Phase II clinical trial for Ropidoxuridine, and the general corporate efforts required to support them, we cannot
currently allocate specific percentages of the net proceeds to us from this offering that we may use for the purposes specified above.
Our management will have broad discretion in the application of the net proceeds from this offering and could use them for purposes other
than those contemplated at the time of this offering. Our stockholders may not agree with the manner in which our management chooses
to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not result
in our being profitable or that increases our market value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments and U.S. government securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_002"></span>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers.
Our goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy
(&#8220;RT&#8221;) is one of the most effective modalities for treating cancers. We are developing a pipeline of products designed to
address the limitations of the current cancer therapies as well as to extend to the new applications of RT. We believe that our product
candidates will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current
standard of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_005.jpg" alt="" style="width: 750px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate structure is based on Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq SHPH &#8211; a Delaware Company) with drug discovery and
development performed in the wholly owned Shuttle Pharmaceuticals, Inc. (a Maryland Company) and diagnostics performed in the wholly
owned Shuttle Diagnostics, Inc. (a Maryland Company). Our product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation
sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics
assets &#8211; the PC-RAD Test, a blood test to predict clinical response to radiation therapy and the PSMA-B ligand for potential use
as a theranostic agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, we submitted an Investigational New Drug (&#8220;IND&#8221;) application with the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
to support the next phase of development of Ropidoxuridine. In January 2024, we received the &#8216;Safe to Proceed&#8217; letter from
the FDA for our IND application for the Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows us to commence
the Phase II study of Ropidoxuridine (IPdR). We have applied for and received FDA approval of Orphan designation for Ropidoxuridine and
RT for treating brain cancer (glioblastoma). The Phase II clinical trial was also approved by the Institutional Review Board &#8220;IRB&#8221;
on June 21, 2024. We believe our management team&#8217;s expertise in radiation therapy, combined modality cancer treatment and immuno-oncology
will help drive the development and, if approved, the commercialization of these potentially curative therapies for patients with aggressive
cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncology has gone through transformative technological innovation over the last decade to better define tumors, allow improved shaping
of radiation delivery and support dose escalation with shorter, more intensive courses of treatment. Furthermore, achieving higher dose
distributions within tumor volumes has reached a practical plateau, since cancers are frequently integrated with or surrounded by more
sensitive normal tissues and further dose escalation increases risks of tissue necrosis. To increase cancer cures at maximally tolerated
radiation doses, pharmacological and biological modifications of cells are needed to sensitize cancers, protect normal tissues, and stimulate
the immune system to react against antigens produced by irradiated, damaged cancer cells. Drugs that show sensitizing properties, or
the ability to make cancer cells more sensitive to radiation, offer a solution to this problem. Currently, such drugs are chemotherapy
agents used off-label, and many have inherent toxicities since they were designed for direct cancer treatments and not for sensitization.
However, the clinical value of using radiation sensitizing drugs in combination with RT has been accepted in a variety of cancer types,
including gynecological, gastro-intestinal, pulmonary and other malignancies. Hence, there is a critical need for new drugs that preferentially
sensitize cancer cells to radiation therapy and that stimulate the innate immune response against irradiated cancer cells. Furthermore,
to advance precision medicine in radiation oncology, there is a need for imaging and molecular diagnostic tests for determining the extent
of cancer spread in the body and for predicting clinical responses to therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our products with the goal of addressing the unmet need in cancer treatment for a commercially marketable radiation response
modifier solution that leads to greater sensitivity of cancer cells to ionizing radiation therapy. The goal of our products is to increase
the therapeutic index for patients receiving radiation and to decrease radiation-related toxicities in patients with solid tumors. Our
products operate across three areas related to the treatment of cancer with RT:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitization
    of growing cancer cells, rendering them more susceptible to the effects of radiation therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the DNA damage response pathway to kill cancer cells and protect adjacent normal cells.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the immune system to kill any remaining cells after RT.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology allows for the creation of an inventory of products for radiation sensitizing, immune modulation, and protection
of healthy tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
to date have focused on continuing our research and development efforts to advance Ropidoxuridine clinical testing and improved drug
formulation, to advance HDAC6 inhibitor (SP-2-225) preclinical development and explore application of the PC-RAD Test, predictive biomarkers
of radiation response. The clinical development of Ropidoxuridine has included completion of a Phase I clinical trial to establish drug
bioavailability and a maximum tolerated dose for use in Phase II clinical trials. TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;),
with whom we have contracted for process research, development and cGMP compliant manufacture of IPdR, has manufactured the active pharmaceutical
ingredient (API) of Ropidoxuridine and the University of Iowa Pharmaceuticals has formulated the drug product for use in the Company&#8217;s
upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. The drug product (capsules) were shipped to contract
research organization (CRO) Theradex Oncology and distributed to clinical trial sites that are fully approved to enroll patients in the
trial. Shuttle received approval from the FDA to begin the clinical trial. The FDA made recommendations to expand the clinical trial
to include a randomized dose &#8220;optimization&#8221; step and we agreed with the recommendation. Meetings with engaged clinical sites
to review the protocol documents have occurred and FDA required Institutional Review Board, or IRB approvals have been received. With
FDA recommended changes incorporated into the revised protocol and the completion of site initiation visits, the Company has commenced
its Phase II clinical study. The radiation biomarker project and the health disparities project have been completed and the Company is
proceeding with plans for clinical validation and potential for commercialization of Ropidoxuridine as a radiation sensitizer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing a pipeline of small molecule radiation sensitizers and immune response regulating drugs. Our most advanced product
candidate is Ropidoxuridine, an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties is in preclinical
studies. In addition, we have a pipeline of complimentary product candidates that we are developing to address solid tumor cancer indications
by radiation sensitization or immune modification. Our therapeutic pipeline is represented in the diagram below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_006.jpg" alt="" style="width: 750px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timeline
for clinical phase (Ropidoxuridine) and pre-clinical phase (HDAC inhibitors) pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidates include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    (IPdR)</span></b> is our lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and
    sarcomas. Phase I clinical trial results supported by an NIH contract to Shuttle Pharma and the NCI (CTEP) were reported in the medical
    journal, Clinical Cancer Research, in July 2019, by our SBIR subcontractor. Eighteen patients completed dose escalations to 1,800
    mg/day for 30 days, establishing the maximum tolerated dose (MTD) of 1,200 mg/day in combination with RT. Four partial responses,
    nine stable disease and one progressive disease in target lesions were reported. Four patients did not have measurable disease and,
    as a result, were not evaluable. These Phase I trial results demonstrate oral bioavailability and an MTD of 1,200 mg per day for
    28 days for use in combination with radiation for Phase II clinical trials that we propose to perform in brain tumors and in sarcomas.
    The brain tumor, glioblastoma multiforme (GB) is eligible for orphan disease designations. Shuttle Pharma has advanced drug manufacture
    and formulation and prepared a clinical protocol of a &#8220;Phase 2 Single-Arm Study of IPdR as a Radiation Sensitizing Agent During
    Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype MGMT Unmethylated Glioblastoma Multiforme.&#8221; In December 2023, we
    submitted an IND application with the FDA to support the next phase of development of Ropidoxuridine. In January 2024, we received
    the &#8216;Safe to Proceed&#8217; letter from the FDA for our IND application for the Phase II study of Ropidoxuridine (IPdR) as
    a radiation sensitizing agent during radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT
    promoter. Receipt of the letter allows us to commence the Phase II study of Ropidoxuridine (IPdR). The clinical development of Ropidoxuridine
    has shown drug bioavailability and a maximum tolerated dose has been established for use in Phase II clinical trials. TCG GreenChem,
    Inc. (&#8220;TCG GreenChem&#8221;), with whom we have contracted for process research, development and cGMP compliant manufacture
    of IPdR, has successfully completed the manufacturing campaign for the active pharmaceutical ingredient (API) of Ropidoxuridine for
    use in the Company&#8217;s upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. Shuttle also worked
    with University of Iowa Pharmaceuticals to develop the formulation and produce the capsules, which have been shipped to contract
    research organization (CRO) Theradex Oncology for distribution to clinical trial sites. Both activities have now been completed.
    In addition, Shuttle received approval from the FDA to begin the clinical trial. The FDA made recommendations that led to an expanded
    clinical trial to include randomized dose optimization and we agreed with the recommendation. We met with representatives from six
    candidate clinical sites to review the protocol documents and FDA required IRB approvals have been obtained. With FDA recommended
    changes incorporated into the revised protocol, the Company has now contractually engaged all of the planned six research
    centers which will be performing clinical trials and has initiated its Phase II clinical study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Phase II clinical study is summarized below:</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_007.jpg" alt="" style="width: 750px"/></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schema
for the Phase II clinical trial. The initial cohort of 40 patients will be randomized to one of two Ropidoxuridine doses. 20 patients
will receive the 1200 mg dose and 20 patients will receive the 960 mg dose. The optimum dose will be determined by comparing drug bioavailability
and side-effects. The optimum dose will then continue to enroll 14 additional patients to provide the required 34 patients for statistical
significance in comparison to historical controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    and Tipiracil (IPdR/TPI)</span></b> is a new combination formulation demonstrating extended bioavailability after oral administration
    in an animal model system. The IPdR/TPI formulation will undergo preclinical development for use as a radiation sensitizer and represents
    a &#8220;next generation&#8221; drug product for clinical evaluation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-2-225
    </span></b>is Shuttle Pharma&#8217;s pre-clinical class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6 has been
    identified as the candidate lead molecule for development as a post-RT innate immune system activator. The macrophage is a key target
    for activating the innate immune system against cancer cells. SP-2-225 has effects on the regulation of the immune system by maintaining
    macrophage cells in an inflammatory, anti-cancer polarization. The interactions of RT with the immune response for cancer treatment
    are of great current interest, offering insight into potential mechanisms for primary site and metastatic cancer treatment. For this
    reason, Shuttle Pharma has selected SP-2-225 as the candidate lead HDAC inhibitor for preclinical development. We have contracted
    with investigators at Georgetown University to perform preclinical studies of immune activation after radiation therapy in an animal
    tumor model. These data have been published (Noonepalle SKR, Grindrod S, Aghdam N, Li X, Gracia-Hernandez M, Zevallos-Delgado C,
    Jung M, Villagra A, Dritschilo A. Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition. Mol Cancer Ther. 2023
    Dec 1;22(12):1376-1389. doi: 10.1158/1535-7163.MCT-23-0215. PMID: 37586844; PMCID: PMC10878032) and additional preclinical studies
    are in progress with our contractors. With the introduction of check-point inhibitors, CAR-T therapies and personalized medicine
    in cancer, regulation of the immune response following RT is of significant clinical and commercial interest.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-303
    </span></b>is Shuttle Pharma&#8217;s pre-clinical selective Class I HDAC inhibitor that preferentially affects histone deacetylases
    HDAC1 and HDAC3 members of the class I HDAC family of enzymes. SP-1-303 data show direct cellular toxicity in ER positive breast
    cancer cells. Furthermore, SP-1-303 increases PD-L1 expression. Completed preclinical in vitro studies have been published (Jung
    M, Nicholas N, Grindrod S, Dritschilo A. Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits
    estrogen receptor positive breast cancer cell growth. PLoS One. 2024 Jul 15;19(7):e0306168. doi: 10.1371/journal.pone.0306168. PMID:
    39008483; PMCID: PMC11249239.). We plan to seek university collaborations to complete SP-1-303 pre-clinical development in 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Approach</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have established a leadership position in radiation sensitizer and response modifier discovery and development. We have
identified a clinical phase product candidate and discovered new pre-clinical phase molecules using our proprietary platform technologies
to increase the therapeutic index for patients receiving radiation for treatment of solid tumors. Our development strategy has four key
pillars: (1) to improve the efficacy of RT by demonstrating improved disease-free survival rates in patients who undergo radiation therapy,
(2) reduce the amount of radiation needed for a favorable tumor response, thereby limiting the potential for radiation related toxicities
to healthy cells, (3) decrease the extent of surgery needed to remove cancers and improve quality of life, and (4) leverage our next
generation technologies to create drugs that regulate the immune response assisting immune checkpoint and CAR-T therapies and other personalized
medicines targeting cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to private and public investment into our candidate therapeutic technology, we have also competed for non-dilutive funding from
the NIH to support our lead sensitizer and to explore development of complimentary diagnostic products. To date, we have completed three
SBIR contracts awarded to Shuttle Pharma by the NIH to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    IPdR as a radiation sensitizer. This funding provided partial support for the Phase I clinical trial of Ropidoxuridine and RT.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    prostate cancer cell cultures from African-American men, with donor matched normal prostate cells, establishing 50 pairs for accelerating
    research to reduce prostate cancer health disparities in African-American men. This project was funded under &#8220;Moonshot&#8221;
    designation. Shuttle Pharma is eligible to apply for additional SBIR (Phase IIb) funding to commercialize these cells for research
    purposes. Currently, cells from African-American patients are distributed, on request, to investigators who are conducting health
    disparities research. We plan to test new small molecules using these cellular reagents for health disparities screening.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    a predictive biomarker for determining outcomes for prostate cancer patients following treatment with RT. This SBIR-funded project
    for blood test (PC-RAD Test) discovery and analytical validation were completed on March 15, 2022, and Shuttle Pharma intends to
    perform a clinical validation study. Shuttle Pharma has licensed the intellectual property for the prostate cancer predictive biomarker
    test from Georgetown University and will seek additional investment from the public market to advance clinical development through
    its Shuttle Diagnostics entity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
three SBIR funded projects have been completed. The Company is eligible to apply for SBIR Phase IIb funding to advance the &#8220;Moonshot&#8221;
health disparities or the predictive biomarker project. The NIH SBIR program is designed to encourage small businesses to engage in Federal
Research/Research and Development (&#8220;R/R&amp;D&#8221;) that has the potential for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma&#8217;s scientists have also developed collaborations to invent intellectual properties for prostate cancer theranostics. From
a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for diagnosis and therapy of prostate cancer.
In a discovery project to develop a novel, boron-containing PSMA ligand to enhance proton radiation therapy of prostate cancer, we discovered
PSMA-B, a molecule containing boron and demonstrating nanomolar binding activity to PSMA. Preclinical evaluations have been initiated
to explore the PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy, as well as a PET diagnostic
reagent and as a targeted prostate cancer therapeutic. By in-licensing our collaborator&#8217;s shares of the intellectual property,
Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application. Theranostic molecules
are suitable for diagnosis and therapy of cancers. The PSMA ligand is a molecule that binds to the PSMA, an enzyme that is highly expressed
in prostate cancer cells. The PSMA ligand is currently used for imaging and therapy to detect and treat prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    PSMA-B as a potential diagnostic and therapeutic molecule in pre-clinical models in collaboration with academic nuclear medicine
    programs. Shuttle Pharma has licensed the intellectual property for the prostate cancer predictive biomarker test from inventors
    and will seek additional investment from NIH by applying for grant applications and from the public market to advance clinical pre-development
    through its Shuttle Diagnostics entity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6
inhibitor (SP-2-225) and, if approved by the FDA, commercialize our product candidates for the treatment of cancers. While this process
may require years to complete, we believe achieving this goal could result in new radiation sensitizer and immunotherapy products. Key
elements of our strategy include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer. </b>To date, there is one drug (Cetuximab, a monoclonal
    antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine and obtaining
    FDA approval, a small molecule sensitizer would then be enabled for clinical applications for radiation sensitization indications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expand
    our leadership position within radiation sensitizers</b>. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop an innovative and well-tolerated drug for proton therapy sensitization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates</b>. We have built our current product
    pipeline through in-house discovery, development, partnerships with leading academic institutions and through in-licensing. We will
    continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other biotechnology
    companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability of clinical
    success, including programs beyond our target franchise areas and current technology footprint.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Invest
    in our HDAC platform technology and maximize its utility across cancer therapies</b>. We are initially applying the platform to develop
    drugs for cancer radiation sensitization, normal tissue radiation protection and post radiation immune stimulation. Based on the
    data we have obtained thus far, these drugs are immune regulatory. We intend to invest to develop other properties of our platform
    technology, as well.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enter
    into collaborations to realize the full potential of our platform</b>. The breadth of our HDAC technology platform enables other
    therapeutic applications, including radiation sensitization and immune therapy. We intend to seek collaborations centered on our
    platform to maximize applications for cancer treatment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Establish
    Shuttle Diagnostics, Inc. as a subsidiary of SHPH</b> to advance development of the predictive biomarker (PC-RAD Test) and the PSMA
    ligand (PSMA-B) to advance prostate cancer treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Radiation
Therapy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncologists use Radiation Therapy (RT) to treat cancers that cannot be completely removed by surgery but have not yet spread to distant
sites within the body. RT has been a mainstay for the treatment of cancer malignancies for more than half a century. The combination
treatment of radiation therapy and chemotherapy has involved the use of cytotoxic drugs, targeted biologic agents and targeted external
beam radiation to increase the destruction of tumor cells and cure or delay cancer progression. The low number of drugs and biologic
agents under investigation as radiation sensitizing agents highlights an unmet need for new approaches and agents that provide greater
effectiveness, increased quality and better tolerability for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
&#8220;chemo-radiation&#8221; treatments are established in cancers of the head and neck, esophagus, lung, stomach, breast, brain, pancreas,
rectum and uterine cervix. The ideal radiation sensitizer would reach the tumor in adequate concentrations and act selectively in the
tumor, as compared to surrounding normal tissues. It would have predictable pharmacokinetics for timing with radiation therapy and could
be administered with every radiation treatment approach. The ideal radiation sensitizer would have minimal toxicity or manageable enhancement
of radiation toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. market for radiation sensitizing agents is experiencing dynamic growth through development of new radiation technology, the introduction
of new agents, growth in the number of diagnosed patients in a variety of cancers and changes in treatment patterns. New agents have
been introduced, including bevacizumab (Avastin&#174;, Roche), panitumumab (Vectibix&#174;, Amgen), temozolomide (Temodar&#174;, Merck)
and cetuximab (Erbitux&#174;, Eli Lilly/Imclone), with potential as radiation sensitizing agents (though all but cetuximab are used off
label); and all are recommended by the NCCN&#174; (National Comprehensive Cancer Network) in clinical practice guidelines for use in combination
with established therapies such as FOLFOX (leucovorin, 5-FU, oxaliplatin), CapeOX (capecitabine, oxaliplatin) and FOLFIRI (leucovorin,
5-FU, irinotecan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growth in the number of patients with cancers is being driven by an aging population and improved diagnostic tools. According to the
National Cancer Institute (NCI), more than half (~50 - 60%) of all cancer patients undergo some type of radiotherapy during the course
of their treatment. Confirming the patient estimate from the NCI, the American Society for Therapeutic Radiology and Oncology (ASTRO)
factsheet states approximately 67% of approximately 1.25 million cancer patients are treated with radiation therapy annually, either
one or more times. In addition, in a study published by the Journal of Clinical Oncology in 2016, it is estimated that the number of
cancer patients needing radiation therapy will increase by 22% in the next 10 years. (<i>See &#8220;The Future of Radiation Oncology
in the United States From 2010 to 2020: Will Supply Keep Pace With Demand?&#8221; Benjamin D. Smith, Bruce G. Haffty, Lynn D. Wilson,
Grace L. Smith, Akshar N. Patel, and Thomas A. Buchholz Journal of Clinical Oncology 2010 28:35, 5160-5165).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Society of Clinical Oncology (ASCO) estimates more than 80% of cancers in the U.S. occur in people in the age group of 50 and
above with over 60% of cancers occurring in those 65 and over. (<i>See</i>, 2018 Clinical Cancer Advances Report, American College of
Clinical Oncology, 2018). For example, according to the American Cancer Society (ACS), more than 90% of colorectal cancer patients are
individuals aged 50 years and older, with approximately 40% of all cases occurring in patients aged 75 years and over. The Colon Cancer
Alliance estimates that 90% of new cases and 95% of deaths from colorectal cancers occur in people aged 50 or older. Also, the U.S. Census
estimates that the age group of 65-84 will grow by 23% within the next five years, indicating a likely increase in the overall number
of cancer patients in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below details the number of cancers estimated in the United States in 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
New Cancer Cases in the U.S.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Male</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Female</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%">Prostate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">299,010</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 23%">Breast</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">310,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lung &amp; bronchus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Lung &amp; bronchus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Colon &amp; rectum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Colon &amp; rectum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Urinary bladder</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Uterine corpus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Melanoma of the skin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Melanoma of the skin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kidney &amp; renal pelvis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Thyroid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-Hodgkin lymphoma</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Non-Hodgkin lymphoma</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Oral cavity &amp; pharynx</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,510</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">Kidney &amp; renal pelvis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Leukemia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Pancreas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Pancreas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Leukemia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All sites</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">983,160</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">All sites</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">934,870</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACS
Facts &amp; Figures, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. estimated incidence, deaths and five-year survival rate of cancer patients responsive to radiation therapy is significant (ACS Facts
&amp; Figures, 2024). The top cancers responsive to radiation are shown, based on the number of newly diagnosed patients. The incidence
rates for some cancers are increasing by approximately 1-2% per year in the U.S. The number of newly diagnosed patients is significant
and growing due to the aging of the population and improved diagnostic techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cancers listed above illustrate the opportunity presented for radiation sensitizers. Of note is the low five-year survival of pancreas,
brain, lung and esophagus cancers&#8212;all are candidates for Shuttle Pharma&#8217;s pipeline of radiation sensitizing compounds. Cancers
with low survival rates are of interest since they show a high unmet need for new therapeutics and an opportunity for Shuttle Pharma
to gain significant uptake of their pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that present challenges and may restrict growth in the radiation sensitizer market include the safety and tolerability of many of the
newer agents with radiation sensitizing properties; a regulatory environment that engenders greater levels of scrutiny of clinical practice
issues; the high cost of newer agents; and the changing (and more restrictive) reimbursement environment in radiation oncology through
CMS (Center for Medicare and Medicaid Services) and private payors. These factors may negatively impact the potential for growth in the
U.S. market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the drugs used &#8220;off-label&#8221; as radiation sensitizers currently require close scrutiny of their potential for side effects
that can affect the safety and tolerability of their use with patients. All of the current agents carry significant potential for side
effects that can affect patients&#8217; therapies and quality of life. Radiation sensitizing agents can cause both acute and chronic
side effects in patients. Side effects can vary from person to person depending on age, sex, type of cancer, dose given per day, total
dose given, and the patient&#8217;s general medical condition. Some common side effects of currently used radiation sensitizers include
leukopenia, skin damage, hair loss, fatigue, bladder problems, nausea, fibrosis, memory loss, infertility, and enhanced risk of developing
a second cancer, which may arise as a result of the patient&#8217;s weakened immune system due to cytotoxic drugs used in treatment or
when newer biologic agents cause the over-production of specific cytokines or proteins, which can lead to developing secondary cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past five years, the FDA has taken an increasingly conservative approach to the approval of new agents for oncology treatment. There
is greater scrutiny of results from clinical trials regarding progression free survival, overall survival, and safety and tolerability
of new agents. Restrictions such as black box warnings and REMS (Risk Evaluation and Migration Strategies) are being applied to more
new products over the past five years compared to the previous five years. These restrictions require physicians to be more careful in
evaluating the use of newer agents and newer diagnostic tools to select the most appropriate patients for newer approved agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the new agents are molecularly targeted therapies that are biologic in their development and manufacturing. The cost of the newer
agents can be significant. For example, the cost for Avastin for one treatment course as a radiation sensitizer is estimated at $9,000-12,000
according to one Key Opinion Leader in the U.S. (Carl Schmidt, Consultant, Shuttle Pharmaceuticals Holdings, Inc., Business Plan 2018).
Recently, a CAR-T gene therapy from Novartis was launched with a yearly cost of $475,000. Further, as many private payors scrutinize
the cost and appropriate use of newer drugs, they require physicians to provide justification through prior authorization requests, use
of step therapy and guidelines that delay treatment, increase administrative costs and limit the therapeutic choices for physicians and
hospitals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
payors for radiation oncology therapies such as CMS have instituted reimbursement reductions that potentially affect the overall cost
of therapy and can limit the acceptance of newer agents. With CMS announced reductions in reimbursement for radiation oncology, there
is increased pressure to find a more potent radiation sensitizer agent with reduced side effects, and greater cost-effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escalating
healthcare spending is adding pressure on government and commercial payors to contain drug costs. While the oncology space is arguably
not as tightly managed by payors as other therapeutic areas, utilization management of costly cancer therapeutics has become an increasing
priority for U.S. payors, especially with the advent of biologics. Payors (and market access agencies in the EU) will most often restrict
high-cost drugs, drugs with limited or no survival benefits, and drugs deemed to be at high risk for widespread off-label use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
efforts at cost containment by insurers (which often require patients to first be prescribed lower cost drugs to determine effectiveness
prior to allowing for reimbursements for more expensive (or less cost effective) drugs), payors are also looking toward implementing
clinical pathways as a way to maintain or improve health outcomes while lowering costs. Clinical pathways are designed to address the
limitations of prior authorization and of reduced fee schedules, offering more durable cost containment to payors. These pathways may
lead to cost savings by encouraging the use of generics, streamlining treatment choices, and reducing side effects while maintaining
outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Engineered
Radiation Sensitizers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for radiation sensitizers in selected cancer types is defined by the need to improve local-regional tumor control. Treatment regimens
have been developed to address patient needs for tumor control and quality of life. Since the initial applications of Ropidoxuridine
and selective HDAC inhibitors are as adjuncts to the standard of care for the treatment of radiation responsive cancers, the unmet needs
of the market lie in the potential for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in efficacy of radiation treatments as determined by overall survival, progression free survival and response rates in comparison
    to currently used &#8220;off-label&#8221; sensitizer drugs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    in radiation doses needed to affect a positive clinical response for the patient.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    in the surgical extent that is needed to remove residual cancer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in quality-of-life outcomes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
sources have estimated that more than 800,000 patients in the U.S. are treated with radiation therapy for their cancers. According to
the American Cancer Society, about 50% are treated for curative purposes and the balance for palliative care. The market opportunity
for radiation sensitizers lies with the 400,000 patients treated for curative purposes. The number of patients being treated with RT
is expected to grow by more than 22% over the next five years. Based on a rough estimate of a course of radiation sensitizing brand drug
therapy (off label at this time) of $12,000 per patient&#8212;the market size would exceed $4.0 billion. This would represent about 4%
of the annual cost of cancer care in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past two decades, developments in the field of oncology have resulted in an increase in the number of clinical trials of marketed
products that exhibit radiation sensitizing properties. The following are a few examples of recently approved products that exhibit radiation
sensitizing properties: topotecan (Hycamtin&#174;) was approved for ovarian and small-cell lung cancer and also in cervical cancer when
used in combination with cisplatin. Irinotecan (Camptosar&#174;) is used for metastatic colorectal carcinoma, trastuzumab (Hercepetin&#174;)
for breast cancer, and gefitinib (Iressa&#174;) for locally advanced non-small-cell lung cancer. However, the claims on radiation sensitization
are anecdotal in the scientific literature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, clinical trials are in progress to develop novel molecules (such as poly (ADP-ribose) polymerase (PARP) inhibitors (such as
Lynparza (olaparib)), histone deacetylase (HDAC) inhibitors (such Zolinza&#174; (vorinostat) and heat-shock protein 90 (hsp90) inhibitors
with potential to increase the therapeutic use of compounds with radiation sensitizing properties for other cancers. Several drugs with
radiation sensitizing properties are currently in Phase III clinical trials, such as nimorazole (for head and neck cancer), motexafin
gadolinium (for brain metastases), and cisplatin (for cervical cancer); though none are likely to apply for a radiosensitizing claim
with the FDA since the radiosensitizing element in their clinical trials are not primary endpoints. While additional drugs with radiation
sensitizing properties are expected to be launched in the future, thereby driving the radiation sensitizers market further, to date,
there is no indication that any drug in development is expected to be approved specifically as a radiation sensitizer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive environment for &#8220;off-label&#8221; radiation sensitizers for solid tumor cancers is anticipated to become predominantly
generic. Avastin, Erbitux, Camptosar and Xeloda have or will lose patent protection in the next three years. Newer products under investigation
or approved, such as Vectibix&#174; (panitumumab) from Amgen will be promoted as having radiation sensitizing properties, along with indications
for treatment for specific cancers. The high cost of these new therapies coupled with limited efficacy compared to current standard of
care will be constrained by both public and private payors. Other new agents are in development but will face similar challenges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that new products launching into the cancer market with anecdotal claims for use as radiation sensitizers with improved effectiveness,
quality and tolerability will initially be limited in their growth until they have been added to established clinical pathways and guidelines.
If their effectiveness, quality and tolerability are demonstrated clinically, as determined by the FDA, it is anticipated the National
Comprehensive Cancer Network (NCCN), the leading authority in oncology drug evaluation for treatment guidelines, would issue a recommendation
and addition to standard of care within approximately six to twelve months after launch. An NCCN recommendation would positively impact
the growth potential for a new product entering the market. Also, payors, both public and private, would add the new product to their
approved drug lists and provide reimbursement giving providers incentive to use the product as neoadjuvant and adjuvant therapy to standard
of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with many cancer therapies, side effects can often have a distinct impact on quality of life and influence the potential for market growth.
Patients increasingly have a stronger voice in the decision-making process for the appropriate therapies and costs to treat their cancers.
As payors are increasingly placing more of the financial burden of the cost of therapy directly on patients, patients are voicing their
opinions to their physicians and payors which have a direct effect on which products are selected. Many of the current therapies have
significant side effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
insurers are expected to have more restrictive formularies and medical benefits in which patients will be expected to carry more of the
burden of the cost of drugs. Also, it is anticipated that increased application of third party developed treatment guidelines, such as
those from the NCCN (National Comprehensive Cancer Network), are expected to be used by private payors to limit the access to products
for specific conditions through prior authorizations and implementation of step therapy or increased out of pocket cost approaches. As
many of the current drugs used as radiation sensitizers are expensive and not approved for use as radiation sensitizers (thus, such treatment
is &#8220;off label&#8221;), and as many of the products in clinical trials are expected to be at the current or higher price levels,
new products that may be specifically approved for an indication as the only approved product as a radiation sensitizer will have increased
consideration for reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMS
is increasingly moving many patients to private insurance through Medicare Advantage and ACOs. Medicare Advantage plans are capitation
HMO and PPO plans offered through private insurers to Medicare patients. ACOs are being developed to increase quality of care for their
patients. Most of the new ACOs are initially positioned for Medicare patients with over 400 approved by CMS. Several studies from the
Center for Health Strategies, 2017, Journal of American Medical Association, 2018 and the Brookings Institute, 2015 estimated that almost
1000 ACOs for Medicare and non-Medicare patient populations would be approved by CMS or developed by a variety of healthcare entities
to begin operating under the ACA in 2017. We expect the growth in ACOs to continue, regardless of any changes that may be made to the
ACA going forward. In early 2017, Health Affairs, a magazine tracking ACOs, estimated that over 22 million patients are enrolled in Medicare
and private ACOs. To address the quality of care measures designated by CMS and to gain additional incentives, use of clinical pathways
or treatment guidelines is anticipated to be increasingly instituted to manage patient care. The impact on the uptake of new products
in this environment can be profound if the new product is first in class and is included in national guidelines from organizations such
as the NCCN and/or approval by the regional CMS contracting groups.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ROPIDOXURIDINE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
halogenated thymidine (TdR) analogs, bromodeoxyuridine (BUdR) and iododeoxyuridine (IUdR), are a class of pyrimidine analogs that have
been recognized as potent radiosensitizing agents since the early 1960s. (<i>See</i> Kinsella TJ. An Approach to the Radiosensitization
of Human Tumors. <i>Cancer J Sci Am.</i> Jul-Aug 1996:2(4); 184-193). Their cellular uptake and metabolism are dependent on the TdR salvage
pathway where they are initially phosphorylated to the monophosphate derivative by the rate-limiting enzyme, thymidine kinase (TK). (<i>See
</i>Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. <i>J Clin Oncol, </i>Sep 10 2007; 25(26):4043-4050). After sequential phosphorylation
to triphosphates, they are then used in DNA replication, in competition with deoxythymidine triphosphate (dTTP), by DNA polymerase. DNA
incorporation is a prerequisite for radiosensitization of human tumors by the halogenated TdR analogs, and the extent of radiosensitization
correlates directly with the percentage TdR replacement in DNA. (<i>See </i>Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD.
The Dependence of Halogenated Pyrimidine Incorporation and Radiosensitization on the Duration of Drug Exposure. <i>International Journal
of radiation oncology, biology, physics.</i> Jun 1990; 18(6);1393-1398). The molecular mechanisms of radiosensitization are most likely
the result of increased susceptibility of TdR analog-substituted DNA to the generation of highly reactive uracil free radicals by ionizing
radiation (IR), which may also damage unsubstituted complementary-strand DNA. Repair of IR damage may also be reduced by pre-IR exposure
to these analogs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rationale for using Ropidoxuridine as a radiation sensitizer is based on prior clinical studies with the active metabolite IUdR; identified
in NIH laboratories as a potent radiation sensitizer. Ropidoxuridine is an orally available prodrug of IUdR. In the body, Ropidoxuridine
is metabolized in the liver into IUdR. IUdR is incorporated into the DNA of actively growing cells and when cells are exposed to ionizing
radiation, DNA strand breaks are generated, resulting in more cell death and radiation sensitization. (<i>See</i> Gurkan E, Schupp JE,
Aziz MA, Kinsella TJ, Loparo KA. Probabilistic modeling of DNA mismatch repair effects on cell cycle dynamics and iododeoxyuridine-DNA
incorporation. Cancer Res. Nov 15 2007; 67(22):10993-11000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of the clinical efficacy data were obtained from NIH supported studies performed with IUdR, the active metabolite of Ropidoxuridine.
However, IUdR requires constant infusion over six weeks of therapy which creates a significant compliance issue for patients. Ropidoxuridine
can be given as a capsule for oral administration, resulting in greater ease of medication delivery and potentially improved compliance
and fewer complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last 20 years, there has been renewed interest in these halogenated TdR analogs as experimental radiation sensitizers in selected
cancer patient groups. These analogs are rapidly metabolized in both rodents and humans, principally with cleavage of deoxyribose and
subsequent dehalogenation by hepatic and extrahepatic metabolism, when given as a bolus infusion with a plasma half-life of &lt;5 min.
Consequently, prolonged continuous or repeated intermittent drug infusions over several weeks before and during irradiation are necessary,
based on in vivo human tumor kinetics, to maximize the proportion of tumor cells that incorporate these analogs into DNA during the S
phase of the cell cycle. (<i>See</i> Fowler JF, Kinsella TJ. The Limiting Radiosensitization of Tumors by S-phase Sensitizers. <i>Br
J Cancer</i>. 1996;74 (Suppl)(27):294-296). Phase I and Phase II trials using prolonged continuous or repeated intermittent intravenous
infusions of BUdR or IUdR before and during radiation therapy (RT) have focused principally on patients with high-grade brain tumors.
These clinically radiation resistant tumors can have a rapid proliferation rate (potential tumor doubling times of 5&#8211;15 days) and
are surrounded by non-proliferating normal brain tissues that show little to no DNA incorporation of the TdR analogs. As such, high-grade
brain tumors are ideal targets for this approach to radiation sensitization. In Phase I/Phase II clinical trials, prolonged survival
outcomes were observed compared to RT alone in patients with anaplastic astrocytomas and in patients with glioblastoma multiforme IUdR
continuous IV infusion (1000 mg/m<sup>2</sup>/ day/ 14 days), Total 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys. 1994;
30(3):583-90.) A therapeutic gain in clinical radiation sensitization using these halogenated TdR analogs was proposed for other types
of poorly responsive (radiation resistant) cancers, including locally advanced cervical cancer, head and neck cancers, unresectable hepatic
metastases from colorectal cancers, and locally advanced sarcomas, based on the results of other Phase I/Phase II clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Target
Indication: Glioblastoma, Sarcomas and Rectal Cancers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the Phase I clinical trial of Ropidoxuridine and RT in advanced GI cancers, we proposed to perform Phase II efficacy clinical
trials in brain tumors (glioblastoma), soft tissue sarcomas, and rectal cancers. Glioblastoma multiforme is a deadly malignancy of the
brain with no known cure. Radiation therapy provides delay of disease progression and is standard of care following surgical resection
or biopsy. Radiation therapy is combined with Temodar, a drug that has shown activity (~ four months survival benefit) in treating brain
tumors. Preliminary data using radiation therapy in combination with IUdR resulted in a delay of disease progression of up to six months.
We propose to test IPdR in combination with radiation therapy in the Phase II clinical trial. Similarly, delay in disease progression
has been observed following treatment of sarcomas by the combination of IUdR and RT. Based on the Phase I data of our clinical trial
we know that therapeutic levels of IUdR are reached by administering the orally available prodrug, IPdR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase I results of the clinical trial supported by an SBIR contract to Shuttle Pharma and a sub-contract to the Brown University Oncology
Group (BrUOG) at the LifeSpan/Rhode Island Hospital were reported by the subcontractor at the 30th EORTC-NCI-AACR Symposium in November
2018 and in the medical journal, Clinical Cancer Research, in 2019. Eighteen patients completed dose escalation to 1800 mg/day for 30
days, establishing the maximum tolerated dose (MTD) of 1,200 mg/day in combination with RT. Therapeutic blood levels of IUdR were achieved.
Four patients were scored as partial responses, nine patients had stable disease and one patient progressed in the target lesions. These
data support advancing IPdR and RT to clinical trials for the FDA to determine efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key to driving the Ropidoxuridine product forward is the development of a clinical plan with aggressive timelines and support within
the radiation oncology community to participate in clinical trials with the appropriate patients to ensure a comprehensive NDA dossier
for each product. Initially, the plan is focused on the Phase I and Phase II clinical trials. Upon completion of Phase II studies, we
will determine whether to extend the Phase II study to a randomized Phase II, or to perform a randomized Phase III clinical trial. Such
determination will be based on results of the initial clinical trials and the end of a Phase II meeting with the FDA. Shuttle Pharmaceuticals
requested and received FDA orphan drug status for Ropidoxuridine as a clinical radiation sensitizer for treatment of glioblastoma and
pre-operative treatment of soft tissue sarcomas. As a result, the application for &#8220;orphan&#8221; designation for Ropidoxuridine
with RT for glioblastoma has been approved. The application for sarcomas, however, was not approved and will require addressing certain
FDA comments and resubmission. The IPdR/TPI formulation clinical plan will focus on resectable stage II and III rectal cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical plan for Ropidoxuridine development as implemented to date, includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMP
    manufacture and formulation of 24 kg of Ropidoxuridine for use in clinical trials has been completed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IND for a Phase II clinical trial of Ropidoxuridine and RT in glioblastoma has been approved for the study to proceed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contract research organizations (CRO), Theradex Oncology has been engaged to assist in the performance the Phase II clinical trial.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of the Phase II clinical trial in glioblastomas to determine appropriate dosing, effectiveness and tolerability of the treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
data obtained from the NIH/NCI SBIR funded Phase I clinical trial supported efforts to raise capital to enable performing the Phase II
clinical trials of Ropidoxuridine. We aim to conduct and complete the Phase II clinical trial so that we may present data to the FDA
for its determination of efficacy. We believe this will support our efforts to raise the additional required capital to complete Phase
II and to fund the Phase III clinical trials and seek FDA approval of an NDA with &#8220;orphan&#8221; designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical plan for the IPdR/TPI formulation will focus on resectable Stage II and Stage III rectal cancer patients and on recurrent glioblastoma
treated with proton therapy. Nonetheless, we cannot guarantee the successful completion of any of these trials. Our inability to meet
any of the aforementioned milestones in the Phase II or Phase III clinical trials will cause us to be unable to proceed with our present
efforts and will likely cause us to be unable to raise additional funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
HDAC Small Molecule Delivery Platform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the founding of Shuttle Pharma, our discovery research and development efforts have been focused on our small molecule technology delivery
platform which uses HDAC inhibitors, designed to target cancer cells, while protecting healthy tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HDACs
are a class of enzymes that regulate gene expression through chemical modification of histones and non-histone proteins. Increased HDAC
activity leads to a more condensed chromatin (which is a protein complex consisting of DNA and other proteins), decreased gene expression
and loss of key gene products, including tumor suppressor gene function. Inhibition of HDAC activity leads to a more open chromatin and
increased expression of the key gene products. This chromatin modification underlies the epigenetic cellular regulatory system and is
an area of intense investigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development efforts to date have focused on the discovery of novel, dual functional molecules for potential use in cancer
treatment as radiation sensitizers of cancers, protectors of normal tissues, and activators of the immune responses to antigens expressed
by irradiated cancer cells. To date, we have produced three candidate molecules:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161,
    a candidate lead of compounds demonstrating activation of the &#8220;ATM&#8221; gene product (mutated in Ataxia-Telangiectasia).
    Ataxia-Telangiectasia is a human genetic disease characterized by neurological, immunological and radiobiological clinical features.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225,
    a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. HDAC6 is a molecule integral to the presentation
    of antigens by macrophages to T-lymphocytes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-161
</span>- A Dual Functional Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
is an HDAC inhibitor of the hydroxamate chemical class of compounds and an ATM activator of the indole chemical class. HDACs modify histones
and non-histone proteins, which are key components of the chromatin structure, gene expression regulation, and cell growth. HDAC inhibitors
inhibit cell proliferation, angiogenesis and immunity. Eighteen human HDACs have been identified, subdivided into four classes based
on sequence and functional homology. In cancer cells, HDAC activity silences tumor suppressor genes important for cell growth regulation
and to chromosomal instability. Abnormal HDAC activity is also associated with tumor cell growth, invasion, metastasis and resistance
to therapy. Therefore, inhibitors of HDACs have emerged as anti-cancer agents for cancer therapy. Vorinostat and romidepsin have been
approved by the FDA for treatment of patients with relapsed or refractory T-cell lymphomas. In addition, panobinostat received FDA approval
for treatment of recurrent multiple myeloma in combination with bortezomib and dexamethasone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, SP-1-161 inhibited the activity of pan-HDACs and activated the ATM gene product. ATM is a critical protein for the
activation of the cell stress response for cellular recovery from radiation exposure in normal cells, but not in cancer cells. ATM activates
the P53 protein, referred to as the &#8220;guardian of the genome,&#8221; and serves as a tumor suppressor critical for normal cell function
and activation of programmed cell death in cancer cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, SP-1-161 protected normal breast epithelial cells (184A1) following exposure to ionizing radiation while increasing
sensitivity of breast cancer cells (MCF7). SP-1-161 provides this dual function in a single molecule and this molecule is differentiated
from other HDAC inhibitors by treatment of cancers while protecting normal cells. (<i>See</i> Grindrod S, Brown M, Jung M. &#8220;Development
of dual Function Small Molecules as Therapeutic Agents for Cancer Research,&#8221; Poster presentation #A178, American Association of
Cancer Research Oct 2017).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-2-225</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
is a selective HDAC inhibitor that affects histone deacetylase (HDAC6) and is a member of the class IIb HDAC family. Class II HDACs play
important roles in cancer motility, invasion, neurological diseases, and immune checkpoint. HDAC6 inhibition has been most extensively
studied for its role in the treatment of hematological cancers. HDAC6 is unique among HDAC enzymes in having two active catalytic domains
and a unique physiological function. In addition to the modification of histones, HDAC6 targets specific substrates including &#945;-tubulin
and HSP90, and are involved in protein trafficking and degradation, cell shape and migration. Selective HDAC6 inhibitors are an emerging
class of pharmaceuticals due to the involvement of HDAC6 in pathways related to neurodegenerative diseases, cancer and immunology. Specifically,
its potential to affect regulation of the immune system and enhance the immune response in cancer is of great interest. With the introduction
of check-point inhibitors, CAR-T therapies and personalized medicine in cancer, regulation of the immune response to this therapy is
of significant clinical and commercial interest. (See Noonepalle SKR, Grindrod S, Aghdam N, Li X, Gracia-Hernandez M, Zevallos-Delgado
C, Jung M, Villagra A, Dritschilo A. Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition. Mol Cancer Ther. 2023
Dec 1;22(12):1376-1389. doi: 10.1158/1535-7163.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
inhibition of HCAC6 reduces dose limiting side effects associated with non-selective HDAC inhibitors. Selective HDAC6 inhibitors may
be combined with other cytotoxic agents. Shuttle&#8217;s discovery of selective HDAC inhibitors has yielded several HDAC6 selective candidate
molecules including SP-2-225. HDAC6 inhibitors are under investigation for roles in the treatment of diseases such as multiple myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-303
</span>- Target Indication: Breast Cancer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Histone
deacetylase inhibitors sensitize cancers to the effects of radiation, protect normal tissues from radiation injury and activate the immune
system. SP-1-303 is a selective Class I HDAC inhibitor that inhibits HDAC1, 3 and 6 and has direct cellular toxicity in ER positive breast
cancer cells. Furthermore, SP-1-303 increases the PD-L1 expression level in a time-dependent manner, support combination of SP-1-303
with an immune checkpoint blocker to enhance the therapeutic benefits. We are currently conducting preclinical efficacy studies of these
molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HDAC inhibitor platform of candidate molecules will require pre-clinical evaluation, completion of IND-enabling studies and the lead
drug candidates will be tested in Phase I clinical trials for pharmacokinetics and MTD determination. We have three lead candidates for
potential development for the treatment of solid tumors, including breast cancer, lung cancer and multiple myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of Phase I and Phase II clinical trials will determine further drug development and Shuttle will seek to establish collaborative
partnerships with other pharmaceutical companies to complete pre-clinical and clinical development, drug manufacturing and marketing
of our product candidates. In the event we are unsuccessful in completing our clinical trials at any stage, or in the event we obtain
negative results, we will likely be unable to raise additional funding related to our HDAC studies or will have to change direction of
our research efforts regarding the HDAC inhibitor platform of candidate molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Manufacturing Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no manufacturing facilities that are owned or operated by us. We have performed laboratory scale synthesis and testing in our research
laboratories in Gaithersburg, Maryland. GMP synthesis of API, drug formulation and human dosage preparation will be performed under contracts
with third-party manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed important strategic agreements with academic institutions for access to resources such as intellectual property, core
facilities and contracting relationships. In addition, we have established an agreement with Propagenix for intellectual property in-licensing.
Our current and ongoing relationships include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Georgetown
    University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    for the SBIR supported African American prostate cancer patient health disparities project (completed). The conditional reprogramming
    of cells (CRC) technology was invented at Georgetown University and Georgetown University owns the intellectual property. Propagenix
    holds the license for the intellectual property for the CRC technology from Georgetown University. The intellectual property for
    cells derived from African American patients under the Georgetown University subcontract belong to Shuttle Pharmaceuticals, Inc.
    based on our sub-licensing agreement with Propagenix.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    for the SBIR supported metabolomic predictive biomarker project (completed). The metabolomic biomarker intellectual property belongs
    to Georgetown University and Shuttle Pharma holds an exclusive option to license the intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    licensing agreement with Georgetown University pursuant to which Georgetown University agreed to license the intellectual property
    known as &#8220;Predictive Biomarkers for Adverse Effects of Radiation Therapy&#8221; (U.S. Patent Application No. 17/476,184, filed
    on September 15, 2021) (the &#8220;Patent Rights&#8221;), which was developed by Dr. Anatoly Dritschilo, the Company&#8217;s Chief
    Executive Officer, Dr. Scott Grindrod, the Company&#8217;s Principal Scientist, and Drs. Amrita Cheema and Yaoxiang Li, employees
    of Georgetown. The Patent Rights will be available for the Company&#8217;s use worldwide.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
    Pharma entered into a research agreement (the &#8220;Research Agreement&#8221;) with Georgetown University for testing small molecule
    radiation sensitizers and immune activation candidates discovered and developed by Shuttle Pharma in cell-based and animal xenograft
    models.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    conjunction with the Research Agreement, Shuttle Pharma also entered into a material transfer agreement (the &#8220;MTA&#8221;),
    dated March 21, 2023, with Georgetown University. Under the MTA, Shuttle Pharma agreed to transfer research quantities of candidate
    drug molecules to Georgetown University, which materials will be used by Georgetown University solely to carry out additional research
    for Shuttle Pharma and which materials shall at all times remain the property of Shuttle Pharma.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brown
    University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    of the SBIR supported Phase I clinical trial of IPdR and RT (completed).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">University
    of Virginia</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    collaboration to develop heavy oxygen molecules for proton radiation sensitizer applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Washington University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    transfer agreement for testing HDAC inhibitor effects in immune model systems</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    material transfer agreement that protects our HDAC inhibitor intellectual property is with George Washington University, transferring
    drugs for research purposes and sharing authorship on publications. There is no transfer of funds related to such activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propagenix,
    Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    agreement for &#8220;conditional re-programmed cell&#8221; (CRC) technology. The cells established by Shuttle Pharma scientists at
    Georgetown University belong to us, based on the sublicense from Propagenix, Inc. An up-front licensing fee of $25,000 was paid to
    Propagenix. No other future milestone or royalty payments owed related to the Propagenix agreement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition
&#8220;Off-Label&#8221; Use</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img src="forms-1_008.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
with radiation sensitizing properties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are advancing a clinical stage product candidate, Ropidoxuridine, that we believe will target cancer cells while protecting healthy tissue
when used in conjunction with RT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ropidoxuridine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine,
an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties, is our lead &#8220;clinical phase&#8221;
product candidate. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and become more sensitive to the
effects of RT. We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University
at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In
connection with the trial, NCI approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode
Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine to Phase II clinical
trials of brain tumors, sarcomas and other tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provide data from reported clinical trials of Iododeoxyuridine and RT therapy in brain cancers (glioblastoma multiforme)
and high-grade sarcomas. Our primary strategy for Ropidoxuridine and RT therapy is to provide oral drug delivery to effect radiation
sensitization of cancers and validate effectiveness in glioblastoma and sarcoma, potential &#8220;Orphan&#8221; indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brain
Cancer Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Efficacy
compared to historical RT-alone controls for treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
high-grade primary brain tumors (RTOG*, NCI** trials)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_009.jpg" alt="" style="width: 750px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR
    continuous IV infusion (1000 mg/m2/ day/ 14 days), Total of 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys. 1994;
    30(3):583-90)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR
    continuous IV infusion (2000 mg/m2/ 4 day infusion/ 6 week treatment), Total of 21 patients (R. Urtasun, et al. Int J Radiat Oncol
    Biol Phys. 1996;36(5):1163-7.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sarcoma
Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Efficacy
compared to historical RT-alone controls for treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
high-grade sarcomas (University of Michigan*** trials)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_010.jpg" alt="" style="width: 750px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16
    patients were treated with continuous infusion (1000-1600 mg/m2/day) plus RT (J.M. Robertson, et al. Int J Radiat Oncol Biol Phys.
    1995; 31(1):87-92).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our primary product candidate, we are developing and planning to develop other cancer radiation sensitizers and radiation
protectors, which target protecting normal tissue during the administration of RT, and other products utilizing our HDAC small molecule
technology platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SBIR
Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
SBIR Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Small Business Innovation Research program, as developed by Congress under the Small Business Innovation Development Act of 1982, is
designed to encourage domestic small businesses to engage in Federal Research/Research and Development (&#8220;R/R&amp;D&#8221;) that
has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their technological
potential and provides the incentive to profit from its commercialization. Some of the SBIR&#8217;s program goals include stimulating
technological innovation, meeting Federal research and development needs and encouraging participation in innovation and entrepreneurship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SBIR program is a three-phase program. Phase 1 is to establish the technical merit and commercial potential of the proposed R/R&amp;D
efforts. Phase 2 is to continue the R/R&amp;D efforts initiated in Phase 1 and funding is based on the results achieved in Phase 1. Phase
3 allows for the small business to pursue commercialization objectives resulting from the Phase 1 and 2 R/R&amp;D activities. In addition,
companies that have successfully completed Phases I and II are also eligible to apply for Phase IIb funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the SBIR contract to fund our Phase I clinical study on Ropidoxuridine in combination with RT for treatment of advanced gastrointestinal
cancers, we have also received awards of SBIR contracts from the NIH to address prostate cancer health disparities and prostate cancer
radiation biomarker development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this registration statement, all SBIR contracts received by the Company have been completed. The Company submitted a final
report for SBIR contract # 75N81018C00031 on March 28, 2022. The following summary of terms for the three Phase II SBIR contracts is
provided below.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Summary
of SBIR Contracts</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contract #261201400013C: Phase I ($191,971) and Phase II ($1,428,117) for Clinical Development of IPdR for Radiosensitization, dates
    September 19, 2014 through August 3, 2017. Subcontract to Brown University/LifeSpan Rhode Island Hospital. No related intellectual
    property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contracts # HHSN261201600038C; Phase I ($224,687) and #261201800016C: Cell-Based Models for Prostate Cancer Health Disparity Research
    - Moonshot Project (Phase II), award amount $1,484,350, dates September 19, 2016 through September 16, 2021. Subcontract to Georgetown
    University. Intellectual property consists of cell cultures and is property of Shuttle Pharmaceuticals, Inc. via licensing agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contracts #HHSN261201600027C ($299,502) and #75N81018C00031: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation
    Late Effects, award amount $1,903,095, dates September 16, 2019 through March 15, 2022. Subcontract to Georgetown University.
    Intellectual property is owned by subcontractor Georgetown University with option to license to Shuttle Pharmaceuticals, Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prostate
Cancer Studies to Address Health Disparities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
cancer health disparities studies have shown that African American men are at higher risk for developing prostate cancer, as well as
at higher risk of cancer specific death rates as compared to Caucasian American men. The causes of disparities have been attributed to
socioeconomic differences, environmental exposures and biological factors. Most disparities studies have been population based, in part,
due to the lack of relevant in vitro and in vivo models to support biological studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma has been awarded Phase I and II SBIR contracts entitled &#8220;Cell-based models for prostate cancer health disparity research&#8221;
to develop African American prostate cancer cell lines with donor matched normal prostate epithelial cell lines from African American
men.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercialization of the prostate cells will require additional support through the SBIR funding mechanism. Companies that have completed
Phase I and II SBIR awards are eligible to apply for Phase IIb SBIR funding. These awards are intended to de-risk a project by providing
up to $4 million of matching funding for product development to commercialization. We intend to apply for such government funding to
advance laboratory facilities and to expand the availability of the cell cultures. We did not raise capital through our IPO for the health
disparities project. Should we not be successful with SBIR IIb funding, we will pause and may have to terminate this project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prostate
Cancer Biomarker Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
treated for prostate cancer may experience treatment related late effects that adversely affect quality of life and may prove life-threatening.
Shuttle Pharma has been awarded a Phase I SBIR contract entitled &#8220;Predictive biomarkers for prostate cancer patient sensitivity
for radiation late effects&#8221; to determine the technical and commercial feasibility of a biomarker panel predictive of radiation
mediated late effects in patients treated for prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
collaboration with Georgetown University, patients treated with SBRT for prostate cancers were analyzed for urinary and rectal symptoms
and their blood was analyzed by mass spectroscopy for predictive biomarkers. The discovery and validation of metabolite panels to serve
as a predictive biomarker of patient outcomes following radiation therapy and supports future development and commercialization of a
diagnostic product through a Phase 2 SBIR effort.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development to commercialization of the metabolite predictive biomarker panel requires additional support through the SBIR funding mechanism.
We will be eligible to apply for Phase IIb SBIR funding the next round of solicitation. A Phase IIb will help de-risk the project by
providing up to $4 million of matching funds for performing the clinical validation trial for product development to commercialization.
We intend to apply for such government funding to advance this project. We also intend to raise capital through the public market for
predictive biomarker development through the Shuttle Diagnostics entity. We do not intend to use the funds raised through our IPO for
the health disparities project. Should we not be successful for SBIR IIb funding, we will terminate this project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to enter into selective collaborative arrangements to further develop our drug candidates in the future, at present we have
not entered into any collaborative arrangements with third parties to develop our drug candidates as we are still completing clinical
trials and, as a result, there can be no assurance that we will be able to do so on commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
invest significant amounts of funds in research and development. Our research and development expenses before contract reimbursements
were $3,517,093 and $1,258,840 for the fiscal years ended December 31, 2023 and 2022 respectively. After reimbursements for contracts
of $0 and $211,455 for the fiscal years ended December 31, 2023 and 2022, net research and development expenses were $3,517,093 and $1,047,385,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking multifaceted protection for our intellectual property that includes licenses, confidentiality and non-disclosure agreements,
copyrights, patents, trademarks and common law rights, such as trade secrets. We enter into confidentiality and proprietary rights agreements
with our employees, consultants, collaborators, subcontractors and other third parties and generally control access to our documentation
and proprietary information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this registration statement, we have filed five patent applications with the USPTO with respect to various aspects of
our HDAC small molecule delivery platform and Ropidoxuridine, our lead product candidate. The following is the status of the patent applications
Shuttle has filed to date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Shuttle Pharma&#8217;s Intellectual Property Portfolio</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="forms-1_011.jpg" alt="" style="width: 750px"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan,
Lewis &amp; Bockius LLP prepared patent applications related to Ropidoxuridine (IPdR) and HDAC inhibitors, and, in the fourth quarter
of 2018, found no freedom to operate (FTO) issue for Ropidoxuridine used as radiosensitizer and used with tipiracil, and HDAC inhibitors
SP-1-161 and SP-2-225.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy around protection of our proprietary technology, including any innovations and improvements, is to obtain worldwide patent coverage
with a focus on jurisdictions that represent significant global pharmaceutical markets. Generally, patents have a term of twenty years
from the earliest priority date, assuming that all maintenance fees are paid, no portion of the patent has been terminally disclaimed
and the patent has not been invalidated. In certain jurisdictions, and in certain circumstances, patent terms can be extended or shortened.
We are obtaining worldwide patent protection for at least novel molecules, composition of matter, pharmaceutical formulations, methods
of use, including treatment of disease, methods of manufacture and other novel uses for the inventive molecules originating from our
research and development efforts. We continuously assess whether it is strategically more favorable to maintain confidentiality for the
&#8220;know-how&#8221; regarding a novel invention rather than pursue patent protection. For each patent application that is filed we
strategically tailor our claims in accordance with the existing patent landscape around a particular technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that an issued patent will remain valid and enforceable in a court of law through the entire patent term. Should
the validity of a patent be challenged, the legal process associated with defending the patent can be costly and time consuming. Issued
patents can be subject to oppositions, interferences and other third-party challenges that can result in the revocation of the patent
limit patent claims such that patent coverage lacks sufficient breadth to protect subject matter that is commercially relevant. Competitors
may be able to circumvent our patents. Development and commercialization of pharmaceutical products can be subject to substantial delays
and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short
period of time following commercialization. We cannot predict with any certainty if any third-party U.S. or foreign patent rights or
other proprietary rights will be deemed infringed by the use of our technology. Nor can we predict with certainty which, if any, of these
rights will or may be asserted against us by third parties. Should we need to defend ourselves and our partners against any such claims,
substantial costs may be incurred. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief,
which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad and could result
in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more
licenses from a third party. There can be no assurance that we can obtain a license on a reasonable basis should we deem it necessary
to obtain rights to an alternative technology that meets our needs. The failure to obtain a license may have a material adverse effect
on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully
protect our trade secrets on a continuing basis. Others may independently develop substantially equivalent confidential and proprietary
information or otherwise gain access to our trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who
receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships.
These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&#8217;s
relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances.
The agreements provide that all inventions conceived by an employee will be the property of our company. There can be no assurance, however,
that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use
or disclosure of such information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to obtain and maintain patent protection, preserve trade secrets, prevent third parties from
infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others, both in the U.S. and other
territories worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
and Supply</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any
of our product candidates. We currently use a number of our suppliers for the raw materials and formulation to meet the preclinical and
any clinical requirements of our product candidates. We do not have a long-term agreement with any of these parties and we believe alternative
sources of supply exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to enter into collaborations for the manufacture of our product candidates, with our collaborators assuming responsibility for
such manufacturing. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements,
which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Any
collaborator or third-party contract manufacturer we use would need to be compliant with cGMP. cGMP is a regulatory standard for the
production of pharmaceuticals that will be used in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current focus is on the development of our existing portfolio, the completion of clinical trials and, if and where appropriate, the registration
of our product candidates. We currently do not have marketing, sales and distribution capabilities. If we receive marketing and commercialization
approval for any of our product candidates, we intend to market the product either directly or through collaborations, strategic alliances
and distribution agreements with third parties. The ultimate implementation of our strategy for realizing the financial value of our
product candidates is dependent on the results of clinical trials for our product candidates, the availability of funds and the ability
to negotiate acceptable commercial terms with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this registration statement, we have nine full-time employees, including our six executive officers, and three engaged
in research and development. We consider our relationship with our employees to be good. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Deficiency and 2024 Reverse Stock Split</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet Nasdaq listing rules in order to
maintain such listing, including a requirement that the Company maintain stockholders&#8217; equity of at least $2.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet Nasdaq listing rules in order to
maintain such listing, including a requirement that the Company&#8217;s stockholders equity remain at or above $2.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2024, we received a letter from The Nasdaq notifying the Company that it is no longer in compliance with the minimum stockholders&#8217;
equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain
stockholders&#8217; equity of at least $2.5 million. In the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30,
2024, the Company reported stockholders&#8217; equity of $801,434, which is below the minimum stockholders&#8217; equity required for
continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). In addition, at present, the Company does not meet the alternatives of
market value of listed securities or net income from continuing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Nasdaq notice has no immediate effect on the listing of the Company&#8217;s securities on the Nasdaq Capital Market. Nasdaq has provided
the Company with 45 calendar days, or until October 25, 2024, to submit a plan to regain compliance with the minimum stockholders&#8217;
equity standard. If the Company&#8217;s plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days
from September 10, 2024 for the Company to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is presently evaluating various courses of action to regain compliance and intends to timely submit a compliance plan to Nasdaq.
However, there can be no assurance that the Company&#8217;s plan will be accepted or that, if it is, the Company will be able to regain
compliance and maintain its listing on the Nasdaq Capital Market. If the Company&#8217;s plan to regain compliance is not accepted or
if Nasdaq does not grant an extension and the Company does not regain compliance by October 25, 2024, or if the Company fails to satisfy
another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company&#8217;s securities will become subject
to delisting. In that event, the Company will have an opportunity to appeal Nasdaq&#8217;s decision to a hearings panel.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2023 we received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq (the &#8220;Staff&#8221;) stating
that for the 30 consecutive business day period the Company&#8217;s common stock had failed to maintain a minimum closing bid price
of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the
&#8220;Minimum Bid Price Requirement&#8221;). In accordance with Nasdaq rules, the Company was provided with an initial period of
180 calendar days, or until February 27, 2024, to regain compliance with the Minimum Bid Price Requirement (the &#8220;Initial Grace
Period&#8221;) and a second Grace Period on February 19, 2024 through August 26, 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to regain compliance with the Minimum Bid Price Requirement, on August 6, 2024, we filed an amendment to our certificate or incorporation
to effect a 1-for-8 reverse stock split of our outstanding common stock (the &#8220;2024 Reverse Stock Split&#8221;). The 2024 Reverse
Stock Split became effective on August 13, 2024, when the Company&#8217;s common stock opened for trading on Nasdaq on a post-split basis
under the Company&#8217;s existing trading symbol, &#8220;SHPH.&#8221; Subsequently, on August 27, 2024, we received notice from Nasdaq
that we regained compliance with the Minimum Bid Price Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
historical share and per share amounts reflected throughout this prospectus have been adjusted to reflect the 2024 Reverse Stock Split.
However, our periodic and current reports, and all other documents included in this prospectus that were filed prior
to August 13, 2024 do not give effect to the 2024 Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Uncertainty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
condensed consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and had
a net loss of approximately $3.8 million and no revenues for the six months ended June 30, 2024 and has working capital of approximately
$1.1 million as of June 30, 2024. In addition, the convertible note, which was paid in full as of September 30, 2024, includes
covenants and certain cash payment requirements. These conditions, and the Company&#8217;s ability to comply with such conditions, raise
substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed
consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company completed its initial public offering, or IPO, generating net proceeds of approximately $10.0 million. And
in January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $4.3 million, along with a four-year warrant to purchase 1,018,079 shares (127,260 shares
post Reverse Split) of common stock, exercisable at $1.93 per share (post Reverse Split, as adjusted), providing the Company
with approximately $3.6 million in net proceeds. To date, the warrant has not yet been exercised. In September 2024, the investor converted
$1.2 million of principal and interest outstanding on the note, leaving a balance remaining on the note of $14 thousand, including principal
and interest as of September 6, 2024, and collateral of $600 thousand of Company cash was released.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations leading up to the manufacture of drug product and FDA approval of the IND
for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the Company agreed to
an expansion of the clinical trial, necessitating additional capital to complete the trial as well as fund ongoing operations. The ability of the Company to continue as a going
concern is dependent upon its ability to successfully raise additional equity or debt financing, including through bridge financing,
to allow the Company to fund ongoing operations, conduct clinical trials and bring a drug candidate to commercialization to generate
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to obtain additional material financing in the near-term, our clinical trials and targeted FDA submission timeline could be delayed,
and we could be forced to abandon such activities entirely and cease operations, with the possible loss of such properties or assets.
If we are unable to obtain a material quantum of financing in the imminent future or unable to continue to obtain additional financing
over at least the next 12 months as we continue to generate negative cash flow, our board of directors could determine to cause the Company
to undertake a process of liquidation under Chapter 7 of applicable U.S. bankruptcy laws, or otherwise seek other protection under such
laws. In such event, we expect that holders of shares of our common stock would recoup little if any material value in such process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_003"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following Management&#8217;s Discussion and Analysis should be read in conjunction with our financial statements and the related notes
thereto included elsewhere in this registration statement. The discussion for the fiscal year ended December 31, 2023 has been impacted
by the restatement described in the Explanatory Note and in Note 2 of the consolidated financial statements of this registration statement.
Certain of the financial and other information provided in this Management&#8217;s Discussion and Analysis has been updated to reflect
the restatement adjustments.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Management&#8217;s Discussion and Analysis contains forward-looking statements that involve risks and uncertainties, such as statements
of our plans, objectives, expectations, and intentions. Any statements that are not statements of historical fact are forward-looking
statements. When used, the words &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; and the like, and/or future-tense or conditional constructions (&#8220;will,&#8221; &#8220;may,&#8221;
&#8220;could,&#8221; &#8220;should,&#8221; etc.), or similar expressions, identify certain of these forward-looking statements. These
forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements in this registration statement. Our actual results and the timing of events
could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not
limited to, those noted under &#8220;Risk Factors&#8221; in this registration statement.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this
registration statement, except as required by U.S. federal securities laws.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
by Georgetown University Medical School faculty members, Shuttle Pharmaceuticals Holdings, Inc. (the &#8220;Company&#8221;) is a discovery
and development stage pharmaceutical company leveraging our proprietary technology to develop novel therapies that are designed to cure
cancer. Originally formed as Shuttle Pharmaceuticals, LLC in 2012, our goal is to extend the benefits of cancer treatments by leveraging
insights into cancer therapy with surgery, radiation therapy, chemotherapy and immunotherapy. While there are several therapies being
developed with the goal of curing cancer, one of the most effective and proven approaches to this is radiation therapy (RT). We are developing
a pipeline of products designed to address the limitations of the current standard of cancer therapies. We believe that our product candidates
will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of
care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
to date have focused on continuing our research and development efforts to advance Ropidoxuridine clinical testing and improved drug
formulation, to advance HDAC6 inhibitor (SP-2-225) preclinical development and explore new SBIR contract work on predictive biomarkers
of radiation response, as well as prostate cell lines for health disparities research. We received Small Business Innovation Research
(&#8220;SBIR&#8221;) contract funding from the NIH for the aforementioned projects. The
clinical development of Ropidoxuridine has shown drug bioavailability and a maximum tolerated dose has been established for use in Phase
II clinical trials. TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), with whom we have contracted for process research, development
and cGMP compliant manufacture of IPdR, has successfully completed the manufacturing campaign for the active pharmaceutical ingredient
(API) of Ropidoxuridine for use in the Company&#8217;s upcoming Phase II clinical trial in brain cancer patients undergoing radiation
therapy. Shuttle also worked with University of Iowa Pharmaceuticals to develop the formulation, produce the capsules, and which have
been shipped to Contract Research Organization (CRO) Theradex Oncology for distribution to clinical trial sites. Both activities have
now been completed. In addition, Shuttle received approval from the FDA to begin the clinical trial. The FDA made recommendations to
expand the clinical trial and the company agreed with the recommendation. With this change incorporated into the revised protocol, the
Company believes it remains on track to commence its Phase II clinical study in the second quarter of 2024. The radiation biomarker project
and the health disparities project have been completed and the company is following up with plans for clinical validation and potential
commercialization. Changes in operational, administrative, legal and professional expenses related to our operations are set forth in
more detail in the discussion below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restatement
of Previously Issued Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed in the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2024, filed with the Securities
and Exchange Commission (&#8220;SEC&#8221;) on May 13, 2024, following the entry of a cease-and-desist order by the SEC against our former
auditor, B.F. Borgers CPA PC (&#8220;BF Borgers&#8221;), we commenced the re-audit (the &#8220;Re-audit&#8221;) of our consolidated financial
statements for the year ended December 31, 2022, which had been audited by BF Borgers. Since that time and as a result of the Re-audit,
as of July 10, 2024, the Company and the Audit Committee have concluded and informed our current auditor, Forvis Mazars, LLP, that our
audited consolidated financial statements for the year ended December 31, 2022 (the &#8220;2022 Financial Statements&#8221;), our audited
financial statements for the year ended December 31, 2023 (the &#8220;2023 Financial Statements&#8221;), and the quarterly periods included
in the Company&#8217;s Annual Report for the year ended December 31, 2023, and the quarterly report for the period ended March 31, 2024
require restatement and are not reliable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting errors impacting our 2022 Financial Statements include (i) correcting historical and fiscal 2022 stock compensation transactions;
(ii) correcting the initial and subsequent accounting for certain convertible notes, promissory notes and warrants to purchase shares
of common stock in fiscal 2022; (iii) correcting the historical and subsequent accounting for the Series A Convertible Preferred Stock
in fiscal 2022; (iv) correcting the initial and subsequent accounting for warrants issued with the Series A Convertible Preferred Stock,
and (v) correcting the recognition of issuance costs related to the initial public offering in fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the accounting errors from the 2022 Financial Statements also impacts the Company&#8217;s 2023 Financial Statements specific
to opening balances of additional paid in capital and accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion of financial results presented here is reflective of the restatement adjustments. Refer to Note 2 of the consolidated financial
statements included elsewhere in this Annual Report for more information on the restatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2024, in order to meet the Minimum Bid Price Requirement, the Company effectuated a 1-for-8 reverse stock split of
its issued and outstanding common stock, rounding up to account for any fractional shares (the &#8220;Reverse Stock Split&#8221;). The
Reverse Stock Split had no effect on the Company&#8217;s authorized shares of common stock or preferred stock. Following the reverse
stock split on August 13, 2024, the Company had a total of 2,111,235 shares issued and outstanding (or 2,008,689 on a post-split basis
as of December 31, 2023). All share, option, warrant and per share amounts (except our authorized outstanding) have been retroactively
restated in these financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the three months ended June 30, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">645,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">839,665</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(193,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(23</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,759</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and professional</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,877</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">416,688</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses and loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,482,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,465,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,588</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(430,685</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(729,351</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,175</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,964</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,534</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,430</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(143,773</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(578,048</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on settlement of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,553</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(548,581</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(718,740</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,031,215</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,184,372</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">153,157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development.</i> Research and development (&#8220;R&amp;D&#8221;) expense was $0.6 million for the three months ended June 30, 2024,
as compared to $0.8 million for three months ended June 30, 2023. The decrease of $0.2 million, or 23%, is primarily related to the Company
having completed production of the drug product and waiting for the initiation of trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
compensation related expenses were $0.3 million in the three months ended June 30, 2024 as compared to $0.3 million in the three months
ended June 30, 2023. Compensation related expenses were 48% for the three months ended June 30, 2024, representing an increase from 39%
of total R&amp;D in the three months ended June 30, 2023. Subcontract work made up 42% of total R&amp;D expenses in the three months
ended June 30, 2024 and 56% of total R&amp;D expenses during the three months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses.</i> General and Administrative expenses in the three months ended June 30, 2024 increased by $0.1 million,
or 48% to $0.3 million in the three months ended June 30, 2024, compared to $0.2 million in the three months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
and Professional Expenses</i>. During the three months ended June 30, 2024, legal and professional expenses increased by $0.1 million
or 26% to $0.5 million compared to $0.4 million in the same period in the prior year. The increase in legal and professional fees was
primarily due to increases in our expenses related to our public filing requirements, contracts and financing related work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income Expense</i>. Other expense was $0.5 million for the three months ended June 30, 2024, which consisted of $0.4 million in interest
expense on convertible loans, interest income of $14 thousand, change in marketable securities of $28 thousand, and a loss on change
in fair value of derivative liabilities of $0.1 million. Other income was $0.7 million for the three months ended June 30, 2023, which
consisted of $0.7 million in interest expense on convertible loans, $3 thousand in interest expense on related party loans, interest
income of $19 thousand, loss on settlement of convertible debt of $0.4 million, unrealized loss on marketable securities of $26 thousand,
and a gain on change in fair value of derivative liability of $0.4 million. The $0.4 million gain in fair value of derivative liability
resulted from the fair value measurement using the Monte Carlo pricing model and the impact of the decrease in the market price of warrant
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the six months ended June 30, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,231,823</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,761,466</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(529,643</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(30</td><td style="width: 3%; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">634,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">464,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and professional</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,001,011</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">784,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses and loss of operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,867,481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,010,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(142,930</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,825</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(928,200</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,328,682</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,611</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,245</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,675,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,621,186</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,976</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28,670</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40,198</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(349</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on settlement of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,315</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(433,807</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">362,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(894,765</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(149,057</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(745,708</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,762,246</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,159,468</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(602,778</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development.</i> Research and development (&#8220;R&amp;D&#8221;) expense was $1.2 million for the six months ended June 30, 2024,
as compared to $1.8 million for six months ended June 30, 2023. The decrease of $0.5 million, or 30%, is primarily related to the Company
having completed production of the drug product and waiting for the initiation of trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
compensation related expenses were $0.6 million in the six months ended June 30, 2024 as compared to $0.9 million in the six months ended
June 30, 2023. Compensation related expenses were 52% for the six months ended June 30, 2024, representing an increase from 51% of total
R&amp;D in the six months ended June 30, 2023. Subcontract work made up 38% of total R&amp;D expenses in the six months ended June 30,
2024 and 56% of total R&amp;D expenses during the six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses.</i> General and Administrative expenses in the six months ended June 30, 2024 increased by $0.2 million,
or 37% to $0.6 million in the six months ended June 30, 2024. The increase in general and administrative expenses was primarily due to
a restricted stock-based grant to an officer of the Company valued at $42 thousand, and increases in marketing, advertising and filing
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
and Professional Expenses</i>. During the six months ended June 30, 2024, legal and professional expenses increased by $0.2 million or
28%. The increase in legal and professional fees was primarily due to increases in our expenses related to our public filing requirements,
contracts and financing related work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income Expense</i>. Other expense was $0.9 million for the six months ended June 30, 2024, which consisted of $0.9 million in interest
expense on convertible loans, interest income of $36 thousand, loss on settlement of convertible debt of $71 thousand, change in marketable
securities of $29 thousand, and a gain on change in fair value of derivative liabilities of $54 thousand. Other expense was $0.1 million
for the six months ended June 30, 2023, which consisted of $1.3 million in interest expense on convertible loans, $7 thousand in interest
expense on related party loans, interest income of $36 thousand, finance fee on convertible loans of $0.1 million, loss on settlement
of convertible debt of $0.4 million, gain on sale of marketable securities of $2 thousand, unrealized gain on marketable securities of
$12 thousand, and a gain on change in fair value of derivative liabilities of $1.7 million. The $1.7 million gain in fair value of derivative
liability resulted from the fair value measurement using the Monte Carlo pricing model and the impact of the decrease in the market price
of warrant shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unaudited condensed consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets
and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception
and has a net loss of approximately $3.8 million and no revenues for the six months ended June 30, 2024 and has working capital of approximately
$1.1 million as of June 30, 2024. In addition, the convertible note payable outstanding at June 30, 2024 includes covenants and certain
cash payment requirements. On July 12, 2024, the Company informed the investor of its convertible note that the Company&#8217;s expected
restatement of its financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms
of the convertible note. On August 6, 2024, the Company paid $0.6 million to the investor of the convertible note and received a waiver
from the investor related to the default. The funds paid are restricted and will be held as collateral to the balance owed under the
convertible note (see Note 9). These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt
about the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $4.3 million, along with a four-year warrant to purchase 127,260 shares of common stock,
exercisable at $18.80 per share ($1.93 post Reverse Split, as adjusted), providing the Company with approximately $3.6 million
in net proceeds. To date, the warrant has not yet been exercised. However, the Company&#8217;s existing cash resources, marketable securities
and the cash received from the equity offering and convertible note are not expected to provide sufficient funds to carry out the Company&#8217;s
operations and clinical trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA approval of the IND for the Phase
2 clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the Company agreed to an expansion
of the clinical trial, necessitating additional capital to complete the trial as well as fund ongoing operations. As a result, management
has submitted an application for a SBIR grant for non-dilutive funding for pre-clinical project through the NIH. The Phase II clinical
trial was also approved by the Institutional Review Board &#8220;IRB&#8221; in June, 2024. In August 2024, the Company took action to
pursue a separate capital raise of up to $10.0 million and entered into a work order with a contract research organization (&#8220;CRO&#8221;)
for purposes of supporting the Company&#8217;s Phase II Study of Ropidoxuridine. Under the terms of the work order, the CRO will oversee
the studies for a period of 53 months in exchange for a fee of approximately $2.3 million, payable in stages and based upon services
performed during the study. The ability of the Company to continue as a going concern is dependent upon its ability to successfully raise
additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials and bring a drug candidate to commercialization
to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the future effects on the
recoverability and classification of assets or the amounts and classification of liabilities if the Company is unable to continue as
a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheet Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,485,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,593,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,107,672</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(56</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,384,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042,237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">342,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,100,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,550,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,450,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, total current assets were $2.5 million and total current liabilities were $1.4 million, resulting in working capital
of $1.1 million. As of December 31, 2023, total current assets were $5.6 million and total current liabilities were $1.0 million, resulting
in a working capital of $4.6 million. As of June 30, 2024, the current assets primarily resulted from $0.7 million cash and $1.6 million
marketable securities, with the decrease from December 31, 2023 being primarily due to ongoing cash burn from our R&amp;D programs, filing
expenses and general operations. The increase in current liabilities is primarily due to the current portion of the $1.0 million convertible
note and accrued interest that increased $0.3 million and an increase in accounts payable of $82 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,638,425</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,984,039</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">345,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(12</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,259,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,890,905</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,150,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(144</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by (used in) financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(501,667</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,904,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,406,194</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash on hand</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">695,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,446,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,751,192</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87</td><td style="text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated positive cash flows from operating activities. For the six months ended June 30, 2024, net cash flows used
in operating activities was $2.6 million, consisting of a net loss of $3.8 million, increased by a gain on change in derivative liabilities
of $54 thousand, offset by amortization of debt discount of $0.8 million, loss on settlement of convertible debt of $71 thousand, accrued
interest settled with common stock of $19 thousand, stock-based compensation of $183 thousand and increased by a net change in working
capital of $85 thousand. For the six months ended June 30, 2023, net cash flows used in operating activities was $3.0 million, consisting
of a net loss of $3.2 million, increased by a gain on change in derivative liabilities of $1.7 million, offset by amortization of debt
discount of $1.1 million, loss on settlement of convertible debt of $0.4 million, accrued interest settled with common stock of $0.2
million, stock-based compensation of $58 thousand and further reduced by a net change in working capital of $12 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2024, we invested in trading marketable securities for $36 thousand and received $1.3 million in proceeds
from disposition of marketable securities. For the six months ended June 30, 2023, we invested in trading marketable securities for $3.0
million and received $80 thousand in proceeds from disposition of marketable securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2024, we paid $0.5 million related to payments on a convertible note. For the six months ended June 30,
2023, we received a net of $3.6 million from the sale and issuance of a convertible note payable and warrants and repaid $0.7 million
in related party notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the year ended December 31, 2023 and 2022 (as restated)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(as restated)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Research and development, net of contract expense reimbursements, as restated</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">3,517,093</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,047,385</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2,469,708</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">236</td><td style="width: 3%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,046,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">473,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">573,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and professional, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,328,435</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">822,727</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">505,708</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses and loss of operations, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,892,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,343,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,548,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,825</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52,010</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,484,193</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(428,688</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,055,505</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">479</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance fee, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,245</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(189,912</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of derivative liabilities, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,216,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(189,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,405,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,273</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liabilities, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(398,675</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on settlement of convertible debt, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(477,221</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,795,652</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,318,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on settlement of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(328,687</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on forgiveness of Paycheck Protection Program note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,007</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other expense, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(700,341</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,652,243</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,951,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(74</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss, as restated</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,592,723</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,996,069</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,596,654</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development, net of contract expense reimbursements.</i> Total research and development (&#8220;R&amp;D&#8221;) expense was $3.5
million for the year ended December 31, 2023, as compared to $1.0 million for the year ended December 31, 2022 (as restated), which included
R&amp;D expense reimbursements of $0 and $211,455, respectively. The increase of $2.5 million, or 236%, is primarily related to the Company
increasing R&amp;D spending as a result of having received funding from the Company&#8217;s initial public offering in the third quarter
of fiscal 2022 and, the convertible note issued during the period ended March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
compensation related expenses were $1.5 million in the year ended December 31, 2023 as compared to $0.7 million in the year ended December
31, 2022 (as restated). Compensation related expenses, excluding reimbursements, for the year ended December 31, 2023 was 43% as a percent
of R&amp;D expense, representing a decrease from the 56% of total R&amp;D incurred in the year ended December 31, 2022. Subcontract work,
excluding reimbursements, made up 52% of total R&amp;D expenses in the year ended December 31, 2023 and 35% of total R&amp;D expenses
during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses. </i>General and Administrative expenses in the year ended December 31, 2023 increased by $0.6 million, or
121%, from $0.5 million in the year ended December 31, 2022 (as restated) to $1.1 million in the year ended December 31, 2023. The increase
in general and administrative expenses was primarily due to increases in insurance expenses of $0.1 million, compensation of $0.2 million
and advertising costs of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
and Professional Expenses</i>. During the year ended December 31, 2023, legal and professional expenses increased by $0.5 million or
61%. The increase in legal and professional fees was primarily due to increases in our expenses related to our public filing requirements,
contracts and financing related work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income (expense).</i> Other expense was $0.7 million for the year ended December 31, 2023, which mainly consisted of $2.5 million in
interest expense on convertible notes, loss on settlement of convertible debt of $0.5 million, and finance fees of $0.1 million, which
were partially offset by a gain on change in fair value of derivative liabilities of $2.2 million, change in fair value of marketable
securities of $0.1 million and interest income of $0.1 million. Other expense was $2.7 million for the year ended December 31, 2022 (as
restated), which mainly consisted of $0.4 million in interest expense on convertible notes (as restated), loss on settlement of convertible
debt of $1.8 million (as restated), finance fees of $0.2 million (as restated) a loss on change in fair value of derivative liability
of $0.2 million (as restated), and a loss on change in fair value of warrant liabilities of $0.4 million (as restated), partially offset
by a gain on settlement of accounts payable of $0.3 million and a gain on forgiveness of Paycheck Protection Program note payable of
$0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and had a net loss of
$6.6 million and no revenues during the year ended December 31, 2023 and working capital of approximately $4.6 million as of December
31, 2023. In addition, the convertible notes payable outstanding at December 31, 2023 includes covenants and certain cash payment requirements.
On July 12, 2024, the Company informed the investor of its convertible note that the Company&#8217;s expected restatement of its financial
statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the convertible note. On
August 6, 2024, the Company paid $0.6 million to the investor of the convertible note and received a waiver from the investor related
to the default. The funds paid are restricted and will be held as collateral to the balance owed under the convertible note (see Note
12). These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $4.3 million, along with a four-year warrant to purchase 127,260 shares of common stock,
exercisable at $18.80 per share ($1.93 post-reverse split, as adjusted), providing the Company with approximately $3.6 million
in net proceeds. To date, the warrant has not yet been exercised. However, the Company&#8217;s existing cash resources, marketable securities
and the cash received from the equity offering and convertible note are not expected to provide sufficient funds to carry out the Company&#8217;s
operations and clinical trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA approval of the IND for the Phase
2 clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the Company agreed to an expansion
of the clinical trial, necessitating additional capital to complete the trial as well as fund ongoing operations. As a result, management
had initiated a $4.5 million rights offering and submitted an application for a SBIR grant for non-dilutive funding for pre-clinical
project through the NIH. The Phase II clinical trial was also approved by the Institutional Review Board &#8220;IRB&#8221; in June, 2024.
In August 2024, the Company took actions to pursue a separate capital raise of up to $10 million and entered into a work order with a
contract research organization (&#8220;CRO&#8221;) for purposes of supporting the Company&#8217;s Phase II Study of Ropidoxuridine. Under
the terms of the work order, the CRO will oversee the studies for a period of 53 months in exchange for a fee of approximately $2.3 million,
payable in stages and based upon services performed during the study. The ability of the Company to continue as a going concern is dependent
upon its ability to successfully raise additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials
and bring a drug candidate to commercialization to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements do not include any adjustments to reflect the future effects on the recoverability and classification
of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheet Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,593,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,578,351</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,985,346</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(35</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042,237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">975,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,561</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,550,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,602,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,051,907</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, total current assets were $5.6 million and total current liabilities were $1.0 million, resulting in working capital
of $4.6 million. As of December 31, 2022 (as restated), total current assets were $8.6 million and total current liabilities were $1.0
million, resulting in a working capital of $7.6 million. The Company&#8217;s current assets as of December 31, 2023 primarily resulted
from $3.6 million in net cash received from the issuance of a convertible note payable, offset by $0.8 million repaid for related party
notes ($685,473 in principal and $98,135 of accrued interest), and $0.4 million repaid in cash for a convertible note ($334,444 in principal
and $59,846 in accrued interest). In addition, we continued progress on our R&amp;D programs during the year ended December 31, 2023
that resulted in increased cash expenditures. The increase in current liabilities is primarily due to the current portion of the $4.3
million convertible note which is $0.7 million of convertible note payable and accrued interest, an increase in accounts payable of $0.2
million, offset by the reduction of $0.8 million in related party notes payable and accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended December 31,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(as restated)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Cash used in operating activities, as restated</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(5,581,147</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(2,666,411</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(2,914,736</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">109</td><td style="width: 3%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,829,723</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,829,723</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing activities, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,570,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,578,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,008,782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents on hand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,576,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,417,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,840,787</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(69</td><td style="text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated positive cash flows from operating activities. For the year ended December 31, 2023, net cash flows used
in operating activities was $5.6 million, primarily consisting of a net loss of $6.6 million, increased by a gain on change in derivative
liabilities of $2.2 million, offset by amortization of debt discount of $2.1 million, loss on settlement of convertible debt of $0.5
million, accrued interest settled with common stock of $0.3 million, stock-based compensation of $0.2 million and further reduced by
a net change in operating assets and liabilities of $0.2 million. For the year ended December 31, 2022, net cash flows used in operating
activities was $2.7 million (as restated), primarily consisting of a net loss of $5.0 million (as restated), decreased by a loss on change
in derivative liability of $0.2 million, amortization of debt discount and finance fees of $0.4 million, a loss settlement of convertible
debt of $1.7 million (as restated), a change in fair value of freestanding instruments in excess of proceeds of $0.2 million (as restated),
and stock-based compensation of $0.2 million (as restated), partially offset by a gain on settlement of accounts payable of $0.3 million,
a gain on forgiveness of Paycheck Protection Program of $0.1 million, a change in fair value of warrant liabilities of $0.4 million (as
restated), and a net change in in operating assets and liabilities of $0.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, we invested in trading marketable securities for $3.0 million and received $0.2 million in proceeds
from disposition of marketable securities and purchased less than $0.1 million of equipment. For the year ended December 31, 2022, we
had no investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, we received net proceeds of $3.9 million from the sale and issuance of convertible notes payable and
warrants and repaid $0.3 million in convertible notes, $0.3 million for finance costs related to convertible note payable, and $0.7 million
in related party notes payable. For the year ended December 31, 2022, we received $10.0 million from the issuance of shares of common
stock and exercise of warrants and $0.6 million from the issuance of convertible notes and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Financings &#8211; Our IPO and Post-2022 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 2, 2022, we closed on our IPO of 1,225,888 units (each a &#8220;IPO Unit,&#8221; and collectively, the &#8220;IPO
Units&#8221;), with each IPO Unit consisting of one share of the Company&#8217;s common stock and one warrant to purchase one share
of common stock, at a public offering price of $8.125 per IPO Unit ($65 per IPO Unit on a post Reverse Split basis). Our IPO, which
was underwritten by Boustead Securities, LLC (&#8220;Boustead&#8221;), resulted in gross proceeds of $9.96 million, before deducting
underwriting discounts and commissions. On September 29, 2022, Boustead exercised its overallotment option, purchasing an additional
183,883 IPO Units, resulting in gross proceeds of $1.49 million, before deducting
underwriter commissions and discounts. As a result, our IPO raised a total of $11.45 million, before deducting underwriting
discounts, commissions and related IPO expenses. On a post Reverse Split basis, 352,443 shares (including exercised warrants) were issued under the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, we entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master Fund, SPC &#8211;
Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to the Investor a $4.3
million convertible note (the &#8220;January 2023 Convertible Note&#8221;) and warrant (the &#8220;January 2023 Warrant&#8221;) to purchase
127,260 (post Reverse Split) shares of common stock of the Company, in exchange for gross proceeds of $4.0 million (the &#8220;Investment
Amount&#8221;). The January 2023 Convertible Note amortizes on a monthly basis and the Company can make such monthly amortization payments
in cash or, subject to certain equity conditions, in registered shares of common stock or a combination thereof. For equity repayment,
the January 2023 Convertible Note is convertible into shares of common stock at price per share equal to the lower of (i) $18.8 (post
Reverse Split) (ii) 90% of the three lowest daily VWAPs of the 15 trading days prior to the payment date or (iii) 90% of the VWAP of
the trading day prior to payment date. The January 2023 Convertible Note is repayable over 26 months and bears interest at the rate of
5% per annum. The January 2023 Warrant is exercisable for four years from the date of closing and is exercisable at $1.93 per
share (post Reverse Split, as adjusted). In the event the Investor exercises the January 2023 Warrant in full, such exercise would result
in additional gross proceeds to the Company of approximately $246 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2023, we entered into an amendment agreement (the &#8220;Amendment Agreement&#8221;) to the SPA. Under the Amendment Agreement,
the Company and the Investor amended the transaction documents as follows: (i) amended and restated Section 2 of the January 2023 Warrant
so as to remove a provision that would have potentially required an adjustment to the number of warrant shares exercisable under the
January 2023 Warrant, (ii) stipulated that the Company would obtain majority shareholder approval to issue up to an additional $10 million
in convertible notes (the &#8220;Subsequent Notes&#8221;) and warrants (the &#8220;Subsequent Warrants&#8221;) equal to 42.5% of the
outstanding principal value of the Subsequent Notes, which Subsequent Note and Subsequent Warrant would be sold to the Investor on substantially
the same terms as the existing Convertible Note and Warrant (each as amended by the Amendment Agreement) and upon conversion and/or exercise
would cause the potential issuance of in excess of 19.9% of the Company&#8217;s issued and outstanding stock, (iii) that, upon obtaining
majority stockholder approval, the Company would file a Schedule 14C related to such potential issuance of the shares of common stock
related to the potential sale of the Subsequent Notes and Subsequent Warrants to the Investor within 30 calendar days of entry into the
Amendment Agreement, and (iv) stipulated that the Investor would release $1.5 million in cash collateral to the Company, with $1.0 million
to be released to the Company immediately upon singing of the Amendment Agreement and $0.5 million to be released upon the Company&#8217;s
filing of the Schedule 14C. The Company obtained majority stockholder consent to the potential sale of the Subsequent Notes and Subsequent
Warrants to the Investor in advance of entry into the Amendment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2023, we entered into amendment no. 1 (&#8220;Amendment No. 1&#8221;) to the Amendment Agreement dated May 11, 2023, for purposes
of amending the terms of the SPA. Under Amendment No. 1 to the Amendment Agreement, the Company and the Investor agreed as follows: (i)
that Section 15(q) to the January 2023 Convertible Note, which required the Company to hold the Cash Collateral in a Controlled Account
Agreement (as defined in the Convertible Note), would no longer be applicable, (ii) that the Investor would stipulate the release to
the Company of the remaining Cash Collateral totaling $2.92 million (thus releasing the full amount of the Cash Collateral to the Company),
and (iii) that, should the Investor exercise its option to purchase the Subsequent Notes and Subsequent Warrants, that such Subsequent
Notes would omit Section 15(q) and that the Company would not be required to maintain any controlled accounts or otherwise be subject
to any controlled account agreements. In August 2024, we entered into an additional Amendment Agreement pursuant to which the Investor
waived certain defaults in exchange for the Company&#8217;s payment of $0.6 million in collateral to be held against the Investment Amount
pending the January 2023 Convertible Note&#8217;s maturity. As of September 30, 2024, the January 2023 Convertible Note had been paid
off in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial
statements, which have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).
The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect
the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed
consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on
our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described
in more detail in the notes to our unaudited condensed consolidated financial statements included elsewhere in this report, we believe
that the following accounting policies are critical to understanding our historical and future performance, as these policies relate
to the more significant areas involving management&#8217;s judgments and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most critical accounting policies and estimates relate to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development Expenses</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value of Common Stock (Common Stock Valuations)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value of Warrants to Purchase Common Stock</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value of Bifurcated Derivative Liabilities and other Financial Instruments</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value of Preferred Stock (upon extinguishment)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are expensed as incurred and, prior to our initial public offering in September 2022, have historically been
offset by contract receivable payments from an NIH SBIR contract that has supported our scientific research. This is stated in the consolidated
financial statements as research and development, net of contract expense reimbursements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Common Stock (Common Stock Valuations)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all periods prior to our initial public offering, there was no public market for our common stock, and, as a result, the fair value of
the shares of common stock underlying our share-based awards, warrants and other financial instruments was estimated on each grant or
measurement date by our board of directors. To determine the fair value of our common stock underlying these grants and financial instrument,
our board of directors considered, among other things, input from management, input from investment banks and financial advisors, valuations
of our common stock prepared by unrelated third-party valuation firms in accordance with the guidance provided by the American Institute
of Certified Public Accountants 2013 Practice Aid, <i>Valuation of Privately Held Company Equity Securities Issued as Compensation</i>,
and our board of directors&#8217; assessment of additional objective and subjective factors that it believe were relevant and factors
that may have changed from the date of the most recent valuation through the date of the grant. These factors included, but were not
limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    results of operations and financial position, including our levels of available capital resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    stage of development and material risk related to our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business conditions and projections;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    valuation of publicly traded companies in the life sciences and pharmaceuticals sectors, as well as recently completed mergers and
    acquisitions of peer companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lack of marketability of our common stock as a private company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    prices at which we sold shares of our Series A Preferred Stock to outside investors in arms-length transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    rights, preferences and privileges of our Series A Preferred Stock relative to those of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    likelihood of achieving a liquidity event for our securityholders, such as an initial public offering or a sale of our Company, given
    prevailing market conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trends
    and developments in our industry; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
    market conditions affecting the life sciences and pharmaceutical industry sectors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the initial public offering in September 2022, it is not necessary to determine the fair value of our common stock for any
fair value measurements subsequent to this date, as our shares are traded in the public market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, and prior to the closing of our initial public offering, the estimated fair value of our common stock
was utilized to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measure
    stock compensation expense</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimate
    the fair value of certain warrants to purchase common stock</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimate
    the fair value of certain bifurcated derivative features in the Convertible Notes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimate
    the deemed dividends recorded related to the extinguishment of the Series A Preferred Stock and the modification of the December
    2021 Warrants</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measure
    any final fair value adjustments upon the settlement, exercise or reclassification of certain financial instruments upon our initial
    public offering</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
developing its fair value estimates, we performed certain sensitivity analysis around the estimated fair value of the common stock and
how changes in this estimate could impact accounting conclusions. For most of these fair value measurements, we determined that $1.00
to $2.00 changes in the estimated fair value per share would not have material impacts on the measurements or ultimate accounting conclusions
or entries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
performing this sensitivity analysis, we identified two measurements that are the most sensitive to changes in our estimated stock price
fair value measurement is the valuation of the Series A Preferred Stock post-extinguishment in April 2022 (upon the modification of terms
that was determined to be substantive and represent an extinguishment) and the estimate of the incremental fair value provided to the
holders of the December 2021 Warrants upon their modification in April 2022 (to allow the warrants to remain exercisable for same number
of shares and at same exercise price as per the contract pre-April 2022 reverse stock split). We estimated that a $1.00 per share increase
or decrease in our estimated fair value of common stock could result in an increase or decrease in these measurements of approximately
$250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting for both transactions was to reflect the determined amounts as a deemed dividend, which would reduce the net loss attributable
to common stockholders and increase the net loss per share available to common stockholders. These measurements are non-recurring fair
value measurements in nature and did not impact any other balance sheet accounts or operating or non-operating income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Warrants to Purchase Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued warrants to investors in our debt and equity offerings. We have also issued warrants to service providers in relation to
our financing offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all warrants issued to determine the appropriate classification under ASC 480 and ASC 815 (as well as under ASC 718 for warrants
issued as share-based payments). In addition to determining classification, we evaluate these instruments to determine if such instruments
meet the definition of a derivative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
warrants that are determined to be equity-classified, we estimate the fair value at issuance and record the amounts to additional paid
in capital (potentially on a relative fair value basis if issued in a basket transaction with other financial instruments). Warrants
that are equity-classified are not subsequently remeasured unless modified or required to be reclassified as liabilities. For warrants
that are determined to be liability-classified, we estimate the fair value at issuance and each subsequent reporting date, with changes
in the fair value reported in the consolidated statements of operations. The classification of all outstanding warrants, including whether
such instruments should be recorded as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
warrants issued with &#8216;vanilla&#8217; or less complex terms, we use the Black Scholes valuation model to estimate fair value. Key
inputs to the Black Scholes valuation model include the fair value of our stock, the exercise price and number of warrant shares of the
contract, the remaining contractual term, stock price volatility (based on our stock price history as well as an analysis of the historical
volatility of the common stock of a group of comparable entities) and a risk-free rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
warrants with uncertain or more complex terms (such as variability in the warrant shares or exercise price), we may utilize more complex
models to address such provisions. These may include probability-weighted scenario models or Monte Carlo simulation models. Monte Carlo
simulation models require the use of simulations that are weighted based on significant unobservable inputs including stock prices, the
average volatility of a population set and probabilities assigned. Each simulation is based on the range of inputs in a scenario with
the mean of the output on each simulation calculated as an average.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of these valuation models requires the input of highly subjective assumptions. Any change to these inputs could produce significantly
higher or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Bifurcated Derivative Liabilities and Other Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities are
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our derivative financial instruments classified as a liability, the Company will select a valuation model that best aligns with the type
of instrument and economic profile of the embedded feature being valued. This may include the use of Monte Carlo or other appropriate
valuation models to value the derivative instruments at inception and on subsequent valuation dates. Monte Carlo simulation models require
the use of simulations that are weighted based on significant unobservable inputs including the average volatility of a population set
and probabilities assigned. Each simulation is based on the range of inputs in a scenario with the mean of the output on each simulation
calculated as an average. For other embed features, the Company may utilize a &#8216;with and without&#8217; income-based valuation approach,
designed to compare the fair value of a financial instrument with the embedded feature and the fair value of the financial instrument
without the embedded feature, in order to isolate the fair value of the embedded feature, or certain probability-weighted scenario analyses
to compare various potential settlement amounts. These complex valuations require the use of key inputs, some of which are based on estimates
and judgements by management and/or external consultants, such as the fair value of the Company&#8217;s stock price, volatility, estimates
of the occurrence or non-occurrence of certain events and estimates of the probability of default or other external impacts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of these valuation models requires the input of highly subjective assumptions. Any change to these inputs could produce significantly
higher or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Preferred Stock (upon extinguishment)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, we agreed to modify the terms of the Series A Preferred Stock, resulting in the conclusion that the
modification was a substantial change in fair value of the Series A Preferred Stock and that extinguishment accounting should be applied.
In order to account for the extinguishment, we estimated the fair value of the Series A Preferred Stock based on the modified terms.
The difference between the estimated fair value of the Series A Preferred Stock post-modification and its carrying value was recorded
as a deemed dividend adjusting net loss available to common stockholders during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
this fair value measurement, we utilized a model that includes a Monte Carlo simulation to estimate the fair value of the Series A Preferred
Stock in an initial public offering or other listing scenario and a discounted cash flow approach to estimate the fair value of the Series
A Preferred Stock in a redemption (or non-conversion) scenario. The Monte Carlo simulation includes management inputs around the fair
value of our common stock and the estimated initial public offering date. The simulation determines whether the estimated future initial
public offering would be a &#8220;Qualified IPO&#8221;, as defined, or a &#8220;Listing&#8221; conversion, as these two conversion types
represented different economic outcomes. The present value calculation for the redemption (or non-conversion scenario) assumes the future
repayment of the Series A Preferred Stock stated value and accrued cumulative dividends, discounted to the date of the modification.
The estimated fair values of these scenarios were then applied a probability of each event occurring (probability of initial public offering
or redemption/non-conversion). These complex valuations require the use of key inputs, some of which are based on estimates and judgements
by management assisted by external consultants, such as the fair value of the Company&#8217;s stock price, volatility, estimates of the
occurrence or non-occurrence of certain events and estimates of the probability of default or other external impacts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of these valuation models requires the input of highly subjective assumptions. Any change to these inputs could produce significantly
higher or lower fair value measurements that could materially impact the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 78; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_004"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers and their respective ages and titles are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)
    and Office(s) Held</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the board of directors and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    J. Lorber</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP
    for Operations and Regulatory, former Chief Financial Officer*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Dritschilo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Operating Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mira
    Jung, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyvin
    Rich, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Clinical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton
    Brown, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Richards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (1)(2)(3)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    Schafer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (2)(3)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    H. Senanayake, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (1)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bette
    Jacobs, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (1)(3)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Audit Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Compensation Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Nominating and Corporate Governance Committee</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Timothy
Lorber became our Chief Financial Officer on June 13, 2024. Prior to that time, Michael Vander Hoek served as our Chief Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a description of the background and business experience of our directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anatoly
Dritschilo, M.D.</b> Dr. Dritschilo is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board
of Directors since the Company&#8217;s formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held
multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department
Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of
Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005
to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation
Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board
of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National
Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania,
a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.
His qualifications support his service as our Chief Executive Officer and Chairman of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Timothy
J. Lorber, CPA</b> serves as the Company&#8217;s Chief Financial Officer, a position he assumed on a part-time basis commencing June
13, 2024. He will assume the full-time position of Chief Financial Officer on September 9, 2024. Mr. Lorber has more than 40 years of
professional finance experience, including Legg Mason, Inc. (&#8220;Legg Mason&#8221;), one of the world&#8217;s larger public global
asset management firms, where he worked from March 2006 to July 2020 serving in various finance leadership roles, including Managing
Director and Chief Accounting Officer until its sale in 2020. From August 2021 until June 2024, Mr. Lorber has served in leadership roles
with several privately held businesses, overseeing finance, technology and human resources functions. Prior to Legg Mason, Mr. Lorber
served as Internal Audit Director of Freddie Mac from August 2003 to March 2006 and has also worked for several international public
accounting firms. Mr. Lorber has extensive experience with mergers and acquisitions, valuations and complex accounting and financial
reporting matters and holds a Bachelor of Arts in Accounting from Loyola University, Maryland, and is a licensed CPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
P. Vander Hoek</b> serves as the Company&#8217;s Vice President, Operations and Regulatory, a position he has held since 2019, and served
as the Company&#8217;s Chief Financial Officer from 2019 until June 13, 2024 . From November 2019 until April 2021, Mr. Vander Hoek served
as Director, Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (&#8220;LCCC&#8221;), where he directed
a new five-year $221.9 million institutional commitment for cancer center research under a new NCI-approved cancer consortium arrangement
and recruited scientists to fulfill strategic objectives with senior leaders to improve cancer research and treatment. From 2007 until
November 2019, Mr. Vander Hoek served as Associate Director, Administration, at Georgetown&#8217;s LCCC, where he was responsible for
direct administrative operations for more than 400 faculty and staff in the department of oncology, radiation medicine, pathology and
biostatistics, bioinformatics and biomathematics, including managing $216.9 million in institutional commitments to LCCC from Medstar
Health, John Theurer Cancer Center (&#8220;JTCC&#8221;), and Georgetown University. and implementing an enterprise-wide clinical trial
management system for Georgetown University and Medstar Health. From 2004 until 2007, Mr. Vander Hoek served as Chief Financial Officer
at Georgetown&#8217;s LCCC. During his time at Georgetown, Mr. Vander Hoek negotiated a series of 12 research integration agreements
between LCCC and the JTCC that resulted in the approval of an NCI recognized Consortium in 2019. From 2001 until 2004, Mr. Vander Hoek
served as Vice-Chair, Planning and Administration, at MedStar Georgetown University Hospital, where he was responsible for managing administrative
and financial operations for some 440 staff, physicians, residents and fellows in the departments of Medicine and Neurology. From 1996
until 2001, Mr. Vander Hoek served as Senior Associate Administrator, Finance and Information Systems, for the Department of Medicine,
Georgetown University Medical Center, where he designed and managed the faculty compensation system, while managing the finances and
information systems for the department. His financial management experience in publicly held companies includes Director of Managed Care
Reimbursement for Critical Care America from 1990 to 1993 and Regional Controller for Laboratory Corporation of America (LabCorp) from
1993 to 1996. His responsibilities at both companies included extensive financial management related to mergers, acquisitions, and start-up
operations. Mr. Vander Hoek holds a Master&#8217;s in Health Services Administration from The George Washington University and a Bachelor
of Arts in Biology and Psychology from Hope College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peter
Dritschilo </b>has served as our President and Chief Operating Officer since Shuttle was formed in December 2012. He also served as our
Chief Financial Officer until 2019. Mr. Dritschilo has more than 25 years of business management experience in medical services and cancer
treatment. He has held administrative positions with Medstar-Rad America from 2001 to 2005, Georgetown University 2005 to 2006, Prince
William Hospital and the Fauquier Hospital Cancer Center 2006 to 2011 and Inova Health System&#8217;s Schar Cancer Institute from 2011
to 2018. In 2014, Mr. Dritschilo filed for Chapter 7 bankruptcy protection due to the failure of a personal business venture. Mr. Dritschilo
graduated from Georgetown University and received his MBA from the George Washington University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mira
Jung, Ph.D.</b>, a co-founder of our company, has served as our Chief Scientific Officer for Biology since December 2012, and was a member
of our board of directors from our formation in December 2012 until 2019. Since 2004, Dr. Jung has served as Professor of Radiation Medicine
and Microbiology at Georgetown University Medical School. With over 30 years of experience in molecular radiation biology research, she
is an expert in mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung&#8217;s
research has been funded by NIH and the DOD leading to 100+ publications and nine patents granted by the USPTO, including the first reports
of HDAC inhibitor drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung
holds an MA degree and a PhD in Microbiology and Molecular Virology from the University of Kansas, Lawrence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tyvin
A. Rich, M.D.</b> serves as our company&#8217;s Chief Medical Officer and is responsible for the clinical development of novel radiation
sensitizers. Since 2010, Dr. Rich has served as a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton
Virginia and Professor Emeritus at University of Virginia Health Sciences Center, Department of Radiation Oncology. From 1995 until 2010,
Dr. Rich was a Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences
Center. Prior to that, from 1984 through 1995, Dr. Rich was a Professor of Radiotherapy and Director of Clinics in the Department of
Radiotherapy of the University of Texas M. D. Anderson Cancer Center. He has served as the protocol chair for RTOG clinical trials that
advanced the use of chemoradiation for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional
5-Fluorouracil for chemoradiation therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and
book chapters. Dr. Rich received his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and
completed residencies in internal medicine at Georgetown University Medical Center and radiation therapy at Massachusetts General Hospital,
Harvard Medical School.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milton
Brown, M.D., Ph.D., FNAI. </b>Dr. Brown is a co-founder of our Company, previously served as our Chief Scientific Officer for Chemistry,
and has served a member of our Board of Directors since the Company&#8217;s formation in December 2012. Since August 2022, Dr. Brown
has also served as Vice Dean of Research, Professor of Internal Medicine and the Prudence and Louis Ryan endowed chair in translational
research at Eastern Virginia Medical School. Previously, he was Director of the Center for Drug Discovery at the George Mason University
from 2020 to 2022 and Director of the Inova Center for Drug Discovery and Development from 2016 to 2020. Dr. Brown was a founder of Rivanna
Pharmaceuticals in 2004 and co-founder, Chairman and CEO of Trocar Pharma in 2020, both of which are Virginia-based biopharmaceutical
companies engaged in the discovery and development of novel small molecule therapeutics for the treatment of neurological, oncological,
and infectious diseases. Dr. Brown has also served as Director of the Drug Discovery Center at Georgetown University Medical School from
2012 to 2016 and principal investigator of the NIH/NCI funded Chemical Diversity Center from 2010 to 2015. Dr. Brown brings to Shuttle
Pharma 25 years of experience in drug discovery with over 100 publications and 67 issued patents, including discovery of novel HDAC inhibitors.
Dr. Brown was a 2015 recipient of the Percy Julian Award by the National Organization of Black Chemists and Chemical Engineers for significant
contributions in pure and/or applied research in science. He has served on government committees including the NIH Experimental Therapeutics
Study Section, the NIH Drug Discovery and Molecular Pharmacology Study Section and was a scientific counselor to the U.S. Secretary of
Health. Dr. Brown holds a Ph.D. in synthetic chemistry from the University of Alabama, and an M.D. from the University of Virginia. He
is an elected fellow of the National Academy of Inventors (FNAI). His extensive experience and expertise in drug discovery makes him
uniquely qualified to guide the company&#8217;s drug discovery program as a member of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Steven
Richards. </b>Mr. Richards was appointed to be a member of our Board of Directors in 2019. He is CEO and Founder of Endurance Media,
a media finance company based in Santa Monica, California, that launched in 2014 with a strategic alliance with eOne Entertainment and
a mandate to produce and finance commercially driven feature films. From 2006 to 2014, Mr. Richards served as Co-President and Chief
Operating Officer of Silver Pictures where he oversaw all business activities and managed a team of more than 20 people responsible for
film development, production, and financial information. From 2000 to 2006, he served as Chief Financial Officer at Silver Pictures and
from 1995 to 2000 as Vice President, Finance, at Silver Pictures. Mr. Richards holds an MBA in Finance from UCLA, a BBA in accounting
from Temple University, and holds his CPA license. We believe his experience as a chief financial officer and his knowledge of accounting
will assist in providing guidance and oversight to our Board of Directors as we grow our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joshua
Schafer. </b>Mr. Schafer was appointed to be a member of our Board of Directors in 2019. From January 2023 until present, Mr. Schafer
has been serving as the Chief Commercial Officer, and EVP Business Development at Zevra Therapeutics, a rare disease company. From November
2022 until January 2023, Mr. Schafer was interim CEO and Chair of the board of directors at PHARNEXT, an entity he has served on the
board of directors since July 2020. From December 2020 until November 2022, Mr. Schafer served as Senior Vice President and General Manager,
Autoimmune and Rare Disease Business for Mallinckrodt Pharmaceuticals Incorporated. In addition, he served as Chief Strategy and Business
Development Officer from September 2019 until December 2020, and from 2015 to September 2019 he was SCP of Business Development and General
Manager of International Operations at Mallinckrodt Pharmaceuticals. From 2009 until 2015, he served as Vice President and Oncology Therapeutic
Area Head at Astellas Pharmaceuticals Incorporated, where he was responsible for building the company&#8217;s global oncology franchise.
From 2000 until 2009, Mr. Schafer served in positions of increasing seniority at Takeda Pharmaceuticals North America, including Manager
and Senior Manager, New Product and New Business Development; Senior Product Manager, Gastrointestinal Marketing; and Director, Oncology
and Renal Marketing and Commercial Development. He began working in the healthcare and pharmaceutical industry in 1998 and has served
in various positions including management consulting at Accenture (formerly Anderson Consulting), G.D. Searle &amp; Co. (later acquired
by Pfizer) and Cognia Corporation. He received his Bachelor of Arts in Biology and German at the University of Notre Dame, his MS in
Biotechnology from Northwestern University and his MBA from Northwestern University. We believe Mr. Schafer&#8217;s extensive experience
in pharmaceutical strategy, marketing and business development will assist our Board of Directors&#8217; oversight role as we build and
develop our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chris
H. Senanayake, Ph.D.</b> Dr. Senanayake was appointed to be a member of the Company&#8217;s Board of Directors in 2021. In 2019, Dr.
Senanayake founded TCG GreenChem, Inc., a U.S. subsidiary of TCG Lifesciences Pvt. Ltd., a leading global Contract Research and Manufacturing
Services (CRAMS) company in the area of drug discovery, development and commercialization, where he serves as chief executive officer.
Dr. Senanayake has more than 30 years of pharmaceutical industry experience, making him an invaluable asset to Shuttle Pharma&#8217;s
mission as the Company advances its pharmaceutical candidates in clinical trials. He has held positions of Senior Scientist at Dow Chemical,
and Research Fellow at Merck &amp; Co, Inc. (from 1990 to 1996), Director and Executive Director of Process Research at Sepracor, Inc.
(1996 to 2002), Director of Chemical Development and Vice President of Chemical Development for Boehringer Ingelheim Pharmaceuticals,
Inc. In 2018, he was appointed as the CEO of Asta GreenChem, Inc in Richmond VA and Astatech (Chengdu) Biopharmaceuticals Corp. in China.
He has a record of leading and delivering high complexity APIs for manufacturing. Dr. Senanayake participated in development activities
of many drugs, including multi-billion-dollar blockbuster drugs, such as Crixivan, Lunesta, Jardiance, Formotorol, Desvenlafaxine and
other drug candidates. He is co-author of 425 scientific publications and is co-inventor of more than 150 patents. Dr. Senanayake received
his Ph.D. in synthetic organic chemistry at Wayne State University, where he developed the total synthesis of complex natural products
and completed the first total synthesis of grosshemin in the guaianolide family. In his postdoctoral fellowship, he conducted total synthesis
of polyol systems such as amphotericin B, compactin and C-nucleosides. We believe Dr. Senanayake&#8217;s detailed and in-depth experience
as an executive and developer of pharmaceuticals will enable him to provide value to us by introducing potential joint venture partners,
as well as enhancing our oversight through his in-depth understanding of and experience in the pharmaceuticals industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bette
Jacobs, Ph.D.</b> Dr. Jacobs was appointed to be a member of the Company&#8217;s Board of Directors in October 2022. Dr. Jacobs is an
experienced researcher, administrator, and businesswoman currently serving as a professor in the department of health systems administration
at Georgetown University and as a distinguished scholar at the O&#8217;Neill Institute for National and Global Health Law. Dr. Jacobs
holds her Ph.D. from the University of Texas and is noted for her groundbreaking transdisciplinary and cross-sector work in systems design.
As a voting member of the Cherokee Nation, she has lifetime involvement in equity programs and has testified before Congress. In addition
to serving on several start-up boards, Dr. Jacobs founded the National Coalition of Ethnic Minority Nurse Associations funded by the
NIH National Institute of General Medical Sciences. Prior to her current role at Georgetown, she served as dean at the Georgetown School
of Nursing and Health Studies, vice president for Honda of America Manufacturing, associate director of applied research at UAB Civitan
International Research Center and acting dean of graduate studies and research at California State University. She has been a fellow
and visiting professor at the University of Oxford and an academic guest scholar and lecturer at several acclaimed universities worldwide.
Her wealth of experience in research, administration and serving on boards coupled with her unique background and perspectives makes
her ideally suited to serving as a member of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Theodore
L. Phillips, M.D.</b> has served as the Chair of our Scientific Advisory Committee since 2018. He held the position of Chief Medical
Officer and Clinical Director at Shuttle Pharmaceuticals from 2014 until 2018. Dr. Phillips&#8217; distinguished career has included
positions of Chair of the Department of Radiation Oncology (from1978 to 1998) and Associate Director (from 1996 to 1999) of the UCSF
Cancer Center at the University of California at San Francisco. He is highly experienced in radiation oncology clinical trials of hypoxic
radiation sensitizers. Dr. Phillips served as the principal investigator of the SBIR contract for the Phase I clinical trial of Ropidoxuridine.
He previously served as Associate Director of the Northern California Oncology Group from 1983-1990, president of the American Society
of Therapeutic Radiation Oncologists from 1984 to 1985 and is an elected member of the Institute of Medicine of the National Academy
of Science. Dr. Phillips holds a BS degree from Dickinson College in Carlisle, Pennsylvania and a MD from the University of Pennsylvania.
He provides advice to the leadership team to help design and implement clinical trials of radiation therapy and radiation response modifying
drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ralph
R. Weichselbaum, M.D. </b>has served as Scientific Advisor to Shuttle Pharmaceuticals for translational research for the discovery and
development of radiation response modifiers since 2013. Dr. Weichselbaum is the Daniel K. Ludwig Professor and Chairman of the Department
of Radiation and Cellular Oncology, the University of Chicago, a position he has held since 1985. He is also an elected member of the
Institute of Medicine, National Academy of Sciences. He has devoted his career to translational research in cancer with combined radiotherapy
and chemotherapy. Dr. Weichselbaum and his colleagues conceived &#8220;genetic radiotherapy&#8221; and developed viral constructs for
use in clinical tumor radiation sensitization. These were commercialized as TNFerade (GenVec, Inc.) and tested in a Phase I clinical
trial in prostate cancer and a Phase III clinical trial for pancreatic cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
Martin Brown, Ph.D.</b> has served as a Scientific Advisor to Shuttle Pharmaceuticals for translational research for the development
of hypoxic radiation sensitizers since 2017. Dr. Brown received his Ph.D.in Cancer Biology from Oxford University in 1968 and was Director
of the Division of Radiation and Cancer Biology at Stanford University from 1984 to 2004. He is an expert in the radiation biology of
hypoxia in cancers and has more than 300 peer-reviewed published articles. He has received awards in recognition of his work, including
the Gold Medal, American Society for Therapeutic Radiology and Oncology (1999, the Failla Memorial Award, Radiation Research Society
(2000), the Weiss Medal, Association for Radiation Research (2001) and the Henry S. Kaplan Distinguished Scientist Award, International
Association for Radiation Research (2007). He developed etanidazole, a hypoxic radiation sensitizer, and tirapazamine, a hypoxic cytotoxic
drug, from bench to clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alejandro
Villagra, Ph.D.</b> has served as a Scientific Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics
and immunology since 2017. Dr. Villagra received his Ph.D. in Molecular Biology from the University of Concepcion, in Chile in 2004 and
completed post-graduate training at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in Molecular Immunology
in 2009, in the Laboratory of Eduardo Sotomayor, MD. He joined the faculty of the Moffitt Cancer Center and Research Institute, as a
research scientist from 2009 through 2015 and advanced to Assistant Professor of Oncologic Sciences. He became an Assistant Professor
in the Department of Biochemistry and Molecular Medicine at the George Washington University (GWU) School of Medicine and Health Sciences
in 2015, as a member of the GWU Cancer Center. His research is focused on molecular and cellular roles of histone deacetylases (HDACs)
in tumor immunology and as adjuvants for immunotherapy of cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joseph
Armstrong, III, Ph.D.</b> joined as a Scientific Advisor to Shuttle Pharmaceuticals in 2021, He received his Ph.D. from the University
of Colorado in 1988, completed his post-doctoral work at the University of Virginia at Charlottesville and holds the position of Chief
Operating Officer at and Global Head of Business Development TCG GreenChem, Inc. He provides industry experience in chemistry, drug development
and process research, having previously held positions at Merck &amp; Co. Inc. in Rahway, N.J and in the U.K. for two pharmaceutical
companies in the areas of Pharmaceutical Research and Development. His primary areas of focus have been in the design and implementation
of efficient synthesis of drug candidates amenable to large scale production. Dr. Armstrong led the development team that designed, developed
and implemented the manufacturing process for the new treatment for Type II diabetes, Januvia TM. His team was awarded the Solvias Prize
in 2004 (Basel, Switzerland), the IChemE Aztra-Zeneca Award for Green Chemistry and Engineering in 2005 (London, England), Dr. Armstrong
has more than 40 publications and holds 10 patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Anatoly Dritschilo and Peter Dritschilo are father and son. There are no other family relationships among our directors and executive
officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past ten years, other than Peter Dritschilo, our President, who filed for personal bankruptcy under Chapter 7 of the U.S. Bankruptcy
Code in 2014, no director, executive officer, promoter, or control person of the Company has been involved in the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    petition under the Federal bankruptcy laws or any state insolvency law which was filed by or against, or a receiver, fiscal agent
    or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general
    partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive
    officer at or within two years before the time of such filing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations
    and other minor offenses);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of any order, judgment, or decree, not subsequently reversed, suspended, or vacated, of any court of competent
    jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
    as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage
    transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the
    foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee
    of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice
    in connection with such activity;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engaging
    in any type of business practice; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engaging
    in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal
    or State securities laws or Federal commodities laws;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any Federal or State
    authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described
    in paragraph (f)(3)(i) below, or to be associated with persons engaged in any such activity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State
    securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended,
    or vacated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated
    any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not
    been subsequently reversed, suspended, or vacated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not
    subsequently reversed, suspended, or vacated, relating to an alleged violation of:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    Federal or State securities or commodities law or regulation; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent
    injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal
    or prohibition order; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
    organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section
    1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that
    has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is responsible for overseeing the Company&#8217;s business consistent with its fiduciary duty to the stockholders.
This significant responsibility requires highly skilled individuals with various qualities, attributes and professional experience. There
are general requirements for service on the board of directors that are applicable to directors and there are other skills and experience
that should be represented on the board of directors as a whole but not necessarily by each director. Our Corporate Governance and Nominating
Committee, detailed below, considers the qualifications of director candidates individually and in the broader context of the board of
directors&#8217; overall composition and the Company&#8217;s current and future needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
of Office</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our directors are elected to one-year terms to hold office until the next annual meeting of our stockholders and until a successor
is appointed and qualified, or until their removal, resignation, or death. Executive officers serve at the pleasure of the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to qualify for continued listing on Nasdaq, our board of directors must consist of a majority of &#8220;independent&#8221; directors,
as defined under Nasdaq listing standards and Rule 10A-3(b)(1) under the Exchange Act. At present, four of the six directors serving
on our board of directors qualify as &#8220;independent.&#8221; Our independent directors consist of Messrs. Richards and Schafer, Dr.
Senanayake and Dr. Jacobs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established three committees consisting of an audit committee, a compensation committee, and a nominating and
corporate governance committee. The members of each committee qualify as &#8220;independent&#8221; as defined under Nasdaq listing standards
and Rule 10A-3(b)(1). Moreover, at least one member of the audit committee qualifies as an &#8220;audit committee financial expert&#8221;
as the term is defined under Nasdaq listing standards and applicable rules and regulations of the SEC, based on their respective business
professional experience in the financial and accounting fields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee, which consists of Steve Richards, MBA, CPA (Chair), Bette Jacobs and Chris H. Senanayake, assists our board of directors
in its oversight of the Company&#8217;s accounting and financial reporting processes and the audits of the Company&#8217;s financial
statements, including (a) the quality and integrity of the Company&#8217;s financial statements (b) the Company&#8217;s compliance with
legal and regulatory requirements, (c) the independent auditors&#8217; qualifications and independence and (d) the performance of the
Company&#8217;s internal audit functions and independent auditors, as well as other matters which may come before it as directed by the
board of directors. Further, the audit committee, to the extent it deems necessary or appropriate, among its several other responsibilities,
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    responsible for the appointment, compensation, retention, termination and oversight of the work of any independent auditor engaged
    for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discuss
    the annual audited financial statements and the quarterly unaudited financial statements with management and the independent auditor
    prior to their filing with the SEC in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    with the Company&#8217;s management on a periodic basis (i) issues regarding accounting principles and financial statement presentations,
    including any significant changes in our company&#8217;s selection or application of accounting principles; and (ii) the effect of
    any regulatory and accounting initiatives, as well as off-balance sheet structures, on the financial statements of the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor
    the Company&#8217;s policies for compliance with federal, state, local and foreign laws and regulations and the Company&#8217;s policies
    on corporate conduct;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
    open, continuing and direct communication between the board of directors, the audit committee and our independent auditors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor
    our compliance with legal and regulatory requirements and will have the authority to initiate any special investigations of conflicts
    of interest, and compliance with federal, state and local laws and regulations, including the Foreign Corrupt Practices Act, as may
    be warranted.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee, which consists of Steve Richards (Chair) and Joshua Schafer, aids our board of directors in meeting its responsibilities
relating to the compensation of the Company&#8217;s executive officers and to administer all incentive compensation plans and equity-based
plans of the Company, including the plans under which Company securities may be acquired by directors, executive officers, employees
and consultants. Further, the compensation committee, to the extent it deems necessary or appropriate, among its several other responsibilities,
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    periodically our Company&#8217;s philosophy regarding executive compensation to (i) ensure the attraction and retention of corporate
    officers; (ii) ensure the motivation of corporate officers to achieve the Company&#8217;s business objectives; and (iii) align the
    interests of key management with the long-term interests of the Company&#8217;s stockholders;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and approve corporate goals and objectives relating to chief executive officer compensation and other executive officers of Shuttle;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations to the board of directors regarding compensation for non-employee directors, and review periodically non- employee
    director compensation in relation to other comparable companies and in light of such factors as the compensation committee may deem
    appropriate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    periodically reports from management regarding funding the Company&#8217;s pension, retirement, long-term disability and other management
    welfare and benefit plans.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee, which consists of Joshua Schafer (Chair), Steve Richards and Bette Jacobs, recommends
to the board of directors individuals qualified to serve as directors and on committees of the board of directors to advise the board
of directors with respect to the board of directors composition, procedures and committees to develop and recommend to the board of directors
a set of corporate governance principles applicable to the Company, and to oversee the evaluation of the board of directors and Shuttle&#8217;s
management. In addition, the nominating and corporate governance committee will consider diversity of background including diversity
of race, ethnicity, international background, gender and age when evaluating candidates for board of directors membership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the nominating and corporate governance committee, to the extent it deems necessary or appropriate, among its several other responsibilities
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
    to the board of directors and for approval by a majority of independent directors for election by stockholders or appointment by
    the board of directors as the case may be, pursuant to our bylaws and consistent with the board of director&#8217;s evidence for
    selecting new directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    the suitability for continued service as a director of each member of the board of directors when his or her term expires or when
    he or she has a significant change in status;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    annually the composition of the board of directors and to review periodically the size of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations on the frequency and structure of board of directors meetings or any other aspect of procedures of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations regarding the chairmanship and composition of standing committees and monitor their functions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    annually committee assignments and chairmanships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
    the establishment of special committees as may be necessary or desirable from time to time; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    and periodically review corporate governance procedures and consider any other corporate governance issue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the
business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge,
to any stockholder requesting a copy in writing from our secretary at our executive offices in Gaithersburg, Maryland. A copy of our
code of ethics is available on our website at <span style="text-decoration: underline">www.shuttlepharma.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 86; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted an insider trading policy, as amended and restated on March 10, 2023 (the &#8220;Insider Trading Policy&#8221;),
overseen by the Company&#8217;s corporate secretary, that applies to all (i) directors, (ii) executive officers and (iii) employees who
are exposed to insider information (together, the &#8220;Covered Persons&#8221;). The Insider Trading Policy prohibits the use of material
non-public information obtained by Covered Persons through their involvement with the Company when making decisions to purchase, sell,
give away or otherwise trade in the Company&#8217;s securities or to provide such information to others outside the organization. Under
the Insider Trading Policy, material non-public information includes, among other things, significant changes in the Company&#8217;s
prospects, significant write-downs, liquidity problems, changes in management, extraordinary borrowings, changes in debt, planned public
offerings or any other information that may be deemed material to the Company or the Company&#8217;s prospects. Further, we have established
black-out periods to which all Covered Persons are subject, including quarterly black-out periods, which commence three weeks before
the end of each quarter and continue until the quarterly results are disclosed by filing the Company&#8217;s Quarterly Report on Form
10-Q or Annual Report on Form 10-K. The Company may impose black-out periods from time to time as other types of material non-public
information occur when material non-public events or disclosures are pending. If the Company imposes a special black-out period, the
Company will notify Covered Persons accordingly. Covered Persons are permitted to trade in the Company&#8217;s securities only when there
is no black-out period in effect and such trade has been pre-cleared by the Company&#8217;s corporate secretary, or when a qualified
10b5-1 plan has been established in accordance with federal securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clawback
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company does not presently have in place any significant incentive compensation agreements or awards related to the Company&#8217;s
overall financial performance, the Company&#8217;s board of directors has adopted a clawback policy in order to comply with federal securities
laws. As such, we have adopted a clawback policy in which we may seek the recovery or forfeiture of incentive compensation paid by us,
including cash, equity or equity-based compensation, in the event we restate our financial statements under certain circumstances. The
clawback policy applies to our Section 16 officers, any employee who was eligible to receive incentive compensation and whose conduct
contributed to the need for a restatement, and any other former Section 16 officer or other employee who contributed to the need for
such restatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors Role in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of the board of directors have periodic meetings with management and the Company&#8217;s independent auditors to perform risk oversight
with respect to the Company&#8217;s internal control processes. The Company believes that the board of directors&#8217; role in risk
oversight does not materially affect the leadership structure of the Company. The Company believes that its founders, leadership team
and members of the board of directors exemplify diversity and inclusivity with respect to race, sex and ethnic origin. The board of directors
presently has two diverse directors and is in the process of reviewing and vetting a female candidate to serve as a director. As such,
the Company anticipates being in full compliance with Nasdaq&#8217;s newly adopted diversity requirements by the end of its first year
of listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 87; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_005"></span>EXECUTIVE
AND DIRECTOR COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes all compensation awarded to, earned by, or paid to our Chief Executive Officer and Chief Financial Officer and
certain of our other executive officers for 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name and principal position</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
                                            Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                            Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation
    ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonqualified
                                            Deferred Compensation Earnings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
                                            Other Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 29%; text-align: center">Anatoly Dritschilo M.D., CEO</td><td style="width: 2%">&#160;</td>
    <td style="width: 4%; text-align: center">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">287,175</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">112,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">399,175</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,921</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Michael Vander Hoek, CFO, VP</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,530</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,792</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,792</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Peter Dritschilo, President and COO</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242,012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,012</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,641</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Tyvin Rich, Chief Medical Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,226</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,077</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our executive officers has entered into an employment agreement with us. The employees each will receive compensation on an annual
basis in cash, payable in monthly installments commencing at the completion of our IPO, as well as restricted stock units (&#8220;RSUs&#8221;)
subject to achieving certain key performance indicators. Certain of our executive officers are entitled to various target bonuses, upon
achievement of certain milestones. The terms of the employment agreements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Anatoly Dritschilo, MD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2019, we entered into an employment agreement with our Chief Executive Officer and Chairman of the board of directors, Anatoly
Dritschilo, M.D. Under Dr. Dritschilo&#8217;s employment agreement, Dr. Dritschilo will receive base compensation of $274,000 per year.
Dr. Dritschilo also received an initial RSU grant of 5,687 RSUs (2,844 on a post-reverse split basis) issuable under the Company&#8217;s
2018 Equity Incentive Plan, which RSUs vested over three years in substantially equal one-third installments on each one year anniversary
of the agreement. Under his employment agreement, if Dr. Dritschilo terminates his employment for &#8220;Good Reason,&#8221; as defined
in the agreement, Dr. Dritschilo will be entitled to his then applicable base salary for period of 12 months, subject to his continued
compliance with certain requirements of his employment agreement. Dr. Dritschilo accepted a reduced salary prior to the Company&#8217;s
completion of its initial public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Timothy J. Lorber</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 10, 2024, we entered into an employment agreement with our Chief Financial Officer, Timothy J. Lorber. Under Mr. Lorber&#8217;s
employment agreement, he will receive base compensation of $227,000 and is entitled to a target bonus of $72,000 upon achievement of
certain milestones. Mr. Lorber also received an initial RSU grant of $100,000 worth of RSU issuable under the Company&#8217;s 2018 Equity
Incentive Plan, which RSUs vest annually in one-third increments commencing on the first anniversary date of the grant of RSU, in accordance
with the terms of the RSUs award agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Michael Vander Hoek</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2019, we entered into an amended employment agreement with our pervious Chief Financial Officer and Vice President for Operations
and Regulatory, Michael Vander Hoek. Under Mr. Vander Hoek&#8217;s employment agreement, he will receive base compensation of $227,000
and is entitled to a target bonus of $72,000 upon achievement of certain milestones. Mr. Vander Hoek also received an initial RSU grant
of 762 RSUs (381 on a post-reverse split basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three
years in substantially equal installments on each one year anniversary of the agreement. Under Mr. Vander Hoek&#8217;s employment agreement,
if he terminates his employment for &#8220;Good Reason,&#8221; as defined in the agreement, he will be entitled to his then applicable
base salary for period of 12 months, subject to his continued compliance with certain requirements of his employment agreement. Mr. Vander
Hoek accepted a reduced salary prior to the Company&#8217;s completion of its initial public offering in September 2022. Effective September
10, 2024, Mr. Vander Hoek assumes the Vice President, Regulatory position on a full-time basis and stops being our Chief Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Peter Dritschilo</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2019, we entered into an employment agreement with our President and Chief Operating Officer, Peter Dritschilo. Under Mr. Dritschilo&#8217;s
employment agreement, Mr. Dritschilo will receive base compensation of $236,000 and is entitled to a target bonus of $72,000 upon achievement
of certain milestones. Mr. Dritschilo also received an initial RSU grant of 2,595 RSUs (1,298 on a post-reverse split basis) issuable
under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one-year
anniversary of the agreement. Under Mr. Dritschilo&#8217;s employment agreement, if Mr. Dritschilo terminates his employment for &#8220;Good
Reason,&#8221; as defined in the agreement, he will be entitled to his then applicable base salary for period of 12 months, subject to
his continued compliance with certain requirements of his employment agreement. Mr. Dritschilo accepted a reduced salary prior to the
Company&#8217;s completion of its initial public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Tyvin Rich, M.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2019, we entered into an employment agreement with our Chief Clinical Officer, Tyvin Rich, M.D. Under Dr. Rich&#8217;s employment
agreement, Dr. Rich receives base compensation of $218,000 per year and is entitled to a target bonus of $43,000 upon achievement of
certain milestones. Dr. Rich also received an initial RSU grant of 481 RSUs (241 on a post-reverse split basis) issuable under the Company&#8217;s
2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one year anniversary of the
agreement. Under Dr. Rich&#8217;s employment agreement, if Dr. Rich terminates his employment for &#8220;Good Reason,&#8221; as defined
in the agreement, he is entitled to his then applicable base salary for period of 12 months, subject to his continued compliance with
certain provisions of his employment agreement. Dr. Rich accepted a reduced salary prior to the Company&#8217;s completion of its initial
public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Mira Jung, Ph.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, we entered into an employment agreement with Mira Jung, Ph.D., our Chief Scientific Officer, replacing the May 30, 2019
employment agreement. Under Dr. Jung&#8217;s current agreement, Dr. Jung receives a base salary of $46,000 (20%) per year and is entitled
to a target bonus of $15,620. She also received an additional grant worth $20,200 worth of RSUs, vesting annually in one-third increments
commencing on the first anniversary date of the grant of RSUs. Under Dr. Jung&#8217;s previous agreement, Dr. Jung received base compensation
of $46,800 and was entitled to a target bonus of $14,200 upon achievement of certain milestones. Dr. Jung also received an initial RSU
grant of 112 RSUs (56 on a post-reverse split basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over
three years in substantially equal installments on each one-year anniversary of the agreement. Under Dr. Jung&#8217;s employment agreement,
if Dr. Jung terminates her employment for &#8220;Good Reason,&#8221; as defined in the agreement, Dr. Jung is then entitled to her then
applicable base salary for period of 12 months, subject to her continued compliance with certain requirements of her employment agreement.
Dr. Jung accepted a reduced salary prior to the Company&#8217;s completion of its initial public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, on a post-reverse split basis, a total of 32,416 RSUs have been granted to our executive officers and Directors
under our 2018 Equity Incentive Plan (the &#8220;Plan&#8221;), 12,415 RSUs were outstanding on December 31, 2022, 20,100 RSUs vested,
of which 24,731 remain subject to vesting. The Company has filed a registration statement on Form S-8 (SEC File No. 333-268758) to register
the shares granted under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the number of shares of common stock underlying outstanding equity incentive awards
for each of our executive officers as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying
    Unexercised Options Exercisable (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying
    Unexercised Options Unexercisable (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Exercise Price ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Expiration Date</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares or Units of Stock
    not yet Vested (#))</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market Value of Shares or Units
    not yet Vested ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Bette Jacobs</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%">10/28/2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,483</td>
    <td style="width: 1%; text-align: right">(1)</td><td style="width: 1%; text-align: left"/><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">5,457</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Milton Brown</td><td>&#160;</td>
    <td>02/15/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,084</td>
    <td style="text-align: right">(1)</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,667</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    RSUs vest in two installments on the anniversary of the grant date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018
Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock- based
awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s compensation committee
or, alternatively, if there is no compensation committee, the Company&#8217;s board of directors. We have reserved 3,000,000 shares of
our common stock for issuance under the Plan, of which 84,779 shares have been granted under the Plan as of the date of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our non-employee directors, pursuant to the terms of director agreements (the &#8220;Director Agreements&#8221;), between each of
the directors and the Company, receives compensation on an annual basis consisting of $25,000 in cash, payable in quarterly installments
commencing 90 days after completion of our initial public offering, and received $100,000 in RSUs upon their respective dates of election.
The RSUs vest over a two-year period in one third increments, with one-third vesting immediately upon signing and one-third vesting on
each of the first and second anniversary of election. In addition, non-employee directors will also be reimbursed for out-of-pocket costs
incurred in connection with attending meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_006"></span>BENEFICIAL
OWNERSHIP OF SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of the date of this registration statement, the beneficial ownership of our common stock by each director
and executive officer, by each person known by us to beneficially own 5% or more of our common stock and by directors and executive officers
as a group. Unless otherwise stated, the address of the persons set forth in the table is c/o Shuttle Pharmaceuticals Holdings, Inc.,
401 Professional Drive, Suite 260, Gaithersburg, MD 20879.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. Unless
otherwise indicated, the stockholders listed in the table below have sole voting and investment power with respect to the shares indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share ownership figures include shares of our commons stock issuable upon securities convertible or exchangeable into shares of our common
stock, whether or not convertible or exchangeable within 60 days of the effective date of this Annual Report. Such shares are deemed
outstanding and beneficially owned by such person only for purposes of computing his or her percentage ownership, but not for purposes
of computing the percentage ownership for any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of October 29, 2024, there were issued and outstanding 2,946,099 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Names and addresses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>common stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>beneficially</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>owned (#)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>common stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>beneficially</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>owned (%)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Named Executive Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly Dritschilo, M.D.<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">538,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">18.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy Lorber<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton Brown, M.D., Ph.D.<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mira Jung, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Michael Vander Hoek</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Dritschilo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tyvin A. Rich, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Steve Richards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Joshua Schafer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chris H. Senanayake</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bette Jacobs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All directors and officers as a group (ten persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">829,070</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other 5% beneficial owners:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>None.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    the holder owns less than one percent of the outstanding common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#177;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    persons named above have full voting and investment power with respect to the shares indicated. Under the rules of the SEC, a person
    (or group of persons) is deemed to be a &#8220;beneficial owner&#8221; of a security if he or she, directly or indirectly, has or
    shares the power to vote or to direct the voting of such security, or the power to dispose of or to direct the disposition of such
    security. Accordingly, more than one person may be deemed to be a beneficial owner of the same security.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 135,650 shares of common stock held of record by Dr. Anatoly Dritschilo, (ii) 138,051 shares of common stock and warrants
    to purchase 2,500 shares of commons stock, each held of record by Joy Dritschilo, his spouse, and (iii) 262,500 shares of common
    stock held by PAL Trust, a trust formed for the benefit of Dr. and Mrs. Dritschilo&#8217;s adult children and for which a third
    party serves as external trustee and two of their children serve as co-trustees . Dr. Dritschilo disclaims beneficial ownership over
    all securities held by Mrs. Dritschilo and PAL Trust.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not include 28,455 RSUs that remain subject to vesting.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Does not include 1,042 RSUs which remain subject
    to vesting.</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 91; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
of Control</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
authorized for issuance under equity compensation plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2018
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers
or directors and to key advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not
less than the fair market value of the underlying shares as determined pursuant to the Plan, restricted stock awards, other stock- based
awards, or any combination of the foregoing. The Plan is administered by the Company&#8217;s compensation committee or, alternatively,
if there is no compensation committee, the Company&#8217;s board of directors. We have reserved 3,000,000 shares of our common stock
for issuance under the Plan, of which 84,779 shares have been granted under the Plan as of the date of this Annual Report, of which 24,731
remain subject to vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information as of December 31, 2023 about our equity compensation plans and arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Plan category</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of securities to be issued upon exercise of
    outstanding options, warrants and rights</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- average exercise price of outstanding options,
    warrants and rights</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of securities remaining available for future
    issuance under equity compensation plans</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">24,731</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,321,820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,321,820</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Outstanding
equity incentive grants consist entirely of RSUs which automatically vest over time into an equal number of shares of common stock at
no additional cost to the holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_007"></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
described below, during the last two fiscal years, there were no transactions or series of similar transactions to which we were a party
or will be a party, in which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amounts involved exceed or will exceed $120,000; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of any
    of the foregoing had, or will have, a direct or indirect material interest.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated two loans obtained in 2018 for a total of $350,000 from Joy Dritschilo, the wife our Chief
Executive Officer, which loans accrued interest at 7.5% since the date of inception, into a single loan between Mrs. Dritschilo
and the Company (the &#8220;2018 Consolidated Loan&#8221;) such that, with accrued interest, the 2018 Consolidated Loan had a principal
balance of $424,005.65, bore interest at a rate of 7.5% per annum, and had a maturity date of December 31, 2021. The 2018 Consolidated
Loan were then extended until June 30, 2022, pursuant to an amendment to the 2018 Consolidated Loan agreement dated January 24, 2022.
On July 29, 2022, the Company and Mrs. Dritschilo entered into an amendment to the 2018 Consolidated Loan, pursuant to which repayment
was extended through June 30, 2023. On January 15, 2023, following closing on the Convertible Note and Warrant offering to Ayrton Capital,
the 2018 Consolidated Loan was paid off in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated the May 2018 Loan and the September 2019 Loan with our Chief Executive Officer (the &#8220;2019
Consolidated Loan&#8221;), such that, with accrued interest, the 2019 Consolidated Loan had a principal balance of $138,448.20, bears
interest at the rate of 7.5% per annum, and has a maturity date of December 31, 2021. The 2019 Consolidated Loan was extended until June
30, 2022, pursuant to an amendment to the 2019 Consolidated Loan agreement dated January 24, 2022. On July 29, 2022, the Company and
our Chief Executive Officer entered into an amendment to the 2019 Consolidated Loan, pursuant to which repayment was extended through
June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan agreement with Mrs. Dritschilo in the amount of $120,000 (principal), bearing interest
at the rate of 7.5% per annum, with a single balloon payment due at maturity on June 21, 2022 (the &#8220;June 2021 Loan Agreement&#8221;).
On July 29, 2022, the Company and Mrs. Dritschilo entered into an amendment to the June 2021 Loan Agreement, pursuant to which repayment
was extended through June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, in conjunction with our private placement of $125,000 of units consisting of 10% notes and warrants to purchase common
stock, which were sold to three accredited investors in total, Mrs. Dritschilo purchased a $50,000 note and received warrants to purchase
2,500 shares of common stock at $20.00 per share. The notes and warrants were sold pursuant to an exemption from registration pursuant
to Rule 506(b) of Regulation D of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR, The Company paid TCG GreenChem $450,000 during the year ended December
31, 2022 and a total of $1,096,370 during the year ended December 31, 2023, completing the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On September 4, 2024, the Company
entered into a loan agreement with our Chief Executive Officer, Dr. Anatoly Dritschilo, pursuant to which Dr. Dritschilo loaned the Company of $250,000 (principal), bearing
interest at the rate of 12% per annum and which is repayable in 12 substantially equal monthly installments over a one year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2024, the Company conducted the initial closing of an up to $1.3 million 5% OID senior secured convertible note warrant
offering, pursuant to which the Company issued a total of $600,000 notes and warrants to purchase 286,169 shares of common stock, exercisable at $1.53 per share. The notes bear interest at the rate of 14.5% per annum, with the interest payable quarterly in cash, mature one year after the date
of issuance, are redeemable at any time by the Company at a 107% premium to the principal value of the notes and, three months after
issuance, can be converted at any time by the holder at a 110% premium to the principal value of the note. The Company&#8217;s CEO
purchased $250,000 of notes and warrants in the October 2024 Bridge Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
Approval and Ratification of Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions are subject to the review, approval, or ratification of our board of directors or an appropriate committee
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_008"></span>CAPITALIZATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents and capitalization as of June 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma basis to reflect the issuance of a $250,000 note payable to Dr. Dritschilo on September 4, 2024, and the conversion of
    $1,172,850 of principal outstanding under the Alto Convertible Note for 719,148 shares of common stock. The Alto Convertible Note
    has been paid in full as of the date of this prospectus; and the $732,134 in convertible bridge notes to related parties (including
    $250,000 to Dr. Dritschilo) in October 2024, excluding proceeds from any exercise of 329,460 warrants issued in conjunction
    with the Convertible Bridge Notes; and;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt">on a pro forma as adjusted basis
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to reflect the
                                            sale of 395,574 shares of common stock, 2,555,246 Pre-Funded Warrants and 2,950,820
                                            Common Warrants in this offering at the combined offering price of $1.525
                                            per share of Common Stock (or less $0.001 per Pre-Funded Warrant) and one accompanying Common Warrant,
                                            resulting in net proceeds of $4.1 million, after deducting approximately $405,000
                                            in expenses, but excluding proceeds from any exercise of the Common Warrants being offered
                                            in this offering, as well as the payment in full of the Alto Convertible Note.</span></p>

</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
capitalization following the closing of this offering will depend on the actual public offering price and other terms of this offering
determined at pricing. Cash and cash equivalents are not components of our total capitalization. You should read this table together
with the section titled &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221;
and the financial statements and related notes included elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">As of June 30, 2024</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">As of June 30, 2024</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">As of June 30, 2024</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Pro Forma As</p></td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Actual</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Pro Forma</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Adjusted</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">695,594</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,390,456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,483,131</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Capitalization:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Alto Convertible Note</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,517,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><p style="margin: 0">Bridge Convertible Notes</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">831,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">831,579</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A convertible preferred stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000
    shares authorized; no shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Common stock, $0.00001 par value; 100,000,000 shares authorized; 2,106,223 shares issued and outstanding at June 30, 2024, actual,
    2,825,371 shares pro forma, and 3,220,945 shares pro forma as adjusted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">28</p>
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,996,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,205,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">35,298,343</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29,195,550</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29,195,550</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(29,195,550</p></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Total stockholders&#8217; equity (deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">801,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,010,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,102,860</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total capitalization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,319,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,091,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">7,184,439</p></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock issued and outstanding actual, pro forma and pro forma as adjusted in the table above excludes 2,321,820
shares reserved for issuance under our 2018 Equity Incentive Plan and 513,460 warrants which remain subject to exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_009"></span>DILUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock
immediately after this offering. As of June 30, 2024, our historical net tangible book value was $801,434, or $0.38
per share. Our historical net tangible book value is the amount of our total tangible assets less our total liabilities. Historical net
tangible book value per share represents historical net tangible book value divided by the 2,106,223 shares of our common stock outstanding
as of June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to our issuance and sale of common stock, Pre-Funded Warrants and Common Warrants in this offering at the public
offering price of $1.525 per share of Common Stock (or less $0.001 per Pre-Funded Warrant) and one accompanying Common
Warrant, and after deducting estimated Placement Agents&#8217; fees payable by us, our pro forma as adjusted net tangible
book value as of June 30, 2024 would have been $6.1 million, or $1.06 per share, after including 2,555,246 of
Pre-Funded Warrant shares. This represents an immediate increase in as adjusted net tangible book value per share of $1.15
to existing stockholders and immediate dilution of $0.47 in pro forma as adjusted net tangible book value per share to new
investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting as adjusted net
tangible book value per share after this offering from the public offering price per share paid by new investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution on a per share basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Public offering price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><p style="margin: 0">1.525</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Historical net tangible book value per share as of June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">0.38</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in as adjusted net tangible book value per share attributable to this offering</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">1.15</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">As adjusted net tangible book value per share after giving effect to this offering</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">1.06</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dilution in as adjusted net tangible book value per share to new investors in this offering</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.47</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information above is as of June 30, 2024 and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 732,134 shares of our common stock issuable from time to time upon the conversion of outstanding Convertible Bridge Notes
    and the exercise of 329,460 related warrants, with a weighted-average exercise price of $1.42 per share; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,000
    shares of our common stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise price of $11.54
    per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,321,820
    other shares of our common stock reserved for future issuance from time to time under our 2018 Equity Incentive Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 94; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_004"></span>DIVIDEND
POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any dividends on our common stock since inception and we currently expect that, in the foreseeable future, all earnings,
if any, will be retained for the development of our business and no dividends will be declared or paid. Any future dividends will be
subject to the discretion of our board of directors and will depend upon, among other things, our earnings, if any, operating results,
financial condition and capital requirements, general business conditions and other pertinent facts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_005"></span>DESCRIPTION
OF CAPITAL STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 100,000,000 shares of common stock, par value $0.00001 per share, and 20,000,000 shares of preferred
stock, par value $0.00001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we had 2,946,099 shares of common stock issued and outstanding. Each holder of common stock is
entitled to one vote for each share owned on all matters voted upon by stockholders, and a majority vote is required for all actions
to be taken by stockholders. In the event we liquidate, dissolve or wind-up our operations, the holders of the common stock are entitled
to share equally and ratably in our assets, if any, remaining after the payment of all our debts and liabilities and the liquidation
preference of any shares of preferred stock that may then be outstanding. The common stock has no preemptive rights, no cumulative voting
rights, and no redemption, sinking fund, or conversion provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to receive dividends, if and when declared by the board of directors, out of funds legally available for
such purpose, subject to the dividend and liquidation rights of any preferred stock that may then be outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series
and to fix the rights, preferences and the number of shares constituting any series or the designation of such series. While our certificate
of incorporation and bylaws, each as amended to date, do not contain any provisions that may delay, defer or prevent a change in control,
the issuance of preferred stock may have the effect of delaying or preventing a change in control or make removal of our management more
difficult. At present, our board of directors has authorized the issuance of up to 10,000 shares of Series A convertible preferred stock,
of which 1,212.5 shares were issued and subsequently converted into common stock following completion of our IPO. As of the date of this
prospectus, no preferred stock is issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A Convertible Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors previously designated and authorized the issuance of up to 10,000 shares of Series A convertible preferred stock,
par value $0.00001 per share (the &#8220;Series A Convertible Preferred Stock&#8221;), of which there were 1,212.5 shares issued, which
were subsequently converted into common stock following completion of our IPO. A total of $1,212,500 was raised during 2018 and 2019
from the sale of our Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock had a stated value of $1,000 per
share, was entitled to receive a dividend at the rate of 8.5% per annum, which dividend was cumulative and payable at our option in shares
of common stock or cash upon the date of conversion or redemption, as so determined by the Company. The Series A Convertible Preferred
Stock, pursuant to its terms, were automatically convertible upon the earlier of (a) the closing of the sale of shares of common stock
to the public at an offering price of at least $32.00 per share (on a post-Reverse Split Basis) in a firm commitment underwritten
public offering pursuant to an effective registration statement under the Securities Act, resulting in gross proceeds to us (before underwriter&#8217;s
discounts, commissions and expenses) of an amount of at least $10 million (a &#8220;Qualified IPO&#8221;), or (b) listing of the common
stock on the NYSE or Nasdaq (a &#8220;Qualified Listing&#8221;). All shares of Series A Convertible Preferred Stock were then convertible
at either (i) 90% of the gross public offering price per share of the Qualified IPO (before deducting underwriter&#8217;s discounts,
commissions and expenses) or (ii) in the case of (b) above, $5.00 per share. Following consummation of our IPO, the Series A Convertible
Preferred Stock was converted into a total of 336,810 shares of common stock (42,101 shares on a post-reverse split basis), plus
an additional 100,517 shares of common stock (12,565 shares on a post-reverse split basis) paid to the Series A Convertible Shareholders
as dividends payable. As of the date of this prospectus, there are no shares of Series A Convertible Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with our sale of Series A Convertible Preferred Stock, our board of directors authorized the issuance of warrants to purchase
up to approximately 42,113 shares of common stock (5,265 shares on a post-reverse split basis) (the &#8220;Series A Warrants&#8221;),
to the holders of Series A Preferred Stock. The Series A Warrants were issued following consummation of our IPO, are exercisable for
a period of three years following issuance and have an exercise price of $32.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
2023 Note and Warrant Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, we entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master Fund, SPC &#8211;
Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;) and consummated the sale to such Investor of a senior secured
convertible note (the &#8220;January 2023 Convertible Note&#8221;) with an initial principal amount of $4,300,000, bearing interest at
5% per annum, and a warrant (the &#8220;January 2023 Warrant&#8221;) to purchase 1,018,079 shares (127,260 shares on a post-2024 Reverse
Split Basis) of our common stock at a fixed exercise price of $2.35 per share ($18.80 per share on a post-2024 Reverse Split Basis, and
subsequently reset to $1.93).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
January 2023 Convertible Note was sold with an original issue discount of $300,000. As such, the Investor paid for the January 2023 Convertible
Note by delivering $4,000,000 in cash consideration to the Company. Boustead served as the sole placement agent for the private placement
(the &#8220;January 2023 Private Placement&#8221;) of the January 2023 Convertible Note and January 2023 Warrant. Boustead received a
placement agent fee of $320,000 at the closing of the January 2023 Private Placement, representing 7.0% of the gross cash proceeds at
the closing plus 1% in non-accountable expenses. In addition, Boustead received a placement agent warrant to purchase 71,266 shares (8,909
shares on a post-2024 Reverse Split basis) of common stock, representing 7.0% of the warrant shares issued in the January 2023 Private
Placement. After deducting the placement agent fee and our estimated expenses associated with the January 2023 Private Placement, our
estimated net cash proceeds at the closing were approximately $3,493,423. As of September 6, 2024, the majority of the January 2023 Convertible
Note had been converted and there remained just over $14,000 outstanding under the note. The Alto Convertible Note has been paid in
full as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
SPA</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SPA contains certain representations and warranties, covenants and indemnities customary for similar transactions. Under the SPA, we
also agreed to the following additional covenants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
    long as the January 2023 Convertible Note remains outstanding, we will not effect or enter into an agreement to effect any variable
    rate transaction other than a bona fide at-the-market offering or equity line of credit. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    obtained majority stockholder consent approving the offering and the issuance of common stock upon conversion of the January 2023
    Convertible Note and exercise of the January 2023 Warrant, as is required under the rules of the Nasdaq, and subsequently filed an
    information statement on Schedule 14C (the &#8220;Information Statement&#8221;) informing all stockholders of the action and mailed
    such Information Statement to all stockholders within 70 days of closing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we granted the Investor participation rights in future equity and equity-linked offerings of securities, subject to certain
limited exceptions, during the two years after the later of (a) the closing or (b) the date the January 2023 Convertible Note no longer
remains outstanding, in an amount of up to 30% of the securities being sold in such offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">January
2023 Convertible Note</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
January 2023 Convertible Note was issued to the Investor on January 11, 2023 and matures on March 11, 2025 (subject to extension in certain
circumstances, including bankruptcy and outstanding events of default).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amortization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
on the earlier of (x) the date of a registration statement which registers the shares underlying the January 2023 Convertible Note is
declared effective by the SEC and (y) February 28, 2023, then on the first trading day of the month for each month thereafter, and on
the maturity date (each, an &#8220;Installment Date&#8221;), subject to certain exceptions and unless deferred as described below, the
Company is required to make monthly amortization payments equal to 1/26<sup>th</sup> of the unrestricted principal (and related unrestricted
original issue discount) and interest of the January 2023 Convertible Note payable (the &#8220;Installment Amount&#8221;), which must
be satisfied in cash at a redemption price equal to 105% of such Installment Amount (each, an &#8220;Installment Redemption&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the noteholder may, at its sole option, elect to defer any Installment Amount until a subsequent Installment Date selected
by the noteholder, provided that any such deferred amounts shall not continue to accrue interest unless the deferral is at the request
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
January 2023 Convertible Note bears interest at a rate of 5% per annum and, upon any conversion or redemption, shall include a make-whole
of interest from such date of determination through the maturity date. After the occurrence and during the continuance of an Event of
Default (as defined in the January 2023 Convertible Note), the January 2023 Convertible Note will accrue interest at the rate of 15%
per annum. See &#8220;<i>Events of Default</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion;
Alternate Conversion upon Event of Default </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
January 2023 Convertible Note is convertible, at the option of the noteholder, into shares of our common stock at the lower of (i) $18.80
per share (post Reverse Split), (ii) 90% of the three lowest VWAPs in the 15 trading days prior to the payment date or (iii) 90% of the
VWAP on the trading day prior to the payment date. The conversion price is subject to full ratchet antidilution protection upon any subsequent
transaction at a fixed price lower than the conversion price then in effect and standard adjustments in the event of any stock split,
stock dividend, stock combination, recapitalization or other similar transaction. If we enter into any agreement to issue (or issue)
any variable rate securities, other than a bona fide at-the-market offering or equity line of credit, the noteholder has the additional
right to substitute such variable price (or formula) for the conversion price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Event of Default has occurred under the January 2023 Convertible Note, the noteholder may elect to alternatively convert the January
2023 Convertible Note at a redemption premium of 115% of the conversion amount. As of September 30, 2024, the January 2023 Convertible
Note was paid in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subsequent
Placement Optional Redemption and Future Right of Participation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time after the earlier of the date a noteholder becomes aware of any placement by us of equity or equity-linked securities or the
date of consummation of such a placement, subject to certain limited exceptions, the noteholder will have the right to have us redeem
a portion of each January 2023 Convertible Note not in excess of 30% of the net proceeds from such placement at a redemption price of
100% of the portion of the January 2023 Convertible Note subject to redemption. In addition, through March 11, 2026, the noteholder
has the right to be notified of any future offering of securities and to participate in up to 30% of the total offering amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Covenants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to certain customary affirmative and negative covenants regarding the incurrence of certain indebtedness, the existence of
liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer of
assets, among other matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">January
2023 Warrant </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the January 2023 Convertible Note, we issued a January 2023 Warrant exercisable for four (4) years for the purchase of an
aggregate of up to 127,260 shares of common stock (the &#8220;January 2023 Warrant Shares&#8221;), at an adjusted exercise price of $1.93
per share. The number of January 2023 Warrant Shares and exercise price are each subject to adjustment as provided under the terms
of the January 2023 Warrant. If, at the time of exercise of the January 2023 Warrant, there is no effective registration statement registering,
or no current prospectus available for, the issuance of the January 2023 Warrant Shares to the Investor, and the registration statement
is not subject to SEC review and the Company has otherwise affirmatively failed to maintain such registration statement&#8217;s effectiveness,
then the January 2023 Warrant may also be exercised, in whole or in part, by means of a &#8220;cashless exercise.&#8221; The January
2023 Warrant may not be exercised if, after giving effect to the exercise the Investor, would beneficially own in excess of 4.99% of
the number of shares of common stock outstanding immediately after giving effect to the issuance of the January 2023 Warrant Shares.
At the Investor&#8217;s option, the ownership limitation blocker may be raised or lowered to any other percentage not in excess of 9.99%,
as applicable, except that any raise will only be effective upon 61-days&#8217; prior notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company issues or sells, or the Company publicly announces the issuance or sale of, any shares of common stock, or convertible securities
or options issuable or exchangeable into common stock (a &#8220;New Issuance&#8221;), under which such common stock is sold for a consideration
per share less than the exercise price then in effect, the exercise price of the January 2023 Warrant will be adjusted to the New Issuance
price in accordance with the formulas provided in the January 2023 Warrant. Any such adjustment will not apply with respect to the issuance
of Excluded Securities (as defined in the January 2023 Warrant). Upon any adjustment to the exercise price, the number of January 2023
Warrant Shares that may be purchased upon exercise of the January 2023 Warrant will be increased or decreased proportionately, so that
after such adjustment the aggregate exercise price payable for the adjusted number of January 2023 Warrant Shares will be the same as
the aggregate exercise price in effect immediately prior to such adjustment. In addition, if the Company enters into a Fundamental Transaction
(as defined in the January 2023 Warrants) at any time that a January 2023 Warrant is outstanding, then, upon any subsequent exercise
of the January 2023 Warrant, the Investor will have the right to receive, for each January 2023 Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares of common stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result
of such Fundamental Transaction by a holder of the number of shares of common stock for which the January 2023 Warrant is exercisable
immediately prior to such Fundamental Transaction, provided, further, that if holders of common stock are not offered or paid any consideration
in such Fundamental Transaction, such holder of common stock will be deemed to have received common stock of the successor entity (which
entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Registration
Rights Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Registration Rights Agreement, dated as of January 11, 2023, between the Investor and the Company, we have granted certain registration
rights to the noteholder and January 2023 Warrant holder. The Registration Rights Agreement requires us to have a registration statement
declared effective by the 60<sup>th</sup> day following the date of the Registration Rights Agreement (of March 11, 2023), or the 90<sup>th
</sup>day (or April 10, 2023) following the date of the Registration Rights Agreement in the event such registration statement is subject
to SEC review. It also grants the Investor customary &#8220;piggyback&#8221; registration rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Additional
Information</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing is only a summary of the material terms of the SPA, the January 2023 Convertible Note, the January 2023 Warrant, the Registration
Rights Agreement, and the other ancillary transaction documents, and does not purport to be a complete description of the rights and
obligations of the parties thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Effects of Provisions of our Certificate of Incorporation, our Bylaws and Delaware Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions
more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal
of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter
transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that
might result in a premium over the market price for our shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the
benefits of increased protection of our potential ability to negotiate with the proponent of a non-friendly or unsolicited proposal to
acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result
in an improvement of their terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware
Anti-Takeover Statute</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Delaware corporations are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder,
with the following exceptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in
    the stockholder becoming an interested holder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
    at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining
    the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by
    persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to
    determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting
    of the stockholders, and not by written consent, by the affirmative vote of at least 66<sup>2</sup>/<sub>3</sub>% of the outstanding
    voting stock that is not owned by the interested stockholder; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    corporation does not have a class of voting stock that is: (i) listed on a national securities exchange; or (ii) held of record by
    more than 2,000 stockholders, unless any of the foregoing results from action taken, directly or indirectly, by an interested stockholder
    or from a transaction in which a person becomes an interested stockholder</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines business combination to include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    merger or consolidation involving the corporation and the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    sale, transfer, pledge, or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series
    of the corporation beneficially owned by the interested stockholder; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or
    through the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation
or any entity or person affiliated with or controlling or controlled by such entity or person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock are traded on The Nasdaq Capital Market under the symbol &#8220;SHPH.&#8221; We do not intend to apply for listing
of the Warrants on any securities exchange or other nationally recognized trading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar of our common stock is VStock Transfer, LLC, of Woodmere, New York. Our transfer agent&#8217;s telephone
number is (212) 828-8436.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_006"></span>DESCRIPTION
OF SECURITIES WE ARE OFFERING </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering, on a reasonable best-efforts basis (i) 395,574 Shares of common stock and 2,555,246 Pre-Funded Warrants,
and (ii) 2,950,820 Common Warrants to purchase up to 2,950,820 shares of common stock. Each share of common stock (or one
Pre-Funded Warrant to purchase one share of our common stock in lieu thereof) will be sold with one Common Warrant to purchase one share
of common stock. The shares of common stock, or Pre-Funded Warrants in lieu thereof, and Common Warrants are immediately separable and
will be issued separately in this offering but must be purchased together in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price for each share of common stock and one accompanying Common Warrant is $1.525. The public offering price for
each Pre-Funded Warrant and one accompanying Common Warrant is $1.524, which equals the price at which one share of common stock and
one accompanying Common Warrant is sold to the public in this offering, minus $0.001. Each Common Warrant offered hereby will be a
warrant to purchase one share of common stock and will have an initial exercise price equal to $1.40.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to offer and sell the securities offered hereby to the purchasers through the Placement Agents. The Placement Agents are
not required to buy or sell any specific number or dollar amount of the securities offered hereby but will use their reasonable best
efforts to solicit offers to purchase the securities offered by this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms and provisions of our common stock are described under the caption &#8220;Description of Capital Stock&#8221; in this
prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the Common Warrants offered hereby is not complete and is subject to, and qualified
in its entirety by the provisions of the forms of Common Warrants which is filed as an exhibit to the registration statement of which
this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Common Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i>.
The Common Warrants are exercisable upon issuance and at any time up to the date that is five (5) years after its <span style="background-color: white">issuance</span>.
The Common Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. No
fractional shares of common stock will be issued in connection with the exercise of the Common Warrants. In lieu of fractional shares,
we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
Limitation</i>. A holder will not have the right to exercise any portion of the Common Warrants if the holder (together with its affiliates)
would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to
the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants. However, any holder may
increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall
not be effective until 61 days following notice from the holder to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
Price.</i> The exercise price per whole share of common stock purchasable upon exercise of one Common Warrant is $1.40.
The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock
combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash,
stock or other property to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i>.
Subject to applicable laws, the Common Warrants may be offered for sale, sold, transferred or assigned without our consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transactions</i>. In the event of a fundamental transaction, as described in the Common Warrants and generally including any reorganization,
recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common
stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the
holders of the Common Warrants will be entitled to receive upon exercise of the Common Warrants the kind and amount of securities, cash
or other property that the holders would have received had they exercised the Common Warrants immediately prior to such fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Rights as a Stockholder</i>. Except by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of Common Warrant
does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Common
Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the Pre-Funded Warrants that are being offered hereby is not complete and is subject
to and qualified in its entirety by the provisions of the forms of Pre-Funded Warrants which is filed as an exhibit to the registration
statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded
Warrant for a complete description of the terms and conditions of the Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &#8220;prefunded&#8221; refers to the fact that the purchase price of our common stock in this offering includes almost the entire
exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.001 per share.
The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more
than 4.99% (or, upon election of the holder, 9.99%) of our outstanding shares of common stock following the consummation of this offering
the opportunity to make an investment in the Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants
in lieu of our common stock which would result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their
option to purchase the shares underlying the Pre-Funded Warrants at such nominal price at a later date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
and Exercise Price</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Pre-Funded Warrant offered hereby will have an initial exercise price of $0.001 per share. The Pre-Funded Warrants will be
immediately exercisable and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The exercise price and
number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits,
reorganizations or similar events affecting our common stock and the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
Limitation. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering a duly executed exercise notice
accompanied by payment in full for the number of purchased upon such exercise (except in the case of a cashless exercise as discussed
below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the holder
would own more than 4.99% (or, at the election of a purchaser, 9.99%) of the outstanding common stock immediately after exercise, except
that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding
stock after exercising the holder&#8217;s Pre-Funded Warrants up to 9.99% of the number of shares of common stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants.
No fractional shares of common stock will be issued in connection with the exercise of a Pre-Funded Warrant. In lieu of fractional shares,
we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transaction</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a fundamental transaction, as described in the Pre-Funded Warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets,
our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding voting securities, the holders
of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind and amount of securities, cash
or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental
transaction, other than one in which a successor entity that is a publicly traded corporation (whose stock is quoted or listed for trading
on a national securities exchange, including, but not limited to, the New York Stock Exchange, the NYSE American, the Nasdaq Global Select
Market, the Nasdaq Global Market or the Nasdaq Capital Market) assumes the common warrant such that the warrant shall be exercisable
for the publicly traded common stock of such successor entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us
together with the appropriate instruments of transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exchange
Listing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Rights as a Stockholder</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&#8217;s ownership of, the holders of the Pre-Funded Warrants
do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Pre-Funded
Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 101; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_007"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A.G.P./<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alliance
Global Partners (&#8220;</span>A.G.P.&#8221;), <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in conjunction
with Boustead, have agreed to act as Placement Agents with respect to this offering subject to the terms and conditions contained in
the placement agent agreement, dated October 29, 2024 (the &#8220;Placement Agent Agreement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agents are not purchasing or selling any shares offered hereby, nor are they required to arrange for the purchase or sale of
any specific number or dollar amount of shares but have agreed to use their reasonable commercial efforts to arrange for the sale of
all of the shares. Because there is no minimum amount of shares of common stock that must be sold as a condition to closing this offering,
the actual number of shares sold in this offering is not presently determinable and may be substantially less than the shares noted herein
above. We have entered into a securities purchase agreement directly with one of the investors. Investors that did not
enter into a securities purchase agreement are relying solely on this prospectus in connection with the purchase of our securities
in this offering.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
negotiated the offering price for the shares in this offering with prospective investors. The factors considered in determining the price
included the recent market price of our common stock, the general condition of the securities market at the time of this offering, the
history of, and the prospects for the industry in which we compete, our past and present operations and our prospects for future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Placement Agents against specified liabilities, including liabilities under the Securities Act, and to contribute
to payments the Placement Agents may be required to make in respect thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement
Agents Fees, Commissions and Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being conducted on a reasonable best-efforts basis and the Placement Agents have no obligation to buy any of the securities
from us or to arrange for the purchase or sale of any specific number or dollar amount of securities. Upon the closing of this offering,
we will pay the Placement Agents a placement agents&#8217; fee equal to 9% of the aggregate gross cash proceeds to us from the sale of
the securities in the offering, of which A.G.P. will receive 60% and Boustead will receive 40%. With respect to gross proceeds raised
from the sale of securities to certain identified purchasers introduced by to us by Boustead, Boustead will receive 60% and 40% shall
be paid to A.G.P. In addition, we have also agreed to reimburse the Placement Agents at closing for legal expenses incurred by them
in connection with the offering in an amount not to exceed $100,000 and up to $50,000 for certain reasonable&#160;non-accountable&#160;fees
and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
further consideration for the Placement Agents&#8217; services, we have also agreed and paid the Placement Agents a refundable,
to the extent not incurred, up-front cash fee (the &#8220;Retainer Fee&#8221;) of $50,000 upon the engagement of the Placement Agents. The Retainer Fee will be applied against the Placement Agents&#8217; accountable
out-of-pocket expenses (in compliance with FINRA Rule 5110(g)(4)) that are payable by us in connection with this offering).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the per share and total cash placement agents&#8217; fee we will pay to the Placement Agents in connection with
the sale of the securities offered pursuant to this prospectus supplement and the accompanying prospectus, assuming the purchase of all
of the securities hereby on a best-efforts basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
                                            Share and<br/>
                                            Accompanying<br/>
                                            Common Warrant</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    Pre-Funded<br/>
 Warrant and<br/>
 Accompanying<br/>
 Common Warrant</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin: 0">Total</p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 43%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering
    price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.525</span></td><td style="width: 1%; text-align: left"/><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.524</span></td><td style="width: 1%; text-align: left"/><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">4,497,445.25</td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agents
    fees to be paid by us (9%)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.137</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.137</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">404,770.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses,
    to us</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.388</span></td><td style="text-align: left"/><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.388</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">4,092,675.18</p></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lock-Up
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to certain &#8220;lock-up&#8221; agreements, our executive officers, directors and holders of at least 5% of our common stock and securities
exercisable for or convertible into common stock outstanding immediately upon the closing of this offering, have agreed, subject to certain
exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise
dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk
of ownership of, directly or indirectly, engage in any short selling of any shares of common stock or securities convertible into or
exchangeable or exercisable for any shares of common stock, whether currently owned or subsequently acquired, without the prior written
consent of the Placement Agents, for a period of sixty (60) days after the closing date of the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agents, in their sole discretion, may release the common stock and other securities subject to the lock-up agreements described
above in whole or in part at any time. When determining whether or not to release common stock and other securities from lock-up agreements,
the Placement Agents will consider, among other factors, the holder&#8217;s reasons for requesting the release, the number of shares
of common stock and other securities for which the release is being requested and market conditions at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have agreed that, subject to certain exceptions, we will not (i) conduct any issuances of our common stock for a period
of 60 days following closing of this offering or (ii) enter into a variable rate transaction (as defined in the securities purchase agreement)
for a period of 120 days following closing of this offering; provided that following the closing date of this offering we will be permitted
to enter into an agreement with A.G.P. in connection with an &#8220;at the market&#8221; offering under Rule 415(a)(4) under the Securities
Act and make sales thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 102; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
retained Boustead to act as underwriter in our IPO, which we closed on September 2, 2022, pursuant to which we sold IPO Units consisting
of shares of our common stock and one warrant to purchase one share of common stock, at a public offering price of $8.125 per unit, resulting
in gross proceeds of $9,960,430, before deducting underwriting discounts and commissions. On September 29, 2022, Boustead exercised its
overallotment option, purchasing an additional 183,883 IPO Units (22,986 shares on a post-reverse split basis), resulting in gross
proceeds of $1,494,041, before deducting underwriter commissions and discounts. As a result, our IPO raised a total of $11,454,474, before
deducting underwriting discounts, commissions and related IPO expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, we entered into a securities purchase agreement with the Investor and consummated the sale to such investor of the
January 2023 Convertible Note with an initial principal amount of $4,300,000, bearing interest at 5% per annum, and a warrant to purchase
1,018,079 shares (127,260 shares on a post-reverse split basis) of our common stock at a fixed exercise price of $2.35 per share
($1.93 per share on a post-2024 Reverse Split Basis, as adjusted). Boustead served as our placement agent in the January
2023 Convertible Note offering and received a placement agent fee of $320,000 at the closing, representing 7.0% of the gross cash proceeds
at the closing plus 1% in non-accountable expenses. In addition, Boustead received a placement agent warrant to purchase 71,266 shares
of common stock, representing 7.0% of the warrant shares issued in the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, we completed private placement offerings pursuant to which we sold to several accredited investors
an aggregate of $365,000 and $225,000, respectively, of our 2022 Convertible Notes. Boustead acted as placement agent in the 2022 Convertible
Note and warrant offering and received commissions and non-accountable reimbursements of 10% of the gross proceeds received and warrants
to purchase 10% of the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, we completed the August 2022 Note and Warrant Offering, pursuant to which we sold to three accredited investors an aggregate
of $125,000 of our 10% promissory notes, which were due upon completion of our IPO, and warrants to purchase 50,000 shares of common
stock, at an exercise price of $2.50 per share (6,250 shares at $20.00 per share on a post-reverse split basis). Boustead acted
as placement agent in the August 2022 Note and warrant offering but deferred its cash compensation in relation to such offering. At the
time of the IPO, 30,000 of the warrants sold in August 2022 Note and Warrant Offering were registered for resale pursuant to a separate
resale prospectus and were subsequently exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agents are full-service financial institutions engaged in various activities, which may include sales and trading, commercial
and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage
and other financial and non-financial activities and services. The Placement Agents may in the future provide various investment banking,
commercial banking and other financial services for us and our affiliates for which they may in the future receive customary fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of their various business activities, the Placement Agents and certain of their respective affiliates may make or
hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may
involve securities and/or instruments issued by us and our affiliates. If the Placement Agents or their respective affiliates have a
lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies.
The Placement Agents and their respective affiliates may hedge such exposure by entering into transactions that consist of either the
purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including
potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock
offered hereby. The Placement Agents and certain of their respective affiliates may also communicate independent investment recommendations,
market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may
at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 103; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
M</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. As an underwriter, each Placement Agent would be required to comply with the requirements
of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and
Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the Placement
Agents acting as principal. Under these rules and regulations, the Placement Agents:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may not engage in any stabilization activity in connection with our securities; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted
under the Exchange Act, until it has completed its participation in the distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
Market</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &#8220;SHPH.&#8221; We do not intend to apply for listing of the
Warrants on any securities exchange or other nationally recognized trading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_008"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered hereby and certain legal matters in connection with this offering relating to U.S. law will be passed
upon for us by Dorsey &amp; Whitney LLP, New York, NY. The Placement Agents are being represented by Sullivan &amp; Worcester LLP,&#160;New
York, New York, in connection with this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_009"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements of Shuttle Pharmaceuticals Holdings, Inc. (the &#8220;Company&#8221;) as of
December 31, 2023 and 2022 and for the fiscal years then ended, have been audited by Forvis Mazars LLP, independent registered public
accounting firm, as set forth in their report thereon, included in the Company&#8217;s Annual Report on Form 10-K/A for the fiscal year
ended December 31, 2023, and included herein. Such consolidated financial statements have been included herein in reliance upon such report
given on the authority of such firm as experts in accounting and auditing. The report of Forvis Mazars LLP contains an explanatory paragraph
regarding substantial doubt about the Company&#8217;s ability to continue as a going concern and an explanatory paragraph regarding a
restatement of previously issued consolidated financial statements to correct misstatements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_011"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
filed with the SEC a registration statement under the Securities Act for the securities offered by this prospectus. This prospectus does
not contain all of the information in the registration statement and the exhibits and schedule that were filed with the registration
statement. For further information with respect to us and our securities, we refer you to the registration statement and the exhibits
and schedule that were filed with the registration statement. Statements contained in this prospectus about the contents of any contract
or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and we refer you to the
full text of the contract or other document filed as an exhibit to the registration statement. The SEC maintains an Internet website
at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that file
electronically with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file periodic reports and current reports under the Exchange Act, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q
and Current Reports on Form 8-K, and other information with the SEC. These periodic reports and other information are available for inspection
and copying at the SEC regional offices, public reference facilities and on the website of the SEC referred to above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge on or through our internet website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current
reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon
as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information found on our website,
https://shuttlepharma.com, other than as specifically included in this prospectus, is not part of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="kpa_001"></span><b>Consolidated
Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_003">Condensed
    Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_004">
    Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023
    (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_005">Condensed
    Consolidated Statements of Changes in Stockholders&#8217; Equity for the three and six months ended June 30, 2024 and 2023 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_006">Condensed
    Consolidated Statements of Cash Flows for the three and six months ended June 30, 2024 and 2023 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_007">Notes
    to Condensed Consolidated Financial Statements (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_001">Report
    of Independent Registered Public Accounting Firm, Forvis Mazars LLP</a> (PCAOB ID 686</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_002">Consolidated
    Balance Sheets as of December 31 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_003">Consolidated
    Statements of Operations for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_004">Consolidated
    Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_005">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_006">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-25</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 105; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="sj_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bk_010"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_zz0UbtyOvOAe" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20240630_zNRIWOSTP0s6" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zSSLobdvTnT1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzEnR_zMho2VjiQfKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000022" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">695,594</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000023" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_i02I_pp0p0_maACzEnR_z7QfsnXB3ZUl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-06-30" id="Fact000025" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">139,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000026" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">114,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i02I_pp0p0_maACzEnR_z4OGSVNyz36j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-06-30" id="Fact000028" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,642,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000029" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestReceivableCurrent_i02I_pp0p0_maACzEnR_zMNQzLT5mKbj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accrued interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2024-06-30" id="Fact000031" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000032" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzEnR_maAzQhT_zkfzwHhirFa9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000034" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,485,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000035" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,593,005</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzQhT_zDub2vbo0Jsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" id="Fact000037" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,953</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000038" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAssetsNoncurrent_i01I_maAzQhT_zD7eAvpDY2Kl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0040">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0041">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0_maAzQhT_zImP7MkWPack" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating lease right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" id="Fact000043" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">305,712</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000044" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">333,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_pp0p0_mtAzQhT_z26TVbrBJeW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30" id="Fact000046" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,812,998</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,951,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zwpsqqjpMxyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_NonrelatedPartyMember" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,860</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCpV5XlMDtp4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0058">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzkr1_zve8gADvOFT" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0061">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--InterestPayableCurrent_i02I_pp0p0_maLCzkr1_zLB8iudwmMVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000064" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">130,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">110,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzkr1_zTGovasC0Te9" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes payable to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0067">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0068">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pp0p0_maLCzkr1_z06sqV49jkTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Convertible notes payable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000070" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">826,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">595,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLiabilitiesCurrent_i02I_pp0p0_maLCzkr1_ztXjpt8YrLO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000073" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0074">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzkr1_zGrrBaB3wk39" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000076" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,479</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzkr1_maLzRHI_zpPi3WNnVEd3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,384,620</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,042,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleLongTermNotesPayable_i01I_pp0p0_maLzRHI_zbJYyAxg08r9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Convertible notes payable non-current, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0082">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">135,089</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_pp0p0_maLzRHI_zMno9en6gOK5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-06-30" id="Fact000085" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">359,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">414,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0_maLzRHI_zeddcKchab9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating lease liability non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact000088" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">267,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">304,127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Liabilities_i01TI_pp0p0_mtLzRHI_maLASEzswR_zxBRRG4J91tj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" id="Fact000091" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,011,564</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,895,965</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquityAbstract_i01B_z76K2neSZDNc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_pp0p0_maSEzByQ_z9EnQL9iQiI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Series A Convertible Preferred Stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240630_zElYD9diOewi" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zJm4tgWr5gN4" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000100" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; $<span id="xdx_901_eus-gaap--PreferredStockLiquidationPreference_iI_c20240630_zoLKVfgXxDSh" title="Preferred stock, liquidation preference per share"><span id="xdx_90C_eus-gaap--PreferredStockLiquidationPreference_c20231231_pdd" title="Preferred stock, liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2024-06-30" id="Fact000104" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share liquidation value; <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630_zhxgAh7feyFe" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20231231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000108" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20240630_zhk7azOy0Pr" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20240630_z4vtvIqm4Tr1" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20231231_zqzci2pMnbgd" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zrkkFI50vkKa" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000112" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000114" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000116" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued or outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzByQ_zOuv84wsEVU3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Common stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240630_zte3diWOfBf1" title="Common stock, par value"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zCrP33FbHTX" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zqTkkiz6Eusd" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20231231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240630_zbcDvRh7Czkg" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_z9gxcZfGpjh4" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,106,233</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20231231_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20231231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,008,689</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" id="Fact000120" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzByQ_zB009RI3F0r1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30" id="Fact000139" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,996,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,489,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzByQ_z0EEFnpQ1pWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000142" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">29,195,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">25,433,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzByQ_maLASEzswR_z5KSdM7Dvlkl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000145" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">801,434</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,055,771</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzswR_zQVsrmkmMfc5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000148" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,812,998</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,951,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_004"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_zVnrqzU3z0C1" summary="xdx: Statement - Condensed Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240401__20240630_ztSEp13iXXL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230401__20230630_zelTKaWojUk4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240630_zDBBoOXJirmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_zpFAGZY5ilw" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_maOILzAy9_zpHIF6fA01Ki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0154">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzrlT_z3oCIgEIPgMh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012024-06-30" id="Fact000161" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">645,719</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-012023-06-30" id="Fact000162" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">839,665</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000163" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,231,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,761,466</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzrlT_z5ywls2Pl9Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30" id="Fact000166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">310,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30" id="Fact000167" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">209,279</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000168" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">634,647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30" id="Fact000169" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">464,633</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LegalFees_i01_pp0p0_maOEzrlT_zZ5RFeQ0Bdg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Legal and professional</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-04-012024-06-30" id="Fact000171" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">526,877</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-04-012023-06-30" id="Fact000172" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">416,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-01to2024-06-30" id="Fact000173" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,001,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-06-30" id="Fact000174" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">784,312</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzrlT_msOILzAy9_zaHwYbgdjaD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-04-012024-06-30" id="Fact000176" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,482,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-012023-06-30" id="Fact000177" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,465,632</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-06-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,867,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-06-30" id="Fact000179" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,010,411</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzAy9_maILFCOzqIm_zSy1eSW20Zy2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,482,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000182" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,465,632</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000183" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,867,481</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,010,411</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zFvhfkY9k39" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0191">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-04-012023-06-30_us-gaap_RelatedPartyMember" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,588</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0193">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-06-30_us-gaap_RelatedPartyMember" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,825</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_msNIEz2Mq_zXeMGKmAa0Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-04-012024-06-30_us-gaap_NonrelatedPartyMember" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-04-012023-06-30_us-gaap_NonrelatedPartyMember" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">729,351</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-06-30_us-gaap_NonrelatedPartyMember" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">928,200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-06-30_us-gaap_NonrelatedPartyMember" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,328,682</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--InvestmentIncomeInterest_i01_maNIEz2Mq_zLx8TKAQmIl1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-04-012024-06-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-04-012023-06-30" id="Fact000202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-01to2024-06-30" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,611</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-012023-06-30" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FinanceFee_i01N_pp0p0_di_msNIEz2Mq_z99XquvJREp5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0206">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0208">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2023-01-012023-06-30" id="Fact000209" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,245</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_pp0p0_maNIEz2Mq_zQTROu7twHG2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-04-012024-06-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">143,773</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-04-012023-06-30" id="Fact000212" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">434,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-06-30" id="Fact000213" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,089</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-06-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,675,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FairValueAdjustmentOfWarrant_i01N_di_msNIEz2Mq_zPDvSxaV8oW6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GainLossOnSaleOfInvestments_i01_pp0p0_maNIEz2Mq_zEd2scVHcBGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2024-04-012024-06-30" id="Fact000221" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-04-012023-06-30" id="Fact000222" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,744</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2024-01-01to2024-06-30" id="Fact000223" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-012023-06-30" id="Fact000224" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i01_pp0p0_maNIEz2Mq_z5MGn37lrIv2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2024-04-012024-06-30" id="Fact000226" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">27,964</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-04-012023-06-30" id="Fact000227" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,534</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2024-01-01to2024-06-30" id="Fact000228" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">28,670</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-012023-06-30" id="Fact000229" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,528</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LossOnSettlementOfConvertibleDebt_i01N_pp0p0_di_msNIEz2Mq_zBmy7FgYEQL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on settlement of convertible debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-04-012023-06-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">415,553</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,315</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-06-30" id="Fact000234" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">433,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--GainOnSettlementOfAccountsPayable_i01_maNIEz2Mq_zxx3UW954qj3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on settlement of accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--GainOnForgivenessOfNotePayable_i01_maNIEz2Mq_zw2pBB3K8aOi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of Paycheck Protection Program note payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_mtNIEz2Mq_maILFCOzqIm_zritPdHJStvh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30" id="Fact000246" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">548,581</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" id="Fact000247" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">718,740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000248" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">894,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-06-30" id="Fact000249" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">149,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzqIm_maNILzfMq_zqyZ4brk7pXd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss </td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_msNILzfMq_zTByhgZwRRWa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Dividend on Series A Preferred Stock</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_iN_di_msNILzfMq_zzS8PSEwBtKf" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deemed dividend on extinguishment of Series A Convertible Preferred Stock, as restated</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrants_iN_di_msNILzfMq_zlgd16apRF72" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deemed dividend on modification of equity-classified warrants, as restated</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_iN_di_msNILzfMq_z64Xmf2O27D6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_pp0p0_mtNILzfMq_zYZD4xTJzqT3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-04-012024-06-30" id="Fact000276" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,031,215</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" id="Fact000277" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,184,372</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000278" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,762,246</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-06-30" id="Fact000279" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,159,468</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zqrGFZGtTFt3" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zW8NGV3QwRz4" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,104,933</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zdfC9uCcrnlf" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zDqQq1W8yDn9" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" id="Fact000285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" id="Fact000287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,780,171</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zwfGps2CEixa" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_z88kG0sQVmJ5" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-06-30" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,090,890</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zIVoOEoQTfMc" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_z2SylNOs5ddj" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30" id="Fact000293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,742,520</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per shares - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20240401__20240630_zsWGNHP0KfRi" title="Net loss per shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20240401__20240630_z9v6AAJquwgb" title="Net loss per shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.96</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20230401__20230630_z7ks7AHVQu3a" title="Net loss per shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zRLG1ESdDDl3" title="Net loss per shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" id="Fact000301" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30" id="Fact000303" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.23</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240630_zV9rdz2S3fnf" title="Net loss per shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240630_zEJMpeNfpRb" title="Net loss per shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000305" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-06-30" id="Fact000307" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.80</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230630_zRfUzp4VLb9b" title="Net loss per shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zHHV5i7dEV35" title="Net loss per shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-06-30" id="Fact000309" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-06-30" id="Fact000311" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.81</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="sj_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
the Six Months Ended June 30, 2024</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_zEBxempytY6c" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zIIzVtlwSIca" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zcMekJfXtnOi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zDkpgwqHy6K3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_zHZu9EV2cJO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_438_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zkdbG1S1ZKbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold">Balance - December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxRgoDdBugbe" title="Balance, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,008,689</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,489,055</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000315" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,433,304</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,055,771</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_zNW4YG8OeOJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for conversion of accrued interest and principal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW8MgH0UT5Dk" title="Common stock issued for conversion of accrued interest and principal, shares" style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2024-01-012024-03-31" id="Fact000323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zr3eFurQbm17" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziYFf715yPEd" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zVVTFdFXot36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,449</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zE0Ddl11TNyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,731,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000342" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,731,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20240401__20240630_eus-gaap--StockholdersEquity_iS_zVadrAITOqC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziH5T658Wh64" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,102,511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,925,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,164,335</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,761,487</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_z8RIpvD1fu1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYioTsUxBcs" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zKQq6JiiUss2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,162</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zuj6cgDFFikk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,031,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,031,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20240401__20240630_eus-gaap--StockholdersEquity_iE_zdUELVWZpnn4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKkSGiYJr7K9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,106,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,996,963</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,195,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
the Six months ended June 30, 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
Paid in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;<br/>
Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_435_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zOAIcyCeWrck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold">Balance - December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk7GDs6hbvK4" title="Balance, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,700,414</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,518,433</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,840,581</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,677,869</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_z5TvIMQG3Tre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrants issued for financing costs, net of issuance fees of $<span id="xdx_902_ecustom--WarrantsIssuanceFees_c20230101__20230331_zPKchRFv6Eol" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2023-01-012023-03-31" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-03-31" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_zWzIKGFx869f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for conversion of accrued interest and principal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIBVWhGztdx5" title="Common stock issued for conversion of accrued interest and principal, shares" style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000394" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-03-31" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,547</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zp2cIcmtCDL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zQoT4Uo1ICmj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000403" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">975,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">975,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20230401__20230630_eus-gaap--StockholdersEquity_iS_z5ZPkBfOkLJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFpeDMwrhXqf" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,706,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,722,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000408" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,815,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,906,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43F_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zt98itd8sDe3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z80R6R8NOsYg" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,706,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,722,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000415" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,815,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,906,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_zzilDggjrTc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for conversion of accrued interest and principal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7dYK7rwWW53" title="Common stock issued for conversion of accrued interest and principal, shares" style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000425" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">228,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,163,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-04-012023-06-30" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,163,992</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_za5V8lB5RwM9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000428" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,522</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zGRa6z1ARyWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,184,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000435" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,184,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20230401__20230630_eus-gaap--StockholdersEquity_iE_zgV61d3h2xre" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTLTeuZvGKj8" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,935,278</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,935,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000439" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,000,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,935,610</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20230401__20230630_eus-gaap--StockholdersEquity_iE_ziGOwKYiN56d" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjEZHZ4IgEwe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000449" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,935,278</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,935,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000446" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,000,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,935,610</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_006"></span><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_zv5hVVpfh5Jk" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240630_zyUrLBzF82vj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230630_z6bsSK9qmFmi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzLhf_zfiU3mqxbye3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000454" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,762,246</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000455" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,159,468</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Depreciation_i02_pp0p0_maNCPBUzLhf_zoe4IYCFAyWl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-06-30" id="Fact000460" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,874</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-06-30" id="Fact000461" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_pp0p0_di_msNCPBUzLhf_zUfQAnoA0zx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-06-30" id="Fact000463" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,089</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-06-30" id="Fact000464" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,675,275</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUzLhf_zsF5XdGgaemj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfDebtDiscountPremium_i02_pp0p0_maNCPBUzLhf_zjbhLIW2Ia5l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and finance fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-01to2024-06-30" id="Fact000469" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">832,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-012023-06-30" id="Fact000470" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,116,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GainLossOnSaleOfInvestments_i02N_pp0p0_di_msNCPBUzLhf_zXA8zPLGkb87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2024-01-01to2024-06-30" id="Fact000472" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,720</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-012023-06-30" id="Fact000473" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,744</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i02N_pp0p0_di_msNCPBUzLhf_zVnD1YPPPTTh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2024-01-01to2024-06-30" id="Fact000475" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">28,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-012023-06-30" id="Fact000476" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,528</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AccruedInterestSettledWithCommonStock_i02_pp0p0_maNCPBUzLhf_zC2sPFfZF4Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accrued interest settled with common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:AccruedInterestSettledWithCommonStock" contextRef="From2024-01-01to2024-06-30" id="Fact000478" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:AccruedInterestSettledWithCommonStock" contextRef="From2023-01-012023-06-30" id="Fact000479" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LossOnSettlementOfConvertibleDebt_i02_pp0p0_maNCPBUzLhf_zBdR2IPSvgF9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Loss on settlement of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000481" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,315</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-06-30" id="Fact000482" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">433,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--GainOnForgivenessOfNotePayable_i02N_pp0p0_di_msNCPBUzLhf_zQHDYMEseGff" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on forgiveness of Paycheck Protection Program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainOnSettlementOnAccountsPayable_i02N_pp0p0_di_msNCPBUzLhf_zl3J11AGxOcb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on settlement on accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUzLhf_zGGxGfgUuBG1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-06-30" id="Fact000490" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">182,611</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30" id="Fact000491" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,855</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccruedInterestReceivableNet_i03N_pp0p0_di_msNCPBUzLhf_zffQos7ibr2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accrued interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2024-01-01to2024-06-30" id="Fact000496" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2023-01-012023-06-30" id="Fact000497" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,950</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_pp0p0_di_msNCPBUzLhf_zlbGhop8KNX4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000499" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,045</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-012023-06-30" id="Fact000500" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">82,199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUzLhf_zHap3ZaX7adl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-06-30" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,031</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-06-30" id="Fact000503" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,004</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDueToRelatedPartiesCurrent_i03_maNCPBUzLhf_zOmwDi7c1cse" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts payable and accrued expenses - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2024-01-01to2024-06-30" id="Fact000505" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">446</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2023-01-012023-06-30" id="Fact000506" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInInterestPayableNet_i03_maNCPBUzLhf_zOcfPBGgp08c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2024-01-01to2024-06-30" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2023-01-012023-06-30" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,511</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInAccruedInterestPayableRelatedParties_i03_maNCPBUzLhf_zXoMBOpDw1Se" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued interest payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties" contextRef="From2023-01-012023-06-30" id="Fact000512" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,135</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_pp0p0_msNCPBUzLhf_zBChLAt9dhDa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzLhf_zEjs4uxrKu7c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Change in operating lease asset and liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-06-30" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">703</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-06-30" id="Fact000518" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzLhf_maCCERCz82s_z1TD5koV6JX3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000520" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,638,425</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-06-30" id="Fact000521" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,984,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_pp0p0_di_msNCPBUzqZZ_z86iDIbWn5A6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Investment in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2024-01-01to2024-06-30" id="Fact000526" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,982</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2023-01-012023-06-30" id="Fact000527" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,970,905</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_pp0p0_maNCPBUzqZZ_zrR2G8HzRrel" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Proceeds from disposition of marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2024-01-01to2024-06-30" id="Fact000529" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,295,252</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-01-012023-06-30" id="Fact000530" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzqZZ_z5W8hr96VI66" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Purchase of equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzqZZ_maCCERCz82s_zf2jkbb8Qltd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000535" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,259,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-06-30" id="Fact000536" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,890,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_maNCPBUzI2s_zU9cZpc7Vhqg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common shares and exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzI2s_z9Xkld46y6h8" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from note payable-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_pp0p0_di_msNCPBUzI2s_z0aCNnXJO8Zk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Repayment of note payable-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2023-01-012023-06-30" id="Fact000548" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">685,473</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUzI2s_zNkaFQSZt112" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Proceeds from convertible notes payable and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-06-30" id="Fact000551" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,935,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromNotesPayableAndWarrants_i01_pp0p0_maNCPBUzI2s_zb1Xm9uetdBj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Proceeds from notes payable and warrants, as restated</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_pp0p0_di_msNCPBUzI2s_zpbVBSYb2Owj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Payment for finance costs related to convertible note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-01-012023-06-30" id="Fact000557" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">345,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_msNCPBUzI2s_zG9azIWok9o7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Payment of convertible note payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">501,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_maCCERCz82s_mtNCPBUzI2s_ztegXVb7oGK9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000562" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">501,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-06-30" id="Fact000563" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,904,527</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCz82s_zcCZoJzkI18b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-06-30" id="Fact000565" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,880,822</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-06-30" id="Fact000566" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,970,417</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000568" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-06-30" id="Fact000571" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">695,594</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-06-30" id="Fact000572" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,446,786</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-06-30" id="Fact000577" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,958</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-06-30" id="Fact000578" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,373</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0_zKpl54fG1X2f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental non-cash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommonStockIssuedForConversionOfAccruedInterest_i01_zrTrthV1fVo7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for conversion of accrued interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--CommonStockIssuedForSettlementOfDebt_i01_pp0p0_zn0XlYCrTCb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for settlement of debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForSettlementOfDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000589" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">325,298</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForSettlementOfDebt" contextRef="From2023-01-012023-06-30" id="Fact000590" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,268,539</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantsIssuedForFinancingFees_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Warrants issued for financing fees, net of issuance fees of $<span id="xdx_906_ecustom--WarrantsIssuanceFees_c20240101__20240630_zukxB7tWHZc2" title="Warrants issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2024-01-01to2024-06-30" id="Fact000595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_901_ecustom--WarrantsIssuanceFees_c20230101__20230630_z6JC5oPLfeRl" title="Warrants issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2023-01-012023-06-30" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span>, respectively</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0592">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2023-01-012023-06-30" id="Fact000593" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--InitialRecognitionOfRightOfUseAssetAndLiability_i01_zJCeZ7OM7IFk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Initial recognition of right of use asset and liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:InitialRecognitionOfRightOfUseAssetAndLiability" contextRef="From2023-01-012023-06-30" id="Fact000600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,556</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p id="xdx_045_c20240101__20240630_zEdnI3IfwOb1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_007"></span>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Unaudited Condensed Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
30, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000602" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLXVKFIsS1ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82D_zXC00uKq6eif">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221;) was originally formed
as Shuttle Pharmaceuticals, LLC in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed articles of conversion
with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name to Shuttle Pharmaceuticals,
Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbp3AWOqkUol" title="Number of shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,625,000</ix:nonFraction></span> shares of common stock in exchange for
<span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhgNNlG0A6ck" title="Sale of stock membership percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed a reverse merger with
Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation, pursuant to which
Shuttle, our operating entity, became a wholly owned subsidiary of the Company. All share numbers referenced herein reflect a 1-for-8 reverse split of our common stock on a post-split basis, which was effective as of August 13, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was initially funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract
provided by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#8217;s initial public offering in September
2022, the Company has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation
with metabolite biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in its clinical trials that will cause the Company or the FDA
to delay or suspend the clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unaudited condensed consolidated financial statements are prepared on a going concern basis, which contemplates the realization of
assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since
inception and has a net loss of approximately $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_zs7rQzF5awJ1" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000608" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">3.8</ix:nonFraction></span>
million and <span id="xdx_90A_eus-gaap--Revenues_dxL_c20240101__20240630_zCRK4PZjgxB" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0610">no</span></span> revenues
for the six months ended June 30, 2024 and has working capital of approximately $<span id="xdx_90A_ecustom--WorkingCapital_pn5n6_c20240101__20240630_z2hYoN0mxKp2" title="Working capital"><ix:nonFraction name="SHPH:WorkingCapital" contextRef="From2024-01-01to2024-06-30" id="Fact000612" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span>
million as of June 30, 2024. In addition, the convertible note payable outstanding at June 30, 2024 includes covenants and certain
cash payment requirements. On July 12, 2024, the Company informed the investor of its convertible note that the Company&#8217;s expected restatement
of its financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the convertible
note. On August 6, 2024, the Company paid $<span id="xdx_905_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20240806_zZosElncYMMa" title="Convertible note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-08-06" id="Fact000614" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million to the investor of the convertible note and received a waiver from the investor
related to the default. The funds paid are restricted and will be held as collateral to the balance owed under the convertible note (see
Note 9). These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt
about the Company&#8217;s ability to continue as a going concern within one year after the date that the unaudited condensed
consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023,
the Company entered into a securities purchase agreement with an institutional investor through which the Company sold a convertible
note with a principal value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgjKBnoYEK3h" title="Debt instrument, face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000616" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million, along with a <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zirqzGcgOZm6" title="Warrant term::XDX::P4Y"><span style="-sec-ix-hidden: xdx2ixbrl0618">four</span></span>-year warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2U5NvKbcKEd" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000620" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></span> shares of common stock, exercisable
at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDNMyH8Ns1G" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share, providing the Company with approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhbTYHHvDnTh" title="Net proceeds from warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000624" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction></span> million in net proceeds. To date, the warrant has not yet been exercised.
However, the Company&#8217;s existing cash resources, marketable securities and the cash received from the equity offering and convertible
note are not expected to provide sufficient funds to carry out the Company&#8217;s operations and clinical trials through the next twelve
months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA approval of the IND
for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the Company agreed
to an expansion of the clinical trial, necessitating additional capital to complete the trial as well as fund ongoing operations. As
a result, management  had initiated a $<span id="xdx_90E_eus-gaap--PartnersCapital_iI_pn5n6_c20230131_zo1XdISLnkXe" title="Initiated a capital offering"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="AsOf2023-01-31" id="Fact000626" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span>
million rights offering and submitted an application for a SBIR grant for
non-dilutive funding for pre-clinical project through the NIH. The Company is also
currently pursuing other financing. The ability of the Company to continue as a going concern is dependent upon its ability to
successfully raise additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials and bring a
drug candidate to commercialization to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the future effects on
the recoverability and classification of assets or the amounts and classification of liabilities if the Company is unable to
continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000628" name="us-gaap:ErrorCorrectionTextBlock"><p id="xdx_807_eus-gaap--ErrorCorrectionTextBlock_zMuTpislNY6" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Note <span style="font-family: Times New Roman, Times, Serif">2
&#8211; <span id="xdx_827_zBsHq7vx4ZIf">Restatement of Previously Issued Financial Statements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>&#160;</span></span></b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000630" name="SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_ztc1gOR7tjkb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>The impact of the errors described above also impact
the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>&#160;</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8B9_zV3IdsUTWKfl">Schedule
 of Error Corrections And Prior Period Adjustments</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpAZDsJ2HHgh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zil2vv7D4Zn1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z2miWDOBG6Jf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_iI_z20joSFUHD9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact000632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,543,363</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,489,055</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z1MXLFGq7K93" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact000636" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,487,612</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000637" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,433,304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Adjustments
    include corrections for stock compensation errors (increase of $<span id="xdx_90C_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9htjoTqHbv2" title="Stock compensation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,843,052</ix:nonFraction></span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zljaKMw5yfJ3" title="Accrued dividends" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDividendsReceivable" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span id="xdx_904_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9y2rds0NWB" title="Issuance cost" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInIssuanceCost" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000644" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,082</ix:nonFraction></span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span id="xdx_90C_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_znckfEMQmWO5" title="Warrants" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInWarrants" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,266</ix:nonFraction></span>),
    reclassifications of warrants from liability to equity (increase of $<span id="xdx_90E_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zf8dTIB15zDj" title="Warrants from liability" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInWarrantsFromLiability" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,554</ix:nonFraction></span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span id="xdx_904_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zVyoTMoi5uwc" title="Debt instrument" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000650" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,213,498</ix:nonFraction></span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Adjustments include corrections for stock compensation errors (increase of $<span id="xdx_90A_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z8gOY06XlUha" title="Stock compensation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,009,461</ix:nonFraction></span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span id="xdx_907_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zvngUaX6yOKh" title="Fair value of warrants" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInFairValueOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,930</ix:nonFraction></span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zFjHB3SKH1u5" title="Accrued dividends" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDividendsReceivable" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span id="xdx_90A_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zSVO2RCnUXYd" title="Derivatives loss" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000658" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,151</ix:nonFraction></span>); correction of issuance cost recognition related to financing transactions (decrease of $<span id="xdx_90D_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zrUKb6hAliXh" title="Issuance cost" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInIssuanceCost" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,407</ix:nonFraction></span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span id="xdx_90A_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zGiFL1ScJAR" title="Net income loss" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInNetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,967,621</ix:nonFraction></span>).</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zYWPsIODHLee" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000664" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zwX833PQD2H7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_829_zWAALifadsVe">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000666" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbNA1oLSmCg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zCBeclORz1k">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial statements and with the instructions to Form 10-Q
and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not
contain all information and notes required by GAAP for annual financial
statements. A complete discussion of the Company&#8217;s significant accounting policies is included in the Company&#8217;s Annual Report
on Form 10-K for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all of
the adjustments necessary to present the financial position of the Company as of June 30, 2024 and the results of operations and
cash flows for the periods presented. The accompanying condensed consolidated financial statements of the Company have not been
audited by the Company&#8217;s independent registered public accounting firm, except that the year-end consolidated balance sheet
was derived from audited financial statements. The results of operations for the six months ended June 30, 2024 are not necessarily
indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial
statements should be read in conjunction with the restated financial statements and related notes thereto for the year ended
December 31, 2023 included in the Company&#8217;s Annual Report on Form 10-K/A filed with the SEC on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000668" name="SHPH:ReverseStockSplitPolicyTextBlock"><p id="xdx_847_ecustom--ReverseStockSplitPolicyTextBlock_zUQwwFrvzScl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zMdaqovuKvXk">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2024, in order to meet Nasdaq&#8217;s minimum bid price requirement of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdpnAuWG6Lol" title="Minimum bid price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember" id="Fact000670" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>
per share (the &#8220;Minimum Bid Price Requirement&#8221;), the Company effectuated a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1d0psoH6nQc" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-08-132024-08-13_us-gaap_SubsequentEventMember" id="Fact000672" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-8 reverse stock split</ix:nonNumeric></span> of its issued and
outstanding common stock, rounding up to account for any fractional shares (the &#8220;Reverse Stock Split&#8221;). The Reverse
Stock Split had no effect on the Company&#8217;s authorized shares of common stock or preferred stock and the par value will remain
unchanged at $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240813_zMXv9hl7eJbj" title="Common stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240813_z0BWOOj98It8" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-08-13" id="Fact000674" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-08-13" id="Fact000676" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span>,
respectively. Following the reverse stock split on August 13, 2024, the Company had a total of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zztmaLiD6Qoe" title="Common stock shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlqhzVPvDeRi" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember" id="Fact000678" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember" id="Fact000680" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,111,235</ix:nonFraction></ix:nonFraction></span></span>
shares issued and outstanding (or <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240630_z7CZ066K6Nl3" title="Common stock shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240630_z8BjDAR117Yd" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000682" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,106,233</ix:nonFraction></ix:nonFraction></span></span>
on a post-split basis as of June 30, 2024).</span> All common stock share, option, warrant and per share amounts (except our
authorized but unissued shares) have been retroactively adjusted in these financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000686" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zVRaxJZ6JGAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zi0eokpZriz4">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned
subsidiaries, Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000688" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zty8POBdZ14f">Correction
of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards
Codification (&#8220;ASC&#8221;) 730. As a result, certain prior year amounts have been corrected for consistency with the current
year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial
statements in accordance with SEC Staff Accounting Bulletin No. 99, &#8220;Materiality,&#8221; (ASC Topic 250, Accounting Changes
and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed
consolidated statements of operations are not material to any previously presented financial statements based upon overall
considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated
balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes
in stockholders&#8217; equity, to these financial statements, or for any previously presented interim or annual financial
statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted
earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was
$<span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zjzxGy9n2Tqg" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,708</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zEx5IEd6PiT8" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,715</ix:nonFraction></span>, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and
six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000694" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zUEa4AVq93g1" style="display: none">Schedule of the Error Correction</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztXtgIiL0mS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Corrected</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,944,181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000697" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,715</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,761,466</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact000700" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,918</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,226,099</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-06-30" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,226,099</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000708" name="us-gaap:UseOfEstimates"><p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3JEbn1v7fOi">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the
reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on
current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed
consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of
bifurcated derivative liabilities and other financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000710" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zokUH3G8A7Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zxtJnn7V0F96">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of June 30, 2024 and December 31, 2023, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000712" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zkEJLZMnX1Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zFoSdsPsZsdh" style="display: none">Schedule of Cash and Cash Equivalents</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zdf2YYEPgH92" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z0DgJpGOb3c6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zpVNW72A3ffa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-06-30" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,594</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,550,098</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zkXzbm1UOUsk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,318</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zESWBcrIg25g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,594</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zn4zpQIooYi6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240630_zFoCnqZK8quc" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-06-30" id="Fact000723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per institution. The
amount in excess of the FDIC insurance as of June 30, 2024 was approximately $<span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20240630_zjyRhVQqCk7e" title="Cash, uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-06-30" id="Fact000725" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000727" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zewlyN8EM7Ig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zWYFKpwXUUxb">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding
balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20240630_zOxm6QfMfZeg" title="Marketable securities, outstanding balance"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-06-30" id="Fact000729" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>
million and $<span id="xdx_907_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20231231_zNyG7iZlRMN7" title="Marketable securities, outstanding balance"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction></span>
million as of June 30, 2024 and December 31, 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company
recognized interest income of $<span id="xdx_90A_eus-gaap--InvestmentIncomeInterest_c20240401__20240630_zcq2CT9LGwf8" title="Interest income"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-04-012024-06-30" id="Fact000733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,158</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--InvestmentIncomeInterest_c20230401__20230630_z07CBpxiZfPd" title="Interest income"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-04-012023-06-30" id="Fact000735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,267</ix:nonFraction></span>,
realized gains of $<span id="xdx_90E_eus-gaap--GainLossOnSaleOfInvestments_c20240401__20240630_zqFcztULftf2" title="Gain on sale of marketable securities"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2024-04-012024-06-30" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,683</ix:nonFraction></span>
and $<span id="xdx_909_eus-gaap--GainLossOnSaleOfInvestments_c20230401__20230630_zztdgOwkA1Al" title="Gain on sale of marketable securities"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-04-012023-06-30" id="Fact000739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,744</ix:nonFraction></span>,
and unrealized loss of $<span id="xdx_90A_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20240401__20240630_zWCIvWQwRsIf" title="Unrealized loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2024-04-012024-06-30" id="Fact000741" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,964</ix:nonFraction></span>
and unrealized loss of $<span id="xdx_907_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20230401__20230630_zVAgkZCa1xv9" title="Unrealized loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-04-012023-06-30" id="Fact000743" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,534</ix:nonFraction></span>,
respectively. During the six months ended June 30, 2024 and 2023, the Company recognized interest income of $<span id="xdx_903_eus-gaap--InterestIncomeExpenseNet_c20240101__20240630_zyDmZWPkZUo7" title="Interest income"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-01to2024-06-30" id="Fact000745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,611</ix:nonFraction></span>
and $<span id="xdx_904_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630_zEhr8qDKa026" title="Interest income"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-06-30" id="Fact000747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,955</ix:nonFraction></span>,
realized gains of $<span id="xdx_902_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20240101__20240630_zq28xeSQy6Xd" title="Marketable securities realized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2024-01-01to2024-06-30" id="Fact000749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,720</ix:nonFraction></span>
and $<span id="xdx_90F_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20230630_zFgLIQUum3e7" title="Marketable securities realized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-012023-06-30" id="Fact000751" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,744</ix:nonFraction></span>,
and unrealized loss of $<span id="xdx_901_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20240101__20240630_zKHoCz44OTX2" title="Marketable securities unrealized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,670</ix:nonFraction></span>
and unrealized gain of $<span id="xdx_908_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230630_ze93KZfxuNKd" title="Marketable securities unrealized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-012023-06-30" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,528</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000757" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvCubePqHs28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zsCyT2nR28g1">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000759" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4Fjp8jYHK5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of June 30, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z04BtaXIERfc" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">June 30, 2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zExD2SVowPH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLJtGezKo55" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmfWKey4sYWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zjoqMgNxUsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLGc9i6fzSJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zxYQDrtyDMk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,995</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2024-06-30_us-gaap_USTreasurySecuritiesMember" id="Fact000769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,995</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zDwqI7ggcyO2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-06-30" id="Fact000774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zr8UHTdpBgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z9RhqCNdYVqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000783" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,919</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zNRORHgltpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember" id="Fact000788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30_custom_AcceleratedFeatureMember" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zwgNXMGU1U4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30" id="Fact000794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zb7iOAM75Kdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z76zr6Fa3GUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z01v4lD9OZA8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zwkx62sH2px7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zvkOmL0nCbfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zoumSoH7GBU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zUOt3GVPWwL6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact000809" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zS2K50xTTHjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zgtC2JqIWhO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zIDEG5nHspT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zm2eBRJ81m98" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zcF4kM03SRN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zsDUSByWTOL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000836" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zU1IAwdJYrok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zc92axd5kqph">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of
our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its
fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed
consolidated statements of operations. For our liability classified derivative financial instruments, the Company used a Monte Carlo
valuation model to value the derivative instruments at inception and on subsequent valuation dates. For our equity classified
derivative financial instruments, we used a Black-Scholes option-pricing model at the grant date to value the derivative instrument.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000838" name="SHPH:WarrantsPolicyTextBlock"><p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zlFf6cI9ITB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zBAgigV4CUnf">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in FASB ASC 480, <i>Distinguishing Liabilities from Equity</i> (&#8220;ASC 480&#8221;)
and ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether
the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a
component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria
for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each
balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the
unaudited condensed consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000840" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zK4BilFFxXkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zCKkoNeWM1e4">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Research and development expenses
are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical
and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief
operating officer, chief financial officer and directors&#8217; compensation. For the three and six months ended June 30,
2024 and 2023, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3sLaUIdASYc" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000842" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDnOqNRLzbMj" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000844" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million, respectively, and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLXJrFhnixJ1" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000846" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxhtNDbme28j" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000848" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million, respectively, was included within research and development due to their active involvement in the research and development
activities, materials, supplies, related subcontract expenses, and consulting costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of government
assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction including the
nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other provisions of
relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable alternative for
the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The Company has concluded
that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements against
incurred research costs. There were no reimbursements received for the six months ended June 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000850" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPYN1jBumNz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXKKuKw3o4M7">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per share on the face of the unaudited condensed consolidated
statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and
denominator of the basic earnings per share computation. In the accompanying unaudited condensed consolidated financial statements,
basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and
potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from
common shares issuable through contingent share arrangements, stock options and warrants unless the result would be
antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#8220;treasury
stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#8220;if-converted
method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000852" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVkGRAVxSzPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0Up43jkQn2f" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zV8FndxIngK" title="Convertible notes (Note 6)"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,744</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zTo8N3BvlMOd" title="Convertible notes (Note 6)"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,378</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXic79bck0k1" title="Warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxRJezezYiRe" title="Warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zO4l3p8AWrTc" title="Restricted stock units"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,839</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG41pxOQnzb2" title="Restricted stock units"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,382</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_ztFD3kr5Ef39" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-06-30" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">323,583</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zTCgcgQrSTIe" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">349,760</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zl7y3OUGU5xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000870" name="SHPH:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zu1RgEyL4q5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zny4h9Jlpx5i">Deferred
Offering Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASC 340-10-S99-1, costs directly attributable to an offering of equity securities are deferred and would be charged against the
gross proceeds of an offering as a reduction of additional paid-in capital. Deferred offering costs may consist of underwriting,
legal, accounting, and other expenses incurred through the balance sheet date that are directly related to a proposed public
offering. Should the proposed public offering prove to be unsuccessful, any deferred costs, as well as additional expenses to be
incurred, will be expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000872" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zPaMS221bwti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zoIhNWXVKYPl">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.
2023-07, Segment Reporting Topic 280, &#8220;Segment Reporting-Improvements to Reportable Segment Disclosures,&#8221; which allows disclosure
of one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance.
Additionally, the standard requires enhanced disclosures of significant segment expenses and other segment items, as well as incremental
qualitative disclosures on both an annual and interim basis. This guidance is effective for annual reporting periods beginning after
December 15, 2023, and interim reporting periods after December 15, 2024. Early adoption is permitted and retrospective application is
required for all periods presented. The adoption of this new guidance is not expected to have a significant impact on our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, Income Taxes Topic 740, &#8220;Income Tax-Improvements to Income Tax Disclosures,&#8221;
which requires enhanced disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation,
disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit,
and income tax expense or benefit from continuing operations. This guidance is effective for annual reporting periods beginning after
December 15, 2024. Early adoption is permitted and should be applied on a prospective basis, however retrospective application is permitted.
The Company is currently evaluating the impact of adopting this guidance on its consolidated and condensed financial statements and disclosures
included within notes to consolidated and condensed financial statements.</span></p>

</ix:nonNumeric><p id="xdx_85B_zXrZEEtLe4f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000874" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_zkftMnGKRIX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82E_zpNBimatGMvg">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use (&#8220;ROU&#8221;) assets and liabilities are recognized at the present value of the future lease payments as of
the lease commencement date. Operating lease expense is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, the Company had a lease agreement which allowed for the use of a laboratory facility for a monthly
payment of $<span id="xdx_90F_eus-gaap--OperatingLeasePaymentsUse_c20230101__20230630_zHUYfXFcZhfl" title="Lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2023-01-012023-06-30" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></span>. The laboratory lease commenced on October 1, 2018 and expired on <span id="xdx_905_eus-gaap--LeaseExpirationDate1_c20230101__20230630_zA0ZrFrtE0Gh" title="Lease expiration term"><ix:nonNumeric contextRef="From2023-01-012023-06-30" format="ixt:datemonthdayyearen" id="Fact000878" name="us-gaap:LeaseExpirationDate1">October 31, 2023</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility, entered into on February 16, 2023, with base
rent of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zoZsDXC0givj" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember" id="Fact000880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,206</ix:nonFraction></span> per month for a period of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_z90MMRHe9x1k" title="Lease term"><ix:nonNumeric contextRef="AsOf2023-02-16_custom_LeaseAgreementMember" format="ixt-sec:durmonth" id="Fact000882" name="us-gaap:LesseeOperatingLeaseTermOfContract">64</ix:nonNumeric></span> months, which increases at the rate of <span id="xdx_901_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zXU3xXYu5Qa1" title="Rent variable rate"><ix:nonFraction name="SHPH:RentVariableRate1" contextRef="AsOf2023-02-16_custom_LeaseAgreementMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% per year, that <span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_ze8OT5LVf6N6" title="Lease commencement"><ix:nonNumeric contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember" id="Fact000886" name="us-gaap:LesseeOperatingLeaseDescription">commenced June 1, 2023</ix:nonNumeric></span>. The lease
included a six-month <span id="xdx_905_ecustom--PercentageOfRentAbatement_pid_dp_uPure_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zvUYrqolu84i" title="Percentage of rent abatement"><ix:nonFraction name="SHPH:PercentageOfRentAbatement" contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction>%</span> rent abatement upon commencement. Additional common area maintenance (&#8220;CAM&#8221;) fees are charged monthly
and revised annually. The estimated monthly CAM fees are $<span id="xdx_90C_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zcYoJffu1Op3" title="Estimated monthly common area maintenance cost"><ix:nonFraction name="SHPH:EstimatedMonthlyCommonAreaMaintenanceCost" contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember" id="Fact000890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300</ix:nonFraction></span> per month for the first year of the lease, which are being expensed as
incurred. An irrevocable letter of credit (&#8220;LOC&#8221;) for the security deposit of $<span id="xdx_90E_eus-gaap--SecurityDeposit_iI_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zeAKOZIE73Qh" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember" id="Fact000892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,234</ix:nonFraction></span> and base rent of $<span id="xdx_909_eus-gaap--PaymentsForRent_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zZQMAJ2qUPfd" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,891</ix:nonFraction></span>, including
<span id="xdx_904_ecustom--PercentageOfRentAbatement_pid_dp_uPure_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zL3jVRGhrh83" title="Percentage of rent abatement"><ix:nonFraction name="SHPH:PercentageOfRentAbatement" contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction>%</span> abatement, and $<span id="xdx_90B_ecustom--CommonAreaMaintenanceCost_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zylt0HN5Fgu8" title="Common area maintenance cost"><ix:nonFraction name="SHPH:CommonAreaMaintenanceCost" contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,315</ix:nonFraction></span> of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is
the beneficiary of the LOC, and the expiry date of the LOC is <span id="xdx_901_eus-gaap--LeaseExpirationDate1_dd_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_ztDTesw2ekc9" title="Expiry date"><ix:nonNumeric contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember" format="ixt:datemonthdayyearen" id="Fact000900" name="us-gaap:LeaseExpirationDate1">March 1, 2025</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000902" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zK422Uc0lu5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the ROU lease expense components and cash flow information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zuH7q1lj8SJd" style="display: none">Schedule of Right-of Use Asset and Lease Information about Operating Lease</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240401__20240630_zo4SVVRAslZ4" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230401__20230630_zbeeaqAgEQqg" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20240630_zhRuAhvewrL8" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20230101__20230630_zxL68u1cciD4" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseCost_maLCzBxV_z9q8sduJrjNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-04-012024-06-30" id="Fact000904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,947</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-04-012023-06-30" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,193</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-06-30" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,894</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-06-30" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,737</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_maLCzBxV_zcBgOYmHf708" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-04-012024-06-30" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,937</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-01to2024-06-30" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,377</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--SubleaseIncome_iN_di_msLCzBxV_z3kL2k1B3bb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublease
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2024-04-012024-06-30" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,163</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2023-04-012023-06-30" id="Fact000915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,121</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2024-01-01to2024-06-30" id="Fact000916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,326</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2023-01-012023-06-30" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,242</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--LeaseCost_iT_mtLCzBxV_zt70iWUKYVJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-04-012024-06-30" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,721</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-04-012023-06-30" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,072</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-06-30" id="Fact000921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,945</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-06-30" id="Fact000922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,495</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zDvzNXhAEmD8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for operating cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-04-012024-06-30" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,707</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-04-012023-06-30" id="Fact000925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,331</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-06-30" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,189</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-06-30" id="Fact000927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,771</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zDgjUOaa64wi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    assets obtained in exchange for new operating lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-06-30" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,556</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_ztNUTeUGd3ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000934" name="SHPH:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zKOOShJEE5dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to operating leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zmYseQ6pdvtj" style="display: none">Schedule of Balance Sheet Information Related to Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin: 0">December 31,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 60%"><p style="margin: 0">Weighted-average remaining lease term (year)</p></td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zJlgJo77R5Ga" title="Weighted-average remaining lease term (year)" style="text-align: right; width: 16%"><ix:nonNumeric contextRef="AsOf2024-06-30" format="ixt-sec:duryear" id="Fact000936" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.18</ix:nonNumeric></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zXbHD3zsmgMd" title="Weighted-average remaining lease term (year)" style="text-align: right; width: 16%"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" id="Fact000938" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.98</ix:nonNumeric></td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20240630_zqJYJPwpJeXi" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-06-30" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.48</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z2wnmDWx5pXc" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" id="Fact000942" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.46</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zP9XtOBsNn76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000944" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmlHgFzUal7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of June 30, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zsVIUUnQJvr1" style="display: none">Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">Years Ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240630_zNDWEz2YNUT9" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzRbr_zHHdpQpnj0cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 80%">2024 (excluding the six months ended June 30, 2024)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2024-06-30" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzRbr_z0YgUsRG8Qv6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-06-30" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,246</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzRbr_ztHycVa7y8O1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-06-30" id="Fact000950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzRbr_zUATw95C4R95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-06-30" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,986</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzRbr_zpEa8QZPruM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-06-30" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzRbr_zvIAUmy9odxl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzRbr_z8Voh6apDace" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-06-30" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zHDliea95yo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-06-30" id="Fact000960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zRffpWzzHwPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-06-30" id="Fact000962" format="ixt:numdotdecimal" decimals="0" unitRef="USD">329,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z4tEeYU5Ws8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000964" name="SHPH:NotesPayableRelatedPartyDisclosureTextBlock"><p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zP7btAoQNmwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_826_zsfoxsulziO5">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2023 the Company incurred $<span id="xdx_905_eus-gaap--InterestExpense_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSa2G3pqRPfl" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-04-012023-06-30_us-gaap_RelatedPartyMember" id="Fact000966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,588</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--InterestExpense_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zNbppl22HDG3" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-06-30_us-gaap_RelatedPartyMember" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,825</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in interest expense. During the three and six months ended June 30, 2023 principal payments of $<span id="xdx_90E_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zwMgXRNbcgZ5" title="Proceeds from related party"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2023-04-012023-06-30_custom_OfficersSpouseMember" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,229</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z8SnsyEB7An" title="Proceeds from related party"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></span>,
respectively,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and accrued interest of $<span id="xdx_90F_eus-gaap--InterestPaidNet_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zYlR3qXv9cy2" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-04-012023-06-30_custom_OfficersSpouseMember" id="Fact000974" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,917</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--InterestPaidNet_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z9j5fEuesSf2" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember" id="Fact000976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,373</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were paid, respectively, on notes to related
parties. The principal and accrued interest for these notes were fully paid by December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000978" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zvYU5YvLJ2vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82D_zulWBaOMF4J6">Convertible Notes and Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alto
Opportunity Master Fund, SPC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, the Company entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master
Fund, SPC &#8211; Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to
the Investor a $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNtDRaoZtrl9" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000980" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,300,000</ix:nonFraction></span>
convertible note (the &#8220;Alto Convertible Note&#8221;) and warrant (the &#8220;Warrant&#8221;) to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWVFzsFu6Yqc" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></span>
shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWcGwhV8OVC" title="Warrants exerciable shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span>
per share, in exchange for gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znRi0JXEEfif" title="Proceeds from convertible note payable"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,935,000</ix:nonFraction></span> (the &#8220;Investment Amount&#8221;) (See Note 7). The Company determined that the Warrant contains a net cash settlement
feature at inception and categorized the Warrant as a liability in the accompanying unaudited condensed consolidated financial
statements. The Alto Convertible Note matures on March 11, 2025, but may be extended at the option of the noteholder. The Alto
Convertible Note amortizes on a monthly basis and the Company can make such monthly amortization payments in cash or, subject to
certain equity conditions, in registered shares of common stock or a combination thereof. Installments may be deferred by the
noteholder, resulting in a variable interest rate. However, the effective interest rate is approximately <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zHGXkMmAHFEa" title="Effective interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember_custom_AltoConvertibleNoteMember" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">218</ix:nonFraction></span>%
based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment, <span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgbKfszLE1Pk" title="Debt description"><ix:nonNumeric contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000990" name="us-gaap:DebtInstrumentDescription">the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $18.80
per share.</ix:nonNumeric></span> The noteholder has an acceleration
of installment amount conversion option (the &#8220;Acceleration Option&#8221;), whereby the noteholder, with certain share
percentage limitations, can convert to common stock any outstanding installment amount at an amount equal to the installment amount
plus five times (5x) the installment amount at any time. The Company has determined the Acceleration Option is an embedded
derivative within the host instrument and has bifurcated it from the host instrument and recorded it as a derivative liability
valued at $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztla3FvLtVm7" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000992" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></span>
at inception, using a Monte Carlo simulation model (Note 7). The Convertible Note is repayable over 26 months and bears interest at
the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGSX9sVhQJVc" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000994" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
per annum. Additionally, the note contains certain redemption options and &#8220;Make Whole&#8221; provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the &#8220;Security
Agreement&#8221;), an intellectual property security agreement (the &#8220;IP Security Agreement&#8221;) and a subsidiary guaranty (the
&#8220;Subsidiary Guaranty&#8221;). The security agreements and guaranty allow, among other things, for the Investor to have a security
interest in and place a lien on all of the Company&#8217;s assets and intellectual property until such time as the Alto Convertible Note
is paid off. In addition, the SPA called for the Company to enter into a springing deposit account control agreement (the &#8220;Springing
DACA&#8221;), which, in the event the Company defaults on its repayment of the Alto Convertible Note, would allow the Investor to assume
control of the Company&#8217;s bank account only with regard to any funds remaining outstanding under the Alto Convertible Note. As such,
in conjunction with entry into the SPA, the Company established a separate bank account in which it deposited the Investment Amount and
pursuant to which the Company, the Investor and the bank holding the Investment Amount, First Republic Bank, entered into the Springing
DACA agreement. As the Investment Amount had been held at First Republic Bank, in light of certain banking crises then affecting smaller
banks, on March 12, 2023, the Company and the Investor moved the Investment Amount from First Republic Bank, after which time the Springing
DACA was no longer in effect. Further, pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor
agreed that all of the Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing
DACA would no longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20240630_zmlZe7B5LWFg" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-06-30" id="Fact000996" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10.0</ix:nonFraction></span>
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Warrant, excluding the Springing
DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an opportunity to participate
in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company expects that such subsequent convertible
notes and warrants would be issued on substantially similar terms as the January 11, 2023 initial agreement, as amended, thus providing
the Company the opportunity to negotiate certain aspects of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$<span id="xdx_90A_ecustom--PaymentForPlacementAgent_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zfcJ9GxVRehj" title="Payment for placement agent"><ix:nonFraction name="SHPH:PaymentForPlacementAgent" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact000998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></span> cash compensation and a warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zNlaNCWlQFEk" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,909</ix:nonFraction></span> shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zciP5gmwiOl2" title="Warrants exerciable shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001002" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfzgohzrdu27" title="Expected years"><ix:nonNumeric contextRef="AsOf2024-06-30_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:durwordsen" id="Fact001004" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span>, volatility of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zWL0h0g74kDi" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">110</ix:nonFraction></span>%, a risk-free rate of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zGw4xw7rEyWk"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.53</ix:nonFraction></span>% for a value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zZTfzl6Rfn1c" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,543</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated the finance costs related to the Boustead placement agent fee of $<span id="xdx_90A_ecustom--PaymentForPlacementAgent_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z4JyrnAVvbLg" title="Payment for placement agent"><ix:nonFraction name="SHPH:PaymentForPlacementAgent" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></span>, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $<span id="xdx_90D_eus-gaap--PaymentsOfFinancingCosts_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zrWgAvpXqS2c" title="Allocation of financing costs"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001013" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,027</ix:nonFraction></span> to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zRgZBhK3xSf5" title="Warrant derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001015" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,245</ix:nonFraction></span> to the warrant derivative liability component,
expensed as a finance fee, and $<span id="xdx_905_eus-gaap--DebtInstrumentFeeAmount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zuCQAQYPFkPg" title="Equity warrant as reduction in additional paid in capital"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span> to the equity warrant as a reduction in additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated to the debt component of the note an original discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zbmjpy9sD1Kc" title="Debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact001019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>, legal fees of $<span id="xdx_908_eus-gaap--LegalFees_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zftX1FdSi2m" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,000</ix:nonFraction></span>, $<span id="xdx_908_ecustom--InterestFeeAmount_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zRdflibszHe9" title="Interest fee"><ix:nonFraction name="SHPH:InterestFeeAmount" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact001023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,000</ix:nonFraction></span> for additional
interest fees on day one added to note principal, $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zzl1hJdfMbC5" title="Debt principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact001025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></span> for the accelerated conversion feature, and $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zd6OUJitGPy" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact001027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,288,543</ix:nonFraction></span> for the fair value
of warrants, resulting in an additional $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zIa7wH7wgpSf" title="Interest expense debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact001029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310,543</ix:nonFraction></span> debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2024, the Company recorded interest expense of $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zLmWmanlrPug"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,685</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zbQvQuOPoK54"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">928,200</ix:nonFraction></span>,
respectively, which included amortization of debt discount as interest expense of $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20240401__20240630_zbRxsjT5yFma"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-04-012024-06-30" id="Fact001032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,505</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20240101__20240630_zchKazdBMQ49"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-01to2024-06-30" id="Fact001033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">832,014</ix:nonFraction></span>, respectively. During the
three and six months ended June 30, 2024, the Company settled $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zeAglM2UxOf9" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zRhgO3GIB9xj" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,200</ix:nonFraction></span>
of principal, and settled $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zvJq2u0LTtu1" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zvAQzKj5FWUi" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,783</ix:nonFraction></span>
of accrued interest, which settlements were made in the form of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3RJm6JzvED5" title="Stock issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFQtuxbx6yr7" title="Stock issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,197</ix:nonFraction></span>
shares of common stock. The Company also settled for cash during the six months ended June 30, 2024 $<span id="xdx_90A_eus-gaap--ProceedsFromInterestReceived_c20240101__20240630_zaXDOH3wagz" title="Settled for cash"><ix:nonFraction name="us-gaap:ProceedsFromInterestReceived" contextRef="From2024-01-01to2024-06-30" id="Fact001047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">501,667</ix:nonFraction></span>
of principal and $<span id="xdx_90D_eus-gaap--InterestPaidNet_c20240101__20240630_zYSujkvbVNdg" title="Interest paid"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-06-30" id="Fact001049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,958</ix:nonFraction></span>
of accrued interest for a total of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630_zGBqCyl7UCjk" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-01-01to2024-06-30" id="Fact001051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">558,628</ix:nonFraction></span>
of principal and interest paid in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2023, the Company recorded interest expense of $<span id="xdx_904_eus-gaap--InterestExpenseDebt_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGT7GdaEWCni"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">729,351</ix:nonFraction> </span>and $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zFPXgYg7KKgb"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,328,682</ix:nonFraction></span> respectively, which included
amortization of debt discount as interest expense of $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20230401__20230630_zMxxM1CXMpc"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-04-012023-06-30" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">549,125</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20230630_zoY2rXLAEqt4"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-06-30" id="Fact001055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,177</ix:nonFraction> </span>respectively. During the three and six months ended June
30, 2023, the Company paid $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zUW43QIDHUXd" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,527,750</ix:nonFraction> </span>and $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z9x2WOo2cGAl" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,593,900</ix:nonFraction></span> of principal, respectively, and paid $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zUe5fHa2cxdk" title="Accrued interest settled with common stock"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,689</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmqCQLosGhb4" title="Accrued interest settled with common stock"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember" id="Fact001063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,831</ix:nonFraction></span>, respectively, of accrued
interest, which payments were made in the form of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCyPHYOAPai" title="Stock issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">228,489</ix:nonFraction></span> and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyBirkFQ3xBi" title="Stock issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,864</ix:nonFraction></span> shares of common stock, respectively, during the three and
six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, the outstanding principal for the convertible note was $<span id="xdx_901_eus-gaap--ConvertibleDebt_iI_c20240630_z8EL5KiE4e8h"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-06-30" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,517,989</ix:nonFraction></span> and the debt discount remaining was $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20240101__20240630_z2iz59NMbfka"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2024-01-01to2024-06-30" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">691,754</ix:nonFraction></span>, with
a net convertible note carrying value of $<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20240630_zlqpdcBCfOu7" title="Convertible note payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-06-30" id="Fact001071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">826,235</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001073" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zubp9uVS5blb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82A_zYlPRc9g3vDd">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2024, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdsDLxcAnab7" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>
    and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAT6Im2P4UUj" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,197</ix:nonFraction></span> shares of common stock to settle $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzNUw4GTFV29" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjQZ0pRzzXnh" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact001081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,200</ix:nonFraction></span> of principal and $<span id="xdx_907_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNgAcatAe9y8" title="Accrued interest settled with common stock"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001083" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_908_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvDezBijxjF5" title="Accrued interest settled with common stock"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact001085" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,783</ix:nonFraction></span> of interest on a convertible note and
    incurred $<span id="xdx_903_ecustom--LossOnSettlementOfConvertibleDebt_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVJTkLAL3qeg" title="Loss on settlement of convertible debt"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_906_ecustom--LossOnSettlementOfConvertibleDebt_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQlD6AmYN1Xf" title="Loss on settlement of convertible debt"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact001089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,315</ix:nonFraction></span> of loss on settlement, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZOJdp03Nw5k" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,722</ix:nonFraction></span>
    and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAJzMnDlVHLd" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,347</ix:nonFraction></span> shares of common stock issued for vesting of restricted stock units, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2023, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg5iQH2Al9ld" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">228,489</ix:nonFraction></span>
    and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV8etwoNF2Wj" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,864</ix:nonFraction></span> shares of common stock to settle $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxu4slUQep81" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact001099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,527,750</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCjBOb1u081" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,593,900</ix:nonFraction></span> of principal and $<span id="xdx_906_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuXR7cKEL242" title="Accrued interest settled with common stock"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact001103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">220,689</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zna8nfAjTQLa" title="Accrued interest settled with common stock"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="Fact001105" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,831</ix:nonFraction></span> of interest, respectively,
    on a Convertible Note and incurred $<span id="xdx_905_ecustom--LossOnSettlementOfConvertibleDebt_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5adwDj3Cn27" title="Loss on settlement of convertible debt"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact001107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,553</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOmdqL20ei81" title="Loss on settlement of convertible debt"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="Fact001109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">433,807</ix:nonFraction></span> of loss on settlement, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zPif5ycVXr3b" title="Number of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,909</ix:nonFraction></span> shares of common stock, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_z7gEP7R4EiKj" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share (Note 5). In addition, Alto was granted warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zrQ8PLWNTO9f" title="Number of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31" id="Fact001115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></span> shares of common stock, at an
exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zZgg2BUMc7Xk" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share (Note 5, 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001119" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpt1jpLKTnHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the six months ended June 30, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zPuNzHLoPhTh" style="display: none">Schedule of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Life (years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGmmy2OE5gHk" title="Number of Warrants Outstanding, Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828" id="Fact001121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_dxL_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcGkCjRORBv1" title="Weighted Average Exercise Price, Outstanding Beginning Balance::XDX::23.21" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">23.20</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOaykqGoQ2hl" title="Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001125" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.77</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmNPQtO3uEl" title="Number of Warrants, Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znf668NBwEk5" title="Weighted Average Exercise Price, Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzfCOsHPgAd9" title="Number of Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_WarrantMember29544859" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJRjwVBNdTqk" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_WarrantMember29544859" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuurucvHOak" title="Weighted Average Life (Years)"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember29544843" format="ixt-sec:duryear" id="Fact001135" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.29</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zQyMJQPWbiZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of the warrants as of June 30, 2024 is $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_c20240630_zrLHD6yyDvj7" title="Aggregate intrinsic value of warrants"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-06-30" id="Fact001137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>. All of the outstanding warrants are exercisable as of June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s
compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKKCH4Els9Bl" title="Common stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact001139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
June 30, 2024, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zXHPCQPnyPv1" title="Share granted under equity incentive plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,234</ix:nonFraction></span> shares have been granted under the 2018 Equity Incentive Plan, of which <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zEPMg6K0JHpj" title="Number of shares vested under plan"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">79,395</ix:nonFraction></span> shares have vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may grant restricted stock units (&#8220;RSU&#8221;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2024 and 2023, pursuant to agreements with officers and consultants, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zVRudqb7T8d8" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,455</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zycSAg4ekbQj" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,455</ix:nonFraction></span>,
respectively and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zi8Vr62kbj4h" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,291</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zcc9v726PQEi" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,416</ix:nonFraction></span>
RSUs, respectively with a value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zVLqaWWaF1Jf" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zahRoVeuXWG1" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,840</ix:nonFraction></span>,
respectively, and $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zSVjDqdcDh89" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,400</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zR3yQfkAExvf" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,400</ix:nonFraction></span>,
respectively, were granted and compensation expense for RSUs of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBfWRddBcxxl" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171" id="Fact001161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,611</ix:nonFraction></span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGHgu9ZQqXGj" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171" id="Fact001163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,855</ix:nonFraction></span>,
respectively, was incurred. During the three and six months ended June 30, 2024 and 2023, $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQouVId4nEB4" title="Compensation under research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,033</ix:nonFraction></span>
and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3hX2VAYfkDf" title="Compensation under research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,986</ix:nonFraction></span>,
respectively, and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvDFsIQLsC4d" title="Compensation under research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,190</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9XvLM6eXVtg" title="Compensation under research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,190</ix:nonFraction></span>, respectively was included in compensation under Research and Development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, there was $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zV8lrdvvbUV9" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,779</ix:nonFraction></span> of unrecognized RSU compensation cost related to non-vested stock-based compensation arrangements
which is expected to be recognized over a weighted-average period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrbVlRGnz8t6" title="Weighted average term"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171" format="ixt-sec:duryear" id="Fact001175" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.97</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001177" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zuu6KI1jjRoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zFcZXEx7rJsb" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value Per RSU</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Outstanding, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVRgs3QKydz5" title="Number of RSUs, Outstanding, Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,731</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaBR0c6rk6W" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001181" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.76</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGKXMKubzvhh" title="Number of Stock Option Outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171" id="Fact001183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5h9v578mi67" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXBbyqQ5zQ7i" title="Number of RSUs, Vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpWt13yUHaGb" title="Weighted Average Grant Date Fair Value Per RSU, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding, June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqeDXbv4Uwll" title="Number of RSUs, Outstanding, Ending Balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYvZB97qXPK2" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.87</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zwD6B45yNhl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rights
Offering and Financing Commitment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase agreement
(the &#8220;Purchase Agreement&#8221;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed to commit
to purchasing from the Company $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207_zIZlzOJYfMOb" title="Sale of stock consideration received per transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-02-072024-02-07" id="Fact001195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span> of units from the Company, with each Unit consisting of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207_zy6wBKPtpeih" title="Share based compensation arrangement by share based payment award description"><ix:nonNumeric contextRef="From2024-02-072024-02-07" id="Fact001197" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">(i) one share of the Company&#8217;s
common stock, (ii) a warrant to purchase one share of the Company&#8217;s common stock exercisable at a purchase price of $18.80 per share,
and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a
22% interest in Diagnostics.</ix:nonNumeric></span> Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90%
of the VWAP of the Company&#8217;s common stock for the five trading days immediately preceding closing. The parties entered into the
Purchase Agreement in anticipation of the Company commencing a rights offering (the &#8220;Rights Offering&#8221;) pursuant to which
the Company intends to offer a total of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207_zsS8UX9UTZ91" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-072024-02-07" id="Fact001199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span> of Units to existing stockholders, which includes the $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207_zvqqAGepJnKe" title="Sale of stock consideration received per transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-02-072024-02-07" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span> of Units being sold
to SRO LLC, an entity which is controlled by Keith Moore, Executive Chairman of Boustead &amp; Company Limited, an affiliate of Boustead.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company filed an initial registration statement on Form S-1 (the &#8220;Form S-1&#8221;) with the SEC in April 2024 related to the
registration of subscription rights to purchase the Units to be sold in the Rights Offering. The Form S-1 has not been declared
effective as of the date these unaudited condensed consolidated financial statements were issued. Upon the Form S-1 being declared
effective, the Purchase Agreement allows SRO LLC up to 60 days to raise the initial $<span id="xdx_90D_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zJpaFIvFceI3" title="Escrow deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2024-02-07_custom_PurchaseAgreementMember" id="Fact001203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>,
which funds will be placed in escrow with Sutter Securities, Inc. (&#8220;SSI&#8221;), an affiliate of BSL, pursuant to the terms of
an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI on February 7, 2024 (the &#8220;Escrow
Agreement&#8221;). The funds will remain in escrow up until closing on the Rights Offering. In addition, in the event the Company
fails to raise the full $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBuFf9clofx7" title="Right offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember" id="Fact001205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span>
in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant to which it would have the right to purchase any remaining
Units not purchased by existing Company stockholders in the Rights Offering, up to an additional $<span id="xdx_900_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaqSR8vowk6j" title="Escrow deposit"><ix:nonFraction name="SHPH:AdditionalEscrowDeposit" contextRef="AsOf2024-02-07_custom_PurchaseAgreementMember" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>
(the &#8220;Back-up Contingency&#8221;). <span id="xdx_90C_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlfeowy1ptsb" title="Initial public offering description"><ix:nonNumeric contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember" id="Fact001209" name="SHPH:InitialPublicOfferingDescription">Unless
the parties waive the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the
Company&#8217;s existing stockholders, the Company will not close on the offering and any funds raised and held in escrow will be
returned to investors</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with its entry into the Purchase Agreement, on February 7, 2024, the Company entered into a placement agent and advisory
services agreement (the &#8220;Placement Agent Agreement&#8221;) with BSL, pursuant to which BSL and BSL&#8217;s affiliates will provide
the Company with regular and customary financial consulting advice and will act as placement agent, on a best efforts basis, for the
Rights Offering. In exchange for its services, BSL will receive a commitment fee equal to $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zamAQiHKQ0Z" title="Commitment fee"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember" id="Fact001211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,500</ix:nonFraction></span> upon the earlier of the Company filing
the registration statement on Form S-1 registering the Rights Offering or upon such date as the Company terminates the Rights Offering,
a commission equal 8% of the gross proceeds disbursed to the Company upon closing the Rights Offering, and $<span id="xdx_906_eus-gaap--OtherGeneralExpense_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zX9SmJTVysWe" title="Related expense"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> in diligence and related
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, the Company has incurred $<span id="xdx_90C_eus-gaap--DirectOperatingCosts_c20240101__20240630_zMx62q2PKDIl" title="Direct cost"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2024-01-01to2024-06-30" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,000</ix:nonFraction></span>
in costs directly related to the planned Rights Offering and initially deferred these costs as other current assets in the unaudited
condensed consolidated balance sheet. However, since that date, the Rights Offering has not been consummated and, therefore, the
deferred costs have been expensed. As of June 30, 2024, there were no deferred costs recorded on the Company&#8217;s unaudited condensed consolidated
balance sheet. Subsequent to June 30, 2024, the Company is pursuing other financing options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001217" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zJNmEEvXSAl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82B_zIhS88dXVUbl">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Assumptions Used in Accounting for Derivative Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_zPAPiNLbogbc" title="Number of shares warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></span> shares of common stock,
with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_z7M6EgL6C2Ca" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31" id="Fact001221" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share, valued at inception at $<span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230131_zJRXsooKvA1g" title="Derivative liability non-current"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-01-31" id="Fact001223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,189,000</ix:nonFraction></span> and as of June 30, 2024, at $<span id="xdx_90F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240630_zDBchRfCnQid" title="Derivative liability non-current"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-06-30" id="Fact001225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,919</ix:nonFraction></span>. The Company determined
our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy the classification as equity
instruments due to the existence of a certain net cash settlement provision that is not within the sole control of the Company. In addition,
there are certain down round provisions that could reduce the exercise price if the Company issues securities at lower prices in the
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined the Acceleration Option is an embedded derivative within the host instrument and has bifurcated it from the host
instrument and recorded it as a derivative liability valued at $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNk3tCUzaOMe" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact001227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></span>, using a Monte Carlo simulation model. The Company determined
our derivative liability from the noteholder&#8217;s Acceleration Option for the Alto Convertible Note is not clearly and closely related
to the host and should be thus accounted for as a bifurcated derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023 ($<span id="xdx_90B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230111_z4UdVj7UHyj8"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2023-01-11" id="Fact001228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,631,000</ix:nonFraction></span> included in debt discount) and June 30, 2024 ($<span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20240630_zkjXlLQevCbe" title="Derivative fair value"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2024-06-30" id="Fact001230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,423</ix:nonFraction></span>). Key inputs for the simulation are summarized
below. The Monte Carlo simulation uses an implied VWAP for the January 11, 2023 valuation date. The implied VWAP was backsolved by setting
the summation of the parts (e.g., derivatives and debt without derivatives) equal to the cash proceeds. The simulation was then iterated
and manipulated to solve for the implied share price, which was approximately $<span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr8rjPrxTp0k" title="Share price"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.64</ix:nonFraction> </span>per share (or an approximate <span id="xdx_904_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWDGDkUud5W8" title="Derivative discount percentage"><ix:nonFraction name="SHPH:DerivativeDiscountPercentage" contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% discount to the
quoted market VWAP on January 11, 2023).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001236" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zddhrcXyuLig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs for the Monte Carlo simulation as of June 30, 2024, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z7WE6Sm8yWM4" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Net cash settlement and down round key valuation inputs &#8211; warrants*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z7lnS5s2jUN9"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">89.76</ix:nonFraction></span>% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmZc9bAYLWi3"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">99.20</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zENOS2CF7rv2"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001239" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.61</ix:nonFraction></span>%
- <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zyedZGpSQBvj"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.48</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zxmx6iG5WaC8"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.12</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zRmUEyhycePc"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zw0Gt6uGAQW"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.5</ix:nonFraction></span>% - <span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zdiXmuzlTMof"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001244" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">30</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zvnG2xSED8Zd"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">15</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z3NcjrfcqcJh" title="Time period (years)"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001247" name="us-gaap:DebtInstrumentTerm">0.11</ix:nonNumeric></span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zpUW5ldGkXt6" title="Time period (years)"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001249" name="us-gaap:DebtInstrumentTerm">2.53</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte
Carlo simulation analysis of 250,000 iterations</i></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Acceleration option key valuation inputs*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z33q7ziTcqyb"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember" id="Fact001250" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">64.76</ix:nonFraction></span>% - <span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zvHaxuOUsMaa"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">74.98</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zWe5o0ZipMb8"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.23</ix:nonFraction></span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zqss6ZSDbcra"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.48</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z9VW6iGSTos3"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember" id="Fact001254" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.12</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zmppDXxJVuna"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">15</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zTfh1HZ0FQ8e" title="Time period (years)"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001257" name="us-gaap:DebtInstrumentTerm">0</ix:nonNumeric></span> - <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zFH5tWpTdkS" title="Time period (years)"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001259" name="us-gaap:DebtInstrumentTerm">0.7</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_zqQfP1wZvzHb" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"/><td style="text-align: justify"><i id="xdx_F15_z5AQlH6MsWM9"><ix:footnote id="Footnote001260" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 250,000 iterations</ix:footnote></i></td>
</tr></table>



</ix:nonNumeric><p id="xdx_8A2_zqtwNN3nAG7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001262" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zB2cIqfiiimd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BD_z0zcJjty7khd" style="display: none">Schedule of Derivative Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accelerated Feature</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance - December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwRqyS7RiOpe" title="Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zMg9AP4dwfr" title="Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember29546515" id="Fact001266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcrO6JJ4haVd" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zbHPKQPIrEPl" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2024-01-012024-03-31_custom_AcceleratedFeatureMember" id="Fact001270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpyk9HeHJchg" title="Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zkDLUMuDhQN1" title="Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-03-31_custom_AcceleratedFeatureMember" id="Fact001274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,035</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">(Gain) loss on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkYuPFzcXtak" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2024-04-012024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact001276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">145,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zAQS817134U3" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2024-04-012024-06-30_custom_AcceleratedFeatureMember" id="Fact001278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,531</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance - June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCSwKsfFnXg5" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact001280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zGNmvRYrn13g" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-06-30_custom_AcceleratedFeatureMember29546593" id="Fact001282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zf5oWZxa1N16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001284" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z6Ygdi2uTzK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82C_zuRgz1jdtTz5">Related Party transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. During the six months ended June 30, 2024 and 2023, the Company expensed
$<span id="xdx_90F_eus-gaap--OtherResearchAndDevelopmentExpense_c20240101__20240630_zFANokcYPHQe" title="Research, development expense"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-06-30" id="Fact001286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20230630_zJVwkXP4auU2" title="Research, development expense"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">608,000</ix:nonFraction></span>, respectively, related to these services.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001290" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zhRykpIpCk17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_z9UOamJIec8j">Income Taxes</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001292" name="SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zuia5MsmHcik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zJ13jlUAhpRd" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001294" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNnudPW8ZBD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z4DEPqCtDR89" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></span></span></span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001296" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zGX2v3cjwAYj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></span></span></span></b></span></p>

</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001298" name="SHPH:QuarterlyFinancialDataTextBlock"><p id="xdx_807_ecustom--QuarterlyFinancialDataTextBlock_zAj1b1gYgbM9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_82D_zMMrfyxDrHZd">Quarterly Financial Data (Unaudited and Restated)</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001300" name="SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock"><p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zWSfLbAcpoNc" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zaVdbSJYZaUe">Schedule
of Quarterly Financial Data</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001302" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zUQoX5990Tac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_827_z2gPZJ4Q7DBh">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2, Summary of Significant Accounting Policies, Reverse Stock Split, above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alto
                                            Opportunity Master Fund, SPC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2024, the Company informed the Investor in the Alto Convertible Note that the Company&#8217;s expected restatement of its consolidated
financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the Alto Convertible
Note. On August 6, 2024, the Company paid $<span id="xdx_90B_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20240806__20240806__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2ZNykpWEqLf"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2024-08-062024-08-06_custom_AltoConvertibleNoteMember_us-gaap_SubsequentEventMember" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the Investor, which funds will be held as
collateral to the balance owed under the Alto Convertible Note, and received a waiver from the Investor related to the default.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alliance Global Partners</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2024, the Company engaged A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) to serve as exclusive underwriter, placement
agent or advisor in any public or private offering or financing (as defined, the &#8220;Offering&#8221;) of up to $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240730__20240730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember__srt--RangeAxis__srt--MaximumMember_zUhRrUXZO3C2"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-07-302024-07-30_us-gaap_SubsequentEventMember_custom_AllianceGlobalPartnersMember_custom_OfferingMember_srt_MaximumMember" id="Fact001304" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
II study of Ropidoxuridine</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2024, the Company entered into a work order (the &#8220;Work Order&#8221;) with Theradex Systems, Inc., a New Jersey contract
research organization (&#8220;CRO&#8221;) for purposes of supporting the Company&#8217;s Phase II Study of Ropidoxuridine as a Radiation
Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promotor.&#8221;
As such, Shuttle Pharma is now in the process of signing up six clinical sites where the clinical studies will be performed &#8211; two
of which have completed initial site initiation visits and one of which is ready to enroll patients &#8211; and where the CRO will oversee
such studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Work Order, the CRO will oversee the studies for a period of 53 months (the &#8220;Term&#8221;), including overseeing
and monitoring the regulatory aspects of the Phase II clinical trial, and managing the documentation surrounding the clinical trial in
exchange for a fee of approximately $<span id="xdx_903_eus-gaap--PaymentsForFees_pn5n6_c20240808__20240808__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCaIeCPJVK59" title="Exchange fee"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2024-08-082024-08-08_us-gaap_SubsequentEventMember" id="Fact001306" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million, payable in stages and based upon services performed during the Term of the study.</span></p>

</ix:nonNumeric><p id="xdx_81C_zdETyspZdwN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index
to Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_001">Report of Independent Registered Public Accounting Firm &#8211; Forvis Mazars, LLP</a> (PCAOB ID <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">686</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span>  <span style="display: none"></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_002">Consolidated Balance Sheets as of December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_003">Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_005">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-25</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_001"></span>Report of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders, Board of Directors, and Audit Committee of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Consolidated Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Shuttle Pharmaceuticals Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash
flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year
period ended December&#160;31,&#160;2023, in conformity with accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restatement
of Previously Issued Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2 to the financial statements, the 2023 and 2022 financial statements have been restated to correct misstatements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note&#160;1
to the financial statements, the Company has suffered recurring losses and negative cash flows from operations since inception. These
conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company&#8217;s ability to continue as
a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>/s/
Forvis Mazars, LLP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Atlanta,
Georgia</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
3, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_002"></span>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_zW7WL5sgcvBe" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zYI93zUE6UCj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zHdRA1h16i8g" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zf0IV4Om33r4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_zHlhnUOqlXYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_z9IPeegfjYz4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact001314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact001315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_i02I_ze8uOQDINGC4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact001317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,473</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" id="Fact001318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,148</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesCurrent_i02I_zY7ozY0BOR1h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Marketable securities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact001320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestReceivableCurrent_i02I_zuzyMJj8uG37" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accrued interest income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact001323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,901</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_i02TI_zr1I7P8zCk22" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact001326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,593,005</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact001327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,578,351</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zR5H4cYvTbmd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and equipment, net of accumulated depreciation of $<span id="xdx_90E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20231231_z32QUfUZjb31" title="Property and equipment, accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,685</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20221231_zbzkEIgrmXod" title="Property and equipment, accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact001334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,875</ix:nonFraction></span> respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,827</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,592</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zzo17Tb4V6X8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,827</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact001337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,592</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_i01I_zBmLHSbVo9n5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" id="Fact001340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zA7mmPpVNwI1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,904</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact001343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,122</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Assets_i01TI_zvVXNQHYTRkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact001345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,951,736</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact001346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,653,545</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zJEIXDZRdvq1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Liabilities and Stockholders&#8217; Equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_ztSII40MoIjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zxszp4Cs08H9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact001354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,860</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" id="Fact001355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,745</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9zn5RrutEZk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accounts payable and accrued expenses related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact001358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zKD6HLFoTZAl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued interest payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact001360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1361">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zrdoFFS472L2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued interest payable - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1363">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact001364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,135</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zReHCzmggtlk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Notes payable to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1366">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact001367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ConvertibleNotesPayableCurrent_i02I_zoVnlMfw1Mlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Convertible notes payable, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_i02I_pp0p0_zic1RqxHxpw4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zYOOF1d7qmX8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact001375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,479</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="Fact001376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,823</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i02TI_zu7wqsXX6aAk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,042,237</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975,676</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleLongTermNotesPayable_i01I_zqwCMfUuOYNb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Convertible notes payable non-current, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,089</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_z69k4gnIIy32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact001384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_z6QNDwOIjGY9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact001387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_ztejsD4qnymb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability non-current</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact001390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,127</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1391">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_zptDgDC6g8g9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact001393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,895,965</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" id="Fact001394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975,676</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&#8217; Equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i01I_zqhiFrkvTWB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Series A Convertible Preferred Stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z4NQxenxPwdc" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20221231_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact001402" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact001404" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreference_iI_c20231231_zT7cuaqUs6L9" title="Preferred stock, liquidation preference per share"><span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreference_c20221231_pdd" title="Preferred stock, liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-12-31" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2022-12-31" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share liquidation value; <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zpWEvZOi9l1j" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20221231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zHaxcabFV2e5" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zzR4TLaxRKq7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001414" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact001416" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1399">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1400">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i01I_zfJAHyjeVKek" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zcWOuc1gmdud" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20221231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact001423" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zF6EcHCKoRk5" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001425" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20231231_z7gm5uhEzSr5" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_ztMWrnDwoaN1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,008,689</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20221231_zpJLVmpI0BMa" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zSTUMafdaLmf" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact001433" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact001435" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,700,414</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact001418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact001419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_i01I_zvfTw0QIcGYd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid in capital, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,489,055</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact001438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,518,433</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_zLBnNxgwnUUg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accumulated deficit, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact001440" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,433,304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact001441" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,840,581</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i01TI_zJPn6cW3wWth" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,055,771</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact001444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,677,869</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_zQs1eDvSZn94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,951,736</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,653,545</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_003"></span>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_zFvJ2hDmdpod" summary="xdx: Statement - Condensed Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zrv6BGk0ccg6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20221231_zceGXZUEjF46" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(as restated)</b></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_zxjptLWhAhde" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1449">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1450">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_z2cUZg4k5ape" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_z9EercKeUXdb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left">Research and development, net of contract expense reimbursements, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact001455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,517,093</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact001456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,047,385</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_zJl32JEOaJgc" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact001458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,517,093</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact001459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,047,385</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01_zSIa2h1NCYm6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact001461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,854</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact001462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,714</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_i01_zxqTLU7kuB6j" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact001464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,854</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact001465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,714</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LegalFees_i01_zkhnyMhyNWji" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Legal and professional, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,328,435</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31" id="Fact001468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822,727</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LegalFees_i01_zVymBzJHhJpl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Legal and professional</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31" id="Fact001470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,328,435</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31" id="Fact001471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822,727</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_z5fVSZz5Yfzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact001473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,892,382</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" id="Fact001474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,343,826</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_i01T_znxQxYkzPMDe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact001476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,892,382</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" id="Fact001477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,343,826</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_z93Hqk1Wm3Da" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001479" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,892,382</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact001480" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,343,826</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_iT_zlC13EHxdmw" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001482" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,892,382</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact001483" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,343,826</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zT9ciliBxqC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zoeqYgxzTkO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,825</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" id="Fact001489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,010</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zBmqCM3MBlb7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember" id="Fact001491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,484,193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember" id="Fact001492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">428,688</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zRm4IYsGoBgc" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember" id="Fact001494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,484,193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember" id="Fact001495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">428,688</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--InvestmentIncomeInterest_i01_zJnhwxrnctQ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-012023-12-31" id="Fact001497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,117</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1498">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FinanceFee_i01N_di_z7VuJtkR6JJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Finance fee, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2023-01-012023-12-31" id="Fact001500" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,245</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2022-01-012022-12-31" id="Fact001501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,912</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--FinanceFee_i01N_di_zZQD7wFX0GS1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Finance fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2023-01-012023-12-31" id="Fact001503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,245</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2022-01-012022-12-31" id="Fact001504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,912</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zB0CljpjeuB6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of derivative liabilities, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact001506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,216,488</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact001507" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zen5e50PxUi7" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact001509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,216,488</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact001510" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_406_ecustom--FairValueAdjustmentOfWarrant_i01N_di_zgmn6XhdXX0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:FairValueAdjustmentOfWarrant" contextRef="From2022-01-012022-12-31" id="Fact001513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398,675</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--GainLossOnSaleOfInvestments_i01_z4jgSZpQalv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Gain on sale of marketable securities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-012023-12-31" id="Fact001515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1516">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i01_zDD3aeeT9DVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of marketable securities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-012023-12-31" id="Fact001518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,568</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1519">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--LossOnSettlementOfConvertibleDebt_i01N_di_zT23ot8QuzCe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on settlement of convertible debt, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact001521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,221</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact001522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--LossOnSettlementOfConvertibleDebt_i01N_di_zxp9WcZI1502" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on settlement of convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact001524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,221</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact001525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_406_ecustom--GainOnSettlementOfAccountsPayable_i01_zKumYMtnt0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Gain on settlement of accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:GainOnSettlementOfAccountsPayable" contextRef="From2022-01-012022-12-31" id="Fact001528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,687</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--GainOnForgivenessOfNotePayable_i01_z93bpxofJ6z7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of Paycheck Protection Program note payable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1530">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2022-01-012022-12-31" id="Fact001531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NonoperatingIncomeExpense_i01T_zn0CyOJrqr4a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total other expense, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact001533" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">700,341</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact001534" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,652,243</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zUKWfArjhLjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net loss, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact001536" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact001537" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,996,069</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zy9xgh4SeoO2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Dividend on Series A Convertible Preferred Stock, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1539">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31" id="Fact001540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_iN_di_zPRY3pw5q105" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deemed dividend on extinguishment of Series A Convertible Preferred
    Stock, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1542">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" contextRef="From2022-01-012022-12-31" id="Fact001543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,427</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrants_iN_di_zDBIpU7lkA95" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deemed dividend on modification of equity-classified warrants, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1545">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants" contextRef="From2022-01-012022-12-31" id="Fact001546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">941,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_iN_di_z3xWG2utOOmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1548">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" contextRef="From2022-01-012022-12-31" id="Fact001549" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,423</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_zXKOlzTrub1a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact001551" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" id="Fact001552" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,747,137</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zKKW8soJ6uN7" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zO1zse5RtAbb" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact001554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,866,275</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zYzr2lEX6C09" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zOorQLB3DzKe" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact001558" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact001560" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,337,742</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zsUA7C6G8g7c" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zdyYeXLYNmd2" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact001562" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact001564" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.53</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zmPWOdY8s7P7" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zasuFUSiolHd" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact001568" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.04</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<!-- Field: Split-Segment; Name: Spl_001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_004"></span>Consolidated
Statements of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31, 2023 (as restated) and 2022 (as restated)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_zXpDipOlWi3e" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zLy6QxnIBp6k" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zS6aDsWwVqai" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zLeY9gfyKpH" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--CommonStockToBeIssuedMember_z0NyK1cuRwnc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zdypto0KZGg3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_zo3W4F5GXcu2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
    A Preferred Stock</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-In</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Common</b></p>
                                                                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Stock</b></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to
                                            be</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Total</b></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issued</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_435_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zD8wvC96thNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December
    31, 2021 (as restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFliYevdwv55" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact001577" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1570">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXGx7GOICgk" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact001579" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,164,039</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,063,940</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact001574" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,844,512</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact001575" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,764,220</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zQyThIPGlbL2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1581">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6q8IAR7VSja" title="Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001588" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">352,443</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,951,352</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1584">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1585">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="Fact001586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,951,356</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zAdOGquoSy0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants issued for financing
    costs, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1590">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1593">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1594">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zcVZCEsxirV4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock issued for conversion
    of accrued interest, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1597">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znNhsd23cGc4" title="Common stock issued for conversion of accrued interest, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1598">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="Fact001600" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,340</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1601">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1602">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z5Pj2zax0IId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock issued upon conversion
    of convertible debt and exercise of related warrants, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1606">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyMDpur9pfPg" title="Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001613" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,876</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1607">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001608" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,916</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1609">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="Fact001611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,916</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zR7615PidMU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock issued for exercise
    of warrants with settlement of notes payable, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1615">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjtLhV5FIyT1" title="Common stock issued for exercise of warrants with settlement of notes payable, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001622" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,250</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,153,123</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1618">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1619">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31" id="Fact001620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,153,124</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zjik8rdCPYr1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock issued upon exercise
    of warrants, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1624">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfotryK1PIxi" title="Common stock issued upon exercise of warrants, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,535</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1625">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl1626">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1627">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1628">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1629">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zaSTwkl871Jl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock issued for restricted
    stock units, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1633">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNmvmYBSWWlf" title="Common stock issued for restricted stock units, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001640" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1634">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1635">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1636">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1637">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1638">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z9haOooiRHC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation,
    as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1642">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1643">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001644" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,547</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1645">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact001647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,547</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DividendsOnSeriesPreferredStock_iN_di_zdPZ9HMfg9za" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    on Series A convertible preferred stock, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Dividends on Series A preferred stock, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1650">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1652">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1653">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact001654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--DeemedDividendOnExtinguishmentOfPreferredStock_zuY2o3pRk5if" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deemed dividend on extinguishment of Series A Preferred Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Dividends on Series A preferred stock, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1656">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1658">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1659">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1661">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount_zaWySFWVcmu1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deemed dividend on modification of equity-classified warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Dividends on Series A preferred stock, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1663">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1664">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1665">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1666">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1667">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1668">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend_zcuCM9uGCuV1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividend</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Dividends on Series A preferred stock, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1672">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1673">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1674">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1675">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_zLsB1OINkrbf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    shares issued for dividends on and conversion of Series A convertible preferred stock, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesDividendReinvestmentPlan_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQfjdqGLkIE" title="Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact001684" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,213</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1677">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesDividendReinvestmentPlan_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeFRQlQveePj" title="Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001686" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,666</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1678">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1680">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1681">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31" id="Fact001682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zmNCU1ni8s1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassification of fair value
    of warrant liabilities to equity, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1688">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1689">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,553</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1691">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1692">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31" id="Fact001693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,553</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zEYgLxdR10a3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss, as restated</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1695">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1696">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1697">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1698">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact001699" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,996,069</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact001700" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,996,069</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_437_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zWXxfBJyA8Zb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2022
    (as restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zN83ga3kZcql" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1709">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1702">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zumshlzwCkNb" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001711" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,700,414</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001703" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,518,433</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1705">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact001706" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,840,581</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact001707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,677,869</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43F_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zCGrJXkYDUEa" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGnRulT0AS88" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1720">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1713">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDODcrvfKTcf" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001722" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,700,414</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,518,433</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact001717" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,840,581</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact001718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,677,869</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ziQtJeDK1wq" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants issued for financing
    costs, net of issuance fees of $<span id="xdx_90B_ecustom--WarrantsIssuanceFees_c20230101__20231231_zPvKu3hzoP6e" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2023-01-012023-12-31" id="Fact001731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1724">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1725">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1727">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1728">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact001729" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_zr2QO4WaIFg3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock issued for conversion
    of accrued interest and principal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1733">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYi0ONAsoWF2" title="Common stock issued for conversion of accrued interest and principal, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001740" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">297,625</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,697,846</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1736">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1737">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31" id="Fact001738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,697,849</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zoFXaORfgP1g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock issued for restricted
    stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1742">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znZAAD3iKFq1" title="Common stock issued for restricted stock units, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001749" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,650</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1743">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1744">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1745">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1746">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1747">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zVM1EOThfsng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1751">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1752">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,960</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1755">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact001756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,960</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zbYc3Dle4Wbe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1758">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1759">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1760">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1761">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact001762" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001763" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_434_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zMFCo7cPoLxc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2023
    (as restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqTTFyOww89d" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1772">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1765">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2sOr2xExlhd" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,008,689</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,489,055</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1768">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact001769" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,433,304</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,055,771</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20230101__20231231_eus-gaap--StockholdersEquity_iE_ztJ6GEJXQS36" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdX7Pi2Mt8fc" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1783">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjV1Mw47bGF1" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,008,689</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001777" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,489,055</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1779">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact001780" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,433,304</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,055,771</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_005"></span>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_zGn3eRS65sei" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z6hfjjQLG4ye" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231_zbJctKaNJaQ7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Years Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(as restated)</b></p>
</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zqtB7SM7dMZc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_zveOwN1tVFu2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001790" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact001791" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,996,069</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zEkJ4fE7GZih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Depreciation_i02_zN0AR4vCzvu6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact001796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,811</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact001797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,972</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_zNmpbaWYrHgd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Change in fair value of derivative liability, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact001799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,216,488</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact001800" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr id="xdx_400_eus-gaap--FairValueAdjustmentOfWarrants_i02_zQ4229rtZtsk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact001803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398,675</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AmortizationOfDebtDiscountPremium_i02_zrLba30rH8me" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Amortization of debt discount and finance fees, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-012023-12-31" id="Fact001805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,123,049</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31" id="Fact001806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377,384</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GainLossOnSaleOfInvestments_i02N_di_zmBEIgdKT4Cg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Gain on marketable securities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-012023-12-31" id="Fact001808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1809">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i02N_di_z0H0QS1AO8Qk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Change in fair value of marketable securities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-012023-12-31" id="Fact001811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,568</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1812">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AccruedInterestSettledWithCommonStock_i02_zwXgCtspYOca" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accrued interest settled with common stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:AccruedInterestSettledWithCommonStock" contextRef="From2023-01-012023-12-31" id="Fact001814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,927</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1815">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossOnSettlementOfConvertibleDebt_i02_zD3YAKY8IzR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Loss on settlement of notes payable and convertible notes payable, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact001817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,221</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact001818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FairValueOfFreestandingInstrumentsInExcessOfProceeds_i01_zEb86DCPFhe4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Fair value of freestanding instruments in excess of proceeds, as restated </p>
</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">&#8212;</span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds" contextRef="From2022-01-012022-12-31" id="Fact001821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,912</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--GainOnSettlementOnAccountsPayable_i02N_di_zelsEnFWWbG7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Gain on settlement on accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1823">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:GainOnSettlementOnAccountsPayable" contextRef="From2022-01-012022-12-31" id="Fact001824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,687</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--GainOnForgivenessOfNotePayable_i02N_di_zHHNN44CrS1e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Gain on forgiveness of Paycheck Protection Program </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1826">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2022-01-012022-12-31" id="Fact001827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_zuteF9LY4o3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Stock-based compensation, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact001830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,547</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zZsDGeESBSx8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccruedInterestReceivableNet_i02N_di_zz9Dv6hzeOc9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Accrued interest income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2023-01-012023-12-31" id="Fact001835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,901</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_zxFkbK54h5J6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-012023-12-31" id="Fact001838" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,675</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-012022-12-31" id="Fact001839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,282</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_znrL0WMd12bi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact001841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,115</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact001842" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">382,881</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInDueToRelatedPartiesCurrent_i02_zRupLQiFu3G3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Accounts payable and accrued expenses - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2023-01-012023-12-31" id="Fact001844" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,054</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2022-01-012022-12-31" id="Fact001845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_zaVAT2YMJpDb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Accrued interest payable, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2023-01-012023-12-31" id="Fact001847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-012022-12-31" id="Fact001848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInAccruedInterestPayableRelatedParties_i02_zvNdejvGRU1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Accrued interest payable - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact001850" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,135</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties" contextRef="From2022-01-012022-12-31" id="Fact001851" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,188</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_di_zZRgU2V9Q04j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Other assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-012023-12-31" id="Fact001853" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,480</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_z0OUimgatHV2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Change in operating lease asset and liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact001856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,001</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" id="Fact001857" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,693</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zErVaPD8Jf8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact001859" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,581,147</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact001860" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,666,411</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zAXQWjoPNm41" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_z262fzpEpoZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Investment in marketable securities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact001865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,998,572</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1866">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_zik4X8hQByoh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from disposition of marketable securities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact001868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,895</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl1869">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_zmeBg4cxgFl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Purchase of equipment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact001871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,046</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl1872">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_z7jMG20xVEc7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact001874" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,829,723</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl1875">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_zY21XR1wp9ki" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact001877" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,829,723</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl1878">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zPdtHq0PExqg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_zDIa7RTbBmEg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from issuance of common shares and exercise of warrants, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1883">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact001884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,995,513</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromRelatedPartyDebt_i01_z9WEiZOwRk4f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from note payable-related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-12-31" id="Fact001887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_di_zfp7twXziIH2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Repayment of note payable-related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2023-01-012023-12-31" id="Fact001889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31" id="Fact001890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromConvertibleDebt_i01_zo2QV6IY1QUb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from convertible notes payable, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact001892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,935,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact001893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,715</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ProceedsFromNotesPayableAndWarrants_i01_z9HXESpufKZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from notes payable and warrants, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1895">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ProceedsFromNotesPayableAndWarrants" contextRef="From2022-01-012022-12-31" id="Fact001896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_z0qWPlxzzpJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Payment for finance costs related to convertible note payable, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact001898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-01-012022-12-31" id="Fact001899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,363</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_z4f8yJjIos9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Payment of convertible note payable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact001901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,444</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1902">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_zEnimB8ZgYO5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact001904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,570,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact001905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,578,865</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_z6F9Ip6RizQd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact001907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,570,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact001908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,578,865</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zEhjSNzttzR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact001910" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,840,787</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact001911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,912,454</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zoY11yhg0CTk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact001913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact001914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,749</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z42Y7BF0oBu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact001916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact001917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zCGaJR3YqbT9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_zmOUGOT1Byo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact001922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,807</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="Fact001923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,201</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i01_zCgx2w72r1k4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1925">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1926">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z8traZ9cAGIl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Supplemental non-cash financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--CommonStockIssuedForConversionOfAccruedInterestAsRestated_i01_zoy7tpA6Evhf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for conversion of accrued interest, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1931">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfAccruedInterestAsRestated" contextRef="From2022-01-012022-12-31" id="Fact001932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated_i01_zR8C1YL86rvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued upon conversion of convertible debt and
    exercise of related warrants, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" contextRef="From2023-01-012023-12-31" id="Fact001934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,697,849</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" contextRef="From2022-01-012022-12-31" id="Fact001935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,916</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zuQbz7e3kHPi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for exercise of warrants with settlement of notes payable, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1937">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact001938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,153,124</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_i01_z5IQHF4lRE3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common shares issued for dividends on and conversion of
    Series A convertible preferred stock, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1940">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact001941" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">402,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantsIssuedForFinancingFees_i01_zA364NLcz7Ib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Warrants issued for financing fees, net of issuance fees of $<span id="xdx_908_ecustom--WarrantsIssuanceFees_c20230101__20231231_zoJtfd4WZLu8" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2023-01-012023-12-31" id="Fact001946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span> and $<span id="xdx_909_ecustom--WarrantsIssuanceFees_c20220101__20221231_zpOFiEnEPDf6" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2022-01-012022-12-31" id="Fact001948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2023-01-012023-12-31" id="Fact001943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2022-01-012022-12-31" id="Fact001944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,662</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_i01_zOU7KlnzVQtg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Reclassification of fair value of warrant liabilities to equity, as restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <span style="-sec-ix-hidden: xdx2ixbrl1950">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2022-01-012022-12-31" id="Fact001951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,553</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--InitialRecognitionOfRightOfUseAssetAndLiability_i01_zjmKEqkeQfe8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Initial recognition of right of use asset and liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:InitialRecognitionOfRightOfUseAssetAndLiability" contextRef="From2023-01-012023-12-31" id="Fact001953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,556</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p id="xdx_041_c20230101__20231231_z2ulZvybLEfb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_006"></span>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001956" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLSnJOFJjx87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82A_zNQTfjOQsJoh">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuWYMCwBa1l" title="Conversion of stock, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember" id="Fact001958" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,625,000</ix:nonFraction></span> shares of common
stock in exchange for <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrFlg9kE6KXj" title="Sale of stock membership percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember" id="Fact001960" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#8220;Company&#8221;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract provided
by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#8217;s initial public offering, the Company
has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay
or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and
has a net loss of approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zvDIDv0jCj34" title="Net income loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001962" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">6.6</ix:nonFraction></span>
million and no revenues for the year ended December 31, 2023 and working capital of approximately $<span id="xdx_90D_ecustom--WorkingCapital_iN_pn5n6_di_c20230101__20231231_zpMi8peYTBP7" title="Working capital"><ix:nonFraction name="SHPH:WorkingCapital" contextRef="From2023-01-012023-12-31" id="Fact001964" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">4.6</ix:nonFraction></span>
million as of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and
certain cash payment requirements. On July 12, 2024, the Company informed the investor of its convertible note that the
Company&#8217;s expected restatement of its financial statements for the years ended December 31, 2022 and 2023 constituted an event
of default under the terms of the convertible note. On August 6, 2024, the Company paid $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20240806__20240806__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zXZVY5oJ2dl5" title="Proceeds from convertible debt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-08-062024-08-06_us-gaap_InvestorMember_srt_ScenarioForecastMember" id="Fact001966" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million to the investor of the
convertible note and received a waiver from the investor related to the default. The funds paid are restricted and will be held as
collateral to the balance owed under the convertible note (see Note 12). These conditions, and the Company&#8217;s ability to comply
with such conditions, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after
the date that the consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLz2DBKNXBw9"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001967" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, along with a four-year warrant to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zl355kJKiw01"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUpMqMf0Hl09"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, providing the Company with approximately
$<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zObOWFtvk5K9"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001970" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in net proceeds. To date, the warrant
has not yet been exercised. However, the Company&#8217;s existing cash resources, marketable securities and the cash received from the
equity offering and convertible note are not expected to provide sufficient funds to carry out the Company&#8217;s operations and clinical
trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA
approval of the IND for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and
the company agreed to an expansion of the clinical trial, necessitating additional capital to complete the trial, as well as fund ongoing operations. As a result, management had initiated
a $<span id="xdx_90E_eus-gaap--PartnersCapital_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsiazBOPM4B4" title="Initiated a capital offering"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001972" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million rights offering and submitted an application for a SBIR grant for non-dilutive funding for pre-clinical project through
the NIH. The Company is also currently pursuing other financing. The ability of the Company to continue as a going concern is dependent
upon its ability to successfully raise additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials
and bring a drug candidate to commercialization to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements do not include any adjustments to reflect the future effects on the recoverability and
classification of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 13, 2024, in order to meet
Nasdaq&#8217;s minimum bid price requirement of $<span title="Share Price"><span id="xdx_900_eus-gaap--SharePrice_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGJmbQWtYsma" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember" id="Fact001974" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span>
per share (the &#8220;Minimum Bid Price Requirement&#8221;), the Company effectuated a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjuBpwCxWvQe" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-08-132024-08-13_us-gaap_SubsequentEventMember" id="Fact001976" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-8 reverse stock split</ix:nonNumeric></span> of its issued and outstanding common stock, rounding up to account for any fractional shares (the
&#8220;Reverse Stock Split&#8221;). The Reverse Stock Split had no effect on the Company&#8217;s authorized shares of common stock
or preferred stock. Following the reverse stock split on August 13, 2024, the Company had a total of <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znxZOrhkU0C1" title="Common stock shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdFH3eQyw6x7" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember" id="Fact001978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember" id="Fact001980" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,111,235</ix:nonFraction></ix:nonFraction></span></span>
shares issued and outstanding (or <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20231231_zaV7QAG26O38" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zhLIdladDdp" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001984" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,008,689</ix:nonFraction></ix:nonFraction></span></span>
on a post-split basis as of December 31, 2023). The Reverse Stock Split also resulted in an adjustment to the consolidated balance
sheets for the years ended December 31, 2023, December 31, 2022 and December 31, 2021 with an increase to additional paid in capital
of $<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20230101__20231231_z7lwD9NG56F4" title="Adjustments to additional paid in capital stock split"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" contextRef="From2023-01-012023-12-31" id="Fact001986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141</ix:nonFraction></span>,
$<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20220101__20221231_zuVy3UoPY47c" title="Adjustments to additional paid in capital stock split"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" contextRef="From2022-01-012022-12-31" id="Fact001988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119</ix:nonFraction></span>
and $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20210101__20211231_zzaW9Jev2whh" title="Adjustments to additional paid in capital stock split"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" contextRef="From2021-01-012021-12-31" id="Fact001990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81</ix:nonFraction></span>,
respectively, and an offsetting adjustment to the carrying value of common stock. All share, option, warrant and per share amounts
(except our authorized outstanding) have been retroactively restated in these financial statements and related disclosures. The
effect of the Reverse Stock Split has been included in Note 2 in the &#8220;As Reported&#8221; and in Note 11 in the &#8220;As
Reported&#8221; amounts for additional paid in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001992" name="us-gaap:ErrorCorrectionTextBlock"><p id="xdx_80B_eus-gaap--ErrorCorrectionTextBlock_zYnQb5pXRUd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Note <span style="font-family: Times New Roman, Times, Serif">2
&#8211; <span id="xdx_826_zS4IaF9iKHzg">Restatement of Previously Issued Financial Statements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As previously disclosed in the Company&#8217;s
Quarterly Report on Form 10-Q for the period ended March 31, 2024, filed with the Securities and Exchange Commission
(&#8220;SEC&#8221;) on May 13, 2024, following the entry of a cease-and-desist order by the SEC against our former auditor, B.F.
Borgers CPA PC (&#8220;BF Borgers&#8221;), we commenced the re-audit (the &#8220;Re-audit&#8221;) of our consolidated financial
statements for the year ended December 31, 2022, which had been audited by BF Borgers. Since that time and as a result of the
Re-audit, and as initially disclosed on Form 8-K dated July 10, 2024, the Company and the Audit Committee have concluded and
informed our current auditor, Forvis Mazars, LLP, that our audited consolidated financial statements for the year ended December 31,
2022 (the &#8220;2022 Financial Statements&#8221;), our audited consolidated financial statements for the year ended December 31,
2023 (the &#8220;2023 Financial Statements&#8221;), and the quarterly periods included in the Company&#8217;s Annual Report
for the year ended December 31, 2023, and the quarterly report for the period ended March 31, 2024 require restatement and are not reliable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accounting errors impacting our 2022 Financial
Statements include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Stock Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Application of the incorrect grant date fair values in determining the value of certain equity awards
granted during the years ended December 31, 2019 and 2020;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Miscalculation of the pattern of recognition of stock-based compensation over the requisite service periods
for certain equity awards granted during the years ended December 31, 2019 and 2020;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Series A Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Utilization of incorrect inputs to the fair value estimates for the warrant obligation related to
                                                                     the Series A Convertible Preferred Stock; incorrectly recording the reclassification of the warrant obligation upon issuance as a
                                                                     gain and not as a reclassification to stockholders&#8217; equity;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recording of accrued dividends on the Series A Convertible Preferred Stock as a liability prior to
                                                                     the dividends being declared;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Failure to recognize the accounting impact for the amendment to the terms of the Series A
                                                                     Convertible Preferred Stock in April 2022, which the Company subsequently concluded should have been recognized as an
                                                                     extinguishment;</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Failure to recognize deemed contribution related to the settlement of the
Series A Convertible Preferred Stock and accrued dividends;</td></tr>
                                                                                                                   </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Notes Payable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Misidentification of certain debt and equity issuance costs and incorrect association with certain of
the Company&#8217;s financings during the years ended December 31, 2022 and 2021;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Application of the incorrect amortization period and pattern of recognition for debt discounts recorded
in relation to the Company&#8217;s debt financings during the years ended December 31, 2022 and 2021;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incorrect recognition of bifurcated derivative liabilities, as well as incorrect initial and subsequent
fair value measurements, in relation to the December 2021 Notes, 2022 Convertible Notes and August 2022 Notes;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Misclassification of certain warrants issued with debt transactions during the year ended December 31,
2022;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Failure to recognize certain liability-classified warrants issued in exchange for services provided related
to the Company&#8217;s financing activities during the year ended December 31, 2022; </td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incorrect application of extinguishment or conversion models in accounting for certain debt instruments
upon their settlement; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Initial Public Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Incorrect identification of deferred issuance costs incurred in relation to the initial public offering; Incorrect identification and classification of issuance costs incurred in relation to the initial public offering.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In addition to the restatement of the consolidated
financial statements, the Company has also restated the following notes to reflect the errors described above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 2 - Summary of Significant Accounting Policies (now Note 3)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 5 &#8211; Notes Payable-Related Party</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 6 &#8211; Convertible Notes (now labeled Notes Payable)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 7 &#8211; Stockholders&#8217; Equity</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 8 &#8211; Derivative Liabilities</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 10 &#8211; Income Taxes</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" continuedAt="ConU002000-01" escape="true" id="Fact002000" name="SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_gL3SOECAPPATT-CTUD_zsjBbHmPqf0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The impact of the errors described above also impact
the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0zZqA0Nnjde" style="display: none">Schedule
 of Error Corrections And Prior Period Adjustments </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwetAMD0zH8g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJmDSENBI7ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_z4uPlYfsUoR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_iI_z2zeGbBRXc0g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,543,363</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact002004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,489,055</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zaoGgdHo6uwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002006" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,487,612</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002007" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact002008" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,433,304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_znh5diDZJD2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Additionally, the Company has provided Note 11 &#8211; Quarterly Financial
Data (unaudited and restated) to present the impact of the above restatements on the unaudited quarterly financial information for the
period ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&#8217;s prior and updated accounting for
the errors described above do not have any effect on the Company&#8217;s previously reported cash or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_C03_gL3SOECAPPATT-CTUD_zjl0AJp8VmS4"><ix:continuation continuedAt="ConU002000-02" id="ConU002000-01"><span><span>&#160;</span></span></ix:continuation></span></p>

<div id="xdx_C0B_gL3SOECAPPATT-CTUD_zZbMdljBzSu" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:continuation continuedAt="ConU002000-03" id="ConU002000-02"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following tables summarize the effect of the restatement
on each financial statement line item as of the dates indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_134_zg7BX6nomyV7" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6IPnX7kMpQd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zqIfqvq3dbla" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_zVBmgAKxgFu2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,572,741</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zRFyZ3enDeJ4" title="Additional paid in capital" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002013" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact002011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,518,433</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z7ch26L7ImB3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002015" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,894,889</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zq9la8ZM1J46" title="Accumulated deficit" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002018" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact002016" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,840,581</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_z6tdetXqK1di" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zNZReqJ1vZk4" style="font-size: 10pt"><ix:footnote id="Footnote002019" xml:lang="en-US">Adjustments
    include corrections for stock compensation errors (increase of $<span id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj" title="Stock compensation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,843,052</ix:nonFraction></span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8" title="Accrued dividends" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDividendsReceivable" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta" title="Issuance cost" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInIssuanceCost" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,082</ix:nonFraction></span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8" title="Warrants" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInWarrants" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,266</ix:nonFraction></span>),
    reclassifications of warrants from liability to equity (increase of $<span id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh" title="Warrants from liability" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInWarrantsFromLiability" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,554</ix:nonFraction></span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l" title="Debt instrument" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,213,498</ix:nonFraction></span>).</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zaNZZatnnmHh" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zzreMJkmsia8" style="font-size: 10pt"><ix:footnote id="Footnote002032" xml:lang="en-US">Adjustments include corrections for stock compensation errors (increase of $<span id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a" title="Stock compensation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact002034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,009,461</ix:nonFraction></span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc" title="Fair value of warrants" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInFairValueOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact002036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,930</ix:nonFraction></span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a" title="Accrued dividends" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDividendsReceivable" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact002038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih" title="Derivatives loss" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact002040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,151</ix:nonFraction></span>); correction of issuance cost recognition related to financing transactions (decrease of $<span id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e" title="Issuance cost" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInIssuanceCost" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact002042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,407</ix:nonFraction></span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf" title="Net income loss" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInNetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact002044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,967,621</ix:nonFraction></span>).</ix:footnote></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zCPDzGSrLKea" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Operations for the year ended December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zfF7oBBVekwd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zwoKT7aBJHO8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zWrYFaOF7wz2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zj2MSn4b2I9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Research and development, net of contract expense reimbursements</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,148,712</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002047" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,327</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact002048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,047,385</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_zfl0BeByAfcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538,796</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002051" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,082</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact002052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,714</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LegalFees_i01_zVxLruGqxV9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal and professional</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">866,770</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002055" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,043</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31" id="Fact002056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822,727</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_zmOcF5iBAFc8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002058" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,554,278</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,452</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact002060" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,343,826</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpense_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zdoL3oeTEEUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember" id="Fact002062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">917,879</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember" id="Fact002063" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">489,191</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember" id="Fact002064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">428,688</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--FinanceFee_i01N_di_zcGL6QyywMmb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2066">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,912</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2022-01-012022-12-31" id="Fact002068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,912</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zuPH3lpTUpn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2070">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002071" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact002072" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zZ7eV5qwPDs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002074" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,025</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">492,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact002076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398,675</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_ztFvHLdBYq75" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on extinguishment of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002079" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,795,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31" id="Fact002080" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,795,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zslkvUkqO935" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002082" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,028,448</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002083" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,967,621</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact002084" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,996,069</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zRrY7MweYN9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend on Series A Preferred Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,055</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31" id="Fact002088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendOnExtinguishmentOfSeriesPreferredStock_iN_di_z5JuaOYNMOtj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed dividend on extinguishment of Series A Preferred Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2090">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,427</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact002092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,427</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_iN_di_zNL0yHlXVCs9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed dividend on modification of equity-classified warrants, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl2094">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<ix:nonFraction name="SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">941,000</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<ix:nonFraction name="SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" contextRef="From2022-01-012022-12-31" id="Fact002096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">941,000</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_iN_di_zu7usXLwRWu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl2098">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002099" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,423</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" contextRef="From2022-01-012022-12-31" id="Fact002100" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,423</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zMdGKJyjwBM2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to common stockholders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002102" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,099,457</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002103" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,647,680</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" id="Fact002104" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,747,137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per shares - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMuzbPGlFEhh" title="Net loss per shares - basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zccDRV02xjSf" title="Net loss per shares - basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002106" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002108" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.32</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB4urI05QeH1" title="Net loss per shares - basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKBYOEmr9nYi" title="Net loss per shares - Diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002110" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002112" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.72</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_z5ihkRTEuiul" title="Net loss per shares - Basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zSznyrVunGh9" title="Net loss per shares - Diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact002114" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact002116" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.04</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_134_zJX9uMgHKaPd" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Stockholders&#8217; Equity as of December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwS0vTQ9jBnd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcwAjgI1jFjg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zV0UlYwvROeh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zWvWqPGPs5Ya" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2118">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,951,356</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="Fact002120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,951,356</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuedForCash_zHDj0uGsfbqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForCash" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,008,095</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:CommonStockIssuedForCash" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,008,095</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2124">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WarrantsExercisedForCash_z2d1h2nIc9ac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants exercised for cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:WarrantsExercisedForCash" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,098</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:WarrantsExercisedForCash" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002127" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,098</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2128">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zhhR4qDxRN8l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Warrants issued for financing costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,241</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002131" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">397,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31" id="Fact002132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,662</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zhykxizzqMlh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for conversion of accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002135" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">588,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zyHZ1nRPI2pe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued upon conversion of convertible debt and exercise of related warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2138">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,916</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="Fact002140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,916</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zwf7FzAmToLf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,476</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,576,648</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31" id="Fact002144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,153,124</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsDHZesDpxNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,956</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002147" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">166,409</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact002148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,547</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DividendsOnSeriesPreferredStock_iN_di_zvqx0AJOOAIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividends on Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,055</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DividendsOnSeriesPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact002152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_zABJ06Gj07Ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002155" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31" id="Fact002156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_z5MiqqZKDCgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reclassification of fair value of warrant liability to equity upon initial public offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2158">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,553</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2022-01-012022-12-31" id="Fact002160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,553</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zxnxLSWBTqm9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002162" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,028,448</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002163" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,967,621</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact002164" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,996,069</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span><span><span id="xdx_C02_gL3SOECAPPATT-CTUD_zbUUVOgV6av4"><ix:continuation continuedAt="ConU002000-04" id="ConU002000-03">&#160;</ix:continuation></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_C09_gL3SOECAPPATT-CTUD_zLvKL6q0ueWd"><ix:continuation continuedAt="ConU002000-05" id="ConU002000-04"><span><span>&#160;</span></span></ix:continuation></span></p>

<div id="xdx_C07_gL3SOECAPPATT-CTUD_zhhDmZ3MOnCh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:continuation continuedAt="ConU002000-06" id="ConU002000-05"><table cellpadding="0" cellspacing="0" id="xdx_307_134_zdfyzfvfDy16" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Cash Flows for the year ended December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zy1sl4WmcFif" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zeDLOhNW3Qh1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_z3HtR4Rnmup1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zCatNeztmy4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002166" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,028,448</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002167" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,967,621</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact002168" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,996,069</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_zobw7LZjY4ph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2170">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002171" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact002172" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01_zH5N7jyNN6bb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,025</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">492,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact002176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398,675</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i01_zuFdOtXI1xQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization of debt discount and finance fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,505</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002179" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">508,121</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31" id="Fact002180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377,384</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LossOnSettlementOfConvertibleDebt_i01_zjcoYliHCWO2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on settlement of convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2182">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact002184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueOfFreestandingInstrumentsInExcessOfProceeds_i01_zOCefK4QX4t2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fair value of freestanding instruments in excess of proceeds</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2186">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,912</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds" contextRef="From2022-01-012022-12-31" id="Fact002188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,912</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GainOnInterestReliefOnConversionOfNotesPayable_i01N_di_zbi2XyEBcw01" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gain on interest relief on conversion of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:GainOnInterestReliefOnConversionOfNotesPayable" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,625</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:GainOnInterestReliefOnConversionOfNotesPayable" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,625</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_z9JN5YP8HCA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,956</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002195" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">166,409</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact002196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,547</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_zdwCVGgYjudb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002198" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,177</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,555</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-012022-12-31" id="Fact002200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zS9xgAWVXgZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,710,454</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,043</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact002204" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,666,411</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_zPeJwFkUi6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of common shares and warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,022,193</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,680</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact002208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,995,513</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_zX9wJ2hh4D47" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,715</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact002212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,715</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromNotesPayableAndWarrants_i01_zB9jBkRcOoei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from notes payable and warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2214">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:ProceedsFromNotesPayableAndWarrants" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:ProceedsFromNotesPayableAndWarrants" contextRef="From2022-01-012022-12-31" id="Fact002216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsOfFinancingCosts_i01N_di_zSy4wmzIPBff" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    for finance costs related to convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2218">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,363</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-01-012022-12-31" id="Fact002220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,363</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_z1cIFFnQqII8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,622,908</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002223" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,043</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact002224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,578,865</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaid_i01_z2AXVU0ATqRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Supplemental non-cash financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CommonStockIssuedUponConversionOfConvertibleDebt_i01_zqxadejLpiX2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued upon conversion of convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedUponConversionOfConvertibleDebt" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedUponConversionOfConvertibleDebt" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">611,392</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedUponConversionOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact002232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,916</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zl91Hr9vTr9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,476</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,576,648</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact002236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,153,124</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_i01_zSvMjywi1h66" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002238" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">402,068</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002239" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact002240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">402,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--WarrantsIssuedForFinancingFees_i01_zEdVHlVkRYRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants issued for financing fees, net of issuance fees of $<span id="xdx_901_ecustom--WarrantsIssuanceFees_c20230101__20231231_z3f2JIJxQ6Sg" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2023-01-012023-12-31" id="Fact002246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span> and $<span id="xdx_909_ecustom--WarrantsIssuanceFees_c20220101__20221231_zdqu9lkBFd4" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2022-01-012022-12-31" id="Fact002248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,241</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002243" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">397,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2022-01-012022-12-31" id="Fact002244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,662</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_i01_zpGNzvsa7kK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reclassification of fair value of warrant liability to equity upon initial public offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,553</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" contextRef="From2022-01-012022-12-31" id="Fact002252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,553</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)" id="xdx_30B_134_zABYLOApGVBf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zLsnU6dc6oAc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z4f2SrKUNhEd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_z9hEcTZm93ad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,948</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AdditionalPaidInCapital_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zSrXYy1elD59" title="Additional paid in capital" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,912,992</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" id="Fact002255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,063,940</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zqI4Ca10eqGi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated Deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002259" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zbPV9duglp2d" title="Accumulated deficit" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002262" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,049,080</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" id="Fact002260" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,844,512</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_zyx8H6MNpq29" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zVcwwitNryW8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002263" xml:lang="en-US">Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $<span id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk" title="Increase decrease of notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInNotesPayableCurrent" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,351</ix:nonFraction></span>); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of <span id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh" title="Increase decrease in preferred stock" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="SHPH:IncreaseDecreaseInPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,118</ix:nonFraction></span>); and stock compensation adjustments (increase of $<span id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l" title="Stock compensation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,009,461</ix:nonFraction></span>).</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_z8KUvJcM4081" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td id="xdx_F11_zlKB34EfShAa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="Footnote002270" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    include reversal of dividend liability recorded (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1" title="Increase decrease in dividend liability"><ix:nonFraction name="SHPH:IncreaseDecreaseInDividendLiability" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="Fact002272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,059</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of deferred IPO costs (decrease of ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi"><ix:nonFraction name="SHPH:IncreaseDecreaseInIssuanceCost" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="Fact002273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,182</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh"><ix:nonFraction name="SHPH:IncreaseDecreaseInPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="Fact002274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,118</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the estimated fair value of warrant liability (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63"><ix:nonFraction name="SHPH:IncreaseDecreaseInFairValueOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="Fact002275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,930</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj"><ix:nonFraction name="us-gaap:IncreaseDecreaseInNotesPayableCurrent" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="Fact002276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,048</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="Fact002277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,009,461</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></ix:footnote></td></tr>
  </table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_C06_gL3SOECAPPATT-CTUD_zXQh9xUmmI5"><ix:continuation id="ConU002000-06">&#160;</ix:continuation></span></span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002279" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zAbDMxtvqVkb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Note 3 &#8211; <span id="xdx_824_zYouvyiEJF0f">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002281" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zN9JmHykJAle">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002283" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zXzky5zRn35g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002285" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i><span id="xdx_864_z51lIHBaxIod">Reclassifications</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002287" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_znBsmi9qpX7i">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company
regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical
experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the
Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results
of operations will be affected. Significant estimates are contained in the accompanying consolidated financial statements for the
recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other
financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002289" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zJkXkj4AZTy2">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002291" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact002293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,550,098</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" id="Fact002294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,411,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact002296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,318</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact002297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,005,825</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact002299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact002300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" id="Fact002302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2023-12-31" id="Fact002304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,849,000</ix:nonFraction></span>. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002306" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zcIP2rrvmXK8">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact002308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></span>. During the year ended December 31, 2023, the Company recognized interest income of $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact002310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,855</ix:nonFraction></span>,
realized gains of $<span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-012023-12-31" id="Fact002312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,970</ix:nonFraction></span>, and unrealized gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-012023-12-31" id="Fact002314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,568</ix:nonFraction></span>. The were <span id="xdx_90F_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zbAdEjByFAZi" title="Marketable securities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2316">no</span></span> marketable securities as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002318" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqfmU6VxYX7j">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002320" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Marketable Securities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember" id="Fact002327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2328">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact002330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact002332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2333">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2334">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact002335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DerivativeLiabilityWarrants_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zLHLaG6Wpet4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative Liability - Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2343">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DerivativeLiabilityWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact002344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DerivativeLiabilityWarrants" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact002345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerivativeLiabilityAcceleratedFeature_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_z1GMbV70G7Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2347">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2348">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DerivativeLiabilityAcceleratedFeature" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember" id="Fact002349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DerivativeLiabilityAcceleratedFeature" contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember" id="Fact002350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2352">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2353">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact002354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact002355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company had non-derivative warrant liabilities that were measured at fair value on a recurring
basis. Each of these fair value measurements was considered to be a Level 3 measurement by the Company as they used significant unobservable
inputs, such as the Company&#8217;s pre-IPO stock price, probability of event occurrence and other management estimates. The key inputs
for each of these warrant liabilities were as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" escape="true" id="Fact002357" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoMWqw0jB0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zKUJ72QdTXY5" style="display: none">Schedule
of Key Inputs of Warrant Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Series A Preferred Stock Obligation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_984_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zLyVGKOArAWd" title="Estimated fair value of company's stock" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><ix:nonFraction name="SHPH:WarrantsEstimatedFairValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002359" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_982_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zgBrdL1LrT7c" title="Estimated fair value of company's stock" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><ix:nonFraction name="SHPH:WarrantsEstimatedFairValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002361" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated IPO or Listing terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_znoxhYjetF0l" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MinimumMember" id="Fact002363" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.00</ix:nonFraction></span> - $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zArhlIcCb06d" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MaximumMember" id="Fact002365" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">166.56</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zp65fcqYKv7b" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002367" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Series A Preferred Stock conversion shares upon IPO or Listing at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_ztMXqnmuU9cb" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MinimumMember" id="Fact002369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,135</ix:nonFraction></span> - <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zMp7IKseQgnc" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MaximumMember" id="Fact002371" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,681</ix:nonFraction></span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7zVZKsduoz2" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,101</ix:nonFraction></span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdcX1kzMoQCd" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002375" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zW1kmGuIywhe" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002377" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z78eGWXIszP4" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002379" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.08</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zbRqcuFc7Kx4" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002381" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.44</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated IPO date</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7abpz07AmNb" title="Estimated IPO date"><ix:nonNumeric contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" format="ixt:datemonthdayyear" id="Fact002383" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">9/30/2022</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zreHcuEZR3gi" title="Estimated IPO date"><span style="-sec-ix-hidden: xdx2ixbrl2385">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated Term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z815JlVntnri" title="Estimated Term"><ix:nonNumeric contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" format="ixt-sec:duryear" id="Fact002387" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.75</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z1GevZdwSlle" title="Estimated Term"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" format="ixt-sec:duryear" id="Fact002389" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.00</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO or Listing Occurring</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zkuIhmucDUIl" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002391" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zP3rqfuREZce" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2393">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO as &#8220;Qualified IPO&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKZbZZdwX904" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002395" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zAVfbA32ifU9" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2397">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of IPO as &#8220;Listing&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zao8vkaRcnof" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002399" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKRwLLcGWTNc" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2401">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdV5UMoJ21Bj" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,955</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z0UVRkniDVEg" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">756,723</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification/Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9nZuNwXlNZ9" title="Estimated fair value of company's stock" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="SHPH:WarrantsEstimatedFairValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002407" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9B1oFEU8qSd" title="Estimated fair value of company's stock" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="SHPH:WarrantsEstimatedFairValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002409" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zL1GvJpV5Cld" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002411" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z7OvmG4tIEqi" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002413" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Number of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zZ3lsYq0BOS3" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002415" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,250</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zWW3jeBT6Epe" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,250</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zsUhFnC28Jl7" title="Estimated Term"><ix:nonNumeric contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" format="ixt-sec:duryear" id="Fact002419" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.0</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zmfGu7F5nHW3" title="Estimated Term"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" format="ixt-sec:duryear" id="Fact002421" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.9</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zBV3c4wuqEq3" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002423" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z0zoN4DV2El9" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002425" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zkEcXWlx3BOc" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002427" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2A0YB3qNMNd" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002429" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z1XDBZyN0Kv5" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,624</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2TqMctNvqrh" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,726</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zGirhz4ePWDd" title="Estimated fair value of company's stock" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="SHPH:WarrantsEstimatedFairValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002435" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsu1obyU1Wfi" title="Estimated fair value of company's stock" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="SHPH:WarrantsEstimatedFairValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002437" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z0coh5dRpsxa" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002439" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoeIDPCXPcQc" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002441" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoXzU7kpwwt5" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002443" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,688</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zgcbWp2u3FLf" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002445" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,581</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zXIPSshDbQ7" title="Estimated Term"><ix:nonNumeric contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact002447" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.0</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXzeaxUL0tM4" title="Estimated Term"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact002449" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.4</ix:nonNumeric></span> &#8211; <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLzgZeRBaps9" title="Estimated Term"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact002451" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.5</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z1Fa93A6ZRvi" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002453" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zNweZGNbvpN3" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002455" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhzYuy6xQ1gh" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember" id="Fact002457" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.8</ix:nonFraction></span>% - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPg7CsZ2CbB2" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember" id="Fact002459" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.0</ix:nonFraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsxT4r0C5eu5" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002461" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.4</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyTizCgvTLpl" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,336</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z72Y855ESgJb" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,140</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zecpDhgOgxS8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A rollforward of these warrant liabilities for the year ended December 31, 2022 is as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002467" name="SHPH:ScheduleofWarrantLiabilitiesTableTextBlock"><p id="xdx_89E_ecustom--ScheduleofWarrantLiabilitiesTableTextBlock_ztBVEOc64Ov8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zeSONc0gOzva" style="display: none">Schedule
of Warrant Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Liability &#8211; Series A Preferred Stock Obligation</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2021 (as restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zNsPYB7LzPi3" title="Warrant liabilities" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:WarrantLiabilities" contextRef="AsOf2021-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,955</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zF5QjxZXZTJg" title="Issued" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised (settled)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_ztUOjfervEfb" title="Exercised (settled)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on change in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z5rYb9iCCVZc" title="Gain on change in fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SHPH:GainOnChangeInFairValue" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">421,768</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassifications to stockholders&#8217;
    equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7151H6TNz22" title="Reclassifications to stockholders' equity" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="SHPH:ReclassificationsToStockholdersEquity" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember" id="Fact002477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">756,723</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z6PdrHa7bupc" title="Warrant liabilities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2479">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zlZwC2L7J5Eg" title="Warrant liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zIeMYiGkql7i" title="Issued" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><ix:nonFraction name="SHPH:WarrantLiabilitiesIssued" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,624</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zhb4cBwGbSah" title="Exercised (settled)" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:WarrantLiabilitiesExercised" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002485" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">91,036</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zXN8bvqeOFIl" title="Loss on change in fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:GainOnChangeInFairValue" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,102</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reclassifications to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_za8LAb6YMJX" title="Reclassifications to stockholders' equity" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:ReclassificationsToStockholdersEquity" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember" id="Fact002489" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,690</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zawcjTzKvje2" title="Warrant liabilities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2491">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zol065gJ4hZg" title="Warrant liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2493">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zHGwX8iZIuNe" title="Issued" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><ix:nonFraction name="SHPH:WarrantLiabilitiesIssued" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,336</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_ziqTyVquujLg" title="Exercised (settled)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zf7xXRmbzS94" title="Gain on change in fair value" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">(<ix:nonFraction name="SHPH:GainOnChangeInFairValue" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002499" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,196</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Reclassification to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Gain on change in fair value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_983_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zjJcvweR4b02" title="Reclassifications to stockholders' equity" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<ix:nonFraction name="SHPH:ReclassificationsToStockholdersEquity" contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact002501" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,140</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyZqV655aYsl" title="Warrant liabilities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2503">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zRZQvVXDUPo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Refer to Note 7 for additional background on
the reclassification of warrant liabilities to equity. See Note 8 for additional disclosures related to the fair value of the Company&#8217;s
derivative liabilities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002505" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUfQ5IhZAVZ7">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine if an arrangement is a lease at inception. <span style="background-color: white">Operating leases are included in operating
lease right-of-use asset (&#8220;ROU&#8221;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with a lease term of 12 months or less at inception are not recorded on our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">balance </span>sheets <span style="background-color: white">and are expensed on a straight-line
basis over the lease term in our statement of operations. </span>We have lease agreements with lease and non-lease components, which
are generally accounted for separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#8220;incremental borrowing rate&#8221; or &#8220;IBR&#8221;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002507" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zhMEboul1fnf">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002509" name="SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%">Furniture</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact002511" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computers and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact002513" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact002515" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002517" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYSObLAWFqrd">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our derivative financial instruments, the Company utilizes the most appropriate valuation model (such as Monte Carlo simulations or probability-weighted expected
return models, based on the nature of the terms of the instrument) to value the derivative
instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such
instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheet sheets as current or non-current based on whether or not net-cash settlement or
conversion of the instrument could be required within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002519" name="SHPH:ConvertibleNotePolicyTextBlock"><p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zIShPO1DVFMg">Convertible
Notes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible notes for embedded features and bifurcates these features (such as conversion options and
redemption options) from their host instruments and accounts for them as free standing derivative financial instruments if certain
criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid
instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under
otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)
a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002521" name="SHPH:WarrantsPolicyTextBlock"><p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_860_zbFQsfTI6WN7">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity
(&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants
are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the
warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a
circumstance outside of the Company&#8217;s control, among other conditions for equity classification. Finally, the Company
determines if the warrants meet the definition of a derivative based on their contractual terms. This assessment, which requires the
use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while
the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and at each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">statements of operations. </span></span>The Company also evaluates if changes in contractual terms
or other considerations would result in the reclassification of outstanding warrants from liabilities to stockholders&#8217; equity (or
vice versa).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">
The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002523" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zMKVdyEG0BI7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002525" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z4CSzyso8ih9">Stock-Based Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost for stock awards, which include restricted stock units (&#8220;RSUs&#8221;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002527" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z01OOEEOeht9">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#8217; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$<span id="xdx_90F_ecustom--ShareBasedCompensations_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhkgxJb4oO55" title="Share based compensation"><ix:nonFraction name="SHPH:ShareBasedCompensations" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact002529" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million and $<span id="xdx_900_ecustom--ShareBasedCompensations_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znRCeUIPhCNa" title="Share based compensation"><ix:nonFraction name="SHPH:ShareBasedCompensations" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact002531" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230101__20231231_zY9s230h9slk" title="Research and development, net of contract expense reimbursements"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact002533" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20220101__20221231_zuzMe32hXUdd" title="Research and development, net of contract expense reimbursements"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact002535" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million in Research and development, net of contract expense reimbursements, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002537" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zjUxdX9ZNGFl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002539" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQkEcVy4u6Y6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zDl56YzwE8M1">Segment
Information</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate and discrete information is available for evaluation by the
chief operating decision-maker (&#8220;CODM&#8221;) in deciding how to allocate resources and assess performance. The Company and the
Company&#8217;s CODM, the Company&#8217;s chief executive officer, evaluates the Company&#8217;s operations and manages its business
as a <span id="xdx_900_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_z3kfWGafUOSj" title="Number of reportable operating segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl2541">single</span></span> operating segment. All of the Company&#8217;s long-lived assets are held in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002543" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwbvAlIY1l46">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per common share on the face of the statements of operations
for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic
earnings per share computation. In the accompanying consolidated financial statements, basic loss per common share is computed by
dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the weighted average
number of shares of common stock outstanding and potentially dilutive shares of common stock during the period to reflect the
potential dilution that could occur from common shares issuable through convertible securities, contingent share arrangements, stock
options and warrants unless the result would be antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units and other stock-based payment awards subject to vesting and common stock warrants is
calculated using the &#8220;treasury stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these
instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible
securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be
converted at the beginning of the period, and the resulting shares of common stock are included in the denominator of the diluted
calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002545" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(as
                                            restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Convertible notes (Note 6)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact002547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,939</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl2549">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember29538078" id="Fact002551" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact002553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,831</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002555" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,731</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,966</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact002559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">328,670</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" id="Fact002561" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,797</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002563" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zSWNCgOEheR1">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not expect the adoption of this standard to
have any material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.</p>

</ix:nonNumeric><p id="xdx_85E_zQNfopfWoCN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002565" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_z08OzEyKAwJ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 - <span id="xdx_82E_zYhGzQEhHDX1">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had two lease agreements during the year which allowed for the use of laboratory facilities. <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zEya2wAH9aKc" title="Lessee, operating lease, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact002567" name="us-gaap:LesseeOperatingLeaseDescription">The first was for a monthly payment
of $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20230101__20231231_z4j16dhXCej9" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-12-31" id="Fact002569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></span>, with a security deposit of $<span id="xdx_90A_eus-gaap--Deposits_iI_c20231231_zO8e4gkFsUJk" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-12-31" id="Fact002571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></span> held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019</ix:nonNumeric></span> and ended on <span id="xdx_90D_eus-gaap--LeaseExpirationDate1_c20230101__20231231_zI0l5Mds2Am4" title="Lease expiration date"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt:datemonthdayyearen" id="Fact002573" name="us-gaap:LeaseExpirationDate1">October 31, 2023</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2023, the Company entered into a new lease agreement for new office and laboratory space, with base rent of $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zzwRNVzOdczf" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember" id="Fact002575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,206</ix:nonFraction></span> per month
for a period of 64 months, which increases at the rate of <span id="xdx_903_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIt1JZKcThLk" title="Rent variable rate"><ix:nonFraction name="SHPH:RentVariableRate1" contextRef="AsOf2023-02-16_custom_NewLeaseAgreementMember" id="Fact002577" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% per year, that <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIlMHykNlrM1" title="Operating lease description"><ix:nonNumeric contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember" id="Fact002579" name="us-gaap:LesseeOperatingLeaseDescription">commenced June 1, 2023</ix:nonNumeric></span>. The new lease included a six-month
50% rent abatement upon commencement. Additional common area maintenance (&#8220;CAM&#8221;) fees are charged monthly and revised annually.
The estimated monthly CAM fees are $<span id="xdx_908_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230215__20230216_zd0rmLCuEgvl" title="Estimated monthly common area maintenance cost"><ix:nonFraction name="SHPH:EstimatedMonthlyCommonAreaMaintenanceCost" contextRef="From2023-02-152023-02-16" id="Fact002581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300</ix:nonFraction></span> per month for the first year of the lease, which are being expensed as incurred. An irrevocable
letter of credit (&#8220;LOC&#8221;) for the security deposit of $<span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20230216_zE3n7U3fwQok" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-02-16" id="Fact002583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,234</ix:nonFraction></span> and base rent of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20230215__20230216_zETIouZ8QDv6" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-152023-02-16" id="Fact002585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,891</ix:nonFraction></span>, including 50% abatement, and $<span id="xdx_909_ecustom--CommonAreaMaintenanceCost_c20230215__20230216_zRiqEIIYf8j8" title="Common area maintenance cost"><ix:nonFraction name="SHPH:CommonAreaMaintenanceCost" contextRef="From2023-02-152023-02-16" id="Fact002587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,315</ix:nonFraction></span>
of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is the beneficiary of the LOC,
and the expiry date of the LOC is February 15, 2024. Subsequent to December 31, 2023, the LOC was renewed with an updated expiry date
of March 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002589" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the right-of use asset and lease information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z3chxPAugTvb" style="display: none">Schedule of Right-of Use Asset and Lease Information About Operating Lease</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Years Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,022</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31" id="Fact002592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,175</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,222</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2595">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Sublease income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2023-01-012023-12-31" id="Fact002597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,819</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2022-01-012022-12-31" id="Fact002598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,070</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,425</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-12-31" id="Fact002601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,105</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other information</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact002606" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,641</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31" id="Fact002607" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,248</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact002609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,556</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2610">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term - operating leases (year)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dxL_c20231231_zyA8Do3k9Nfg" title="Weighted-average remaining lease term - operating leases (year)::XDX::P4Y11M23D" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2612">4.67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" title="Weighted-average remaining lease term - operating leases (year)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" id="Fact002614" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.80</ix:nonNumeric></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average discount rate - operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dpxL_uPure_c20231231_zWuyyS7WvFVl" title="Weighted-average discount rate - operating leases::XDX::10.46" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2616">10.48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_z8NlF0txAYKc" title="Weighted-average discount rate - operating leases" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" id="Fact002618" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zAskMv6Jd9Ib" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002620" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOSrvaX8p16l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zhh9Zl5mOtfe" style="display: none">Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Years ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz2AR_zxdBtjySLTu6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024 (excluding the six months ended June 30, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz2AR_z7Q1UTfjXlRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" id="Fact002624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,502</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz2AR_zxt7KD3Psq8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" id="Fact002626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,247</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz2AR_zCEFnZuV9lP6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" id="Fact002628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,074</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz2AR_zB3e7mhwfEwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" id="Fact002630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,986</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz2AR_zjrflcieALdj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2023-12-31" id="Fact002632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,235</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz2AR_zKCt4MJzhhad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total future minimum lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-12-31" id="Fact002634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,044</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-12-31" id="Fact002636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,438</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact002638" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zGZjjGq7mVc5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002640" name="SHPH:NotesPayableRelatedPartyDisclosureTextBlock"><p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zd061yowJNd3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_825_zH1XaP0tjrW5">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zamdIkxYJlAj" title="Loan transaction amount"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" id="Fact002642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,243</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWqcEUtfPTu6"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" id="Fact002643" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity date of <span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zfFRy9Sub3Hc"><ix:nonNumeric contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:datemonthdayyearen" id="Fact002644" name="us-gaap:RelatedPartyTransactionDate">December 31, 2021</ix:nonNumeric></span>; and (ii) a single loan
owed to an officer of the Company in the principal amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z23uTB9maqmg" title="Principal amount"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember" id="Fact002646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,229</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_90A_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zerWcgbpUGVj"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember" id="Fact002647" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity
date of December 31, 2021. <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211231_zT9SOlLu3LFk" title="Debt instrument maturiy date description"><ix:nonNumeric contextRef="From2021-12-012021-12-31" id="Fact002649" name="us-gaap:DebtInstrumentMaturityDateDescription">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_906_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zgvqBs3CjI55" title="Loan transaction amount"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" id="Fact002651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> (principal) with
an interest rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z7JDA19McyJa"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" id="Fact002652" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum due June 21, 2022. In July of 2022, the loan was extended to June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company accounted for these loan extensions during
the year ended December 31, 2022, as a troubled debt restructuring as the Company was experiencing financial difficulties and the extensions
represented a concession by the lenders. As the future undiscounted cash flows of these related party notes exceeded their carrying value,
no gain or loss was recognized upon the extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023 principal payments of $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zSYaCBxemUD8"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember" id="Fact002653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></span> and interest of $<span id="xdx_905_eus-gaap--InterestPaid_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z83SkWky2Pa" title="Interest paid"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember" id="Fact002655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,968</ix:nonFraction></span> were paid. As of December 31, 2023, there were <span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_do_c20230101__20231231_z5bCjpTtB4u2" title="Increase accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-01-012023-12-31" id="Fact002657" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> outstanding
principal or interest balances for these related party notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On August 1, 2022, in conjunction with a private placement of notes and
warrants (as detailed in Note 6 below), in exchange for a $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCQ4BFsht1I5" title="Payments upon subscription"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember" id="Fact002659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> payment upon subscription, the Company issued a convertible note to
the spouse of an officer of the Company in the amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWcxBHe7uvM8" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-08-01_custom_OfficersSpouseMember" id="Fact002661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction> </span>(principal) with an interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z6n2o8Hg614f" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-08-01_custom_OfficersSpouseMember" id="Fact002663" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum, and warrants to purchase
<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z40JRGFDyq7c" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-08-01_custom_OfficersSpouseMember" id="Fact002665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span> shares of common stock. The loan was fully repaid, including $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z6p8z1cYrBy7" title="Repayments of accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2022-09-30_custom_OfficersSpouseMember" id="Fact002667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822</ix:nonFraction></span> of accrued interest, in September of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002669" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zFKpdNkIRYg4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Note 6 -<span> Notes Payable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82B_zZ6z698dByx6" style="display: none">Convertible Notes and Notes Payable</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alto
Opportunity Master Fund, SPC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, the Company entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master
Fund, SPC &#8211; Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to
the Investor a $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1qYaf3PFxbb" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002671" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,300,000</ix:nonFraction></span>
convertible note (the &#8220;Alto Convertible Note&#8221;) and warrant (the &#8220;Alto Warrant&#8221;) to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zI1s666a13S3" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></span>
shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDE7HRqOETJb" title="Warrants exerciable shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span>
per share, in exchange for gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqpTwBuXgLIh" title="Proceeds from convertible note payable"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002677" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,935,000</ix:nonFraction></span>
(the &#8220;Investment Amount&#8221;) (See Note 7). The Company determined that the Alto Warrant contains a net cash settlement
feature at inception and categorized the Alto Warrant as a liability in the accompanying consolidated financial statements. The Alto
Convertible Note matures on March 11, 2025, but may be extended at the option of the noteholder. The Alto Convertible Note amortizes
on a monthly basis and the Company can make such monthly amortization payments in cash or, subject to certain equity conditions, in
registered shares of common stock or a combination thereof. Installments may be deferred by the noteholder, resulting in a variable
interest rate. However, the effective interest rate is approximately <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYihioEmX1N1" title="Effective interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002679" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">346</ix:nonFraction></span>%
based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment, <span id="xdx_900_eus-gaap--DebtInstrumentDescription_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQZdUUfRm3u2" title="Debt description"><ix:nonNumeric contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002681" name="us-gaap:DebtInstrumentDescription">the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20230111_zqknXDQiiXwl" title="Share Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-01-11" id="Fact002683" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span>
per share.</ix:nonNumeric></span> The noteholder has an acceleration of installment amount conversion option (the &#8220;Alto Acceleration
Option&#8221;), whereby the noteholder, with certain share percentage limitations, can convert to common stock any outstanding
installment amount at an amount equal to the installment amount plus five times (5x) the installment amount at any time. The Company
has determined the Alto Acceleration Option is an embedded derivative within the host instrument and has bifurcated it from the host
instrument and recorded it as a derivative liability valued at $<span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zw9FmdP2k1rj" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002685" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></span>,
using a Monte Carlo simulation model (Note 8). The Convertible Note is repayable over 26 months and bears interest at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIDfdUAlNQL7" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact002687" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
per annum. Additionally, the note contains certain redemption options and &#8220;Make Whole&#8221; provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: Spl_002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the
&#8220;Security Agreement&#8221;), an intellectual property security agreement (the &#8220;IP Security Agreement&#8221;) and a
subsidiary guaranty (the &#8220;Subsidiary Guaranty&#8221;). The security agreements and guaranty allow, among other things, for the
Investor to have a security interest in and place a lien on all of the Company&#8217;s assets and intellectual property until such
time as the Alto Convertible Note is paid off. In addition, the SPA called for the Company to enter into a springing deposit account
control agreement (the &#8220;Springing DACA&#8221;), which, in the event the Company defaults on its repayment of the Alto
Convertible Note, would allow the Investor to assume control of the Company&#8217;s bank account only with regard to any funds
remaining outstanding under the Alto Convertible Note. As such, in conjunction with entry into the SPA, the Company established a
separate bank account in which it deposited the Investment Amount and pursuant to which the Company, the Investor and the bank
holding the Investment Amount, First Republic Bank, entered into the Springing DACA agreement. As the Investment Amount had been
held at First Republic Bank, in light of certain banking crises then affecting smaller banks, on March 12, 2023, the Company and the
Investor moved the Investment Amount from First Republic Bank, after which time the Springing DACA was no longer in effect. Further,
pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor agreed that all of the
Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing DACA would no
longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20231231_zhjUClDQimI" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31" id="Fact002689" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span>
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Alto Warrant, excluding
the Springing DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an
opportunity to participate in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company
expects that such subsequent convertible notes and warrants would be issued on substantially similar terms as the January 11, 2023
initial agreement, as amended, thus providing the Company the opportunity to negotiate certain aspects of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_ziS9eEQtuv1f" title="Payment for placement agent"><ix:nonFraction name="SHPH:PaymentForPlacementAgent" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></span> cash compensation and a warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zAqlkvNNaDpd" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002693" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,909</ix:nonFraction></span> shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zojy77XppzIe" title="Warrants exerciable shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPC674AVJKXc" title="Expected years"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:durwordsen" id="Fact002697" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span>, volatility of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znMOWfqPGjYf" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact002699" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">110</ix:nonFraction></span>%, a risk-free rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zILXwC7DhWBl"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact002700" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.53</ix:nonFraction></span>% for a value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zEonjOrQ2ZU" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,543</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated the finance costs related to the Boustead placement agent fee of $<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z1qEjzidygn" title="Payment for placement agent"><ix:nonFraction name="SHPH:PaymentForPlacementAgent" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></span>, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $<span id="xdx_902_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGBEljeJa0Nb" title="Allocation of financing costs"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,027</ix:nonFraction></span> to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmNk8FczQ6Wh" title="Warrant derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,245</ix:nonFraction></span> to the warrant derivative liability component,
expensed as a finance fee, and $<span id="xdx_90F_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zSUixncCkJS1" title="Equity warrant as reduction in additional paid in capital"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span> to the equity warrant as a reduction in additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated to the debt component of the note an original discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zMx5hPAesnIi" title="Debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact002712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>, legal fees of $<span id="xdx_90D_eus-gaap--LegalFees_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zLBOZ1MJKbi8" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact002714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,000</ix:nonFraction></span>, $<span id="xdx_900_ecustom--InterestFeeAmount_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zqJJyHoHEi83" title="Interest fee"><ix:nonFraction name="SHPH:InterestFeeAmount" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact002716" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,000</ix:nonFraction></span> for additional
interest fees on day one added to note principal, $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zayR1vJlE2s9" title="Debt principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact002718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></span> for the accelerated conversion feature, and $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zxa2TC77bmFd" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact002720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,288,543</ix:nonFraction></span> for the fair value
of warrants, resulting in an additional $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_znnI28Rtm2fb" title="Interest expense debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact002722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310,543</ix:nonFraction></span> debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded interest expense of $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_znhWETUYiYQb"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,484,193</ix:nonFraction></span>, which included amortization of debt discount as
interest expense of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20230101__20231231_zpTyEbkt4Xac"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31" id="Fact002724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,123,049</ix:nonFraction></span>. During the year ended December 31, 2023, the Company settled $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJLs4MfXiOZ5" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,925,700</ix:nonFraction></span> of principal and settled $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIH04jwIMOkl" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,927</ix:nonFraction></span>
of accrued interest, which settlements were made in the form of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z61rjBMkQSyb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact002729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">297,625</ix:nonFraction></span> shares of common stock during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the outstanding principal for the convertible note was $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_c20231231_zSRsEaMmQVQd"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-12-31" id="Fact002730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,254,856</ix:nonFraction></span> and the debt discount remaining was $<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20231231_zLkKrYZw6Y46"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-012023-12-31" id="Fact002731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,523,768</ix:nonFraction></span>,
with a net convertible note carrying value of $<span id="xdx_90C_ecustom--ConvertibleNotesPayableCurrentNonCurrent_iI_c20231231_zuETJj7Bxv4l" title="Convertible note payable"><ix:nonFraction name="SHPH:ConvertibleNotesPayableCurrentNonCurrent" contextRef="AsOf2023-12-31" id="Fact002733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">731,088</ix:nonFraction></span>, which represents the current and non-current portions of the convertible note
as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company and the Investor agreed to certain changes in terms of the Alto Convertible Note as well as the waiver
of certain covenant violations. See Subsequent Events for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Paycheck
Protection Program Term Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $<span id="xdx_905_eus-gaap--MediumTermNotes_iI_c20210309_zqzjdB5Jbxke" title="Term notes issued"><ix:nonFraction name="us-gaap:MediumTermNotes" contextRef="AsOf2021-03-09" id="Fact002735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bore an interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_z99RiodwMrtj" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-03-09" id="Fact002737" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum, had a six-month deferral period with payments
due on the seventh month, with all outstanding principal and interest due and payable within two years from the note&#8217;s inception
date. Under its terms, all or a portion of the note may be forgiven in accordance with PPP requirements, with <span id="xdx_908_eus-gaap--ShortTermDebtDescription_c20210309__20210309_zYoBKdc2rg0k" title="Term note description"><ix:nonNumeric contextRef="From2021-03-092021-03-09" id="Fact002739" name="us-gaap:ShortTermDebtDescription">no more than 25% of the
amount forgiven to be attributable to non-payroll costs</ix:nonNumeric></span>. As of December 31, 2021, a &#8220;Loan Forgiveness Application&#8221; was submitted
to PNC Bank along with the requested documentation. Thereafter, during the quarter ended March 31, 2022, the note liability was reduced
in its entirety and the Company recognized a gain on forgiveness of $<span id="xdx_90B_eus-gaap--MediumTermNotes_iI_c20221231_zScgzlhv1dok" title="Term notes issued"><ix:nonFraction name="us-gaap:MediumTermNotes" contextRef="AsOf2022-12-31" id="Fact002741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></span> in its statement of operations for the year ended December
31, 2022. (as restated)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>December
2021 Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued promissory note units, consisting of an aggregate $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20211228_z8zCyT3ROlM8" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-28" id="Fact002743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>
in <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_zTW6LR0Kzba8" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-12-28" id="Fact002745" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
unsecured promissory notes with a maturity date of <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_z2nwNfHdgjxk" title="Debt maturity date"><ix:nonNumeric contextRef="From2021-12-282021-12-28" format="ixt:datemonthdayyearen" id="Fact002747" name="us-gaap:DebtInstrumentMaturityDate">December
28, 2022</ix:nonNumeric> </span>(the &#8220;December 2021 Promissory Notes&#8221;) and warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zNoT2sbNViB4" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-28" id="Fact002749" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction></span>
shares of common stock exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_z5iMOMfl5y8k" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-28" id="Fact002751" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span>
per share with an expiration date of December 28, 2026. The Company received net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20211228__20211228_zsaZJ1BsY731" title="Promissory note"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2021-12-282021-12-28" id="Fact002753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,925</ix:nonFraction></span>
upon the issuance of these promissory note units and incurred $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20211228_zvn3OApisrb5" title="Issuance cost"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2021-12-28" id="Fact002755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,890</ix:nonFraction></span> in additional issuance costs which were allocated between the December 2021 Promissory Notes
and the warrants. The Company assessed the embedded features of the December 2021 Promissory Notes
and determined that the accelerated repayment upon an initial public offering represented a derivative feature requiring
bifurcation. The Company estimated the fair value of the derivative to be $<span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20211228__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUD8Ry6bhtO7" title="Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-28_us-gaap_FairValueInputsLevel3Member" id="Fact002757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,000</ix:nonFraction></span>
at issuance (see Note 8 for fair value considerations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the warrants issued with the December 2021 Promissory Notes should be classified as equity. The Company
measured the fair value of these warrants using a Black-Scholes model and allocated fair value to these warrants on a relative fair
value basis. The proceeds from the December 2021 Promissory Notes allocated to the warrants at issuance was $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_c20211228__20211228_zqbgjTw8ZEB2" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2021-12-282021-12-28" id="Fact002759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,449</ix:nonFraction></span>. The inputs to
the Black-Scholes model included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20211228__20211228_zpY9EgGY1YV5" title="Conversion price per share"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2021-12-282021-12-28" id="Fact002761" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.00</ix:nonFraction></span>,
the exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zAR1l1qtI5Kj" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31" id="Fact002763" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span>
per share, a five year term, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20211228__20211228_zPXD89MZnqYk" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-12-282021-12-28" id="Fact002765" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.3</ix:nonFraction>%</span>
volatility and a risk free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20211228__20211228_zqFIbTWnireh" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-12-282021-12-28" id="Fact002767" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.27</ix:nonFraction>%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discount on the December 2021 Promissory Notes was being amortized using the straight-line method as the initial proceeds received were
fully allocated to the warrants and bifurcated derivative, through the maturity date of the notes. The Company recognized amortization
expense of $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231_zkuIO5Agz0Qb"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-01-012022-12-31" id="Fact002768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,978</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related
to the discount on the December 2021 Promissory Notes as interest expense in its statement of operations for the year ended December
31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In April 2022, the warrants were modified by the Company
to nullify the effect of the April 2022 reverse stock split, allowing the warrant to remain outstanding and exercisable for <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220430_zgVPTzfdkwIi" title="Warrants outstanding and exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-04-30" id="Fact002770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction></span> shares
of common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zAmiQlpLmEgj" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-30" id="Fact002772" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span> per share. The Company calculated the incremental fair value provided to the holders of
the warrants due to the modification as $<span id="xdx_908_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrants_c20220101__20221231_zAhnDE9G1f13" title="Deemed dividend on modification of equity classified warrants"><ix:nonFraction name="SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants" contextRef="From2022-01-012022-12-31" id="Fact002774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">941,000</ix:nonFraction></span>, which was recorded as a deemed dividend during the year ended December 31, 2022. The
incremental fair value was estimated using a Black-Scholes model, with inputs including the estimated fair value of the Company&#8217;s
common stock of $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220430__20220430_zpBlE4y3tN23" title="Conversion price per share"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-04-302022-04-30" id="Fact002776" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span>, the exercise price of either $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220429_z2Tjj9vjnFh5" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-29" id="Fact002778" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span> (pre-modification) or $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zKAy7DyBmHD6" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-30" id="Fact002780" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span> (post-modification), a remaining term of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220430__20220430_z2Yg4OdIZeW1" title="Expected term"><ix:nonNumeric contextRef="From2022-04-302022-04-30" format="ixt-sec:duryear" id="Fact002782" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.75</ix:nonNumeric></span>
years, volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220430__20220430_ztFZjO6SaNya" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-04-302022-04-30" id="Fact002784" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">83.6</ix:nonFraction></span>% and a risk free rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220430__20220430_zCU9XEt1wWb2" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-04-302022-04-30" id="Fact002786" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.55</ix:nonFraction></span>%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the warrants were exercised by the lenders in exchange for tendering the outstanding principal balance ($<span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20220930_zNOkFecwyUhg"><span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930_zzztFeBEnntc"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2022-09-30" id="Fact002787" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-09-30" id="Fact002788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></ix:nonFraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
on the December 2021 Promissory Notes. The Company treated the settlement as a debt extinguishment for accounting purposes. The Company
recognized a loss on extinguishment of $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220930__20220930_zmDjf6XXKwjf" title="Gain (loss) on extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-09-302022-09-30" id="Fact002790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,531,852</ix:nonFraction></span> upon this settlement and issuance of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220930__20220930_znW9JkwrD5N3" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-09-302022-09-30" id="Fact002792" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock upon exercise, based on
the difference between the estimated fair value of the common stock issued ($<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220930__20220930_z7wjBfLimlIb" title="Stock issued during period, value, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-302022-09-30" id="Fact002794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,031,250</ix:nonFraction></span>) and the carrying value of the December 2021 Promissory
Notes. The Company paid all accrued interest under the December 2021 Promissory Notes from issuance through settlement to the lenders
in cash during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022
Convertible Bridge Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, the Company sold $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zQlxj9Q5Ql6d" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zGDLoRiCyxh" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,000</ix:nonFraction></span>, respectively, in <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zqwZx4citFg4" title="Interest rate"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zzZ1LFFS3Mg3" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002800" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002802" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">6</ix:nonFraction></ix:nonFraction></span></span>% convertible notes (the &#8220;2022 Convertible
Notes&#8221;), which bore <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z5SRnogjh75e" title="Interest rate"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zulLgLSgXCz6" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002804" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002806" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></ix:nonFraction></span></span>% interest (which would be waived upon a conversion event), were repayable on December 31, 2024,
and were convertible upon the completion of the Company&#8217;s initial public offering or other liquidity event at <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zIkIVWHdFLo7" title="Debt instrument conversion rate"><span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zNp9Sn8aTy3d" title="Debt instrument conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002808" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002810" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></ix:nonFraction></span></span>% of the per share
price paid by investors in such an event. In addition, if the 2022 Convertible Notes were not converted during the period 12 months after
their initial issuance, the outstanding principal amount of the 2022 Convertible Notes would be increased by <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zlYP9u9a0jFd" title="Interest rate"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zTGMOJrwbLzl" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember" id="Fact002812" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember" id="Fact002814" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>%. The Company received
net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zxtsxaAEaMm6" title="Promissory note"><span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zsqVooPhdkD6" title="Promissory note"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002816" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">525,715</ix:nonFraction></ix:nonFraction></span></span> from the 2022 Convertible Notes, after deducting a total of $<span id="xdx_905_eus-gaap--PaymentsForFees_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zFnz4XMrMQ35" title="Fees paid"><span id="xdx_90F_eus-gaap--PaymentsForFees_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zOLqo5nrMuP2" title="Fees paid"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002820" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,285</ix:nonFraction></ix:nonFraction></span></span> in fees paid to Boustead Securities LLC
for services provided as placement agent for the offering. Boustead also received warrants in connection with the issuances with a total estimated fair value of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220208__20220208_zfx0Ekvr8o1b" title="Warrants issuance"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220311__20220311_zZro2KRDmNX1" title="Warrants issuance"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-02-082022-02-08" id="Fact002824" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-03-112022-03-11" id="Fact002826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,336</ix:nonFraction></ix:nonFraction></span></span> (see
discussion below) and the Company incurred $<span id="xdx_902_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220208__20220208_zA0uTo9mqO9i" title="Debt issuance costs"><span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220311__20220311_zlztB8r0gx7g" title="Debt issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-02-082022-02-08" id="Fact002828" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-03-112022-03-11" id="Fact002830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,363</ix:nonFraction></ix:nonFraction></span></span> in additional costs which were recorded as debt issuance costs upon issuance of the
2022 Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assessed the embedded features of the 2022 Convertible Notes and determined that the automatic conversion feature with a <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z5IAgS7IL8j2" title="Debt instrument conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002832" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
discount to per share price paid (a share-settled redemption feature) and the <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zXVSuxRrisQ7" title="Principal increase decrease rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002834" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
principal increase feature were not clearly and closely related to the debt host instrument and met the definition of a derivative
and as such, required bifurcation from the 2022 Convertible Notes. The Company estimated the fair value at issuance of these
features to be $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z6H0bw1GU022" title="Convertible Notes"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,000</ix:nonFraction></span>
and recorded as a discount to the 2022 Convertible Notes (see Note 8 for fair value considerations). Of the total $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeIKoXaDnoRl" title="Debt issuance costs related party"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_us-gaap_RelatedPartyMember" id="Fact002838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,984</ix:nonFraction></span> of
issuance costs incurred related to the 2022 Convertible Notes, the Company allocated $<span id="xdx_904_eus-gaap--PaymentOfFinancingAndStockIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zKum10API6K6" title="Debt issuance costs related party"><ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,858</ix:nonFraction></span> of the debt issuance costs to the 2022
Convertible Notes (as a discount) and $<span id="xdx_907_eus-gaap--PaymentsOfDerivativeIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zcmsPGjnjx24" title="Payments of derivative issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDerivativeIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,126</ix:nonFraction></span>
allocated to the derivative liability and expensed as a component of the finance fee (as restated)
in the statement of operations. The discount on the 2022 Convertible Notes was amortized under the effective interest method through
the maturity dates of the notes. The Company recognized amortization expense of $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zLem4dHIES25" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,745</ix:nonFraction></span>
related to the discount on the 2022 Convertible Notes as interest expense in its statement of operations for the year ended December
31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
services provided in the offering, Boustead Securities LLC also received warrants to purchase <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zYRM3ija2OU9" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002846" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>%</span> of the shares of common stock
issuable upon conversion of the 2022 Convertible Notes, at the conversion price of the notes. Upon conversion, the warrant became
exercisable for a total of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zgtdsATR8uhj"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,582</ix:nonFraction></span>
shares of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zD1w3meaWV4l"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002848" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span>
per share. These warrants were accounted for under ASC 718 and classified as liabilities due to the fact that the conversion of the
2022 Convertible Notes would impact their fair value. The fair value at issuance of the warrants was estimated as $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zhF1rI2RViwa"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,336</ix:nonFraction></span>
using a Black-Scholes model, with inputs that included an estimated fair value of the Company&#8217;s common
stock of $<span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220101__20221231_zvAeKYk7lF56" title="Conversion price per share"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-01-012022-12-31" id="Fact002851" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span>, an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221231_zphB410M6SZ3" title="Common stock trading price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31" id="Fact002853" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span> per share (based on the estimated conversion terms), a five year term, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20221231__20221231_zsbef1bln51b"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-12-312022-12-31" id="Fact002854" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.1</ix:nonFraction>%</span> volatility and
a risk free rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zQP9ACdPtKXh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MinimumMember" id="Fact002855" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.81</ix:nonFraction>%</span> to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKPFT8LVZdda"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MaximumMember" id="Fact002856" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.96</ix:nonFraction>%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the 2022 Convertible Notes were automatically converted into the securities issued by the Company
to the investors in the initial public offering, at a discounted price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zaZSeiFu6ENl"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002857" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span>
per unit. Consistent with the investors in the initial public offering, the 2022 Convertible Note holders received <span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z2KIozp5gaNb" title="Common stock"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002859" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,438</ix:nonFraction></span>
shares of common stock and warrants to purchase <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zbCa8RGTqZJg" title="Warrant"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002861" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,438</ix:nonFraction></span>
shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zg1CenawUwSc"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002862" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction> </span>per
share. The warrants issued to the 2022 Convertible Note holders were immediately exercised. Pursuant to the automatic exercise of
the share-settled redemption feature, the Company accounted for the conversion as an extinguishment of debt. The Company recognized
the issuance of the shares of common stock and warrants at their estimated fair value, and recorded a loss on extinguishment of
$<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zlQ9GDshnun5"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">310,621</ix:nonFraction></span>
based on the difference between the estimated fair value ($<span id="xdx_907_eus-gaap--GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c20220101__20221231_zNe91AEjzuI8" title="Gain (loss) on sale of assets and asset impairment charges"><ix:nonFraction name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" contextRef="From2022-01-012022-12-31" id="Fact002865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198,438</ix:nonFraction></span>) and the net carrying amount of the 2022 Convertible Notes
(including the carrying value of the bifurcated derivative liabilities, which were adjusted to then fair value upon settlement). The
accrued cash interest was waived upon conversion and was included as a component of the loss on extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August
2022 Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, the Company issued promissory note units, consisting of an aggregate $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zYMm3h2Z6Jla" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
in <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zdmGRqygbDSh" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002869" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
promissory notes with a maturity date of July 31, 2023 (the &#8220;August 2022 Promissory Notes&#8221;) and warrants to purchase <span id="xdx_904_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zKExtJPYWj6" title="Notes issued"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500</ix:nonFraction></span>
shares of common stock exercisable at a price of the lesser of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zDLw326Qekd8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002873" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>
per share or <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zUJI3EnS6Bf6" title="Debt instrument conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002875" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the per share price paid in the Company&#8217;s initial public offering. In addition, the Company issued convertible note units,
consisting of an aggregate of $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zJG5INTNLW83" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember" id="Fact002877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>
in <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zneO0eW0aEY" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember" id="Fact002879" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%
convertible notes with a maturity date of December 31, 2024 (the &#8220;August 2022 Convertible Notes&#8221;, and collectively, the
&#8220;August 2022 Notes&#8221;) and warrants to purchase <span id="xdx_90D_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zDCuroyddOQ5" title="Notes issued"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember" id="Fact002881" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,750</ix:nonFraction></span> shares of common stock exercisable at a price of the lesser of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zVaVSQ1CrCl3" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember" id="Fact002883" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share or
<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zQumnPGZM0ch" title="Debt instrument conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember" id="Fact002885" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the per share price paid in the Company&#8217;s initial public offering. The Company received net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfDebt_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zN0SEm1WMah8" title="Promissory note"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
upon the issuance of the August 2022 Promissory Notes, $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z83ZCk3k6UHh" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-08-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>
upon the issuance of the August 2022 Convertible Notes (non-related party) and $<span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zrWY6Dw0HyQj" title="Proceeds from note payable-related party"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
upon the issuance of the August 2022 Convertible Notes issued to a related party (as detailed in Note 5 above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company assessed the embedded features of the August 2022 Promissory Notes and determined that the accelerated repayment upon an initial
public offering represented a derivative feature requiring bifurcation. The Company estimated the fair value of the derivative to be $<span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zR3hLi26HtHd"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-08-01_us-gaap_FairValueInputsLevel3Member" id="Fact002892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></span>
at issuance (see Note 8 for fair value considerations). The Company assessed the embedded features of the August 2022 Convertible Notes
and determined that the automatic conversion feature with a <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z1vMpx7rwZQk" title="Debt instrument conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-08-012022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002894" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction>%</span> discount to per share price paid (a share-settled redemption feature)
and the <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20220801__20220801_zL3NX9ArYLl9"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2022-08-012022-08-01" id="Fact002895" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>%</span> principal increase feature were not clearly and closely related to the debt host instrument and met the definition of a derivative
and as such, required bifurcation from the August 2022 Convertible Notes. The Company estimated the fair value at issuance of these features
to be $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zbf9S5mk9j5j" title="Convertible Notes"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact002897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction></span> and recorded as a discount to the August 2022 Convertible Notes (see Note 8 for fair value considerations).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the warrants issued with the August 2022 Notes should be classified as liabilities under ASC 815, as the
settlement amount could vary based on the occurrence of the initial public offering. The Company measured the fair value of these
warrants using a Black-Scholes model with inputs that included an estimated fair value of the Company&#8217;s common stock of
$<span id="xdx_904_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220801_zNQSa6fh5Jyb" title="Conversion price per share"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-08-012022-08-01" id="Fact002899" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span>, an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801_zhDjOeqYB3Ig" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-01" id="Fact002901" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share, a five-year term, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220801_zTB5zBB5Z3r"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-08-012022-08-01" id="Fact002902" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.0</ix:nonFraction>%</span> volatility and a risk free rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220801_zhDninb2yZ8c"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-08-012022-08-01" id="Fact002903" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.66</ix:nonFraction>%</span>, and recognized them
at their full fair value of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220801_zglbH34c0Oq4" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-08-012022-08-01" id="Fact002905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,624</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of these warrants, the fair value of the bifurcated derivative liabilities and the other debt issuance costs incurred (totaling $<span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zG3VvAvMBPrb" title="Fair value measurement"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,162</ix:nonFraction></span>,
including the fair value of the Boustead warrants described below), exceeded the proceeds received and as such, the Company
recorded a loss at issuance of $<span id="xdx_902_ecustom--FinanceFee_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zzVapSNIHQPb" title="Finance fee"><ix:nonFraction name="SHPH:FinanceFee" contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,786</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
in finance fee (as restated) in the statement of operations. The discount on the August 2022 Notes was being amortized under the
straight-line method, as the initial carrying value was $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zm5pd5EFmREa"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
through the maturity date of the respective notes. The Company recognized amortization expense of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z51deQhstPIe"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,661</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to the discount on the August 2022 Notes
as interest expense in its statement of operations for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities LLC acted as placement agent for the August 2022 Notes and received warrants to purchase <span id="xdx_90B_ecustom--IssuanceOfWarrantsShares_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJ3Zz8ChVC4b" title="Issuance of warrants shares"><ix:nonFraction name="SHPH:IssuanceOfWarrantsShares" contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact002913" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625</ix:nonFraction></span> shares of common stock at an
exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zMw5BDNiLCTb" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact002915" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share. The fair value of the warrants was estimated as $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zcaazmVLUtQ5"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact002916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,662</ix:nonFraction></span> using a Black-Scholes model with inputs that included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_908_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zsK4QqlvOI64" title="Conversion price per share"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact002918" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span>, an exercise price
of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zFehufcMrrG4" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact002920" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share, a five-year term, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z62TFWnzUBXf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact002921" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.0</ix:nonFraction>%</span> volatility and a risk free rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zsGSYYxEm8w6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact002922" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.66</ix:nonFraction>%</span>, and recorded by
the Company in stockholders&#8217; equity at issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the lender under the August 2022 Promissory Notes and one lender under the August 2022 Convertible
Notes exercised warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zIDoBp88TF2d" title="Number of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002924" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction></span>
shares of common stock in exchange for tendering their outstanding principal balance ($<span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z3hPJeUx9oIi" title="Principal balance"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>)
on their respective notes. As the warrants being exercised were classified as liabilities, the Company accounted for the settlement
as an extinguishment of debt. The Company recognized the issuance of the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z3062R9HrRQ1" title="Principal balance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002928" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction></span>
shares of common stock at their estimated fair value ($<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoNotesMember_zAtoWELHHhX5"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoNotesMember" id="Fact002929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,875</ix:nonFraction></span>), and recorded a gain on extinguishment of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zAl5sY7U1d37"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,614</ix:nonFraction></span>
based on the difference between the estimated fair value and the net carrying amount of the tendered August 2022 Notes. The
remaining $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zCSU5eZDdFdj"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
outstanding under the August 2022 Convertible Notes (and owed to the related party) was fully repaid in cash during the year ended
December 31, 2022 (see Note 5), resulting in the recognition of a gain on extinguishment of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z4l3Icw5MxTd" title="Unamortized discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember" id="Fact002933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,206</ix:nonFraction></span>
based on the difference between the repayment in cash and the net carrying
amount of the notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact002935" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRCb1RVFvgkc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 - <span id="xdx_825_zr458jZvyJC5">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231_zZds9nkiSPPl" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31" id="Fact002937" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">297,625</ix:nonFraction></span>
    shares of common stock to settle $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRAn1fkxWHy9" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact002939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,925,700</ix:nonFraction></span> of principal and $<span id="xdx_90B_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jBXJnIxDLa" title="Accrued interest settled with common stock"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact002941" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,927</ix:nonFraction></span> of interest on a Convertible Note and incurred $<span id="xdx_908_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBMO1eJwiZXi" title="Loss on settlement of convertible debt"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact002943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,221</ix:nonFraction></span> of
    loss on settlement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z96iryR5Kbn2" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact002945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,650</ix:nonFraction></span>
    shares of common stock issued for vesting of restricted stock units.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20220101__20221231_zK4bFGW68v1d"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="Fact002946" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">105</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for conversion of $<span id="xdx_90F_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20220101__20221231_zCR0LvynQrpk"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2022-01-012022-12-31" id="Fact002947" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,340</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of accrued interest</span>.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--CommonStockVestingOfRestrictedStockUnit_c20220101__20221231_zTGhXRDb9rbf" title="Common stock vesting of restricted stock unit"><ix:nonFraction name="SHPH:CommonStockVestingOfRestrictedStockUnit" contextRef="From2022-01-012022-12-31" id="Fact002949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500</ix:nonFraction></span>
    shares of common stock upon vesting of restricted stock units.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--StockIssuedUponCompletionShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm82jSpb10G9" title="Common stock issued for cash, shares"><ix:nonFraction name="SHPH:StockIssuedUponCompletionShares" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531" id="Fact002951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">352,443</ix:nonFraction></span>
    shares of common stock upon completion of the Company&#8217;s initial public offering (including the exercise of the underwriter&#8217;s overallotment option),
and the immediate exercise of warrants issued as part of the IPO Units, for net proceeds of $<span id="xdx_90D_ecustom--StockIssuedUponCompletion_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztBO8w1FCG9i" title="Stock issued upon completion"><ix:nonFraction name="SHPH:StockIssuedUponCompletion" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact002953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,951,356</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredShares_pp0p0_c20220101__20221231_zMXs1V3yATd" title="Number shares issued for conversion of note, shares"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfPreferredShares" contextRef="From2022-01-012022-12-31" id="Fact002955" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">42,113</ix:nonFraction></span>
    shares of common stock upon the automatic conversion of preferred shares and <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesConversionOfDividends_pp0p0_c20220101__20221231_zeGN8oiBf77k" title="Number shares issued for conversion dividends payable, shares"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfDividends" contextRef="From2022-01-012022-12-31" id="Fact002957" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">12,553</ix:nonFraction></span>
    shares of common stock to settle cumulative dividends on the preferred shares totaling  $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueDividendsPayable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxo9SNpEoe9d" title="Common stock issued for dividends payable"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueDividendsPayable" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact002959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zxyDKKIWjKuk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember" id="Fact002960" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,876</ix:nonFraction></span>
                                                                              shares of common stock issued to the lenders upon conversion of the 2022 Convertible Notes, including <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_z1Xao5Bob1b1" title="Number of shares of common stock issued for exercise of warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember" id="Fact002962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,438</ix:nonFraction></span>
                                                                              shares of common stock issued upon the conversion of the 2022 Convertible Notes into units with an estimated fair value of
                                                                              $<span id="xdx_909_eus-gaap--GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c20220101__20221231_zbf8lmaUR3k9"><ix:nonFraction name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" contextRef="From2022-01-012022-12-31" id="Fact002963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198,438</ix:nonFraction></span> at settlement, and <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zrdc6TSg0esi"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember" id="Fact002964" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,438</ix:nonFraction></span>
                                                                              shares of common stock upon the exercise of the common stock warrants, for total proceeds of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zr3w3mA5VSn5"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember" id="Fact002965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,475</ix:nonFraction></span>.</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A total of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThousandTwentyOneNotesMember_zcDW6A0xy2Ql"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_DecemberTwentyThousandTwentyOneNotesMember" id="Fact002966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,250</ix:nonFraction></span>
                                                                              shares of common stock upon the exercise of warrants and settlement of the December 2021 Notes and certain August 2022 Notes .
                                                                              Includes <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zPGVu9X1DeC1" title="Shares exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="Fact002968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction></span> shares of common stock issued upon the exercise and settlement of the December 2021 Notes with an estimated fair
                                                                              value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231_zjIknkL1dEr" title="Common stock issued for cash upon initial public offering and exercise of warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31" id="Fact002970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,031,249</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231_zQbLTUGQQzi5" title="Principal balance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31" id="Fact002972" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction></span> shares of common stock issued upon the exercise and settlement of certain August 2022 Notes with an
                                                                              estimated fair value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoNotesMember_zJolIab5z3z"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoNotesMember" id="Fact002973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,875</ix:nonFraction></span>.</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zHEE3kox8S48"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember" id="Fact002974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,535</ix:nonFraction></span> shares of common stock upon the cashless exercise of warrants issued
to Boustead Securities LLC for placement agent and underwriter services provided to the Company</p>
</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#8217;s
common stock upon the closing of the sale of shares of common stock to the public in a qualified offering (at a 10% discount to the
initial public offering price, as set forth in the Series A certificate of designation) or upon listing of the Company&#8217;s
common stock on a national securities exchange at a fixed price. The Series A Preferred Stock, while outstanding, accrued cumulative dividends at a
rate of <span id="xdx_908_ecustom--CumulativeDividendsPercentage_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBwB2pdVcS3h" title="Cumulative dividends percentage"><ix:nonFraction name="SHPH:CumulativeDividendsPercentage" contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact002976" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>%
per annum. In addition, the Series A Preferred Stock is callable by the Company, at a price equal to the stated value of the Series
A Preferred Stock ($<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdvc3pjAqQeh" title="Preferred stock value share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact002978" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span>
per share), plus accrued and unpaid cumulative dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company and holders of the Series A Preferred Stock agreed to modifications of the Series A certificate of designation
which changed the definition of a &#8220;Qualified IPO&#8221; by lowering the minimum required proceeds to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220430__srt--RangeAxis__srt--MinimumMember_ze0aX768wD2h"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-012022-04-30_srt_MinimumMember" id="Fact002979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and removing the minimum per share IPO price,
and changed the conversion price upon the listing of the Company&#8217;s common stock from $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220401__20220430__srt--RangeAxis__srt--MinimumMember_zua3GSvpnDZ5"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-04-012022-04-30_srt_MinimumMember" id="Fact002980" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.92</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to $<span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220401__20220430__srt--RangeAxis__srt--MaximumMember_zgy4dbYdgdv9"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-04-012022-04-30_srt_MaximumMember" id="Fact002981" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company determined that these
changes represented a substantial change in the terms of the Series A Preferred Stock and accounted for the changes as an extinguishment.
The Company recognized the excess of the post-amendment fair value of the Series A Preferred Stock over its carrying value as a deemed
dividend of $<span id="xdx_90E_ecustom--DeemedDividend_c20220101__20221231_zISNNccnJ8b" title="Deemed dividend"><ix:nonFraction name="SHPH:DeemedDividend" contextRef="From2022-01-012022-12-31" id="Fact002983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,427</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which increases net loss attributable to common stockholders during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 and upon completion of its initial public offering, the Company converted <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXJuvuls14Dg" title="Converted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember" id="Fact002985" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></span>
shares of Series A Preferred Stock into <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zezrTqDjoPjc" title="Stock issued for cash, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember" id="Fact002987" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,113</ix:nonFraction></span>
shares of common stock, based on a conversion price of <span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionRatio_iI_uPure_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXiemcZ6GUL2" title="Conversion price percentage"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember" id="Fact002989" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">90</ix:nonFraction></span>%
of the per share IPO price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXWzm5lHgLsd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember" id="Fact002991" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span>
per share, resulting in a discounted conversion price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhe5cDcFIHUi" title="conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember" id="Fact002993" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.80</ix:nonFraction></span>
per share. Based on the nature of the settlement (as the exercise of a share-settled redemption feature) the Company recognized
a deemed contribution of $<span id="xdx_90D_ecustom--DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_c20220101__20221231_zCwQGOw28NSl" title="Deemed contribution"><ix:nonFraction name="SHPH:DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" contextRef="From2022-01-012022-12-31" id="Fact002995" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,423</ix:nonFraction></span> during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company accrued $<span id="xdx_901_eus-gaap--CumulativeDividends_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2gKCbTpzqQf" title="Cumulative dividends"><ix:nonFraction name="us-gaap:CumulativeDividends" contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember" id="Fact002997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></span> for the <span id="xdx_909_ecustom--CumulativeDividendsPercentage_dp_uPure_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGEXxzV26fXb" title="Cumulative dividends percentage"><ix:nonFraction name="SHPH:CumulativeDividendsPercentage" contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember" id="Fact002999" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>% cumulative dividends on the Series A Preferred stock, and
as of the date of conversion of the Series A Preferred Stock, the total cumulative dividends accrued were equal to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuSkbBGJR2bd" title="Stock issued for conversion, vallue"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember" id="Fact003001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,064</ix:nonFraction></span>. Upon the
conversion of the Series A Preferred Stock, the cumulative dividends were also converted into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGWSrwY7YB0g" title="Cumulative dividends, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact003003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,553</ix:nonFraction></span> shares of the Company&#8217;s common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the Company had no shares of Series A Preferred Stock outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--WarrantsDescription_c20220101__20221231_zhMFkvoqAKeg" title="Warrants description"><ix:nonNumeric contextRef="From2022-01-012022-12-31" id="Fact003005" name="SHPH:WarrantsDescription">The
Series A Preferred Stock sold in the Company&#8217;s 2018 and 2019 private placement offerings included warrants to be issued upon
the earlier of a closing of the sale of shares of common stock to the public or upon a listing of the Company&#8217;s common stock.
The warrants will be exercisable for a period of three years after the date of issuance at an exercise price contingent on the terms
of the public offering. The initial form of the warrants were expected to include contingent call features based on the terms of the
public offering. As originally drafted, if an initial public offering occurs at a price at or above $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zSPV5KxElvHk" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31" id="Fact003007" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">111.04</ix:nonFraction></span>, then the warrants are
callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise price. In the scenario where the common
stock is listed with a common stock issuance price below $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zKLZSjEWej99" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31" id="Fact003009" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">111.04</ix:nonFraction></span>, then the warrants are callable if the 20-day VWAP of the common
stock is at or above the $<span id="xdx_907_ecustom--WarrantSharePrice_iI_c20221231_zwhTOC8pVm83" title="Warrant share price"><ix:nonFraction name="SHPH:WarrantSharePrice" contextRef="AsOf2022-12-31" id="Fact003011" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">166.56</ix:nonFraction></span> exercise price. Upon the issuance of the warrants in September 2022, the contingent call features
were not included in the agreements. Given the variability in the number of warrants and exercise price, the detachable warrants
contained terms and features that gave rise to liability classification.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2022, the Company modified the terms of the Series A Preferred
Stock as discussed above. These modifications impacted the potential terms of these contingently issuable warrants (potential warrant
shares and exercise price). The impact of this modification was reflected in the fair value of the warrant obligation recorded during
the interim periods within the year ended December 31, 2022. Upon
completion of our initial public offering, the Series A Preferred Stock was converted, and warrants were issued in relation to the conversion,
with each warrant then exercisable at the equivalent of the per share initial public offering price. In total, the Company issued warrants
to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhjYBEwkaq45" title="Warrants shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember" id="Fact003013" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,113</ix:nonFraction></span> shares of common stock, at an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z07rLdSPBaXg" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact003015" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.00</ix:nonFraction></span> per share in settlement of this warrant obligation. In addition,
upon the issuance of these warrants, the Company reassessed the classification accounting and concluded that the issued warrants met
the requirements for classification in stockholders&#8217; equity. The Company reclassified the then fair value of these warrants, totaling
$<span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6rHDj3XOS1j" title="Additional paid in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact003017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">756,723</ix:nonFraction></span>, to additional paid in capital in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liability related to the Series A Preferred Stock was $<span id="xdx_90A_ecustom--WarrantLiability_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zijLF2pHWOn7" title="Warrants liability"><ix:nonFraction name="SHPH:WarrantLiability" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact003019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>
as of December 31, 2022. For the period ended December 31, 2022 (prior to reclassification), the change in fair value of warrant
obligation liability was a loss of $<span id="xdx_90C_ecustom--WarrantObligationLiability_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1BslpzMON86" title="Warrants obligation liability"><ix:nonFraction name="SHPH:WarrantObligationLiability" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact003021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">421,768</ix:nonFraction></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Warrants Issued to Boustead as Placement Agent
or Underwriter</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For services provided in relation to the 2022 Convertible
Notes and August 2022 Notes offerings, Boustead received warrants to purchase <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220831_zlaXxGjIK6u2" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-08-31" id="Fact003023" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>%</span> of the shares of common stock issuable upon conversion
of the 2022 Convertible Notes, at the conversion price of the notes. Upon conversion, the warrant became exercisable for a total of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zzZCbYOypgg5"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact003024" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,582</ix:nonFraction></span>
shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zxYSEOIYeGQ9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember" id="Fact003025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span> per share. These warrants were accounted for under ASC 718 and classified as liabilities
due to the fact that the conversion of the 2022 Convertible Notes would impact their fair value. These warrants were exercised on a cashless
basis in September 2022. The Company reclassified the then fair value of the warrants of $<span id="xdx_909_ecustom--WarrantLiabilitiesExercised_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsWthAVovwJ4" title="Warrant liabilities exercised"><ix:nonFraction name="SHPH:WarrantLiabilitiesExercised" contextRef="From2022-08-012022-08-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember" id="Fact003027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,140</ix:nonFraction></span> at the initial public offering to equity, with the estimated
fair value based on a Black-Scholes model, with inputs that included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831_zEX66QT8buA" title="Conversion price per share"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-08-012022-08-31" id="Fact003029" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.50</ix:nonFraction></span>,
an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831_zoa3je9Yw6Kb" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31" id="Fact003031" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span> per share, a remaining term of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220831_z7pwhPfE80Ud"><ix:nonNumeric contextRef="AsOf2022-08-31" format="ixt-sec:duryear" id="Fact003032" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.5</ix:nonNumeric></span> years, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220831_zegwdnEEv8cd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-08-012022-08-31" id="Fact003033" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.5</ix:nonFraction>%</span> volatility and a risk free rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220831_ze2LVFKjUYKj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-08-012022-08-31" id="Fact003034" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.43</ix:nonFraction>%</span>. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Boustead acted as placement agent for the August 2022
Notes and received warrants to purchase <span id="xdx_904_ecustom--IssuanceOfWarrantsShares_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zBWMmocLKco4" title="Issuance of warrants shares"><ix:nonFraction name="SHPH:IssuanceOfWarrantsShares" contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember" id="Fact003036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801_zlLQGpblHuI3" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-01" id="Fact003038" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share. These warrants were classified
in equity and exercised on a cashless basis in September 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Boustead additionally received a warrant to purchase
<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zP9zmXLeAhEc" title="Four year warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact003040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,453</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zo1W4YbGHOAa"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember" id="Fact003041" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">97.52</ix:nonFraction></span> per share upon the closing of the IPO. These warrants were classified in
equity and exercised on a cashless basis in September 2022. Upon the closing of the overallotment option to the IPO, Boustead received
an additional warrant to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_znYBxCL7ikwl" title="Four year warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" id="Fact003043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,218</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIFBmHSGKKoi"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember" id="Fact003044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">97.52</ix:nonFraction></span> per share. The Company determined that these warrants should be classified in equity.
The fair value of the warrant issued at the closing of the IPO was estimated to be $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zUZUtgjgxeQ5" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember" id="Fact003046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,752</ix:nonFraction></span> using a Black-Scholes model, with inputs that
included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_90F_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zUEfIv8BIgM3" title="Exercise price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember" id="Fact003048" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.50</ix:nonFraction></span>, an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zXA1uFVP0yQ6" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember" id="Fact003050" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">97.52</ix:nonFraction></span> per share, a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zDGIsWnXriP3" title="Warrant term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl3052">five-year</span></span> term,
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zC6zYGIE33ha" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember" id="Fact003054" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101.8</ix:nonFraction></span>% volatility and a risk free rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_z5q1wYXMoDc3" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember" id="Fact003056" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.27</ix:nonFraction></span>%. The fair value of the warrant issued at the closing of the overallotment option was estimated
to be $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zMEmyrWnrd5h" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" id="Fact003058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,296</ix:nonFraction></span> using a Black-Scholes model, with inputs that included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_901_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zCkzORPa939j" title="Exercise price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" id="Fact003060" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50.88</ix:nonFraction></span>,
an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBAJJgavIVIi" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" id="Fact003062" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">97.52</ix:nonFraction></span> per share, a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBlCg0hh75ij" title="Warrant term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl3064">five-year</span></span> term, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsJZMdsOaRmg" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" id="Fact003066" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101.4</ix:nonFraction></span>% volatility and a risk free rate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zXxjeYY46rya" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" id="Fact003068" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.74</ix:nonFraction></span>%. The fair value of these warrants
was recorded to additional paid in capital and represented an issuance cost of the initial public offering (recorded as a deduction to
additional paid in capital). These warrants remain outstanding
as of December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Alto Opportunity Master Fund, SPC</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zam6FgbDoIvd" title="Number of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember" id="Fact003070" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,909</ix:nonFraction></span> shares of common stock, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_ziFSekf5Pqm7" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember" id="Fact003072" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share (Note 6). In addition, Alto was granted warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zxfR1IUHlnT6" title="Number of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31" id="Fact003074" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></span> shares of common stock, at an
exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zCr58QMvgMwh" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31" id="Fact003076" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span> per share (Note 6, 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003078" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zQPSvyFjdRPc" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" title="Number of warrants outstanding, balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact003080" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" title="Weighted average exercise price, outstanding balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact003082" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUtrsMLQInh5" title="Weighted average life (years), outstanding balance"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531" format="ixt-sec:duryear" id="Fact003084" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1">4.99</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" title="Number of warrants outstanding, granted" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact003086" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270,910</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" title="Weighted average exercise price, outstanding granted" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact003088" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.57</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted average life (years), granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember" format="ixt-sec:duryear" id="Fact003090" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">4.68</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9CkaYjHRKW6" title="Number of warrants outstanding, exercised" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531" id="Fact003092" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">285,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zcPe5lHTomfb" title="Weighted average exercise price, outstanding exercised" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531" id="Fact003094" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.58</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8212;</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" title="Number of warrants outstanding, balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact003096" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,831</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" title="Weighted average exercise price, outstanding balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact003098" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.77</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted average life (years), outstanding balance"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531" format="ixt-sec:duryear" id="Fact003100" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.78</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - Boustead</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" title="Number of warrants outstanding, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact003102" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,909</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" title="Weighted average exercise price, outstanding granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact003104" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted average life (years), granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember" format="ixt-sec:duryear" id="Fact003106" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">5.00</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Granted - Ayrton</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" title="Number of warrants outstanding, granted" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember" id="Fact003108" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" title="Weighted average exercise price, outstanding granted" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember" id="Fact003110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted average life (years), granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember" format="ixt-sec:duryear" id="Fact003112" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">4.00</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" title="Number of warrants outstanding, balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828" id="Fact003114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" title="Weighted average exercise price, outstanding balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828" id="Fact003116" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.21</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted average life (years), outstanding balance"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact003118" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.77</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote003119" xml:lang="en-US">Granted
    warrants include those granted on the issuance of the August 2022 Promissory Notes</ix:footnote></span> (<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoPromissoryNotesMember_z8eerCsA7Vic" title="Granted warrants, shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" id="Fact003121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction></span> warrants); Notes Payable &#8211; Related
    Parties  (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zRpN5cBP0s45" title="Granted warrants, shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_NotesPayableRelatedPartiesMember" id="Fact003123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span> warrants); upon conversion of the
    Series A Preferred Shares (<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zScqfutTyNe1" title="Converted shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact003125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,114</ix:nonFraction></span> warrants);
    automatic conversion of the 2022 Convertible Notes  (<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyTwoConvertibleNotesMember_zts6c3ymErAi" title="Granted warrants, shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyTwoConvertibleNotesMember" id="Fact003127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,447</ix:nonFraction></span> warrants); issued during the IPO, including overallotment option (<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8ldYZ9uZqP4" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_IPOMember" id="Fact003129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,222</ix:nonFraction></span> warrants) and issued to Boustead Securities LLC  (<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--BousteadSecuritiesLLCMember_zWH28ubFIhwb" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember" id="Fact003131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,877</ix:nonFraction></span> warrants).</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercised warrants include the exercise of the warrants
issued with the December 2021 Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyOnePromissoryNotesMember_z3vUeINzv4nc" title="Number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_custom_AugustTwoThousandAndTwentyOnePromissoryNotesMember" id="Fact003133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction>
</span>warrants); the exercise of the warrants issued with the August 2022 Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zUXECz6R3mD5" title="Number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_custom_NotesPayableRelatedPartiesMember" id="Fact003135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction>
</span>warrants); the exercise of the warrants issued upon conversion of the Convertible Notes (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zV8n48EOlaxg" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" title="Converted shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" id="Fact003137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,447</ix:nonFraction></span>
warrants); and the exercise of the warrants issued during the IPO, including overallotment option (<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiePm976S3i" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_us-gaap_IPOMember" id="Fact003139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,222</ix:nonFraction></span>
warrants), and warrants exercised on a cashless basis (<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zBFrdGlEuIid" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" title="Number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="Fact003141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,660</ix:nonFraction></span>
warrants).</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_z33AkX1pnRpc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of the warrants as of December 31, 2023 is $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20231231_zEluMLI6PNGh" title="Aggregate intrinsic value of warrants"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2023-12-31" id="Fact003143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>. All of the outstanding warrants are exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s
compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zrwC5T6Afeh" title="Common stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact003145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
December 31, 2023, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zZqAzrExO8Pf" title="Share granted under equity incentive plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact003147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,779</ix:nonFraction></span> shares have been granted under the 2018 Equity Incentive Plan, of which <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231_zdTmHNQqbfgf" title="Number of shares vested under plan"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-01-012023-12-31" id="Fact003149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,048</ix:nonFraction></span> shares have vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may grant restricted stock units (&#8220;RSU&#8221;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, pursuant to agreements with directors, officers and consultants, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zgXIzzjME8hg" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember" id="Fact003151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,415</ix:nonFraction></span> and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zr5k4LAu04y5" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember" id="Fact003153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,449</ix:nonFraction></span> RSUs
with a value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zOZ0Qy75taC1" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember" id="Fact003155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,400</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zlWaoMfX80Tl" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember" id="Fact003157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> were granted, respectively. Compensation expense for the vesting RSUs were as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003159" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zc5RchDtdYW" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<span id="xdx_8BF_zWWEFBZRefcb" style="display: none">Schedule
of Restricted Stock Units&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_49A_20230101__20231231_zO2ONL04juDe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_495_20220101__20221231_zsR9hqKKMoLh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">(as restated)</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFSDfn5qktl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Recognized in general and administrative expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact003161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact003162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,582</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zP0z6A5Wtzm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Recognized in research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact003164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact003165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,965</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zypbbKjXmu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact003167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact003168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,547</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zBje0QYIgd4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, there was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEzBhMNnlrN8" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,550</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5mtOdUbbZX" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,111</ix:nonFraction></span>, respectively, of unrecognized stock-based compensation expense
related to unvested RSUs, which is expected to be recognized over a weighted-average period of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXuwnfeYO91d" title="Weighted Average Life (Years), Outstanding Ending"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546" format="ixt-sec:duryear" id="Fact003174" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.06</ix:nonNumeric></span> years
and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSrNXYP6sZG7" title="Weighted Average Life (Years), Outstanding Ending"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562" format="ixt-sec:duryear" id="Fact003176" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.83</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003178" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zXV9pKVawChd" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Outstanding, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" title="Number of RSUs, Outstanding, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003182" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">185.60</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" title="Number of Stock Option Outstanding, Granted" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562" id="Fact003184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562" id="Fact003186" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Vested (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Number of RSUs, Vested" id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE3XiT4Awrd8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562" id="Fact003188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Weighted Average Grant Date Fair Value Per RSU, Vested" id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zczNKvkuf77f" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562" id="Fact003190" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2022 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" title="Number of RSUs, Outstanding, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,966</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" title="Number of Stock Option Outstanding, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546" id="Fact003196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,415</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546" id="Fact003198" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.88</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested (as restated)</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" title="Number of RSUs, Vested" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546" id="Fact003200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,650</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" title="Weighted Average Grant Date Fair Value Per RSU, Vested" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546" id="Fact003202" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" title="Number of RSUs, Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,731</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003206" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.76</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A5_zV6HtUCMIcil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003208" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zM0LnaDFnXNf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82A_z4aTbusRJlK5">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Assumptions Used in Accounting for Derivative Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Alto Opportunity Master Fund, SPC</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_z11cwYracUa3" title="Number of shares warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31" id="Fact003210" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,260</ix:nonFraction></span>
shares of common stock, with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zIh20NrCUX41" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31" id="Fact003212" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span>
per share, valued at inception at $<span id="xdx_909_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20230131_zH7frUfNB0S" title="Warrants price"><ix:nonFraction name="SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" contextRef="AsOf2023-01-31" id="Fact003214" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,189,000</ix:nonFraction></span>
and as of December 31, 2023, at $<span id="xdx_906_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20231231_zg9NwO9znFZi" title="Warrants price"><ix:nonFraction name="SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" contextRef="AsOf2023-12-31" id="Fact003216" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">410,660</ix:nonFraction></span>. The Company determined our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy
the classification as equity instruments due to the existence of a certain net cash settlement provision that is not within the sole
control of the Company. In addition, there are certain down round provisions that could reduce the exercise price if the Company
issues securities at lower prices in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined our derivative liability from the noteholder&#8217;s Acceleration Option for the Alto Convertible Note is not clearly
and closely related to the host and should be thus accounted for as a bifurcated derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023, and for each reporting period. Key inputs for the simulation are summarized below. The Monte Carlo simulation
uses an implied VWAP for each valuation date. The implied VWAP was backsolved by setting the summation of the parts (e.g., derivatives
and debt without derivatives) equal to the cash proceeds. The simulation was then iterated and manipulated to solve for the implied share
price, which was approximately $<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TLyu8dorpa" title="Share price"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember" id="Fact003218" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.64</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (or an approximate <span id="xdx_902_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjE6Jw38fbK2" title="Derivative discount percentage"><ix:nonFraction name="SHPH:DerivativeDiscountPercentage" contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember" id="Fact003220" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount to the quoted market VWAP on January 11, 2023). Additionally, the Company estimates probability for various specific scenarios
impacting the warrant valuation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003222" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_znb7Uj9EztTl" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash settlement and down round key valuation inputs &#8211; Alto Warrants*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 78%">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z4g0dzX4U7zf"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_custom_AltoWarrantsMember" id="Fact003223" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">77.51</ix:nonFraction></span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z301m69d8Gyi"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_custom_AltoWarrantsMember" id="Fact003224" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">92.33</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZAEk7427avk"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_custom_AltoWarrantsMember" id="Fact003225" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.01</ix:nonFraction></span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zgCPUuxlHzHc"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_custom_AltoWarrantsMember" id="Fact003226" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.23</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKg_____zynIkUyUvoc5"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_custom_AltoWarrantsMember_srt_MinimumMember" id="Fact003227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.72</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zx3O4OnWlhIe"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_AltoWarrantsMember" id="Fact003228" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability assessment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZhnjkBS7Tu6"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_custom_AltoWarrantsMember" id="Fact003229" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5</ix:nonFraction></span>% - <span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zyEeLFE48kV1"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_custom_AltoWarrantsMember" id="Fact003230" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">25</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zUzGci9OyFOe"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_custom_AltoWarrantsMember" id="Fact003231" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zp3kUyM7mCF1" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_AltoWarrantsMember" format="ixt-sec:duryear" id="Fact003233" name="us-gaap:DebtInstrumentTerm">0.53</ix:nonNumeric></span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z2QZvDKXSZc8" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_AltoWarrantsMember" format="ixt-sec:duryear" id="Fact003235" name="us-gaap:DebtInstrumentTerm">3.03</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_985_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zzfOPZcmFp21" title="Estimated fair value issuance" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_custom_AltoWarrantsMember_custom_MeasurementInputEstimatedFairValueMember" id="Fact003237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,189,000</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zoconmEERXL5" title="Estimated fair value" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_AltoWarrantsMember" id="Fact003239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Alto Acceleration Option key valuation inputs*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsLip3AEalOf"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember" id="Fact003240" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">34.23</ix:nonFraction></span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zrecJIDgSDtl"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember" id="Fact003241" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">59.15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zJ1iIi9Tuuh5"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember" id="Fact003242" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.68</ix:nonFraction></span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zzEjaz9gjDGe"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember" id="Fact003243" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.60</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zq9lJmRsxA0c"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember" id="Fact003244" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.72</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zHhUsf9wJkQl"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember" id="Fact003245" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zBDp4x7lFOLe" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact003247" name="us-gaap:DebtInstrumentTerm">0</ix:nonNumeric></span> - <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zN3n43wPlwJ7" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact003249" name="us-gaap:DebtInstrumentTerm">1.2</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____z1a2AIcEwJo7" title="Estimated fair value issuance" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember" id="Fact003251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zMZsZdoRik44" title="Estimated fair value" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember" id="Fact003253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zP9EgyZUvD22">*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F10_zpHGdXc8eMz1"><ix:footnote id="Footnote003254" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 50,000 iterations</ix:footnote></i></span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A5_z9FqO83Hz1gf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>December 2021 Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003256" name="SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_zjlCwF4i7uJj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the December 2021
Notes, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative liability
as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value of the
derivative just prior to the settlement of the December 2021 Notes. Key inputs for this valuation model are summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b><span id="xdx_8B2_zjG7V0BTJGN6" style="display: none">Schedule
of Derivative Liability Valuation</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">December 2021 Notes derivative key valuation inputs</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zCCUZkonud72" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Date</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231__us-gaap--AwardDateAxis__custom--SettlementDateMember_zi03jzsAnAh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Amount due upon acceleration</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcTc9BXjF7gb" title="Amount due upon acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfAcceleration" contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember" id="Fact003258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533,699</ix:nonFraction></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_902_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zWOG2jS5GJUb" title="Amount due upon acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfAcceleration" contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="Fact003260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533,973</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Carrying value of December 2021 Notes at measurement date</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIEsyqfZYvLg" title="Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl3262">&#8212;</span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zcwi7FULk9jc" title="Carrying value"><ix:nonFraction name="SHPH:DerivativeLiabilityOfCarringValueMeasurementDate" contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="Fact003264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337,398</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">IPO date</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zVBlR0B9tUP7" title="IPO date"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember" format="ixt:datemonthdayyear" id="Fact003266" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">8/31/2022</ix:nonNumeric></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zJw91gnzLS2j" title="IPO date"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember" format="ixt:datemonthdayyear" id="Fact003268" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">9/2/2022</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO acceleration</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_903_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zFuITDP3UXf" title="Probability of IPO acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfProbabilityAcceleration" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember" id="Fact003270" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">90</ix:nonFraction></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zpxKsbtLWcB9" title="Probability of IPO acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfProbabilityAcceleration" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="Fact003272" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of maturity</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zzFXbd5Og0G4" title="Probability of Maturity"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember" id="Fact003274" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10</ix:nonFraction></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_z7lRzYZKo0S2" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3276">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period to maturity (years)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zX1096vaLn9i" title="Time period to maturity (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember" format="ixt-sec:duryear" id="Fact003278" name="SHPH:DerivativeLiabilityMeasurementDuration">1.00</ix:nonNumeric></span> years</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z6tjv8ZW9Ry1" title="Time period to maturity (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember" format="ixt-sec:duryear" id="Fact003280" name="SHPH:DerivativeLiabilityMeasurementDuration">0.32</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discount rate</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcAOY0484Dgi" title="Discount rate"><ix:nonFraction name="SHPH:DerivativeLiabilityDiscoutRate" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember" id="Fact003282" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zUkS1jzZb5c9" title="Discount rate"><ix:nonFraction name="SHPH:DerivativeLiabilityDiscoutRate" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="Fact003284" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z8IXFIyc2pgh" title="Estimated fair value"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember" id="Fact003286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,000</ix:nonFraction></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z11mi2p3YAV3" title="Estimated fair value"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember" id="Fact003288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,000</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z3urm4comLn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022
Convertible Bridge Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the 2022 Convertible Notes in February and March 2022, the Company identified certain embedded features
that required bifurcation as a combined derivative liability, including the share-settled redemption of the 2022 Convertible Notes at
a 50% discount and the automatic increase in principal of 10% if conversion does not occur within 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
classified this derivative liability as a Level 3 fair value measurement and used the a with and without probability weighted scenario
model to estimate the fair value as of each issuance date of the 2022 Convertible Notes, as well as just prior to their settlement upon
the initial public offering. Key inputs for this valuation model are summarized below.</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003290" name="SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock"><p id="xdx_896_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_z5brvl3KzAle" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zD9WNYfYXy6">Schedule
of Derivative Key Valuation Inputs</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
    Convertible Notes derivative key valuation inputs*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    Dates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zrI7eNI0ycE5" title="Annualized volatility"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact003292" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">75.0</ix:nonFraction></span>%
    - <span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z0yV9SlEpTnf" title="Annualized volatility"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact003294" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">82.0</ix:nonFraction></span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zKgfUKZ0UPn4" title="Annualized volatility"><span style="-sec-ix-hidden: xdx2ixbrl3296">&#8212;</span></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIJa6GBq3Vu9" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact003298" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.6</ix:nonFraction></span>%
    - <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7kAtMbqmLOb" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact003300" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.2</ix:nonFraction></span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMKLBnZnSszd" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl3302">&#8212;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price (implied)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zusIOIenjwY5" title="Exercise price (implied)"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MinimumMember" id="Fact003304" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">45.52</ix:nonFraction></span>
    - $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zSrzItTHe8Xl" title="Exercise price (implied)"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MaximumMember" id="Fact003306" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">85.92</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z59iWMKVRj15" title="Exercise price (implied)"><span style="-sec-ix-hidden: xdx2ixbrl3308">&#8212;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    IPO date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_z48Fv311BmSl" title="Estimated IPO date"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember" format="ixt:datemonthdayyear" id="Fact003310" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">8/31/2022</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zWHulQCfI3ce" title="Estimated IPO date"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember" format="ixt:datemonthdayyear" id="Fact003312" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">9/2/2022</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of default</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember_zq8jLqAQ0tdi" title="Probability of default"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember" id="Fact003314" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50</ix:nonFraction></span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMACi2a6YyD" title="Probability of default"><span style="-sec-ix-hidden: xdx2ixbrl3316">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of IPO or Alternative Liquidity Event</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_znwcKoeawLJg" title="Probability of IPO or Alternative Liquidity Event"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember" id="Fact003318" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">45</ix:nonFraction></span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zT1PeOh2Neth" title="Probability of IPO or Alternative Liquidity Event"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_SettlementMember" id="Fact003320" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100</ix:nonFraction></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of Maturity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zlGZHJ3XRNug" title="Probability of Maturity"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact003322" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5</ix:nonFraction></span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zjjniTfeAEkc" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3324">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
    period (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_ztMKhfW5VVmg" title="Time period (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact003326" name="SHPH:DerivativeLiabilityMeasurementDuration">0.47</ix:nonNumeric></span>
    - <span id="xdx_904_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zwX6ZWWfyt65" title="Time period (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact003328" name="SHPH:DerivativeLiabilityMeasurementDuration">1.00</ix:nonNumeric></span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zwYvRAgB6W9h" title="Time period (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember" format="ixt-sec:duryear" id="Fact003330" name="SHPH:DerivativeLiabilityMeasurementDuration">0.00</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zc3b3riNCOg1" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember" id="Fact003332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,000</ix:nonFraction></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z86312yZwukb" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember" id="Fact003334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">571,000</ix:nonFraction></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AC_zgVopIKtfTcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>August 2022 Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_AugustTwoThousandTwentyTwoNotesMember" escape="true" id="Fact003336" name="SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock"><p id="xdx_895_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_zgGEkQpbb6be" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the August 2022
Promissory Note, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative
liability as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value
of the derivative just prior to the settlement of the August 2022 Promissory Notes. Key inputs for this valuation model are summarized
below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b><span id="xdx_8B3_zXnr1bjxbu8" style="display: none">Schedule
of Derivative Issuance Valuation Inputs</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-size: 10pt"><b>August 2022 Promissory Notes derivative key valuation inputs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-size: 10pt">Issuance Dates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-size: 10pt">Settlement Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Amount due upon acceleration (estimated at issuance)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zX5muKr38VWd" title="Amount due upon acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfAcceleration" contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember" id="Fact003338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,411</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_908_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zlLZamz1oBT8" title="Amount due upon acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfAcceleration" contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="Fact003340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,438</ix:nonFraction></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Carrying value of August 2022 Promissory Notes at measurement date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_90C_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zVydJGz543cb" title="Carrying value"><ix:nonFraction name="SHPH:DerivativeLiabilityOfCarringValueMeasurementDate" contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember" id="Fact003342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_908_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zj9Ng4Pbbdij" title="Carrying value"><ix:nonFraction name="SHPH:DerivativeLiabilityOfCarringValueMeasurementDate" contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember" id="Fact003344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,521</ix:nonFraction></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">IPO date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zbhJNV5W9Fb5" title="IPO date"><ix:nonNumeric contextRef="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember" format="ixt:datemonthdayyear" id="Fact003346" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">8/31/2022</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zAzR2pIn59Hh" title="IPO date"><ix:nonNumeric contextRef="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember" format="ixt:datemonthdayyear" id="Fact003348" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">9/2/2022</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Probability of IPO acceleration</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zQN6XCDs8M2c" title="Probability of IPO acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfProbabilityAcceleration" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703" id="Fact003350" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zNspkjjAgVO5" title="Probability of IPO acceleration"><ix:nonFraction name="SHPH:DerivativeLiabilityOfProbabilityAcceleration" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703" id="Fact003352" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction>%</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Probability of maturity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zRY8a4wqnEzc" title="Probability of Maturity"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703" id="Fact003354" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zjb0uw9A2rnf" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3356">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Time period to maturity (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIWJR1XsIxRj" title="Time period to maturity (years)"><ix:nonNumeric contextRef="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember" format="ixt-sec:duryear" id="Fact003358" name="SHPH:DerivativeLiabilityMeasurementDuration">1.00</ix:nonNumeric></span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z84rwfz9M3L5" title="Time period to maturity (years)"><ix:nonNumeric contextRef="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember" format="ixt-sec:duryear" id="Fact003360" name="SHPH:DerivativeLiabilityMeasurementDuration">0.91</ix:nonNumeric></span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Discount rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zIO5KOr85SO8" title="Discount rate"><ix:nonFraction name="SHPH:DerivativeLiabilityOfDiscountRate" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703" id="Fact003362" format="ixt:numunitdecimalin" decimals="INF" unitRef="Pure">16.03</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zipUF0l5Eyj8" title="Discount rate"><ix:nonFraction name="SHPH:DerivativeLiabilityOfDiscountRate" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703" id="Fact003364" format="ixt:numunitdecimalin" decimals="INF" unitRef="Pure">18.81</ix:nonFraction>%</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zOHFLWCnr45d" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDatesMember" id="Fact003366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zbkhZ58Bq7H3" title="Estimated fair value"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember" id="Fact003368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></span></p></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zqWwxoGLbSTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_AugustTwoThousandTwentyTwoNotesMember" escape="true" id="Fact003370" name="SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock"><p id="xdx_897_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_ziGGYyZ5pmTh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the August 2022
Convertible Notes, the Company identified certain embedded features that required bifurcation as a combined derivative liability, including
the share-settled redemption of the 2022 Convertible Notes at a 50% discount and the automatic increase in principal of 10% if conversion
does not occur within 12 months. Key inputs for this valuation model are summarized below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;<span id="xdx_8BC_zWO7z0wylKdf" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Derivative Key Valuation Inputs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">2022 Convertible Notes derivative key valuation inputs*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated IPO date</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_zYV50vMb4Kpl" title="Estimated IPO date"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember" format="ixt:datemonthdayyear" id="Fact003372" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">8/31/2022</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zK2pnOjpOfEl" title="Estimated IPO date"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember" format="ixt:datemonthdayyear" id="Fact003374" name="us-gaap:DebtSecuritiesAvailableForSaleMaturityDate">9/2/2022</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Probability of default</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z8XT09NZrZS2" title="Probability of default"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_IssuanceDatesMember" id="Fact003376" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zyickfmFFPwk" title="Probability of default"><span style="-sec-ix-hidden: xdx2ixbrl3378">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO or Alternative Liquidity Event</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zViedUQmqePa" title="Probability of IPO or Alternative Liquidity Event"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-08-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_IssuanceDatesMember" id="Fact003380" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">45</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221203__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_zeCONxG8il3e" title="Probability of IPO or Alternative Liquidity Event"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-03_custom_MeasurementInputSharePriceProbabilityOfIPOMember" id="Fact003382" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of Maturity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z70biHfaABAd" title="Probability of Maturity"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember" id="Fact003384" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zBayx5yPk7Le" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3386">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z57pzvg3q9Nf" title="Time period (years)"><ix:nonNumeric contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_IssuanceDatesMember" format="ixt-sec:duryear" id="Fact003388" name="SHPH:DerivativeLiabilityMeasurementDuration">1.00</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z3l5G2HZZkl6" title="Time period (years)"><ix:nonNumeric contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember" format="ixt-sec:duryear" id="Fact003390" name="SHPH:DerivativeLiabilityMeasurementDuration">0.00</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zSD24dEZxe4b" title="Estimated fair value"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDatesMember" id="Fact003392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z78qN4UlNr08" title="Estimated fair value"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember" id="Fact003394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_zJDBxpywOaf1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003396" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zHuN5mIWCcld" style="display: none">Schedule of Derivative Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Alto Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Alto Acceleration Option</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zWuG16l7lUb4" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3398">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_ztFTCUemysu2" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3400">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Addition of new derivative</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zdAHyDuWCfwc" title="Addition of new derivative" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3402">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td title="Beginning balance, accelerated feature" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Gain loss on change in fair value" id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z8RTtBdyQRV1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3404">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zPbLi4vsu6Y5" title="Gain loss on change in fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3406">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Settlements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Settlements" id="xdx_98B_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zvjRWlcR4Oq4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3408">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Beginning balance, accelerated feature" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z227U3NgZrsg" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3410">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zIZ54psJBNEa" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3412">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivatives</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zi2intGd88Ic" title="Addition of new derivatives" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="Fact003414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,189,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zulYRhCn5Bo4" title="Addition of new derivatives" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember" id="Fact003416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zN2fSOlVe2Hg" title="Gain loss on change in fair value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="Fact003418" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">778,340</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zl9oFisctE59" title="Gain loss on change in fair value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember" id="Fact003420" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,438,148</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zqedp41mnRcc" title="Balance, warrants" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember" id="Fact003422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zfSvJfrVCkJi" title="Balance, warrants" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember" id="Fact003424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 2021 Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">August 2022 Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022 Convertible &#160;Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%">Balance - December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zMfR6d3t1ZTc" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember" id="Fact003426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zvQSmx5SZQT9" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3428">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zpfuhLUsv1Kc" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3430">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--NotesDerivativeMember_zWqliR34XJic" title="Addition of new derivative" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3432">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zaBmeMoUsWw1" title="Addition of new derivative" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember" id="Fact003434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zrcnlskbqQTb" title="Addition of new derivative" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" id="Fact003436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss (gain) on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_znz5bKggSfBl" title="Gain loss on change in fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember" id="Fact003438" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">205,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zNYi4yyZGiY" title="Gain loss on change in fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember29546843" id="Fact003440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_ztLRWglWKal8" title="Gain loss on change in fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember29546859" id="Fact003442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Settlements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zOwd68kF1fT8" title="Settlements" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DerivativeSettlementsOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember" id="Fact003444" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">162,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zHWin4V5gVni" title="Settlements" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DerivativeSettlementsOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember29546843" id="Fact003446" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">120,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zqIBjN8wVsyj" title="Settlements" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DerivativeSettlementsOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember29546859" id="Fact003448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">571,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zWxsN5hlwSIg" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3450">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zmOWqAKHdd28" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3452">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_z224mM1Sbfoe" title="Balance, warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3454">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivatives</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zEiFnJUobl0a" title="Addition of new derivatives" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3456">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zMvnSYCrVEHa" title="Addition of new derivatives" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3458">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zxo25N8sCZEj" title="Addition of new derivatives" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3460">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zlxz2dtxaAqi" title="Gain loss on change in fair value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3462">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zKJxXoIfZ5oi" title="Gain loss on change in fair value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3464">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zkRrGHyYGnb7" title="Gain loss on change in fair value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3466">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_z5rEzxpFNtYh" title="Balance, warrants" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3468">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zOIIACleWQL4" title="Balance, warrants" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3470">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zFv0uFQF4CY3" title="Balance, warrants" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3472">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A3_zixrotcpmfIc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003474" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zysAiD3uWv96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span>Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_82D_z9InGb4rQSfk" style="display: none">Related Party transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. The Company paid TCG GreenChem $<span id="xdx_909_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20221231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zs0HwiZEVXj3" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-01-012022-12-31_custom_TCGGreenChemIncMember" id="Fact003476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span> during the year ended December
31, 2022 and a total of $<span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20230101__20231231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zEZHhc9Bky7j" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2023-01-012023-12-31_custom_TCGGreenChemIncMember" id="Fact003478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,370</ix:nonFraction></span> during the year ended December 31, 2023, completing the contract.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003480" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zIzNnGyFJnD8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_zYL3mUjUjp33">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no income tax expense or benefit for the years ended December 31, 2023 and 2022, since the Company has a full valuation allowance
for the net operating loss carryforwards in these periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination
by the taxing authorities based on the technical merits of the position. The tax benefits recognized from such positions are estimated
based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain
tax positions to be reported for the tax years 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) amended IRC Section 174 to require capitalization of all research and development
(&#8220;R&amp;D&#8221;) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over
five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. For
tax reporting purposes, the Company capitalized $<span id="xdx_90F_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20231231_zXvHn7wdQpqg" title="Research and development expenses"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2023-12-31" id="Fact003482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,517,485</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20221231_zCI5g925C8v7" title="Research and development expenses"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2022-12-31" id="Fact003484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,488,530</ix:nonFraction></span> of R&amp;D expenses incurred as of December 31, 2023 and
2022, respectively.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003486" name="SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact003488" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z2tRzaeOyVg3" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zdjdEVmue1Gk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zfJ37FBIxa2e" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(as restated)</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact003490" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,384,472</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact003491" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,049,174</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes, net of federal tax effect</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact003493" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">452,682</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact003494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">351,022</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Rate change</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-012023-12-31" id="Fact003496" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,710</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31" id="Fact003497" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">409</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzspy_zFfwkzSx8Rlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R &amp; D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31" id="Fact003499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31" id="Fact003500" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,461</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Return to provision adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationProvisionAdjustments" contextRef="From2023-01-012023-12-31" id="Fact003502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286,015</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationProvisionAdjustments" contextRef="From2022-01-012022-12-31" id="Fact003503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,235</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_iB_zfBXR3fVjSNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Permanent differences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_i01_maITEBzspy_zFPKFfQPSv17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative Debt Discount Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" contextRef="From2023-01-012023-12-31" id="Fact003508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">562,568</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3509">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_i01_maITEBzspy_zWZOWC4F5JIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in FMV of Warrant Liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" contextRef="From2023-01-012023-12-31" id="Fact003511" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">617,655</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" contextRef="From2022-01-012022-12-31" id="Fact003512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,926</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_i01_maITEBzspy_zmAom1OVDsn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on convertible note conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" contextRef="From2023-01-012023-12-31" id="Fact003514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,984</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" contextRef="From2022-01-012022-12-31" id="Fact003515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">503,249</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_i01_maITEBzspy_zVvkEdEmZTEh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" contextRef="From2023-01-012023-12-31" id="Fact003517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,012</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" contextRef="From2022-01-012022-12-31" id="Fact003518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,946</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact003520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,535,466</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact003521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377,709</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shortfall of stock compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:ShortfallOfStockCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact003523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,674</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3524">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact003526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,800</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-01-012022-12-31" id="Fact003527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3529">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3530">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zdVsqCFpXlch" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003532" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zPU61r3hFOe7" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(as restated)</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax asset:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact003534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,727,566</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact003535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">751,844</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3537">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact003538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">804</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Intangibles (includes Section 174 capitalization)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-12-31" id="Fact003540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,197,938</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-12-31" id="Fact003541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,172</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact003543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,915</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" id="Fact003544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,715</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsbasedCompensation" contextRef="AsOf2023-12-31" id="Fact003546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsbasedCompensation" contextRef="AsOf2022-12-31" id="Fact003547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,626</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest &amp; other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact003549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,140</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" id="Fact003550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,336</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease asset/(liability)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsLeaseLiabilities" contextRef="AsOf2023-12-31" id="Fact003552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,326</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsLeaseLiabilities" contextRef="AsOf2022-12-31" id="Fact003553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,889</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact003555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,429,136</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" id="Fact003556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,401,386</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(as restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Change in fair market value of securities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFairMarketValue" contextRef="AsOf2023-12-31" id="Fact003558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,943</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3559">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2023-12-31" id="Fact003561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,544</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2022-12-31" id="Fact003562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,718</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsDeferredIncome_iNI_di_zxk4s8z19xdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income tax deferred</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3564">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2022-12-31" id="Fact003565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,196</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFiniteLivedAssets" contextRef="AsOf2023-12-31" id="Fact003567" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,746</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3568">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact003570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,233</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" id="Fact003571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,914</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="AsOf2023-12-31" id="Fact003573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,375,903</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="AsOf2022-12-31" id="Fact003574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,294,472</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact003576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,375,903</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact003577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,294,472</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3579">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3580">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zrwMVAPp8x91" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003582" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zI3yIfzm5n7c" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zaqDxtXO4WE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z1v7OlEmFVIa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact003584" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact003585" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income tax benefit, net of federal tax effect</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact003587" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact003588" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in tax rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate" contextRef="From2023-01-012023-12-31" id="Fact003590" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3591">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31" id="Fact003593" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31" id="Fact003594" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Return to provision adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="From2023-01-012023-12-31" id="Fact003596" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="From2022-01-012022-12-31" id="Fact003597" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_iB_uPure_zOBXO0OlU256" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Permanent differences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_i01_pid_dp_uPure_maDEF_znJQzfgFZxP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative Debt Discount Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" contextRef="From2023-01-012023-12-31" id="Fact003602" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">8.6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3603">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_i01_pid_dp_uPure_maDEF_zq633uEUFSgc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in FMV of Warrant Liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" contextRef="From2023-01-012023-12-31" id="Fact003605" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" contextRef="From2022-01-012022-12-31" id="Fact003606" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_i01_pid_dp_uPure_maDEF_zC9Kr4APSLOc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on convertible note conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" contextRef="From2023-01-012023-12-31" id="Fact003608" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" contextRef="From2022-01-012022-12-31" id="Fact003609" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">10.1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_i01_pid_dp_uPure_maDEF_zRz4rIboyPlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" contextRef="From2023-01-012023-12-31" id="Fact003611" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" contextRef="From2022-01-012022-12-31" id="Fact003612" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact003614" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">23.2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact003615" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">7.6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shortfall of stock compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact003617" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3618">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact003620" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl3621">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3623">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3624">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_ziTYp8KTsYlh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalTaxableIncomeMember_zrG81Ug3Peyl" title="Net operatiing loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_custom_FederalTaxableIncomeMember" id="Fact003626" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.4</ix:nonFraction></span>
million and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--StateTaxableIncomeMember_zXVNaHVK7E06" title="Net operatiing loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_custom_StateTaxableIncomeMember" id="Fact003628" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.9</ix:nonFraction></span> million of net operating losses (&#8220;NOL&#8221;) carried forward to offset federal and state taxable income, if
any, in the future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making
this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax
asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be
realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">NOLs created prior to
2018 could be carried back two years and carried forward <span id="xdx_90E_ecustom--DeferredTaxAssetsOperatingLossCarriedForward_dtY_c20230101__20231231_ztKkx6mJrK2h" title="Carried forward"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact003630" name="SHPH:DeferredTaxAssetsOperatingLossCarriedForward">20</ix:nonNumeric></span>
years. As amended by the Tax Cuts and Jobs Act of 2017 (TCJA), NOLs created after 2017 can no longer be carried back and are instead
carried forward indefinitely. The Company has $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2016Member_zzagpmkbLOni" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_TaxYear2016Member" id="Fact003632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,813</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2017Member_zflhOv8qsPn8" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_TaxYear2017Member" id="Fact003634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">238,380</ix:nonFraction></span>
of federal NOL carryforwards from 2016 and 2017, respectively, which begin to expire in 2036. The Company has an additional $<span id="xdx_907_eus-gaap--CurrentFederalTaxExpenseBenefit_pn5n6_c20230101__20231231_zmwr2NmmCXT6" title="Federal income tax"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact003636" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span>
million and $<span id="xdx_90B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn5n6_c20230101__20231231_zwfL0wOfQM5e" title="State income tax"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact003638" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.9</ix:nonFraction></span>
million of federal and state NOLs created after 2017, respectively, which can be carried forward indefinitely. The NOLs can be used
to offset future income limited to the lesser of the NOL or <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_pid_dp_uPure_c20230101__20231231_zA745rNSZcVk" title="Future taxable income"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" contextRef="From2023-01-012023-12-31" id="Fact003640" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>%
of the year&#8217;s taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2023, the Company has $<span id="xdx_904_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_zyM9U2Dualt9" title="Federal Research and Development"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-01-012023-12-31" id="Fact003642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,715</ix:nonFraction></span>
of federal Research and Development (R&amp;D) tax credits. These can be carried forward <span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_dtY_c20230101__20231231_zE0Rx6zu1dBh" title="Carried forward"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact003644" name="SHPH:DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome">20</ix:nonNumeric></span> years to offset future federal income tax.
These begin to expire in 2037. Additionally, the Company has $<span id="xdx_900_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zgHvq6C4B1f" title="R&amp;D tax credits"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact003646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span> of state R&amp;D tax credits which can be carried forward seven years.
These begin to expire in 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003648" name="SHPH:QuarterlyFinancialDataTextBlock"><p id="xdx_804_ecustom--QuarterlyFinancialDataTextBlock_zAR4xkS5UMZb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_822_zXYsPgZKlPo1">Quarterly Financial Data (Unaudited and Restated)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is providing restated quarterly unaudited consolidated financial information as of
September 30, 2023 in the table below. See Note 2, Restatement of Previously Issued Consolidated Financial Statements, for further background
concerning the events preceding the restatement of financial information in this Comprehensive Form 10-K/A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003650" name="SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock"><p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zCJ5d5NxEJJe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restated consolidated balance sheet line items for the third fiscal quarter of 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zpA95ya3gad8">Schedule
of Quarterly Financial Data</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8jkE4tUBFO6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z81uuwNEseHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230930_z4FaFFsGclHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_zTeRcSTsNBP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Additional paid in capital <span id="xdx_F42_zJDO1gumiNob">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact003652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,456,841</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact003653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" id="Fact003654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,402,533</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z9CGSTF3pEoc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact003656" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,847,112</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact003657" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,945,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" id="Fact003658" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,792,804</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zBq7OWkLDr08" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zuvLr0XRWxrh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote003659" xml:lang="en-US">The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $<span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-09-30" id="Fact003661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140</ix:nonFraction></span> and an offsetting adjustment to the carrying value of common stock.</ix:footnote></span></td>
</tr></table>


</ix:nonNumeric><p id="xdx_8A9_zwjvQAsnkhR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The adjustments did not have an effect on the consolidated
statement of operations or cash flows for the three fiscal quarters of 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has included its restated quarterly unaudited
consolidated financial information for the interim periods ended March 31, 2023 and June 30, 2023 within Form 10-Q/A for the period ended
March 31, 2024 and Form 10-Q for the period ended June 30, 2024, respectively, filed concurrent with this Form 10-K/A.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact003663" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zgVbCW0iKpTk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 &#8211; <span id="xdx_824_zs2tFHK7qGtg">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through the date the consolidated financial statements were issued
and determined that the following items are required to be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restatement
of Previously Issued Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Bid Price Requirement Extension Granted until August 26, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 7.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2023, after the Company&#8217;s common stock had traded below $<span id="xdx_906_eus-gaap--SharePrice_iI_c20230831_zMaOM7ZhXbF7"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-08-31" id="Fact003664" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uTradingDays_c20230831__20230831_zz8MxLwLRTY8" title="Consecutive trading days"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="From2023-08-312023-08-31" id="Fact003666" format="ixt:numdotdecimal" decimals="INF" unitRef="TradingDays">30</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consecutive trading days, the Company received
notice from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the
&#8220;Bid Price Requirement&#8221;). In accordance with Nasdaq Rules, the Company was provided with an initial period of 180 calendar
days, or until February 27, 2024, to regain compliance with the Bid Price Requirement. On February 19, 2024, the Company submitted a
plan of compliance to Nasdaq seeking an additional 180-day grace period to regain compliance with the Bid Price Requirement. On February
29, 2024, the Company received formal approval from Nasdaq granting it an additional 180 days, or until August 26, 2024, to regain compliance
&#8211; whether organically through market forces or by effectuating a reverse stock split, should such action be required. On August
6, 2024, the Company filed a certificate of amendment to its certificate of incorporation, effective August 13, 2024, to effectuate a
one-for-eight reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the &#8220;Reverse
Stock Split&#8221;). The Reverse Stock Split had no effect on the Company&#8217;s authorized shares of common stock or preferred stock.
Following the reverse stock split on August 13, 2024, the Company had a total of <span id="xdx_903_ecustom--ReverseCommonStockSharesOutstanding_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBur87NIR7jg" title="Reverse common stock shares outstanding"><ix:nonFraction name="SHPH:ReverseCommonStockSharesOutstanding" contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember" id="Fact003668" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,111,235</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares issued and outstanding (or <span id="xdx_907_ecustom--ReverseCommonStockSharesOutstanding_iI_c20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd7cI2lLYPFc" title="Reverse common stock shares outstanding"><ix:nonFraction name="SHPH:ReverseCommonStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SubsequentEventMember" id="Fact003670" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,008,689</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a post-split basis as of December 31, 2024)
and trades under the new CUSIP number 925693302. All common stock share, option, warrant and per share amounts (except our authorized
but unissued shares) have been retroactively restated in these consolidated financial statements and related disclosures. Following the
Reverse Stock Split, on August 27, 2024, the Company received a written notice from Nasdaq informing the Company that it has regained
compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Approval to Proceed with Phase II study of Ropidoxuridine (IPdR)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release announcing
that the Company had received the &#8220;Safe to Proceed&#8221; letter from the U.S. Food and Drug Administration for the Company&#8217;s
investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence
the Phase II study and, as a result, the Company is currently finalizing site enrollment with &#8220;first patient, first dose&#8221;
expected in the coming months. </span>The Phase II clinical trial was also approved by the Institutional Review Board &#8220;IRB&#8221;
on June 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 8, 2024, the Company
entered into a work order (the &#8220;Work Order&#8221;) with Theradex Systems, Inc., a New Jersey contract research organization (&#8220;CRO&#8221;)
for purposes of supporting the Company&#8217;s Phase II Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in
Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promotor.&#8221; As such, Shuttle Pharma is now in the
process of signing up six clinical sites where the clinical studies will be performed &#8211; two of which have completed initial site
initiation visits and one of which is ready to enroll patients &#8211; and where the CRO will oversee such studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under the terms of the Work
Order, the CRO will oversee the studies for a period of 53 months (the &#8220;Term&#8221;), including overseeing and monitoring the regulatory
aspects of the Phase II clinical trial, and managing the documentation surrounding the clinical trial in exchange for a fee of approximately
$2.3 million, payable in stages and based upon services performed during the Term of the study.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase
agreement (the &#8220;Purchase Agreement&#8221;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed
to commit to purchasing from the Company $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJDnbJVClHRk" title="Sale of stock consideration received per transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact003672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>
of units from the Company, with each Unit consisting of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUwwlJvcREg6" title="Share based payment award description"><ix:nonNumeric contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact003674" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $18.80
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.</ix:nonNumeric></span> Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90% of the VWAP of SHPH common
stock for the five trading days immediately preceding closing. The parties entered into the Purchase Agreement in anticipation of
the Company commencing a rights offering (the &#8220;Rights Offering&#8221;) pursuant to which the Company intends to offer a total
of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlQLd9zaTDXg" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact003676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span>
Units to existing stockholders, which includes the $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEVUQW1Y2LFg" title="Sale of stock consideration received per transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact003678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>
Units being sold to SRO LLC, an entity which is owned by Keith Moore, CEO of Boustead Securities, LLC
(&#8220;BSL&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement allows SRO LLC up to 60 days to raise the initial $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zeJXcEGJ6F95" title="Escrow deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact003680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>, which funds will be placed in escrow with Sutter Securities,
Inc. (&#8220;SSI&#8221;), an affiliate of BSL, pursuant to the terms of an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI
on February 7, 2024 (the &#8220;Escrow Agreement&#8221;). The funds will remain in escrow up until closing on the Rights Offering. In
addition, in the event the Company fails to raise a full $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zAbw8U4vQqh" title="Right offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact003682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span> in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant
to which it would have the right to purchase any remaining Units not purchased by existing SHPH stockholders in the Rights Offering,
up to an additional $<span id="xdx_905_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLidexbeXPOd" title="Escrow deposit"><ix:nonFraction name="SHPH:AdditionalEscrowDeposit" contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact003684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span> (the &#8220;Back-up Contingency&#8221;). <span id="xdx_901_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjbhaGD0F2h6" title="Initial public offering description"><ix:nonNumeric contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact003686" name="SHPH:InitialPublicOfferingDescription">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#8217;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Restricted Stock Awarded to Chief Financial Officer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On March 8, 2024, the Company&#8217;s then CFO
was awarded <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zrFoglyhoPx1" title="Restricted stock units"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember" id="Fact003688" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span>
restricted stock units (&#8220;RSUs&#8221;), with a value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zz0X64iPXAvj" title="Restricted stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember" id="Fact003690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,840</ix:nonFraction></span>,
with such RSUs vesting in full as of the date of issuance. Each RSU represents the right to receive one share of SHPH common
stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 13, 2024, the Company&#8217;s newly appointed CFO was awarded <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240613__20240613__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRJIfmRYFdT5" title="Restricted stock units"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-132024-06-13_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember" id="Fact003692" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,455</ix:nonFraction></span>
restricted stock units (&#8220;RSUs&#8221;), with a value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240613__20240613__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zn7ip2Rkozz3" title="Restricted stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-06-132024-06-13_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember" id="Fact003694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>,
with such RSUs vesting annually in three equal installments following the date of issuance. Each RSU
represents the right to receive one share of SHPH common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Alto Opportunity Master Fund, SPC</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2024, the Company informed the Investor in the Alto Convertible Note that the Company&#8217;s expected restatement of its
consolidated financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of
the Alto Convertible Note. On August 6, 2024, the Company paid $<span id="xdx_905_eus-gaap--ConvertibleDebt_iI_c20240806__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWhRE3Lfrsz7" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-08-06_us-gaap_SubsequentEventMember_us-gaap_InvestorMember" id="Fact003696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span>
to the Investor, which funds will be held as collateral to the balance owed under the Alto Convertible Note, and received a waiver
from the Investor related to the default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Alliance Global Partners </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On July 30, 2024, the Company
engaged A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) to serve as exclusive underwriter, placement agent or advisor in
any public or private offering or financing (as defined, the &#8220;Offering&#8221;) of up to $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20240730__20240730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSfHFktjdED8"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-07-302024-07-30_us-gaap_SubsequentEventMember" id="Fact003697" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction>
</span>million.</p>
</ix:nonNumeric><p id="xdx_811_zk9IyDKVqIfd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>395,574
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2,555,246
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded Warrants to Purchase up to</b></span><b>
2,555,246 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b>2,950,820 </b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Warrants to Purchase up to</span> 2,950,820 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Common Stock</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2,555,246</b><b> Shares of Common Stock
Underlying such Pre-Funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2,950,820
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock Underlying the Common
Warrants</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="forms-1_001.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lead
Placement Agent</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>A.G.P.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Co-
Placement Agent</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 14pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>Boustead
Securities, LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PROSPECTUS</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
29,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 150; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 9 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB!^SAXHCFMH@<M>>"]>GN);)D<-E$BG1H%7"A3&X#<''\R/_  42_8%^(O\
MP3V^/&L_"[Q8;G5O#S7EQ'X3\6_9S';:QIUJD)\J-#\I,DDCM$P#;H@& Y&>
MY_X)#_M4#]EW]L[P%KNK7DT/P^^(]Y#\-_'$4CM'!;:=XCD6WBU*92?+/V&Z
MGMEB9U+1'S-A1V8LOI0\!9;](?Z/G$.#R.K'%X^E@Z_$_">(;BYU,\X>HU,9
ME$:<IJU.G46'J7I1E2=2I.2BFE&0>'&>XG@GC;!SQEW@Z56. QD).7)*GC9T
MZ<H/HX/VKM%J44DVX61_K/\ PH\6P>-O NA^(XG)>ZL8C(H8$K*BK',I )!*
MN"O.#D8.""1Z4IW;')(&#GCOCKCH!D@CCJ>G>OSW_8\\;?9+C5_ %Y<PO&LA
MO](",=LEJZ[S-"&.%64E92N %+9Y!%?H/%\H )R0,@>W& >.3@C'Y]*_R]\*
M>*Z_$_!F!QV9I+/,MA#)<ZA:2<<RP,?JV+YH22E3;K4IOEE!2C:S4;6/UGB_
M+'E'$>*H4;/ XI/%X*HDESX;%.56A.-G;DY:LDN5=$VHIQ2L1JZH !PSG..H
M4D#\.,G(SCC\+ & !Z#%,C)(.<<-C@8[ ]/J33Z_3?77S[GS27*E'^5)?=I^
M@4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDTJ-/C+\?+&W\9>(M2GMXAJ&D>'-14W?A[1[5V4/&CZ<]E+.$90S/R,[@/\
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MERP22A"*22W;]'!8*C@H16%44G%?#'E4FU_*M5=V>^K1F?%,HG@'QEO.Y/\
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M+I\[1]T:3.  3Z?, !T (Z9S^!3DY&<EE6)3D8/F*BA\K_OAP#SGG-?T&?\
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M:[/^W=X[?/ \.:..IP L6J8QD^QZ<=23D5^39D.U1]XD+QQP0-R''3*DL5Z
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M1110 4'H?I]:*:Q&#@@'!QS_ "_&CTT?>U[>=NOIU I23!"23G!;KV!+$\]
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MILO(_<GN?!_[2O@Z+QU^T]#X9E&#?_"G7&M@J!F^UV, GLBIZ[Y)P8P5PW)
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M@!PVV)5FRPRBABRY(##(!;G))&<^X'D7PHN((M,\=7TLZP6Y\>>)R+BXD\N
M11SPJ7+.=H._>I8]U /?'^9B4HZ2MS+65MKMZNW2_P"#V['Z[S.7O/>23?35
M]+:?D?-_B?+?MU>#5/3_ (0&\Z\_<?<.ON< =CR.IKWSXW^&-=O="O?%'@Z+
M=XHT72+^ P@LW]K:7<A3<:=)$K$2A%,DT,;@J)2S;"S$GY_\1RQG]NGP9)(Z
M1QR>!KV.!@P9;C< 5:-E!!#@JPVY/S#TY^^/+CVY*@@95&V_."%$;/N/<H
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MLMRMNVV6V@E >(^:KJ85E0%I">##N.01S]'?$[Q[I?P\\-:CK]],IFC2?[#
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M1%#>:C!&MSJ#QQAIY9)'D8LS$_JC_P %R_\ @I!;?%7Q0G[&_P "-=%W\,O
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MXY^#'CC3M2FCU7P?XR\)ZO9ZKI=ZPN+2]TW6=-G6>RO%E787V2Q[$9)" C.
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M$9 XYP1G'&,U" 0?O Y)PH8#&222.,G&:AN)FCS([A(T3<V2J #<V=TCMM
M!^\1R<9ZUEQ:SI<\_EQ7]G)/L&(([R"><G<5XCB<ECD,#@=B>.30H5FKT:%6
MO!\SJRBY6A;26MGRI+6UU:S>BNPJ5J=%PC/$4:;G>T)N[;NEO=:>BMHO,Z.+
MH1D'GH.<9)/7'.>O4_ATJ2JEKYA#F3&"05 R#CG!8$<,1R1G(XS5NFDHKEB[
MI::MO7KJVWHWW-'_ (HR[2C\+71H****8!1110 4444 %%%% !1110 4444
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M2@7@9!^P?V5/V;=8_9R\,>)?#&L?&3QY\75O]7NKO3+[QK>&[N= TUEW1:5
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M+LVVKZ:V;M?16>ZZ$V25K*UG&UE;E;;:MM9N3NMG?6^EJQM8B<G/4$CGG&
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M[DDEY(****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>forms-1_002.jpg
<TEXT>
begin 644 forms-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $K E@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **1LX..N#CZXX_6O-[KXN_#ZRNKFRN]?\JZL[B:UN8O[+UF3RKBWD:*:
M,O'IS1N4D1EW1NZ-C*LRD$@'I-%>7_\ "YOAM_T,?_E)US_Y6T?\+F^&W_0Q
M_P#E)US_ .5M 'J%%>7_ /"YOAM_T,?_ )2=<_\ E;1_PN;X;?\ 0Q_^4C7/
M_E90!ZA17F'_  N;X;_]#'_Y2-<_^5M'_"YOAMC/_"1_^4G7/3=_T#?3GZ4
M>GT5YA_PN;X;'G_A(QCG_F$ZYVZ_\PW].M'_  N;X;<_\5&.,?\ ,)USN<#_
M )AN>31==T!Z?17E_P#PN?X;?]#'_P"4G7/_ )6T?\+F^&W_ $,?_E)US_Y6
MT >H45YA_P +F^&__0Q]!G_D$ZYT'?\ Y!M'_"Y?AO@'_A(^#R/^)3KG.?\
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MP:7J4MEXAAN4266%=%<NSS87Q&_8C_:.^-/A+]HG7O&5M^SA\._B5\3?@_\
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MB;22+MA=:%=IO^R:FA-I=O'(EO.\D4B+U6A_'7X*^)_B-JGPC\-_%KX=Z_\
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M[OQI=7_@FXUBT\6V47AR.Z_M/[7X?D\/ZQ_:%J8!<1QZ7J%Q''):6DLZ>/\
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M.OA+I6BVNKZ'J5Q9^'&F@\5-=0ZS-H=A8S3Z05U&>6XU&QFU"^5N1\ _L/\
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M]_Y\=2_\'%]_\=KV"B@#Q_\ X49\/?\ GQU+_P '%]_\=H_X49\/?^?'4O\
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MFALS<3712>XFNI#/<"-96\V=G<*5AC"H"$4+P!71T44 %%%% !1110 4444
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M>,IQ4\52O.$)8:#E%1YKQ4L50O=KF4I.',H2<?W\_P"%S?#C@_\ "0$#./\
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MU%RARJ:F[+]M/^%S?#CI_P ) <\]-*U@_B!]@_'^M+_PN;X<=?\ A(#UP?\
MB5:SU]_^)?U_7BOQW\+_ +6/P?C\)? 6?XM_%+X+_#KXD_'KP=X4\2>&/!6F
M?$NR\0:5KU[XFALU@C\#:Y<6FFW/B3P_=WUVECH>OSV&GVVKSO\ 9;5KBY0I
M)[1\4/'5A\*_AI\1/B;JVG7NIZ=\-_!/BKQSJ6DZ<T$>I:A:>%-'O-:N["QE
MNWCM([RY@L9(+>2YFB@CF:-I&,8;//4RS'4<3AL+6PU>G4Q>*GA</*5.:I8J
MI2QW]G5'@Z\XTJ.+IQQ35/VE%RI)W3JWBT:4\9A:E*=>%:#ITJ$<162E%U*%
M*6&AC/W\(RDZ52.'FJE2G+WX6LV[H_1[_A<WPX'_ #,&!DC_ )!6L=>,#_D'
MXSCMU]*7_A<_PX_Z&$_^"O6/?_IP]C^1]*_'*#]M7]F2RT'P+JGCOXR?#SX4
MZWX^\&?#/QM9>"_B#XPT;1O$FG:=\6-#N-=\(0WT4LZVT@N+>PU&"34K2672
M[::P=K^YLDNK,3^H:C\=_@GI?Q=L_@#J?Q6\ V/QPU"!IK3X477B*RC\=3*N
MC2>(U0Z"&^U0W+^';:?7XK*<17LVC*=2@@>S:&>>JF3YO1<E6RO,*;A2KUY*
M6$Q'+[#"S=/%8B-;V3HRH8>M"I3J5HSG2B^3FJQNR88[!347'%X=\TJ4%^_I
M<SJ5HN=&'LW-5%*I%7A"25224N6FW&2C^GO_  N;X<?]# ?_  5:Q_\ (%'_
M  N;X<?]# ?_  5:Q_\ (%?#0.3D\#&,Y7N,D_+P2<#H2,C/)Y,H_P ^O''/
MJ>.M>?OJMGT>^M[)]+JSO:Z[=3J3>ETTWK\FDT_1III]4T[M--_<'_"Y_AQ_
MT,!_\%6L?_(%:&D_%#P5KVI6FCZ/K'VO4KYY4M;8Z?J<(E:"VFNY1YT]I%#'
MLM[>:3+N VS:/F(!^$*]#^$O_)2?"?\ U\ZM_P"HWK?^/\J!GW;1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XA_Y
M &N?]@?4_P#TBGK\WUSY*Y'2),>N=J\#W/OTXS@5^F%W;17MK<V<^XPW=O-;
M3!&*.8IXVBDVL.5;8YVL.5.".E>2#X$?#X!0+35<*  /[7NR !P ,L<   <8
M]Z3U6]O^&?9KRZK;=.S1_7]:K\&GV:W7X'_MS?LJ_%S]J::S\-^$_#_[-FEZ
M9::-ID?@?X^^*[WXJ:-^T9\!/%;ZR][X@\2?#BZ\#6O]G:_97=G;:2NG>'K_
M ,0>'K*._&HSZG]M6:&6UQOB'^Q3\1/%M_\ M":MIVL_#V;5_BM^V7^RY^T)
MX:\1:U)J$&NIX$^!NA>!]-\3V/B6\T_PE(VG^+-6N="UZ[T?2=#>]\/R_P!I
MMYVIZ.MW<10_T$?\*(^'O_/IJG_@VNO\?_K>U'_"BOA]WM-4&<<?VO==3U'W
MO7D^O:OJ\-QIG>"PF"P&%J82EAL!!1P\/JKJSY7C(8ZHY5*^+KS?M:U*BZU.
ME]7PM91J3K8"K6Q%>M+Q:_#^6XFOB,37A6J5L0U*I*5;2ZH5</%J/L5S2A3J
MM0JUI8C$Q:5L7[L/9_SQ>#?V.?V@/"OQI^%UT_B+X+7?P(^$7[<_Q%_:ZT6>
M*Z\>1_%WQ%IOQ2L]<DU+PMJEE+HTO@S3;KPM/?KIUFMMJ=['XCCO1>2ZIHL>
MD"RU;%\-_L=_M0>"/@#\%/A=H>K_ +/>M>)_V6OVJ?$7QJ^$-WK.K?$:P\/_
M !#\$>+/%_QD\;ZIIWQ.FM/"EWJ/ACQ+::S\9+VTT^Q\,V.NZ2^D:%9I<ZL+
M^Z>5/Z.!\"?A_D_Z)JG;G^U[KGG/KV/^/7FD_P"%$_#[M::H?;^U[KGCZ\9S
M[=3VKHEQYGTY493662]A4H5HP>70Y)U:%+'T76JI8U.I5Q5/,L93QLG**Q%.
MLX\E&4:5:AE'AO+(*:@\;'G4HW6,GS0A+ZLU3IOZLE&%&6#PL\/&<*OL94(7
M=6+JTZO\WGQ8_8,^-_B7QIXG^*'@?Q[X0TGQ?I_[9?Q?_:+\#:2OC7QWX(@U
M7P=\6/AGX1\!3V>I^.O#/A76=;\#^/-"N?#<UY9W.D:'XJTZXTS4KS3GU!'O
M+@IZ_J_['OC%?^";'BO]C3PI=>!M%^(&O?#[Q7H6G74_B#Q?K?P\TOQ'XJ^+
M.I?$R=6\0:UH=[XMN])B_M&>VEGF\-LTFI-+]GTFUTN6&*#]Y?\ A1/P_P#^
M?353Z_\ $WNNF/KWP!3?^%%?#X?\NFJ]P/\ B;78''(.<CKU'49S6-7C?/Z]
M+*:56KA)4\ES# 9C@(K!PBHULM5&.%C62JOZQ2A*A"HU4:JRG*K+ZRHU'!73
MX>RRG/&3C3JWS#"U\'B4Z\G&=#$QJ1KI*4/=E.-6>L9J*M!\EXOG_![XE_L"
M?#\?L_>)/A5\#/"WACP[XG\>?$O]FOQO\1_$?C[Q3X[\97'C>Q^"WQ1\'>,=
M8L-?\5>+[CQSXHU.V3P[I/B+3/"'A^ZV:!:S:FMB(M*M+FYN4X'X@?L>?M)?
M\)G\<_%OPE\>_#_PYI_Q,_:^L_CW:>%(?&7Q"^&5WKO@%O@O#\/Y] U'XC?#
MWPM+XS^&OB.R\6C_ (22Y'P_>5?%6EVT>EZOX@LK>[OK1OZ'S\"OA\"!]DU0
MX!/_ "%[OWX R,Y_SWIW_"BOA\.?LFJ<<X_M>[],?WNPZ=/3I2PW&_$.&4E/
M%T\=.K6K5JL\SPZS"=6IB*F"K3<ZE>NIVA4P&'>'472EA:<(T,/4IT:5.$76
MX>RJM;]S.C:E2HI8:J\-%4Z<<1'D4*%.*<9O$3G44Y5)3J>]*I.]H_S^?LF?
ML3^/?@+XE_8OU3QMJWP[\2V7[-'PG_:@\!^(9M';6+Z[OM>^,WQHMO'GA36O
M"-OK?AZT"6\/A$W^F^(I[^]T_4+"_O9=-L%U.REGO4R/@?\ L+>-/AQ>?L#7
M?B9_A3JA_9@US]O_ %KXK'3XM0OY?%D_[4E]J$WPMN_#<FH^$;,Z[?\ A>QN
M+>#Q+/XD.E2:*(O)\/2ZHL4.?Z&O^%$_#[_GUU0]?^8M=X]SP1S_ /7KQ[QA
MX1\)>'/BY\&OAW;:))<:7\2K/XEW&K7]QK&J?VAI[>"=$T;5; :<(IUM2MY-
MJ4T5[]JBE;RXXS;^6Q=C=?CKB+%5L97JXC#>TQ\<1#$.&$C"/^U5.(*M;V45
MB5&DG5XGS>JH4U%>UK4*C<JN%HU)1#AO*:=.C2C2JRCAW3=+VE55)ITEED8<
M\Y4.>;C3RG!TX-OFC#V\4U]8J'\VGBO_ ()O?M=ZC^S!\'OV>=)^*WPL-AX6
M_9D\1_!7QKI1\>_%7PGX;C\:77Q*\3^-]+\3Q2>%/!<=Y\6_"\V@ZGHWA6'P
M=\1;>P\->%[VVO?$%AH>J71DBO?L+0_V6?C5X5^+'QQ.D:G\$]4^#G[3UC\,
M9/B3XKUZW\7O\=_AEJ/@;]G?3_@??6WPS^RZ4OAOQ1#]LTU?$'@G4_$.N^'Y
M?"%I>7EF;"[FE>5_WH_X45\/N]GJAYQC^U[H]0.?O>O';K]!0/@5\/LD?9-4
M&./^0M=8/3.>>,\?7MTK?%>(/$.,H3P^(>62HU9YA6J4Z>5TJ$95\QQE/'U:
M]\/BZ$G4H8NG"MAG.52$91BL32QT+TY9T>&,JH5%5I+%*<8X6$9RQ+FU#"8?
MZI3II2P\J<:=3"OZO5C"$'[)R5"I@YSG5?\ +;X)_P""8GQE7X/_ !2^%OQ"
M\9?#O^U-4_96U']FKX<^-=(^(7Q6\7VL=JWC7PSXWTYKGP)XA\+:#HOP^\'Q
MWWAE&ET30;WQ?=V]_J-QJ%G< 1W%E<>F^-/V+_VH_BQH7[7NM>/_ !#^SYH?
MQ(_:!\)?L:6/@O3/!E_\1K_P'H.L?LJ^.H?$]QIWB;4=>\-V_B%]/\5:=H^G
MQG6M*L+F87VKWML-#MK71X[K4_Z1O^%$_#X\?9-4[_\ ,7NR!C P,G^G8T?\
M*)^'W_/IJGL/[7NORZ]#G_/-:U/$?B:IB*V*J5<OJ5Z^)I8J52IET9.G4IUL
M%B*D,._KE/V%#%U\OP\\917M(5E'DA+"T^51F/"F3QIPHQABHTX4JE'D6+E:
M4)K$03G>A*,JE&GBZ].A4=.]*#@DI<GO?ST_&']COX\_%SQ[\7/B]/JWP2T?
MQWXOUW]A7XH>&/"=S<^,]=^&UY\0OV7K;QL?'7@OQ:;CPW:ZS'\/-;N_%[?\
M(EK%K;ZMK,[Z58W>KZ!IC@QQ^;?M;?L:?MJ?M/\ A?6-*D\9_L_>#X?'WP>U
M_P &>*? 7A'QK\8/!7P]\,>-IOB5XE\:67B+9H/@UM0^-EKKVBWN@:;K$/Q0
MAL=(T/Q>NN>.=(\+O=W?DW']+X^!7P^QQ::IV_YBUUP2 <CGKT_SQ1_PHGX?
M<?Z)JG/?^UKKT/OZ<?0FLL'X@9]@<1E^)H1RMU,J<5ETZV6PK2PE.G3P-.-.
MFZF+:G"*RS!34JT*M15*,I^W_?UJ=6\1PQEF*IXJE6>,E#&N4L4HXR<%7G)X
MF]2I&-&SG;&8N,N7V=*I]9J2J4)35.=+^=[XT_L7?&'QEXI_:)\6^#5^$U[J
M_P 3OC=\$_BI\+]:UWXC?%OX<>,?AC<_#/\ 9WNOA/<>+/#OC+X<^'[F[\/>
M.+/Q/<--9Z=/8^*_#7B+P9/J6GZJ^DZE>6YLOJ;]GF_^/6F>)/$?PK^)UMI&
MM>"_@S\+/@5X/M?B[#X2U'P=>?%_XUWWAF^UKXLZIX;TX7%OH-Y\.?#6G3>#
MM,L]3TK0=(B/C"[\0:5'<7KZ3?VVG_KY_P *)^'W_/IJG_@VNN_7J>^23_\
M7H/P*^'W&;35"/3^UKL@GD_WLYZGC%>;C>*,=F.6K*\=A\!B*%*FJ>"F\-*G
M5P-58;+\%]9H..)G&5;ZEE\:-IP5%SQ%?%SHU<4Z56GU4,FPV%Q3Q>&K8JC5
MFVZ_+6YHXF+JXO$<M7FI*[6(QE6KSI^T:C&CS1I2J\_\_?@[]BSXAZ'\5?!/
MC;6]4^'&J^'O#?\ P43^,W[7FHZ6]SK=]=77P^\>_#+6/"OA72;>ROO#"V,_
MCC2?$USINJ7UE//!H]A#:I?Z?X@N;ZWMX3YKX$_8?_:.^"P^$7C'X;WG[-GB
MWQO\/1^VCX0O_ _Q3;QT?AK'X%_:8^-&I_$WPIK/AK4/#WA6;5;77]%TN[32
M/&_AB30+72-;L&?P_8:^+)IKV3^DW_A1/P^.#]DU3_P;W1^O.?KG'OB@? KX
M?$_\>>J\CDG5[OH1V&[WP<="3C!-=SX\X@:J0E/ SHU:+H5<-+!S5"K0]C4H
M.G.%+'X5J4Z53EJUL/4PN(JN$'*JDN0YWPUE5^:,<13FJDJD:D,0E.$G)37*
MYX>K%QC.,;4ZE.M2Y7.*I1E)5:?YV^"D^**:Q\08OB"OPZ'ABW\3:?#\(V\!
MIXCBU5_ \?AC1DOV^(%OKI:RMO$8\6C7AIT'AEY-(B\-#2HY7:^6X=_6_#O_
M ",7A\]_[?T0'V/]IVF1UYQ@>O7@\G'UN?@5\/N/]$U7DCIJUUP>W?'KG'3M
MQ5FS^"7@.QN[2^M[;4UGLKJWO("VJW3()[69)XBZ$X=1(BED;*L,J1@U\G6J
MNO5E5=.C2YE!>SP]+V-%<E.%.\:?M:W*YN'M*G[V7-5G.24%)4X>W3@J<5%2
MG.SDW*I-SF^:<YVE)J%U!3Y(+DCRTXQBW-IS?K60?U_3K^1./KFEI ,#&2>2
M<G&>23V '?CCI2UD:!1110!YM\7R!\./$^3C_1K(<^IU2Q 'XG@>]?"^Y2,Y
M&#[U^C6O:)8>(])O-%U-)7L+](TN%AE>"4K%-'<)LE0AT(DB0DJ<D CH:\S/
MP)^'Q.3:ZIV_YBUR.@QT!P/H./0"@#XQR/[P_,5&P&!@].2 <\ YQZG&3VY&
M>E?:/_"B/A]_SZ:I_P"#:Z_QH_X41\/O^?35/_!M=?XTGJGKHTUM=6:LT[-.
MS3:=G%V;M*+2E$TTND[.]GJGZJZ\NJV[73_ O]MC]E'XN_M0:YINE>%]$_9N
M\/Z?I5MX:D\ _M$ZW>?%+1_VFO@5K%KK$.J>*;[P-)X.M4T+Q3::DMMLT;1M
M8\1:+I-HU]?27]I/>&*^6KKW[%WQ!U+7?&'B"TU/X<?VGKG_  4P^'G[8]EJ
M]W+J::R_PI\':9IUG<^'=1OK;PJ9%\<RW$6H7-KHMO+)X7#W<D@URT:>01_O
M]_PHGX?<_P"B:H<<8_M>[';_ 'N.#C([=>E+_P *)^'V<_9-4X_ZBUU]1U/;
MIZ?C7U>&XTSW!8+"9?A:F$HX7!PE"C#ZHZDDY5)59SG4JXRI*HZDYMU:7)2P
M<Y1A66 H8AU<3B/$J\/Y;6Q%;%58UYU\1+GJR]ORQE[E.GI"G0HJ,O9T^3VM
MYUG!J#K2A"$(_P [7PL_8S^/_@#XS_ &[O/$7P4O?@9^SS^V3\;OVE_#LMC=
M^/!\6/$VA?&NS\:3SZ#K-A>Z&/!]E?\ A"_U^UTV""UU*ZAURWNYM3FU:P?2
M8].UO'\$?L<_M2_#WX(?LP_#_2-7_9VUKQ=^Q[^T9K/Q)^'5QJFJ_$BR\,_$
MKP!X@M?BA#>CQ[/:^%;G5?#7BZVF^)4C6VE>'K36-'>'1;<SZV);@!?Z/#\"
MOA\,C[)JG S_ ,A>[[YS@;O\]^^4_P"%%?#X\&SU4]",ZM==.,]^WMZ<&NF?
M'N?59PG5CE<W"4)<KRY13DGC_K$Y.&.IU)5<=3S3'T\;5=1SJK$N=/ZK4A":
MRAPWEU.,HTYXV'-&4%*.+;<%RX.-.,(RPTJ,:>'67X.5"E[%QA.BY5)UO;5H
MS_FX^(7[!/QQU+6=-\>^ _'WA#3?&W@G]L+]K+X\>%=.B\=^//A]%KG@/]I;
M0? V@VL%S\0?"_@_7=>\&>/O"\?@HB0:?X:\1:/<:;K^N:0FJM;WLF?6?&W[
M%?BC5_\ @F1KW[#?A*_\$^'O%^J?#BQ\*Z??2ZYXMO\ P%IFJR?&;3/BKK*P
MZ[JFCZAXPGTD10ZE8:9->:&9TN386R:?9Z6(S9_O?_PHGX?'G[)JG3.!J]V>
MN?\ :YS^1_.C_A17P^ !^R:KV'_(6NQCW.&[#CN/;(R,JO'/$-99.IXC#-Y'
MF.!S; 2C@Z:<<9EL\-4P<JT56=.M3HU,-&K&FX4G[2=9NNX3]BM(\/993ECI
M4J=2$LPP=7!8B]>I47L:SJ<SIJ:?LZBA.$5--J3I0G.$I2J<_P#//\4/V3/V
ME?VB4^,'C;XS:]\"?#/CO4OV5OB/^S7\#O ?PQU'Q]JW@K0G^*%Q97_BGQA\
M1?'7BGPW8^(KV>[GT31;2RL-$\(30:?9BZEV/<6T$=[S/Q&_8@_:<\>_'+P1
MXE;XE_#Z^^%7A7XH_LD?$32-$OO&OQ)\.S>'+/X&>&_A[X7\;^&8OA_X?\,3
M?#[Q=JNKZCH'B;Q5X:^)?BZYU#Q3;VMW9^$K9?#6EW<[6W]'Q^!7P^S@VFJ<
M\@G5KK )/0<]336^!GP_7!^R:IW&3J]V, #!/?(YSSCU'.*UPW'N?81J&'CE
M5*C"E5HT*"RJG*AA:%;#PPDZ>&ISQDW%SHJLZLZE:O5K5,37E6G*,E1CE5X9
MRJK']Y'%SG[6-:566+J2J5YTZJK4Y8EJC'V[ISC2:]VDK4*2<7&'*_X\/V4?
M#/Q)\<>+/%7PN@\#:_J.M?$/X*?MT^ )KSQUX7_:)^'EG^QJ/BEK'BWQ;HND
M:KIWBK1Y_@LD/QV\8'P;!K=A\'Y?$NJ:>8[;4Y+F:>TU:+5/LKX@_P#!.?QW
MXY\+7_A*Q\3_  S\(65Y^P1\#OV;%FL;+6+NPD^+?P@^+W@GXK7>H:SH=IH&
MF0ZK\-O$LOA&;1[N_-S'XB=-6DN)?#TI$L,_[E^'M#TO7?VI/C'\%+^VF?P7
M\//V?/V9_B;X>(O]2&L+XE^+?Q(_:X\*>+%O;V6\>";3%TKX)^"O[*LXK.W:
MQNO[8G>:X&HA+?WS_A1/P^S_ ,>>J#_N+7>.W')[Y/OUKOQ_B1G%7'QQV64J
M&5J$:3=.3EF,IUZ4:5/V\JF*<*;BZ5"A25!X65)RC6Q=6,\QQ>(QDN7"<)9=
M2PWU;&2GC+.I&,TH89JA-RE*DW2@ZDI5)U*DJU;VBG.,J=!6P]"C!?SI^+?V
M.OCY\2YOV@?BC\0O#O[,3_%?XT:S^S6NE?#SP+XR^-?P_P# /@33/V=+;QDN
MC>.?#'Q<\,:#I_Q$T/XMR:KXL@NM"U:W\)ZCHNBZ%I'_  C-]#JME=Q?9>E\
M!_LI?M/>#_%W@OQ+XE^(OPF^)VH:_P#L9>,/V8OCEXHUA/$OA_Q&-?N?$OCS
MQYX1\7>!+31?#?\ 96OJ^M:OX2\)^*-3\1KH>I7FC:=XC\6-9WNOZK;:>G]
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M?\)7I']^X_\  =Z .DHKF_\ A*](_OW'_@.]'_"5Z1_?N/\ P'>@#I**YO\
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M7418?J./%UF !]DN^ !TB[?\#'\J .NHKDO^$OL_^?2[_*+_ ..4?\)?9_\
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MLQ_RZ7?Y1_T<]>W;/<5MZ7JD6JPR3PQR1K')Y9$NW);:KDC:S# # =>N1VH
MTZ*** "BBB@ KQ[Q[=:E8GQ#>Z-I0U[6;/1;R\T?0#J-IHXU[5K329I]+T(Z
MS?YL-'_MF_2WTX:M?JUCIOVG[9=J\$,@7V&O,/$G_(8O/^N5M_Z(% '\\EC_
M ,%D_P!JP7'[;-CXR_X)6>)/AK/^P%\)/%GQ"_:/U/6?VV?@#XRTCP+XIC_9
MJ\0_M&_"CP)+:^ =!U76O%W_  M*RT_P[X5FU_X>6WBFT\"W?B2:_P#$%OO\
M.ZQIR?;'[/'_  5G_8,_:%^!'CCXYZ-^TS\'=(T?X'?#GX;^._VG(;CQ7?QZ
M/\#+OXB:!;WUKI&H^(=<T#0(_%UC_P )'_:/@O0M<\*V.I1^)O$EC!H5A8Q^
M(M2L-)E\O\=_\$Y_B/XM/_!;EK7XC^ K)_\ @J3X)\&^$_A4;BU\3./AE<>&
M?V1Y?V>;K4/B/Y&F,98;GQ-<-KEO!X5_MN1="M]TDB:A,ME%\F_M'?\ !$3X
MB_M :/\ %+P_'\>? ?@.Q\9_\$V_V&?V//#%]I.@^-9I=$^+7[&?QS\,_&Z'
MQ/JNFZ1?>&9E^%_BV[\*6?AVS&B:['XOT./4!K=IIL%]HNGFZ /T/;_@KE_P
M363X%Z1^TQ+^V+\*[?X&ZW\0?$7PGM?'MW#XQM(;3XH>%?!^M_$#5?AYKOA^
M[\+0>+O#7C*?PAH%_K/A_0?$/A_2K[Q8ESHEEX5@UJ]\2>'X=2[3X=_\%+_V
M"_BS^T)H_P"RI\.?VHOAWXL_:#\0VS7.@_#;3[?Q9;WNLR)X)B^)%UI6G>(-
M0\-6?A"?Q%I_@>4^(-5\,CQ#_P )%IL$-U:7^EV>I6EU9VOYK? W_@D-\=O"
MWB'X&?$WXO\ Q&^!&K?%7PA_P4>^'7[;?QCU+PGXI_:Z^*D?CKPQ\+/V>?&O
MP0\):)#XZ_:R^*'QH^)GB'XC6<GB:SU"PU/5]<\.^'-)T;3K+3[?S9-&L+B2
M3_ATO^V'XE_X*;_#S]L/XB_M9^ OB7\&_AA^V=XJ_:2\ >%_%>O?M,3_ !*T
M'X?^.?!FO>%;7X*:5X"OOB-JO[*_@S1?A?+JMO;>&O$'@?X8Z'XT\:6]QK&N
M^,?&:RRIX<N@#]#/@#_P54_X)T_M2^+[GP%\ _VP?@]\0_%UC\.9/BU>Z/!J
M6M>&S:_#ZSTZWU?7->FU'QCH?A[1XYO"&DW:7_CW0VU ^(O <$-\/&.D>'Y-
M-U-;3,\#?\%9_P#@G%\3/AQ\5?BYX!_:Z^&_BSX=_ [5_AOHOQ6\1:3I_CC?
MX2N?B]XZTOX9?#.]GT2[\)0>(M4\/>,O'6LZ=X>TGQ=H.C:OX4%Q-+/J&LZ?
M8VMW?VWX(?\ !.3_ ()"?M2_M"_L?_L(6_[8WCGPM\$/A=^SK^QE_P % ?@I
M\%OA5X<^!GQ(^&/[4WA;Q-_P4)\+^-?@Q\5;W]HO2/B!XBB\(ZE%\/= O+SQ
M+\.5\/\ AGP=JOC*XO=+U?Q>D\ES+JM_Z]X*_P""!_[2T_[-_P"T;\)?BO\
MM"? >Z^*_B[]G;]FC]GKX$?&#0M5_;*^*=WI7AO]E_\ :"^'O[0GA#3?B+I/
M[1'QM\>^'O!_@?4=?^&ND:1;> _@?X4\.^&O"B:_KNH:%ID=LJ:!<@'ZO_ML
M?\%@?V*/V#9-5T[XQ^.]4U+Q-X0_:$^#G[.WQ.\*^%= UVYU3X7^(/C-X'TS
MXJZ9XK\37-[I$.E:CX7\/_"C5;7XA:D?">H>(-3U#2_/T+2;6]\46E_I5KM1
M_P#!1OX,_#[6OVT/''[0WQZ_9L\"?LV_L^^*OV9-,^'WBO2;GXMVGQ0M+#]H
M+X!>#?BQIFC?&3PCXG\)00:MXT\7WGBBWU_X6Z3\%X?$=S)\/[Z6W\:Z3I?B
M?PGKS2_ _C/_ ()4?MU?$NP_:L^,'C[]HO\ 90E_:Z^-G[8/_!/K]M'P!<^$
M/AU\:/#O[..B^-OV'_#'AKPQ9_#SQGH5[XHUOXGR>#-2L- L8;?6=#\1W7B'
M7+K25U:[7PC)K*V^A][\<_\ @EG^TW\2?BY\;?VF/!OQN^ 'A[X_:K^VK^PK
M^W'\%=.\6^!_B)XF^"]Q\0_V5_V0]._9M\=^#_BSH=MJ=EXOTSP?XMUV_P#%
M7B?P/>^$-?\ $?BGP_IUIX:%UK5EXAN;V_T4 ^\/#?\ P5"_X)]^,/''[/OP
MU\*_M7?#37O'G[5&B:9XA^ 7AK3X_%DU]X^TG7-5US0="G>7_A&?L?@ZYUW7
MO"_B+1-&TWX@7/A74M6U;1;_ $_3K.>[@>(?4GP8^-?PL_:$\ 6?Q2^#'C.Q
M\?\ P^U#Q#XW\*V7B?3K'5]/M;CQ!\-O&FO?#KQKIJVNN:?I>HK)H7C'PQK>
MC23-9_8[W[&M_I5UJ&EW5G?W/Y)ZW^P-^WEX]_;._9>_:R\2_'C]E'X1>(O!
M!^&M[^U7XW_9B\)_M/\ @#XB_'O0/!'B7QGXCU;]GB_\$:[\8M7^!'Q+^!NL
M1^(M/LM \4_&WP5XB^,?@?48M1\0Z!XE6X^PZ<_ZM_ 31OC'X>^&=CI7Q\U;
MX5ZW\3(O%7Q(O+_4/@OX9U;PA\/9/"^K_$3Q1K'P^@L- ULM?VVOVG@2^\/V
MOC>Y9Y8-0\91:[?VUS?07"ZA> 'LM%%% !1110 4444 %%%% !1110 4444
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M4$XZT %%&>W^?\__ %_2C(H **** "BC.>E% !1110 4444 %%%&>W^?\_\
MUO6@ HHHH *EM_\ CYM?^ONT_P#2B*HJEM_^/FU_Z^[3_P!*(J /8(_N#ZM_
MZ$:?3(_N#ZM_Z$:?0 4444 8OB+_ ) M_P#]<X__ $=%7F->G>(O^0+?_P#7
M./\ ]'15YC0 44F1T_S_ )_Q'J*6@ HHHS_G_/\ GKZ4 %%%% !111D>M !1
M110 4444 %%%% !1110 449_P_S_ )Z\49H **** "BBB@ HHHS_ )_S_GKZ
M4 %%&?\ &C/;_/\ G_Z_I0 4444 %%%% !7<^#?^0?<?]?)_] 6N&KN?!O\
MR#[C_KY/_H"T =?1110 4444 %>;:W$9_$+6X;89Y+"#S-NX)YRI&'*;EW["
MX.W<NX#&03E?2:\D\::]I7A6YUKQ3KMP]GH7AC37\2ZW>16EY?RVFC>']/?6
M-6NH[#3H+O4;Y[;3[*XF2ST^TNKZ[=5MK.VN+J6&"0 _"O\ 8T_X+;>&?VM?
MB5^S)X/UC]D3XT? GP'^VI?_ +2>C_LL_&+Q/\3/@IXZ\-_$+7?V3[3Q+J'Q
MCTSQ5X1\(>(U^(7PQM]$L?">KK::WXF\/'2M2U)+:"RN)]&N'\0VWV_\.O\
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M#^$_"UG>6NM:YXE\7^)H=-O=:O-"\&^"_">E>(/&7B_4],T+3-4\0:S;>&M
MU1]$\.Z7J7B#5OL6C:?>7T/\]W_!,SX5?&"PT[]L'6_ 7C3]DSXL?M;_ !H\
M0?L7ZWXHN/B_-_P49^+_ ,/+WX/_ +.7C34O#^LZWXK\;_M3_#WP1K]QXXT/
MPAXWU&W^!7A3P3HYM/!_B;2_"[>)-<U?2;"/6M&_9O\ :3^"WQGUG]H+]F/]
MJG]GFU^$_B_QW^SIH7[1_@"[^%GQS\8>+_AKX6\;^"/VD[/X0OJFMZ3\4_ ?
MPV^,>M>!_'W@G7?@GX4EL'/PP\4:1XG\,:]XX\-7<NA7FIV.N6H!V$W[</['
MT6O_  6\+1?M(?"C4_$/[1V@>'_%?P%TOP_XAD\3S?%OPKXHUL>&]&\3^"IO
M#EGJMIJ?AZ77&73M1UI[B#3M F*R>(;C2K=A,?%?B%_P4M_9QM?V?_C9\<?@
M'XV\)_M#7?P2T_X3:QKO@O0]:UKP=<WWA_XP_$G1_A_X.\6V.H>(O"1N-2\#
M^(?M'B34/"?CGP[H^O\ A#Q3<^%-5TW3-;DD@N);7R3]CO\ X)X_$S]EWXI^
M"_'MS\3OA_JLNE?L>_M$_"+7->\-^&=5T^;1_CS^TI^VMXD_;"\2ZSX%\"ZK
M;RZ;_P *4\':MXRU/P]X7T/7/%T>OZEI?A[P]I>OZ=)'/<ZG!\7Z!_P2C_;;
M\1^'?C+<?&7XN?"[Q1\3?B9^R#^SM^SK>^-O$_[3_P"U5^T'J'C?XF?"#]IS
M3/C=X\^+VLWGQC^&FEV7P9\)_$;2[6^N/#_P8^$&@'P9X%\0W"Z6BZI:37/B
M.( _I!EMWCO)K1-TTD=U+;)M7:966=X(PJ[F +E5.S<<%@"V1@? /B7_ (*)
M?L\W_@S_ (2SX#^-_"?[0#V/Q^_9+^"6O6GA36=7TG2;73/VJ/VG?!_[->G_
M !&\,^*K[PQ<:#\0?#/A[4]?\1:OI^J^![C7O"OBC4?"%[X<3Q5I+77]J6GN
M?PY\4_$CXXZ/^T5!\4/ .H?"/P9J?Q9^+WPG^#LT/]M:-\1_%'P9TO1K+P'-
M\7-=T?7X%D\,:MXI\?K\2=9^&:16L-KK/POM?AWXV-L4\1J]Q\.^"OV3OVP)
MOV1/V?OV3/B3?_LOZ9HO[*WCC_@FS'\//$WP[\4?%S4[CXC^"OV)?VB?@]\0
M?'7B_P 3Z1XD^'.@Z=\,/$'C#X6?"+2+#P?\)?#Z?$/2;?XA7>J_V[\8[;PW
M+I]Q8@'OTW_!0W]F/P1X'TOQ?\>?BU\,?@_>>(?&'[3OA[PKH%OXPUCXCW?B
MK1/V5_C9K?P:^)'B'0!X<\$6>LZM=^%IK'2]?^)>@:?X;NYOA?%?:XFK:GJG
MAOP?KGB^/T;6?VM?@[X6\1?$F;Q?\1/A+X<^$'PV_9X^#O[1^H?&.?XL:%=Z
M1<>!OC-XL^)?AKPOK3Z1::>UM'X-UL_#U)/ 'C/2_$VNQ_$K5=8D\.^&-$>_
MT^&75/E;]G7]ACXH_!_XM?"+Q_XC\4?#K4]+^'GAW_@L!I&I6VB7OBBYU*>Z
M_P""A/[>?@/]J7X13Z6FH^$M-MFB\)^ /"VHZ%\3#/=6DVF^++FVT[PNGB_1
M99]<@^<O#7_!+W]H+P[\#_ '@BU^(WP7'Q"^%/[%/_!';X1>%;C4I_'NL> ?
M$OQ\_P""7W[27CS]HKQ%I_C.-?">FZW:?!+XJ3:EX8\(Z-XLTRRU+QMHC76J
M>*;KX>&;P[I^B^( #]#-;_X*(?L2>&?"GA?QMXF_:-\$>&?#'B^3Q<NF:EXB
MT[QKH3Z7;> -<L_#7CG5O'.F:IX3M=8^%OASPAKVHZ=I?B+Q5\4--\'^&=)N
M-0LGNM56"XCD;OOA'\?Y?BG\>?VP?@:?!TF@W'[)_P 1?@O\/WU\ZX-4;QY<
M?%[]GWP#\=/M\>D)I5E_PC0\/R>-_P#A%!9?VIX@.J_V;_:XO+)KK^SHOS@_
M;N_9$_X*+_MH_#W5_#EQ\0/@=X0TWXB?LW?M(_!CQ+\$?"?[5?[7?PG^%?P^
M^('Q/>PTSX:_%O7_ !W\*OA7H_C']L6#1O T>M>$?%GPH^*_A'X2_":&ZUUM
M4L_!WB:S&JV.K?=/[-'[/'C#X*_'K]LWXJ^)->\,ZEH?[1_C_P#9J\6>"[7P
M_+JUQK.A6/P7_94^%GP)\21^)[?5-&TNPAO-1\6>!]4U?P_%I-]JT$^@7-C/
MJ4^EZD\^F6X!Y[\1/^"HG[$_P^^&&K?%ZT^+H^)O@K0?C!\&O@KK-Y\(_#'B
M?QS+;>)/CC\2K+X9>$-?LVM=+M;#Q%X"COCXAUN3QGX6U#6]&\2:3X'\7:5\
M.I_&OCBRT[PAJON6D?MB?LQ:S\7- ^ FG_&;PS+\8O%,6F'P_P" KK3_ !5I
M.K:CJ&M?#:U^,FE^%Q>:QX=T[1+3Q]>?":\M_B2GPWU#5+/X@1>#)/[;G\,Q
M6L<C)^:_AG]@3]K/P]^SU\;OA-H%_P# ;X?:$_Q0_8&^+7[,/[,&C?'KX^_$
MG]F_X9>+_P!C_P#:B\-?M(?%:/PWX^^(7P8@^)GP(^&?[1">"_!GA+PS\$_!
M'@[XG^!_@%<>&#J7A22_T[7+W1+3;\?_ +#?[:WQ>_;0^%_QU\??$[X?ZU\,
MOA[^V-\&?VF_#V@S_M-_M,3V'P_^'G@_X#CP'XH_9Z\ _LQVWPY\.?LY:UK]
MA\5=1\7>-]'_ &E/&EY'\1/'6E^)#9ZIH_P[D::SB /MOPO_ ,%"OV(_&?BO
MQGX-\,_M,?#34]6^'G@/QC\4_&FHFXU[3_!&@?##X>ZU<>&_&OQ(G^)VJZ%8
M_#.[\!>'?$5G?Z#>^,-,\7WWAZ76-.U+3;+4;N\TZ]A@]F^"G[0/P9_:,T'5
MO$?P2^(&D>/].\/Z_P#\(KXFMK&TUO1O$?A/Q,VG:?K5OH'C#P9XJTK0/&7A
M+5M0T+5]'\0Z19>)- TN76?#FL:3XATD7NBZG8WUQ_*7^Q-^RY\4/VB?V?H_
MV0_$-OXKG\;^-_V&= \/:C\:/&/A[]M'P%:?L+^)_@Y\9_@E\9_!7[)GQ"^'
M/Q,/@[P]X8M?C=X^M-4L/%FA_LS^-M%\4>$-!^#.HV/@R^/@#P[\,M2T+^CO
M]B[]G?7/@;-\6?&GCGX>^&O /Q,^+?B/P3=>*=0\/?MB?M7?MOZSXETCX>:%
M>Z/X4NO$?Q9_:XT3PCXKM[O0UUC6K+0_#?AWPWI^C66C2VRZAJ6JWJI_9H!V
M>D_MP_LAZ[X/^*_Q"TC]H;X;WW@3X(WN@Z?\3?&$>H:C'X<T.Z\6>)-2\&>#
MO[)U6XTN&U\=VWC;QMH^K>"/ ]]\/'\66/C7QMIMYX0\*W.K^(H6TVJ>H?MW
M_L=:5X \$_%#4/VAO %MX*^)/B/Q9X)\!7^[Q!<:QXK\?^!$OF\9?#;2?!EI
MH5QXY?XG^&WTS4;?5?AI<^&K;QW!>V5S8KX>DNXS#7Y?ZA_P3!_:9\1_#3QS
MX&B\6_#+X.>!?"GQF_9;^.G[-W[+WPO_ &G?VK=1^!?ASQ_\"O'GQ!\1?%BX
M\._%:'P3\.OCI^R1X"^./AKQAH&G^$OA3\"SXX\,_ 3QWX*TOQUX5NM6L[K4
MO"M_].?"/]A3QCX.^*G[&OQ:D\,_#7X<WOP:_:<_:7_:(^.F@67[1W[27[5/
MB/QEJ?QG_9/\1?LU>&=9T_XX?M'>%]/^(/C_ ,<Q0MX1_P"$ID\16/@/P]HG
MA/2FTOPU%J]U8DZN ?70_;3_ &3)6^""VG[0GPTU1/VD=)TKQ#\$;G0-7N?$
MEGX]\-:WK.C^&](\46M[H-CJ5EX?\,:EXH\0:)X0L_$7C&X\-Z+-XRU.V\'K
M?CQ+YNEQ^*6__!1_X%:5\3O@+\&OB#'K6@^/_P!I#XG?M1_#CX<2_#^RUKXO
M^"+>;]F#XT^(?@OK,OBSQ=X>\.:5+HWB#Q%KFA^5>>%K/0]6_P"$!UZ/6-$\
M9ZUI^E:5:>*=6^0/!G_!.G]I[X;:'^S%9?#?Q-\%OAU\4OA/XY^(=WXI_:A\
M%_%SXV:#X[T?X1>/_P!M_P"(/[2GC#X*ZE\#8?A=-\)OVK_AS\0OA3XKM/ U
MCX0^,>N?#NV^"/Q1OO$GQ%\#:OKKBRFN?:_ 7[%OQY^%?CW]D7XF>&-4^#WB
M35?@+^UK_P %./B/XX\)ZWXS\>>&=(U3X(_\%!_VC_BC\6=&U+PEXCT_X7^)
M[N_^*WPN\*^(O"*ZAX&U[PWHOA'Q'K[^)=&M?B3IEI9:7XFU$ ]]\/\ [?\
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MY9_'2;]GH?$K56\;CXHK\#X]?_X5I\4Y/@VOQRN/#Z>+-/\ @1=?M%1>!Q\
M;?XX7OA^6"XMOA;-\1XO&4FIS1>&O[&_X2J1=#JIX$_;N_94^)7Q/M_A-X1^
M*4MQXBUB7XDV_@KQ%K?@#XF>$OA#\5[GX-375O\ &&R^"?QV\6>#=%^"_P 9
M[SX4R:=J[>/[7X8^._%4_AZWT#Q%>W*O8^'-=N;#YZA_8:^,\7C/4? #?&SX
M<O\ L=ZA^WG!_P %"&\,GX;Z^O[1W_"PX/CUI_[6D/P>?QNWB9_AS#\/8_VF
M],L_%/\ PG,'A/\ X34_"R*;X3?V8UQ>S_$$>7> /^"87Q%@\)_L]_L\?%_X
MZ^#O$G[)W[(/ASX]^%/@38?#SP#X@\+?'WQGH?QK^ WQ@_9C\/P?&3Q?K7B7
M6?!FE7GPD^"WQT\?Z9]N^'>AK/\ %#Q[%X7\=ZD_@>UTK4?">N@'T'\$_P#@
MHG\*/VD_VG? _P $_@8^H^*_ 7BG]EGXG?M(3?$'Q+\.OC!\+[_5-.\.?%3X
M)> OAKKWPZL_B?X*\&Z=\1O@Y\3]%^)7BO7_  ]\4?""Z_X;URX\))#H6N7$
M/VS.GX>_X*,? F]^*_[:OPQ\9Z;\2_A;I7[#FO\ A?1OB3\5O'?PP^)VE_"[
M7XO$OP[^&GC>)O#WBR7P+#HC>([O5/B;I/A/P'\/[34]7\;_ !B0:9XU^%FB
M^)?!_BCP]J%UQG[+W[(?[3'PP^,'P2^)'QY^./P5^(VB?L^_L6^)/V,? ?A[
MX3_"/Q?\.[_5]-O/&'[/OB&T^+/BJ^\2>.?%=G%X@\2V/P2CM-?\#:'96GAW
MPE=_V</#VK:Y;W^J/:<'\?\ _@FUXO\ CIJ/_!0+PVWQ9\"Z'\)_VY=?_95^
M-,$&I>!/%&N>-_AY^T'^R38_L\:5X'LM733O&7AW0O&?P&\4P?LV^$+SQKHN
MF7W@GXDL/$7BO2]!\7Z05T;6]/ /I27_ (*$?LMP>#E\62>)?BD-6/Q,7X-M
M\&D_9K_:1D_:>B^*/_"OW^+C>#)_V5(?A1)^T5#J*?!V*3XR&X?X9'2I/A*A
M^(4&HR>&'34VT/A#^VO\./C/^TM\>OV9?#'@SXQ6FN_ C2OAEK=W\0M;^$GQ
M/T;X5>,]-^)7@N'QI;3:-X^UCP3I?A'2GLK2ZM;?1K;6O$4=]X[C:_U/PC:Z
MA8:+JAM?A[4_^"8WC*;]GGQ9\._"_@K]@_X??%+QK\6+'XD7OBSPIX4_:[LK
MSPGK/AOX:7WP^^'_ ,3_  #\<-/^/^D?'SPS\<O +ZEJ(TCQ1X;U3PIIES\,
M]7UCX0[-/L]5U'Q?>_8'[/W[,'Q<^!GQZ^)'Q%U7XS:+\8O!OQ@^"_[-7A;X
MC:WXX\,:MIOQQUSXR?LZ_#JZ^&!^(C:GHNK-\/Y-"^)VF7">+_$^E/HUOJFB
M^*WU6TTR[O\ 2M0L9M& /%=)_P""EV@6?[1_[9?@;XF:'-\-?@/^R3XU^$WP
M0LO%%_\ !S]J+5?BM\8?CK\5O!OP@\4Z%X=^'VDV'PI;PGXJN]=UGXM6?@SP
M%\)? @\:_%OQYIEAI?QDT"UN_A/XJTC6G]NU3_@HY^R%HW@3PE\0+WXA>,?L
M?CCXI^+O@3H'@JR^!/Q^U7XU#XY^!?#&J^,O$OP6UOX :9\,;OXU^%_BI:>&
M=)GURS\%>)? >E:QK&DWNC:AHMIJ&G:YI.H7/E'Q._8+\>>)O'7QL^+_ (!^
M+'A'PS\4-<_;H_9S_;D^!)\5^#]7\2>!- \1_ []CSX4?LB>(OAY\7=%T[5=
M)UC7- \?^%/"WQ&FLM<\%ZOI>K>$+[Q5X/\ $<":K=^%[_0M1;X(_82^)-K\
M;/A%^TE\2OBMX+U[XMZ=^V1\4_VN_C;9>#/"?B30/ E_)XH_X)]^)?\ @G_\
M-OAK\([+6=9UC7K&Q\"^ ;;X:ZWXB\4^--3FU;QGKFE^,];2TT"/5]#\,:,
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M7?%G]LS]L;PE^V/\1?%7@ZQ36=8C\(_#K0_%5CXQ\*>%?#.H:CKGB2ST*_\
M#$FHZ[J5]8:M>7(!ZMX6_P""@7[(/B\^-+BP^,<6D>'/!'P\\??%Z?X@^.?
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M 4444 %=SX-_Y!]Q_P!?)_\ 0%KAJ[GP;_R#[C_KY/\ Z M '7T444 %%%%
M!7FNN))+X@=(9!%*S68CD+F-8V,:$2/(H+(L>W<77+* 6 ) KTJO+O$[7":K
M?O9O%%>);Q-92SB8P1W@M2UH]Q]G9;DVZW C:X%NRW'D"3R")-E 'XR?#S_@
MMO\ "3XF_LU_&_\ ;*\/?LY_MN6'[*/PD^$7Q/\ C1X1^/OB+P-X"TSP!\??
M"_PG^(4OPQ\1:1\,98/BY?:UH7C*_P#%%O>S>'?"_P 5-(\":AJ?AW2M9UN=
M+$:1=VA^B?V-_P#@I!X6_;#\:?$WX6?\*>_:5_9L^+_PJ\#_  M^*FM?#/\
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M?CB/1M/\-2W6JZM=3Z5<WUO))#)+%:?S_P#[1_\ P0O_ &Z?C-<27WB;XB?
MCXQWOQJ_8M_9F_9V_:%T_3/B=9?LP^!_#7Q'^ !OKBXU'PIX<TW]C#XTS:]\
M']8UR?2?&-KX=^%*?LX:V?%NFZQ=OIVE:?J>EV-C]%_M1?\ !(;]KCXH?$SX
MM?&GX8>//AUIWB./_@J!XE_;3^%_@EOB<W@E/&?PS\5_LI_#WX [M7\:^)O@
M#\<_"_P_^+G@[Q!X4U'6/#']O_"'XCZ+_9.JZWLU'3-2O+*Z< _=+QM^VU^R
MC\-?!OPO^(WQ#_:^_9^\#_#WXW^4WP8\=^*_CQX!T/P=\6XI([";[3\-O$M_
MXHATCQI8PQ:IIDE[J.@7=[I^FIJ5@=2N[/[9;^9\8ZO_ ,%AO@#XW\)_M0)^
MRGX[^&?QN^,'[*7QP^'GP8\>?#?XB_M&?#7]GWP]JMMXM^+'PK^%NO?$[PY\
M2O%.NZ]HEW\.M(U7XF?V#X9UF\L;&Z\>_$K09_AMX>TVX\2:EHUIJGYU_"S_
M ()+?M7_ +,]E^RAXL^$_P '_P!ASX\ZO\,?V7/VKOV:O'W[/7[57Q:\;>*_
MA7\/K_X_?M7^*?VE= ^*7@3XB:=^S3#:_$"^ELO%$O@KXLZ%;?!;X5)?Z;:R
M:+X-EDT:^34=-]!^,7_!+;]J7Q%X8_X*F?";X?:!^S!;^"/VROVS_P!GO]L#
MX,_$V;QKXA\,?$*V'@?XR?LK^-O'7PD^(7A*T^%=Y8:!X=T/1/@QX[USPWK6
MF^,?$ UWQ;K.E(WAS3FUS5]3T< _<VT_:2^ WB*T\"WND_'KX:>(-)^*7Q)\
M2_"'X775OX_T6\A^('Q5\%WGB>P\4_#OPDAU"1M6\<>&KCPAXJA\0^&[02:G
MI#^']4^V0Q+:,QQ_@M^U#^S1^TF?&<?[.G[1'P.^/<GP\U#3]+\?)\&OBKX(
M^)4G@J_UAM131H_$Z>$-9UAM&BUA]&UA=&O;M5L-7?1M873+F\?2M0%O^(K_
M /!&_P"-VM_MQ?M9^*]2^*7@7P?^Q1XNTO\ ;S^)G[)5IX8U7Q+??%WX<?M4
M?\%(/@-\*_@K\=/&_B[PA%IN@^&;;PKX%DTOXQ:[\.H=+\07>IVL?CV^%M?6
M]SXGU2TTC>_X(^?\$M?VA_V(OB@WQ+_:+3X>W/B#PY^Q[X&_9*T37O 'Q_F^
M)FG>)='\'^-/#_BNUN=(^'EC^R=^S?:> ?"-E/I6J7VE1^-O%/Q=^(<5YK7]
MG3^)UT^.^NKD ^P_B'_P5J^ /PW_ &>?^"@_[26L?#OXU7O@K_@G#^T%?_LX
M?&+2-.TKP4WB/QKXVT_7OAKX?DU?X8I=>-(-+NO##77Q0T2;SO%>I^'=82QL
MM3G;3!<16D-WQW[0'_!8_P"$W[.WQR_:N^$>O_LK_MG_ !"\$?L07OPHC_:?
M_:(^#_P^^'/COX6?"G1_B[\-_#GQ0T+Q;K?AX?%+2OBO>>%?#_AS7I;CQIJN
MC^!M2'A^R\/^(-9E@GT>TBFN/S$_:@_X-\O$O[0GPE_X*T:_>Z!\++W]K7]K
M+]KWQ)\8OV1/'=S\>OCCX=\%>%OA'KWC#X4ZK)I/Q7\*:!]D^'J^*AHN@?$*
M6&VU/X<^.Y(=5U/2K3_A)O(M]+O=*^L_VA/V&_\ @HWJWQ^_X*^2?LXZ;^R)
M#\)/^"IVE_ GP3;_ !E^,'Q>^(]EXR^"7@SP7^S#I?[/GQ.U*/X%^%?@[K4'
MC;Q1J-EJ_C8>"5NOB;H>DV6HVN@:SK5GJ6G3W&F  ^Y_CY_P5&_9B_9Z^-O[
M'GP0UJ3QIX^E_;,M_"FM>#_B7\,].TCQ!\+/AEX&^)7B;PQX#^#/Q&^+GB6\
MUO39_#_@OXU^.O$J>%_AWJFF:?K+:AJ&BZX+^VLFCM/MU#XY?\%-_!/PI_:#
M^(7[,7PO_9@_;#_;(^+7P/\ "/@KQM^T3I/[)OPS\'^-+'X":1\2=+DU_P"'
M6D>-[_QU\0_AZ-2\>>//#$-SXL\+^!/!L7B/6M5\/VT]Q$BW-O<6<'Y:?%?_
M ((4?'_XN?#W]L7PG!^USXJ^$=IKGP%_9@_97_9'\">$9_AKXE\.>)/A)^PA
M\._"6J_LW:W\=/'?B/X)S?%#X4:WXG_:=T77/C#XLTKX$>)M'G\,_P!N0BZU
MKQI-I%B8/JGP1^S=_P %4?V>/VB?VDOVEO@SX;_8@^+6O?MV_#?]F/Q9\<?
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M%/Q3HWPUB@^+<DGA_P .V^DW_P ']3TCXB66I7&AWHEK\7/V3_\ @B-^VO\
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M"'7;3P5I5UJ'@Y_"EMX>\/7&N^++&QU77Y?$&LZU?_HF.Y]23Z8SV [ =
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ML_\ !2;]HCP-HMWIWQ*TK]HWQSK_ ,8/C'^W)\'?#GAWQCX.\2>&= \)>#O
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M^Q1^TA^SW\-/^"7NK?"C6O@'X[^-O[ /[)WBG]E+QKX+^(WB/XC^"/A+\4=
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M/CWPJ++P_-)#?P:KXI\"AO&GAGPWJ,=EXEU_PHDGB#2-'O-*1KH9OAS]N/\
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M4\1^%+'P1XQ;PCIRE-/UGQ?,5@6G^PA^P9JG[#/Q4DU;P4WA"?X5?$_]E_\
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M-&\46_@O0XH=3FZCQ7^P]\2=9\9_M >*M+O/A5;/\5_^"LG[&?[=7A^[GO\
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MABY^"7_!#W]L'_@F/X'UKP[\?+;Q?+\5_C=\1?#7[,WA;P7XZ6TU#P-X/M?
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MW[\4KM))Y?F2R2>5&L4?F,S".- =B1@G"HG\*#Y0,@?>?<44 %%%% !1110
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M68O%FLZC9O>ZS=>'K>5/">@>*O$,^G^'[[SSP)_P46_9L\3?M'?%W]F/Q/\
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MI=YXYUGX;0>/?$EK:^!+#3=/\3^)?^%1:*=>\6_VK<:9X)\.>'KFULK+Q?\
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MH6\$G]GMJ*6,.N:!)J/\G8\*ZGKOPC_X*!_#GX'^)_V5OV'OV=/CK^Q#\4_
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M?TV672=?UG2+R*T34-.U*XLKJ*6OP+_X+EZI\%OVV]*_9?\ !_@?]I']EO\
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MI\,=0^(D=S9:7>>*8=8^*\OCBZTR^\):?%\-TU2#PK?V&HZMXPNM+TV!%?\
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MCG4W\0"Q\'V7BB>SNX/#EUXDN-,M]=GM;F#2I+N:WFC3^?;X(_ OQ?\ &O\
M:0_:.M?A]^S=X:TRZ^'_ /P7UUW]H'Q3^W ?$'PLL[SP5X&^!EM\-]>\?_#%
M;"VUBW^/%[XY^(FA2:A\$=,\/Z1X4U_X;WG@+XN^,=;\5>+-"%M>^'M0[#_A
MVG\8O!W[)'[(&F>!_AD_A7XE_"/]L?XV?M"_M/\ @+X(O^RG+\9/C/H/COQ%
M^UEIGPV\2Z#KO[3/A;QW^S%\2_B'\*)/C7X%^)'A3P_\<VBTKPUX?MM=M_A[
MXC\$_$KPQX*6S /Z&-.U/3M8L+#5M(U"PU?2-6LK;4M)U;2KVUU/2M5TV]AC
MN;+4=,U*QFN++4=/O+:6*XM+VRGGM;FWECFAE>-PU:=N?])M?^ONU_\ 2F,?
MS!&?8U^=7['7[)?B#X*?"/X :'HWQ1_:Q^#GAOX<:I\:/$>N_LW>-M5_8A\3
M:=XOO/BI\=?BU\6)(/B_JWP<_9XOM%TADG^(2W&@^$_V9?B/\//!/@+PW;>'
M/ M@VIR^'=5U?7/T3M<_:+7/_/Y:X)&"1]HBY(R<$]<9.,XW-]Y@#V*/[@^K
M?^A&GTR/[@^K?^A&GT %%%% &+XB_P"0+?\ _7./_P!'15\Q_%'XV?!/X&Z9
MHFO_ !T^,_PG^"'ASQ%X@MO"FA^(?B[\1/!WPXT?6O$EW;7-[#H.B7_C+6]#
MM=:UHV%G=ZB=(TR>>^.GV=W=21100M/%].>(O^0+?\9_=Q_^CXJ_+W]IGX0_
M&[4/VFOV5?VG?@K\,O@U\9[KX(?#G]JWX/>)/AQ\7OB/>?";R+']IR[_ &<+
MVR^(WACQK;_"SXLP)_PBY^ VH^$_&VC_ /",OKFH> ?B%J[>&8==U*PE\-ZV
M 4OV??\ @H?\(/C;\,OAI\6?$L.@? GP;X^_92T_]K;6=8^+'QN^!VC6WPW\
M#7_CVZ\!/8^,M,O_ !OI/C:PTRTOK-[R;XJ7G@S3?A*9I(_"Y\7#Q<?[&?WJ
M7]KW]DJ'X3VWQZG_ &J/V:X?@5>>(Y/!UI\:IOCO\+8OA)=>,(;FXLY_"$'Q
M%D\5+X2F\5075G=V]QX;CU5M:@EM;E9K%!#(5_&+X6_\$W?V[O@I\'_AOHGP
MQ\4?!'PW\6?AO_P2X^&?[']GX@3Q+9WFG#XI^$/VN[7XM^,['PB?%GPM\>>'
M_#MGX@^#<>LZ3\,OB5XC\$^,-*^'WQ'U+PYJVM>!]9L?#MU!<?.'QW^#/[2/
M[,_B;X9^/OB!\4/!/[,'C3XJ_P#!0SXK?M%>!OC?\5?VM]/UO0?A)H=M_P $
MN?A_^RR+'XL_MG_%S]D_XK_"[PY\3O'>J:9XQT'0?!OC#]G'QEIOBK2I+C2?
M /CVVO\ P)H_B;Q* ?T%7?[=?[#MAX>\,^+[_P#;2_9&L?"7C73X=6\%^*;[
M]I3X,V7ASQCI-SXI\0^!X-5\)ZW=>,X=-\1Z7-XT\(>*_"2:CH]S>67_  DG
MACQ!HS3B_P!&U""W]$\>?M&_L\?"OQ]X0^%/Q1^/WP/^&?Q2^(4FGQ> ?AI\
M0_BW\/\ P5\0/&\FKZTWAO2%\(^#?$OB'3/$/B+^V/$2/H.CG2=/NAJVM*VE
M:<;F_'V>OQ0^ G[)^L_'[]GC7?'WPL^!VC_";X;_ !'_ ."*/CO_ ()X? OP
M)\5?&6H^+/%^F>,-+^)'Q_\ #&C:F_BSQEX%\-^*]5^"?Q<\-7'@+XC>&OB;
MK_AOPIJ7C?P/XB\*Z_XA^'NC70&EZ7U/Q?\ ^"??[6GB?P7^V?\  G0- ^ /
MC;P?_P %#/@[^RW\/_&?QT\>_$G7K+QA^RYJ_P %O@#X(^!WBY;;P0WPX\0:
MI\8]%\,:IX1U#X[?L\KX8\7>$VA^-?C?Q=/XK_X06UOI?&VH 'ZH_%']KGX#
M?#>T^.^DVWQ3^#_C+XM_L\?"_P 1?%CXC_ 73_CW\#?"'Q1\.^&/#V@V/B&2
M[\9V?Q%^(/A31?A9H]S8:QH$\_C'XIZIX1\&Z'9>(-%U7Q!K>G:;J-I<S^D6
M?QO^"=]\6-5^ EA\9/A/??'?0M#MO$VN_!*S^)7@F\^,.B>';NRL=4M]=U?X
M:6FN2^,;#1I-.U73-0CU6?1DL)=.U+3M2CN'L-0LKF?\=?VC_P!A+]KSXF:O
M_P %$?!OP7T?X:_";X(_M9_L[?MB^'-4\':_\<F^)'AKXQ?M'?''P7H'@WX0
M_&#P7X;U3X,:%XK_ &5-?FT[2=2N/VG;&P\?:Y\-_&&N76F2:!X0\7ZE%+\1
M;'ZV\(_ ']H;PG^W_P"./C%X,T7PY\,_V<?B'K/B#QG\<;1OC<_Q1TC]H'QE
M+\&?#7PN^'?C_P %_!+6?@]HNN_LW?&O0G\'>$--^*/B7PM\63\._'7@;PS<
M6FI>&/B#XI\66/B#P  2?M3?\%)-#_9:^*]U\*6^#WC;X@VOA?PU^S_XP^*6
MK:+X]\!^#]6AT+]I[XRZ]\"/A+I7P.^'GBG48/$/[2/CYO&GA;7;SQQX+\.2
M^$HO#NA?V!9Z-K_BOQKXJTKP?)]9_M.?M!_"S]D+X%_%O]HOXZ^(D\*_"WX+
M>&;[Q1XTU9/L37T\4-S;Z9I6B>';35+_ $BVUCQ3XKU[4-)\.>#M!:]M+GQ+
MXAUC2=$T_??ZG:1-^47[4W[#?[9WCC]M36_VH/@I>?#.^^(FAZ]\']7_ &.O
MV@O'WQC\0:7I?['/A#P_\+E^'G[0?P0\;?LS7/PP\8^'OC!\-_CSJFL>/?B!
MJFJ> ]9\-_$'Q3XD\5^&;34_&WPQOO@U\-/&FF_0L_['OQC\8_\ !'?Q'^P1
MKDGA3P?\<M<_8@\9_LJIK&L?$[7?BQX/F\8P>!]<^'/A_P >>(/BBGP_\+>)
MM>T?QV\&F>/M<O#\.=.USPR/$ESHTGA^\O-"EM[@ ].O_P#@I3^Q[H?QE_X5
MIXF^/WP#\+^!=4^!O@+XV^ ?V@O$/[07PFT?X/?$]?'GQ;^+7P?3P+X!\1:K
MXBLM,\2^(="UOX2:O>:C=Z/J]_;"._ATZ6VMKVVD,GU!XB^/GP(\&_%'PM\#
MO&'QO^#GA/XV^.((+GP5\&_%'Q2\"^'OBQXQM[E]0BM)O"WPZU?7K/Q?K\=[
M)I&K+8MI>D77VYM*U,68G.GW8A_-CX[_ +)/[0?[3FJ?MF?%#Q;\+?A+X#\;
M?M,?\$B_$7[&7@_P3J7Q,TSXBOX)^-WB#QY^TUKUYH&H>.8? 6E6J^ -5TSX
MA_"W4]:\4Z5IZV;ZM936$FE:I+X1LM6N/+M7_P""=?QMU#]ICXB>*/&>BS_%
MCX,_'WXB?L5?%KQ;<:'^V5XW^"=GX \6?LG?"W]GCPFEGX]^%=G\'_&-S\97
MT;XD?L_:;\7OAGK7A_Q=I/\ PD6L>([WPKXOMO 5G97/B[7 #].M=_;3_8T\
M+7'C*T\3_M??LK^&KOX<WITWXA6?B#]H?X0Z/>> ]37Q3JG@9M+\96E_XP@N
M?#.J#QMH>M>#?[-UF*SOSXJTC4_#XMSJEC<VT=_Q9^U]^R1X"\&^"_B+XZ_:
MK_9G\%?#SXD>'=0\8?#GQ_XM^/GPI\.>!_B%X1TB[\/6&K^*? ?BW5O%EIH'
MC'PYI-_XN\*6.IZWX=U#4=-T^\\3:!:W=S#/J]C'/\":C^R9^UA\/OV?/&_A
MWX(0^!=$^)OCK_@I=^TW^U/\2T\#>/\ P[\*/B'\2OV??C'\8_C#XI\,:1X2
M^/6K_"?XA6OPU^+C>&/$?PFMO$VL77A:37;?X;^&/%WPI\+>/?"NI7V@ZW:_
M&7PD^ ?[4O['OQ<_X)3?#V+X-_!OXZ?'?X>?"O\ X+F^.]=\'ZW\=M6M/#-K
MI'Q\_;0_9P^)VAWGA+X]ZW\$;V75/&=OX1^*NB:9XBU/Q%\-? \OB#PY>_$F
MT2*VUAK7PQK !^^UQ\??@/::-X]\277QO^#=MX<^%?A;PYXY^*'B&?XH^!HM
M!^&W@?QCH,GBKP?XT\?:RVN_V;X/\(^+O"\4WB/PKXDU^ZL-%\1Z%#/JNCWM
MY9033)9^+OQP^"G[/WAVW\7_ !\^,7PI^!GA*[UB/P[9^*/C)\1?!_PP\/7G
MB"6SN]0BT*SUGQKK&BZ?=:R^G:?J&HKIEO<27QT^POKX0&ULKJ:'^?2']@GQ
MG\%/B#_P2J_8FD\7^'O&>C_%G]FKPS\._P#@H!'I,'B*?1?$_P ,/^"9WQ/^
M'_[5GPHU+P8+^RTU(OAQ_P +G^*6M_LI3V_C8IK'B#X.?&71M'L_#:QZ/K<>
MB?K9^TU\+?CQ-^TU^RK^UK\#OA[\-?C5K'P#\"_M/?#77_A-\1OB0WPDOGB_
M:.N/@3J%C\4OASXZNO GC_1++Q;X0?X-:AX.\1Z3K%AI,^L?#_XB^(1HNMM>
M6$^@>)@!/&?[??PBT7]KK]FO]CKP-JOP[^)?Q$_:'^'&K_&T7UC\>/ACX<@\
M/_!FTN=%M/#_ (K\':#>7FI:S\:=?\;VNIZUXS\)>#_ JV[ZM\,?A_X^\;V>
MNW,6C66EZE[]XR_:?_9F^&OCC2/A?\2/VC_V?_AW\3==O/#VG:+\.?'OQI^&
MO@WQ]J^H>+6,?A6STWP=XD\3:=XBO;GQ1,K0^'8H-/D?7)QY&F_:IF5&^!/V
M)OV$?BY^R_\ $S]G77?%.I_#._\ #?PV_8C_ &@?@WXO@^'-[K%EX8\,_%CX
MX?MB^#OVE+?P!\)_#>M:-IVKM\#_ (:>'HM?^'OP_P!7U6+1+Z'PUX8\+65S
MX8TB2]>RLN?_ &OOV _B=^T#>_\ !4N?3/#GPGU^U_;!_9B_8?\ @Y\&K7QI
MJ-G*#XC_ &??&?QG\5_$&W\:P:CX;U&W\.:!%=^,_!FJ>'+A&UE-4U>QENTL
M;2[TJWGF /T1TK]J[]EG7?A5XG^.^A_M-?L[ZU\#?!.J?V'XS^-.D?&[X9:E
M\)/"&MF]TC35T7Q/\2++Q//X/T'5Y=1\0:!8V^EZIK%K?75WKVB0VMO,^K:<
M+GR_Q!_P4*_8H\/>._V</A]=?M-_!6_U;]K.V\87?P"UC0?B?\/M<\&>/8?!
MUS#I5P^F^+=/\5/IES_PD?B>6;P/X(72VU0^+/'NG:MX.L FN:=<6R?#W[4_
M_!/GXZ?%#XO_ +1'Q:^%]QX4TVVU+]L7]C;]JGX8>#=*^*>L_!W5OBA9_ 3]
ME'5OV=/&N@:I\0M \%^*9/A#XYT:\UK3?%OPO\2WWAGQ7I=_J_PQ\$Z7JQ\.
M:7<1>(?#?3_##]C3XU?![Q;^Q9\6_ 7PMT*#6/AW^T%^UW\1_P!H?X9^/?VN
M/$OQ.\2P6W[9%O:V'B_XI^'_ (Q:O\(](TOQ5XMTW4]+?Q_XJ^&&B^'O#6BS
M:UXIU73_  OXOU>]MKO6M3 /T,\)_M5?LL^.YOB5;^!?VG/V<_&T_P %]+U'
M7/C%#X0^.?PN\2R?"70M(EU*WU77?B:NC>*KT^ ]$TNXT36+;4]8\4?V7IFG
MW6D:I:WEU!<V%W%%Y)=_\%%?V'X?B+^SU\,K+]J+X'^(-;_:GM/B%<? _6?"
MOQ5^'?B3P3XSN?AOX@T3PCK.B6WB[2O%<VF-XCUSQGK3^"O!>A67]H:EXJ\9
M>'_%OABP@35_#U];K^77A3_@GQ^VGXY\3:_J?[8/@WX8?M":7>_L5?M<?LP>
M/-!U#]K?6?"W@/XV:]\<_BU^S5XPT:V^$_@KX>?LW>$8/V//A2WA'X2>(4\+
M)HD?C7QIH/BRU\*IXUE?4M'D^)_BKZ'^#O[-?[?'A+XE?L6_'#XK3_#_ .+?
MB'X)_$7]K_PIXI\,>)_C%IJ?$WPA^SI^TZ?@_9>!]<\6?&+PS\%_"WA/]H'X
MN_"33OA5>'Q=)9>"_!6H^+-/\2>'=%B\8>,/$'A77O'?BD ^PO'O_!0_]B/P
M%\)?C_\ &IOVIO@-XY\&_LO^$KGQA\;;7X4?&'X8?$CQ1X-LUO;S1]'T>_\
M#GAOQA/=6WBGQ?XILY?!/@G1-0DT^;Q3XX:+PEIC3ZU+]EC[?PU^UO\  GQ?
MK-_-X7^*'PF\0?"O3?@(?VB;CXZ:/\=?@IJ?PYC\!VGCKQ7X"UR_OH;3QY)X
MKTKPYX<U'P9K[ZU\3]3T.V^%-K>Z5K?A<^,4\6>']6TBT_%O3?\ @FW_ ,%
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MX;;Q1);?#SXM_ OPQ-\)[[Q-)H^L_#NUTGQD^@ZY!J&EVVK:2/JC]N3]G_\
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MW^R'X)U:;4=9\ >/O$7@X^,4U'QUI_@/4_'7B#Q3=?$[5+'PRX!^I&G?M)?
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MA6V,0"&&&_A^95R<'C/%8?\ PBVE\_+=CG.!<G'//'M]>:Z6B@#FO^$6TO\
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M"%SCU)S6A10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>forms-1_003.jpg
<TEXT>
begin 644 forms-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $G G # 2(  A$! Q$!_\0
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MH>&M"\>:'X-O=7C@\2ZU!-<6&GB-V>=(?O\ S ;5_P"!>C5I>(O&FA>$]/\
MM^KZM9:;9)/#;-/<3*B"29T2),_[;.F/K7A_Q'_9T\8>-/BM<^.K+QC9V4]I
MJ>DW&EZ;)8B2/[-:99XWF^^F\W-[]S^^E<-<?L/W\>@W%E!+X<FGFL8?-CNK
M1WAO;R'6OMZ23_)\_P"Y+P[_ +_[Q_X>* /J?2O&>D:Q;W]Q:W9DBL[R:SEW
M1.A\Z+.]$W#Y_NG[F:L>'?$VG^)-%TW4K"X\VUU&%;FV\Q&B=XV7<#L?YNGM
M7SYH?[,?B'2?B FO2W.@:M:M>:K-]COH'D33OM=U]I6>VX_UR?ZO^#Y-OS\;
M*\^\%_LE>,K7Q[I\4\FE:=#X<AT..'Q,UNSW5P]GICVSI;<_ZEW?YT?9]S^/
M^  ^OM4\:Z#I-]H]I>:O9P76K736>GQR2K_I,R([NB>K;$?CVK3;4[6.&:5[
MB,11/L=M_P!U_P"[7R'\//V-?$WAF;1[[5-1\.ZEJ-AXHAUG8UJ_DQ(-,^QS
M/#\B>7-O"W*;$";TC_N;ZA\)_L3:YX3\,:;:O>:/K>H6>JVMS>6^L37%S8:S
M'%;7-KYT\.SY)O\ 2?/_ (\O&F]SPZ 'UAX-\8:;XZ\*Z3XCTB1I-+U2V2[M
MGD0H[(XRA*_2MYNM</\ !KP/<_#7X3^$?"=Y<Q7=UHNEVVGRW$";$=DC"%D_
M*NX;K0)#J**3- Q:*** "BBB@ HHHH **** "BDI: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \RG^!/A.\USQ]J\UF[:KXUM_L>IWOR>>D'V
M5+;RX9-FY%V)TS]_FLM_V:_"+^+M'\2>5<_VCIMA;::T<@AF2[@MM_D^871W
M'WW)V.F_/SYKV&B@#QG5/V7_  ?=3:NNFB\\,Z9K&COH6HZ3H;1VMG=VQ29$
M#ILX:/[1-L*%/O\ S[^*BNOV6_!MY_;0:;5!_:UMJ=M<[;GHE_;6MM/M^3^Y
M9P[/3Y^M>UT4 >,Z?^S3X:T7Q8/$&G:CKFFZG/-</<R6UV@%S#-Y)>V?Y/N?
MN$;Y</G?\_-9/P[_ &1_!/PUU6PO-)FU22ZL;^&^A:>Y3_60VL]K&'V(N_\
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MUH?\,&^"O^AS^)G_ (6M]_\ %U[[X5_Y%C2/^O.'_P! %:Y[5\Q,]B)\V?\
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M1110 4444 %%%% !5NV\02>%=#\1ZND2S/8Z=-=*C'".Z54JKXE_Y)_XT_[
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MINIZ>B26,^G_ -IV*7\CZ)_KK)--\F;Y'3?\]S_P.FJ="C[GU;_TH/:U9_\
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ME<:-<^)/"OBK3;3_ (^KS2YH4W_WWJGINE6>CV:6>GV=O862?<@M841$_P"
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M !^H)/V;_%L?\$/_ 'P]?>]Q5&XKHAFN(_F,/[,PY\)O^SOXMC_@3_OBH_\
MAGGQ5_<7_OBON.XJJ];_ -IX@S_L_#GQ-_PS[XJ_N)_WQ1_PS[XJ_N)_WQ7V
MMS1S6G]H8@/[/PY\4_\ #//BK^XO_?%3VO[-_BV^F>&+R=Z)O_CK[22MCPS_
M ,A6Z_Z]D_\ 0ZSGF>(A <,OPY\/_P##+WC/_IC_ ./TS_AF7QA_<A_\?K]
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MKC0T2W>!;J;[\T;O&9%^?Y]F_;O8\4?\,]Z&7OA_:>H'[7(DDG*?P:G)J/\
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M**^>/5*/]FQ?]-?^_P ]-_LV#_IO_P"!#_\ Q5:%% %/^SXM^_\ >Y_Z[/\
MXTW^RX=NW][C_KL]7J* */\ 9<7_ $U_[_/1_9<7_37_ +_/5ZB@"B^F1/U\
MW_O\]._L^+_II_W]?_&KE% %$:7"O3S?^_ST?V7%_P!-?^_SU>I,T 4O[+B_
MZ:_]_GH_LN';M_>X_P"NSU>HH Y?Q1I\*K;/^]^__P ]GKD9[&'_ *;?]_GK
MM/%GW;;_ ('_ "KE9Z]+#_ <D_B,B>UA_P!O_O\ /5*2QA_V_P#O\]:EQ5&Z
MD\M'>N^!R&7)8P_[?_?YZJR6J?[?_?;UP'@'XU6WB/Q)J/A[5=EIJ,-S,EG)
M_!<IO^Y_OUZ,]>E*E.C[LSDC.%;X"K]AA_V_^_ST?98?]O\ [_/4_-'-0:$<
M=C#_ --O^_SUL>&;&'^U;K[_ /Q[)_RV?^_6<E;'AG_D*W7_ %[)_P"AUSU?
M@+C\9KR6,/\ M_\ ?YZHR6,/_3;_ +_/6J]5)*Y(&YER6,/^W_W^>JLEC#_M
M_P#?YZT9*JO71 DSGM8?]O\ [_/5;[+'_M_]]O5QZBK>)B5)+&'_ &_^_P ]
M'V6'_;_[_/4_-'-:$D'V&'_;_P"_ST^.QA_Z;?\ ?YZDYIZ4 :GA&QA\G5/O
M_P#'S_SV?_GBE:\]C#_TV_[_ #U2\(_ZG5/^OG_VBE:DE>;/XSKA\!G26,/^
MW_W^>J4EC#_M_P#?YZU'JC/5P(,^>U3_ &O^^WJE):I_M_\ ?;UH3U5DKKB8
ME+[+#_M_]_GH^PP_[?\ W^>I^:.:T)(/L,/^W_W^>GQV,/\ M_\ ?YZDYIZ4
M 7?#-C#'KTWW_P#CS_Y[/_?K>GL8?^FW_?YZR/#/_(>G_P"O/_V>NAGK@K?&
M;TO@,N>QA_V_^_SU2DL8?]O_ +_/6I/5&>B!I,S)+5/]O_OMZJR6,/\ M_\
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M*R?[=>J76I>$/[!\%^&=5>)$\0:=;0N\%I;(EB_V]]]Z]S]_?L39LKZ3$87
MT)\GU<^=I8C%UH\WMC?_ .&^O&$?_,"T$_\ ?[_XNG?\-\>,O^@%H(_[_?\
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MJ.7>P]M[$Y_K>-Y^3VIZX/V^?&#?\P/0O_(W_P 71_PWUXS_ .A?T'_R-_\
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MID_V+?\ _0=N_P#OS#_\11_8M_\ ]!V[_P"_,/\ \16MNHW4<P<ID_V+?_\
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M_P"@E-_WYA_^(K7GJK)77 R,^2QN?^@E-_WYA_\ B*C^PW/_ $$[C_OS#_\
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M?_B*)+&\\E_^)K<?<_YXP_\ Q%7N:?)_J9/]RCG ]3\+:5?-X;TC_B<W,?\
MH</R^5#_ '!_L5K?V/?X_P"0[=_]^8?_ (BCPK_R+&D?]></_H IOB;Q%I_A
M/1+K6-2E:"RMOGF=5+8_A_PKY*4O>/:A'0=_8U__ -!V[_[\P_\ Q%']C7__
M $';O_OS#_\ $5QUI\</!UV+WR=58M9ZK>:+<H+:0&*ZMXI9IT.5Z;(7??\
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MBLKP/^RZ=#U31KK69?#MS#IM];3?V?IVE>3;2K;V=U"DSI([_P"DO]JWN_\
MTS0?[=9NH?M#>*M%OKY;/3].N;#3I;^\U![N:5Y&AAU!+;9#C[F]'WIO_N5U
MWP1^-&K?%+QWXTT^5-*31M&N'ME6U5Q=0S+/-'LFWO\ /\D2/O1-G[PIU0T
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M38Z/LW_^.5]&?\,!Z!_S^7?_ '^H_P"& ] _Y_+O_O\ 5/UW+>3E]X/JN/\
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MH$WA[P]XKAAT/^Q/+=WM;.:VM9K:Y1]B)\CI<OL^2OI/FGI42I1#G/G[P_\
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MU>GJC/6D F4IZJR5:GJK)77$YB'FCFCFCFM"0YI\G^ID_P!RF<T^3_4R?[E
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M5DKS;QI^T-IO@_XE?\(?<:)?7;H^FQS7T%S#\CW[ND.R'?OF^=/GV?<J_/\
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MKCXD?"?P+J.MZMJ?B"\AU HEXEQJZ0^3)_:3[$@F3_CV3[*?O_[G\=>BZ/\
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MNO@_P_I6M^(+GXIZW<6VLVGBBPL+S5M-U+9<_N9K;4WN84N4?_ELZ(B(B?\
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MS/// _[.=GI4T%YHGB&[TV?1_$\.M6?F6R3(B)IB6#PO_?WP_P ?]^NE\%_
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M,^:1YS\.?A#;?#G4OMD6JW%^_P#PCVF>']D\*)\EFC[)O^![Z] YHYHYKK,
MYI\G^ID_W*9S3Y/]3)_N4 >T>%/^19TG_KSA_P#0!6NU9'A3_D6=)_Z\X?\
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MO_??2N?V&6?R2-)5L?\ SGJ>K?MR^%M02+;X?UA-IS]Z'_XNLF3]LKPS)_S
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M871-CS;$WNF]'3?_ !UV0G RE&1ZOS1S1S1S6YB'-/D_U,G^Y3.:?)_J9/\
M<H ]H\*?\BSI/_7G#_Z *UVK(\*?\BSI/_7G#_Z *UVKY&7Q'N1/,?$/QO\
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M,V?$7[G]E)L_YY^=7ZG>3'_=6CR8_P"ZM'^L6+[1#^QZ!^6G_#-_Q(_Z!O\
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MPBH^_/XAG-'-'-'->:=X]*V/#/\ R%;K_KV3_P!#K'2MCPS_ ,A6Z_Z]D_\
M0ZYZOPEQ^,WGJI)5MZJ25PP.S4Q/$&AV'B/2KK3=5MDO].N4V302?QUSVC?#
MGPKX8N-.FTK0;&PFL(9K:VG@3YT29T>;Y_X][HCOOKKY*JO75$P.7\>> _#W
MQ*T3^Q_%&E0Z[I:/O^RW3OLW_P# 'J#6?!>@^(_"/_",:GIJW_A[R4A_LZ>9
M]FQ/X/O[ZZ%ZBKHY3(XF/X.^!H_[$_XIC3W_ +$39IOF([_9DW[T3Y_OIO\
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M]WO7]YUKVNO/?AO\%O"GPMOM4O/#]C+:7.I8CG>:X>8[$=W6--_1?WCUZ%0
M4444 >8_'7XA^'OASX+35?$NIKI.G/=I!]H>)W ?YCCY$<_P^E?/_P#PUU\&
M_P#H>;?_ , +S_XS7V9Q]:*ZJ6(G3AR&$Z,9[GQG_P -=?!O_H>;?_P O/\
MXS1_PUU\&_\ H>;?_P  +S_XS7V;Q1D5I]>F1]7@?&7_  UU\&_^AYM__ "\
M_P#C-'_#77P;_P"AYM__   O/_C-?9N11D4?7IA]7@?&7_#77P;_ .AYM_\
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M5_\ ] ^X_P"_+U[OQ1Q6G]H2_E#ZNCPC^RK_ /Z!]Q_WY>GQZ5?_ //G<?\
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M 4E%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>forms-1_004.jpg
<TEXT>
begin 644 forms-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '? ^@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M23R--).[F5W)+,<T ?8AN0&*A-P!V[D=3AP<%2.&'/0X((#9*L-M6-V#@C'
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MQ/X>U_XF_M8?%+P_X[\5V'A*SOHO"?A31_ OA2R\$>$?#FCW.IJFJ:G+;Z)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#\'$__ $9I_P $R/\ Q*3XV_\ SLZ_=.B@#\+/^%O_ /!Q/_T9I_P3(_\
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M)Q7WE7\>_P#P:S_\%)?V/;G]B[]F;_@GO9_$_5]5_:WMKKXPZ_J/PSLO 7Q
MODTK1D\5:_XMEU;4O&4>@3>#;;38-!N+:1IY=?A6![J+3S )E*U_8*KAL8!(
M/0X^7\QQ[=>O% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF\D>Q(T@ D>H !H_X9#_ ."EO_26C7_Q_8X_9P(_$?V3R/;O0!_,?_P> ?\
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M'^-?E-_PR'_P4M_Z2T:__P"(<_LX?_*BC_AD/_@I;_TEHU__ ,0Y_9P_^5%
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M0^"OB[SKS3->U.UM(3+<V/@KQ;'!9W&I'<=.T_Q/=27#):6\DL7] G_#(?\
MP4M_Z2T:_P#^(<_LX?\ RHKDO'W[!'[?7Q/\#^+_ (;_ !!_X*CZAXF\">/?
M#NL>$_&?AZ__ &-OV<3::[X<U_3WTK6;"X TEO+^W6%S=QR/$H\N5HIX@LJ%
MB ?@!_P9^_\ !,?4_AA\/?&__!1WXJZ5JND^+/C#H]_\+O@?H^J6WV-4^%:W
M^G:EXC^('ES1K<74WB_6=/L=+T6Z5EA&CV-T\:NEXC'^X.-/*0(,GDY/UR>?
MT%>-?L_?!_0_@!\%_A7\$/"K,_AGX3> _#/@#1)C;06;76F^&].MM.M[IK:
M>3:M.EL'EMH0(@9'*]%Q[30 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !14;,0&/R_*>Y(!& <\ G(![ YQQ31,,J"I&=O)(XW
M@D @$G.%)X!'3F@":BF[U]?T/^%&]?7]#_A0 ZBHGE"] 6[G'&!W//4CK@=O
M?%)YV,AE.<@97[N3NZDXP RLI)Q@C! H EQR>X///8\8Q[<9^O-!SCC&>V>G
MZ5'YH.,#D^_4  DKC[V >W&:<'4C.<?G_A0 X9P,G)P,GU/<TM-WKZ_H?\*-
MZ^OZ'_"@!< ]0#^%+@#H *;O7U_0_P"%&]?7]#_A0 ZBF[U]?T/^%&]?7]#_
M (4 .HIN]?7]#_A1O7U_0_X4 .HIN]?7]#_A1O7U_0_X4 .HIN]?7]#_ (4;
MU]?T/^% #J*;O7U_0_X4;U]?T/\ A0 ZBF[U]?T/^%&]?7]#_A0 ZBF[U]?T
M/^%&]?7]#_A0 ZBF[U]?T/\ A3?,PVT@9X&!G))*C(XP5 ))YR .G7 !)113
M'8JN0,\@8SCJ<9^@)!8]E!/:@!]%1)*'_P!GE@,\;BKE"5SV)4[<\D8.,&G%
MCQ@>N<@Y'UQTH ?14>Y_[OZ&FF7&[<,;=N3R0,AC@@#((V].>&0]Z )J:1NR
M#@J0..0<@YZCMT_*A6#*& (R.A&"/8CL:=0 A&<<D8(/!QG'8^H/<4M%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4KM))(U
M1&*."CEAOQ@,"P'ED2=ND;+(>-C!L&OX_/$/[=__  7E_:=_X*0?\%"OV4?V
M _$7[%^F^ _V.OB-I.@VL7QP\':A9:R?#?B*TBETD#6]-GU0ZO?BXCO%NI)K
M"S18UC Q*"&_L+;EU4_=ZD>IP_?TXZ=Z_E<_X) *!_P7/_X+_#_JI7PO//)R
M;.X;KUP"3@9P,\"@",:%_P '=Q&?^$W_ ."77_@L\2'^6@D?K2_V#_P=W?\
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MCZ9 ./44 ?N9;IY?F* 0OF-L!)("Y/ )YZ\\DC&,58H_S^=% !1110 4444
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M .6M?.LG_!OO_P $:4 /_# 7P2)+!0/(\2 DGH!N\1*"2<#!9>"3G(JD/^"
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M._W5/!X[5+_Q#Z?\$:?^C O@E_X#^)?_ )H: /H?_A[/_P $R?\ H_+]E?\
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M  0#_P""-.8U/_!/WX+;I&>-?W/B':7C4.S*6\0H[)M/SL(B1CY$;DE9?^"
M?_!&B(JI_P""?_P5)8R*66W\0% 8U1B#++XE@C4G<^Q<DR+&Y &!0!],?\/9
M_P#@F3_T?E^RO_X>?P5_\M:/^'L__!,G_H_+]E?_ ,//X*_^6M?,[?\ ! #_
M ((V -M_X)_?!(LCLI5D\1; P4G9++'KTJ0@$KG>0V2I)V!LQ2?\$!_^",T:
MR/)^P'\$42/'FR>7XB*0Q[-\LTSKKS"!(1N)FN/+MBH0^8 S%0#Z=_X>S_\
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M?\$]_P#M*=^QW_ZD'B"@#]U**** "FL2%)&>W0$GD@=%5B<?3ZD#D.) !)Z
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M^UY+;_\ "3:VMP_QY'B"#Q%+XRFNVOWN&\S6[?[>=%2(Z+Y)18ASY0A\6_L
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M,\NH10M.RJLK0$H @!/TGO/.(WZX.1CG ]>H[9]CCC!(!)4<O^J?_=-&]O\
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MG=I'!,GG.#*4(90P:0(\N$211M9>(@BAL+EB'F-6:-P\ARSE&,TH4Y+/G:K
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M/_E/0!^7Y_X.#O\ @C'@D_\ !03X*9 )XA\<9X!/!'A G/I@$YZ G /Y1_\
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M0SVC^!#\-Y?!3_#K3K:TC\'-XG?Q')!;ZQ'>MJ,6IR-+]DGU"".3>H#!&.&
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M+/ VFZWJ_B3PU)H/AK4KVZ:TT6PU.]:*6_L-.>[BO[FVL@D:R([&, \+LO\
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MZ1J^F^'KG3M2T^[BD2:UO;.XGMIXV22*9D()Y[XB?\$EOA[\'_"M]X\^+/\
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MW(!;_AZ+_P %5,!3E3^T^AR.I.?^$7 _7\:^;OCO_P $]/V?OV>-+E@^+O\
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MXCVUY/\ !3X&:-'\8OBC;16[O#KL6A:K:1>'O!5[.T3):Q^)-=98KN"8_O\
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M'PPUOQ9X=Q+!KOAK1_%E[JNE7<%W:ZA;07L36U 'POX _P""?_QXU76/V4?
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MO65E<SZ?+IU[;Q2V<T%S)^2'_!; C_AO/_@@21T/[?VKG/KGP=I@']*_9O\
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M/UQ7\E/_  <4?#KXK_M4?M<_\$H_V!?!_P >?%OP-\#?M$?$7XC^*M<UOPG
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MO?B_+\#)OCYI\,=UH\?AN[\-+XAG\+VFCO?MJ?VA==O-1@6[CLWL&@_LITU
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M\0^(YM/2YU2ZM8$N)I6M0Y /U>5@XR,XR1D]]I()'MD$5^5__!;@X_X)-?\
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M0H58,9"I=FD0E0'?!5Q.B*L<@<EW9)5$;L5+[$*J*4AERTC_ '(9@D<Y9HC
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M6@WVHVFH6-M?66IZ;9W,<EU8W4(,6'A=693^8EO_ ,$5?C%''%##_P %L/\
M@L';000Q000+\>?AE&D44*[$C"1_"(Q@*N%38J8C55.[:#7[SX'![CI[=J*
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M*ZS]NU-;G4+F.2]LH=.T;6[U)I(HX)" ?GQ_PS;_ ,'6HZ_\%)/V&1D*5/\
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M\.K:>Y\7^&]6MM5M;&[M=7T=[9X+ZQ:-C&X$;,QE44 ?S_+^S9_P=:,Q4?\
M!27]ADD $A?@+X1)Y&2"!\%,C8I4L>GS<9 R5'[-7_!UNPRG_!2/]AMAZK\!
M/")'X$?!,\?D?85^MG[.W[4'B#P[^S=\*-<_;"\<>'M-_:#^('PX\3_&O5O#
MFB^%KTQ^'/!%_KFI:EX7MUTCP_:ZI<Q:5X7\.W_A[2M3UJ]8R:C>K=OO;*K;
M^A?#?]M+X>6?[,_PJ^//QS\1Z/X,A\=?#+2OB5XBU;3- \1-X1TNSU,[&ODN
M8(M9;3M)C2/<LNI7AF\A1=3F%6*( ?BE_P ,T_\ !US_ -)(?V'/_#!^$O\
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M"=!O;C4M*T40IX,6VMX[34+JYNHY[:&WF$DC8.*]3_XB$/V ]I7_ (0S]N
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M J?\,)_M)F.-L$,\<;^ FC4D'*IM,*LJ.8G8,7_=S9_M'\D_^(HV?[1_)/\
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M:75M,B2PSQO'(JLI ^SJIPP,"&8YPI .!NRW)<]@Y.#E550<X49JY0 4444
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M8U;P_P##%;BVNW^&GB+5=-\507_C_P  3W=G:W$WA7QQ<:_I<TD*/) \B[R
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M!",@@]""/SK\)?\ @XE)_P"'>FC>_P"V1^Q3G\/VCO ZC]%4?A[FOW9?.QL
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M_"TEOH&G'X&PZ/!J/A/XU>%M2NDTN3XPZ;KEK9ZIX;T62&\MM3@EM+:+LO\
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M?R3:5>P7>G:MH7Q,6XT^\\,ZKX:NK:VU;2=0TZ]TK5+2^@$EG)$Z(P_,YO\
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MEK)#\L,^3T/I^5)_P\D_X*MY)_X<"?&DD@@D_MO?LM$D-MW=8N^Q,^NT9Z4
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M (ASOVM.G_#_ (_X*- =#C5_$0S]<?& 9QVSTK^JS ]!^0HP/0?D* /Y4_\
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M4 5X8O+\P'Y@2O7GH-QY(Y&YB1[Y. 34^!Z#J3T[GJ?J>]+10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-89&,9)Z<XP<'D\@
MX'?&3Z"G44 51 ^5'GNH0EMJ8PVX8^;(Y&03C'7)SDU*%8CB0\$C/!STYZ+C
MZ<CT/6I:* (MC_\ /4_]\_\ UZ8Z3$$>8"N#VP2.X/8YZ<GI5BB@"&&,QJ><
MYP< 8QQ]T<D<=!TZ<^M3444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !02!U]0/Q)P/U-%(P.!CG!!QZ__ *NH
M]P* (99XHB$+KYI5F2/DNRJ5W[54%F(W*=J@L<C -2JP*@Y R 2#E2,@'D,
MP.,<$ ^U?F-_P6-_:4^*'['/_!-S]JW]I/X+7UAI7Q1^&O@*UU'P;JFIZ?;Z
MM9:9J^H^(='T--3DTR[#6MW+9Q:I++%%.K1LZ@,,&OS#^$_['_\ P7D^*/PK
M^&_Q-C_X+-^$M'B^(/@7PGXV&E/^RK\/+AM+'BG1+3618M<?80)5MC=M DS!
M%<( >020#^G;(]1^8HR/4?F*_G)'[ ?_  7H;.W_ (+6^#VP5!Q^RC\.VP7&
M4W;;)MN[HN<9.<9&"7#]@'_@O2?^<UG@_KM_Y-0^'>0Y_@.+$_/_ +(S[9H
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MPM8^"?BYXO\ !^GZ=H;)XMTT1V*V6B0-!;)9P0VR?NXU8LQ'V9_Q#^_MZ?\
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MUZ?F*:?^" /[>((!_P""^G[>H^NH:O@' (#'_A.\*2",!B">@YH _J=\P_\
M/-_R/^%'F'_GF_Y'_"OY8A_P0!_;Q)8#_@OI^WJ2I(8#4=6.",Y''CLC(QR.
MHR 0"P!4_P#! #]O(=?^"^?[>P'))_M#5\+@ G<?^$[PG!!^8CCZ&@#^ISS#
M_P \W_(_X4>8?^>;_D?\*_EB/_! +]O!2 W_  7U_;T!;&T'4M5#,2"0 O\
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MS8:V ?\ @ZE\ 'G(_P""2NKD>G_):=5!_0Y_3WK^D^@ HHHH **** "BBB@
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MX.A0,#_@EM^QX!NWX'QGN0-V22P ^(^ Q).6^\>N<X-(?VQ_^#H5CG_AUO\
ML>@XQD?&>YSPP93D_$<GY'&]1]W<3N5A@#^I/RU]#_WTW^-'EKZ'_OIO\: /
MY:F_;%_X.@F4*?\ @EG^QT0C,T8_X7/=CRRX97V;/B2A7<KNK$,&97=6+*S
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M.!@\$<\G.* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9]0U+5-=\0^*YM<U>[G6&WBB%](#:00)#$YC7!^I/^'?_P#P5^.1_P /R]:
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M?2@#]R:*_#?_ (5/_P '#_\ T>!_P3!_\1;^._\ \]JC_A4__!P__P!'@?\
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MN]?7]#_A1O7U_0_X4 .HIN]?7]#_ (4;U]?T/^% #J*;O7U_0_X4;U]?T/\
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MVCMT]>P^BCK13335TTUW6PPHHHI@%%%% !1110 4444 %%%% !1110 4444
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MXMCXMTZ[U7173X=>)9#-:65\^GSO(J6Q\IA<1D*I+ IC+*^4K#_X?6?L*?\
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MFF\ZGBOQ72<(U,%"#J? G0J^]>?L]+0?V]-;=]M3^QS_ (?5_L*_]#=\0/\
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M\F%_\%R_R/[%?^'UG["G_0W>/_\ PV_B;_Y'H_X?6?L*?]#=X_\ _#;^)O\
MY'K^.K _N?HO^-&!_<_1?\:/^)6_#W_H*XK_ /#GEG_S$'_$8N(OY,+_ ."Y
M?Y']BO\ P^L_84_Z&[Q__P"&W\3?_(]'_#ZS]A3_ *&[Q_\ ^&W\3?\ R/7\
M=6!_<_1?\:,#^Y^B_P"-'_$K?A[_ -!7%?\ X<\L_P#F(/\ B,7$7\F%_P#!
M<O\ (_L5_P"'UG["G_0W>/\ _P -OXF_^1Z/^'UG["G_ $-WC_\ \-OXF_\
MD>OXZL#^Y^B_XT8']S]%_P :/^)6_#W_ *"N*_\ PYY9_P#,0?\ $8N(OY,+
M_P""Y?Y']BO_  ^L_84_Z&[Q_P#^&W\3?_(]'_#ZS]A3_H;O'_\ X;?Q-_\
M(]?QU8']S]%_QHP/[GZ+_C1_Q*WX>_\ 05Q7_P"'/+/_ )B#_B,7$7\F%_\
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MZ+_C1_Q*WX>_]!7%?_ASRS_YB#_B,7$7\F%_\%R_R/[%?^'UG["G_0W>/_\
MPV_B;_Y'I#_P6M_84!Q_PEOQ!_#X:^*"/S%L17\=>!_<_1?\::5!/1A]-O\
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M-<?\^6I?^"Z^_P#D:C[-<?\ /EJ7_@NOO_D:J^MX7_H)H_\ @_"__-@N6?\
MU,__  AJ?_(C=B^GZG_&C8OI^I_QIWV:X_Y\M2_\%U]_\C4?9KC_ )\M2_\
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MO".I^'M(?0H[6W\8A-=U?2]1@TW3M0,%TT]I;S2'R72)#EC7QA\2X[AOA[\
ME%I?LT?@;Q/&[0V5Z'C+>,=4 WA("\3E665 W52,@KP?$'TU9"Q;1[DLX568
M:1=@E$.5B8"TVR1 %U*2*X822;B25*_FN,X;I<29-E\*>:3P57!<4XK.Z4:T
M,+B,'7HRQV8IPK4/K'M_:JEB5447)TG*$8:24IKZ7+<T628^M6AA\?6IU,.H
MI4\'6A555MW3K.+_ '5E&T+;N;^T?TK_ !8_:E^&>D>#_P!IWQ1\/?'GPO\
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M6?A))^U[JGBG4?@O9Z5\.OB%\.-;_9>\+:7!\/9/%$GB==4BN/%$4NBZ7O\
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M4_XT[[-<?\^6I?\ @NOO_D:C[-<?\^6I?^"Z^_\ D:CZWA?^@FC_ .#\+_\
M-@<L_P#J9_\ A#4_^1&[%]/U/^-&Q?3]3_C3OLUQ_P ^6I?^"Z^_^1J/LUQ_
MSY:E_P""Z^_^1J/K>%_Z":/_ (/PO_S8'+/_ *F?_A#4_P#D1NQ?3]3_ (T;
M%]/U/^-.^S7'_/EJ7_@NOO\ Y&H^S7'_ #Y:E_X+K[_Y&H^MX7_H)H_^#\+_
M /-@<L_^IG_X0U/_ )$;L7T_4_XT;%]/U/\ C3OLUQ_SY:E_X+K[_P"1J/LU
MQ_SY:E_X+K[_ .1J/K>%_P"@FC_X/PO_ ,V!RS_ZF?\ X0U/_D1NQ?3]3_C1
ML7T_4_XT[[-<?\^6I?\ @NOO_D:C[-<?\^6I?^"Z^_\ D:CZWA?^@FC_ .#\
M+_\ -@<L_P#J9_\ A#4_^1&[%]/U/^-&Q?3]3_C3OLUQ_P ^6I?^"Z^_^1J/
MLUQ_SY:E_P""Z^_^1J/K>%_Z":/_ (/PO_S8'+/_ *F?_A#4_P#D1O&0...G
M&2.F.<=N>_<5^TW_  0J_P"3M/&^.O\ PJ+5,_\ @ZTOO].W;GKFOQ<%M<]K
M/4.W_,-U'((/_7MZ<<=^F,9K]H_^"%HDA_:Q\<-+;W< /PBU,*UQ:74"#?K6
MG^2!)-%'$[R+$[!$<MCG! K\D\;:M&7ACQE"G556I4R^A*,*5;#5)6C7@VY1
MCBG+E2UTC)VZ'W'AYA,1'C/(:TZ&*ITY1K6J5:,Z<+VDUS-Z1;WL^KMT/ZXU
MZ#Z#^5+2+T'T'\J6O\S*?\./R_-']=A1116@!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5I5QD*/O
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M .0Z\8P/?\S_ (T8'O\ F?\ &J^I87_G_7_\'XO_ .>Q/N?\^,+_ .$>%_\
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M0P&"P]&,7]84?:5.51KUHJTZDIJZ6+2O[UFUI<VJ<ONR5##.\4W?"86]^O\
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M-RLWIKL)0JI*^'PSEU?U/"VOK_TYOVW\_(_8S_A:^@_]$K\%?CI-D?Y6&/\
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MO2+-WTNPLI++3K*R7S9$\HR7-Q+*C'Z$\#_MJ?!/Q[X3TGQYI=[JNG^$-=^
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MX+_\%5A_\AUXQ@>_YG_&C ]_S/\ C1]2PO\ S_K_ /@_%_\ SV#W/^?&%_\
M"/"__*SV?_A:_A__ *)3X+_\%5A_\AT?\+7\/_\ 1*?!?_@JL/\ Y#KQC ]_
MS/\ C1@>_P"9_P :/J6%_P"?]?\ \'XO_P">P>Y_SXPO_A'A?_E9[/\ \+7\
M/_\ 1*?!?_@JL/\ Y#H_X6OX?_Z)3X+_ /!58?\ R'7C&![_ )G_ !HP/?\
M,_XT?4L+_P _Z_\ X/Q?_P ]@]S_ )\87_PCPO\ \K/9_P#A:_A__HE/@O\
M\%5A_P#(='_"U_#_ /T2GP7_ ."JP_\ D.O&,#W_ #/^-&![_F?\:/J6%_Y_
MU_\ P?B__GL'N?\ /C"_^$>%_P#E9[/_ ,+7\/\ _1*?!?\ X*K#_P"0Z/\
MA:_A_P#Z)3X+_P#!58?_ "'7C&![_F?\:,#W_,_XT?4L+_S_ *__ (/Q?_SV
M#W/^?&%_\(\+_P#*SV?_ (6OX?\ ^B4^"_\ P56'_P AT?\ "U_#_P#T2GP7
M_P""JP_^0Z\8P/?\S_C1@>_YG_&CZEA?^?\ 7_\ !^+_ /GL'N?\^,+_ .$>
M%_\ E9[/_P +7\/_ /1*?!?_ (*K#_Y#H_X6OX?_ .B4^"__  56'_R'7C&!
M[_F?\:,#W_,_XT?4L+_S_K_^#\7_ //8/<_Y\87_ ,(\+_\ *SV?_A:_A_\
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MEA?^?]?_ ,'XO_Y[![G_ #XPO_A'A?\ Y6>S_P#"U_#_ /T2GP7_ ."JP_\
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M;"UU 6]W;:7:PVTD+_II_P *VT;@?;]5R6VC]Y%G=NV[?N9#;A@@_EC!I/\
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M]^V_QHWGT;_OVW^->U_\*ST7_G[U?_O];_\ Q-'_  K/1?\ G[U?_O\ 6_\
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MJ?\ X"_\P]G4[+[_ /@'BF\^C?\ ?MO\:-Y]&_[]M_C7M?\ PK/1?^?O5_\
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MU/\ \!?^8>SJ=E]__ /%-Y]&_P"_;?XT;SZ-_P!^V_QKVO\ X5GHO_/WJ_\
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M "7_ .1"[[O[W_F-V_[3?G1M_P!IOSIU%'-/^>7_ )+_ /(A=]W][_S&[?\
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M _XG]IST*VNINI/ID60.0 3C'3I7Y@_%/]L?X(_!?QWK'PZ\90_%.\\0>&/
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MCQ=H-WX7\4Z=#=1^?%::_P"&]4ACU+0]5@C<17MC>QI+%.DB8.T@;./]A?\
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MQ?\ Q%&/]A?^^8O_ (BC^R<+_P!!/X?\ /K4NWY?Y'TG_P )=X4_Z&*R_P#
M74__ )"H_P"$N\*?]#%9?^ NI_\ R%7S9C_87_OF+_XBC'^PO_?,7_Q%']DX
M7_H)_#_@!]:EV_+_ "/I/_A+O"G_ $,5E_X"ZG_\A4?\)=X4_P"ABLO_  %U
M/_Y"KYLQ_L+_ -\Q?_$48_V%_P"^8O\ XBC^R<+_ -!/X?\  #ZU+M^7^1])
M_P#"7>%/^ABLO_ 74_\ Y"H_X2[PI_T,5E_X"ZG_ /(5?-F/]A?^^8O_ (BC
M'^PO_?,7_P 11_9.%_Z"?P_X ?6I=OR_R/I/_A+O"G_0Q67_ ("ZG_\ (5'_
M  EWA3_H8K+_ ,!=3_\ D*OFS'^PO_?,7_Q%&/\ 87_OF+_XBC^R<+_T$_A_
MP ^M2[?E_D?2?_"7>%/^ABLO_ 74_P#Y"H_X2[PI_P!#%9?^ NI__(5?-F/]
MA?\ OF+_ .(HQ_L+_P!\Q?\ Q%']DX7_ *"?P_X ?6I=OR_R/I/_ (2[PI_T
M,5E_X"ZG_P#(5 \7>%-V&\06:@D*"+;4V))." HL021TQD9. *^;-O\ L+_W
MS'_\12 )E1M4^A*IP1T/"G)R,\Y^O-..48:4FEB)-*G.6BOK%773_@=P^MU%
M\-)3[WDU;[K7OYGU%=>)O#"6NEN=<MS'+:LT;&SU$AXQ<29?9]B;J?E'! )!
MR& %9Y\6>%%Y/B*T3YFP7MM07EN $::R4!P"=J[L Y(7"YKPG558Z9X:^X"-
M-N%7*@!&%RZ*"JKN9<E7* [W;$:LC.&'S+\8?VI/@)\!=;\'^&/BC\1-.T#Q
M3\0=>T#PQX1\*66D:IXB\2ZEJ/BG5%T;0[FYT[3+5TT?1;O4WBLVUK4KBUMT
MN"T$*W#$NF%/+*7(V\1)OFDM81O;TY;?UZA];E]NDH2[)N5TNK>MNNA^B7_"
M6>%">?$%IR3@-%?,VPX4!EBM74#: 7<*AD!^4@DD*/%?A4;0NOVFY202+?5
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M%1_PEWA3_H8K+_P%U/\ ^0J^;,?["_\ ?,7_ ,11C_87_OF+_P"(J_[)PO\
MT$_A_P  /K4NWY?Y'TG_ ,)=X4_Z&*R_\!=3_P#D*C_A+O"G_0Q67_@+J?\
M\A5\V8_V%_[YB_\ B*,?["_]\Q?_ !%']DX7_H)_#_@!]:EV_+_(^D_^$N\*
M?]#%9?\ @+J?_P A4?\ "7>%/^ABLO\ P%U/_P"0J^;,?["_]\Q?_$48_P!A
M?^^8O_B*/[)PO_03^'_ #ZU+M^7^1])_\)=X4_Z&*R_\!=3_ /D*C_A+O"G_
M $,5E_X"ZG_\A5\V8_V%_P"^8O\ XBC'^PO_ 'S%_P#$4?V3A?\ H)_#_@!]
M:EV_+_(^D_\ A+O"G_0Q67_@+J?_ ,A4?\)=X4_Z&*R_\!=3_P#D*OFS'^PO
M_?,7_P 11C_87_OF+_XBC^R<+_T$_A_P ^M2[?E_D?2?_"7>%/\ H8K+_P !
M=3_^0J/^$N\*?]#%9?\ @+J?_P A5\V8_P!A?^^8O_B*,?["_P#?,7_Q%']D
MX7_H)_#_ ( ?6I=OR_R/I(^+?"A_YF&RZ$'_ $;4^^.G^A5WOPZUW1-2UJX@
MTW4X;ZX6QE+Q00W("JMR 6,DD*@@\X&.V,]Z^+\#D;%XS_"ASCT^3O@_EZFO
M=OV?"6\8ZCEC_P @27/S$Y*W0R1R,D]2.G7->=FV64L+@,34CB'.+47;E6[4
M=W;3>QMAZU25:*;5HZ15EHGOTUW>Y]K+RJGV'\J6FI]Q?]U?Y"G5\.>P%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_?3?X4;H_P#9_P"^F_PHY:?_ #]E^'^8#]@]3^G^%&P>I_3_  IFZ/\ V?\
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M%[;^$=#U:WOO$%OK6I>&]030?$IT[19[37-4O)[@Q6K,GUO^TS\'?BK\</\
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M)<O2Z6_:[>[OW/M(#  '0 #\J6BBOS4]T**** "BBB@ HHHH **** "BBB@
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M-T^D7MOJ\ID>:U9D5@,&G7J+7FE=)I/GGITM\6B^:7>RO9J,;KW8[K[,>_\
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M,/[')T?X1:U\*?@3\:OVE?$_@C2?B7%XW\+>)V^*?@3PUX0\6QVVB>+?!?\
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MK?C)KO6O@7X9TW6YY[CPG?\ A;3M=\&VVB:9: ^&[72]7TQ+&V:X$N'[>?\
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MGL[B.V;Q!9VT,4DUN8BGB*G6I*_=U)MV]74O^/R-*<8V?NQW7V8__(GZD?\
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MG_P$/_QVC^P=#_Z ND_^ A_^.UO44_K%3^>7_@R?_P F%EV7W+_(P?[!T/\
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M2BUW35CTW#^H_P _A1A_4?Y_"O,C\3=('_,N7WX:I;?_ "MQ^M(/B=I!W?\
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M[L+E(;O-XK),\2PJ!@-7AGPX_9F\1V/Q>^'GQU^,GQ!L?B5\1?A+\%[OX(^
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M?P^N5\"^+K?5;!K6Z\5?#_2;+0M;?Q-9:I]FG:XU;3-MQ*8H_I<?%#20Q?\
MX1R_#L>3_:5LY&>N]WT]GF.<D,V&VG!5<8*?\+.TI22GAZ_)(SEM4M@2W0C
MTW &/N]AW.>J>78A_!2JQ?G!_GM\]1^WC)6NHQ6UWT73773M\S?N_!VFS?#J
M[^'&E1MH^A2> )_A_I20J'.CZ*/#J^%;%8D*IYKZ=I\,/V=&55GB569%)"CX
M>\9_\$Z/A/\ %3]FW]G+]E'XUWMS\3/@U\"_"8T:XTBXM8[6Y\>>(=+\'W7A
MKPKXKU!%>.STR\\+7EQ=^*=/LK,206>M&R;81"%/V&?B=I7)'AV^QDX']K6W
M3/'73>X]:3_A9VD<_P#%/:@/FWC_ (F5J,D@*=I&G$Q\ 9(4' X!I?V=B?\
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M_P K:T^J8W_H%A_X+0_:07VX_>>F8?U'^?PHP_J/\_A7F?\ PLS2?^A=O?\
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MZEJ=K%?RW3"VGE==I^5E^%?QE7PM^V'\,)_AGXVO-0\<?ME'X[>!_$H70O\
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M3^.47C;2;"YW2:QI>@V<]AX:N[2>[TW4[_4[&]6YBMF@F;[!M?VG_P!G2_\
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M"7_R(<LNW_DT?_DA]%,WGT'_ 'T*-Y]!_P!]"C7^67_@$O\ Y$.67;_R:/\
M\D/HIF\^@_[Z%&\^@_[Z%&O\LO\ P"7_ ,B'++M_Y-'_ .2'T4S>?0?]]"C>
M?0?]]"C7^67_ (!+_P"1#EEV_P#)H_\ R0^BF;SZ#_OH4;SZ#_OH4:_RR_\
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MVR%KCY2 P7</)RQ"NZL"K;BRLVYE#+]D>6OH?^^F_P :=M &,<?4_P ^M/\
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M_P#&*^Q?*7U;_OHT>4OJW_?1H_UAS3_G^O\ P!!]0H]W]W_VQ\=?\,Z^)_\
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..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>forms-1_005.jpg
<TEXT>
begin 644 forms-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 Q$# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "JFI?\>3_A5NJFI?\>3_ (4 8E%%% !1110
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M9I*HZ;IS:>UZS7DUQ]IG,P$ISY6<_*OMS5ZN9VOH:H6BBBD,**** "KNE?\
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M39V[><6M8R9AB7,8^<>_K75[5_NC\J-J_P!T?E1=A9',)&(XUC2/:BC:%"X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_9,7]]J7^R(?[[5H44 9W]DQ?WVH_LF+^^U:-% &?_9,7]]J3^R(O[[5HT4
M9W]D1?WVH_LB+^^U:-% &=_9$7]]JGM;%+5V96)+#'-6J* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BF/($QD=:9]H7T- $U%0_:%]
M#1]H7T- $U%0_:%]#1]H7T- $U%0_:%]#1]H7T- $U%0_:%]#1]H7T- $U%0
M_:%]#1]H7T- $U%0_:%]#1]H7T- $U%0_:%]#1]H7T- $U%0_:%]#1]H7T-
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M^T'^[1]H/]V@">BH/M!_NT?:#_=H GHJ#[0?[M'V@_W: )Z*@^T'^[1]H/\
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M[/MG8E-@"@[SCD],'O7>B@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M@",PQ&5)3%&9(QA'VC*CT'I4E%% !1110 4444 %%%% !1110 4444 %%%%
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M=01]: $HHHH **** +,/^K6I*CA_U:U)0 4444 %%%% #)O]4:JU:F_U1JJ
M3T% !12E2!D@X]:-K?W3S[4 )10.3BEVD#.#B@!**4 D9 I ">@H **4@KU!
M% !/:@!**"".M&: "BC!(R <>M&: "BFAT+E ZEUY*@\CZB@NBNJ,ZAV^ZI/
M+?0=Z '44F:6@ HHIJR)("4=7 .TE3G!]/K0 ZBCD8R.O2C- !11UZ4'(X/%
M !14?GP^?]G\^+S\;O*WC?CUQUQ4E !1110 4449H ***8LL;JK)(C*W"LK
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MX2 TT<8D _,*.?QK06S75M=\2V-WJ]S;0:'$J64:S;3&/*5_.8]6P21SD<4
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M0!'-_JC5"YM;>]M9+:ZA2:"0;7C<9#"M";_5&L^ZN[>QM9+J[F2&")=SR.<
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M=WX3U7P_<WBG4KF*UNK2:X>5)0ZY+88GD9H ]@+*&"EU#-T!8 G\*4G ))
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M*MFB^VWEV[MN:6ZF+G/MD\#V%7Z** "BBB@":VZ&IZ@MNAJ>@ HHHH ****
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; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-1_006.jpg
<TEXT>
begin 644 forms-1_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H R<# 2(  A$! Q$!_\0
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M'\JWEZ<C!K$\+:+)X?T&WTV2<S21EV+XXY8G^M;2_=SZ\T"%%% HH&+1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% ',>)_"=OXFU32)[M@UO8-([0G(,A8#
M'(],?K36\*0#79[])EAMYK(62PQJ%"=>1_A74%03FC:* .#\/_#NVTFW:UN_
M)DC6$01/;M)'(5!!^9LY[#@8'M4Z^#;RUNM6CLKY(M.U2)A/'(I:17\ORP5;
M^[CGGFNTV"EVB@#@#\/7*L#? J8K2,93/$+[R/QJ:[\ F\U">:2]413W[7CJ
M%Y"E57:/?Y:[C8,YYHV@4 <#+X)U6;PU:Z1)J\'DV3KY(5&59(P"-LF,$]1T
MQTJUX:\%/X?O=/G%[YGV6UEMRFWKO</GV QWYKM-@QCM0$ [D^N>] #J***
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MI/[+TW_H&V?_ 'X6D?3-."C_ (EEGU'_ "P7UH='0/:*XX_%_P $ X_MI/\
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MZ!MG_P!^%H]@P]HAW_"W_!'_ $&H_P#O@T#XO^"",C6DZ9^XW^%']F:;D_\
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MTP*!XDT?./MJDCVXH]G+L'-'N:PI'^ZO^\*R_P#A(])_Y_%I&\2:05&;U?O
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MG1?&VE:[JTNG6LW[Y,LF"#YB@X)'T-0P^([Z768[3RX]AOG@R!SL6(-GZYH
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MO=;N;.2V("I%M.16]@CJ,5TD8!A3('W12G-PDFAJ*DK,\0_X0#51_$GY4?\
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MFJO@?PUJ'AJQFMKN>+R68-%;PDL$(ZG<P!.>N/>NPHQ0 4444 %%%% #)/\
M5-]*YGU^I_G732?ZIOI7,^OU/\ZWHF50*/T!ZT48/;D]>*Z#&YROCS4;K3-)
ML&L[F>W$]ZD4CVZY<H58D*"#N/ Z52T7Q'?)X<O;Z6:*XACO&ALY+Z18GV*2
M,2=/FXZ<5U.IZ3;ZP+478D!M9Q<Q%#@[P" 3[<GBLRY\&:5=RSS&2Y62>Y%Y
ME)!B*3!!VC'?)S]:BSN5=&=:>.VU6TL?[,TOSKV\$S&/SAM01A@Q#=#G:<?4
M5F^&-=N#_9+7DEQ).UE<39ED C&&;ACCKQU[5OKX)TF*"UCBGO(Y;=W9)TE
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MJ<X]!4;=.@JT(B/F_P#//_QZF[I/[@_.I#]!3,?3\JI"&$R]H_\ QZD#2_\
M/(?]]5)^ I,>PIB&DRD?ZO\ \>J/RF\P2>0-XXW9YJ;'L*7 ]!0 P--_SR_6
MD<RYC/E=94_B]ZD ^E(XYCX'^L3^=)[ :K&7/^J[_P!ZHF,O_/+_ ,>JPW7H
M.M1M6'4UZ$),O_/+_P >J-C+_P \A_WU4YQZ"HV^@JD20YD[QX_&HV+_ -S]
M:G./05&V/;\JM"9"6?\ N?K3=TO_ #S'_?52D?3\J9CV%6(:3+_SR'_?5&9?
M^>7_ (]3L>PI<#T% B/,O_/+_P >I09?^>7_ (]3\#T% QZ"@"*8R^0X\KT_
MB]ZV 9?*C/E?P#^+VK+FQY#<#M_.M91^Z3I]T5G,J!"6FS_JO_'J8QE_YY?^
M/5.1SVIC?05FBR F7_GG_P"/5&3(.L?ZU.?H*C;GTK1$,A)D[)^M1DR_\\O_
M !ZIC^'Y4TX]!5H1%F7_ )Y_^/49E_YY_P#CU.(]A1CV%,0W,O\ SR_\>I-T
MO_/+]:?CV%+CZ4 )F7)_=#I_>K9T)I1IY_=?\M&_BK)QR>!TK:T,?\2\]/\
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M*1>G-(W2@!U%1Y QD\>O]:53DGT% #Z*!TIK9XP"?84 .HIH[8/?TIU !13
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MU-)XTS<6\B6;[(?,VJ[@D[P1V Z9XH<\1:P*-(A_X1:[9$D2ZM7#Q&6)5?\
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MH_X5<O\ ST>O5:*7UFH/V$#RO_A5XQ_K'I/^%7#_ )ZO7JM%'UF8>P@>5?\
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MQ3C3*L0N*,4E% A<4HIM.% #9O\ 4-^'\ZUU_P!4G^Z/Y5D3?ZAOP_G6NO\
MJD_W1_*LIEP&&F-3S3&J$61MTJ,U(W2HS6B,V1FFFG&FFK0AN*,4E%,0N*,4
ME% #^Y^E;6A?\@__ +:-6+W/TK:T+_D'_P#;1JPK;&E/<U!10**Y#<6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@".4_NWQC..]<H6NAG]U#C)QECZUUD
M@_=M]*YG/7 QR?YUO1,:A#ONO^>4'_?1HWW7_/*#_OHU/FDS709(AWW7_/*#
M_OHT;[K_ )Y0?]]&ILT9HN!#ONO^>4'_ 'T:-]U_SR@_[Z-39HS3N!#ONO\
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MY11<"GNU#_GG;_\ ?1HW:A_SSM_^^C5RBBXBGNU#_GG;_P#?1I"VH8_U=O\
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M)L+&BS7>?]7!_P!]&HV:[_YY0?\ ?1JVW]:C-8=37H5"]W_SRA_[Z-,+W?\
MSRA_[Z-6S3&IID6*C/=?\\H?^^C49:Y_YY0_]]&K1IA-6A%8FY_YYP_]]&DS
M<X_U</\ WT:G--S6B @S=?\ /.'_ +Z-&;O_ )YP?]]&IZ3BBXB'-W_SS@_[
MZ-+NN_\ GG!_WT:EIU*XK%69[OR'_=P=OXCZUKJ]WY2?NX/NC^(UGS#]PWX?
MSK84?ND_W1_*LYLJ"*I:[S_JH/\ OHTQFNO^>4'_ 'T:M'K3&J+EV*C/=_\
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MDU.WU6ZMO/5%EA3[K[00/YFHV\'V#6UO;EY?*B:5@$;J9,Y_G18#%NO'AO\
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M\)#JNFW5[)=0Q6\,R.\84J6SE>!STKIN.W3M]*T("BES10 [U^E;6A?\@_\
M[:-6+W/TK;T+_D'_ /;1JPK;%PW-,56U*Z^PZ9=W>POY$+R;1U. 3_2K(I)%
M#(RE0P(P5/0UR'0<'*=8B\,3ZV^N22O<0AUCC0*D>>@7Z<9J?_A*;R&7[+9Z
M?)>74ES)" \N H1$).?3YJTXO!NDPO<(INC%."/L[7#F-,\G:I.!UJY%X>TZ
M.Y6X2)ED29Y5.X\,P /!]E% '/?\)NI5+Q;:9C-:I)%!GH['[OIFI-9\:7>@
MVEH]_I\<<\CXFA60N57=MW# Z<]\5JGPCHPM7MO(<1F$0X\ULA0>,'.0?>H+
MCP-HUU' LZW3F)2A<W+[I%W!L,<Y(R <&@ T:>XU/^VXQ=2*K3A87SEHU,:G
MCT/-<Y8ZK>>'M)U#4]1U>ZU'9="TMXI 0-QQ@G&2>37>V6FVVG"4VT97S2&;
M+=2  /T JG+X=TR:PGM'B;RII?/<B0@A_4$'(/ Z4 8,'CB6>UL)ETIXUFE:
M*9Y<HB$8X!(SSGC.!Q4-KXGU5Y;D:E L<2ZHUK;O W+ !CM8?AUK<F\*:=<6
M]M;7#W<L,!W8EN782?[V3\WXU)_PC&F&YFG$<H,TPG9?,8*'P1E1GC.3TH Q
MK3QS+*[O=::T-LRS>2X?)=HR001VZ&K_ (7\0W6NFY6XLXK=8BNUHY"X<,H8
M8.,=\'WS3M1\)V<NF&"T AF19%A9B2%+YR3ZYR:K^"O#%[X8LY;>>ZCDA8C9
M#%G9&<<D%N>: .MHHHH **** &2?ZIOI7,^OU/\ .NFD_P!4WTKF?7ZG^=;T
M3*H%%%%=!B%%%% !1110 4444 %%%% !1110!FZ\/^))=^ICX%>/K%,/^64O
M'HIKV^6)9HF1P""*TXO#]B8D_=+]T?PUHL1[)6(=#VAX 3>N<L]V6Z9WL>/0
M9HQ>>6(\W.S&TKN;&/I7T%_PCUC_ ,\D_P"^:/\ A'K#_GBO_?-+ZZOY0^J6
M^T?/Q:\+AR]WO&0&WMD ]@<\4T"Z#[PLWF Y#\[L^YKZ#_X1ZQ_YXI_WS1_P
MCUC_ ,\D_P"^::QR7V1/"7^T?/92X(VE9RH)(4Y(&>O6@+=!E8+.& V@@MD#
MV]*^A/\ A'K'_GDG_?-'_"/6/_/%/^^:?U]?RA]3U^(^?5:\5-B&Y5#U568
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M@_=':K@\'6C6[1S75S+<.LWFSL0&E,BA23QC. * &-XYM(;U+1[6Z<+Y?G7
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MR^^:Y$]N?EM@N9,<\D>E4]'MXKC0-;EDC#/% AC;^Z2PS5;_ (2S51/)<F2
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M6V=C(J"-I0 MOMZA3G)S]!2_?QD@M3:=C R0,-U'7_ZU+NJ#>1P0W'KQ1O\
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M"KN@Z])K?ALZO);F%QO#(#E'*_Q*?0U1A\/:FIU&[N!IMWJ6H,OG0S*6@VH
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MY^Q&ZBGQ\K<D<_E6'=?#.^EBO&BU*-9VG;[*Y!Q' QRZ?CEOSK?G\,W":O\
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MJ=E'+:O)91W4-V]LUZJ[HWVHS#"XQR0!^-.N?&FMZ+96K:JD+RZA8L]KY:@
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MS6ED%U=O;203"Y6*)0<J8RV#P.X6M3P1K6I:W!>7=[=Q75H9%^SO'&%Q\H+
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M@4 4H=,L[>]^U10JDOE^5E1_#G/\Z3^RK WS7S6</VHC:9=OS$>AJ]@4  4
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M]#)I/_@+_P#8T?\ ",_$;_H9-)_\!?\ [&BBCG860?\ ",_$;_H9-)_\!?\
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M=,!_Y:G\J**7,QM#?[*'_/9OR%-.D _\MF_(444<[%9#?[%&?]>WY4AT0?\
M/=ORHHI^TD%D-_L-?^>[?E1_8:_\]V_*BBG[21/*@_L)?^>[?E1_82_\]V_*
MBBCVDA\J'?V(/^>S?E5RQL_L5OY6[=\Q;/UHHJ7-RW&E8MT445)04444 %%%
M% !1110 4444 %%%% !1110!GZCJ?V"^TFV\GS/[0NVMMV['EXAEEW8QS_JL
+8X^]GM@E%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-1_007.jpg
<TEXT>
begin 644 forms-1_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &' Q@# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC=&Z,^HZ-(;M%CG+7,9\Q1T!Y[9J5-8\+I=K=+JNDB=8A")/M<>0F<[>O3-
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MZVO^$G\/_P#0<TS_ ,"X_P#&@#5HK*_X2?P__P!!S3?_  +C_P :/^$G\/\
M_0<TW_P+C_QH U:*RO\ A)_#_P#T'--_\"X_\:/^$G\/_P#0<TW_ ,"X_P#&
M@#!^)_\ R*4/_82L_P#T>E=G7GGQ&US2+[PS!!::I93S'4K/$<5PCL?WZ=@:
M]#H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5O44 8/_  A/A7_H7-*_\ X_\*/^$)\*_P#0N:5_X!Q_X5O44 8/_"$^%?\
MH7-*_P# ./\ PH_X0GPK_P!"YI7_ (!Q_P"%;U% &#_PA/A7_H7-*_\  -/\
M*/\ A"?"O_0N:5_X!Q_X5O44 8/_  A/A7_H7-*_\ X_\*/^$)\*_P#0N:5_
MX!Q_X5O44 8/_"$^%?\ H7-*_P# ./\ PH_X0GPK_P!"YI7_ (!Q_P"%;U%
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M^ ;_ /Q==-10!S/V/QG_ -!;2/\ P#?_ .+H^Q^,_P#H+:1_X!O_ /%UTU%
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M2\%?\^]__P"!TG^- 'H'VB#_ )[1_P#?0H^T0?\ /:/_ +Z%>?\ _"D?!?\
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MTJPUKQUX0L-3M8[JTD-V6AE&5)$0(./K5FZ\ _#VR*BZT/2("_W?- 7/TR:
M.D_M_1O^@M8_^!"?XT?V_HW_ $%K'_P(3_&L,?#+P00"/#.G$'H?+I?^%8^"
M/^A9T[_OU0!M_P!OZ-_T%K'_ ,"$_P :/[?T;_H+6/\ X$)_C7/-\.O :W*6
M[>'=,$KJ65#'RP'4C\ZF_P"%9>"/^A9T[_OU0!M_V_HW_06L?_ A/\:/[?T;
M_H+6/_@0G^-89^&7@@=/#.G?]^JAMOAYX!NXS)!X>TN158H2B9 (."/PH Z+
M^W]&_P"@M8_^!"?XT?V_HY.!JMC_ .!"_P"-8?\ PK+P1_T+.G?]^ZYSQ_\
M#_PEIO@'6[VS\/V,%S#:L\<J1X*MZB@#T]6#J&4@@C(([TM9GAW_ )%G2C_T
MYP_^@"M.@ HHHH \Y^-O_).9/^OVW_\ 0Q7H5O\ \>\7^X/Y5Y[\;?\ DG,G
M_7[;_P#H8KT*W_X]XO\ <'\J )**** "N-F_Y+';?]@*3_T<*[*N!UC5=/T?
MXN6<^HWD%I"VB2('F<*"?.'&3WH G\5V]M=ZUIUK9N(]7,R2FZ\[!MH4;+=_
MXONX[Y]JPO->8?VJ)7&O#7O( WD,(=^W9M_N;.?UKII_$7@*ZN/M%QJ6B2S<
M?O)'C9N.G)J8>+/!0N_M8UG2!<[=OG>:F_'IGKB@!FM:O>6VKW=M#?V]K';V
M8N561 3*V2-O)Z' Z<\UGI<:K;ZEXFN+>[22?9 \-M*%4#*#H2>O4#/!/6IY
MM>\$7.K-J%QKFDS2>4L:K)*C!=I)!&>AYJW+XJ\$SN[S:OH\C.GELSRH2R^A
M]1[4 7-,UI;_ ,*_VI"S2D1.Q,D>P[ESD$#CJ.W'I7GM\T\C;YR]Q>-*%^T/
M"SN%,>_S(V'"#<0J@<?6NZ3QEX/CA$*:[I:Q!=H19U"@>F*S+75? MG.CV_B
M&U2-&W);B_\ W2GV3.* -^RCO+GPM;1ZA</;7DEL@GF0A61B!DY[&L3X=2PP
M^#D0W.Y$O+B,/)+N)_>L!DD\FK\WC+P?<1-%-KNER1L,,CSJ01Z$5G3:OX"E
M%LB:SI4$4$ZW'E03(BNZ_=W =<=?PH RM49;;4=;U+P[,$%G83),8Y2YN+D\
MCC/)09Y]3CM5"_\ )T^>WATJ[E2QN].B;4)(IB>3(@WLV>&(+ GTKK(?$7@*
MVN/M$&HZ'%-R?,C:-6YZ\BGQ>*/ \$4D4.K:-''+DR(DB /GKD#K0!#X>466
MO>(;2QP-*@2&2W53E$D*$N%_($CU-95EXEU^ZMK%GO+8->:;->9%O_JVC/0<
M\@@\YZ=JWX/%W@RU@$%OK6DPPC.(XYD5>?84B^+/!2!0NLZ0 B%%Q*G"GJ![
M4 <S;^-]5U>_L[:VGAMII5M'\D0[PZ2#=(=YX!'8?SK2UK6KJ+4=7U:UC$D.
MC0K;1!@=KS2%=['V08_6JUS<^"[A[M1XJL8[6ZEBE>%)D&TQXVA3_"O X_+%
M;-GXI\&V5M) GB'3F61WD??<*=Q8Y.?SH Q;?56T_P 1:Y)/JJS2/%:11SPP
MABS-NP N<9J=_&5[::)!J<Q619DF@CB:/:TEPK83H?XO3VK2_P"$C\!^08/[
M3T3R2 #'OCVG'(X]JJWNM>"+TZ>K:]I<<-C<BYCBCF0*7 (''MG- '6P"<::
MGVEE:?ROWA48&['.!]:XWX/_ /)/H/\ K[N?_1S5LR>.?"IB<#Q#IO(/_+PM
M8OP=97^'=NRD%6NKD@CN/-:@#O:*** "BBB@#C?BC_R(MQ_U\VW_ *.2NRKC
M?BC_ ,B+<?\ 7S;?^CDKLJ "BBB@ HKA/%GBKQ!8^,=*\.:!:6$MQ>VTEP7O
M'8*-IZ<4W[1\4?\ GR\-?]_I?\* .]HK@O/^*7_/EX:_[_2_X4>?\4O^?+PW
M_P!_I?\ "@#O:*X+S_BE_P ^7AK_ +_2_P"%+Y_Q2_Y\O#?_ '^E_P * .\H
MK@O/^*7_ #Y>&O\ O]+_ (4>?\4O^?+PU_W^E_PH [VBN#\_XI?\^7AO_O\
M2_X4>?\ %+_GR\-_]_I?\* .\HK@_/\ BE_SY>&_^_TO^%'G_%+_ )\O#?\
MW^E_PH [RN,U#_DKVB_]@JY_]#CJGIGB7Q;;>-].T'Q%9Z4B7T$LJ26<CL5V
M#OFKFH?\E>T3_L$W/_H<= '9T449H #7+R^)[J&?4)#I\9T^PN1!/,)_W@&%
M)?;C&!N'?UKIR:Y27PYJ$TNKVK7%J--U*<RR85O-4;5!4=OX>OO0!I_VS%#-
M?R7,D:6MO(D2,H)9F*@D8'7J  !2R>*=&CMX)GO JSEEB4QMN9E&6 7&<CTQ
M66VC2R75Y';'RI;>^CO8&E4['R@!!([<'ITXK.U+2=7BU_0KF#R9+MKFXGF?
M8QA0M& !Z@<=: -9O&>GOKUMI=L?.%Q:/<I.H8H,'&#@?F>V*FM_%VDI:0/>
MZA;)+)$DK>7N*!6) ;)'"Y'4UG:?X-N-,NK2>&\C<K!/%<AT(#&5]Y*8Z8/&
M#VJJG@2X&D7=D;Z(M/ID=B&V' *L3N_7I0!U$7B+29L[+Q"1,L!!!!WM]T8(
M[]CT-27&N:=:QL\MP %E,)"J6)<#)4 #).*Y^\\(W,VIW6H07<*S.UJ\*NA*
MAH<\-['/:K]IHEU'+'/<W$+2B]>Z<1J0OS+C:,_SH LP>(=/U)O)T^Z62X:(
MR1!D8*V/<CG'<=15O2;QK[2;:ZE0))(@+JO0-T('XUF)I$EBMG<&42?83/*R
MJIR^_. />K.AVY_X1JUBN(60R19>)N"-V3@_G0!H6]W!=^;Y$@?RI#$^/X6'
M45S%IXNGNM2^S?8(PDEU-:0LL^YM\>>77;\JG!YYK1T+PQI^@RW,MJA#SRM)
MDL?E#8^7D^W6LZR\)2:=?1WUM- EU]NFGFD\KF6&0Y,9/7(XP?:@"[H6MZCJ
MM_J%O<6%O EC.8'=+@N6;:&X&T<<TLFMW3:QJ-A:6L<HLH8F9GEV NY/!/.
M%&?6K&CZ2^F7FK3O,L@OKLW"@#&P;57!_*LI=.O8/$VO+##"T6H0PS(UPA:(
MLN496 ]@/SH ;;^,VN8XH(; /J,MX]FD0F_=,4&YG#XY0#N!G/%:>DZU-K.D
M37%M:JEY#,\$EO++A5D4X(W 'CT.*Q(/!MY:7,&H6UW;QWD-P\\=J$/V9 R!
M651U .,_6N@T#2#HUG.C2"6:XN'N9G P-[G) 'IV% &9HWBT7UO'<:E';:>D
MTDL<(\\N7:,D-SM '0D<UJV6K1W>IM;(08VMTN(6P064D@]?P_.N=N? \MYX
M;AT*XO4%J+F2YE9$.]F+ET /8 GGUQBM;3[&Y_X23[9=;3)!8);,T:D([%MQ
MQGZ#\Z .AHHHH *X'X1_\BG>?]A2[_\ 1AKOJX'X1_\ (IWG_84N_P#T8: -
MGQCXQM/!]K:2W%G>7DMW-Y,,%HFYV;&>GTKF?^%N,/\ F2/%/_@'_P#7JY\0
MO^1G\"_]A8_^BS73:KKPTW4;2P2RN+NYNE=T2':,*F,DEB/44 <=_P +=;_H
M2/%/_@'_ /7H_P"%NM_T)'BG_P  _P#Z]=W_ &M:+,D$L\<5PVT&)G&Y2>@.
M._\ .J]OKL<\\4?DLOF2S19+# \OJ?QH XS_ (6ZW_0D>*?_  #_ /KT?\+=
M;_H2/%/_ (!__7KN$US3),[+^W.-O\8_B.!]<GC-3#4[,L5%U"6$WD$!QQ)U
MV_7VH X'_A;K?]"1XI_\ _\ Z]'_  MUO^A(\4_^ ?\ ]>O0WN8XWV/(JOL+
MX)_A'4U4;7=+4JIU"W!95<#>/NM]T_0^M '#_P#"W6_Z$CQ3_P" ?_UZ/^%N
MM_T)'BG_ , __KUZ2.1FEH \U_X6ZW_0D>*?_ /_ .O1_P +=;_H2/%/_@'_
M /7KTJB@#S7_ (6ZW_0D>*?_  #_ /KT?\+<8\?\(1XI_P# /_Z]>E44 <[X
M.\76?C+29;^TM[FW$4[0217"@.KKC(.#[T5S/P=_Y!/B+_L.7/\ ,44 :WB+
M_DI/@W_M\_\ 10J;Q+;7%UJR"WB@D<:?/@31EE)RO'L:A\1?\E)\&?\ ;Y_Z
M*%=>Q11N8@#U- 'FVM:]=6=EIPT>34'DMH;:0@D+&R,P4A@1F0XSD#[M2VNI
MZ[%<QWK7EU/OU>>S^S.@\ORMK%3P,\$#!S[5Z$SQ)MW,B[CA<G&?I3L*.>*
M/,;:>]_M;3M2^W75U>-I5S+(LB9$,A*\*,<?[OM5^_O=3L[/48M.U*\N8A;P
M2)=R'>\<C2!6"\=-O..U=_A1Z5'-/;V\3232QQQJ0&9V  )Z9H X*:76+"]O
M2NIW\Z6.I6\,*2@,)(Y-N\/Q\V-QP>V*A@U"]GDL+9K^^BNIM2N%)5O+C6W2
M0Y+#&"2,*/7->CX4^G-&$ R<8'<T <-X>N?$-_KAN[N[B@B^T312V+L<A%)"
M%5QP> <Y.0:T/B7_ ,DS\0?]>;UU/R^V:Y;XF?\ ),_$/_7F] &EI%Y;6'@_
M3;F[GC@@CLH6>21MJJ-@ZFH?^$Y\*?\ 0QZ7_P"!2?XU9T6"&Z\):9!<1)+$
M]E"&1U#!AL'4&G?\(UH7_0%T_P#\!D_PH J?\)SX4_Z&/2__  *3_&C_ (3G
MPI_T,>E_^!2?XU<_X1K0O^@+IW_@,G^%'_"-:%_T!=._\!D_PH \X^+_ (GT
M'5/ ;VMAK%C<W#7<!$<,ZLQ <9X!KU:W/^CQ?[@_E5 >&]"4Y&C6 /J+9/\
M"M,  8 Z4 +1110 5G:CH6DZNZ/J6FVEVT8PAGA5RH]LUHT4 8/_  A7A?\
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M+C^9KM-5TZ348XXUN3"J2))Q&&R58,.OTH SM8\1/8ZS8:;:VXG:651=.3Q
MC<*?]XGH/3-7-4\06NEWL%F\%U/<3H\D<=O'N)5,;NX]:IWWA"QU"Z-T\UW%
M.\J2RM#<.@D9.!\H.!4>JZ;?S^+M)N+5GBAAM9TDGVA@I;;@'/T_2@""'QQ;
M7&MO#'!*VF+IPOOM@7@#<P.1G/\ #CIG-=!I>IPZO81WENDJQ2#*B1<$CL>X
MK'TOPC#I,T,UI=2;DL_LC>8@;>-Y?<??+&M'1=&CT2">&%LI+,TVT*%5">H5
M1T'&?Q- &!>^-#!<SCRO*A1@J,(FF9LMM5F"XVAFX'4UTNCWLFH:>L\T2Q2A
MFCD13D!E)!P?3BN1N?!=U-J#CY?*>1'$\=RT9&QBR$Q[2&9<GO@^E=G86B6-
MFEO&78+G+.<LQ)R23ZDT 6J*** "BBB@#@M<X^,OA4G_ )\;O^0KDOB[XINO
M#WBCP]JNA7]K]I>.6T<D+*%5F4DD9]JZW70#\9?"H(R/L-WQ^ KPCXP^"/\
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MPQ&,9 &1F@#IM/U:TU-YX[:0F2W8+*C*59"1D9!]15ZLC0])&E0R@PV<<DC
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M_LKXF_\ 0RZ'_P" #?XTHTGXEDX;Q-HH'<K8-G^==Y10!P?]C?$?_H;-)_\
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M#]=_^"Z#_"NRHH XW3O!5_!XIL]>U7Q)<ZG-:0R10H]M'$%#]?N]:[(=***
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M_()\1?\ 8=N?YBBKGPJT75M&T'4O[9LOL=U>:C-="'>'VJV.X_&B@#O****
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M4Y4/I$IP?8XXKO:* .&MO'VB6<"P6VAZ_%$O1$TF4 ?I4W_"R-+QC^R/$/\
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M'M'.2/:O8J1E#J58 @\$'H: .&_X6_X)_P"@N?\ P'D_PH_X6_X)_P"@N?\
MOQ)_A79?8K7_ )]H?^_8I?L5K_S[0_\ ?L4 >1>+_''A_P 4ZGX6M-'O6N)X
M]8BD9?*9<+R,\CWKV2H!9VRL&6WA!'((0<5,.* %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_")^'?^@%IO_@*G^%8FG_\ )7M:_P"P3;?^AO79T 8__")^'?\ H!:;_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T#N+13=P]:4'-
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AKS'XFW5S;Z
MK9B&XEB!A)(1R,\^U>G&O+/BE_R%K+_KB?YUV8))UTF<^(=J;..%[J9&1<WF
M.N=[8IO]I7__ #_7/_?UO\:ZC2+R:3PD(I+AB#?Q0X+8_=G@K]*M1:;H#:KJ
M9>T0)9NL4<*;GW@GE\ Y)[>U>J\1&+:E#8XE!NUF<;_:5]_S_7/_ '];_&C^
MTK[_ )_KG_OZW^-=OIOAW1ITNS)"AB>2182S'?& ,C/.%_'.:AAAL+V#2DGT
MR!H%LG8RAB#N7/RDY_&E]:IO:/Y![.75G'?VE??\_P!<_P#?UO\ &C^TK_\
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M^M_C1_:5_P#\_P!<_P#?UO\ &JM%')'L'/+N6O[2O_\ G^N?^_K?XT?VE?\
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MJA;=5CED!_UC_P 1KLVD2'7M1#2-'!%I*")UQD# Y7WJJE512DH[BC%MM-G
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M:5__ ,_US_W];_&JM%=O)'L<_-+N6O[2O_\ G^N?^_K?XT?VE?\ _/\ 7/\
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M\NY:_M*__P"?ZY_[^M_C1_:5_P#\_P!<_P#?UO\ &JM%')'L'/+N6O[2O_\
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M&]_Y]+G_ +]M7MG]I7'^Q_WS1_:5Q_L?]\T_KT_Y4'U5?S'B?V&]/_+I<?\
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MNM CNKZ&\"R0SQ;\,BKABPP201R<=Z9I7AFUT9@]K',7$0A!=LX7<6P/Q)-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6A%_JU^@K/K0B_P!6OT%3(:'T445 PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "J-[(B2*&8#CO5ZL?5_\ 7QY]*J"NQ,7SXO\
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M4O\ =^Z23FGS^((_[1MK:T,4\=P9H5DYP)T&0GT/-+E079UOGQ?\]!1Y\/\
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M.#S74#I4_P!DE]%_.C[)+_L_G1= 045/]EE_V?SH^RR_[/YT70$%%3_99?\
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M@<FK&N:,U]?V%_%;6]U):"1#;W!PCJXQG.#@@@=JZ3[)+_L_G1]DE_V?SHT
MYG_A'Y'\'#1WE4W"QY1QG:D@.Y<=\ X'T%9UAX:U9;O=>SPB&YB:2[\MB2+D
MJ5RO'3!_2NW^R2^B_G1]DE_V?SHT&<$?"5[)I-O;LL*7=BD2P7!G9O.$;;@I
M&/D!Q[X-6;[PF=5M5CEB2T9Y))I-DQD/F$#:Q)'S<@9'3%=I]DE]%_.C[)+_
M +/YT>Z!RL&EZI_:EK=NEM;R;4%W/!(<3A5(V[,8Z]#VJ]>)(FOVD\:Y+6TL
M0)!VAN",X['FMS[)+[?G1]DE]OSHT%J<1-X7N;RVOU6WM].:=8V5(Y3*'E1@
MP9B1TXQCWK8TS3[M=8O=6OTBBGN(XX5AB?>%1<\EL#)))K?^R2_[/YT?9)?]
MG\Z+H+'*7NAWTTNNF'[.5U+R44R'[B!=KG&.OI6;;Z5>Z9)H&G2QK)#IDTUQ
MYT8/S1*I"[O]L[N1WQ7>_9)?]G\Z/LLOM^=&@'.>$;.:R\-VZ3HR2RO).R'J
MN]RP!_,5N5/]EE_V?SH^RR_[/YT[H+$%%3_99?\ 9_.C[++_ +/YT70$%%3_
M &67_9_.C[++_L_G1= 045/]EE_V?SH^RR_[/YT70$%%3_99?]G\Z/LLO^S^
M=%T!!14_V67_ &?SH^RR_P"S^=%T! >E=);_ /'M'_NBL+[)+_L_G6] ,0(#
MU"BLJC3L5$DHHHK$H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,$<^U=>.@^E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+NX-03>)]+MOM/VF2:#[/#Y[>9"PW1YP67^\,^E'*@N=-]LB]'_*C[9%Z/\
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M&BCE0[E_[9%Z/^5)]LB]'_*J-%'*@N7OMD7H_P"5+]LB_P!O\JH44<J"Y?\
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M;^X?SH_LVV_N'\Z/:(+,P:*WO[-MO[A_.D_LVV_N'\Z/:(+,PJZ2V_X]H_\
M=%0?V;;?W#^=6D4(H4= ,"HG)2&E8=1116904444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-1_008.jpg
<TEXT>
begin 644 forms-1_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &= S<# 2(  A$! Q$!_\0
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M5X_IC,VJ6P9W(+<@L?0U#<LXO)P)' $C<;C4?V8^;EYBO[8CR\W*>S?:8/\
MGM'_ -]"C[3!_P ]H_\ OH5XIO?_ )Z2?]]FC>__ #TD_P"^C5_V5+^8G^VH
M_P I[7]I@_Y[1_\ ?0H^TP?\]H_^^A7BF]_^>DG_ 'V:-[_\])/^^S1_94OY
M@_MJ/\I[7]I@_P">T?\ WT*/M,'_ #VC_P"^A7BF^3. \A/H&-*6D!PSR@^C
M,12_LM_S!_;,=^0]J^TP?\]H_P#OH4?:8/\ GM'_ -]"O%2T@ZO*/JQ%&Z3^
M_)C_ 'C1_9;_ )@_MF/\A[5]I@_Y[1_]]"C[3!C_ %T?_?0KQ3>__/1_^^S1
MO?\ YZ2?]]FC^RI?S!_;4?Y3U9M:N&\R>WLC+9QL0TF[!..I [UI17MM+$LB
M3)M89'S5Y?:^)[^TTMK"/88R" Q'(!K'#2= \GT#&LH9;4DWS.QO4S:E%+E5
M[GM?VF#_ )[)_P!]"C[3!_SVC_[Z%>*YEY&9LCKRW%)O?_GI)_WV:U_LM_S&
M']LQ_D/:_M,'_/:/_OH4?:8/^>T?_?0KQ3>__/23_OHT;W_YZ2?]]&G_ &5+
M^8/[:C_(>U_:8/\ GM'_ -]"C[3!_P ]H_\ OH5XIO?_ )Z2?]]&C>__ #TD
M_P"^S1_94OY@_MJ/\A[7]I@_Y[1_]]"C[3!_SVC_ .^A7BF]_P#GI)_WV:-[
M_P#/23_OHT?V5+^8/[:C_*>U_:8/^>T?_?0H^TP?\]H_^^A7BF]_^>DG_?9H
MWO\ \])/^^C1_94OY@_MJ/\ *>U_:8/^>T?_ 'T*/M,'_/:/_OH5Y%:%CI=^
M2SDC;@[CQUJB'?'^LD_[Z-2LL;;7-L5+.(I)\NY[7]I@_P">T?\ WT*/M,'_
M #VC_P"^A7BF]_\ GI)_WT:-[_\ /23_ +[-5_94OYB?[:C_ "GM?VF#_GM'
M_P!]"C[3!_SVC_[Z%>*;W_YZ2?\ ?1HWO_STD_[[-']E2_F#^VH_RGM?VF#_
M )[)_P!]"C[3!_SVC_[Z%>*YFQD&<CU&Z@F8#+&8#U)84O[,?\P_[97\C/:O
MM,'_ #V3_OH4?:8/^>T?_?0KQ3>__/23_OLT;W_YZ2?]]&C^RI?S"_MJ/\A[
M7]I@_P">T?\ WT*/M,'_ #VC_P"^A7BF]_\ GI)_WV:7=)_?DQZ[C1_9<OY@
M_MJ/\A[5]I@_Y[1_]]"C[3!_SV3_ +Z%>*AI3]UI3]"303*HRQF4>Y84?V6_
MYA_VRM^1GM7VF#_GM'_WT*/M,'_/:/\ [Z%>*;W_ .>DG_?1HWO_ ,])/^^S
M1_94OYA?VU'^0]K^TP?\]H_^^A1]I@_Y[1_]]"O%-[_\])/^^C1O?_GI)_WT
M:/[*E_,']M1_D/:_M,'_ #VC_P"^A1]I@_Y[1_\ ?0KQ3>__ #TD_P"^C1O?
M_GI)_P!]&G_94OY@_MJ/\A[7]I@_Y[1_]]"C[3!_SVC_ .^A7BF]_P#GI)_W
MV:-[_P#/1_\ OHTO[*E_,']M1_D/:_M,'_/:/_OH4?:8/^>T?_?0KQ3>_P#S
MTD_[Z-&]_P#GI)_WV:?]E2_F#^VH_P I[7]I@_Y[1_\ ?0H^TP?\]H_^^A7B
MF]_^>DG_ 'T:-[_\])/^^S1_94OY@_MJ/\I[7]I@_P">T?\ WT*S[C596NFM
M]/MQ<M&,R-OP![9]:\DWO_STD_[[-;OAG5+ZUO/LMLZ?Z0<$R9.#ZUC6RZ5.
M#DG<WP^:PJS4&K7/2;"]2_MO-52C E60]5(HI-.L186WEER[LQ9W/<FBO,/8
M+=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+11176<84444 6]+_P"0M;?[W]#4-U_Q^7'_ %T;^=3:7_R%K;_>_H:ANO\
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M^="0.)16A:WOFZ/#9PW-I%<VK%6$Z@JX]0:K7.JF#6[)Q=)<)!\KM&FU0#U
M]J:J5G)I>9+IT5%-^1G6NER75@UR'VL91%&F/OMW_*KAT&$R/:Q:@KWR+DP[
M3@GN <59U#4K.RU6PCLR'M+=O,;:>I;K_.KDMX1<RW::E8I;D%D*Q@R9/:E*
MM6T>UQJC15UNT8\6BVXTV&]O+[[.LC%=I7)!I6\/NM]=6[3C$,/G*P'WQS_A
M2:G<Q7&@6*B0-*)69E[C)'6M=]0LSJH0W"".:R\KS,\*W/7\Z'4K)7]0]G1;
MM;^K'.VNG-=:7<7JO@PN$$>/O$D?XU>&@0K+':S:@L=](NX0[3@>@)Q5F);;
M2=!NH?ML,]P9EDV(>P(Z?E5Z:_%Y=)>07]C% R@L)(P9$('ZTI5ZK;ML$:%)
M+WMSD)H7MYY(95VR1MM8>],JQ?3_ &F_FFWE][?>QC/OBJ]>E%MQ39YLDE)V
M"BBBJ)"M/P]_R';7_?%9E:?A[_D.VO\ OBL,3_!EZ'3A/X\?4]>HHHKY$^Z"
MN8\4^-K#PI/;Q7D,LC3@E?+'2NGKQ_XR_P#(2TO_ *YM_,UE6DXPNB)NRNC;
M_P"%Q:+_ ,^EU_WS_P#6H_X7%HO_ #ZW7_?/_P!:O&**X?K,S#VLCV?_ (7%
MHO\ SZW7_?/_ -:C_A<6B_\ /K=?]\__ %J\8HH^LS#VLCV?_A<6B_\ /K=?
M]\__ %J/^%Q:+_SZW7_?/_UJ\8HH^LS#VLCV?_A<6B_\^MU_WS_]:C_A<6B_
M\^MU_P!\_P#UJ\8HH^LS#VLCV?\ X7%HO_/K=?\ ?/\ ]:C_ (7%HO\ SZW7
M_?/_ -:O&**/K,P]K(]G_P"%Q:+_ ,^MU_WS_P#6H_X7%HO_ #ZW7_?/_P!:
MO&**/K,P]K(]G_X7%HO_ #ZW7_?/_P!:C_A<6B_\^MU_WS_]:O&**/K,P]K(
M]G_X7%HO_/K=?]\__6H_X7%HO_/K=?\ ?/\ ]:O&**/K,P]K(]G_ .%Q:+_S
MZW7_ 'S_ /6H_P"%Q:+_ ,^MU_WS_P#6KQBBCZS,/:R/9_\ A<6B_P#/K=?]
M\_\ UJ?!\7M"EG1)(;B)2<%RI('Z5XK11]9F'M9'U!IVJV.JVXGL;F.=",Y1
M@<?6N-\4:)J&J:Z\MI$'1$"DEL<UXUI^HWNE74<UA=20/N'W3P?PZ5]$VLKM
M*SEOF:-&/N2HKT,)C'"7.EJB:M..(IN$CA/^$0UK_GW7_OL4?\(AK7_/NO\
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MYLG]\T?VM5[(/[)H=V><_P#"'ZSG_CV7/^^*/^$0UK/_ ![+_P!]BO1O-?\
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M[UT&AS:OJ.O:AJBVM^UE'8R>3"JJ#N<#.6]N12S>)I[2:6!K,70L507\\;8
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MW3[Z]U#3&M+.>X"H=QC0MCDUA77N,BI\)Y715_\ L+6?^@3>?]^C1_86L_\
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MC#L>L_\ "\I_^@&O_?8H_P"%Y3_] -?^^Q7DU%'U*A_*'L8=CUG_ (7E/_T
MU_[[%3V?QQ0W2"\T8I ?O,C D5X_12^I4.P>QAV/JO0O%&B>(H!)IUW%(>\9
MX<?@>:D+A=1N@5ST_I7R]H<LMOXATYX)'B8W,8)1B,C/?%?3G6^F)Z[5_D*\
MO$86-*26Z9S3IJ++/FK_ '*/-7^Y48!(S_6DK#V<>Q'*B7S5_N4>:O\ <K&O
M_$%AI\[P2^;))&NZ41+GRAZM6A%/!/'%)',A689CRV"P]@:.2'8.5%GS5_N4
M>:O]RL^TU.SO5F:&90L,IA<N=N'!P1S]*LF2-2%:6-6/0%P":/9P[!RHG\U?
M[E'FK_<J%F5%+.ZHH[L<"D,D2@%IHE!Z$N!FCV<>P<J)_-7^Y1YJ_P!RJ&HZ
ME::5;&XO)E1 0,9&3GT%66=$ +.JYZ;F S1[.'87*B;S5_N4>:O]RH5=&9E6
M1"R_> 8$CZU6N-2LK1H%FN8P;B3RHL,#N;&<?H:/9P[#Y47_ #5_N4>:O]RJ
M5Y?6UC:3W4\R>5;KNEVL"5'TJ5)HW@2?>JQ.H8,QP,'ZT>SAV#E18\U?[E'F
MK_<J R1KMW2QC=]W+CGZ4N^/?L\R/?\ W=XS^5'LX=@Y43>:O]RCS5_N5"'0
MLRB1"R_> 897Z^E()8BF\31[/[V\8_.CV<>PN5$_FK_<H\U?[E1 @C(.0>A%
M%'LX]@Y42^:O]RCS5_N5%11[./8?*B7S5_N4>:O]RHJ*/9Q[!RHE\U?[E'FK
M_<J*BCV<>P<J)XY%\Q?DI&E7<?D[U''_ *Q?K2-]]OK1[.-]@Y42>:O]RCS5
M_N5&01UQ^=0W-Q':6LMS,<11*7<^@%'LX]@Y46O-7^Y1YJ_W*P]/\2:?J4T,
M48FB:X7?"9EP)![5JAXSNQ+&=OWL./E^OI1R0[!RHG\U?[E'FK_<JOYT)QB>
M'GI^\'-+YD6S?YT>SINWC'YT>SAV#E1/YJ_W*/-7^Y6=-JEG!>?9&F5KDQ^:
M(U(R5XY_44EOJUE=RM%;RB5DD,3[2/D8=0:.2'87*C2\U?[E'FK_ '*A5T?.
MR1'QP=K XI:/9Q[#Y42^:O\ <H\U?[E144>SCV#E1+YJ_P!RCS5_N5%11[./
M8.5$OFK_ '*/-7^Y45%'LX]@Y42^:O\ <H\U?[E144>SCV#E1+YJ_P!RCS5_
MN5%11[./8.5$OFK_ '*/-7^Y45%'LX]@Y43K(OEN=G2F^:O]RFK_ *J3\*91
M[./8.5$OFK_<H\U?[E144>SCV#E1+YJ_W*/-7^Y45%'LX]@Y42^:O]RCS5_N
M5%11[./8.5$OFK_<H\U?[E144>SCV#E1+YJ_W*/-7^Y45%'LX]@Y42^:O]RC
MS5_N5%11[./8.5$OFK_<H\U?[E144>SCV#E1+YJ_W*/-7^Y45%'LX]@Y42^:
MO]RCS5_N5%11[./8.5$OFK_<H\U?[E144>SCV#E1+YJ_W*/-7^Y45%'LX]@Y
M42^:O]RCS5_N5%11[./87*B7S5_N5#<R*RQ +C]ZO\Q2U%/TB_ZZ+_.ATXI;
M!RHW:***Q)"O$?CK_P A71_^N;?S->W5XC\=?^0KI'_7-OYFNS!?QT:T?C1Y
M/1117T)WA1110 5T&F>"M8U6SAN8OL\*W&?LZ3R;6F_W1BN>894BN_N5TOQ;
M::'<G7(=,-A (;B*1MKKC^).><YK&K.4;6(DVCB);*[AN)H&MI#) Q60*N=I
MIBV]PZ;TMIF3KN5>*]4\#ZKH>DZ6ZOK4;*T[B59R%++MP&P>36K!=I8:+HUR
MFL6MCIXN;AY8WQBYC+-@#U[<5A+$R3MRDNH^QXHL<KQM(D4C1K]YPO ^M BE
M:(RK#(T0."X7Y1^->PV'BOP^/#\AL6L[:,/*9K:? +@D8PO4YYK&GU>VN_#%
MK_96N6NF6<=LT=S8R("TC\]%SDYR.:I8B3^R'.^QR">$]6E:80I',(;<7$C(
M<A5].G6LA()W6-A!($D8*KE>,GWKUJ+Q)I_VV^MK;5X;>.;24CC<L HD!&?Q
MQ4LVMZ+'X/FL3JUM<$V\80%ANW@KNX[=ZCZQ43^$7.^QY;J^A:AH>H&RO8<2
M#'SKRG/3FH[[2;RPO6M&C\^10"3""PYKU?6_$.F.FIS7&MVM[I\\$<=M9+@L
MDHS\W7CM5+5/%5G:0^(9]+U&%;J5X/(9""2 1NQ^%"Q%3^4.=]CRM89VD,:P
M2M(O5 O(IG.<$$$=0>U>UVGBC01JM_)#=V:7\T,+?:'8!6PJ[AGIG.>*\K\4
MWEOJ'B>^NK58Q$[]8AA6/<CZUM2JRF[.-BXR;>QD4445T%A1110!;TC_ )#V
MF_\ 7U'_ .A"OI\?\?LW^ZO\A7S!I'_(>TW_ *^H_P#T(5]/C_C]F_W5_D*\
MK'?%$YJVZ.3\1^&-<U7Q?I>J6&K&VL+;_7V_F$>9^'0UV1(+D@<9Z56EOK.W
MG2">[@BGD^Y$[@,WT'>K&.<5P)&!RL=TWAW4]9%U:3S_ &V0S6[1)N$N1C8?
MR_6L>^@NY+R\>]TV=+RX6,Z<L/*P<C(!['J3^-;=SXOEM[K4$CL$>WL91%*Q
MF =CZJN,GK6LOB#2]TB&\57C17E4]4R 0#Z'D<5%K@<)96-S:WIEUNSN)K',
M@947.9R>&(_/FF1Z+J+6.I37UM<27L5E%]E)))5ANX'^U7?G7M-6T6Z^V+Y3
M-L7CYB?3%!U[2U,'^G1GSAE"O/![GTIV P_%:W$UCI,;0R-"W^OD"[]AVC&5
M[\US6A:1=W2 :C:W4BPVDPB\T8^;S"5X]<8Q7?:/KUKK+7WV;<OV24Q2%AP<
M '/TYIZ:]I<T<\B7T92 _O#P,=N/6BP'G%W9WDVC&+4K"[N-3D\AK9P,[5 Y
MR>V.,UV6O6$M]XDT?;$TD<<$IS_ LFT;2?QK2/B324MUF:_149M@!^\6],>M
M.?7M*CCMW-]'LN?]40<[O\*+(#SVUT_6F@V0"=+Z-'%WB/;O&3P6SSQTK3O;
M2QFT_29['2[@1VUR&E5TYW^6PR/Q[^M=HVL6 O?L;7:"<#)7L.,]?7%.LM4M
M-25Y+*X$R(2K,HXSW%%@/+)K34II6:*VNM\MM*EQ$(\ ,2N S9^8]>M=EKT#
MG3]#:X@EET^+_C\AC&2>!C(_.NKW-ZT D'(I\H'FOB>">XE9+2TNX81 IL_W
M>]F^?.!S\I^G:DATR_\ [.GOOLUQ_:7VF'RY&^\!Y9!Q[9ZUZ7N([T;CG.:.
M45CSPVERWAR_MK.UNDUX _:IB.)!WP>^>U5DTVYNW@"0SMI[W<6Z)8_+3((W
M' [>M>F;CQSTHW$]Z.48FU4^1%"HO"@= ****H HHHH **** "BBB@!T?^L7
MZT$@.V?>B/\ UB_6D;[[?6EU X_P;X9US0=2U2XU;5C?0W39@C,A;RQGWZ5T
M&N1O+X?U".-2[M"P51U/%6(+VSNW=+6[@G:/AUB<,5^N.E)?70L-/N+PJ7$"
M%]H[X[4= ..:6XUO2-#T_3H)UN[-%DDEE3:(B$(QGUR:P?[/U672)HTCN1<"
MU9+M4CVEW/J<\GKS7;V_B>X9;*34=/%K!?(&@E$@89(R V!QQ5Y?$6G".W:>
M\B1Y5# *0P /3)]*FPCC-3\/EIM4\FRF 5+86^PXQ\WS;?PZU#J-C=6NHW-J
MEI,FF,ZE7"[T5O*Y^7H<G]:[E_$>CQ2.DFH1J8W$;'L&/0?7D56TGQ=IVIW4
MUJ)!!/'*8U1_X^,Y_*BR&>?V^F7RV(EEL[HW9M)88I"F''SK@>W J\FDRPW<
MD"6MU#ONI7G>!<$H<8(]3P:] BUS3IWF5+V/,()D)(  '4@]Z?8ZK9ZD'^QW
M D\O[RXP1^%%@L<YX,6:"XO;<0$VJ*-MT8_+,C9Z%1WQWKK:4DGK2525@"BB
MBF 4444 %%%% !1110 4444 %%%% #U_U4GX4RGK_JI/PIE( HHHI@%%%% !
M1110 444 9(% !17)S^*;\^+_P"R+2VMS%&P$D<KA99 1]Y/859TOQ'+J>LW
M%N)+:.WBF:)49<2/M[@YI7 Z.BN57QC(8]7DDTZ2 64R0Q))PSEB &/H,FM7
M2]4FN+F[LKU8EN[1!)(8ON[2 W\C1= :M%<\OC;17(V/<ON#%-L!.\*<,1ZX
MJ'4/&$=O(@LO+N4<CM@J#T-%P.GHKG;'Q;:RVIFNV".%'[B-=SY+8 'K4[^+
M-(18OWDS22[L1)$2XQUR.HQ@T70&W145K<PWMI%=6[[X95#(WJ*EI@%%%% !
M1110 4444 %13](O^NJ_S%2U%/TB_P"NJ_S%*6P&[1117,9A7B/QU_Y"ND?]
M<V_F:]NKQ#XZ_P#(5TC_ *YM_,UV8+^,C6C\:/*****^A.\**** "D*@G) -
M*2!W%% "%5/50:O6D%YK$D-@LI>.)2RJ_P!V)>YJE6OX<NX;34)DG?RX[F!H
M?,_N$\Y_2IEM<3)/^$7E:R74DNX'T[RRS7..%8?P8Z[JB@\+ZG+- );;R5FS
MB1N0O^]CI6];7]C;Z0FBY@.G>7ND4D[FG[2?SX]ZNS:_;RW8NC>'+<R0=$!'
MIZ_C7)[>0<E3L<?+X=U2*(.UD60OM 4@G.<9(Z@>]6;CPAJ=M':LR0F2YW%4
M$B_+@X.3G%=0OB*V@NYK^"1/M=R@BG61CL"?[/OBFQZIH<$$,$3N4B+NLLAW
M,K,VXX!X/I1]8D/DJ=CCKG0KNSM9YIHU1[>01SQ?Q1YZ'Z'!K/"@= *['6]6
MMIHM9NDD5I-0:.-8LY(VYR?UKC@1TR*Z:<G)78E?J&U<8P*7I1D>HHR/45H,
M**** "BBB@"WI'_(>TW_ *^H_P#T(5]/C_C]F_W5_D*^8-(_Y#VF_P#7U'_Z
M$*^G_P#E]F_W5_D*\K'?'$YJVZ.;UWP-9:_XGT_7I[NXBGL?N1IC:WUKJBVY
MRQ[G-8FI>*M&TC6+72;ZZ\N]NO\ 4QXSNK:(PVT]:X%8P.&O/#=W-?ZT'TA;
M@WTV^"Z\X+Y0XY(SVZTD_A'49=-U"'>OG/<Q3(XQF4(J@C/;H>M3W7B/4EN]
M:\N_MH%T^0K%;,F6EP,XSCOTJ_\ \)G8PFV2[@FB:4*KOQM1R <>O>IT$8C>
M&=6W_:!;,8Y92TL'F+YG0@'/W>_:J]EX3UBQTRU2"S$6I1[@MPDBE5!Q@,&)
MR/I72P^,M-EE.^*X@AW.BSR ;&9#@@<^M/?Q9;1V,=U)8WB^;*L4,94;I2WW
M2.>E%D!'I.CWEO8ZW8W*K&;QF:.=",-N0+TZCFJ#Z7K4GAM=-CT^&&2W*CS
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M_P *93U_U;_A3*2&PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI4:%V9JZMX78107=NTL]S:P)#$B8!!4 ;^?I^M6?#>D7J6FK2:P2[ZC*25.
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MJ-I_NG\JST-K,HQZ59Q"_"1D"_)-QS][(P?TJF?"VE;HRL<L810C*CX$@!R
MW'-;6T_W3^5&T_W3^5+0-3";PCH[3*YBEV++YRP[_P!VK\Y(&/<U+9^&=,L-
M2COX%F\^)62(,^5C4]0H[#BMC:?[I_*C:W]T_E1H&IB7?A32;VYEGE2;][*)
MI(U?"-(,8;&.O _*I1X<TL000&W+10.TB*QSRV<Y_,UK;3_=/Y4;3_=/Y4]
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M112&%%%% !1110 4444 .3[XI#]X_6E3[XHXWMGWI]!$,<$$)9HH(HF;[Q1
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M170<X5\^?&C_ )'6#_KV_K7T'7SW\:/^1U@_Z]OZUC6^$[<#_%/.Z***XSW
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M2)_JI/PJ.@2W"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK+V$3K^OU.QP_P#PK+QA_P! K_R*M)_PK+QA_P! K_R*M=S_ ,)GX@_Y_O\
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M@=SZ5!9>&?'<6LC5;K32]Q%"T<6R11U]?:MO_A,_$'_/]_XX/\*/^$S\0?\
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M_P#KLG\Z]DB_X_;CZ+_(4 3T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 *OWA0>6-"_>%&<,<4 4K'5]-U.6:
M*POH;F2$XE6-LE/K3]2NFL-*N[Q8_,:"(R!,XW$#I6)X9\#Z3X3OK^\TYIVE
MOCF7S6R!SGBMG5;:2]T>\M(B!)-$44GH#0!S^F^-X=4TK2+V*VV->SB">)S@
MV[8).?RK47Q3HK+._P!LPD(W,S# 8>J^HKF[SP)=37VCW%M<QPK'$L6H1CHY
M5-H=?<?UJ!/ FH2:>;.1HT-O;-#!*T@;S">AQ_"..] '6WOB32-/9UN;K:Z[
M 5 R<L<*!]33&\4Z.)WA%R3(JD].,@9VY]<=JP?^$9UJ\U;^T+M+:+][ PC5
M@V%C8$\^O%/E\*:E)YNF[X!ISW3W(N<_O.0?EQ]3U]* +]CXWTFZTRWO)V>!
MIRV(BN64 XW'T%7I/$VCQ[U^VJ9%<)M[DGICV]ZYRU\,:W8&5X4M9'GB:W<.
MX^1<C##\!TIJ>#=4@U.UU&.6W>6R@%G#&W22(_>8_P"UZ4 =%#XGTQS:QO<J
MTUP,J(AN YP,GMS6?+XYTZVU2&RN#E9 Q:>/E$PVW!_&J^@^'=7\/7*O"MO.
MMPH6<NP'E?,3QZ\5##X7N;!S/=^5):[)UF /(#.64@=SG% '7Q7UM/=RVL4H
M>:)5=U'8-R/SJQ7+^ M-NK'P^9KXLUU<OG<PP?+'W,_@:ZB@ HHHH **** "
MBBB@ HHHH **** '#[C4VG#[C4V@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J"[_P!7'_UU7^8J>H+O_5Q_]=5_
MF* -2BBB@ KSCXF?\?MA_N'^9KT>O./B9_Q^V'^X?YF@#AJ*** "BBB@ HY&
M"#@CD&BB@#I#KFDW5S;ZA?64QOX% PC#9(1T)_2I-/\ %-O;&\EN+>22>^<^
M?M; 5.P7WZ5R]:NFZ9#<Q027!;]_+Y: >@!R?TH V=-\3Z7IMDEO%;W V!E)
M!'S@]"?>J[>)K4( (9>+-K?J.ISS^M55TRUFU!;81A =W*2%B<5'_8.9&C%V
MIDC8)*,?<8G"T ;M]KFG6#VUQ%YD]]]C$0VM^[&>N1ZU5C\46/V[SY;>;'V9
M8@ZD;E88Y'MQ6:/#S+?O8O<@3)C=M7@$]*LOX=A4)$LY:?:Q<GID-C(H M7'
MBBQN[B_,T$XBNHT4;2,@KG_&H=1\2V]Y!J,<<4J&Z,>PYZ;2.M5#H<45S'&U
MSYR22-!N48VR#^E8SHT<CQM]Y20: -#7=2CU6_CN(D956%8\-UR !_2LVBB@
M HHHH **** +%A_R$[/_ *[)_.O9(O\ C]N/HO\ (5XW8?\ (3L_^NR?SKV2
M+_C]N/HO\A0!BZQXUT;0O$%EH=[)(+V\_P!4%4D?B:Z(J0VWO6=>:#I.H:C!
MJ%Y8Q37EO_JIF'*?2M'))SWH YO[5J^LZAJ4>FW:VD5A)Y*#;GS9 ,_-[<CI
M3I?%'V.9[>>R>9[15^W2PD;(B<#C/)Z@U+=^'[AKR[GTW4FL1>C%R@0-D]-R
MYZ&JC^#44R):ZC-%;7"J+M'&YI2".<GD$XH K:;XPFN))X!;M?W!E=H8XB%Q
M "?F)/MBI6\=VC%WMK"XF@AB2:>4$ 1JV>QZD8IT'@M;"<W.F:@]O<?,H8H&
M'EL<[<'\.:6/P1:P6-]:0W<BQW=NL#$CD8S\WU.: -76-;BTBSAN/),QF^XH
M8*,8SR3Q6-#X\MKM(FL=.N+@O$TS@,!L56VGKUY%:6K^'_[4CT\)<^5)9<+N
M4,C\8^93P:H:3X)BTI9 M^\A>&2'.P#&]BQ.!Z$T 5=:\;2#2FN=%MI)%4QA
M[@D;8]PS@CJ:WM5UQ=,O[&R%K)/+=*SY5@ BJ 6)S]:PV\!!;#[!;:K)#:/Y
M9G78"79!C(/;-=!>Z/%?:K:7LDC 6\4D)C'1PX /\J ,>'QYIK@O+$\4+*3
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MY4 7**** '#[C4VG#[C4V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (B]QG_CS?\ [Z%&^Y_Y\W_[Z%:5% &;ON?^?-_^^A1ON?\ GS?_ +Z%:5%
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M )\W_P"^A1ON?^?-_P#OH5I44 9N^Y_Y\W_[Z%&^Y_Y\W_[Z%:5% &;ON?\
MGS?_ +Z%&^Y_Y\W_ .^A6E10!F[[G_GS?_OH4;[G_GS?_OH5I44 9N^Y_P"?
M-_\ OH4;[G_GS?\ [Z%:5% &;ON?^?-_^^A68Z?VEJ4\%Y.]HD(!CCW 9_VL
MUTM5+O3;2^96N(0S+T/0T 5]$N9;BR;S7\S8Y19,?> /6BM"**.&-8XD"(HP
' !BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-1_009.jpg
<TEXT>
begin 644 forms-1_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "I @,# 2(  A$! Q$!_\0
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M>7<TO[;G_P">4?ZT?VW/_P \H_UK-HH]G'L'/+N:7]M3_P#/*/\ 6C^VY_\
MGE'^M9M%'LX]@YY=S2_MJ?\ YY1_K1_;4_\ SRC_ %K-_"C\*.2'8.>7<TO[
M;G_YY1_K1_;<_P#SRC_6LW\*/PH]G'L'/+N:7]MS_P#/*/\ 6C^VI_\ GE'^
MM9OX4?A1[./8.>7<TO[:G_YY1_K1_;4__/*/]:S?PH_"CV<>P<\NYI?VU/\
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MVW/_ ,\H_P!:/[;G_P">4?ZUF_A1^%'LX]@]I+N:7]M3_P#/*/\ 6C^VI_\
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M#H0/?-=H<AC]:YO_ (0RT6&Q6*\GCFLKEKB*4 $Y))((].:Z0G)IQOU)E;H
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M/U&>M9TO@9;H[KW6KRZ?[-]F!=% 5,@\ ?2KVN^%;+Q!-I\MW)*CV1 4H?\
M6*,?(WL<4O>#W1EOXB@_MN:WN+@""1HDMU\O!5G!(#'WJQ?^*-'TV.XDNIWV
M6\ODR%$+ -C)_(5!J/A2SU/^U#+/*IU!8P2O!A*?=9?>J3^ ;*31+/2Q?W2I
M;N[O*<%IBXP=V>]'O#]TNVWB!=0\0Z?#8R)+IMW9/<!]O)(.*HZ[XCO[(Z^U
MEY6S3+:(C<N?WK'I],5?T?PK;:,]@T%Q+)]BMWMHPX'S*QSD^]077AMK^]UZ
MVF9H['58HF,J]5D7@C\J'S6!<MSET^(.J30^&!&(?.OLB^'E_<(;'X5V?_"6
MZ$=0^Q"]_>%]BOL/ELXZJ&Z9K,3X>Z7'<"9+B97\Z.4\#!*+C'X]33T\":?'
M-&%O+G[!'.US'9<;5E/5L]?PI+G0WR,LP>./#]Q-%%'<3[I@WE%H6"N5SD ]
MSQ7-Z9\0;BXU'2/M2;+2YBE:94@)?<K$#:/IBNC_ .$1M/LVBP?:9=NDR,\1
MP/G+9R#^=-TOP;;:5JEG?K?3S/9K(D*.HP%<DX_#)HM(+P)9?&OA^%+1VO6(
MNANB54).,XR1VJ4:E<Q^+_[,F*?9;BU,UL0/F)&,_P ZR[CX?V<]A#:+J%Q&
ML9;Y@H)(9BQQW!YZUH#3+E_%EK=NA%C869A@D9LL[' .?RI^\+W>ANT=Z*.]
M:&8AZT4'K14E%BZ_X_)_^NC?SJ&M"XT]GN96\]!N<G!^M1?V:V?]?'4J:L-Q
M=RI15O\ LYO^>\?Y4?V<W_/Q'3YT'(RI15O^S6_Y^(Z7^S6_Y^(Z.>(<C*=%
M7/[-?_GO'1_9S?\ /Q'1SQ#D93I.]7?[-;_GXCI/[-;_ )^(Z.>(<C*3*&&&
M4$=P:01QC/[M.?\ 9J]_9K?\]XJ/[-;_ )^(Z.:(TIK8H^7'C_5I_P!\BCRT
M_N)_WR*O_P!FM_S\1TG]FM_S\1T<T1VGW*(BC_YYI_WR*4 *,  #T J]_9K?
M\_$=)_9K'_EXCHYHB:F]&4A3JN?V:W_/Q'2?V:W_ #\1T^>(N5E2BKG]G-_S
M\1T?V<W_ #WCI<Z%R,IT5<_LYO\ GXCH_LU_^?B.CG0^1E.BK?\ 9K?\_$=+
M_9K?\_$='/$.1E,TG:KO]G-_S\1TG]G-_P _$='.A<C*TO\ KC]!3:NR:<S2
M$^?&.!2?V:W_ #\1TE-#<&4Z*N?V:W_/Q'1_9S?\_$=/GB+D93I*N_V<W_/Q
M'1_9K?\ /Q'1SH.1E.BKG]G-_P _$=']G-_SWCHYT'(RG15S^S6_Y^(_RH_L
MYO\ GXCHYXCY&4J6KG]FM_S\1T?V<W_/Q'1SQ%R,ITAZ5=_LYO\ GXCH_LUO
M^?B.CGB'(RK)]V/_ ':;W-7GTYB$_?QC IO]FM_S\1TE-#Y&4Z*N?V:W_/Q'
M1_9K?\_$=/G0N1E.BKG]FM_S\1T?V:W_ #\1T<\1\C*5%7?[-;_GXCH_LUO^
M?B.CGB'(RE2\5<_LYO\ GXCH_LYO^?B.CG0N1E+BBKO]G-_S\1T?V:W_ #\1
MT<\0Y&4J*N_V:W_/Q'1_9K?\]XZ.>(^1E*BKO]FM_P ]XZ/[-;_GXCHYT'(R
MG15S^S6_Y^(Z/[.;_GXCHYT+D93I!5W^SF_Y^(Z/[.;_ )^(Z.>(<C*1HQ5W
M^S6_Y^(Z/[.;_GXCHYXAR,I4=ZN_V:W_ #WCH_LUO^?B.CG0^1E$]:*N_P!F
M'O<)12YT/D9:NY8[<7$\K!8H@SNQ., =:P_#_BK3_$&C2ZFF;2**0I(MR0I3
MT)]CQ5'XCM>7&C2:7931P&\DV2RN"=L>>< #DUPUQHMQ;G5;6#5TOK+4;6.-
MS+ T95T(QP!TP*PN;V/5HM8TR<2F'4K200C=(5E!V#U/M1_;&F?9OM7]HVAM
M\[1+YHVD^F:\RU72X%UF]O-'-M'%-8);A&B<!F!&<C'MUK#BT>?3=(:V:)+Q
MY=7CNEB"N5V#KN..*.9ARGL,GB"Q&H:7:PR)<C49'2.6%@RJ57<<U9CU;3)F
ME6+4+5S""T@64'8!U)]*\NT72_[.U2"^^TP1#[9/<^0B.4A#QE0!QSS6=::%
M*\UV]Z]N%GLY+<I'O 9BP(/"\=*.9A8]5O\ Q3HMAIDFHM?V\L$;K&3$X;YF
M. *EM-=L[H7SLR006CJIGDD78^1G(->56^D3'2-3M96M@DGD-;PNC%BR,"=S
M!<=*NWFG"^AU"0201&6]BN4LRCE)%5<%20..:+L+'JUO=6UW )[:>*:$YQ)&
MP*G'7FHH=4TZY$I@O[600C,I24'8/?TKDK/4[:'PS>VR16UA<SEBD$22/&I/
M&2<?RKB]&TKRO[0.H2P8NK'[/MC5PI8,3D8' -#D"A<]2U3Q5HNDZ2-3FO8I
M+=G$:M$P;<Q/2KT&JZ=<2-'#?VTDBKN95D!*C&>?2O(5TPR>&;JPFEM]_P!H
MCFMH3"Y("]=S8QSZUJ)9V,N@Z[;_ &C['?:A.TBR16[L A4#:3C@=J7,/D9Z
M9'J5A-:2745];/;Q_?E60%5^I[40:E87*QFWOK>42$A-D@.XCJ!7DIT^*:UO
M)/,AM&D$ 6PCCD,4OEXR6;'&<5HZC<P3Z&TMC:0:?JJ7?GVT<,3LO(VG<<>A
M-'.'(SMKGQ?HEMK&GZ4;R.2YO6*Q[&!48]36@FK:9)YPCU&U<P F4+*#L'J:
M\PU#3-.34/#DVG2K)'I]N\,Y>%P^64C>..>3FJ?]GI)8):[;:V>VLI;<3(CD
MWC-T+<<#O]:.8?LV>L#7-'8?+JUD>0.)U[]*L37UG;7$5O/=PQ3R_P"KC>0!
MG^@KQZ70=,%I%'%Y0D331!GRG_UV\'/3T!YJUX@CFU?6[2Y%S 8(/(*L(G#@
MH?F!XYHYQ<C/54U&PDO#:)>V[70SF$2#?^5,N]3MK*[@@F.#(K2,Q/$:+U8^
MW:O+=/MELO&L.I0/%%9BY::1GCD9CD=%&,@UVFIV4/B+4)A'))]AU'3WLA,$
M(,3AMW(/J/Y4T[B<;%J'Q;!/+'+%I]T^E2/Y<>HJ,H[>R]<9[UJMJNF@R@W]
MMF(XD'F#Y/K7)Q>&]>MM&TW1[:2.,V!5$O5FPK1@YY3&=V*FN/#6I1Z&8+:&
MU:Y.H/<N20"T9.>">_L:+BLCI7U;38X(YGOK=8I,[&+C#8]*@LO$&FW=E;73
M7,4 N<^6DC@$X)']*YG2/#.JZ3=)=O8VU[@R@023#*!CD$$C&?6JR>#M8BMV
MBQ$RSVXA9$D $/S$]2,XY[4786.XU*].GV33I;2W,F0J0Q=78]!GH![FC3+^
M/5-.AO8D90^04;JC X(IEQ%<PZ2D%M&ES(J"-T=]GF+C!P?6H?#NGS:7HB6=
MQM!5W9(U.1$A.0N>^/6J$:K_ 'SBD_"G/]\TVF(/PH_"EHH 2BJU[J-EIJ(]
M]=PVRN<*97"[C[57?Q!HR01SOJMFL,N=CF4 -CK@T: :-'X5';W$-U D]O*D
ML3C*NAR#3O,4R^4&7S-N[9GG'KBC0!U&?:CGTHHT /PH_"BEH 3-%+2=J '-
MT7Z4VG-]U?I24D GX4?A2T4P$_"C\*6B@!,^U&?:EHH 3FC\*6B@!**6HY9H
MX(GEFD6.-!EG8X 'O1H _-'X576_LWL_MBW4+6P&3,'&T?C4R.LB*Z,&5AD,
M.A%&@#OPH_"EHH 3\*/PI:* $_"C/M2T4 )^%%+10 E%&** $HI:*0Q\O^O?
M@'YCU%,X'\*_E3YB/.D_WC_.F;A32T![AQ_='Y4HXZ #\*3<*-PHLA!Q_=7\
MJ7C^ZOY4FX49HL@*VH7]OIMHUS<*=@(4*BY+,3@ #US7/ZMXO:U6&"RTYVO9
M+I;:2.90/))&02 ><BMK5]._M33FMUE\J4.LD4F,[74Y4D=Q6./"US<317E_
M?1R7_P!K6YG>./:C!1@*!VXJ7Y%(L>*?$3^'=($\=HMU>, 1#]T8XW,?0#-2
M/K+Q26L9LXBUU:>?;J.,N!DI^O%-\3^%[/Q+:2I(6BN6C\M)PQ^5<YQ@=:2W
MT-H=4TM<,;33+8JCLV2\AQ^@ I687+MC?2OH?V_4;(6<BQL\L/4H%YQ6;<:U
MJ4.C_P!J/#IUK;&#S0)V.Z3/(4>AQC\36[=P"\LKFV8X$\31D_48KCY_"^MZ
MDM@\US9!;2!8EM;F)F577C?P><\=:+#NS6E\07":OHUG_96R'4$#-,[#Y"5S
MM [FM#4M8M]+FMX7MY9IKC/EI#&"3M'/Z5%=:3)>:AI5Y-.HEL26<*N!(2,<
M>@JGXATW5KW5-,GTJ2.%X2^^:1=P4$8Z=Z87'77B[2+2VCN2LKPO&)2ZQC"J
M/7/<>E5+;QC%<ZM<6AM!%#'/%#%.5R)-PW9]JJ7_ (#EF\M+74(Q!]G,,BW,
M9?!/5D[ Y/>IX?!3PZ@LWV\-!OBE>/9\Q9%V]?0BD%_,M+XUT5DED"R^4F\J
M_EC$A7[P6EO_ !3#9PL1ID_VDB.1(I$ +HS!=P/MFLR#X?+;K=6Z7L?V9U<0
M?N_WB%CSN/<#M6SK'AYM4D22.Y$3QVR0IN7(RK!MQ_+I1J%R:T\06>HZ@]E:
M02.ZL4,C1C8K@=#W%6=*U!M0MI&DC$4T,S0S(O0,OI[5C+X;O%\30ZO+>0&*
M!C)Y<$7ER2G&,,>A%:>AV<]K:W$ETNR>ZN'G=/[N3P/RQ36XGJ:E %&:,U1(
MM%)FC-  :.]&:.]# <_WS]*2E<_/^ IN:$ M!I,T$TP.:\3Z=-J6K:.D5M;3
M[/.)6Z!,8^48SCI7-76AK/X8O8;O2XEO8M04FWB0E(@<?</=2.:])[^]''H,
MGK46'<Q=:N&T+P\IT^)X@A5$$* [ >IYZ"N<TW4M=FDDU%K<S7<=K)&'*8&T
M/PV.YQ7>D @A@"#U!I1@#  'TXIV XB+5_$%U.([:\D-J%D9+HVX#2[0" 1V
MYR*)=>UXZG:QAX[59(XF$3QDB8G[W05VR@*  H '8"@JI()521T) XI<H[CC
MQQ1249JB1:*3<*,YH <WW5^E)2L>%^E-S20"T4F:-PI@+12;A1N% "T4FX4;
MA0 M%)N%&X4 +69X@:T30+I[Z*2:V !>*/JYSPOTK2S2$*PPP!'H10P/+=4T
MZ]?P!?0::BS6LTC33PVYQY?(VQJ#U'J17H>A>9_8&GB6(Q2"%0R$YQ5Y511A
M451Z  4[(%)(;8M%)FC<*8A:*3<*-PH 6BDW"C<* %HI-PHW"@!:2C-&: "B
MBBD,EE8><_R#[QIFY?[@I9<><_\ O&F<4(3';E_N"C<O]P4W HXH =N7^X*-
MR_W!3<"EXI@&X?W!1N']P4<4<4 &X?W!2[A_=%-HP* ';A_<%&X?W!3>*.*
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M4?@:,'T-(!**7GTHH&2RNPF?G^(TW>_K2R_ZY_\ >-,IH3';W_O4;W]:;10
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+I>U B*BI**!G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-1_010.jpg
<TEXT>
begin 644 forms-1_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) R@# 2(  A$! Q$!_\0
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M].__ (__ /6I?[;_ .G?_P ?_P#K5CTM:>RCV,_:2[FO_;?_ $[_ /C_ /\
M6H_MO_IW_P#'_P#ZU9%%'LH]@]I+N:_]M_\ 3O\ ^/\ _P!:C^V_^G?_ ,?_
M /K5D44>RCV#VDNYK_VW_P!._P#X_P#_ %J/[;_Z=_\ Q_\ ^M6111[*/8/:
M2[FO_;?_ $[_ /C_ /\ 6H_MO_IW_P#'_P#ZU9%%'LH]@]I+N:_]M_\ 3O\
M^/\ _P!:C^V_^G?_ ,?_ /K5D44>RCV#VDNYK_VW_P!._P#X_P#_ %J/[;_Z
M=_\ Q_\ ^M6111[*/8/:2[FO_;?_ $[_ /C_ /\ 6H_MO_IW_P#'_P#ZU9%%
M'LH]@]I+N:_]M_\ 3O\ ^/\ _P!:C^V_^G?_ ,?_ /K5D44>RCV#VDNYK_VW
M_P!._P#X_P#_ %J/[;_Z=_\ Q_\ ^M6111[*/8/:2[FO_;?_ $[_ /C_ /\
M6H_MO_IW_P#'_P#ZU9%%'LH]@]I+N:_]M_\ 3O\ ^/\ _P!:C^V_^G?_ ,?_
M /K5D44>RCV#VDNYK_VW_P!._P#X_P#_ %J/[;_Z=_\ Q_\ ^M6111[*/8/:
M2[FO_;?_ $[_ /C_ /\ 6H_MO_IW_P#'_P#ZU9%%'LH]@]I+N:_]M_\ 3O\
M^/\ _P!:C^V_^G?_ ,?_ /K5D44>RCV#VDNYK_VW_P!._P#X_P#_ %J3^V_^
MG?\ \?\ _K5DT'I1[*/8/:2[FM_;G_3O_P"/_P#UJDEU?RB!Y&<C/W__ *U8
M@_K5FZ^\GTJ?9Q[![25MR]_;?_3O_P"/_P#UJ7^V_P#IW_\ '_\ ZU9%%5[*
M/8/:2[FO_;?_ $[_ /C_ /\ 6H_MO_IW_P#'_P#ZU9%%'LH]@]I+N:_]M_\
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MP]I+N:/]N?\ 3O\ ^/\ _P!:C^V_^G?_ ,?_ /K5D4HJO91["]I+N:_]M_\
M3O\ ^/\ _P!:C^V_^G?_ ,?_ /K5D44>RCV'[27<U_[;_P"G?_Q__P"M1_;?
M_3O_ ./_ /UJR**/91[![27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/
M91[![27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/91[![27<U_[;_P"G
M?_Q__P"M1_;?_3O_ ./_ /UJR**/91[![27<U_[;_P"G?_Q__P"M1_;?_3O_
M ./_ /UJR**/91[![27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/91[!
M[27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/91[![27<U_[;_P"G?_Q_
M_P"M1_;?_3O_ ./_ /UJR**/91[![27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_
M /UJR**/91[![27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/91[![27<
MU_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/91[![27<U_[;_P"G?_Q__P"M
M1_;?_3O_ ./_ /UJR**/91[![27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJ
MR**/91[![27<U_[;_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/91[![27<U_[;
M_P"G?_Q__P"M1_;?_3O_ ./_ /UJR**/91[![27<UO[<_P"G?_Q__P"M1_;G
M_3O_ ./_ /UJR/6@=*/91[![27<W[/4_M4YB\G;QG.[/]**S](_X_C]**YII
M)Z'1!MK4DU?[S?[P_E69WK4U;[S?[P_E681711V,*NX=Z*04M:F3"BBB@ HH
MHH **** "BBB@ HHI* %HIR1NX.U<XZTIAE .4(%*X#**08-+^-, HI!2].M
M !101UQSBDH 6BCFDH 6BBB@ HHHH **** "BBB@ H/2B@]* $']:LW7WD^E
M5A_6K-U]Y/I4]1K8KT4450@HHHH ***2@!: "3P.:3-9VM:=?ZI:)#IVH&QE
M!R9 ,Y'I28T:6QA_"?>D_#'M7E.FS^)9]<U6UF\0.8=+7S'^7[X';K70Z-\2
M;'5PHAL+CR8P?-N"/E7'4U*FBW!G;45R5A\0M,O]32T:"6".8XAG;[KTNN>/
MK'1-0FM?L<UR( &FD3[J T<Z)Y6=6,EL<\4H_6N \;^.+G3-/TV32[>0QWCJ
M?-QU![59N/B58VMXEA)I]T]WY0D*@>HHYT/D9VU)7"K\5=(=(W%G<!2_ER-C
MB,^];VO>*K+08K8F-[F>Z7=%"G#$>M'.A<K-VD-<\OC/3F\*3>(%1_)@.V6+
M^)3G&*S]-^).F:CJ-I:_8KB);I<PRL.']J?.A\C.QY(R<XI:\]M?'%]<_$9M
M'>SD6U"X"]P?6O0F R1FFG?8EIH**04M,04444 %%%% !V_*I;G_ %H^@J+M
M^52W/^M'T%2]Q]"&E%)2U0@HHHH .3P.]'(.".?2LGQ1=SV'AB]N[=MDT:95
MO2F^%+R?4/"MA=7+[[B5<LQ[TN9#LS8HKE]?\=6.@ZC]@^S375PJ;Y%C'W%]
M35L>+]);PXVN+*3;J,%>^[TI<R'RLW:*Y?0_'>GZS??8I+::SN64-&LH^\/6
MJK?$?34U-;9K.?R&F\D7!^[NHYD'*SLL'MT]:3CK7(/K%]_PLR#3!-FRD@\S
M9^==!K>L6>@Z<]_>MB-3A0.I/H*%)!RLT**YG0?&UAKEQ/;O;RV<L,?FE91U
M3UK//Q/TC[41';3R62OY;W8'R@T<Z#E9VU)_GBN0UKXC:7HNK0Z?);S3/,@>
M,Q]\C(J"3XBP3Z#?W=E92K=VIPT3?P^]+G0<K.WY#8-%>8Z#\3C%X8?4M9M)
MG8S;%*C&?85T9\>6D6BR:I=V,]M""!$K=9">PHYT#@SJ\YX'6D(((R"/2N<\
M/^-=/U^YGLS!)9WL<9=8I>XQP15?P)JM]JT&J&^E\QH;IHT]ADTU),'%HZSB
MCKP,_A7.>(O&-IX?N5MC:RW4Y7>4C_A [FL3Q'\0A#X.&J:1;2.TO&XC[ASW
MH<D@46SO2<<'\12[3C(4FL?POJLNL>&;6_DA=9FCY5OXC7'>(;SQA:6M[KES
M>)86UL0(;<#/F4.20*+;L>DT51TV]EN]!MM0EBQ(\/F.@]<5C'QSIJ^&+C76
MC<102F)H^^[.*.9"Y6=/17)W'CVRM].LK@6<TD]XN^.V'W@OK5^W\6:;<^&Y
M=<4L(8!B6/N&]*.9#Y6;M%<KHGCRQUK438-:S6D^SS$$G\0JM;_$>PN=1N;1
M+"XQ;$B:7'"X[T<R#E9V=)FN)MOB;IMS<QH+&X6V>3RQ<=1FNVXQGU&1333$
MTT+124M,0GK0.E+0* +VC_\ 'Z?]VBC1_P#C]/\ NT5QU?B.NGL2ZM]YO]X?
MRK,-:>K?>;_?'\JS#WK>CL8U=Q!2T@I16IDPHHHH **** "BBB@ HHHH ***
M3KTH Y_Q9;ZRVGRWFE:I]C%M$SLFW._ ^M<)X9\2^()]!?Q%JNLL]I!,(V@5
M>6YQZUZ=K<;R^'M11%WNT#!5'<X->5Z#H.J/\*-1M392)="X$@B<8+ 'L*PD
M]3>*;6QW^L>-=.TB?3HIX9"=1 :+!^YGUJA??$C3;.ZNH#87<QM6'G,@RJCU
M)Q7":Q<:KXDU3PZ\>BW4,%D%1RR=QBMIM+O_ +'XQ"V<FZ=1Y?'WQ@\"ESOH
M5[+R.D3XC:3+<VBQVMV;:Y8*MRR$)N/:K&L^.-/TG5!ID-M/?WF-S1VPS@5S
M5[IUX? GAZ%;-C*ERC,BKRHR.33)GU/P5X]N-5;3);VPN8P0\2[B#CI2YV/V
M7D=)-\0-)AT ZLT4NU)/+E@QAT;T(J_X?\3)XCWM#I]U;0 96688#_3BO-[[
M1-7NO#EYJ<MBZR7]^LJ6X'*ID\D?C7K>G(T6DVJ.FS" % .E5"5R)PL6/2BE
M_I2"MS 6BBB@ HHHH **** "BBB@ H/2B@]* $']:LW7WD^E5A_6K-U]^/Z5
M/4:V*]%'>BJ$%%%% !1110 G2G)@/DTWFC'/3- SSO3]+OX]=\62M:2HD\!6
M$E?OG':K/A;0+D?#2ZL#:F"_E5@-XP>M=YD],FD.21N'Y5#@B^=GB?AKP?<S
M:C96MSI^H));G+RRDA!].*L>+]*UZ_U#5+(Z=<NA4"V> ':X']XXKV4LV,$\
M4H=AD$_3%2Z:'[0\W\2Z;?3?#SP[Y-A)+/9R(9H%7YQ@^E2^'[&>]^(-[JEU
MIDD4$MF AD3HV!Q]:]"#$'(X)ZGUHW$@;CQGTZ4E30W5/'X] O\ _A$M:C_L
MN3[1)?;T78<E<GD5>\;>'=0N9]$U)8;F:WBMPDD=O_K$.*]2#/G)(H#8Z'\,
M4W30O:,\QM_#=Q:_#35(HK*X6>[D#+;R'<^,CG&*N:GHTP?P9]FL&Q;!?.VK
M]SCG->A;CNW9YHR>>>/I1[- ZAPMQ#=:=\6'O?[-FFM+B,()HURJ&NZ8$,2<
M?A1N8<9RO\J3IV^E7%61,FV+1115$!1110 4444 ':I;G_6CZ"HNWXU+<_ZT
M?05+W'T(:6DI15""BBDP>QH R/%EO+=>$[^"!#)*\9"H.IKEO#/BR\TC0K&P
MN/#&IL\0VLP0X_E7H/3D=?6E\Q^YR*APNRU))'FEQ]OT3Q1J.JOH$VH0:E!M
MB"KDQDC&#Q6;#X$UN/P9<E@/,>X%RMIG^'.=M>N[V'0_2DW-GKSZTG3'[1G%
MZ9J=YJ]]"\7A0VIABVF:X&T@@=N*\_O=*UZ^O89+G2[SSX;O<X12(MN1STYK
MW0N[<$\=Z7>V"<\'VI>S#VAPZV%VWQ-L;W[-(+86FUI"O ..E6OB'HEYK.BQ
M-8H)7@D$C0]W /:NMR0,=O2DR0<]#ZBJY!<^IQ%M/=^);2[MH?#K::QM3%]I
ME&&)QT'%<CI^EZQIOA"Z\'S>'I9+RXGRMX!\@!QSG%>S%V)Y/':C>^!C\:GV
M2*]H>2GPQJ,/Q$T7S[*2>WMH51YMI*@@5L6FAWDGB#Q4!9E([@'R6*X5OI7H
M6X[<>M&3C&<8Z"CV:$ZC/$UTS5)?"5KHS:+=)-!J*N[-&<,N>O3VKO?B#HUS
M?Z5I-QIUMYRZ:Z22VJC_ %@&.!78;FXYY-("1@C[WK1[-#=0\VM-.U'Q3XR3
M6XM-DTBWMX-I608:0XZ8XK8^'EG=64.K?:K>2'S;MG7>,9&3S79,V[J3^%(2
M3][GT/K3C!(F4KGF'C>VURYUYH5TZ9[-XF5)+89;/N:33=!U%O@Y<Z<;*5;Q
M92PB<?,1G->HAVQA>*3)SG.*/9ZL?/HC$\*W4DWA6U::REM9+>,(T3KAC@>G
MX5P7B'5]6\1:_%'?:%J!T.U;<L449S(WOQ7K!.3DCGU]:7S'QV_ 4.&B$IV9
M7L94FLK>40-;HRX\IQR@]#7D=]HEQ=^-IO"D#HVF3R_:I"ISBO8B,Y#8.1^E
M4-/T#2=(N);FQ@9;F?EY'.XT2CLAQE8\]\>^%;J/7--N[:WNIK"&W\C;:_?!
M&!_2IK'P]J.E> ;Z:PLI!=3\K;2G+8]<>M>F E1Q^-&YB0<YXQ]*7LQ^T/&_
M#.EZG!XQAU";3KY8GAV.TRGAN>G' KI_!^CS0Z7XB%QIS"6XE;8L@P77V-=]
MN)!R<TA))Y_ T_9H3J,\/@T;5+.XACTC2-0AF$P+1SJ3#CU'%>VH&\J/S,!P
MH# =,T\.Y'+&D(-.,;"E*X4M HJR H%% H OZ/\ \?I_W:*-'_X_3_NT5QU-
MSJI?"/U?[S?[P_E6::T]7^\W^\/Y5F=JWH[&57<04M)BEK4R"BBB@ HHHH *
M*** "BBB@ Z4@I:2@"M-9">7>9I%']U3W]:8=.&1FYF9NY!ZBKG\Z*AP3-HU
MII%3^SSR!=2#\>OM2?V:H/\ Q\2^W/3VJ[2?A1R1#V]0IC31@XN)0/X1GH:!
MIX'RFYEV'^$GOZU<HZT<D1^WJ=RG_9P!&;F8_P![GK4MM;_9P<RM(3ZFIZ*:
MBD3*K*2U%[T4F**HR%HHHH **** "BBB@ HHHH *0]*6@]* $']:L77WX_I5
M?_&K%U]Z/Z5/4:V(!10**H04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 G8_6IKG_7#Z"H>U37'^M'^Z*BVH^A#2T4
M58@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *!110!?T?_C]/^[11I'_ !_'_=HKCJ?$
M=5+X2;4HGFE98QD[A_*J7]GW?_/,5I71(NF(.#N'\J:9)#GYS3@VD$XILS_[
M/NO^>=']G77_ #SK0\Q_[QH\Q_[YK12D9N*,_P#L^Z_YYT?V?=?\\ZT/,?\
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MO&CS9/[QHYI"Y8E#^S[K_GG1_9]U_P \ZO\ FOZFCS9/[QHYI#Y8E#[!=?\
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M)'S.!WQ1=A9'2V_Q$N=8\<6]CIY:&Q9-TD4J885T,WQ(T"+6?[/)E(\SRC<
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M6BBDS2T#47FC\:2B@0M%)13 **,^E*,FBX!1111J%PQ12?R]:,T +1BDS2T
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M1<!/QIL<<<:%(XT1#R5 X)I^QO2C:WI0!$MM;(KHEO&B/RZJN WUIZJL:!$
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MI2T@I:8@HHHH **** "BBB@!DC>7#(XY*J6'X"N)T_7-?U2TN+J/4M-@6-V
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M !1110 4444 %%%% !1110 4@I:04 2VW_'XGT-%%M_Q^)]#16,MS6.P7?\
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M_3ZU))]\?2CRGX^4T^2)RPPIZ47 BI,T_P I_P"Z:/*?^Z:+CL,S1FG^4_\
M=-'E/_=-%PL,HI_E/_=-'E/_ '31<0RBG^4_]TT>4_\ =-%P&44_RG_NFCRG
M_NFBX#*,T_RG_NFCRG_NFBX6&9HS3_*?^Z:/*?\ NFBX6&44_P I_P"Z:/*?
M^Z:+@,SSG.3V!H!.>OYT_P I_P"Z:/*?^[3N,;GM@ >@%(&QP !Z\4_RG_NT
M>4W]TT@&9[# '<#I13_*?^Z:#$_]TT7$,HI_E/\ W31Y3_W31<!E%/\ *?\
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M:/-?^\:2CK2L OFR?WC1YC_WC^=)C%)18!WF/_>-'F/_ 'C28HQ18+B^8_\
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MY49&V3_GDWY4;9/^>3?E6O11SL.4R-LG_/)ORHVR?\\F_*M>BCG8<ID;9/\
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EVR?\\FI0LF?]4U:]%'.PY3-M8'DF+R+A,$%2.N:*TJ*EL:/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-1_011.jpg
<TEXT>
begin 644 forms-1_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (' Z\# 2(  A$! Q$!_\0
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M^6J_]^H__BZ/^%T^'/\ GRU7_OU'_P#%UX311]4I!]8F>[?\+I\.?\^6J_\
M?J/_ .+H_P"%T^'/^?+5?^_4?_Q=>$T4?5*0?6)GNW_"Z?#G_/EJO_?J/_XN
MC_A=/AS_ )\M5_[]1_\ Q=>$T4?5*0?6)GNW_"Z?#G_/EJO_ 'ZC_P#BZ/\
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MN^OT]Z7U6E_3%[>I_2/<O^%T^'/^?+5?^_4?_P 71_PNGPY_SY:K_P!^H_\
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MU/Z1[A_PNKPY_P ^6J_]^H__ (NC_A=/AS_GRU7_ +]1_P#Q=>%.C1N4=2K
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M"S&44_RI?^>;_P#?)H\J7_GF_P#WR:+H+,913_*E_P">;_\ ?)H\J7_GF_\
MWR:+H+,913_*E_YYO_WR:/*E_P">;_\ ?)HN@LQE%/\ *E_YYO\ ]\FCRI?^
M>3_]\FBZ"S&44_RI?^>;_P#?)H\J7_GF_P#WR:+H+,913_*E_P">;_\ ?)H\
MJ7_GF_\ WR:+H+,913_*E_YYO_WR:/*E_P">;_\ ?)HN@LQE%/\ *E_YYO\
M]\FCRI?^>;_]\FBZ"S&44_RI?^>;_P#?)H\J7_GF_P#WR:+H+,913_*E_P">
M;_\ ?)H\J7_GF_\ WR:+H+,913_*E_YYO_WR:/*E_P">;_\ ?)HN@LQE%/\
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M-]1JK-'<:MXPTZZ\.O8VX?S3:BV*O Q#D/G?G?A2>OW2<]\5PE/\F3_GD_\
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M48IV*3% 6$Q1BEQ1B@+"8HQ2XHQ0%A,48I<48H"PFWKBC%+2T!8;BC%+BC%
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M./8@@_7/I76T8&:6ID[LI*P4444AA1110 4444 %%%% !1110 4444 %%%%
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MK'QR6P>I. ,54E\3RB]CM5L8XI6M_.9;RY$&WYBNW[ISR.OI1RL=T=)FC(K
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MQJ_>N3:)EW.@ZA9BWO)YDF>S6".%;>!WSY9/S.HY((/.W.#ZU<T33+\:/+<
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M0 4444 %%%% !1110 4444 %%%% !1110!C7F@K<W%Q+'>75L+H 7$<)4"3
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MH451_M:P^T?9_MD'G&7R=F\9WXSM^N.<5);ZA:W,\\$-S%)-;L%FC1@3&3R
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MLT;!@&'4''<4K,+HLT444#"BLV?7]*MKM[6:_@2X3&Z(O\RYY&1VS6B&#=*
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M(DJ&3/E;4W CCY@P^E*TG=V'HGN6- $FGV2:5>6=S)=K<2LTWD$H=SL1)O\
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MJ2:<^F(84D:]N5@;#G"94G(XYZ>U8FH^-TT^"Y>:".,1:B;%99)#Y8PH;<Q
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MSR@J^T DA@",@'\J]"I*3J-@H'FLOA[4+K4=/D\B:$-=WEU VT_Z+N ,>['
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MNVE_:-5@O'@GC6":T*Q1L2V/G\L>O][O71:+<*;6UM/[/N8IH+<([26Y58R
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MU(!5FVAAD<C/&>W>II]"\ 6[2+)I.G;HY#&RK;%B& #'@#L""3T'>J4HKI^
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M<G ZU.\VM2(^Z^O=BV%R\)C=T/F!P8P<G<6QG&[DCJ*Z?_A _"G_ $+VG_\
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MA+:W=XT]W8R-,KW#R'B$MY@W$E2&P./[U5%7);L=[17)ZEK#6$VG7'G.T?\
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M9KNYMH8D=59W+NH&X <D\D_A5""[O;W3;.S2XE>YMIY(98)KA[6:Z55^5MV
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MKG'-2D4WJ;\-CI]MY,<-O!'Y+'R@J@%&(YQ[D&HI=-TEK>:.6UM?)>4RR!E
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M.0QR.<>N:V_#NHW>IRSO/E5MPMO(NP#,X^^?IT]N:EQ:&I(Z"BBBI*"BBB@
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M*%(+E93([' 7H,>O/H:H-H6JR>'+G17-CY3JX23<^22Y897;TY]35EM&NY8
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MKNVGMI4CT^[6.*5##<[MB;WW@)\K<#I6Q?Z9/?V5A%^X@>WN8IG5,E,*>0O
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MB@ HHHH **** "BBB@ HHHH **** ,*XU_RM3GM(;)YQ;%!,4<;QN (*IU8
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M[B)T,,<,H$TJKMC8D$!2-V0>AQ@^M:.E>'[RPU*SDDEMFM;.&:*,J#YCAV#
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M<7C+S=/T:?[ 5FU&8120F3_4#."2<<\E1V^\*N+K\QMTU!K)1I<D@19O-_>
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MC.<5=L]2L]0\S[+.LGEMM? (P<9'7U'?O6"WA&2::]N)[Y6N+R":*4K#A09
M@!4;C@ )TSSGK6OI^EFRO+NX,V_SQ&-NW&W8NW]>M)J/0+OJ:5%%%06%%%%
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M=:??PI$$(5HURX9@HP0V,Y(X)!'<4Z[\0-910M<:7?(\\ZP11?NBSL03U$F
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M=F46YFVH4B+ $9^;)Z\D T<K'=&_135;<N0<BG4AA1110 4444 &*3'%+10
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MQ-$7^[M(W CJ%_"FG.]A/EM?L:FN:?K&N>'[JQ>SM(F;RMBF<G>5=6;)V\#
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MTJ*&>*"WEM=-DLX0)BX=W51N)QP/E]^M%]XGO;?4=/=+B-;&VA@?405&6,W
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M6S7"EC;3">/!(PXX!]^M6\"C%*["R,IO#NGN;AC&XDGN/M)D60AEDQMW*>W
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MRC.?4UOT4^9BY48LGAC37=W431R-,TX>*5E*.PPQ4CID=?6FW?A72[T$2I,
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M %HHS29%,!:*3-&10 M%)FC-(!:*3-&:8"T4F11D4 +129 HR* %HI,BC(H
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MT4F1ZTN: "BDR*,B@!:*3(I: "BBB@ HHHH **** "BBC- !1110 4449Q0
M4444 %%%)Q0 M%&129% "T49HH **3(I<T %%&:* "BBB@ /0UR5EXQ6^\27
M6DQBVC>WD:-HI9"LQ &0ZJ1A@3V!R.M=:>E<Q<>$X[S6X-3NYXY)+>4RPL+<
M)*." K.#\RCTP#QUJH\M]297Z%+3O&,U_HTNHYTTM';23FTCG8RC:#@'C\ZT
M-5\12:=H>GWZQP!KR2)&\V0A(]XSDD#.!4=IX:O;;P^VAMJ<,ED;=X!BU(D
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MWXAO=-5EO[2!97M9;F 12$C,:[BC9'7W'%5!XQN8+83W5K#,&T]KY1:.6V@
M?*V1QG=U]C5^?PW+?*WVZ_\ .D6VDMH'6';Y8=<%F&3N;'?@>U1VOA,:=+OT
MZ\^R%[1;><) I$K*,+)@\9ZYZYS^-"<+#U+'AGQ OB&S>X22S=%(VM;2EB,C
MHRL 5/\ .J=AXIN+C3;G5+E;..T@$Q:*.1FFPC$=,8YQ^M7-"\-0:)>7MXGD
M^?=[?,$$/E1_+G&%R>>3DYI+#PK86>D3V,L<<QG\T23",([!V)(SUXSZ]J3Y
M;Z K]2M<^);S3H8WOK.%3<0236XCD)Y1-^Q\CKCN/2GZ1X@N;V^L[:YAMR+N
MU-RKVSEA'C'RMD<=?TI9O#,EY$L=[J'G^3!)!;D0[2F]=I=N3N;'T'M4FE^&
M8='U"*YLY1&IMEAN(EC 68J,*_7AOSS3O"PO>&-J^J#Q-)I1@L_*6W%SYF]L
M[-Q7&,8SQ]*S[3QU%>6NEM&D#7%VLK30I+DP[%+>G?&*WSI(/B&35?..7M!:
M^5MZ?,6W9S[XQ6;#X32'3M(M/MC$:<LBAO+^_O4KZ\8SGO0G#J-I]/ZV%\-^
M(I=<AAE>;3AYD(E:&"4M)'GLP-..KZJ/$-QII@LO+A@%R7WON*$D 8QC/'TJ
MWHFF7VDV=O9R7\%Q:V\0C0+;%'.!@$MO(_2I#I(.MW&I><09K46WE[>@!)SG
M/O2;C<:O8PK+Q?>36]C/-:VS+>PRRHD$I9HBBEL/D=#C&?6K>A>)?[4L?MD]
MQIPC%OY[QP2EGC&,_,#4-IX+@L([46ER(94M6M;AUA ^TH0<%AGJ"<@\^E3?
M\(YJ#>'?[$EU:+[-Y"P!H[4K)M& >3(1R 1T[TWR="=;ZD6F>)K_ %31+RZ6
MSAM[NU.]H)7)!B*[T;(&>5_7-5Y/&%[:VN@W%U9VYCU61<^4[?N4(!R<CD\U
MH1>%X;:^NI[>[G"W-I]EDCE8R>NU@2>P)&*BO/"$5YI6G6$EVP6RMG@#A.6W
M)MW=>,8S3O"X6D9A\?2N]P$M;:*)-26RCFFE(4H0Q\PX'^S^M79_%[6=[I,4
MRVMQ;WK2>9<VDA9(E7 !YZC)Y]*;#X(^RI;_ &74-DD$T$R%X-P)CC*<C<.N
M2>M:%QX>DU&]M;K4KN*8PQS1,D<!1760 =V;!&*'R=!)2,YO%6I2:997UO:6
MFVZOC9;7D;Y6\QD#9 Y'RYK<U'5)M.MK1#$DMY=2K"B*Q";B"22>NT $UF67
MA!+/0M-TL7KNMC>BZ61DY?#LP4\_[6,UL:IIBZE% 1*89K>430R@9VL..1W!
M!((]Z&X7TV*2>[,*^\575A(UG+;6PODN((F)D(B*RYP^<9&,$8-:EYJEQIWA
MN[U*9;:::WB:4+"YV-CIR>:IW/A1+^3S[RZ66Y>YAFE;R0$98\[4"DG Y/<]
M:U-1TB"\T.ZTN+;:QSQ-&#&@PF>X Q4OET!7N<[>^.8HI"MDEM=JMHEPS)-G
M:S2*A4X]FS4OB#Q?<:/)J20V*3M9QV[J"Y!?S&((Z<8Q5O4/"D6I3&26Y=1]
MB%H%5.A#AP_YCI39_"S7C337EZ)+F>2!G=(=B[(FW!0NX]><G/>JO 5ID=EX
MN2\\23:>L*BTBLQ<M<;^<X#%<=. PJDOCBX/AC4M4?352YM&0I;&0_/&^W8V
M<<9!_,4Z#P#%:VDMO!J,B&6*6%G\O)VR.&/?LH"C\_:I;_P+!<B=+?4+B%)[
M9+=Q(3-PCAE(+-QC!&/>FW3N+W[&CI'B%=7U.6UBA"Q);1S[B?F#,S J1V(*
MFJ-OXINS&;NXMK=+'[>UCE9#O#!]H8@C&">P]:T-,\.PZ9K^HZK#*W^G*@:'
M;PK G)!]\U5M_"KQJUO/?++9?;&O1$(-K%RVX MN.5!] #P.:GW;C2E;4R3\
M0L6^EF2"UMI;^)Y0;F5EBRKE=@8#@G&<G@5HKXIFDUV[T[S-,M_(>-%\^<AY
M=R!OE '/7%1OX($F@6^C27D4UK$C(PGM _)8G>AR"K<XZD>U7-/\.76CW-P^
MGZA$L$WE9CGMC(P"($'S!QU ]*;Y-; N8)/$K1>+8]'^S#[,0$:YW?=F*EE3
M'NHS^(JGI_C-=1U:^LXUM4:U:56@DE*S@IT;:1@@^QXS4DW@R.=;B1M1N1=R
MWHO!+EMBN&!7]WNP<*-M/F\(1W>L1ZE=7,4D\._RY$M@DAW*1AV!PP /3 ]S
M1> /FZ#O#7B.77HH96FTX>9%YA@@F+2Q_4'BNF'05BZ)I5]I%G;V3ZA!/;6\
M?EH!;%'..A+;R/TK;'2LW:^A4;VU"BBBD4%%%% !1110 4E+2=Z .'ET#1+S
M5KZ"P\+Z/,UJZ_:'GB"EW8;L+@'G!&2?6IVT3P,EY]E?1M,68':W^B JK8SM
M+;=N[';.?:J<]YK\.JWEQI_AS4H!<L/..8'W%1M#IF0;20!U!'3BJ4L6K2S2
MAO"^K?99;H7KQ>9!N,P P0WF?=R <8_''%;I/O\ B8MKL:$5I\.YXO-CTO3"
MGEK*&-D5!1FVAAE>1NX)[=ZGGTGP) 9$ET?3=\<AC9%L]Q#!0QP IR #DD<#
MO6%:V6I6\4,4OA;5IHX]-:P(,D W*6W;O]9P?;]:A;3-1.GV,/\ PC&JR7%J
M92T\SP/YQD^^67S!STQSV[U5O-_?_P $EM=CH%T[X??:1;KI6F,^]$RMEE<N
M-R#<%QR.G/-5+.T\&7TMN8O#NF10.UPKFYM?+8>5U(!7!'KD\?6J"6>IQB18
M_"^JHCW%M.JAK<;?)4 *,/CG'IQGI1]BU-X_(E\+:LUL#=819( <3\D;O,Z@
MDX.*$M-_Q"ZOM^!L?V=X $'G-I&FJF]$^>Q(;+G"'!7.#V/0^M7[#POX-U.V
M\^TT+37C#,AW684A@<$$$ @Y[$5S,MOK-S)%/<^&M5>>)K?:ZM H\N)MP7'F
M'DGJ?R%=AX2AN(;&]:YL;FS>:\DF\N<H3\V#QM)&.WX5,KI7O^(XV;M;\ _X
M0?PO_P!"_IG_ (#+_A1_P@_A;MX>TS_P&7_"N@HK+GEW->2/8R].\-Z+I%R;
MC3M*L[68H4+PPA3MX.,CMP*U***3;>XTDM@HHHI#"J]X\\=J[6T:23 ?(LC[
M5)]S@U8K(\17.H6VF9TRTN+BY9PH%OY>Y!UW$.0". /7FFE=B9A2>-)A:VKI
M:Q RS3QR3D.\2K%UD^52=I/KBKR>)O.UA[*$VC)#M$FZ?#OE Y,:X^8 $?G7
M-;_$:VMU%'H.JHUZ\CW9_P!'*OO !VCS,H0!QR??-1BSU&.YC:#PKJ\4"2Q3
M&,2VY8R1IL5MQ?IC&1@YK?D1ES,VH?&=S+H4U\;2,W.8O+LPLHD D;"E@5R1
MC)RH(XJQ?>,%LM)L;A5ANKBZN%A"Q%@JC>%9CN&X8R!@CKQ6+%/XFCNI;XZ#
MJK:@\:0B<?9@OEJQ;#)YF"22<D$>V*H3Z1>SVI7_ (1?74N6E$LDZ7<2ACYG
MF$;1)@#/XCCDTE%7U#F9V%CXI^T:V+!X$C26::"+Y_W@:+DEE[ C.,5THZ5P
MFGG5+CQ/;7=[X=OXXU=MDLGD#RMRXR[*^7 &0.,\]Z[L=*RDDMC2+;%HHHJ2
M@HHHH **** $)KG[77+K4,7-K%:_83,T*^;,5D<*VTL!C'4'BMZ5BD;.JEF4
M$A1W]J\QNK35KFV%FOA;4H]/^T?:!$?LS2(Q?>55S)\H)]B?>K@KD2=CN$\4
MZ0]L\Z3R-$DAB++;R'+@D$#Y>2,'..E(WBS1%VG[<"K1I-N6-F 1SA6) P!G
MC)Z=ZX@6VLIIL-FGAO5L174MSEG@*OYA8E67S.<;N.>H!Q5>+2]5CTN:Q'AS
M5BLEG%:;MUOP$<L&_P!9U.:T]G'N0ZCZ'>6_BW3)UN&)GC\FX:W :!RSLHR=
MH )(')/IWQ4.M^+;+3K!IK:1+J8)'(J+N*E78!26 (7.3C/6N.NM/U.XD:3_
M (1;4]PN9+B/>T#!?,7#J1YHW#@$=,>]%Q8:LUM-;VOAG58(9HH8Y5!MSGRC
ME2N) %ST(Q],4>SB'M&>I@\"EJ.,DQH2I4D#*GM[5)6!L(>E<K<>+S;WTRFT
MWVJRS6Z%"3(\D:;SQCH<$?6NI<D*2!DBO.,:N-4-XOA;5E0327,<0DM\I*Z[
M2V2_([@8ZG\*N"3W(FVMCJM!\0?VO+/!(L*S11QR_N9-ZE)!D<^HP0:Y^?XA
MRP:;J,QTY#<6U]]FCC\PXD3)R^<>BM^5063:M;M-++X5UAKB4IO>VG@MP0F<
M#"R=\DGL2>@K*GT/4)II)3X:U?<T4Z?ZR#K(Y;./,ZJ"P_&M5"-]2'-V/0F\
M2Z5#.8)KG9,J,[ HV/E7<P!Q@D#G YJU#J2:AIQN]/4S!E)B\Q6B#\<<L,X/
MKBO-KG3-8N+MKAO#NK'+3%=QMRR^9'L(W&3H.H  ]*UC<ZXNE0VL'AS7()8;
M;[/'*EU"%'RXW%/,P3WYJ7370%-]32'BZY:YDL$MK:2_CG:$LDA\GY8][<XS
MD=,>M3OXIE6STS4%M8A97S0HBF3]ZS2>BXQ\O>N4L[/6[+3+2VB\,WZS6CLT
M<ZB$;BR[7+@S'<3G.<BG16NM6VK:?>0^&M1:'3[=;>WMY_)<1@?>8$2CYCZX
M.*?)$7,SM;#6KF77Y-)O+>%)EM_M'[F3?L7=M ;@<GJ*W:X+P9#K%AJUP+[1
M[M1>NTLU[.L>[=U )61N,< !>]=[6<TD]#2#N@HHHJ"PI,"EHH ,4F!Z4N<4
MF10 N!Z4F!Z49'K1D>M !M'I1@#M1D>M&1ZT +@4FT>E&1ZT9'K0 N*3 %&1
MZTN10 F!Z48'I1D>M&X>M !@>E&!Z4;AZT9% !@>E&!Z49%&10 8![4;1Z49
M%&X>M !M'I1@49'K1D4 &!Z48'I1D>M&1ZT &!Z48%&X>M&X$9!XH ,#THP/
M2C(]:,CUH ,#THP/2C(]:,@=Z # HP/2C(HR* # ]*,"C(HR* %P*3 ]*6B@
M!,"C I:* $P*,"EHH 3 ]*,"EHH 3:/2EP*** $P/2C ]*6B@!,#THP*6B@!
M,"EQ110 F!Z4;0>U+10 F!Z48'I2T4 )@>E+@444 &!28%+10 F!Z48'I2T4
M )@>E+110 4444 %%%% !1110 4444 &!28%+D4F10 8'I1@>E+D4F1ZT &!
MZ48'I2YHH 0@'J*4#%%% !1110 4444 %%%% !01FBC- "8%&!1D4;AZT &!
MZ48%+D4F10 8'I2TF1ZTO6@ HHHH **** "BBB@ (!ZTFT>E+2;AC.: #:/2
MC:/2C</6C</6@ P*-H]*,CUHR/6@!<"BC.:* "DP/2EI,B@!<"DP/2C(HR*
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M$LYES^Z>7:V3_LDTG*_3^M!V.%34[JX%U<WD>I70CL8F5[:Y,(3)<"1E#KU
M5B0#]*T;N2]B22ZEO7NTMK>$RRV=WL>W;;EG\LX60-UY[=!762/I]M</YK6L
M4TB!&W%5+*,X'N.3^=0R:9HBS6RR6=BLT8"VX9$#*!T"C_"FY+L+E?<TXFWQ
M*PZ$ YQBGTB].*6LBT%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y-+>YO/%6I
MH\L$$T(!_M"6+RQY:DXC4;6]>2,U5E\5ZC%I)OB+ -Y<DRP!9&<HC%>W3./O
M=!Z&NK8VEI,S.T$,D[#)8A3(1P/KQQ44FC:9<)&DVGVKK&"$#1*0H/4#CO57
M74FS[G/MXJO8_,N6M8#9K.80JD^8?W>\'/3VZ>]++XDU&*ULMT5I)/>L#%Y
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M>1"L46'$6!M3!R#CV(_2ES);H;BWU.:BFU&W\26J/YLGVB\E5Y1<!HVB"DJ
MF?E*_+G@?4YKL1TJC;6NG^<]];P6_FS#YIXU&7'NPZU,M];>29?M,'E X+B0
M;<^F:ENXTK%FBH_-7*\K\QP.>M->YCB95D=$+G"[F W'T'K2*N345$+B(RM$
M)(S(HR4##('J11%<1SKNBDCD4'&48$9_"@"6BF"0%BH(+#J,]*?0 C=JXG[6
M4TS^U[J746N%N664P3@+!A\",QLP4\8'0GG-=JW2LY[/2GU%97@LS?XRI95\
MSZ^M4F2]C";Q)J0T\W)%@CNTQBBV2.Q2,D'@=<\<\8SWIMKXHU"\6.X6WM4M
MWGC@ )8N&>(.#GI@$XQW]JZ272-.N(XXY;&V=(V+(K1 A2>I'IFG1Z980H%C
MLX$56#JJQ@88# (]P.*KFCV$T^YQFF^+-46PM$D@^U2I;Q2SR"%R9-Y(X(^5
M2 ._!/'%:&G:M>ZEX@TV:0Q1VL]M<O'#&QR KH!O[$_RR16\NBZ5NB(TZTS"
M2T9$2_(2<DCCCGFG1Z;IMO?FYBM+:.[D!S(L:AV!QGGJ>U)RCT06?<O#I2T@
MI:@L0]*X:2:]:X>XANY(KV74+BU >4F-4"-MRF=HQA6SC-=R>E9RV>F?VG+,
ML%I]N9<.P5?,(/KWQTJD[">I@:+J-Q9ZC<6T]K?>2((6^\;IO,;=N.5+84X!
MZ_@,US\FIZDFAZA8"_N/M-S--<PS>8=\<*.^X ]N4"@=MU>AZ?;V%O"4TZ.W
MCBW'<( H&[WQWIAL]+\MF\BT\M5>-CM7 #'+*3Z$\D>M4I*^Q#3[G.S^*[FU
MGC15MIXF295V;\AHXRW+]"<J00.1ZFM+^T!<:8J:K)+;%HUEDFMT>.,*<':)
M/7G'!SZ5H?V+I;3&8Z=:&1LDOY*Y.1CKCT)%27ME8W%D8+V"WDM0!F.904 '
M3@\<4G*/1#2:W.1"W;.EO=7-Y#:-!=75N&N'210-NP,V<G )."3UYZ5:LS+>
MSZ=+!>W1NVB2:_8S$QQ(8_N;?NAB2".,\$]*V#IF@BRB5[/3OLQ?>@94V%CW
M';-*VD:$^H.S6-B;M_F<^6N]LC&3WZ4^9!8K:#&3?W,UK<W$NF%%2-IYFD\R
M0$[G4L>G0<<$CBNAK+TS3](LW9M,MK.+^!C;JHQCL=M:E0W<I!1112&%%%%
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M\ >]=&_B;3EA$F;ACEU:)86+ILQNW+U&,C\ZE_X2"P$Z1;I@K\),86$;G&[
M;&"<4[OL&E]S,T2YM]1UMKR.VEM1% ;>"![9XODW ECE0!D@8'I]:ZFLZPU>
MUU"=X8A,DB*',<T10E3G# 'MQ6C4/<<0HHHI%!1110!#=*[VTB1K&SLA"B3[
MI..A]JXFXT/5)=,NK:TLKBVA>U:-K62[61'DRNWRB6)5<!NI7J.*[>XE$,+R
ML&*HI8A1D\#-<X/%I_LN;4#8;H%@,\;1SAU(R!M8@81N>G/0^E5%M;$RM;4@
MFLKEK2);72-01XKJ"=DN+M)-X5@3MS*P!Q]*2]M+N]UZ/4)M&U P_93#LBNT
MB=6WYR=LH!&/<UH)K\JI')-;6VV2>*$?9KP2X+MC)^48Q3]2UY[+5ET^*"W9
MS!YQ>XNA"N-V,#Y3DU5V39%:*+4=/N[R>VTUIQ>K&R*\R!H75-N)"6Y& #D%
MCUJU]BO'U[3+R5(RD-I+%,R'"AV*< 'G'RFD?6[EII(K73OM,ENB/<!)AA2P
MR%0X^=L<]AR.:;)K=\-6MK&/3$87$;2QN]R4.P;<[EV<'YAQ^M+4K0RD\.WX
MTVW1 L5PTDT%S\W_ "[R2%CC'?ICZFI6TF6W\07]P=+OIK>3RO(:TO!$H"K@
M@KYB_P C5[3?$\%Z]SYT!MEAC>4,SA@Z*S*Q'T*_^/"J]MXIN+N=H4L+>%T6
M-F6YO1&WSC< !M.3C'XT[RNR?=+6KZ2^IZQI4KQR?9X!-YI28QLI90!RI!['
MI6+_ ,(W?Q7#".SBFAS>82XF+!UD9"H8Y+9(!Y[5TM[J\-AJ-E:W 5!="0^8
MSA57: ><]<YK,E\86T1E;[.[Q(+@EXW#;A$5!(^N?TI1<N@Y6ZB:?IU^B7Z>
M7<PVLEMY<-O=W"RL),')# G"\@<G\J6#3KZQM]$N5MC-+96GV>:W5U#<JN2I
M)"Y!7UZ=ZG&MWLEI-/'IL;&)!+N6Z#1.F"3API^88Y&.XYIMOKUU<6MDZZ<O
MVJ]3S8(!<9'E[02SMM^7&0. >HIZA9&;-X;NM1U+[5=Q");B261@K@M;_(BQ
MG/=LKGC(]ZHVVA:NEW;W&IV,]RZR7/FFRN1$269-K9WJ<$*3C/'I6W)XN@MK
MRUM;FUDBDEG:WFY#"!@ 021U4Y&#[T3>*BE\MI#:1;S),A:>Y$2CRRH/.T\G
M<./:J3F2U'J3ZG:W-QX>ACMK.?S4FA?[/)*K/A9%)!8L03@$_>-9.L:3J&JW
M\>HMITZHDL*_9DN$24HF\EMP< '+ ##9^E;]YJTMGHT=Z;:.25WC011S94EV
M"C#XZ<YSBJ%YXHEL)!;7%@B7AEC0(UR!&0^[#;]O3Y2#Q^=1&_0MVZD4NEW>
MH?9+:.&YL+2%WD<W<BW#.V, <NW'S'J>U1Z;8:KH\L,[6C7IBMS9D)(@<JCD
MQN,D#!!P1G(P.#6A=:]+9Z,]_+:12R;PD<-K<"7S#_O;1VR<>U2RZT9)((=-
MMQ=S2P"Y ,FQ%C/0EL'DGH,=C1=BLC%DTW4'UIKZ^TNXG\RT1,:?=B((P=S@
MYD0G@CGIG-;#V=Q)XBTV]$)6"*TEC?<P)5F*$ \G/W3SSTJL_B:7[:+-+&..
M00+,PO+D0%<LPVXVG/W>OTJ6?6M1BU6"P32[=WGB:5&^V$#"[<Y^3U84_>%9
M:D9T/9K6LWD< 'VJV"1-NXWD$-QG@G"Y..<"J_V75;[1K#238S62IY8N)Y6B
M==J#. %8YR0!R.F:M0^*8YE1([5S=!9&N8-W-ML'.[ZG 'KG-7I-6CBT :L8
MF*F 2B('+$D<*/<D@4M5N5H]C &B7UO$+2>S>]MX+AWAFMYA!.H<9RF&4  E
M@02.,=:A31]2&H6MS?6E[>*MJ\6;>[6.1"9-RAB'3=\O4CO6P_B:/[!I\T4"
MF6])54EF$:HRCYE9\'!&,8QS4<OB65;NWM18)%-) TS"[N1#MPVW ^4[O4'T
MIWD39$^HV5Q>VVE>3;NOD7<4LB2R LBKD')R<GZ$YKGXO#&IVL>D"WC4)PU[
M"7'RNL;*K@YP2=P!^@KJ;K539P6,DL*EKJ=(<1R;E4MWSCD?E6;8^,+:^TRW
MO([:57EG,#PN<-&=K,"?4$*,?6B+DEH-I&?'X6N(-+TA8XYC<PP.DZO=,ZJ3
M"R\!FVCYB!Q55O#NH&&XB.GW/GR6]ND,T=VJ11NB $NN\;L$?W6SBMY?%EH]
MC87$:J[W<;2&)95+1[8R_./IBJQ\8XW.+%/+2.%V4W($I\P X1,?,1GU&:=Y
MBM$;-HFH/IVHQ"(&2?5$N$^<?-&&C)/_ (Z>*T'BO;#6+NZMK,WD=VJ<)(JF
M-E&WG<1\N,'C)Z\57O/$T\,=S+#IJRQVUV+1RUQL)8E0"!M/&6'Y5:.K7IG:
MV@TY9KF%%>X47 "QYR0H8K\S8YZ#J.:3<NO];#T,"#PIJ<2W:QWLEL[VB*C0
ML-CR;G9E((R%^8 $8X-33Z5?E5>TTJ2RN?(C2&6UNE"Q[1C;*I;#@=B V1Z5
M?7Q/+=R2_P!GZ>)X8K=+B1I+@1D!MWRXVGD;2#R*4>*EGE L[)IU\F.9E,@6
M4JXR-B8^? Z\C\:=Y$VB='&&$:AR"V.2/6G4BG*@\_C2UD:H**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#C-2T"[GUZ6_%E'/&+Z&>,,RYVK"4)Y/&&P?7CBLZ+
MPYJ<M^CS:;%;6SB(SHCH%)5R6;AB6X)^8\GVKIKCQ 8M4GLX;-IS;E!,%E D
M.X Y1/X@,\\COUQ5Q=:TN266);^V+Q F1?,'R@<'/TK12D1RJYF>$X9GCN+N
MX99""+6"16W!XH\@-GW))KI*REUS3#$CV]Y:&W!9682A0NU=QP/8<]N.:MV>
MH6E^KFTN8IPAPQC;.#4N[=QK1%NB@=**DH**** "BBB@ HHHH **** "L[7+
M3[=I4MOY#SAL$QI*(V;!!X8].GM]16C4%Y+)#;-)# 9Y!]V,,%R?J>!0!R#:
M7J\-S+=1VD\T<T$UO%;RW*L\"L%P69F.1D-G!) (ZU)-I^I7BQ:;=:?-]CMH
M1'!-'+&5>39M\QLL& &3@ 9[^U6U\5-,L"0VD1GDDEC(DN@L?[O&2K[3N!+#
M''KZ5;&N[]2EMH[=62 [9W$Z@JP4,<*?O  @$_I6EV9V1D0PZ[:)]K@TH_:8
M[.&R6-IH\G:26D^]@@<8!()]J5[;4/LD&F+HMX=/;,EVS2P>;,Y;)!'F8 ;J
M2#T.,"KR>)I#HW]HO:0!7>-(D6[#$ER -QVX3 .3UJ>\U]=/M+*2Y@4SW<R1
M)'!)Y@&2!NW8' R.<4KOL/3N8%[X>U.\M9-.6W\M$N)[E;AI%P^]6VJ #D'+
M8.1CCJ:M'3]3?5X];.GN&CF7_1/.CWE?*9"<[MN<MZ]*U+;Q D]^L/V<K#+/
M);Q2F0$M(@)8%<<#@\\UN #'2FYR0DD]CA;7P]JEM;3636^X7K02/,)5VP%7
M+,I!.3QTP.?:I]8T6_UB]>=;1[9U4"3=<*PG"R*RK&<_)]T\X7DC.>M=I@48
M'I2YWN/E1RIM+_\ LNZM;C3[J>UN)&\N$W@\V%-HP&8MR-VX\,>#CGI45IH^
MIVES 4BF%V&C>>Y%U^XD54"E?+R,$XQ]TXZY'2NOP*7%+F8^5'/Z3:72ZQ>7
M\EJ]HD\:!XY91(S2 G+ @G"X( ''T%=!28'I2TF[C2L-;M7)'3]8M[%--LEF
MC:*9C'=QRQB)D9]WSJ06S@] /QKK6&<5B1:U<3_O;?39); 2F+SU?+'#;2P3
M'*Y[YSCM0@9S\_AJ[32U@32;>:29YWF<E6(9B=C$$@$8/7DKV%+I_AJ^$,,U
MU;*;P7,/F2-(&/E")4<9SR"001WKIG\1:.B.S:E:A4;8Y\P8#=Q3SK>EB;R?
MM]N9,9V"0$_=W?RYJ^>78FR.+MO"VJPQ64?V9HQ%#'&GEF+,#*Q+,"3E=W!R
MH)/0@5JZ+HMY::]:W$]AM:*&=+B\\Q3]H9G4JW7=T'<#'3I6S8>)=*OK2TG2
M\CC%VN88Y& 8\XZ4Y=>LY=:BTRWD2:5HY&<HX/EE"HP1[[OTHYI=A<J-8=*6
MD'2EK,T$/2N/;1;V2Y:SELP]HM[-=&9I5"R*ZL F!\P.6QG&*[!NE<[-XI2W
MFE:2U864<DL7GJX)+QJ6(VXZ<$9SUJHWOH)^95TC1-1BO9KSS[FS+110B.=D
MG;:FX]1P!\W'?CFLF3PMJC6\L"PH89EGFD3>/FFWOY7X%7!]BHKK-,U<W\[V
M\T @N%B2;8)-XV/G:<X'/!X_G62?&T"Z)?ZB;*;=:7)M_(W#=(=V 0?0X)_
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MO$?FZHEO)%&D4US):Q'S/WF] 22RXX!QQ@]Q70CIFH=^I2MT%HHHI%!1110
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M:$A?OQ@C:V[K^E'(UU%S(] 7I3J9$V^)6YY //6GUF6@HHHH&%%%% !1110
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M.6P1THY)"YHG;]!BEIJG<@8=QFG5F6%%%% PHHHH *0TM1SHTD3(DAC8C <
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>shph-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeEibP9z5Z8+ekhvWBzbZkK/ysmtNxZmiHh5PpGQXEH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:SHPH="http://shuttlepharma.com/20240630" elementFormDefault="qualified" targetNamespace="http://shuttlepharma.com/20240630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://shuttlepharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" id="StatementsOfChangesInStockholdersEquityParenthetical">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" id="OrganizationAndLiquidity">
          <link:definition>00000009 - Disclosure - Organization and Liquidity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements" id="RestatementOfPreviouslyIssuedFinancialStatements">
          <link:definition>00000010 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/Leases" id="Leases">
          <link:definition>00000012 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" id="NotesPayable-relatedParty">
          <link:definition>00000013 - Disclosure - Notes Payable-Related Party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable" id="ConvertibleNotesAndNotesPayable">
          <link:definition>00000014 - Disclosure - Convertible Notes and Notes Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000015 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" id="DerivativeLiabilities">
          <link:definition>00000016 - Disclosure - Derivative Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000017 - Disclosure - Related Party transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000018 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated" id="QuarterlyFinancialDataUnauditedAndRestated">
          <link:definition>00000019 - Disclosure - Quarterly Financial Data (Unaudited and Restated)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000020 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" id="RestatementOfPreviouslyIssuedFinancialStatementsTables">
          <link:definition>00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000024 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000025 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" id="DerivativeLiabilitiesTables">
          <link:definition>00000026 - Disclosure - Derivative Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000027 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables" id="QuarterlyFinancialDataUnauditedAndRestatedTables">
          <link:definition>00000028 - Disclosure - Quarterly Financial Data (Unaudited and Restated) (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" id="OrganizationAndLiquidityDetailsNarrative">
          <link:definition>00000029 - Disclosure - Organization and Liquidity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" id="ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails">
          <link:definition>00000030 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" id="ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical">
          <link:definition>00000031 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" id="ScheduleOfErrorCorrectionDetails">
          <link:definition>00000032 - Disclosure - Schedule of the Error Correction (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" id="ScheduleOfCashAndCashEquivalentsDetails">
          <link:definition>00000033 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:definition>00000034 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>00000035 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" id="ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails">
          <link:definition>00000037 - Disclosure - Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" id="ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails">
          <link:definition>00000038 - Disclosure - Schedule of Balance Sheet Information Related to Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" id="ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails">
          <link:definition>00000039 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000040 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" id="NotesPayable-relatedPartyDetailsNarrative">
          <link:definition>00000041 - Disclosure - Notes Payable-Related Party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative" id="ConvertibleNotesAndNotesPayableDetailsNarrative">
          <link:definition>00000042 - Disclosure - Convertible Notes and Notes Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
          <link:definition>00000043 - Disclosure - Schedule of Warrants Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" id="ScheduleOfRestrictedStockUnitsRsusDetails">
          <link:definition>00000044 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" id="ScheduleOfMonteCarloSimulationAssumptionDetails">
          <link:definition>00000046 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" id="ScheduleOfDerivativeLiabilitiesDetails">
          <link:definition>00000047 - Disclosure - Schedule of Derivative Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" id="DerivativeLiabilitiesDetailsNarrative">
          <link:definition>00000048 - Disclosure - Derivative Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000049 - Disclosure - Related Party transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" id="ScheduleOfKeyInputsOfWarrantLiabilitiesDetails">
          <link:definition>00000050 - Disclosure - Schedule of Key Inputs of Warrant Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails" id="ScheduleOfWarrantLiabilitiesDetails">
          <link:definition>00000051 - Disclosure - Schedule of Warrant Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" id="ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails">
          <link:definition>00000052 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" id="ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure">
          <link:definition>00000053 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" id="ScheduleOfWarrantsActivityDetailsParenthetical">
          <link:definition>00000054 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails" id="ScheduleOfRestrictedStockUnitsDetails">
          <link:definition>00000055 - Disclosure - Schedule of Restricted Stock Units (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails" id="ScheduleOfDerivativeLiabilityValuationDetails">
          <link:definition>00000056 - Disclosure - Schedule of Derivative Liability Valuation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails" id="ScheduleOfDerivativeKeyValuationInputsDetails">
          <link:definition>00000057 - Disclosure - Schedule of Derivative Key Valuation Inputs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails" id="ScheduleOfDerivativeIssuanceValuationInputsDetails">
          <link:definition>00000058 - Disclosure - Schedule of Derivative Issuance Valuation Inputs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" id="ScheduleOfReconciliationOfIncomeTaxBenefitDetails">
          <link:definition>00000059 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
          <link:definition>00000060 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails" id="ScheduleOfQuarterlyFinancialDataDetails">
          <link:definition>00000062 - Disclosure - Schedule of Quarterly Financial Data (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical" id="ScheduleOfQuarterlyFinancialDataDetailsParenthetical">
          <link:definition>00000063 - Disclosure - Schedule of Quarterly Financial Data (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000064 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="SHPH_CommonStockToBeIssuedMember" name="CommonStockToBeIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InstitutionalInvestorMember" name="InstitutionalInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AcceleratedFeatureMember" name="AcceleratedFeatureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NewLeaseAgreementMember" name="NewLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OfficersSpouseMember" name="OfficersSpouseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_RelatedPartyOfficerMember" name="RelatedPartyOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AltoConvertibleNoteMember" name="AltoConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_BousteadSecuritiesLLCMember" name="BousteadSecuritiesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ConvertibleNoteMember" name="ConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" name="TwentyTwentyTwoConvertibleBridgeNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember" name="AugustTwentyTwentyTwoPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember" name="AugustTwentyTwentyTwoConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AugustTwoThousandAndTwentyTwoNotesMember" name="AugustTwoThousandAndTwentyTwoNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DirectorsAndOfficersMember" name="DirectorsAndOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember" name="TwentyTwentyTwoConvertibleNoteDerivativeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DecemberTwentyThousandTwentyOneNotesMember" name="DecemberTwentyThousandTwentyOneNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" name="WarrantLiabilityBousteadPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_BlackScholesModelMember" name="BlackScholesModelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DirectorsOfficersAndConsultantsMember" name="DirectorsOfficersAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_BousteadMember" name="BousteadMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AyrtonMember" name="AyrtonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" name="MeasurementInputVolumeWeightedAveragePriceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AugustTwoThousandTwentyTwoNotesMember" name="AugustTwoThousandTwentyTwoNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputIlliquidityDiscountMember" name="MeasurementInputIlliquidityDiscountMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AltoWarrantsMember" name="AltoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputEstimatedFairValueMember" name="MeasurementInputEstimatedFairValueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AltoAccelerationOptionMember" name="AltoAccelerationOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember" name="DecemberTwoThousandTwentyOneNotesDerivativeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" name="AugustTwoThousandTwentyTwoNotesDerivativeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" name="TwoThousandTwentyTwoConvertibleNotesDerivativeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesDerivativeMember" name="NotesDerivativeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TCGGreenChemIncMember" name="TCGGreenChemIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AllianceGlobalPartnersMember" name="AllianceGlobalPartnersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OfferingMember" name="OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" name="WarrantLiabilitySeriesAPreferredStockObligationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember" name="MeasurementInputProbabilityOfIPOListingOccurringMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember" name="MeasurementInputProbabilityOfQualifiedIPOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputProbabilityOfIPOListingMember" name="MeasurementInputProbabilityOfIPOListingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" name="WarrantLiabilityAugustTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" name="AugustTwoThousandAndTwentyTwoPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableRelatedPartiesMember" name="NotesPayableRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember" name="TwoThousandAndTwentyTwoConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember" name="AugustTwoThousandAndTwentyOnePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember" name="TwoThousandAndTwentyOneConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IssuanceDateMember" name="IssuanceDateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SettlementMember" name="SettlementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputIpoDateMember" name="MeasurementInputIpoDateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember" name="MeasurementInputSharePriceProbabilityOfIPOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IssuanceDatesMember" name="IssuanceDatesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_FederalTaxableIncomeMember" name="FederalTaxableIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StateTaxableIncomeMember" name="StateTaxableIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_FinanceFee" name="FinanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_FairValueAdjustmentOfWarrant" name="FairValueAdjustmentOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_LossOnSettlementOfConvertibleDebt" name="LossOnSettlementOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_GainOnSettlementOfAccountsPayable" name="GainOnSettlementOfAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_GainOnForgivenessOfNotePayable" name="GainOnForgivenessOfNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" name="DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" name="DeemedDividendOnModificationOfEquityclassifiedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" name="DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" name="StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" name="StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DividendsOnSeriesPreferredStock" name="DividendsOnSeriesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock" name="DeemedDividendOnExtinguishmentOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" name="DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsIssuanceFees" name="WarrantsIssuanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AccruedInterestSettledWithCommonStock" name="AccruedInterestSettledWithCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_GainOnSettlementOnAccountsPayable" name="GainOnSettlementOnAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" name="IncreaseDecreaseInAccruedInterestPayableRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" name="ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ProceedsFromNotesPayableAndWarrants" name="ProceedsFromNotesPayableAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForConversionOfAccruedInterest" name="CommonStockIssuedForConversionOfAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForSettlementOfDebt" name="CommonStockIssuedForSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsIssuedForFinancingFees" name="WarrantsIssuedForFinancingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" name="InitialRecognitionOfRightOfUseAssetAndLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" name="FairValueOfFreestandingInstrumentsInExcessOfProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated" name="CommonStockIssuedForConversionOfAccruedInterestAsRestated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" name="CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" name="CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" name="CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" name="ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DisclosureNotesPayablerelatedPartyAbstract" name="DisclosureNotesPayablerelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" name="NotesPayableRelatedPartyDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" name="DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_QuarterlyFinancialDataTextBlock" name="QuarterlyFinancialDataTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ConvertibleNotePolicyTextBlock" name="ConvertibleNotePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" name="ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock" name="ScheduleofWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" name="ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock" name="ScheduleOfDerivativeOfSettlementValuationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock" name="ScheduleofDerivativeKeyValuationInputsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" name="ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock" name="ScheduleofQuarterlyFinancialDataTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" name="DeemedDividendOnExtinguishmentOfSeriesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" name="DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" name="DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForCash" name="CommonStockIssuedForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsExercisedForCash" name="WarrantsExercisedForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_GainOnInterestReliefOnConversionOfNotesPayable" name="GainOnInterestReliefOnConversionOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt" name="CommonStockIssuedUponConversionOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInIssuanceCost" name="IncreaseDecreaseInIssuanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInWarrants" name="IncreaseDecreaseInWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInWarrantsFromLiability" name="IncreaseDecreaseInWarrantsFromLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInFairValueOfWarrants" name="IncreaseDecreaseInFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInNetIncomeLoss" name="IncreaseDecreaseInNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInPreferredStock" name="IncreaseDecreaseInPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInDividendLiability" name="IncreaseDecreaseInDividendLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityWarrants" name="DerivativeLiabilityWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityAcceleratedFeature" name="DerivativeLiabilityAcceleratedFeature" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensations" name="ShareBasedCompensations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_RentVariableRate1" name="RentVariableRate1" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PercentageOfRentAbatement" name="PercentageOfRentAbatement" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" name="EstimatedMonthlyCommonAreaMaintenanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonAreaMaintenanceCost" name="CommonAreaMaintenanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaymentForPlacementAgent" name="PaymentForPlacementAgent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InterestFeeAmount" name="InterestFeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ConvertibleNotesPayableCurrentNonCurrent" name="ConvertibleNotesPayableCurrentNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IssuanceOfWarrantsShares" name="IssuanceOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AccruedInterestValueToIssueShares" name="AccruedInterestValueToIssueShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AdditionalEscrowDeposit" name="AdditionalEscrowDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InitialPublicOfferingDescription" name="InitialPublicOfferingDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockVestingOfRestrictedStockUnit" name="CommonStockVestingOfRestrictedStockUnit" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedUponCompletionShares" name="StockIssuedUponCompletionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedUponCompletion" name="StockIssuedUponCompletion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" name="StockIssuedDuringPeriodSharesConversionOfPreferredShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" name="StockIssuedDuringPeriodSharesConversionOfDividends" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodValueDividendsPayable" name="StockIssuedDuringPeriodValueDividendsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CumulativeDividendsPercentage" name="CumulativeDividendsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" name="DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsDescription" name="WarrantsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantSharePrice" name="WarrantSharePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantObligationLiability" name="WarrantObligationLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantLiabilitiesExercised" name="WarrantLiabilitiesExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" name="AdditionOfNewDerivativesRecognizedAsDebtDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeGainLossOnDerivativeWarrants" name="DerivativeGainLossOnDerivativeWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeSettlementsOnDerivativeWarrants" name="DerivativeSettlementsOnDerivativeWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeDiscountPercentage" name="DerivativeDiscountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaymentsToInvoicesInResearchAndDevelopment" name="PaymentsToInvoicesInResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsEstimatedFairValue" name="WarrantsEstimatedFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantLiabilities" name="WarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantLiabilitiesIssued" name="WarrantLiabilitiesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_GainOnChangeInFairValue" name="GainOnChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ReclassificationsToStockholdersEquity" name="ReclassificationsToStockholdersEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OtherInformationAbstract" name="OtherInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityOfAcceleration" name="DerivativeLiabilityOfAcceleration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" name="DerivativeLiabilityOfCarringValueMeasurementDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityOfProbabilityAcceleration" name="DerivativeLiabilityOfProbabilityAcceleration" nillable="true" xbrli:periodType="instant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityMeasurementDuration" name="DerivativeLiabilityMeasurementDuration" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityDiscoutRate" name="DerivativeLiabilityDiscoutRate" nillable="true" xbrli:periodType="instant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeLiabilityOfDiscountRate" name="DerivativeLiabilityOfDiscountRate" nillable="true" xbrli:periodType="instant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationProvisionAdjustments" name="IncomeTaxReconciliationProvisionAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" name="IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" name="IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" name="IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" name="IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" name="IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShortfallOfStockCompensationExpense" name="ShortfallOfStockCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsbasedCompensation" name="DeferredTaxAssetsbasedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxLiabilitiesFairMarketValue" name="DeferredTaxLiabilitiesFairMarketValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" name="DeferredTaxLiabilitiesFiniteLivedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" name="EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ReverseCommonStockSharesOutstanding" name="ReverseCommonStockSharesOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" name="DeferredTaxAssetsOperatingLossCarriedForward" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" name="DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ConvertibleNotePayableCurrent" name="ConvertibleNotePayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ChangeInFairValueOfDerivativeLiability" name="ChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDifferencesChangeInFMVOfWarrantLiability" name="IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDifferencesChangeInFMVOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AltoOpportunityMasterFundSPCMember" name="AltoOpportunityMasterFundSPCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>shph-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="shph-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="shph-20240630.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="shph-20240630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:href="shph-20240630.xsd#OrganizationAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:href="shph-20240630.xsd#RestatementOfPreviouslyIssuedFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/Leases" xlink:href="shph-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20240630.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable" xlink:href="shph-20240630.xsd#ConvertibleNotesAndNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:href="shph-20240630.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:href="shph-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxes" xlink:href="shph-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated" xlink:href="shph-20240630.xsd#QuarterlyFinancialDataUnauditedAndRestated" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:href="shph-20240630.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesTables" xlink:href="shph-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:href="shph-20240630.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:href="shph-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:href="shph-20240630.xsd#QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:href="shph-20240630.xsd#OrganizationAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="shph-20240630.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="shph-20240630.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20240630.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:href="shph-20240630.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:href="shph-20240630.xsd#ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:href="shph-20240630.xsd#ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:href="shph-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20240630.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:href="shph-20240630.xsd#ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20240630.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20240630.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:href="shph-20240630.xsd#ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="shph-20240630.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="shph-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20240630.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:href="shph-20240630.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails" xlink:href="shph-20240630.xsd#ScheduleOfRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeLiabilityValuationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeKeyValuationInputsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20240630.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20240630.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="shph-20240630.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails" xlink:href="shph-20240630.xsd#ScheduleOfQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="shph-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHFinanceFee" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueAdjustmentOfWarrant" xlink:label="loc_SHPHFairValueAdjustmentOfWarrant" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHFairValueAdjustmentOfWarrant" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnSettlementOfAccountsPayable" xlink:label="loc_SHPHGainOnSettlementOfAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHGainOnSettlementOfAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:label="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:label="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:label="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AccruedInterestSettledWithCommonStock" xlink:label="loc_SHPHAccruedInterestSettledWithCommonStock" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHAccruedInterestSettledWithCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnSettlementOnAccountsPayable" xlink:label="loc_SHPHGainOnSettlementOnAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHGainOnSettlementOnAccountsPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:label="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromNotesPayableAndWarrants" xlink:label="loc_SHPHProceedsFromNotesPayableAndWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SHPHProceedsFromNotesPayableAndWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:title="00000009 - Disclosure - Organization and Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:title="00000010 - Disclosure - Restatement of Previously Issued Financial Statements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000011 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Leases" xlink:title="00000012 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000013 - Disclosure - Notes Payable-Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable" xlink:title="00000014 - Disclosure - Convertible Notes and Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:title="00000016 - Disclosure - Derivative Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated" xlink:title="00000019 - Disclosure - Quarterly Financial Data (Unaudited and Restated)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:title="00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesTables" xlink:title="00000024 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000025 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:title="00000026 - Disclosure - Derivative Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:title="00000028 - Disclosure - Quarterly Financial Data (Unaudited and Restated) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="00000029 - Disclosure - Organization and Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:title="00000030 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:title="00000031 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:title="00000032 - Disclosure - Schedule of the Error Correction (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000033 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000034 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:title="00000037 - Disclosure - Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:title="00000038 - Disclosure - Schedule of Balance Sheet Information Related to Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:title="00000039 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000041 - Disclosure - Notes Payable-Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:title="00000042 - Disclosure - Convertible Notes and Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000043 - Disclosure - Schedule of Warrants Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000044 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:title="00000046 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:title="00000047 - Disclosure - Schedule of Derivative Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000048 - Disclosure - Derivative Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - Related Party transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:title="00000050 - Disclosure - Schedule of Key Inputs of Warrant Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails" xlink:title="00000051 - Disclosure - Schedule of Warrant Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000052 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:title="00000053 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000054 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails" xlink:title="00000055 - Disclosure - Schedule of Restricted Stock Units (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails" xlink:title="00000056 - Disclosure - Schedule of Derivative Liability Valuation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails" xlink:title="00000057 - Disclosure - Schedule of Derivative Key Valuation Inputs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:title="00000058 - Disclosure - Schedule of Derivative Issuance Valuation Inputs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000059 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:label="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShortfallOfStockCompensationExpense" xlink:label="loc_SHPHShortfallOfStockCompensationExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHShortfallOfStockCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000060 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails" xlink:title="00000062 - Disclosure - Schedule of Quarterly Financial Data (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:title="00000063 - Disclosure - Schedule of Quarterly Financial Data (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000064 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>shph-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="shph-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="shph-20240630.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="shph-20240630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:href="shph-20240630.xsd#OrganizationAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:href="shph-20240630.xsd#RestatementOfPreviouslyIssuedFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/Leases" xlink:href="shph-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20240630.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable" xlink:href="shph-20240630.xsd#ConvertibleNotesAndNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:href="shph-20240630.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:href="shph-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxes" xlink:href="shph-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated" xlink:href="shph-20240630.xsd#QuarterlyFinancialDataUnauditedAndRestated" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:href="shph-20240630.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesTables" xlink:href="shph-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:href="shph-20240630.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:href="shph-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:href="shph-20240630.xsd#QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:href="shph-20240630.xsd#OrganizationAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="shph-20240630.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="shph-20240630.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20240630.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:href="shph-20240630.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:href="shph-20240630.xsd#ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:href="shph-20240630.xsd#ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:href="shph-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20240630.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:href="shph-20240630.xsd#ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20240630.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20240630.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:href="shph-20240630.xsd#ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="shph-20240630.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="shph-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20240630.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:href="shph-20240630.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails" xlink:href="shph-20240630.xsd#ScheduleOfRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeLiabilityValuationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeKeyValuationInputsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20240630.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20240630.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="shph-20240630.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails" xlink:href="shph-20240630.xsd#ScheduleOfQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="shph-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapAssetsCurrentAbstract_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapPrepaidExpenseCurrent_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapInterestReceivableCurrent_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapAssetsCurrent_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapOtherAssetsNoncurrent_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapAssets_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapInterestPayableCurrent_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapNotesPayableCurrent_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapLiabilitiesCurrent_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilities_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapStockholdersEquityAbstract_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapPreferredStockValue_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommonStockValue_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapAdditionalPaidInCapital_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_100" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRevenues_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_190" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_190" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_190" xlink:to="loc_us-gaapLegalFees_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_190" xlink:to="loc_us-gaapOperatingExpenses_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_us-gaapInterestExpenseNonoperating_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_us-gaapInvestmentIncomeInterest_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_SHPHFinanceFee_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueAdjustmentOfWarrant" xlink:label="loc_SHPHFairValueAdjustmentOfWarrant_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_SHPHFairValueAdjustmentOfWarrant_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnSettlementOfAccountsPayable" xlink:label="loc_SHPHGainOnSettlementOfAccountsPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_SHPHGainOnSettlementOfAccountsPayable_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_190" xlink:to="loc_us-gaapNonoperatingIncomeExpense_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:label="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_190" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:label="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants_190" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:label="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_190" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_190" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_190" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_190" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_190" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_190" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHCommonStockToBeIssuedMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_SHPHStockIssuedDuringPeriodValueWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueWarrantsExercised_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesWarrantsExercised_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DividendsOnSeriesPreferredStock" xlink:label="loc_SHPHDividendsOnSeriesPreferredStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDividendsOnSeriesPreferredStock_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfPreferredStock" xlink:label="loc_SHPHDeemedDividendOnExtinguishmentOfPreferredStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedDividendOnExtinguishmentOfPreferredStock_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaapEquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" xlink:label="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:title="00000009 - Disclosure - Organization and Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:title="00000010 - Disclosure - Restatement of Previously Issued Financial Statements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000011 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Leases" xlink:title="00000012 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000013 - Disclosure - Notes Payable-Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable" xlink:title="00000014 - Disclosure - Convertible Notes and Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:title="00000016 - Disclosure - Derivative Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated" xlink:title="00000019 - Disclosure - Quarterly Financial Data (Unaudited and Restated)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:title="00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofWarrantLiabilitiesTableTextBlock" xlink:label="loc_SHPHScheduleofWarrantLiabilitiesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHScheduleofWarrantLiabilitiesTableTextBlock_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:label="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_40" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesTables" xlink:title="00000024 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000025 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:title="00000026 - Disclosure - Derivative Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesMember" xlink:label="loc_SHPHAugustTwoThousandTwentyTwoNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHAugustTwoThousandTwentyTwoNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock" xlink:label="loc_SHPHScheduleOfDerivativeOfSettlementValuationTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHScheduleOfDerivativeOfSettlementValuationTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock" xlink:label="loc_SHPHScheduleofDerivativeKeyValuationInputsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHScheduleofDerivativeKeyValuationInputsTableTextBlock_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:title="00000028 - Disclosure - Quarterly Financial Data (Unaudited and Restated) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="00000029 - Disclosure - Organization and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InstitutionalInvestorMember" xlink:label="loc_SHPHInstitutionalInvestorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHInstitutionalInvestorMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenues_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WorkingCapital" xlink:label="loc_SHPHWorkingCapital_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SHPHWorkingCapital_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaapPartnersCapital_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPartnersCapital_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_150" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_150" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit_150" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:title="00000030 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHFinanceFee_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" xlink:label="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStock_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStock_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" xlink:label="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" xlink:label="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_170" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForCash" xlink:label="loc_SHPHCommonStockIssuedForCash_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonStockIssuedForCash_170" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsExercisedForCash" xlink:label="loc_SHPHWarrantsExercisedForCash_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsExercisedForCash_170" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_170" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_170" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_170" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_170" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_170" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DividendsOnSeriesPreferredStock" xlink:label="loc_SHPHDividendsOnSeriesPreferredStock_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDividendsOnSeriesPreferredStock_170" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_170" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:label="loc_SHPHReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_170" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_170" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_170" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt_170" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:label="loc_SHPHFairValueOfFreestandingInstrumentsInExcessOfProceeds_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHFairValueOfFreestandingInstrumentsInExcessOfProceeds_170" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnInterestReliefOnConversionOfNotesPayable" xlink:label="loc_SHPHGainOnInterestReliefOnConversionOfNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHGainOnInterestReliefOnConversionOfNotesPayable_170" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_170" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet_170" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_170" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_170" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_170" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromNotesPayableAndWarrants" xlink:label="loc_SHPHProceedsFromNotesPayableAndWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHProceedsFromNotesPayableAndWarrants_170" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_170" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_170" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid_170" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedUponConversionOfConvertibleDebt" xlink:label="loc_SHPHCommonStockIssuedUponConversionOfConvertibleDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonStockIssuedUponConversionOfConvertibleDebt_170" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_170" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:label="loc_SHPHCommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_170" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuedForFinancingFees" xlink:label="loc_SHPHWarrantsIssuedForFinancingFees_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsIssuedForFinancingFees_170" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuanceFees" xlink:label="loc_SHPHWarrantsIssuanceFees_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsIssuanceFees_170" xlink:type="arc" order="50" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:title="00000031 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDividendsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInDividendsReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDividendsReceivable_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInIssuanceCost" xlink:label="loc_SHPHIncreaseDecreaseInIssuanceCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInIssuanceCost_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInWarrants" xlink:label="loc_SHPHIncreaseDecreaseInWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInWarrants_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInWarrantsFromLiability" xlink:label="loc_SHPHIncreaseDecreaseInWarrantsFromLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInWarrantsFromLiability_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInFairValueOfWarrants" xlink:label="loc_SHPHIncreaseDecreaseInFairValueOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInFairValueOfWarrants_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInNetIncomeLoss" xlink:label="loc_SHPHIncreaseDecreaseInNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInNetIncomeLoss_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInNotesPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInNotesPayableCurrent_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInPreferredStock" xlink:label="loc_SHPHIncreaseDecreaseInPreferredStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInPreferredStock_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInDividendLiability" xlink:label="loc_SHPHIncreaseDecreaseInDividendLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInDividendLiability_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:title="00000032 - Disclosure - Schedule of the Error Correction (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000033 - Disclosure - Schedule of Cash and Cash Equivalents (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000034 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_SHPHAcceleratedFeatureMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaapAssetsFairValueDisclosureAbstract_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosureAbstract_330" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaapDerivativeAssetsCurrent_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeAssetsCurrent_330" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_330" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_330" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_330" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_330" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsAbstract_330" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract_330" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityWarrants" xlink:label="loc_SHPHDerivativeLiabilityWarrants_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_SHPHDerivativeLiabilityWarrants_330" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityAcceleratedFeature" xlink:label="loc_SHPHDerivativeLiabilityAcceleratedFeature_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_SHPHDerivativeLiabilityAcceleratedFeature_330" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_200" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_200" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensations" xlink:label="loc_SHPHShareBasedCompensations_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHShareBasedCompensations_200" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_200" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_200" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:title="00000037 - Disclosure - Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:title="00000038 - Disclosure - Schedule of Balance Sheet Information Related to Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:title="00000039 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LeaseAgreementMember" xlink:label="loc_SHPHLeaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SHPHLeaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NewLeaseAgreementMember" xlink:label="loc_SHPHNewLeaseAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SHPHNewLeaseAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeAxis" xlink:label="loc_us-gaapPledgingPurposeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPledgingPurposeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaapPledgingPurposeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPledgingPurposeAxis" xlink:to="loc_us-gaapPledgingPurposeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaapPledgingPurposeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPledgingPurposeAxis" xlink:to="loc_us-gaapPledgingPurposeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaapLetterOfCreditMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPledgingPurposeDomain" xlink:to="loc_us-gaapLetterOfCreditMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapPaymentsForRent_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_RentVariableRate1" xlink:label="loc_SHPHRentVariableRate1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHRentVariableRate1_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PercentageOfRentAbatement" xlink:label="loc_SHPHPercentageOfRentAbatement_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHPercentageOfRentAbatement_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:label="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapSecurityDeposit_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonAreaMaintenanceCost" xlink:label="loc_SHPHCommonAreaMaintenanceCost_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHCommonAreaMaintenanceCost_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapDeposits_120" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000041 - Disclosure - Notes Payable-Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OfficersSpouseMember" xlink:label="loc_SHPHOfficersSpouseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHOfficersSpouseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="loc_SHPHRelatedPartyOfficerMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHRelatedPartyOfficerMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestExpense_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPaidNet_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPaid_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_130" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:title="00000042 - Disclosure - Convertible Notes and Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNoteMember" xlink:label="loc_SHPHConvertibleNoteMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHConvertibleNoteMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" xlink:label="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwentyTwentyTwoPromissoryNotesMember" xlink:label="loc_SHPHAugustTwentyTwentyTwoPromissoryNotesMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwentyTwentyTwoPromissoryNotesMember_650" xlink:type="arc" order="651" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_SHPHAugustTwentyTwentyTwoConvertibleNotesMember_670" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwentyTwentyTwoConvertibleNotesMember_670" xlink:type="arc" order="671" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember_790" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember_790" xlink:type="arc" order="791" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_640" xlink:type="arc" order="641" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_560" xlink:type="arc" order="562" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_610" xlink:type="arc" order="611" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_620" xlink:type="arc" order="621" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt_810" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_810" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_810" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_810" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_810" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_810" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_810" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_810" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_810" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PaymentForPlacementAgent" xlink:label="loc_SHPHPaymentForPlacementAgent_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHPaymentForPlacementAgent_810" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_810" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_810" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_810" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_810" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_810" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_810" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_810" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLegalFees_810" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InterestFeeAmount" xlink:label="loc_SHPHInterestFeeAmount_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHInterestFeeAmount_810" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_810" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_810" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_810" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_810" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_810" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaapProceedsFromInterestReceived_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromInterestReceived_810" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaidNet_810" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_810" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_810" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice_810" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNotesPayableCurrentNonCurrent" xlink:label="loc_SHPHConvertibleNotesPayableCurrentNonCurrent_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHConvertibleNotesPayableCurrentNonCurrent_810" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MediumTermNotes" xlink:label="loc_us-gaapMediumTermNotes_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapMediumTermNotes_810" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaapShortTermDebtDescription_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtDescription_810" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_810" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_810" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_810" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_810" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_810" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_810" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_810" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_810" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_810" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_810" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:label="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants_810" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_810" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_810" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_810" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_810" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_810" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate_810" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsForFees_810" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_810" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_810" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts_810" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDerivativeIssuanceCosts_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDerivativeIssuanceCosts_810" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_810" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_810" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges_810" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesIssued1_810" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_810" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHFinanceFee_810" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_810" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_810" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceOfWarrantsShares" xlink:label="loc_SHPHIssuanceOfWarrantsShares_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHIssuanceOfWarrantsShares_810" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_810" xlink:type="arc" order="63" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000043 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadMember" xlink:label="loc_SHPHBousteadMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AyrtonMember" xlink:label="loc_SHPHAyrtonMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHAyrtonMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000044 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember" xlink:label="loc_SHPHTwentyTwentyTwoConvertibleNoteDerivativeMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwentyTwentyTwoConvertibleNoteDerivativeMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DecemberTwentyThousandTwentyOneNotesMember" xlink:label="loc_SHPHDecemberTwentyThousandTwentyOneNotesMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHDecemberTwentyThousandTwentyOneNotesMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" xlink:label="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember_490" xlink:type="arc" order="492" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DirectorsAndOfficersMember" xlink:label="loc_SHPHDirectorsAndOfficersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsAndOfficersMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DirectorsOfficersAndConsultantsMember" xlink:label="loc_SHPHDirectorsOfficersAndConsultantsMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsOfficersAndConsultantsMember_620" xlink:type="arc" order="622" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PurchaseAgreementMember" xlink:label="loc_SHPHPurchaseAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHPurchaseAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_560" xlink:type="arc" order="562" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BlackScholesModelMember" xlink:label="loc_SHPHBlackScholesModelMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHBlackScholesModelMember_570" xlink:type="arc" order="572" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_430" xlink:type="arc" order="432" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_690" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_690" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AccruedInterestValueToIssueShares" xlink:label="loc_SHPHAccruedInterestValueToIssueShares_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHAccruedInterestValueToIssueShares_690" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt_690" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_690" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_690" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_690" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_690" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_690" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_690" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_690" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_690" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_690" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_690" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_690" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_690" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_690" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_690" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_690" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEscrowDeposit_690" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_690" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="loc_SHPHAdditionalEscrowDeposit_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHAdditionalEscrowDeposit_690" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="loc_SHPHInitialPublicOfferingDescription_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHInitialPublicOfferingDescription_690" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForFees_690" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherGeneralExpense_690" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts" xlink:label="loc_us-gaapDirectOperatingCosts_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDirectOperatingCosts_690" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:label="loc_SHPHCommonStockVestingOfRestrictedStockUnit_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHCommonStockVestingOfRestrictedStockUnit_690" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedUponCompletionShares" xlink:label="loc_SHPHStockIssuedUponCompletionShares_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedUponCompletionShares_690" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedUponCompletion" xlink:label="loc_SHPHStockIssuedUponCompletion_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedUponCompletion_690" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares_690" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends_690" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable_690" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_690" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_690" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges_690" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_690" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_690" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_690" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_690" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CumulativeDividendsPercentage" xlink:label="loc_SHPHCumulativeDividendsPercentage_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHCumulativeDividendsPercentage_690" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_690" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_690" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividend" xlink:label="loc_SHPHDeemedDividend_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHDeemedDividend_690" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaapPreferredStockConvertibleConversionRatio_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionRatio_690" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_690" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_690" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:label="loc_SHPHDeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHDeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_690" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CumulativeDividends" xlink:label="loc_us-gaapCumulativeDividends_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCumulativeDividends_690" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_690" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsDescription" xlink:label="loc_SHPHWarrantsDescription_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantsDescription_690" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantSharePrice" xlink:label="loc_SHPHWarrantSharePrice_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantSharePrice_690" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_690" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiability" xlink:label="loc_SHPHWarrantLiability_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantLiability_690" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantObligationLiability" xlink:label="loc_SHPHWarrantObligationLiability_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantObligationLiability_690" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_690" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesExercised" xlink:label="loc_SHPHWarrantLiabilitiesExercised_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantLiabilitiesExercised_690" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_690" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_690" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_690" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceOfWarrantsShares" xlink:label="loc_SHPHIssuanceOfWarrantsShares_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHIssuanceOfWarrantsShares_690" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_690" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_690" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_690" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_690" xlink:type="arc" order="63" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:title="00000046 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="loc_us-gaapMeasurementInputDefaultRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDefaultRateMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIlliquidityDiscountMember" xlink:label="loc_SHPHMeasurementInputIlliquidityDiscountMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIlliquidityDiscountMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoWarrantsMember" xlink:label="loc_SHPHAltoWarrantsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHAltoWarrantsMember_190" xlink:type="arc" order="193" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_430" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_430" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts_430" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_430" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:title="00000047 - Disclosure - Schedule of Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SHPHAcceleratedFeatureMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoWarrantsMember" xlink:label="loc_SHPHAltoWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHAltoWarrantsMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesDerivativeMember" xlink:label="loc_SHPHNotesDerivativeMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHNotesDerivativeMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:label="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:label="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoAccelerationOptionMember" xlink:label="loc_SHPHAltoAccelerationOptionMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHAltoAccelerationOptionMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember" xlink:label="loc_SHPHDecemberTwoThousandTwentyOneNotesDerivativeMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHDecemberTwoThousandTwentyOneNotesDerivativeMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:label="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:label="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:label="loc_SHPHDerivativeGainLossOnDerivativeWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHDerivativeGainLossOnDerivativeWarrants_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeSettlementsOnDerivativeWarrants" xlink:label="loc_SHPHDerivativeSettlementsOnDerivativeWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHDerivativeSettlementsOnDerivativeWarrants_390" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000048 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeDiscountPercentage" xlink:label="loc_SHPHDerivativeDiscountPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHDerivativeDiscountPercentage_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:label="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - Related Party transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TCGGreenChemIncMember" xlink:label="loc_SHPHTCGGreenChemIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHTCGGreenChemIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:title="00000050 - Disclosure - Schedule of Key Inputs of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" xlink:label="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember" xlink:label="loc_SHPHMeasurementInputProbabilityOfIPOListingOccurringMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputProbabilityOfIPOListingOccurringMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfQualifiedIPOMember" xlink:label="loc_SHPHMeasurementInputProbabilityOfQualifiedIPOMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputProbabilityOfQualifiedIPOMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfIPOListingMember" xlink:label="loc_SHPHMeasurementInputProbabilityOfIPOListingMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputProbabilityOfIPOListingMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsEstimatedFairValue" xlink:label="loc_SHPHWarrantsEstimatedFairValue_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsEstimatedFairValue_360" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_360" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_360" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_360" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_360" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_360" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails" xlink:title="00000051 - Disclosure - Schedule of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" xlink:label="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilities" xlink:label="loc_SHPHWarrantLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantLiabilities_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesIssued" xlink:label="loc_SHPHWarrantLiabilitiesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantLiabilitiesIssued_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesExercised" xlink:label="loc_SHPHWarrantLiabilitiesExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantLiabilitiesExercised_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnChangeInFairValue" xlink:label="loc_SHPHGainOnChangeInFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHGainOnChangeInFairValue_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReclassificationsToStockholdersEquity" xlink:label="loc_SHPHReclassificationsToStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHReclassificationsToStockholdersEquity_100" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000052 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:title="00000053 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000054 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyTwoPromissoryNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyTwoPromissoryNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesPayableRelatedPartiesMember" xlink:label="loc_SHPHNotesPayableRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHNotesPayableRelatedPartiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember" xlink:label="loc_SHPHTwoThousandAndTwentyTwoConvertibleNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwoThousandAndTwentyTwoConvertibleNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyOnePromissoryNotesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyOnePromissoryNotesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="loc_SHPHTwoThousandAndTwentyOneConvertibleNotesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwoThousandAndTwentyOneConvertibleNotesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_120" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails" xlink:title="00000055 - Disclosure - Schedule of Restricted Stock Units (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails" xlink:title="00000056 - Disclosure - Schedule of Derivative Liability Valuation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIpoDateMember" xlink:label="loc_SHPHMeasurementInputIpoDateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIpoDateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHIssuanceDateMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHSettlementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDateMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHSettlementMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfAcceleration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfAcceleration_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" xlink:label="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfProbabilityAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityMeasurementDuration" xlink:label="loc_SHPHDerivativeLiabilityMeasurementDuration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityMeasurementDuration_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityDiscoutRate" xlink:label="loc_SHPHDerivativeLiabilityDiscoutRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityDiscoutRate_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails" xlink:title="00000057 - Disclosure - Schedule of Derivative Key Valuation Inputs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIpoDateMember" xlink:label="loc_SHPHMeasurementInputIpoDateMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIpoDateMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="loc_us-gaapMeasurementInputDefaultRateMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDefaultRateMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputSharePriceProbabilityOfIPOMember" xlink:label="loc_SHPHMeasurementInputSharePriceProbabilityOfIPOMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputSharePriceProbabilityOfIPOMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHSettlementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDateMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDatesMember" xlink:label="loc_SHPHIssuanceDatesMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDatesMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityMeasurementDuration" xlink:label="loc_SHPHDerivativeLiabilityMeasurementDuration_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHDerivativeLiabilityMeasurementDuration_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_320" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:title="00000058 - Disclosure - Schedule of Derivative Issuance Valuation Inputs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIpoDateMember" xlink:label="loc_SHPHMeasurementInputIpoDateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIpoDateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDatesMember" xlink:label="loc_SHPHIssuanceDatesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHIssuanceDatesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHSettlementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHIssuanceDateMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDatesMember" xlink:label="loc_SHPHIssuanceDatesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDatesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHSettlementMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfAcceleration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfAcceleration_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" xlink:label="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfProbabilityAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityMeasurementDuration" xlink:label="loc_SHPHDerivativeLiabilityMeasurementDuration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityMeasurementDuration_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfDiscountRate" xlink:label="loc_SHPHDerivativeLiabilityOfDiscountRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfDiscountRate_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000059 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000060 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails" xlink:title="00000062 - Disclosure - Schedule of Quarterly Financial Data (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:title="00000063 - Disclosure - Schedule of Quarterly Financial Data (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000064 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AllianceGlobalPartnersMember" xlink:label="loc_SHPHAllianceGlobalPartnersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHAllianceGlobalPartnersMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OfferingMember" xlink:label="loc_SHPHOfferingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHOfferingMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PurchaseAgreementMember" xlink:label="loc_SHPHPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHPurchaseAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FederalTaxableIncomeMember" xlink:label="loc_SHPHFederalTaxableIncomeMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHFederalTaxableIncomeMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StateTaxableIncomeMember" xlink:label="loc_SHPHStateTaxableIncomeMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHStateTaxableIncomeMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2016Member" xlink:label="loc_us-gaapTaxYear2016Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2016Member_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2017Member" xlink:label="loc_us-gaapTaxYear2017Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2017Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForFees_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReverseCommonStockSharesOutstanding" xlink:label="loc_SHPHReverseCommonStockSharesOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHReverseCommonStockSharesOutstanding_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEscrowDeposit_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="loc_SHPHAdditionalEscrowDeposit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHAdditionalEscrowDeposit_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="loc_SHPHInitialPublicOfferingDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHInitialPublicOfferingDescription_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConvertibleDebt_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_220" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit_220" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit_220" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_220" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_220" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_220" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_220" xlink:type="arc" order="26" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>shph-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="SHPH_CommonStockToBeIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssuedMember" xlink:to="SHPH_CommonStockToBeIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockToBeIssuedMember_lbl" xml:lang="en-US">Common Stock to be Issued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InstitutionalInvestorMember" xlink:label="SHPH_InstitutionalInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InstitutionalInvestorMember" xlink:to="SHPH_InstitutionalInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InstitutionalInvestorMember_lbl" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="SHPH_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SecuritiesPurchaseAgreementMember" xlink:to="SHPH_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AcceleratedFeatureMember" xlink:label="SHPH_AcceleratedFeatureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AcceleratedFeatureMember" xlink:to="SHPH_AcceleratedFeatureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AcceleratedFeatureMember_lbl" xml:lang="en-US">Accelerated Feature [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LeaseAgreementMember" xlink:label="SHPH_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LeaseAgreementMember" xlink:to="SHPH_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NewLeaseAgreementMember" xlink:label="SHPH_NewLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NewLeaseAgreementMember" xlink:to="SHPH_NewLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NewLeaseAgreementMember_lbl" xml:lang="en-US">New Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OfficersSpouseMember" xlink:label="SHPH_OfficersSpouseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficersSpouseMember" xlink:to="SHPH_OfficersSpouseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OfficersSpouseMember_lbl" xml:lang="en-US">Officers Spouse [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="SHPH_RelatedPartyOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyOfficerMember" xlink:to="SHPH_RelatedPartyOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_RelatedPartyOfficerMember_lbl" xml:lang="en-US">Related Party Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="SHPH_AltoConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoConvertibleNoteMember" xlink:to="SHPH_AltoConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AltoConvertibleNoteMember_lbl" xml:lang="en-US">Alto Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="SHPH_BousteadSecuritiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadSecuritiesLLCMember" xlink:to="SHPH_BousteadSecuritiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_BousteadSecuritiesLLCMember_lbl" xml:lang="en-US">Boustead Securities LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNoteMember" xlink:label="SHPH_ConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNoteMember" xlink:to="SHPH_ConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" xlink:label="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" xlink:to="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember_lbl" xml:lang="en-US">2022 Convertible Bridge Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwentyTwentyTwoPromissoryNotesMember" xlink:label="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember" xlink:to="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember_lbl" xml:lang="en-US">August 2022 [Promissory Notes Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwentyTwentyTwoConvertibleNotesMember" xlink:label="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember" xlink:to="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember_lbl" xml:lang="en-US">August 2022 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoNotesMember" xlink:label="SHPH_AugustTwoThousandAndTwentyTwoNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandAndTwentyTwoNotesMember" xlink:to="SHPH_AugustTwoThousandAndTwentyTwoNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AugustTwoThousandAndTwentyTwoNotesMember_lbl" xml:lang="en-US">August 2022 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="SHPH_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DirectorsAndOfficersMember" xlink:label="SHPH_DirectorsAndOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DirectorsAndOfficersMember" xlink:to="SHPH_DirectorsAndOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DirectorsAndOfficersMember_lbl" xml:lang="en-US">Directors And Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PurchaseAgreementMember" xlink:label="SHPH_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PurchaseAgreementMember" xlink:to="SHPH_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember" xlink:label="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember" xlink:to="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember_lbl" xml:lang="en-US">2022 Convertible Note Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DecemberTwentyThousandTwentyOneNotesMember" xlink:label="SHPH_DecemberTwentyThousandTwentyOneNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DecemberTwentyThousandTwentyOneNotesMember" xlink:to="SHPH_DecemberTwentyThousandTwentyOneNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DecemberTwentyThousandTwentyOneNotesMember_lbl" xml:lang="en-US">December 2021 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:label="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:to="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember_lbl" xml:lang="en-US">Warrant Liability Boustead Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BlackScholesModelMember" xlink:label="SHPH_BlackScholesModelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BlackScholesModelMember" xlink:to="SHPH_BlackScholesModelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_BlackScholesModelMember_lbl" xml:lang="en-US">Black Scholes Model [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DirectorsOfficersAndConsultantsMember" xlink:label="SHPH_DirectorsOfficersAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DirectorsOfficersAndConsultantsMember" xlink:to="SHPH_DirectorsOfficersAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DirectorsOfficersAndConsultantsMember_lbl" xml:lang="en-US">Directors Officers and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadMember" xlink:label="SHPH_BousteadMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadMember" xlink:to="SHPH_BousteadMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_BousteadMember_lbl" xml:lang="en-US">Boustead [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AyrtonMember" xlink:label="SHPH_AyrtonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AyrtonMember" xlink:to="SHPH_AyrtonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AyrtonMember_lbl" xml:lang="en-US">Ayrton [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:to="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_lbl" xml:lang="en-US">Measurement Input Volume Weighted Average Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesMember" xlink:label="SHPH_AugustTwoThousandTwentyTwoNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandTwentyTwoNotesMember" xlink:to="SHPH_AugustTwoThousandTwentyTwoNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_AugustTwoThousandTwentyTwoNotesMember_lbl" xml:lang="en-US">August 2022 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="us-gaap_MeasurementInputDefaultRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDefaultRateMember" xlink:to="us-gaap_MeasurementInputDefaultRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDefaultRateMember_lbl" xml:lang="en-US">Measurement Input, Default Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIlliquidityDiscountMember" xlink:label="SHPH_MeasurementInputIlliquidityDiscountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputIlliquidityDiscountMember" xlink:to="SHPH_MeasurementInputIlliquidityDiscountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputIlliquidityDiscountMember_lbl" xml:lang="en-US">Illiquidity Discount [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoWarrantsMember" xlink:label="SHPH_AltoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoWarrantsMember" xlink:to="SHPH_AltoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AltoWarrantsMember_lbl" xml:lang="en-US">Alto Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="SHPH_MeasurementInputEstimatedFairValueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputEstimatedFairValueMember" xlink:to="SHPH_MeasurementInputEstimatedFairValueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputEstimatedFairValueMember_lbl" xml:lang="en-US">Measurement Input Estimated Fair Value [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoAccelerationOptionMember" xlink:label="SHPH_AltoAccelerationOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoAccelerationOptionMember" xlink:to="SHPH_AltoAccelerationOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AltoAccelerationOptionMember_lbl" xml:lang="en-US">Alto Acceleration Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember" xlink:label="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember" xlink:to="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember_lbl" xml:lang="en-US">December 2021 Notes Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:label="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:to="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember_lbl" xml:lang="en-US">August 2022 Notes Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:label="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:to="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember_lbl" xml:lang="en-US">2022 Convertible Notes Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesDerivativeMember" xlink:label="SHPH_NotesDerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesDerivativeMember" xlink:to="SHPH_NotesDerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesDerivativeMember_lbl" xml:lang="en-US">Notes Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TCGGreenChemIncMember" xlink:label="SHPH_TCGGreenChemIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TCGGreenChemIncMember" xlink:to="SHPH_TCGGreenChemIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TCGGreenChemIncMember_lbl" xml:lang="en-US">TCG Green Chem Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AllianceGlobalPartnersMember" xlink:label="SHPH_AllianceGlobalPartnersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AllianceGlobalPartnersMember" xlink:to="SHPH_AllianceGlobalPartnersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AllianceGlobalPartnersMember_lbl" xml:lang="en-US">Alliance Global Partners [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OfferingMember" xlink:label="SHPH_OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfferingMember" xlink:to="SHPH_OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OfferingMember_lbl" xml:lang="en-US">Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" xlink:label="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" xlink:to="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember_lbl" xml:lang="en-US">Warrant Liability Series A Preferred Stock Obligation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember" xlink:label="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember" xlink:to="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember_lbl" xml:lang="en-US">Measurement Input Probability of IPO Listing Occurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfQualifiedIPOMember" xlink:label="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember" xlink:to="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember_lbl" xml:lang="en-US">Measurement Input Probability of Qualified IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfIPOListingMember" xlink:label="SHPH_MeasurementInputProbabilityOfIPOListingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputProbabilityOfIPOListingMember" xlink:to="SHPH_MeasurementInputProbabilityOfIPOListingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputProbabilityOfIPOListingMember_lbl" xml:lang="en-US">Measurement Input Probability of IPO Listing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:label="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:to="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember_lbl" xml:lang="en-US">Warrant Liability August 2022 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" xlink:label="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" xlink:to="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember_lbl" xml:lang="en-US">August 2022 Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesPayableRelatedPartiesMember" xlink:label="SHPH_NotesPayableRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartiesMember" xlink:to="SHPH_NotesPayableRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableRelatedPartiesMember_lbl" xml:lang="en-US">Notes Payable Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember" xlink:label="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember" xlink:to="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember_lbl" xml:lang="en-US">2022 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember" xlink:label="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember" xlink:to="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember_lbl" xml:lang="en-US">August 2021 Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:to="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember_lbl" xml:lang="en-US">2021 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="SHPH_IssuanceDateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IssuanceDateMember" xlink:to="SHPH_IssuanceDateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IssuanceDateMember_lbl" xml:lang="en-US">Issuance Date [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="SHPH_SettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SettlementMember" xlink:to="SHPH_SettlementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SettlementMember_lbl" xml:lang="en-US">Settlement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIpoDateMember" xlink:label="SHPH_MeasurementInputIpoDateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputIpoDateMember" xlink:to="SHPH_MeasurementInputIpoDateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputIpoDateMember_lbl" xml:lang="en-US">Measurement Input Ipo Date [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputSharePriceProbabilityOfIPOMember" xlink:label="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember" xlink:to="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember_lbl" xml:lang="en-US">Measurement Input Share Price Probability Of IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDatesMember" xlink:label="SHPH_IssuanceDatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IssuanceDatesMember" xlink:to="SHPH_IssuanceDatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IssuanceDatesMember_lbl" xml:lang="en-US">Issuance Dates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FederalTaxableIncomeMember" xlink:label="SHPH_FederalTaxableIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FederalTaxableIncomeMember" xlink:to="SHPH_FederalTaxableIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_FederalTaxableIncomeMember_lbl" xml:lang="en-US">Federal Taxable Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StateTaxableIncomeMember" xlink:label="SHPH_StateTaxableIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StateTaxableIncomeMember" xlink:to="SHPH_StateTaxableIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StateTaxableIncomeMember_lbl" xml:lang="en-US">State Taxable Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2016Member" xlink:label="us-gaap_TaxYear2016Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2016Member" xlink:to="us-gaap_TaxYear2016Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2016Member_lbl" xml:lang="en-US">Tax Year 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2017Member" xlink:label="us-gaap_TaxYear2017Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2017Member" xlink:to="us-gaap_TaxYear2017Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2017Member_lbl" xml:lang="en-US">Tax Year 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest payable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable non-current, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.00001 par value; 100,000,000 shares authorized; 2,008,689 and 1,700,414 shares issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and professional</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="SHPH_FinanceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FinanceFee" xlink:to="SHPH_FinanceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_FinanceFee_lbl" xml:lang="en-US">Finance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueAdjustmentOfWarrant" xlink:label="SHPH_FairValueAdjustmentOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FairValueAdjustmentOfWarrant" xlink:to="SHPH_FairValueAdjustmentOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_FairValueAdjustmentOfWarrant_lbl" xml:lang="en-US">Change in fair value of warrant liabilities, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US">Gain on sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Change in fair value of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LossOnSettlementOfConvertibleDebt" xlink:to="SHPH_LossOnSettlementOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt_lbl" xml:lang="en-US">Loss on settlement of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnSettlementOfAccountsPayable" xlink:label="SHPH_GainOnSettlementOfAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnSettlementOfAccountsPayable" xlink:to="SHPH_GainOnSettlementOfAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_GainOnSettlementOfAccountsPayable_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="SHPH_GainOnForgivenessOfNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnForgivenessOfNotePayable" xlink:to="SHPH_GainOnForgivenessOfNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_GainOnForgivenessOfNotePayable_lbl" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividend on Series A Convertible Preferred Stock, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_lbl" xml:lang="en-US">Deemed dividend on extinguishment of Series A Convertible Preferred Stock, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:to="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants_lbl" xml:lang="en-US">Deemed dividend on modification of equity-classified warrants, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_lbl" xml:lang="en-US">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:label="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest and principal</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest and principal, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Common stock issued for restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Common stock issued for restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Warrants issued for financing costs, net of issuance fees of $8,727</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest, as restated, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable, as restated, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="SHPH_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="SHPH_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Common stock issued upon exercise of warrants, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Common stock issued upon exercise of warrants, as restated, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DividendsOnSeriesPreferredStock" xlink:label="SHPH_DividendsOnSeriesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DividendsOnSeriesPreferredStock" xlink:to="SHPH_DividendsOnSeriesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DividendsOnSeriesPreferredStock_lbl" xml:lang="en-US">Dividends on Series A convertible preferred stock, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfPreferredStock" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock_lbl" xml:lang="en-US">Deemed dividend on extinguishment of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" xlink:label="us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" xlink:to="us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount_lbl" xml:lang="en-US">Deemed dividend on modification of equity-classified warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend_lbl" xml:lang="en-US">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Reclassification of fair value of warrant liabilities to equity, as restated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuanceFees" xlink:label="SHPH_WarrantsIssuanceFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuanceFees" xlink:to="SHPH_WarrantsIssuanceFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsIssuanceFees_lbl" xml:lang="en-US">Warranst of issuance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of derivative liability, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount and finance fees, as restated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xml:lang="en-US">Gain on marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xml:lang="en-US">Change in fair value of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AccruedInterestSettledWithCommonStock" xlink:label="SHPH_AccruedInterestSettledWithCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestSettledWithCommonStock" xlink:to="SHPH_AccruedInterestSettledWithCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AccruedInterestSettledWithCommonStock_lbl" xml:lang="en-US">Accrued interest settled with common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LossOnSettlementOfConvertibleDebt" xlink:to="SHPH_LossOnSettlementOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt_2_lbl" xml:lang="en-US">Loss on settlement of notes payable and convertible notes payable, as restated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnForgivenessOfNotePayable" xlink:to="SHPH_GainOnForgivenessOfNotePayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_GainOnForgivenessOfNotePayable_2_lbl" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnSettlementOnAccountsPayable" xlink:label="SHPH_GainOnSettlementOnAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnSettlementOnAccountsPayable" xlink:to="SHPH_GainOnSettlementOnAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_GainOnSettlementOnAccountsPayable_lbl" xml:lang="en-US">Gain on settlement on accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Accrued interest payable, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:to="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_lbl" xml:lang="en-US">Accrued interest payable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Change in operating lease asset and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Investment in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from disposition of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:to="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of common shares and exercise of warrants, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from note payable-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of note payable-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes payable, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromNotesPayableAndWarrants" xlink:label="SHPH_ProceedsFromNotesPayableAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromNotesPayableAndWarrants" xlink:to="SHPH_ProceedsFromNotesPayableAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ProceedsFromNotesPayableAndWarrants_lbl" xml:lang="en-US">Proceeds from notes payable and warrants, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payment for finance costs related to convertible note payable, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment of convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:to="SHPH_CommonStockIssuedForConversionOfAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterest_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForSettlementOfDebt" xlink:label="SHPH_CommonStockIssuedForSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForSettlementOfDebt" xlink:to="SHPH_CommonStockIssuedForSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForSettlementOfDebt_lbl" xml:lang="en-US">Common stock issued for settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuedForFinancingFees" xlink:label="SHPH_WarrantsIssuedForFinancingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuedForFinancingFees" xlink:to="SHPH_WarrantsIssuedForFinancingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsIssuedForFinancingFees_lbl" xml:lang="en-US">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:label="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:to="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_lbl" xml:lang="en-US">Initial recognition of right of use asset and liability</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:label="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:to="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds_lbl" xml:lang="en-US">Fair value of freestanding instruments in excess of proceeds, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated" xlink:to="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" xlink:label="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" xlink:to="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated_lbl" xml:lang="en-US">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:label="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:to="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:label="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:to="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_lbl" xml:lang="en-US">Reclassification of fair value of warrant liabilities to equity, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="us-gaap_ErrorCorrectionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionTextBlock" xlink:to="us-gaap_ErrorCorrectionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionTextBlock_lbl" xml:lang="en-US">Restatement of Previously Issued Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="SHPH_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureLeasesAbstract" xlink:to="SHPH_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:label="SHPH_DisclosureNotesPayablerelatedPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:to="SHPH_DisclosureNotesPayablerelatedPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DisclosureNotesPayablerelatedPartyAbstract_lbl" xml:lang="en-US">Notes Payable-related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:label="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:to="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable-Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes and Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" xlink:label="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" xlink:to="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract_lbl" xml:lang="en-US">Quarterly Financial Data</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_QuarterlyFinancialDataTextBlock" xlink:label="SHPH_QuarterlyFinancialDataTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_QuarterlyFinancialDataTextBlock" xlink:to="SHPH_QuarterlyFinancialDataTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_QuarterlyFinancialDataTextBlock_lbl" xml:lang="en-US">Quarterly Financial Data (Unaudited and Restated)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReverseStockSplitPolicyTextBlock" xlink:label="SHPH_ReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReverseStockSplitPolicyTextBlock" xlink:to="SHPH_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsPolicyTextBlock" xlink:label="SHPH_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsPolicyTextBlock" xlink:to="SHPH_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredOfferingCostsPolicyTextBlock" xlink:label="SHPH_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredOfferingCostsPolicyTextBlock" xlink:to="SHPH_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNotePolicyTextBlock" xlink:label="SHPH_ConvertibleNotePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotePolicyTextBlock" xlink:to="SHPH_ConvertibleNotePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ConvertibleNotePolicyTextBlock_lbl" xml:lang="en-US">Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" xlink:label="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" xlink:to="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Error Corrections And Prior Period Adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US">Schedule of the Error Correction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Key Inputs of Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofWarrantLiabilitiesTableTextBlock" xlink:label="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock" xlink:to="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:to="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Useful Lives for Property Plant Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Right-of Use Asset and Lease Information About Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Sheet Information Related to Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units (RSUs)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2_lbl" xml:lang="en-US">Schedule of Monte Carlo Simulation Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock" xlink:label="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock" xlink:to="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Issuance Valuation Inputs</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock" xlink:label="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock" xlink:to="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Key Valuation Inputs</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:to="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" xlink:to="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract_2_lbl" xml:lang="en-US">Quarterly Financial Data Unaudited And Restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock" xlink:label="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock" xlink:to="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock_lbl" xml:lang="en-US">Schedule of Quarterly Financial Data</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Sale of stock membership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net income loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WorkingCapital" xlink:label="SHPH_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WorkingCapital" xlink:to="SHPH_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xml:lang="en-US">Convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument, face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Net proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapital" xlink:label="us-gaap_PartnersCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapital" xlink:to="us-gaap_PartnersCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapital_lbl" xml:lang="en-US">Initiated a capital offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WorkingCapital" xlink:to="SHPH_WorkingCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_WorkingCapital_2_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Adjustments to additional paid in capital stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development, net of contract expense reimbursements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Net loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FinanceFee" xlink:to="SHPH_FinanceFee_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="SHPH_FinanceFee_2_lbl" xml:lang="en-US">Financing fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Dividend on Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock_lbl" xml:lang="en-US">Deemed dividend on extinguishment of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" xlink:to="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_lbl" xml:lang="en-US">Deemed dividend on modification of equity-classified warrants, as restated</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_lbl" xml:lang="en-US">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net loss per shares - Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Net loss per shares - Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForCash" xlink:label="SHPH_CommonStockIssuedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForCash" xlink:to="SHPH_CommonStockIssuedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForCash_lbl" xml:lang="en-US">Common stock issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsExercisedForCash" xlink:label="SHPH_WarrantsExercisedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsExercisedForCash" xlink:to="SHPH_WarrantsExercisedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsExercisedForCash_lbl" xml:lang="en-US">Warrants exercised for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xml:lang="en-US">Warrants issued for financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Common stock issued upon conversion of convertible debt and exercise of related warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DividendsOnSeriesPreferredStock" xlink:to="SHPH_DividendsOnSeriesPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="SHPH_DividendsOnSeriesPreferredStock_2_lbl" xml:lang="en-US">Dividends on Series A preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_2_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:to="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_2_lbl" xml:lang="en-US">Reclassification of fair value of warrant liability to equity upon initial public offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of debt discount and finance fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LossOnSettlementOfConvertibleDebt" xlink:to="SHPH_LossOnSettlementOfConvertibleDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt_3_lbl" xml:lang="en-US">Loss on settlement of convertible debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:to="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds_2_lbl" xml:lang="en-US">Fair value of freestanding instruments in excess of proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnInterestReliefOnConversionOfNotesPayable" xlink:label="SHPH_GainOnInterestReliefOnConversionOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnInterestReliefOnConversionOfNotesPayable" xlink:to="SHPH_GainOnInterestReliefOnConversionOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_GainOnInterestReliefOnConversionOfNotesPayable_lbl" xml:lang="en-US">Gain on interest relief on conversion of notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_2_lbl" xml:lang="en-US">Accrued interest payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:to="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_2_lbl" xml:lang="en-US">Proceeds from issuance of common shares and warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_3_lbl" xml:lang="en-US">Proceeds from convertible notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromNotesPayableAndWarrants" xlink:to="SHPH_ProceedsFromNotesPayableAndWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_ProceedsFromNotesPayableAndWarrants_2_lbl" xml:lang="en-US">Proceeds from notes payable and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment for finance costs related to convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Supplemental non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedUponConversionOfConvertibleDebt" xlink:label="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt" xlink:to="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt_lbl" xml:lang="en-US">Common stock issued upon conversion of convertible debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_2_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:to="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_2_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuedForFinancingFees" xlink:to="SHPH_WarrantsIssuedForFinancingFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_WarrantsIssuedForFinancingFees_2_lbl" xml:lang="en-US">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDividendsReceivable" xlink:label="us-gaap_IncreaseDecreaseInDividendsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDividendsReceivable" xlink:to="us-gaap_IncreaseDecreaseInDividendsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDividendsReceivable_lbl" xml:lang="en-US">Accrued dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInIssuanceCost" xlink:label="SHPH_IncreaseDecreaseInIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInIssuanceCost" xlink:to="SHPH_IncreaseDecreaseInIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInIssuanceCost_lbl" xml:lang="en-US">Issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInWarrants" xlink:label="SHPH_IncreaseDecreaseInWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInWarrants" xlink:to="SHPH_IncreaseDecreaseInWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_IncreaseDecreaseInWarrants_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInWarrantsFromLiability" xlink:label="SHPH_IncreaseDecreaseInWarrantsFromLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInWarrantsFromLiability" xlink:to="SHPH_IncreaseDecreaseInWarrantsFromLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInWarrantsFromLiability_lbl" xml:lang="en-US">Warrants from liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Debt instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInFairValueOfWarrants" xlink:label="SHPH_IncreaseDecreaseInFairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInFairValueOfWarrants" xlink:to="SHPH_IncreaseDecreaseInFairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInFairValueOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_4_lbl" xml:lang="en-US">Derivatives loss</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInNetIncomeLoss" xlink:label="SHPH_IncreaseDecreaseInNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInNetIncomeLoss" xlink:to="SHPH_IncreaseDecreaseInNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInNetIncomeLoss_lbl" xml:lang="en-US">Net income loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:to="us-gaap_IncreaseDecreaseInNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInNotesPayableCurrent_lbl" xml:lang="en-US">Increase decrease of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInPreferredStock" xlink:label="SHPH_IncreaseDecreaseInPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInPreferredStock" xlink:to="SHPH_IncreaseDecreaseInPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInPreferredStock_lbl" xml:lang="en-US">Increase decrease in preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInDividendLiability" xlink:label="SHPH_IncreaseDecreaseInDividendLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInDividendLiability" xlink:to="SHPH_IncreaseDecreaseInDividendLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInDividendLiability_lbl" xml:lang="en-US">Increase decrease in dividend liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Total cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="us-gaap_DerivativeAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsCurrent" xlink:to="us-gaap_DerivativeAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsCurrent_lbl" xml:lang="en-US">United States Treasury Bonds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityWarrants" xlink:label="SHPH_DerivativeLiabilityWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityWarrants" xlink:to="SHPH_DerivativeLiabilityWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityWarrants_lbl" xml:lang="en-US">Derivative Liability - Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityAcceleratedFeature" xlink:label="SHPH_DerivativeLiabilityAcceleratedFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityAcceleratedFeature" xlink:to="SHPH_DerivativeLiabilityAcceleratedFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityAcceleratedFeature_lbl" xml:lang="en-US">Derivative Liability - Accelerated feature</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Minimum bid price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, uninsured amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Marketable securitie outstanding balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_3_lbl" xml:lang="en-US">Unrealized loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Marketable securities realized gain loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Marketable securities unrealized gain loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_4_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensations" xlink:label="SHPH_ShareBasedCompensations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensations" xlink:to="SHPH_ShareBasedCompensations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensations_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of contract expense reimbursements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable operating segments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureLeasesAbstract" xlink:to="SHPH_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Right-of Use Asset And Lease Information About Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureLeasesAbstract" xlink:to="SHPH_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="SHPH_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Balance Sheet Information Related To Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term (year)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024 (excluding the six months ended June 30, 2024)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US">Lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_RentVariableRate1" xlink:label="SHPH_RentVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RentVariableRate1" xlink:to="SHPH_RentVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_RentVariableRate1_lbl" xml:lang="en-US">Rent variable rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operating lease description</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PercentageOfRentAbatement" xlink:label="SHPH_PercentageOfRentAbatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PercentageOfRentAbatement" xlink:to="SHPH_PercentageOfRentAbatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PercentageOfRentAbatement_lbl" xml:lang="en-US">Percentage of rent abatement</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:label="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:to="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_lbl" xml:lang="en-US">Estimated monthly common area maintenance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonAreaMaintenanceCost" xlink:label="SHPH_CommonAreaMaintenanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonAreaMaintenanceCost" xlink:to="SHPH_CommonAreaMaintenanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonAreaMaintenanceCost_lbl" xml:lang="en-US">Common area maintenance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Loan transaction amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US">Related Party Transaction, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="us-gaap_RelatedPartyTransactionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDate" xlink:to="us-gaap_RelatedPartyTransactionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDate_lbl" xml:lang="en-US">Related Party Transaction, Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt instrument maturiy date description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Increase accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Payments upon subscription</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Repayments of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Principal balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Number of warrants to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Effective interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PaymentForPlacementAgent" xlink:label="SHPH_PaymentForPlacementAgent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentForPlacementAgent" xlink:to="SHPH_PaymentForPlacementAgent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaymentForPlacementAgent_lbl" xml:lang="en-US">Payment for placement agent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Expected years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and rights outstanding measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Estimated fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Allocation of financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Warrant derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Equity warrant as reduction in additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_2_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InterestFeeAmount" xlink:label="SHPH_InterestFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InterestFeeAmount" xlink:to="SHPH_InterestFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InterestFeeAmount_lbl" xml:lang="en-US">Interest fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_3_lbl" xml:lang="en-US">Debt principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Debt, principal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Principal balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Settled for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_3_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_3_lbl" xml:lang="en-US">Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNotesPayableCurrentNonCurrent" xlink:label="SHPH_ConvertibleNotesPayableCurrentNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotesPayableCurrentNonCurrent" xlink:to="SHPH_ConvertibleNotesPayableCurrentNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ConvertibleNotesPayableCurrentNonCurrent_lbl" xml:lang="en-US">Convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MediumTermNotes" xlink:label="us-gaap_MediumTermNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MediumTermNotes" xlink:to="us-gaap_MediumTermNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MediumTermNotes_lbl" xml:lang="en-US">Term notes issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtDescription" xlink:label="us-gaap_ShortTermDebtDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtDescription" xlink:to="us-gaap_ShortTermDebtDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtDescription_lbl" xml:lang="en-US">Term note description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value measurement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Warrants issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding and exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:to="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants_2_lbl" xml:lang="en-US">Deemed dividend on modification of equity classified warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Stock issued during period, value, new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Debt instrument conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Fees paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Debt issuance costs related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Principal increase decrease rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Debt issuance costs related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl" xml:lang="en-US">Payments of derivative issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Gain (loss) on sale of assets and asset impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Notes issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FinanceFee" xlink:to="SHPH_FinanceFee_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_FinanceFee_3_lbl" xml:lang="en-US">Finance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-Term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceOfWarrantsShares" xlink:label="SHPH_IssuanceOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IssuanceOfWarrantsShares" xlink:to="SHPH_IssuanceOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IssuanceOfWarrantsShares_lbl" xml:lang="en-US">Issuance of warrants shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of warrants outstanding, balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average life (years), outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants outstanding, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of warrants outstanding, balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average life (years), outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average life (years), granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants outstanding, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Per RSU, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Per RSU, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs, Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Per RSU, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Common stock issued for conversion of convertible debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AccruedInterestValueToIssueShares" xlink:label="SHPH_AccruedInterestValueToIssueShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestValueToIssueShares" xlink:to="SHPH_AccruedInterestValueToIssueShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_AccruedInterestValueToIssueShares_lbl" xml:lang="en-US">Accrued interest settled with common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted stock award granted shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share granted under equity incentive plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of shares vested under plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted stock award granted value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Compensation under research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of stock consideration received per transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Right offering</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="SHPH_AdditionalEscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionalEscrowDeposit" xlink:to="SHPH_AdditionalEscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_AdditionalEscrowDeposit_lbl" xml:lang="en-US">Escrow deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="SHPH_InitialPublicOfferingDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialPublicOfferingDescription" xlink:to="SHPH_InitialPublicOfferingDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InitialPublicOfferingDescription_lbl" xml:lang="en-US">Initial public offering description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForFees_2_lbl" xml:lang="en-US">Commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Related expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts" xlink:label="us-gaap_DirectOperatingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCosts" xlink:to="us-gaap_DirectOperatingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectOperatingCosts_lbl" xml:lang="en-US">Direct cost</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:label="SHPH_CommonStockVestingOfRestrictedStockUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:to="SHPH_CommonStockVestingOfRestrictedStockUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockVestingOfRestrictedStockUnit_lbl" xml:lang="en-US">Common stock vesting of restricted stock unit</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedUponCompletionShares" xlink:label="SHPH_StockIssuedUponCompletionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedUponCompletionShares" xlink:to="SHPH_StockIssuedUponCompletionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedUponCompletionShares_lbl" xml:lang="en-US">Common stock issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedUponCompletion" xlink:label="SHPH_StockIssuedUponCompletion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedUponCompletion" xlink:to="SHPH_StockIssuedUponCompletion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedUponCompletion_lbl" xml:lang="en-US">Stock issued upon completion</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_lbl" xml:lang="en-US">Number shares issued for conversion of note, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_lbl" xml:lang="en-US">Number shares issued for conversion dividends payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:label="SHPH_StockIssuedDuringPeriodValueDividendsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:to="SHPH_StockIssuedDuringPeriodValueDividendsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodValueDividendsPayable_lbl" xml:lang="en-US">Common stock issued for dividends payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xml:lang="en-US">Cumulative dividends, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_2_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CumulativeDividendsPercentage" xlink:label="SHPH_CumulativeDividendsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CumulativeDividendsPercentage" xlink:to="SHPH_CumulativeDividendsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CumulativeDividendsPercentage_lbl" xml:lang="en-US">Cumulative dividends percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock value share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividend" xlink:label="SHPH_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividend" xlink:to="SHPH_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US">Conversion price percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:label="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:to="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_lbl" xml:lang="en-US">Deemed contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CumulativeDividends" xlink:label="us-gaap_CumulativeDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeDividends" xlink:to="us-gaap_CumulativeDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeDividends_lbl" xml:lang="en-US">Cumulative dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_3_lbl" xml:lang="en-US">Stock issued for conversion, vallue</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsDescription" xlink:label="SHPH_WarrantsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsDescription" xlink:to="SHPH_WarrantsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsDescription_lbl" xml:lang="en-US">Warrants description</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantSharePrice" xlink:label="SHPH_WarrantSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantSharePrice" xlink:to="SHPH_WarrantSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantSharePrice_lbl" xml:lang="en-US">Warrant share price</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiability" xlink:label="SHPH_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiability" xlink:to="SHPH_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantLiability_lbl" xml:lang="en-US">Warrants liability</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantObligationLiability" xlink:label="SHPH_WarrantObligationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantObligationLiability" xlink:to="SHPH_WarrantObligationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantObligationLiability_lbl" xml:lang="en-US">Warrants obligation liability</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesExercised" xlink:label="SHPH_WarrantLiabilitiesExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilitiesExercised" xlink:to="SHPH_WarrantLiabilitiesExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantLiabilitiesExercised_lbl" xml:lang="en-US">Warrant liabilities exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Four year warrant to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Life (Years), Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Time period (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:to="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_lbl" xml:lang="en-US">Estimated fair value issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Estimated fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Balance, warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:to="SHPH_DerivativeGainLossOnDerivativeWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants_lbl" xml:lang="en-US">Gain on change in fair value of the derivative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4_lbl" xml:lang="en-US">Balance, warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:to="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_2_lbl" xml:lang="en-US">Addition of new derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:to="SHPH_DerivativeGainLossOnDerivativeWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants_2_lbl" xml:lang="en-US">Gain loss on change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeSettlementsOnDerivativeWarrants" xlink:label="SHPH_DerivativeSettlementsOnDerivativeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeSettlementsOnDerivativeWarrants" xlink:to="SHPH_DerivativeSettlementsOnDerivativeWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeSettlementsOnDerivativeWarrants_lbl" xml:lang="en-US">Settlements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Number of shares warrant to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xml:lang="en-US">Derivative liability non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Derivative fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMeasurementInput_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeDiscountPercentage" xlink:label="SHPH_DerivativeDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeDiscountPercentage" xlink:to="SHPH_DerivativeDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeDiscountPercentage_lbl" xml:lang="en-US">Derivative discount percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:label="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:to="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_lbl" xml:lang="en-US">Warrants price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research, development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:to="SHPH_PaymentsToInvoicesInResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment_lbl" xml:lang="en-US">Payments to invoices in research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsEstimatedFairValue" xlink:label="SHPH_WarrantsEstimatedFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsEstimatedFairValue" xlink:to="SHPH_WarrantsEstimatedFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsEstimatedFairValue_lbl" xml:lang="en-US">Estimated fair value of company's stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Estimated IPO date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Estimated Term</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilities" xlink:label="SHPH_WarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilities" xlink:to="SHPH_WarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="SHPH_WarrantLiabilities_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesIssued" xlink:label="SHPH_WarrantLiabilitiesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilitiesIssued" xlink:to="SHPH_WarrantLiabilitiesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantLiabilitiesIssued_lbl" xml:lang="en-US">Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilitiesExercised" xlink:to="SHPH_WarrantLiabilitiesExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_WarrantLiabilitiesExercised_2_lbl" xml:lang="en-US">Exercised (settled)</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnChangeInFairValue" xlink:label="SHPH_GainOnChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnChangeInFairValue" xlink:to="SHPH_GainOnChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_GainOnChangeInFairValue_lbl" xml:lang="en-US">Gain on change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReclassificationsToStockholdersEquity" xlink:label="SHPH_ReclassificationsToStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReclassificationsToStockholdersEquity" xlink:to="SHPH_ReclassificationsToStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ReclassificationsToStockholdersEquity_lbl" xml:lang="en-US">Reclassifications to stockholders' equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilities" xlink:to="SHPH_WarrantLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SHPH_WarrantLiabilities_2_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment useful life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OtherInformationAbstract" xlink:label="SHPH_OtherInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OtherInformationAbstract" xlink:to="SHPH_OtherInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OtherInformationAbstract_lbl" xml:lang="en-US">Other information</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases (year)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfAcceleration" xlink:label="SHPH_DerivativeLiabilityOfAcceleration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfAcceleration" xlink:to="SHPH_DerivativeLiabilityOfAcceleration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityOfAcceleration_lbl" xml:lang="en-US">Amount due upon acceleration</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" xlink:label="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" xlink:to="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate_lbl" xml:lang="en-US">Carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleMaturityDate_lbl" xml:lang="en-US">IPO date</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfProbabilityAcceleration" xlink:label="SHPH_DerivativeLiabilityOfProbabilityAcceleration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfProbabilityAcceleration" xlink:to="SHPH_DerivativeLiabilityOfProbabilityAcceleration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityOfProbabilityAcceleration_lbl" xml:lang="en-US">Probability of IPO acceleration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Probability of Maturity</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityMeasurementDuration" xlink:label="SHPH_DerivativeLiabilityMeasurementDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityMeasurementDuration" xlink:to="SHPH_DerivativeLiabilityMeasurementDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityMeasurementDuration_lbl" xml:lang="en-US">Time period to maturity (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityDiscoutRate" xlink:label="SHPH_DerivativeLiabilityDiscoutRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityDiscoutRate" xlink:to="SHPH_DerivativeLiabilityDiscoutRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityDiscoutRate_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_2_lbl" xml:lang="en-US">Estimated fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleMaturityDate_2_lbl" xml:lang="en-US">Estimated IPO date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityMeasurementDuration" xlink:to="SHPH_DerivativeLiabilityMeasurementDuration_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DerivativeLiabilityMeasurementDuration_2_lbl" xml:lang="en-US">Time period (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfDiscountRate" xlink:label="SHPH_DerivativeLiabilityOfDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfDiscountRate" xlink:to="SHPH_DerivativeLiabilityOfDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DerivativeLiabilityOfDiscountRate_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">R &amp; D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:label="SHPH_IncomeTaxReconciliationProvisionAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:to="SHPH_IncomeTaxReconciliationProvisionAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationProvisionAdjustments_lbl" xml:lang="en-US">Return to provision adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_lbl" xml:lang="en-US">Derivative Debt Discount Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_lbl" xml:lang="en-US">Change in FMV of Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_lbl" xml:lang="en-US">Loss on convertible note conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShortfallOfStockCompensationExpense" xlink:label="SHPH_ShortfallOfStockCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShortfallOfStockCompensationExpense" xlink:to="SHPH_ShortfallOfStockCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShortfallOfStockCompensationExpense_lbl" xml:lang="en-US">Shortfall of stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles (includes Section 174 capitalization)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsbasedCompensation" xlink:label="SHPH_DeferredTaxAssetsbasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsbasedCompensation" xlink:to="SHPH_DeferredTaxAssetsbasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsbasedCompensation_lbl" xml:lang="en-US">Equity based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Interest &amp; other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:label="SHPH_DeferredTaxAssetsLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:to="SHPH_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease asset/(liability)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:to="SHPH_DeferredTaxLiabilitiesFairMarketValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue_lbl" xml:lang="en-US">Change in fair market value of securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US">State income tax deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:to="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_lbl" xml:lang="en-US">Total deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Federal income tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_lbl" xml:lang="en-US">Change in tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">R&amp;D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xml:lang="en-US">Return to provision adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_lbl" xml:lang="en-US">Derivative Debt Discount Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_lbl" xml:lang="en-US">Change in FMV of Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_lbl" xml:lang="en-US">Loss on convertible note conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_lbl" xml:lang="en-US">Shortfall of stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Increase decrease in additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_3_lbl" xml:lang="en-US">Exchange fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Consecutive trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReverseCommonStockSharesOutstanding" xlink:label="SHPH_ReverseCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReverseCommonStockSharesOutstanding" xlink:to="SHPH_ReverseCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ReverseCommonStockSharesOutstanding_lbl" xml:lang="en-US">Reverse common stock shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_2_lbl" xml:lang="en-US">Share based payment award description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xml:lang="en-US">Restricted stock units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3_lbl" xml:lang="en-US">Restricted stock value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operatiing loss</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_lbl" xml:lang="en-US">Carried forward</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_lbl" xml:lang="en-US">Future taxable income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Federal Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_lbl" xml:lang="en-US">Carried forward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">R&amp;D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNotePayableCurrent" xlink:label="SHPH_ConvertibleNotePayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotePayableCurrent" xlink:to="SHPH_ConvertibleNotePayableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ConvertibleNotePayableCurrent_doc" xml:lang="en-US">Convertible note payable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FinanceFee" xlink:to="SHPH_FinanceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_FinanceFee_doc" xml:lang="en-US">Finance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LossOnSettlementOfConvertibleDebt" xlink:to="SHPH_LossOnSettlementOfConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt_doc" xml:lang="en-US">Loss on settlement of convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnForgivenessOfNotePayable" xlink:to="SHPH_GainOnForgivenessOfNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_GainOnForgivenessOfNotePayable_doc" xml:lang="en-US">Gain on forgiveness of note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssuedMember" xlink:to="SHPH_CommonStockToBeIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockToBeIssuedMember_doc" xml:lang="en-US">Common Stock To Be Issued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_doc" xml:lang="en-US">Stock Issued During Period Value Conversion O fAccruedInterest And Principal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_doc" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Accrued Interest And Principal.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ChangeInFairValueOfDerivativeLiability" xlink:label="SHPH_ChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ChangeInFairValueOfDerivativeLiability" xlink:to="SHPH_ChangeInFairValueOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ChangeInFairValueOfDerivativeLiability_doc" xml:lang="en-US">Change in fair value of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestSettledWithCommonStock" xlink:to="SHPH_AccruedInterestSettledWithCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AccruedInterestSettledWithCommonStock_doc" xml:lang="en-US">Accruedi nterest settled with common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:to="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_doc" xml:lang="en-US">Increase decrease in accrued interest payable - related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:to="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_doc" xml:lang="en-US">Proceeds from issuance of common stock and exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuedForFinancingFees" xlink:to="SHPH_WarrantsIssuedForFinancingFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsIssuedForFinancingFees_doc" xml:lang="en-US">Warrants issued for financing fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:to="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_doc" xml:lang="en-US">Initial recognition of right of use asset and liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuanceFees" xlink:to="SHPH_WarrantsIssuanceFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsIssuanceFees_doc" xml:lang="en-US">Warrants issuance fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_doc" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InstitutionalInvestorMember" xlink:to="SHPH_InstitutionalInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InstitutionalInvestorMember_doc" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SecuritiesPurchaseAgreementMember" xlink:to="SHPH_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WorkingCapital" xlink:to="SHPH_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:to="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule of Useful Lives for Property Plant Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotePolicyTextBlock" xlink:to="SHPH_ConvertibleNotePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ConvertibleNotePolicyTextBlock_doc" xml:lang="en-US">Convertible Note [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsPolicyTextBlock" xlink:to="SHPH_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TCGGreenChemIncMember" xlink:to="SHPH_TCGGreenChemIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TCGGreenChemIncMember_doc" xml:lang="en-US">TCG Green Chem Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NewLeaseAgreementMember" xlink:to="SHPH_NewLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NewLeaseAgreementMember_doc" xml:lang="en-US">New Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RentVariableRate1" xlink:to="SHPH_RentVariableRate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_RentVariableRate1_doc" xml:lang="en-US">Rent Variable Rate1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonAreaMaintenanceCost" xlink:to="SHPH_CommonAreaMaintenanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonAreaMaintenanceCost_doc" xml:lang="en-US">Common area maintenance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OtherInformationAbstract" xlink:to="SHPH_OtherInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OtherInformationAbstract_doc" xml:lang="en-US">Other information [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficersSpouseMember" xlink:to="SHPH_OfficersSpouseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OfficersSpouseMember_doc" xml:lang="en-US">Officers Spouse [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyOfficerMember" xlink:to="SHPH_RelatedPartyOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_RelatedPartyOfficerMember_doc" xml:lang="en-US">Related Party Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadSecuritiesLLCMember" xlink:to="SHPH_BousteadSecuritiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_BousteadSecuritiesLLCMember_doc" xml:lang="en-US">Boustead Securities LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNoteMember" xlink:to="SHPH_ConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ConvertibleNoteMember_doc" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InterestFeeAmount" xlink:to="SHPH_InterestFeeAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InterestFeeAmount_doc" xml:lang="en-US">Interest fee amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestValueToIssueShares" xlink:to="SHPH_AccruedInterestValueToIssueShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AccruedInterestValueToIssueShares_doc" xml:lang="en-US">Accrued interest value to issue shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:to="SHPH_CommonStockVestingOfRestrictedStockUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockVestingOfRestrictedStockUnit_doc" xml:lang="en-US">Common stock vesting of restricted stock unit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_doc" xml:lang="en-US">Stock issued during period shares conversion of preferred shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_doc" xml:lang="en-US">Stock issued during period shares conversion of dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:to="SHPH_StockIssuedDuringPeriodValueDividendsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodValueDividendsPayable_doc" xml:lang="en-US">Stock issued during period value dividends payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoConvertibleNoteMember" xlink:to="SHPH_AltoConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AltoConvertibleNoteMember_doc" xml:lang="en-US">Alto Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadMember" xlink:to="SHPH_BousteadMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_BousteadMember_doc" xml:lang="en-US">Boustead [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AyrtonMember" xlink:to="SHPH_AyrtonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AyrtonMember_doc" xml:lang="en-US">Ayrton [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding, Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartiesMember" xlink:to="SHPH_NotesPayableRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableRelatedPartiesMember_doc" xml:lang="en-US">Notes Payable Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="SHPH_TwoThousandEighteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember_doc" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:to="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_doc" xml:lang="en-US">Class pf warrant or right number of securities called by warrants or rights value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeDiscountPercentage" xlink:to="SHPH_DerivativeDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeDiscountPercentage_doc" xml:lang="en-US">Derivative discount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:to="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_doc" xml:lang="en-US">Measurement Input Volume Weighted Average Price [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:to="SHPH_DerivativeGainLossOnDerivativeWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants_doc" xml:lang="en-US">Derivative gain loss on derivative warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AcceleratedFeatureMember" xlink:to="SHPH_AcceleratedFeatureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AcceleratedFeatureMember_doc" xml:lang="en-US">Accelerated Feature [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:to="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_doc" xml:lang="en-US">Addition of new derivatives recognized as debt discounts.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:to="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_doc" xml:lang="en-US">Schedule Of Pretax Income From Continuing Operations [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsbasedCompensation" xlink:to="SHPH_DeferredTaxAssetsbasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsbasedCompensation_doc" xml:lang="en-US">Deferred tax assetsbased compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:to="SHPH_DeferredTaxAssetsLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsLeaseLiabilities_doc" xml:lang="en-US">Deferred tax assets lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_doc" xml:lang="en-US">Deferred tax assets liabilities net before valuation allowances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:to="SHPH_DeferredTaxLiabilitiesFairMarketValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue_doc" xml:lang="en-US">Deferred tax liabilities fair market value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_doc" xml:lang="en-US">Effective income tax rate reconciliation change in tax rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_doc" xml:lang="en-US">Effective income tax rate reconciliation return to provision adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:to="SHPH_PaymentsToInvoicesInResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment_doc" xml:lang="en-US">Payments to invoices in research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:to="SHPH_IncomeTaxReconciliationProvisionAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationProvisionAdjustments_doc" xml:lang="en-US">Income tax reconciliation provision adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PurchaseAgreementMember" xlink:to="SHPH_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionalEscrowDeposit" xlink:to="SHPH_AdditionalEscrowDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AdditionalEscrowDeposit_doc" xml:lang="en-US">Additional escrow deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialPublicOfferingDescription" xlink:to="SHPH_InitialPublicOfferingDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InitialPublicOfferingDescription_doc" xml:lang="en-US">Initial public offering description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:to="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_doc" xml:lang="en-US">Deferred tax liabilities finite lived assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:to="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_doc" xml:lang="en-US">Notes Payable Related Party [Disclosure Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShortfallOfStockCompensationExpense" xlink:to="SHPH_ShortfallOfStockCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShortfallOfStockCompensationExpense_doc" xml:lang="en-US">Shortfall of stock compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_doc" xml:lang="en-US">Effective income tax rate reconciliation short fall of stock compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_doc" xml:lang="en-US">Deferred tax assets operating loss carried forward</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_doc" xml:lang="en-US">Deferred tax assets operating loss carried forward future federal income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputIlliquidityDiscountMember" xlink:to="SHPH_MeasurementInputIlliquidityDiscountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputIlliquidityDiscountMember_doc" xml:lang="en-US">Illiquidity Discount [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FederalTaxableIncomeMember" xlink:to="SHPH_FederalTaxableIncomeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_FederalTaxableIncomeMember_doc" xml:lang="en-US">Federal Taxable Income [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StateTaxableIncomeMember" xlink:to="SHPH_StateTaxableIncomeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StateTaxableIncomeMember_doc" xml:lang="en-US">State Taxable Income [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:to="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_doc" xml:lang="en-US">Estimated monthly common area maintenance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentForPlacementAgent" xlink:to="SHPH_PaymentForPlacementAgent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaymentForPlacementAgent_doc" xml:lang="en-US">Payment for placement agent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock_doc" xml:lang="en-US">Deemed dividend on extinguishment of series preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:to="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds_doc" xml:lang="en-US">Fair value of free standing Instruments In excess of proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt" xlink:to="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedUponConversionOfConvertibleDebt_doc" xml:lang="en-US">Common stock issued upon conversion of convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock" xlink:to="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleofWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Warrant Liabilities [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilities" xlink:to="SHPH_WarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantLiabilities_doc" xml:lang="en-US">Warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilitiesIssued" xlink:to="SHPH_WarrantLiabilitiesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantLiabilitiesIssued_doc" xml:lang="en-US">Warrant liabilities issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilitiesExercised" xlink:to="SHPH_WarrantLiabilitiesExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantLiabilitiesExercised_doc" xml:lang="en-US">Warrant liabilities exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_QuarterlyFinancialDataTextBlock" xlink:to="SHPH_QuarterlyFinancialDataTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_QuarterlyFinancialDataTextBlock_doc" xml:lang="en-US">Quarterly Financial Data [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock" xlink:to="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock_doc" xml:lang="en-US">Schedule of Quarterly Financial Data [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiability" xlink:to="SHPH_WarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantLiability_doc" xml:lang="en-US">Warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock" xlink:to="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock_doc" xml:lang="en-US">Schedule of Derivative Key Valuation Inputs [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember" xlink:to="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputSharePriceProbabilityOfIPOMember_doc" xml:lang="en-US">Measurement Input Share Price Probability Of IPO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SettlementMember" xlink:to="SHPH_SettlementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SettlementMember_doc" xml:lang="en-US">Settlement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember" xlink:to="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember_doc" xml:lang="en-US">2022 Convertible Note Derivative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CumulativeDividendsPercentage" xlink:to="SHPH_CumulativeDividendsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CumulativeDividendsPercentage_doc" xml:lang="en-US">Cumulative dividends percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantObligationLiability" xlink:to="SHPH_WarrantObligationLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantObligationLiability_doc" xml:lang="en-US">Warrant obligation liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnSettlementOfAccountsPayable" xlink:to="SHPH_GainOnSettlementOfAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_GainOnSettlementOfAccountsPayable_doc" xml:lang="en-US">Gain on settlement of accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="SHPH_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" xlink:to="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_doc" xml:lang="en-US">Schedule Of Error Corrections And Prior Period Adjustments [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputIpoDateMember" xlink:to="SHPH_MeasurementInputIpoDateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputIpoDateMember_doc" xml:lang="en-US">Measurement Input Ipo Date [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember" xlink:to="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AugustTwentyTwentyTwoPromissoryNotesMember_doc" xml:lang="en-US">August 2022 [Promissory Notes Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" xlink:to="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember_doc" xml:lang="en-US">2022 Convertible Bridge Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnSettlementOnAccountsPayable" xlink:to="SHPH_GainOnSettlementOnAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_GainOnSettlementOnAccountsPayable_doc" xml:lang="en-US">Gain on settlement on accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityWarrants" xlink:to="SHPH_DerivativeLiabilityWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityWarrants_doc" xml:lang="en-US">Derivative liability warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityAcceleratedFeature" xlink:to="SHPH_DerivativeLiabilityAcceleratedFeature_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityAcceleratedFeature_doc" xml:lang="en-US">Derivative liability accelerated feature.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DividendsOnSeriesPreferredStock" xlink:to="SHPH_DividendsOnSeriesPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DividendsOnSeriesPreferredStock_doc" xml:lang="en-US">Dividends on series preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromNotesPayableAndWarrants" xlink:to="SHPH_ProceedsFromNotesPayableAndWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ProceedsFromNotesPayableAndWarrants_doc" xml:lang="en-US">Proceeds from notes payable and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:to="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_doc" xml:lang="en-US">Reclassification of fair value of warrant liability to equity upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:to="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_doc" xml:lang="en-US">Common shares issued for dividends on and conversion of series preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReclassificationsToStockholdersEquity" xlink:to="SHPH_ReclassificationsToStockholdersEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ReclassificationsToStockholdersEquity_doc" xml:lang="en-US">Reclassifications to stockholders equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DecemberTwentyThousandTwentyOneNotesMember" xlink:to="SHPH_DecemberTwentyThousandTwentyOneNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DecemberTwentyThousandTwentyOneNotesMember_doc" xml:lang="en-US">December 2021 Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandAndTwentyTwoNotesMember" xlink:to="SHPH_AugustTwoThousandAndTwentyTwoNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AugustTwoThousandAndTwentyTwoNotesMember_doc" xml:lang="en-US">August 2022 Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsDescription" xlink:to="SHPH_WarrantsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsDescription_doc" xml:lang="en-US">Warrants description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" xlink:to="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember_doc" xml:lang="en-US">August 2022 Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember" xlink:to="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember_doc" xml:lang="en-US">2022 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DirectorsOfficersAndConsultantsMember" xlink:to="SHPH_DirectorsOfficersAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DirectorsOfficersAndConsultantsMember_doc" xml:lang="en-US">Directors Officers and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensations" xlink:to="SHPH_ShareBasedCompensations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensations_doc" xml:lang="en-US">Share based compensations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityMeasurementDuration" xlink:to="SHPH_DerivativeLiabilityMeasurementDuration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityMeasurementDuration_doc" xml:lang="en-US">Derivative liability measurement duration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IssuanceOfWarrantsShares" xlink:to="SHPH_IssuanceOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IssuanceOfWarrantsShares_doc" xml:lang="en-US">Issuance of warrants shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedUponCompletion" xlink:to="SHPH_StockIssuedUponCompletion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedUponCompletion_doc" xml:lang="en-US">Stock issued upon completion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedUponCompletionShares" xlink:to="SHPH_StockIssuedUponCompletionShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedUponCompletionShares_doc" xml:lang="en-US">Stock issued upon completion, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:to="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants_doc" xml:lang="en-US">Deemed dividend on modification of equity-classified warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_doc" xml:lang="en-US">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividend" xlink:to="SHPH_DeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedDividend_doc" xml:lang="en-US">Deemed dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnChangeInFairValue" xlink:to="SHPH_GainOnChangeInFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_GainOnChangeInFairValue_doc" xml:lang="en-US">Gain on change in fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated" xlink:to="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated_doc" xml:lang="en-US">Common stock issued for conversion of accrued interest as restated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" xlink:to="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated_doc" xml:lang="en-US">Common stock issued upon conversion of convertible debt and exercise of related warrants as restated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" xlink:to="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_doc" xml:lang="en-US">Deemed dividend on modification of equity classified warrants as restated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_doc" xml:lang="en-US">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends as restated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" xlink:to="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember_doc" xml:lang="en-US">Warrant Liability Series A Preferred Stock Obligation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:to="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember_doc" xml:lang="en-US">Warrant Liability August 2022 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:to="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember_doc" xml:lang="en-US">Warrant Liability Boustead Placement Agent Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember" xlink:to="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember_doc" xml:lang="en-US">August 2021 Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:to="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwoThousandAndTwentyOneConvertibleNotesMember_doc" xml:lang="en-US">2021 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IssuanceDatesMember" xlink:to="SHPH_IssuanceDatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IssuanceDatesMember_doc" xml:lang="en-US">Issuance Dates [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IssuanceDateMember" xlink:to="SHPH_IssuanceDateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IssuanceDateMember_doc" xml:lang="en-US">Issuance Date [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfProbabilityAcceleration" xlink:to="SHPH_DerivativeLiabilityOfProbabilityAcceleration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityOfProbabilityAcceleration_doc" xml:lang="en-US">Derivative liability of probability acceleration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:to="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_doc" xml:lang="en-US">Deemed contribution of conversion of preferred stock and settlement of preferred stock dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock" xlink:to="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock_doc" xml:lang="en-US">Schedule of Derivative of Settlement Valuation [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfDiscountRate" xlink:to="SHPH_DerivativeLiabilityOfDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityOfDiscountRate_doc" xml:lang="en-US">Derivative liability of discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesDerivativeMember" xlink:to="SHPH_NotesDerivativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesDerivativeMember_doc" xml:lang="en-US">Notes Derivative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfAcceleration" xlink:to="SHPH_DerivativeLiabilityOfAcceleration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityOfAcceleration_doc" xml:lang="en-US">Derivative liability of acceleration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" xlink:to="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityOfCarringValueMeasurementDate_doc" xml:lang="en-US">Derivative liability of carring value measurement date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReverseCommonStockSharesOutstanding" xlink:to="SHPH_ReverseCommonStockSharesOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ReverseCommonStockSharesOutstanding_doc" xml:lang="en-US">Reverse common stock shares outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FairValueAdjustmentOfWarrant" xlink:to="SHPH_FairValueAdjustmentOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_FairValueAdjustmentOfWarrant_doc" xml:lang="en-US">Fair value adjustment of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_doc" xml:lang="en-US">Deemed dividend on extinguishment of series preferred stock as restated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantSharePrice" xlink:to="SHPH_WarrantSharePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantSharePrice_doc" xml:lang="en-US">Warrant share price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInIssuanceCost" xlink:to="SHPH_IncreaseDecreaseInIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInIssuanceCost_doc" xml:lang="en-US">Increase decrease in issuance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInWarrants" xlink:to="SHPH_IncreaseDecreaseInWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInWarrants_doc" xml:lang="en-US">Increase decrease in warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInWarrantsFromLiability" xlink:to="SHPH_IncreaseDecreaseInWarrantsFromLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInWarrantsFromLiability_doc" xml:lang="en-US">Increase decrease in warrants from liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInFairValueOfWarrants" xlink:to="SHPH_IncreaseDecreaseInFairValueOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInFairValueOfWarrants_doc" xml:lang="en-US">Increase decrease in fair value of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInNetIncomeLoss" xlink:to="SHPH_IncreaseDecreaseInNetIncomeLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInNetIncomeLoss_doc" xml:lang="en-US">Increase decrease in net income loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsEstimatedFairValue" xlink:to="SHPH_WarrantsEstimatedFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsEstimatedFairValue_doc" xml:lang="en-US">Warrants estimated fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember" xlink:to="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember_doc" xml:lang="en-US">Measurement Input Probability of IPO Listing Occurring [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputProbabilityOfIPOListingMember" xlink:to="SHPH_MeasurementInputProbabilityOfIPOListingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputProbabilityOfIPOListingMember_doc" xml:lang="en-US">Measurement Input Probability of IPO Listing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember" xlink:to="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputProbabilityOfQualifiedIPOMember_doc" xml:lang="en-US">Measurement Input Probability of Qualified IPO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BlackScholesModelMember" xlink:to="SHPH_BlackScholesModelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_BlackScholesModelMember_doc" xml:lang="en-US">Black Scholes Model [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputEstimatedFairValueMember" xlink:to="SHPH_MeasurementInputEstimatedFairValueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputEstimatedFairValueMember_doc" xml:lang="en-US">Measurement Input Estimated Fair Value [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandTwentyTwoNotesMember" xlink:to="SHPH_AugustTwoThousandTwentyTwoNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AugustTwoThousandTwentyTwoNotesMember_doc" xml:lang="en-US">August 2022 Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInPreferredStock" xlink:to="SHPH_IncreaseDecreaseInPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInPreferredStock_doc" xml:lang="en-US">Increase decrease in preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInDividendLiability" xlink:to="SHPH_IncreaseDecreaseInDividendLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInDividendLiability_doc" xml:lang="en-US">Increase decrease in dividend liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfPreferredStock_doc" xml:lang="en-US">Deemed dividend on extinguishment of series A preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnInterestReliefOnConversionOfNotesPayable" xlink:to="SHPH_GainOnInterestReliefOnConversionOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_GainOnInterestReliefOnConversionOfNotesPayable_doc" xml:lang="en-US">Gain on interest relief on conversion of notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember" xlink:to="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AugustTwentyTwentyTwoConvertibleNotesMember_doc" xml:lang="en-US">August 2022 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityDiscoutRate" xlink:to="SHPH_DerivativeLiabilityDiscoutRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeLiabilityDiscoutRate_doc" xml:lang="en-US">Derivative liability discout rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoWarrantsMember" xlink:to="SHPH_AltoWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AltoWarrantsMember_doc" xml:lang="en-US">Alto Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeSettlementsOnDerivativeWarrants" xlink:to="SHPH_DerivativeSettlementsOnDerivativeWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeSettlementsOnDerivativeWarrants_doc" xml:lang="en-US">Derivative Settlements on Derivative [Warrants]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoAccelerationOptionMember" xlink:to="SHPH_AltoAccelerationOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AltoAccelerationOptionMember_doc" xml:lang="en-US">Alto Acceleration Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember" xlink:to="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember_doc" xml:lang="en-US">December 2021 Notes Derivative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:to="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember_doc" xml:lang="en-US">August 2022 Notes Derivative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:to="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember_doc" xml:lang="en-US">2022 Convertible Notes Derivative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend_doc" xml:lang="en-US">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForCash" xlink:to="SHPH_CommonStockIssuedForCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForCash_doc" xml:lang="en-US">Common stock issued for cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsExercisedForCash" xlink:to="SHPH_WarrantsExercisedForCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsExercisedForCash_doc" xml:lang="en-US">Warrants exercised for cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_doc" xml:lang="en-US">Income Tax Reconciliation Foreign Income Tax Permanent Differences [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_doc" xml:lang="en-US">Permanent differences loss on convertible note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_doc" xml:lang="en-US">Permanent differences other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_doc" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_doc" xml:lang="en-US">Permanent differences loss on convertible note conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_doc" xml:lang="en-US">Permanent differences other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_doc" xml:lang="en-US">Differences derivative debt discount amortization.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDifferencesChangeInFMVOfWarrantLiability" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDifferencesChangeInFMVOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDifferencesChangeInFMVOfWarrantLiability" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDifferencesChangeInFMVOfWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDifferencesChangeInFMVOfWarrantLiability_doc" xml:lang="en-US">Differences change in FMV of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_doc" xml:lang="en-US">Differences derivative debt discount amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_doc" xml:lang="en-US">Differences change in FMV of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_doc" xml:lang="en-US">Change in FMV of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:to="SHPH_CommonStockIssuedForConversionOfAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterest_doc" xml:lang="en-US">Common stock issued for conversion of accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForSettlementOfDebt" xlink:to="SHPH_CommonStockIssuedForSettlementOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForSettlementOfDebt_doc" xml:lang="en-US">Common stock issued for settlement of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReverseStockSplitPolicyTextBlock" xlink:to="SHPH_ReverseStockSplitPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ReverseStockSplitPolicyTextBlock_doc" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredOfferingCostsPolicyTextBlock" xlink:to="SHPH_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred Offering Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PercentageOfRentAbatement" xlink:to="SHPH_PercentageOfRentAbatement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PercentageOfRentAbatement_doc" xml:lang="en-US">Percentage of rent abatement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LeaseAgreementMember" xlink:to="SHPH_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_LeaseAgreementMember_doc" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of Balance Sheet Information Related to Operating Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xml:lang="en-US">Intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotesPayableCurrentNonCurrent" xlink:to="SHPH_ConvertibleNotesPayableCurrentNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ConvertibleNotesPayableCurrentNonCurrent_doc" xml:lang="en-US">Convertible notes payable current noncurrent.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoOpportunityMasterFundSPCMember" xlink:label="SHPH_AltoOpportunityMasterFundSPCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoOpportunityMasterFundSPCMember" xlink:to="SHPH_AltoOpportunityMasterFundSPCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AltoOpportunityMasterFundSPCMember_doc" xml:lang="en-US">Alto Opportunity Master Fund SPC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AugustTwoThousandTwentyTwoNotesMember" xlink:to="SHPH_AugustTwoThousandTwentyTwoNotesMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AugustTwoThousandTwentyTwoNotesMember_3_lbl" xml:lang="en-US">August 2022 Notes [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FairValueAdjustmentOfWarrant" xlink:to="SHPH_FairValueAdjustmentOfWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_FairValueAdjustmentOfWarrant_3_lbl" xml:lang="en-US">FairValueAdjustmentOfWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_3_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated_3_lbl" xml:lang="en-US">DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends_3_lbl" xml:lang="en-US">DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DividendsOnSeriesPreferredStock" xlink:to="SHPH_DividendsOnSeriesPreferredStock_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DividendsOnSeriesPreferredStock_4_lbl" xml:lang="en-US">DividendsOnSeriesPreferredStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnSettlementOnAccountsPayable" xlink:to="SHPH_GainOnSettlementOnAccountsPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_GainOnSettlementOnAccountsPayable_3_lbl" xml:lang="en-US">GainOnSettlementOnAccountsPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:to="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedInterestPayableRelatedParties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated" xlink:to="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated_3_lbl" xml:lang="en-US">CommonStockIssuedForConversionOfAccruedInterestAsRestated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" xlink:to="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated_3_lbl" xml:lang="en-US">CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" xlink:to="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock_3_lbl" xml:lang="en-US">DeemedDividendOnExtinguishmentOfSeriesPreferredStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" xlink:to="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_3_lbl" xml:lang="en-US">DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" xlink:to="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_3_lbl" xml:lang="en-US">DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnInterestReliefOnConversionOfNotesPayable" xlink:to="SHPH_GainOnInterestReliefOnConversionOfNotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_GainOnInterestReliefOnConversionOfNotesPayable_3_lbl" xml:lang="en-US">GainOnInterestReliefOnConversionOfNotesPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_2_lbl" xml:lang="en-US">Income Taxes Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInWarrants" xlink:to="SHPH_IncreaseDecreaseInWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInWarrants_3_lbl" xml:lang="en-US">IncreaseDecreaseInWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Operating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_2_lbl" xml:lang="en-US">Sublease Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_2_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_2_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestValueToIssueShares" xlink:to="SHPH_AccruedInterestValueToIssueShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AccruedInterestValueToIssueShares_3_lbl" xml:lang="en-US">AccruedInterestValueToIssueShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionalEscrowDeposit" xlink:to="SHPH_AdditionalEscrowDeposit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AdditionalEscrowDeposit_3_lbl" xml:lang="en-US">AdditionalEscrowDeposit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantLiabilities" xlink:to="SHPH_WarrantLiabilities_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantLiabilities_4_lbl" xml:lang="en-US">Warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeLiabilityOfDiscountRate" xlink:to="SHPH_DerivativeLiabilityOfDiscountRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeLiabilityOfDiscountRate_3_lbl" xml:lang="en-US">DerivativeLiabilityOfDiscountRate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:to="SHPH_DeferredTaxLiabilitiesFairMarketValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesFairMarketValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_2_lbl" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:to="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesFiniteLivedAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_3_lbl" xml:lang="en-US">DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_3_lbl" xml:lang="en-US">DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>shph-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="shph-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="shph-20240630.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="shph-20240630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:href="shph-20240630.xsd#OrganizationAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:href="shph-20240630.xsd#RestatementOfPreviouslyIssuedFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/Leases" xlink:href="shph-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20240630.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable" xlink:href="shph-20240630.xsd#ConvertibleNotesAndNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:href="shph-20240630.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:href="shph-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxes" xlink:href="shph-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated" xlink:href="shph-20240630.xsd#QuarterlyFinancialDataUnauditedAndRestated" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:href="shph-20240630.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesTables" xlink:href="shph-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:href="shph-20240630.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:href="shph-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:href="shph-20240630.xsd#QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:href="shph-20240630.xsd#OrganizationAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:href="shph-20240630.xsd#ScheduleOfErrorCorrectionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="shph-20240630.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="shph-20240630.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20240630.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:href="shph-20240630.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:href="shph-20240630.xsd#ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:href="shph-20240630.xsd#ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:href="shph-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20240630.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:href="shph-20240630.xsd#ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20240630.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20240630.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:href="shph-20240630.xsd#ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="shph-20240630.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="shph-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails" xlink:href="shph-20240630.xsd#ScheduleOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20240630.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:href="shph-20240630.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails" xlink:href="shph-20240630.xsd#ScheduleOfRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeLiabilityValuationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeKeyValuationInputsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:href="shph-20240630.xsd#ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20240630.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20240630.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="shph-20240630.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails" xlink:href="shph-20240630.xsd#ScheduleOfQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:href="shph-20240630.xsd#ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="shph-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHFinanceFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueAdjustmentOfWarrant" xlink:label="loc_SHPHFairValueAdjustmentOfWarrant" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHFairValueAdjustmentOfWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnSettlementOfAccountsPayable" xlink:label="loc_SHPHGainOnSettlementOfAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHGainOnSettlementOfAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:label="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:label="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:label="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_SHPHCommonStockToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_SHPHStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DividendsOnSeriesPreferredStock" xlink:label="loc_SHPHDividendsOnSeriesPreferredStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDividendsOnSeriesPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfPreferredStock" xlink:label="loc_SHPHDeemedDividendOnExtinguishmentOfPreferredStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedDividendOnExtinguishmentOfPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaapEquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" xlink:label="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuanceFees" xlink:label="loc_SHPHWarrantsIssuanceFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_SHPHWarrantsIssuanceFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AccruedInterestSettledWithCommonStock" xlink:label="loc_SHPHAccruedInterestSettledWithCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHAccruedInterestSettledWithCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnSettlementOnAccountsPayable" xlink:label="loc_SHPHGainOnSettlementOnAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHGainOnSettlementOnAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:label="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromNotesPayableAndWarrants" xlink:label="loc_SHPHProceedsFromNotesPayableAndWarrants" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SHPHProceedsFromNotesPayableAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:label="loc_SHPHCommonStockIssuedForConversionOfAccruedInterest" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedForConversionOfAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForSettlementOfDebt" xlink:label="loc_SHPHCommonStockIssuedForSettlementOfDebt" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedForSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuedForFinancingFees" xlink:label="loc_SHPHWarrantsIssuedForFinancingFees" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHWarrantsIssuedForFinancingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:label="loc_SHPHInitialRecognitionOfRightOfUseAssetAndLiability" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHInitialRecognitionOfRightOfUseAssetAndLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:label="loc_SHPHFairValueOfFreestandingInstrumentsInExcessOfProceeds" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHFairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated" xlink:label="loc_SHPHCommonStockIssuedForConversionOfAccruedInterestAsRestated" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedForConversionOfAccruedInterestAsRestated" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" xlink:label="loc_SHPHCommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:label="loc_SHPHCommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHCommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:label="loc_SHPHReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SHPHReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuanceFees" xlink:label="loc_SHPHWarrantsIssuanceFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_SHPHWarrantsIssuanceFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:title="00000009 - Disclosure - Organization and Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:title="00000010 - Disclosure - Restatement of Previously Issued Financial Statements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="loc_us-gaapErrorCorrectionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapErrorCorrectionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000011 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Leases" xlink:title="00000012 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000013 - Disclosure - Notes Payable-Related Party">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:label="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:label="loc_SHPHNotesPayableRelatedPartyDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" xlink:to="loc_SHPHNotesPayableRelatedPartyDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable" xlink:title="00000014 - Disclosure - Convertible Notes and Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:title="00000016 - Disclosure - Derivative Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated" xlink:title="00000019 - Disclosure - Quarterly Financial Data (Unaudited and Restated)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" xlink:label="loc_SHPHDisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_QuarterlyFinancialDataTextBlock" xlink:label="loc_SHPHQuarterlyFinancialDataTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" xlink:to="loc_SHPHQuarterlyFinancialDataTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReverseStockSplitPolicyTextBlock" xlink:label="loc_SHPHReverseStockSplitPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHReverseStockSplitPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsPolicyTextBlock" xlink:label="loc_SHPHWarrantsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_SHPHDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNotePolicyTextBlock" xlink:label="loc_SHPHConvertibleNotePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHConvertibleNotePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:title="00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" xlink:label="loc_SHPHScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_SHPHScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofWarrantLiabilitiesTableTextBlock" xlink:label="loc_SHPHScheduleofWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHScheduleofWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:label="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesTables" xlink:title="00000024 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_SHPHScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_SHPHScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000025 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:title="00000026 - Disclosure - Derivative Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesMember" xlink:label="loc_SHPHAugustTwoThousandTwentyTwoNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHAugustTwoThousandTwentyTwoNotesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock" xlink:label="loc_SHPHScheduleOfDerivativeOfSettlementValuationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHScheduleOfDerivativeOfSettlementValuationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock" xlink:label="loc_SHPHScheduleofDerivativeKeyValuationInputsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHScheduleofDerivativeKeyValuationInputsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:label="loc_SHPHScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables" xlink:title="00000028 - Disclosure - Quarterly Financial Data (Unaudited and Restated) (Tables)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" xlink:label="loc_SHPHDisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock" xlink:label="loc_SHPHScheduleofQuarterlyFinancialDataTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract" xlink:to="loc_SHPHScheduleofQuarterlyFinancialDataTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="00000029 - Disclosure - Organization and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InstitutionalInvestorMember" xlink:label="loc_SHPHInstitutionalInvestorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHInstitutionalInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WorkingCapital" xlink:label="loc_SHPHWorkingCapital" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SHPHWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaapPartnersCapital" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPartnersCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WorkingCapital" xlink:label="loc_SHPHWorkingCapital_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SHPHWorkingCapital_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" xlink:title="00000030 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHFinanceFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock" xlink:label="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedDividendOnExtinguishmentOfSeriesPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" xlink:label="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" xlink:label="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForCash" xlink:label="loc_SHPHCommonStockIssuedForCash" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonStockIssuedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsExercisedForCash" xlink:label="loc_SHPHWarrantsExercisedForCash" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsExercisedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DividendsOnSeriesPreferredStock" xlink:label="loc_SHPHDividendsOnSeriesPreferredStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHDividendsOnSeriesPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:label="loc_SHPHReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:label="loc_SHPHFairValueOfFreestandingInstrumentsInExcessOfProceeds" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHFairValueOfFreestandingInstrumentsInExcessOfProceeds" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnInterestReliefOnConversionOfNotesPayable" xlink:label="loc_SHPHGainOnInterestReliefOnConversionOfNotesPayable" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHGainOnInterestReliefOnConversionOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ProceedsFromNotesPayableAndWarrants" xlink:label="loc_SHPHProceedsFromNotesPayableAndWarrants" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHProceedsFromNotesPayableAndWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedUponConversionOfConvertibleDebt" xlink:label="loc_SHPHCommonStockIssuedUponConversionOfConvertibleDebt" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonStockIssuedUponConversionOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:label="loc_SHPHCommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHCommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuedForFinancingFees" xlink:label="loc_SHPHWarrantsIssuedForFinancingFees" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsIssuedForFinancingFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsIssuanceFees" xlink:label="loc_SHPHWarrantsIssuanceFees" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsIssuanceFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical" xlink:title="00000031 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDividendsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInDividendsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDividendsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInIssuanceCost" xlink:label="loc_SHPHIncreaseDecreaseInIssuanceCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInWarrants" xlink:label="loc_SHPHIncreaseDecreaseInWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInWarrantsFromLiability" xlink:label="loc_SHPHIncreaseDecreaseInWarrantsFromLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInWarrantsFromLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInFairValueOfWarrants" xlink:label="loc_SHPHIncreaseDecreaseInFairValueOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInNetIncomeLoss" xlink:label="loc_SHPHIncreaseDecreaseInNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInNotesPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInPreferredStock" xlink:label="loc_SHPHIncreaseDecreaseInPreferredStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncreaseDecreaseInDividendLiability" xlink:label="loc_SHPHIncreaseDecreaseInDividendLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHIncreaseDecreaseInDividendLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:title="00000032 - Disclosure - Schedule of the Error Correction (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000033 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000034 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_SHPHAcceleratedFeatureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaapAssetsFairValueDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosureAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaapDerivativeAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityWarrants" xlink:label="loc_SHPHDerivativeLiabilityWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_SHPHDerivativeLiabilityWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityAcceleratedFeature" xlink:label="loc_SHPHDerivativeLiabilityAcceleratedFeature" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_SHPHDerivativeLiabilityAcceleratedFeature" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensations" xlink:label="loc_SHPHShareBasedCompensations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHShareBasedCompensations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:title="00000037 - Disclosure - Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:title="00000038 - Disclosure - Schedule of Balance Sheet Information Related to Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:title="00000039 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LeaseAgreementMember" xlink:label="loc_SHPHLeaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SHPHLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NewLeaseAgreementMember" xlink:label="loc_SHPHNewLeaseAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SHPHNewLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeAxis" xlink:label="loc_us-gaapPledgingPurposeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPledgingPurposeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaapPledgingPurposeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPledgingPurposeAxis" xlink:to="loc_us-gaapPledgingPurposeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaapLetterOfCreditMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPledgingPurposeDomain" xlink:to="loc_us-gaapLetterOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_RentVariableRate1" xlink:label="loc_SHPHRentVariableRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHRentVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PercentageOfRentAbatement" xlink:label="loc_SHPHPercentageOfRentAbatement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHPercentageOfRentAbatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:label="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonAreaMaintenanceCost" xlink:label="loc_SHPHCommonAreaMaintenanceCost" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHCommonAreaMaintenanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000041 - Disclosure - Notes Payable-Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:label="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OfficersSpouseMember" xlink:label="loc_SHPHOfficersSpouseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHOfficersSpouseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="loc_SHPHRelatedPartyOfficerMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHRelatedPartyOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative" xlink:title="00000042 - Disclosure - Convertible Notes and Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNoteMember" xlink:label="loc_SHPHConvertibleNoteMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" xlink:label="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwentyTwentyTwoPromissoryNotesMember" xlink:label="loc_SHPHAugustTwentyTwentyTwoPromissoryNotesMember" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwentyTwentyTwoPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_SHPHAugustTwentyTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwentyTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember" />
      <link:presentationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PaymentForPlacementAgent" xlink:label="loc_SHPHPaymentForPlacementAgent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHPaymentForPlacementAgent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InterestFeeAmount" xlink:label="loc_SHPHInterestFeeAmount" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHInterestFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaapProceedsFromInterestReceived" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromInterestReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ConvertibleNotesPayableCurrentNonCurrent" xlink:label="loc_SHPHConvertibleNotesPayableCurrentNonCurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHConvertibleNotesPayableCurrentNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MediumTermNotes" xlink:label="loc_us-gaapMediumTermNotes" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapMediumTermNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaapShortTermDebtDescription" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:label="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHDeemedDividendOnModificationOfEquityclassifiedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDerivativeIssuanceCosts" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDerivativeIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHFinanceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceOfWarrantsShares" xlink:label="loc_SHPHIssuanceOfWarrantsShares" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHIssuanceOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000043 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadMember" xlink:label="loc_SHPHBousteadMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AyrtonMember" xlink:label="loc_SHPHAyrtonMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHAyrtonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000044 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember" xlink:label="loc_SHPHTwentyTwentyTwoConvertibleNoteDerivativeMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwentyTwentyTwoConvertibleNoteDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DecemberTwentyThousandTwentyOneNotesMember" xlink:label="loc_SHPHDecemberTwentyThousandTwentyOneNotesMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHDecemberTwentyThousandTwentyOneNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyTwoNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember" xlink:label="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwentyTwentyTwoConvertibleBridgeNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DirectorsAndOfficersMember" xlink:label="loc_SHPHDirectorsAndOfficersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsAndOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DirectorsOfficersAndConsultantsMember" xlink:label="loc_SHPHDirectorsOfficersAndConsultantsMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsOfficersAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PurchaseAgreementMember" xlink:label="loc_SHPHPurchaseAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BlackScholesModelMember" xlink:label="loc_SHPHBlackScholesModelMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHBlackScholesModelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="110" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AccruedInterestValueToIssueShares" xlink:label="loc_SHPHAccruedInterestValueToIssueShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHAccruedInterestValueToIssueShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="loc_SHPHAdditionalEscrowDeposit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHAdditionalEscrowDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="loc_SHPHInitialPublicOfferingDescription" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHInitialPublicOfferingDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts" xlink:label="loc_us-gaapDirectOperatingCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDirectOperatingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:label="loc_SHPHCommonStockVestingOfRestrictedStockUnit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHCommonStockVestingOfRestrictedStockUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedUponCompletionShares" xlink:label="loc_SHPHStockIssuedUponCompletionShares" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedUponCompletionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedUponCompletion" xlink:label="loc_SHPHStockIssuedUponCompletion" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedUponCompletion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapGainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_CumulativeDividendsPercentage" xlink:label="loc_SHPHCumulativeDividendsPercentage" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHCumulativeDividendsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedDividend" xlink:label="loc_SHPHDeemedDividend" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaapPreferredStockConvertibleConversionRatio" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionRatio" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:label="loc_SHPHDeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHDeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CumulativeDividends" xlink:label="loc_us-gaapCumulativeDividends" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCumulativeDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsDescription" xlink:label="loc_SHPHWarrantsDescription" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantSharePrice" xlink:label="loc_SHPHWarrantSharePrice" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiability" xlink:label="loc_SHPHWarrantLiability" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantObligationLiability" xlink:label="loc_SHPHWarrantObligationLiability" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantObligationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesExercised" xlink:label="loc_SHPHWarrantLiabilitiesExercised" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHWarrantLiabilitiesExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceOfWarrantsShares" xlink:label="loc_SHPHIssuanceOfWarrantsShares" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHIssuanceOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:title="00000046 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="loc_us-gaapMeasurementInputDefaultRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDefaultRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIlliquidityDiscountMember" xlink:label="loc_SHPHMeasurementInputIlliquidityDiscountMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIlliquidityDiscountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoWarrantsMember" xlink:label="loc_SHPHAltoWarrantsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHAltoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:title="00000047 - Disclosure - Schedule of Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_srtStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SHPHAcceleratedFeatureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoWarrantsMember" xlink:label="loc_SHPHAltoWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHAltoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesDerivativeMember" xlink:label="loc_SHPHNotesDerivativeMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHNotesDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:label="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:label="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoAccelerationOptionMember" xlink:label="loc_SHPHAltoAccelerationOptionMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHAltoAccelerationOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember" xlink:label="loc_SHPHDecemberTwoThousandTwentyOneNotesDerivativeMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHDecemberTwoThousandTwentyOneNotesDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember" xlink:label="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandTwentyTwoNotesDerivativeMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember" xlink:label="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwoThousandTwentyTwoConvertibleNotesDerivativeMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:label="loc_SHPHDerivativeGainLossOnDerivativeWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHDerivativeGainLossOnDerivativeWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:label="loc_SHPHDerivativeGainLossOnDerivativeWarrants_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHDerivativeGainLossOnDerivativeWarrants_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeSettlementsOnDerivativeWarrants" xlink:label="loc_SHPHDerivativeSettlementsOnDerivativeWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHDerivativeSettlementsOnDerivativeWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000048 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeDiscountPercentage" xlink:label="loc_SHPHDerivativeDiscountPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHDerivativeDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:label="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - Related Party transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TCGGreenChemIncMember" xlink:label="loc_SHPHTCGGreenChemIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHTCGGreenChemIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails" xlink:title="00000050 - Disclosure - Schedule of Key Inputs of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" xlink:label="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember" xlink:label="loc_SHPHMeasurementInputProbabilityOfIPOListingOccurringMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputProbabilityOfIPOListingOccurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfQualifiedIPOMember" xlink:label="loc_SHPHMeasurementInputProbabilityOfQualifiedIPOMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputProbabilityOfQualifiedIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputProbabilityOfIPOListingMember" xlink:label="loc_SHPHMeasurementInputProbabilityOfIPOListingMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputProbabilityOfIPOListingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantsEstimatedFairValue" xlink:label="loc_SHPHWarrantsEstimatedFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantsEstimatedFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails" xlink:title="00000051 - Disclosure - Schedule of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember" xlink:label="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilitySeriesAPreferredStockObligationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityAugustTwentyTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:label="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHWarrantLiabilityBousteadPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilities" xlink:label="loc_SHPHWarrantLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesIssued" xlink:label="loc_SHPHWarrantLiabilitiesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantLiabilitiesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilitiesExercised" xlink:label="loc_SHPHWarrantLiabilitiesExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantLiabilitiesExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_GainOnChangeInFairValue" xlink:label="loc_SHPHGainOnChangeInFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHGainOnChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReclassificationsToStockholdersEquity" xlink:label="loc_SHPHReclassificationsToStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHReclassificationsToStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_WarrantLiabilities" xlink:label="loc_SHPHWarrantLiabilities_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHWarrantLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000052 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure" xlink:title="00000053 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OtherInformationAbstract" xlink:label="loc_SHPHOtherInformationAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHOtherInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000054 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyTwoPromissoryNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyTwoPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_NotesPayableRelatedPartiesMember" xlink:label="loc_SHPHNotesPayableRelatedPartiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHNotesPayableRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember" xlink:label="loc_SHPHTwoThousandAndTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwoThousandAndTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember" xlink:label="loc_SHPHAugustTwoThousandAndTwentyOnePromissoryNotesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAugustTwoThousandAndTwentyOnePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="loc_SHPHTwoThousandAndTwentyOneConvertibleNotesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHTwoThousandAndTwentyOneConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails" xlink:title="00000055 - Disclosure - Schedule of Restricted Stock Units (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails" xlink:title="00000056 - Disclosure - Schedule of Derivative Liability Valuation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIpoDateMember" xlink:label="loc_SHPHMeasurementInputIpoDateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIpoDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHIssuanceDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHSettlementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDateMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHSettlementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfAcceleration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfAcceleration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" xlink:label="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfProbabilityAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityMeasurementDuration" xlink:label="loc_SHPHDerivativeLiabilityMeasurementDuration" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityMeasurementDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityDiscoutRate" xlink:label="loc_SHPHDerivativeLiabilityDiscoutRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityDiscoutRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails" xlink:title="00000057 - Disclosure - Schedule of Derivative Key Valuation Inputs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIpoDateMember" xlink:label="loc_SHPHMeasurementInputIpoDateMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIpoDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="loc_us-gaapMeasurementInputDefaultRateMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDefaultRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputSharePriceProbabilityOfIPOMember" xlink:label="loc_SHPHMeasurementInputSharePriceProbabilityOfIPOMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputSharePriceProbabilityOfIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHSettlementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDatesMember" xlink:label="loc_SHPHIssuanceDatesMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityMeasurementDuration" xlink:label="loc_SHPHDerivativeLiabilityMeasurementDuration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHDerivativeLiabilityMeasurementDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails" xlink:title="00000058 - Disclosure - Schedule of Derivative Issuance Valuation Inputs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputIpoDateMember" xlink:label="loc_SHPHMeasurementInputIpoDateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIpoDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_MeasurementInputEstimatedFairValueMember" xlink:label="loc_SHPHMeasurementInputEstimatedFairValueMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputEstimatedFairValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDatesMember" xlink:label="loc_SHPHIssuanceDatesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHIssuanceDatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHSettlementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDateMember" xlink:label="loc_SHPHIssuanceDateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_SHPHIssuanceDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IssuanceDatesMember" xlink:label="loc_SHPHIssuanceDatesMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHIssuanceDatesMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_SettlementMember" xlink:label="loc_SHPHSettlementMember_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SHPHSettlementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfAcceleration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfAcceleration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfCarringValueMeasurementDate" xlink:label="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfCarringValueMeasurementDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleMaturityDate" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfProbabilityAcceleration" xlink:label="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfProbabilityAcceleration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityMeasurementDuration" xlink:label="loc_SHPHDerivativeLiabilityMeasurementDuration" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityMeasurementDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DerivativeLiabilityOfDiscountRate" xlink:label="loc_SHPHDerivativeLiabilityOfDiscountRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SHPHDerivativeLiabilityOfDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000059 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:label="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ShortfallOfStockCompensationExpense" xlink:label="loc_SHPHShortfallOfStockCompensationExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHShortfallOfStockCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000060 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsbasedCompensation" xlink:label="loc_SHPHDeferredTaxAssetsbasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHDeferredTaxAssetsbasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_SHPHDeferredTaxAssetsLeaseLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHDeferredTaxAssetsLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:label="loc_SHPHDeferredTaxLiabilitiesFairMarketValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHDeferredTaxLiabilitiesFairMarketValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:label="loc_SHPHDeferredTaxLiabilitiesFiniteLivedAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHDeferredTaxLiabilitiesFiniteLivedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_SHPHDeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHDeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferencesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails" xlink:title="00000062 - Disclosure - Schedule of Quarterly Financial Data (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical" xlink:title="00000063 - Disclosure - Schedule of Quarterly Financial Data (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000064 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AllianceGlobalPartnersMember" xlink:label="loc_SHPHAllianceGlobalPartnersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHAllianceGlobalPartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_OfferingMember" xlink:label="loc_SHPHOfferingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SHPHOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_PurchaseAgreementMember" xlink:label="loc_SHPHPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_FederalTaxableIncomeMember" xlink:label="loc_SHPHFederalTaxableIncomeMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHFederalTaxableIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_StateTaxableIncomeMember" xlink:label="loc_SHPHStateTaxableIncomeMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHStateTaxableIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2016Member" xlink:label="loc_us-gaapTaxYear2016Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2017Member" xlink:label="loc_us-gaapTaxYear2017Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2017Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_ReverseCommonStockSharesOutstanding" xlink:label="loc_SHPHReverseCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHReverseCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="loc_SHPHAdditionalEscrowDeposit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHAdditionalEscrowDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="loc_SHPHInitialPublicOfferingDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHInitialPublicOfferingDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20240630.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773564016976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">424B4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Shuttle Pharmaceuticals Holdings, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001757499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461086336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 695,594<span></span>
</td>
<td class="nump">$ 2,576,416<span></span>
</td>
<td class="nump">$ 8,417,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">139,518<span></span>
</td>
<td class="nump">114,473<span></span>
</td>
<td class="nump">161,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,642,995<span></span>
</td>
<td class="nump">2,887,215<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest income</a></td>
<td class="nump">7,226<span></span>
</td>
<td class="nump">14,901<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,485,333<span></span>
</td>
<td class="nump">5,593,005<span></span>
</td>
<td class="nump">8,578,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,953<span></span>
</td>
<td class="nump">24,827<span></span>
</td>
<td class="nump">12,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">305,712<span></span>
</td>
<td class="nump">333,904<span></span>
</td>
<td class="nump">56,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">2,812,998<span></span>
</td>
<td class="nump">5,951,736<span></span>
</td>
<td class="nump">8,653,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable - related parties</a></td>
<td class="nump">130,898<span></span>
</td>
<td class="nump">110,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net</a></td>
<td class="nump">826,235<span></span>
</td>
<td class="nump">595,999<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">504<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">62,092<span></span>
</td>
<td class="nump">52,479<span></span>
</td>
<td class="nump">62,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,384,620<span></span>
</td>
<td class="nump">1,042,237<span></span>
</td>
<td class="nump">975,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable non-current, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">135,089<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">359,919<span></span>
</td>
<td class="nump">414,512<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability non-current</a></td>
<td class="nump">267,025<span></span>
</td>
<td class="nump">304,127<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,011,564<span></span>
</td>
<td class="nump">1,895,965<span></span>
</td>
<td class="nump">975,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value; 100,000,000 shares authorized; 2,008,689 and 1,700,414 shares issued and outstanding, respectively</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital, as restated</a></td>
<td class="nump">29,996,963<span></span>
</td>
<td class="nump">29,489,055<span></span>
</td>
<td class="nump">26,518,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit, as restated</a></td>
<td class="num">(29,195,550)<span></span>
</td>
<td class="num">(25,433,304)<span></span>
</td>
<td class="num">(18,840,581)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">801,434<span></span>
</td>
<td class="nump">4,055,771<span></span>
</td>
<td class="nump">7,677,869<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">2,812,998<span></span>
</td>
<td class="nump">5,951,736<span></span>
</td>
<td class="nump">8,653,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses related party</a></td>
<td class="nump">364,891<span></span>
</td>
<td class="nump">282,860<span></span>
</td>
<td class="nump">116,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable - related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,453<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable - related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">98,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 685,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773462045488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,106,233<span></span>
</td>
<td class="nump">2,008,689<span></span>
</td>
<td class="nump">1,700,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,106,233<span></span>
</td>
<td class="nump">2,008,689<span></span>
</td>
<td class="nump">1,700,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,685<span></span>
</td>
<td class="nump">$ 114,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461155360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">645,719<span></span>
</td>
<td class="nump">839,665<span></span>
</td>
<td class="nump">1,231,823<span></span>
</td>
<td class="nump">1,761,466<span></span>
</td>
<td class="nump">3,517,093<span></span>
</td>
<td class="nump">1,047,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">310,038<span></span>
</td>
<td class="nump">209,279<span></span>
</td>
<td class="nump">634,647<span></span>
</td>
<td class="nump">464,633<span></span>
</td>
<td class="nump">1,046,854<span></span>
</td>
<td class="nump">473,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="nump">526,877<span></span>
</td>
<td class="nump">416,688<span></span>
</td>
<td class="nump">1,001,011<span></span>
</td>
<td class="nump">784,312<span></span>
</td>
<td class="nump">1,328,435<span></span>
</td>
<td class="nump">822,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,482,634<span></span>
</td>
<td class="nump">1,465,632<span></span>
</td>
<td class="nump">2,867,481<span></span>
</td>
<td class="nump">3,010,411<span></span>
</td>
<td class="nump">5,892,382<span></span>
</td>
<td class="nump">2,343,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,482,634)<span></span>
</td>
<td class="num">(1,465,632)<span></span>
</td>
<td class="num">(2,867,481)<span></span>
</td>
<td class="num">(3,010,411)<span></span>
</td>
<td class="num">(5,892,382)<span></span>
</td>
<td class="num">(2,343,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">14,158<span></span>
</td>
<td class="nump">19,267<span></span>
</td>
<td class="nump">35,611<span></span>
</td>
<td class="nump">35,955<span></span>
</td>
<td class="nump">79,117<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FinanceFee', window );">Finance fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(104,245)<span></span>
</td>
<td class="num">(104,245)<span></span>
</td>
<td class="num">(189,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(143,773)<span></span>
</td>
<td class="nump">434,275<span></span>
</td>
<td class="nump">54,089<span></span>
</td>
<td class="nump">1,675,275<span></span>
</td>
<td class="nump">2,216,488<span></span>
</td>
<td class="num">(189,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FairValueAdjustmentOfWarrant', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(398,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of marketable securities</a></td>
<td class="nump">39,683<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">43,720<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Change in fair value of marketable securities</a></td>
<td class="num">(27,964)<span></span>
</td>
<td class="num">(26,534)<span></span>
</td>
<td class="num">(28,670)<span></span>
</td>
<td class="nump">11,528<span></span>
</td>
<td class="nump">71,568<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(415,553)<span></span>
</td>
<td class="num">(71,315)<span></span>
</td>
<td class="num">(433,807)<span></span>
</td>
<td class="num">(477,221)<span></span>
</td>
<td class="num">(1,795,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnSettlementOfAccountsPayable', window );">Gain on settlement of accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">328,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnForgivenessOfNotePayable', window );">Gain on forgiveness of Paycheck Protection Program note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">73,007<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, as restated</a></td>
<td class="num">(548,581)<span></span>
</td>
<td class="num">(718,740)<span></span>
</td>
<td class="num">(894,765)<span></span>
</td>
<td class="num">(149,057)<span></span>
</td>
<td class="num">(700,341)<span></span>
</td>
<td class="num">(2,652,243)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,592,723)<span></span>
</td>
<td class="num">(4,996,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Series A Convertible Preferred Stock, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(402,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated', window );">Deemed dividend on extinguishment of Series A Convertible Preferred Stock, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(439,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants', window );">Deemed dividend on modification of equity-classified warrants, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(941,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends', window );">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">31,423<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (2,031,215)<span></span>
</td>
<td class="num">$ (2,184,372)<span></span>
</td>
<td class="num">$ (3,762,246)<span></span>
</td>
<td class="num">$ (3,159,468)<span></span>
</td>
<td class="num">$ (6,592,723)<span></span>
</td>
<td class="num">$ (6,747,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">2,104,933<span></span>
</td>
<td class="nump">1,780,171<span></span>
</td>
<td class="nump">2,090,890<span></span>
</td>
<td class="nump">1,742,520<span></span>
</td>
<td class="nump">1,866,275<span></span>
</td>
<td class="nump">1,337,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">2,104,933<span></span>
</td>
<td class="nump">1,780,171<span></span>
</td>
<td class="nump">2,090,890<span></span>
</td>
<td class="nump">1,742,520<span></span>
</td>
<td class="nump">1,866,275<span></span>
</td>
<td class="nump">1,337,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (1.81)<span></span>
</td>
<td class="num">$ (3.53)<span></span>
</td>
<td class="num">$ (5.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (1.81)<span></span>
</td>
<td class="num">$ (3.53)<span></span>
</td>
<td class="num">$ (5.04)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,588)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (6,825)<span></span>
</td>
<td class="num">$ (6,825)<span></span>
</td>
<td class="num">$ (52,010)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">$ (430,685)<span></span>
</td>
<td class="num">$ (729,351)<span></span>
</td>
<td class="num">$ (928,200)<span></span>
</td>
<td class="num">$ (1,328,682)<span></span>
</td>
<td class="num">$ (2,484,193)<span></span>
</td>
<td class="num">$ (428,688)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on extinguishment of series preferred stock as restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on modification of equity-classified warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_FairValueAdjustmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_FairValueAdjustmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_FinanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_FinanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnForgivenessOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnForgivenessOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnSettlementOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on settlement of accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnSettlementOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LossOnSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LossOnSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773456487616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock to be Issued [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12,063,940<span></span>
</td>
<td class="num">$ (13,844,512)<span></span>
</td>
<td class="num">$ (1,764,220)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">1,164,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">237,547<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">237,547<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,996,069)<span></span>
</td>
<td class="num">(4,996,069)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs, net of issuance fees of $8,727</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">9,951,352<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,951,356<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares</a></td>
<td class="nump">352,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock issued for conversion of accrued interest, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Common stock issued for conversion of accrued interest, as restated, shares</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,199,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,199,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares</a></td>
<td class="nump">36,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for exercise of warrants with settlement of notes payable, as restated</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,153,123<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,153,124<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for exercise of warrants with settlement of notes payable, as restated, shares</a></td>
<td class="nump">66,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueWarrantsExercised', window );">Common stock issued upon exercise of warrants, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued upon exercise of warrants, as restated, shares</a></td>
<td class="nump">22,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DividendsOnSeriesPreferredStock', window );">Dividends on Series A convertible preferred stock, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(402,064)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(402,064)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnExtinguishmentOfPreferredStock', window );">Deemed dividend on extinguishment of Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount', window );">Deemed dividend on modification of equity-classified warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend', window );">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">402,064<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">402,064<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated, shares</a></td>
<td class="nump">54,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of fair value of warrant liabilities to equity, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">881,553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">881,553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">26,518,433<span></span>
</td>
<td class="num">(18,840,581)<span></span>
</td>
<td class="nump">7,677,869<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">1,700,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">104,547<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">104,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal, shares</a></td>
<td class="nump">6,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(975,097)<span></span>
</td>
<td class="num">(975,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs, net of issuance fees of $8,727</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">90,816<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">26,722,129<span></span>
</td>
<td class="num">(19,815,678)<span></span>
</td>
<td class="nump">6,906,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">1,706,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">26,518,433<span></span>
</td>
<td class="num">(18,840,581)<span></span>
</td>
<td class="nump">7,677,869<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">1,700,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,159,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares</a></td>
<td class="nump">234,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares</a></td>
<td class="nump">234,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">28,935,641<span></span>
</td>
<td class="num">(22,000,050)<span></span>
</td>
<td class="nump">6,935,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">1,935,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">26,518,433<span></span>
</td>
<td class="num">(18,840,581)<span></span>
</td>
<td class="nump">7,677,869<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">1,700,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,697,846<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,697,849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal, shares</a></td>
<td class="nump">297,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="nump">10,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,592,723)<span></span>
</td>
<td class="num">(6,592,723)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs, net of issuance fees of $8,727</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">90,816<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 90,816<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares</a></td>
<td class="nump">297,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">29,489,055<span></span>
</td>
<td class="num">(25,433,304)<span></span>
</td>
<td class="nump">$ 4,055,771<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">2,008,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">26,722,129<span></span>
</td>
<td class="num">(19,815,678)<span></span>
</td>
<td class="nump">6,906,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">1,706,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,163,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,163,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal, shares</a></td>
<td class="nump">228,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">49,522<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">49,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,184,372)<span></span>
</td>
<td class="num">(2,184,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares</a></td>
<td class="nump">228,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares</a></td>
<td class="nump">228,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">28,935,641<span></span>
</td>
<td class="num">(22,000,050)<span></span>
</td>
<td class="nump">6,935,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">1,935,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">29,489,055<span></span>
</td>
<td class="num">(25,433,304)<span></span>
</td>
<td class="nump">4,055,771<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">2,008,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">325,297<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">325,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal, shares</a></td>
<td class="nump">78,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="nump">15,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">111,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">111,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,731,031)<span></span>
</td>
<td class="num">(1,731,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">29,925,801<span></span>
</td>
<td class="num">(27,164,335)<span></span>
</td>
<td class="nump">2,761,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">2,102,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">29,489,055<span></span>
</td>
<td class="num">(25,433,304)<span></span>
</td>
<td class="nump">4,055,771<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">2,008,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="nump">19,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,762,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares</a></td>
<td class="nump">78,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares</a></td>
<td class="nump">78,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">29,996,963<span></span>
</td>
<td class="num">(29,195,550)<span></span>
</td>
<td class="nump">801,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">29,925,801<span></span>
</td>
<td class="num">(27,164,335)<span></span>
</td>
<td class="nump">2,761,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">2,102,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="nump">3,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">71,162<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">71,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,031,215)<span></span>
</td>
<td class="num">(2,031,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 29,996,963<span></span>
</td>
<td class="num">$ (29,195,550)<span></span>
</td>
<td class="nump">$ 801,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed contribution on conversion of preferred stock and settlement of preferred stock dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedDividendOnExtinguishmentOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on extinguishment of series A preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedDividendOnExtinguishmentOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DividendsOnSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends on series preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DividendsOnSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Conversion Of Accrued Interest And Principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Conversion O fAccruedInterest And Principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for freestanding written call option classified as equity from modification recognized as dividend. Includes, but is not limited to, exchange by issuer and holder. Excludes share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480299/815-40-35-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479083/946-230-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773460848192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuanceFees', window );">Warranst of issuance fees</a></td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773463801328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,762,246)<span></span>
</td>
<td class="num">$ (3,159,468)<span></span>
</td>
<td class="num">$ (6,592,723)<span></span>
</td>
<td class="num">$ (4,996,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,874<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
<td class="nump">6,811<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability, as restated</a></td>
<td class="num">(54,089)<span></span>
</td>
<td class="num">(1,675,275)<span></span>
</td>
<td class="num">(2,216,488)<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">398,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and finance fees, as restated</a></td>
<td class="nump">832,014<span></span>
</td>
<td class="nump">1,116,422<span></span>
</td>
<td class="nump">2,123,049<span></span>
</td>
<td class="nump">377,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on marketable securities</a></td>
<td class="num">(43,720)<span></span>
</td>
<td class="num">(1,744)<span></span>
</td>
<td class="num">(4,970)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Change in fair value of marketable securities</a></td>
<td class="nump">28,670<span></span>
</td>
<td class="num">(11,528)<span></span>
</td>
<td class="num">(71,568)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccruedInterestSettledWithCommonStock', window );">Accrued interest settled with common stock</a></td>
<td class="nump">18,783<span></span>
</td>
<td class="nump">240,831<span></span>
</td>
<td class="nump">294,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of notes payable and convertible notes payable, as restated</a></td>
<td class="nump">71,315<span></span>
</td>
<td class="nump">433,807<span></span>
</td>
<td class="nump">477,221<span></span>
</td>
<td class="nump">1,795,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnForgivenessOfNotePayable', window );">Gain on forgiveness of Paycheck Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(73,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnSettlementOnAccountsPayable', window );">Gain on settlement on accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(328,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, as restated</a></td>
<td class="nump">182,611<span></span>
</td>
<td class="nump">57,855<span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="nump">237,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued interest income</a></td>
<td class="nump">7,675<span></span>
</td>
<td class="num">(6,950)<span></span>
</td>
<td class="num">(14,901)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(25,045)<span></span>
</td>
<td class="nump">82,199<span></span>
</td>
<td class="nump">46,675<span></span>
</td>
<td class="num">(156,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">82,031<span></span>
</td>
<td class="num">(28,004)<span></span>
</td>
<td class="nump">166,115<span></span>
</td>
<td class="num">(382,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related parties</a></td>
<td class="num">(446)<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
<td class="num">(12,054)<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable, as restated</a></td>
<td class="nump">20,445<span></span>
</td>
<td class="nump">75,511<span></span>
</td>
<td class="nump">110,453<span></span>
</td>
<td class="nump">18,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties', window );">Accrued interest payable - related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(98,135)<span></span>
</td>
<td class="num">(98,135)<span></span>
</td>
<td class="nump">51,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,480<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating lease asset and liabilities</a></td>
<td class="nump">703<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">16,001<span></span>
</td>
<td class="num">(5,693)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,638,425)<span></span>
</td>
<td class="num">(2,984,039)<span></span>
</td>
<td class="num">(5,581,147)<span></span>
</td>
<td class="num">(2,666,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="num">(35,982)<span></span>
</td>
<td class="num">(2,970,905)<span></span>
</td>
<td class="num">(2,998,572)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from disposition of marketable securities</a></td>
<td class="nump">1,295,252<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">187,895<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,046)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,259,270<span></span>
</td>
<td class="num">(2,890,905)<span></span>
</td>
<td class="num">(2,829,723)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants', window );">Proceeds from issuance of common shares and exercise of warrants, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,995,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable-related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of note payable-related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(685,473)<span></span>
</td>
<td class="num">(685,473)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,935,000<span></span>
</td>
<td class="nump">3,935,000<span></span>
</td>
<td class="nump">550,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromNotesPayableAndWarrants', window );">Proceeds from notes payable and warrants, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment for finance costs related to convertible note payable, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(345,000)<span></span>
</td>
<td class="num">(345,000)<span></span>
</td>
<td class="num">(17,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment of convertible note payable</a></td>
<td class="num">(501,667)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(334,444)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(501,667)<span></span>
</td>
<td class="nump">2,904,527<span></span>
</td>
<td class="nump">2,570,083<span></span>
</td>
<td class="nump">10,578,865<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,880,822)<span></span>
</td>
<td class="num">(2,970,417)<span></span>
</td>
<td class="num">(5,840,787)<span></span>
</td>
<td class="nump">7,912,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">2,576,416<span></span>
</td>
<td class="nump">8,417,203<span></span>
</td>
<td class="nump">8,417,203<span></span>
</td>
<td class="nump">504,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">695,594<span></span>
</td>
<td class="nump">5,446,786<span></span>
</td>
<td class="nump">2,576,416<span></span>
</td>
<td class="nump">8,417,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">56,958<span></span>
</td>
<td class="nump">102,373<span></span>
</td>
<td class="nump">164,807<span></span>
</td>
<td class="nump">39,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForConversionOfAccruedInterest', window );">Common stock issued for conversion of accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForSettlementOfDebt', window );">Common stock issued for settlement of debt</a></td>
<td class="nump">325,298<span></span>
</td>
<td class="nump">2,268,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuedForFinancingFees', window );">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively, as restated</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">90,816<span></span>
</td>
<td class="nump">90,816<span></span>
</td>
<td class="nump">14,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InitialRecognitionOfRightOfUseAssetAndLiability', window );">Initial recognition of right of use asset and liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 365,556<span></span>
</td>
<td class="nump">365,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds', window );">Fair value of freestanding instruments in excess of proceeds, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">189,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated', window );">Common stock issued for conversion of accrued interest, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,697,849<span></span>
</td>
<td class="nump">1,199,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable', window );">Common stock issued for exercise of warrants with settlement of notes payable, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,153,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock', window );">Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">402,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering', window );">Reclassification of fair value of warrant liabilities to equity, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 881,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AccruedInterestSettledWithCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accruedi nterest settled with common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AccruedInterestSettledWithCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares issued for dividends on and conversion of series preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForConversionOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for conversion of accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForConversionOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for conversion of accrued interest as restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for exercise of warrants with settlement of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for settlement of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued upon conversion of convertible debt and exercise of related warrants as restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of free standing Instruments In excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnForgivenessOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnForgivenessOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnSettlementOnAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on settlement on accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnSettlementOnAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued interest payable - related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_InitialRecognitionOfRightOfUseAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of right of use asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_InitialRecognitionOfRightOfUseAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LossOnSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LossOnSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ProceedsFromNotesPayableAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from notes payable and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ProceedsFromNotesPayableAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of fair value of warrant liability to equity upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuedForFinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued for financing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuedForFinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773455837440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuanceFees', window );">Warranst of issuance fees</a></td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773568105776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Liquidity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLXVKFIsS1ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82D_zXC00uKq6eif">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221;) was originally formed
as Shuttle Pharmaceuticals, LLC in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed articles of conversion
with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name to Shuttle Pharmaceuticals,
Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbp3AWOqkUol" title="Number of shares issued">5,625,000</span> shares of common stock in exchange for
<span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhgNNlG0A6ck" title="Sale of stock membership percentage">100</span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed a reverse merger with
Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation, pursuant to which
Shuttle, our operating entity, became a wholly owned subsidiary of the Company. All share numbers referenced herein reflect a 1-for-8 reverse split of our common stock on a post-split basis, which was effective as of August 13, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was initially funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract
provided by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#8217;s initial public offering in September
2022, the Company has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation
with metabolite biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in its clinical trials that will cause the Company or the FDA
to delay or suspend the clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unaudited condensed consolidated financial statements are prepared on a going concern basis, which contemplates the realization of
assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since
inception and has a net loss of approximately $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_zs7rQzF5awJ1" title="Net loss">3.8</span>
million and <span id="xdx_90A_eus-gaap--Revenues_dxL_c20240101__20240630_zCRK4PZjgxB" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0610">no</span></span> revenues
for the six months ended June 30, 2024 and has working capital of approximately $<span id="xdx_90A_ecustom--WorkingCapital_pn5n6_c20240101__20240630_z2hYoN0mxKp2" title="Working capital">1.1</span>
million as of June 30, 2024. In addition, the convertible note payable outstanding at June 30, 2024 includes covenants and certain
cash payment requirements. On July 12, 2024, the Company informed the investor of its convertible note that the Company&#8217;s expected restatement
of its financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the convertible
note. On August 6, 2024, the Company paid $<span id="xdx_905_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20240806_zZosElncYMMa" title="Convertible note">0.6</span> million to the investor of the convertible note and received a waiver from the investor
related to the default. The funds paid are restricted and will be held as collateral to the balance owed under the convertible note (see
Note 9). These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt
about the Company&#8217;s ability to continue as a going concern within one year after the date that the unaudited condensed
consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023,
the Company entered into a securities purchase agreement with an institutional investor through which the Company sold a convertible
note with a principal value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgjKBnoYEK3h" title="Debt instrument, face amount">4.3</span> million, along with a <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zirqzGcgOZm6" title="Warrant term::XDX::P4Y"><span style="-sec-ix-hidden: xdx2ixbrl0618">four</span></span>-year warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2U5NvKbcKEd" title="Warrant to purchase common stock">127,260</span> shares of common stock, exercisable
at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDNMyH8Ns1G" title="Exercisable price per share">18.80</span> per share, providing the Company with approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhbTYHHvDnTh" title="Net proceeds from warrants">3.6</span> million in net proceeds. To date, the warrant has not yet been exercised.
However, the Company&#8217;s existing cash resources, marketable securities and the cash received from the equity offering and convertible
note are not expected to provide sufficient funds to carry out the Company&#8217;s operations and clinical trials through the next twelve
months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA approval of the IND
for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the Company agreed
to an expansion of the clinical trial, necessitating additional capital to complete the trial as well as fund ongoing operations. As
a result, management  had initiated a $<span id="xdx_90E_eus-gaap--PartnersCapital_iI_pn5n6_c20230131_zo1XdISLnkXe" title="Initiated a capital offering">4.5</span>
million rights offering and submitted an application for a SBIR grant for
non-dilutive funding for pre-clinical project through the NIH. The Company is also
currently pursuing other financing. The ability of the Company to continue as a going concern is dependent upon its ability to
successfully raise additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials and bring a
drug candidate to commercialization to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the future effects on
the recoverability and classification of assets or the amounts and classification of liabilities if the Company is unable to
continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLSnJOFJjx87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82A_zNQTfjOQsJoh">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuWYMCwBa1l" title="Conversion of stock, shares issued">5,625,000</span> shares of common
stock in exchange for <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrFlg9kE6KXj" title="Sale of stock membership percentage">100</span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#8220;Company&#8221;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract provided
by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#8217;s initial public offering, the Company
has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay
or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and
has a net loss of approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zvDIDv0jCj34" title="Net income loss">6.6</span>
million and no revenues for the year ended December 31, 2023 and working capital of approximately $<span id="xdx_90D_ecustom--WorkingCapital_iN_pn5n6_di_c20230101__20231231_zpMi8peYTBP7" title="Working capital">4.6</span>
million as of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and
certain cash payment requirements. On July 12, 2024, the Company informed the investor of its convertible note that the
Company&#8217;s expected restatement of its financial statements for the years ended December 31, 2022 and 2023 constituted an event
of default under the terms of the convertible note. On August 6, 2024, the Company paid $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20240806__20240806__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zXZVY5oJ2dl5" title="Proceeds from convertible debt">0.6</span> million to the investor of the
convertible note and received a waiver from the investor related to the default. The funds paid are restricted and will be held as
collateral to the balance owed under the convertible note (see Note 12). These conditions, and the Company&#8217;s ability to comply
with such conditions, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after
the date that the consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLz2DBKNXBw9">4.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, along with a four-year warrant to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zl355kJKiw01">127,260
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUpMqMf0Hl09">18.80
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, providing the Company with approximately
$<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zObOWFtvk5K9">3.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in net proceeds. To date, the warrant
has not yet been exercised. However, the Company&#8217;s existing cash resources, marketable securities and the cash received from the
equity offering and convertible note are not expected to provide sufficient funds to carry out the Company&#8217;s operations and clinical
trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA
approval of the IND for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and
the company agreed to an expansion of the clinical trial, necessitating additional capital to complete the trial, as well as fund ongoing operations. As a result, management had initiated
a $<span id="xdx_90E_eus-gaap--PartnersCapital_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsiazBOPM4B4" title="Initiated a capital offering">4.5</span> million rights offering and submitted an application for a SBIR grant for non-dilutive funding for pre-clinical project through
the NIH. The Company is also currently pursuing other financing. The ability of the Company to continue as a going concern is dependent
upon its ability to successfully raise additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials
and bring a drug candidate to commercialization to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements do not include any adjustments to reflect the future effects on the recoverability and
classification of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 13, 2024, in order to meet
Nasdaq&#8217;s minimum bid price requirement of $<span title="Share Price"><span id="xdx_900_eus-gaap--SharePrice_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGJmbQWtYsma" title="Share price">1.00</span></span>
per share (the &#8220;Minimum Bid Price Requirement&#8221;), the Company effectuated a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjuBpwCxWvQe" title="Reverse stock split">1-for-8 reverse stock split</span> of its issued and outstanding common stock, rounding up to account for any fractional shares (the
&#8220;Reverse Stock Split&#8221;). The Reverse Stock Split had no effect on the Company&#8217;s authorized shares of common stock
or preferred stock. Following the reverse stock split on August 13, 2024, the Company had a total of <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znxZOrhkU0C1" title="Common stock shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdFH3eQyw6x7" title="Common stock shares outstanding">2,111,235</span></span>
shares issued and outstanding (or <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20231231_zaV7QAG26O38" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zhLIdladDdp" title="Common stock, shares outstanding">2,008,689</span></span>
on a post-split basis as of December 31, 2023). The Reverse Stock Split also resulted in an adjustment to the consolidated balance
sheets for the years ended December 31, 2023, December 31, 2022 and December 31, 2021 with an increase to additional paid in capital
of $<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20230101__20231231_z7lwD9NG56F4" title="Adjustments to additional paid in capital stock split">141</span>,
$<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20220101__20221231_zuVy3UoPY47c" title="Adjustments to additional paid in capital stock split">119</span>
and $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20210101__20211231_zzaW9Jev2whh" title="Adjustments to additional paid in capital stock split">81</span>,
respectively, and an offsetting adjustment to the carrying value of common stock. All share, option, warrant and per share amounts
(except our authorized outstanding) have been retroactively restated in these financial statements and related disclosures. The
effect of the Reverse Stock Split has been included in Note 2 in the &#8220;As Reported&#8221; and in Note 11 in the &#8220;As
Reported&#8221; amounts for additional paid in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773462353088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionTextBlock', window );">Restatement of Previously Issued Financial Statements</a></td>
<td class="text"><p id="xdx_807_eus-gaap--ErrorCorrectionTextBlock_zMuTpislNY6" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Note <span style="font-family: Times New Roman, Times, Serif">2
&#8211; <span id="xdx_827_zBsHq7vx4ZIf">Restatement of Previously Issued Financial Statements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>&#160;</span></span></b></p>

<p id="xdx_89C_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_ztc1gOR7tjkb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>The impact of the errors described above also impact
the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>&#160;</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8B9_zV3IdsUTWKfl">Schedule
 of Error Corrections And Prior Period Adjustments</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpAZDsJ2HHgh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zil2vv7D4Zn1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z2miWDOBG6Jf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_iI_z20joSFUHD9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">19,543,363</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,489,055</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z1MXLFGq7K93" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(15,487,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,433,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Adjustments
    include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9htjoTqHbv2" title="Stock compensation">7,843,052</span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zljaKMw5yfJ3" title="Accrued dividends">402,064</span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9y2rds0NWB" title="Issuance cost">174,082</span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_znckfEMQmWO5" title="Warrants">416,266</span>),
    reclassifications of warrants from liability to equity (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zf8dTIB15zDj" title="Warrants from liability">881,554</span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zVyoTMoi5uwc" title="Debt instrument">2,213,498</span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Adjustments include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z8gOY06XlUha" title="Stock compensation">8,009,461</span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zvngUaX6yOKh" title="Fair value of warrants">240,930</span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zFjHB3SKH1u5" title="Accrued dividends">402,064</span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zSVO2RCnUXYd" title="Derivatives loss">296,151</span>); correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zrUKb6hAliXh" title="Issuance cost">166,407</span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zGiFL1ScJAR" title="Net income loss">1,967,621</span>).</span></td></tr>
  </table>

<p id="xdx_8A4_zYWPsIODHLee" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_eus-gaap--ErrorCorrectionTextBlock_zYnQb5pXRUd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Note <span style="font-family: Times New Roman, Times, Serif">2
&#8211; <span id="xdx_826_zS4IaF9iKHzg">Restatement of Previously Issued Financial Statements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As previously disclosed in the Company&#8217;s
Quarterly Report on Form 10-Q for the period ended March 31, 2024, filed with the Securities and Exchange Commission
(&#8220;SEC&#8221;) on May 13, 2024, following the entry of a cease-and-desist order by the SEC against our former auditor, B.F.
Borgers CPA PC (&#8220;BF Borgers&#8221;), we commenced the re-audit (the &#8220;Re-audit&#8221;) of our consolidated financial
statements for the year ended December 31, 2022, which had been audited by BF Borgers. Since that time and as a result of the
Re-audit, and as initially disclosed on Form 8-K dated July 10, 2024, the Company and the Audit Committee have concluded and
informed our current auditor, Forvis Mazars, LLP, that our audited consolidated financial statements for the year ended December 31,
2022 (the &#8220;2022 Financial Statements&#8221;), our audited consolidated financial statements for the year ended December 31,
2023 (the &#8220;2023 Financial Statements&#8221;), and the quarterly periods included in the Company&#8217;s Annual Report
for the year ended December 31, 2023, and the quarterly report for the period ended March 31, 2024 require restatement and are not reliable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accounting errors impacting our 2022 Financial
Statements include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Stock Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Application of the incorrect grant date fair values in determining the value of certain equity awards
granted during the years ended December 31, 2019 and 2020;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Miscalculation of the pattern of recognition of stock-based compensation over the requisite service periods
for certain equity awards granted during the years ended December 31, 2019 and 2020;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Series A Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Utilization of incorrect inputs to the fair value estimates for the warrant obligation related to
                                                                     the Series A Convertible Preferred Stock; incorrectly recording the reclassification of the warrant obligation upon issuance as a
                                                                     gain and not as a reclassification to stockholders&#8217; equity;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recording of accrued dividends on the Series A Convertible Preferred Stock as a liability prior to
                                                                     the dividends being declared;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Failure to recognize the accounting impact for the amendment to the terms of the Series A
                                                                     Convertible Preferred Stock in April 2022, which the Company subsequently concluded should have been recognized as an
                                                                     extinguishment;</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Failure to recognize deemed contribution related to the settlement of the
Series A Convertible Preferred Stock and accrued dividends;</td></tr>
                                                                                                                   </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Notes Payable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Misidentification of certain debt and equity issuance costs and incorrect association with certain of
the Company&#8217;s financings during the years ended December 31, 2022 and 2021;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Application of the incorrect amortization period and pattern of recognition for debt discounts recorded
in relation to the Company&#8217;s debt financings during the years ended December 31, 2022 and 2021;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incorrect recognition of bifurcated derivative liabilities, as well as incorrect initial and subsequent
fair value measurements, in relation to the December 2021 Notes, 2022 Convertible Notes and August 2022 Notes;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Misclassification of certain warrants issued with debt transactions during the year ended December 31,
2022;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Failure to recognize certain liability-classified warrants issued in exchange for services provided related
to the Company&#8217;s financing activities during the year ended December 31, 2022; </td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incorrect application of extinguishment or conversion models in accounting for certain debt instruments
upon their settlement; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Initial Public Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Incorrect identification of deferred issuance costs incurred in relation to the initial public offering; Incorrect identification and classification of issuance costs incurred in relation to the initial public offering.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In addition to the restatement of the consolidated
financial statements, the Company has also restated the following notes to reflect the errors described above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 2 - Summary of Significant Accounting Policies (now Note 3)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 5 &#8211; Notes Payable-Related Party</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 6 &#8211; Convertible Notes (now labeled Notes Payable)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 7 &#8211; Stockholders&#8217; Equity</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 8 &#8211; Derivative Liabilities</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>&#9679;</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 10 &#8211; Income Taxes</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p id="xdx_890_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_gL3SOECAPPATT-CTUD_zsjBbHmPqf0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The impact of the errors described above also impact
the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0zZqA0Nnjde" style="display: none">Schedule
 of Error Corrections And Prior Period Adjustments </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwetAMD0zH8g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJmDSENBI7ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_z4uPlYfsUoR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_iI_z2zeGbBRXc0g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">19,543,363</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,489,055</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zaoGgdHo6uwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(15,487,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,433,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A7_znh5diDZJD2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Additionally, the Company has provided Note 11 &#8211; Quarterly Financial
Data (unaudited and restated) to present the impact of the above restatements on the unaudited quarterly financial information for the
period ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&#8217;s prior and updated accounting for
the errors described above do not have any effect on the Company&#8217;s previously reported cash or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_C03_gL3SOECAPPATT-CTUD_zjl0AJp8VmS4"><span><span>&#160;</span></span></span></p>

<div id="xdx_C0B_gL3SOECAPPATT-CTUD_zZbMdljBzSu" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following tables summarize the effect of the restatement
on each financial statement line item as of the dates indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_134_zg7BX6nomyV7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6IPnX7kMpQd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zqIfqvq3dbla" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_zVBmgAKxgFu2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">16,572,741</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zRFyZ3enDeJ4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">26,518,433</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z7ch26L7ImB3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,894,889</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zq9la8ZM1J46" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(18,840,581</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_z6tdetXqK1di" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zNZReqJ1vZk4" style="font-size: 10pt">Adjustments
    include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj" title="Stock compensation">7,843,052</span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8" title="Accrued dividends">402,064</span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta" title="Issuance cost">174,082</span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8" title="Warrants">416,266</span>),
    reclassifications of warrants from liability to equity (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh" title="Warrants from liability">881,554</span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l" title="Debt instrument">2,213,498</span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zaNZZatnnmHh" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zzreMJkmsia8" style="font-size: 10pt">Adjustments include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a" title="Stock compensation">8,009,461</span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc" title="Fair value of warrants">240,930</span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a" title="Accrued dividends">402,064</span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih" title="Derivatives loss">296,151</span>); correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e" title="Issuance cost">166,407</span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf" title="Net income loss">1,967,621</span>).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zCPDzGSrLKea" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Operations for the year ended December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zfF7oBBVekwd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zwoKT7aBJHO8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zWrYFaOF7wz2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zj2MSn4b2I9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Research and development, net of contract expense reimbursements</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,148,712</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(101,327</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,047,385</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_zfl0BeByAfcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">538,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(65,082</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">473,714</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LegalFees_i01_zVxLruGqxV9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal and professional</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">866,770</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(44,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">822,727</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_zmOcF5iBAFc8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,554,278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210,452</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,343,826</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpense_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zdoL3oeTEEUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(917,879</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">489,191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(428,688</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--FinanceFee_i01N_di_zcGL6QyywMmb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2066">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zuPH3lpTUpn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2070">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zZ7eV5qwPDs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(492,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(398,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_ztFvHLdBYq75" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on extinguishment of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zslkvUkqO935" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,028,448</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,967,621</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,996,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zRrY7MweYN9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend on Series A Preferred Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(71,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(331,055</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendOnExtinguishmentOfSeriesPreferredStock_iN_di_z5JuaOYNMOtj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed dividend on extinguishment of Series A Preferred Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2090">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(439,427</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(439,427</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_iN_di_zNL0yHlXVCs9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed dividend on modification of equity-classified warrants, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl2094">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(941,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(941,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_iN_di_zu7usXLwRWu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl2098">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">31,423</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">31,423</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zMdGKJyjwBM2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to common stockholders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,099,457</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,647,680</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,747,137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per shares - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMuzbPGlFEhh" title="Net loss per shares - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zccDRV02xjSf" title="Net loss per shares - basic">(2.32</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB4urI05QeH1" title="Net loss per shares - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKBYOEmr9nYi" title="Net loss per shares - Diluted">(2.72</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_z5ihkRTEuiul" title="Net loss per shares - Basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zSznyrVunGh9" title="Net loss per shares - Diluted">(5.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_134_zJX9uMgHKaPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Stockholders&#8217; Equity as of December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwS0vTQ9jBnd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcwAjgI1jFjg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zV0UlYwvROeh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zWvWqPGPs5Ya" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2118">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,951,356</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,951,356<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuedForCash_zHDj0uGsfbqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,008,095</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10,008,095</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2124">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WarrantsExercisedForCash_z2d1h2nIc9ac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants exercised for cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,098</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(14,098</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2128">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zhhR4qDxRN8l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Warrants issued for financing costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">412,241</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(397,579</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,662</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zhykxizzqMlh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for conversion of accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">588,524</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(588,524</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zyHZ1nRPI2pe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued upon conversion of convertible debt and exercise of related warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2138">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,199,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,199,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zwf7FzAmToLf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">576,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,576,648</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,153,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsDHZesDpxNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">403,956</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(166,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">237,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DividendsOnSeriesPreferredStock_iN_di_zvqx0AJOOAIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividends on Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(71,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(331,055</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_zABJ06Gj07Ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_z5MiqqZKDCgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reclassification of fair value of warrant liability to equity upon initial public offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2158">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zxnxLSWBTqm9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,028,448</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,967,621</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,996,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span><span><span id="xdx_C02_gL3SOECAPPATT-CTUD_zbUUVOgV6av4">&#160;</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_C09_gL3SOECAPPATT-CTUD_zLvKL6q0ueWd"><span><span>&#160;</span></span></span></p>

<div id="xdx_C07_gL3SOECAPPATT-CTUD_zhhDmZ3MOnCh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" id="xdx_307_134_zdfyzfvfDy16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Cash Flows for the year ended December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zy1sl4WmcFif" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zeDLOhNW3Qh1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_z3HtR4Rnmup1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zCatNeztmy4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(3,028,448</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,967,621</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(4,996,069</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_zobw7LZjY4ph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2170">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01_zH5N7jyNN6bb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(94,025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">492,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">398,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i01_zuFdOtXI1xQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization of debt discount and finance fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">885,505</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(508,121</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">377,384</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LossOnSettlementOfConvertibleDebt_i01_zjcoYliHCWO2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on settlement of convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2182">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueOfFreestandingInstrumentsInExcessOfProceeds_i01_zOCefK4QX4t2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fair value of freestanding instruments in excess of proceeds</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2186">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GainOnInterestReliefOnConversionOfNotesPayable_i01N_di_zbi2XyEBcw01" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gain on interest relief on conversion of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_z9JN5YP8HCA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">403,956</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(166,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">237,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_zdwCVGgYjudb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,177</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,555</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,378</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zS9xgAWVXgZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,710,454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,666,411</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_zPeJwFkUi6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of common shares and warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,022,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,995,513</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_zX9wJ2hh4D47" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,715</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">550,715</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromNotesPayableAndWarrants_i01_zB9jBkRcOoei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from notes payable and warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2214">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsOfFinancingCosts_i01N_di_zSy4wmzIPBff" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    for finance costs related to convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2218">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,363</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,363</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_z1cIFFnQqII8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,622,908</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44,043</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,578,865</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaid_i01_z2AXVU0ATqRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Supplemental non-cash financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CommonStockIssuedUponConversionOfConvertibleDebt_i01_zqxadejLpiX2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued upon conversion of convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">588,524</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">611,392</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,199,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zl91Hr9vTr9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">576,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,576,648</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,153,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_i01_zSvMjywi1h66" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--WarrantsIssuedForFinancingFees_i01_zEdVHlVkRYRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants issued for financing fees, net of issuance fees of $<span id="xdx_901_ecustom--WarrantsIssuanceFees_c20230101__20231231_z3f2JIJxQ6Sg" title="Warranst of issuance fees">8,727</span> and $<span id="xdx_909_ecustom--WarrantsIssuanceFees_c20220101__20221231_zdqu9lkBFd4" title="Warranst of issuance fees">0</span>, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">412,241</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(397,579</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,662</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_i01_zpGNzvsa7kK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reclassification of fair value of warrant liability to equity upon initial public offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zABYLOApGVBf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zLsnU6dc6oAc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z4f2SrKUNhEd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_z9hEcTZm93ad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">4,150,948</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AdditionalPaidInCapital_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zSrXYy1elD59" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital">7,912,992</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">12,063,940</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zqI4Ca10eqGi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated Deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,795,432</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zbPV9duglp2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(8,049,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,844,512</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_zyx8H6MNpq29" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zVcwwitNryW8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk" title="Increase decrease of notes payable">7,351</span>); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh" title="Increase decrease in preferred stock">89,118</span>); and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l" title="Stock compensation">8,009,461</span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_z8KUvJcM4081" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td id="xdx_F11_zlKB34EfShAa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    include reversal of dividend liability recorded (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1" title="Increase decrease in dividend liability">331,059</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of deferred IPO costs (decrease of ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi">55,182</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh">89,118</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the estimated fair value of warrant liability (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63">240,930</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj">274,048</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc">8,009,461</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></td></tr>
  </table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_C06_gL3SOECAPPATT-CTUD_zXQh9xUmmI5">&#160;</span></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773456153840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zwX833PQD2H7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_829_zWAALifadsVe">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbNA1oLSmCg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zCBeclORz1k">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial statements and with the instructions to Form 10-Q
and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not
contain all information and notes required by GAAP for annual financial
statements. A complete discussion of the Company&#8217;s significant accounting policies is included in the Company&#8217;s Annual Report
on Form 10-K for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all of
the adjustments necessary to present the financial position of the Company as of June 30, 2024 and the results of operations and
cash flows for the periods presented. The accompanying condensed consolidated financial statements of the Company have not been
audited by the Company&#8217;s independent registered public accounting firm, except that the year-end consolidated balance sheet
was derived from audited financial statements. The results of operations for the six months ended June 30, 2024 are not necessarily
indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial
statements should be read in conjunction with the restated financial statements and related notes thereto for the year ended
December 31, 2023 included in the Company&#8217;s Annual Report on Form 10-K/A filed with the SEC on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_ecustom--ReverseStockSplitPolicyTextBlock_zUQwwFrvzScl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zMdaqovuKvXk">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2024, in order to meet Nasdaq&#8217;s minimum bid price requirement of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdpnAuWG6Lol" title="Minimum bid price">1.00</span>
per share (the &#8220;Minimum Bid Price Requirement&#8221;), the Company effectuated a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1d0psoH6nQc" title="Reverse stock split">1-for-8 reverse stock split</span> of its issued and
outstanding common stock, rounding up to account for any fractional shares (the &#8220;Reverse Stock Split&#8221;). The Reverse
Stock Split had no effect on the Company&#8217;s authorized shares of common stock or preferred stock and the par value will remain
unchanged at $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240813_zMXv9hl7eJbj" title="Common stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240813_z0BWOOj98It8" title="Preferred stock, par value">0.00001</span></span>,
respectively. Following the reverse stock split on August 13, 2024, the Company had a total of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zztmaLiD6Qoe" title="Common stock shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlqhzVPvDeRi" title="Common stock shares outstanding">2,111,235</span></span>
shares issued and outstanding (or <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240630_z7CZ066K6Nl3" title="Common stock shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240630_z8BjDAR117Yd" title="Common stock shares outstanding">2,106,233</span></span>
on a post-split basis as of June 30, 2024).</span> All common stock share, option, warrant and per share amounts (except our
authorized but unissued shares) have been retroactively adjusted in these financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zVRaxJZ6JGAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zi0eokpZriz4">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned
subsidiaries, Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zty8POBdZ14f">Correction
of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards
Codification (&#8220;ASC&#8221;) 730. As a result, certain prior year amounts have been corrected for consistency with the current
year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial
statements in accordance with SEC Staff Accounting Bulletin No. 99, &#8220;Materiality,&#8221; (ASC Topic 250, Accounting Changes
and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed
consolidated statements of operations are not material to any previously presented financial statements based upon overall
considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated
balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes
in stockholders&#8217; equity, to these financial statements, or for any previously presented interim or annual financial
statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted
earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was
$<span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zjzxGy9n2Tqg" title="General and administrative expense">93,708</span> and $<span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zEx5IEd6PiT8" title="General and administrative expense">182,715</span>, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and
six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zUEa4AVq93g1" style="display: none">Schedule of the Error Correction</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztXtgIiL0mS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Corrected</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,944,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(182,715</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,761,466</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">281,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">182,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">464,633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3JEbn1v7fOi">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the
reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on
current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed
consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of
bifurcated derivative liabilities and other financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zokUH3G8A7Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zxtJnn7V0F96">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of June 30, 2024 and December 31, 2023, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zkEJLZMnX1Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zFoSdsPsZsdh" style="display: none">Schedule of Cash and Cash Equivalents</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zdf2YYEPgH92" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z0DgJpGOb3c6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zpVNW72A3ffa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">645,594</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,550,098</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zkXzbm1UOUsk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,026,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zESWBcrIg25g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">695,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,576,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zn4zpQIooYi6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240630_zFoCnqZK8quc" title="Cash FDIC insured amount">250,000</span> per institution. The
amount in excess of the FDIC insurance as of June 30, 2024 was approximately $<span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20240630_zjyRhVQqCk7e" title="Cash, uninsured amount">0.4</span> million. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zewlyN8EM7Ig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zWYFKpwXUUxb">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding
balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20240630_zOxm6QfMfZeg" title="Marketable securities, outstanding balance">1.6</span>
million and $<span id="xdx_907_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20231231_zNyG7iZlRMN7" title="Marketable securities, outstanding balance">2.9</span>
million as of June 30, 2024 and December 31, 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company
recognized interest income of $<span id="xdx_90A_eus-gaap--InvestmentIncomeInterest_c20240401__20240630_zcq2CT9LGwf8" title="Interest income">14,158</span>
and $<span id="xdx_90C_eus-gaap--InvestmentIncomeInterest_c20230401__20230630_z07CBpxiZfPd" title="Interest income">19,267</span>,
realized gains of $<span id="xdx_90E_eus-gaap--GainLossOnSaleOfInvestments_c20240401__20240630_zqFcztULftf2" title="Gain on sale of marketable securities">39,683</span>
and $<span id="xdx_909_eus-gaap--GainLossOnSaleOfInvestments_c20230401__20230630_zztdgOwkA1Al" title="Gain on sale of marketable securities">1,744</span>,
and unrealized loss of $<span id="xdx_90A_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20240401__20240630_zWCIvWQwRsIf" title="Unrealized loss">27,964</span>
and unrealized loss of $<span id="xdx_907_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20230401__20230630_zVAgkZCa1xv9" title="Unrealized loss">26,534</span>,
respectively. During the six months ended June 30, 2024 and 2023, the Company recognized interest income of $<span id="xdx_903_eus-gaap--InterestIncomeExpenseNet_c20240101__20240630_zyDmZWPkZUo7" title="Interest income">35,611</span>
and $<span id="xdx_904_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630_zEhr8qDKa026" title="Interest income">35,955</span>,
realized gains of $<span id="xdx_902_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20240101__20240630_zq28xeSQy6Xd" title="Marketable securities realized gain loss">43,720</span>
and $<span id="xdx_90F_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20230630_zFgLIQUum3e7" title="Marketable securities realized gain loss">1,744</span>,
and unrealized loss of $<span id="xdx_901_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20240101__20240630_zKHoCz44OTX2" title="Marketable securities unrealized gain loss">28,670</span>
and unrealized gain of $<span id="xdx_908_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230630_ze93KZfxuNKd" title="Marketable securities unrealized gain loss">11,528</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvCubePqHs28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zsCyT2nR28g1">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4Fjp8jYHK5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of June 30, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z04BtaXIERfc" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">June 30, 2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zExD2SVowPH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLJtGezKo55" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmfWKey4sYWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zjoqMgNxUsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLGc9i6fzSJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zxYQDrtyDMk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,642,995</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,642,995</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zDwqI7ggcyO2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,642,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,642,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zr8UHTdpBgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z9RhqCNdYVqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">359,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">359,919</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zNRORHgltpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zwgNXMGU1U4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">360,423</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">360,423</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zb7iOAM75Kdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z76zr6Fa3GUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z01v4lD9OZA8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zwkx62sH2px7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zvkOmL0nCbfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zoumSoH7GBU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zUOt3GVPWwL6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zS2K50xTTHjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zgtC2JqIWhO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zIDEG5nHspT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zm2eBRJ81m98" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zcF4kM03SRN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zsDUSByWTOL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zU1IAwdJYrok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zc92axd5kqph">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of
our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its
fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed
consolidated statements of operations. For our liability classified derivative financial instruments, the Company used a Monte Carlo
valuation model to value the derivative instruments at inception and on subsequent valuation dates. For our equity classified
derivative financial instruments, we used a Black-Scholes option-pricing model at the grant date to value the derivative instrument.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zlFf6cI9ITB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zBAgigV4CUnf">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in FASB ASC 480, <i>Distinguishing Liabilities from Equity</i> (&#8220;ASC 480&#8221;)
and ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether
the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a
component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria
for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each
balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the
unaudited condensed consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zK4BilFFxXkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zCKkoNeWM1e4">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Research and development expenses
are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical
and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief
operating officer, chief financial officer and directors&#8217; compensation. For the three and six months ended June 30,
2024 and 2023, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3sLaUIdASYc" title="Share based compensation">0.1</span>
million and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDnOqNRLzbMj" title="Share based compensation">0.3</span>
million, respectively, and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLXJrFhnixJ1" title="Share based compensation">0.2</span> million and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxhtNDbme28j" title="Share based compensation">0.6</span>
million, respectively, was included within research and development due to their active involvement in the research and development
activities, materials, supplies, related subcontract expenses, and consulting costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of government
assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction including the
nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other provisions of
relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable alternative for
the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The Company has concluded
that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements against
incurred research costs. There were no reimbursements received for the six months ended June 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPYN1jBumNz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXKKuKw3o4M7">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per share on the face of the unaudited condensed consolidated
statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and
denominator of the basic earnings per share computation. In the accompanying unaudited condensed consolidated financial statements,
basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and
potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from
common shares issuable through contingent share arrangements, stock options and warrants unless the result would be
antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#8220;treasury
stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#8220;if-converted
method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVkGRAVxSzPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0Up43jkQn2f" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zV8FndxIngK" title="Convertible notes (Note 6)">80,744</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zTo8N3BvlMOd" title="Convertible notes (Note 6)">155,378</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXic79bck0k1" title="Warrants">184,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxRJezezYiRe" title="Warrants">184,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zO4l3p8AWrTc" title="Restricted stock units">58,839</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG41pxOQnzb2" title="Restricted stock units">10,382</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_ztFD3kr5Ef39" title="Anti-dilutive securities">323,583</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zTCgcgQrSTIe" title="Anti-dilutive securities">349,760</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zl7y3OUGU5xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zu1RgEyL4q5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zny4h9Jlpx5i">Deferred
Offering Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASC 340-10-S99-1, costs directly attributable to an offering of equity securities are deferred and would be charged against the
gross proceeds of an offering as a reduction of additional paid-in capital. Deferred offering costs may consist of underwriting,
legal, accounting, and other expenses incurred through the balance sheet date that are directly related to a proposed public
offering. Should the proposed public offering prove to be unsuccessful, any deferred costs, as well as additional expenses to be
incurred, will be expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zPaMS221bwti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zoIhNWXVKYPl">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.
2023-07, Segment Reporting Topic 280, &#8220;Segment Reporting-Improvements to Reportable Segment Disclosures,&#8221; which allows disclosure
of one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance.
Additionally, the standard requires enhanced disclosures of significant segment expenses and other segment items, as well as incremental
qualitative disclosures on both an annual and interim basis. This guidance is effective for annual reporting periods beginning after
December 15, 2023, and interim reporting periods after December 15, 2024. Early adoption is permitted and retrospective application is
required for all periods presented. The adoption of this new guidance is not expected to have a significant impact on our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, Income Taxes Topic 740, &#8220;Income Tax-Improvements to Income Tax Disclosures,&#8221;
which requires enhanced disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation,
disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit,
and income tax expense or benefit from continuing operations. This guidance is effective for annual reporting periods beginning after
December 15, 2024. Early adoption is permitted and should be applied on a prospective basis, however retrospective application is permitted.
The Company is currently evaluating the impact of adopting this guidance on its consolidated and condensed financial statements and disclosures
included within notes to consolidated and condensed financial statements.</span></p>

<p id="xdx_85B_zXrZEEtLe4f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zAbDMxtvqVkb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Note 3 &#8211; <span id="xdx_824_zYouvyiEJF0f">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zN9JmHykJAle">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zXzky5zRn35g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i><span id="xdx_864_z51lIHBaxIod">Reclassifications</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>


<p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_znBsmi9qpX7i">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company
regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical
experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the
Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results
of operations will be affected. Significant estimates are contained in the accompanying consolidated financial statements for the
recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other
financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zJkXkj4AZTy2">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,550,098</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5,411,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,026,318</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,005,825</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,576,416</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,417,203</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount">250,000</span> per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount">1,849,000</span>. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zcIP2rrvmXK8">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance">2,887,215</span>. During the year ended December 31, 2023, the Company recognized interest income of $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income">52,855</span>,
realized gains of $<span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss">4,970</span>, and unrealized gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss">71,568</span>. The were <span id="xdx_90F_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zbAdEjByFAZi" title="Marketable securities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2316">no</span></span> marketable securities as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqfmU6VxYX7j">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Marketable Securities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2328">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2333">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2334">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DerivativeLiabilityWarrants_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zLHLaG6Wpet4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative Liability - Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2343">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerivativeLiabilityAcceleratedFeature_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_z1GMbV70G7Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2347">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2348">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2352">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2353">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">414,512</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">414,512</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company had non-derivative warrant liabilities that were measured at fair value on a recurring
basis. Each of these fair value measurements was considered to be a Level 3 measurement by the Company as they used significant unobservable
inputs, such as the Company&#8217;s pre-IPO stock price, probability of event occurrence and other management estimates. The key inputs
for each of these warrant liabilities were as follows:</span></p>

<p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoMWqw0jB0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zKUJ72QdTXY5" style="display: none">Schedule
of Key Inputs of Warrant Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Series A Preferred Stock Obligation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_984_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zLyVGKOArAWd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock">40.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_982_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zgBrdL1LrT7c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated IPO or Listing terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_znoxhYjetF0l" title="Exercise price">40.00</span> - $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zArhlIcCb06d" title="Exercise price">166.56</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zp65fcqYKv7b" title="Exercise price">32.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Series A Preferred Stock conversion shares upon IPO or Listing at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_ztMXqnmuU9cb" title="Number of warrants">12,135</span> - <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zMp7IKseQgnc" title="Number of warrants">33,681</span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7zVZKsduoz2" title="Number of warrants">42,101</span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdcX1kzMoQCd" title="Warrants and rights outstanding measurement input">86.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zW1kmGuIywhe" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z78eGWXIszP4" title="Warrants and rights outstanding measurement input">1.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zbRqcuFc7Kx4" title="Warrants and rights outstanding measurement input">3.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated IPO date</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7abpz07AmNb" title="Estimated IPO date">9/30/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zreHcuEZR3gi" title="Estimated IPO date"><span style="-sec-ix-hidden: xdx2ixbrl2385">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated Term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z815JlVntnri" title="Estimated Term">3.75</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z1GevZdwSlle" title="Estimated Term">3.00</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO or Listing Occurring</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zkuIhmucDUIl" title="Warrants and rights outstanding measurement input">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zP3rqfuREZce" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2393">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO as &#8220;Qualified IPO&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKZbZZdwX904" title="Warrants and rights outstanding measurement input">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zAVfbA32ifU9" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2397">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of IPO as &#8220;Listing&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zao8vkaRcnof" title="Warrants and rights outstanding measurement input">67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKRwLLcGWTNc" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2401">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdV5UMoJ21Bj" title="Estimated fair value">334,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z0UVRkniDVEg" title="Estimated fair value">756,723</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification/Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9nZuNwXlNZ9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9B1oFEU8qSd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zL1GvJpV5Cld" title="Exercise price">20.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z7OvmG4tIEqi" title="Exercise price">20.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Number of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zZ3lsYq0BOS3" title="Number of warrants">6,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zWW3jeBT6Epe" title="Number of warrants">6,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zsUhFnC28Jl7" title="Estimated Term">5.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zmfGu7F5nHW3" title="Estimated Term">4.9</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zBV3c4wuqEq3" title="Warrants and rights outstanding measurement input">80.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z0zoN4DV2El9" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zkEcXWlx3BOc" title="Warrants and rights outstanding measurement input">2.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2A0YB3qNMNd" title="Warrants and rights outstanding measurement input">3.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z1XDBZyN0Kv5" title="Estimated fair value">146,624</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2TqMctNvqrh" title="Estimated fair value">151,726</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zGirhz4ePWDd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsu1obyU1Wfi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z0coh5dRpsxa" title="Exercise price">16.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoeIDPCXPcQc" title="Exercise price">16.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoXzU7kpwwt5" title="Number of warrants">3,688</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zgcbWp2u3FLf" title="Number of warrants">2,581</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zXIPSshDbQ7" title="Estimated Term">5.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXzeaxUL0tM4" title="Estimated Term">4.4</span> &#8211; <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLzgZeRBaps9" title="Estimated Term">4.5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z1Fa93A6ZRvi" title="Warrants and rights outstanding measurement input">86.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zNweZGNbvpN3" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhzYuy6xQ1gh" title="Warrants and rights outstanding measurement input">1.8</span>% - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPg7CsZ2CbB2" title="Warrants and rights outstanding measurement input">2.0</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsxT4r0C5eu5" title="Warrants and rights outstanding measurement input">3.4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyTizCgvTLpl" title="Estimated fair value">92,336</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z72Y855ESgJb" title="Estimated fair value">64,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zecpDhgOgxS8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A rollforward of these warrant liabilities for the year ended December 31, 2022 is as follows:</span></p>

<p id="xdx_89E_ecustom--ScheduleofWarrantLiabilitiesTableTextBlock_ztBVEOc64Ov8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zeSONc0gOzva" style="display: none">Schedule
of Warrant Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Liability &#8211; Series A Preferred Stock Obligation</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2021 (as restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zNsPYB7LzPi3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Warrant liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">334,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zF5QjxZXZTJg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised (settled)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_ztUOjfervEfb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on change in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z5rYb9iCCVZc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">421,768</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassifications to stockholders&#8217;
    equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7151H6TNz22" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(756,723</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z6PdrHa7bupc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2479">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zlZwC2L7J5Eg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zIeMYiGkql7i" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued">146,624</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zhb4cBwGbSah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)">(91,036</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zXN8bvqeOFIl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loss on change in fair value">5,102</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reclassifications to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_za8LAb6YMJX" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity">(60,690</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zawcjTzKvje2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2491">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zol065gJ4hZg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2493">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zHGwX8iZIuNe" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued">92,336</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_ziqTyVquujLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zf7xXRmbzS94" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Gain on change in fair value">(28,196</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Reclassification to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"><p id="xdx_983_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zjJcvweR4b02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Reclassifications to stockholders' equity">(64,140</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyZqV655aYsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2503">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zRZQvVXDUPo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Refer to Note 7 for additional background on
the reclassification of warrant liabilities to equity. See Note 8 for additional disclosures related to the fair value of the Company&#8217;s
derivative liabilities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUfQ5IhZAVZ7">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine if an arrangement is a lease at inception. <span style="background-color: white">Operating leases are included in operating
lease right-of-use asset (&#8220;ROU&#8221;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with a lease term of 12 months or less at inception are not recorded on our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">balance </span>sheets <span style="background-color: white">and are expensed on a straight-line
basis over the lease term in our statement of operations. </span>We have lease agreements with lease and non-lease components, which
are generally accounted for separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#8220;incremental borrowing rate&#8221; or &#8220;IBR&#8221;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zhMEboul1fnf">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%">Furniture</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computers and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life">10</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYSObLAWFqrd">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our derivative financial instruments, the Company utilizes the most appropriate valuation model (such as Monte Carlo simulations or probability-weighted expected
return models, based on the nature of the terms of the instrument) to value the derivative
instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such
instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheet sheets as current or non-current based on whether or not net-cash settlement or
conversion of the instrument could be required within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zIShPO1DVFMg">Convertible
Notes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible notes for embedded features and bifurcates these features (such as conversion options and
redemption options) from their host instruments and accounts for them as free standing derivative financial instruments if certain
criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid
instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under
otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)
a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_860_zbFQsfTI6WN7">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity
(&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants
are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the
warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a
circumstance outside of the Company&#8217;s control, among other conditions for equity classification. Finally, the Company
determines if the warrants meet the definition of a derivative based on their contractual terms. This assessment, which requires the
use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while
the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and at each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">statements of operations. </span></span>The Company also evaluates if changes in contractual terms
or other considerations would result in the reclassification of outstanding warrants from liabilities to stockholders&#8217; equity (or
vice versa).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">
The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zMKVdyEG0BI7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z4CSzyso8ih9">Stock-Based Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost for stock awards, which include restricted stock units (&#8220;RSUs&#8221;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z01OOEEOeht9">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#8217; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$<span id="xdx_90F_ecustom--ShareBasedCompensations_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhkgxJb4oO55" title="Share based compensation">0.8</span> million and $<span id="xdx_900_ecustom--ShareBasedCompensations_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znRCeUIPhCNa" title="Share based compensation">0.5</span> million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230101__20231231_zY9s230h9slk" title="Research and development, net of contract expense reimbursements">3.5</span> million and $<span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20220101__20221231_zuzMe32hXUdd" title="Research and development, net of contract expense reimbursements">1.0</span> million in Research and development, net of contract expense reimbursements, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zjUxdX9ZNGFl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQkEcVy4u6Y6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zDl56YzwE8M1">Segment
Information</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate and discrete information is available for evaluation by the
chief operating decision-maker (&#8220;CODM&#8221;) in deciding how to allocate resources and assess performance. The Company and the
Company&#8217;s CODM, the Company&#8217;s chief executive officer, evaluates the Company&#8217;s operations and manages its business
as a <span id="xdx_900_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_z3kfWGafUOSj" title="Number of reportable operating segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl2541">single</span></span> operating segment. All of the Company&#8217;s long-lived assets are held in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwbvAlIY1l46">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per common share on the face of the statements of operations
for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic
earnings per share computation. In the accompanying consolidated financial statements, basic loss per common share is computed by
dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the weighted average
number of shares of common stock outstanding and potentially dilutive shares of common stock during the period to reflect the
potential dilution that could occur from common shares issuable through convertible securities, contingent share arrangements, stock
options and warrants unless the result would be antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units and other stock-based payment awards subject to vesting and common stock warrants is
calculated using the &#8220;treasury stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these
instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible
securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be
converted at the beginning of the period, and the resulting shares of common stock are included in the denominator of the diluted
calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(as
                                            restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Convertible notes (Note 6)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)">119,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl2549">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants">184,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants">47,831</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units">24,731</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units">2,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities">328,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities">50,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zSWNCgOEheR1">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not expect the adoption of this standard to
have any material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.</p>

<p id="xdx_85E_zQNfopfWoCN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773459197472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_zkftMnGKRIX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82E_zpNBimatGMvg">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use (&#8220;ROU&#8221;) assets and liabilities are recognized at the present value of the future lease payments as of
the lease commencement date. Operating lease expense is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, the Company had a lease agreement which allowed for the use of a laboratory facility for a monthly
payment of $<span id="xdx_90F_eus-gaap--OperatingLeasePaymentsUse_c20230101__20230630_zHUYfXFcZhfl" title="Lease payment">6,480</span>. The laboratory lease commenced on October 1, 2018 and expired on <span id="xdx_905_eus-gaap--LeaseExpirationDate1_c20230101__20230630_zA0ZrFrtE0Gh" title="Lease expiration term">October 31, 2023</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility, entered into on February 16, 2023, with base
rent of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zoZsDXC0givj" title="Payments for rent">7,206</span> per month for a period of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_z90MMRHe9x1k" title="Lease term">64</span> months, which increases at the rate of <span id="xdx_901_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zXU3xXYu5Qa1" title="Rent variable rate">3</span>% per year, that <span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_ze8OT5LVf6N6" title="Lease commencement">commenced June 1, 2023</span>. The lease
included a six-month <span id="xdx_905_ecustom--PercentageOfRentAbatement_pid_dp_uPure_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zvUYrqolu84i" title="Percentage of rent abatement">50%</span> rent abatement upon commencement. Additional common area maintenance (&#8220;CAM&#8221;) fees are charged monthly
and revised annually. The estimated monthly CAM fees are $<span id="xdx_90C_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zcYoJffu1Op3" title="Estimated monthly common area maintenance cost">3,300</span> per month for the first year of the lease, which are being expensed as
incurred. An irrevocable letter of credit (&#8220;LOC&#8221;) for the security deposit of $<span id="xdx_90E_eus-gaap--SecurityDeposit_iI_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zeAKOZIE73Qh" title="Security deposit">43,234</span> and base rent of $<span id="xdx_909_eus-gaap--PaymentsForRent_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zZQMAJ2qUPfd" title="Payments for rent">3,891</span>, including
<span id="xdx_904_ecustom--PercentageOfRentAbatement_pid_dp_uPure_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zL3jVRGhrh83" title="Percentage of rent abatement">50%</span> abatement, and $<span id="xdx_90B_ecustom--CommonAreaMaintenanceCost_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zylt0HN5Fgu8" title="Common area maintenance cost">3,315</span> of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is
the beneficiary of the LOC, and the expiry date of the LOC is <span id="xdx_901_eus-gaap--LeaseExpirationDate1_dd_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_ztDTesw2ekc9" title="Expiry date">March 1, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zK422Uc0lu5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the ROU lease expense components and cash flow information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zuH7q1lj8SJd" style="display: none">Schedule of Right-of Use Asset and Lease Information about Operating Lease</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240401__20240630_zo4SVVRAslZ4" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230401__20230630_zbeeaqAgEQqg" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20240630_zhRuAhvewrL8" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20230101__20230630_zxL68u1cciD4" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseCost_maLCzBxV_z9q8sduJrjNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,894</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_maLCzBxV_zcBgOYmHf708" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,937</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,377</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--SubleaseIncome_iN_di_msLCzBxV_z3kL2k1B3bb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublease
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,163</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,121</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,326</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,242</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--LeaseCost_iT_mtLCzBxV_zt70iWUKYVJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,721</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,072</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,945</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zDvzNXhAEmD8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for operating cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,707</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,331</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,189</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,771</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zDgjUOaa64wi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    assets obtained in exchange for new operating lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">365,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8A2_ztNUTeUGd3ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zKOOShJEE5dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to operating leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zmYseQ6pdvtj" style="display: none">Schedule of Balance Sheet Information Related to Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin: 0">December 31,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 60%"><p style="margin: 0">Weighted-average remaining lease term (year)</p></td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zJlgJo77R5Ga" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)">4.18</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zXbHD3zsmgMd" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)">4.98</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20240630_zqJYJPwpJeXi" title="Weighted-average discount rate - operating leases">10.48</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z2wnmDWx5pXc" title="Weighted-average discount rate - operating leases">10.46</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A2_zP9XtOBsNn76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmlHgFzUal7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of June 30, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zsVIUUnQJvr1" style="display: none">Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">Years Ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240630_zNDWEz2YNUT9" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzRbr_zHHdpQpnj0cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 80%">2024 (excluding the six months ended June 30, 2024)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzRbr_z0YgUsRG8Qv6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,246</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzRbr_ztHycVa7y8O1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,074</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzRbr_zUATw95C4R95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,986</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzRbr_zpEa8QZPruM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">68,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzRbr_zvIAUmy9odxl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzRbr_z8Voh6apDace" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zHDliea95yo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(76,737</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zRffpWzzHwPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">329,117</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z4tEeYU5Ws8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_z08OzEyKAwJ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 - <span id="xdx_82E_zYhGzQEhHDX1">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had two lease agreements during the year which allowed for the use of laboratory facilities. <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zEya2wAH9aKc" title="Lessee, operating lease, description">The first was for a monthly payment
of $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20230101__20231231_z4j16dhXCej9" title="Payments for rent">6,480</span>, with a security deposit of $<span id="xdx_90A_eus-gaap--Deposits_iI_c20231231_zO8e4gkFsUJk" title="Deposits">6,480</span> held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019</span> and ended on <span id="xdx_90D_eus-gaap--LeaseExpirationDate1_c20230101__20231231_zI0l5Mds2Am4" title="Lease expiration date">October 31, 2023</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2023, the Company entered into a new lease agreement for new office and laboratory space, with base rent of $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zzwRNVzOdczf" title="Payments for rent">7,206</span> per month
for a period of 64 months, which increases at the rate of <span id="xdx_903_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIt1JZKcThLk" title="Rent variable rate">3</span>% per year, that <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIlMHykNlrM1" title="Operating lease description">commenced June 1, 2023</span>. The new lease included a six-month
50% rent abatement upon commencement. Additional common area maintenance (&#8220;CAM&#8221;) fees are charged monthly and revised annually.
The estimated monthly CAM fees are $<span id="xdx_908_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230215__20230216_zd0rmLCuEgvl" title="Estimated monthly common area maintenance cost">3,300</span> per month for the first year of the lease, which are being expensed as incurred. An irrevocable
letter of credit (&#8220;LOC&#8221;) for the security deposit of $<span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20230216_zE3n7U3fwQok" title="Security deposit">43,234</span> and base rent of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20230215__20230216_zETIouZ8QDv6" title="Payments for rent">3,891</span>, including 50% abatement, and $<span id="xdx_909_ecustom--CommonAreaMaintenanceCost_c20230215__20230216_zRiqEIIYf8j8" title="Common area maintenance cost">3,315</span>
of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is the beneficiary of the LOC,
and the expiry date of the LOC is February 15, 2024. Subsequent to December 31, 2023, the LOC was renewed with an updated expiry date
of March 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the right-of use asset and lease information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z3chxPAugTvb" style="display: none">Schedule of Right-of Use Asset and Lease Information About Operating Lease</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Years Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">112,022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">70,175</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2595">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Sublease income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,819</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,070</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">128,425</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">63,105</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other information</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">95,641</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76,248</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">365,556</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2610">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term - operating leases (year)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dxL_c20231231_zyA8Do3k9Nfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)::XDX::P4Y11M23D"><span style="-sec-ix-hidden: xdx2ixbrl2612">4.67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)">0.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average discount rate - operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dpxL_uPure_c20231231_zWuyyS7WvFVl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases::XDX::10.46"><span style="-sec-ix-hidden: xdx2ixbrl2616">10.48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_z8NlF0txAYKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A8_zAskMv6Jd9Ib" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOSrvaX8p16l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zhh9Zl5mOtfe" style="display: none">Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Years ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz2AR_zxdBtjySLTu6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024 (excluding the six months ended June 30, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz2AR_z7Q1UTfjXlRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">91,502</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz2AR_zxt7KD3Psq8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,247</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz2AR_zCEFnZuV9lP6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">97,074</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz2AR_zB3e7mhwfEwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">99,986</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz2AR_zjrflcieALdj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">68,235</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz2AR_zKCt4MJzhhad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total future minimum lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">451,044</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(94,438</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">356,606</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zGZjjGq7mVc5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461412384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable-Related Party<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureNotesPayablerelatedPartyAbstract', window );"><strong>Notes Payable-related Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_NotesPayableRelatedPartyDisclosureTextBlock', window );">Notes Payable-Related Party</a></td>
<td class="text"><p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zP7btAoQNmwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_826_zsfoxsulziO5">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2023 the Company incurred $<span id="xdx_905_eus-gaap--InterestExpense_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSa2G3pqRPfl" title="Interest expense">2,588</span> and $<span id="xdx_902_eus-gaap--InterestExpense_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zNbppl22HDG3" title="Interest expense">6,825</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in interest expense. During the three and six months ended June 30, 2023 principal payments of $<span id="xdx_90E_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zwMgXRNbcgZ5" title="Proceeds from related party">139,229
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z8SnsyEB7An" title="Proceeds from related party">685,473</span>,
respectively,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and accrued interest of $<span id="xdx_90F_eus-gaap--InterestPaidNet_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zYlR3qXv9cy2" title="Accrued interest">25,917
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--InterestPaidNet_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z9j5fEuesSf2" title="Accrued interest">102,373
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were paid, respectively, on notes to related
parties. The principal and accrued interest for these notes were fully paid by December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zd061yowJNd3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_825_zH1XaP0tjrW5">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zamdIkxYJlAj" title="Loan transaction amount">426,243</span>, bearing interest at the rate of <span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWqcEUtfPTu6">7.5</span>% per annum, with a maturity date of <span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zfFRy9Sub3Hc">December 31, 2021</span>; and (ii) a single loan
owed to an officer of the Company in the principal amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z23uTB9maqmg" title="Principal amount">139,229</span>, bearing interest at the rate of <span id="xdx_90A_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zerWcgbpUGVj">7.5</span>% per annum, with a maturity
date of December 31, 2021. <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211231_zT9SOlLu3LFk" title="Debt instrument maturiy date description">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_906_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zgvqBs3CjI55" title="Loan transaction amount">120,000</span> (principal) with
an interest rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z7JDA19McyJa">7.5</span>% per annum due June 21, 2022. In July of 2022, the loan was extended to June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company accounted for these loan extensions during
the year ended December 31, 2022, as a troubled debt restructuring as the Company was experiencing financial difficulties and the extensions
represented a concession by the lenders. As the future undiscounted cash flows of these related party notes exceeded their carrying value,
no gain or loss was recognized upon the extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023 principal payments of $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zSYaCBxemUD8">685,473</span> and interest of $<span id="xdx_905_eus-gaap--InterestPaid_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z83SkWky2Pa" title="Interest paid">104,968</span> were paid. As of December 31, 2023, there were <span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_do_c20230101__20231231_z5bCjpTtB4u2" title="Increase accrued interest">no</span> outstanding
principal or interest balances for these related party notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On August 1, 2022, in conjunction with a private placement of notes and
warrants (as detailed in Note 6 below), in exchange for a $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCQ4BFsht1I5" title="Payments upon subscription">50,000</span> payment upon subscription, the Company issued a convertible note to
the spouse of an officer of the Company in the amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWcxBHe7uvM8" title="Principal amount">50,000 </span>(principal) with an interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z6n2o8Hg614f" title="Interest rate">6</span>% per annum, and warrants to purchase
<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z40JRGFDyq7c" title="Warrants to purchase of common stock">2,500</span> shares of common stock. The loan was fully repaid, including $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z6p8z1cYrBy7" title="Repayments of accrued interest">822</span> of accrued interest, in September of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureNotesPayablerelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureNotesPayablerelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_NotesPayableRelatedPartyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable Related Party [Disclosure Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_NotesPayableRelatedPartyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773564358304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes and Notes Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes and Notes Payable</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zvYU5YvLJ2vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82D_zulWBaOMF4J6">Convertible Notes and Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alto
Opportunity Master Fund, SPC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, the Company entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master
Fund, SPC &#8211; Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to
the Investor a $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNtDRaoZtrl9" title="Convertible debt">4,300,000</span>
convertible note (the &#8220;Alto Convertible Note&#8221;) and warrant (the &#8220;Warrant&#8221;) to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWVFzsFu6Yqc" title="Warrants to purchase common stock">127,260</span>
shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWcGwhV8OVC" title="Warrants exerciable shares">18.80</span>
per share, in exchange for gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znRi0JXEEfif" title="Proceeds from convertible note payable">3,935,000</span> (the &#8220;Investment Amount&#8221;) (See Note 7). The Company determined that the Warrant contains a net cash settlement
feature at inception and categorized the Warrant as a liability in the accompanying unaudited condensed consolidated financial
statements. The Alto Convertible Note matures on March 11, 2025, but may be extended at the option of the noteholder. The Alto
Convertible Note amortizes on a monthly basis and the Company can make such monthly amortization payments in cash or, subject to
certain equity conditions, in registered shares of common stock or a combination thereof. Installments may be deferred by the
noteholder, resulting in a variable interest rate. However, the effective interest rate is approximately <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zHGXkMmAHFEa" title="Effective interest rate">218</span>%
based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment, <span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgbKfszLE1Pk" title="Debt description">the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $18.80
per share.</span> The noteholder has an acceleration
of installment amount conversion option (the &#8220;Acceleration Option&#8221;), whereby the noteholder, with certain share
percentage limitations, can convert to common stock any outstanding installment amount at an amount equal to the installment amount
plus five times (5x) the installment amount at any time. The Company has determined the Acceleration Option is an embedded
derivative within the host instrument and has bifurcated it from the host instrument and recorded it as a derivative liability
valued at $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztla3FvLtVm7" title="Derivative liability">1,442,000</span>
at inception, using a Monte Carlo simulation model (Note 7). The Convertible Note is repayable over 26 months and bears interest at
the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGSX9sVhQJVc" title="Debt interest rate">5</span>%
per annum. Additionally, the note contains certain redemption options and &#8220;Make Whole&#8221; provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the &#8220;Security
Agreement&#8221;), an intellectual property security agreement (the &#8220;IP Security Agreement&#8221;) and a subsidiary guaranty (the
&#8220;Subsidiary Guaranty&#8221;). The security agreements and guaranty allow, among other things, for the Investor to have a security
interest in and place a lien on all of the Company&#8217;s assets and intellectual property until such time as the Alto Convertible Note
is paid off. In addition, the SPA called for the Company to enter into a springing deposit account control agreement (the &#8220;Springing
DACA&#8221;), which, in the event the Company defaults on its repayment of the Alto Convertible Note, would allow the Investor to assume
control of the Company&#8217;s bank account only with regard to any funds remaining outstanding under the Alto Convertible Note. As such,
in conjunction with entry into the SPA, the Company established a separate bank account in which it deposited the Investment Amount and
pursuant to which the Company, the Investor and the bank holding the Investment Amount, First Republic Bank, entered into the Springing
DACA agreement. As the Investment Amount had been held at First Republic Bank, in light of certain banking crises then affecting smaller
banks, on March 12, 2023, the Company and the Investor moved the Investment Amount from First Republic Bank, after which time the Springing
DACA was no longer in effect. Further, pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor
agreed that all of the Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing
DACA would no longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20240630_zmlZe7B5LWFg" title="Convertible notes payable">10.0</span>
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Warrant, excluding the Springing
DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an opportunity to participate
in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company expects that such subsequent convertible
notes and warrants would be issued on substantially similar terms as the January 11, 2023 initial agreement, as amended, thus providing
the Company the opportunity to negotiate certain aspects of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$<span id="xdx_90A_ecustom--PaymentForPlacementAgent_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zfcJ9GxVRehj" title="Payment for placement agent">345,000</span> cash compensation and a warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zNlaNCWlQFEk" title="Warrants to purchase common stock">8,909</span> shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zciP5gmwiOl2" title="Warrants exerciable shares">18.80</span> per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfzgohzrdu27" title="Expected years">five years</span>, volatility of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zWL0h0g74kDi" title="Warrants and rights outstanding measurement input">110</span>%, a risk-free rate of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zGw4xw7rEyWk">3.53</span>% for a value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zZTfzl6Rfn1c" title="Fair value of warrants">99,543</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated the finance costs related to the Boustead placement agent fee of $<span id="xdx_90A_ecustom--PaymentForPlacementAgent_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z4JyrnAVvbLg" title="Payment for placement agent">345,000</span>, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $<span id="xdx_90D_eus-gaap--PaymentsOfFinancingCosts_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zrWgAvpXqS2c" title="Allocation of financing costs">232,027</span> to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zRgZBhK3xSf5" title="Warrant derivative liability">104,245</span> to the warrant derivative liability component,
expensed as a finance fee, and $<span id="xdx_905_eus-gaap--DebtInstrumentFeeAmount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zuCQAQYPFkPg" title="Equity warrant as reduction in additional paid in capital">8,727</span> to the equity warrant as a reduction in additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated to the debt component of the note an original discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zbmjpy9sD1Kc" title="Debt discount">300,000</span>, legal fees of $<span id="xdx_908_eus-gaap--LegalFees_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zftX1FdSi2m" title="Legal fees">65,000</span>, $<span id="xdx_908_ecustom--InterestFeeAmount_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zRdflibszHe9" title="Interest fee">215,000</span> for additional
interest fees on day one added to note principal, $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zzl1hJdfMbC5" title="Debt principal amount">1,442,000</span> for the accelerated conversion feature, and $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zd6OUJitGPy" title="Fair value of warrants">1,288,543</span> for the fair value
of warrants, resulting in an additional $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zIa7wH7wgpSf" title="Interest expense debt">3,310,543</span> debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2024, the Company recorded interest expense of $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zLmWmanlrPug">430,685</span>
and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zbQvQuOPoK54">928,200</span>,
respectively, which included amortization of debt discount as interest expense of $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20240401__20240630_zbRxsjT5yFma">386,505</span>
and $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20240101__20240630_zchKazdBMQ49">832,014</span>, respectively. During the
three and six months ended June 30, 2024, the Company settled $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zeAglM2UxOf9" title="Debt, principal">0</span> and $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zRhgO3GIB9xj" title="Debt, principal">235,200</span>
of principal, and settled $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zvJq2u0LTtu1" title="Accrued interest">0</span> and $<span id="xdx_900_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zvAQzKj5FWUi" title="Accrued interest">18,783</span>
of accrued interest, which settlements were made in the form of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3RJm6JzvED5" title="Stock issuance">0</span> and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFQtuxbx6yr7" title="Stock issuance">78,197</span>
shares of common stock. The Company also settled for cash during the six months ended June 30, 2024 $<span id="xdx_90A_eus-gaap--ProceedsFromInterestReceived_c20240101__20240630_zaXDOH3wagz" title="Settled for cash">501,667</span>
of principal and $<span id="xdx_90D_eus-gaap--InterestPaidNet_c20240101__20240630_zYSujkvbVNdg" title="Interest paid">56,958</span>
of accrued interest for a total of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630_zGBqCyl7UCjk" title="Debt, principal">558,628</span>
of principal and interest paid in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2023, the Company recorded interest expense of $<span id="xdx_904_eus-gaap--InterestExpenseDebt_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGT7GdaEWCni">729,351 </span>and $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zFPXgYg7KKgb">1,328,682</span> respectively, which included
amortization of debt discount as interest expense of $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20230401__20230630_zMxxM1CXMpc">549,125</span> and $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20230630_zoY2rXLAEqt4">1,012,177 </span>respectively. During the three and six months ended June
30, 2023, the Company paid $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zUW43QIDHUXd" title="Debt, principal">1,527,750 </span>and $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z9x2WOo2cGAl" title="Debt, principal">1,593,900</span> of principal, respectively, and paid $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zUe5fHa2cxdk" title="Accrued interest settled with common stock">220,689</span> and $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmqCQLosGhb4" title="Accrued interest settled with common stock">240,831</span>, respectively, of accrued
interest, which payments were made in the form of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCyPHYOAPai" title="Stock issuance">228,489</span> and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyBirkFQ3xBi" title="Stock issuance">234,864</span> shares of common stock, respectively, during the three and
six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, the outstanding principal for the convertible note was $<span id="xdx_901_eus-gaap--ConvertibleDebt_iI_c20240630_z8EL5KiE4e8h">1,517,989</span> and the debt discount remaining was $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20240101__20240630_z2iz59NMbfka">691,754</span>, with
a net convertible note carrying value of $<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20240630_zlqpdcBCfOu7" title="Convertible note payable">826,235</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zFKpdNkIRYg4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Note 6 -<span> Notes Payable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82B_zZ6z698dByx6" style="display: none">Convertible Notes and Notes Payable</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alto
Opportunity Master Fund, SPC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, the Company entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master
Fund, SPC &#8211; Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to
the Investor a $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1qYaf3PFxbb" title="Convertible debt">4,300,000</span>
convertible note (the &#8220;Alto Convertible Note&#8221;) and warrant (the &#8220;Alto Warrant&#8221;) to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zI1s666a13S3" title="Warrants to purchase common stock">127,260</span>
shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDE7HRqOETJb" title="Warrants exerciable shares">18.80</span>
per share, in exchange for gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqpTwBuXgLIh" title="Proceeds from convertible note payable">3,935,000</span>
(the &#8220;Investment Amount&#8221;) (See Note 7). The Company determined that the Alto Warrant contains a net cash settlement
feature at inception and categorized the Alto Warrant as a liability in the accompanying consolidated financial statements. The Alto
Convertible Note matures on March 11, 2025, but may be extended at the option of the noteholder. The Alto Convertible Note amortizes
on a monthly basis and the Company can make such monthly amortization payments in cash or, subject to certain equity conditions, in
registered shares of common stock or a combination thereof. Installments may be deferred by the noteholder, resulting in a variable
interest rate. However, the effective interest rate is approximately <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYihioEmX1N1" title="Effective interest rate">346</span>%
based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment, <span id="xdx_900_eus-gaap--DebtInstrumentDescription_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQZdUUfRm3u2" title="Debt description">the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20230111_zqknXDQiiXwl" title="Share Price">18.80</span>
per share.</span> The noteholder has an acceleration of installment amount conversion option (the &#8220;Alto Acceleration
Option&#8221;), whereby the noteholder, with certain share percentage limitations, can convert to common stock any outstanding
installment amount at an amount equal to the installment amount plus five times (5x) the installment amount at any time. The Company
has determined the Alto Acceleration Option is an embedded derivative within the host instrument and has bifurcated it from the host
instrument and recorded it as a derivative liability valued at $<span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zw9FmdP2k1rj" title="Derivative liability">1,442,000</span>,
using a Monte Carlo simulation model (Note 8). The Convertible Note is repayable over 26 months and bears interest at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIDfdUAlNQL7" title="Debt interest rate">5</span>%
per annum. Additionally, the note contains certain redemption options and &#8220;Make Whole&#8221; provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the
&#8220;Security Agreement&#8221;), an intellectual property security agreement (the &#8220;IP Security Agreement&#8221;) and a
subsidiary guaranty (the &#8220;Subsidiary Guaranty&#8221;). The security agreements and guaranty allow, among other things, for the
Investor to have a security interest in and place a lien on all of the Company&#8217;s assets and intellectual property until such
time as the Alto Convertible Note is paid off. In addition, the SPA called for the Company to enter into a springing deposit account
control agreement (the &#8220;Springing DACA&#8221;), which, in the event the Company defaults on its repayment of the Alto
Convertible Note, would allow the Investor to assume control of the Company&#8217;s bank account only with regard to any funds
remaining outstanding under the Alto Convertible Note. As such, in conjunction with entry into the SPA, the Company established a
separate bank account in which it deposited the Investment Amount and pursuant to which the Company, the Investor and the bank
holding the Investment Amount, First Republic Bank, entered into the Springing DACA agreement. As the Investment Amount had been
held at First Republic Bank, in light of certain banking crises then affecting smaller banks, on March 12, 2023, the Company and the
Investor moved the Investment Amount from First Republic Bank, after which time the Springing DACA was no longer in effect. Further,
pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor agreed that all of the
Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing DACA would no
longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20231231_zhjUClDQimI" title="Convertible notes payable">10</span>
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Alto Warrant, excluding
the Springing DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an
opportunity to participate in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company
expects that such subsequent convertible notes and warrants would be issued on substantially similar terms as the January 11, 2023
initial agreement, as amended, thus providing the Company the opportunity to negotiate certain aspects of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_ziS9eEQtuv1f" title="Payment for placement agent">345,000</span> cash compensation and a warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zAqlkvNNaDpd" title="Warrants to purchase common stock">8,909</span> shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zojy77XppzIe" title="Warrants exerciable shares">18.80</span> per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPC674AVJKXc" title="Expected years">five years</span>, volatility of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znMOWfqPGjYf" title="Warrants and rights outstanding measurement input">110</span>%, a risk-free rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zILXwC7DhWBl">3.53</span>% for a value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zEonjOrQ2ZU" title="Fair value of warrants">99,543</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated the finance costs related to the Boustead placement agent fee of $<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z1qEjzidygn" title="Payment for placement agent">345,000</span>, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $<span id="xdx_902_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGBEljeJa0Nb" title="Allocation of financing costs">232,027</span> to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmNk8FczQ6Wh" title="Warrant derivative liability">104,245</span> to the warrant derivative liability component,
expensed as a finance fee, and $<span id="xdx_90F_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zSUixncCkJS1" title="Equity warrant as reduction in additional paid in capital">8,727</span> to the equity warrant as a reduction in additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated to the debt component of the note an original discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zMx5hPAesnIi" title="Debt discount">300,000</span>, legal fees of $<span id="xdx_90D_eus-gaap--LegalFees_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zLBOZ1MJKbi8" title="Legal fees">65,000</span>, $<span id="xdx_900_ecustom--InterestFeeAmount_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zqJJyHoHEi83" title="Interest fee">215,000</span> for additional
interest fees on day one added to note principal, $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zayR1vJlE2s9" title="Debt principal amount">1,442,000</span> for the accelerated conversion feature, and $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zxa2TC77bmFd" title="Fair value of warrants">1,288,543</span> for the fair value
of warrants, resulting in an additional $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_znnI28Rtm2fb" title="Interest expense debt">3,310,543</span> debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded interest expense of $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_znhWETUYiYQb">2,484,193</span>, which included amortization of debt discount as
interest expense of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20230101__20231231_zpTyEbkt4Xac">2,123,049</span>. During the year ended December 31, 2023, the Company settled $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJLs4MfXiOZ5" title="Debt, principal">1,925,700</span> of principal and settled $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIH04jwIMOkl" title="Accrued interest">294,927</span>
of accrued interest, which settlements were made in the form of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z61rjBMkQSyb">297,625</span> shares of common stock during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the outstanding principal for the convertible note was $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_c20231231_zSRsEaMmQVQd">2,254,856</span> and the debt discount remaining was $<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20231231_zLkKrYZw6Y46">1,523,768</span>,
with a net convertible note carrying value of $<span id="xdx_90C_ecustom--ConvertibleNotesPayableCurrentNonCurrent_iI_c20231231_zuETJj7Bxv4l" title="Convertible note payable">731,088</span>, which represents the current and non-current portions of the convertible note
as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company and the Investor agreed to certain changes in terms of the Alto Convertible Note as well as the waiver
of certain covenant violations. See Subsequent Events for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Paycheck
Protection Program Term Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $<span id="xdx_905_eus-gaap--MediumTermNotes_iI_c20210309_zqzjdB5Jbxke" title="Term notes issued">73,007</span> term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#8217;s Paycheck
Protection Program (the &#8220;PPP&#8221;). The note bore an interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_z99RiodwMrtj" title="Interest rate">1</span>% per annum, had a six-month deferral period with payments
due on the seventh month, with all outstanding principal and interest due and payable within two years from the note&#8217;s inception
date. Under its terms, all or a portion of the note may be forgiven in accordance with PPP requirements, with <span id="xdx_908_eus-gaap--ShortTermDebtDescription_c20210309__20210309_zYoBKdc2rg0k" title="Term note description">no more than 25% of the
amount forgiven to be attributable to non-payroll costs</span>. As of December 31, 2021, a &#8220;Loan Forgiveness Application&#8221; was submitted
to PNC Bank along with the requested documentation. Thereafter, during the quarter ended March 31, 2022, the note liability was reduced
in its entirety and the Company recognized a gain on forgiveness of $<span id="xdx_90B_eus-gaap--MediumTermNotes_iI_c20221231_zScgzlhv1dok" title="Term notes issued">73,007</span> in its statement of operations for the year ended December
31, 2022. (as restated)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>December
2021 Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued promissory note units, consisting of an aggregate $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20211228_z8zCyT3ROlM8" title="Notes payable">500,000</span>
in <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_zTW6LR0Kzba8" title="Interest rate">10</span>%
unsecured promissory notes with a maturity date of <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_z2nwNfHdgjxk" title="Debt maturity date">December
28, 2022 </span>(the &#8220;December 2021 Promissory Notes&#8221;) and warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zNoT2sbNViB4" title="Warrants to purchase of common stock">62,500</span>
shares of common stock exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_z5iMOMfl5y8k" title="Exercise price of warrants">8.00</span>
per share with an expiration date of December 28, 2026. The Company received net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20211228__20211228_zsaZJ1BsY731" title="Promissory note">494,925</span>
upon the issuance of these promissory note units and incurred $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20211228_zvn3OApisrb5" title="Issuance cost">21,890</span> in additional issuance costs which were allocated between the December 2021 Promissory Notes
and the warrants. The Company assessed the embedded features of the December 2021 Promissory Notes
and determined that the accelerated repayment upon an initial public offering represented a derivative feature requiring
bifurcation. The Company estimated the fair value of the derivative to be $<span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20211228__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUD8Ry6bhtO7" title="Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value">367,000</span>
at issuance (see Note 8 for fair value considerations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the warrants issued with the December 2021 Promissory Notes should be classified as equity. The Company
measured the fair value of these warrants using a Black-Scholes model and allocated fair value to these warrants on a relative fair
value basis. The proceeds from the December 2021 Promissory Notes allocated to the warrants at issuance was $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_c20211228__20211228_zqbgjTw8ZEB2" title="Proceeds from issuance of warrants">418,449</span>. The inputs to
the Black-Scholes model included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20211228__20211228_zpY9EgGY1YV5" title="Conversion price per share">40.00</span>,
the exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zAR1l1qtI5Kj" title="Exercise price of warrants">8.00</span>
per share, a five year term, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20211228__20211228_zPXD89MZnqYk" title="Volatility">86.3%</span>
volatility and a risk free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20211228__20211228_zqFIbTWnireh" title="Risk free rate">1.27%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discount on the December 2021 Promissory Notes was being amortized using the straight-line method as the initial proceeds received were
fully allocated to the warrants and bifurcated derivative, through the maturity date of the notes. The Company recognized amortization
expense of $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231_zkuIO5Agz0Qb">331,978</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related
to the discount on the December 2021 Promissory Notes as interest expense in its statement of operations for the year ended December
31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In April 2022, the warrants were modified by the Company
to nullify the effect of the April 2022 reverse stock split, allowing the warrant to remain outstanding and exercisable for <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220430_zgVPTzfdkwIi" title="Warrants outstanding and exercisable">62,500</span> shares
of common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zAmiQlpLmEgj" title="Exercise price of warrants">8.00</span> per share. The Company calculated the incremental fair value provided to the holders of
the warrants due to the modification as $<span id="xdx_908_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrants_c20220101__20221231_zAhnDE9G1f13" title="Deemed dividend on modification of equity classified warrants">941,000</span>, which was recorded as a deemed dividend during the year ended December 31, 2022. The
incremental fair value was estimated using a Black-Scholes model, with inputs including the estimated fair value of the Company&#8217;s
common stock of $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220430__20220430_zpBlE4y3tN23" title="Conversion price per share">32.00</span>, the exercise price of either $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220429_z2Tjj9vjnFh5" title="Exercise price of warrants">16.00</span> (pre-modification) or $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zKAy7DyBmHD6" title="Exercise price of warrants">8.00</span> (post-modification), a remaining term of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220430__20220430_z2Yg4OdIZeW1" title="Expected term">4.75</span>
years, volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220430__20220430_ztFZjO6SaNya" title="Volatility">83.6</span>% and a risk free rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220430__20220430_zCU9XEt1wWb2" title="Risk free rate">2.55</span>%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the warrants were exercised by the lenders in exchange for tendering the outstanding principal balance ($<span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20220930_zNOkFecwyUhg"><span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930_zzztFeBEnntc">500,000</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
on the December 2021 Promissory Notes. The Company treated the settlement as a debt extinguishment for accounting purposes. The Company
recognized a loss on extinguishment of $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220930__20220930_zmDjf6XXKwjf" title="Gain (loss) on extinguishment of debt">1,531,852</span> upon this settlement and issuance of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220930__20220930_znW9JkwrD5N3" title="Share-based compensation arrangement by share-based payment award, options, exercises in period">62,500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock upon exercise, based on
the difference between the estimated fair value of the common stock issued ($<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220930__20220930_z7wjBfLimlIb" title="Stock issued during period, value, new issues">2,031,250</span>) and the carrying value of the December 2021 Promissory
Notes. The Company paid all accrued interest under the December 2021 Promissory Notes from issuance through settlement to the lenders
in cash during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022
Convertible Bridge Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, the Company sold $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zQlxj9Q5Ql6d" title="Convertible notes payable">365,000</span> and $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zGDLoRiCyxh" title="Convertible notes payable">225,000</span>, respectively, in <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zqwZx4citFg4" title="Interest rate"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zzZ1LFFS3Mg3" title="Interest rate">6</span></span>% convertible notes (the &#8220;2022 Convertible
Notes&#8221;), which bore <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z5SRnogjh75e" title="Interest rate"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zulLgLSgXCz6" title="Interest rate">6</span></span>% interest (which would be waived upon a conversion event), were repayable on December 31, 2024,
and were convertible upon the completion of the Company&#8217;s initial public offering or other liquidity event at <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zIkIVWHdFLo7" title="Debt instrument conversion rate"><span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zNp9Sn8aTy3d" title="Debt instrument conversion rate">50</span></span>% of the per share
price paid by investors in such an event. In addition, if the 2022 Convertible Notes were not converted during the period 12 months after
their initial issuance, the outstanding principal amount of the 2022 Convertible Notes would be increased by <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zlYP9u9a0jFd" title="Interest rate"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zTGMOJrwbLzl" title="Interest rate">10</span></span>%. The Company received
net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zxtsxaAEaMm6" title="Promissory note"><span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zsqVooPhdkD6" title="Promissory note">525,715</span></span> from the 2022 Convertible Notes, after deducting a total of $<span id="xdx_905_eus-gaap--PaymentsForFees_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zFnz4XMrMQ35" title="Fees paid"><span id="xdx_90F_eus-gaap--PaymentsForFees_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zOLqo5nrMuP2" title="Fees paid">64,285</span></span> in fees paid to Boustead Securities LLC
for services provided as placement agent for the offering. Boustead also received warrants in connection with the issuances with a total estimated fair value of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220208__20220208_zfx0Ekvr8o1b" title="Warrants issuance"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220311__20220311_zZro2KRDmNX1" title="Warrants issuance">92,336</span></span> (see
discussion below) and the Company incurred $<span id="xdx_902_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220208__20220208_zA0uTo9mqO9i" title="Debt issuance costs"><span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220311__20220311_zlztB8r0gx7g" title="Debt issuance costs">17,363</span></span> in additional costs which were recorded as debt issuance costs upon issuance of the
2022 Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assessed the embedded features of the 2022 Convertible Notes and determined that the automatic conversion feature with a <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z5IAgS7IL8j2" title="Debt instrument conversion rate">50</span>%
discount to per share price paid (a share-settled redemption feature) and the <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zXVSuxRrisQ7" title="Principal increase decrease rate">10</span>%
principal increase feature were not clearly and closely related to the debt host instrument and met the definition of a derivative
and as such, required bifurcation from the 2022 Convertible Notes. The Company estimated the fair value at issuance of these
features to be $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z6H0bw1GU022" title="Convertible Notes">221,000</span>
and recorded as a discount to the 2022 Convertible Notes (see Note 8 for fair value considerations). Of the total $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeIKoXaDnoRl" title="Debt issuance costs related party">173,984</span> of
issuance costs incurred related to the 2022 Convertible Notes, the Company allocated $<span id="xdx_904_eus-gaap--PaymentOfFinancingAndStockIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zKum10API6K6" title="Debt issuance costs related party">108,858</span> of the debt issuance costs to the 2022
Convertible Notes (as a discount) and $<span id="xdx_907_eus-gaap--PaymentsOfDerivativeIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zcmsPGjnjx24" title="Payments of derivative issuance costs">65,126</span>
allocated to the derivative liability and expensed as a component of the finance fee (as restated)
in the statement of operations. The discount on the 2022 Convertible Notes was amortized under the effective interest method through
the maturity dates of the notes. The Company recognized amortization expense of $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zLem4dHIES25" title="Amortization expense">37,745</span>
related to the discount on the 2022 Convertible Notes as interest expense in its statement of operations for the year ended December
31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
services provided in the offering, Boustead Securities LLC also received warrants to purchase <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zYRM3ija2OU9" title="Interest rate">10%</span> of the shares of common stock
issuable upon conversion of the 2022 Convertible Notes, at the conversion price of the notes. Upon conversion, the warrant became
exercisable for a total of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zgtdsATR8uhj">2,582</span>
shares of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zD1w3meaWV4l">16.00</span>
per share. These warrants were accounted for under ASC 718 and classified as liabilities due to the fact that the conversion of the
2022 Convertible Notes would impact their fair value. The fair value at issuance of the warrants was estimated as $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zhF1rI2RViwa">92,336</span>
using a Black-Scholes model, with inputs that included an estimated fair value of the Company&#8217;s common
stock of $<span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220101__20221231_zvAeKYk7lF56" title="Conversion price per share">32.00</span>, an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221231_zphB410M6SZ3" title="Common stock trading price per share">16.00</span> per share (based on the estimated conversion terms), a five year term, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20221231__20221231_zsbef1bln51b">86.1%</span> volatility and
a risk free rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zQP9ACdPtKXh">1.81%</span> to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKPFT8LVZdda">1.96%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the 2022 Convertible Notes were automatically converted into the securities issued by the Company
to the investors in the initial public offering, at a discounted price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zaZSeiFu6ENl">32.00</span>
per unit. Consistent with the investors in the initial public offering, the 2022 Convertible Note holders received <span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z2KIozp5gaNb" title="Common stock">18,438</span>
shares of common stock and warrants to purchase <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zbCa8RGTqZJg" title="Warrant">18,438</span>
shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zg1CenawUwSc">0.08 </span>per
share. The warrants issued to the 2022 Convertible Note holders were immediately exercised. Pursuant to the automatic exercise of
the share-settled redemption feature, the Company accounted for the conversion as an extinguishment of debt. The Company recognized
the issuance of the shares of common stock and warrants at their estimated fair value, and recorded a loss on extinguishment of
$<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zlQ9GDshnun5">310,621</span>
based on the difference between the estimated fair value ($<span id="xdx_907_eus-gaap--GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c20220101__20221231_zNe91AEjzuI8" title="Gain (loss) on sale of assets and asset impairment charges">1,198,438</span>) and the net carrying amount of the 2022 Convertible Notes
(including the carrying value of the bifurcated derivative liabilities, which were adjusted to then fair value upon settlement). The
accrued cash interest was waived upon conversion and was included as a component of the loss on extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August
2022 Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, the Company issued promissory note units, consisting of an aggregate $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zYMm3h2Z6Jla" title="Convertible notes payable">50,000</span>
in <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zdmGRqygbDSh" title="Interest rate">10</span>%
promissory notes with a maturity date of July 31, 2023 (the &#8220;August 2022 Promissory Notes&#8221;) and warrants to purchase <span id="xdx_904_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zKExtJPYWj6" title="Notes issued">2,500</span>
shares of common stock exercisable at a price of the lesser of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zDLw326Qekd8" title="Exercise price">20.00</span>
per share or <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zUJI3EnS6Bf6" title="Debt instrument conversion rate">50</span>%
of the per share price paid in the Company&#8217;s initial public offering. In addition, the Company issued convertible note units,
consisting of an aggregate of $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zJG5INTNLW83" title="Convertible notes payable">75,000</span>
in <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zneO0eW0aEY" title="Interest rate">6</span>%
convertible notes with a maturity date of December 31, 2024 (the &#8220;August 2022 Convertible Notes&#8221;, and collectively, the
&#8220;August 2022 Notes&#8221;) and warrants to purchase <span id="xdx_90D_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zDCuroyddOQ5" title="Notes issued">3,750</span> shares of common stock exercisable at a price of the lesser of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zVaVSQ1CrCl3" title="Exercise price">20.00</span> per share or
<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zQumnPGZM0ch" title="Debt instrument conversion rate">50</span>% of the per share price paid in the Company&#8217;s initial public offering. The Company received net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfDebt_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zN0SEm1WMah8" title="Promissory note">50,000</span>
upon the issuance of the August 2022 Promissory Notes, $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z83ZCk3k6UHh" title="Convertible notes payable">25,000</span>
upon the issuance of the August 2022 Convertible Notes (non-related party) and $<span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zrWY6Dw0HyQj" title="Proceeds from note payable-related party">50,000</span>
upon the issuance of the August 2022 Convertible Notes issued to a related party (as detailed in Note 5 above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company assessed the embedded features of the August 2022 Promissory Notes and determined that the accelerated repayment upon an initial
public offering represented a derivative feature requiring bifurcation. The Company estimated the fair value of the derivative to be $<span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zR3hLi26HtHd">45,000</span>
at issuance (see Note 8 for fair value considerations). The Company assessed the embedded features of the August 2022 Convertible Notes
and determined that the automatic conversion feature with a <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z1vMpx7rwZQk" title="Debt instrument conversion rate">50%</span> discount to per share price paid (a share-settled redemption feature)
and the <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20220801__20220801_zL3NX9ArYLl9">10%</span> principal increase feature were not clearly and closely related to the debt host instrument and met the definition of a derivative
and as such, required bifurcation from the August 2022 Convertible Notes. The Company estimated the fair value at issuance of these features
to be $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zbf9S5mk9j5j" title="Convertible Notes">31,000</span> and recorded as a discount to the August 2022 Convertible Notes (see Note 8 for fair value considerations).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the warrants issued with the August 2022 Notes should be classified as liabilities under ASC 815, as the
settlement amount could vary based on the occurrence of the initial public offering. The Company measured the fair value of these
warrants using a Black-Scholes model with inputs that included an estimated fair value of the Company&#8217;s common stock of
$<span id="xdx_904_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220801_zNQSa6fh5Jyb" title="Conversion price per share">32.00</span>, an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801_zhDjOeqYB3Ig" title="Exercise price of warrants">20.00</span> per share, a five-year term, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220801_zTB5zBB5Z3r">80.0%</span> volatility and a risk free rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220801_zhDninb2yZ8c">2.66%</span>, and recognized them
at their full fair value of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220801_zglbH34c0Oq4" title="Estimated fair value">146,624</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of these warrants, the fair value of the bifurcated derivative liabilities and the other debt issuance costs incurred (totaling $<span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zG3VvAvMBPrb" title="Fair value measurement">27,162</span>,
including the fair value of the Boustead warrants described below), exceeded the proceeds received and as such, the Company
recorded a loss at issuance of $<span id="xdx_902_ecustom--FinanceFee_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zzVapSNIHQPb" title="Finance fee">124,786</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
in finance fee (as restated) in the statement of operations. The discount on the August 2022 Notes was being amortized under the
straight-line method, as the initial carrying value was $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zm5pd5EFmREa">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
through the maturity date of the respective notes. The Company recognized amortization expense of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z51deQhstPIe">7,661
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to the discount on the August 2022 Notes
as interest expense in its statement of operations for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities LLC acted as placement agent for the August 2022 Notes and received warrants to purchase <span id="xdx_90B_ecustom--IssuanceOfWarrantsShares_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJ3Zz8ChVC4b" title="Issuance of warrants shares">625</span> shares of common stock at an
exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zMw5BDNiLCTb" title="Share price">20.00</span> per share. The fair value of the warrants was estimated as $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zcaazmVLUtQ5">14,662</span> using a Black-Scholes model with inputs that included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_908_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zsK4QqlvOI64" title="Conversion price per share">32.00</span>, an exercise price
of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zFehufcMrrG4" title="Exercise price of warrants">20.00</span> per share, a five-year term, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z62TFWnzUBXf">80.0%</span> volatility and a risk free rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zsGSYYxEm8w6">2.66%</span>, and recorded by
the Company in stockholders&#8217; equity at issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the lender under the August 2022 Promissory Notes and one lender under the August 2022 Convertible
Notes exercised warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zIDoBp88TF2d" title="Number of warrants to purchase">3,750</span>
shares of common stock in exchange for tendering their outstanding principal balance ($<span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z3hPJeUx9oIi" title="Principal balance">75,000</span>)
on their respective notes. As the warrants being exercised were classified as liabilities, the Company accounted for the settlement
as an extinguishment of debt. The Company recognized the issuance of the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z3062R9HrRQ1" title="Principal balance">3,750</span>
shares of common stock at their estimated fair value ($<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoNotesMember_zAtoWELHHhX5">121,875</span>), and recorded a gain on extinguishment of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zAl5sY7U1d37">44,614</span>
based on the difference between the estimated fair value and the net carrying amount of the tendered August 2022 Notes. The
remaining $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zCSU5eZDdFdj">50,000</span>
outstanding under the August 2022 Convertible Notes (and owed to the related party) was fully repaid in cash during the year ended
December 31, 2022 (see Note 5), resulting in the recognition of a gain on extinguishment of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z4l3Icw5MxTd" title="Unamortized discount">2,206</span>
based on the difference between the repayment in cash and the net carrying
amount of the notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773563855680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zubp9uVS5blb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82A_zYlPRc9g3vDd">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2024, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdsDLxcAnab7" title="Common stock issued for conversion of convertible debt, shares">0</span>
    and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAT6Im2P4UUj" title="Common stock issued for conversion of convertible debt, shares">78,197</span> shares of common stock to settle $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzNUw4GTFV29" title="Debt, principal">0</span> and $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjQZ0pRzzXnh" title="Debt, principal">235,200</span> of principal and $<span id="xdx_907_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNgAcatAe9y8" title="Accrued interest settled with common stock">0</span> and $<span id="xdx_908_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvDezBijxjF5" title="Accrued interest settled with common stock">18,783</span> of interest on a convertible note and
    incurred $<span id="xdx_903_ecustom--LossOnSettlementOfConvertibleDebt_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVJTkLAL3qeg" title="Loss on settlement of convertible debt">0</span> and $<span id="xdx_906_ecustom--LossOnSettlementOfConvertibleDebt_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQlD6AmYN1Xf" title="Loss on settlement of convertible debt">71,315</span> of loss on settlement, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZOJdp03Nw5k" title="Restricted stock award granted shares">3,722</span>
    and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAJzMnDlVHLd" title="Restricted stock award granted shares">19,347</span> shares of common stock issued for vesting of restricted stock units, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2023, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg5iQH2Al9ld" title="Common stock issued for conversion of convertible debt, shares">228,489</span>
    and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV8etwoNF2Wj" title="Common stock issued for conversion of convertible debt, shares">234,864</span> shares of common stock to settle $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxu4slUQep81" title="Debt, principal">1,527,750</span> and $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCjBOb1u081" title="Debt, principal">1,593,900</span> of principal and $<span id="xdx_906_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuXR7cKEL242" title="Accrued interest settled with common stock">220,689</span> and $<span id="xdx_90A_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zna8nfAjTQLa" title="Accrued interest settled with common stock">240,831</span> of interest, respectively,
    on a Convertible Note and incurred $<span id="xdx_905_ecustom--LossOnSettlementOfConvertibleDebt_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5adwDj3Cn27" title="Loss on settlement of convertible debt">415,553</span> and $<span id="xdx_90F_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOmdqL20ei81" title="Loss on settlement of convertible debt">433,807</span> of loss on settlement, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zPif5ycVXr3b" title="Number of warrants to purchase">8,909</span> shares of common stock, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_z7gEP7R4EiKj" title="Exercisable price per share">18.80</span> per share (Note 5). In addition, Alto was granted warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zrQ8PLWNTO9f" title="Number of warrants to purchase">127,260</span> shares of common stock, at an
exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zZgg2BUMc7Xk" title="Exercise price per share">18.80</span> per share (Note 5, 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpt1jpLKTnHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the six months ended June 30, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zPuNzHLoPhTh" style="display: none">Schedule of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Life (years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGmmy2OE5gHk" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">184,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_dxL_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcGkCjRORBv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance::XDX::23.21"><span style="-sec-ix-hidden: xdx2ixbrl1123">23.20</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOaykqGoQ2hl" title="Weighted Average Life (Years)">2.77</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmNPQtO3uEl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znf668NBwEk5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzfCOsHPgAd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending Balance">184,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJRjwVBNdTqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">23.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuurucvHOak" title="Weighted Average Life (Years)">2.29</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zQyMJQPWbiZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of the warrants as of June 30, 2024 is $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_c20240630_zrLHD6yyDvj7" title="Aggregate intrinsic value of warrants">0</span>. All of the outstanding warrants are exercisable as of June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s
compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKKCH4Els9Bl" title="Common stock reserved for future issuance">3,000,000</span> shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
June 30, 2024, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zXHPCQPnyPv1" title="Share granted under equity incentive plan">138,234</span> shares have been granted under the 2018 Equity Incentive Plan, of which <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zEPMg6K0JHpj" title="Number of shares vested under plan">79,395</span> shares have vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may grant restricted stock units (&#8220;RSU&#8221;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2024 and 2023, pursuant to agreements with officers and consultants, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zVRudqb7T8d8" title="Restricted stock award granted shares">28,455</span> and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zycSAg4ekbQj" title="Restricted stock award granted shares">53,455</span>,
respectively and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zi8Vr62kbj4h" title="Restricted stock award granted shares">4,291</span> and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zcc9v726PQEi" title="Restricted stock award granted shares">7,416</span>
RSUs, respectively with a value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zVLqaWWaF1Jf" title="Restricted stock award granted value">100,000</span> and $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zahRoVeuXWG1" title="Restricted stock award granted value">141,840</span>,
respectively, and $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zSVjDqdcDh89" title="Restricted stock award granted value">47,400</span> and $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zR3yQfkAExvf" title="Restricted stock award granted value">95,400</span>,
respectively, were granted and compensation expense for RSUs of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBfWRddBcxxl" title="Share based compensation">182,611</span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGHgu9ZQqXGj" title="Share based compensation">57,855</span>,
respectively, was incurred. During the three and six months ended June 30, 2024 and 2023, $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQouVId4nEB4" title="Compensation under research and development">13,033</span>
and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3hX2VAYfkDf" title="Compensation under research and development">46,986</span>,
respectively, and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvDFsIQLsC4d" title="Compensation under research and development">41,190</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9XvLM6eXVtg" title="Compensation under research and development">41,190</span>, respectively was included in compensation under Research and Development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, there was $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zV8lrdvvbUV9" title="Unrecognized compensation cost">190,779</span> of unrecognized RSU compensation cost related to non-vested stock-based compensation arrangements
which is expected to be recognized over a weighted-average period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrbVlRGnz8t6" title="Weighted average term">1.97</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zuu6KI1jjRoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zFcZXEx7rJsb" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value Per RSU</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Outstanding, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVRgs3QKydz5" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">24,731</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaBR0c6rk6W" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">11.76</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGKXMKubzvhh" style="text-align: right" title="Number of Stock Option Outstanding, Granted">53,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5h9v578mi67" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXBbyqQ5zQ7i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Vested">(19,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpWt13yUHaGb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">7.58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding, June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqeDXbv4Uwll" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Outstanding, Ending Balance">58,839</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYvZB97qXPK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance">4.87</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zwD6B45yNhl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rights
Offering and Financing Commitment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase agreement
(the &#8220;Purchase Agreement&#8221;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed to commit
to purchasing from the Company $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207_zIZlzOJYfMOb" title="Sale of stock consideration received per transaction">2,250,000</span> of units from the Company, with each Unit consisting of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207_zy6wBKPtpeih" title="Share based compensation arrangement by share based payment award description">(i) one share of the Company&#8217;s
common stock, (ii) a warrant to purchase one share of the Company&#8217;s common stock exercisable at a purchase price of $18.80 per share,
and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a
22% interest in Diagnostics.</span> Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90%
of the VWAP of the Company&#8217;s common stock for the five trading days immediately preceding closing. The parties entered into the
Purchase Agreement in anticipation of the Company commencing a rights offering (the &#8220;Rights Offering&#8221;) pursuant to which
the Company intends to offer a total of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207_zsS8UX9UTZ91" title="Proceeds from issuance of common stock">4,500,000</span> of Units to existing stockholders, which includes the $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207_zvqqAGepJnKe" title="Sale of stock consideration received per transaction">2,250,000</span> of Units being sold
to SRO LLC, an entity which is controlled by Keith Moore, Executive Chairman of Boustead &amp; Company Limited, an affiliate of Boustead.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company filed an initial registration statement on Form S-1 (the &#8220;Form S-1&#8221;) with the SEC in April 2024 related to the
registration of subscription rights to purchase the Units to be sold in the Rights Offering. The Form S-1 has not been declared
effective as of the date these unaudited condensed consolidated financial statements were issued. Upon the Form S-1 being declared
effective, the Purchase Agreement allows SRO LLC up to 60 days to raise the initial $<span id="xdx_90D_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zJpaFIvFceI3" title="Escrow deposit">2,250,000</span>,
which funds will be placed in escrow with Sutter Securities, Inc. (&#8220;SSI&#8221;), an affiliate of BSL, pursuant to the terms of
an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI on February 7, 2024 (the &#8220;Escrow
Agreement&#8221;). The funds will remain in escrow up until closing on the Rights Offering. In addition, in the event the Company
fails to raise the full $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBuFf9clofx7" title="Right offering">4,500,000</span>
in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant to which it would have the right to purchase any remaining
Units not purchased by existing Company stockholders in the Rights Offering, up to an additional $<span id="xdx_900_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaqSR8vowk6j" title="Escrow deposit">2,250,000</span>
(the &#8220;Back-up Contingency&#8221;). <span id="xdx_90C_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlfeowy1ptsb" title="Initial public offering description">Unless
the parties waive the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the
Company&#8217;s existing stockholders, the Company will not close on the offering and any funds raised and held in escrow will be
returned to investors</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with its entry into the Purchase Agreement, on February 7, 2024, the Company entered into a placement agent and advisory
services agreement (the &#8220;Placement Agent Agreement&#8221;) with BSL, pursuant to which BSL and BSL&#8217;s affiliates will provide
the Company with regular and customary financial consulting advice and will act as placement agent, on a best efforts basis, for the
Rights Offering. In exchange for its services, BSL will receive a commitment fee equal to $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zamAQiHKQ0Z" title="Commitment fee">112,500</span> upon the earlier of the Company filing
the registration statement on Form S-1 registering the Rights Offering or upon such date as the Company terminates the Rights Offering,
a commission equal 8% of the gross proceeds disbursed to the Company upon closing the Rights Offering, and $<span id="xdx_906_eus-gaap--OtherGeneralExpense_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zX9SmJTVysWe" title="Related expense">40,000</span> in diligence and related
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, the Company has incurred $<span id="xdx_90C_eus-gaap--DirectOperatingCosts_c20240101__20240630_zMx62q2PKDIl" title="Direct cost">142,000</span>
in costs directly related to the planned Rights Offering and initially deferred these costs as other current assets in the unaudited
condensed consolidated balance sheet. However, since that date, the Rights Offering has not been consummated and, therefore, the
deferred costs have been expensed. As of June 30, 2024, there were no deferred costs recorded on the Company&#8217;s unaudited condensed consolidated
balance sheet. Subsequent to June 30, 2024, the Company is pursuing other financing options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRCb1RVFvgkc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 - <span id="xdx_825_zr458jZvyJC5">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231_zZds9nkiSPPl" title="Common stock issued for conversion of convertible debt, shares">297,625</span>
    shares of common stock to settle $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRAn1fkxWHy9" title="Debt, principal">1,925,700</span> of principal and $<span id="xdx_90B_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jBXJnIxDLa" title="Accrued interest settled with common stock">294,927</span> of interest on a Convertible Note and incurred $<span id="xdx_908_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBMO1eJwiZXi" title="Loss on settlement of convertible debt">477,221</span> of
    loss on settlement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z96iryR5Kbn2" title="Common stock issued for conversion of convertible debt, shares">10,650</span>
    shares of common stock issued for vesting of restricted stock units.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20220101__20221231_zK4bFGW68v1d">105</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for conversion of $<span id="xdx_90F_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20220101__20221231_zCR0LvynQrpk">16,340
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of accrued interest</span>.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--CommonStockVestingOfRestrictedStockUnit_c20220101__20221231_zTGhXRDb9rbf" title="Common stock vesting of restricted stock unit">3,500</span>
    shares of common stock upon vesting of restricted stock units.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--StockIssuedUponCompletionShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm82jSpb10G9" title="Common stock issued for cash, shares">352,443</span>
    shares of common stock upon completion of the Company&#8217;s initial public offering (including the exercise of the underwriter&#8217;s overallotment option),
and the immediate exercise of warrants issued as part of the IPO Units, for net proceeds of $<span id="xdx_90D_ecustom--StockIssuedUponCompletion_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztBO8w1FCG9i" title="Stock issued upon completion">9,951,356</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredShares_pp0p0_c20220101__20221231_zMXs1V3yATd" title="Number shares issued for conversion of note, shares">42,113</span>
    shares of common stock upon the automatic conversion of preferred shares and <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesConversionOfDividends_pp0p0_c20220101__20221231_zeGN8oiBf77k" title="Number shares issued for conversion dividends payable, shares">12,553</span>
    shares of common stock to settle cumulative dividends on the preferred shares totaling  $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueDividendsPayable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxo9SNpEoe9d" title="Common stock issued for dividends payable">402,064</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zxyDKKIWjKuk">36,876</span>
                                                                              shares of common stock issued to the lenders upon conversion of the 2022 Convertible Notes, including <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_z1Xao5Bob1b1" title="Number of shares of common stock issued for exercise of warrants">18,438</span>
                                                                              shares of common stock issued upon the conversion of the 2022 Convertible Notes into units with an estimated fair value of
                                                                              $<span id="xdx_909_eus-gaap--GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c20220101__20221231_zbf8lmaUR3k9">1,198,438</span> at settlement, and <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zrdc6TSg0esi">18,438</span>
                                                                              shares of common stock upon the exercise of the common stock warrants, for total proceeds of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zr3w3mA5VSn5">1,475</span>.</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A total of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThousandTwentyOneNotesMember_zcDW6A0xy2Ql">66,250</span>
                                                                              shares of common stock upon the exercise of warrants and settlement of the December 2021 Notes and certain August 2022 Notes .
                                                                              Includes <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zPGVu9X1DeC1" title="Shares exercised">62,500</span> shares of common stock issued upon the exercise and settlement of the December 2021 Notes with an estimated fair
                                                                              value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231_zjIknkL1dEr" title="Common stock issued for cash upon initial public offering and exercise of warrants">2,031,249</span> and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231_zQbLTUGQQzi5" title="Principal balance">3,750</span> shares of common stock issued upon the exercise and settlement of certain August 2022 Notes with an
                                                                              estimated fair value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoNotesMember_zJolIab5z3z">121,875</span>.</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zHEE3kox8S48">22,535</span> shares of common stock upon the cashless exercise of warrants issued
to Boustead Securities LLC for placement agent and underwriter services provided to the Company</p>
</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#8217;s
common stock upon the closing of the sale of shares of common stock to the public in a qualified offering (at a 10% discount to the
initial public offering price, as set forth in the Series A certificate of designation) or upon listing of the Company&#8217;s
common stock on a national securities exchange at a fixed price. The Series A Preferred Stock, while outstanding, accrued cumulative dividends at a
rate of <span id="xdx_908_ecustom--CumulativeDividendsPercentage_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBwB2pdVcS3h" title="Cumulative dividends percentage">8.5</span>%
per annum. In addition, the Series A Preferred Stock is callable by the Company, at a price equal to the stated value of the Series
A Preferred Stock ($<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdvc3pjAqQeh" title="Preferred stock value share">1,000</span>
per share), plus accrued and unpaid cumulative dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company and holders of the Series A Preferred Stock agreed to modifications of the Series A certificate of designation
which changed the definition of a &#8220;Qualified IPO&#8221; by lowering the minimum required proceeds to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220430__srt--RangeAxis__srt--MinimumMember_ze0aX768wD2h">10,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and removing the minimum per share IPO price,
and changed the conversion price upon the listing of the Company&#8217;s common stock from $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220401__20220430__srt--RangeAxis__srt--MinimumMember_zua3GSvpnDZ5">99.92
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to $<span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220401__20220430__srt--RangeAxis__srt--MaximumMember_zgy4dbYdgdv9">40.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company determined that these
changes represented a substantial change in the terms of the Series A Preferred Stock and accounted for the changes as an extinguishment.
The Company recognized the excess of the post-amendment fair value of the Series A Preferred Stock over its carrying value as a deemed
dividend of $<span id="xdx_90E_ecustom--DeemedDividend_c20220101__20221231_zISNNccnJ8b" title="Deemed dividend">439,427</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which increases net loss attributable to common stockholders during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 and upon completion of its initial public offering, the Company converted <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXJuvuls14Dg" title="Converted shares">1,213</span>
shares of Series A Preferred Stock into <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zezrTqDjoPjc" title="Stock issued for cash, shares">42,113</span>
shares of common stock, based on a conversion price of <span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionRatio_iI_uPure_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXiemcZ6GUL2" title="Conversion price percentage">90</span>%
of the per share IPO price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXWzm5lHgLsd" title="Share price">32.00</span>
per share, resulting in a discounted conversion price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhe5cDcFIHUi" title="conversion price">28.80</span>
per share. Based on the nature of the settlement (as the exercise of a share-settled redemption feature) the Company recognized
a deemed contribution of $<span id="xdx_90D_ecustom--DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_c20220101__20221231_zCwQGOw28NSl" title="Deemed contribution">31,423</span> during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company accrued $<span id="xdx_901_eus-gaap--CumulativeDividends_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2gKCbTpzqQf" title="Cumulative dividends">71,009</span> for the <span id="xdx_909_ecustom--CumulativeDividendsPercentage_dp_uPure_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGEXxzV26fXb" title="Cumulative dividends percentage">8.5</span>% cumulative dividends on the Series A Preferred stock, and
as of the date of conversion of the Series A Preferred Stock, the total cumulative dividends accrued were equal to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuSkbBGJR2bd" title="Stock issued for conversion, vallue">402,064</span>. Upon the
conversion of the Series A Preferred Stock, the cumulative dividends were also converted into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGWSrwY7YB0g" title="Cumulative dividends, shares">12,553</span> shares of the Company&#8217;s common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the Company had no shares of Series A Preferred Stock outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--WarrantsDescription_c20220101__20221231_zhMFkvoqAKeg" title="Warrants description">The
Series A Preferred Stock sold in the Company&#8217;s 2018 and 2019 private placement offerings included warrants to be issued upon
the earlier of a closing of the sale of shares of common stock to the public or upon a listing of the Company&#8217;s common stock.
The warrants will be exercisable for a period of three years after the date of issuance at an exercise price contingent on the terms
of the public offering. The initial form of the warrants were expected to include contingent call features based on the terms of the
public offering. As originally drafted, if an initial public offering occurs at a price at or above $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zSPV5KxElvHk" title="Class of warrant or right, exercise price of warrants or rights">111.04</span>, then the warrants are
callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise price. In the scenario where the common
stock is listed with a common stock issuance price below $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zKLZSjEWej99" title="Class of warrant or right, exercise price of warrants or rights">111.04</span>, then the warrants are callable if the 20-day VWAP of the common
stock is at or above the $<span id="xdx_907_ecustom--WarrantSharePrice_iI_c20221231_zwhTOC8pVm83" title="Warrant share price">166.56</span> exercise price. Upon the issuance of the warrants in September 2022, the contingent call features
were not included in the agreements. Given the variability in the number of warrants and exercise price, the detachable warrants
contained terms and features that gave rise to liability classification.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2022, the Company modified the terms of the Series A Preferred
Stock as discussed above. These modifications impacted the potential terms of these contingently issuable warrants (potential warrant
shares and exercise price). The impact of this modification was reflected in the fair value of the warrant obligation recorded during
the interim periods within the year ended December 31, 2022. Upon
completion of our initial public offering, the Series A Preferred Stock was converted, and warrants were issued in relation to the conversion,
with each warrant then exercisable at the equivalent of the per share initial public offering price. In total, the Company issued warrants
to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhjYBEwkaq45" title="Warrants shares">42,113</span> shares of common stock, at an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z07rLdSPBaXg" title="Share price">32.00</span> per share in settlement of this warrant obligation. In addition,
upon the issuance of these warrants, the Company reassessed the classification accounting and concluded that the issued warrants met
the requirements for classification in stockholders&#8217; equity. The Company reclassified the then fair value of these warrants, totaling
$<span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6rHDj3XOS1j" title="Additional paid in capital">756,723</span>, to additional paid in capital in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liability related to the Series A Preferred Stock was $<span id="xdx_90A_ecustom--WarrantLiability_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zijLF2pHWOn7" title="Warrants liability">0</span>
as of December 31, 2022. For the period ended December 31, 2022 (prior to reclassification), the change in fair value of warrant
obligation liability was a loss of $<span id="xdx_90C_ecustom--WarrantObligationLiability_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1BslpzMON86" title="Warrants obligation liability">421,768</span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Warrants Issued to Boustead as Placement Agent
or Underwriter</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For services provided in relation to the 2022 Convertible
Notes and August 2022 Notes offerings, Boustead received warrants to purchase <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220831_zlaXxGjIK6u2" title="Interest rate">10%</span> of the shares of common stock issuable upon conversion
of the 2022 Convertible Notes, at the conversion price of the notes. Upon conversion, the warrant became exercisable for a total of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zzZCbYOypgg5">2,582</span>
shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zxYSEOIYeGQ9">16.00</span> per share. These warrants were accounted for under ASC 718 and classified as liabilities
due to the fact that the conversion of the 2022 Convertible Notes would impact their fair value. These warrants were exercised on a cashless
basis in September 2022. The Company reclassified the then fair value of the warrants of $<span id="xdx_909_ecustom--WarrantLiabilitiesExercised_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsWthAVovwJ4" title="Warrant liabilities exercised">64,140</span> at the initial public offering to equity, with the estimated
fair value based on a Black-Scholes model, with inputs that included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831_zEX66QT8buA" title="Conversion price per share">32.50</span>,
an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831_zoa3je9Yw6Kb" title="Exercise price of warrants">16.00</span> per share, a remaining term of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220831_z7pwhPfE80Ud">4.5</span> years, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220831_zegwdnEEv8cd">82.5%</span> volatility and a risk free rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220831_ze2LVFKjUYKj">3.43%</span>. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Boustead acted as placement agent for the August 2022
Notes and received warrants to purchase <span id="xdx_904_ecustom--IssuanceOfWarrantsShares_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zBWMmocLKco4" title="Issuance of warrants shares">625</span> shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801_zlLQGpblHuI3" title="Exercise price of warrants">20.00</span> per share. These warrants were classified
in equity and exercised on a cashless basis in September 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Boustead additionally received a warrant to purchase
<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zP9zmXLeAhEc" title="Four year warrant to purchase">21,453</span> shares of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zo1W4YbGHOAa">97.52</span> per share upon the closing of the IPO. These warrants were classified in
equity and exercised on a cashless basis in September 2022. Upon the closing of the overallotment option to the IPO, Boustead received
an additional warrant to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_znYBxCL7ikwl" title="Four year warrant to purchase">3,218</span> shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIFBmHSGKKoi">97.52</span> per share. The Company determined that these warrants should be classified in equity.
The fair value of the warrant issued at the closing of the IPO was estimated to be $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zUZUtgjgxeQ5" title="Fair value adjustment of warrants">426,752</span> using a Black-Scholes model, with inputs that
included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_90F_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zUEfIv8BIgM3" title="Exercise price">32.50</span>, an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zXA1uFVP0yQ6" title="Exercise price of warrant">97.52</span> per share, a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zDGIsWnXriP3" title="Warrant term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl3052">five-year</span></span> term,
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zC6zYGIE33ha" title="Volatility rate">101.8</span>% volatility and a risk free rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_z5q1wYXMoDc3" title="Risk free rate">3.27</span>%. The fair value of the warrant issued at the closing of the overallotment option was estimated
to be $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zMEmyrWnrd5h" title="Fair value adjustment of warrants">111,296</span> using a Black-Scholes model, with inputs that included an estimated fair value of the Company&#8217;s common stock of $<span id="xdx_901_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zCkzORPa939j" title="Exercise price">50.88</span>,
an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBAJJgavIVIi" title="Exercise price of warrant">97.52</span> per share, a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBlCg0hh75ij" title="Warrant term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl3064">five-year</span></span> term, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsJZMdsOaRmg" title="Volatility rate">101.4</span>% volatility and a risk free rate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zXxjeYY46rya" title="Risk free rate">3.74</span>%. The fair value of these warrants
was recorded to additional paid in capital and represented an issuance cost of the initial public offering (recorded as a deduction to
additional paid in capital). These warrants remain outstanding
as of December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Alto Opportunity Master Fund, SPC</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zam6FgbDoIvd" title="Number of warrants to purchase">8,909</span> shares of common stock, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_ziFSekf5Pqm7" title="Exercisable price per share">18.80</span> per share (Note 6). In addition, Alto was granted warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zxfR1IUHlnT6" title="Number of warrants to purchase">127,260</span> shares of common stock, at an
exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zCr58QMvgMwh" title="Exercise price per share">18.80</span> per share (Note 6, 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zQPSvyFjdRPc" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance">62,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance">8.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUtrsMLQInh5" title="Weighted average life (years), outstanding balance">4.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of warrants outstanding, granted">270,910</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price, outstanding granted">14.57</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted average life (years), granted">4.68</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9CkaYjHRKW6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, exercised">(285,579</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zcPe5lHTomfb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding exercised">9.58</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8212;</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance">47,831</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance">35.77</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted average life (years), outstanding balance">2.78</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - Boustead</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted">8,909</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted">18.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted average life (years), granted">5.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Granted - Ayrton</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted">127,260</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted">18.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted average life (years), granted">4.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance">184,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance">23.21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted average life (years), outstanding balance">2.77</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
    warrants include those granted on the issuance of the August 2022 Promissory Notes</span> (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoPromissoryNotesMember_z8eerCsA7Vic" title="Granted warrants, shares">3,750</span> warrants); Notes Payable &#8211; Related
    Parties  (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zRpN5cBP0s45" title="Granted warrants, shares">2,500</span> warrants); upon conversion of the
    Series A Preferred Shares (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zScqfutTyNe1" title="Converted shares issued">42,114</span> warrants);
    automatic conversion of the 2022 Convertible Notes  (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyTwoConvertibleNotesMember_zts6c3ymErAi" title="Granted warrants, shares">18,447</span> warrants); issued during the IPO, including overallotment option (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8ldYZ9uZqP4" title="Number of shares issued">176,222</span> warrants) and issued to Boustead Securities LLC  (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--BousteadSecuritiesLLCMember_zWH28ubFIhwb" title="Number of shares issued">27,877</span> warrants).</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercised warrants include the exercise of the warrants
issued with the December 2021 Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyOnePromissoryNotesMember_z3vUeINzv4nc" title="Number of shares issued">62,500
</span>warrants); the exercise of the warrants issued with the August 2022 Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zUXECz6R3mD5" title="Number of shares issued">3,750
</span>warrants); the exercise of the warrants issued upon conversion of the Convertible Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zV8n48EOlaxg" title="Converted shares issued">18,447</span>
warrants); and the exercise of the warrants issued during the IPO, including overallotment option (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiePm976S3i" title="Number of shares issued">176,222</span>
warrants), and warrants exercised on a cashless basis (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zBFrdGlEuIid" title="Number of shares issued">24,660</span>
warrants).</td></tr>
  </table>
<p id="xdx_8A4_z33AkX1pnRpc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of the warrants as of December 31, 2023 is $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20231231_zEluMLI6PNGh" title="Aggregate intrinsic value of warrants">0</span>. All of the outstanding warrants are exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s
compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zrwC5T6Afeh" title="Common stock reserved for future issuance">3,000,000</span> shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
December 31, 2023, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zZqAzrExO8Pf" title="Share granted under equity incentive plan">84,779</span> shares have been granted under the 2018 Equity Incentive Plan, of which <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231_zdTmHNQqbfgf" title="Number of shares vested under plan">60,048</span> shares have vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may grant restricted stock units (&#8220;RSU&#8221;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, pursuant to agreements with directors, officers and consultants, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zgXIzzjME8hg" title="Restricted stock award granted shares">32,415</span> and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zr5k4LAu04y5" title="Restricted stock award granted shares">4,449</span> RSUs
with a value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zOZ0Qy75taC1" title="Restricted stock award granted value">352,400</span> and $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zlWaoMfX80Tl" title="Restricted stock award granted value">100,000</span> were granted, respectively. Compensation expense for the vesting RSUs were as follows:</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zc5RchDtdYW" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<span id="xdx_8BF_zWWEFBZRefcb" style="display: none">Schedule
of Restricted Stock Units&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_49A_20230101__20231231_zO2ONL04juDe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_495_20220101__20221231_zsR9hqKKMoLh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">(as restated)</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFSDfn5qktl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Recognized in general and administrative expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">105,582</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zP0z6A5Wtzm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Recognized in research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">66,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">131,965</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zypbbKjXmu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">181,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">237,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zBje0QYIgd4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, there was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEzBhMNnlrN8" title="Unrecognized compensation cost">231,550</span> and $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5mtOdUbbZX" title="Unrecognized compensation cost">61,111</span>, respectively, of unrecognized stock-based compensation expense
related to unvested RSUs, which is expected to be recognized over a weighted-average period of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXuwnfeYO91d" title="Weighted Average Life (Years), Outstanding Ending">1.06</span> years
and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSrNXYP6sZG7" title="Weighted Average Life (Years), Outstanding Ending">1.83</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zXV9pKVawChd" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Outstanding, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">2,017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">185.60</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Number of Stock Option Outstanding, Granted">4,449</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Granted">22.48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Vested (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE3XiT4Awrd8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested">(3,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zczNKvkuf77f" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">116.48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2022 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">2,966</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">22.48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Outstanding, Granted">32,415</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">10.88</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested (as restated)</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested">(10,650</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">12.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Ending Balance">24,731</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance">11.76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A5_zV6HtUCMIcil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773459198912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zJNmEEvXSAl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82B_zIhS88dXVUbl">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Assumptions Used in Accounting for Derivative Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_zPAPiNLbogbc" title="Number of shares warrant to purchase">127,260</span> shares of common stock,
with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_z7M6EgL6C2Ca" title="Exercise price per share">18.80</span> per share, valued at inception at $<span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230131_zJRXsooKvA1g" title="Derivative liability non-current">1,189,000</span> and as of June 30, 2024, at $<span id="xdx_90F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240630_zDBchRfCnQid" title="Derivative liability non-current">359,919</span>. The Company determined
our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy the classification as equity
instruments due to the existence of a certain net cash settlement provision that is not within the sole control of the Company. In addition,
there are certain down round provisions that could reduce the exercise price if the Company issues securities at lower prices in the
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined the Acceleration Option is an embedded derivative within the host instrument and has bifurcated it from the host
instrument and recorded it as a derivative liability valued at $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNk3tCUzaOMe" title="Derivative liability">1,442,000</span>, using a Monte Carlo simulation model. The Company determined
our derivative liability from the noteholder&#8217;s Acceleration Option for the Alto Convertible Note is not clearly and closely related
to the host and should be thus accounted for as a bifurcated derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023 ($<span id="xdx_90B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230111_z4UdVj7UHyj8">2,631,000</span> included in debt discount) and June 30, 2024 ($<span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20240630_zkjXlLQevCbe" title="Derivative fair value">360,423</span>). Key inputs for the simulation are summarized
below. The Monte Carlo simulation uses an implied VWAP for the January 11, 2023 valuation date. The implied VWAP was backsolved by setting
the summation of the parts (e.g., derivatives and debt without derivatives) equal to the cash proceeds. The simulation was then iterated
and manipulated to solve for the implied share price, which was approximately $<span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr8rjPrxTp0k" title="Share price">12.64 </span>per share (or an approximate <span id="xdx_904_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWDGDkUud5W8" title="Derivative discount percentage">14</span>% discount to the
quoted market VWAP on January 11, 2023).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zddhrcXyuLig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs for the Monte Carlo simulation as of June 30, 2024, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z7WE6Sm8yWM4" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Net cash settlement and down round key valuation inputs &#8211; warrants*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z7lnS5s2jUN9">89.76</span>% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmZc9bAYLWi3">99.20</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zENOS2CF7rv2">4.61</span>%
- <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zyedZGpSQBvj">5.48</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zxmx6iG5WaC8">3.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zRmUEyhycePc">18.80</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zw0Gt6uGAQW">2.5</span>% - <span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zdiXmuzlTMof">30</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zvnG2xSED8Zd">15</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z3NcjrfcqcJh" title="Time period (years)">0.11</span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zpUW5ldGkXt6" title="Time period (years)">2.53</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte
Carlo simulation analysis of 250,000 iterations</i></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Acceleration option key valuation inputs*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z33q7ziTcqyb">64.76</span>% - <span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zvHaxuOUsMaa">74.98</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zWe5o0ZipMb8">5.23</span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zqss6ZSDbcra">5.48</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z9VW6iGSTos3">3.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zmppDXxJVuna">15</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zTfh1HZ0FQ8e" title="Time period (years)">0</span> - <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zFH5tWpTdkS" title="Time period (years)">0.7</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_zqQfP1wZvzHb" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify"><i id="xdx_F15_z5AQlH6MsWM9">Based on a Monte Carlo simulation analysis of 250,000 iterations</i></td>
</tr></table>



<p id="xdx_8A2_zqtwNN3nAG7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zB2cIqfiiimd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BD_z0zcJjty7khd" style="display: none">Schedule of Derivative Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accelerated Feature</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance - December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwRqyS7RiOpe" style="width: 16%; text-align: right" title="Beginning balance">410,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zMg9AP4dwfr" style="width: 16%; text-align: right" title="Beginning balance">3,852</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcrO6JJ4haVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">(196,045</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zbHPKQPIrEPl" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">(1,817</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpyk9HeHJchg" style="text-align: right" title="Beginning balance">214,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zkDLUMuDhQN1" style="text-align: right" title="Beginning balance">2,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">(Gain) loss on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkYuPFzcXtak" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">145,304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zAQS817134U3" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">(1,531</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance - June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCSwKsfFnXg5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">359,919</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zGNmvRYrn13g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">504</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zf5oWZxa1N16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zM0LnaDFnXNf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82A_z4aTbusRJlK5">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Assumptions Used in Accounting for Derivative Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Alto Opportunity Master Fund, SPC</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_z11cwYracUa3" title="Number of shares warrant to purchase">127,260</span>
shares of common stock, with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zIh20NrCUX41" title="Exercise price per share">18.80</span>
per share, valued at inception at $<span id="xdx_909_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20230131_zH7frUfNB0S" title="Warrants price">1,189,000</span>
and as of December 31, 2023, at $<span id="xdx_906_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20231231_zg9NwO9znFZi" title="Warrants price">410,660</span>. The Company determined our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy
the classification as equity instruments due to the existence of a certain net cash settlement provision that is not within the sole
control of the Company. In addition, there are certain down round provisions that could reduce the exercise price if the Company
issues securities at lower prices in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined our derivative liability from the noteholder&#8217;s Acceleration Option for the Alto Convertible Note is not clearly
and closely related to the host and should be thus accounted for as a bifurcated derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023, and for each reporting period. Key inputs for the simulation are summarized below. The Monte Carlo simulation
uses an implied VWAP for each valuation date. The implied VWAP was backsolved by setting the summation of the parts (e.g., derivatives
and debt without derivatives) equal to the cash proceeds. The simulation was then iterated and manipulated to solve for the implied share
price, which was approximately $<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TLyu8dorpa" title="Share price">12.64
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (or an approximate <span id="xdx_902_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjE6Jw38fbK2" title="Derivative discount percentage">14</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount to the quoted market VWAP on January 11, 2023). Additionally, the Company estimates probability for various specific scenarios
impacting the warrant valuation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_znb7Uj9EztTl" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash settlement and down round key valuation inputs &#8211; Alto Warrants*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 78%">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z4g0dzX4U7zf">77.51</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z301m69d8Gyi">92.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZAEk7427avk">4.01</span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zgCPUuxlHzHc">5.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKg_____zynIkUyUvoc5">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zx3O4OnWlhIe">18.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability assessment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZhnjkBS7Tu6">5</span>% - <span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zyEeLFE48kV1">25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zUzGci9OyFOe">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zp3kUyM7mCF1" title="Time period (years)">0.53</span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z2QZvDKXSZc8" title="Time period (years)">3.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_985_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zzfOPZcmFp21" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance">1,189,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zoconmEERXL5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value">410,660</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Alto Acceleration Option key valuation inputs*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsLip3AEalOf">34.23</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zrecJIDgSDtl">59.15</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zJ1iIi9Tuuh5">4.68</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zzEjaz9gjDGe">5.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zq9lJmRsxA0c">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zHhUsf9wJkQl">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zBDp4x7lFOLe" title="Time period (years)">0</span> - <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zN3n43wPlwJ7" title="Time period (years)">1.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____z1a2AIcEwJo7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance">1,442,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zMZsZdoRik44" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value">3,852</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zP9EgyZUvD22">*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F10_zpHGdXc8eMz1">Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p id="xdx_8A5_z9FqO83Hz1gf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>December 2021 Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p id="xdx_892_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_zjlCwF4i7uJj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the December 2021
Notes, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative liability
as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value of the
derivative just prior to the settlement of the December 2021 Notes. Key inputs for this valuation model are summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b><span id="xdx_8B2_zjG7V0BTJGN6" style="display: none">Schedule
of Derivative Liability Valuation</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">December 2021 Notes derivative key valuation inputs</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zCCUZkonud72" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Date</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231__us-gaap--AwardDateAxis__custom--SettlementDateMember_zi03jzsAnAh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Amount due upon acceleration</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcTc9BXjF7gb" title="Amount due upon acceleration">533,699</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_902_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zWOG2jS5GJUb" title="Amount due upon acceleration">533,973</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Carrying value of December 2021 Notes at measurement date</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIEsyqfZYvLg" title="Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl3262">&#8212;</span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zcwi7FULk9jc" title="Carrying value">337,398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">IPO date</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zVBlR0B9tUP7" title="IPO date">8/31/2022</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zJw91gnzLS2j" title="IPO date">9/2/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO acceleration</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_903_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zFuITDP3UXf" title="Probability of IPO acceleration">90</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zpxKsbtLWcB9" title="Probability of IPO acceleration">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of maturity</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zzFXbd5Og0G4" title="Probability of Maturity">10</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_z7lRzYZKo0S2" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3276">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period to maturity (years)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zX1096vaLn9i" title="Time period to maturity (years)">1.00</span> years</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z6tjv8ZW9Ry1" title="Time period to maturity (years)">0.32</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discount rate</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcAOY0484Dgi" title="Discount rate">50.0</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zUkS1jzZb5c9" title="Discount rate">50.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z8IXFIyc2pgh" title="Estimated fair value">367,000</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z11mi2p3YAV3" title="Estimated fair value">162,000</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z3urm4comLn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022
Convertible Bridge Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the 2022 Convertible Notes in February and March 2022, the Company identified certain embedded features
that required bifurcation as a combined derivative liability, including the share-settled redemption of the 2022 Convertible Notes at
a 50% discount and the automatic increase in principal of 10% if conversion does not occur within 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
classified this derivative liability as a Level 3 fair value measurement and used the a with and without probability weighted scenario
model to estimate the fair value as of each issuance date of the 2022 Convertible Notes, as well as just prior to their settlement upon
the initial public offering. Key inputs for this valuation model are summarized below.</span></p>

<p id="xdx_896_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_z5brvl3KzAle" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zD9WNYfYXy6">Schedule
of Derivative Key Valuation Inputs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
    Convertible Notes derivative key valuation inputs*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    Dates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zrI7eNI0ycE5" title="Annualized volatility">75.0</span>%
    - <span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z0yV9SlEpTnf" title="Annualized volatility">82.0</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zKgfUKZ0UPn4" title="Annualized volatility"><span style="-sec-ix-hidden: xdx2ixbrl3296">&#8212;</span></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIJa6GBq3Vu9" title="Risk-free interest rate">0.6</span>%
    - <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7kAtMbqmLOb" title="Risk-free interest rate">1.2</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMKLBnZnSszd" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl3302">&#8212;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price (implied)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zusIOIenjwY5" title="Exercise price (implied)">45.52</span>
    - $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zSrzItTHe8Xl" title="Exercise price (implied)">85.92</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z59iWMKVRj15" title="Exercise price (implied)"><span style="-sec-ix-hidden: xdx2ixbrl3308">&#8212;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    IPO date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_z48Fv311BmSl" title="Estimated IPO date">8/31/2022</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zWHulQCfI3ce" title="Estimated IPO date">9/2/2022</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of default</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember_zq8jLqAQ0tdi" title="Probability of default">50</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMACi2a6YyD" title="Probability of default"><span style="-sec-ix-hidden: xdx2ixbrl3316">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of IPO or Alternative Liquidity Event</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_znwcKoeawLJg" title="Probability of IPO or Alternative Liquidity Event">45</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zT1PeOh2Neth" title="Probability of IPO or Alternative Liquidity Event">100</span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of Maturity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zlGZHJ3XRNug" title="Probability of Maturity">5</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zjjniTfeAEkc" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3324">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
    period (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_ztMKhfW5VVmg" title="Time period (years)">0.47</span>
    - <span id="xdx_904_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zwX6ZWWfyt65" title="Time period (years)">1.00</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zwYvRAgB6W9h" title="Time period (years)">0.00</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zc3b3riNCOg1" title="Estimated fair value">221,000</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z86312yZwukb" title="Estimated fair value">571,000</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p id="xdx_8AC_zgVopIKtfTcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>August 2022 Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p id="xdx_895_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_zgGEkQpbb6be" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the August 2022
Promissory Note, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative
liability as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value
of the derivative just prior to the settlement of the August 2022 Promissory Notes. Key inputs for this valuation model are summarized
below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b><span id="xdx_8B3_zXnr1bjxbu8" style="display: none">Schedule
of Derivative Issuance Valuation Inputs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-size: 10pt"><b>August 2022 Promissory Notes derivative key valuation inputs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-size: 10pt">Issuance Dates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-size: 10pt">Settlement Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Amount due upon acceleration (estimated at issuance)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zX5muKr38VWd" title="Amount due upon acceleration">50,411</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_908_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zlLZamz1oBT8" title="Amount due upon acceleration">50,438</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Carrying value of August 2022 Promissory Notes at measurement date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_90C_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zVydJGz543cb" title="Carrying value">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_908_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zj9Ng4Pbbdij" title="Carrying value">4,521</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">IPO date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zbhJNV5W9Fb5" title="IPO date">8/31/2022</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zAzR2pIn59Hh" title="IPO date">9/2/2022</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Probability of IPO acceleration</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zQN6XCDs8M2c" title="Probability of IPO acceleration">90%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zNspkjjAgVO5" title="Probability of IPO acceleration">100%</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Probability of maturity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zRY8a4wqnEzc" title="Probability of Maturity">10%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zjb0uw9A2rnf" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3356">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Time period to maturity (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIWJR1XsIxRj" title="Time period to maturity (years)">1.00</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z84rwfz9M3L5" title="Time period to maturity (years)">0.91</span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Discount rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zIO5KOr85SO8" title="Discount rate">16.03%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zipUF0l5Eyj8" title="Discount rate">18.81%</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zOHFLWCnr45d" title="Estimated fair value">45,000</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zbkhZ58Bq7H3" title="Estimated fair value">45,000</span></p></td></tr>
  </table>
<p id="xdx_8A4_zqWwxoGLbSTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p id="xdx_897_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_ziGGYyZ5pmTh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the August 2022
Convertible Notes, the Company identified certain embedded features that required bifurcation as a combined derivative liability, including
the share-settled redemption of the 2022 Convertible Notes at a 50% discount and the automatic increase in principal of 10% if conversion
does not occur within 12 months. Key inputs for this valuation model are summarized below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;<span id="xdx_8BC_zWO7z0wylKdf" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Derivative Key Valuation Inputs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">2022 Convertible Notes derivative key valuation inputs*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated IPO date</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_zYV50vMb4Kpl" title="Estimated IPO date">8/31/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zK2pnOjpOfEl" title="Estimated IPO date">9/2/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Probability of default</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z8XT09NZrZS2" title="Probability of default">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zyickfmFFPwk" title="Probability of default"><span style="-sec-ix-hidden: xdx2ixbrl3378">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO or Alternative Liquidity Event</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zViedUQmqePa" title="Probability of IPO or Alternative Liquidity Event">45</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221203__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_zeCONxG8il3e" title="Probability of IPO or Alternative Liquidity Event">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of Maturity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z70biHfaABAd" title="Probability of Maturity">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zBayx5yPk7Le" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3386">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z57pzvg3q9Nf" title="Time period (years)">1.00</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z3l5G2HZZkl6" title="Time period (years)">0.00</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zSD24dEZxe4b" title="Estimated fair value">31,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z78qN4UlNr08" title="Estimated fair value">75,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A2_zJDBxpywOaf1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zHuN5mIWCcld" style="display: none">Schedule of Derivative Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Alto Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Alto Acceleration Option</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zWuG16l7lUb4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3398">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_ztFTCUemysu2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3400">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Addition of new derivative</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zdAHyDuWCfwc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition of new derivative"><span style="-sec-ix-hidden: xdx2ixbrl3402">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance, accelerated feature">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z8RTtBdyQRV1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3404">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zPbLi4vsu6Y5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3406">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Settlements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zvjRWlcR4Oq4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"><span style="-sec-ix-hidden: xdx2ixbrl3408">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance, accelerated feature">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z227U3NgZrsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3410">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zIZ54psJBNEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3412">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivatives</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zi2intGd88Ic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives">1,189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zulYRhCn5Bo4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives">1,442,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zN2fSOlVe2Hg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">(778,340</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zl9oFisctE59" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">(1,438,148</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zqedp41mnRcc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zfSvJfrVCkJi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 2021 Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">August 2022 Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022 Convertible &#160;Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%">Balance - December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zMfR6d3t1ZTc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants">367,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zvQSmx5SZQT9" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3428">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zpfuhLUsv1Kc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3430">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--NotesDerivativeMember_zWqliR34XJic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"><span style="-sec-ix-hidden: xdx2ixbrl3432">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zaBmeMoUsWw1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative">76,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zrcnlskbqQTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative">221,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss (gain) on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_znz5bKggSfBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">(205,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zNYi4yyZGiY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">44,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_ztLRWglWKal8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">350,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Settlements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zOwd68kF1fT8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements">(162,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zHWin4V5gVni" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements">(120,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zqIBjN8wVsyj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements">(571,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zWxsN5hlwSIg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3450">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zmOWqAKHdd28" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3452">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_z224mM1Sbfoe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3454">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivatives</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zEiFnJUobl0a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"><span style="-sec-ix-hidden: xdx2ixbrl3456">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zMvnSYCrVEHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"><span style="-sec-ix-hidden: xdx2ixbrl3458">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zxo25N8sCZEj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"><span style="-sec-ix-hidden: xdx2ixbrl3460">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zlxz2dtxaAqi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3462">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zKJxXoIfZ5oi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3464">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zkRrGHyYGnb7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3466">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_z5rEzxpFNtYh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3468">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zOIIACleWQL4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3470">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zFv0uFQF4CY3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3472">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A3_zixrotcpmfIc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773462638592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party transactions</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z6Ygdi2uTzK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82C_zuRgz1jdtTz5">Related Party transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. During the six months ended June 30, 2024 and 2023, the Company expensed
$<span id="xdx_90F_eus-gaap--OtherResearchAndDevelopmentExpense_c20240101__20240630_zFANokcYPHQe" title="Research, development expense">0</span> and $<span id="xdx_90F_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20230630_zJVwkXP4auU2" title="Research, development expense">608,000</span>, respectively, related to these services.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zysAiD3uWv96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span>Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_82D_z9InGb4rQSfk" style="display: none">Related Party transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. The Company paid TCG GreenChem $<span id="xdx_909_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20221231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zs0HwiZEVXj3" title="Payments to invoices in research and development">450,000</span> during the year ended December
31, 2022 and a total of $<span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20230101__20231231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zEZHhc9Bky7j" title="Payments to invoices in research and development">1,096,370</span> during the year ended December 31, 2023, completing the contract.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773563758704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zhRykpIpCk17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_z9UOamJIec8j">Income Taxes</span></b></span></p>

<p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zuia5MsmHcik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zJ13jlUAhpRd" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></span></b></span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNnudPW8ZBD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z4DEPqCtDR89" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></span></span></span></b></span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zGX2v3cjwAYj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></span></span></span></b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zIzNnGyFJnD8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_zYL3mUjUjp33">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no income tax expense or benefit for the years ended December 31, 2023 and 2022, since the Company has a full valuation allowance
for the net operating loss carryforwards in these periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination
by the taxing authorities based on the technical merits of the position. The tax benefits recognized from such positions are estimated
based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain
tax positions to be reported for the tax years 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) amended IRC Section 174 to require capitalization of all research and development
(&#8220;R&amp;D&#8221;) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over
five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. For
tax reporting purposes, the Company capitalized $<span id="xdx_90F_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20231231_zXvHn7wdQpqg" title="Research and development expenses">3,517,485</span> and $<span id="xdx_904_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20221231_zCI5g925C8v7" title="Research and development expenses">1,488,530</span> of R&amp;D expenses incurred as of December 31, 2023 and
2022, respectively.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate">21</span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z2tRzaeOyVg3" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zdjdEVmue1Gk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zfJ37FBIxa2e" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(as restated)</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,384,472</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,049,174</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes, net of federal tax effect</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(452,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(351,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Rate change</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,710</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(409</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzspy_zFfwkzSx8Rlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R &amp; D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(240,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(69,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Return to provision adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">286,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">201,235</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_iB_zfBXR3fVjSNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Permanent differences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_i01_maITEBzspy_zFPKFfQPSv17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative Debt Discount Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">562,568</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3509">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_i01_maITEBzspy_zWZOWC4F5JIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in FMV of Warrant Liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(617,655</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">217,926</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_i01_maITEBzspy_zmAom1OVDsn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on convertible note conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">132,984</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">503,249</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_i01_maITEBzspy_zVvkEdEmZTEh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">126,012</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">169,946</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,535,466</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">377,709</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shortfall of stock compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,674</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3524">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3529">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3530">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zdVsqCFpXlch" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zPU61r3hFOe7" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(as restated)</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax asset:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,727,566</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">751,844</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3537">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">804</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Intangibles (includes Section 174 capitalization)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,197,938</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">405,172</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">423,915</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">200,715</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,251</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,626</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest &amp; other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72,140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29,336</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease asset/(liability)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,326</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,889</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,429,136</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,401,386</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(as restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Change in fair market value of securities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(19,943</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3559">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(30,544</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(46,718</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsDeferredIncome_iNI_di_zxk4s8z19xdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income tax deferred</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3564">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(60,196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,746</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3568">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(53,233</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(106,914</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,375,903</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,294,472</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,375,903</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,294,472</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3579">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3580">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zrwMVAPp8x91" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zI3yIfzm5n7c" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zaqDxtXO4WE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z1v7OlEmFVIa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income tax benefit, net of federal tax effect</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in tax rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3591">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Return to provision adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_iB_uPure_zOBXO0OlU256" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Permanent differences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_i01_pid_dp_uPure_maDEF_znJQzfgFZxP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative Debt Discount Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3603">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_i01_pid_dp_uPure_maDEF_zq633uEUFSgc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in FMV of Warrant Liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_i01_pid_dp_uPure_maDEF_zC9Kr4APSLOc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on convertible note conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_i01_pid_dp_uPure_maDEF_zRz4rIboyPlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(23.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shortfall of stock compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3618">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl3621">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3623">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3624">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_ziTYp8KTsYlh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalTaxableIncomeMember_zrG81Ug3Peyl" title="Net operatiing loss">6.4</span>
million and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--StateTaxableIncomeMember_zXVNaHVK7E06" title="Net operatiing loss">5.9</span> million of net operating losses (&#8220;NOL&#8221;) carried forward to offset federal and state taxable income, if
any, in the future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making
this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax
asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be
realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">NOLs created prior to
2018 could be carried back two years and carried forward <span id="xdx_90E_ecustom--DeferredTaxAssetsOperatingLossCarriedForward_dtY_c20230101__20231231_ztKkx6mJrK2h" title="Carried forward">20</span>
years. As amended by the Tax Cuts and Jobs Act of 2017 (TCJA), NOLs created after 2017 can no longer be carried back and are instead
carried forward indefinitely. The Company has $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2016Member_zzagpmkbLOni" title="Operating loss carryforwards">139,813</span>
and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2017Member_zflhOv8qsPn8" title="Operating loss carryforwards">238,380</span>
of federal NOL carryforwards from 2016 and 2017, respectively, which begin to expire in 2036. The Company has an additional $<span id="xdx_907_eus-gaap--CurrentFederalTaxExpenseBenefit_pn5n6_c20230101__20231231_zmwr2NmmCXT6" title="Federal income tax">6.0</span>
million and $<span id="xdx_90B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn5n6_c20230101__20231231_zwfL0wOfQM5e" title="State income tax">5.9</span>
million of federal and state NOLs created after 2017, respectively, which can be carried forward indefinitely. The NOLs can be used
to offset future income limited to the lesser of the NOL or <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_pid_dp_uPure_c20230101__20231231_zA745rNSZcVk" title="Future taxable income">80</span>%
of the year&#8217;s taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2023, the Company has $<span id="xdx_904_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_zyM9U2Dualt9" title="Federal Research and Development">360,715</span>
of federal Research and Development (R&amp;D) tax credits. These can be carried forward <span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_dtY_c20230101__20231231_zE0Rx6zu1dBh" title="Carried forward">20</span> years to offset future federal income tax.
These begin to expire in 2037. Additionally, the Company has $<span id="xdx_900_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zgHvq6C4B1f" title="R&amp;D tax credits">80,000</span> of state R&amp;D tax credits which can be carried forward seven years.
These begin to expire in 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773563844320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited and Restated)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_QuarterlyFinancialDataTextBlock', window );">Quarterly Financial Data (Unaudited and Restated)</a></td>
<td class="text"><p id="xdx_807_ecustom--QuarterlyFinancialDataTextBlock_zAj1b1gYgbM9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_82D_zMMrfyxDrHZd">Quarterly Financial Data (Unaudited and Restated)</span></b></span></p>

<p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zWSfLbAcpoNc" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zaVdbSJYZaUe">Schedule
of Quarterly Financial Data</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_804_ecustom--QuarterlyFinancialDataTextBlock_zAR4xkS5UMZb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_822_zXYsPgZKlPo1">Quarterly Financial Data (Unaudited and Restated)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is providing restated quarterly unaudited consolidated financial information as of
September 30, 2023 in the table below. See Note 2, Restatement of Previously Issued Consolidated Financial Statements, for further background
concerning the events preceding the restatement of financial information in this Comprehensive Form 10-K/A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zCJ5d5NxEJJe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restated consolidated balance sheet line items for the third fiscal quarter of 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zpA95ya3gad8">Schedule
of Quarterly Financial Data</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8jkE4tUBFO6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z81uuwNEseHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230930_z4FaFFsGclHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_zTeRcSTsNBP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Additional paid in capital <span id="xdx_F42_zJDO1gumiNob">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">19,456,841</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">29,402,533</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z9CGSTF3pEoc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,847,112</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(23,792,804</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zBq7OWkLDr08" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zuvLr0XRWxrh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital">140</span> and an offsetting adjustment to the carrying value of common stock.</span></td>
</tr></table>


<p id="xdx_8A9_zwjvQAsnkhR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The adjustments did not have an effect on the consolidated
statement of operations or cash flows for the three fiscal quarters of 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has included its restated quarterly unaudited
consolidated financial information for the interim periods ended March 31, 2023 and June 30, 2023 within Form 10-Q/A for the period ended
March 31, 2024 and Form 10-Q for the period ended June 30, 2024, respectively, filed concurrent with this Form 10-K/A.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_QuarterlyFinancialDataTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quarterly Financial Data [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_QuarterlyFinancialDataTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773563814048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zUQoX5990Tac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_827_z2gPZJ4Q7DBh">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2, Summary of Significant Accounting Policies, Reverse Stock Split, above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alto
                                            Opportunity Master Fund, SPC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2024, the Company informed the Investor in the Alto Convertible Note that the Company&#8217;s expected restatement of its consolidated
financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the Alto Convertible
Note. On August 6, 2024, the Company paid $<span id="xdx_90B_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20240806__20240806__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2ZNykpWEqLf">600,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the Investor, which funds will be held as
collateral to the balance owed under the Alto Convertible Note, and received a waiver from the Investor related to the default.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alliance Global Partners</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2024, the Company engaged A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) to serve as exclusive underwriter, placement
agent or advisor in any public or private offering or financing (as defined, the &#8220;Offering&#8221;) of up to $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240730__20240730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember__srt--RangeAxis__srt--MaximumMember_zUhRrUXZO3C2">10.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
II study of Ropidoxuridine</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2024, the Company entered into a work order (the &#8220;Work Order&#8221;) with Theradex Systems, Inc., a New Jersey contract
research organization (&#8220;CRO&#8221;) for purposes of supporting the Company&#8217;s Phase II Study of Ropidoxuridine as a Radiation
Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promotor.&#8221;
As such, Shuttle Pharma is now in the process of signing up six clinical sites where the clinical studies will be performed &#8211; two
of which have completed initial site initiation visits and one of which is ready to enroll patients &#8211; and where the CRO will oversee
such studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Work Order, the CRO will oversee the studies for a period of 53 months (the &#8220;Term&#8221;), including overseeing
and monitoring the regulatory aspects of the Phase II clinical trial, and managing the documentation surrounding the clinical trial in
exchange for a fee of approximately $<span id="xdx_903_eus-gaap--PaymentsForFees_pn5n6_c20240808__20240808__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCaIeCPJVK59" title="Exchange fee">2.3</span> million, payable in stages and based upon services performed during the Term of the study.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zgVbCW0iKpTk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 &#8211; <span id="xdx_824_zs2tFHK7qGtg">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through the date the consolidated financial statements were issued
and determined that the following items are required to be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restatement
of Previously Issued Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Bid Price Requirement Extension Granted until August 26, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 7.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2023, after the Company&#8217;s common stock had traded below $<span id="xdx_906_eus-gaap--SharePrice_iI_c20230831_zMaOM7ZhXbF7">1.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uTradingDays_c20230831__20230831_zz8MxLwLRTY8" title="Consecutive trading days">30
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consecutive trading days, the Company received
notice from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the
&#8220;Bid Price Requirement&#8221;). In accordance with Nasdaq Rules, the Company was provided with an initial period of 180 calendar
days, or until February 27, 2024, to regain compliance with the Bid Price Requirement. On February 19, 2024, the Company submitted a
plan of compliance to Nasdaq seeking an additional 180-day grace period to regain compliance with the Bid Price Requirement. On February
29, 2024, the Company received formal approval from Nasdaq granting it an additional 180 days, or until August 26, 2024, to regain compliance
&#8211; whether organically through market forces or by effectuating a reverse stock split, should such action be required. On August
6, 2024, the Company filed a certificate of amendment to its certificate of incorporation, effective August 13, 2024, to effectuate a
one-for-eight reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the &#8220;Reverse
Stock Split&#8221;). The Reverse Stock Split had no effect on the Company&#8217;s authorized shares of common stock or preferred stock.
Following the reverse stock split on August 13, 2024, the Company had a total of <span id="xdx_903_ecustom--ReverseCommonStockSharesOutstanding_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBur87NIR7jg" title="Reverse common stock shares outstanding">2,111,235
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares issued and outstanding (or <span id="xdx_907_ecustom--ReverseCommonStockSharesOutstanding_iI_c20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd7cI2lLYPFc" title="Reverse common stock shares outstanding">2,008,689
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a post-split basis as of December 31, 2024)
and trades under the new CUSIP number 925693302. All common stock share, option, warrant and per share amounts (except our authorized
but unissued shares) have been retroactively restated in these consolidated financial statements and related disclosures. Following the
Reverse Stock Split, on August 27, 2024, the Company received a written notice from Nasdaq informing the Company that it has regained
compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Approval to Proceed with Phase II study of Ropidoxuridine (IPdR)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release announcing
that the Company had received the &#8220;Safe to Proceed&#8221; letter from the U.S. Food and Drug Administration for the Company&#8217;s
investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence
the Phase II study and, as a result, the Company is currently finalizing site enrollment with &#8220;first patient, first dose&#8221;
expected in the coming months. </span>The Phase II clinical trial was also approved by the Institutional Review Board &#8220;IRB&#8221;
on June 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 8, 2024, the Company
entered into a work order (the &#8220;Work Order&#8221;) with Theradex Systems, Inc., a New Jersey contract research organization (&#8220;CRO&#8221;)
for purposes of supporting the Company&#8217;s Phase II Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in
Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promotor.&#8221; As such, Shuttle Pharma is now in the
process of signing up six clinical sites where the clinical studies will be performed &#8211; two of which have completed initial site
initiation visits and one of which is ready to enroll patients &#8211; and where the CRO will oversee such studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under the terms of the Work
Order, the CRO will oversee the studies for a period of 53 months (the &#8220;Term&#8221;), including overseeing and monitoring the regulatory
aspects of the Phase II clinical trial, and managing the documentation surrounding the clinical trial in exchange for a fee of approximately
$2.3 million, payable in stages and based upon services performed during the Term of the study.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase
agreement (the &#8220;Purchase Agreement&#8221;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed
to commit to purchasing from the Company $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJDnbJVClHRk" title="Sale of stock consideration received per transaction">2,250,000</span>
of units from the Company, with each Unit consisting of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUwwlJvcREg6" title="Share based payment award description">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $18.80
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.</span> Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90% of the VWAP of SHPH common
stock for the five trading days immediately preceding closing. The parties entered into the Purchase Agreement in anticipation of
the Company commencing a rights offering (the &#8220;Rights Offering&#8221;) pursuant to which the Company intends to offer a total
of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlQLd9zaTDXg" title="Proceeds from issuance of common stock">4,500,000</span>
Units to existing stockholders, which includes the $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEVUQW1Y2LFg" title="Sale of stock consideration received per transaction">2,250,000</span>
Units being sold to SRO LLC, an entity which is owned by Keith Moore, CEO of Boustead Securities, LLC
(&#8220;BSL&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement allows SRO LLC up to 60 days to raise the initial $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zeJXcEGJ6F95" title="Escrow deposit">2,250,000</span>, which funds will be placed in escrow with Sutter Securities,
Inc. (&#8220;SSI&#8221;), an affiliate of BSL, pursuant to the terms of an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI
on February 7, 2024 (the &#8220;Escrow Agreement&#8221;). The funds will remain in escrow up until closing on the Rights Offering. In
addition, in the event the Company fails to raise a full $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zAbw8U4vQqh" title="Right offering">4,500,000</span> in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant
to which it would have the right to purchase any remaining Units not purchased by existing SHPH stockholders in the Rights Offering,
up to an additional $<span id="xdx_905_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLidexbeXPOd" title="Escrow deposit">2,250,000</span> (the &#8220;Back-up Contingency&#8221;). <span id="xdx_901_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjbhaGD0F2h6" title="Initial public offering description">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#8217;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Restricted Stock Awarded to Chief Financial Officer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On March 8, 2024, the Company&#8217;s then CFO
was awarded <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zrFoglyhoPx1" title="Restricted stock units">12,500</span>
restricted stock units (&#8220;RSUs&#8221;), with a value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zz0X64iPXAvj" title="Restricted stock value">41,840</span>,
with such RSUs vesting in full as of the date of issuance. Each RSU represents the right to receive one share of SHPH common
stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 13, 2024, the Company&#8217;s newly appointed CFO was awarded <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240613__20240613__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRJIfmRYFdT5" title="Restricted stock units">28,455</span>
restricted stock units (&#8220;RSUs&#8221;), with a value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240613__20240613__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zn7ip2Rkozz3" title="Restricted stock value">100,000</span>,
with such RSUs vesting annually in three equal installments following the date of issuance. Each RSU
represents the right to receive one share of SHPH common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Alto Opportunity Master Fund, SPC</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2024, the Company informed the Investor in the Alto Convertible Note that the Company&#8217;s expected restatement of its
consolidated financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of
the Alto Convertible Note. On August 6, 2024, the Company paid $<span id="xdx_905_eus-gaap--ConvertibleDebt_iI_c20240806__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWhRE3Lfrsz7" title="Convertible debt">600,000</span>
to the Investor, which funds will be held as collateral to the balance owed under the Alto Convertible Note, and received a waiver
from the Investor related to the default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Alliance Global Partners </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On July 30, 2024, the Company
engaged A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) to serve as exclusive underwriter, placement agent or advisor in
any public or private offering or financing (as defined, the &#8220;Offering&#8221;) of up to $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20240730__20240730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSfHFktjdED8">10
</span>million.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773462743328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbNA1oLSmCg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zCBeclORz1k">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial statements and with the instructions to Form 10-Q
and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not
contain all information and notes required by GAAP for annual financial
statements. A complete discussion of the Company&#8217;s significant accounting policies is included in the Company&#8217;s Annual Report
on Form 10-K for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all of
the adjustments necessary to present the financial position of the Company as of June 30, 2024 and the results of operations and
cash flows for the periods presented. The accompanying condensed consolidated financial statements of the Company have not been
audited by the Company&#8217;s independent registered public accounting firm, except that the year-end consolidated balance sheet
was derived from audited financial statements. The results of operations for the six months ended June 30, 2024 are not necessarily
indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial
statements should be read in conjunction with the restated financial statements and related notes thereto for the year ended
December 31, 2023 included in the Company&#8217;s Annual Report on Form 10-K/A filed with the SEC on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zN9JmHykJAle">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p id="xdx_847_ecustom--ReverseStockSplitPolicyTextBlock_zUQwwFrvzScl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zMdaqovuKvXk">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2024, in order to meet Nasdaq&#8217;s minimum bid price requirement of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdpnAuWG6Lol" title="Minimum bid price">1.00</span>
per share (the &#8220;Minimum Bid Price Requirement&#8221;), the Company effectuated a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1d0psoH6nQc" title="Reverse stock split">1-for-8 reverse stock split</span> of its issued and
outstanding common stock, rounding up to account for any fractional shares (the &#8220;Reverse Stock Split&#8221;). The Reverse
Stock Split had no effect on the Company&#8217;s authorized shares of common stock or preferred stock and the par value will remain
unchanged at $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240813_zMXv9hl7eJbj" title="Common stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240813_z0BWOOj98It8" title="Preferred stock, par value">0.00001</span></span>,
respectively. Following the reverse stock split on August 13, 2024, the Company had a total of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zztmaLiD6Qoe" title="Common stock shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlqhzVPvDeRi" title="Common stock shares outstanding">2,111,235</span></span>
shares issued and outstanding (or <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240630_z7CZ066K6Nl3" title="Common stock shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240630_z8BjDAR117Yd" title="Common stock shares outstanding">2,106,233</span></span>
on a post-split basis as of June 30, 2024).</span> All common stock share, option, warrant and per share amounts (except our
authorized but unissued shares) have been retroactively adjusted in these financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zVRaxJZ6JGAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zi0eokpZriz4">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned
subsidiaries, Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zXzky5zRn35g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zty8POBdZ14f">Correction
of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards
Codification (&#8220;ASC&#8221;) 730. As a result, certain prior year amounts have been corrected for consistency with the current
year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial
statements in accordance with SEC Staff Accounting Bulletin No. 99, &#8220;Materiality,&#8221; (ASC Topic 250, Accounting Changes
and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed
consolidated statements of operations are not material to any previously presented financial statements based upon overall
considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated
balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes
in stockholders&#8217; equity, to these financial statements, or for any previously presented interim or annual financial
statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted
earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was
$<span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zjzxGy9n2Tqg" title="General and administrative expense">93,708</span> and $<span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zEx5IEd6PiT8" title="General and administrative expense">182,715</span>, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and
six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zUEa4AVq93g1" style="display: none">Schedule of the Error Correction</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztXtgIiL0mS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Corrected</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,944,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(182,715</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,761,466</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">281,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">182,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">464,633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i><span id="xdx_864_z51lIHBaxIod">Reclassifications</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3JEbn1v7fOi">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the
reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on
current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed
consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of
bifurcated derivative liabilities and other financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_znBsmi9qpX7i">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company
regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical
experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the
Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results
of operations will be affected. Significant estimates are contained in the accompanying consolidated financial statements for the
recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other
financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zokUH3G8A7Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zxtJnn7V0F96">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of June 30, 2024 and December 31, 2023, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zkEJLZMnX1Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zFoSdsPsZsdh" style="display: none">Schedule of Cash and Cash Equivalents</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zdf2YYEPgH92" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z0DgJpGOb3c6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zpVNW72A3ffa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">645,594</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,550,098</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zkXzbm1UOUsk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,026,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zESWBcrIg25g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">695,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,576,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zn4zpQIooYi6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240630_zFoCnqZK8quc" title="Cash FDIC insured amount">250,000</span> per institution. The
amount in excess of the FDIC insurance as of June 30, 2024 was approximately $<span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20240630_zjyRhVQqCk7e" title="Cash, uninsured amount">0.4</span> million. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zJkXkj4AZTy2">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,550,098</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5,411,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,026,318</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,005,825</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,576,416</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,417,203</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount">250,000</span> per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount">1,849,000</span>. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zewlyN8EM7Ig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zWYFKpwXUUxb">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding
balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20240630_zOxm6QfMfZeg" title="Marketable securities, outstanding balance">1.6</span>
million and $<span id="xdx_907_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20231231_zNyG7iZlRMN7" title="Marketable securities, outstanding balance">2.9</span>
million as of June 30, 2024 and December 31, 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company
recognized interest income of $<span id="xdx_90A_eus-gaap--InvestmentIncomeInterest_c20240401__20240630_zcq2CT9LGwf8" title="Interest income">14,158</span>
and $<span id="xdx_90C_eus-gaap--InvestmentIncomeInterest_c20230401__20230630_z07CBpxiZfPd" title="Interest income">19,267</span>,
realized gains of $<span id="xdx_90E_eus-gaap--GainLossOnSaleOfInvestments_c20240401__20240630_zqFcztULftf2" title="Gain on sale of marketable securities">39,683</span>
and $<span id="xdx_909_eus-gaap--GainLossOnSaleOfInvestments_c20230401__20230630_zztdgOwkA1Al" title="Gain on sale of marketable securities">1,744</span>,
and unrealized loss of $<span id="xdx_90A_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20240401__20240630_zWCIvWQwRsIf" title="Unrealized loss">27,964</span>
and unrealized loss of $<span id="xdx_907_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20230401__20230630_zVAgkZCa1xv9" title="Unrealized loss">26,534</span>,
respectively. During the six months ended June 30, 2024 and 2023, the Company recognized interest income of $<span id="xdx_903_eus-gaap--InterestIncomeExpenseNet_c20240101__20240630_zyDmZWPkZUo7" title="Interest income">35,611</span>
and $<span id="xdx_904_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630_zEhr8qDKa026" title="Interest income">35,955</span>,
realized gains of $<span id="xdx_902_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20240101__20240630_zq28xeSQy6Xd" title="Marketable securities realized gain loss">43,720</span>
and $<span id="xdx_90F_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20230630_zFgLIQUum3e7" title="Marketable securities realized gain loss">1,744</span>,
and unrealized loss of $<span id="xdx_901_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20240101__20240630_zKHoCz44OTX2" title="Marketable securities unrealized gain loss">28,670</span>
and unrealized gain of $<span id="xdx_908_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230630_ze93KZfxuNKd" title="Marketable securities unrealized gain loss">11,528</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zcIP2rrvmXK8">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance">2,887,215</span>. During the year ended December 31, 2023, the Company recognized interest income of $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income">52,855</span>,
realized gains of $<span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss">4,970</span>, and unrealized gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss">71,568</span>. The were <span id="xdx_90F_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zbAdEjByFAZi" title="Marketable securities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2316">no</span></span> marketable securities as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvCubePqHs28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zsCyT2nR28g1">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4Fjp8jYHK5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of June 30, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z04BtaXIERfc" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">June 30, 2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zExD2SVowPH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLJtGezKo55" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmfWKey4sYWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zjoqMgNxUsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLGc9i6fzSJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zxYQDrtyDMk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,642,995</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,642,995</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zDwqI7ggcyO2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,642,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,642,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zr8UHTdpBgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z9RhqCNdYVqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">359,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">359,919</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zNRORHgltpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zwgNXMGU1U4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">360,423</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">360,423</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zb7iOAM75Kdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z76zr6Fa3GUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z01v4lD9OZA8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zwkx62sH2px7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zvkOmL0nCbfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zoumSoH7GBU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zUOt3GVPWwL6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zS2K50xTTHjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zgtC2JqIWhO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zIDEG5nHspT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zm2eBRJ81m98" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zcF4kM03SRN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zsDUSByWTOL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqfmU6VxYX7j">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Marketable Securities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2328">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2333">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2334">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DerivativeLiabilityWarrants_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zLHLaG6Wpet4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative Liability - Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2343">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerivativeLiabilityAcceleratedFeature_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_z1GMbV70G7Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2347">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2348">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2352">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2353">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">414,512</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">414,512</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company had non-derivative warrant liabilities that were measured at fair value on a recurring
basis. Each of these fair value measurements was considered to be a Level 3 measurement by the Company as they used significant unobservable
inputs, such as the Company&#8217;s pre-IPO stock price, probability of event occurrence and other management estimates. The key inputs
for each of these warrant liabilities were as follows:</span></p>

<p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoMWqw0jB0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zKUJ72QdTXY5" style="display: none">Schedule
of Key Inputs of Warrant Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Series A Preferred Stock Obligation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_984_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zLyVGKOArAWd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock">40.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_982_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zgBrdL1LrT7c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated IPO or Listing terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_znoxhYjetF0l" title="Exercise price">40.00</span> - $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zArhlIcCb06d" title="Exercise price">166.56</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zp65fcqYKv7b" title="Exercise price">32.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Series A Preferred Stock conversion shares upon IPO or Listing at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_ztMXqnmuU9cb" title="Number of warrants">12,135</span> - <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zMp7IKseQgnc" title="Number of warrants">33,681</span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7zVZKsduoz2" title="Number of warrants">42,101</span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdcX1kzMoQCd" title="Warrants and rights outstanding measurement input">86.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zW1kmGuIywhe" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z78eGWXIszP4" title="Warrants and rights outstanding measurement input">1.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zbRqcuFc7Kx4" title="Warrants and rights outstanding measurement input">3.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated IPO date</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7abpz07AmNb" title="Estimated IPO date">9/30/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zreHcuEZR3gi" title="Estimated IPO date"><span style="-sec-ix-hidden: xdx2ixbrl2385">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated Term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z815JlVntnri" title="Estimated Term">3.75</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z1GevZdwSlle" title="Estimated Term">3.00</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO or Listing Occurring</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zkuIhmucDUIl" title="Warrants and rights outstanding measurement input">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zP3rqfuREZce" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2393">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO as &#8220;Qualified IPO&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKZbZZdwX904" title="Warrants and rights outstanding measurement input">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zAVfbA32ifU9" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2397">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of IPO as &#8220;Listing&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zao8vkaRcnof" title="Warrants and rights outstanding measurement input">67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKRwLLcGWTNc" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2401">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdV5UMoJ21Bj" title="Estimated fair value">334,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z0UVRkniDVEg" title="Estimated fair value">756,723</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification/Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9nZuNwXlNZ9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9B1oFEU8qSd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zL1GvJpV5Cld" title="Exercise price">20.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z7OvmG4tIEqi" title="Exercise price">20.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Number of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zZ3lsYq0BOS3" title="Number of warrants">6,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zWW3jeBT6Epe" title="Number of warrants">6,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zsUhFnC28Jl7" title="Estimated Term">5.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zmfGu7F5nHW3" title="Estimated Term">4.9</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zBV3c4wuqEq3" title="Warrants and rights outstanding measurement input">80.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z0zoN4DV2El9" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zkEcXWlx3BOc" title="Warrants and rights outstanding measurement input">2.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2A0YB3qNMNd" title="Warrants and rights outstanding measurement input">3.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z1XDBZyN0Kv5" title="Estimated fair value">146,624</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2TqMctNvqrh" title="Estimated fair value">151,726</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zGirhz4ePWDd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsu1obyU1Wfi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z0coh5dRpsxa" title="Exercise price">16.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoeIDPCXPcQc" title="Exercise price">16.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoXzU7kpwwt5" title="Number of warrants">3,688</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zgcbWp2u3FLf" title="Number of warrants">2,581</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zXIPSshDbQ7" title="Estimated Term">5.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXzeaxUL0tM4" title="Estimated Term">4.4</span> &#8211; <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLzgZeRBaps9" title="Estimated Term">4.5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z1Fa93A6ZRvi" title="Warrants and rights outstanding measurement input">86.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zNweZGNbvpN3" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhzYuy6xQ1gh" title="Warrants and rights outstanding measurement input">1.8</span>% - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPg7CsZ2CbB2" title="Warrants and rights outstanding measurement input">2.0</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsxT4r0C5eu5" title="Warrants and rights outstanding measurement input">3.4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyTizCgvTLpl" title="Estimated fair value">92,336</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z72Y855ESgJb" title="Estimated fair value">64,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zecpDhgOgxS8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A rollforward of these warrant liabilities for the year ended December 31, 2022 is as follows:</span></p>

<p id="xdx_89E_ecustom--ScheduleofWarrantLiabilitiesTableTextBlock_ztBVEOc64Ov8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zeSONc0gOzva" style="display: none">Schedule
of Warrant Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Liability &#8211; Series A Preferred Stock Obligation</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2021 (as restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zNsPYB7LzPi3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Warrant liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">334,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zF5QjxZXZTJg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised (settled)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_ztUOjfervEfb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on change in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z5rYb9iCCVZc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">421,768</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassifications to stockholders&#8217;
    equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7151H6TNz22" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(756,723</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z6PdrHa7bupc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2479">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zlZwC2L7J5Eg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zIeMYiGkql7i" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued">146,624</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zhb4cBwGbSah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)">(91,036</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zXN8bvqeOFIl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loss on change in fair value">5,102</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reclassifications to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_za8LAb6YMJX" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity">(60,690</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zawcjTzKvje2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2491">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zol065gJ4hZg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2493">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zHGwX8iZIuNe" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued">92,336</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_ziqTyVquujLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zf7xXRmbzS94" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Gain on change in fair value">(28,196</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Reclassification to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"><p id="xdx_983_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zjJcvweR4b02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Reclassifications to stockholders' equity">(64,140</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyZqV655aYsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2503">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zRZQvVXDUPo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Refer to Note 7 for additional background on
the reclassification of warrant liabilities to equity. See Note 8 for additional disclosures related to the fair value of the Company&#8217;s
derivative liabilities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zU1IAwdJYrok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zc92axd5kqph">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of
our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its
fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed
consolidated statements of operations. For our liability classified derivative financial instruments, the Company used a Monte Carlo
valuation model to value the derivative instruments at inception and on subsequent valuation dates. For our equity classified
derivative financial instruments, we used a Black-Scholes option-pricing model at the grant date to value the derivative instrument.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYSObLAWFqrd">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our derivative financial instruments, the Company utilizes the most appropriate valuation model (such as Monte Carlo simulations or probability-weighted expected
return models, based on the nature of the terms of the instrument) to value the derivative
instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such
instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheet sheets as current or non-current based on whether or not net-cash settlement or
conversion of the instrument could be required within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zlFf6cI9ITB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zBAgigV4CUnf">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in FASB ASC 480, <i>Distinguishing Liabilities from Equity</i> (&#8220;ASC 480&#8221;)
and ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether
the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a
component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria
for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each
balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the
unaudited condensed consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_860_zbFQsfTI6WN7">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity
(&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants
are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the
warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a
circumstance outside of the Company&#8217;s control, among other conditions for equity classification. Finally, the Company
determines if the warrants meet the definition of a derivative based on their contractual terms. This assessment, which requires the
use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while
the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and at each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">statements of operations. </span></span>The Company also evaluates if changes in contractual terms
or other considerations would result in the reclassification of outstanding warrants from liabilities to stockholders&#8217; equity (or
vice versa).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">
The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zK4BilFFxXkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zCKkoNeWM1e4">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Research and development expenses
are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical
and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief
operating officer, chief financial officer and directors&#8217; compensation. For the three and six months ended June 30,
2024 and 2023, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3sLaUIdASYc" title="Share based compensation">0.1</span>
million and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDnOqNRLzbMj" title="Share based compensation">0.3</span>
million, respectively, and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLXJrFhnixJ1" title="Share based compensation">0.2</span> million and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxhtNDbme28j" title="Share based compensation">0.6</span>
million, respectively, was included within research and development due to their active involvement in the research and development
activities, materials, supplies, related subcontract expenses, and consulting costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of government
assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction including the
nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other provisions of
relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable alternative for
the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The Company has concluded
that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements against
incurred research costs. There were no reimbursements received for the six months ended June 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z01OOEEOeht9">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#8217; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$<span id="xdx_90F_ecustom--ShareBasedCompensations_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhkgxJb4oO55" title="Share based compensation">0.8</span> million and $<span id="xdx_900_ecustom--ShareBasedCompensations_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znRCeUIPhCNa" title="Share based compensation">0.5</span> million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230101__20231231_zY9s230h9slk" title="Research and development, net of contract expense reimbursements">3.5</span> million and $<span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20220101__20221231_zuzMe32hXUdd" title="Research and development, net of contract expense reimbursements">1.0</span> million in Research and development, net of contract expense reimbursements, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Stock</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPYN1jBumNz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXKKuKw3o4M7">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per share on the face of the unaudited condensed consolidated
statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and
denominator of the basic earnings per share computation. In the accompanying unaudited condensed consolidated financial statements,
basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and
potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from
common shares issuable through contingent share arrangements, stock options and warrants unless the result would be
antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#8220;treasury
stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#8220;if-converted
method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVkGRAVxSzPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0Up43jkQn2f" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zV8FndxIngK" title="Convertible notes (Note 6)">80,744</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zTo8N3BvlMOd" title="Convertible notes (Note 6)">155,378</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXic79bck0k1" title="Warrants">184,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxRJezezYiRe" title="Warrants">184,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zO4l3p8AWrTc" title="Restricted stock units">58,839</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG41pxOQnzb2" title="Restricted stock units">10,382</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_ztFD3kr5Ef39" title="Anti-dilutive securities">323,583</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zTCgcgQrSTIe" title="Anti-dilutive securities">349,760</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zl7y3OUGU5xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwbvAlIY1l46">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per common share on the face of the statements of operations
for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic
earnings per share computation. In the accompanying consolidated financial statements, basic loss per common share is computed by
dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the weighted average
number of shares of common stock outstanding and potentially dilutive shares of common stock during the period to reflect the
potential dilution that could occur from common shares issuable through convertible securities, contingent share arrangements, stock
options and warrants unless the result would be antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units and other stock-based payment awards subject to vesting and common stock warrants is
calculated using the &#8220;treasury stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these
instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible
securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be
converted at the beginning of the period, and the resulting shares of common stock are included in the denominator of the diluted
calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(as
                                            restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Convertible notes (Note 6)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)">119,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl2549">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants">184,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants">47,831</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units">24,731</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units">2,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities">328,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities">50,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zu1RgEyL4q5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zny4h9Jlpx5i">Deferred
Offering Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASC 340-10-S99-1, costs directly attributable to an offering of equity securities are deferred and would be charged against the
gross proceeds of an offering as a reduction of additional paid-in capital. Deferred offering costs may consist of underwriting,
legal, accounting, and other expenses incurred through the balance sheet date that are directly related to a proposed public
offering. Should the proposed public offering prove to be unsuccessful, any deferred costs, as well as additional expenses to be
incurred, will be expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zPaMS221bwti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zoIhNWXVKYPl">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.
2023-07, Segment Reporting Topic 280, &#8220;Segment Reporting-Improvements to Reportable Segment Disclosures,&#8221; which allows disclosure
of one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance.
Additionally, the standard requires enhanced disclosures of significant segment expenses and other segment items, as well as incremental
qualitative disclosures on both an annual and interim basis. This guidance is effective for annual reporting periods beginning after
December 15, 2023, and interim reporting periods after December 15, 2024. Early adoption is permitted and retrospective application is
required for all periods presented. The adoption of this new guidance is not expected to have a significant impact on our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, Income Taxes Topic 740, &#8220;Income Tax-Improvements to Income Tax Disclosures,&#8221;
which requires enhanced disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation,
disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit,
and income tax expense or benefit from continuing operations. This guidance is effective for annual reporting periods beginning after
December 15, 2024. Early adoption is permitted and should be applied on a prospective basis, however retrospective application is permitted.
The Company is currently evaluating the impact of adopting this guidance on its consolidated and condensed financial statements and disclosures
included within notes to consolidated and condensed financial statements.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zSWNCgOEheR1">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not expect the adoption of this standard to
have any material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUfQ5IhZAVZ7">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine if an arrangement is a lease at inception. <span style="background-color: white">Operating leases are included in operating
lease right-of-use asset (&#8220;ROU&#8221;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with a lease term of 12 months or less at inception are not recorded on our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">balance </span>sheets <span style="background-color: white">and are expensed on a straight-line
basis over the lease term in our statement of operations. </span>We have lease agreements with lease and non-lease components, which
are generally accounted for separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#8220;incremental borrowing rate&#8221; or &#8220;IBR&#8221;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zhMEboul1fnf">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%">Furniture</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computers and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life">10</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ConvertibleNotePolicyTextBlock', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zIShPO1DVFMg">Convertible
Notes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible notes for embedded features and bifurcates these features (such as conversion options and
redemption options) from their host instruments and accounts for them as free standing derivative financial instruments if certain
criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid
instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under
otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)
a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zMKVdyEG0BI7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z4CSzyso8ih9">Stock-Based Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost for stock awards, which include restricted stock units (&#8220;RSUs&#8221;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zjUxdX9ZNGFl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQkEcVy4u6Y6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zDl56YzwE8M1">Segment
Information</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate and discrete information is available for evaluation by the
chief operating decision-maker (&#8220;CODM&#8221;) in deciding how to allocate resources and assess performance. The Company and the
Company&#8217;s CODM, the Company&#8217;s chief executive officer, evaluates the Company&#8217;s operations and manages its business
as a <span id="xdx_900_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_z3kfWGafUOSj" title="Number of reportable operating segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl2541">single</span></span> operating segment. All of the Company&#8217;s long-lived assets are held in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ConvertibleNotePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Note [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ConvertibleNotePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773462442256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock', window );">Schedule of Error Corrections And Prior Period Adjustments</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_ztc1gOR7tjkb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>The impact of the errors described above also impact
the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span>&#160;</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif"><span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8B9_zV3IdsUTWKfl">Schedule
 of Error Corrections And Prior Period Adjustments</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpAZDsJ2HHgh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zil2vv7D4Zn1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z2miWDOBG6Jf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_iI_z20joSFUHD9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">19,543,363</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,489,055</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z1MXLFGq7K93" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(15,487,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,433,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Adjustments
    include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9htjoTqHbv2" title="Stock compensation">7,843,052</span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zljaKMw5yfJ3" title="Accrued dividends">402,064</span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9y2rds0NWB" title="Issuance cost">174,082</span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_znckfEMQmWO5" title="Warrants">416,266</span>),
    reclassifications of warrants from liability to equity (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zf8dTIB15zDj" title="Warrants from liability">881,554</span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zVyoTMoi5uwc" title="Debt instrument">2,213,498</span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Adjustments include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z8gOY06XlUha" title="Stock compensation">8,009,461</span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zvngUaX6yOKh" title="Fair value of warrants">240,930</span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zFjHB3SKH1u5" title="Accrued dividends">402,064</span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zSVO2RCnUXYd" title="Derivatives loss">296,151</span>); correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zrUKb6hAliXh" title="Issuance cost">166,407</span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zGiFL1ScJAR" title="Net income loss">1,967,621</span>).</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_gL3SOECAPPATT-CTUD_zsjBbHmPqf0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The impact of the errors described above also impact
the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0zZqA0Nnjde" style="display: none">Schedule
 of Error Corrections And Prior Period Adjustments </span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwetAMD0zH8g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJmDSENBI7ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_z4uPlYfsUoR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_iI_z2zeGbBRXc0g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">19,543,363</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,489,055</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zaoGgdHo6uwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(15,487,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,433,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<span><span>&#160;</span></span><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following tables summarize the effect of the restatement
on each financial statement line item as of the dates indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_134_zg7BX6nomyV7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6IPnX7kMpQd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zqIfqvq3dbla" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_zVBmgAKxgFu2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">16,572,741</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zRFyZ3enDeJ4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">26,518,433</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z7ch26L7ImB3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,894,889</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zq9la8ZM1J46" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(18,840,581</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_z6tdetXqK1di" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zNZReqJ1vZk4" style="font-size: 10pt">Adjustments
    include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj" title="Stock compensation">7,843,052</span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8" title="Accrued dividends">402,064</span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta" title="Issuance cost">174,082</span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8" title="Warrants">416,266</span>),
    reclassifications of warrants from liability to equity (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh" title="Warrants from liability">881,554</span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l" title="Debt instrument">2,213,498</span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zaNZZatnnmHh" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zzreMJkmsia8" style="font-size: 10pt">Adjustments include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a" title="Stock compensation">8,009,461</span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc" title="Fair value of warrants">240,930</span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a" title="Accrued dividends">402,064</span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih" title="Derivatives loss">296,151</span>); correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e" title="Issuance cost">166,407</span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf" title="Net income loss">1,967,621</span>).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zCPDzGSrLKea" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Operations for the year ended December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zfF7oBBVekwd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zwoKT7aBJHO8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zWrYFaOF7wz2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zj2MSn4b2I9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Research and development, net of contract expense reimbursements</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,148,712</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(101,327</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,047,385</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_zfl0BeByAfcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">538,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(65,082</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">473,714</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LegalFees_i01_zVxLruGqxV9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal and professional</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">866,770</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(44,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">822,727</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_zmOcF5iBAFc8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,554,278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210,452</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,343,826</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpense_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zdoL3oeTEEUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(917,879</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">489,191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(428,688</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--FinanceFee_i01N_di_zcGL6QyywMmb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2066">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zuPH3lpTUpn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2070">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zZ7eV5qwPDs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(492,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(398,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_ztFvHLdBYq75" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on extinguishment of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zslkvUkqO935" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,028,448</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,967,621</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,996,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zRrY7MweYN9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend on Series A Preferred Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(71,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(331,055</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendOnExtinguishmentOfSeriesPreferredStock_iN_di_z5JuaOYNMOtj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed dividend on extinguishment of Series A Preferred Stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2090">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(439,427</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(439,427</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_iN_di_zNL0yHlXVCs9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed dividend on modification of equity-classified warrants, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl2094">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(941,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(941,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_iN_di_zu7usXLwRWu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl2098">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">31,423</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">31,423</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zMdGKJyjwBM2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to common stockholders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,099,457</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,647,680</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,747,137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per shares - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMuzbPGlFEhh" title="Net loss per shares - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zccDRV02xjSf" title="Net loss per shares - basic">(2.32</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB4urI05QeH1" title="Net loss per shares - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKBYOEmr9nYi" title="Net loss per shares - Diluted">(2.72</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_z5ihkRTEuiul" title="Net loss per shares - Basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zSznyrVunGh9" title="Net loss per shares - Diluted">(5.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_134_zJX9uMgHKaPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Stockholders&#8217; Equity as of December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwS0vTQ9jBnd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcwAjgI1jFjg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zV0UlYwvROeh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zWvWqPGPs5Ya" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2118">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,951,356</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,951,356<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuedForCash_zHDj0uGsfbqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,008,095</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10,008,095</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2124">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WarrantsExercisedForCash_z2d1h2nIc9ac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants exercised for cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,098</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(14,098</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2128">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zhhR4qDxRN8l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Warrants issued for financing costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">412,241</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(397,579</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,662</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zhykxizzqMlh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for conversion of accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">588,524</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(588,524</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zyHZ1nRPI2pe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued upon conversion of convertible debt and exercise of related warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2138">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,199,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,199,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zwf7FzAmToLf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">576,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,576,648</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,153,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsDHZesDpxNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">403,956</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(166,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">237,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DividendsOnSeriesPreferredStock_iN_di_zvqx0AJOOAIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividends on Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(71,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(331,055</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_zABJ06Gj07Ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_z5MiqqZKDCgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reclassification of fair value of warrant liability to equity upon initial public offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2158">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zxnxLSWBTqm9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,028,448</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,967,621</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,996,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>
&#160;<span><span>&#160;</span></span><table cellpadding="0" cellspacing="0" id="xdx_307_134_zdfyzfvfDy16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Statement of Cash Flows for the year ended December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zy1sl4WmcFif" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zeDLOhNW3Qh1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_z3HtR4Rnmup1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zCatNeztmy4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(3,028,448</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,967,621</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(4,996,069</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_zobw7LZjY4ph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2170">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01_zH5N7jyNN6bb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(94,025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">492,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">398,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i01_zuFdOtXI1xQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization of debt discount and finance fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">885,505</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(508,121</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">377,384</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LossOnSettlementOfConvertibleDebt_i01_zjcoYliHCWO2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on settlement of convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2182">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,795,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueOfFreestandingInstrumentsInExcessOfProceeds_i01_zOCefK4QX4t2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fair value of freestanding instruments in excess of proceeds</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2186">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">189,912</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GainOnInterestReliefOnConversionOfNotesPayable_i01N_di_zbi2XyEBcw01" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gain on interest relief on conversion of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_z9JN5YP8HCA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">403,956</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(166,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">237,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_zdwCVGgYjudb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,177</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,555</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,378</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zS9xgAWVXgZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,710,454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,666,411</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_zPeJwFkUi6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of common shares and warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,022,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,995,513</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_zX9wJ2hh4D47" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,715</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">550,715</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromNotesPayableAndWarrants_i01_zB9jBkRcOoei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from notes payable and warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2214">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsOfFinancingCosts_i01N_di_zSy4wmzIPBff" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    for finance costs related to convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2218">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,363</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,363</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_z1cIFFnQqII8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,622,908</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44,043</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,578,865</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaid_i01_z2AXVU0ATqRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Supplemental non-cash financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CommonStockIssuedUponConversionOfConvertibleDebt_i01_zqxadejLpiX2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued upon conversion of convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">588,524</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">611,392</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,199,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zl91Hr9vTr9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">576,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,576,648</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,153,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_i01_zSvMjywi1h66" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">402,064</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--WarrantsIssuedForFinancingFees_i01_zEdVHlVkRYRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants issued for financing fees, net of issuance fees of $<span id="xdx_901_ecustom--WarrantsIssuanceFees_c20230101__20231231_z3f2JIJxQ6Sg" title="Warranst of issuance fees">8,727</span> and $<span id="xdx_909_ecustom--WarrantsIssuanceFees_c20220101__20221231_zdqu9lkBFd4" title="Warranst of issuance fees">0</span>, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">412,241</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(397,579</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,662</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_i01_zpGNzvsa7kK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reclassification of fair value of warrant liability to equity upon initial public offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">881,553</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zABYLOApGVBf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Consolidated Balance Sheet as of December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zLsnU6dc6oAc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z4f2SrKUNhEd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_z9hEcTZm93ad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left">Additional paid in capital</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">4,150,948</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AdditionalPaidInCapital_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zSrXYy1elD59" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital">7,912,992</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">12,063,940</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zqI4Ca10eqGi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated Deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,795,432</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zbPV9duglp2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(8,049,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,844,512</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_zyx8H6MNpq29" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zVcwwitNryW8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk" title="Increase decrease of notes payable">7,351</span>); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh" title="Increase decrease in preferred stock">89,118</span>); and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l" title="Stock compensation">8,009,461</span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_z8KUvJcM4081" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td id="xdx_F11_zlKB34EfShAa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    include reversal of dividend liability recorded (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1" title="Increase decrease in dividend liability">331,059</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of deferred IPO costs (decrease of ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi">55,182</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh">89,118</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the estimated fair value of warrant liability (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63">240,930</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj">274,048</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc">8,009,461</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></td></tr>
  </table>
&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Error Corrections And Prior Period Adjustments [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773564016336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of the Error Correction</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zUEa4AVq93g1" style="display: none">Schedule of the Error Correction</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztXtgIiL0mS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Corrected</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,944,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(182,715</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,761,466</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">281,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">182,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">464,633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zkEJLZMnX1Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zFoSdsPsZsdh" style="display: none">Schedule of Cash and Cash Equivalents</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zdf2YYEPgH92" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z0DgJpGOb3c6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zpVNW72A3ffa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">645,594</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,550,098</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zkXzbm1UOUsk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,026,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zESWBcrIg25g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">695,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,576,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,550,098</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5,411,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,026,318</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,005,825</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,576,416</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,417,203</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4Fjp8jYHK5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of June 30, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z04BtaXIERfc" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">June 30, 2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zExD2SVowPH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLJtGezKo55" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmfWKey4sYWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630_zjoqMgNxUsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLGc9i6fzSJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zxYQDrtyDMk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,642,995</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,642,995</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zDwqI7ggcyO2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,642,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,642,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zr8UHTdpBgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z9RhqCNdYVqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">359,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">359,919</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zNRORHgltpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zwgNXMGU1U4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">360,423</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">360,423</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zb7iOAM75Kdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z76zr6Fa3GUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z01v4lD9OZA8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zwkx62sH2px7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zvkOmL0nCbfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zoumSoH7GBU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zUOt3GVPWwL6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zS2K50xTTHjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zgtC2JqIWhO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zIDEG5nHspT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zm2eBRJ81m98" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative Liability </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zcF4kM03SRN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Marketable Securities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2328">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2333">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2334">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,887,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DerivativeLiabilityWarrants_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zLHLaG6Wpet4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative Liability - Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2343">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerivativeLiabilityAcceleratedFeature_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_z1GMbV70G7Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2347">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2348">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2352">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2353">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">414,512</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">414,512</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVkGRAVxSzPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0Up43jkQn2f" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zV8FndxIngK" title="Convertible notes (Note 6)">80,744</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zTo8N3BvlMOd" title="Convertible notes (Note 6)">155,378</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXic79bck0k1" title="Warrants">184,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxRJezezYiRe" title="Warrants">184,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zO4l3p8AWrTc" title="Restricted stock units">58,839</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG41pxOQnzb2" title="Restricted stock units">10,382</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_ztFD3kr5Ef39" title="Anti-dilutive securities">323,583</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zTCgcgQrSTIe" title="Anti-dilutive securities">349,760</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(as
                                            restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Convertible notes (Note 6)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)">119,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl2549">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants">184,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants">47,831</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units">24,731</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units">2,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities">328,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities">50,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Key Inputs of Warrant Liabilities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zddhrcXyuLig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs for the Monte Carlo simulation as of June 30, 2024, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z7WE6Sm8yWM4" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Net cash settlement and down round key valuation inputs &#8211; warrants*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z7lnS5s2jUN9">89.76</span>% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmZc9bAYLWi3">99.20</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zENOS2CF7rv2">4.61</span>%
- <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zyedZGpSQBvj">5.48</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zxmx6iG5WaC8">3.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zRmUEyhycePc">18.80</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zw0Gt6uGAQW">2.5</span>% - <span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zdiXmuzlTMof">30</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zvnG2xSED8Zd">15</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z3NcjrfcqcJh" title="Time period (years)">0.11</span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zpUW5ldGkXt6" title="Time period (years)">2.53</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte
Carlo simulation analysis of 250,000 iterations</i></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Acceleration option key valuation inputs*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z33q7ziTcqyb">64.76</span>% - <span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zvHaxuOUsMaa">74.98</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zWe5o0ZipMb8">5.23</span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zqss6ZSDbcra">5.48</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z9VW6iGSTos3">3.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zmppDXxJVuna">15</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zTfh1HZ0FQ8e" title="Time period (years)">0</span> - <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zFH5tWpTdkS" title="Time period (years)">0.7</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_zqQfP1wZvzHb" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify"><i id="xdx_F15_z5AQlH6MsWM9">Based on a Monte Carlo simulation analysis of 250,000 iterations</i></td>
</tr></table>



<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_znb7Uj9EztTl" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash settlement and down round key valuation inputs &#8211; Alto Warrants*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 78%">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z4g0dzX4U7zf">77.51</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z301m69d8Gyi">92.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZAEk7427avk">4.01</span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zgCPUuxlHzHc">5.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKg_____zynIkUyUvoc5">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zx3O4OnWlhIe">18.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability assessment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZhnjkBS7Tu6">5</span>% - <span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zyEeLFE48kV1">25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zUzGci9OyFOe">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zp3kUyM7mCF1" title="Time period (years)">0.53</span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z2QZvDKXSZc8" title="Time period (years)">3.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_985_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zzfOPZcmFp21" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance">1,189,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zoconmEERXL5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value">410,660</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Alto Acceleration Option key valuation inputs*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsLip3AEalOf">34.23</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zrecJIDgSDtl">59.15</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zJ1iIi9Tuuh5">4.68</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zzEjaz9gjDGe">5.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zq9lJmRsxA0c">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zHhUsf9wJkQl">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zBDp4x7lFOLe" title="Time period (years)">0</span> - <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zN3n43wPlwJ7" title="Time period (years)">1.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____z1a2AIcEwJo7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance">1,442,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zMZsZdoRik44" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value">3,852</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zP9EgyZUvD22">*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F10_zpHGdXc8eMz1">Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleofWarrantLiabilitiesTableTextBlock', window );">Schedule of Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleofWarrantLiabilitiesTableTextBlock_ztBVEOc64Ov8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zeSONc0gOzva" style="display: none">Schedule
of Warrant Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Liability &#8211; Series A Preferred Stock Obligation</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2021 (as restated)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zNsPYB7LzPi3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Warrant liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">334,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zF5QjxZXZTJg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised (settled)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_ztUOjfervEfb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on change in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z5rYb9iCCVZc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">421,768</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassifications to stockholders&#8217;
    equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7151H6TNz22" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(756,723</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z6PdrHa7bupc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2479">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zlZwC2L7J5Eg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zIeMYiGkql7i" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued">146,624</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zhb4cBwGbSah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)">(91,036</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zXN8bvqeOFIl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loss on change in fair value">5,102</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reclassifications to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_za8LAb6YMJX" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity">(60,690</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zawcjTzKvje2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2491">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zol065gJ4hZg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2493">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zHGwX8iZIuNe" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued">92,336</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised (settled)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_ziqTyVquujLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zf7xXRmbzS94" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Gain on change in fair value">(28,196</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Reclassification to stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"><p id="xdx_983_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zjJcvweR4b02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Reclassifications to stockholders' equity">(64,140</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyZqV655aYsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2503">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock', window );">Schedule of Useful Lives for Property Plant Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%">Furniture</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computers and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life">10</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Key Inputs of Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoMWqw0jB0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zKUJ72QdTXY5" style="display: none">Schedule
of Key Inputs of Warrant Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Series A Preferred Stock Obligation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_984_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zLyVGKOArAWd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock">40.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</td><td id="xdx_982_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zgBrdL1LrT7c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated IPO or Listing terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_znoxhYjetF0l" title="Exercise price">40.00</span> - $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zArhlIcCb06d" title="Exercise price">166.56</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zp65fcqYKv7b" title="Exercise price">32.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Series A Preferred Stock conversion shares upon IPO or Listing at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_ztMXqnmuU9cb" title="Number of warrants">12,135</span> - <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zMp7IKseQgnc" title="Number of warrants">33,681</span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7zVZKsduoz2" title="Number of warrants">42,101</span> shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdcX1kzMoQCd" title="Warrants and rights outstanding measurement input">86.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zW1kmGuIywhe" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z78eGWXIszP4" title="Warrants and rights outstanding measurement input">1.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zbRqcuFc7Kx4" title="Warrants and rights outstanding measurement input">3.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated IPO date</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7abpz07AmNb" title="Estimated IPO date">9/30/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zreHcuEZR3gi" title="Estimated IPO date"><span style="-sec-ix-hidden: xdx2ixbrl2385">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated Term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z815JlVntnri" title="Estimated Term">3.75</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z1GevZdwSlle" title="Estimated Term">3.00</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO or Listing Occurring</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zkuIhmucDUIl" title="Warrants and rights outstanding measurement input">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zP3rqfuREZce" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2393">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO as &#8220;Qualified IPO&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKZbZZdwX904" title="Warrants and rights outstanding measurement input">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zAVfbA32ifU9" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2397">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of IPO as &#8220;Listing&#8221;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zao8vkaRcnof" title="Warrants and rights outstanding measurement input">67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKRwLLcGWTNc" title="Warrants and rights outstanding measurement input"><span style="-sec-ix-hidden: xdx2ixbrl2401">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdV5UMoJ21Bj" title="Estimated fair value">334,955</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z0UVRkniDVEg" title="Estimated fair value">756,723</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; August 2022 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification/Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9nZuNwXlNZ9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9B1oFEU8qSd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zL1GvJpV5Cld" title="Exercise price">20.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z7OvmG4tIEqi" title="Exercise price">20.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Number of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zZ3lsYq0BOS3" title="Number of warrants">6,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zWW3jeBT6Epe" title="Number of warrants">6,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zsUhFnC28Jl7" title="Estimated Term">5.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zmfGu7F5nHW3" title="Estimated Term">4.9</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zBV3c4wuqEq3" title="Warrants and rights outstanding measurement input">80.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z0zoN4DV2El9" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zkEcXWlx3BOc" title="Warrants and rights outstanding measurement input">2.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2A0YB3qNMNd" title="Warrants and rights outstanding measurement input">3.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z1XDBZyN0Kv5" title="Estimated fair value">146,624</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2TqMctNvqrh" title="Estimated fair value">151,726</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Warrant Liability &#8211; Boustead Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Reclassification Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Estimated fair value of Company&#8217;s stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zGirhz4ePWDd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsu1obyU1Wfi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock">32.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z0coh5dRpsxa" title="Exercise price">16.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoeIDPCXPcQc" title="Exercise price">16.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of warrants (based on estimated Convertible Note conversion terms at issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoXzU7kpwwt5" title="Number of warrants">3,688</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zgcbWp2u3FLf" title="Number of warrants">2,581</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Remaining term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zXIPSshDbQ7" title="Estimated Term">5.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXzeaxUL0tM4" title="Estimated Term">4.4</span> &#8211; <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLzgZeRBaps9" title="Estimated Term">4.5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z1Fa93A6ZRvi" title="Warrants and rights outstanding measurement input">86.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zNweZGNbvpN3" title="Warrants and rights outstanding measurement input">82.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhzYuy6xQ1gh" title="Warrants and rights outstanding measurement input">1.8</span>% - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPg7CsZ2CbB2" title="Warrants and rights outstanding measurement input">2.0</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsxT4r0C5eu5" title="Warrants and rights outstanding measurement input">3.4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyTizCgvTLpl" title="Estimated fair value">92,336</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z72Y855ESgJb" title="Estimated fair value">64,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Useful Lives for Property Plant Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleofWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrant Liabilities [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleofWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773456551424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Right-of Use Asset and Lease Information About Operating Lease</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zK422Uc0lu5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the ROU lease expense components and cash flow information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zuH7q1lj8SJd" style="display: none">Schedule of Right-of Use Asset and Lease Information about Operating Lease</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240401__20240630_zo4SVVRAslZ4" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230401__20230630_zbeeaqAgEQqg" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20240630_zhRuAhvewrL8" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20230101__20230630_zxL68u1cciD4" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseCost_maLCzBxV_z9q8sduJrjNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,894</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_maLCzBxV_zcBgOYmHf708" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,937</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,377</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--SubleaseIncome_iN_di_msLCzBxV_z3kL2k1B3bb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublease
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,163</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,121</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,326</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,242</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--LeaseCost_iT_mtLCzBxV_zt70iWUKYVJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,721</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,072</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,945</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zDvzNXhAEmD8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for operating cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,707</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,331</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,189</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,771</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zDgjUOaa64wi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    assets obtained in exchange for new operating lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">365,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
<td class="text"><p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the right-of use asset and lease information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z3chxPAugTvb" style="display: none">Schedule of Right-of Use Asset and Lease Information About Operating Lease</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Years Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">112,022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">70,175</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2595">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Sublease income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,819</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,070</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">128,425</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">63,105</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other information</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">95,641</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76,248</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">365,556</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2610">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term - operating leases (year)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dxL_c20231231_zyA8Do3k9Nfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)::XDX::P4Y11M23D"><span style="-sec-ix-hidden: xdx2ixbrl2612">4.67</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)">0.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average discount rate - operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dpxL_uPure_c20231231_zWuyyS7WvFVl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases::XDX::10.46"><span style="-sec-ix-hidden: xdx2ixbrl2616">10.48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_z8NlF0txAYKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Balance Sheet Information Related to Operating Leases</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zKOOShJEE5dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to operating leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zmYseQ6pdvtj" style="display: none">Schedule of Balance Sheet Information Related to Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin: 0">December 31,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 60%"><p style="margin: 0">Weighted-average remaining lease term (year)</p></td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zJlgJo77R5Ga" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)">4.18</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zXbHD3zsmgMd" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)">4.98</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20240630_zqJYJPwpJeXi" title="Weighted-average discount rate - operating leases">10.48</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z2wnmDWx5pXc" title="Weighted-average discount rate - operating leases">10.46</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</a></td>
<td class="text"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmlHgFzUal7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of June 30, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zsVIUUnQJvr1" style="display: none">Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">Years Ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240630_zNDWEz2YNUT9" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzRbr_zHHdpQpnj0cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 80%">2024 (excluding the six months ended June 30, 2024)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzRbr_z0YgUsRG8Qv6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,246</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzRbr_ztHycVa7y8O1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,074</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzRbr_zUATw95C4R95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,986</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzRbr_zpEa8QZPruM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">68,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzRbr_zvIAUmy9odxl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzRbr_z8Voh6apDace" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zHDliea95yo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(76,737</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zRffpWzzHwPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">329,117</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOSrvaX8p16l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zhh9Zl5mOtfe" style="display: none">Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Years ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz2AR_zxdBtjySLTu6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024 (excluding the six months ended June 30, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz2AR_z7Q1UTfjXlRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">91,502</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz2AR_zxt7KD3Psq8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,247</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz2AR_zCEFnZuV9lP6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">97,074</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz2AR_zB3e7mhwfEwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">99,986</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz2AR_zjrflcieALdj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">68,235</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz2AR_zKCt4MJzhhad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total future minimum lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">451,044</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(94,438</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">356,606</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Balance Sheet Information Related to Operating Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773462466528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpt1jpLKTnHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the six months ended June 30, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zPuNzHLoPhTh" style="display: none">Schedule of Warrants Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Life (years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGmmy2OE5gHk" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">184,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_dxL_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcGkCjRORBv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance::XDX::23.21"><span style="-sec-ix-hidden: xdx2ixbrl1123">23.20</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOaykqGoQ2hl" title="Weighted Average Life (Years)">2.77</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmNPQtO3uEl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znf668NBwEk5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzfCOsHPgAd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending Balance">184,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJRjwVBNdTqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">23.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuurucvHOak" title="Weighted Average Life (Years)">2.29</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zQPSvyFjdRPc" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance">62,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance">8.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUtrsMLQInh5" title="Weighted average life (years), outstanding balance">4.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of warrants outstanding, granted">270,910</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price, outstanding granted">14.57</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted average life (years), granted">4.68</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9CkaYjHRKW6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, exercised">(285,579</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zcPe5lHTomfb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding exercised">9.58</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8212;</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance">47,831</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance">35.77</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted average life (years), outstanding balance">2.78</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted - Boustead</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted">8,909</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted">18.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted average life (years), granted">5.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Granted - Ayrton</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted">127,260</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted">18.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted average life (years), granted">4.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance">184,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance">23.21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted average life (years), outstanding balance">2.77</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
    warrants include those granted on the issuance of the August 2022 Promissory Notes</span> (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoPromissoryNotesMember_z8eerCsA7Vic" title="Granted warrants, shares">3,750</span> warrants); Notes Payable &#8211; Related
    Parties  (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zRpN5cBP0s45" title="Granted warrants, shares">2,500</span> warrants); upon conversion of the
    Series A Preferred Shares (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zScqfutTyNe1" title="Converted shares issued">42,114</span> warrants);
    automatic conversion of the 2022 Convertible Notes  (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyTwoConvertibleNotesMember_zts6c3ymErAi" title="Granted warrants, shares">18,447</span> warrants); issued during the IPO, including overallotment option (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8ldYZ9uZqP4" title="Number of shares issued">176,222</span> warrants) and issued to Boustead Securities LLC  (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--BousteadSecuritiesLLCMember_zWH28ubFIhwb" title="Number of shares issued">27,877</span> warrants).</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercised warrants include the exercise of the warrants
issued with the December 2021 Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyOnePromissoryNotesMember_z3vUeINzv4nc" title="Number of shares issued">62,500
</span>warrants); the exercise of the warrants issued with the August 2022 Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zUXECz6R3mD5" title="Number of shares issued">3,750
</span>warrants); the exercise of the warrants issued upon conversion of the Convertible Notes (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zV8n48EOlaxg" title="Converted shares issued">18,447</span>
warrants); and the exercise of the warrants issued during the IPO, including overallotment option (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiePm976S3i" title="Number of shares issued">176,222</span>
warrants), and warrants exercised on a cashless basis (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zBFrdGlEuIid" title="Number of shares issued">24,660</span>
warrants).</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units (RSUs)</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zuu6KI1jjRoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zFcZXEx7rJsb" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value Per RSU</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Outstanding, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVRgs3QKydz5" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">24,731</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaBR0c6rk6W" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">11.76</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGKXMKubzvhh" style="text-align: right" title="Number of Stock Option Outstanding, Granted">53,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5h9v578mi67" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXBbyqQ5zQ7i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Vested">(19,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpWt13yUHaGb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">7.58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding, June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqeDXbv4Uwll" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Outstanding, Ending Balance">58,839</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYvZB97qXPK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance">4.87</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zXV9pKVawChd" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Outstanding, December 31, 2021 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">2,017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">185.60</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Number of Stock Option Outstanding, Granted">4,449</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Granted">22.48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Vested (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE3XiT4Awrd8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested">(3,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zczNKvkuf77f" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">116.48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2022 (as restated)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">2,966</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">22.48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Outstanding, Granted">32,415</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">10.88</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested (as restated)</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested">(10,650</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">12.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Ending Balance">24,731</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance">11.76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zc5RchDtdYW" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<span id="xdx_8BF_zWWEFBZRefcb" style="display: none">Schedule
of Restricted Stock Units&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_49A_20230101__20231231_zO2ONL04juDe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_495_20220101__20221231_zsR9hqKKMoLh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">(as restated)</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFSDfn5qktl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Recognized in general and administrative expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">105,582</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zP0z6A5Wtzm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Recognized in research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">66,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">131,965</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zypbbKjXmu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">181,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">237,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773458694320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Monte Carlo Simulation Assumption</a></td>
<td class="text"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zddhrcXyuLig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs for the Monte Carlo simulation as of June 30, 2024, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z7WE6Sm8yWM4" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Net cash settlement and down round key valuation inputs &#8211; warrants*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z7lnS5s2jUN9">89.76</span>% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmZc9bAYLWi3">99.20</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zENOS2CF7rv2">4.61</span>%
- <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zyedZGpSQBvj">5.48</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zxmx6iG5WaC8">3.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zRmUEyhycePc">18.80</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zw0Gt6uGAQW">2.5</span>% - <span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zdiXmuzlTMof">30</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zvnG2xSED8Zd">15</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z3NcjrfcqcJh" title="Time period (years)">0.11</span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zpUW5ldGkXt6" title="Time period (years)">2.53</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte
Carlo simulation analysis of 250,000 iterations</i></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Acceleration option key valuation inputs*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z33q7ziTcqyb">64.76</span>% - <span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zvHaxuOUsMaa">74.98</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zWe5o0ZipMb8">5.23</span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zqss6ZSDbcra">5.48</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Quoted VWAP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z9VW6iGSTos3">3.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zmppDXxJVuna">15</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zTfh1HZ0FQ8e" title="Time period (years)">0</span> - <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zFH5tWpTdkS" title="Time period (years)">0.7</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_zqQfP1wZvzHb" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify"><i id="xdx_F15_z5AQlH6MsWM9">Based on a Monte Carlo simulation analysis of 250,000 iterations</i></td>
</tr></table>



<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_znb7Uj9EztTl" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash settlement and down round key valuation inputs &#8211; Alto Warrants*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 78%">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z4g0dzX4U7zf">77.51</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z301m69d8Gyi">92.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZAEk7427avk">4.01</span>% - <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zgCPUuxlHzHc">5.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKg_____zynIkUyUvoc5">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zx3O4OnWlhIe">18.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability assessment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZhnjkBS7Tu6">5</span>% - <span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zyEeLFE48kV1">25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zUzGci9OyFOe">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zp3kUyM7mCF1" title="Time period (years)">0.53</span> - <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z2QZvDKXSZc8" title="Time period (years)">3.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_985_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zzfOPZcmFp21" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance">1,189,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zoconmEERXL5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value">410,660</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Alto Acceleration Option key valuation inputs*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left">Annualized volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsLip3AEalOf">34.23</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zrecJIDgSDtl">59.15</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zJ1iIi9Tuuh5">4.68</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zzEjaz9gjDGe">5.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Quoted VWAP*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zq9lJmRsxA0c">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Illiquidity discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zHhUsf9wJkQl">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zBDp4x7lFOLe" title="Time period (years)">0</span> - <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zN3n43wPlwJ7" title="Time period (years)">1.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (issuance)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____z1a2AIcEwJo7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance">1,442,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value (December 31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zMZsZdoRik44" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value">3,852</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zP9EgyZUvD22">*</i></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F10_zpHGdXc8eMz1">Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Derivative Liabilities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zB2cIqfiiimd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BD_z0zcJjty7khd" style="display: none">Schedule of Derivative Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accelerated Feature</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance - December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwRqyS7RiOpe" style="width: 16%; text-align: right" title="Beginning balance">410,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zMg9AP4dwfr" style="width: 16%; text-align: right" title="Beginning balance">3,852</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcrO6JJ4haVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">(196,045</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zbHPKQPIrEPl" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">(1,817</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpyk9HeHJchg" style="text-align: right" title="Beginning balance">214,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zkDLUMuDhQN1" style="text-align: right" title="Beginning balance">2,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">(Gain) loss on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkYuPFzcXtak" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">145,304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zAQS817134U3" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative">(1,531</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance - June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCSwKsfFnXg5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">359,919</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zGNmvRYrn13g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">504</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zHuN5mIWCcld" style="display: none">Schedule of Derivative Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Alto Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Alto Acceleration Option</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zWuG16l7lUb4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3398">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_ztFTCUemysu2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3400">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Addition of new derivative</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zdAHyDuWCfwc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition of new derivative"><span style="-sec-ix-hidden: xdx2ixbrl3402">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance, accelerated feature">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z8RTtBdyQRV1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3404">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zPbLi4vsu6Y5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3406">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Settlements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zvjRWlcR4Oq4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"><span style="-sec-ix-hidden: xdx2ixbrl3408">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance, accelerated feature">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z227U3NgZrsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3410">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zIZ54psJBNEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3412">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivatives</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zi2intGd88Ic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives">1,189,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zulYRhCn5Bo4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives">1,442,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zN2fSOlVe2Hg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">(778,340</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zl9oFisctE59" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">(1,438,148</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zqedp41mnRcc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants">410,660</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zfSvJfrVCkJi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants">3,852</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 2021 Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">August 2022 Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022 Convertible &#160;Notes Derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%">Balance - December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zMfR6d3t1ZTc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants">367,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zvQSmx5SZQT9" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3428">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zpfuhLUsv1Kc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3430">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--NotesDerivativeMember_zWqliR34XJic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"><span style="-sec-ix-hidden: xdx2ixbrl3432">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zaBmeMoUsWw1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative">76,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zrcnlskbqQTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative">221,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss (gain) on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_znz5bKggSfBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">(205,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zNYi4yyZGiY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">44,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_ztLRWglWKal8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value">350,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Settlements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zOwd68kF1fT8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements">(162,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zHWin4V5gVni" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements">(120,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zqIBjN8wVsyj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements">(571,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance - December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zWxsN5hlwSIg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3450">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zmOWqAKHdd28" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3452">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_z224mM1Sbfoe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3454">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Addition of new derivatives</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zEiFnJUobl0a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"><span style="-sec-ix-hidden: xdx2ixbrl3456">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zMvnSYCrVEHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"><span style="-sec-ix-hidden: xdx2ixbrl3458">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zxo25N8sCZEj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"><span style="-sec-ix-hidden: xdx2ixbrl3460">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zlxz2dtxaAqi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3462">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zKJxXoIfZ5oi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3464">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zkRrGHyYGnb7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl3466">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_z5rEzxpFNtYh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3468">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zOIIACleWQL4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3470">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zFv0uFQF4CY3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"><span style="-sec-ix-hidden: xdx2ixbrl3472">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock', window );">Schedule of Derivative Issuance Valuation Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_zjlCwF4i7uJj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the December 2021
Notes, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative liability
as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value of the
derivative just prior to the settlement of the December 2021 Notes. Key inputs for this valuation model are summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b><span id="xdx_8B2_zjG7V0BTJGN6" style="display: none">Schedule
of Derivative Liability Valuation</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">December 2021 Notes derivative key valuation inputs</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zCCUZkonud72" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Date</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231__us-gaap--AwardDateAxis__custom--SettlementDateMember_zi03jzsAnAh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Amount due upon acceleration</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcTc9BXjF7gb" title="Amount due upon acceleration">533,699</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_902_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zWOG2jS5GJUb" title="Amount due upon acceleration">533,973</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Carrying value of December 2021 Notes at measurement date</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIEsyqfZYvLg" title="Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl3262">&#8212;</span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zcwi7FULk9jc" title="Carrying value">337,398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">IPO date</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zVBlR0B9tUP7" title="IPO date">8/31/2022</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zJw91gnzLS2j" title="IPO date">9/2/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO acceleration</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_903_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zFuITDP3UXf" title="Probability of IPO acceleration">90</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zpxKsbtLWcB9" title="Probability of IPO acceleration">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of maturity</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zzFXbd5Og0G4" title="Probability of Maturity">10</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_z7lRzYZKo0S2" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3276">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Time period to maturity (years)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zX1096vaLn9i" title="Time period to maturity (years)">1.00</span> years</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z6tjv8ZW9Ry1" title="Time period to maturity (years)">0.32</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discount rate</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcAOY0484Dgi" title="Discount rate">50.0</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zUkS1jzZb5c9" title="Discount rate">50.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z8IXFIyc2pgh" title="Estimated fair value">367,000</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z11mi2p3YAV3" title="Estimated fair value">162,000</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock', window );">Schedule of Derivative Key Valuation Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_896_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_z5brvl3KzAle" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zD9WNYfYXy6">Schedule
of Derivative Key Valuation Inputs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
    Convertible Notes derivative key valuation inputs*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    Dates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zrI7eNI0ycE5" title="Annualized volatility">75.0</span>%
    - <span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z0yV9SlEpTnf" title="Annualized volatility">82.0</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zKgfUKZ0UPn4" title="Annualized volatility"><span style="-sec-ix-hidden: xdx2ixbrl3296">&#8212;</span></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIJa6GBq3Vu9" title="Risk-free interest rate">0.6</span>%
    - <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7kAtMbqmLOb" title="Risk-free interest rate">1.2</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMKLBnZnSszd" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl3302">&#8212;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price (implied)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zusIOIenjwY5" title="Exercise price (implied)">45.52</span>
    - $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zSrzItTHe8Xl" title="Exercise price (implied)">85.92</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z59iWMKVRj15" title="Exercise price (implied)"><span style="-sec-ix-hidden: xdx2ixbrl3308">&#8212;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    IPO date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_z48Fv311BmSl" title="Estimated IPO date">8/31/2022</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zWHulQCfI3ce" title="Estimated IPO date">9/2/2022</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of default</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember_zq8jLqAQ0tdi" title="Probability of default">50</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMACi2a6YyD" title="Probability of default"><span style="-sec-ix-hidden: xdx2ixbrl3316">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of IPO or Alternative Liquidity Event</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_znwcKoeawLJg" title="Probability of IPO or Alternative Liquidity Event">45</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zT1PeOh2Neth" title="Probability of IPO or Alternative Liquidity Event">100</span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of Maturity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zlGZHJ3XRNug" title="Probability of Maturity">5</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zjjniTfeAEkc" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3324">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
    period (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_ztMKhfW5VVmg" title="Time period (years)">0.47</span>
    - <span id="xdx_904_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zwX6ZWWfyt65" title="Time period (years)">1.00</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zwYvRAgB6W9h" title="Time period (years)">0.00</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zc3b3riNCOg1" title="Estimated fair value">221,000</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z86312yZwukb" title="Estimated fair value">571,000</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=SHPH_AugustTwoThousandTwentyTwoNotesMember', window );">August 2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock', window );">Schedule of Derivative Issuance Valuation Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_zgGEkQpbb6be" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the August 2022
Promissory Note, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative
liability as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value
of the derivative just prior to the settlement of the August 2022 Promissory Notes. Key inputs for this valuation model are summarized
below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b><span id="xdx_8B3_zXnr1bjxbu8" style="display: none">Schedule
of Derivative Issuance Valuation Inputs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-size: 10pt"><b>August 2022 Promissory Notes derivative key valuation inputs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-size: 10pt">Issuance Dates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-size: 10pt">Settlement Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Amount due upon acceleration (estimated at issuance)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zX5muKr38VWd" title="Amount due upon acceleration">50,411</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_908_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zlLZamz1oBT8" title="Amount due upon acceleration">50,438</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Carrying value of August 2022 Promissory Notes at measurement date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_90C_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zVydJGz543cb" title="Carrying value">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">$<span id="xdx_908_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zj9Ng4Pbbdij" title="Carrying value">4,521</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">IPO date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zbhJNV5W9Fb5" title="IPO date">8/31/2022</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zAzR2pIn59Hh" title="IPO date">9/2/2022</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Probability of IPO acceleration</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zQN6XCDs8M2c" title="Probability of IPO acceleration">90%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zNspkjjAgVO5" title="Probability of IPO acceleration">100%</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Probability of maturity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zRY8a4wqnEzc" title="Probability of Maturity">10%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zjb0uw9A2rnf" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3356">&#8212;</span></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Time period to maturity (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIWJR1XsIxRj" title="Time period to maturity (years)">1.00</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z84rwfz9M3L5" title="Time period to maturity (years)">0.91</span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Discount rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zIO5KOr85SO8" title="Discount rate">16.03%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zipUF0l5Eyj8" title="Discount rate">18.81%</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zOHFLWCnr45d" title="Estimated fair value">45,000</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">$<span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zbkhZ58Bq7H3" title="Estimated fair value">45,000</span></p></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock', window );">Schedule of Derivative Key Valuation Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_897_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_ziGGYyZ5pmTh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the issuance of the August 2022
Convertible Notes, the Company identified certain embedded features that required bifurcation as a combined derivative liability, including
the share-settled redemption of the 2022 Convertible Notes at a 50% discount and the automatic increase in principal of 10% if conversion
does not occur within 12 months. Key inputs for this valuation model are summarized below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;<span id="xdx_8BC_zWO7z0wylKdf" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Derivative Key Valuation Inputs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">2022 Convertible Notes derivative key valuation inputs*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Issuance Dates</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Settlement Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated IPO date</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_zYV50vMb4Kpl" title="Estimated IPO date">8/31/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zK2pnOjpOfEl" title="Estimated IPO date">9/2/2022</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Probability of default</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z8XT09NZrZS2" title="Probability of default">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zyickfmFFPwk" title="Probability of default"><span style="-sec-ix-hidden: xdx2ixbrl3378">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Probability of IPO or Alternative Liquidity Event</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zViedUQmqePa" title="Probability of IPO or Alternative Liquidity Event">45</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221203__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_zeCONxG8il3e" title="Probability of IPO or Alternative Liquidity Event">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Probability of Maturity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z70biHfaABAd" title="Probability of Maturity">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zBayx5yPk7Le" title="Probability of Maturity"><span style="-sec-ix-hidden: xdx2ixbrl3386">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Time period (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z57pzvg3q9Nf" title="Time period (years)">1.00</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z3l5G2HZZkl6" title="Time period (years)">0.00</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Estimated fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zSD24dEZxe4b" title="Estimated fair value">31,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z78qN4UlNr08" title="Estimated fair value">75,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Derivative of Settlement Valuation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Derivative Key Valuation Inputs [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_AugustTwoThousandTwentyTwoNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_AugustTwoThousandTwentyTwoNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461009904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock', window );">Schedule of Reconciliation of Income Tax Benefit</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zuia5MsmHcik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zJ13jlUAhpRd" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></span></b></span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNnudPW8ZBD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z4DEPqCtDR89" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></span></span></span></b></span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zGX2v3cjwAYj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></span></span></span></b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate">21</span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z2tRzaeOyVg3" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zdjdEVmue1Gk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zfJ37FBIxa2e" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(as restated)</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,384,472</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,049,174</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes, net of federal tax effect</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(452,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(351,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Rate change</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,710</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(409</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzspy_zFfwkzSx8Rlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R &amp; D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(240,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(69,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Return to provision adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">286,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">201,235</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_iB_zfBXR3fVjSNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Permanent differences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_i01_maITEBzspy_zFPKFfQPSv17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative Debt Discount Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">562,568</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3509">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_i01_maITEBzspy_zWZOWC4F5JIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in FMV of Warrant Liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(617,655</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">217,926</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_i01_maITEBzspy_zmAom1OVDsn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on convertible note conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">132,984</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">503,249</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_i01_maITEBzspy_zVvkEdEmZTEh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">126,012</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">169,946</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,535,466</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">377,709</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shortfall of stock compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,674</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3524">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3529">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3530">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNnudPW8ZBD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z4DEPqCtDR89" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></span></span></span></b></span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zGX2v3cjwAYj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></span></span></span></b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zPU61r3hFOe7" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(as restated)</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax asset:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,727,566</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">751,844</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3537">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">804</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Intangibles (includes Section 174 capitalization)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,197,938</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">405,172</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">423,915</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">200,715</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,251</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,626</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest &amp; other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72,140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29,336</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease asset/(liability)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,326</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,889</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,429,136</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,401,386</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(as restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Change in fair market value of securities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(19,943</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3559">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(30,544</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(46,718</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsDeferredIncome_iNI_di_zxk4s8z19xdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income tax deferred</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3564">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(60,196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,746</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3568">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(53,233</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(106,914</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,375,903</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,294,472</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,375,903</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,294,472</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3579">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3580">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zGX2v3cjwAYj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></span></span></span></b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zI3yIfzm5n7c" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zaqDxtXO4WE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z1v7OlEmFVIa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income tax benefit, net of federal tax effect</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in tax rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3591">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Return to provision adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_iB_uPure_zOBXO0OlU256" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Permanent differences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_i01_pid_dp_uPure_maDEF_znJQzfgFZxP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Derivative Debt Discount Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3603">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_i01_pid_dp_uPure_maDEF_zq633uEUFSgc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in FMV of Warrant Liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_i01_pid_dp_uPure_maDEF_zC9Kr4APSLOc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on convertible note conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_i01_pid_dp_uPure_maDEF_zRz4rIboyPlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(23.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shortfall of stock compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3618">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-hidden: xdx2ixbrl3621">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3623">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3624">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Pretax Income From Continuing Operations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773456141152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited and Restated) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock', window );">Schedule of Quarterly Financial Data</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zWSfLbAcpoNc" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zaVdbSJYZaUe">Schedule
of Quarterly Financial Data</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zCJ5d5NxEJJe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restated consolidated balance sheet line items for the third fiscal quarter of 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zpA95ya3gad8">Schedule
of Quarterly Financial Data</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8jkE4tUBFO6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z81uuwNEseHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230930_z4FaFFsGclHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Restated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_zTeRcSTsNBP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Additional paid in capital <span id="xdx_F42_zJDO1gumiNob">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">19,456,841</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">29,402,533</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z9CGSTF3pEoc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,847,112</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,945,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(23,792,804</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zBq7OWkLDr08" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zuvLr0XRWxrh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital">140</span> and an offsetting adjustment to the carrying value of common stock.</span></td>
</tr></table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Quarterly Financial Data [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773460542624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Feb. 08, 2022</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 12, 2016</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,031,215<span></span>
</td>
<td class="nump">$ 1,731,031<span></span>
</td>
<td class="nump">$ 2,184,372<span></span>
</td>
<td class="nump">$ 975,097<span></span>
</td>
<td class="nump">$ 3,762,246<span></span>
</td>
<td class="nump">$ 3,159,468<span></span>
</td>
<td class="nump">$ 6,592,723<span></span>
</td>
<td class="nump">$ 4,996,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 826,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.04<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,336<span></span>
</td>
<td class="nump">$ 92,336<span></span>
</td>
<td class="nump">$ 418,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Initiated a capital offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,935,000<span></span>
</td>
<td class="nump">$ 3,935,000<span></span>
</td>
<td class="nump">$ 550,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008,689<span></span>
</td>
<td class="nump">1,700,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008,689<span></span>
</td>
<td class="nump">1,700,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Adjustments to additional paid in capital stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-8 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,111,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,111,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SHPH_InstitutionalInvestorMember', window );">Institutional Investor [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Initiated a capital offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock membership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Institutional Investor [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of ownership interest of different classes of partners in limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SHPH_InstitutionalInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SHPH_InstitutionalInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773449183520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Error Corrections And Prior Period Adjustments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,996,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,996,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,489,055<span></span>
</td>
<td class="nump">$ 26,518,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 12,063,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 29,402,533<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,195,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,195,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,433,304)<span></span>
</td>
<td class="num">(18,840,581)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,844,512)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(23,792,804)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of contract expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 839,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,823<span></span>
</td>
<td class="nump">$ 1,761,466<span></span>
</td>
<td class="nump">3,517,093<span></span>
</td>
<td class="nump">1,047,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,647<span></span>
</td>
<td class="nump">464,633<span></span>
</td>
<td class="nump">1,046,854<span></span>
</td>
<td class="nump">473,714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001,011<span></span>
</td>
<td class="nump">784,312<span></span>
</td>
<td class="nump">1,328,435<span></span>
</td>
<td class="nump">822,727<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,482,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,465,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,867,481)<span></span>
</td>
<td class="num">(3,010,411)<span></span>
</td>
<td class="num">(5,892,382)<span></span>
</td>
<td class="num">(2,343,826)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FinanceFee', window );">Financing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(104,245)<span></span>
</td>
<td class="num">(104,245)<span></span>
</td>
<td class="num">(189,912)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,089<span></span>
</td>
<td class="nump">1,675,275<span></span>
</td>
<td class="nump">2,216,488<span></span>
</td>
<td class="num">(189,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (146,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(398,675)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 1,531,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,795,652)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,592,723)<span></span>
</td>
<td class="num">(4,996,069)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(402,064)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock', window );">Deemed dividend on extinguishment of Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(439,427)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated', window );">Deemed dividend on modification of equity-classified warrants, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(941,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated', window );">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,423<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,031,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,184,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,762,246)<span></span>
</td>
<td class="num">$ (3,159,468)<span></span>
</td>
<td class="num">$ (6,592,723)<span></span>
</td>
<td class="num">$ (6,747,137)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (1.81)<span></span>
</td>
<td class="num">$ (3.53)<span></span>
</td>
<td class="num">$ (5.04)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per shares - Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (1.81)<span></span>
</td>
<td class="num">$ (3.53)<span></span>
</td>
<td class="num">$ (5.04)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs</a></td>
<td class="nump">$ 2,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,951,356<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,031,249<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForCash', window );">Common stock issued for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsExercisedForCash', window );">Warrants exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,816<span></span>
</td>
<td class="nump">14,662<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock issued for conversion of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,153,124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,162<span></span>
</td>
<td class="nump">$ 111,449<span></span>
</td>
<td class="nump">$ 49,522<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="nump">237,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DividendsOnSeriesPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402,064)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,064<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering', window );">Reclassification of fair value of warrant liability to equity upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">881,553<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,031,215)<span></span>
</td>
<td class="num">$ (1,731,031)<span></span>
</td>
<td class="num">(2,184,372)<span></span>
</td>
<td class="num">(975,097)<span></span>
</td>
<td class="num">$ (3,762,246)<span></span>
</td>
<td class="num">$ (3,159,468)<span></span>
</td>
<td class="num">(6,592,723)<span></span>
</td>
<td class="num">(4,996,069)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(434,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,089)<span></span>
</td>
<td class="num">(1,675,275)<span></span>
</td>
<td class="num">(2,216,488)<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">398,675<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and finance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,014<span></span>
</td>
<td class="nump">1,116,422<span></span>
</td>
<td class="nump">2,123,049<span></span>
</td>
<td class="nump">377,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,315<span></span>
</td>
<td class="nump">433,807<span></span>
</td>
<td class="nump">477,221<span></span>
</td>
<td class="nump">1,795,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds', window );">Fair value of freestanding instruments in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">189,912<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnInterestReliefOnConversionOfNotesPayable', window );">Gain on interest relief on conversion of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,611<span></span>
</td>
<td class="nump">57,855<span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="nump">237,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,445<span></span>
</td>
<td class="nump">75,511<span></span>
</td>
<td class="nump">110,453<span></span>
</td>
<td class="nump">18,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,638,425)<span></span>
</td>
<td class="num">(2,984,039)<span></span>
</td>
<td class="num">(5,581,147)<span></span>
</td>
<td class="num">(2,666,411)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants', window );">Proceeds from issuance of common shares and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,995,513<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,935,000<span></span>
</td>
<td class="nump">3,935,000<span></span>
</td>
<td class="nump">550,715<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromNotesPayableAndWarrants', window );">Proceeds from notes payable and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment for finance costs related to convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,363)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(501,667)<span></span>
</td>
<td class="nump">2,904,527<span></span>
</td>
<td class="nump">2,570,083<span></span>
</td>
<td class="nump">10,578,865<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedUponConversionOfConvertibleDebt', window );">Common stock issued upon conversion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,153,124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">402,064<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuedForFinancingFees', window );">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,816<span></span>
</td>
<td class="nump">$ 90,816<span></span>
</td>
<td class="nump">$ 14,662<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuanceFees', window );">Warranst of issuance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(428,688)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,543,363<span></span>
</td>
<td class="nump">16,572,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,150,948<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,456,841<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,487,612)<span></span>
</td>
<td class="num">(8,894,889)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,795,432)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,847,112)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of contract expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,148,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,796<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866,770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,554,278)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FinanceFee', window );">Financing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,028,448)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,009)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock', window );">Deemed dividend on extinguishment of Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated', window );">Deemed dividend on modification of equity-classified warrants, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated', window );">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,099,457)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per shares - Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForCash', window );">Common stock issued for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,008,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsExercisedForCash', window );">Warrants exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,098<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock issued for conversion of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,476<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DividendsOnSeriesPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,009)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering', window );">Reclassification of fair value of warrant liability to equity upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,028,448)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,025)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and finance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds', window );">Fair value of freestanding instruments in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnInterestReliefOnConversionOfNotesPayable', window );">Gain on interest relief on conversion of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,177)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,710,454)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants', window );">Proceeds from issuance of common shares and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,022,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,715<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromNotesPayableAndWarrants', window );">Proceeds from notes payable and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment for finance costs related to convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,622,908<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedUponConversionOfConvertibleDebt', window );">Common stock issued upon conversion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576,476<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuedForFinancingFees', window );">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412,241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(917,879)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,945,692<span></span>
</td>
<td class="nump">9,945,692<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,912,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">9,945,692<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,945,692)<span></span>
</td>
<td class="num">(9,945,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">$ (8,049,080)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">$ (9,945,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of contract expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,327)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,082)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,043)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FinanceFee', window );">Financing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189,912)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(492,700)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,795,652)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,967,621)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(331,055)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock', window );">Deemed dividend on extinguishment of Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(439,427)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated', window );">Deemed dividend on modification of equity-classified warrants, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(941,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated', window );">Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,423<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,647,680)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per shares - Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,951,356<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForCash', window );">Common stock issued for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,008,095)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsExercisedForCash', window );">Warrants exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,098)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(397,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock issued for conversion of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(588,524)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible debt and exercise of related warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,576,648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166,409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DividendsOnSeriesPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(331,055)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering', window );">Reclassification of fair value of warrant liability to equity upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,553<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,967,621)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and finance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(508,121)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,795,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds', window );">Fair value of freestanding instruments in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,912<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnInterestReliefOnConversionOfNotesPayable', window );">Gain on interest relief on conversion of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166,409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,555<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,043<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants', window );">Proceeds from issuance of common shares and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,680)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromNotesPayableAndWarrants', window );">Proceeds from notes payable and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment for finance costs related to convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,363)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,043)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedUponConversionOfConvertibleDebt', window );">Common stock issued upon conversion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,576,648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuedForFinancingFees', window );">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (397,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member] | Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,191<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital">140</span> and an offsetting adjustment to the carrying value of common stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Adjustments
    include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj" title="Stock compensation">7,843,052</span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8" title="Accrued dividends">402,064</span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta" title="Issuance cost">174,082</span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8" title="Warrants">416,266</span>),
    reclassifications of warrants from liability to equity (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh" title="Warrants from liability">881,554</span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l" title="Debt instrument">2,213,498</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk" title="Increase decrease of notes payable">7,351</span>); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh" title="Increase decrease in preferred stock">89,118</span>); and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l" title="Stock compensation">8,009,461</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Adjustments include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a" title="Stock compensation">8,009,461</span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc" title="Fair value of warrants">240,930</span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a" title="Accrued dividends">402,064</span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih" title="Derivatives loss">296,151</span>); correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e" title="Issuance cost">166,407</span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf" title="Net income loss">1,967,621</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    include reversal of dividend liability recorded (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1" title="Increase decrease in dividend liability">331,059</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of deferred IPO costs (decrease of ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi">55,182</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh">89,118</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the estimated fair value of warrant liability (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63">240,930</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj">274,048</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc">8,009,461</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares issued for dividends on and conversion of series preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for exercise of warrants with settlement of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedUponConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued upon conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedUponConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends as restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on extinguishment of series preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on modification of equity classified warrants as restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DividendsOnSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends on series preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DividendsOnSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of free standing Instruments In excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_FinanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_FinanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnInterestReliefOnConversionOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on interest relief on conversion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnInterestReliefOnConversionOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LossOnSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LossOnSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ProceedsFromNotesPayableAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from notes payable and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ProceedsFromNotesPayableAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of fair value of warrant liability to equity upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuedForFinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued for financing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuedForFinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479083/946-230-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773446662688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivatives loss</a></td>
<td class="num">$ (143,773)<span></span>
</td>
<td class="nump">$ 434,275<span></span>
</td>
<td class="nump">$ 54,089<span></span>
</td>
<td class="nump">$ 1,675,275<span></span>
</td>
<td class="nump">$ 2,216,488<span></span>
</td>
<td class="num">$ (189,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,843,052<span></span>
</td>
<td class="nump">$ 8,009,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDividendsReceivable', window );">Accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInIssuanceCost', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInWarrants', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInWarrantsFromLiability', window );">Warrants from liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,213,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent', window );">Increase decrease of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInPreferredStock', window );">Increase decrease in preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,009,461<span></span>
</td>
<td class="nump">8,009,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDividendsReceivable', window );">Accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInIssuanceCost', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,407<span></span>
</td>
<td class="nump">55,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInFairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,930<span></span>
</td>
<td class="nump">240,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivatives loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInNetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,967,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent', window );">Increase decrease of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInPreferredStock', window );">Increase decrease in preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInDividendLiability', window );">Increase decrease in dividend liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInDividendLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in dividend liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInDividendLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in net income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInWarrantsFromLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in warrants from liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInWarrantsFromLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDividendsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash disbursements due from investments, representing the shareholders' portion of profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDividendsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773459384336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of the Error Correction (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 645,719<span></span>
</td>
<td class="nump">$ 839,665<span></span>
</td>
<td class="nump">$ 1,231,823<span></span>
</td>
<td class="nump">$ 1,761,466<span></span>
</td>
<td class="nump">$ 3,517,093<span></span>
</td>
<td class="nump">$ 1,047,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 310,038<span></span>
</td>
<td class="nump">$ 209,279<span></span>
</td>
<td class="nump">$ 634,647<span></span>
</td>
<td class="nump">464,633<span></span>
</td>
<td class="nump">$ 1,046,854<span></span>
</td>
<td class="nump">473,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,226,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,148,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,226,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (65,082)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461422800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Cash and Cash Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 645,594<span></span>
</td>
<td class="nump">$ 1,550,098<span></span>
</td>
<td class="nump">$ 5,411,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">1,026,318<span></span>
</td>
<td class="nump">3,005,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 695,594<span></span>
</td>
<td class="nump">$ 2,576,416<span></span>
</td>
<td class="nump">$ 8,417,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773446768640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 1,642,995<span></span>
</td>
<td class="nump">$ 2,887,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="nump">504<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">360,423<span></span>
</td>
<td class="nump">414,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="nump">359,919<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityWarrants', window );">Derivative Liability - Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=SHPH_AcceleratedFeatureMember', window );">Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityAcceleratedFeature', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="nump">1,642,995<span></span>
</td>
<td class="nump">2,887,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">1,642,995<span></span>
</td>
<td class="nump">2,887,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityWarrants', window );">Derivative Liability - Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityAcceleratedFeature', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="nump">1,642,995<span></span>
</td>
<td class="nump">2,887,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityWarrants', window );">Derivative Liability - Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityAcceleratedFeature', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">360,423<span></span>
</td>
<td class="nump">414,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="nump">359,919<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityWarrants', window );">Derivative Liability - Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityAcceleratedFeature', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityAcceleratedFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability accelerated feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityAcceleratedFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=SHPH_AcceleratedFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=SHPH_AcceleratedFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773463996544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">323,583<span></span>
</td>
<td class="nump">349,760<span></span>
</td>
<td class="nump">328,670<span></span>
</td>
<td class="nump">50,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">80,744<span></span>
</td>
<td class="nump">155,378<span></span>
</td>
<td class="nump">119,939<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">47,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">58,839<span></span>
</td>
<td class="nump">10,382<span></span>
</td>
<td class="nump">24,731<span></span>
</td>
<td class="nump">2,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773449164032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 13, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Integer </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Minimum bid price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008,689<span></span>
</td>
<td class="nump">1,700,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008,689<span></span>
</td>
<td class="nump">1,700,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,038<span></span>
</td>
<td class="nump">$ 209,279<span></span>
</td>
<td class="nump">$ 634,647<span></span>
</td>
<td class="nump">$ 464,633<span></span>
</td>
<td class="nump">$ 1,046,854<span></span>
</td>
<td class="nump">$ 473,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securitie outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,887,215<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,158<span></span>
</td>
<td class="nump">19,267<span></span>
</td>
<td class="nump">35,611<span></span>
</td>
<td class="nump">35,955<span></span>
</td>
<td class="nump">79,117<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,683<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">43,720<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,964<span></span>
</td>
<td class="nump">26,534<span></span>
</td>
<td class="nump">28,670<span></span>
</td>
<td class="num">(11,528)<span></span>
</td>
<td class="num">(71,568)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,611<span></span>
</td>
<td class="nump">35,955<span></span>
</td>
<td class="nump">52,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Marketable securities realized gain loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,720<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Marketable securities unrealized gain loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,670<span></span>
</td>
<td class="nump">11,528<span></span>
</td>
<td class="nump">71,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,611<span></span>
</td>
<td class="nump">57,855<span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="nump">237,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,964)<span></span>
</td>
<td class="num">(26,534)<span></span>
</td>
<td class="num">(28,670)<span></span>
</td>
<td class="nump">11,528<span></span>
</td>
<td class="nump">71,568<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development, net of contract expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">608,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable operating segments | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 66,960<span></span>
</td>
<td class="nump">131,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensations', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Minimum bid price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-8 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued | shares</a></td>
<td class="nump">2,111,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="nump">2,111,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773455646288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 22,947<span></span>
</td>
<td class="nump">$ 25,193<span></span>
</td>
<td class="nump">$ 45,894<span></span>
</td>
<td class="nump">$ 42,737<span></span>
</td>
<td class="nump">$ 112,022<span></span>
</td>
<td class="nump">$ 70,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">9,937<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,377<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,222<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(2,163)<span></span>
</td>
<td class="num">(2,121)<span></span>
</td>
<td class="num">(4,326)<span></span>
</td>
<td class="num">(4,242)<span></span>
</td>
<td class="num">(7,819)<span></span>
</td>
<td class="num">(7,070)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">30,721<span></span>
</td>
<td class="nump">23,072<span></span>
</td>
<td class="nump">61,945<span></span>
</td>
<td class="nump">38,495<span></span>
</td>
<td class="nump">128,425<span></span>
</td>
<td class="nump">63,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating cash flows from operating leases</a></td>
<td class="nump">22,707<span></span>
</td>
<td class="nump">23,331<span></span>
</td>
<td class="nump">45,189<span></span>
</td>
<td class="nump">42,771<span></span>
</td>
<td class="nump">95,641<span></span>
</td>
<td class="nump">76,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 365,556<span></span>
</td>
<td class="nump">$ 365,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773567324640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Balance Sheet Information Related to Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (year)</a></td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">10.48%<span></span>
</td>
<td class="nump">10.46%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773458773872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (excluding the six months ended June 30, 2024)</a></td>
<td class="nump">$ 46,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">94,246<span></span>
</td>
<td class="nump">$ 91,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">97,074<span></span>
</td>
<td class="nump">94,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">99,986<span></span>
</td>
<td class="nump">97,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">68,235<span></span>
</td>
<td class="nump">99,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">405,854<span></span>
</td>
<td class="nump">451,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(76,737)<span></span>
</td>
<td class="num">(94,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of payments</a></td>
<td class="nump">$ 329,117<span></span>
</td>
<td class="nump">$ 356,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773456700080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2023<span></span>
</td>
<td class="text">Oct. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The first was for a monthly payment
of $6,480, with a security deposit of $6,480 held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EstimatedMonthlyCommonAreaMaintenanceCost', window );">Estimated monthly common area maintenance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 43,234<span></span>
</td>
<td class="nump">43,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonAreaMaintenanceCost', window );">Common area maintenance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=SHPH_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 7,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">64 months<span></span>
</td>
<td class="text">64 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_RentVariableRate1', window );">Rent variable rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">commenced June 1, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PercentageOfRentAbatement', window );">Percentage of rent abatement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EstimatedMonthlyCommonAreaMaintenanceCost', window );">Estimated monthly common area maintenance cost</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=SHPH_LeaseAgreementMember', window );">Lease Agreement [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Mar.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 3,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PercentageOfRentAbatement', window );">Percentage of rent abatement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 43,234<span></span>
</td>
<td class="nump">$ 43,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonAreaMaintenanceCost', window );">Common area maintenance cost</a></td>
<td class="nump">$ 3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=SHPH_NewLeaseAgreementMember', window );">New Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_RentVariableRate1', window );">Rent variable rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">commenced June 1, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonAreaMaintenanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common area maintenance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonAreaMaintenanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EstimatedMonthlyCommonAreaMaintenanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated monthly common area maintenance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EstimatedMonthlyCommonAreaMaintenanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PercentageOfRentAbatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of rent abatement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PercentageOfRentAbatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_RentVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent Variable Rate1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_RentVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=SHPH_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=SHPH_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=SHPH_NewLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=SHPH_NewLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773459938592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable-Related Party (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Jun. 21, 2021</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,958<span></span>
</td>
<td class="nump">$ 102,373<span></span>
</td>
<td class="nump">$ 164,807<span></span>
</td>
<td class="nump">$ 39,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturiy date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Increase accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments upon subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">685,473<span></span>
</td>
<td class="nump">$ 685,473<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Loan transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 426,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related Party Transaction, Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Related Party Transaction, Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments upon subscription</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Repayments of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember', window );">Related Party Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Loan transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related Party Transaction, Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773438614048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes and Notes Payable (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 06, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,517,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,517,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,254,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.04<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,935,000<span></span>
</td>
<td class="nump">3,935,000<span></span>
</td>
<td class="nump">$ 550,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">398,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Allocation of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,512<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,877<span></span>
</td>
<td class="nump">$ 416,688<span></span>
</td>
<td class="nump">1,001,011<span></span>
</td>
<td class="nump">784,312<span></span>
</td>
<td class="nump">1,328,435<span></span>
</td>
<td class="nump">$ 822,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,505<span></span>
</td>
<td class="nump">549,125<span></span>
</td>
<td class="nump">832,014<span></span>
</td>
<td class="nump">1,012,177<span></span>
</td>
<td class="nump">2,123,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Principal balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Settled for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,958<span></span>
</td>
<td class="nump">102,373<span></span>
</td>
<td class="nump">164,807<span></span>
</td>
<td class="nump">$ 39,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,523,768<span></span>
</td>
<td class="nump">331,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ConvertibleNotesPayableCurrentNonCurrent', window );">Convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MediumTermNotes', window );">Term notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtDescription', window );">Term note description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no more than 25% of the
amount forgiven to be attributable to non-payroll costs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 28,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,336<span></span>
</td>
<td class="nump">$ 92,336<span></span>
</td>
<td class="nump">$ 418,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">83.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants', window );">Deemed dividend on modification of equity classified warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,531,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,795,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,951,356<span></span>
</td>
<td class="nump">$ 2,031,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,363<span></span>
</td>
<td class="nump">$ 17,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="nump">17,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Principal increase decrease rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Gain (loss) on sale of assets and asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable-related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FinanceFee', window );">Finance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">104,245<span></span>
</td>
<td class="nump">104,245<span></span>
</td>
<td class="nump">$ 189,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Principal balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,527,750<span></span>
</td>
<td class="nump">$ 235,200<span></span>
</td>
<td class="nump">$ 1,593,900<span></span>
</td>
<td class="nump">$ 1,925,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Principal balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">228,489<span></span>
</td>
<td class="nump">78,197<span></span>
</td>
<td class="nump">234,864<span></span>
</td>
<td class="nump">297,625<span></span>
</td>
<td class="nump">352,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember', window );">Boustead Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="nump">22,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentForPlacementAgent', window );">Payment for placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Allocation of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Equity warrant as reduction in additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,685<span></span>
</td>
<td class="nump">$ 729,351<span></span>
</td>
<td class="nump">928,200<span></span>
</td>
<td class="nump">$ 1,328,682<span></span>
</td>
<td class="nump">2,484,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,527,750<span></span>
</td>
<td class="nump">235,200<span></span>
</td>
<td class="nump">1,593,900<span></span>
</td>
<td class="nump">1,925,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 220,689<span></span>
</td>
<td class="nump">18,783<span></span>
</td>
<td class="nump">$ 240,831<span></span>
</td>
<td class="nump">294,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IssuanceOfWarrantsShares', window );">Issuance of warrants shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember', window );">Alto Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_ConvertibleNoteMember', window );">Convertible Note [Member] | Boustead Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InterestFeeAmount', window );">Interest fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,310,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,310,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember', window );">2022 Convertible Bridge Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">$ 365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,715<span></span>
</td>
<td class="nump">$ 525,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Debt instrument conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,285<span></span>
</td>
<td class="nump">$ 64,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Principal increase decrease rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Debt issuance costs related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Payments of derivative issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember', window );">2022 Convertible Bridge Notes [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember', window );">2022 Convertible Bridge Notes [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember', window );">2022 Convertible Bridge Notes [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember', window );">2022 Convertible Bridge Notes [Member] | Boustead Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwentyTwentyTwoPromissoryNotesMember', window );">August 2022 [Promissory Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Principal balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Debt instrument conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable-related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FinanceFee', window );">Finance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt Instrument, Unamortized Discount, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwentyTwentyTwoConvertibleNotesMember', window );">August 2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Debt instrument conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoNotesMember', window );">August 2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal balance</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase | shares</a></td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable, as restated</a></td>
<td class="nump">$ 3,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">346.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt description</a></td>
<td class="text">the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $18.80
per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Alto Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">218.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ConvertibleNotesPayableCurrentNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes payable current noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ConvertibleNotesPayableCurrentNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on modification of equity-classified warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_FinanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_FinanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_InterestFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest fee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_InterestFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IssuanceOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IssuanceOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PaymentForPlacementAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for placement agent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PaymentForPlacementAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt instrument classified as medium-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of borrowing classified as short-term upon issuance. Includes, but is not limited to, description of underlying arrangement, repayment terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwentyTwentyTwoPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AugustTwentyTwentyTwoPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwentyTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AugustTwentyTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773462913088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Activity (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding, balance</a></td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">47,831<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding balance</a></td>
<td class="nump">$ 23.21<span></span>
</td>
<td class="nump">$ 35.77<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average life (years), outstanding balance</a></td>
<td class="text">2 years 3 months 14 days<span></span>
</td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">2 years 9 months 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants outstanding, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding, balance</a></td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">47,831<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding balance</a></td>
<td class="nump">$ 23.20<span></span>
</td>
<td class="nump">$ 23.21<span></span>
</td>
<td class="nump">$ 35.77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average life (years), outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants outstanding, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Boustead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants outstanding, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="nump">270,910<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="nump">$ 14.57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average life (years), granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 8 months 4 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Ayrton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants outstanding, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average life (years), granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Granted
    warrants include those granted on the issuance of the August 2022 Promissory Notes</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life in Years Outstanding, Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life in Years Outstanding,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_BousteadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_BousteadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_AyrtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_AyrtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461004992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (RSUs) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Outstanding, Beginning Balance</a></td>
<td class="nump">24,731<span></span>
</td>
<td class="nump">2,966<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per RSU, Beginning Balance</a></td>
<td class="nump">$ 11.76<span></span>
</td>
<td class="nump">$ 22.48<span></span>
</td>
<td class="nump">$ 185.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Stock Option Outstanding, Granted</a></td>
<td class="nump">53,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 2.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="num">(19,347)<span></span>
</td>
<td class="num">(10,650)<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per RSU, Vested</a></td>
<td class="nump">$ 7.58<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 116.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Outstanding, Ending Balance</a></td>
<td class="nump">58,839<span></span>
</td>
<td class="nump">24,731<span></span>
</td>
<td class="nump">2,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per RSU, Ending Balance</a></td>
<td class="nump">$ 4.87<span></span>
</td>
<td class="nump">$ 11.76<span></span>
</td>
<td class="nump">$ 22.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Option Outstanding, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,415<span></span>
</td>
<td class="nump">4,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.88<span></span>
</td>
<td class="nump">$ 22.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773439002416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 07, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Feb. 08, 2022</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 12, 2016</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,625<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 558,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccruedInterestValueToIssueShares', window );">Accrued interest settled with common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,553<span></span>
</td>
<td class="nump">71,315<span></span>
</td>
<td class="nump">$ 433,807<span></span>
</td>
<td class="nump">$ 477,221<span></span>
</td>
<td class="nump">$ 1,795,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.04<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock award granted value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,611<span></span>
</td>
<td class="nump">57,855<span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="nump">$ 237,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock consideration received per transaction</a></td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation arrangement by share based payment award description</a></td>
<td class="text">(i) one share of the Company&#8217;s
common stock, (ii) a warrant to purchase one share of the Company&#8217;s common stock exercisable at a purchase price of $18.80 per share,
and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a
22% interest in Diagnostics.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockVestingOfRestrictedStockUnit', window );">Common stock vesting of restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares', window );">Number shares issued for conversion of note, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfDividends', window );">Number shares issued for conversion dividends payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Gain (Loss) on Sale of Assets and Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">398,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,951,356<span></span>
</td>
<td class="nump">$ 2,031,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock value share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 439,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends', window );">Deemed contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued for conversion, vallue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsDescription', window );">Warrants description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Series A Preferred Stock sold in the Company&#8217;s 2018 and 2019 private placement offerings included warrants to be issued upon
the earlier of a closing of the sale of shares of common stock to the public or upon a listing of the Company&#8217;s common stock.
The warrants will be exercisable for a period of three years after the date of issuance at an exercise price contingent on the terms
of the public offering. The initial form of the warrants were expected to include contingent call features based on the terms of the
public offering. As originally drafted, if an initial public offering occurs at a price at or above $111.04, then the warrants are
callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise price. In the scenario where the common
stock is listed with a common stock issuance price below $111.04, then the warrants are callable if the 20-day VWAP of the common
stock is at or above the $166.56 exercise price. Upon the issuance of the warrants in September 2022, the contingent call features
were not included in the agreements. Given the variability in the number of warrants and exercise price, the detachable warrants
contained terms and features that gave rise to liability classification.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantSharePrice', window );">Warrant share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,518,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,996,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,996,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,489,055<span></span>
</td>
<td class="nump">$ 26,518,433<span></span>
</td>
<td class="nump">$ 12,063,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 29,402,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">83.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Four year warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CumulativeDividendsPercentage', window );">Cumulative dividends percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock value share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantObligationLiability', window );">Warrants obligation liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 421,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 421,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember', window );">Boustead Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,527,750<span></span>
</td>
<td class="nump">$ 235,200<span></span>
</td>
<td class="nump">1,593,900<span></span>
</td>
<td class="nump">$ 1,925,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="nump">22,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IssuanceOfWarrantsShares', window );">Issuance of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Cumulative dividends, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CumulativeDividendsPercentage', window );">Cumulative dividends percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeDividends', window );">Cumulative dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued for conversion, vallue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Right offering</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionalEscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InitialPublicOfferingDescription', window );">Initial public offering description</a></td>
<td class="text">Unless
the parties waive the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the
Company&#8217;s existing stockholders, the Company will not close on the offering and any funds raised and held in escrow will be
returned to investors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Commitment fee</a></td>
<td class="nump">$ 112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Related expense</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">66,960<span></span>
</td>
<td class="nump">$ 131,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Compensation under research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,190<span></span>
</td>
<td class="nump">46,986<span></span>
</td>
<td class="nump">41,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,611<span></span>
</td>
<td class="nump">$ 57,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,550<span></span>
</td>
<td class="nump">$ 61,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Life (Years), Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 21 days<span></span>
</td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Directors And Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock award granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,291<span></span>
</td>
<td class="nump">53,455<span></span>
</td>
<td class="nump">7,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock award granted value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,400<span></span>
</td>
<td class="nump">$ 141,840<span></span>
</td>
<td class="nump">$ 95,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Directors Officers and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock award granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,415<span></span>
</td>
<td class="nump">4,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock award granted value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,400<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share granted under equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember', window );">Alto Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember', window );">2022 Convertible Note Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_DecemberTwentyThousandTwentyOneNotesMember', window );">December 2021 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoNotesMember', window );">August 2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember', window );">2022 Convertible Bridge Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,285<span></span>
</td>
<td class="nump">$ 64,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember', window );">2022 Convertible Bridge Notes [Member] | Boustead Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,489<span></span>
</td>
<td class="nump">78,197<span></span>
</td>
<td class="nump">234,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,527,750<span></span>
</td>
<td class="nump">$ 235,200<span></span>
</td>
<td class="nump">$ 1,593,900<span></span>
</td>
<td class="nump">$ 1,925,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccruedInterestValueToIssueShares', window );">Accrued interest settled with common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,689<span></span>
</td>
<td class="nump">18,783<span></span>
</td>
<td class="nump">240,831<span></span>
</td>
<td class="nump">294,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,553<span></span>
</td>
<td class="nump">$ 71,315<span></span>
</td>
<td class="nump">$ 433,807<span></span>
</td>
<td class="nump">$ 477,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock award granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
<td class="nump">15,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,650<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock award granted value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueDividendsPayable', window );">Common stock issued for dividends payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Cumulative dividends, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,489<span></span>
</td>
<td class="nump">78,197<span></span>
</td>
<td class="nump">234,864<span></span>
</td>
<td class="nump">297,625<span></span>
</td>
<td class="nump">352,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued for conversion, vallue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedUponCompletion', window );">Stock issued upon completion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,951,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Cumulative dividends, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Four year warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Four year warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Black Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2022 Convertible Note Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Cumulative dividends, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedUponCompletionShares', window );">Common stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember', window );">Warrant Liability Boustead Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilitiesExercised', window );">Warrant liabilities exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="29"></td></tr>
<tr><td colspan="29"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital">140</span> and an offsetting adjustment to the carrying value of common stock.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AccruedInterestValueToIssueShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest value to issue shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AccruedInterestValueToIssueShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AdditionalEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional escrow deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AdditionalEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockVestingOfRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock vesting of restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockVestingOfRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CumulativeDividendsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative dividends percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CumulativeDividendsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed contribution of conversion of preferred stock and settlement of preferred stock dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_InitialPublicOfferingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial public offering description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_InitialPublicOfferingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IssuanceOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IssuanceOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LossOnSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LossOnSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesConversionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesConversionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodValueDividendsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value dividends payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodValueDividendsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedUponCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued upon completion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedUponCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedUponCompletionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued upon completion, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedUponCompletionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantLiabilitiesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantLiabilitiesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantObligationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant obligation liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantObligationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends distributed to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate direct operating costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SHPH_DirectorsOfficersAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SHPH_DirectorsOfficersAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_DecemberTwentyThousandTwentyOneNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_DecemberTwentyThousandTwentyOneNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SHPH_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773464017808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Monte Carlo Simulation Assumption (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_AltoWarrantsMember', window );">Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 410,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">64.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">34.23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">89.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77.51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74.98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">59.15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">99.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92.33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4.68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5.48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Minimum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">18.80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Minimum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Maximum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember', window );">Illiquidity Discount [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember', window );">Illiquidity Discount [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember', window );">Illiquidity Discount [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">0 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">0 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">1 month 9 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">6 months 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">2 years 6 months 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">3 years 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Estimated fair value issuance | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,442,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,852<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Estimated fair value issuance | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,189,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Based on a Monte Carlo simulation analysis of 50,000 iterations</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Based on a Monte Carlo simulation analysis of 250,000 iterations</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition of new derivatives recognized as debt discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_AltoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_AltoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773456289712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_AltoWarrantsMember', window );">Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=SHPH_AcceleratedFeatureMember', window );">Accelerated Feature [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,531)<span></span>
</td>
<td class="num">(1,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">504<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain loss on change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">214,615<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145,304<span></span>
</td>
<td class="num">(196,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">359,919<span></span>
</td>
<td class="nump">214,615<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain loss on change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (145,304)<span></span>
</td>
<td class="nump">196,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | December 2021 Notes Derivative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">205,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain loss on change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(205,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeSettlementsOnDerivativeWarrants', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | August 2022 Notes Derivative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain loss on change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeSettlementsOnDerivativeWarrants', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | 2022 Convertible Notes Derivative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain loss on change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeSettlementsOnDerivativeWarrants', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(571,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Alto Acceleration Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,148<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain loss on change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,438,148)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Alto Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,660<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778,340<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,660<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain loss on change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (778,340)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeSettlementsOnDerivativeWarrants', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Notes Derivative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | August 2022 Notes Derivative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | 2022 Convertible Notes Derivative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Based on a Monte Carlo simulation analysis of 50,000 iterations</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition of new derivatives recognized as debt discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeGainLossOnDerivativeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative gain loss on derivative warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeGainLossOnDerivativeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeSettlementsOnDerivativeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Settlements on Derivative [Warrants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeSettlementsOnDerivativeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_AltoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_AltoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=SHPH_AcceleratedFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=SHPH_AcceleratedFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_AltoAccelerationOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_AltoAccelerationOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_NotesDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_NotesDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773457750688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liabilities (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 28, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares warrant to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.04<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability non-current</a></td>
<td class="nump">$ 359,919<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 414,512<span></span>
</td>
<td class="nump">$ 1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative fair value</a></td>
<td class="nump">$ 360,423<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue', window );">Warrants price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 410,660<span></span>
</td>
<td class="nump">$ 1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Share price | $ / shares</a></td>
<td class="nump">3.12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeDiscountPercentage', window );">Derivative discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares warrant to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Based on a Monte Carlo simulation analysis of 250,000 iterations</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class pf warrant or right number of securities called by warrants or rights value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative discount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773570425472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research, development expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 608,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember', window );">TCG Green Chem Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,096,370<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to invoices in research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PaymentsToInvoicesInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773459639200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Key Inputs of Warrant Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 28, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.04<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Estimated Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value | $</a></td>
<td class="nump">$ 146,624<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 398,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsEstimatedFairValue', window );">Estimated fair value of company's stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Estimated IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Estimated Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,723<span></span>
</td>
<td class="nump">$ 334,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.825<span></span>
</td>
<td class="nump">0.863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0344<span></span>
</td>
<td class="nump">0.0108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member] | Measurement Input Probability of IPO Listing Occurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member] | Measurement Input Probability of Qualified IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member] | Measurement Input Probability of IPO Listing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Series A Preferred Stock Obligation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability August 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsEstimatedFairValue', window );">Estimated fair value of company's stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Estimated Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,726<span></span>
</td>
<td class="nump">$ 146,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability August 2022 Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.825<span></span>
</td>
<td class="nump">0.800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability August 2022 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.033<span></span>
</td>
<td class="nump">0.027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Boustead Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsEstimatedFairValue', window );">Estimated fair value of company's stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,581<span></span>
</td>
<td class="nump">3,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Estimated Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Estimated fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,140<span></span>
</td>
<td class="nump">$ 92,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Boustead Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.825<span></span>
</td>
<td class="nump">0.861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Boustead Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Boustead Placement Agent Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Estimated Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Boustead Placement Agent Warrants [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Boustead Placement Agent Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Estimated Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability Boustead Placement Agent Warrants [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputProbabilityOfQualifiedIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputProbabilityOfQualifiedIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputProbabilityOfIPOListingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputProbabilityOfIPOListingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773457330816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember', window );">Warrant Liability Series A Preferred Stock Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 334,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilitiesIssued', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilitiesExercised', window );">Exercised (settled)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnChangeInFairValue', window );">Gain on change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReclassificationsToStockholdersEquity', window );">Reclassifications to stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(756,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember', window );">Warrant Liability August 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilitiesIssued', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilitiesExercised', window );">Exercised (settled)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnChangeInFairValue', window );">Gain on change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReclassificationsToStockholdersEquity', window );">Reclassifications to stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember', window );">Warrant Liability Boustead Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilitiesIssued', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilitiesExercised', window );">Exercised (settled)</a></td>
<td class="nump">$ 64,140<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnChangeInFairValue', window );">Gain on change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReclassificationsToStockholdersEquity', window );">Reclassifications to stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on change in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ReclassificationsToStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassifications to stockholders equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ReclassificationsToStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantLiabilitiesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantLiabilitiesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantLiabilitiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantLiabilitiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773460004848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Useful Lives for Property Plant Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773457529904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 22,947<span></span>
</td>
<td class="nump">$ 25,193<span></span>
</td>
<td class="nump">$ 45,894<span></span>
</td>
<td class="nump">$ 42,737<span></span>
</td>
<td class="nump">$ 112,022<span></span>
</td>
<td class="nump">$ 70,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">9,937<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,377<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,222<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(2,163)<span></span>
</td>
<td class="num">(2,121)<span></span>
</td>
<td class="num">(4,326)<span></span>
</td>
<td class="num">(4,242)<span></span>
</td>
<td class="num">(7,819)<span></span>
</td>
<td class="num">(7,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">30,721<span></span>
</td>
<td class="nump">23,072<span></span>
</td>
<td class="nump">61,945<span></span>
</td>
<td class="nump">38,495<span></span>
</td>
<td class="nump">128,425<span></span>
</td>
<td class="nump">63,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_OtherInformationAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">22,707<span></span>
</td>
<td class="nump">23,331<span></span>
</td>
<td class="nump">45,189<span></span>
</td>
<td class="nump">42,771<span></span>
</td>
<td class="nump">95,641<span></span>
</td>
<td class="nump">76,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 365,556<span></span>
</td>
<td class="nump">$ 365,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases (year)</a></td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">10.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.46%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461372704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Activity (Details) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="nump">176,222<span></span>
</td>
<td class="nump">176,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="nump">42,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember', window );">August 2022 Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_NotesPayableRelatedPartiesMember', window );">Notes Payable Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="nump">18,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_BousteadSecuritiesLLCMember', window );">Boustead Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="nump">27,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember', window );">August 2021 Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_TwoThousandAndTwentyOneConvertibleNotesMember', window );">2021 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_NotesPayableRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_NotesPayableRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_BousteadSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_BousteadSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_TwoThousandAndTwentyOneConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_TwoThousandAndTwentyOneConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773459362848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,611<span></span>
</td>
<td class="nump">$ 57,855<span></span>
</td>
<td class="nump">$ 181,960<span></span>
</td>
<td class="nump">$ 237,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, as restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">105,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, as restated</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 66,960<span></span>
</td>
<td class="nump">$ 131,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773456471952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liability Valuation (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Issuance Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfAcceleration', window );">Amount due upon acceleration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfCarringValueMeasurementDate', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfProbabilityAcceleration', window );">Probability of IPO acceleration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityDiscoutRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfAcceleration', window );">Amount due upon acceleration</a></td>
<td class="nump">$ 50,438<span></span>
</td>
<td class="nump">$ 533,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfCarringValueMeasurementDate', window );">Carrying value</a></td>
<td class="nump">$ 4,521<span></span>
</td>
<td class="nump">$ 337,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfProbabilityAcceleration', window );">Probability of IPO acceleration</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityDiscoutRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  02,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member] | Issuance Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period to maturity (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">Sep.  02,  2022<span></span>
</td>
<td class="text">Sep.  02,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period to maturity (years)</a></td>
<td class="text">10 months 28 days<span></span>
</td>
<td class="text">3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Issuance Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Estimated fair value</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityDiscoutRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability discout rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityDiscoutRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityMeasurementDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability measurement duration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityMeasurementDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityOfAcceleration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability of acceleration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityOfAcceleration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityOfCarringValueMeasurementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability of carring value measurement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityOfCarringValueMeasurementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityOfProbabilityAcceleration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability of probability acceleration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityOfProbabilityAcceleration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_SettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_SettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_IssuanceDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_IssuanceDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_SettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_SettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_IssuanceDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_IssuanceDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461247344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Key Valuation Inputs (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 03, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">Estimated IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">Estimated IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  02,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputSharePriceProbabilityOfIPOMember', window );">Measurement Input Share Price Probability Of IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputSharePriceProbabilityOfIPOMember', window );">Measurement Input Share Price Probability Of IPO [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputSharePriceProbabilityOfIPOMember', window );">Measurement Input Share Price Probability Of IPO [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period (years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Estimated fair value</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Issuance Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Estimated fair value</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityMeasurementDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability measurement duration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityMeasurementDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_SettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_SettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_IssuanceDatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_IssuanceDatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputSharePriceProbabilityOfIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputSharePriceProbabilityOfIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_IssuanceDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_IssuanceDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773457249344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Issuance Valuation Inputs (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfAcceleration', window );">Amount due upon acceleration</a></td>
<td class="nump">$ 50,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfCarringValueMeasurementDate', window );">Carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfProbabilityAcceleration', window );">Probability of IPO acceleration</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfDiscountRate', window );">Discount rate</a></td>
<td class="nump">16.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfAcceleration', window );">Amount due upon acceleration</a></td>
<td class="nump">$ 50,438<span></span>
</td>
<td class="nump">$ 533,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfCarringValueMeasurementDate', window );">Carrying value</a></td>
<td class="nump">$ 4,521<span></span>
</td>
<td class="nump">$ 337,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfProbabilityAcceleration', window );">Probability of IPO acceleration</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfDiscountRate', window );">Discount rate</a></td>
<td class="nump">18.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Issuance Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfAcceleration', window );">Amount due upon acceleration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfCarringValueMeasurementDate', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityOfProbabilityAcceleration', window );">Probability of IPO acceleration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Probability of Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  02,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">Sep.  02,  2022<span></span>
</td>
<td class="text">Sep.  02,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period to maturity (years)</a></td>
<td class="text">10 months 28 days<span></span>
</td>
<td class="text">3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember', window );">Measurement Input Ipo Date [Member] | Issuance Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate', window );">IPO date</a></td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeLiabilityMeasurementDuration', window );">Time period to maturity (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Issuance Dates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember', window );">Measurement Input Estimated Fair Value [Member] | Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 571,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityMeasurementDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability measurement duration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityMeasurementDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityOfAcceleration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability of acceleration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityOfAcceleration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityOfCarringValueMeasurementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability of carring value measurement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityOfCarringValueMeasurementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityOfDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability of discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityOfDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeLiabilityOfProbabilityAcceleration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability of probability acceleration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeLiabilityOfProbabilityAcceleration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_IssuanceDatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_IssuanceDatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SHPH_SettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SHPH_SettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_IssuanceDatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_IssuanceDatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_SettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_SettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=SHPH_IssuanceDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=SHPH_IssuanceDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIpoDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputEstimatedFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773446748368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Income Tax Benefit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">$ (1,384,472)<span></span>
</td>
<td class="num">$ (1,049,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax effect</a></td>
<td class="num">(452,682)<span></span>
</td>
<td class="num">(351,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Rate change</a></td>
<td class="num">(5,710)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R &amp; D tax credits</a></td>
<td class="num">(240,000)<span></span>
</td>
<td class="num">(69,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationProvisionAdjustments', window );">Return to provision adjustments</a></td>
<td class="nump">286,015<span></span>
</td>
<td class="nump">201,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract', window );"><strong>Permanent differences</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization', window );">Derivative Debt Discount Amortization</a></td>
<td class="nump">562,568<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability', window );">Change in FMV of Warrant Liability</a></td>
<td class="num">(617,655)<span></span>
</td>
<td class="nump">217,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote', window );">Loss on convertible note conversion</a></td>
<td class="nump">132,984<span></span>
</td>
<td class="nump">503,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther', window );">Other</a></td>
<td class="nump">126,012<span></span>
</td>
<td class="nump">169,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,535,466<span></span>
</td>
<td class="nump">377,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShortfallOfStockCompensationExpense', window );">Shortfall of stock compensation expense</a></td>
<td class="nump">40,674<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Foreign Income Tax Permanent Differences [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in FMV of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Differences derivative debt discount amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent differences loss on convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent differences other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShortfallOfStockCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shortfall of stock compensation expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShortfallOfStockCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461960128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Components of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,727,566<span></span>
</td>
<td class="nump">$ 751,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles (includes Section 174 capitalization)</a></td>
<td class="nump">1,197,938<span></span>
</td>
<td class="nump">405,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D tax credits</a></td>
<td class="nump">423,915<span></span>
</td>
<td class="nump">200,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsbasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">11,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Interest &amp; other accrued expenses</a></td>
<td class="nump">72,140<span></span>
</td>
<td class="nump">29,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsLeaseLiabilities', window );">Lease asset/(liability)</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">3,429,136<span></span>
</td>
<td class="nump">1,401,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxLiabilitiesFairMarketValue', window );">Change in fair market value of securities</a></td>
<td class="num">(19,943)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(30,544)<span></span>
</td>
<td class="num">(46,718)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">State income tax deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(60,196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxLiabilitiesFiniteLivedAssets', window );">Fixed assets</a></td>
<td class="num">(2,746)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total</a></td>
<td class="num">(53,233)<span></span>
</td>
<td class="num">(106,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances', window );">Total deferred tax asset</a></td>
<td class="nump">3,375,903<span></span>
</td>
<td class="nump">1,294,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(3,375,903)<span></span>
</td>
<td class="num">(1,294,472)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities net before valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assetsbased compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxLiabilitiesFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities fair market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxLiabilitiesFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxLiabilitiesFiniteLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities finite lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxLiabilitiesFiniteLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773460017152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefit at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal tax effect</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments', window );">Return to provision adjustments</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract', window );"><strong>Permanent differences</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization', window );">Derivative Debt Discount Amortization</a></td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability', window );">Change in FMV of Warrant Liability</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion', window );">Loss on convertible note conversion</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(10.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther', window );">Other</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.20%)<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense', window );">Shortfall of stock compensation expense</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation change in tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Differences change in FMV of warrant liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Differences derivative debt discount amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent differences loss on convertible note conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent differences other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation return to provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation short fall of stock compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461399872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Quarterly Financial Data (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">$ 29,996,963<span></span>
</td>
<td class="nump">$ 29,489,055<span></span>
</td>
<td class="nump">$ 29,402,533<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 26,518,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 12,063,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (29,195,550)<span></span>
</td>
<td class="num">(25,433,304)<span></span>
</td>
<td class="num">(23,792,804)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,840,581)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,844,512)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,543,363<span></span>
</td>
<td class="nump">19,456,841<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,572,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,150,948<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,487,612)<span></span>
</td>
<td class="num">(13,847,112)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,894,889)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,795,432)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,945,692<span></span>
</td>
<td class="nump">9,945,692<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,945,692<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,912,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,945,692)<span></span>
</td>
<td class="num">$ (9,945,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (9,945,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">$ (8,049,080)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital">140</span> and an offsetting adjustment to the carrying value of common stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Adjustments
    include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj" title="Stock compensation">7,843,052</span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8" title="Accrued dividends">402,064</span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta" title="Issuance cost">174,082</span>);
    corrections to the Company&#8217;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8" title="Warrants">416,266</span>),
    reclassifications of warrants from liability to equity (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh" title="Warrants from liability">881,554</span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l" title="Debt instrument">2,213,498</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk" title="Increase decrease of notes payable">7,351</span>); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh" title="Increase decrease in preferred stock">89,118</span>); and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l" title="Stock compensation">8,009,461</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Adjustments include corrections for stock compensation errors (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a" title="Stock compensation">8,009,461</span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc" title="Fair value of warrants">240,930</span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a" title="Accrued dividends">402,064</span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih" title="Derivatives loss">296,151</span>); correction of issuance cost recognition related to financing transactions (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e" title="Issuance cost">166,407</span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf" title="Net income loss">1,967,621</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    include reversal of dividend liability recorded (decrease of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1" title="Increase decrease in dividend liability">331,059</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of deferred IPO costs (decrease of ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi">55,182</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh">89,118</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the estimated fair value of warrant liability (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63">240,930</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj">274,048</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    and stock compensation adjustments (increase of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc">8,009,461</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773461273056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Quarterly Financial Data (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Increase decrease in additional paid in capital</a></td>
<td class="nump">$ 140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45773455739264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 08, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 06, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 13, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 13, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock consideration received per transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based payment award description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) one share of the Company&#8217;s
common stock, (ii) a warrant to purchase one share of the Company&#8217;s common stock exercisable at a purchase price of $18.80 per share,
and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a
22% interest in Diagnostics.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,517,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,254,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,517,485<span></span>
</td>
<td class="nump">1,488,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForward', window );">Carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,727,566<span></span>
</td>
<td class="nump">$ 751,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases', window );">Future taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Federal Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome', window );">Carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member', window );">Tax Year 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member', window );">Tax Year 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_FederalTaxableIncomeMember', window );">Federal Taxable Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operatiing loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_StateTaxableIncomeMember', window );">State Taxable Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operatiing loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Exchange fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Right offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionalEscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InitialPublicOfferingDescription', window );">Initial public offering description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Unless
the parties waive the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the
Company&#8217;s existing stockholders, the Company will not close on the offering and any funds raised and held in escrow will be
returned to investors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Exchange fee</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ReverseCommonStockSharesOutstanding', window );">Reverse common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008,689<span></span>
</td>
<td class="nump">2,111,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock consideration received per transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based payment award description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $18.80
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,455<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 41,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Right offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionalEscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InitialPublicOfferingDescription', window );">Initial public offering description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#8217;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Alliance Global Partners [Member] | Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember', window );">Alto Convertible Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from (Repayments of) Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AdditionalEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional escrow deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AdditionalEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carried forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsOperatingLossCarriedForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carried forward future federal income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_InitialPublicOfferingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial public offering description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_InitialPublicOfferingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ReverseCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse common stock shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ReverseCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_FederalTaxableIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=SHPH_FederalTaxableIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_StateTaxableIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=SHPH_StateTaxableIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SHPH_OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SHPH_OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,>$:5?E%E*7(ZU.)?T2B0LVXU-C*H-Y6DVNK;*%5ML@J6WP-&^B\=$3GRZ)
MK:!&TCW<)\[8G#G/A8J0(D>5R-KPV(CRLZS%L_I6R<6N'.^#0*8:<'_0 Z'$
MES&]_PU1JCL31^]_EY#%$%G@.7K/,^IRQ2S5I]C8G&./]<S+I1_FK#<JG>:#
M!3J$XZZ^D ]!G JN@?Q 3HU=XNOZ#V$>=OE@Z#.J=$4#]+DY?B,Y;U*A)N9E
M76?M';1&_D61[V59IXW^B7P&O2,S\;>L((89\XU:YKDNU=L& 'J88E=O&XB0
M4M_Q]-:!@)ZGIB>]?0 @]@*7NV,K@#ZOQ^;$_CCHG#6 6"R*77,W<RN^-KT
M;  C\3?/1#;90JMLD56V^!HV>"8"# \U5O@C5@_I_0EB]B=>8V)9E"NU!,QE
MU=[6?A)?%VNY^(R>RJ+NMD:HCZM2;%"NCIB"Q5SCMP:+5;;0*EMDE2V^A@T,
M%C)T7CSJ.&.QTMLNQ)BGOQJ#K?G2F2YOKF$[RG._B/FN;D'-(*"'?8]ITV$(
M ?V >?H]@@@"8A8XKCXV@U4[#F7ZV P!U<Q."*,CVO8>!3%[%+]*E1NH"?)M
M0:](\PV]RR9;:)4MLLH6DZ&+<L/=@'CZ/:,YA&1!P!T>C+1R[Y00LU,2IOLT
MD7G2C+B?5-XM*_13L[OHN )Z*N52EF6[S:A8?'X[&JQNSK#*%EIEBZRRQ=>P
MP6,MX-<PASA\Y$X6Z?T:8O9K0JF6: E*3D)&?FENR.S2:OVZ>+,31%?L,# $
MD4VVT"I;9)4MOH8-#B+ CF(T8&-W\DAO1Q&S'04$T:9(TF6Z:&]%-2$D_]RE
M]=>;12:J2OV@T)U7=<%<9-6@LLH66F6+K++%U[#!@0,85 '#HSXFZ0TJ8C:H
MNL!1V7E=IL^[0[#D7;9>=:&S/0XT53/0M#?>SY-+'?$:B!?$UA5&D2&V;+*%
M5MDBJVSQ-6QP; %.(V9D;*7;^W#$[,.]KG21J ^AU5IO=:%B:[-IW(DF4-9%
MEJ@X P/C0.^>+<(=BHENSLQ )/8;BU//*0 D];A:V',]J8"0V V8;K3%$')D
MP0DA/>9A.C;^]YX;,7MNO[?/&ZCN)U2W%2MY%'DM5.NC8E>K'I@GS3:/9U&E
M"U#PH2-%L,,"?>_/# !BSW>PAW6Y 48G</Q MSY!1D9<W:*.(:#/^> 6T1P"
M4NHITA&I>W>-F-VU;Y Z2;/=V+ '[$2!Q0:VU,!B XRPV! C*#8 A,4&@":Q
M:6];4;-M=1Q$MK(\*(QNQB.X(_-/.YAS&VA]>P;!\*W>74,8IG7_: 2E[Z>!
M8/16]Z/G$,R]=4:2#-I;.M1LZ8 Z&L*SHWM320 &*0G"!DK"J(&2  Q2$H 9
ME.P-'&HV<#[*K'T\Z$F4]5?TQP>Y>98E_#R%50?'*EMHE2VRRA9;99O;8CL/
MEY-G<LP/Y5R^A8W:??[&[@,X=I_ L?L(CMUG</X?#^'0W@RB9C/HN(6MBQ0P
M4&P]D-,1G:^;W<&F9UOU15!]W"?Z[I[+8',(IM8P>"0EIKV70LU>RJ]%7EX^
MR%NU1JRRA5;9(JMLL56VN2VV\XCI313*;0WR5MT.JVRA5;;(*EMLE6UNB^T\
M7'IGA)J=D8L&>< K8-3AOFY^0$"/!-35\T,(&!"?.'I^" %QNPM!?WX%0A+F
M,SQXG@J\G(;2UT;KZ<ES_!M9KMI7-%2HW;IR>)KU>/3X&HB?VI<?:,??X;L9
M!HZ'^"Z"CL?X;GYX^4-?[>%=%!]$N4KS"F5RJ4[!N?74592'USL<OM3%MGV[
MP'-1U\6F_;B6(I%E U"_+XNB?OW25'!\R<;C_P!02P,$%     @ F&!?69X
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MHD19+ %">@*2(J\A3UZ7]3 !67OK@_^]_3#1-]N[IZ:[_SPU.95?1>8IS0"
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M5*U$J>EQHLADRI-)ES<(O)3#()(2.XZ#(#;W@"U1!HN)!N4<@XQKS\$ 4\4
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M5*U$J6GQEBEJE[E3N]\T;2>S81\57GPW7,,+JE9 U214K42IZ>&E8%\VZ71
M,R6$7)\>I%B$D%';A?-<Y,(\"8XH>1GF09XD5M8.433S@S@ROS*3[ZNS9\[!
MZC+%ZK))9_2=2MJA/42DV 6^",UC^!:\;>>[%9IC!U634+42I:;'A )^&0[X
M91. 7S89^!$E3P$_2I0$?GQGG5US#N"7*>"7X8%?-A7X\;:=;U<H\(.J2:A:
MB5+38T(!OVS>:7_37]+S!AQ>RJ"$EBBA B4DYP@Q(7..3;^90I(9\H0_=MYN
M@\HH-;=(+?CF.(\L4$H)59-0M1*EIH>)0I49CRI=WM'S4BYCB$TUTR 0YBX_
ME+UBFCTYQQ[CV'.PQ4RQQ6P^6^2KNC@2)+3," 88^E$0!M:D<&I).:=QC#O/
M00LS10NS?S=:F-FTT'ROR/?)^9D )850-0E5*U%J6JSEBA3FOW-2F-NDT PM
MO@NNH055*Z!J$JI6HM3TT%*4,,=1PGP"):3*T)20*'F*$A)%24K(]]79,^>@
MA+FBA#F>$N93*2%OV_ENA5)"J)J$JI4HM9>8N.KNZ[I?5GUU_>ZQNJM_K-J[
M9MMYF_IVD/>_'?-GVN;N_O67?O?X_F((RYM=W^\>]C_>U]6Z;L<"P^>WNUW_
M^9>K0?]YU_Z\MW']_U!+ P04    " "88%]9\IY;E,H"   7"0  &    'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;*V6;6_:,!#'OXJ535LK;4U( JT81&IY
M4#>I$BKJ^F+:"Y,<Q&IB4]N!]MOO[(2,=B'C!6^('^[W]_E\^#S8"OFD4@!-
M7O*,JZ&3:KWNNZZ*4\BINA!KX#BS%#*G&KMRY:JU!)I8*,]<W_-Z;DX9=Z*!
M'9O):" *G3$.,TE4D>=4OMY )K9#I^/L!N[9*M5FP(T&:[J".>B']4QBSZU5
M$I8#5TQP(F$Y=*X[_6EH[*W!3P9;M=<F9B<+(9Y,YWLR=#SC$&00:Z- \;.!
M$629$4(WGBM-IU[2@/OMG?K4[AWWLJ *1B)[9(E.A\Z50Q)8TB+3]V)["]5^
MND8O%IFROV1;V7H.B0NE15[!Z$'.>/FE+U4<]@#4:0;\"O"/!8(*"-X#X0$@
MK(#P/= [ '0KH'OL"KT*Z-G8E\&RD1Y33:.!%%LBC36JF88]+DMC@!DWB377
M$F<9<CH:"9Y@FD!"L*5$QA*JL3/7^,'\T8J()1FEE*] $<9Q0L1/J<@2D.HS
MF3P73+^2LQF5:)N"9C'-SLE7\C ?D[./YP-7HX]F)3>N_+DI_?$/^!.0.X%*
MBDS0KZ2!'[7SO?_QDW:^X[<(N!C<.L+^+L(W?JOB'947).A\(;[G!TT;:L=_
M%!QQS^)A SX^'F]:?=*.CR%N=7YZ/.ZWQ#*HLS6P>L$!O3HM358VIN*OZX72
M$N^KWTVY5ZJ'S>KF#N^K-8UAZ. EK4!NP(D^?>CTO&]-YW9*L?$IQ2:G%)N>
M2.S->8?U>8=MZM$CE9)R98^;*550'@-9 JBFPRVENE;*U---='7I7P[<S?ZA
M_6ODO;48'R,S.<9HVK96&0YW[^+.0:YLB54D%@77Y;^B'JVK^+4M7N_&1YW^
MN-,P/L&J7Q;IO_+EDP&OI17CBF2PQ*6\BTOT4Y9EN.QHL;9E8R$T%B';3/'E
M M(8X/Q2"+WKF 7JMU#T!U!+ P04    " "88%]9$K2$"=X,  #230  &
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M[63%V(N:?(TGAJ4"@APBJ10H/K8PA3Q70AC&KT;3:%TJ\'"\5Y_KO>->5E3
ME.7/62S3B7%KD!@2NLGE(]M]@68_ Z47L5SH7[*K;4>>0:*-D*QH8(R@R,KZ
M25^;/!P J-,-. W@G NX#> > Z="\AK .P:&)X!! PS.]3!L@*'.?9TLG>F0
M2AKXG.T(5]:HI@;ZN#2-"<Y*55A+R?%MAIP,IJR,L4P@)C@2+,]B*G&RE/C
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M4_PT :X,\'W"F-Q/E(/V8R?X U!+ P04    " "88%]9PST 0A4,  #Y*P
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;.U:;6\;-Q+^OK^"4(OB"JBR
M)#NJVR0&'.=R<=$F1MSV/ASN [5+26QVR2U?+*N__IX9<E>2H[AIKTWO ']H
M+.V2PWEYYIGA5$_6UKWU*Z6"N&UJXY\.5B&T7Q\=^7*E&NE'ME4&;Q;6-3+@
MJUL>^=8I6?&FICZ:CL>SHT9J,SA[PL^NW-D3&T.MC;IRPL>FD6[S3-5V_70P
M&70/WNCE*M"#H[,GK5RJ:Q5^:*\<OAWU4BK=*..U-<*IQ=/!^>3KBQ-:SPM^
MU&KM=SX+LF1N[5OZ<ED]'8Q)(56K,I $B3\WZD+5-0F"&C]GF8/^2-JX^[F3
M_H)MARUSZ=6%K?^IJ[!Z.C@=B$HM9*S#&[M^J;(]CTA>:6O/_XIU7CL>B#+Z
M8)N\&1HTVJ2_\C;[X4,V3/.&Z8=N.,X;CMG0I!F;]5P&>?;$V;5PM!K2Z /[
MAG?#&FTHBM?!X:W&OG#VVBVET;_(Y%-3B6_USU%7.FR>' 7(IU5'99;U+,F:
MOD?63'QG35AY\7=3J>K _HO[]T^F]P@X@F&]==/.NF?3>R5^$\U('(^'8CJ>
MGAQ2Z/[MSU6)[1/>?GR/.L>]LX]9WO$'.'LH+JSQMM;5UO=73GEE0GI@%^*%
M-M*46M;B&@\5DB=X\:_SN0\.\/_WH0@E!4X.*T"4\+5O9:F>#EHZR]VHP=EG
MGTQFX\>'O/,'"=OSU4GOJY/[I/]&8-XKZ["FKVQ0Q41\]LGI=#)Y+-Y_WMZK
M(KTRBN+S+'I\\EY<KV((M2JN5A+44JH8="EK+U[:NM)FZ8?BT@!*?Z/#IN/'
M:\4?)H^'(C^)_NX3&UW_**Q4]_C"-JTTF_SJ<[&67EBGET!*76\$T;JJ"MFK
M).ZH-!3??GLAM&&9C"HRY#L0>$V6P7: 7C5SY<3DE( _F8[$:R/.XQ)D)"93
M?C9+.F5EQ$+7JA+2X8A:>1)86G.C'%%]L=9A]9[3@LT+@U@XV\#MK!T>2W&!
M5ZZU+B>+#&*]TB4DH8;L'5ZNI%GB>(W<,))>VO<:7^R%(:_J?#E"D$@?DRM,
MK_C6F+V#M?<1YSX:SJ:/AN/Q6$SPW_<K5>S$:/+E8R]:IZE"BC;"(*^PD72L
MU UJ:,M8*VW3*$>9KG]1(AI 3XG*Q:6GB/*IGBIGZ !*+@8U0"O>WSJ N>S>
M&*IO=1%8042\-V1I0258H!MLN $P!>HZSE;IF"11M#B"F<8!"9J7.5GI=##$
M.-EN1KV+5\!:I=K:;G(,(!H&JT 60ZF5L;5=;HH=BXW%W^XTW331V"16D[;8
M7\623I6BU:VJ<[+ETG^CQ,OGYP3AE9[K8-V>[N2,78D;(=NV1O!)>3\JOM_&
MKP\/BVMK&2AY*#B5\GII%.,39BS12T%\14RM1&.A1B28LUM;.-X$HFAGZ:'N
M7,28\V*N-I8"S.H-\;JL(U%"(6.PK*FBIXM:HHN"-9NA:."[.0I#.11&14?N
M(_0FV\R"XQRAI?8*_8L?B4-&O;&MKNQM=* P^"\Y-0QS$L'(Z,$3;,([P26[
M.[BISK,E.BW"DB0;-5E,=!.I4(LYW"RN@;EZ2XF7!F%.8M^ <J7#L7WB/;M\
MTS,8LHO+6<&8S.((K:]X-PR_2!I<&A]TB(A!)^?5Q64G!@Q!>1,(*7N;^UW,
M2R^5K,-6D5>7+[?9O^^R@H ]5\K 2$>.Z>!+N%C9N%SMDD'O=_1C-:*7:"MC
MQ)>43]HC.4!CM.L'HYE14%R@U(_:@;^U9"!'(@CBH68.3@\]@U**[X<H9;'J
M\A6-N+O1-[(>B9<X"T6AI!@-,T%HXA%[4.<<3_#3'*B#1@OE*/^@QK5J U>#
M BW0=)_UR4%V'G!3@$L(";1G)\TSYD!V*\?^@K?%TDE0RTXB4):GA;07Y;G2
M^%A3JJD%@9WCUF,T.:-+$2R::PMR?=LQX<[AGNO-#GP%40FGZ"K! "G42@?C
M%9%= BFG4Y%5ZGH!/B$P82X.NK"WE9.4=#9+R\S987]'.>KCTOTE';W6T&VN
M>(ETH/HX_PF&$V6JVT")B"@[M8QURB?DAXFH%\0"2R# &9)(#!&!S&Q/+O%
M6D!XN/:"*JXZ'&PM.K200+/IC2J(7[=X)!_T]FZ3(F=MAXZ&V@6B![>T @V*
M9741WQ)18#[[&YHJ<,;GJ0+V3U>QD>9SE [/ZK%3S-81178$J)*X'1E R'6V
M)-)!2M3<)F_U>6%MQ4*>HYR*\PIW*$W],UO2\<"+Y^<]'['._=9AVD<"+JP'
M[I @YV7@2N(8710Y@XX%Q=81UK U9WGG"HXO*I)0IK01RCE2> Y-.4P$E][\
MX#0UCBR#]Y62&&%77&X(H',JJK7D9SYZ7.VKU+'LBQL=;$M\+-EI? Q*N.+Z
M CI!.V:36G*N:R(IG),RG<B&>X/<=7#>@C00&T517E%NT_" %\/-%74NI5.!
M,545@(JCM*0T1O-!!8VXAE,K 7&W?T@2"7!<SR%CC@\'(9O+8UHHV,^0DDP_
M'*B"G=P9E+LYLM1U%KT#ZCZ2$(6^LZX5M9[$9D A]P<5;2^U*V-SPS@<IGAE
M2&2#F 6YD$ W!ES!HG,)W//!;F_'>=@"A-P'R>H&8N12^3O,#A77M#C[:1%#
M=&JTO='P)>8?S$^XA((>C7@=71&-!"637JC)57) V5]2B>3[^ZC?WD>)L9#6
M@(WB^X,4B?G*+'DNO?9=XT'%7C74;)'2Y!!%/6_'*[BX>)71Q4TO7OB%[#O;
M6B=$ZAQOZIMU2'ID8U/S2P!PGOO&>>Y(]OHD+EZH0=&1UK7%L4@(3:B@?]J>
M^6F=1!\6>!')8]*Y!7,%A0[H4W$\.B583483,1[-Z [QC321(D=3@V&Q&Q="
M!!V(_* [#C(C9KK&W0" @L9RZ11[-O4.@*W.'4SJ9P U1=6]KZKY6K1S"@(&
MRNNN5AI$4P"S*@ND7@!!;"$+H(WLHT_%R>@8[4?$K6_ZY7 ZPV7F='0ZAG$S
MYH[+J]?L#I0FKW Y,=02MYJ*CI-H1.&G&RI<+6YLG 2<YM0"I9X!E!XICL A
MG4=7FYX^2"[(;,OFN<9>OGI>=+>?*_;-Y>4=9J.E=SI=DO9N1PMP+&L-SI4T
M49,)"W0HZA'=O;B-[5#7^9%#41')<@'",Y]Q^"['4J].;*II>D-EJT(FI8AU
MCN+;+A6HD/@\60!\K:DWP5_JH?K&8>O!D3CWA:1.(M:!V-4@Y1DA*UGEYHU\
M+CF,CSA>LBR3$23J]^5U99GI4J.FN"&0U4^HZNDUK'%J05>R'8[9MFRF2-E=
M4G_2E9%4Z)'C>I&O9)Q0*>=SI&5#U.W?LW:7 /1>*\9W&B,!=JA6$,]H W!S
M^NX1TD@<&G7]Q0.DG?K,5ZPTQQ&_,L<9_BF#G.+P($=\[$%.<<\@1SP,<AX&
M.0^#G/]RD/-'CF^ZWK4J'L8W_Q/CFSUF+_Z288VX,ZPI'H8U#\.:_^]AS>\;
MU(AN4%/L#&H>AC0/0YK?/J3YN ,9L3^0*?Z"@8S8&\@4OSZ0F8UFN ?/\C2F
MV)O&[ 7@XTUCBKUIC/B0:4S1 &OIQE2C/G7+:4;SQ095"@V<(X!R(<[J%GEX
M4WA<E[K[6]/ <]"Q?#L$,=/EQ/,M&6#_-$UY"J2[X"W##&YN#O92B@[?]7-!
M@Z]9IR3%FD+"U*XJ"BT(#PN3P[.J'#M*S(T*J3?+^J@*38]=HSJYX<&*K6YU
M*C"E]"LJT_!"J9C%J#*R/3OAZP8Y>35=?BA9Z&9*(%;(,&[=\O_G2L"]$Q[*
M(BX#MRT2.Y%.E_D^+A::NT)NI3BS2]BXH6O800.VTYR] EKT5<3U+:E!]11A
MK>H;NJ/0SZ%&'VL$5QP8P8F//8(KTDU]=P0G_M01W/ #9W#BUV=PQ7MG<'_Z
MO$T<GK<5'V7>)NZ=M[VAQ/8T-P()B6M<X\/N).HX_3R/AUG6<3^'EE>I4+R2
MOI(_]TE$W6 3&S'7?",JR5ZDLDN!8.*<C&A\\P4P^\4IWJ9SF?R$YW.GP\ED
M,IP>/\*G\?AT.#O]2DQ.)F(R^4J<3L2A'ZX=[?RZ$HW\DG]TZE/WDGYHV3_M
M?]=ZSC_G/-HN3S^*_4[25=&+6BVP=3SZ\M$@=1O=EV!;_JTF.B@D"7_$]0<^
MH05XO[#@IOR%#NA_[7OV'U!+ P04    " "88%]9MC3WM[L/  #&-   &0
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MEKM=GB42\U5I@VTR/[#;*@9K9$BVCK.*W<5YRXDN\B&D1@>C$4A\0P027C7
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M-WUA>:'I1K[Q9UZ <Y4_4II;T6M7D45]%WL7 9L'OC#.*?-"%]0\XSV_55L
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MV>;JSR].1(<!YHHBY2U5^-^MONJ8FXW9FXT9G.VQ^'4E@RX3U.<7%0MS52W
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M+6L:RE>YP(>*?9K? >DNSD%2XQX)A?(+T+./_6)+0,3)/T".\=<Y@%I5>/&
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MQHA/7* ,X%7X+(8P_%J5E1(7=;%Y+R_V65K+U[DX:R[A2LJQ?BY"((";PD@
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M30D(^:.)2Y@+48+T&@4\+@%)6 (<*G&\:$^+$,T?<SP)' 8*>/.9W,0-'*T
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MH;; FX.(C$G:;2[?I*#?P_'R+45]W7<T>I.7RGA-G#5XGR=&W'_5C!0 5ES
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M8I/E @?$ "XT80A[K3O+]R/R=UQUJ[*.\&.!,9LBU\B*DX2"+IC2"JK\  /
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M:ZSI#X8'0Z//VZ@YCLHR93Q,@UX2 LA(+!_I9AY^::S=)O6Y9-&Z39WOT,]
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M<6O]O8X=8YD002]9\2W/Y/QLD P@HU-2%_*&+7^C33RALI>R0NC_L#2RKC^
MM!:2E8TR>E#FE7F2AP:'GD+B/*'@-0K>2Q7\1L'7@1K/=%COB"3GIYPM@2MI
MM*8&&ANMC='DE3K%6\EQ-4<]>?Z1(@;B="31EIH9I8W>6Z/G/:$7P2=6R;F
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MX6F;\+ZM52]9N2#5"N8$8VP,D1FGQLWE/$_G0 KLW*B.#*!U%)(8.HJ3"<,
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M9*4>SBG!\U("N#YE2$/-B]J@^X)W_C=02P,$%     @ F&!?62*VD8'T!
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M>G1^NP'\X!U,^0^:MQH.C[]S>*B/5^4#JT;3V]++=B!\TC(]D,Q\TA]<.B@
MV@]@JAL,,\KVG$A,_9G[\>CW%86LU_RS$^H32 S]4XOAZO#+EA/^0<?Q[G']
MLQ@ RK5""N1RA:4..,>1J/5/3?2'MMKRKS6650L\PF\W2 )9TP.XOZI@M/E
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M+OM-$+%&=]ZU4Q6T1B,>/ZGL?'_BHEA^V<B\'TLM%OMT)8(E0.49ZC')T)^
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M62,,1#>5P)0VUEO8)Q] J#[NWF[<C:3@*;&5RA"*-O&TR;%KATI6J4>U<MX
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M^H/ ?T.OYY#Z6/(E,FCNX2AHDZ4I?(YPM8@R[R--!6A#FD%E4RXK:C@4#/O
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M!#HML&+Z0M8HZ)M<JHH96JI-H&N%+'.@J@SB,+P,*L:%-Y^Z=_=J/I6-*;G
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MH='0/18TO*.R&^C[7-*QV"^L@_[GP/Q?4$L#!!0    ( )A@7UE07@<_( T
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M%F*&,RU ,<O$5(F%RL"9C0![&80TD#;LF\H,XBM1K,'[EL].;?=88@,]((6
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M/F7H!3R?%=10^2]T0/-#L+?_ E!+ P04    " "88%]9^TM_S4HK  #^M@
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M]2Y*KY5\GNWW<4&2W@!]]?*Y@7E(TB7? $:2VP"'O96;3*99*0#G980X3!*
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M5Z.2& @O(M.@C4(^+^[_A7B6-3R+>^$Y^"*(KG'/A>6>BQ/R;)U$(/BW9&S
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M 1=H_,F'@$OY&SA_:SF>@5WN#?.<X-8&$^VP(^X"K J04RQ=:)6,!N<@&O3
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M\5W1O*_N_R;:]82D+ZL*I?^R>_-MY$]8ME--M6F%8<%&EN;*/[8X# 02YX2
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MG%T=W,;!U4#KS#2LCT22Z1%G*^!J-$93AJZ-]D8T::&Z>"TY/DW13T[/*=9
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MS24EV"\U )\O&)/MA9J@^_XS_1=02P,$%     @ F&!?60O/B+=,!0  3Q
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M+.7+*O\'Y?,*EJQ"EA;F_$ SO#;E^IRM+XPXTO$"C!-=UR-L#S^>BWMJ0AZ
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M,R"B^&ZIN,C2E?KT9YYF@$<U7'(&GL0)\'R1@FO+"]R@_GKL_+]02P,$%
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MA@#/YP(3TGP8!>NGL\-_ %!+ P04    " "88%]9Z15=@5 #  !A"   &0
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M_@.@=@KT?*\HI9W@#/3_*M;_ 5!+ P04    " "88%]9HK:!M]@3  !C8 $
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M>IL5]0*KO[_+\^KYAWJ [WGQ^_IE7OT?4$L#!!0    ( )A@7UEY@!FJ'2T
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M4S,'G!$OKWDVI(=R$<O%+)>P7,IR&<OE+%=TW/A+WPL<5W)RSP;P*$XH^D$
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MV?MG<I%_T)*7.<I2NDBS5'[KLY,6--1.D# ?$A9 PD)(6#3IV,GSL&V?7M.
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M80#Z><&YVDY,4^T^NLE_4$L#!!0    ( )A@7UG.$<[140@  (I;   9
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M^'G_IDBW]5'(UVE1I)OZY9T(UR*K&I2_OTG3XN>;ZG3EP_';R_\!4$L#!!0
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M105GSTC$8&Z=9H_  "4$4'&F"@D1Y.1YZ'J6;R/R_3U3$(Y1I:>IKO8,_FR
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M7_;ZH%[/C^UNLTTPI_<=?O"6T?0;[<S^^7=IU/M7W>Z.Q!0DIB(Q#8GI2,Q
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M99*PPXM\@+<D_;I;G=G_ %!+ P04    " "98%]9ZAXRO3Y!   0 @4 &0
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M\Z<F\5Y*OK[L!?BZ?KC?K?OC;LGCZW'X>E??I>WRL7KYVC\O?Z_NS_OH7[[
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MCR2E+#T;3F\$W22'GT]4"!HFEVO97!*F!.3\DDHFLAME(#^AG_T'4$L#!!0
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M0;44U>2&-?KVA,(6D5+<>4(Y%I%V7RO(?M!%L6AI*:J-4$U!-175-%334<U
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M/*44NU9F;YW;6T_=G$S0]EE44U!-134-U714,U#-1#4+U6Q4<_;:V>E9%?T
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M I:;LES(<A'+Q2R7L%S*<K(,>_#"+7,K=RG8G)2QYE]?L3-FL]L9L]AL7O*
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M237)*SBI3-WQAH9S DIUZN6D1$>U-5P2JD'SV\]7FB:P1 ]">\4CU3A*39T
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MQX_N/=1+>ZV#O><0%!E1:JKC$AF=#MIK;VI$JW8@4(YT2KIPSRL21R55_96
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M][^.80WV*@M:2MOT+CC6DQSK:??<ZA29YG!%CT-[X4,!%Z6FSH$$7,_NI=1
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M(BB-H6AJ8J61N@ CI1G&V1A L[2) (%8"]KNQKUP8MMR%Z5&5ZJMNX?:'G1
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MFJO;AM2IWW<<#E)C*_W=?^^9Y70%QH&'&KFOF_7N31U_NC/'>DBU9 *D9_L
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M6J\@/G_(Q9ZC?5-7L'D:T^7_ %!+ P04    " "98%]9"J[@<?0&  #+00
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M._HL*;PHS),=L'O?_>PLP_5-:]@B2_9L1V[XP7]565:@?LQ;^&Z0_)+7-.U
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M[I5POQ'N=PK_/KY!-QR HK&JP>B6QNC7'10SX+_;9'>2Z:K>%R6)86BILBV
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MEI"8A# E(Z?KC)P.793>CXN/1IAG6?6#,JN&+(WWU4,X[=JD'61H2DC,)[&
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MA&HQJ@E42U!-4IJ2*:]I_7@_1.NGM31RSSGUAS<T\:CFHUJ :B&J1:@6HYI
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M*RNT$%JZ/90]*/9Q(BI9KG3<I-]^DNRH&23N*/C%EF2=OW[G8HZF:ZF>] H
MR4;P4L^"%6)U%H8Z6X&@^EA64)HOA52"HIFJ9:@K!31W1H*'212-0T%9&:13
MMS97Z536R%D)<T5T+015K^? Y7H6Q,%VX8XM5V@7PG1:T27< SY4<V5FH5?)
MF8!2,UD2!<4L^!Z?G<>1-7 [?C%8ZYTQL:XLI'RRD^M\%D26"#AD:"6H>;W
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M^J >EB\O7V:!.9G0]'L2B_7(&!@@)DN\3<57NO^3U"_D%GH137GY"?8UUC)
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MGL@'=OH():&AQ@M9(LPO.A5]@Z&#PEQ(EI;!*H,TSHI_^JTLQ%D #EX((&4
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M4BLG+\Z>BAO)#N;X9L.D9*FYW*NU';CNH)YOF7IGRAL]0'4"./L/4$L#!!0
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M(B]^F2U,M#+EK)A&WWTU>5E]WYH5OS*(MH>VYN*E1PK_D<$90-MB5-.4YF;
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M:'@D+O*JRE?;A]<R6<BB>4'][Y=Y/<#>_:7IX#8O_MR^G;/_ %!+ P04
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M5B$XM2X+T\@XG9>26@T;1-,PM#,FQ!W\C'S/=[A7>6?E;+7(MFD$-4U'XSK
MWV5SW%W:Y%6\0<4?2_UI:=*1M@_;DMTJEO.5[:_R5@#&'N'LM*K$^J/@<UDP
ME_R+ XZ'=(,+%J7BOTPT*)69,3!%@D>F-)]U+3\5K>[92F_*:97CFOM'J/GO
MSO.<2::HZ(HVM7_(L_QJQ<US]U]HMC\K^XJ](N.KP]?8G#4.761R#"*/8KD'
MQR R/7R1\1%H;,ZUARXR.@:1_8,4&39GRL[!=>?8VEH#>#T8D6_PNB&V08/I
MD@O-9=-;\"QC\LGIU=!K.C6OUCO\9GS&<KH4^KYUCLBV_95E?%FD[:A;F(AF
MU+;]!=(S1^'-NXF)Q67&5BR;-%TUG]IF8!HF:G,!8-]S8R^_!\,XG]\#/BP.
MI@##.!06YW_*9X#FXWR8MH'7,T Q Q3C4#[/Q'ZP.'Y,:BY_IFD:QTF"S>AD
MXE4PP>8M2>#/SX9I P06!R+]V5SCJXU7R/-U@*WI<Q6"98I7(I8I/M?@\<\;
M(-+4O]I8'$!@JX#5#L3WQX&:\F/B&%85TX;M8-R3II@':M%?HTF"S$X"'__Z
M8+LDCM/4[P&?7T$<8Q[8C;@'4P :,$\<V^?@WO,HW#RGPNW_F\>_ 5!+ P04
M    " "98%]9EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_
MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+
MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D
M5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/
M['X 4$L#!!0    ( )E@7UF*\,M^/@4  *XJ   /    >&PO=V]R:V)O;VLN
M>&ULQ9IM4^,V$(#_BB:?KC.E2?R2NV,(,Y27-G.42PG0CS>*K1 -MI23Y'#P
MZ[NRR75-8*=?9'\!QW:<Q[*]S^[*1X_:/"RU?F _RD+9Z6#MW.9P.+396I3<
M_J8W0L&6E38E=_#1W _MQ@B>V[40KBR&T6@T&99<JL'QT>Y8<S/$'[03F9-:
MP4J_XDZ*1_O?=O^1;:652UE(]S0=U,N%&+!2*EG*9Y%/!Z,!LVO]^*<V\EDK
MQXM%9G113 ?C9L.=,$YF>ZL7'O*&+VV]QO'E-0>0Z6 R@@.NI+&NWJ,^/@?&
MK8"=FT^5TQ>R<,*<<2?^,+K:2'7O#P-G,42G48_#[G\SB(?F_PRC7JUD)LYT
M5I5"N68<C2@\H+)KN;$#IG@IIH-3O17&GP_\P"QOSLT!%!HI<RAA@YGE-5Y(
M%)4+947.8,GJ0N; D;/?><%5)AB"C C(J$?(;Q&"C G(N!?(A<>!KR+(A(!,
M>H1LC61*0*9]0L8(<D) 3OJ$3!#D1P+R8Y^0*8+\1$!^"@OYU=QS)9_K#8RK
MG%W*[Y7,P1R([S/!]SDLW[6P+\^P8WK%YD9LI:YL\<1FUE8"Q_$1%<A'83$7
M55ER\^01%_)>2?@:!^*3+-.5<A)CDKX)+)Q+P:VPF(82RSBP6:X@D[%LSI\X
M_.[!M=\%GH\Y-ZV;;TQI91S>*UN?"\&OL@;7/R,_P3$F)99Q8+,LG,X>UKK(
MA;'?V#D\P>TAI'PR#BR4,V'DEOMD$&(+K[-2V;X'*9&, YND==<Q9[BRO,ZN
M6X241<:!-3)3F2X%N^$_VJ-&26,<V!I_5S!<PD 4OI *TD#)"P:)/6<?;A6O
M<HQ)N6,<6!Z+:FG%]\J[XWP+?_'X190NHCYUT<H$(TH746!=D/)M8Y(%2F"/
MT*.)4]:(<DD4V"6-?-F'&Z\[^PO&HMP1]>".-R$IB42]2.1-3,HF46";X%C]
M)APEDBBP2,B@W7Z:*;=$O54D[,.9<!B3<DL4VBUPC+R"M!"BSKDQVD"59TS3
MF;/L!+=%*-/$H4U#8;:[-Y1IXL"FP9AN+5ZC8DS*-'%HTR#,4V[7]?U9+_BX
MN<689#,LL&DPY@67AMWQHA*_LA-KA;.XKQA3YHE#FP=AGD"5?)#+HJIC_$)D
M%>[1QI1[XL#NH=,+W&R**??$@=V#1_-:WJ_= 2S<6M%<]=9%IRP4![80QMPU
MNNM9 S93<$",25DH#FRAUB-4N<KX^E\=9)ZWX$N,25DH#FRA74X)8N2RL.R*
M&U.G23CK2"@!)8$%1#1Y/#;&I 24A)^*>;_1T_)D0@DHZ5! __AK#44M1"*X
MXG5^A#$I 24="L@7D49F3>L;2@UVVYJ.(>=C>BE]?CY+&),24!):0&@T_]+*
M"4@Y3*'!1F4%NV-,2D!)AP)ZHU[#F)2 DL ">J^4?+GL&),24!)80.\W)E^7
M00DEH*3#,NB+> *);RH(2;OPA.<T*0NE'99!+W'SG6YT2EDH[; ,@M1M515
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M<',O87!P+GAM;%!+ 0(4 Q0    ( )A@7UFEWO_G[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    " "88%]9.S%K&(L#  #[#0  &
M    @(&#$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MF&!?64M]2%I5"@  <$,  !@              ("!1!8  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( )A@7UF> %]"3A$  (6\   8
M          " @<\@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " "88%]9\IY;E,H"   7"0  &               @(%3,@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ F&!?61*TA G>#   TDT
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )A@7UD4*T")R08  ,T3   9
M      " @2J+  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ F&!?62*VD8'T!   J0P  !D              ("!*I(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "88%]9+7]X2Y@.  #[,P
M&0              @(%5EP  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( )A@7UEO1/+Y=1$  !8V   9              " @22F  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ F&!?66NYO^G.
M"P  =2L  !D              ("!T+<  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " "88%]99PDH.8P#  ">"@  &0
M@('5PP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )A@
M7UGWWQ XJ@@  $ 6   9              " @9C'  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ F&!?60 E ?]T!   &@P  !D
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M=#(S+GAM;%!+ 0(4 Q0    ( )A@7UECC-DOGP4   L2   9
M  " @5XD 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MF&!?60O/B+=,!0  3Q   !D              ("!-"H! 'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " "88%]9X"!78G8)  !))@  &0
M            @(&W+P$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( )A@7UE.>(#RC@8  $83   9              " @60Y 0!X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ F&!?6>D578%0 P
M80@  !D              ("!*4 ! 'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " "88%]9HK:!M]@3  !C8 $ &0              @(&P
M0P$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )A@7UEY
M@!FJ'2T  )AA @ 9              " @;]7 0!X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ F&!?64(.]H59!@  HS0  !D
M     ("!$X4! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )A@7UEAB8?#JPD   Y6   9              "
M@?R? 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ F&!?
M69"BFY L!   6A$  !D              ("!WJD! 'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " "88%]9RV?Y,9$"  !%!P  &0
M        @(%!K@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( )A@7UD:D)#510,  'D*   9              " @0FQ 0!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ F&!?65LT-4IE!@  &3
M !D              ("!A;0! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " "88%]9Q2;?A6D*   ]AP  &0              @($ANP$
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( )E@7UGJ'C*]
M/D$  ! "!0 9              " @<'% 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ F6!?68ET&Y-O!0  K1\  !D
M ("!-@<" 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "9
M8%]97 VTF2($   W$   &0              @('<# ( >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( )E@7UFSKR:.-U<  &)?!@ 9
M          " @341 @!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#
M%     @ F6!?6=&W:[4A#0  /I<  !D              ("!HV@" 'AL+W=O
M<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "98%]9 '2*;^8)  "9
M:0  &0              @('[=0( >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM
M;%!+ 0(4 Q0    ( )E@7UD*KN!Q] 8  ,M!   9              " @1B
M @!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ F6!?6=SR
M(HC> @  *0D  !D              ("!0X<" 'AL+W=O<FMS:&5E=',O<VAE
M970T.2YX;6Q02P$"% ,4    " "98%]9HOHX5# .  !AT0  &0
M    @(%8B@( >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M )E@7UE*+R*R2@0  .\6   9              " @;^8 @!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ F6!?68<0\-)_ @  %PD  !D
M             ("!0)T" 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " "98%]9\(,)U_H$  "$%P  &0              @('VGP( >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( )E@7UD:?TWI\ ,
M  T4   9              " @2>E @!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ F6!?6:!PIO9R P  Q@\  !D              ("!
M3JD" 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "98%]9
MXASYN\<'  "Q5   &0              @('WK ( >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( )E@7UG /96;K P  )R_   9
M      " @?6T @!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ F6!?646(9.XR!P  1$,  !D              ("!V,$" 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "98%]9^5Y%K98$   -$
M&0              @(%!R0( >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( )E@7UF0$Q*'8P0  -0/   9              " @0[. @!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ F6!?65)1^C-6
M!   KQ   !D              ("!J-(" 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " "98%]9S]:&6]D%  !D%@  &0
M@($UUP( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( )E@
M7UDZK9&!2@(  -$$   9              " @47= @!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ F6!?64>CR.AL%0  ,$4! !D
M         ("!QM\" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
M    " "98%]9%4]SN5P#  !\%@  #0              @ %I]0( >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( )E@7UF7BKL<P    !,"   +
M  "  ?#X @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )E@7UF*\,M^/@4  *XJ
M   /              "  =GY @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "98%]9TDF\;1$"   7)@  &@              @ %$_P( >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "98%]9P(AM=.D!  !^)0
M$P              @ &- 0, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..2 !( *\3  "G P,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>508</ContextCount>
  <ElementCount>451</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>107</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OrganizationAndLiquidity</Role>
      <ShortName>Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Restatement of Previously Issued Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements</Role>
      <ShortName>Restatement of Previously Issued Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Notes Payable-Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayable-relatedParty</Role>
      <ShortName>Notes Payable-Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Convertible Notes and Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable</Role>
      <ShortName>Convertible Notes and Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Related Party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Quarterly Financial Data (Unaudited and Restated)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated</Role>
      <ShortName>Quarterly Financial Data (Unaudited and Restated)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/DerivativeLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Quarterly Financial Data (Unaudited and Restated) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited and Restated) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Organization and Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative</Role>
      <ShortName>Organization and Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/OrganizationAndLiquidity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails</Role>
      <ShortName>Schedule of Error Corrections And Prior Period Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical</Role>
      <ShortName>Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of the Error Correction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails</Role>
      <ShortName>Schedule of the Error Correction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails</Role>
      <ShortName>Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Balance Sheet Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Schedule of Balance Sheet Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails</Role>
      <ShortName>Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Notes Payable-Related Party (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative</Role>
      <ShortName>Notes Payable-Related Party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/NotesPayable-relatedParty</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Convertible Notes and Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative</Role>
      <ShortName>Convertible Notes and Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>Schedule of Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails</Role>
      <ShortName>Schedule of Monte Carlo Simulation Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails</Role>
      <ShortName>Schedule of Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Derivative Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative</Role>
      <ShortName>Derivative Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Related Party transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Key Inputs of Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails</Role>
      <ShortName>Schedule of Key Inputs of Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails</Role>
      <ShortName>Schedule of Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails</Role>
      <ShortName>Schedule of Useful Lives for Property Plant Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure</Role>
      <ShortName>Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical</Role>
      <ShortName>Schedule of Warrants Activity (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Schedule of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Schedule of Derivative Liability Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails</Role>
      <ShortName>Schedule of Derivative Liability Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Schedule of Derivative Key Valuation Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails</Role>
      <ShortName>Schedule of Derivative Key Valuation Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Schedule of Derivative Issuance Valuation Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails</Role>
      <ShortName>Schedule of Derivative Issuance Valuation Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails</Role>
      <ShortName>Schedule of Reconciliation of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Schedule of Quarterly Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails</Role>
      <ShortName>Schedule of Quarterly Financial Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Schedule of Quarterly Financial Data (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical</Role>
      <ShortName>Schedule of Quarterly Financial Data (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SubsequentEvents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="424B4" isDefinitelyFs="true" isUsgaap="true" original="form424b4.htm">form424b4.htm</File>
    <File>shph-20240630.xsd</File>
    <File>shph-20240630_cal.xml</File>
    <File>shph-20240630_def.xml</File>
    <File>shph-20240630_lab.xml</File>
    <File>shph-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>forms-1_001.jpg</File>
    <File>forms-1_002.jpg</File>
    <File>forms-1_003.jpg</File>
    <File>forms-1_004.jpg</File>
    <File>forms-1_005.jpg</File>
    <File>forms-1_006.jpg</File>
    <File>forms-1_007.jpg</File>
    <File>forms-1_008.jpg</File>
    <File>forms-1_009.jpg</File>
    <File>forms-1_010.jpg</File>
    <File>forms-1_011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1694">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form424b4.htm": {
   "nsprefix": "SHPH",
   "nsuri": "http://shuttlepharma.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "form424b4.htm"
     ]
    },
    "schema": {
     "local": [
      "shph-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "shph-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "shph-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "shph-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "shph-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 318,
   "keyCustom": 133,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 41,
   "memberCustom": 55,
   "hidden": {
    "total": 356,
    "http://fasb.org/us-gaap/2024": 250,
    "http://shuttlepharma.com/20240630": 102,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 508,
   "entityCount": 1,
   "segmentCount": 107,
   "elementCount": 719,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1694,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://shuttlepharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://shuttlepharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockLiquidationPreference",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://shuttlepharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "SHPH:WarrantsIssuanceFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://shuttlepharma.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "SHPH:WarrantsIssuanceFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://shuttlepharma.com/role/OrganizationAndLiquidity",
     "longName": "00000009 - Disclosure - Organization and Liquidity",
     "shortName": "Organization and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
     "longName": "00000010 - Disclosure - Restatement of Previously Issued Financial Statements",
     "shortName": "Restatement of Previously Issued Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://shuttlepharma.com/role/Leases",
     "longName": "00000012 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://shuttlepharma.com/role/NotesPayable-relatedParty",
     "longName": "00000013 - Disclosure - Notes Payable-Related Party",
     "shortName": "Notes Payable-Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:NotesPayableRelatedPartyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:NotesPayableRelatedPartyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable",
     "longName": "00000014 - Disclosure - Convertible Notes and Notes Payable",
     "shortName": "Convertible Notes and Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://shuttlepharma.com/role/StockholdersEquity",
     "longName": "00000015 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://shuttlepharma.com/role/DerivativeLiabilities",
     "longName": "00000016 - Disclosure - Derivative Liabilities",
     "shortName": "Derivative Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://shuttlepharma.com/role/RelatedPartyTransactions",
     "longName": "00000017 - Disclosure - Related Party transactions",
     "shortName": "Related Party transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://shuttlepharma.com/role/IncomeTaxes",
     "longName": "00000018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated",
     "longName": "00000019 - Disclosure - Quarterly Financial Data (Unaudited and Restated)",
     "shortName": "Quarterly Financial Data (Unaudited and Restated)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:QuarterlyFinancialDataTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:QuarterlyFinancialDataTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://shuttlepharma.com/role/SubsequentEvents",
     "longName": "00000020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
     "longName": "00000022 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)",
     "shortName": "Restatement of Previously Issued Financial Statements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://shuttlepharma.com/role/LeasesTables",
     "longName": "00000024 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://shuttlepharma.com/role/StockholdersEquityTables",
     "longName": "00000025 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://shuttlepharma.com/role/DerivativeLiabilitiesTables",
     "longName": "00000026 - Disclosure - Derivative Liabilities (Tables)",
     "shortName": "Derivative Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://shuttlepharma.com/role/IncomeTaxesTables",
     "longName": "00000027 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables",
     "longName": "00000028 - Disclosure - Quarterly Financial Data (Unaudited and Restated) (Tables)",
     "shortName": "Quarterly Financial Data (Unaudited and Restated) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SHPH:QuarterlyFinancialDataTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SHPH:QuarterlyFinancialDataTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
     "longName": "00000029 - Disclosure - Organization and Liquidity (Details Narrative)",
     "shortName": "Organization and Liquidity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:PartnersCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
     "longName": "00000030 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)",
     "shortName": "Schedule of Error Corrections And Prior Period Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:AdditionalPaidInCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
     "longName": "00000031 - Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)",
     "shortName": "Schedule of Error Corrections And Prior Period Adjustments (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:IncreaseDecreaseInDeferredCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
     "longName": "00000032 - Disclosure - Schedule of the Error Correction (Details)",
     "shortName": "Schedule of the Error Correction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails",
     "longName": "00000033 - Disclosure - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "00000034 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "00000035 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-13",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "SHPH:ReverseStockSplitPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
     "longName": "00000037 - Disclosure - Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)",
     "shortName": "Schedule of Right-of Use Asset and Lease Information about Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails",
     "longName": "00000038 - Disclosure - Schedule of Balance Sheet Information Related to Operating Leases (Details)",
     "shortName": "Schedule of Balance Sheet Information Related to Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails",
     "longName": "00000039 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)",
     "shortName": "Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://shuttlepharma.com/role/LeasesDetailsNarrative",
     "longName": "00000040 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-06-30",
      "name": "us-gaap:OperatingLeasePaymentsUse",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-06-30",
      "name": "us-gaap:OperatingLeasePaymentsUse",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
     "longName": "00000041 - Disclosure - Notes Payable-Related Party (Details Narrative)",
     "shortName": "Notes Payable-Related Party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-12-012021-12-31",
      "name": "us-gaap:DebtInstrumentMaturityDateDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:NotesPayableRelatedPartyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
     "longName": "00000042 - Disclosure - Convertible Notes and Notes Payable (Details Narrative)",
     "shortName": "Convertible Notes and Notes Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
     "longName": "00000043 - Disclosure - Schedule of Warrants Activity (Details)",
     "shortName": "Schedule of Warrants Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember29544828",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
     "longName": "00000044 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)",
     "shortName": "Schedule of Restricted Stock Units (RSUs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000045 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "SHPH:AccruedInterestValueToIssueShares",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
     "longName": "00000046 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)",
     "shortName": "Schedule of Monte Carlo Simulation Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_AltoWarrantsMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
     "longName": "00000047 - Disclosure - Schedule of Derivative Liabilities (Details)",
     "shortName": "Schedule of Derivative Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_AltoWarrantsMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_AcceleratedFeatureMember29546593",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
     "longName": "00000048 - Disclosure - Derivative Liabilities (Details Narrative)",
     "shortName": "Derivative Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000049 - Disclosure - Related Party transactions (Details Narrative)",
     "shortName": "Related Party transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_TCGGreenChemIncMember",
      "name": "SHPH:PaymentsToInvoicesInResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
     "longName": "00000050 - Disclosure - Schedule of Key Inputs of Warrant Liabilities (Details)",
     "shortName": "Schedule of Key Inputs of Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2022-08-01",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember",
      "name": "SHPH:WarrantsEstimatedFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails",
     "longName": "00000051 - Disclosure - Schedule of Warrant Liabilities (Details)",
     "shortName": "Schedule of Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember",
      "name": "SHPH:WarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleofWarrantLiabilitiesTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember",
      "name": "SHPH:WarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleofWarrantLiabilitiesTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails",
     "longName": "00000052 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)",
     "shortName": "Schedule of Useful Lives for Property Plant Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure",
     "longName": "00000053 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)",
     "shortName": "Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
     "longName": "00000054 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)",
     "shortName": "Schedule of Warrants Activity (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2021-01-012021-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-01-012021-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails",
     "longName": "00000055 - Disclosure - Schedule of Restricted Stock Units (Details)",
     "shortName": "Schedule of Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
     "longName": "00000056 - Disclosure - Schedule of Derivative Liability Valuation (Details)",
     "shortName": "Schedule of Derivative Liability Valuation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember",
      "name": "SHPH:DerivativeLiabilityDiscoutRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
     "longName": "00000057 - Disclosure - Schedule of Derivative Key Valuation Inputs (Details)",
     "shortName": "Schedule of Derivative Key Valuation Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
     "longName": "00000058 - Disclosure - Schedule of Derivative Issuance Valuation Inputs (Details)",
     "shortName": "Schedule of Derivative Issuance Valuation Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember",
      "name": "SHPH:DerivativeLiabilityOfAcceleration",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails",
     "longName": "00000059 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)",
     "shortName": "Schedule of Reconciliation of Income Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "longName": "00000060 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)",
     "shortName": "Schedule of Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails",
     "longName": "00000062 - Disclosure - Schedule of Quarterly Financial Data (Details)",
     "shortName": "Schedule of Quarterly Financial Data (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:AdditionalPaidInCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical",
     "longName": "00000063 - Disclosure - Schedule of Quarterly Financial Data (Details) (Parenthetical)",
     "shortName": "Schedule of Quarterly Financial Data (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-09-30",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock",
       "SHPH:QuarterlyFinancialDataTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-09-30",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock",
       "SHPH:QuarterlyFinancialDataTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000064 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2023-08-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-312023-08-31",
      "name": "us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
      "unitRef": "TradingDays",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "SHPH_AcceleratedFeatureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AcceleratedFeatureMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accelerated Feature [Member]",
        "documentation": "Accelerated Feature [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses related party",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "SHPH_AccruedInterestSettledWithCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AccruedInterestSettledWithCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest settled with common stock",
        "documentation": "Accruedi nterest settled with common stock."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AccruedInterestValueToIssueShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AccruedInterestValueToIssueShares",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest settled with common stock",
        "documentation": "Accrued interest value to issue shares.",
        "label": "AccruedInterestValueToIssueShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r143",
      "r587"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ]
    },
    "SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AdditionOfNewDerivativesRecognizedAsDebtDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated fair value issuance",
        "verboseLabel": "Addition of new derivatives",
        "documentation": "Addition of new derivatives recognized as debt discounts."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AdditionalEscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AdditionalEscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Escrow deposit",
        "documentation": "Additional escrow deposit.",
        "label": "AdditionalEscrowDeposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital, as restated",
        "verboseLabel": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r771",
      "r972"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r850",
      "r851",
      "r852",
      "r855",
      "r924",
      "r973"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease in additional paid in capital",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r366"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for financing costs, net of issuance fees of $8,727",
        "verboseLabel": "Warrants issued for financing costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r104"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to additional paid in capital stock split",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r104"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of fair value of warrant liabilities to equity, as restated",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r35",
      "r104"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AllianceGlobalPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AllianceGlobalPartnersMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alliance Global Partners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AltoAccelerationOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AltoAccelerationOptionMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alto Acceleration Option [Member]",
        "documentation": "Alto Acceleration Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AltoConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AltoConvertibleNoteMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alto Convertible Note [Member]",
        "documentation": "Alto Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AltoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AltoWarrantsMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alto Warrants [Member]",
        "documentation": "Alto Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount and finance fees, as restated",
        "verboseLabel": "Amortization of debt discount and finance fees",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r88",
      "r327",
      "r945"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r327",
      "r840",
      "r945"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r125",
      "r145",
      "r173",
      "r209",
      "r213",
      "r228",
      "r229",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r448",
      "r452",
      "r493",
      "r578",
      "r668",
      "r739",
      "r740",
      "r771",
      "r786",
      "r878",
      "r879",
      "r956"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r151",
      "r173",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r448",
      "r452",
      "r493",
      "r771",
      "r878",
      "r879",
      "r956"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r759"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "SHPH_AugustTwentyTwentyTwoConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AugustTwentyTwentyTwoConvertibleNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 Convertible Notes [Member]",
        "documentation": "August 2022 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AugustTwentyTwentyTwoPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AugustTwentyTwentyTwoPromissoryNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 [Promissory Notes Member]",
        "documentation": "August 2022 [Promissory Notes Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AugustTwoThousandAndTwentyOnePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AugustTwoThousandAndTwentyOnePromissoryNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2021 Promissory Notes [Member]",
        "documentation": "August 2021 Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AugustTwoThousandAndTwentyTwoNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AugustTwoThousandAndTwentyTwoNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 Notes [Member]",
        "documentation": "August 2022 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AugustTwoThousandAndTwentyTwoPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AugustTwoThousandAndTwentyTwoPromissoryNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 Promissory Notes [Member]",
        "documentation": "August 2022 Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AugustTwoThousandTwentyTwoNotesDerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AugustTwoThousandTwentyTwoNotesDerivativeMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 Notes Derivative [Member]",
        "documentation": "August 2022 Notes Derivative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AugustTwoThousandTwentyTwoNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AugustTwoThousandTwentyTwoNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "August 2022 Notes [Member]",
        "documentation": "August 2022 Notes [Member]",
        "label": "August 2022 Notes [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "SHPH_AyrtonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "AyrtonMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ayrton [Member]",
        "documentation": "Ayrton [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_BlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "BlackScholesModelMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black Scholes Model [Member]",
        "documentation": "Black Scholes Model [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_BousteadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "BousteadMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Boustead [Member]",
        "documentation": "Boustead [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_BousteadSecuritiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "BousteadSecuritiesLLCMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Boustead Securities LLC [Member]",
        "documentation": "Boustead Securities LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r580",
      "r637",
      "r663",
      "r771",
      "r786",
      "r827"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r142",
      "r728"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r91",
      "r169"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r91"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r147",
      "r148",
      "r149",
      "r173",
      "r199",
      "r200",
      "r203",
      "r205",
      "r211",
      "r212",
      "r265",
      "r296",
      "r298",
      "r299",
      "r300",
      "r303",
      "r304",
      "r336",
      "r337",
      "r340",
      "r343",
      "r351",
      "r493",
      "r616",
      "r617",
      "r618",
      "r619",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r655",
      "r677",
      "r697",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r807",
      "r843",
      "r856"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable price per share",
        "verboseLabel": "Exercise price of warrants",
        "terseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase of common stock",
        "verboseLabel": "Number of warrants to purchase",
        "terseLabel": "Number of shares warrant to purchase",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants price",
        "documentation": "Class pf warrant or right number of securities called by warrants or rights value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant to purchase common stock",
        "verboseLabel": "Warrants outstanding and exercisable",
        "terseLabel": "Four year warrant to purchase",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "SHPH_CommonAreaMaintenanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonAreaMaintenanceCost",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common area maintenance cost",
        "documentation": "Common area maintenance cost."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated",
        "label": "Common shares issued for dividends on and conversion of Series A preferred stock",
        "documentation": "Common shares issued for dividends on and conversion of series preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConvertibleConversionPriceDecrease",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price per share",
        "verboseLabel": "Exercise price",
        "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "SHPH_CommonStockIssuedForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockIssuedForCash",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash",
        "documentation": "Common stock issued for cash."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedForConversionOfAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockIssuedForConversionOfAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest",
        "documentation": "Common stock issued for conversion of accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedForConversionOfAccruedInterestAsRestated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockIssuedForConversionOfAccruedInterestAsRestated",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued for conversion of accrued interest, as restated",
        "documentation": "Common stock issued for conversion of accrued interest as restated.",
        "label": "CommonStockIssuedForConversionOfAccruedInterestAsRestated"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued for exercise of warrants with settlement of notes payable, as restated",
        "label": "Common stock issued for exercise of warrants with settlement of notes payable",
        "documentation": "Common stock issued for exercise of warrants with settlement of notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedForSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockIssuedForSettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for settlement of debt",
        "documentation": "Common stock issued for settlement of debt."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedUponConversionOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockIssuedUponConversionOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon conversion of convertible debt",
        "documentation": "Common stock issued upon conversion of convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated",
        "documentation": "Common stock issued upon conversion of convertible debt and exercise of related warrants as restated.",
        "label": "CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r780",
      "r781",
      "r782",
      "r783",
      "r850",
      "r851",
      "r855",
      "r924",
      "r970",
      "r973"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r655"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r655",
      "r674",
      "r973",
      "r974"
     ]
    },
    "SHPH_CommonStockToBeIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockToBeIssuedMember",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock to be Issued [Member]",
        "documentation": "Common Stock To Be Issued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.00001 par value; 100,000,000 shares authorized; 2,008,689 and 1,700,414 shares issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r582",
      "r771"
     ]
    },
    "SHPH_CommonStockVestingOfRestrictedStockUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CommonStockVestingOfRestrictedStockUnit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock vesting of restricted stock unit",
        "documentation": "Common stock vesting of restricted stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r731"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of stock, shares issued",
        "verboseLabel": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal balance",
        "verboseLabel": "Convertible debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118",
      "r967"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable non-current, net",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "SHPH_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note [Member]",
        "documentation": "Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ConvertibleNotePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ConvertibleNotePolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes",
        "documentation": "Convertible Note [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable",
        "verboseLabel": "Estimated fair value",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118",
      "r967"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, net",
        "verboseLabel": "Convertible note",
        "terseLabel": "Convertible Notes",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "SHPH_ConvertibleNotesPayableCurrentNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ConvertibleNotesPayableCurrentNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note payable",
        "documentation": "Convertible notes payable current noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r38",
      "r74",
      "r102",
      "r346"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CumulativeDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CumulativeDividends",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative dividends",
        "documentation": "Amount of cumulative cash dividends distributed to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CumulativeDividendsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "CumulativeDividendsPercentage",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative dividends percentage",
        "documentation": "Cumulative dividends percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal income tax",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r846",
      "r922"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r846",
      "r922"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentRate",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument conversion rate",
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r24"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes and Notes Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r171",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r294",
      "r295",
      "r305",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r321",
      "r328",
      "r329",
      "r331",
      "r502"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r61",
      "r62",
      "r115",
      "r118",
      "r178",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r769",
      "r844",
      "r874",
      "r875",
      "r876",
      "r944",
      "r946"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118",
      "r332"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r308"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r66",
      "r102",
      "r103",
      "r308"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consecutive trading days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r38",
      "r59",
      "r61",
      "r115",
      "r118",
      "r502"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, face amount",
        "verboseLabel": "Principal amount",
        "terseLabel": "Debt principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r502",
      "r503",
      "r746",
      "r747",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity warrant as reduction in additional paid in capital",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase accrued interest",
        "verboseLabel": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument",
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r333",
      "r502",
      "r503",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal increase decrease rate",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r307"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r745",
      "r930",
      "r931"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument maturiy date description",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Measurement Input",
        "verboseLabel": "Share price",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r178",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r769",
      "r844",
      "r874",
      "r875",
      "r876",
      "r944",
      "r946"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time period (years)",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r943",
      "r944",
      "r946"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount, Current",
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r946"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleMaturityDate",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO date",
        "verboseLabel": "Estimated IPO date",
        "documentation": "Maturity date of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r929",
      "r930",
      "r931"
     ]
    },
    "SHPH_DecemberTwentyThousandTwentyOneNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DecemberTwentyThousandTwentyOneNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2021 Notes [Member]",
        "documentation": "December 2021 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DecemberTwoThousandTwentyOneNotesDerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DecemberTwoThousandTwentyOneNotesDerivativeMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2021 Notes Derivative [Member]",
        "documentation": "December 2021 Notes Derivative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed contribution",
        "documentation": "Deemed contribution of conversion of preferred stock and settlement of preferred stock dividends."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed contribution on conversion of preferred stock and settlement of preferred stock dividend",
        "documentation": "Deemed contribution on conversion of preferred stock and settlement of preferred stock dividend."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated",
        "documentation": "Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends.",
        "label": "DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated",
        "documentation": "Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends as restated.",
        "label": "DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedDividend",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend",
        "documentation": "Deemed dividend."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedDividendOnExtinguishmentOfPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedDividendOnExtinguishmentOfPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend on extinguishment of Series A Preferred Stock",
        "documentation": "Deemed dividend on extinguishment of series A preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedDividendOnExtinguishmentOfSeriesPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed dividend on extinguishment of Series A Preferred Stock",
        "documentation": "Deemed dividend on extinguishment of series preferred stock.",
        "label": "DeemedDividendOnExtinguishmentOfSeriesPreferredStock"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed dividend on extinguishment of Series A Convertible Preferred Stock, as restated",
        "documentation": "Deemed dividend on extinguishment of series preferred stock as restated.",
        "label": "DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedDividendOnModificationOfEquityclassifiedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed dividend on modification of equity-classified warrants, as restated",
        "label": "Deemed dividend on modification of equity classified warrants",
        "documentation": "Deemed dividend on modification of equity-classified warrants."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed dividend on modification of equity-classified warrants, as restated",
        "documentation": "Deemed dividend on modification of equity classified warrants as restated.",
        "label": "DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance cost",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r943",
      "r944",
      "r946"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r116",
      "r422"
     ]
    },
    "SHPH_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Deferred Offering Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State income tax deferred",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangibles (includes Section 174 capitalization)",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D tax credits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "SHPH_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease asset/(liability)",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax asset",
        "documentation": "Deferred tax assets liabilities net before valuation allowances.",
        "label": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "SHPH_DeferredTaxAssetsOperatingLossCarriedForward": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredTaxAssetsOperatingLossCarriedForward",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carried forward",
        "documentation": "Deferred tax assets operating loss carried forward"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Carried forward",
        "documentation": "Deferred tax assets operating loss carried forward future federal income.",
        "label": "DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "verboseLabel": "Operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest &amp; other accrued expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "R&amp;D tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "SHPH_DeferredTaxAssetsbasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredTaxAssetsbasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation",
        "documentation": "Deferred tax assetsbased compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "SHPH_DeferredTaxLiabilitiesFairMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredTaxLiabilitiesFairMarketValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair market value of securities",
        "documentation": "Deferred tax liabilities fair market value.",
        "label": "DeferredTaxLiabilitiesFairMarketValue"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeferredTaxLiabilitiesFiniteLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DeferredTaxLiabilitiesFiniteLivedAssets",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets",
        "documentation": "Deferred tax liabilities finite lived assets.",
        "label": "DeferredTaxLiabilitiesFiniteLivedAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r33"
     ]
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States Treasury Bonds",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r647",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r692",
      "r693",
      "r694",
      "r709",
      "r710",
      "r713",
      "r715",
      "r775",
      "r777",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r939",
      "r940"
     ]
    },
    "SHPH_DerivativeDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeDiscountPercentage",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative discount percentage",
        "documentation": "Derivative discount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative fair value",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liabilities",
        "negatedLabel": "Change in fair value of derivative liability, as restated",
        "negatedTerseLabel": "Change in fair value of derivative liabilities",
        "verboseLabel": "Derivatives loss",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "SHPH_DerivativeGainLossOnDerivativeWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeGainLossOnDerivativeWarrants",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on change in fair value of the derivative",
        "label": "Gain loss on change in fair value",
        "documentation": "Derivative gain loss on derivative warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r111",
      "r645",
      "r647",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r692",
      "r693",
      "r694",
      "r709",
      "r710",
      "r713",
      "r715",
      "r730",
      "r775",
      "r777",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r939",
      "r940"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative liability",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r470",
      "r471",
      "r484",
      "r492",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r669",
      "r671",
      "r672",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r730",
      "r929",
      "r930",
      "r931",
      "r971"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "verboseLabel": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative liability",
        "label": "Warrant derivative liability",
        "terseLabel": "Derivative liability non-current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "SHPH_DerivativeLiabilityAcceleratedFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityAcceleratedFeature",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability - Accelerated feature",
        "documentation": "Derivative liability accelerated feature."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DerivativeLiabilityDiscoutRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityDiscoutRate",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate",
        "documentation": "Derivative liability discout rate."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DerivativeLiabilityMeasurementDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityMeasurementDuration",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time period to maturity (years)",
        "verboseLabel": "Time period (years)",
        "documentation": "Derivative liability measurement duration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probability of Maturity",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474"
     ]
    },
    "SHPH_DerivativeLiabilityOfAcceleration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityOfAcceleration",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due upon acceleration",
        "documentation": "Derivative liability of acceleration."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DerivativeLiabilityOfCarringValueMeasurementDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityOfCarringValueMeasurementDate",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value",
        "documentation": "Derivative liability of carring value measurement date."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DerivativeLiabilityOfDiscountRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityOfDiscountRate",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Discount rate",
        "documentation": "Derivative liability of discount rate.",
        "label": "DerivativeLiabilityOfDiscountRate"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DerivativeLiabilityOfProbabilityAcceleration": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityOfProbabilityAcceleration",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probability of IPO acceleration",
        "documentation": "Derivative liability of probability acceleration."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DerivativeLiabilityWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeLiabilityWarrants",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability - Warrants",
        "documentation": "Derivative liability warrants."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DerivativeSettlementsOnDerivativeWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DerivativeSettlementsOnDerivativeWarrants",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlements",
        "documentation": "Derivative Settlements on Derivative [Warrants]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r52",
      "r56",
      "r177",
      "r194"
     ]
    },
    "us-gaap_DirectOperatingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DirectOperatingCosts",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct cost",
        "documentation": "The aggregate direct operating costs incurred during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "SHPH_DirectorsAndOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DirectorsAndOfficersMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors And Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DirectorsOfficersAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DirectorsOfficersAndConsultantsMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors Officers and Consultants [Member]",
        "documentation": "Directors Officers and Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Right-of Use Asset And Lease Information About Operating Lease",
        "terseLabel": "Schedule Of Balance Sheet Information Related To Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DisclosureNotesPayablerelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DisclosureNotesPayablerelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable-related Party"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DisclosureQuarterlyFinancialDataUnauditedAndRestatedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Data",
        "verboseLabel": "Quarterly Financial Data Unaudited And Restated"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DividendsOnSeriesPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "DividendsOnSeriesPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on Series A convertible preferred stock, as restated",
        "negatedTerseLabel": "Dividends on Series A preferred stock",
        "documentation": "Dividends on series preferred stock.",
        "label": "DividendsOnSeriesPreferredStock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r800",
      "r801"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - basic",
        "verboseLabel": "Net loss per shares - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r191",
      "r196",
      "r199",
      "r203",
      "r204",
      "r205",
      "r208",
      "r442",
      "r445",
      "r467",
      "r468",
      "r575",
      "r594",
      "r733"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - diluted",
        "verboseLabel": "Net loss per shares - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r191",
      "r199",
      "r203",
      "r204",
      "r205",
      "r208",
      "r442",
      "r445",
      "r467",
      "r468",
      "r575",
      "r594",
      "r733"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Stock",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r207"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. statutory rate",
        "verboseLabel": "Federal income tax benefit at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r410",
      "r433",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r755",
      "r847",
      "r913"
     ]
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInTaxRate",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in tax rate",
        "documentation": "Effective income tax rate reconciliation change in tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future taxable income",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to lease expense."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r913",
      "r915"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r847",
      "r913",
      "r914"
     ]
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Permanent differences",
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Differences [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in FMV of Warrant Liability",
        "documentation": "Differences change in FMV of warrant liability",
        "label": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Debt Discount Amortization",
        "documentation": "Differences derivative debt discount amortization.",
        "label": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss on convertible note conversion",
        "documentation": "Permanent differences loss on convertible note conversion.",
        "label": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "documentation": "Permanent differences other.",
        "label": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Return to provision adjustments",
        "documentation": "Effective income tax rate reconciliation return to provision adjustments.",
        "label": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shortfall of stock compensation expense",
        "documentation": "Effective income tax rate reconciliation short fall of stock compensation expense.",
        "label": "EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax benefit, net of federal tax effect",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r755",
      "r847",
      "r913"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "R&amp;D tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r847",
      "r913",
      "r915"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend on modification of equity-classified warrants",
        "documentation": "Amount of increase (decrease) in equity for freestanding written call option classified as equity from modification recognized as dividend. Includes, but is not limited to, exchange by issuer and holder. Excludes share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r460",
      "r463",
      "r464"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r136",
      "r157",
      "r158",
      "r159",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r192",
      "r194",
      "r210",
      "r266",
      "r269",
      "r280",
      "r353",
      "r431",
      "r432",
      "r439",
      "r440",
      "r441",
      "r443",
      "r444",
      "r445",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r466",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r505",
      "r508",
      "r527",
      "r592",
      "r600",
      "r601",
      "r602",
      "r626",
      "r697"
     ]
    },
    "us-gaap_ErrorCorrectionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ErrorCorrectionTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement of Previously Issued Financial Statements",
        "documentation": "The entire disclosure for reporting error correction."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r724"
     ]
    },
    "SHPH_EstimatedMonthlyCommonAreaMaintenanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "EstimatedMonthlyCommonAreaMaintenanceCost",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated monthly common area maintenance cost",
        "documentation": "Estimated monthly common area maintenance cost."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_FairValueAdjustmentOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "FairValueAdjustmentOfWarrant",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liabilities, as restated",
        "documentation": "Fair value adjustment of warrant.",
        "label": "FairValueAdjustmentOfWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities, as restated",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "verboseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Estimated fair value",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r484",
      "r759"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r484",
      "r759"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r762"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r762"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Key Inputs of Warrant Liabilities",
        "verboseLabel": "Schedule of Monte Carlo Simulation Assumption",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r762"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r485",
      "r760"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r485",
      "r760"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r483",
      "r484",
      "r486",
      "r542",
      "r543",
      "r544",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r481",
      "r482",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r573",
      "r759",
      "r763"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r355",
      "r360",
      "r471",
      "r484",
      "r542",
      "r751",
      "r752",
      "r753",
      "r759"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r355",
      "r360",
      "r471",
      "r472",
      "r484",
      "r543",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r759"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r471",
      "r472",
      "r473",
      "r474",
      "r484",
      "r544",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r480",
      "r485"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement",
        "verboseLabel": "Estimated fair value",
        "periodStartLabel": "Balance, warrants",
        "periodEndLabel": "Balance, warrants",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r485"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r483",
      "r484",
      "r486",
      "r542",
      "r543",
      "r544",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "SHPH_FairValueOfFreestandingInstrumentsInExcessOfProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "FairValueOfFreestandingInstrumentsInExcessOfProceeds",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of freestanding instruments in excess of proceeds, as restated",
        "verboseLabel": "Fair value of freestanding instruments in excess of proceeds",
        "documentation": "Fair value of free standing Instruments In excess of proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_FederalTaxableIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "FederalTaxableIncomeMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Taxable Income [Member]",
        "documentation": "Federal Taxable Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_FinanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "FinanceFee",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance fee",
        "negatedTerseLabel": "Financing fee",
        "label": "Finance fee",
        "documentation": "Finance fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r330",
      "r349",
      "r461",
      "r491",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r593",
      "r744",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r867",
      "r868",
      "r869",
      "r870",
      "r926",
      "r929",
      "r930",
      "r931",
      "r938",
      "r941"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of marketable securities",
        "negatedLabel": "Gain on marketable securities",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on sale of assets and asset impairment charges",
        "verboseLabel": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "SHPH_GainOnChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "GainOnChangeInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on change in fair value",
        "documentation": "Gain on change in fair value."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_GainOnForgivenessOfNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "GainOnForgivenessOfNotePayable",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on forgiveness of Paycheck Protection Program note payable",
        "negatedLabel": "Gain on forgiveness of Paycheck Protection Program",
        "documentation": "Gain on forgiveness of note payable."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_GainOnInterestReliefOnConversionOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "GainOnInterestReliefOnConversionOfNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on interest relief on conversion of notes payable",
        "documentation": "Gain on interest relief on conversion of notes payable.",
        "label": "GainOnInterestReliefOnConversionOfNotesPayable"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_GainOnSettlementOfAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "GainOnSettlementOfAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on settlement of accounts payable",
        "documentation": "Gain on settlement of accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_GainOnSettlementOnAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "GainOnSettlementOnAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on settlement on accounts payable",
        "documentation": "Gain on settlement on accounts payable.",
        "label": "GainOnSettlementOnAccountsPayable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "verboseLabel": "Gain (loss) on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r37"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "verboseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r679"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r98"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss, as restated",
        "verboseLabel": "Net loss",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r120",
      "r124",
      "r576",
      "r589",
      "r735",
      "r739",
      "r857",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r288",
      "r289",
      "r476",
      "r480",
      "r485",
      "r597",
      "r599",
      "r682",
      "r727",
      "r761",
      "r969"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r476",
      "r480",
      "r485",
      "r597",
      "r599",
      "r682",
      "r727",
      "r761",
      "r969"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r410",
      "r411",
      "r419",
      "r428",
      "r755",
      "r920"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r410",
      "r411",
      "r419",
      "r428",
      "r755",
      "r920"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r406",
      "r410",
      "r416",
      "r417",
      "r418",
      "r420",
      "r426",
      "r434",
      "r436",
      "r437",
      "r438",
      "r621",
      "r755"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r134",
      "r193",
      "r194",
      "r209",
      "r218",
      "r229",
      "r409",
      "r410",
      "r435",
      "r595",
      "r755"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r407",
      "r408",
      "r420",
      "r421",
      "r425",
      "r430",
      "r615"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r755",
      "r913"
     ]
    },
    "SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Income Tax Reconciliation Foreign Income Tax Permanent Differences [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in FMV of Warrant Liability",
        "documentation": "Change in FMV of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Debt Discount Amortization",
        "documentation": "Differences derivative debt discount amortization."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on convertible note conversion",
        "documentation": "Permanent differences loss on convertible note."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Permanent differences other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate change",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r414",
      "r755",
      "r913"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal tax benefit at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r755"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Research and Development",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r915"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other adjustments",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r913",
      "r914"
     ]
    },
    "SHPH_IncomeTaxReconciliationProvisionAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncomeTaxReconciliationProvisionAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return to provision adjustments",
        "documentation": "Income tax reconciliation provision adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal tax effect",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r755",
      "r913"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "R &amp; D tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r913",
      "r915"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental non-cash financing activities:",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r93",
      "r842",
      "r918",
      "r919"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r168",
      "r427",
      "r428"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInAccruedInterestPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest payable - related parties",
        "documentation": "Increase decrease in accrued interest payable - related parties.",
        "label": "IncreaseDecreaseInAccruedInterestPayableRelatedParties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued interest income",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation",
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "SHPH_IncreaseDecreaseInDividendLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInDividendLiability",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease in dividend liability",
        "documentation": "Increase decrease in dividend liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDividendsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDividendsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued dividends",
        "documentation": "The increase (decrease) during the reporting period in cash disbursements due from investments, representing the shareholders' portion of profits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses - related parties",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "SHPH_IncreaseDecreaseInFairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInFairValueOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Increase decrease in fair value of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest payable, as restated",
        "verboseLabel": "Accrued interest payable",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "SHPH_IncreaseDecreaseInIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInIssuanceCost",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance cost",
        "documentation": "Increase decrease in issuance cost."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IncreaseDecreaseInNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income loss",
        "documentation": "Increase decrease in net income loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInNotesPayableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease of notes payable",
        "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating lease asset and liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r839"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "SHPH_IncreaseDecreaseInPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease in preferred stock",
        "documentation": "Increase decrease in preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "SHPH_IncreaseDecreaseInWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInWarrants",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "documentation": "Increase decrease in warrants.",
        "label": "IncreaseDecreaseInWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IncreaseDecreaseInWarrantsFromLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IncreaseDecreaseInWarrantsFromLiability",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants from liability",
        "documentation": "Increase decrease in warrants from liability."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_InitialPublicOfferingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "InitialPublicOfferingDescription",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering description",
        "documentation": "Initial public offering description."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_InitialRecognitionOfRightOfUseAssetAndLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "InitialRecognitionOfRightOfUseAssetAndLiability",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial recognition of right of use asset and liability",
        "documentation": "Initial recognition of right of use asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_InstitutionalInvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "InstitutionalInvestorMember",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Institutional Investor [Member]",
        "documentation": "Institutional Investor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expenses",
        "label": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r213",
      "r217",
      "r219",
      "r229",
      "r501",
      "r739",
      "r740"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r325",
      "r334",
      "r748",
      "r749"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r836"
     ]
    },
    "SHPH_InterestFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "InterestFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest fee",
        "documentation": "Interest fee amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income",
        "label": "Interest Income (Expense), Operating",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r859"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "verboseLabel": "Accrued interest",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r166",
      "r167"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest payable - related parties",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of accrued interest",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r966"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest income",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r216",
      "r229",
      "r739",
      "r835"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953"
     ]
    },
    "SHPH_IssuanceDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IssuanceDateMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Date [Member]",
        "documentation": "Issuance Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IssuanceDatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IssuanceDatesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Dates [Member]",
        "documentation": "Issuance Dates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_IssuanceOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "IssuanceOfWarrantsShares",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants shares",
        "documentation": "Issuance of warrants shares"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_LeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "LeaseAgreementMember",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement [Member]",
        "documentation": "Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r812"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r812"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r770"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Right-of Use Asset and Lease Information About Operating Lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and professional",
        "verboseLabel": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r525"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r525"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 (excluding the six months ended June 30, 2024)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities [Default Label]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r61",
      "r62",
      "r63",
      "r68",
      "r69",
      "r70",
      "r73",
      "r173",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r449",
      "r452",
      "r453",
      "r493",
      "r654",
      "r734",
      "r786",
      "r878",
      "r956",
      "r957"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r119",
      "r584",
      "r771",
      "r845",
      "r871",
      "r942"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r141",
      "r173",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r449",
      "r452",
      "r453",
      "r493",
      "r771",
      "r878",
      "r956",
      "r957"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r927"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_LossOnSettlementOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "LossOnSettlementOfConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on settlement of convertible debt",
        "label": "Loss on settlement of notes payable and convertible notes payable, as restated",
        "verboseLabel": "Loss on settlement of convertible debt",
        "documentation": "Loss on settlement of convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "verboseLabel": "Marketable securitie outstanding balance",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of marketable securities",
        "negatedLabel": "Change in fair value of marketable securities",
        "negatedTerseLabel": "Unrealized loss",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities realized gain loss",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities unrealized gain loss",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r362",
      "r402",
      "r474",
      "r571",
      "r596",
      "r598",
      "r610",
      "r646",
      "r647",
      "r705",
      "r706",
      "r707",
      "r708",
      "r717",
      "r725",
      "r726",
      "r743",
      "r750",
      "r754",
      "r762",
      "r763",
      "r767",
      "r768",
      "r774",
      "r880",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_MeasurementInputDefaultRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDefaultRateMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Default Rate [Member]",
        "documentation": "Measurement input using likelihood loan will not be repaid as proportion of outstanding loan."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r929",
      "r930",
      "r931"
     ]
    },
    "SHPH_MeasurementInputEstimatedFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputEstimatedFairValueMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Estimated Fair Value [Member]",
        "documentation": "Measurement Input Estimated Fair Value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "SHPH_MeasurementInputIlliquidityDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputIlliquidityDiscountMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Illiquidity Discount [Member]",
        "documentation": "Illiquidity Discount [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_MeasurementInputIpoDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputIpoDateMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Ipo Date [Member]",
        "documentation": "Measurement Input Ipo Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r929",
      "r930",
      "r931"
     ]
    },
    "SHPH_MeasurementInputProbabilityOfIPOListingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputProbabilityOfIPOListingMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Probability of IPO Listing [Member]",
        "documentation": "Measurement Input Probability of IPO Listing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_MeasurementInputProbabilityOfIPOListingOccurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputProbabilityOfIPOListingOccurringMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Probability of IPO Listing Occurring [Member]",
        "documentation": "Measurement Input Probability of IPO Listing Occurring [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_MeasurementInputProbabilityOfQualifiedIPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputProbabilityOfQualifiedIPOMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Probability of Qualified IPO [Member]",
        "documentation": "Measurement Input Probability of Qualified IPO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "SHPH_MeasurementInputSharePriceProbabilityOfIPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputSharePriceProbabilityOfIPOMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Share Price Probability Of IPO [Member]",
        "documentation": "Measurement Input Share Price Probability Of IPO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r762"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r762"
     ]
    },
    "SHPH_MeasurementInputVolumeWeightedAveragePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "MeasurementInputVolumeWeightedAveragePriceMember",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Volume Weighted Average Price [Member]",
        "documentation": "Measurement Input Volume Weighted Average Price [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MediumTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MediumTermNotes",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term notes issued",
        "documentation": "Amount of debt instrument classified as medium-term."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118",
      "r967"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r362",
      "r402",
      "r474",
      "r571",
      "r596",
      "r598",
      "r610",
      "r646",
      "r647",
      "r705",
      "r706",
      "r707",
      "r708",
      "r717",
      "r725",
      "r726",
      "r743",
      "r750",
      "r754",
      "r762",
      "r763",
      "r767",
      "r774",
      "r880",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market funds",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "negatedLabel": "Net income loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r121",
      "r139",
      "r154",
      "r155",
      "r159",
      "r173",
      "r182",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r193",
      "r194",
      "r201",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r442",
      "r445",
      "r468",
      "r493",
      "r591",
      "r676",
      "r695",
      "r696",
      "r784",
      "r878"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r184",
      "r185",
      "r187",
      "r188",
      "r196",
      "r197",
      "r202",
      "r205",
      "r445"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_NewLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "NewLeaseAgreementMember",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Lease Agreement [Member]",
        "documentation": "New Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, as restated",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r849"
     ]
    },
    "SHPH_NotesDerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "NotesDerivativeMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Derivative [Member]",
        "documentation": "Notes Derivative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118",
      "r967",
      "r968"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable to related parties",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "SHPH_NotesPayableRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "NotesPayableRelatedPartiesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Related Parties [Member]",
        "documentation": "Notes Payable Related Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_NotesPayableRelatedPartyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "NotesPayableRelatedPartyDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable-Related Party",
        "documentation": "Notes Payable Related Party [Disclosure Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable operating segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r742",
      "r858"
     ]
    },
    "SHPH_OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "OfferingMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_OfficersSpouseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "OfficersSpouseMember",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers Spouse [Member]",
        "documentation": "Officers Spouse [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Net loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r735",
      "r857",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r770"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for operating cash flows from operating leases",
        "verboseLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r519"
     ]
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease payment",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r770"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term (year)",
        "verboseLabel": "Weighted-average remaining lease term - operating leases (year)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r770"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operatiing loss",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Liquidity",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r110",
      "r611",
      "r612"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_OtherGeneralExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralExpense",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related expense",
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r739"
     ]
    },
    "SHPH_OtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "OtherInformationAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other information",
        "documentation": "Other information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development, net of contract expense reimbursements",
        "verboseLabel": "Research, development expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnersCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnersCapital",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initiated a capital offering",
        "documentation": "The amount of ownership interest of different classes of partners in limited partnership."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "SHPH_PaymentForPlacementAgent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "PaymentForPlacementAgent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for placement agent",
        "documentation": "Payment for placement agent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt issuance costs related party",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees paid",
        "verboseLabel": "Commitment fee",
        "terseLabel": "Exchange fee",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for finance costs related to convertible note payable, as restated",
        "label": "Debt issuance costs related party",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfDerivativeIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDerivativeIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of derivative issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of a derivative security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for finance costs related to convertible notes payable",
        "label": "Allocation of financing costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "SHPH_PaymentsToInvoicesInResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "PaymentsToInvoicesInResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to invoices in research and development",
        "documentation": "Payments to invoices in research and development."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_PercentageOfRentAbatement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "PercentageOfRentAbatement",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of rent abatement",
        "documentation": "Percentage of rent abatement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_PledgingPurposeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PledgingPurposeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Axis]",
        "documentation": "Information by pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r756",
      "r772",
      "r810"
     ]
    },
    "us-gaap_PledgingPurposeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PledgingPurposeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r756",
      "r772",
      "r810"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price percentage",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend on Series A Convertible Preferred Stock, as restated",
        "negatedTerseLabel": "Dividend on Series A Preferred Stock",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r74",
      "r843",
      "r882"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r780",
      "r781",
      "r782",
      "r783",
      "r970",
      "r973"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "verboseLabel": "Preferred stock value share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r655"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r655",
      "r674",
      "r973",
      "r974"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r581",
      "r771"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r278",
      "r279",
      "r729"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible notes payable, as restated",
        "verboseLabel": "Proceeds from convertible debt",
        "terseLabel": "Proceeds from convertible notes payable",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromInterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settled for cash",
        "documentation": "Interest received on loans and other debt instruments during the current period."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common shares and exercise of warrants, as restated",
        "verboseLabel": "Proceeds from issuance of common shares and warrants",
        "documentation": "Proceeds from issuance of common stock and exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from warrants",
        "verboseLabel": "Warrants issuance",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r616"
     ]
    },
    "SHPH_ProceedsFromNotesPayableAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ProceedsFromNotesPayableAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable and warrants, as restated",
        "verboseLabel": "Proceeds from notes payable and warrants",
        "documentation": "Proceeds from notes payable and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable-related party",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from related party",
        "verboseLabel": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from disposition of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r154",
      "r155",
      "r164",
      "r173",
      "r182",
      "r189",
      "r193",
      "r194",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r442",
      "r445",
      "r447",
      "r450",
      "r451",
      "r468",
      "r493",
      "r576",
      "r590",
      "r625",
      "r676",
      "r695",
      "r696",
      "r757",
      "r758",
      "r785",
      "r834",
      "r878"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r524",
      "r577",
      "r588",
      "r771"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r130",
      "r133",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_QuarterlyFinancialDataTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "QuarterlyFinancialDataTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestated"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Data (Unaudited and Restated)",
        "documentation": "Quarterly Financial Data [TextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r354",
      "r362",
      "r393",
      "r394",
      "r395",
      "r402",
      "r474",
      "r545",
      "r555",
      "r571",
      "r596",
      "r598",
      "r610",
      "r646",
      "r647",
      "r705",
      "r706",
      "r707",
      "r708",
      "r717",
      "r725",
      "r726",
      "r743",
      "r750",
      "r754",
      "r762",
      "r763",
      "r767",
      "r768",
      "r774",
      "r777",
      "r877",
      "r880",
      "r930",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r354",
      "r362",
      "r393",
      "r394",
      "r395",
      "r402",
      "r474",
      "r545",
      "r555",
      "r571",
      "r596",
      "r598",
      "r610",
      "r646",
      "r647",
      "r705",
      "r706",
      "r707",
      "r708",
      "r717",
      "r725",
      "r726",
      "r743",
      "r750",
      "r754",
      "r762",
      "r763",
      "r767",
      "r768",
      "r774",
      "r777",
      "r877",
      "r880",
      "r930",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "SHPH_ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reclassification of fair value of warrant liabilities to equity, as restated",
        "label": "Reclassification of fair value of warrant liability to equity upon initial public offering",
        "documentation": "Reclassification of fair value of warrant liability to equity upon initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ReclassificationsToStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ReclassificationsToStockholdersEquity",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications to stockholders' equity",
        "documentation": "Reclassifications to stockholders equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r361",
      "r531",
      "r532",
      "r579",
      "r585",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r673",
      "r675",
      "r704"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r531",
      "r532",
      "r533",
      "r534",
      "r579",
      "r585",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r673",
      "r675",
      "r704"
     ]
    },
    "SHPH_RelatedPartyOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "RelatedPartyOfficerMember",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Officer [Member]",
        "documentation": "Related Party Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan transaction amount",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r531"
     ]
    },
    "us-gaap_RelatedPartyTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDate",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Date",
        "documentation": "Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r361",
      "r531",
      "r532",
      "r579",
      "r585",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r673",
      "r675",
      "r704",
      "r955"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r532",
      "r535",
      "r622",
      "r623",
      "r624",
      "r680",
      "r681",
      "r682",
      "r701",
      "r703"
     ]
    },
    "SHPH_RentVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "RentVariableRate1",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent variable rate",
        "documentation": "Rent Variable Rate1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of convertible note payable",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of note payable-related party",
        "label": "Payments upon subscription",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation under research and development",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development, net of contract expense reimbursements",
        "terseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r727",
      "r739",
      "r964"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r208",
      "r267",
      "r268",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r465",
      "r466",
      "r467",
      "r468",
      "r504",
      "r506",
      "r526",
      "r527",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r613",
      "r863"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r137",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r208",
      "r267",
      "r268",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r465",
      "r466",
      "r467",
      "r468",
      "r504",
      "r506",
      "r526",
      "r527",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r613",
      "r863"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit, as restated",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r104",
      "r583",
      "r604",
      "r609",
      "r620",
      "r656",
      "r771"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r192",
      "r194",
      "r266",
      "r269",
      "r280",
      "r431",
      "r432",
      "r439",
      "r440",
      "r441",
      "r443",
      "r444",
      "r445",
      "r454",
      "r456",
      "r457",
      "r459",
      "r466",
      "r505",
      "r508",
      "r600",
      "r602",
      "r626",
      "r973"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r160",
      "r173",
      "r209",
      "r214",
      "r215",
      "r227",
      "r229",
      "r231",
      "r232",
      "r233",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r493",
      "r576",
      "r739",
      "r878"
     ]
    },
    "SHPH_ReverseCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ReverseCommonStockSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse common stock shares outstanding",
        "documentation": "Reverse common stock shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split",
        "documentation": "Reverse Stock Split [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r191",
      "r192",
      "r193",
      "r194"
     ]
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r863"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets obtained in exchange for new operating lease liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r770"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock consideration received per transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock membership percentage",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r363",
      "r854"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r194",
      "r208",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r465",
      "r466",
      "r467",
      "r504",
      "r506",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r613",
      "r811",
      "r814",
      "r815",
      "r816",
      "r853",
      "r863",
      "r872",
      "r873",
      "r925",
      "r950",
      "r951"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "auth_ref": [
      "r195",
      "r363",
      "r808",
      "r854"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "SHPH_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balance Sheet Information Related to Operating Leases",
        "documentation": "Schedule of Balance Sheet Information Related to Operating Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r41",
      "r42",
      "r43"
     ]
    },
    "SHPH_ScheduleOfDerivativeOfSettlementValuationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleOfDerivativeOfSettlementValuationTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Issuance Valuation Inputs",
        "documentation": "Schedule of Derivative of Settlement Valuation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r755",
      "r913"
     ]
    },
    "SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Error Corrections And Prior Period Adjustments",
        "documentation": "Schedule Of Error Corrections And Prior Period Adjustments [TableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Error Correction",
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928"
     ]
    },
    "SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Income Tax Benefit",
        "documentation": "Schedule Of Pretax Income From Continuing Operations [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r524"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Units (RSUs)",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Units",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Useful Lives for Property Plant Equipment",
        "documentation": "Schedule of Useful Lives for Property Plant Equipment [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ScheduleofDerivativeKeyValuationInputsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleofDerivativeKeyValuationInputsTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Key Valuation Inputs",
        "documentation": "Schedule of Derivative Key Valuation Inputs [TableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ScheduleofQuarterlyFinancialDataTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleofQuarterlyFinancialDataTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/QuarterlyFinancialDataUnauditedAndRestatedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Quarterly Financial Data",
        "documentation": "Schedule of Quarterly Financial Data [TableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ScheduleofWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ScheduleofWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liabilities",
        "documentation": "Schedule of Warrant Liabilities [TableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r230",
      "r232",
      "r737",
      "r738",
      "r741"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r832",
      "r883"
     ]
    },
    "SHPH_SettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "SettlementMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement [Member]",
        "documentation": "Settlement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, as restated",
        "verboseLabel": "Stock-based compensation",
        "terseLabel": "Share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation arrangement by share based payment award description",
        "verboseLabel": "Share based payment award description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Stock Option Outstanding, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of RSUs, Outstanding, Beginning Balance",
        "periodEndLabel": "Number of RSUs, Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per RSU, Beginning Balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per RSU, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Life (Years), Outstanding Ending",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of RSUs, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Per RSU, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "verboseLabel": "Volatility rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding, exercised",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding, granted",
        "verboseLabel": "Number of shares issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of warrants outstanding, balance",
        "periodEndLabel": "Number of warrants outstanding, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108"
     ]
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding balance",
        "periodEndLabel": "Weighted average exercise price, outstanding balance",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value of warrants",
        "documentation": "Intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share granted under equity incentive plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Stock Option Outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, outstanding exercised",
        "documentation": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, outstanding granted",
        "documentation": "Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeIssuanceValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeKeyValuationInputsDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilityValuationDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r371",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "SHPH_ShareBasedCompensations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ShareBasedCompensations",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "documentation": "Share based compensations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "verboseLabel": "Minimum bid price",
        "terseLabel": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value of warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average life (years), granted",
        "documentation": "Weighted Average Remaining Life in Years Outstanding, Granted."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average life (years), outstanding balance",
        "documentation": "Weighted Average Remaining Life in Years Outstanding,"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average life (years), outstanding balance",
        "documentation": "Weighted average remaining contractual term1.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares vested under plan",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtDescription",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term note description",
        "documentation": "Description of borrowing classified as short-term upon issuance. Includes, but is not limited to, description of underlying arrangement, repayment terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ShortfallOfStockCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "ShortfallOfStockCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shortfall of stock compensation expense",
        "documentation": "Shortfall of stock compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r170"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "SHPH_StateTaxableIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StateTaxableIncomeMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Taxable Income [Member]",
        "documentation": "State Taxable Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r147",
      "r148",
      "r149",
      "r173",
      "r199",
      "r200",
      "r203",
      "r205",
      "r211",
      "r212",
      "r265",
      "r296",
      "r298",
      "r299",
      "r300",
      "r303",
      "r304",
      "r336",
      "r337",
      "r340",
      "r343",
      "r351",
      "r493",
      "r616",
      "r617",
      "r618",
      "r619",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r655",
      "r677",
      "r697",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r807",
      "r843",
      "r856"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r78",
      "r79",
      "r136",
      "r157",
      "r158",
      "r159",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r192",
      "r194",
      "r210",
      "r266",
      "r269",
      "r280",
      "r353",
      "r431",
      "r432",
      "r439",
      "r440",
      "r441",
      "r443",
      "r444",
      "r445",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r466",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r505",
      "r508",
      "r527",
      "r592",
      "r600",
      "r601",
      "r602",
      "r626",
      "r697"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r210",
      "r508",
      "r572",
      "r614",
      "r638",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r678",
      "r679",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r779"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r363",
      "r808",
      "r809",
      "r854"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetailsParenthetical",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfQuarterlyFinancialDataDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r210",
      "r234",
      "r508",
      "r572",
      "r614",
      "r638",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r678",
      "r679",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r779"
     ]
    },
    "SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest and principal, shares",
        "documentation": "Stock Issued During Period Shares Conversion Of Accrued Interest And Principal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated, shares",
        "verboseLabel": "Common stock issued for conversion of convertible debt, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r38",
      "r75",
      "r78",
      "r104",
      "r322"
     ]
    },
    "SHPH_StockIssuedDuringPeriodSharesConversionOfDividends": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesConversionOfDividends",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number shares issued for conversion dividends payable, shares",
        "documentation": "Stock issued during period shares conversion of dividends."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredShares",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number shares issued for conversion of note, shares",
        "documentation": "Stock issued during period shares conversion of preferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest, as restated, shares",
        "verboseLabel": "Cumulative dividends, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r38",
      "r74",
      "r75",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated, shares",
        "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r697",
      "r720"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares",
        "verboseLabel": "Principal balance",
        "terseLabel": "Stock issued for cash, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74",
      "r75",
      "r104",
      "r616",
      "r697",
      "r719"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for exercise of warrants with settlement of notes payable, as restated, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for restricted stock units, shares",
        "verboseLabel": "Restricted stock award granted shares",
        "terseLabel": "Restricted stock units",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation arrangement by share-based payment award, options, exercises in period",
        "verboseLabel": "Shares exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74",
      "r75",
      "r104",
      "r377"
     ]
    },
    "SHPH_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of warrants, as restated, shares",
        "documentation": "Stock issued during period shares warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest and principal",
        "documentation": "Stock Issued During Period Value Conversion O fAccruedInterest And Principal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated",
        "verboseLabel": "Common stock issued upon conversion of convertible debt and exercise of related warrants",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r78",
      "r79",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest, as restated",
        "verboseLabel": "Common stock issued for conversion of accrued interest",
        "terseLabel": "Stock issued for conversion, vallue",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r78",
      "r79",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueDividendReinvestmentPlan",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated",
        "verboseLabel": "Common shares issued for dividends on and conversion of Series A preferred stock",
        "documentation": "Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r626",
      "r697",
      "r720",
      "r778",
      "r785"
     ]
    },
    "SHPH_StockIssuedDuringPeriodValueDividendsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValueDividendsPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for dividends payable",
        "documentation": "Stock issued during period value dividends payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated",
        "verboseLabel": "Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs",
        "terseLabel": "Stock issued during period, value, new issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74",
      "r75",
      "r104",
      "r626",
      "r697",
      "r719",
      "r785"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for exercise of warrants with settlement of notes payable, as restated",
        "verboseLabel": "Common stock issued for exercise of warrants with settlement of notes payable",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for restricted stock units",
        "verboseLabel": "Restricted stock award granted value",
        "terseLabel": "Restricted stock value",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74",
      "r75",
      "r104"
     ]
    },
    "SHPH_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of warrants, as restated",
        "documentation": "Stock issued during period value warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_StockIssuedUponCompletion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedUponCompletion",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued upon completion",
        "documentation": "Stock issued upon completion."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_StockIssuedUponCompletionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "StockIssuedUponCompletionShares",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash, shares",
        "documentation": "Stock issued upon completion, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r78",
      "r79",
      "r96",
      "r657",
      "r674",
      "r698",
      "r699",
      "r771",
      "r786",
      "r845",
      "r871",
      "r942",
      "r973"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r172",
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r353",
      "r462",
      "r700",
      "r702",
      "r723"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r770"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r538"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for:"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_TCGGreenChemIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "TCGGreenChemIncMember",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TCG Green Chem Inc [Member]",
        "documentation": "TCG Green Chem Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_TaxYear2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxYear2016Member",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2016 [Member]",
        "documentation": "Identified as tax year 2016."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_TaxYear2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxYear2017Member",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2017 [Member]",
        "documentation": "Identified as tax year 2017."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r954"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r330",
      "r349",
      "r461",
      "r491",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r593",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r867",
      "r868",
      "r869",
      "r870",
      "r926",
      "r929",
      "r930",
      "r931",
      "r938",
      "r941"
     ]
    },
    "SHPH_TwentyTwentyTwoConvertibleBridgeNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "TwentyTwentyTwoConvertibleBridgeNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Bridge Notes [Member]",
        "documentation": "2022 Convertible Bridge Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_TwentyTwentyTwoConvertibleNoteDerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "TwentyTwentyTwoConvertibleNoteDerivativeMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Note Derivative [Member]",
        "documentation": "2022 Convertible Note Derivative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_TwoThousandAndTwentyOneConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "TwoThousandAndTwentyOneConvertibleNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Convertible Notes [Member]",
        "documentation": "2021 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_TwoThousandAndTwentyTwoConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "TwoThousandAndTwentyTwoConvertibleNotesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Notes [Member]",
        "documentation": "2022 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_TwoThousandEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2018 Equity Incentive Plan [Member]",
        "documentation": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_TwoThousandTwentyTwoConvertibleNotesDerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "TwoThousandTwentyTwoConvertibleNotesDerivativeMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Notes Derivative [Member]",
        "documentation": "2022 Convertible Notes Derivative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r751",
      "r753",
      "r759",
      "r965"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r128",
      "r129",
      "r131",
      "r132"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r770"
     ]
    },
    "SHPH_WarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrant liabilities",
        "periodEndLabel": "Warrant liabilities",
        "documentation": "Warrant liabilities.",
        "label": "Warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantLiabilitiesExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantLiabilitiesExercised",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities exercised",
        "verboseLabel": "Exercised (settled)",
        "documentation": "Warrant liabilities exercised."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantLiabilitiesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantLiabilitiesIssued",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued",
        "documentation": "Warrant liabilities issued."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants liability",
        "documentation": "Warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantLiabilityAugustTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantLiabilityAugustTwentyTwoWarrantsMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability August 2022 Warrants [Member]",
        "documentation": "Warrant Liability August 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantLiabilityBousteadPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantLiabilityBousteadPlacementAgentWarrantsMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability Boustead Placement Agent Warrants [Member]",
        "documentation": "Warrant Liability Boustead Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantLiabilitySeriesAPreferredStockObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantLiabilitySeriesAPreferredStockObligationMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability Series A Preferred Stock Obligation [Member]",
        "documentation": "Warrant Liability Series A Preferred Stock Obligation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "SHPH_WarrantObligationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantObligationLiability",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants obligation liability",
        "documentation": "Warrant obligation liability."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantSharePrice",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant share price",
        "documentation": "Warrant share price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated IPO date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesAndNotesPayableDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant term",
        "verboseLabel": "Expected years",
        "terseLabel": "Estimated Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "SHPH_WarrantsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantsDescription",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants description",
        "documentation": "Warrants description."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantsEstimatedFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantsEstimatedFairValue",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfKeyInputsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated fair value of company's stock",
        "documentation": "Warrants estimated fair value."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantsExercisedForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantsExercisedForCash",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised for cash",
        "documentation": "Warrants exercised for cash."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantsIssuanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantsIssuanceFees",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranst of issuance fees",
        "documentation": "Warrants issuance fees."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantsIssuedForFinancingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantsIssuedForFinancingFees",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively, as restated",
        "verboseLabel": "Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively",
        "documentation": "Warrants issued for financing fees."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r205"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205"
     ]
    },
    "SHPH_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20240630",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "negatedLabel": "Working capital",
        "documentation": "Working capital."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480299/815-40-35-17"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479083/946-230-55-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001493152-24-043154-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-043154-xbrl.zip
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M.PO^!%-'-CV.!C">Q03AB2BZ;-NP!HKLP(<]]9]@Q>N]C4A%02X.[#DT=K/
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M(U!KTKNSWZ0YD<%SP;H1JM14& QERWMUHI>*8F&X]##:$A\'1Z!3P;A 4DB
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M0? %YW Q/_9!.EEP,9%U5T>?;OKWWS?$M(0W9N3D5>6A5Y*SW\6%^+-_<_O
M-G"#Q_O^=>TCI%><^&8%!:2\M00WX^9V>/W4'Z!<>1LXKJ*DX?/C]?_4?F&;
M==G%E;3&YXEK'/@_TE_@83[=[DV,_.KL$$,PX+ -[GO^\L)N]OFI_SED+FN\
MH!<'+L'@-=[??N'AAV^]Y^?;^F<]KJX.44JO<%L_@(V56+^:"V6K=?3IKZ^W
M3RSJ_8_'[^ U/6"D\$;Z]@C6M/]P]_CTK;<7^K?:HNJORL\9K^& 1;C]N_3\
M&,HMQ1.(6UN&NY/6ID])5JT <)--)_R39DM*KCN_2X_TGB'[ X[.6Q#_+OV)
MMYY_*'8WVUY69*^L,@YSV^/S[]+S? ;OOS??B$47\'?I09X2MAX/)G)9B]0>
M>]_$3T3%MZCX/JB*[][GQ^_/C>>O_:$4E!#N<]5W;<[)X]DHBXRQQ8A,SU73
MGM'LOH<1OPX\X2*Z*79TP;O=6?]Z^M@;7NNJ$Y4UK5^O;W7D:MGA[;5WVU+#
MOY^/_)IH+WC1/+UA AM4:RIAM[JH>-V4?T7*5'8<O%M*U6S%M>V4:T=67 ?A
M7Z'#N[0T_-?'IX9]MJ-71]#.-9FOCY#6OSXBN F'-B.;RC_Q^[2;>ZCEO-?8
M/397?2Z9!OT7?7N(N@9G:A+#CKWK*)(OV#$M=M&*U]-F9!$BO>&2LQ8;_BBF
MU5!-Q:4W$^!1?A\Q)O+O#;MH^"UP8AUZXBN$3<-ES4 ZIB S[,X/O\T.G0M.
MWW^0S<LVIWC^C[93#R@)U@6YKQGL AA*";75\&;:HH#W*V=W1H6^/PHU.A?7
M,NY<E44O@O)5B#;%"S)D>AU#().LX02] 29ZP5+D<B^J$$Q^?WKPY7D@6C\-
M\\T322:&>"G,XET*87'$CC+^75G\XISP\!'H)AQ9E?$>'7JBE4DG/=V*EW=1
M)Y-?3\</O097=7'1'UDP.KSBE=UEM2#Q>"&4A)<RCA=5OX8R0SM]L%L#0FRC
MMVGC/69X-Y$OU:"-9R8H8^P+@L3RBWV0,I!S!P<,E@?%B?? HLH9>>]??R'K
M>@8>&2GJL1&HQYX>7*_EJY*$L7!BV+),&VG^;>":)<%@FD6<N7=O7%PYG(*9
MFW'MQ+6/%-$^#:IG^+U^3/^P7F0O!!: VIMC_^XG9GY,R_\#H-NT@'%4[[[,
M0TI+#AM-DUNSI1:^D00Q:M[9_33LYA"P'2]4QRK^O  E=EB?1NY-IS?#93%X
MC;C!\VZ&K*E"JK4V]>[T!%5U['M%"VW]0H^X  :+7J0(&HG>V67Z[AKJJ+#L
MXF4E)KN,1EZX'<3F^I9?.@@(:RR5=>Z$T"L;$]T/0OM[ 9R9I)CT!K(7,I%U
M; @FL2$\IZ3A=03TI9.Z)'_!?)!<PZ1W@*)2>M%TO) 69L48I,B&/V%X#/6[
M)7.!].50UV3^/7/$+H1;-"YH$AKTSS85.]I[C%+QG,5.4-\D]#F\K"&#ZP9;
M<GJ'7#*S4/9!I]-K'ZG#*%-)1V6"2ON8MP?4\1(X_G='8]J-6P;*87K]#+_8
M+F8(&X^AB^2.0;,9P"4-5*??O0E?8KNZ0]]@SHC%<8%<]BAEK*$KQ785J@0C
M*MR@4OM24\FKM=JX T_?OXX1;X!$XTVQ_]W ^YFE(5H?^X-_TRNZ0BJJ"T ,
M()A>RXE745(_:8;W#3EHBV*M[1.NQ;3PND>0=9LIF(8::IN9V/F#Z8Q_P@"V
MJBFA>R)YAS%V8Z=,;^]%'P8EP[N*]SBLH_A%FI$)GDH#$%\ ;2.5!_2V8P4]
M \U 71FB?I%:>E,L$WT<:6H3>HD8=6*9^C'!^[->/86*<U>8U-#-&?JDCGD<
MO9-QD8N>HE_%/&]2?(38U-&HH]<4OKB8TX[N&*.]P1QPF5TNOI)Z[\KET.V?
MFZ"UIF)6:QWQ\>43(*2Q1FABN8%C-]\NL_R^W6\DVOW3B!9:ZL&@"TRC/)&P
MCG]!,E[F>NQY(JI_@_,Q4R#^+!K)9IJ!?FD(!6W_HH_.VPK3YHAX8R]EX](+
M46F @S[&''-%L\!YQTN?%>)S-*P3;:X4-;I7T^4WO-\-WJ?"*\V,'LERU^)4
MRNL8-#([!B+RG%<+K$Q =D6N<0>Y1I%LK'NR\4#UR28#%NASHB7W743?+N(&
ME/STX[HVO[@># 3K\Q^YZW3)UL!WG^F0N+_56']PME,! W[:R+*SB7JT\3W,
M2M<VE=#&1O<PZ?NXE7N81LQ?6^:L>2[0@J>_X)*DTY.\[6C$MTQ;V'9XL[5=
M94*GW$B8<B@>0U\$*Q6>J=B>[(#X[P8&MQI!#D,#[U-!9!YSG'B1=EBRX<1U
M'%B]P40&%U@A+C5"MO35U-'JP6OZAG)*MP;@[?+0]QLY]G*Y_"^N[?\%GN1_
MA*VR=]\'?:>]_@N9)^_8-"FDJ1I>LOS.2[-'1@B]-I2*OXY<:__;'N%P:RYR
M.6_A7LPF]^)]0P72K3G=17V3K9_$D6YD1Z[Q]=M[JW_6WFK#APJQV*T_- '*
MUMBW7E.ZSM2#"&HQZ(::4#<$[QYRS ;_TS%/IGO#C8D!?]?Y=0ZAZ#P;%OT
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MCY^S,!R3G>GU=PSX<&)DY]B#$VRW7)W'OD*:&+$' TV(K#N3.8_WB0U]=0I
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ML=SQ1M<RE@^'\??0H=N#[-P0FP7)C84P4]+.C?GO> \ MM/"?4*W&0X:L8U
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ML7/6$3QCO!2&3#4>YK#2\M='?^+E2XNB70T\30]:S& X/EN!,X$4B8*QN!8
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M_> =UDFFX/9.D.%D"+X!)@@ID)0Y1&T534BLP,V57<!6H.N5I,3J$$)T34-
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MX^>F)AE++4T\VI B^8:SGF=I+1U+ RLB0$CU)W0+&))8C5C]5DYS:^QRYW2
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M*])\4R-DH8R Y4*FU?EYQ#\7Q%Z.]4D^BOXEV9J\=6*8GT(!@<F7,1X!6XL
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M18PVVVU:^=+Y7O =PGO9#79IRH4!1"JS3BNEL8@O2D73@_6#?@AP]5B<8<>
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MS8E^>!"H3O1P=$CMWY=\UF57[ L)G6M#2J&1_DM;+SR?Q"%!Y);><1$AQD]
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M<:<]K\U)97/L XI$7<?^A0L5?/YF_M9B="&*H^:^<S89_T'_HS] ':!&\BS
M!"_ ]UPWA!+[4AH*"KZZG.WA<3)OBACMA@_"?DK^?L[J6ZOQ45"^\:P.1R=:
M7K_ R)N;55E(0QV9W O3B(UG$*M-9YOKW%OOUY:%!')L$XX&D2S+#7("1C-N
M8@_++-IF659!F.C%\[-1C ]^5J.^V[LM^5[U'?Q3H1C6[KA>#BFMC,_7)@*
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M9G!47-.&B4?L9!UKI/W#/*MG;2V];$+5>E84+1-W<?NN,G<*7R><B9T1U]W
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M D\]8-ZT;^LZXFU$R&W&=7;<KK64SZ/^DCKZ ;L,I6-.&4K2@-?'[D*/GR2
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MY+ZU3;(HZGYX^*R!>HFQ//OP9S5JJ;W;DN]52R&A;(JL8U)Q 1@#TWE<[.L
M_T=!._A9C1II[[;D>]5("H,?YIA=84UL2/6(-B(U=%&E(^OB'9C5J'SV;DN^
M5^637J99KG"[+AENV_R#;OW!0KMN\=PH;P<_JU$Q[=V6?*^*:5UELU[EG>_;
M[_#VI+5VW@AS49HWI+12Z6-P1<MC1^V=F-6HH/9N2[Y7!35H.06ZQU-3=]@8
M.FT;.PBN*PN#*1J-M=C8D+L'DW>T-]S.H7V@'6K D-LB*])BIJ1N7!/ ?777
M$8_N$H@M7,'@BU$0EXS3>$%2B>8Z_RCF<RT,8@QIM:%QUUE#C[M:&C0JF;FT
M+ 7$Q5P9RQTS:)_*\T1[94E\9R9N:R%1R=--(@R ":T$S<1$Z+'1XK/.%+NM
MQI+I\>2"VCK;JYNGXU-6S=CK=YN3?X?.JZC''1M(.XRO//>-$4+]5 O]S]20
M?,VY8TLY):5)S[C.[^L((S#@R^=GS^)ZA4>LRAPLG2;:[JI+E7*9QN$3.-!]
M^+9<9_/R8UME\ZQ0YAM[#' "1*(AM'[F*],(GR0JP*>M2"KW)YJ/68V3&]5-
M.?NP+',ZV;2(Z$8T--6T=FWQ9,->\E&@JP -U'*2S]^\MF]8TTLI(K)]C7<_
MG;^5IZ;,:_H;YI-K._T 1V\$^N2/W%<6ZB&_&==P]I:%EKESQ[BF/ 9W9*MW
MW+"]S42L\B[14%FJ?$^/N32'!FQ/TBQ^75FKZS,U\V2+U53K7T2=:/=D="TI
MD;88SI8E=]27]-5*"$=D6.[YK)40E?0X#:,DS0*/8(:[WG<2KR81[1(F 3T?
M2K[M^>^<  N$(&H;/]F^)&I>AD1;_6$H<'.E-DMR=2=,AQ+'HT#V/8"+I3U(
MHE6'78#KB934P(MOMZ6IIK]:(BQ/\M6GJ.TQQ,JFM(6'$9CKVM$&1&F5U?2+
MGQ31 C)8M@VSO^JF<O-KN-F*5H#>6.7M=6@7(:\ZL!Q*($AL8D.'=)4J#D(J
M,$L"'A'<AI$0&N\&3-A) [Z;#*PGMM=)I$6@&Z$0;H<,KZ-9M8=\QA?"E< A
M9)=2P8(=A]Y.5<TJ0>T/#R?'EF:7'I#GY164*N>8R?'#L22I]!= TH5]MD^(
M"M/X1Y. _?!@\MB.2R<^1Z^PJ^.S]X^[PIRN3T19:0MUW:)Q(,,\6=7I!1,:
M7H41(N)T08HC8OEW9/!R,Q1<_<[G5^U980MO..2KODI=MZH*Z1B')K"=858L
MVMI2$0?0(O8RPR7,I,#&?(A"$UI9D=V%VD[S;(8C9:]6F. - __/S;3Q-G=
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M:SABY295!XEGLS,\(,[1&)@_^%F-&9R]VY+O704R)A@B7]O@+4C@*&/9)SG
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M<9E592$$.^J/]HTX#.ANR+9@(W'6B_2F\26I8\,Q>#&B;%30AU;</B&VF'[
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M1O4GF'_AVW+%P+E"?&N&'MZ#*9A /)TNK5,,5$YL:85<8U5TNX5RI^4I>HX
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M.]B ]"Y(AB&SO8.>M+_1INSUPZQ-UG7E$J$9GYF#U"OE,D9[+$L3Z)TWW86
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M]:$.E3D0O8=UY V#=T%6Y0%G!./AE3E7\>&<-*BE+9WIG;$^,[,^ W,QPWB
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MZ,SVHT4AJ"N9!Y38=<0I]B<4$=L$X* RVH>[GN"BS5KRVXN\?W&DHW\S,?3
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M+&LJ?]-UY[/IZD<U.S$7]TJ>JF$[GV<BK"4 R(R\@4G[\T!ENV;H*V8;!-]
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M3&SXU6]>4#V7!B$Y"MM_^RWG/+GC-(9@2"";"RR_G/HRQW32;8ZJ*!,G=.F
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M![T*6O'?J8J[CB$O6CGN+,1$*,O5K9N7Z]6/:K9K%_=*GJI=*PGI3W:%K([
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MAWCC[>!@MZS>:XK"WE2Y3U9 ;ZI\9F1C#F+Q^(J*#NX6ER>@>$%;8Y _F$O
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M+U^<KR]>^UH#G/YA DOG(,"V0 I,R<Y=Y-G(F+%6SS:X,0=A-"F!FVS YX)
MVBGXR9C7[6@*I%2VBA_3ZXP1Z@W[CK%[B.LZ"A;1DE%'F2EB$%[%20)HW6A!
M0_C WTJ6X3\.MG=#FF(26[H5/"/-Z#$F'X&*3 %TCR7B]T>4YQ$SH/UA&'XW
M923I2CC+,,/@AAD*"Z]"GY_.(OK6R4DX2N*4L8)+)AR9**TR/0?K$(X0500_
MFL\<\H^][7TW[C@-:;)*E<MPTO2'@.::70G0]<7,Y-'8? C/ET5IYK0:)^EH
M>\!#=F]W'#59/HW2^*^(.4@VCL_>;89%M0#$-=Y\P] +-W9Z6\S?#PK:C+@D
MR<A)<A;Q./M0Y3%-0<&,\86K+&>^D5&TB)D;R*,3&F4YO1A2M*CH7[2O/:CU
M'3$2.$SJ2D[%1TXS4-$A4JGR*O)A$81CH>.I%EG:8%Q<))%R1@VK@B2D$&ZG
M6#EZF$<H4*89X=AIH&.#B(#/S4V/"0W3^VPCBR!D0W2:XU&\:"BJ>?1GEL?E
MTA[^QE3MX1+FK<R>C8^>Z2[QQ\-71=U,)L"3KZD5O;?0-^;,P$1J(<W*0!</
M]%5)DHWP=2#+QY-XA' "KJ5H:HK.F;#BZE13RG(,-/)*B!CYV_8,VE<@(S+,
M:#F#=Q5H?E)Z%:MK5K8"NI]GT9@ICG*C#,S\*%+#EB>L<VP=HQ+.:FR_JMLY
M#\P-2CC':>RI,@R!X-K,%PE?$+JU=%^H3O=9F4.,OP!R_BQ+QB8O>.J 4H^F
MS 1M62)HCBE7?RJM5=:<]VB682C@P7+;P5QE"Z.[[4]R.WR3Y29SY +>@^S*
MKZX+S7A5*=;@\1BS@+U;SHRA40[K22PPW+R9$5#B1^##,H6^G+FU+D':W.O8
M3S2<@WO*)_QP?(C/+BU=8> K22V?&L[C!DQ04YN 'S5?KWR3,$XOR3I=_2((
MYID3SLC]8JT>OBSSRTB5)+[,%AW(?JW55\SH"M@B&WD^\#ZR-85Q-Q V"/K=
MUI#L.'P\3HLR5PH2:"&FYZUI&#V&WO[ WP4)1&/8'DOY*9.S6Y;W'\.#)\_"
M?T$OTS>9O'R%V_TC>(?*\V[_OC94[UW8B UB!W_5['H]"R^6"WK_41X-X]&S
M\&TT-[*F;S.LWL%^@Q'>?@U_JB-'_^S@D?<7G"[.]W3.Z#:F9R]XOW21:59K
MM,*-U?1Q"Z];!'_IL*8LCVM[Z-9RV&L3P?IB1(]W%6A\WV!-?/[[^<G;E^=?
M+<2X3E2<7W$.Y[.J+!,3D.^=SYE>.*K=[P+>;[C@/XU,Q=H1U7OT\B5I0R[G
MLU$M,M$6,,NB?$EC'LU2,@JG2^:QI0\FV8*<*_HO3+J<C#8#'N."9B4.^@@A
M"'+*1^0]BC\\S>A=,;O9M +6 1R2NT^>6"&V'SX>EG2;B+$GCF91Y5.3+P=U
M&$W?2;\:D=N;Z4]LU,7S>97:WVR'9^VO!!O*^GMVH2R^FQA4ECJ[=IZ1G2J,
M<J EFV=CVBSFV66_'X.3\)S,#9%/(='F16'//%S$"T-KSL_4P&5C>0*Z ,'V
MRR],XCF9O!*/T3'8&)!=$;?$'B.YMXZ9VM57?AR!'W9VP0.L*:2CTH^F!BZ:
M*H&<T @;="5\Q?0M$HF.?>'G,-%S-(&[/J>+O\DQC;^'4WP#11PD9OSR5$?0
MF&7 E:)1/A89R'M_N[:<V#-KV:L[7YX+XY_QG-RK?(3'Y/-B:Y<T_>'VGXOI
M=V&4E/_UW7<M@^GQX<[BPW<_?-U;[5N6CKN(>-=Q-OC1(PXRQT7-)J\W3WC:
MN%Z*\'66P-K7-$NX\38JQM&_P_/7IZ]=;7@4OC!)= 65<BS7T:8H_W%>33E>
M"C^=57R@FI9]]H7)(:$U->35C/R$99A=0=%>,R([D"A\0Y=; G7E7BIU9=$T
MI5L@'A77O2!HON!%_8T;'BYQU95$EB-$78V)NPCZP-WA6W*'=Z64\ 6$=S%@
MZ-+7+XZ.Z=FS>!@S+?W&^>G6[M;NHUW:Y].MO:V]O4.>+_]Z?V=_4Z/P5QG"
M+_:% Z9G!?"X7@1;&9D%*8+(WD(%45$8NAGLAF*I3H^WSHY>A!>F*#&T89)E
M]'0. _$;QC&6P4NX+>C6,DQ%V[ZV77K@]/S-T=9SNC.G-E^VR#B30D^H"A.
M?EF^) ,+(Z1*^QOE#@9_D@:.'UNXL:](=51#LG8X Y'224'0CK826TT;B&>_
MP(&W1MK)VQ?.2O-3)"X!P3&\5Y KB -_]V@\)XDB%:496WW4JQ=']E%!,X%$
MAM.'$D:QQ#9]]0(+JG$FMVG,X2]16L$J%N+L*U@^(\.<XW@:GX!'S\[),H(H
MGTJDT^;J$U/"(D*\E,G$:5@N34RS;<S2YIE<&JTHJ_%R=5#AQLGI^&R3J<>]
MHV,5 YND. 7AN))4)'W$FL@!9\O+N#:WR8PD!:I'F^9T\N+U%MF&XW*Y,.$T
MB;-A$A5DB$3R\2J=FW*VE*S2FY_?7$!=D$UN<K*^L2X+9^_IW)$*NBK4QD3K
M$.)-P2=,E$U:3J?Q:AG1 T(&K!N!9>72ADL2*Q#*Y@M8GV*"UZO;>CQNE[.+
MIIT_S"-:(C6!-_SYTS@N_$&WDIQ7V(ZDR'0<-*CADI?A)"69+RN5^3-S&9/8
M/\]@ %NQ/WNNLAK00)FH?6]7^==]<[Z5)2M--%<Y*[CP(R]1LD'#[_*<LODP
MQAVF#LYRQ<SW_*FM+!VQ^Q=(*M,D"[J9XTO)R/DGAKXS"..)F[1656"7<]#9
MVT(*$0D:G5/?)'3D$$2E/E4='M;P#?F,IE.X3F!SMC[8FBK(M=;NSK,.WJEL
MT)$LR,M/C:6>)U&*T@+6B.ZJC2+P*8G3--/\#FP[T1!TLDB<1M&8=>=0%,;8
M3' ZRXK<3!H1ZP\23#U5Q2Q:<'IJXHFYNJYB-UA=/T86W, 9]6X13B(Y'Y83
M5I MI-;S0BL%[(F@JZ;*(9OX+ UD-*-C""4QBZ="<4\6R!AW3SRLQ ?'.V Y
M8NSA99946&4L%#US-,,U2/HR&DDDAG/S434(BQ@A>!5O=K0G.0?F4=F ,4YS
MUK<\ WIP09XT,G>B9# Z:Q9>@@*=-H"T4EP4E1:*360:*RM2Y\#SN'@OD^>O
MT:TP(BLP+DCG9>YC5F4@V%.$G')'*1F.<IDEAL<8>)N"W/S AI^<('!M2NQ^
M)'V$<HTZAL$9 B%SIXM4ZS^LT6L7B:U4$K"R-5TQ:5$75V%Q^9IAG4:F"%=_
ML;E)>X':A@@I0BZ!H>NR4$M=UC3.91[0:.-H3BIW[&:/\6VS\:&1$9*IJ\;U
MBU@:M#'&D^4\B&@8L]:EU\^C]Z;Q,)'%>@=]BW@@&5:2FX*D271Z)JE7>LLP
M,?/M\-A6P9 D52-QHF0%_7A9P$9!(94[]-"M)**+119LCH @7['D/QB.1979
MAW@D@3 13WK,DJP?CGUI9 O:>ASG9E1V!(WP7-1CX$-V<7A*V\'K[,IPW4>C
M!(^++R !*%R:7F/9R-QP1?.%YIULNLEQT(;&I'141V91BA?7RC?+,,FX:>26
MITN2>"N3@W!*BBG/MG#T2)92]HJJ9$XWN.H87E1:-NA;>B22R.%K&#8\)_&4
MHW"$_#*F!DGFA4#0;EQ+#GE%$UYNOA"#MIBK>-S@(4'ZK+#S:I*:Q3]5YIV3
M986]ENN6./N:C@MXQI?X.WN&<8$7S^' 03$W# QK*33F[:9+VF%JBY?FI")&
M--#<\R/9/91;?VR0V2=1X HL(\'.,JCWK*"A1,XO'V;CI:NA5.>2X[1M_[+0
M>"D'B-?T\NVP'&Y.F3_M4^:?,65^T*?,[VW*?-T-]#731'^8H)7]\M)+11VH
MX>P?Z6Y-?%FESM$#N1YJ+[OV0-FO][Q',BRE,)//17WI6-T>B/&(R\$91[@2
M$[HH6.^[C)3:5G'#"G"W*WU1K(N5:U9\?CN;QEPEMVEM8S;RY$L<=Z8_H.6@
MX<]*N*+YGD@2>N0$B8GM_K*5&PFR>(;82O"&U;5Z2AQN#MSP!)J=;GX8\C W
M4,D;X25A_60I"G;K7R^-6E0_/IP+TU.NOC)M*]M/GF!#UUZKD[]K->??]OG=
M3(6?-+*=[;W#./VR\ /W<)"[VY]G@%^Z?L/WC 1+:4)J*[NJBPY$9@=T;$FE
M:(<".;+B-%8%/)T8HJW'66H9V)5>56<?P8SX\F)Y/^7P?H[J:ZO)7B:^U*CV
MUD,9':$&JJ&)H%!>O#W2&%@=3R S9'85<3CK/5($#8L*-HT-ST7C/R-X8C9.
M)^&&7N36:%2]&GHH,K&_SFIH)8S/B@>!Z]S,(PD<JO[A1OJSBVXU8R$QUJ8*
M>ZWSANR3VB(EKZY8JP)LS<.(\^^2*(ZD RPMLWS9J*C%ASNS @,K''/Z9*)Y
M$^\6@B31@V8F2LK94G-%#R@8O#Z#?^<(XY!D0#F<I)TFV:C2ND+T+<=I96-+
M#IB!2_6\T@/;)^XE*UKU'76%!F=QIEKAH(EDI&$"B*63&.])J*5[5!?3<2T=
M5]!M^K5R[5((5&$D<,LZ^KL;U7$V88$6\3CC&%=>-%/:UM22"%3G&U<+9I
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M-(+1O-^>O':A;KRR"3/AHGQOCT_"C>.+EZ<:*"?74YZB?B?WSY"_C;'\20O
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M$BYKI$FN+X)]P</X)/P+-Z3/AW\ALO&I&!BK;13_*08&C^-OX6!\RH0_I1*
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M.5HOF,X:[5]!MWHDY(Z*W^:<524<MOWU*D_0C+4%48/% .4%%HTS@GQM+P?
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M#Y_R3<.GG (7<13HG=/,A'CAQS;\*@*1C MM"8?A=#>"FF0H5VH 2SC91FQ
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M>R2TIL6A9MP.)D$4#Y<..E/MW'#RQZNG"S[Z&$8O<?D=FL_I#(,\.3EI[^3
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MGVZ(+ E=FK6SC)88&]83Q-RK#,O36'E1RDIT8?81UAGJ$7([(D#9/F<R^LL
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MJX+4_2VCE\F]@F]AJ"SXR@D=573 KV?S8(Q>K7#6L!!*4V5G,\CG+"H1HQJ
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MD)8PN]RD*$[.U#M&ZT?EG(R!BX?*,QGHYC;U%=C>$?B<RM8O>#Q5W^C/JNW
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MT+&O?<XFN5EA,M$-Z/LK9 )'/>.C)IZT/\8W2&A/,MTJ0%B%1&&+_BN-E,K
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MVG:PD,X24M>A[K>^[M-J@6-L_#8, ;\F&7%<)*F.'C&G3M<>8W;OQ(OMB?>
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MQ(0$Q%XQ6??JB@)=:GJJBH'P(^_>GMNZ[$I\TY<?WUI*&5+-LPN51?AHH4,
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M-2_^3#A/4<DNH .MTBS-9@@O=ZR[SF"(X(%;5*:\R-8!+9VV,VCMN&IG:WI
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M\N-;;9Q<X=6W6H7C@D]>1\M@$GV% P]7591_;Q*PM8S^46^)MI4]@]LYFGO
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M^J3PUVHL956(IMYE=,\-Q6?F!TTP:!@U>Q(;#>@%,+2_]6__@Q_0+QD"P5)
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M?JGJ<=K!3(O65Y<.J0WFN+/L-G( I5!&$33Q0V.V]24&VC_NT8_X#Z4_6-N
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M_FS^(_W<<[>0%YU*+G1*= P7[L4$"0C;:A&NX%BT,KAY 2H1S;:J9SM7^9=
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M6$3S$4<K)7M)M[ 3W P+10RI)3LF5E5VW57P@F37!@%]>#()\[R&G%Q)4JO
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M/ YB$K">V7;'\QU5W?:OB=38VGMF(@]ZEBW%8FBXW,CBSV)\)3C,:(X)Y/H
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M,&<.6?IDDWK/]+*6_%IL0Q'E)-'JN47+MJ]+,>I2C-8I>Z=+,7JL (Z.R_@
MJ$@8)*/F=)N&49(E\^G"BM24,J<B04AL(+ 3Q%QQSFIAGJ>J:80H:"I+2=0_
MY;Y3ZI\(KQ\EJF*-,4OH2W[CK5)80U"/IF&@5-&EJ"T)PUXA\&+"-_0E7F9.
MQ900DJB@++@_!PL[D&6"71$)NQTI%+ ?;_NXC0;PC=I=_FW3Y.HZTEFE<%5U
M[D%7G?N U;G'NUUU;E>=NTX4=IK@.BE9G2;X6)J@JF1,$];JRA)17T&VE=I3
MI0<-%*])TPBM*H;\/AN$+;8VG /3(L^CH/->;SQ579AC[;;DI<JVF?]9E]+
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M9Z/Q.H!6G&.1>+PDO?+C\-_\2,_])W1:KD-K7T?/K)F[9,VDG!$'02K-Q&M
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MG5^+.' 'QVC W3_A]G]W%XFW(\S[(63(\NY+GF8*I\(4O5>JAS/Q2L_B%].
MJ(TFK_9P532C?6!-/D_<[P9'^W#B0-QQ7Z*>4QO#CS+3OT\U.0]SH.63.'6O
M4E_DUH%W>'R$/Y&X'7C'^_LL_ &9GN^D@71YRN91F+M\#VR[8985? %(0\*V
M-I&T'\=N*ZRE[FW,W[LF08E>ZM<\#'H<8QY\U9"01V_#7+IN!<!B)+J"G7P:
MIN/J?4/D\FU&/_/[N+:XJQ,:1*C=,PNM]V8:+MN(<%+?"TCP,.9.4[77T$)
M75&_),G8_1CX61)[ZJJ"3!\'$[0O=U1;K%LV?%B]?O"UG%OKHI/C2+HK@!<R
MQB_GSZOVOC3/_D#N8W3K+J](C*$;0H^=>F\L?6E5FE_16,N6IU<GVQ^- M5K
MD\Y=,<(%+L3-B:YT61_1JD: JU[SINK4K#M^@Q<N\06T0OMV71J^C;!=W0#K
MN&N ]9 -L/:Z!ECUA7[6#;">C938'.)O4Z+I]22?+MQ?>^YO23I$7*_3GY]:
M?^[O0G\>['^Q_MSHPN0U-UJK7>>I_HM1!=JUL&EP)Q5X<,0JL.H]:NM.?L5H
MYZ<E=YF-=[=JO#MMQGM)ZQTUZ>^0<H@OW"0I5FC"/]^N+KN6NNS<HBXKGTPD
M;=(MA7BDM3?+_9*(TBFM2RVMV.5VJTHU-N33-[@K.:ET=!M!1Y2&O'G=B<'$
M< \O2S'<T%.PT4?X-GG;@G#02=PGE;BE*=-?X;4@U35&?[S5TI<LOVOV3JYH
MAN?^3O]EE<7 8OQ +[((S;C+],?@JHC@(5UX;0QC2V[KS[=X,^XEOIVO%=^M
MOM<:P7>0X7 6'!T.E"]D[[C_]9X0]QZ>$,L/XJST@]S9^^$N\W[<:S.=<.*J
M*^ KO2!NTPNB&>5VSX?S59Z/1E?P^WL^RD5SA*&^R/7A?HWKPWW-[>?!0N87
MIU3@&BQ/_#GC?O-!31!XUK$WW1&%W=%#?2<G229<SE*$SM1<MUE?H?AU2L :
M*@'U*LE. WA2#>#<7[A[NU\<LJA5N/(Y5!<ZG4UC@-4WW1;\S9#$$AOL_/XA
MB;W#K[?'G!47^KVC&P/OX.1 W>A];W!R?-<[W7GH.WUU;&/9G;Z#MYR[WNEW
MCC;1E7[^A4$.YW&N]_L&-IS'N-[O'=AP'O)VWU"AMM$2^5:7I56:@-!N=WL^
M_>VYRG2^B\/R+*(S.:KX*VN[; 7P\<<68>K4(KEX3-]&V;+;L7]<"=C?\9J4
M6HT[NRT--7>[(/?)S%7!__T','CO$_K_ZLMQF<'K-"['%3O9$OOGY7N<J#_]
MJ[;C#Q[DK]^%ADOF:7(=9G#\W![B%PYZ8 O7>4EWX.K@_DD7W'_(X/Y^%]SO
M@ON;*"4VA_C;@TVI[_Y:Q%>>>S'M-.5UT)1941[LW5-1KF^D9ZG.EZ,0N@NI
MS:7RG ;SB&4>*P.V?ZO5KV2K9/A*J384:=J2%(MG2LW:K^A&K!Z+RVEKL/O]
M]E+5VFE7K?L'WN%@M^=>0DFKJ\L0[%!B2 $5;5G"^M^AD+L6Y*>M@$++)0^W
MQ.>=KXG/9TL7;T[Z.@<#5ZS>N&F7.&H%CY73[L:_U1SI[_/T[QJ&,T2L,D<<
M,\E^7\??#@Z?(/SF?*VK[D[AM\;N+8V[F=6SK1$:X8&B;V9X;8-4#!-9T]CY
M&L.$QO@")UUUAN7Z.24W??O@VX;>!1M]D9'2\:'(<02A9#OJ))\B]RA#==F;
M,(,CY[_IY.V\CL>=OO$TQ)]FN$A>D7#GX[)G%(^5$MS#]8(F]#B+>P-OOW\H
MXGCJ(\(4D#SB>T'$T;*2/;JU7NF2'!6TP:/+);^[!<F@1";^H"L+/1)B1(0*
M%]V0ND0C&>;#7.HS'.#_]\C$LNM9/*R%7"Z#?>]HKT\2:N;+9:+EHM(6I$)0
M"2FNZ9R$D1)J5V&62YX.;1$)?KED8_=-DL[<RYUC=^OR]1D= )+*[Y.>N[>W
MMS,X/#XZ.-[&!^1]OM!HS:=^2ONI%[.\+C'[3JX] ?&T[8Z4>[+>S'=K%N2H
M 856&<9<P,J;3]<G,7JL]>NX8 8D%E.["KV+5$IF$ZF<I=V-%I*J47)O($<A
M-$>!$S@S![>X:##+JV+Y(XW3_9SJ5._ES[G[!._F^?G;G0!BFN OBE3C ^S/
M\_MT1F]]_;Y=VOM[=3?74H_E'=NX?Y@SV\L=?P>:;R&P;"/_\,OUJ"M[]- +
M>\GBX<[K>AO%=T8V:C+NO2?TMY_@\7W(97[8I?V%S==7=$L_"BL,'IH5WIM+
MY)*D?4H6$$FQ?YJ+@RGX9TQ703H*,](8Y$QF*)7&7UA8;OVO[8?@HN>Z5.9O
M+VFQE.Q6;()\4V2=;GWWLB8_#Y7>_D "8>UG;IT1I9.FQ/^A.'/XVF$BXB1W
M%T'N_BYE_W0FMEN%\MTF^<BJSMHO^KF??L9B(HK<LO2M*_XP!_%Q(0V58CQ
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M,1J4YG_R%CICA-@99+7T5<1)9&\:$U:&CX6V?8O<Y[/<!@63"'R7765H>$9
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MP*6EL:,>-X*$AY) .DCN&DZ<@?2:$]VPB\]EB@R^PI-A<F@)90,U'; P"*G
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MW2DTJNH!\+-;!S0/_",RPDF:UD 5HRET"QMXI7,2J>^,SCHC ?Z&J%830<=
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MYF<=T#$*8G065-$/M4.[3[N':JQ? @6BJ![FZ?VA$Y+GZQ/;PK'DMJ=#WG#
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MA \-=KS8QM8._=IG$SN)YO58C%?]9CUYLP5%D'Q;,688V'=0H^-.>"7(_,-
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M^:H%R*RPBCU_N!?#:$A8R NV V<>8'%E4E]!GJ96:1@MLUH:\6L\/*4.JZ_
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M2KK+; 2S0KX_])WJ^*/7NYY_2:;MQ+SW9W8B34!P>WM\TJC<W?YE+;@+"]\
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M5^=W8?W$)U&C)S'U/JQB?+O1:II&O3F_E+#P=LV=@O3.]H@-YI)]Z Y&CN>
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MA=CE>W'TH^_&(,NQKO&*V#Y7]FCL!U8P.1F-B0$T0\LT/K[S:BTW.+G;F)#
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M?(*V+@QE\2MSCN4D!>NY!O"K^+_TM_,M^(LG/AS9\>_?&,X1$->1\+@W) .
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MS_]XN&?V&)<\F%3D\69KXU/%)[/O0(ZM9HMR1OR+8=T@;*L*H;^J.^2^2H*
MB_F-?KJ_Z#;YIU^K W79M\C"2U*6+N1?C5L 8-J#T/1_ ICZT+@Z:?V>=J?R
M&@"36+&0#C#IVH+7N(8^[4IM^84YPQ^=&,PAYMNL2]'7MUL\'_G4BZ8(IYBE
M0*K8(' 5OI]ZLR7+1@N+[5S.'5F ?A L0 =E?Z%K3S*6+_OS&P.:NOHSI LF
M!E5;-.4GV921T1X:)@2A!O+^VXQ&C&SF;E\=,]W3_MT5T[WLGS']B\/+]G7O
M_(AI=ZY[M[WKWN'5/VON@OB8S?_UV*X$&>OWV:P\*P^FPGGG8O]F<3H9#18C
M^:8R_?TRG*,\"Q R-*O91F.]'+FT-*XK88V[8KEZKJ6]R;6R53J#U=3HS\L!
MY5J6"F>,![0J%5!A&W6>Y:O)J[PV9DOOVB ?F'X; ?<L5<K)<.=JK52C;=+
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M)#[5@W$0Q=8QL6V*A\#K/GWK[OD!YX#L*W,]G^$3M'4LZ,2OS#F6D!2LYQK
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M(]@+A/%,YWX9FDK2O=BZ1[1:0I1UT9I"+Z@(Y$FO[TY">Y[(XH1H4/)AVI\
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M._,-?'*XBV ?&!*BV#2B%2"P%A?&Q0CN#>9DR1I6B% 9J 0VY[JC7NRVG)D
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MJ_UU\E_<U\\E>#G\KLG5Z"-]UAG\[1C;C_C92\_ GW>>\84!+>B[-B@(&>M
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MNZ;(G&@2ZY29T?0%=A^LJ=/:X?LN-O9%A"3#^30I6B35(R](%V7#D<1&J(=
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MYY)0#]'FZ_SN2K7%-B)7)!9'F]EF>7<&"Z4QK_1OCFYJ+[^VIDSB/>K8&^7
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MRQV1MF%CNE$UD"WL=O^GEX;I)^\]756'._H[#C4P[;:IR I\"5;NV1;P9^Y
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M3%TI/'4B- 8*P.:OX\YYX?XCU'9K>4H\=%V>5G#"#N@6X,^8#X6J)CSK#6%
MGF9:6 H38'G $@'GK)YH 4\R3;OO9FJ:#O6*JLK]QT-M_ O5OWB/%]$FR,!>
M.3%7*/R5])[=I+SF5F3.#&L8[<!IG)\R)L\R"^F;VP058-F!% "$T@^#E-L*
MFZOG_\HY2]X_-%JIK@&;(-!FTCA& 5@45<IE<6AR2K]/0(A86&4T0$Y&/Y)4
MW?2FU@Q$@\J+D"3!?MCC)T) P?D521DP4@IOCFZ*,-5#9(H]@L=138+"AZDM
MG*NV^...HF(D%UP>[TN3Z=0CNBJ\Q,+ZD-C>#T* \;0,70(A9"*ANJ-@FIW
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M8X^H80V!J@Z@%%LVMK;!TRHT-JD;9H)':FL\K6#SIUH.</+9UA@CI)H=R@A
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M-?:^HQ[H]AN'SYRNJ%B!90:+>;U.(#G_="ZL=@&\=.B SFB$@2:V=\@ "Z]
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MMNE>]6+.9O.?P)7BR4#(@(0[Z4T"AB2-/-@W +UU-!)T_A5([% 4W@W.BX%
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MOU;^V(J,(Q8NU^Q#%'[;IJ7T)X>@N3(X8^A@!,_MQ#DW#><VSFP3_F2:CJM
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M3DB=0OA!L&'H$D)\9>2.>YRMIZGK,G[(.;1@J+H\@N]!<R[Q3CP0;I[7?66
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M14CUS(<O)XDNN'-7RWSDRHKVX=]DM^3-/P12NR94:EO<=1AN%@7*(5U7#LU
MP::Z6Q2)*_9F%TOC\2\R0$,2H'YTS9"94^M.DW"K"M%(9]D\\293R;;A?6--
M%)&M>5,;YN[^(X<:]U!O%%1"*WD#%MUS'8O0]C"<6USG+W7%(8C3GFAB%3Z#
M& I5\[C&G3.X&W5@0$M$\K2<B95FZ*%3:1SZCF][S G6 S1CCJI3@2D9R&]T
MT\-8%1#T)^B_/5!\MY3@2+ 9\BO:V+;\ 8 S\*?0&-,1'BGFF;M>E%+OP8<[
MCYK-*\%%HUO_G^,^1PO%Y]D.L%D.?Y9G]1/+Y84KEN_4T+N-@]A13&<;R/MV
M9W!9GO^YL"A4K1^HHW$=%1=8B3),PN/W/AN@*(DD&3:.9J,>/]35YY;LQ&$O
MY\S\J\[]$>#I,?EL63V 5BPC_H#O)R>?Y.2;HJ*B*F5<NXP-GJG3@A;P/QW'
MTP<S$?7$!=,V<[/ /"9)Y\#7<1H$BCID+W4NS#4W;,8OGX%(-XLDF4/=5N6Y
MO(^[<2?BI:6S=$AM2#QH$0X1K8+VVEZ9<]O[X'?*B#+JEI.=RQJ4GKV@.-U[
M2= U(%[F (4HX\$4"B@M MW\+>H[_[^C-.3Q;;-4QQG02"QV8K&GXMHC>;;F
M[%C/_\8-G$CZ74?<MV$EW?0N<_!-?&AWZE+P4A#O*7K_)"Q6[C>&FC$]^MGP
M39;8+ZG'YL21;OA75KDI!UPH$A[EZ7O]O2B3Y51*./X10*DG1_$$1E<N'OY\
M:S#A@!UQ0,L_[H6(74_IVX;D%.; [Z-KH:#%%VB7FQNP$/3KG8N)YH=:G 0<
M_!$049$/3K?@/JE%UO#/&%=Q8A7GGG70)G%4'WJ-VZ& /X%_2U@A:4QW*8#A
M0;8;Q/!+UC&>8YFU9K=>+DGMJ@PP.:#4C'SO@/R@P:EWB.B4%DYM\8)7-]1N
M^O>X>?[!R0J4GLUN"%S'%'WH6#8_4^34MT)H<5Y;S[O(SB4K_BW'(UT&*DZD
M!4(1P4P*EEW%GXQJ.G,]X!DJ1L KQ%621YXL:;D:K>-<M??_L_?FS8EJW_[P
M_[X*;M<]SZ^[BN0(SMWG=I6:R702TYF3?RR$K9(@&) D^NJ?O38S@@."(W5O
M??LD4=A[[37M-7Q6TP1^V9A6YXVX7^$;?XPB3>[SL4BD':R)[9F3%8O>*D13
M!YAEB$N]><Z*22]*M>V(35SB!"N(X[NUV:-3 GRQD#F3OZC0%P7C+"S_RD,W
M3:THT]XH))<YL(O/+8+YQEGXNZPR065R_C9>S6[?,LKV25+.K@.5B:_M0^@P
M"ZL$I/&JV(;P;UOYV(#"J8W0AZE_,Z\^,]LU#JA;O=\W9Z3?XH\0]8$YNNKX
M+]<P5QD\SN\P*(Y\,?<C=2JC$KU 61T&GC#RP8V9(P!<O]&.DQ>[>#:%V[^3
MH'+1IO)D](+PL<2U$=3Q>PYAU]DZ>;J7;+K?!M0[&/@A*9&7)'+9)O*1$R2\
M<(*$*8&7)#"3M2ELS *D[K@O-UWWSP,VWSDONF4NFZ);QHIN64S1+7<(W=(C
MQU$Z>RUD1*$Z!* 7^3Z;9;/9+/Y4>-<O?.";>Z+F+=]#@@[@V+Y.7JTJ"]=0
M!7=-$I#N;GZ@;4AO<"7K# ==^M&M[D7NMGE<KUY?5^_N#NIW]T>ML?9::Y_U
MK]\[V=>5MA5#<Y-9469>]8.OX<9UWOAD8++=TYCF[CW],Q\,2R#F"FN-PIN"
MW6#6#NE]W6S[1S $84B;K9*D9,Z:J Z#B)VH4@<[%4:1)7['M!W\6UU+%_ZR
M)E$0M8'$C7X"0#A:RD+&-^[;VWI>J[7&V?'+>S5[);\*R.9\S\J__;9$+@-G
M1:2.<HD=/CB"F(A_:T@>Y0;^\/>E)QG2F<]FQ!?<-DXN++[=QC>4N1YKTL!F
M!.:P &=5=[?&ULRAF[> K!0&YA3LL"Z[CJ"@.R8LG.?_?6._V=R4K]0=9"1C
M0((+R2!@@*P#;&!!<UC0>9]H6+T\RH[/REV_0Q#JUBVXV4EOBG3\6RM)G)1K
M/*;J?,=T@T\'<H_-CLNJWOCZ#QQ1M\[NO']T>WQ5:Y1$M-*SLQ>RRT=7<&&/
MY?5KZ;FCW2LWI94+B9%52)[25EH(:VN;"!X<PQ $*( P'+-C=-JNW3SQV6X$
M8Q*L[+&1P23M$MA8,#2*^I-2N^WO;#9/L[DRS18*/V)(>.:+_P3=5*JA;ECT
M6(7Y1O:?>-.K3. &EJNV=QZ>]SV=#'&9#1T6R"O3(!T]D\+#[)7O)C0O-.4D
MB%N%+N1S=*XX.0]V>8HE>1PI[X3R3B0CZF.H7%2&JM"5?($N5MB4GW: GWQ<
M,2^\[ 17L!4Z7Z[0V4(0S''B;!%HT=W0;S<(ZMF0<,RI !:A59W8PI$16B#&
MG5-.N\*94M0_A42-^V-/'*)E+'J %9^,EBS3?Q:#G,0O' $"\7VZ1,P^][@-
M]0* MQK>R/]].YBPV 4L2B6ZR,2I82</XT?*'G&P1QRVN+0TSR1AE%.6B9]E
M? >_ #1SR,&S6%GDL'N?S:_BY"<+*OVPKZ[\2K74&LN]@B >O9P?L>)*,R K
M2#R[+\Z ONPOE;2[)2SL8"M%[V!Z.MAR1]R0H[[KLH5@:$ >&P&1'\8X:*01
M/(")U(Z1R7&5=]I@$L[C')! I\S30'KD[+8\Z.OV8 ;>HL'0# 4;J)*YK4R8
M+)=&\V?$#+ -.!Y]8 31O:T3F2G9-G.V'4%%<"8]A4WK<<'$JJ;#80P9A_X,
M^+<C*9_:&I&D+4&O9W.!V<]7*5L]'Y0?^K=YX^)B)H$-E@O-")NA26^2V'BE
M^;\^$%_S']\+?,DAJ"MP%EP+7/!+^U*07FOC6ST97;4(%7*35&!)^GK%_.^"
M^065KU$:*<"U($R\Z.LN)00#0Q#']X+@5RD)1H5CQ=0W<TX$<X:@.8FR())^
MTFVI$+=X*I<MMYA<OC7NEFI/15GICQX@@&Y4*Y./_*2.;.QZ*&0VTY\1LI_?
MC\ 'D;0?:39ST6PFN^Y<2\X9,K)<-K/8N):?2F^7@[]"FLV,Z9C2Q&*\S,ZZ
M)NJ\-SKO'^\YH2UQ^Y589.9,+#[4^MWJGZ_NB<YN76+1'ZU.$XNK#>:SD>.5
M3.2Y1$R1+I18NA0XIRM-!/D6:P_)*N?GTP?\7'Y"M'*:SI^CXT%K?',R>LDA
M^0B=N^?,A<GL$MV0*^7_& *RS"8F1W.!;/:=B1R4397I5&;RL003.3.*]213
MABCMQF1&JXMG1DM\CRU>E!K]6B[-C.YQ'F,)3Z.P=+*C3)<K>;H<.+YVC[)<
MCB_!+BS(";L5#>Q6O%<DKOQRR9SGBXY;,2F#$=3(6K@\#G]B^3S?BA*\W]F-
MY_Z-YQK?V<=0$(+U7CY+%P(GP:X@Q[OI,?C(WM,6H5;%(EW^S-U)MM(:%S$S
M#I_>_S""-T7O:?$BUXR$T:KL53$GK?'5RPUZ/V<^7M[RX:L"*>XHRA"0APRA
M,W\@@E?Y1GWUI9\2!VR"Y(/[6W?<52-[, >Y4;PK]T(P#PF"N6<(D9G4_6X/
MB@\:!5]T&>2&^<$C9/S;P#=M UO+/3\M</YXRWZ(/73.P** ;RHR+-^PUK,B
M"5:V0)7QR\33Y_?JJVV3;R?V^,W Y#(V,^C)V/B=2N-G]NN#SSV,7FZKP\;)
MU2MW^O F/'Y)C=-*OW'\,.+[E5'C^.J#E\^EY]S-H,T6QHWC$_VE7OO+]Z4/
M7JS]?7DZQ[__V_W[>/,N/%UEVX\/NG!VV?US?",)IR>#]MGEH%'O_7U^.I?:
M\HWR\G0S>&9/M#]_JZU9=[OYZ#S?Z'2+H*VI]/1J>#;RU;"$]7J.SA:"C#H1
MMA^_")?Z4'=!E!"@[T\@[D^,%?DNH"G<FIW.K=93L+.#Q ]0Q:MAUO;1\7N[
M5*_U^F6W ^G=VL[PZB25$V35R(&M?):EL\6@(C,WHSIJ= +.S\/$K@$3#EBL
M!R-X.N,6G,[]28HVS-?6\5M7P[#X;W]&7T=_AYS-KPWWWK>+5PG6PG2R)LBA
M"T0)?%YR*4]GR[-4J=O0A\ 76]"2/GQ*HR3/HX@#D)/G8&>RC@F6/IK&TH_F
MBU;#SOG'._WL_OCY[L'1O]8*=H*579M)BHT7*.GV*5JF2+/%8B@;TY9'X.%.
MS<..';P3UX PS.?F)([ISFM^'A8$*EG87:/5\*.B%INC\<O?5Z4WP8^^O>X4
M>WI(G2"O5J+R:KG,T(7" DZ!B=DR':/<55!+X,:]XZ?\D.0S>-K=!':$O]JP
MO^FG^XD5V[M"*W(;[HNU0K/$713+DLW71][M;1<_6U[N_(1.CJMST1-V-,OD
MZ'RE',K7A^0O5N3A=R#F]-HC1BO$.7?B24>M,7?U\L(-9;E_UIL23V)7&4^J
MML9C%5V>O_4UD2M'C"?EV.GQI-AC2>RZ8DG^\+>EKP3V03H[:P^%"I<&D>91
M5\&$].FIR"W793J;K=#Y8E!6P+2_%&?SIXT$9TY.%L+#2 &SB%V3F68R;;@/
M>8*?0E VFYV8;S1A+'MS41WVJX7\\Q=OL^R)LQ>7T[Q=;!OB.080. F672"E
MY3.M^2Q=R66G,*R*8#@-OGV[IB2',NJ\<<ZC-<4YP[AR5)11XTD?M?-<&N",
MB2<72+$O&-F<:^B=9L>'["'?DJ+AWPZ=,.ATS5GRW%2LYY[BG5_@!S5EYW?Q
M75#"&#17[WTJG>M14^RY;B;.7F%KV\F?,RF; &_F(]=8LY4BS12F&?A51=QS
M*XZXAQKT=[7XK/)H6$%IK#TR0T9'$RL6Z7RV-,WCE(VY0%RWJR+L/2*7#TI"
M[@0!6$9#4S]"FS1T,V+>;"-)^9RA)8^G\2$67P/_'N0Z849\[1PW*H_9\W:O
M8S,B?C\9<MI'6Z@A0UC10],D>#'R_8>A*\42763#U>,\<9KM*7-R6HU+1JMQ
M_?IH?'JK7OQ!7-IJO-)6XUOW*+7F *F<$^Z9->%TW4V9QZT@O;A4+W+GI*34
M:@_H[3/M18[_P)A%#RPBQO*G\N>NQ-7.SYKEM!4Z[D.L!QWB^%%]/N&:)Z7/
M\6J[S]?>%.W%9M2PNN1[V! =H0_L PZ(6_8%45?4$C'%QJ_LY:V<;[.-2F?K
M>J.#09>M31-_67"V31/7&&:JXQ>!/T,A@Q#X!B?VV[JJ&1A/6]+T][]KZO>;
MRE-S>K&+MSCE(P=&&9K)E^E2K)"/N]-+G1P7S6P$B8>-8N@ARB\/$HF-#YUC
M@R[OB;#8MC0F;[&.\K%(Y!@X0V/^HG/ES0%OSKD<A%,DXQN6A.E4%?JB+&I#
ME41K/2Y"1\K64&U4[?#M;6M0-O=G#+WR[' ?>O&F"\F,LT_,E!<BQ^P+V'<L
M58(*..-KU5ON&+:).V88Z/C8(P8375B@Y"S$1!<+(37L>]3>OB5*Q7?VD5,J
M^5(.._[)PC?/-+<%E[F]0%U..D%(,PSKP]>%JI^^?SU4H@RQ7,_=>Y("9%/$
MP@Y4I8,TC521IJ)@'W9REC1Z@5NQ2)=*0=5"J26-W9)&880X;.;RJ##Y/+Z]
MQ FNE-K,Y?G#=\J1 V-EEJ5+L<8L(EA'-X2GF>V3NZY*@W&_R9\4Q%KUA"]O
MV^7SRJK$((U4BIW+W >.GZ$2 XXZ.2L9PR@0Z,6BV5)0WTJJ"F-4A<OQ11Q&
M,W+''LMDZ7P@WD3J4FV._O">=G&!4%2H:LCE<W29338J]6/."V8#LM!(<Z=X
MKUJ"V.JY4L*D6O6:4X>C.U>1:FWD_HNO4N]*D5777^VN)>4BIZ"[X^/[*".(
M-N7^:M',2@>G]AEZ#3Q\%*-MMBL8 WG*)YZ1(S\5ID272WL.9IF\N8[.)M$*
MJ1;AG07P>,)NO^4*S522109,+?I2K+0(0T0.EN79,ETLK\3W#S3P%:<PWQAK
MATZ08]K'_.E%\>]H]'G9W[KT[(G=+]-!^Y&1)3T7YI,.-,0?B%\'/5$0$/X,
M/FU6_&JK$F;6(KR^S#+L+T]I_29L;)OH':)T2$.&(TNKO6(6(P,8,=@@5=+9
MQ9O%%K[#C5XHM+K#G5DW/+M)EN0O]>NSG#2XNQ_(6WS]J_<XN8L(P)P'O<!I
M0+8QL,3]N!O.:Z1*V=1(K< SCJNO.B;S55J^% =473:;;/9YG^U8S)SC._\%
M@C+K/_] 4^<&+;%Q71RN=T'HV)>LEQ)Z*+Q_7A]IA6V[9(49. N+:-^LVU21
MF<H.B:4H2PO$)L*FF.3I+!MGD7EJD1-GDCBL<610YWR%I4NI$=X&9O$=>>2*
MGURE3!=+R2J):7;7/10!/!(-7!*$G9)C#TQMLP,HI\85<WCR<78AU)[?2\G:
MW81+9*$*", IO7"\)N;N/@C)W'?*<GJG7$5SQRSI6[$56Z#J)NQ.09<J!;J8
M< %.:M!BXQTO!Y27K\19*0<$VC<?K+!9F 0$J"N NJYC4CF0-C6$-XR,S]UQ
M7TC#M%0Y G+(J:/&$/6U*T4F8 6*))%:)R-%VAIKTMO'_=M[LY+;NMNH512;
M"M+/!%DDL9MJ>?GH3PY?5,MT/I\6T^X'@\7@'Y27+^:9!FF7<MU.<9V/=Y:/
MK>7I2J5(9XLKJ2><&;&VH;H)4K>- 6V0TX;/:_0'>(TMT0A?WZC/I<M/]'Q5
MZ6WQ-=K:*UREX4,H +D\%<"?BS!(<HY"Y"A5B8'I"ZF:WDXNB</:1RZ0RN4P
M[Q16$N!,>2=6WO%Q0 (C!U9>JWN$,!4$BSB3H1+#@GE):=GKPKG.-9^O+IO#
M9)$A$KC@&]NVAVT$A[WWV7K/&PJOI.55B1=[1I'1U1K#2N1A>_E<A<XGW-^_
MS\8P80;RL4%T$*35L4&@12R&6\1+1;"EH-DQID58LH$$*T=>U2Q$9<LZ7EUD
M1V?2TT-=JVSS;7;24/9=!"'C6PE)#AR:V#/5:!COH4Y%FMXM(4QHAL0"YC@_
M:8X'J4G>K,-<1%4OJGU6;/<C%W95\DQ(=6V\[+H7MG^'.=7';Y'C=2OFM[#,
MN]?)@+2#*K9U0C(9_P2S+TV)=/MB55FXM8>@^_]H!S8F71"]I&M/%Y\WCWIN
M2R_HO(M"X'OP-HW \QC8]W)CQC+ .WJGQ?L_84_73%V3E;LF 45SJ6NR:8<Y
M2]\GI;)6[+<L7\J78_"%-0AU,N7IE*<C>SA,=OD2PS5PYLQR ,\4R>H')THP
M\O!.J2O]OB(3 O842<!TKW&:R+?&E\+IG_/1ZV?MDMWBZ(D-KLD-#0XC@QZ'
M"F8,V+?AE)@;WP<9GY&Q6Y!+DBH+8+*QU ]6*G2^D$:VMY=IEG<TF.SR-8$Y
MNI@OT<5RV@2WE9SDXX?EZ_R*= GS Y-;=;)DN^('MN4=(+ST'H>O^M0!?C4^
M-V/DHBCIFWCS7V(866@6WYF>[H;/L89R8[5V"_0Q'*_ H>E+#0>^U,?MZU/I
MY+C7\PQ*#SF=]0Y-KU9;K4FR'4TAVY'!2 D0CN>/;AZR[-?K;6=;"#=#P0:R
M7')>W+S!XL;528BVO2;+U&;A,83P1'([F[?R;(Z=L8>YH%ZTB5^8$;O82WPV
MS_%(5@4?QZZ"(X[[KN5UM9$M_$5GS+:H%S\MJPGHY8C4_%-[;A[WU8K\+,Z@
MIJ,<UD[/A-5U#/<G9MYPV ;H\#BV.V_@82[%7DH5^PH5>R628A\7Q-[;S=VQ
M+NK2#,51VU0U7(^HAL>W8WFD/NCR::^2*DU_J("9-U2P7M7G6W2,/G?A,!O4
M(K%J!6:%0/XEP?O?F4Q"B2KO$L!*B)V1HPL'*W^S^4XC9\$C21IP@H#YA 2G
MX&=,<=[ZV=(&.:P'F5R^-3Y_JNB7W;,_W#5F)$WOX]>.R$=^8F'6>"SBNHJP
M9-_R/23H$@'[.U951:7JBJHB8]X+594%BEA3RC"GE&,_->K[$1IRHJ3]B) A
M:BNJ@%0(0$G<0$,_*>N_G,'EV>P_WV(.?H7%N-J*),SU6/,([--C#@N0XJQC
M6BF2*$#6D;);FT@/BRMJ2:HO2K\HHS8+"F#P!XX03QP1*L?0%(AUL @MN\(@
MDXY)#D+[?]]8AW_RE>-6[)&4S]OLQ]W?RFM-%FQ6,1G 6F9-XO@WBL'[(X3\
M12VX;;<$X?4,L6?WNZI1UDH2)^HV'5C$*Q;_67WM-IC7D]?N2D_17L@N'V(]
MZ!#'#]E[Z?GSXZ:)>BL7G&FE>7'2/+!VX<3ETA(5VM T'0E'NHJ?9C L@4O$
M+R9_T5KCQX_']^O3:ZWPS&UQQ4+=59A B633X-!1/*?U*'V _R1B7TWD)&J@
MMR61QR:D@X H)*N"OI#*BYH;N1>_3$;$%,'38&@!YD!MN'GE#DG<#F=613+,
M/D()QDSJJ9>;N:1WQ5&>R.,[*W2EP-"Y0K)S'%.NB9-KO&?/+E#?-_?9NW4-
M$.6@P_5%:?1S%EG(9S5QC PJ?DOB%CW3U+I:+UV%%@;M3Q2UC@U/:WQV])K5
M3[5.^QUM6R?#-(NZ<3*V,BA[4GX;=MZ))4[9R W*3);.9LMTMI*BUR??KQX#
M7\1@IMD8\/Q6PS6;EVI9'R()PP:T0*_0G!4<<V;U/!Z;MR+'G+$"TV/E!E_A
M^"V^*UK[LZ]]J6$S%5C8R2=GV"(WQC)YK)Z21;E-C5I,/!&'45L MB[,J"7/
M,:E!<QNTE86(PL#B[%"H*_MVIU0%0823YZ1K3A0:<IT;B$-.<KEM#3/B5X>
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M[P1/-=@.:K!([:@!<I58.08;.;W%9.DBR]*5;!# Q ;KOM0YWV%YB];_O9S
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M$TFG#%&G'-G6J.]':,B)DO;CF^U^Y+*U%I/+M\;5VO-%LSHX?:A% 9YK*ZJ
M5' %)&Z@H9^4]5^_J$]1&/;@*=E_OL7<61CF8K0529CKL>81V&?''!8&)!$E
M:XHD"@1;KL9))'QQVT-H2'$DV'2$>*(HJ1Q#4U@NF&".G7,=P4H(4Q#XYO^^
ML<YIY2LE"+PP)/ "^AU<1FV(UPD'7/T2-?.WLZ[7K?&%)M\7!;ZH5)VYEN8I
M6M2H2=C)HQB\?$(-HSUC >JZA1&O9X@-R^^J1EDKB8]FR1%^A82QY70;Z.(P
M9,%AR'&^P]ZJ?^ZO>L?"RGF*2$&</!6&76_W&56Q[@"EBVTH)PH-N<X-Q"$G
MM<1&:USI'?-W+_U*CA.VYM)E*NI\_I\@.^KL%FM-4<"W*8HW-AS=6IMO9/^)
MR0VS3$W@!I;MW[ >[B?/5!?- BX(X16ONU75FAT0ILAATD+D.$B>9@I9NA)K
MQ=0J3F,MK&/G2\K'\ZD#?BZ;'>FJUNK\.3H>M,:WZM/SB$'24:%B9V'"13:"
M3EH+^\=Q>UU@Y*A7)DITA6'I2JR-!"85<X%L]IV)'!5.=>E49O*Q1/3"4B@'
MR&$]&90H3%Q/!GHD59<*NH'KG8R$8TZ5\;5&J_*\WM<)1/81PN(B#HES\M[(
MUSDFB]Y/MVZ8CFM'E+FEC0O])-![.@.;;/:YQ^UH+( 1'#85CBY5"G0^EVSR
M9?/2;*&^Q-'"@IRP6]' ;D7[^J$BZ%UIP J.6^&20<%BK^W@\AC\B>("T<X0
MUB_3V7R%S@9.,8^1];^S&\_]&\\UOK-?H)TYY.R9'%W.Y^D"LQ*]M^* M_O9
M<4&^^(+F[B"Y/X@>V?.*-32-Z13=Y[$(:9F%DVRE-1Y]E<^*EU>#=[;R+182
MDXM&W A*H#3%SFAB!TRQ-7[@/S_%X94Z>BS'LP.0^8ZB#*$GU!!1\P<BIKEO
MU%=?^BEQP!A(/KB_=<=7-7P1YB5=0!1G_XZ08*A0PQYF,TY51U!P:I<6>#I/
M:?/K\ D5\4I7%JV"!($;40PE*9I&?<?*0$6<T=4:5&?IABLB'SPRO]"0W2U2
M=5U5\?H,6V]77II6WW[&K67WC?1>7>D/%!FV:O@!LV(45DY ?;C3QJ\WW8_.
MFVWMK>51[@UY"((%$>RGL;=!#R_VYE0:/[-?'WSN8?1R6QTV3JY>N=.'-^'Q
M2VJ<5OJ-XX<1WZ^,&L=7'[Q\+CWG;@9MMC!N')_H+_7:7[XO??!B[>_+TSG^
M_=_NW\>;=^'I*MM^?-"%L\ONG^,;23@]&;3/+@>->N_O\].YU)9OE)>GF\$S
M>Z+]^5MMS;I%SD7VP'0H8Z=#+=?"?&9K*GE]IB3R';1$YPI!]8Q$GG_\HJ"B
M?NBIDS%F)6'N;B/"Y\"U*@#*<UUL&K6ATT!E%]Q3I.+>+PH>IO;SM&NLZR1M
M?4UK*^'FRE'IY?JV7QI^]*9PLRC[V\:VBY])$< L@B?(QY'#:^4*S3"A /"8
MD:%"W0 +X#$'(%DS&)IS)[1%>8J6+4S5LD<F@>JNAZ^&,>O%*E,MJ'RQ+-F,
M>3NQT>UBPW"U&D3G!/DQ\O0B?"O+5NA\,5RW'I*_6&['[\1@DY?R(&VO-GO(
M%D1YTJ&LML;E/_<?Y_QE/EMF8G(HV6"'TG$" ;KD3RV7/^[<]JK<DO$"Q]6<
MY@:6L@%N8'SW%)=#2?9K.94J@BXV3B(.H=G@YBI*M8UOD(>XD1+OTJBY:3;>
MZN:SJ\UBTJ;^&[RE1IO'O2>^>7.O:,QT^SYY"@L:TXF=+:B_@G?@55RER%5T
MN1Q#9PM![0J><8?QC5[X9?#[A)\I6&Y4X[II.IT>)O^^)5Q>G\;E5G,:C M+
MF,&SIU\-Z;5=NKT7%V18]R*3X-4%>FQ\4?\"S92#0E\K9E77E2C6Z]"FLS:S
M\DM:&',?]RJOJO;<'BF]55YMYF+OR&4TT^\T2;&W<R.R0E@(^T=]DJ"9U2,3
M=(/:=":N36/BR>IW+6%.[EXJS>+G-3LNYA;DY("U)L'.D4--;#Y+5W)3YK*O
MBI_C"<EN(:L?KRE0',;KM?>S+NK\.7T>OZXCP#H7NT<'""O!(+35J^]H<:Y-
M9]W\NJ)O8;Q;R/_--=J=ZN5??BU1K+F8-WHX=5;X*G[V/;2?[ V+!66>R6>
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M()I3UST.W]5XI)/\/5X^OC@>$HUI?>)(Y+JR@LG!6W^M2A)6A4.D\L;[J"%
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M'X*XF#]G/ 8=BS.^,N#C-2027P$\<6?7PU42SS&R3* 23-(;.X(#FRU6</1
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MC%F%2Y0:N+:8AKW3E$%*NY1V^T6[L%05KVM8*[LS59:J'#URJ@J(5NY4U22
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MDO;\GJTU;W-;.#IB$6T2;8Z;I4F*6,CVV=RO0/ZBCGG9:O/^^)A[1;6[XO$
M;>'PAD7D+UKH;:WRMQ77^4!@8-3G1-D:BKP_RB0)$(QY"R*W"\5FAEK2[GLG
M<ITMGTNE]:+7S- P\X!>Y)D(H!>%P[5B7J3"&DU8JSN)6#-#6/N=4[UT4I#/
M'G/K1:J)0UA99G%AS1]6=A^@)LX+_\,FCFY:V45C;BS9K>BB"OU(0@-69BBC
MVD..SW_J[\?ON1UIFPJ#[EYHL,H"-R5VH;CGE($JV<.]PY)9F0Z)=?;;VMND
M-DR'9,?*5?[H@3V6ENO'WGSX_\1T2%RSWG9Q*%,2 9>-G\2T,LV8CF%*6CV^
M'?-/C])7KM9<KFUT\UVLQ:>C+*(C8QI<QQ[N74/Z=E[5-M?-6J,R8:O9YUKN
M_>KR:I/GZZYGU-(BRB0F<(O<2F?K;E_D:L,;]%=1&U?9R>[\&6J*>3JJO8RN
MLG\^"MO<E;^ 1LG-6Z,ZT?G+Y(MTD5W)I+8-S5DE*X G.]F*/\M/N'N_Y(=7
M'^]J;YM;\!<1P,AP&$R!H4ML,6V]3UOOU]EZ7U,PJR-.H*[Q*PQOO=J%_TW[
M\-,^_+GZ\-/F^[3Y/KBQ]V2WFN\M56EK2J(H_3[0J:CVQGET_7BT4_V],=QK
MYJ&?S[N*5H^?MN)'E5AFMUKQYY-836>4]NB>>>P$36'<6HF-X2(406)C <](
M&_,7NM]Y6SVI[VU.PXR+F0?97%Q79+)$N#1=*4,$#(-_H0&+0?F_1G%#2C2=
MXA][%JNI[4^W_WP:,<LKO8)P,]"^N+7W$Z_'\5@>7X0IIKW_6P+0L0M.C((:
M1]?UIVO^+[]VD5V+YY%?'JYC+2*[?<&-R?U,-J/NHA.R@E*6F9 F6PDO,*<&
M>QK?E]X&GY_#PA:B#$106-&@2^QK$ETLE_?8OTC!!A*5QB[??ARP>N[DHK.%
MF ,1I'$YZ ^6+I29W70=4NB!C>YFKNTD],!\2NJI<7VK]8[:?]<,0#"?NIFK
MM3E?2G$(]D1RZSN)0S"7Y+8T=7AP<,/)7;/JG?Q\B6U"7^_;TCU&W-?]179X
MF5\O9,%<6\([:'DV,*_ 1P >R1_FPP3>JNM)F6T6LW%?;F:[&'=?T$V-&VA!
MT/D;R6SN#<S);(5(P!F%%#@C!<Z($IG?X=;.A)K>Y_-[F1.NDJL67VX^Q WN
MQUHY?L;BM_Y"7# :Q<.5W/[WLK\SA=%(7J-<?:*7TZOVQ^!JDQ%Y5HZF$4&C
MI* :*:C&MD<F\OOAPR7941]?&*0W?M9'Q:^_3+>WP:IY/4@>42,S'HT=$\0'
M<QB:COV'.I@(R*00.!L4_;GNENK:"UMOU]A4QF(*2'ED+";D"S8<K?"?-,N1
M4$GT#M^YUJZ=QMK775[-U@M(+VRPYED/M,[BMZ_B0D6@TQ!V5H*,D2+L;&\%
M^M%.(NS,I[1&=^*XWOVXNQA(VPRT$T&_1(;[J+!T+K=RM(^]D<;:3L+MS">-
M)?:Y7"@<WW;/V]N,NA-!&N>-M4Y(8S%/,_FUM7HXV#O^O/K 9NERM=P:(WYP
MU.LVNU^WY0B=QG.@]'A7#*<N=D9)0_<D SB4^%:JE*I($N:W3TX5H AZV$,:
MLDJA*<GD8Q$_%'\(_DKJ(R@D"U@,CQ!/.)C*,30% D.)V+^'CTJ2\JG]])(H
MO-#$E+R<+7DY0_*^40B[LP.\R:$*#>$>.;%K"DD?^2W?0X(N(:7C$T&\]#O@
MS#O\LIH$[>T>CJP<.^@ \S^C-1[6'HZ;?#'?_-AR+O;8G'(MAP7TMGG%9[O-
M\0=G;TT0M8'$X;?@$\0ZUZ)4!G.,'X9)1$[US!Z!6\WOBR2FB((4_-QH6DFN
M:GE<ISFW$0SN%-_63%XG^YF$'8-OX<=5J6L5=9"J8@UY"X :5+.-%\2!-=[\
ML]JZB[LMYZ7R/W&2IL9)T+))DW7Y+1U#?<=V#B(^X(_^6-K'<H'DK$00XP4<
M25JC34/?<IF=EG@[XR84\<IB"';5%FLBU8Y0V_4FVO5SK70QOA8GZDW<GM02
M^#KE$'R=^)+F,Y%Z+MP;F9+/";D0S45*GZ<W;YYEXD:4R^7I2B&!DI/U2<-6
MU+3$20, M43"DB>VJ5IUG:J4G:9*#:JO59N>%/Z^?KT\O=R==VUM:BPK@@)=
M0:61^23H4S@0OPYZHB @_#9,;%;\:JL2FR\QWWX?^.]&\45E=D#O)(OH$1^!
M+ 09@?JNH2%FS:5=P%1#36JHW#0-91_!6I74\+[YBC_P<=QI3R 4N9AC:S56
M+E&-M1-]__&=RH6B:0 NQ/>@L(L294\B.E4O,:N7HJ->3CE1;LIU0O>&[(#"
MKE.U%-3G=D6LUQ]>'/ S6&<8AVR<C@F_2H:0>\YT7'PWRU+D7%N>9>A2<250
M1:E;MS("^:< :-10H0@F<D^1!*1J)HH]63TB0K]5>CF9&0JKUMME1V]/'-B=
M<NLZ+D,OKU6+EY@"<U:\NQJS3A'V3#;[?R9S)3S\(G:5_WV*SI_KJ%9O >;M
MDX#4)"8:]I;]IJ!4*-(E=B7#"^,[J1_['52T<CN3%0S;K\]9F#5#"8K>EM"V
MJ/09:9WCM:KPXK6@GG&EMCZ8F#H=F-9)[%36%P:HP!%BUX?]M<7A2Z=$;6O+
MM?9P:%RD&M^HI16K&5*V5#&+O]S**3\Q)CP:=7A6A6GBU-BZ&^04XS]1U+%A
MU>8^!G?,9W4M51$SYJ9*+Y]U]J)T7CCNQEP-,<LF3K%D94\*;J\CV>ZJ*2O)
MOA4SOD+%H+RNC/8,26B@RV?Q].U=*HG+9[)GE0(M4L!C+6*92_<"<X7+T><*
MAP[VWI$!6LE&2 /3U=MBW+)KS +/$.Q>.\_7/D_;MUPO^>SOM.#:%,*L3KH7
M2*:$A-(J#)T-[">,SU#_V"H;/;G^Z3GB;9'I_)I2KS/D^>FJW/YX1\V3AM,"
M/(W@,?FN*TZ4+B+3"X3'O:)<H)DLFZ@D[Y:1#KUKSYN3M/.1*QC/OH)TXCQ.
M_AJS?S,4"5>^J+:+SY?G3YN:]%MSJFX1';1 ^7^(7U',TL5*G.-W V5E^]T-
M_[980P5,RY;%14$VFK:)+]D5JG"*:\E-S5(PG_SKW?C/QRN:P'9;?TYJ2ORM
MPDQFDF)EH<7A"E::"K*6DF9NTLR-D[FQ4$(H&R:$(C@A:1IGK](X4_L=$DOC
MS#G(5,H6"]WS?.]E@[(YE5R:S=G9;,Y4:4@RFS.?0)R=?CZ5Q9>&?H5V+ZFS
M.&Q5)7(I?2B(7)K:V?743F6-J9WYI%Q\OQL]O.OZZT5WQ?U]T\Q>*35[BP9B
MIG5.K3)FFL#6YK&@*\VRS"=:G=+7TTV_/;ZMY)/J;YN#A'.$0Q-)PD2PL,O'
M0=DRS53B-+6;&0>-T^+.O4-_T'POTS2+B'&R/4V#8#VXQI31?%KQ]9S_^$0W
M^79VF7ZQ6$.9:T\6+:PK"]EY(?.GY(S"T'0'.Z<OT[Q1PHGJ%>:-YL2Z?WE_
M*!8*W+,F;5/ZJ)#-;5SZ: ;:]<W+WX^'IZ/[:X59*4ZP)]&TTA37#733@86Z
M4H:(*A'<:" UJ$].<JD?["%D %!:]7M.2B<0@!H_TC!SAWB1R'A\V?]X0=1X
M28$9+9 "D A://XBO,?Q04R@:PJ$BI-'IFNF93"/BQ]X#1_(_>)#0L5M;1GS
M-(OMQBZV=1,!W7L$%1U]\9(NH-___<_! 74B(DGX25US702(PN\ZPB84/R&7
M_T61>R?^;^K@P#1S@O@QKS_MVW"1D'6A%/1\B>6@TW/\%[]7@@\DL!G4T>B3
MJ51?'OODP$TXBV2_*!B5]9.JJEB0^5_4%799#;)>*4"_7-;]K7^MK\&?)EM&
M__L7$SJ Y"KBW@[:".L@_.P!.3(WHVT-C3WT]-N[("*X20<T-<CFXN7ME=+_
MVK__$VTBB'A;;9_Z\9O\6 <;%+*%;[X9)A=(TQ"Z0)R&M&LLS/PH9)A!WCU5
M?,JW6N/<2VWX^#GZ>#OC5N&6Q-WA;9R1;W9!,=\:WW?^%AJ]E^K#2^G;;V/O
M]MD%'>66\N@.32!Y1-CMPDJ]+\J($CL4?BSQ_;KF*$"-XC#[X(.D.!@,R*,!
M>'J'E&<%DW?:3^-.VQP@%3MT<M=X!GZ8"O$HHJ,$"$PIU@<RQDO(A>1 Z1SH
M\$8L04/J._B';/;73?.>_!?SZP?M?,]<G&07]1Q0O*ZJ>.TT&74X[8-8:YB?
MA6@9]D@S6'D0<TW\UK9Q?Z:T'D)#[1 K7)G\'+*5@0KOP@^&UX*G/.B352CX
MP:JU*+=C:RZ0_%E2\%4(CL']@0P02%>IJ:NZ<QQI['T+>%-#2H<Y]&-,0/R[
M#EDU$&#8PT>HPLI@- )V^Y6N+%H>?\>[.4%7C:^@# R<T4(FSN3(%N#Z?!@X
M=&1+A6*'Y!M+38;($=S'!OA:1K@=,Q61-+B;$4F3*2R\2)5&<.J&W%D#APRY
M(;P)A^T5(Q'YGZO8 "[P\#[W9CXA,^!&(! @.*(&K^E@Z^R\X9#R*0L*+YTR
METY>['HER)[)P&/,EIBO>:7?!P>2:"V0%"PHD",V!)LR5YBQ[Y_&*^PU*1_(
MO]M#JJJ1'5DBH1#9PF+^(0J$9&)_@.VZB(4*OX^F/A&A)7P%ZP5C2BG<N!55
M53YA6ZJ]K(RY+&2/5"-_P^L2S4FFA/S$^<0_<Q+9IOTDVE@O1VDBY@I.-4['
MO%7[=A9$&T-K^'6O36^*DS3%TFT:T2*^A_8Y0@&LY[[,#QD?  ,APP4>*Z:F
M13JR.OC.R'HF?K4=2,?LCT -JAG#"@$=G&U\]A"F,[%#V-G7%!F[PB/LO*M#
MR'$0C8;)_BE*$GZ041=@_%8Q[11Q0O#?!DC&_P)1?5LA3[8Y29$SF*I#E2-V
M2 *CB ],#&:0G5 0.Z/K@D+KIAMB>**93W'8L]T92V08ENKC!_7P$0-O:)K'
MT2&:!L0>>$05#(4"$FX1++9S<!OYS'S>E>4*F&LQ/((Y/3,07MB;*1ED7S[.
MSX1R/F4Z)IH5) ="FNH$;^/06M$CHGK<A_5-KJLB9 @=.0GSMS+X+/*!\1-O
MQ]EI6"G?R\ BNT@&)8@EG^-YO!DR@Q(?EX8&'"A.:93*XH9M!1N8C.V66A<,
MS6V+G5@P_I/8U_M41Q_JZH0!@X-6_/>(]LBRG<1AF32?Q A@P_&IZ)*0(5R(
MC0U^*/QC&%*#Y?TVUN%YKWFER=6H#]P'WCTV[&9<VV]O0;#L;V*M(2M]D<?^
M\X>H*C)\)O,=OF;>:L(]!?.R VK)_&RC=F/=@'Q^OY? W #N(JH(-,'? 6)A
MCT6&(S:I!3D"\ @RA&ZP9.RHD;_98UHU@X1#<. P515R"\&/,63<=:VP;#D\
MQ3+,A"8'V@#QD%:@>%'E]3Y,A^?!,S@Q/4OO,FAW3@ \*0$H;J0<J+8N2OA>
M,Z"QWZJ]F<LTW28:9E["=VU_S.8"^//NJH:$ V$E?R#LVKSA7F.S,ZS*PK%U
MR9T>%3MV1<7F?41K7+[L5[F'2^'E)K<[(;)L:]R[/&YCG<1TY,ZWWQ8Y,B \
M-BW2D-E&;\5S:':@AWA31L^3<>?"ZL=P)WFL^W0C%2K 59D7.>-N<@R^ER .
M2;84S%R? \UE!&+@X?AFS8FJ<=WE>WBG1C;5NLU@M2<:$2SA5\9*PN*%8YV*
M/O$=CCRCC89@',R;-WX.-Q"'AK$[I![A>A4<N#+OV$,2+ (3#'&J3[A?P3!:
MA;B,'=K4X\;N8,^$*&%;-I_9Q^95<*[_>/?84)"TK^G>F:$QL -=4LL& 3*-
MW-4"@H?$XSQROT;I9$(VA9]@7N %;&+,$)?OPM='PYYB.IAZ&ZS64#2<3WS+
M- ,2Q(%U;N\27'E7-'JYD*T$CEYN=NXUU-&E"U@+-K$>56OKEJG#F-G)8<Q1
MGMH:/]X._A:$LR:O]9(JBDM*-7DU=HUIC2^42N^U=SGZO'F;-9 97%"#7A0A
M&&$BBV04H5F FE]O-W(E_F;D%4V<+9/TLZ[*1(5N9\-=Y(<7$Y]%ZI&$2G8N
M-\Y2%AW4$ALM8?A,RNQRON*ZT*_71E U8)38V9^V3QA_\D3\(N;2JJ2[?_F4
MT)GR]MRIV)5TMKP-B+QY#8!N2*>$5_AMFL=<-<:IFNK86DPK?"V>BE>HH?LI
MZ"KD3KS*FV'F]JH=6G[[79AP]@WE09'L3+(#5;>P+VER$W"OU+$CI'GY8=.;
M]6+O:XM5)537I1*LT[0_9>F#XZ_7VG4Q^Z&)^97H@Y"%S*L,<INH##9! R3;
MM7N#-$PION?VQ5(]$%T/E->E!R;D_^)Y+ [/+\0'I;T2^8\H]Q,U9G/)/9/=
M!,&?K_:^VAI_'15%K7GWT;UIK[3V?IN#KLQ$T/7(+HJ?47QXXA+"\"^UQK7+
MAZJ>^] O+EYW)[!::(V?;YOMB^KCR;LJ?/OM$"!CE&V)G$0U9 U3G(3"TA#K
M1F_%DSU4\%=)51O$'IT6$=$Y30B*]I#0)>ELL_L$,E:<UJ,ZDO))PQ[>T! "
MB5 LCI=M%N3Q(Y)0T@ZI1_QER$B2A)@DD8RVKF8Z-O?XWN>IFM1T[$RX/P"!
M3F>MI+8 5 ,$,SN(,R*^)+\&F41,/(@=@@41!!(RM;](DF7NQIB0]<"CX)W>
M_#A^J*?>$&*=@10T(JNB&>>T:QU("E5S=>Z0Z*Y(LFTR_M@!^27Y'.(P!50T
M4%22D16,BBB(DAI=R/!\?QN0\7$CE@M_\M0YVK4%FJ^X8"<8?(=D%1@4BD%F
M,:DOOVN4J!J)VSXD2]Q9:T,0(93?5P0D4=^)@&%VO@3[2M4Y55(@QPXY!I)\
MQLR.O]TV:WL//A&XO$@@J1(>*FI4A(7.?!Q>BJ<X4"8":=7/&=5JY@_.^G^
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M:X=BDT$Z]XY-V  !?=EWBXP/!XM2/J'D&3^"4T>4AN\;)NT#GD>9.(]F@&N
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M.QYI2EGL5;[])L-'#@AI*#=M4K.WT5MQ'U6&8%<0^ ,X3(K#'KY@X7'9-1J
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M<LYT@"R@P]"?54S0AX6=DJF%?D_]="AG0L81]M5IZOG2K[[BR[)(994)21O
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MH*GB)E?5@0XR80C,:3 &#Y\-6#NAT<W"V!IQO<>OV3C"D8R_\)L)MRE>KR[
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M8>PKW[V\9.(9#27U[40FY\^8"EZUT*.] SRB%<H>G7)X*Y7LK=R#K=2T%]O
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MH2_U;=.PQ1UDO(J[Z.:&U) U@>?P;VVCDX=N5H>]6H)ANE-DCH$!^#0T>L/
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MJ5Y)&9=3I9E27'R#WK3EP-SPC8#KVX*5A%.7>@HD9M_I01+$Q<_@,W0TC2?
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M;!+53E[XJ&2U4U;20G%B?"A.-W"#72H&Q[)W@-*\G2N7=W?-QSOK8%C=O#M
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MB8%*IBZ._71UTW[Z&J%?28;556(4/[GJV8KPP!TA,6V5II=V<_1PVC1"@:D
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MA22AZ; L/2%<W&6E+&ZHTI'SGM;G\2N_VO9\7!VH)]U8IV2!FMV\ZY(JEZP
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MT9PB><O2M4A_"DOH6K__+?1J('I!FLB>D-KN,9])1<.*28M"Z(.KE8TYO7$
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MH^3/P;Q^25YX0RBLA7-CMII7XK::U_'0?+MQD<,QK_11]4<A!PD&2>C)DI2
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MN(2UQ?XA]AWR'E'^M? W]#O\UX\2IHXX[.[PYA!3ICV%9WE&GNU) _2D"WX
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M QZGPBNJ,3Q( ^P&DK(2R.[=Z)SP6_& )._>57"9'+4Z7#4,)'ES@1D,R4"
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M4;!IA)7,(21/0"@9D63KNRB"QDF%XJ((L6E\4'*(24ZNJGDB0<9Z0Y@B;+,
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MKN&.'/G([V)I4@6XQU,?Z^V)ZX/9N-VT5AWF&N[V$'$X/[FEQ&!"+;BCD_O
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M'CLZJ2G8FYF3:_W^,XXKDD)3 ? _#^4Q"NO=U$0\>VPQ[3,^3XH"XD19J\1
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MS]7"2PF1? 8'>]:NF9=9L(G^^:JB5Q/4;W>NX\.$MY*VS4N4(L"),IO$_+%
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MC>ZR>S%WE/I^(5PN%1ZH!IZ")>,9]"-?)[E_<[;S?8LHV^ELN.L-,1C ,*J
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MS!@'=W@L[P-SBF6RA7*?!RF;?MO?SDOJ?='2)SST.LC.0337DL\F\TNI28@
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M+MC3SQ4@UR^940SSOOQ&%!(1'[7HDBND,J>'[@M=3^')M&Z-;*.GMULP[=W
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M=#$RY,A0G(OO1Z.3PF%E&BY 8LQX1>8971>76Y>)0<5)15-;>UN=KX@K=JO
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M<]8F=$[I"^<3Y6CS*9>F45*>5YFJS,@5Y<\CFL([;!\&9E39G+D)*3N)JZ^
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M#D^FK4B;_X4OGMOWJT,_BD;O5(?W5VPR?\7_TS2P_X]%\'?U?P%02P,$%
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M#*X(("W$[AET-E4&(8*SFN">8D?USDL@F]814LB#\*C28(M)NCV:-4B[S==
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MB(C:K^^BXYTQI.E@CGS=L[6HM?KA5?F;,T\_>\QLWZH!.ACCU&Z#@XE#ODK
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M;.@3-R0&OUB8Y3]*;W'$WCQ-VD"2P404= TV+5^Y*U(USK<T4O6FIZ>=!58
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M=EI6@D<9J%ZO%<KAE?;!7A^H.]@=QD0IA:&EFS=T:'E??OPS3?Z;;XF:SD4
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M\PP>'CW)JI*1E+S[X!?)XW\I+06_8HDJ[LXV,E+X""LJ00H;I61WG F;V">
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MA#G"CKW?7 SK:T]+YHJ5AWK.]7HVMVYGDZ.>^?K,WT#N$A*4)Q;FW5W.' A
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MJX2V#KKM2.L*E:N/3T-^/1'YUR#']SG"3P")4,W!](_J_W.*E@4A'% 7LJG
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M)DD*VW%A$N>QN"'B/70=[DATQR[1*"<)=J-'\EU'PN$JS]9\3[#YC^Y+;>;
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M59FPF5]Y&[/O;SD =]FW7;PX_^EV>-LA3BD;=\T^VF,8"SS'("G<XE(%(HY
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MKZ46!C=&I=3=DJMOQQHV7R09K&ZX!)#Q&Z>R;V6,N#WX$C1K%<C U;3^K*2
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M8VZ)UU@^PVMJ:9 N1*V%"MQ _8GHS"_I)41J5[H2=Z?JAZ,I1\3*OCKWX_L
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MJ&E>B:P0XX[&+ XNA::'^0EJ$-RK9VK">D4$ZS%#"%L 6=L/DNQ0"9:II7!
MB3<]\=KO>0<?GO<VP/Y-3><#1T.'_02HF3[I1?@80&'?EUXA78?2I5N\R:_W
M$@\+L]H)])6P'U1>,,UD4-JH*4:FT&LQ=1/I+"0&+;"I-!U>&UD?2HX54S0Q
M)<(@F%#H->F[#MC9(.P.FEUX>UIKU)0)F27.Z!01H]@8$] AC8PF;N2TX0U:
MD>3NL5U]Z%CI5OF@KR:8GL6AI/BN Z,ZM7XB[:X%C%X!-_K8T=ST2(HZ\>#4
MCWES@V/,_KH?)$?@*^=T+>,5E"DH'%BZHA2Y.G(['6 *<5WIAT7\-+1#,2D4
M7.S2BJ>IMR*)#@(4A[X9)H.X3NQ=YYN8?40OY!"/1=-80*5[W<P'ZM4/4,1/
M&+1508_UC;)B"Z8\K%=RO'NK4%@E]0GRD"^IL^8@4DB_,Z^LL.97YA6M>$JM
M-;QI3A ZVP)XGX=>2;'GX>VR$F:0$UX5/@#Z/@'SD%2\YCQ^6%5<R4ZM>"U&
M;9CPW01= H^S\9N;_43F'FUYN@F'*S?W'>^%#SV;8#I-T@ ';KH2>F&"D)[!
MK&V8S1'2$O%U>)8",8*4JVE('8DH;Y ^\T/Y&J3P2@&P*%?3"A,\08<"Y1R,
M%G9#LYW(B;8!V@1C@'<E0EH2!@GZYBKM?W6^7RGDY:3^X9HY C/X'BLHI[T,
M2+N&#?A 4@5+O*#'V"#NZB#*!OGFC[ 9A )9(N=*.JL;+WJ$5YEM#@/MQ>T*
MA.;"^=:UD"]?K.(+6PY$AJ:&"-=8XO0FEL92*W)M8RVDRLAB3#26JZL^)_?B
M-6;0!"":<UJ6<ZU9&=)7V4 >THW$I^1^;.WX[+;R2:0V>I^(GSRV ]BNCV3E
M=*L+Q^-$ (<=FH0',EZ'A#^#LIU>*! !(;[>Y@?$?P MW&32H?#P+R7R-?ZB
M4?5CLD384* UHL]A;:;41,ZT[@&1'"?*T!3_F(QNM1PJRR7WP/%9;3#'#<*!
MU#;^)I*Y/R 5+K)S_41&U8*0  $S [8#O86+\;")/Z&TO9@8UY7E];@@9GHX
M -X8*O+--*&B]V*#D>NFL&NMM"!3#Y86M">Q@ZMV =9Y50L&W(D,,1:O9H*I
M2H;MP&\@UK,X7T;8[JU[!Q:06H%R5=!$LCFE=7,?;!<32RF91M$M<IXA8O=5
M*?7"BWD1K]G 'LG%B5')(H WLS2VDP'%@2O[!'A.I8<P<JQ!P$^2_P0=%86J
MPM9003')L@DP82,- VF;,"9$U;;%5@WH4A64TZE51<Q[9^JMGDJD7YMMZ6OC
MUU/;M)*B>3.+PEP5+^A.L5+X\FMES[_*-Q#=.-A5Y+TD:]#G+?EUZ\\,@,YY
MBS(BAG/R5 %)+5#B"G@DA8;,)YEA=G@1?<<[K?>S6PV=S[^]=@UKVVRG),@Z
M)3RK2S&D"%EZ\PXIGJ0&.LQ$B=)Q'"7,:P-8\?B,G3 T3=*JW;\\36VVUNQN
M4:RVF%Q:!KOTF9/-B7XGLW')9$T@]DM\(83JLE5NL]/NL,@NKSR(#A\"\IYH
M]5.J V;"I2?(?R/74?SI<0?('SQHFUKU2+]4RPJ8PIO$@$Z\YK6O?%$DKPNY
M,2C/&%(7TA):3<"L#,S/R]@*+$K\ L#-\?F!P_Q.E&$PV;(GTB!B8.ZJ64A$
M)9)U!%GPPE'%9I)[+0:XI7?(!GW[2-NADKZS6V_<P-D=9<>L++N=\4/MU;N;
M]"-3_Y\773=]!83"<5^QTTK"GE"_8!6%49K"'[$<&8DF6Q&H0O^O?+U/:;()
MR@XPG4N7)WO-3WU';J#\'3PG?Z5T[(G,9^N\=OW][G#/D57&Z^[:'47^:=Q_
M<WMDT?/;^BO,?)+-ALQP;FUZV+MIT>%_>#XI[3]S9'G)BE6; N#E=2%^]/SG
MP^7;:1?;]RM.Z,W**5RE]?>F_>='+3@T^3]IP3Z&0ONN0 PN_,=D-D5*2Z;F
MX)>D2O;I32K;\Y@OQX10IK_V*1"G?GFF=9'Z5:N<,F%/^^U_W?FWL2VMORCW
MU5R!D(53%0B'$[Y^OKDBU(^5?"6#V"@02H/_8HDXXWB_;_E3@D;/']]6VU6
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M_*/T*2-$=6_>V(3*DGVB7,U1NM*'=!&*DV(_D'G,E0Q<.EX]@FY ,#H$!15
M;^P"NO3/T5DXS6 C"X@:5#(<=+#A);$<#Z@F6*83O$':/=@P7*2E0PQ^>Q14
M"5XRK\A>76N8,2SGTZI_?YSMGA\J=2*A6OH66HP%FYN*IO2OY9<'9\>R<Z1N
M4[QLDYF);U/Z-ZF1_GXQ8.+I/@82.FX9:Q_C?.4;QZ4_,J82PSWYLKDU[D<\
M9"4842#BANDS7$"$' Z7!(+6,S)EE9>@::D;N5^!J,E**93E4@3/O%1GC4&F
MB,>.0:;I+[+X*O)>^<_XH>\^ (\UEVAK396;O2: 'GCH!G]])#^)K (T)%XU
M;SY4,'TP;-0CE;1#=G_9/,G_8 VQ 7,)3$9H.W;35-Y>*$NJ2A["JY'\Q;BA
M DDG4#:)K3>9&2F'"*[*[,OD9$<I"7#HX#L"=<BX2U??7.DR*SU8UH.8;9!3
M\514JR$.<<'\,S_II.I"-8B2J^E)-6']&K"^!/23%$*.P-QO4!A(<(<TQ)6X
MKNP!268)T4^,216HTU)L$UG.]DL^9L-(G9([YCMY9C/F5UXYG_M'_^!#*PDS
M*J@(]\D7J>P/#TAJ@%+$@N92D74E[.5%VZS;:'&T.GRB7(-D"Z7GDYQYI!.H
MY B\'KP7P'925#CB7*0K,)@34T(Z!VY^(LJIO$72%DP[1QM@U49>ESG_W!<1
M,QL]!_@)L^*;L=9=7#7X=T@F/0&O '63E!8I>&FK"V_*$1D]!*22*-DK$5#4
M<%<H>V1!WN +H=H;'=*85W*#O\VQ6_6@)^&AU@GCO,@<YP/G@4%JJ/A5)%V=
MF $0M9U&H=H2(@D.5.89%UA35HA1'86]>[""LOWR,:8*>BU8(E"=[8L"LCKY
M6@QEE0,ZD+4)3&%HJH>OCBS'  \$=%:NC#7Q!$/O6%'73)(/]UF^?>NSQ]%*
M_=8"X>'SV^0JTBIE?6H#L<@%YE #OM<<&Z <1/ 6Z"UH(E?S$)J'=Y*W0>)2
M8AS;=ORV G%Q_@%.@^0)J?@)N2H.0GZROFJZY=LP,39)XA%5_[A5#?#-]W]!
M).#!WWHX$@7BI7P]I=U>^;Y0:C=H2=*355,":$G727J >4FG I'"6T)VYFXV
M-&[#:EK4C<2ZXPTAJN? IS[+')Q:X&"#.TBL]<J0$%"K@A\4)XI^6-J%,&O+
M?V1 _D!4^]BFAQ+'9M!A%@NX3)^%].A*- U<F$,R[V(#L".4#K)>_U>FH'!L
MW</CD#U- ]X1+K4*'C_20S*NQ%FV'@*^EHN4+BQ<_SZ>D1@?R4W2'GFRXV_0
M8X8!($6J'5BEFJ@NA YS.HP0O3!6.::69XV_2R!R.S$KEM=2R4D_P0PT-Q'C
M6-CT]<3Q4WVX&9Z0B'8&HBX,-FN7>T%5<^?[279BNRO\3J_VAZR58I]^"P%"
M_JQY@[+$2%D<9@<).2C'$E4EU= !$3\N;PO(C9/K031.M'52E86E K$.^B[2
M2HI@JA,-6+Z_]!FX4#N]#,=3(UL(OS6\MXATUN<Y]U=:;!^HG,LY6=O*K%_$
MIU/J5-MI0]P3/0MSZ;3UEA3$$/2P4TN(5?<<\YKV&D\FX46!$2.CP=^/ :%W
M89,BY8'U1?7/=ZO_-H ^6C%")!P90/X*?,U2'G%WZ>;TDC'\<7B1TGX HT.Z
M^+*/>=4PM,W74O808T8>5!(,^JA4=YJ\ZR^(J8R3 4HK9+W]=Y7-K'0KE-:T
M+3\%#I6ZP7: /3-,G*[5863='R)?171KMSU4!U"2ZYCJ#<E6W7C'EU2O'J8R
M!@=A[_+U%FC#ZA(_61DE( =_3XX"^3.3^>0>.:()\@2Y;",41!"&&D#&DH>U
MT+&EXH9"V U LD+3HGEWX%A!;I2 %K_C93C ZM)W2(;WT8EBEL>-"8_LW(Q7
MP2L^.$NORSD]RTN=-)OKSFX#"MQ K5G#9T1*%V5%!%,+2L!I=X.A':V[!CD)
M\Z':T)Y03<^I^FQ:8A%/+V+6P2LFR7)VY>4:8H+X5,.E?2!>&?=<^4-LGH0"
M#8$< 3*]V41ZW ?>V"?7)NC/W9VW(W@!D=V+B?*]L&./' D=[JJW34QJWG[-
M"J4")<X:;>]'FXAIFA-+"L0]M%NXT-G#N<_JU?:[(F_\=EG&<GC':F/]^2ED
M=7"6VSF7N%31Z#$3(_T5_H5G-:<!!9SK^](C1\M[:?4-R=BKJ(W3F%6 17FH
M18X"H>;6/MR0QL!J$?''>6@?(V9I$/G_8NU?PYJXUC]N/!85 2$""@)":CU0
MBY JI\HA4VL5#[5IBXJ"D%JJG,34 A)EF%%.$1%3MUMI84NJ"*@(J0)2(2:0
M!%(WU<BYA$J2R6X1 3.SA;"VF0S_X7?]GQ?/^^<=5[C((NN^[^_]^6:M6<L'
M-Y=)QGNC(I_5VG:^M25=1.81@B5$-O\)'P6/\+9.EBNR'OD-:FR9G,@Q\ETI
M&IZ;8Z9L;PMT6)*"J<WX#+PP:DJT3\>ZH*+R^+(.L1VYHW>*WQ !T4JX^"SL
MH><M^S/@6LG=V+T9V$=GH5L>Z:/A3^I=,WNCLOP?I,?7'#@TND31\#?CT?[P
MT%5NC(<[;-LYZ^BR*D8TH?-W8!<TZJ%2TM?R<:1(;1IFZZ\]3C'L38KIS:R(
M#S3?MM;"+$OP^/P-'H%8G6GIX61H&1QHF.+R"#=)[2N9[:]#4C^L-$KA+EO%
M79'BGV6]D_(:=8*CB37&2R++]JW$MO8PH0):G(JZ(6S8%X0'02.QH2H:SSQZ
MI]/8"YX2&?$],\"-NS1U= /QEMPUB'C<.O"+=@)RF$*\P1\CRPG/QVJES-YZ
M17[<3OXM=]AB_@Q<02WL\7+V9+U1!-;_CC)I#3!ULMR#PT7G*7MK,9HLSM<M
M@[/H\G =]UD+,GX>URV-V&ID%HJ7-)4P;<EU^%MX6V\ZM3K^E7Q$OG)*&AH@
M/OG- E,?VK$-I=%7P-I#H&IQ"6\IPAP5"+M832:AU._G.* \"$396+VK.08,
MUY.>X#+FS1!D=+B=>5:?;4BYE_D8Q1+.U8(3K_F%!"^MN"[U3&T1R6H0R* =
M@S32Y\O<"'?53U(>X6I@"SG+X!!K)<>)ZGDK[-I";4R..;-=?4X6*&C$>$52
M=CWG<DIM<Q/B.*A1]E]I]PGL)?<VJ F__8-K<5-14)2\SU"V[W]QYBQK$>=]
MD@6:\1(UM8:(4M9S]X#3!AW8N/CRG;CD,MG[C_IKYX\Q*Z!&$1OK'<296UU3
M9? /&;Z)B\]&^-]^R7-=.GO@2HILXZ.'?=* 2G;/4?'A_#&V(]K!1I/93B03
MM\WS1]; [JQELN54)X1'\0L25OS:7TN\OJ]GN9 P_>8\I#<APGI3NKT6/ O&
M*ROJM; +N!-2;1 M>3FZL6]C,]LKN33KKJ!FPF"H4+8B)1B#^?PIG[)?;7$1
M)"DJW8F68GFR;J$@2>G#OM+979-*ZZ\T[0:G+%WO^+U&F;!E0)I1DUKIVCS(
M<0,9"D]S56T*\AX1T^D8VD%Y])X(=O!M'3C@</X_)RP&EOI_R ;RM/479+'8
M=M?/?R)/Z Q&'$@H%Y[(W\?W.3Q_W2=L0_1-$>-VU8=015 $Y%M*MZ;E;CQM
MY;MA$C/?_*OT09ID\J7\(^B$:=B5LF=;DLG( 7++2<)&GSV_["1NS)Y:@R>J
MY MA7\M^:@BUHU:0''".B)P,TA3)W6;F&-[D!R"F"JC-G?D[\* S0P7P(;P*
MDQ<@+N3ZHHGX]*\T':/K&SWK+]7/<B=[+!$"I5ZBEHR$8I+B8-/25[&L*9:1
MAHRZSDJ'9IQL;>YJO'&0=+=>Y;C!=L1:Q+=E("@]0.'U-*JSTG8@&&5VWM*E
M/N?^?/@/S1UN]2LNYZ<3"\;DSI#^MO@^I#05>;9T3G!+JC!^7A/K(FNQS'XB
M5+R$W(2AJ[K3,>XER.6>S$.PC=>8%A\PJ%0EO',) &'<E2[$K3_XL9>JG'N.
MC*^&P\1=LH\>]$E7W[5<NVSY!OD]5M/YU$:_7DQ4*#?3WO2SV"/X'.-L0],<
M8T5*V,.JVVD\QWID<PKB[EZN%F9.N?2IA\1V$G]J;:TR=]N^1G#./7\M-2)6
M;HI5K_']6UZ$?LW5:I2ZQJ$N4X&6AJ5VOE#K2GYA/2?SIUFX<7$I,6$TJ<3#
M<D-9"6V7YQC:$B6O2=B93(8:3>=YB]\%/^%K#.*I994.>%*!-!#G=O@X ;$>
M/1OCLS*LK'"MO*^Y^X5+'U]-TY)NJI[(,3\'/&)(K7.5L29X2V4^U!^ZQ6B*
MG)D<2/6A32HSBTGY""#]1SCK I0D85"_G](YP5LL6])BK<+.^*C.T= >NI5R
M/1.B"%=U+*_8L?).%1E^N:;QO,V4W(&&I$_DWT >0-*%..*:J4UX7_2 S$?
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M(_\3*D5@K?R2U,Y _Z/^_?>D"XRYD )9:&V>Y@WKC+H+Z'')2';"8)#<F1I
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M?#_^=:B)-YQ"^0FN&'CGFJ)K2 A_6M@J2%268#NICI#[)^M&T\*ZVD[>.7O
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MXF;N!<3Q%R#.P>IT3LFC[#YIJ&W>B69!\YN&5S)WPB=?DMP:=\C_[T>UJ>;
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M/@L>8R);FK7 B(&]8$*V#J!$X&=@#^&@#+M6@IW"H4L;I8%&>=&H$W[]]W^
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M&!I!NM4^CM9R>DJSMQ.O\_$V8\L41#2:CQ+K'Q';.A(@W/V\U+&>] 6)EB]
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MZ+\=MYV8[/YR[[VU<1J'KYSWBJ[G/:3M65&V;2?PBX3R_?IR19WO)>H>VQ[
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M05MQY>0V[/.HV+8HQ(9T@=CST\H2Z<N(E%XI<=RH\\"IJ-+5:R8G4M.1GX*
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M87VYWR]\><^6W=H/-AS[^U_T;-8&N&TW?(R17>8NZ?#>9JFE*,H/MD^>HWE
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M?>HVPR<_-'^]?7OZ]AO S;+EE@KX!"5)2)]ZE*.4:GWU@ IP3_&VJL.KCB'
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MN-TW7UV/2-]0S2H\?I=\A(O(G8.ZF3]!BY>+P&-^*V6.IO\91'6*AB;"J<3
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MBG9Z%L>>(7>!]J"A<[2L%WWRML"0CNH:@HD6<T=7EAG9K/5?VF<9FPC7]#:
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M ="G^*!QRI>TR3B%N<*XSZ!2]_P PE%JEAP6='D4M6I6\.=H"*-@CM; ]#<
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MO@X]-$=[;D28.IL&>$4<=&% L +B=)$.?-''EKN0ISF8B,6 R7*D<)U1.?X
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MI6DFGM0E$"'K=#__#+-MM D;'3&(FJ^<1"]T:N\(Y2T2C*J@#;=%]^,Y:?5
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MU<7A <=.ZBM61:OOW1N;I628GE,-.5,V_S[ +?@$'9/EP6ISI_5[Z9%92H'
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M)1-YWNV/%(=\0SRGW6LY@'CM_0-L_CIDR@4]Z\\LO[/3$(1^U49S/'X=.YL
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MZ;K8)F85A1;G-Z=^BA_ W N%Q["\9MZ:%H83RNM*3-+,1/;C91RPAM?=Q.I
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M0S4T3$;2%2HO$'? 6D%^HE49N3,%3/W'7$2OG>3I:N,SHPZA=GSQ3IW1N'P
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M+B?G;8G=1(&_[Y;0;[.^C/IHQ1?9:PX=](E<OV!)[M)=AV<*F\/WYNA9#B^
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MR^U:(_6V&QZ"3_1<^I_)/- X+,#'$?/XRIQKK:B79@PRS/C_)@!02P,$%
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M XLOF:!#.T,G/6'K7A7686^=C+WVJ4G> <-'9!6NUP\_/X@G>?-:N+YJ?XJ
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MB":&5/?H'JX $><\NBM+BNX+5*..ST>WW>\J;:SW&CX"F3\/KNDC>4/G.AZ
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MJ?A76LP]A[<9%8F;_CIP]:V2Z?2GR/W22XR-IYIVGES(YM6&3O_KTC ;(CW
M)E*M5-*Q<%.Z0?'._SN5@?A[9;!??'D'3,8=K@Z^E4-;_N'IQ[YHW(\3ZD-*
M373TW'H?TL^W$-L>_L=X:A^/<'UK<_/IU@?;G__[#O_"-1BB;+*M^N;]=52Q
MX"04[FXVK;$C3A@Z#=W, VE/0%[X+.(N9FKQSUW 4@2+H";#?@Q5!(B P^<I
MS$\HP5&$4RGLCADT[A "VIIEZ5!:O13UI@]LM,;RIR5%@)1))Q8UHJXGG(/9
MN9O^V++A_VKZT^_3#J@_?7IJVJX4CG%7\$ES Y(P/.O-,!N#E."$:SL.O5UX
M0S=T*Z;X80KB 8Q:<N"8'-'WAU.3$PR:MD-5,*9Y-D'[3C[3J_5*=L*08>09
M-3Z<1Z!;1> WH0@,.Q$PO^8SW"<LZ*3]\[&Q V$?82-<@+N_1C\F)*@0 966
MPOMP;!WNH7SGS+;GY6>3/=?C4)UP=,XHOH/A$]R6L]>!O]UD73BF9_EI4RJ:
M ^<3H?@5.$J_Z?3WFV0S2R):O<5W1/W^")/?;_*XDNR[Z?W_'E_%)S4KXZVF
M3-9,N'^%:Y,@9T'^+.<@!>J\1.]WTT^6GN=Z4;[ \7Y^O+6BKO> "P+__E'U
MO[Z18A@Q+%SJ_)/'HH5CG>;;D2?/K#=7(,VOL/BAY)T9,7JD&6GB#X'+JJP"
M^Z3W:9$KX"1^>,=/'RJ&[9!9\\/,O4WUV$^FUOJ_<-/*JH\8YF1V""RNH :Z
M4%\?H& 9KS\SZV11!7>N4,:[4#,'!S,UK[XUH6FKY)3^0NWUZ7._.(S=0M@?
M/S'R=>^EG%_\]G7MQ8!_V?&HM7(LV:*,--IJ#K/PKR39"\ZX[8<S9NJ]3,^"
M!0GYKX(D_"((9N\VQ!NXK6FT'OBN@;,/.Q?X^3&RRG(;/3\=ML6_7%<O<2')
MR-@1>',B(!'6*74=;,I"M=^D>6F@#*6=%0'9).'SZ%?;KC8XSG4LYX>J+.A8
M]H>.K<[O^B5H,HM>:S6MD)]ZDKN@![,?>K"ZE+/ Z>/OXA<,+^PGK7HPM^L*
M^(^ +Z%ODND3OM]A4YP<3WORB- )+U&_]E,EZ#?_59C-<,V#9<1:?)=F^KLT
MH/#C2-IOLF0P?S\Q>NM>1]-+05RM2OS%RY+_P\L,+1/O'E>361_TFV5@'T/]
MZV.E"V=*MS_-G2C^59YD!KQ&]NU/2D'Q!]*'-R=S8%_]Z62PXTQA(-4BA#>$
M^R;/I-L4^"I*^/' W[.HE6XV]?0R94A-;Z\(2*J8FCLE JZ".;:T3BX/+C _
MDTAR.65JE]OWXZD=9%7V>A+=4'K\7&N*ZZY,<D#"V4)4F$!],$43QTE2% <O
M8GZ+U(A?(]7>-ZU&4MSA/DW-ZD)[8.;0_>LWNP]=*"D*/Y]F%#V:*Q<L GQS
MJL[Q0/:M"II4<EQ^&KD@7N%2F8?#Z?*@'>2&04;<Z4L63>2:BE9ON8^^J,Z.
MWQ/1;\^VV;OPGP,<E=BI-WW?^94VSQ1VLCY[Q!#^B-T^6N:(V*\Z4\.V)CU
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MRUA(!NC&= $R)NZH['&MM;O_D.+LNI1#YLX*5@S#EGS#7/I>]>2VZ3:)G[[
MGL#'QTRDVG(D<Y.N9_ZZ&,)G*^*G[\D:WEDH<I%.W,(P<)^7^0(99=[X>% K
MWE=%3/?C:_8S?2E[5=N9V#>2021UL<UDYJTA?)UH?]G$ ;QUP>2Y2RWY?;CD
M>>_\P'L1K;.QJA*XQZ\UG'!CO\(,M==TQR.;-)Z+G6QD3XWJ= VG%3K+DH:
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MNQN5&!9(@>,4AV+R,WS,WK\,34OB4,YVZFF&IV)GQ$^TJJP(<YFWHJ6 )F7
M_RQ.^YVKDI%M_A[6A5H>\<G+Y<DBV]>JM@[A'.5CI542V[1Z#OB0+TOT #C2
MJ/A!+V@P5X8;K<O7^^B/CV,>7]<2JGJ/Y1[.W)&T.7,_*4D=^%A=& %L,Z3?
MMUO*:$MQRW5H=K^Y>PO@>TF60L$?_/PP:2K3=',I. @+>GKV..P6ZS]X8HC^
M?RZ@MRF*K,A1HO<MV@DQ'.&6*L7U4A37I,F6/ @_TKU WXI>BZTJ?F0Q2T92
M8RAS]NZNOTI_%VGPUCEVXIWT4H<7".??E_H:>%<(UU#!EH4/F"=@T#%FG)8L
M9E*V-/T\TVTU_!BN!*-D]:5\0U#CF3ZMI,S>S\+$'COFK:,8.4R7%C:'IYB=
MG\'KO"+$?)I)UJ*HYIGK^7V[^V[SYD'$$IZB,5.8:D2[ QI1OT@)&:Z7+N-*
MSW=9_))\_4$ARW<UR1NR SEL[^SU2 G'6,@J]:2#36;(WNE&"C?^Z!4!':*6
MRKYK0@3(?D4P8\%5"_N-Q6?B)<BA0(J)<,73)0-PL[.Q%2,3;"QF94H3;A$>
M(;_(8=.DEGG@K8YY?251C1<1=BT/1U11D:DSO?,+7E2(33@!29!G@1-EB_RL
M2.(Z_/D88#6UC(,H]]QXI[31TPEBZ!:W6?.;(EL@!\ ,$H($"0A473!D]4I&
MCA=&+*!T9CX)7@=TEC-NO.B6/N4.L@7/&:C 8F0/-IPQAY60]XV#0[<H#GT3
MM[O-U1BHRC+9QR.QA_VB)4\A5S("W,J:EU:+D U+=I4CZRCW0P:;*DJ]1QZL
M6]?JA.JLN R.^V)0<VZV3P&QWT14% 0B#OA.P^^8J>6F277:71O5@J2:9H4I
M^3[6YISY&S=<VW#   IJDFUY>]OV6SWFY([*87U""#'<:S@<&D .<4)R-$#%
M5&I1/GP=SM:&M[W88&K[)_-T9#,HP]AN7C0-=5_[!LAKZ(6G]+ANE?H&WPR\
MN7?@U?C(CKOC4^:KSWD_$6"9$^1!\)B820GDA3:;/9+ECW5]0@=B#!E'-9,O
M(#7IQ8,"/XFD'0ZP"ADTT44$!*Q?^ 4 ]=E<NFR%>YKD5J149 "VY,MA2/2G
M#?[O4W_AJ<7+R-F7!] >0B0F&5FZQX(!$*'0Q.'36#F.8%6^*/=<J,Q^=D=0
MX=JC[%ISQ#$4U!(Q>XD%_WIJ.L3X[(=)2PI63@U1^QFB?4F?M%/0,=EB=8$U
MC=V&E?"= ^6P1LXNGQV ;_)EIBQEACEI^/6<9_CPO+.J  O$C8JG%Q7 ;:X1
MP(2J*IR;@S> @LG7B53@=%;S,8W8-_AMZ(\UA=MPL>+VL>390</T]DHQDMB*
M''L N?E?"N+S?$-VFZ4;NWK=W6#3.E.H$0-?_$)CH:4W=19#__%8E>7'2K\_
M=E(.R]LZ^VDF3+(-(@L,_A[)-P52N3H8]WK@I!Q&9<IA[N&JT@E\8I 8$80C
MHCA.2M( WGKBM@[#?.0QL+6ZXV5I1/\YU)R B>;5QU T:#PIITYG(0S<9O^O
MFFJ_US2=?*EU#?#9M'UW11ER;%+LE6K.,P-\@EW?A)T+5Z^ZN\%XZYUV> @^
MBKQYF<@B0DI-FO25+SNOR^849,93>]]8YKA1(?X&1[Z3!BZ%R6%K"QO@"QMC
M2**+Q)U0QP8$9@EF%9<4-"1Z65(9TH"Z'W^Q$]QO[;OW_9\'4E6B"_!C+$.6
MF?9<D!C0W%\ZBJ9P9$O#%@_H8D$B* J18;YW'&5IU5YMZ2^%Z^6P+P?W=XRL
M=AMN.4$"3Z$NIU[,HIM28HG.=*D$H@GXLV,#4(N5L81-Q->XM&$@HD,'4^US
MDUIU"=R%"P7Q6^KVW5P_10A+"-86TEL+]=@@#HK#^ M$Y\_ _'LH+-"LM$2^
MPQPQUX9/B4E5Z"@KC%@:Z+8#)EW0+6,]QPRJ3N.?1RA]#%;G492LS#],1%.M
M@*K=@0OTMY0[G*M<W[X^((,@NA(GVD^! 9ZLF<XP%]Y*Y&0AF+D&.?:(L&LL
MW;L8,69QPXTN23X^5&21*GWO_UU@=23US<+?1-D"_EHN"*&MN2EJ9>?$7JS,
MB5VF3V@*9+6]:!3O>F[^E,O/W1V@T*&*X<*?J;8PAE"R9Z#@J?5+]"(TOF^.
M@VRN_4LZ5WBL&*=OJ+,.M>Y"46FHKC%.7=:4C)29:[Q"L@H^+I]%H;["]/.\
M?@3MQP/2'X92%([5=0&56+PE&[CF4^)$2)JM9;/ #+B[E",-;/L*MN[/<*56
M9HDH$I,F>%]V;K^SPP2W(:O?S+&NHK'4JI>?1A6R^-2/PAVO<XDG=_%/\G)=
M>VFH8O+;/_JG%=42AX01OK]]*PHW6I-B(I/0::,U-34-CM1?1"J>(X5PU$AB
MMYZN5C)&&2BQ6NLGAT5C&)\I2 DQ,,33T-_QUN_TYUS(^JZ%KJO3:32&<V-=
MK625&3[*[BT"#]E'%Q\X-@B"8LB6\U.NI3OZ"O0+ N2PG:[>)O9QTZD!E"L1
MV($I*OHY!2G< G\"X=)"W_'4>$K)G_Z?^?058-OMD M?7+Q2U6L8GNU2],9R
MSW$GS0]1R5<=+/1E,BYD],+I#*[KVRC\CB%@%\XM<#*KA*?]//78=M;U<L;9
MH7F@'5-9K2UDB4SDL!_M@_\Z\W_W#V';&_2 A1):%K\0SZ6%U5J.K*O3=^FP
M,+C%W_L0H1;Q464TU*14-A],J@,)8!"+&>]K)2-;''0/'L+8.O:./ JMKU#,
M:LB9LFMA,[5;1FM9L_519+6ZE.7Y_I^M3$=<-]$\59!1\,V%^/,W\V6QYJ*
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M;6%\_A+$"\UI;7%8EFQ),.<]::6Y(MDS5FHD>^8G-9"]?-&'2^5(-"YR8W&
MTUU;0Q:P-OA## F*H:ZRO=^_MVZ(U8NUX3HWA\^==[#F!*A>-$(BUBGNY1A?
M0OE%FT#CZITQQ(1%(_:OO^<% /],"WAGMYEMIJ[GI6;)<Q_2K6S,M[U J^Q&
M%GMV&P(SNG:F"U\#5^OK5M:DS0!5A\RIS7+8C2)@.-GO@%_@23_\4<)/G7T)
MCW(=G*W]2 +S%.,N]<@0X),'@8(<D"S.G>_:-?'PYRU)?%84T@.CT&C7=\0G
M9'"POR$XFSF])7A?=)[E-W%;#.5M]"&-5T#Q>2^@U .AVE&KC\&.Y$XNJJKU
MVY77=GI66!&L]>6P;V,LMA@.^5W9_>^GJ+2O/;.<!(#<2-S4CS?MI/9NS[T)
MV0B7Y)T*[[781]F;C&BA#85.?UE>UBHHA?T?9!E\RSW^5L8_I&H,1(\F*]8#
M*_JF[96)E)S!@1;WVXFY+[6*.!M3)<(QW3#B6)#QS?LUBF_U5QW-;,YLOA8H
MN(!ST.[SL&AP%ZRDRXK]"$0?[B7$)NGO#.)>_/'N,DOXF>+.&[1*-?K97K<M
M0/I;RO78/@\9O[5.:90RBDZM;CW_3@[;M@#<CVM)GPIA9@V3+?<S3E>F#JNI
M?'9"MO@;QN%+C=KAR%@Y3(M.N;'T)/5!H.0WT0G?T.EK<0YWVV:<:+WYB]8)
M.\<C/^V_%9V2;3)WGBW(Y_PH->8VUUO^$MB>%JJR;S8MPK[Z3?"V/?>H",\%
MYN(0^ .7TR12YSX/$4KW[EA;O=@VX2)3[\VJ/LP?H/6E"%^:F"OA^^6PKV)C
M/QPP[!D%>:A>1KV:6E5[H*X=0>%"A#/Z:&?YZKGTSBOWKS.CYA'-KE5[-*H5
M!^^)]ZWHT! 9#+6&6G$;O/F7C0IB2 *503-Q0ZW>\."N+]*)SU' T+9]HAW#
M+8'DE(L9790+;[K4NQY-3QU*BCV);XPQQ/.VMV2B* ./>Q)]JX'&*E =9\Q^
M!^[JK%4=WNDNAUEW=/AZ#??N&;RA="1NQHIY!?L$SI$M?%T\S7A'VU:&@9\J
MZ=2K=2OPWJ)J/'W!5M5E:V??V,R@]LGK0:C'^?38.?*R<IY)!BRDC%+*"L<L
M!!\H$[%+GAS375GOZ;_^<3VW7@(\N'([AU::]2Z4=H>Z@=PP/SV9UZ\29KAF
M0^7C!#E,3Y%70Y7>,!]8+(00RSW];WN%T19>-\H?W6)VS\]OK8AI;%BYWR]P
MY]JZ,I8W(2:!> LY=SY%#@-&"VU%SNFB+&M1]+??%C7RG46!GY&]/7VM(PCC
M:Q9OW*V ."\6&YG H;&MWB_!!-_/^,+^9\+ CO]%!MKM^%;[X ];OY^+=1QF
MS::U\&DMPE_,]KWX,4>$'=& ^)R*U&0HS7WW9,%$Y5*82Q(51_PL:"GUE!"#
M0%.[W'OE<EC<>Y&K'':U@":'I94MC38"*UF*/,J%=FM;E\W3/WT_>>M<Q_6'
M7WYLMTY>7OG6\FK]UX%<YZ[?A['_8Q]RSO^FBB>Y_ZDSSXT:>:T^.-HQ<5N;
MJ+FQF[GY"S;0J2SXYPH49S= F&9$4F^=2CW98?B5<BNGSL"F^X#T<(;CE"/A
MH_/7@<R%5+/0GA.91TV_JZ^46&7\YT%8[AE_/19+9$MZC[6\$)M?=R'VS97;
M/N=B<^H<H5_@V[>O%K?9+&[#*FU!_&WU6G@/Z)RB+/(A^GNN7#./MEH.R^Y"
M3K/E,*\,'VL7/]"@ /[#OU56-_^'(LR'?RO"I#YM\Y[\73EU>5%^00Y;A&XN
M[3EJZ<_\VX7@>*)!0>+;<\MJ!%DY!MV/USS]MR3!BF?_(TGPCYVMGO_46X6%
M<,++5[JNGX2_>2.'D7X#QAX ?]CE^NS+K_SX!BEHFBH,!T8=.I#?567L:-Q_
MK'EO!<KV#((YWY"+31 0Y9VGE2F!N,MR&"NAX.A(8I2^U!P>SJS_]D%RO<[3
M$_DQ"Z]/"R'&SR\@X;4W?8=4S#?8-R%.5%ML!=4Q=K]=09<=-6JCC#H36J,F
MV<Y'H'@SC\T^(#DJ.8QDA]-E8A]D6>(_'U^8VC^B1\N0ZHM:$4DC63S+RH@#
MJ@O 5G,G\]('2-,G*1KSSL/$PE(XL@UQ_I*Q'*9F@1ZB*$Z>%9_!/=]@3'"W
MJ^LL_W#C>LS6V@CX+[LP/Y]T%J!H(J\5D[39E7)8J@E2.#:I=/8$Q'/MX<*Q
MZ3'];<3.Y/>E(QNP)SKZ3W6L(A5,0IPC>?9E1>H@A]GM476 ',<^*E65PX8"
M<].(7Y2;NE^JY1]\V/\Y(5J@XE0GJ&D/Q/"/2!"XZQ)E,\+GS(^P)7>)-?"/
M#W/]=Z738W6A@C<\O;#AK:GLW[^\X.UMK+C>ICB[*ZL\L*K4Y-=WXYKF4O:^
M\W-^H*XL=\I)H<I7):CZF&W"(XM.='6^U$'F]0.M;W]ET!-_RM+(P@0VP=M8
M;/ 2BKD6:ZO^FPF3^OO["OB/_U,D0N<]N$=ZI$CD)/D=I]$4Q/T4B,WR,HLG
M._4]_$#W-ZJ@R[0 R5Q=+/6\K"!]7NKT"NCYOA6AYUY#PS:GK]VBC:>.>P][
M^[\5HD58RAHH,-;D@6?D,%X T( 7G0?#9]WG(R$&:_\96+<@R>5$(GZAMDN1
MV!'5V_T7&&X1I@N=M;)/XGZ&)U=C!IU:L\%_B!89:.E[OO8+V*/W ..?_R#I
MP%[63R\K*JQ?HI9/[AA$]O<Z=;T=>^K3]GQHP53]P?ON2 NM4$^I2?,]Z,V<
MNX%]@&@,SF6I;9'#7@9=@F@'4GJKEER/7#6#_ZUO56XP!DPYQ'1L];5@^=S%
M+)WJV3<I>;J\)ZNJ#MG/<O$>_CJC+EKQVJ>D-:O/AU0@>Z0W5\:IL&@1Z()'
M$,WS1.!;UFZU2\B[6_2G';[B_1$9<EB$F$N1K:NF@X?EL)&)OY6GWZ?)4A=.
M6AP6^%9VI76,=X^7E%+:T MD0X8:.P1!I[#1M,MM&=S2XV'UV!%+1,/E+K K
MP[NR:"(A<3_;B9"AQ3*@Q?%?62 '0#/@_$?SDXCR9_#C4/OB;,'P5D\Y[&>H
MO3\NJ_%!6._(7"GD,J 6"-XF;$ K^MI7YS]Z>@[G?KSF08.;7HNU&WE6DY.D
MRH H,]&5L[PE3L()1ZATE*FT^IXIZEY@5S(R:PD_3O&V3!K[K/&+X8S*FJU8
M0N3=5[]=SA)KNG8?A,!JZ+(^W3V2ZT9?;5#ZS\KQVM\K)Z5#K4VU%(4-/\,K
M\0P<N6.UK4&^[MF$)$T*IQJH=&G]!FS V3>I(;HMM#.\!$+EF >$X$!_K12,
M[%E"M[?R'D=I%.>6A 5\B,^_3-/-FAEKT3E5OW/ ;^!;*S>U:EF%<%A_:8<1
M10IQ].9ED6T1-Q&[<1HI5EBVLR@?8 7>--/'OMH^)>>RL^5XN2\F0.O8R7,=
MO7KG0_S$0DZO=%LTM_08=[QX"%CKXC,1;4F/T<VK;2RS3AVS>"K[))TL1G*J
M*=EC_I&&&GO&[C?7XTN>+-@O?S'M/\P+H0295^@E*33\OL6/G<.A3^UP4:MX
MPQVGP._=N-K#<NKZZ:[V5RDY.U9!@N::^1T[QH)"Q*ULQ4B$\IOV -VU<IA$
MCW6&.\:,-XD:C_@CD8KJ73Z0F58U9EY/$[)LV()=GO,G.RX60PT>DIHON25R
M.G.R0@0XH+*0(7!0K\1#5E)KH"U]6^XJF5(69XW<"^DFCZB\#G3=T"^ZL1JK
MYU9ZTK"SPNH8 '7S)X_>4K88E-UD^10"&YY>\;1*W6PQU9NIIS2*J(L3O.6.
M4O@KNVB<-[Y/1/&2DUZIOW'CY^*],WPVH6Z1MU@+_ K)8 \X"/>%G$W-_K'?
M;/S9O[&3KOZBEL9-&^EB-Z38NG-JVF^XRK1ZY#!/M&!ZFJ#C4,I;15Z5D360
M/QC_$6O]K9!.*K=_C?])%)XO IK.>-N=H69DL&B<? #J551LZ><BPZE"C&)4
MCWY3FW[OJ27)]W!6^!3Q(N2O<K3=9O\W>=I[;Z1_UX3KUF[L+U3Z*EKA4L6]
M>,\L\?YP!2NSCR[4 I://<?WCZ#[5KP/:AT>-'E7G9"5[>OO7=W0ZAXX;"CQ
MG>KV/Q)]S7\MXI.'3- <0* T4RO9HP:C"$K(_=K(;YY-==@&B G6'LT7N<QW
M,!JI:A(30=X..Z5347,3I+7F,U9B%D>ZV(X_QVM<0H?C;Z?NHL; MXI";<EG
M'KM\;3V@HZP%TO8@94(G_JU=\RG-AOZN%M,4>/DC;1=NIPDVR.U5/PYKS5M5
MF>TP630@%<:)S>&AF1^"Y+";JB @T/D"JHG(C2&%3?#H5#7>3ZUY L<-;12!
M8E%_L+EZ5?CX5SD,"7&ZV>[GX_BLEWRTC;B=YD5P'QYD1V.HZD[.AT>V5J%G
M"A4S2(F^_KY&[-[\@I>U*,XA_"0M!&L%KOU"D^722@-8%<@[Y1L2^BSZNC-V
M"Y'70[W<ZB0J,U8H/D! C"^ 8YZS5W?'(9+^(IK$KY3J3[[D;<P>'BVJ^5*(
MJ75+GXQ>&:?=5SB;F:3.KTV,'*T .&DU<MB;1<H0K<^@R7$\?GB#>^/V[69^
M0@%S;W6H@WZ[H?AE49(2GF&AQYT1@\M+F<W%OUW[C9_RQ\,JQ33F:[K+#G?)
M)<OWV</Y>L*W(>4%V=F7)I?"90]O\%%N&T;G$EBWX)11%(?6\I7""ND,^Y;"
MCJ9NQI_@;2A83MWJB<*;>.(@@N(8)^ZQ8VCJ<64YJM&E<P1ZBBKB6YVKQ>I1
MR],04L./L\IOOTQC9;15OO*YO01(]U2CIAQ8#K)DWQ2;^>D69@P4#MNIP!SP
M5L?=3I9S8"%_QV%:#7>A" WXCPY,,@:JG8]0,!*3YU%</)<C;F>U,"FS4HB<
M%AF,/9D=:&_%9440#:?5?A.]&PY=IZ/ P*L#F,)7UIH?.$2!_]&-,K)) Y\C
M1O87_-(CN-<]"Z%*G=P-1R\F(W]"%!O'N8%W)(^L&2V1+>5BD[K/)GJ@/Z>W
M&'$L7U:V7HQ^#6%47% 3[6&?L('RH-KY+B$.W/0U %TQO<5:D>['=[8L,\""
M(\@XFBPRC[,"[*3T&>#.6W4:VM;97JAB!"25/[)YOZ,78S2*N+T0OIEQ%8"W
MD4VDY"G+O*,)GAU_1Z=X0B&QR[$0"L/#3KAQYRW.!O6I/]MF;VG2>YF,L>F9
M*1#TLSR73#@56.!-M)!95SF"?&AQ5@Y;MVZ8<\<PE(S<,*6F64KKU#>"[]67
M4DHU32.V$J+F."8L<(3P<207B9^(?!MBL7@BA">'[00[[)@K>&21_9FB2,?J
MBM+:X,*\&T2@K/^2Y;?T+S.]&Q?0G!KIY+Q?7IV)X 7Y4E5)^PC7HUV4=HY\
M"F6"BKN(WN-16Q+:&$3V;"E6)TQ"?O;N<^U-3]&>$#IW,<T!.[=WIQ[@;8R&
MS*7@I9D7TCMB?DHAZ.0-3!ZU8V(Y_3A29,*!#//=>9S]MZ[QJA'X:F_'YK!Q
M;C4N]IV^WUQAN68 F2@\Z1: (ADW,B?K5)>/=KE]Y(]#3SU":-_/M7)Z]M^<
MB?"7XC_.1#C(4WP/-=QD4'*G0>^4XT/EG<%ZG/RRWKVE$1[OW?C$"3)[=VBW
M4)!X#ZNLBIB6:.W2YI>].8 ]]4O'*U.K<"41XR"A7?9Q.) 41MWSAE'K.CR-
MWN1=)+*ZG##%TR"C@VHKJ][$A6;*8>;NS;4U\V0J@;J8%"@YV!2<S_(I\3&^
MY?()5VG'KZ#P(<K?.(ZR70NU1'_OHHHLYT3(C:1"D:U$ZY/-H[)9XXXYIGWD
MR6?'-XKL(QN1 XLYRFK90[=KB]H-552-0WU;S;Z=*2?H,;7*8U<F;4'%4+19
M 86&13)R8/ZZV2+O:D'<SKJ.4<9HIUX98#;5RD,T5V D%Y'XH+054H"53[I#
M*Y6QZ\W)H>24JSI%V:_!D9T9O;NJ4W=%]"1#Q+@%J 7&,F#>(JN1H#OX*U3-
M9,R/[ ;!;88X)*,GN@R8$;G<0%@%4R72:6?MJ-IK0^@?^TX'UIT_TH')"\\[
ME;CE2*I-C?A7*:T^Z=:#16P(%,.C7$N?,TVYLMEG7>[W@W@'J.KWU]QK6<$)
M:YG7FK]NC7Q(70CY2)4EWKA&<JQ@+*HJ-Y]._82^R^S&Z,ZYQXZWSB9I5?&S
M@H"$?L\/D_-(>MT79=@,]6><_G!ADRT*P6C,QBK&X;J[;SY@E5A"<29['QG.
MMI(\*Y##CG;7(@55>&3&E/$69V^O)[:9?0-IK7[/(':<TB+J>3"-+'G3@S5R
M:BFW7:-7D'AF^XQ I35M@-406(< AN:/=&%[FX=9#RU4>2N:'2G19:L-187L
MF]=>YWU)G"=V&;9LU)##'"A4_3K!;VT#-W^'6Y\]OO6'_U^B.(6)@#=G_93+
MKZ*T88*"522]2R^@G_SZ"KAT9)(&^8L[&83CEU5+YF3%B)WPI7@HE,M4L]H7
MHX?D, )LJ?8@8I0>GR8C@YI:<I@.:EX(45#S9 ^@U+/1@7'5VU89H!LFT\[7
M/I/#JLN"(4P:Z(/LWFWO19*HW1%[RV'K63R-43DL&CL@AV4E>TH-/!M=JV1/
MR4@V)<4UFWD*&'2T^'XOD.= ;5><"5$8RY(: (VDI55RV&@KG-LJAVT&)E2D
M*L@>X"=BAGBY"J]Y=W"J'2P:J3FV+->80.&V4C9[H"B]KMI2/G]YXRY6]$"C
MADH>-Y?)88=\9+;?;QAMEG6ER=R:!%& QQGD 6 X&=P#P99?TUERF'.V'/:]
MKB .V"J6P]A9T.L1_^?UY+#N ZY>#R3PC41'H,%$>E(.>X$%3RTK3_;P5, [
MULO[41?U6TB27*LXN- N<:GIP>QF".!\0>HBAY\C-$^2D:5$M)@MH,221-?I
M432DU(8*L6R9D%782=-"SN6K+=?VO?$BEP4Q*R0" D^J@FB'QGY1JD?_5*)T
M'TT%^&($@6+98=[E@ULK/NKSEB=ILNX@W\0/6IDWGE:PF']N*H:^:2UR65+R
M\_)_TW*D.CQ$I)OEV&SRX97[ZT99KFE*;RD#-GS6(P2\B@?_TPAE@@[7K*Y"
M13L'^/L=8W.>\S_MOQ4:^4YM=SM'>C'GG5M6/9]N IJZ>DHU14<]AS;L5[M@
MO;@#:C6+>)-WK#!C^(:  .:_=[1NF#YE9SI"^(!7OU?_"T(*JB_O[6IO#<["
M_7]>CCJ%WN1U6TVCHZ!LT*Y7?V'Z::_A%D#5O\^D@;)6=/7;:;+-%S\_K:((
M7U_O(73*%D\K,ANTG(OB4*O%O^3V7#BUT;4Y=057V)BO)($W*5\PFTL@T68J
M3TN@ /!6[44W?L<+$:D>R7WH$^+#$H6VG 1*LY($?N@AB63Z9<C]:M-3,5K(
M,.HJDD0)W/_(4@XK5KI.'M>@]<81%] 4#M0S%'?9QYKAY?UG.[F%T4;H31-+
M%L;*S-SEI9SVFAK(ZFEUTQGC,;ZGCVP\@KR'6//(Z)@<=L\=_<3(523E;V:U
MB:$A]18!4$9[^5W9""418JIUML#"Q-U"_\J2;3-"R+K.85OH+>NB\WML6RUU
M$"=WM)WE%M8#J]"O?9;RJ"K%<6<)-BJL\I-D5ENDQQ>:1&59](*8115MY@J6
M^@1]W]XM>214DF[Q#Q<+D'VW";DB$"51(@10_Y++]T9;$0KK]7_\@5?G7GO4
MENBO&)G_K;HC[MISR7C0,1;-';+6%),:&IWZ ![ALNW+ L'5IN0+YF=&^:/)
M[,-\6O]FQO5F%E]&CZW1SC%H_V'W[5SNIWK''#,74<C[6;5Z56TA%,'U_J"*
MW)87T-KBH[/QV[EJ&0+]<I'=>\[,FI)>-G,NFM8FD8  A0V-P9@:\?)\VNJ=
MNS,3N<WUCO!H-F\C97A:137$,XFYM!+Z"P&L 26]_.[;&5RGMR$%N8C<T&'=
M0]_.5I%GT1:/(;J%%<]0!H X3A;=N7)Y+>CM":WLH3J%QAWVE6:I)&_ 4A8V
M:7+H-%DZ;4+@K(,ZF)KS5:K/32"_]@X2I*J5E55WY+\L*8W=,#G:H+CT5 [#
M>G*QDO@.",K?/>U;3ULA_4&MV'#_D$R[16)('[6&P(XYWL /_29J8HZ,8-.=
M$Z/ 73C[QKZ-B:]\JC=D@(D9?I*56[ L3+&Q5K-D<AY/(6;][:2*/$M^ ?P'
MMH%4D;LR.6[*E1LY"6!P+CL@6VN.G*%#7]TPCX60RD61^1#&KB_4MW#M)*/A
MT*6T9>FA$K\*,;CD9Q6 HK *YI>W_%S1N%\MLA\2&^E 5BFRRB-V!6,$.DD:
M+,G$[6!S"&5+*5K+IS4G06Y#V+!Y6MDE)WEOEB B?JV3 QH*LVE[M!J_4OQ'
MT7$ JV Y%2_@][?_F.$LN/O_E!OW[_/:"Z5&3_Y^85DKU<=\8^$S#N(@;HXU
MLNIE9CXI:?@9/G!CO*Q*$!647UP>SNR?D9C(A$AD'<'T JTT'V S]1>9 #2@
M$BBL26&.+>( %YC](4_[+O@S%)O7I'2"VK5?;I2W&GO/J5=+E+4'JHY)(&M"
M+V I+1(=CF1QEK*:JN/C*"35V@_3E7QN<WW,=CM>3S(JN_.S7>=N9_.6';?Y
M:2>O'P.'"^TBZZMU:_T/A*#N:W98<$H&$4$ 9/X<9#[*?[A.3WBNK-.SZ*YM
M_Z7:"<]])FDS 8,4H2;D<']\H;B')AJPT CE*<U6QX=W+B&C#"6_E4T_>#8<
MV]?FP>BPIH@$VGTIPKHK \1.Y?CN(B?K]@7RX*KN2;"7('O5Q(3/!C'.#O6K
M-4O(H!PFV3;'P%D=K>W4*U^S@$&$]K\F?C+J3(CJL%44JD9]*BS.W2P";"N=
MB[T%KY_UC^79*+ &(2+NO_A"<;]H!X]\4=20)\KZ7,;0+</\$E!QW]8T,[@#
MTX&-P/!>88\YL(2A/<(4W[YI.E%%NIV;5=\_>X[?(#C4=WG*(28H>7C<?/-@
MMR&K'< M3ER +6.0<:0J45T4.DR_R[C(T\NL/OU<Z*W0IZ;]!WS\-_%F.G?)
M'K)/;H\K%+TG@BLAS[:.#AJX7K^Y^*HZ^ZKVZ=T12FF[YO"><MB&0"X6C"0#
M4EBM'/;-$&APQJM ;SX.Q6*8/E+42B W[=J6U9-IU36$O_;?_/W)B>-PEV<$
M%X7WKG^OWTIJU/..MJ2&@5[M1\BB'_;T5FWU.+LX&?E?/]QJ*R'$;1'W?TU>
M$D/2^</Y1\M;ZW3JKLNQ[OS0MZGTQ);[/-F=%1]O^TP\]-ZT[?#G1;5_^_\S
MU(3?BC_L'AAHX_*<+RQ$TTUHEZRK2+CB!=C$#SI.J%C$/C?WD/*)NOH=.]_&
MK/EF;O_YK?G?CW%]&EGW1.<:6[H]GWXRN?@_@]WE^OO\(>F7\^V?GWO\[\_>
MJG\7W5ASOQY+?Q/XJ"@S?/[GYZ"#1.-6G5P:#VR\@8Y-K?KNI_%HZZ\O^Z?T
MKUY\R'[3>F!@R8,5];\!EA&_V._4WY^^OOS 8J8M_X -TIE_0^7$Y:;7 ZTJ
M!XW3!Q^>5?ND:LVY;^6"RV]._INB__?7-]X=BY>FVQ3/OVG2)ZM\/N[8\W^U
MP-IQ'_C,4(BSYS:Z78SYSQ"9^ENDTOKE]?F?WX)M7.FY[%X]Q%7?_ ]-VO;K
MR6[!KR454V:%/O_S$^2.%6#W/3_W'.BUZN4BA:%?7]9KU,;*"?Z="CIF^W?_
M[T]?ZE-!1V+:@7Q?O>^BV\6H^HS3/SU^[7PH?S/\/\,7?M!YI/K^_5[[@16V
M-5##UW>S7:5=Y6\9_0OXM?/)/M'+[QZWA_!G%DI6S_^9R0TZ%'9MI$Y>_?-;
M^;\?[97.TUB7F71[ZIM\J3";?=[2\W]^F_WO1]5JM=F5L!"Y]JW+0./7[3?Z
M2?UBDWWWP&P)\]7ZS_"OYIW]^]/7=WQT%UU_?>F?)4"GB_^=# I,<:#6E_.1
M7!CW_JA,V/Q;0D!7[;)1_@W2W/@=I.CC2Z B:#SNO9RQ.&/Q;[?X4^Y7STM_
M>#>W7&ZO\=ZE1S*_V>]7 4;%B^6@0V?G9^Y_W_7%3N-MS*6C.T]],V]593[]
M#";1OFI3YG98NMB;G[&8J7^=8;5*Q99?I=! !RI LO%XE\7:NKWZ3Y5?O?B
ME$(6(USX^NZW+K.NRU!7<?P[!3KRN184J36S0O\S3 (FL'+0@:][JY>Q2HC4
M9WC_='ZUXO2'7;M^Y'NZA[E'>SAKE_UD%UWO*OID[D&4$^JIB#U=11BVX,AM
ME.#Z_S<!4$L#!!0    ( )E@7UF%8_D+-]@! ,T@ @ /    9F]R;7,M,5\P
M,#0N:G!G[+P'5!-_NRXZ-.E$NM2@H(@H"-*4$FP@(D:QH"!$1:6)J(A$"1D$
M 1$!%96_J 0%!$6,2E,IH2,BTKN0IH(4F0B$D4PF=_SV_L[=^Y[_.6OO<^Y=
M=^VU#J[?8F!FWM_;W^?)C(@&1"Q@Z4X7-Q= 3$P,.('] T3#P-8_/_UO??T1
M\K\K0TQ4 RC+B#$EQB7$5@#BRF(2RF*B!@ / &)2_W(!\*]?8N(2DE)+I&5D
MY>2Q"TJ7 N)B$A+BDA)24I*2V-EH[#P@J2RELMQB\Q+5O<>D5YQ3L[QRZ[&,
MX9;7M>J>G9#1AN/G8V7E-#27:6FO7&6\VF2-E;6-K=W&35NW;7=QW>&V<]_^
M P>]#AWV]C]Q\E1 8%!P^(6(BY'D2Y?CKL8G)%Y+NGX[_<[=>QE_W<]\DI.;
M]S2_X-GS-\4EI67E;]^]KZMO:&QJ_M#RL:N[I[>O?V!PB,WA?OWV?6S\QP3O
MU^S</'\!_KWXQRXQ0.*_F?ZW=BEC=HE+2DI(2O^Q2TP\\L\%RI)2RRV6J&S>
M*WWLG.H*RRLR:EMN/7Y=*VNXP1-2/WZ^4T[#R(J]DO?'M']8]A\S+/9_R;+_
M9MC_;=<0H" AA@5/0AD@ "BZ^LEUX/^L_[/^ATL$$+B+ 2*@J.^Z1??PK=_*
M2%*VW.U15[5"607?) F#Y\A;X^^&@79?!HQ4GG^R%&N8^):P17FJ0>*W0JJK
MH>0-95(: 2*!U_1MX0,B0#)%6.H0!3$;O9FQE(!<BLWK1#<>(6%FK&N^S2*"
MJ#ZN[2$(6KQ;Z!H1L*[I471$<+=/JV[![6*7"=;ZW^[\2R(@5AJL)5 -$$G8
MA,M0]1 <'H4?--'D*L4XCZ@_S8?]^8^+$R8/\Z03+HSL._ NM:N=<^)BWS/'
M^=Z&UK PR3W;C&2UGZ<"A)PCY0L@C^WB(V# $+VN7@0L@<!:.^D#PJ+?1@K4
M+_C2S1\D-HJ VWD]LZ4NAU+/.H46B8!K9 +KX6&#9H'/!2-EP3EJ#]Q2N^TH
M4^UN_=M6!4.# Z&?9+0 8<<E7\M=N_8'K%7:(2>VT;<B]9+R[V/U2R74/F]S
MB])-<'Y.S(B[[:*U8^3=N=O.1_2=O^!:*EGX;ZJH7 KF(2]A,N$D'39.G$X4
M;$.6]3*"Z3B*%TR #)O\-L$@1WYFV)2?T1]:DJ82:,/S#2HO#EQL;GC09NJ9
M:F)KZAULDV'S\K;3<95KW](6QE#9R1>3^J;"!,8)4)6<L;^ZWV$[G=J.EYO7
M"_'I^;FRHJ?4YW>E<5[[NNGYGA?=1WS='%*LTBON^[:L;;82XR]_)W;]ZA>Q
MX7=ZNW5UU0T3=.?L#&(&U]2''AJ)B[6H:::,T8F[LT1 ^^\6+#)O*7N%90Z;
M!1014+L)/"8"!HWYE3T,_T<$_B-HICDEJHFI<H&4H*\-YQ=@D50L$6[PZGJB
MK]T?H:A U.OQ) 8^)2@'W30\4OJE.LJG**\.K"\$6267FI%M]MS7,98Y?%GX
M^-D!R5],':7+LP_U[TO<<L9W5L_/"W'PWJIH<"NJCGP5 ?^X"9Q[M9!&X(D[
M:8*S$SFHGH\(D,H1 7F)E=C.UY2A"A% .P" +L/]_7,$MLL_9'C-IHL )2S,
ML9TBH*M^U$$$-,C OIAYS]/@B#!$(PV]I\\;0PU<ZV;0Z/UB0ITP$JE#!,3K
M_$,(Z3,1V52.RKN* '<<>58$+#5D1XH I^<X1 7[M4MN *JDS_N.$QXBUK'.
M38L S0(T8/X'9D+9OS?A7\QFS+V:25W$_WY%BQ=&G1,!\H5SD^WZ/S -Z?_4
M,,M1BX6'CX()QK=BB<B]*S>CSDL[J-Y8BAOG7EY$$Y'5H]6,QR) #CVOB<K^
MPP-V[8@N@?L)O_@*C&>A#&UXH7VWT$0'E27].:M'8+%G]%4?@BU7*>OM%J?A
MK@'DK..XQ*+=OPJRI=/'P3K&PW]Q1[HN%NCZ:D=I:?0TGGVEA=_>=-<@ZCS1
M?\ 8V52!6;R$^&>WXB8W_"M"'2(4%P%UDT8/+_P$*S"CF_Z]T7AX922B<5,%
MA^@Z<FN(AI%3.*C*E4-L>B7+_^#4PX F9N!U&F)XZ.Q8VK7:WVE3RE"-^,:A
M/X[)GEY6>_00]Z9.U7\7T%0&M%,$P.M,E3#3VO7Q1ZBU>(5S69M%0&;[!*[*
M_!\!<V.B2GC>=WLN?PGLUZS?BHE\=6)1X<;<AVS<.//?>_)<.Z+"P$Q[C(F(
M2T0N'EH>0(!J\?(U=F-D">Z^Z3WO5KI;&*=PK7+^Q:=/[$1 *I9TM[-Y DG$
M_.CFK^N/\7*!9><U'X+D#NFYL'_8K_:OB01N)$ 33'@=7KC6D=N..*?%,Y'%
M A&0>!#S=* (^'%L1A_D2%+,1,!8[W^?./]+N>\19)-@[R;?@^I1[[-NT1[_
M('TF_7T>SZ8EBP!H=SN\#E?7?E4$J%8;VR*ZJMRB2%2]O7Y&"_XZ/L9?!@?E
MKGI.,62/N/I&6Y2NKEX?3!A,^.EN5:;ZP'1L_ZVO2\OJU"06(]UCIC3]S<Z5
M/*2,!9Y:[<0?F$T\)9\@=B[]H.GL#"KKRTMN%@$EMHAJ(=\2_L'S\0-5$#?X
MF8  RS=1K?N_E9>591SF*97G-T<6D%JD<C7X/(>N6^^.7E]]GIPFYBR4S!:_
MOOJ_Y,(UA,%V P&H#$,0CB<F>BOC83]X#[@B9 9_Y7+6XR?46J9L:=LJ_[#G
M/_!O,JZ6>MBPU;4/12C:LD-3YF\4&"VQ?/UEV\OQB8_#!R[>/(2/$P$L+NGW
M%A$PW2X"3HQAB=LCJ(M8E!78CALV$EZ[UC 5K+L/Y2>!I\( ^!+=TRK3W7R:
MEK!XAL8OR+[Y(KQ2-MRH;M51(XLU&@?";^):F8/Y7./I SDH%J!BXVDZES#D
MU<#0\N+BKE&5QPFJJ#IYMI:&NS"C6)N/'(9S J"Q:::B-4DJ<%2GS\'\)7QF
MTN=5CV26 <VW>Z:DPJ?PX)L$P8R@ :]'"!*JHO)X=OM@1I.3 W1.^ @Y*5!%
MO.$VUDRBGUK'*D%$62F+<8.$JUR>BXU])]/>Z83G0X(!<N*^\@>[NP+0VH@+
M=X\%^7NNI;:3( _P&DV18@H9LUT;9X;HA^$JR)1_MF<N!60WUPEQ;+\KT,=U
M80U9NCTO2W'R),2S_X)PGW</Q=^?G3SY=MX7ORLF4%G1[S-S?^7MW\=V=!?Q
M7*?,>6-^6/N-)8?SQ[L9P56:;D0YBF4_56H<E*6QB(GTJ7VLA>N5H6P&GIRQ
MO8J7#C_1\YYL\-+N3YCRK&\XY[WM/<6S5>+P$=D3HV)WL<)L$P%WG+'JWK:A
M5@0D'(;OWE1R1>*>S%RAO5P2+16U@*@>"D!E!0(MA5NT03K;[H.=H9-2UY+-
M>KC'4R$U(.L=X]<U/+PZ41)L6HOL9-W<(0*2+AQ1D95,V[-CP7H&*U@/TF_7
MA2E_$7!J$'H@ O8(]6,(:["DR):31C3IJ$Q!]E'S&$8(E'U1GAV]>O7B:@D
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MG8NI9;_I&%R.B5-.3Q<L VLMW.H5:$/)W,-VE#!=Q'(<UDGD'0VPHX\$KY:
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M'OVP6/5U\6*&8 <%WV/.ZG(@OK0N<3+OOL_<#9UZ'/&4_-R'9';8:?!<MM_
MB/=$YH'7M/UE61I,X*!SY P8PAS,\8#]'U-.]5 W(19O8!(G).?88W(O<CBO
M-6=B*#LZ?7SQG(M/895W2_G*T0=ZY<,O=DI$G;GZID-ZMN," ;8OVFS.I<,K
M/^(.=COLD-9]W=*18%.P-CJ1Z[')%M'K6@*R,9UC?>:D']DW^,=]&!/(Z][0
M/RMC*-D_\VUF.AK2\1)F4B($7F13CNM5I^4430@?AX1R?B !K&GJL"<T6HR/
MNS YUE,R8GI$YE[_>8_HX O)46_5<]+WW?3>EK:F/X8LX".0;1UQD+05+N3M
M.X(A_O94/P.L(^-2+]O6^C#5/'*KZ=895_<U]%W>LKU@7=.[O*#BIKX^U_T,
MBQUF61P[[KNWVZ\"U"TBX-^Z^=U7L*&XH0J'43<#_;F_C<#/A1A"*"FNG(EC
M!%2%<6@IB#)$;R;@G73).DV+N"NEM*7/WH4PM(+NI6_/"^K7E)5SEPOV<C]V
M,CS:^EU5ND6#[)&TH^"0)FLHD.K(VT#9#>TD@^S$Z\,US*7S01&"95.5JER9
MW.Z<]'KJ\@>?R"\B[J_LG?L0.O7]OO[W4)>Z(<5?G]J=\6TCGV]AC2MB:/C(
MB#L7&X,#J4.C(?=ENAU<9%*7C;H:5%\M4.JQ,_MX_]O@?A7"3@;K&JF,WLP8
M;N7K=E)MT*Z+3A+%<'D>A0170#F-YRDV73]+0+E@6X("Q8V0T)0?<BPR^G)'
M%=+A9NJF5BBA1C(;5;9\0GT5DF$2R78\\]U2KIT]XKGM7$=.T*SE>BV'31]T
M%;^&&GXW^,Z@,6";Y?LQI]E4;CGWD3I(*GUV1&43<K!ZBP[M87B%XJTJ?\J9
M[082BZ8%3X&FFKGZ,^RDX9*?-9[+;K\#Q'$;]2P\NY;JQ%INY$[(;$1DLW%7
M1<!I\\$T;O^T<3Z\IIU5/EW+*^>;O8>J1I^%T_THNA"M/DR]E?N7M4QV&K&\
MK[V!@ NQ. R>DE%L,,DM>ASY[M&9;35-^]@Y6),O%E:]"<=Z>K_P;62$'>PJ
ML(QOF9-@\Z4[+G 8X4CIYW/M6HX?M&J<ZJWR-H\Q"IH)W@!B)@(2#Z.CC+E'
M:<,8(U TGFH3 9_1Z@W"5TXJ5"83(A;Y\.WAAP16$;/4JWG:D!,YW2AP0&1X
M ?6D:Z!2M7A@M69?)9ZGX\,HZ]>8$ 'U?G+%O=/?+09<):F[:D^D7HIS_2Z3
MA^_Y7CL!$B%ZW0QLUK>//8:H<H,,"=#^F8$I_<MI\ [KV;2GSG;S:F*"^V>R
M2']E+ZWV/RUY6_PK)#M&=[AM<>/ =4+[V'9 ;>__?.U_6Y$ZM'$L:P>[K-SE
M=E">O:=5DO;AKY'&P5MUR>:FY_0'Y<4!^I4P JL0A#P>;>)/[JX6O@=/%OI,
MZCR;HJ\=@QM9<'YY1<E]UOORNS[[5ZZZOLVB9+N[:<ZO&H1Q'/'$<+%<-T>'
M]8PD#M?;$>HHA.>ZL1M]&Q)67C("PJ^D?6M&93 72I[".@4)[:)!NQB#KMS$
M9MP DTUL(%T7 4LKEW.*2$W5MOV/^TF'>!I/:2H4__R\:8%/B$:'5<O)8P&G
MBW17'[2[.*90$T/E@/6#V&2X3YBCDMXP4'U0"OS5EP9'$1!58S2ME>^%>;R=
M14>]^]OQ/%P^HIR/WI!G9: 2,-9L,[4)'#P1-B0*EVG6FB/2?V:+E978' %Q
MI*&RZ2+ ]9O 5 2PQR!,S#ILD"068]EM"8XCC),@XH#*8>B@B#)IC.C\01%!
MSCADO6;M"G<IB0\\ Z.LF#,\E5BWFMJ3K/2'UW,)K!@\Y/*F 3\@P8K16D[,
MX*Q2JKD)[.?)+WTI%CIZ;&A83#"\0[H+FP5\$%Y%%.(SINC8CK1:$E*:@^JW
M8SNTB("<7\*[V"6S,*;7O=)?68^Q7VMBOC0+*A[P85)KF6)K5_7,:!*[CU6_
M[0L]8ZTSN"+S1'%).:W!HBV\H'+/3FA@<.5(J^2IJ+"5)VX["D#8=A+%NL>6
MO0( 49%K?*7(2"J.7[G;E0_KWMRQILM0P>I\BX[I4EP.R)["-MY%6R28#Y)$
M (X0R_@=XOJWG@KY_AN+"9,.&QXYDH;9FZSPU/4NY\#1O.O%0,3WT<VKGRW[
M_>BO&ZD6]S%*(XG[A_J=:Q<PX!)9$^ID?&MY@L_OTL)E*]\^D%5\=1M4+M8R
MHJKOE:^D&<F?W103[8KM'O#GW3\1T/F;^E$$P)<0=1'0ZDWX.Q5)&S' NP0!
M:[5S4W31&H)DT]2YK^0[8V6;1<#5*^?MA;T.^O;[&7^3', B_N_]7O)W25=-
M%@'7H@FL%,+<49(D \)CF*2C9Q]86XW=YU+031;&5,M2WAGI@"JLF!=G0<[C
M#R,WQ-^M:3Q4:'#2 ._R'T[DUDP2LI2(RA05^DYH:("O,FIT'FW=L=ZU\ >_
M.V26%!2I:7$_.W%/,7'I@^0-5EL_E8<4L$+^8D2K.1WVO-B,Z/S + IN)KS2
MK#6(=DA3>4@E0#?E@$7#_XRM9Q^@BEB,8VT,PLSY +SB4XXQQ<]PQZ)J @CO
M.)S#"KB4U'_C[.[@^]@UXICK[Y;18..96L_UV6[?0L;/(R8GTAOVKCY;D^3O
M>5C'P&43@'N*9<]_(L$P]"XIA@FWFL9FMH($M-W=9*T-^9HEBW4,+/\R%;ED
MQ:\U4F<JB#NE41EC[-HCFNL/E4^I0NNL=0I.O8OSN!1QI: U]/2MY/OL8OV5
M06>6E[V-*']_K^-(<YAIRB^%^#VX9XS_C#['L#TD_NCSW9H $9FQP[D!*6 X
M1R^/NV?JHT_#ZJD'Q,]U*UR<MIUQ.PRR8D#(Y=KU9]CU(**^\L;UPZ&(\YYE
MO<OBUE:OC+4V#I\ZDKZBZ:O8%6?\KO]P6GR:QE0 _L0$& 99-*9DLN&;NR=X
M&C6U;H-K7T]VY1JHO!O=>N*9\='3C<;(4CS6A[4__*+6@))[#9L?&&=P5MQL
M+J84[YJDK[^R7"<ID]M:MF;I[Y@-ZL!BY'\F-4YV,U@Q?U)^W<%1G5;\ )[E
M\2WE4]"ZJF^%Y(2)4?)PY,SR+,7HHN\W[MH;Q0;M?;7YY,DU5B+@GYT87XLQ
MF#/H2NXPZB+W/R[!)LS2$K#6LN<$.DIX4R;+)6A5:F0K(2(@N"SJ(O KG.0H
M AJ<:) +;7&]>2P)QF$P+C#H-E:/#,@E^T8]7QPVDHLEE_.,PUY6NWY7!*)G
M,7;_67A'! 05$;TZP0#:$)XE II22/5EKTAPW"Z,\57)-Y8/6:<TM(6I?W\<
MFCO2[EB:F_[XNGW2BE\CT!(Q!6KF007+30%XTKGI&=+'@"E5@3DB(;S)8''P
MPZ8L^E0GQ*BG25=K#*&U- G*YC 60W;EUTU6WM_?<>2?E?H2/U965-S_2<_;
M?LGW^_+=V[98K0Q9?"G7V1@;J28A>51%4U+BW=WS9S>WBDT$B@>ON1.I4AFO
MH!HO<2E<NZGRJTS3B;-C=L</)"S94+.Q^+L^[P-!BM"2 KAM=_T.OC86SHJ
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MX+UL93&F[G-P\?AB9BJBS//BFPGIIQG!83ID4RZS@1%[.;$A;=C6AZ=YE7*
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M!2_81A:%YE&;4+/NHJ'9/8]^AOT<DK<[EO22_O)$5')K[-.0^X_R[H\,O.[
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M:#R\ S9#!IOH-B\&Z8;4R=;:86KL3->AY]#,L\I =;_.OVJUIT5VV6]:2F,
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MN_GJH1X;5I6/[0 &_,EC1!<CF3#^"/R-\PCUJ>JSF?9L'ET_B&D@% &81-L
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M"_:(65UWUI;I+;+7%387TY@B#BH&48MH@,&$@QGPYO-H1I%8'PO+0R$ 4ER
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MRZJ7?9K>A-X&78!@5II/$1;Y<57$55!17&G=60&@0^4TL!;7&\#G/?HZ$AR
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M&&J'J(%-+#PMK)1ZLQ'5[7)84RJI=??-W?YMB^6I_.Z*L-,S*VZLY%Z/IM-
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M'&B'%#=PV.CB.,MP*;55DW9*V-BF\]Y5P^7UZS'%I1+\/EE3<<(8:TZ-^2T
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MH5?,;]6H3@&JNDN*NU^.M@-P2C\923ZP33Q_Y]*K5785+,@S?>#PH\G?!%%
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M2)7L[X-FJ2^KLHR#-+TF1R;]('XW/[V!J0EK3'&O(9>J7S*VYW7PRM*;VV
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MC@7)?IVZ1BZ?;<''8!G&$EG"X,[&51)40^83#F&" ]T4T21E=4JA$>'%@]1
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MGO*/M;:#F,0QF!KL1F]B;I77QRQLPS3&;PCC;VHC]#[&- .S@_-AW&BYR4]
M9P.Y]Z3B721.QRCVIZ8,4OP/KS+^X55,P/[C%PI0X_>24FQ<$S%QO9^!Z%,3
MI+@\">CQU_QK_YU[L1\ IS$/KNQ 5>J<I+@.>CJ<8"\JQR0BQ@8:=X%0&)^
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M1LVC3Z2S46'A<IW;W=N=5P?)_C+QF-_\<YJCCK&E#?3EZ*!>1%J=/M31REC
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MR9T;QDK/[^&X@RBG>8(ZD@2X1/;X3FEI>M8-^%4RLBB ,?N$ ,UY+DW* "-
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MM) ?.+[5D'>J >O> -F!CSE;86>/5?4L$)(U"2J5ARPD0%X-AI[("6&&[<K
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MR?3XL:G=DZYSK4;HQ+MF./6ZF'<_K] \F#@0458S;(K_&G)8CZM!2-QX8.:
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MKQON*T&NCK>[?PV*)N%**J9_VB9"\V&1TL_3[M2@O'LC\NF=S5CHKG]9?U0
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M##*%YFPN(%'S4.0_7I/[6PU_K\A)PWK*\4$DP'UK,S)O2C4DP+MP(B\; TR
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MY(38;0J8-)J,A6\;N[-F&0M1/+EN/A)<% <7N^E,M*PN3/./P]RY69$1^M&
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M"Z7 U<+J+^,J$(MWRQT-< 5E9L@Y&E@(1C<-%[(\G/?K>S*=C;.G]I4),-?
M)M>=/PNS"QBY+MB%#7B->F4GA(- @T5N_O9%2\2S@1@T6DK]11[B(H",A>UM
MX,MM/U=JE"OC>E)XN]RO-#$,<MAU7KQ/M&8#SVU='ZOH21BID1_SF*BQ^NST
M/LRRI K@=I2:"+]%07%%\4EMY=W5/_1*[Q;NKM:\GQ$Y_W+H4$+N<@DO!'YJ
M/O>]6AO?"GWU7A\T)TRPD--E,"P30<]3B)3J%'"I]0^;;/0U7)TVP9D[VS?=
MTA%.<-!/O-6HF28UF]>?%):OKW!%D]I?T=P15#3QNXU%.O-T<J'64#^P'+I+
M?!UZB0 ^S2( 3U0(LB/2E73^FABZ-,Q@<NQ;PK/1Z7[0)0*(>[ZJR#4P7V8G
M*3IQ"<*5$;D2MZ.:T>4GYO'4RN3JN\$ZF(+?H.-I7NB<C]3<S!5=0SV5.>>+
M_;.UHWXW:J.WU)R:WCS*#RG0F/UX:^"YNJDLYTOZ3S^U\DP\!=Z\.#+Y<F/0
M,MW7;;?"POCE:(2#*6, &TCBF*=0]9;)%;NB]I$\EN>VEWA=;GY,V+I\^V+(
M[_//Z<PZ9KYM<.K&B#R#S>%*]>5U=BBBNA:+]9W'DSC21(?KY$_D"ZXU.!?-
MP3LOYU)>Q7%;$]-9XP<]K]U"[WOEORH-.!FV1J4SN+?,#>TW?O.Y\.)@OV.I
M79Z2!)B.DY5 K,/Z<MVWZ:W$="M@O[A#5BD))T&P:&;XLT82 "YV=@;M] (A
M$?))C2$B0JCS2;',90TV7VQ#<#$),.'X?D]<"NKV-?"Q2T%AQI38S^V^30AX
M@HPJ.=G&#T!+^B<R_80C%PA>O)V,\UU4ACQ) !7+#")-)?*(HW3#'W),E4\"
MA&.1A!EQ<A,R@2(!+KO =GE?_,568OS:,1R'",E<(@;721#8(+!=&>#_S);F
M%!:YSZ1) E"B84>?%<A]@1&(<(/,VI?$F78X^2_'WQ+F'+HF'^U.(+$V(6>_
MFOS/)*W(O=J('I  )#=6*QW+\-.'9+ ?A2 !;LH].0Y%$)S^0<IOM@+T>]"0
M7/E]_Y QN\$_T8224\U]:1@VE-SJ9%&DPPZD2( N#C@AYN=?<N3_1<MYX9\$
M^">:!ZT2IQ?(W4 G'D)TH_M?KI/61?LPJ90?]E.1OY+=*#:&)0-]+S LP'7^
M233#,KF'JZ7V1>F\RP8(R,$7ZDON451\WJO^:P;"[USV/N;'(@*-<AP'K>A.
MOQCD3+?$I2T7OGG1O-%4)ZQONH)XIQUD&8BZ:&'EY^!44&G5)AHDT3,.CX;7
M3$..& @/F.D*HA-]Q3YXY:^(7I)*^7//+;*RE@!"Q[8+PSH56NFQTUTJO%@9
M1/(6R'E(UU96Y29N)Z*5MQ@?I!5"?=<*=BUBVC=$PB!<;[R.XN(XV!DJ'?W5
M)Y;.?+H/R+C4"(U& E(M(36:BU"FOJTK::O^@_[]QA3^6C0]RQ8.]WX:)X2U
M J^&R#P5M=)L$D6;O'-F>YRJEA;[LO8[WSTVP[<B48S:C6^-*U<:ASD+>M[+
M0J@#/F%-GEL;Q0VO:=3>;DS@#I3L?R;454=?%@1S*7YBHLXFJ#W $/76,//8
MND':0D"ESLD.=U \T5U4 *:T9#$Q_3E>AB$!?!TX5;\W(6MA.N02!'*!1 5J
MAI, S@O,P<JXWV0/Y I^B+?#,BV"(VK!K"ZNZ 5&30PXIIE_\C2]H=A?'V4E
M< ))><B607-X(E_QIH*=S^O$Y-L"9; G=KR?A_\TGBCAV@["2]=G@C>K<#1=
M,.:"21D2X()39AVR9\OJ8;48M CO8N&VHU_@*9. 6E'.MC-4L. W7.<C.IN.
MCO1L%-I>BFB*1%9M6WW=\UP)N%$VH\HE'';S,L!D[MS*AZ8QXD0*56W 3X_K
M_N("65I- 7%:7H_NU#%=[1=]_BURTF)RYKR*%/%ZJ$GT8)[:E=[&;RK*BOLE
MSR"S1]Y@RIBO2^D3W5UI7 -I+]*TFJM2BMD%55P%F68*^L9*;4*\;_K'^6GW
MR5/7[NM)'Q3NR*8A1-I??!\AOJX@Z&+H(V'5P,A:9"0'7R8RKO7^B;Q+[G5P
M5"X[%MP=HONP;4()C!$#/VK'MX5@]%P.6H,\Q7*33C*G%G2;QEMKKD8MJ^8@
MD^"?]P.OG1806((P$,8U%>;/X_8X\6KH05'P7<9URV%X(<1F;HT5AV\6P$[6
M5Q7;RB=KA:CKE9</K[R^%A:W'KVUACL$1:?S7*S!]G<'*8/UL)0$X9\@S#Z$
MAA?([JX$$,O\YF^XT-_WLZ)<.KF*I5YV"JO*<[U48&DP6,N=&[.;I=>6+DGE
M*9#B=_/++Y:<]T_K'19D5\P>GZ.(N),D4A/F3Z$PB ]*DG3K9X\>6&"RYS=,
M%Z3(&NEO&DOC,A$"K^^PJ-L]'YK\A,Z8REZ76/">]'O%OG-UL<I_$\$=-5CU
M.O\EXO*@N(6[^6A<O/NXD?;)@RSH^U[!H>JJT]N6A(=X!=\32W^K_N,M$N"E
M=-,V"? 8Q2T7D]'7O-!5_B0($L,!2WY*[*S'2>&]^+ .J'AQM_+R]&%N@5D/
M_BKMFYQY[N6OL'\PX,[D& [HYA$NI8]CI^/!:4$=_6S\DC6'0%6)WJ(>FVHX
MIC"KTM\%>.$^AOMJO#N-WD142D!I?=II&]21^XOI;J[:$$S.&7&YTWR_],O(
M5ZYR#F>Y>":E.T>>0)'-%LITR4<E%5P9E-((,*UU>XK/213=Z<VU#NI(WANV
MHZ]KKZ?0--?PVE4_O[.LUN'6+B^CC4NR.W@W7J AE7A-0RGU<V,V[_+R<( =
MQYL>H8'L)YA\'>G%J91D$WTE$Q>!QM#G!6WIE\H/M6U5AEQJ=6UXRN^:G]J2
M &%I^%."YR+]#.H$VAMZ <?6<X47#8^SQR<AZ0\JJ5T58=&M#^<J,CWLFDF
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MVV\'/\"9]9$K"?$.OF;)71A%9*+GF%>>;Q"/S5N757S^^H'[4]<G'W6+&AX
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MAX&+&#X#N(E]I&=%45A'JE3-S_6(6!'MM1)]6:;]JV;9@^@S_O+QQ4Y/+N=
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MDY);3>2+#T0S$MIW[$1XW+(YVDF'MQ%&^=JS1!@<R*+L! <2C=]1JN_CR5)
M"\1,=K=M(EH-5<*VSSOT_=+<=&\U:H(*5'7JF8_&XZ4(T0&REM/#=@R-GZ"4
MT\61KQG-AUT0H=U@SONI^RY!GU8A%ULGY;>VN!RPM$KBB3[[":M#NLV!?/TU
MS(S&M:?'1(&[9R^C+1@ZS;"];,U>H@:AG22"UM&]23S0CZQ*U$;L U2:'QG#
M6DF[4,X^IBS;T9:-@AR+OC-^A2_#QQ?SXJ"Z%B:.533YC%F\<3[1:W$CMFJD
MO@87&K3X\^M"@Q+KEBFCTA:PRL5\R9*B?WF3R[ZXB==79)G-9>D!^=0A^EJT
MOMB$T,-C)B OG;WA^X!W_!!#)T'_@O%2]V;<:\^18WW5_+YJ(_S7$PFH268N
MHY'0OHE@N@%F=&ZM$F' MPG$-Q ZHDZ5WR#$J:T@8E*E3;*#U/ 4.!\JZ%(,
MO&YH56@O:F3CR[3/=I9M_X)F)NQB5=P<R S:)M,"RF):1X875DL!G0MT?#,A
M&E$%:Z'MQGR \L%NU1M-8F4< +Y6:=M*NN^P?;^(577X?$O6P=HPF3:!4K/C
MVKU-P06J57X9WB^G_9K1O)OQ)$_$-R0U,::-MKMS0CUQA/00ZP*-AE5"DZHL
MO*GR(.^[7O @6Z5QB*#990=G< LCAFTR,AQ1^&;([N*+$P65^U+Y]8_[O-MC
MO-,F9Z3^1\5B4-@JBU90D!)N5JT8IA=4:[.!]P3@S"Y !<LZPH9MOB;*>W/E
M @\H#G2>ZT&N?L,<&&O-?>\L/UQ=K*_E-[&(O=*7NC3D6*;8]F;,HW]^#[7]
MEQ]S77K0W2/[ QPX ENXR9"RFR1'NKR-:#6C=!F9O>MG(]RH@E#KM]H"WL'4
MQL-K+59SSJ+T_(VY5&%/.2V&+#&3HGI!H#/X=F L]8[=##P6]GJME;"' VDZ
M:2B-^>!@,'P_D/"0*#.,$4;AVFIU!U=JY'A)=7U$]0Z&8\=0C:!6=*["6%1#
MD%UJND%#ZNZ1R(_>N\IN5UPS]WG Z&=* 6T,@58HW2;3O^486ZLFC=D#'& 9
MLH\#BF%%\[T_TZ.(N?1ZRCS@WGH/U*J/.+/,/IYG4?I1[ M>]LE&[>CUQ'*W
MRMJG1W/O8KY5_>RJ)FCTCHR5/LYJ_%WM7\@/5KL[H*,ES(N;SU?-&T4F\>UA
ML/=I=?<>4PA[O/IT(L']J QS^J_GDQ:7/,"="!%4?#-&?*@**C0&O.) ;DJK
M1A.P;J'8?:^_M]SV\3WXE$'RHN$0>]D"H2PUM ; YYU-9E_9+,+HS,J)]JV2
M13V6YT9T(@SW>H2(T7 8)13-BC[9Z1H<DHZ,O)UVOJ^L7*%_I+/582QOR>C
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MV8JX6L;,R6&IP-J[$8?F6KB='G-X@0.1\?FM#3VXW%O;_+6;FZK7 CD0DP%
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MKL,B7ZX:D\Q]G1 )QY\7_2[J^CADQXJW: )/&R6@5?<%_KQ_[^UR*F?;(-F
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M!;0PXGKES]I!AY,-B.65>8P4T->)E22[TYY@(5 1E#3#L0.,PQ+@,8+CO*M
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M[)>^,N2 8RPT'QTXBK,2_&#EUJ56F)5#V'-FO,:<8]:KD+$9P5XMKI&@GZ9
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MW#X' W9C 6; 9:O_W\K_,ZQD!.OLWNX054":.G>C>H=T7_?JI4_^W/K#CY?
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M>OO3>%3G% 0'5>=9 V%<_0FT/V#."FNCB:P'0%"3\ 2H N#WMN4=.MA%11@
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MKP$ZQV<E5;%^F,3'9YAH7,X]P]_CC0^,U-FL-A!1,99TE?_% R[W.CTJG!9
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M("+O/N8@/^=>C?>7(*@<;<!B.L);F*EQ@1'9;YQ47;5QQDD[7XC:C.V(M7S
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M\&!9HI-%/P02G1$;%_TG%KT%XT,"<M'>:/>#^%(9DN5B]/@K7;3/W.Y^C-Z
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MLG_!UZ9)KHMW):J80!Z8COI<VW:/02=J2-2PK;!:TVY(ZEINMU;OH8Y*3"!
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MZ!'!D?%@"//3EYB0S0THKDXXQZJ=R!SA0#K'#01H8)J/[V@Y!"A,FBJAX6Z
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MJ4?G44IS7IEX.1J[PAM&+#;=FGJ[*%_R?CVYB]1.VPDU\0#T-XJ)DH,8D[>
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MK3TV#M=VON6@R#]7@!_0YS$PL&&JZB0K(S:'PM%B;0_*B:40TI98NAY7/*X
MI^ JXS]B$Z/SXGLKZV,' V^FP:LDN]%VG.$F-I@9-RDFM2-2&Z*QN\555=BC
M@%T7GPE@X2 TC2UIX,#P>8EFZ.C.;<#]F2-HTLF&3Q:S-%6DE:_N0/;Y![K'
MD93MK8]FKQL$7R-!+%#]2PV^+:4O7+-7ONV865XEV@.+ IKX;Z@Z4+C2AMO6
M8@D8M$GV#BP70#H:FW-J+2MT"/C(<>S'@<73]7Q+BOH32P*[(M[M^!A\3E@5
M)81G+<X?-C_^Z&V6\7%!MS@W$KX%<Y(?2>QFR5??Y15?_!1!3O7*%,XPKT"5
MF_D^@VY8#<WFK-)29K"2'R?NW9^ZD*&JNME,+;>(QT84Q?.WU58U!&7BI]A]
M&#M 3I8X6CP\OF675:K(D<_MQBE1$'BFZ]B/3"M"'5E1)O69(1\R1LPZ=V!@
MX64SZ1K,SNV&\\&7$$;)O\!,NL !6.3[=2/J+Q6">#K+WXA9,#_RJ%4[3F5?
M(?<,(Z)/4V0/Z'"EH&WHXLM #"IJI=O1QVODG+H@JL&+4FE983RK%=>5E&-!
M<=T6'&>=V_!K-5:U=\?S6&-UH;&&\S#,V29,Z(19!R CN3TR$O;F(1)_8C70
M >V28T!:7G>1Q2L>+@&#*M?1D@WIB'Z<R\:L_.J9.&.CFSDW#P[LS=VC%/^+
M1+PBF<"]SBS-JGKA@QV *1?7]&/L0]BVP1)]S0SW1LLB['!%Z%H94?_OO,+\
MYSXG<1M[:>E3=7"ETLIR#//]B8MVJU;\V4F#^0"A0Y\P!MTX*SC/QR6:$S)Q
MM?BY![P%ME4RQKT";<+MA%HT V%\U],CHOCG /G/AA%4Q()RL+7/(\TG^<[9
MO__-5K=)$S%OF<.=FUZ0@C1I-V@IC2N=1.! 0PH5PK,T[$%D05[!.E@)$/GJ
M(H9(+P26)@I[#L ZK4-8=^N>C=QWO"IHS!Q^XJ?G4U7XQ%Q]N'HEM/Y5>2'&
MCC%Z::1'HHBY[T"[54"AK#0XN;LN[<#"JG+GD2BA^:Q;[&TZAW9GGM_ GF@B
M%=LPQZOQY'?%Z/:>"]0SAR;>W0I=:K9S1&N\\PY^8E->VA#X_2BKSHI.W(6Q
M 8J%IIBM@%\).NZ"3+K/;^-;SK2O7.!?+AC_F<3N2X*"&(14J/[,H39D.-)F
M0I_&@/86H:];*&O.6!,+M7J37"1&@,NDJ2YY_JUPB]?LFF[%QH6Y>9DN^#QB
M#L[0S/SV=>,27 M@+K:OZ3YFZSC,,P4C+L.DW(Z\I_U=R(@_A#;*?]6>V^5B
MFR\@#=K?@X42 0-\IVUL7*]I&_-[+;]G,F0EM3,,FL^F:<B46E7BA(J#P<.S
M,@1;MHU:L,_KL,<XT%P\0D:SEMU*E[-D)+& ZIXEB6#_9 6NI*^62;Z.]F-<
MI*![R:(=,N>!2_AM]+2")S0 $A>5"JD[W="*TOB1%TJN\FRX$^!T1#+5J5EI
M_=1+00!.MT!LF;%T\9S%ZC(B+?.=-$P:'N:_F-@VWX"C+,P-D8#<KD(P#6AB
M]Z"VH\W.\*-3EH4'*C'V&[8%0C=<,TVG&!NZO.G?/2!R"&&_*32=S^7U?J_.
MNUW .)KDY;+J-TF^BZCS*<#/07AF7N)'F.#G7[ ]B'IZNF0WYA+0IU:X/9LM
M*)UT\NLL/#:8S2'>63X;6<M!;7W'J;"-ZN9VYS3DZ1+BBH/4+W:[>UW* #\7
MV19)^EEJ6 N1'$P=JBRZ5#<@T49W<,=I756X+AD3A<A-)OIJ\T,?<V@JP"DZ
M6QU?$JS9D"KR82-V_'"W=A@V#>7T^_S47XQ4WGKE?>:&]K(])I+W3IY5^3KE
M^SZ4QLP_?]B_T/A9F.\F+J$%B%7 ^ 8O4C=D_>BHR(N7U<!E)>?6S%0/8X_S
M8,GFAHBM:$)G"Z0I2]'XZX"YSY[O$RLNC4UQ9^<[^6?H'\-V,@$7/IF-HMON
M6>R$*(I\0KBV*NVKYK/CIQA.PTO9P9$6!:7B9SF,3J_03(R F53PU>QST'W/
MGI+QSKUHE)=MI@%G8>Z)4+>UT%#\6J3*USL[C#V&V2^^'T%.H;TVF*ME$[?,
MYLQSC+W95EV*10"=FZ]\W#5GIL<)H8W&.?-][_*ZC]VDW5MP0BG9^_<9U3J_
MQCZ0T(>EH)W&SP$""<WJ(.ZDFO(J3C3SK)*A<DA673P^T9R5:075_62CA0P@
M$[81-_D&'=!(7"HX6W9W,L5"D33(I)\7^@QU4.B/-4X?7%XM*=2%YQU)*Z"4
M30PXQF-U+'[-O2UF\7!?HR!@7!!-!2.C$-G4KB$Z"&F:&UF)HMT<B+H]7Z/;
M2]M7AQ>=D=O><I!!A9"]@.T?O\?8G.3H6':X#U7YZ>Z3]-7UDQ5SCAO./M'[
M18CCD[F6N;]/B]@YLFRJ$B0YF-L-VR;#'<:Y_KI,[XY&G=9AS,VPZ(V9RS^+
M.#%5=4(G*&ONMNU<KM7F;?ON/K\WM5*AT;M&SL2$APF#T*Y=?4)SR5#X[_6%
M'5Q:@A44)@4EA;&/8;1". 7>G)$$&[N RND1>\ZYH&C=+40GANE/EF?VN9J<
MB1G+7TM3&S\+-;IA"C]R)(K-Z726,E0?.XS=3N/#\26#+:J??V"W\7/*G^TC
M,1>,J7YLFLK,=D#?^&9$>BJTS28,G6;K-G&<$NQ/O7GXZ&//:X/:^M^<75>>
M>MW^GHW#F_0N?T:27A&U)$?0M6RK=C369!P-=^0-U>/Y8/;')]P00Y_A.J+Z
MIM\'%=(;[1,C>\1F'KQO*P*UV-+,ZM>6E% @,L_8)#"TI$9E'^3<JXQS&-+V
M4R<"]WW1[M$*N/7^Q$X'5[^[?;?JT; ,B*ID!YITYO>]Z,$HY9.3.%717AZ1
M3LAHV<2CS8EY=G3PS6 .$>0%S'(4$JAF.Y*&<HA50*YS/]G&GB.'XXS:' ZI
M'J<_\_!P-(H^K[19_/<]];KDB8_NXOFDTJK$=PU:^VH:LH:=Z($]3XJRU^UJ
MNW(L]/3E Y==OCW:^WC9#>M#7MD1X+^VITNME]L RX(15\6!$_$*XB7#$%P.
M MA 6]WJT'Q1=)UVS   /W]"70,+?[C\NR3_ZI&"0+E2T![M&AD@9]M+00\A
MI\UBEB KGXK_72*^Y4K6F4K^/'9S3 K2)TA!>Z%I_HL_8 M%9_Y=TGI,1>L1
MHI3;/0T2)XCD;+Q:[]0G'.M4YK_+_VK"MUR4* \FNK]V(+_OF134DJ3U[P]-
M*<B(QE/$_=K=8\):-<>M[EYRM2*>E(+B-_^O#PN))VYRNQ3TU2['A_8K4 KZ
M9?>C# 5-D*RI_;L,%OT^6&&?%/0/WJ@)][5?]E5\__E_#<'^?Y<CJ[\OC)>)
M^@<JGE%2T+MBV?/_#\7_FT,!RXB'2^Y1%F"U+.CAP3L+1>=@QUMA56@KUZ=1
MQ@1?-2SMJSM5TA>C>W@0#/FU(5O.-BQ*:]<N[27M!PN^9Z+5:S+:*"7CN@BH
MN]9T(Z5P6EY+_/,A*T<T/,QL^<@*#V >//1,MQ7\S\4!N?O@%PJ+NTK)O03,
M_N=IH/_=)^VT4:PV!G]WW(,XZZO MV<[UW(S0WLNO!HT"KG>4.L=G37U\>.W
M1^\/^66^]??[ GH6?0QV@K'94/LI\=8D]JF$TJ*EZJV(&.O_=O%"F%/%[(^Y
MENCE\^\CKKG-A% ^ RS)+D;GEVV52-B!4QG0 :\CB?473\I+0=23+DU!!Q-=
M7O^M&]WY?[1WI=%0_^W[J[*D[$N6&!I%3&4-\9L11?(PZ%?9:FQ%A#0T6<:(
M9%^24I9&EB3[,I01"HWL^R1DRSJR&XQ9GF_+<_[G]#_G?_[G/*^><YX7G[?W
MYW-?UW5_[NM^=>/+[)Z?J"@I6;E8%Q*(S)VSJ<5/'#N!7!%-9F2))D^82GA5
MN'Z5Z6W,8T;FW]"$?C]Y("$I43PX@5V&;1.9]*SCJ_^&UTKNF#?)C-T?1Y'V
MN.:6\&7H^) 8B?.\)F%SM6MK'.<2+YI=VI$R\%@X#V:Y/;\)=PY@$U3V4M+Y
M-E)]F3,P[ !:V9Q7-')'<73+W4P"$4[^<(KCT4'R!=++V<IRJT$8N5..C''\
MJJ OF9\?>34@,MVD54E-Y7 DPMO/?7XT?9>&=%TD8F8UGP58K8%".O$"]%ED
M4"\7/EA4ML^N+TT%I1>OP;40Y751!VM]8Y5F.MD6E]\>EW3EYTE]W*)B6M#"
M8:S;@Q\D-V9_FZ>9R^6-I&;J&<*BWMYGY[9>B3.C=MPE?9XZ3?FQ<OSCHU:4
MP<_M$3W@=>7(;08?7;1N^Q \*XQR-O#;EYVB0!^$"T[P^)A&K!)O6YOF%6!H
M<C5->=6*?Q:08:N?%%?OW='9>CK#E#]EP:XGF_(M9E*R1 95C1&[UQQ#9-^^
M\YKQL-3(:2L1]RS+D1:42W?]?0^$?@#2'VNO'#EB$>6_,'J%S@*$)M$_8CWW
MQ1ZKQDZGWY-\'"&;H3WL%(YV\E8NXFIU43TQ&&]+J.[WW;>O>-\0ROW8==J[
MA4NKA8O%AU,,>-)2TEL^R!$]3@T(5Y4*JMC>%9\\R]81-/2Y%I\'C@ZFT61.
M)LUK*LTRF7\ZEK39W3VR\_"*;EU1%BV=O4"VF5:QY/NNEH%\H+$T"$>)\(C=
M?=U;SSP$EUSA39_HY"FJ<SB>PPB=*!0S2T%&^D0>OO\IE^(?B,$@G&K#$JUT
MMT]*W\(\HF)6C(=[W?WAMH<KH].:IQYNZE0<+EM5W [U%N1Y?T_P#>+:312R
MCP7$2@K'V$\66R(>YC!+IJL>44L'OJP6)2^.!C'MEY.<R>I^Y%1_?]L >GQL
M,M5W15$$:M-3EBO# K+S;QFPNU@9-!/K[UR6.S=N_<!"F0_D.H-=HB-Q5T)K
MJ _O%':V/0)WM\5[31O6Z D3?XHOI6=3XK 8D.5M]]F?.T D$ .P(680B06P
MG:GA$"!6JWB]&]W&'SRQ,#?A&5TPI[>+5PV=R-$=,BW8>%+MB+&JT!/YDM%R
M?.0RVX Z>C5,=UA&UO;6N,.X@>#0 :Z]'7L_PDFKY&%<?2KMD?'4B7S<J&'\
M1JBZ?W7KE C3D?8 LD!Z?,=T: 6+C#-:H$PD&C,'>^)LY9^E\=7H7>D*3A.^
M4,'S2<)3;@:&**^*>GSOBLLY=OU@&Y.2>@_N!J6]T'8(+ -^.$91Z_.N^++
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MZ$1EO\DJKP_I5ZW[A"W. O_7P;$&_PE02P,$%     @ F6!?63Z@(CYHC@
MC9P   \   !F;W)M<RTQ7S P-2YJ<&?,N058F^V6+AR*%2]67(I3W(M#*5:*
MNU.@2((4UP!%6UR*NVN@2' I7HH'" Y%BKL[/^W^]OZ^F=ESKCTSY_SGO%R+
M),_2>ZWU/N]ZDONI^Q^ )Z]EY&4 " @( ).'/\#]+$ *\!@%!14%^3$J*BH:
MVF-T3 (L3 P,3!(\?!P""E(J2@I2<G)J.G9&:AI66G)R)@%F5DXN7EY>*D9!
MT1?<(NP\O-R_C" \1D/#Q, DQL(BYGY&_HS[OWS=?P7@/D;01,1%1* !/,)%
M0,1%N.\"4 $ ",@(OR_ 'Q?"(T0D9!34QVCH& \"T"> 1PB(B(^0$)&1D9 >
MN. '/@ )%QGO&9<D"K[J6U0:!P+N#S'9CVE?5K83JHT>T/&8.OJCH3\E(B8A
MI6=@9&)^SLO'+_!"4$CJE;2,K)S\:W4-32UM'5T],_-W%I96UD G9Q=7-W</
MSX# H."0CY]"8^,^QR<D)B6GY.3FY1<4%A675%770&OKZAL:.SJ[NGMZO_5]
MAXV-3\ GIZ9GEI975G^NK6]L;AT>'9^<GIU?7%[]PH4 0$3X^_5/<>$^X'J$
MA(2(A/H+%\(CMU\"N$C(S[A0\"154=\ZX--P?WA,\#(FN[(=C99'[8#0U'$4
M_2D=[Q+]X2]HOY']:\#\_UO(_@'L3UPS $Q$A(?B(>("Q 'G5TPY?NC_*LF8
MY+)*4.;!)A05[D0R#[+0;B[:UDM\%U]&B7%<;F6>CY0[(<+"<5X#-OYK#/3_
M9!W;T]QE/1_@[.-M?#PAOI\MFTET<ZI\O:'-&T5>1"D@_^3$W.3K'4WB(S\A
MY3_T<H?#[CP+;T]8TF9['+J1WW/+H!9G84?]L<ITO'P/R"B^!X#1UV)68A![
M-FDHP\.)J;K4OX@R(>;^R17Y(YR&5I[P<C#/(,-&5ZNN,YZ9, ;6U&FO@:H%
MJL)Z]SU 5/WNBL#CT'=8XQ[0&N241&#BJ8(J^\\XE)^3"!!@_UB@_ .1P1IJ
M/C$!PNCE?V LH.:S(_\3Z"^(& %.*H-.MO9T#L,B#B*06CY70,,)@0YVX7\$
MN?ZX5X_SGP/+=Y_[(BO[_'V[#D7AR)5ZY:X$!=4?/E3_#H!P\(>7U_%#':9H
M9_Y)BE-<(WDY:'.HMX;:)6X4.?HCILD<TM;#/=?^B6R\0$(8'5=JD<!P)A,J
MZD"O@>?X12^0S41(_#\4[FMNU#]ME$=QX2OA5RJH\O\\\_]IXO\7-?F76:4T
M7!V-E6>"Y?:(L IKJ5OFMODLK)3_RKWSWZ'B8M_>N#M"NQ*@\>'J/2 (8*HJ
M30#X16JN^5DC2-IHO EQO7;MC%93,KW59J%+(LSDI':%%!FE]D5ZH(Q7?GV\
M98<&-X6%=!9-I47($V5?2"C%N5SWI8*-'71JQ8B> '&-%H&)>H%?9/H 20#:
M;SWN6R!/M==L/,S=M66.1I3P4T.,CD;#=O_IDV2.E,58;]A +^,8(N$XA>>I
M7;,R42()J<IMW_K:/< SX,>VV5*J*/ZNDX=KG2](][T 5]\+T<I!<8V#SZ0)
MI5Z>=>=:?9Y9!I)/^5N%CP>MUI64=N))(.$D?%1/@*23(870E!G^IMJ%F/19
M-X>F]Q3@DK48A@;&,)>I@OH//S[)IF5R 0AM;$[.(20W] 0),WI210;ZPX4,
MW];#,;^L"*)&3EC>X:XJ/U$LE?(2D5EZI Q -/MAQMCF66&MG-5 YZ@G^]%B
M](8L6W?FL73WF/SU])$:'_&0Q.II>47'S-S,_.>U-5[=W9]<U3V/Y5%->08U
MQ-!K[GJ_5.HWQ(*>6@2O ^.&521_G$!LJ13NOM6Z1_3/-;6>Q8QJ9^8<JJHY
MSQG6/7]NO5VY=A4FQ5ZY3!#CPES1=5%]S2/WDM)SQ4_(!=*'KV],8HW[E1JL
M?4U=%NSH&IG,2'&EK9Z_,;JI%YGO07 D;"Q']\X&D&=9N*Y&P2R^Q!AF<*P_
M&#D-Z=(ADQ/=2K=:7'U=L./TQ;WJ:K]C9 OM3!@4YP@_2JXC1';X7K1Z6D34
M4[=X$ HD#9-"-)PVI*,K>D:G-?Q")*#;V!AQ5K9 RIKP9).52-F)X%HCGBT\
MG)*KF_E NGC4OJ83_+[?@_O-4;SAUW)/'V<GU;H!UR+N8ZU#^H#-!"=)D\ES
MV+=LC=HN _:YZR,GW:CE83R&Y"+#VX2O$=R&B8QLU\/GH(IQWJ+]4T6ARWQS
MKZ>L)8#.5>RV>$OQP-U%Q8F=U@DF0R5CKEE$)C RTU Z5&)%++QPF0//>/.H
M!XXW3:<(K-Y)-EPU=8H)VGBQ927&,.Z"/+KK7.K^]%HE<*C'^W.$K%':1-@]
M %5_80$C:;^PSK56W]K_>2:7#-C3193)%U7R3%1,V.LZS*L4F9D0AE!?O".Y
MG+XQC5QB4%ARD:HUML_&6ZC/ I;\<5Q.G^@DTYP&0!59#K,G,C+LS/Y6VT=F
M9 B%=GP1,2.O6->VNZ'"&IYF,'RYQ&&[<M0*^UYN;A#WS29R+=-AZ04C#,)Z
M-_\^;J9_7=JY)#L +.2:FQ(?K>?&U2P%V8K3=<^!HX02G]S6.T1?XQA0Z57R
MUCG@8)1#D-.[NR99JE3(SJTTW\OXAM:P-3^S1JXM1JIS(\(HII8W>F.'"D_'
M"49RV 3QYSJ\G_&^<[:G"?_RM2/3CFF]H.;ESV3LN#)0X\_QQ%HX/"Q/UG$D
MWM$;AO"S&E9M<AB92]EDC;1KQM=\CD(1S;(GF898?U-XP%=JOT0,X<B+G55M
M"OTN_Z;"/,^&U?-XDE!O\6OMV?G3O<:(3FE;\71,>@+D=3I+$EYF-?A*S15)
M-%#;4\2(N;&J[CC_;ER#KO@M\?-D4U0Z,$OYP<3)57R@ !'W3/^SSX_@73N]
M]2(!.\!/!SVC/O"9],'FND1Q:_8/2F-^_#\.9"FV]D-.]'VQIZ$MU<W!\LV7
M%%^1,R<1/ZBKJ3B,.71P*ZN'C+KTV5 ?LC7I HDR;.?J$VCCPW[V8'MZ'FJ?
M1%C<S78VHJ07YB@4&2?SR[_O*O'3B?7*B!_=]*&*>@V=, E=TS*4T8[O^SJE
M8_:HN"Y@MZVJC(VVI3YTN3TYJU%" #-6F4(XI4XME3%6KFN2SVM[&/TBY,W$
MLR".L@%=*_FI+</W'E<3LQ S[<8$6QYY_ZE.RX)< ]ZNG]7$U_5G?%YW3[;5
M<X%/N8T,%$2O691=+]C?2P*PDY;3O9:(V2M\QK"S78!&\[;K.I6?-#40,I4"
M\NF%O%!9!RC0K59"VBOY\KAY(9RZQL(YU_< USS?I]O][UR*;U,&IO2,4JT=
ME<[)SOQ9/"<[SLXB<C\W?(Y@2^MY3"6V<^"37$"%IB\6XI4'G<L1;JJHJ4DB
M46]S1852PE+GO*NYH6U/M[0FZ]Y/L55=HI%$,N/.K[,CK-@CDNQOJFV)T<!W
MH!C" @H*X /:/MZ-:SJG\)(,O_",UOA/I=8SX9[PG$,=(!40'/:.KT&=ZGNV
M%+^G#^&8X86>+7!A]EI=HYYL^:.A?DFQC LB'?ZW5=?2V$(RO(;YH<_F.944
MLG:R2P;@TZXOWM(6LC8,&4-/*F=C(B=*\Z:-92%; FXH<KN/\EOR,"^1-1#:
M9@NWU0PN?,C2'4ZUZF/,04YV9@ SU):WJ,3R<S#MV)&OE8=:M8M3=6ZUM?Z=
M*HG?:;C= @*./5TA&(IFAA-0_?V=69!DX=0\F352WF7L$SE68>ST+8<E'934
MO&EPB6&C32N0'\7@BE3Y0IHV2KN^I6:\?#>[(7,X8T;$UFU+29FV E@.M-%*
M$7I*+(HM;!%;M-GH9+WK.>C!USMCR8/ /!R?=E.Z.VA4;@G:  ;EA#)C,N6$
M I[OQ=\#J!3O=M5*&[5OP +7-0C5T@0J"/\G29./X^+(MP/R]]$:\_6_&P;P
M0O68$#FTX"B)?(%H"!E>TUUR?BN(:957OGILS9(%"Z!$4A$>KF8_KG=O_1PF
M4:I.;7P[P$N[]P G\U3?A6]E'%5O9D(^\BG0#YZE%J&IX"PKISK>B5!U-.:^
M9G^^QIVJ+%4_!E4PU"+)ASJJD>@1L7(%&T'?FX3[/SY%I6G^SK*M?"'%GC_+
MFG NU(G$3"L#H#OJ?B]1= )W@WE+F:;D3'^MDJ&)&X@9=6KRZV4+B&P=7Z "
M2^]Z1ZD2]TBJB4HN%TF72O*WB$56]JUW/D[.^S8EN2.\'GK<P!'CS<P&;9S3
MEV@,=)C_%B<2JK%.3QSKL'VAN4TTQBHB6<&?2M_='>CIJE%:+5ZO)9(B5A[K
MA@-R&I7!D5'?#DA!0Q1\1[P=RS(@PN7X]M V9(KX^9S>MT&\.7DFQG"[!7?Q
MU\.A^K(C-NQM->RI^HDJJDYDK^\!;J+H)\2Y6S-[E+.*4>H3+L*&1(J)*BT6
M^NX?,37,CV&Y$R[,K+SYK;75L2?5.65R$O3Z;2\V=8UQVU9EV[[>,=T#();N
MI=HUC0?<&!BG'F894^*Q782KAZKH\GDWWS_/V%(T #@-RN60,(]U5[1K4V;.
M%!B(U*;W</ .%!#2,"=)BD5;ZB*?+GL%M^C:T4:HD:2;U[T@)UAZ?7VL:@7W
MM UL97QE;3;^5KZ[D<183%5%ON>]<L-:Q12+814XUQ+\UGDRX8E!/T*M!Y%#
MT-0[X##QD(RH4^^ZD8>M#9_^XN-I@SD##Y[IAD3SLOP#935LD/BNVNR%WO+X
MG-)!=YF'I)[,9;3MI0*VQ%IL9V$U%;1VO?A1X5Y5W749END6)2O,N7^M.GW-
M(X[2,A[_193X K6#;BM*3=VKMJ9(%X]WB8\(XQ?[E#@+W5H]SLN&GQBVYVSI
M!4.RMP[S-Y_9U6R:S:]G2L9LRJL9[+&2+[(-W>KJ2K$\>HQ:8<ISH=J@?%@N
MM/Z^0FBRPIXW;/9;MJ[&-CPF22/6NUC_)[6G0RC4*:=3/,RV)NS3GL\P=B1)
M/,.[N16'/NJKL3,,U\Z92XH?/3^XN3TQ3\NNL4P755O:H!%T$3MYN-]@N"%T
MB$=W+NNN#C5"E#$0C-*"YKO1)RC6214)5 ]G$W4H5WYM]G(R1_FZ_\_'H'>A
M,BK&5G?[ZCO !$K1KJW6WF)*5#J$+25DE0D7=]Y J/5RK*039Y!(\WMEIXR)
M;@7NA:U&K(I/>X5U8ZE*>.3",A1'[W43TU8(E1:L\T9LI?I8:P^WLUD7#'[F
MK)!G-(^7H-FUCXM*_. B08JLYXLJN<A5&"T/@HX-C.TN]&&^^4DT_H-<_61U
M3-M@0@^VI6LWW3MC9D$G\Y[+S_VDW+X+-FM]!5VH* "I3F\=OGH*LJ:=JP['
MQ#0YZW[%W-T?G\C,1Y9;; CL/E40%32,Z%ZEL@JTI28X+UKL(G5V!#(=<0HY
MEAIXMR#T<%V&KA8FJDUX6RY-VUJ2OCN9 ?&O?>14\KB4HTTI.YR3PHE8:6T@
MTL:PITKFSC)<=/NRD@_:H;WU3+Z6<;FR#.>%J/UDLUW+$#17&RVKK$(#D*S0
MHH9FS':1@A?B7(J[=FPAN@EJ&JN$+_B&K?2>%GHW,D"*%_1%6R(*;)\%*>T0
M?)V3.^$+*9@%'ET(&&1,:LFQ:NEZ]YNA5_HFW0-P2:C2*7M2/3G/XO1SZ\5H
MZP12GM.]@3=6/0W^<4"P0HV[AVQS"QK>C[I1,\+FNKT'\+,%M,U7O(R[-;,<
MA_-1Y\1'/&/8=WC8N;M&?FW??Z?_.]LXZ^VGPZWG\TB(<#_!-*J]NI\R..?Z
M1^6)P/N'P[R&K?%>U'<_P;+_\XP7AF8RMDI@L37F-T1/U3_AGJT['L??N-^4
MRIN$,L8L?U#Y[OA3'3FJ#>)"IGV=>Y3[6U?38 A.&+_G**5<HV]F4ZL2YBK(
MY2%E+5;?PXR2:DYKU1WX2 # _5B&&#N9N+SI+^XB+>=8(Q5M(+%3L_1I"G:>
M731DRDOAJH3Q-:B<,])4_=6K'W$2QPI?;_-7G,O^E)FXV[@I=A);,G?DW(2[
M#E$N]#Q.PY.2?:+&,QG-(JQW,$=:@UO&U0UZ/I>W__PE KCA1YK;H-OU7P)]
M_3 \X8<">SE$N.9D1@<?Q_)O12:C'I3TY6T>YM)8UWX/EWRG T"*3%Z!N@K_
M14]DN'XG4GF'O\WZ6GEJZ5KVYO0H>'^8)+L,DN*6#J'A$?KL@2GEQ+R%UDO3
M.%AZ.WJI"O5M%'\NF/F^2E"ZQE_@$VR:,)LX(M"=210U_QW(B)PTC1-#4#I\
M9'#=_TNPK)W@.UK40L\3K#]5@;;"V2\*RCSN@I;.1M>:F^L;KA5W1U%TM9Z1
M^@F]E0% &,;*\NJ)V,SLCEWPDC[8#Q.. DM08CS\Q,?%C_@H@[,V$I(1;PT%
M! 7>J\KKK)Z*8D$506]:$M2H*^EOTM.:S@1/R+62_?GK!5"0CT-WC_F]9\$\
MFX9*OW)<--,V3Q7/R "3JA+D>@NDT0E*,]*K/55F-1$H(MY6!/-_UV*C#\3N
MKHL=\7?S//DW)4WDV7LJR^QDC;QJ*ERJLRXY:A[.2?4&!LW#(G> UEB\B%3U
M;B6X^C#3"/EW:3*OBQ2DBWU!2!?]<UH=N;6P19H]W=*!,P7TF.ZSLUL@_F6,
MH>N?P1&]-7?L6>"O5PAXE!SC6I8J]H[2[TI=,;W)HQMBQO#VDQ/Q9>]#DWK]
M64,-PZ"8 3K3%W#>*"#3# $[@#*I"#8T_\Q=;>(I8Y\S[I*^J*/PI/;O@'ZW
MF_34SOO$%+SYK2M%^#[[I-*<VK0Z0I(_P@T"Q(9K-7@8UFCX)P0[Q3VZV/_L
MKLJSY NXA=\4M=]M^VC"=G\M1?Q254'];ZV7["7@S*0&G(-9S/YP@ICUR.]I
M*%/6H__K9!-+)V<DJZ$Z7OFUI&VFT??F3NH>  X%-$BKWTV,W0/6CZBN=U1O
M2POO <.KXN=361B?-<5W#<7O?)_= UJ[J?X5%>0)#QB'^'; /8!6U<HD F^,
M]H(%HQ=?+/?'K0P6K98": DWEE^6Q+9Y]\93$R<X=D'G@G]N^ZIJ$"Q,@BZW
MPL4AT5;@2PK89RKQ_=.=.-3Y'G!Y$W)W38#@&%KXI[O<:VWE>T#F-]_]2@FB
M?T&%ZGRJ5)[F]8<5D^\>F(74(XA%?WFX_+]*'8>FI1M;Y=F?!_R*25#*V8/R
MGH@OZUJ.W;E77&@:$QSG%0C>7FG!;D<E",2_U$1=H>C> Q8?GI/H__;32(X?
MSSW@?X= M"-OO\@]8)+P80T[*"\NKD W[AY@H'W#\C(4,'S7 1/?(+&\!_AH
MWS#]]</_E#MDBR$WX[NL_0LYQP-R-"9CG%<ECXH25  ;J$ES6F/@L9,R8W2'
MK!Z<F[/4>X ,'\!V](\O5___(K6GB,6/$JI<[$]';YD0U1WO >X^SDV3UYW'
MY1:_DK>=A9WZMT5[XWV<H8:X7A+$P]SC+.Q$S]^K=K]72S@]G20H^$_O#FXV
M%MH6J-*=Q-7$ D]S_(0,^V^7+D<;?)O%A=;:AO4>T[91Z0$VZRK.0]9E?HEO
M)U^1WV(1((S]-A2Q_2 ]R7,Q*D'!_MO8W&]C&BJHBBV_3"C^YO-) YQG?X68
M]S=?QA'$#_'\-70]0=-DM^[GWQIZ-%8M89E_M_8W<0.$?H33%SE^@OMAGO8?
M]YU3T9KYO-['Y7^-U'EF@X)U(WL[YP.=WW3=-\N?U1MV/>?N)M9.D3H6/.4+
M1T.E7H[+_\-[[N\,N R,_EODO/59V)_)81.&PG<B9J4:_\ATX ^GWXBW:K/O
M 91J/H1!_U9/(RD+"P=?;WZ+DJRU=LS>'-IB]2E8)Q63V!%U)=R';\";<0PZ
M+]X1P?BQPB)A;]G-@6#P+N^1C#@>SP6\A8,5;(68]SM;9+\S8/7#A1JL2(
MV_\SKWPR8C4(8[_K&/>WV ?!<E3JH4R(^0M_:@(34>\!XU;_9DWW742>%5S3
M&G^?6B2JJ'#41,CVET78WZI?T1/Z4%*.AY+*_ZW01?]HCZ;$7^J6**GDE0-H
MH=+1B/X:ZZBP,(1Q^[^46X;[[][8_]82#WUC^[MO?A=]S9>4";'@+]A !*8/
MC?5+=X08OQUUTP#^_"[FKM7X7/8X"\OS?_)C1]]$VZ3L"03XM]<LS*T5$0L.
M?+6:C)7=]5<:-/9?*C&CA@? C=J6.E?E<<7&!C4)GJNUJB(^!M$?SXLIOJV:
MP&O,<UFJ&%*U9/F*YI[&=7!O'//G*,A1>V0B7]VN#"MO:E/U:%=:$\4IOT,W
MGC&$-!>1,;GA?GMQ#B&S1YN=K@UE*Z=0?^/JS;TZH"](=[:M.KCTN#! *U2A
M]A[P*;##Q22MJY-X?_CU_%#<:++C() ]M]RXH-HA7T\2UW[GV+%\-YP<S\NU
MW-;%'N\>T%%?TWJ<VSD@T7@<E=:_9I8AM+=2\7K3>1]C$%3"G^M5TN_%,Y-J
M.9?J3ATIN!(:BH-:8T1>/THW01<[D>K2MG>XZCW;XK$6) 1ZA<WS3KBA J5M
MZ=,I%ZD!AH>1*OZ[]XA/O)Q"0Q=[CQ5<[%D3X!T=RRO?I.71DCV^FG*-B9W6
MM)+'K\,*FL?UUA2(,QC-*$5&OD89<>)L:I3=$-C81;<7+P_2'VOAH^B7.S2)
MBJ,+%O,5.0[:B"^3PV8N7'G(CZ3O$DKVR4QV]X=AE;S% W';?86&1G-6 4JF
ME!MQGQR&8+ZDVS?2N3A/='IM+#EMZG7/D>?3R)<KC-K/!L66QWS:>678OCI_
MZW%0)ZT,QV-N;S!8;N:KV.+G-Z*L;J[\Q&I/B]O)%,<1+103>5%*Y,/;\F4"
MMK"\T)T%RJ3M#S6%%0TAXM910:Q].YZW68QD"X3<T1N>^4)^1!D)P;W<'R<^
M;JP.TVB\UGB?Y"AE-^<XO=YBS/=TKP_ZJBQLNQPX24D_[MROP$2ZT+678.E-
MT>3DQS7YHLQA!6SH/&NH>I)$VN,59Q6H$.+!+;%"CLU25 U#+J@L!5)ZV.\"
MQ!3KC^X,7/9U&=M+O/G>YH(;*JV][446.?;-X^I(SK=5\A4J%=^ HSZZ,#9.
MU%Q?$]..LYKB!<K[R*".KRR46K5RIAQKQ?;<LGZ'5"O1UT37(YG]%'Q4P^'-
M1G@'*3/J=_[>F(:!$*%]:S3GE'8,*]GTP0%1O!;NA[R:WZD%V7/T3?%GH#HI
MG>BY$9:@)"Z+JNUU;0MXVG!:#>++A5=9J*"^"7>[FC DZZDCFHE($W"%%V-M
MV#-)/;,,_Q!-;J(YS],1NWE 1L+GL<<;0R:3$%[_50R2X7"2-WI#RQ#G8K>N
M?@S9/:X2IP51<O5;IG HJ-2<L B$[?4&,L!]^HG2*39KCX[;27I\:K:%=SWN
MGAGIKN$#O[#4R$A!::F7/IOM4YY2]/HM@#QVQO12A$D8KU_.7GJ@7PXSBL"[
M4C S#SY'V,VJN N\_#*,/?") --EF."RF&5**W5NW1GB=2W^TI^"1>&3W3X?
MFFDHQ<6;@'[\4'@;'-HBK/2A'.*\[948$S^C^RT<820J,>WV.=</J"$[F=4I
M"6UC7:-7DIVFX,O>F/!CI<:#]/FIZ@Q#.]EQMO1O]>YUC\C(;8>)NXGRIG:%
MB1L+ZA>H#R*"MKN>Q;AH?.K@EV3)D+;M7/::K2 <+J"'U+SO%$CH9PUZ]_;V
ME'C5AX_<"$.GAFX,)6O@X<[=;;6.BKL;XKF:"(O"D/<JERTRVJI21,(GR0GI
MO_Q\9CB]>:'R4WYSBZZP870E Q2H:+&MT'0(WC 3F#97)W<4^"XT*;U4,]X=
M?DY:^IJAOMZ:-E@J#A.<4#QW(6UG-JF^V^T+E:.[]-VJS/3QA+__&0:4[D_.
M&^GGP#>.<"1CT^L0UF&WU5LCBCCG1.<)^+J>$B<!AT+,.ST84I&$-*YK7\1Q
MLPOA<8W< N<6J.1/T\7NY/L4%"QJK5SO 668@"$OYY)&\>#R$]<GO>5*9[@A
MN/J?K_,;\9R&GJ<6P%,_,2^JYVPJ:-24"N[P;D#V*LQ;DGD:/5!(2G:=1$_X
M9=;2'YZ07!,EI86^O9]=@-'(!*H2OXC0!>?B*.Z@3&RBH>B!DQGT-O+S[V=K
M_.#%*!\#;'>FVTX/.8FLIM9&SNRL/!KN6OH6[/X6+*X9IQS+[:@I@'H5'MIH
M!U.,XW,Q"QVWL\D[L%',GS><?P[DNMO;C$HF\WV?,A?53?J9>^NL,2*0RTA7
M'YS]5&"N#)L3K=?(>O$@J/<V!;YV)UN?<&BW7F]^O2-L)J)YV2Q*?O7S+I=N
M-?]GQ70*19NSB5-F1Z/!9@M):/AWXX,XPTLCLG>U'ULAYQ-1Z*ZQ7+O1+%1*
MX\W*;(6?B'GQP"G61$X#3AB8!VG.B"^NT,>J#LSADWH&U2#N.=F"OL;'*2*
M>A&7[7UM-F]N>&-P,<T6'IFH=/HJ='IT5F1=;"WH.<BD9F&=1W2HV&,)"]WV
M52Y12UA?O$'UMWJ1MA:KK0SAE%F5<6DHM%IO\^A2'<V<1E?NA3 *CC+$(*0#
M7S;O875KF-4UD847J?M<4_;A= ,S<F=5*)Z?G]X2MU!H$)G.M7)+G^Y[[LB5
MXCV>.BYHD1!T#W@RGWC GPVV&23QXN*UP29QE*0::M"N:1@58<R_B.U7;Q%
MIO%83E';9/C!T[MBV)I;4)Z=;6 MHQ;&^XB*A^0K\3I5D$G[C[X4819;!;V4
MO9YA^T1@Y8YZC8EEG*J2@RKT*OY%;5==JQQT\8F!WN9!6#TD-V[ <G8-3P@_
M$EDV_^+[\O+9%GP/0U>/Q4D(FA?TH4=,/5IP[6&/8\:Z:>Q7</Z>DJ9 HFG@
MX>40,)D1GRP0Q%YS[34H8=1R.U(%<@XRG6Z*"7=T^%JJ]+F.OCC;.>HIT+,
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M/U)_XRM>*PM+]#8N3=0V'%8=<<=$CYMBB+@ ;D]7<^1[\HVU!YQ\%^A6_^3
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M8.VW\HYH\"_[WEAA-&/\G1M9PY7'U *L?H)Z/"DCDV_A&YWAKC;8'4U_LV.
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M'/'H&NDP[LWTOO$FH2Z0!F55\.)MG4:U:7R&9/UGN=4X7\5VQ 4=^;8J:/"
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M3/(@E\@9\T=WM*:?K?""-<*"#W 7IWGRVDAI557;K%DH'6=J>)A8]$-L4NA
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MDZD _<\/:,UBSZ:_%B<8(L^Y<;W4QB7?@V*J]#4XNV#ROEZ]AHWE$-J3V$S
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M,C=F =KC*L?S"JUQ) ]G7]IYJN=UT]!7AH1]:CZW%]7]T8!@\,M;$;W1"8D
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MCJLV;I$=<T"EFUIB.YJ#*6*_ 29U>":_+_7W6 2[QX^*(/Q!SD>@*1D1=H^
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M<N:+K@<=MZU5GL)VPRU7,M8/!I%]YQ6I!2^LP\4JT\:Z/D-EJO)9J+>++IK
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M\>?HURQI/7Y-K[=H" $(KX$KMOJ,W+*W3];9R*%"+AJ!2V\9B^HM"-DJ]YU
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M;;M83L,J5;JH>8RYSJ7/8$2B1N/=+P=U#+>T9I7[OH=[*L&G<BE[IH( L!"
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M(EO=:;92\S[D7=[0-@(8K0#SYW.L$<)U;DH2*DLO %8[E+3KBS>5U]\CQA)
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MJ( L**Z?FXR51Y\*6]GT:D&!<85D?^X:6<<ZN#*OZJ[)R4/XT^9K5NPWTA
M^\^QI[SCI:BDU5L4(+$T =A!S[7AAE2<\*[SC$1'T)SA,C7C$#>,:>H6ZX;T
MB.W0DS?RGFAEO#?U%^';(/ @:>$U+Z#[Y"F.?+1![697Y[QF.^6:^OVZWQYE
M.V0V/*E(*'_M#+"=-(5[T#\@.HP?VPEE UM51R$'G=0@/0%]6*\@"*,I>YPY
MG$)X ,:1Z#6K<4%3OP;4$DLU]!Z1_N$O: I<;@6OW=!)BNW-6S_]WY>*884'
MQ-NSU[^XM7B#K/LH&![U0Q(8F]K>\TW#AG]Z67#<SF_W*Y\92>,+4#-X\^ $
M]HN/F]=TKYG5[.;*R90*#+IV67!@R+P0]E/W>=(?%77PM..3SE9PKPZM>*"A
M1X[7ALCBG1QYB\GSA^_@OYQFI<^_?QOP6\D#VW]N9V2I5N9KQ&Y?!EQ-4M:_
M/1^IKIN)3*KQVPZ=YTNZ?]7L0]U33N"S=EULE\2S8N;J[$#6DZ\)<\7]"9Y2
MST&RU*4?V;U_-2\-UN<>#W]*!B9TFK%$K$153%=ZURX3 ?W#V5/>01U&(C;\
MOS> J86?,#EKS)5OH7^][Q\2I,Y*?=U)FFH<O&@K=Y:I@_>>F?I=F8(QNNGR
M^R'QG0O+X>!G*8Z3)3_#YAHM^&]0Z@BAA"C2FAZ89A?R)!?\.\"UGQC)ADUD
M97GJMPNV\R+I_HS'V;_!?+UZC.PZRM <S@>/;?. &_%U2.'^"=!K0@5$[89]
M*I4K&8#&=7!>^X'T%1AJ/ZU=5C/^:HHKQ%,93?_\UWR\#F"L?KKV79%]]T:J
MTJJ-=CDTD\)_!>?79-SS;"[X7EZI,K=@[ ^O692M.!:PA@>3:LAPQ4!5XLJZ
MS7^>)*A(.9.\N7[WF4!%K@&\(@)78I:78 +RDBWC_94<K)HM3HPM_35\"<P?
M>G75=%P94@/9;I+K,:>G[25K$04RIS97@M#:UV_"@/C28JN?]9B[J8/O(CE9
MID;LI38Z6:9?6O;6$=TL7/:>^76"E:<%VYA89<W34B#R5QH*SJ5C50.WEM1Z
M$Q\SF0+I83:L=[FC*9Q#QN FDTZ7<V>36_8. <<*EA#30-13?8TH7TU25"H<
M"YM-Z3!(YB2UYW*MT#R^F6;G9G2Y0_7*J5B>Y4!D&E1(74Y3)&7ZG?@Z JAE
M(8S,-KH(JU:MGS0\>6-\-R5U<M2^M%D);-K:0\9@(6'-H^E_?\AN -PJG?-D
M;[>1V0D.6G?</DHCH"J-;-!3"510G8\ ?IU((8!?1U*K]3T9;[K_'DD5_SV2
MBF/X>205-/(6K'"<GO!.:KSEDF;ADF;^_*:5.7/P#=NMA?_;C7=9_;]LO$_C
MZ7D'GXA99>9@VC.W,C*W:KSF8$YO)=#&.+]BL_ES.-5Z],\7((+-0><>I!=L
MA?K0CA267J00D+O&RRYWX<X_,JG/)AS0?%*0HFM=XC'(\XHF')E@(4 U:Z\1
M=/=E6R_#'$4[DQB\1LJ3")ZI-H(C[>84 T^*T)&DU(VX(8=TV5PE&ZA=+A&S
MR9L/35,![%"=$O<'378Z7<HS]Z/'N_,;ID[Z"@>4*@FFB/\OSMXZ+HYF6Q<>
M @&")KA+(#@$=R=X<'<"!!C<W0*$P. 0)+C[X#"X!'>W08*[N_/!^^Y]]KY'
M[CV_[X]BNIF:JE75W;76ZO6LIWZ_R56 J_JS:$!H/6 %08_&2*LC:5(R9+-U
M?A"^/M1[SS?VNDF4"HDQ+/D*GA(7 7EBO)J!W\S2V\=ZNO^0TIBNBSX/0R(L
MJLWGTR.VP$A03H)>K IDR@;<="$>CW575OU6Z%?!?/LEJK6MC;X!'56<G\2N
MR;!O*@XLSEY/T!- 'EC=NX&+,U,AQD"QR5329NCM"*KG"DURB=!4UU$-XHMV
MMJ7SVM[^YM>SBKXF#NF8EP+GAY39A%7RVU"A!HGA$W+>>65SV'L16J[?..HM
MRK%)L@ZP<0W11KO$>+?!8FDBSG=?EO_YD%G5$(T[@+&0Y15LP#VR;N%I@"/I
MN8H];EQ1C[1RJ1O]G0\1-;(3].$X/*5BH3#)X#P WS@MF2UR2],'[[@;DGU=
M>OJH9%,[P[2_SF-TPX.'MQH*PZY/WUA[@@;Y<(Y+;V;>9VWYJM1KRQ!-LA[\
M^B2']4,1U2^WF<KA48[2D20JY+IG1>MWIE[:1&OF?'EYEA\A6Q]CMSUK;B+B
MIYZ<?ZT-[?>TC'46Z)I4;AKA!\?2QT&E[[DONYAY.2@+* VC)\;C0?_/-X__
MME[\>Q&;Q6BDV<,4:(EUIC0I#ESYUN7>?YVMCUC$H=7>!K"A:D8P>+X]&>>>
M 'G.6VGO+'VOI<&"H\:D].ZF\LF7J?7W]GI.QFB25+4\Q3R.E+^L+ 5I7!$A
MSVNZJQUE.36Q@D!1W8EIG1VA6ET[=_=:RG2I?U*EF__Q+J.3F(B=QK#M3TYT
MY+39'GDZJ7,\#>'ZF%U$E% ;ZN]9C'4I:5L;?3TR6#OY)5*7SB3C++XK]#-"
MVXS.T4\ .712;0>W]$Z,WJ*DU(GZNTS=E*3YA,\3&*?]VSL'#^GO*X.G=(8U
M\+HO^,NW"H94)JR@':O$S57NL$#*&Y3/;K,*/B*7'%[GVN/O[0J)UY5L,:[]
M*1>@<>/DE*\&9ZE;]V3X)5<9=].AN,F+#L7U$.;+8A_J9_V%6)LR_X-+@YKB
MX6I/^Q)LP2^RXOS+C M^UOHKA=D2==H%_[',?;!7E>TJS_7%$P!3*G.UL<6M
MAR]("D4 &'T=VZD"NV'!%1-]%>C.?7NKWAZI&BLSFOS9W15Y)^P[X3I1&?IL
M)-A"C#,]9Q=S4=+Y=9-'^-'/S"#7;A@4>%X']:K+\D?111Y?EOZ.52$,W0H=
MS[L^^S[-4ZE[H$JGX(>?Y1&7-R"'3I.#2X[BHIT$=4'2I 'IL]>='@'XWRO(
M!]WYT"2YNWE5+SF-]H0GK#<LJX$DQJ[\K/NGO8O^]V=M1 2E'K[]'\T^;C*3
MGWP,IO(NW]5PB+T2-A72!4GS*Y5U;WR88@I XXRG RZ1-%OJ-%X/I78=-!5\
MB9'E/PHS\1MX DR#)T?W&>85X]V#<MD=WY.RZ$NJDFV1.S@>:<OD<C<ZO%>E
M>AP+\I)<Y:C%)85R6;XSRA+M@0,%7Y?I(@A!KP!.*Q$PI6D#\A-E3O/T7$RU
M]-Y\$I6UR#!C<BIR7')I.TM\C#,5VDVMIG0G):6$L##E\@BYHL6R)4B7SD*)
MW22T,W-^>O+;9^5?(MAD/X9XB5E3='!F.\50+TDXUIE-5Z\ 38Y#U,>704H%
M[_M#4WOS;8=V>:>#Q]B+'^0OB3/EOD/Y]T]C]%&+I"C3RV2(9>CW0V.R[R39
MG@!OU.L$E8IU[1_',MR*GXV_#/#(C#NXIWP,_A?JR%QHESUR7V+< /W)M_0&
MP%4IO@$2SPBQ@L=V7L$DE$K%,5+%ZCI!VZ8A]=E"^#;ANT(Q]038IK!_-A>F
M)5:DZ]3[PW#%/@*9-EOO*;5['N"HGXV1@B= 8*B&@/.;9T>AJ'>!UA7]E/:.
MVP7-W94C,IC#^ G \O)-@\+!@\:C;][S#_;HG^W"][%V^7UH[2-,FY#+PV=O
M76C"]X]3^GQ#_OWS0_/2G?J*Q(ID5< V-0]C.*USN*C;H,-B;Z]'D-74\]>N
MP/ZK BXDKKLIRJR2P'F;_=U[GE45$_'4-=M:XT"AA=*#7A;ZTFG1@=XR_ 5N
MR@=ZR+'UP7[MD2TSHU4)I]1B<W' .^D/3LZC!?-5 L0M5\2T06ES(V2P$?Z)
ME@.2N5^"BH?L;;%VD!=$8WGO*_@S<'G6(BX,9U+VN@5PNW]HA>P[LSBROUT
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M*$^ 3-JA^EJ^$,I.Q]/8ZR3;2_C8#3G26>-Y_O=OW(78C;D-\JDBU!G1E)\
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M0 BV54H^F>@9;&9+);K[4BR"E*QOV!!I=U$/-B^VJ\L!W44VHK0!SR$C7 Q
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M.EV%CC;=YCB-/*!I05G96 $WOBGGUU5ROFABM1_53.?IPQ)&Z8K-!*$M%S$
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M\E,*.M6]OJ<.='Z2SV..D7]7M%TQ%SF8]]YAPOSQV%3DZX68^X3F6/BLX]V
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M4#('Y_<@*]$DT23UF>UFJ;?:E>]RJ1-XHGWP;$]9^R*7;C^5E]=2/O>X5%O
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M@O?E]&PHR_UX_9]8I7B*FDVQI+.&"B'9</?QFSUHMF^W=2:B>M5(W1,IWW.
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M.!4!L8X8V[<2=N;#)I;%E9PNP=\:.,X9]Z6P. YKJV2PHA<*=O)>"%@J6H7
M8H' .__X8GU (TYT#J^RIKQ>&0(9CG$,#*?\W$6J]+HQ*F0XP&"NG*U78-O1
M?U;CDL+/[=.2EY[OB9=8/W4AB]1C"/2WC/@G%77IK#L/2^='>?2I*NXKO/39
M(=?.MP77A<<"TW4V0DT)'8IR@S?"9&S7Q#%ZL;-0JR]+JD/F<><N0V]8%[(F
M_LX^ :LDIKO9:8.'19JND_?19O5,(=(!;N5?N)DWJ>B_;5U 2G>(N +L;9.=
MIQ367<<'%&*^=7N$-C>;[9N2%.V_[8!*U]U\5JGJ?.OP"^3!,R#[N059.=]
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M/RKK=U O&1C ^]ZAXC[\)BW\9A_9 M13#GZ/]%2T//NZ(_2FBFI5N'3W"6C
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M7XO_1'?MQXMGA-?ELTDGW$("F%\OGWH&]>'H6NK@"5U/T6*DBO?IC''-*<$
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M_3:4"_1[MT<V#)?1V*O8IE@=1;?FU/Z-'BCWRJCJ*2-5-^4W"C"\A/JMBMX
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M-X#2?YEZ,3Z^E/IQSA84DY&:=;N)&9?-\F8N(X@IKI?IJ\\?JY>7BT?N5Q@
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M N+T_?AI@Y&^^RT8:Y#!AO9]M(6-V'PI9)R%J"2QSN,:-^ H^$ OJMJE=.\
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MOKT*BMKY/7[>D!CK+O9'T$YY;=Z>C;K2'4!YM,=:6OF?N_W6F/=_UY_(PO\
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M]3C6YH@;1'SA2Y![K^_QV.%<N7B>M*9B7RFM$!>\N_DAFFCV<7L0]Z6/)(.
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M&'-8>7YMCMP1M(;E+X+JO;E.$LD.$\%!H>"4^['#3EGYBBVZV^PV[Z,@RT'
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M8-NU0ARH0O%Z(]J\B>QVX5T(@Z3;G#3NLLF6VN'FH5N\C8T7?[BR&=[(CD8
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M?-2QJ8EDW2?$WY9XTDV(.AY"9VPOD;=9S2JJ!W:S7)E<G=CES&]4BYD?-S.
MJ&:X1.YRPWN/2RPD&\-D)V"_WL88>B2GM'\T#$8$H F5. .K)?*G5"EQTLW\
M2E#A*0"7G?5F>>GD--#I*2?&.U=H;CC'VB\A&\4-((:&Y+-/P4(_:>G]<9VQ
MUEVP<3@$C<2SDGC?5(26/HJZ7J'IZN9WT"#&-DHB>>UCY!:&EQI4%A4+J]U(
M&U5E*ASKQ8+V&7,K/XM&)XWZX!-$+FQ Z+$L910>;JW $;V1M#A*J8UCNE-<
MTC3_G'&+V=+K%MA,')>>:S:APE/I/)([.NW:P,!:^ZGTBW<(7E:+PU!.99EQ
MZ*K_:!0S 0>/.[IZPN?PK?K>HU&C]Q2VQ*T-5])^/QOEH3-:$OIYXCM84J_R
M;>' +1D+*YTK\Q5Q0XTV5VT.N?8$U[TSN\LAW;5#WG/H]KB:-F[&$4GH<]W8
MDTQ+RW$F6BM]C-VY"AN\D^)(Y"FOR+8HY-#AQ:EIK14(M=U6TGR. GU)NF%Q
M7Y7MX]G8:J@$P\M!]%@V6DJ=6;T."1$$4@\"[N=XC&0.N*U&WK^.\\,\;.L_
M8@0-V%6'7XY^D4.4LK",D2"?:2?6.0G'V?,RHZB !3,3*@^1(\T"M$/&\[)\
MR_X]+]*_"[\4\:D3-I2"=WH1WV_9GXS^F)F6XH=??IYP6#$!K380+#:Z?!B%
M247H?,(IFZW2E6F_\+P:OZTEZ%V\^< U6E')\!B<L^3;%&#8,+SD/R"!@4U_
M^/41;9NAD<-&!\[EVU0O#RLGY^CX:H9/KP">R[%;P[7<?-QDY?L];!.QC^6-
M(@X^-PD/$KVSP-\H,1HNR1U-,D!+="+R3YB]/7E/%HF<<B -N<H>,:HJ2V*#
MJ$*UV7#%+*WD-]*^2)RB</6W^T]CO6]V(]4U*+BF'[2&ELI,3#,:0 31D_T_
MVEMS78BB(?>'CX[S\(_-?BO)1#WJ9+OPA*[XQ:PCD,@F9C"MN"A#\Z5?74YJ
MK&W8?PM'(#TM)*WZ5OTES!6ZG%A+QEPSD=!A4L" T?Y*/':[G"KC^4R<+T'Y
M).'E>(Q9O%UQ//#%4(/5IZ_BN.L]E"8(7!W8*!=$HYU=%/5BJ+6ZA#2H#FFL
M0%-&RCHU?"[\->8H6<Z"4JZ7VG#44V=Y&=OD;$&+-OJ -1,+!%_O;)@T8ZE,
ML6W'DQ_CXVKJ:PJRJ!\Y^.M+)1EP>$]@Y3$F<7I5;A(74[:R7IO BN^BJ!C+
MUK-6MR3 7'L!O#)(F^)PE3";76^^\<_ZUXD"FB;\EQ-&[Z44:*RL=J*@#1CM
MT%'23N_*143ZZI>='.O6.'GN2^DB9''CG?UZKLK#&*]3ZJQ^#D/CLE"I<NCX
M(?E9ON4D4SNG<8<4TVX4-HIJRFEX%95CHCE&$+/16)+$R%CJJB>60T+%#S<?
M'AQTB*$/.0JS"U_??$H/$A."+-X_^V>TLHBGJM0L2\VKZ"#9C%<)PX4U7>B)
M=HD%_.6,3"9MG?]JJ\!*TJQ1AJ77M@M1P>O)!CZ9/%@@CND(3Q]+.:5A#5RS
M5!Y4RY%O@I14%]![&_X=2Y?;\AC@/O$H?T9+<CP)4AE/8HQ=BOCBN94)-X'4
MDXT4Y=4?$)NG,^IS7U,E1WI38ZCPI$T0P8'N?K+M>?WQ!\3I1$FSG&DN@A R
MC/1WG'GSC1TX F1EE1AN6[81Y+OTJQP&FLN,< 0!6$^;8>SL8-%6^1P0<8(@
M*V86:^K0+P8)W=+Q*^<K&>H0[39%T+8$Q[(-GUEMJHMG ;PT7YT!Q\24,B)+
M[6/HZK=@%6I P'QT7JA\@GADT%R0K@2)Y)J3!7TRE+[->>+E.Z,T,@=":2$Y
MS!5"YQ*[XZ_U5LR45=6U:OT=/:\;0S$6G<&-/$MA+RJJ!2A&GK14LS2GD/1.
M5=YLFY#$F5$6+**M*I+V9!,R7]/WH:466$='Y*PVP'G+!R^+3035RU_ EB8'
MB>8:9S:_,>CHVLIB C@]T&Y,RVH3-\A^-+60XVQ5OAM<E=)$2L_7FI'0<]9+
MWX$6U:1]:+_=3I=-MOB!KBB>TWZ//]Q_,(Y/]B>_<S$7TG&[/_QG#,[%B$:L
M8. OFBS0Z/+SB[UEL6MPF<]$]4EI)OWZ8 3)(4_+'4![8;P<NI]:0[*4YB2"
MJ8*W^UO#P1HSPV?\<DM<W03I-XG1@(!$W=KU,(FS09[$Z+ FCT)&FY5#<H:#
M"K'#.IJ!1X/LFL7=8Z#9E:\^0C'36M2*Y:E5B<\EO=14\![#;#QQC-:E&)LR
M5]2M,3J-E]<G<5<N%4GWM?*GEX)E)'*CY63X3%,LN0@)KT#FC*_IHF*P??!;
MG$YSL//F%#Y".C]RTRER(?\@'(L_, Y] UT3(]Q7_QBZ@I8AX&TO:NLP74Z^
M?ZPR3S[&L)///*6&8T !_A PLJ4<VQ+=2W0<;1XM001R&\'":_>J/_EY('M(
M563:[+4TQW&TD[M2XYKZI>6I4) XG-=O<%'XO TH3R#&V!U%^J3</Q]W.2DO
M#:W:(PCT0GCG58X%V]"7Z<><TH0G*XK6U[B?]YY #Y+.R;YH;'^?BN+BWNKG
M[5+.D[R$PL8B;G:7*ZYX> 73]_AJ* 1.X&C^4'/L'^J:W398+7%+]N%V?G [
M+2)P=-:F<IEXN8REU'6:P?4$'9(& J'+6NY<4EX&6!:TN3C,QMN;^G8Q\+0J
M/I+2&(LWX5L,,G\(%E%<,*2PN-M+O]\JOSZKA[+%>+"GD9_U0F'5X/3S&DV&
M2>-_U$SZ_]),>/Z[9H)'-5;)2LDR*T)8>B:?_*0ICH.[P_[RS*_XY Z :79Y
M?&;?P1\_&R'V0DN>VPO>:&K_-64,'D8=[/7>8.2ZU^+91T5QPS82)Z++\8P#
MI 2U'PM9#::EY#'VOKZB7A=8/?/GSDM6PFJO3#=L)RILJNN/F%?1WMF!YTS3
M6]V_)#EG$J\>S6_BQ8V5&3\M0N>OPW=_[>P8GP0)]<AUJU:1[S:B,. 6]+C$
ME_(2_C"26>T_OXD[[)/$1Q@_:&^18(.VV60S'529QYW+R*#MLU?W$FW;;F+X
MZY2KCDK9B%4,"BMV3G*<B<2A+[%?)S=)W.-Z7AEJ;=AXTK$&JT]FCWY4=<FC
MP9&D:/8Y#M-UQ^:(F(5065GL;Y6IY(?S<(WR&J6(DJEP![+%:E+MU-HB]#SS
MO<6.D>P1?9"&?D9W\UKJ>R*NG[>.6,Z.R.WNDC.,+:/Z&*R6R-24E_IIE[N)
MA,Z[$P>!M7< !7MO\^7C2!3S=Q;=;NP94C:PT.\0K6TD=&IPPU@$@? 8F\:1
MXRG&/$-M9 ^+[D=>XK3CY]N;,\HC'0??++INAY$D7^^DK\I^&[4\P7+^5J,V
M1F#!<HP\7%.UGY9_^C79^9448372HO%16< J BY<FWF\+AUM4BK/5$Y=&A23
MS:W;M"V#(%.A *+)D?M/B1G_LQ*RH"A4%R7L9&4[4*8I0D^-BO%-94NFL0Z;
M P<G/#?PJ8[IIIWF69 GNLDBO[!\ ZP.XM+$[>0=-N!ZO>6@7!VS)]I8%8C
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MVM'P,@T#LO94JYK%/2-R9F1!1H=1HN 'Y*8ZMYO,$H1E[+F,66"$N^1.B8V
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MI].OW:3/1P6;3B_3KVMY#_,M2M3>5/*3KWKVL6_7W #6X[R+J*8=;@#]H!N
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M%\L9&<C$)L_!!\#3'1<M=&TH4B=F*5^WF&1+F))94Q&*D1*GIK1GMM 8;JH
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M[V4((GUW^\:<.NS$Z@RC']&>Z7.A^!#]FM&W7!0W8IU@+NH.C0_U$7J<(0X
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M76_MVSXI?W[G/Z%#=(G[$$0,&]%#E,8W />8F*B[AV1CH8@F/I,YS$9T]@U
MP%12\4^7/U3I#>5D_*%6C?,%3ILN283T%FBB]BUK@8LV/-03\?75!!*MG!7F
M\],)8DL2+24I$LJ&P@GZDC<HV6PJ20(\!_W;4KJY\)&XK+#@-]=GV5]."M)W
MD^784'7=D_D0'9ZU3-<_%L$QEPV.0P3W&"8EUEU=EN+KD%O+S<EX8&%4=?N/
MQ_4 [Y,O\*VQJ\7P&T"SI%96@O]ZHCUJ$.BK*K?:=SCP,M(]:DBM.L7&[BWE
M#[--96"YKCHIXD-%<7DN1QCQV>(^D(2__QWZY00!\G/K+[ =_\HHTIWO"(Q
M_P&!-T(8=LLNW9T+,17^+[12$<B/N!F NG<.C[*R<[;%@O,13ZK9S>1_ 5!+
M P04    " "98%]9P@-;+[E#   ,50  #P   &9O<FUS+3%?,#$P+FIP9^V[
M!5A47?LO/" ADM(-2J?2(2G2X-"MB" I(-V"(C7$T,@0@W27I)2TH#2"M'0C
MW<R<&5"?>)_W^K_?__N^<\YUKC->&_=>Z\[??=]KK[7WVO!O\.\  B4Y13D
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MHIO0QH%DY<.GNZX[R5M]^^GO]\'',$DE#H@5R[L!C/'A&-VS'M@V3#MQNE+
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M'/,+?+#RC=K'IM^?P%&8)>\@PX'>3LQB*(M)%?>KV$MQ5,1T[R:7M>1&K<0
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M?7-#ROIK>1[N9E"-%QO=]?*OA2\X@.J@WB4:;D,*U:IW3TATGD ]I)I[7.
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M<6XRI9C"=K08\7.(+Y^549&Y;GTQ>_A0NG-6VR^RA$=HT6!?X^''KU_"2^
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M\Q([\W&!^)^*2A;S0N8Q7^G(04 SY-+2&XC%4.N"9PIT\$$CX/FP7[:"!D7
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M?8]R@<4 57PDW(A')I*K<B40,#EV=!]63Q^16])?!*G4<N^Z4#<[H6%Y=O-
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M5U)W S-+$.TK'%>;'#(&E+9K3]>\EP8=.>-11MB=\G-36@4['L?-=-G7&!Y
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M)M(WR!6W*#,0><8G:^Q328U@^^/Z*O?M-DD?V8A4V,3Q$A P<OH!3UK2?]#
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M9=W;I+X7@_NW=8K7C1'["#G%^NQ?WZ^\^;E44+MXYU"IQ(K9%/$W8Z>Q65=
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MEW3XB""QSYCB[-%G+3_4B\#30 AC^7:^LUL:D5_*64<!%>/:7D++NFYRIXH
M71LZ0SL&4/@H^F').VD2.&D/B78!!/18)J TVYN<KKS^]/3N4GK K6(1 K37
MRE $6NC\*O8BDA'!B< UT-=;_VEHK*>?L@H6=CT5DG[OA?L.TO& 4/2WOCJA
MTOLZLM'7T:EPJ*\S2 EYY2434P<+AH[L--N6_A4@FDNLRV;1TKC =G:HE6@L
MI;LR8M3,(?0]]G">T.]$P6#-0;?:B381>B W$,S -N;&]35^!'VN(&(- Y@K
MBE\+5!3(FIC?R*1'L@S-KG0=.?P4KDM)U:0DVC<AQY=FB9/JQOF3T=CGUGZU
M &+C8"B@-ED3M@.A"V&5N&+=:X9LZ@;'1N&]MQUE3DQ<1M+*$!:ROQ<,+\U@
MASR) [=BR]^(80RK?/>$MC'>L-=S5'N0.8R7GUO9?1FU@'SZ_K7!@DB;W/)O
MK_,B0'!VL+%AN&[H%!N59TL-C$0'  "RA[%Y^AL%:5P80+IA"=C\G?^9]$^_
M4?^&2<67']6^B'4" E![AJ*-7E 3.D/!U_^9-*,F1KR<B;Z^;JA L;]8VP8P
ME$%3!?4,JZ-I0#B+2/-=MRJ9LT*!&T9O6J-KQKR<),*0@5[L?C;1QPPE60;H
M0V^7(ZA;@]@-UX?V/G>SS7$0FW*B4O_9S3YL8JH*1&^,6%@3]_4E4(GGT;&Y
M8-\?"C1FER.WB#ZV+9W\X%:(L-QW?Y_9X?>MM25)%RZ1?Y]+54;O)'L[NM/\
MJR 9?,Z=]+^.Z/PWRH]36<M6Y.R;-=9\0Y%U4;%1FL1/=!A^8/H',!W#B:')
MJM_7F 2I$O$BQ#":[8,Y)J4W*2,4?($MK2VY>M;1>M;@_+QQ4RU91.)="A$'
MMVAO\[K/*T#[NF-,DTD(491.7 L(/[ #O=RUR/#G6GH-#]H]NT<J?TAX*J\P
MX\C(;FPLZ6I!3'BL72,J6XF%I\C I5E'NS?0TO][^1"RW[O8Y-@K#;LG]14E
MEDGAY7>R%1%R7B&$?A_'4!1S_99R_I:EA/]FR_X+GDJ\OUZ.O@RH.&*Q= ?"
M&57#DEMNXGILLA$-&C4ZPQ:G_';[4I>)$M:RLE)D)[*_5!$+C".@ G^Y)BK8
M;3L8*-C^T*NFL,@4Z#7GU,-EH! T1?_%4#K-MCT&T?_T5O?S#!X+=)]F. W"
MRQ(MIY;4:FA#0DQ7H_O;C8SLMY-%6ZOE5Q"$F,QI9'$$A(F9*S:D!)Z5X7K/
MA/LO820IS"DE@ALMZ>G\C,=_T3\[]'K("].%X/L(8AG)R7]I-R&$@RUNX\AZ
M#N*[8ER/\<0$PYZ;)$)TGS)M7F@R[7L1B@RL(1)G+H2?Z]_E]&:11V"*0Y\8
MVK$UW?A$"?W-L!:KEKV]55'G*.:DX_#9MGCWV96)X[/*'BH%;2)>H%AFK>#,
MK_A!Q4,5UC'^[ZY;*:0O%'44I$1M'#!2R(]];,::0[@7JA?/HMC'RG$M,=G[
MSTT/6X4/,W6_<#8UNTR#RXR&:C_7R>#AM55 6L:2,+P%)CVXU2:&+:W@=E0V
M70:M3N=.Q9\YAJS7GF$@?&3 E(N @+!V,8%F[+_;AHQ<\G[:'OH'&2*[^I)!
MSK0]YB7LNT*1:G<_I"-L)]5)H;&)4C1&?>IZBARUKI&N>=_]<G$H%\K+5T9Y
M%N0\,>0<_@%0H9._>T_R&.G$@%%P;EOV(Y<YR^<P1"J)D8!3,#L")4$&IF84
M).\?V6PDL5$<6^N),Y:R__7)=.8]]XV4:K+N?&&T .7]AKILIJ7Y+A8Q"8M(
M,##SBU].=@W^L"<&B3F7-").QJ<.D5;R6>OW4F/,[ Y/"I(LA6K-C'AO5OB%
MW.>2U@9(M4X&4N%QC5!&&G8(]C6RLHC/04ZZ$6E&T32A-):%2FNJ[(_.$#D@
M4GUAB!B%G=EBXW-XDZTS=:)3PQZAR^?TD^9EXN*_TM=G,TO@L)!U0P/8'H*!
MY0V]Q"Y'C=&$$'HX[(R5]>R<]'5%G']"W3<46T0&1F3FKL*MI=75Y)_2K+?+
MQ1UH&\LWH<&_$:^8P-2ZW CK<) ,0H&K-7&+=UDY2_ZRK3V/8V)*NX<%=SR3
M= 0;WEXWQ_U\;9-:O'V H!'=(Z0A5;&0FTMP)8BXACZJ63.GE54H5>A6Y_PI
M<-HF,I!\W!^:+,V?_)QYG@'"5TZ;(2ZD%CK?=I^_*>BQ4],"+CCNU_'5;4C<
MYRN0I/2JHFCDV=<@=Q:O]X-F?JYUJ#'8N+PPB& ''*V&3PHR<Y]DFM;QE;RN
MZU>^M5.(^W%(_'10VK  YD&%*RBDEVCRF\=E4_EIF[EM$,H\FRBS]_.MF5Z7
MF"<V746:97\]EL;95VMJ+Y9./7^*JR_NP7I' L#&D1 I:\ HE(\>IZ2>B[M8
MZ6YD?5UL=T[I/IA63N'V@X4U1\Q^I'8(!Q'WQZU[4NFS]/WJE+(9K#J:'\2L
M,S'H<!> \&*C>I&,4+Y0C25-&\WSH'5D"?VB=^-$ F='>YEYV%K'+GEDGJ<1
M'M4GO6XXB:.;L_$A^"'>_7" ZW4XB >]:=&YGC!KQ3JZ^^M([K**J#+]45^>
M;&\.D04F4EFMKY8H^< F>YXE[OL6?\^N9BYI-,M-3H[EZX()C,>">O,KNGAA
M9Y!^2L-094=]EYBQP),;X]+KASEG4IZF!7 Q)^\ ?.O<J86R-%1Y@LU>3;-P
ML8JVXQGDG2#28ZV!W\*:,K0=[QC[Q^Z!-!Q:=7]I:#A(WHRI3N %&)%1+>QD
M9F]C5=.T6:QB=4I:\A\!YES5\[J@3:M,%2CY*R2=PHMOL?C=2>(,0.RO5- W
M[LK1^=Y51TOXW-XZM1+'A-$CV[)(6Y0!*@3U]DUXBI>CWNCRD&\CAI9<?V;O
M1#IM&S *[@C%809(>2,.(T0FW)*U+5/7?&^'JP4&I< [%#17T6O'VG,)58>.
MP2^%Y4_H?ZUIKZ;[#^ R^5>NI6N<^D)',('J(\M?%\J(5'@MW2XT/2N8&'R3
M3'^X(%X7C"\KF&"+0["=U'A=J/_H&'*.OZS'SG:5P<[I];30M)Q@_-FJ.84V
MENN#I0#9UUZJKW_-3S_)YL#OD&E6[S\;Y @&NI--'F!%]VR%!+@/L@XUE.H]
M%AP\;7YD8$SV_UK+AY%7C2WZ72]\-E]*JZ&[J?O;N)VPNS0VQH<IG&+V8R\3
MNY:F]RX9T!GAV0BR0HV91'B<Q#Z<F7?\;XB0& L)_::W1'&):VBF<#]25G)0
M2AK]B/^Z"C5Z@:7+\A)-<>1F3!/\1[;:ZU+ML\SJZRI*MM6UES/)S]BSI]UL
MS=2G<.C$32_6A+J24Z]U'/$[$N%@&7N$7S I:X4=+":,>1NV?*<TZMTQUAN;
M([GWWSPR#M@'RPPZ@A.T3/B!-?O_"0?K9![,]ZKK:[0#^%4);1=Z!'N<3Z%:
MR*TE/-$_L216X%RG[Z*0^U:'N.8%=E+2)\GG%ND73G?XT!]4RYO0K<?C-_8L
MG6ZG[2$B[HJIW#X79ZO&XO@)NVG"X4_/?PM!H73T)&SYMOTHC+?Y_D;6/3SN
M)MOS53K^[ \S?MX91M!&P O_;K;-T5]-[-3TFMH.,OR=60=AM_C]Z.>)L[U:
ME$6WY=C04FB(2=:(Z"CU6[I-WEH1=O]_J^GZW"(QCP%96CAU>XAT#F8BDHM"
MV;%,;;GCQ9DGDG=C2[2'#$>#=&^PV0*Y-T%5WZ\&*0)5]H(&F^7;2H=F6.8K
M4HNBT[?NB=8]2Z])VPBLN6"B_]7$0 ."[$K%Z#M:(*@Q;W& IOA^.%#6G#/8
M"V5 U=4DD>P&F:6E5T&/;D%6BQ,U7B(\!QZ,SIA?/V!IZ4EP_#\P7?[_@WGZ
M#.IT" ,+L+(5MAHYKE_X>VOJODP.-B<V[OML/=2(B3"'M/X.6\H,A/+=^]B=
M5G=\*[A1N4ACO3DD#UBZ.]*7S#+6_ P%RV[5=T1@"0Y657>L4:@;C,J&1Q-?
M[Q$ZFD6M([^9\M=RP* PGTRZ-F*3"E"&;SNCXY]U]OJ,,U"Q<>KDZ?^BN](8
M-JLPC.'Y9-8FB_"8]X5=,C<[X!_ 7%5_I;VZ3RJ8%>HXX"J=S!UB RK$1T;>
M[ A@JJ$-^%1S/+#J8;:MD/<[X6A)!6N!:PTN7<^R-"=-$ Z(K0\.0G#X)#D/
M$[>JD@%^V\X\/K'$%Y/DW7%9NYFY.])NG'ZG4&DO&)[-6S=D/MJ8)(>]%J[-
M,-FSA4Q\ 2_/>V\RO'UT%U5UFL1_+CI5>1\Q]+E+SYK6A^)(7\</.75]J'7^
MHOK67Y>FK@U_Q;:9=ZZR9SR#A%"B6F8ZFZH]L^8? .I!/47C;]8]HD-IJR8W
M5/0)U<;/]P)8RPW^.EH?H]A2F3D \VS%;6W/G.EL&84JWYMTPT^&5?P6YW@D
M ]/DN!VP!HL.T%(,W/8 ;M@H2+AV-V.]EIN[K#4T[3*ZCD[FEI%.1^!8,=<'
M9+'I[<0+PS _Y6*Z^&TAC^9<QH*(;9!U;#RH\3/6NNLD6-=GCCE&2?O\>*67
M,/-Q=KN9)!\4[GI''3_6V+56]2=5+G-H4C9^0G&=5V2QR_"08DB*>4P$I?#8
M+"#UX'Q9$A8RM+-I)"+7\A%-2Y7&BJ%*FLH5>'ZX5"\L4&"?Z?D/(#Q47[DI
MT#!9G@0;O,^18KJ9U?+)\&GI-)!Y@71<M@4LNMY44CTKG5RW]FT\V*W39]"X
MX4K8N_ZH]\.?C<'D3<7][H6RGF%E7U @H=PHLVX6??&4B<DL3.!%JVS2SHXC
MXG&[(5.L%!D_N!UQ':OEQ?XAXN]0H+N5^]1W5IBF B'0;+:Q7=5[^*#*R=5"
MGLM_2%A:[)-[HC-W01\]Q, &'C'#G,OFEO)FML3F%#+/0(EAZ^HOV#""BR4>
M.W_='QL8R-7[DETVNEO\/J75D?+LPIU/"M8^ PL0N(!6-[&ESA)%;,J%.5JO
MXYZB)'2/0>WH' *"M'QI%W] _+=!KK0QQ$7JT9P&XR#_EW[*Q0!A)9>F)9UF
M7CF*E,?!=C0TUQ26K"%V3A1SU\S*@M]KSX9V3"QA&L:C-/(1BH\&&B[ ^'3V
M)_7&G(W( O]4[C=T>9:96OLY$VD.KLS<F^(,WD)X=/\ VF<@CY0I,6:EQEE@
M[%XH&Q%8T""RQ3HJQ+3JJU<3^RJ+X+O?.N)5/FG/'PWKZX@V'=53^+B<AU<7
ML\SQ1=8@BSF^N_%UZPZI!^,/F>X,WS+XLRE:#\GQ6EPG&6Z<4O]^ZOJ_5'K9
MU*^K7+8_T[)<#+YXU55^=MQ'^9#&3^LB>_(UL[T*7EV7+]*]YGF02"<';.%E
MJ4'$W X)D^A?)N%Q^5URS-O=DC3UIG35.$:.7/'+E'S<[[78+_VQ3XLY#@-*
MA2>"4E'-^%*!I_%L+[ZZ0]@<4PIOI)MA;3'*55/S.TN6E]C%R&6YX&V(1UP2
M11SGUIEY.M*[H]BGN=%2^^[+^"/D[:X%5JOF3 6/4(LPK7X$#(H!?&S^YTZF
M*N-/OO-N<'A/7!E/@8*[BQHO$@MYMO??/)IKO\(N1!+T:+JR2Y,+<&DZ >DH
MCA&'N"=TQ'^?_S)ZW/QV[)Z39XWL3-Y(XFD,OFV>J< =9XR,.9&T7\3@L@+X
M.B7HI_TS\D='C,Z2Y8*Y<Y-0Z<4<9^TX,=4'XX[X'1+AQ0#)(5>[N,I^CZ9R
M=S-T.7+K7;N<##>)/9O08;_Z39HVVPN;Q@:(@<-;*EN;[Q'6*^1AQ+T]P&J!
MX@L>!QR%S4-6RLCRDOA"(H/#56^7:<=9MI6O>BX^1NM[GO10K2SIQ;/;,[H+
MQ>> ZDJL,)?.CM0(63: P,J&1.+KDI"[D8)/TU:.] $&OXERG>ZF#&<B$/CC
M2_@0/TJ)W<DNZL&58B:W@E/-.Z9$[D&0BR;%"$<$^>V4_??BE=3"]5QBMNDX
MRU:?'+7&@?@)+5K$"U"P QT&6=/,+90$3 ]Y6CH#I;KCK>0;IKH<AK9XH0C?
M&&%MEKKP:,T[FD(,$G%RSUC"U=[SDP<KRTWOZR7\KMYY?87/C<$WC&5!22:-
M4YK2(\\D/AJY_D^:I:QG?^RUD@3 ]!*+5=*A36.N8-KU>4/ID=4(\0/ @!=F
M4:!$F\I;EB6X50YT %ZAF(B[-+_Z/0K;_U/JIUN@@7YJ.5WVDSFQNG1GJRX9
MMDN&NAO_82G,W%Z43TD4(RT3=1?/GF[0*DER/Y8!/"$&LN'O0<YRRX2%6U$6
M&TEO'BC$$^JQYJPI!,YB6!.=J\6G(I_]AK,'R!YIV"JXFE78,WN*0DG\[SWC
M6&*D&#Y([VSJ;67_ \"M?"_Z,8DYCI?J=ZK4?;MW^B3/ 0V9++$VXL&4NWX;
MI-339OMA80LRYQ7]CNLKX\H8<J VX/"Z:$U^$D&N?7WOE)7GVYT!V*IQU,S_
MZ "RW4LG%:URYY],HMJNT^U^8D"J_5N8#SN9+<_S_A=K#D77E!<*/-#TKZW_
M 7@D3_,P_2Y:6S]2.ZZTL4^[[-ATAK.7 =21=3&3VV^KGITI.M=3\S64F_2V
M?$,WC+YK-$D$(S9G[WZ*XYM8K'HOM[G?C>);:\>KW3!=X3MJ7S%CN)J^&_MU
MAB^U6Z7#'MJ5XDK?+]V4M.G1]94V$PG]<PQ3.R>NX"'_TP%TXW?)-7Q7_?K,
M<2]2)4*@Z)/MAZ+U]B[QYCPGW^*8P7C7JO65T)*U;\;<6FUMC*"L68/P89,L
M*C6Y&R>1C^:QO.#"8V.R=/A&HQI<V0D$V=@W8SX%U:K^&R5:+Y(.%0ZD*8MG
MJ5G,T+BV@&@Y[\]?)J*(*PC';= [VZ/7D@?FAAU<RS'^MM[U/[+[KDEP,OK!
M;.^)X3A=]F ^_<X%3^81=0S^LS.GS(T8Q4T+4\2$=M>?2SG[5UZ$*57NI+!<
M*/TWFL5;YV9)5Q?J9ZFXP7);:V.!C1"":I7-7N*=QA?A!KUCOMEUA8H>JX62
M1%,BR[YC@]#N<6$JH[YVJ2,%M>GBZ+VEP^S?\S+M"YY'+^TDA\U)FXO$1981
M"%]J1V[)%Z5G88D!_I@SZ_L\S(31!_SC1%%\@9>6> FHTZHX^G?H3"G:*5][
M^=RGBF?OB%\D] K:6U3.ONW?[,5^&:$&NL(!/<(VA!J*\S"<TQR:#Y0%-VOB
M+O6][K86$-R1_CUP3"H]P&W#88'1SE_' 86F<PHH7=<1?=A':=7XB[7Q")A>
MCPL$EP&<)7M/CK2XF84F>9^8G]N%:C[0=DA48G -33,P/8N!(@"QP4%,MTSR
MRH6F/WRKNB@7V& 4HBHTMI)&FT9B:RI/;%N8_G4]HR3#K83%A13&_=MG\SFB
M'@N;<F-K80*;U^3DGL,"T\7>2-80N[:X2ET"EG-?JX/(<GT[P8C8-L62I1TA
M7S6SB0HC/6W%!,':-W6G=LN"RE"P9\4P;<[$3"]K<',*C<W-!SFTLR3Y\MX+
MXV)9NXJ:VLY,@;,/M $..@L#&E)V+C1X58F<7(0:K4T)J*<"B,7N<*6F&C!T
MU4']2!UH8BB?9LG!!@SZKY31M,SE=)@1XVXI4Z]]=(( QQ?./*CP:6$YO6UM
M"U:Z  DTG$:4HP<9>M%%.4?GQC4LB\^DY/%@C\0LV7E.Z:I^"R<7@"$ASIEQ
M5#3CL\R*@),OK"DOJ%2F0%^A=$..+:MLY&::7+%OBW@EROTG:/=D4._R+!=:
M<D+TOIG48?A/(7G(W6),PEZ:1/]_.E;[6^P%C7LH-#1YXO <?$XV3.K9$ZWR
M@>5 .P&Q$7\T6*5\T/QWH% ,6'!GR8[',J6X=<U^R?*S)%>"]V/ -<[F/P#T
M\SHI%=%4,AU^ X/QD2XJ\1+XJDF<HEYQ=^I2T@]I?G5OPF&2OZM)]B\PD;+P
M+*"@4;.@780.V&%;J;:'C/$! ,_M=>=*?A$,@^KE3B&NK0=-?LH-V W>/!L=
M<X,V_HZKFO1G[ 6<$52;0"99BD&##K")YL)9]JK\4L)Q@K!&0%2^M5%-2WW=
M% HB"/WB2HIR=O,,(WEB2_B3@^_?UK7=+LAVT;3#AS[.-'.F2JV.-3YOG+)[
M\\*(*,:E9&EI_EGT@/%',^H9;:M6;/ ;U>%JE0<W?BA</XWY>V(O;4F1*)6>
MG>O*E!.;#8<"&4(XD)/(?"#^.R'QZ.N=6LO<1]#<.??HCP7N@X:N9ZGPP6PE
MS@%B(L1]$E,TLYY=FDZ&:(Y)':'W'PY<:KYM\>HL:W-.^F/G>9(VXA)B3ASC
MIB#NTU<+7OI \]#M'N"4E;2QJ5A81??E].GQ!Q^SNYGQ7=@-0G^3GO[*7W#^
M\9UUX2TK@;;BS';J-EC8 JK$>O>G44,8^5.#P6,4VSL4^G&G2$A!0_7'NY3V
M:Z*=V]H%-MWZ.N:]]/BT&X^A4U,OGL @[%]\F;!;(E&BN5)_'9-&X7XS&]=V
MC-Y#% '^$VV<R [4M#S+ "HEO5YX_^FCEJ.-TZF%E\"0^YE!2:R^%>IA=XSB
M?."\=QF!/Y$OIKN0PGT7;P3)B'%'P/HACZZ]7_O/C<_.-F!EWL:5Q!&E%EJ9
MK'8J!@J_5_*E,'WG_JC=&^"\QUP6D=+00K!6EJU9XL@TR=EF29[$Y=MVV7H[
M0:]?>QSUT#IS8L!PL! "F@B*7S%#=5ZP7E>)5G7^#D%C5]*.75'>J!G(=N*3
M[X&+!3WDG3"U /&%8GV>;N[AZ8V)28R6?V?\@;!5FGGZM=S&0K;E87P?+*CN
M]>\D:A!D=12A_BN=:"!NBK/0BV/D:)I'>5KY4NIEAKCC4ZF,TYE@NZ&8A=F^
M)S5>B(@O<:GGWU=7/:?"2#YZXJ#]>KL_]8,-:IE>?VX[(MS )J/\AXG"?/-0
M"699WYFI=V&5N>,?8\T<]:46%RR9@(;XNVY8H'PJ_O+*E(LWI90&Y;/0F7QV
M-UHO2>^I'Y5^N\7VQ[?VVIL!)9&E<I0[87_R[#"Q4:F#Q5'JR@\47HF+,B:=
MEX!)U_<"]._3>%.EI=EVF?C3 8+\T^(W;BZ""Q>\,!K1DY.-&#.WR_2-F<>O
MO;'D.8-UV4Y[D(*VH-]B+XS_ "3N\_X!!+ZENOSJH_$:?O;I]05=8(=-CU#X
M(WGA@&#V RM'Z@Z&]]N<:*KD@Y[G'Q%G"P',U55Q7/VDE'$>3AYG3$M+;N&8
MB=($*2#\3^*/VIU6=%DS<XS%96I2A+1O";3\AW.%;/QMD_2"']5^FM*OWQ.\
M$;5S2!9E:A/$A%?HK3T2#:EQP88(0\BMN9H/IOGI";E%Z=_KY\,B^!&D"<;J
MI^LUOO],4?S2@\ U[5>MK<(I:"^_>]IA1;N9W8P%1EA78E&3=#1:[$VL+7Y@
M>'2=DI8A!.72=P8(PH^GIN!R="V\N9(38T.J@\KSC2\_$-S\U4;Z,RBL6,W8
M&ERZ:.(5<N?8:>/VX@K3W)FJ16V(M_!=!,X,0L_G[/L5]?]O>S .7E7,2M87
MJC3^0@9>M5S<XD7917&PZ%1$XB'Q78%\>[I3YUG=HYV #S]\4X]RN1,&]$P3
M]GNIR_I>!DP/20:!/I6?C7[\S,<AE4?5!EID,^,C ^AC,ZOUO# *K:/[FZ^T
MTS@-A83KOCF1KD>&/PA]I+=%!+TYFN^4@OZN'U:LLX/N08[!B2-UY4+R[0 T
M4U22:9(3A93PV9E9)6--4L\/X021Q>X7.R0Z UQV%BI9EE[URO7)H8SJR 1^
M[@L/)<G^:.T4R+;5WOW&(-$/[ZCHN/%8'$D9^6JFN!JS,3EO@9NI'_$?<UF2
M99YY5PCEBY?^ 70S!4^D#UL)3-GN>]>Z,QO^*JM*N1*-GI5AZ(X%U8TR<2 A
ME+D<)JY<:>B>$)$6)<O8"7B'.F=6Q8;S8<9&(,*(S#Q,"EH-_@$0CA>O&TD&
MV>&/4M2UQ'W(\NUQ^?$)T4F.^.3G7/8K;8>1Z%-0O7[D?)%'^T<7+>1%3-Z<
M5H'I+^Y*XC$9%%*L[HF_<PZ6;BM!\P>RSMN<C]<Y+7W(<!3W*1Q%'1FY2BRA
M< (U63-#I>7^$2?K)(TRSO;BOFRI(2MS\:'SRM2G0YC7@H:Z@QEW[B'7I[ )
MJ#O^YMN&]E2!<QH.JY@?)FVK6Q2%0)03G3PI]\I->XX-QZ2=67"*EXW9VV].
M'7_.<Q?KY*(%BHAD.$I_"XIP'LKG8DELYXZ2\N'CCS/5[KW)2\OF"_Q^>%E)
MA2-73'NI[5#HT<"MUWOS90*,R7^VU&;H+LUX,V)8L<3^L=%(0?49E'3,&R-2
M/-(2ES09DO>]'(F$T^]NI-Q\IBA2?@$\=\JZ\2PT[@8<HHA8#Y\V148.(ET;
M)"[V=D!AZIQ2><5U,)IEZ&AAQZ"K3Q4@[KKE7VM,OMZ*?8#&^&/<Q>VV+^#;
M3DB#-)M7U\C2]_;^L(M4JD>39Y%&RPB@A'=\^_*):HTOR/+=:/P?)]6:&@KW
MS?*UWZ U?0=<F?)/+XIO(+P<[LYXYO(?A?\<'$)@R^:Q&AH)K5KG[DVO1 HB
MT@I9_J--"G;W.A!SRZV .31A"_I8[R)* DF+?/W.I?VY*97S?P#+6.$<RY"N
MN]F=N$;W\996M:GA;>]GD9SLASX#9F"6[0"_J42*T5E>%N J6%#+  =QT"R@
MP)AVEZ1Q1?_]@,^[$%2DV)<B)U'8TJQ$=L*CVH2]*(Z2.EC9[@XC^*&B+(13
MRQQ=U##V9<6QV;XT8(MV@>7"HF4!+?=@1^@K9W]<; 5!K-,>.TIWD/WI$8=$
M=FJ?B^)!T#9AREY7A,&OS:'K2Z-1W.#($2:OBW7IGPE!V/;.>+_UODBH=LY&
M6N(/M&N WJ]%' L2$L[LQ*I-L@Z/020^(G46]M+F_O@V8UCU"]3,UO$9V/LF
M(L ]]Z[2M]#PF+$TJ[VE8TT!UKI!\%;K/H1WJV[8N!5:P>#NK(W.Z.B^W$7\
MWL*0RH'Q3R6^U&N-J/;B6F['Z_?X[?)4H1:P\P#O0\7;L71O#B$$_,A/C-28
M>SP>FFH3_2GDY9>AD0O4T4_<M5UX1;6/))Z?Q=JU'BP2A,I/E!<Z/E!6EJ^M
M;RB]@< U4_&;>A2S?%%!*.=7,^6B=POJYA!?%";.&H^,XH5D]?HV!?_\]PF;
MEL;F@C9 H(L 2OZTWW33I54LW_TR_J,W(R:^M$4N8<#YM3.G>X_ -,"[.HV@
ML37]42VMT@Y1+7IY/,4T<\DJ%YFQ51(@C;YG:9JX$. @TL'QH;8E>,-@E':C
MW] PZNS+2#$+8&AR%0#@B)A>:I/GD  CRF6G1(:"9HMJ SA?&2:KU(>;_-UI
M\CA"R0''8D@NG Y>#RIIJK-LCO0Y2&FXW$I,TF)O(S@)DA^M&SFDL)7.:0F:
M."QFY.U)M7["!>;/<K':/RTYH7,MQ[?KM06%.=UF;&>.:X1ZN B#E.QU<>=(
MN 9"4;)U]*1$_ZY>P. "6:ILW7ACW9!^C1ZW4:.(F/=:FM]JE![I)O8?0)Q^
MXRP/,X7T_3F6_,*?NCDY;05I?J9\9=0$SR$_;^B+6K3AU)+I3HU[3G+?_E9N
MC]'7XFF.3(4@YH]):]&1T^@J3;XGVAX_L?6/'IJ;8Q,F7=W=YJM*<"G9Q<@D
MW?RU1XB+\T<C_VM+6>I_8B+\;T'+2O"FQ]#D1/NI^&PH9WM#GPK&?A,53<)'
M2"9)?R&-1GR,X\3TO1NN/LT@2K+T.LJZTNG3U-LR!GC]R'6^AQ@;R%^C.$@'
MGU49B<3A&H="G<U"4*TNAYI97(^@I;5KJ.L83AMY7*%G:J)Y@4M$'%18)VY&
M!B1ZARGF-!;T/VD_%^8B"_0,^]TYJD4'+MZ_*W4?3X(_T2;27$XU)L(&&\?R
MJ?N^B;T)6O(>WA:'=7O@*FQ#7:%?V_HJ^J!-3K(;!W=(N:[&A=&\LV=?NMGO
M VW2%2BAGB"-]=_>>KX[#BY5=7V%X^$/;X>S%I)'I[>-@L+,<X7(EEOJVQI]
M:RRSQEM1R;!"AY;,(*Z_/:I#"1JSSZMX,/XM]_\G990P<4>H_42$RRO/P=/5
MY9Q0JKZ0TWL46PP8ZSG-4R,K)F+[3CCW>EZ_PS;F%VGE1SC\VL<8-59#7@SC
M.NHK.L<\?6Y)]?2?0M[B^YK?TCSIB]7 MD0\ZM&,][8?.J;>ETCC*,..? K)
ME[KF1^)M#GS#^G4[<FJ<7D2J%,H^INQ-U(E5Y!H0J>M,[B4IN\A0<&BLYDC,
M!0B*;P> PXN2%<>_<8"2[ISOLBWH$7-A1V12Q(5PCUHW<IZ<I;J@'07&FELC
M;?X/B1,L5WT%K..AG:F2K6)'X92/U7L>A;;%0TR@<W5M]/\+K_Q-4IWL:D@J
M-3Z!IVA?1]?Q3]6V)H,/VP'Z0CB- ?D6[ :-=4EK8X49[#_R[N4>:M2!W.!!
M3:LQQ4+W\0']"KN$U=)(6)6,-VN_DZR\+(A%OOZQD'^C=UHMVZMBUJ[MN[[F
M$K ?O@2JCY[W3D,A(V\Z]>TXY!_TFV(8-(%= U=SM=RMRJ:!LEVD2X@8Y4XT
MZXFX7>;;BW7LT\HX5''O>?V2#2:=[;8[S3=)=B($=,:^QI]#Q WE$0[SB447
MCUL*"?Y4XECSTBC*RZ> L''4SE2*AHF+JY2D6_N28Y]UWOC[EQD?E]R],%<S
M.#"RK!+T8).'MO!E].YT F*C.939IO9@[I.-\^6KD79?A':0$XK4D)MMS1Z!
M2&QB"7LWHQ>_F.KUC]6^T9+B?(M;]RZY'-&G"(_!EY[F0V3RNJO1&"0LA05$
MW=LD-"66=:BM=4?>=3?T$UP-5"0@4UI$(C5GA8:(( =4*@_M&L>H+537" M!
M&XRX6:".LY\#/\/%*<UVU^@ZF<'$_UX&M'KLJTCDUS2IYRPL5&G85"27Y$Q'
MF^([!OBRPUN-0DPRR/LTK]<5)_F+M/R&;7)C 8PIS1S9@XX>U8O.>SLZ6J,[
M2%QZ9F+Z-R70X1'EOE#;97<?"^UOJQ?2CV;PM1[UH"5\P G$H0V%VP*(',RA
MU^RVX,A*H*:N^I][:[0\Z2SGV3;DM'4-0[!1A91<TY(,C^ \84W-WG$B&[%Q
MG)W](SYAS>E\^)H1/;O/BVHZM.T49X2CQ_K]NDJEAKY3L_\ ;)2X:.IHI/^L
M*$(.Z>.A-GK'.J/%?R(<8OI=L?[47%CK0.2 B<O4$8 $[/W;'H)'XM:I^^B!
M*\5Y\>TX"5U+GWW9*&T9)O'ILB.](:$<T0!V6;KF=\9A'H)AS6^&AGIHG]S7
M5C2+A'*L"'OM^3(K'08]3LI)"A:H<%-I:;6".>*O!)Y(C;BTP-[JNN'[?;J&
MZX:<.])Q45KQ>)9N+>-);\A#=4;.7-TI]@D'CU6E64^_Y.C?[[[2V=F?I[E]
M0)4;HZAZ RPY[_ L@0WV+#MYS'N[4V1M2KYQ%HBA>20+B:"G;L#N#!*4YZ/B
M6%,S)(*RE2*7<7<RJWY'/3>SA>N17 Z"+-YQ"%@):5[+D76E^"LNF:C77Q$N
M.'/Z&K(X#G!C?R#[[H>[^NKA)F0H *M;GC4&@RN.59P+C@Y>O7*G?#*OE0X]
MQO90^RFW0H9?$?4K75VXR0(<C0UY7AH*&NG,+4"CC8/[?V:_)LX+>^;W_C@0
MDF>.RSV_>"4<G!QIR3H3,G$LD"#[8X:(M>"JDBLT*3I'Z\J3WMH6C4;[UX)"
MJH>@]\]AV6PR#^5N(8G+LX8Y\VQ9%:OPM6-O[(A[#A"^XI0%9GRP;I*L^9M>
M^DP(\UK:55VPX1AX<+PTE?QL9T.9XU0YL"2/08 BG'!XDO#L(H:'/TG@(((V
M^"WI]Z8=X7)Z]&SR>5*'R@"-,_7U:=8&$]2D@\T3/VIZY^^7N2C"1"0B1VZA
M*9"IZ'U8<5O+%2NL$8.E_%[&*\JYJ(ED$_FT5%]*NBU+^_W[9>VA?GL)_/W@
MN"^U:VMY>:!< Q&&?8JIBN@;WD5G^DC5ME8C197]M6\'(;^&L=H[%,;9+@'K
M;H'J M5Y.FT+K'>L;UE'4N5(Q5D"[>) -,)[V90O$,867<-A!2G?WPNP=V7L
MN0^GCE9=ZOIN5X--W&O)0Q+)N=F62Q$YY%!7MCR_Y<N1^P)5HL<].?; )UE4
MST.JCXAW^7U]!T+HS!&S+Z-5W*A6'9UH01@*PG'>'^PHQ)CRH\8.0=NR4TS,
M:U M3Z2Z^9KBH :3Q/?I^QTS'S;-W%\,KY)'1FX+DPUPTB_*:@3B-5N78+*!
MH[03">/^[-=8ZZG/$GV1=LPC\-6=-@HS>MAE;2SW_75C'3.XW=L*BR9$N$^2
M$@N;%S90[+]R9%N-8^B?([H#%AT[/MJQ<-S7/U<:F62;Z[)6 /3_?%P\DZIV
MY+:PBVDWJ#P*DY_94/*F8>.<:B4A5O7#D1>0F?!<T"$S"^)MYLVP\^090#5-
MF_KL';Z7RHLN#L3D?ZSKW=,RN\_JQL50,&B]8_@ $_X'8"L'CL"OSTY_O2(>
M4BDFSY_P]M!A+-?=-9[-Y_HIG88@SFT7Q(YB[SH;&?CG>4&-K:@M9^C[@UN6
M =*S^N1!'J]6P!K08B'\0[W[U/M-B.J_ADP%*_L(HU@()%FWMS9%@#RUO=F.
MD;=00-<JVYK4[9V=\XZG<SLZK4VYLE8A#I&PS".M0.V-X)ZM2KS--&9LBY:"
M%E2;C@5/,F8?I;,>!=^!1*7 ^].J^K/]PJEK09MN8U@G5/A>7R1DZ+KO'X!C
MD_3 Q"&R%!*1<*V(P(G2T%1/L7M^0<?QLNX"N*"QJ;T]8W SOPUN/DS[.982
MWW\+(%.V"Y-S+C_!VOY#L?_6(LF\9,LH-4D\<COBI]GZ;>GI2FN\>$''+!M,
MP*.UAL@@ ZLKQX'QN\E(.%J\.T6>Y^C)C6<E/';>T':3NNW9ZK@3-O:-5"@#
MN((N,T08?*XL,DDY&9+RMP!N7QSF*2_1-X2<'PAI$%9P=9P>4%_76K\=/22W
M:=Z6J^'9B(0WGF#)'_,D;=)OSC7&.QU8J?:F)X>@;>5N?F]E$[5H+6A5PM%J
M[;JB&(2.<ZHXV$:Y8BO/TMT_!O_UFVGHD9&1@C:I]_^+__G_#6Z FF&FE+?W
M3J<L.%.7.A47=<'JFS2FO3+0)*73M^+Z=_4K*^BGL#;UHYMB;2A0=,#1 [%+
M\);0L#.J%:YF&/.[XIPWR9>5YIG4D%A,AT[RN?/Q]H[@4Y0G*I@E-G5IR/\
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M*%WF:5%30C1?+9[#0EUZ*KRP2Z51_6)5FH_-2S&:C?NV#W5$[\1^NO7^$IT
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MY;M81"^!-,BSO!YRG(^XZ7 6'A4F]BEN.5D7MJ$:E(1."!D=BS#[6'>$B.Q
M:LY?H1'FL^7?U+ ??T@SF"]L"V>-8OD&=[ ;Y3NU#L)TE13&<UM(4X8?>F#.
M71MAYT=QGV%$[:41*[\WDP+LJ2V@?:GMTF/-3!KW:'0PU/W6)U1J^?)K?E)
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M#?&0M<%"LI>:*E"JYLNI5.PI-/FM+%HW9-JKUW0"8N$I_7:<+U,OB^+JJ5C
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M&PW3J*7RN>-J>_:<<LZV3-^D?W8A1Y/TWE,W]*\_X^C(Y-C&?TMR%\_)1>;
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MTR \+=XH/GQZD&;,:]ED]I,',$19:O3#M[AJ@=<GU8M"R#9$9"V=X"]@VQ7
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MJ]&:@UYS]/SWANJY"9>6%6L$D$"))H)HSWM8@L%<S9E8+2UIZ3%:J$NI,$3
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MTE8<[CERVNTEC] LHGC%D^+Y/@9V*]J_4K\>+*Z'8Y-("K!Q:V<^:57!2AK
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MQD2*O,]G%"6[KR2</_FHLLDUJH='F4A+E<:?-DXH=? Q9NI?GN#=/H5%2XJ
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MM\O%LLJ3*#IH%BB>K4ZX.O']'PP+([L$:E-V!A8.39B.TN!$JF\P+&NO>NW
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MAG8O.;WJ*JJ!\+ZH^%P7@.CE9:'WTJA0,T%*9.QJ9-5ECP/%"N\(]GJ=E?M
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M9I\IQ['TJ<T\YA7K6T*7"3?B13*[< ;M$?J.R8*4J'CRN;!^@7KDAEN88R!
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MH_B./,X+^(>F:+3PZQ:UMG?2NS@I=-M[ ++;);'/_:ZN?I3!CZL2@\]E5_X
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M13AVB0=3>A]!?]6-*\(ZSE/Y)CT5;JWECHYN[I:TH<>:,-4MY2!&74K[3 B
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MRUPWE2._J%?L2JJ%HR>S(Z;U0'1E_'S(QSW$CT+L;GAFD&K=- 77EW90]<=
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MFK3B-YBI]#O)@P/L$D=5GSVSMO$S,2HJ)V1QI^+\IEP-I0@MI/;!85'  ZJ
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MC.$BZ:),7ZQ@@B)36$^,UULB\CN>,#\60:>'7I5O2*"Y[=,.ZKK4.!3& ?F
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M"% $RBSK.W4[\ ^OH[X/14&"#8RR7I8[^V"IECVQ+@XZ45HZ83>4*WW7 :8
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M.D;,T0D"$[T2(GZ[?!\7,*Q<+_; RP+;9LR\<P]/I+4G_7,55'$<+"&TL3W
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MO&8<6N'(/ ^!PU-G217>/R329;:,5RK+T1[5K__Z_+:WM:V@W,'X$"W:'WF
MO@,1'SKX@3T@4[/X*Q9^:1*EV2[KX'_HFX&.TE3] **T3%=6V">]9"6/;Y'4
M62+XU)YC):9VM#:\]OI7FLR7]:43]<Z5$IZ^E41ZCS82K2]JQX1J1_97TJD:
MW+-V#389ZJC=JF\3KVK<>A(MSID;Q+<?L1\^5OXRE@HX["JR$>Q4PJV:!'+$
MS E%8D]:#^[5R$4>N<OWRN/IUIA^P&=N_>3V"Z<'9V-)I'*%UZ8]A]%HB?+;
MB*";:4J^5\0\1G/>V%PW:UFPB]P2#R1W6RI,Z(_%IKS+?C+:JX'5IY&@TLU?
MNKH]G;J\);A*5'D6B.$/2:EX!(*"$@>Y\*XE/N;E%4>8'<UAC*5!NHH .P!5
M,0!9*"Y>@QG7-NI%F\5(RRQD2^,VU9.-,8:-EHXR:T@=T;NL?ZJ1,L^7POV6
MFB'@] 9O_XMFD [$5#G]^W^> N2JN=W;\&WQKH9Y>D+N]54&N4$''<HA-UKM
MBSY@J<Z\N99<7,-HT4CY@9$2^3G,%\D2LOEX7M"4EZ8](KVB_.V;9AZ?A$<8
M#9NPE9$9Z0.>F(%-(J<M+G9/>,KP7[7#'2X3((V!M$049(.<OS#KPID(#6O.
M+69'KF.<(]M'7]-NE*B!=Y(HSR(PPT??*C_9*I&D\WIM#5H0KV5J]VX\#8C!
M,I;+JN1KS?]LW&,NE)/$3)1BM.7J(\ Y\*&_G37]I1^BP")F<"5\M-6P9-..
M&"&I$@S^*O$0\H&U&X10BIE1HY:OLLH(UQ1OY#0G=H(B7/=G/76N>*AUW3R<
M#WLA6*]Z_IT'A0<_;VN3'E]R@74]+]56^5RM$T)>SWL+J0B_A;H ;%RN\3XP
M/!&_E=2L]5&HYJVPX95.88QHL8J&;&+10U2^Z2E7A*'S3T @FY,^Z$!38VYS
M+E$:2C1IG5/)S)]F3,ECV!=E'\[Z/9Y$JG-@D'$)3-0Z'6_>_I1@ML(@4V5Q
MEFXE"G$8-RY*TO%-<!6M5Z<[Y\!2QXF^6&%0<SO,GW^?Y=[U(?[V(<RX-$NR
MXG9UJZ]A;_".)<D/A,7J2/4F>/^7 ;KWM\\5@HX^NGLT-.;G/*F; S>20-5!
MM4\/>G&3F!X'-^K:WS_\6W(^XN5S5[/=E#3W:RANTLF,4>K-PD'HZZKGJ16&
M53X^E\\-9>"^F++<U?P:[62LM+!,6\=^YAY#^\X5G%X^TGFW9M3#LK1/55W,
M=G+4"4@=>/E*(_=%XT740%/L$T]Z=ZSMM$VJQ_SQ^Y7N#&_O+&J/SE5NON!-
M&@6&#=CE)<#G/%'?^I=E_PJ$><4F9MI$LLT!19=#=W#R&'8UJU5WTNJ(Z,A"
M'0>F;F('KR3P7/A6CP$>X>)7Y T>4A7UC%O]&X=O@$&&V5-GF)6$K!5L"UW@
MFE:WXA:-( \/:7P/'\S4V1=?/G5^2Q>C&R_L^ETS_,:?Q_MKRQ;613WCM8[!
M1\_N'50J3W$IA9U;LCRW&G,3I+ER;EEYQQ5V>.Z*BN /3RI5Q/L=BY1 ,,VY
MSA%2#2;YX5'I3U=7P SN4SM.EQX=(<]7:=VV&&^P%CZS*<_LRMZ>BF!>ZN*N
M[7:).X;_.PS M]/W9](L/A7JZ-# TM:AY7"(A2#$"">5@)8V*=R^3Z_GBK7.
MLF;499KVV%7ZH^]4-A^1DNN)%!$-,$@7/.)W+_GIW: 7W\;6!3\<.LU%]CI/
M7&(?+^!15TT11E^E%%9EZB2IAICTP=F,)]$2?NUK:\+_(&9/&Q98O>7O>7%Q
MR&>[PO@4J$Y3]B?[P:FF!X<B-( ;)%7KJG9QC1Q>F":]QOT I9QI?8T&N.;,
MK^0GP+<Y>1RKJ=A6J?S3<&@/96H==VE@'=O&.:>U(:,4/\[5UOFN"].U,B4P
M?7VTK6&\QQ4-V]1FB"^A2<;8OVG>L?\2&+D\W.IX^$JS7]5,Q.$]"#M-NG0T
M4W63X'U&5.$?SHZ*>M/C1Y+,/F20AU@67M85MY2[H*<XY8!<@1;&9UF83)MQ
MR$![@KI(MZ,O5X=A)@[*?B2!UE)FA<5".@_NN]8O8K[=M=(ID*8)R/E,3)R=
M2U)CY].6S LS5Y'RU?IV;#9SP6W,^$Q=E&DR8++_4Y_$*;S);E7$LCZ/BI?%
MG'<5&-9D'!_A.8<M]0$-1_SQMLZ KS:%R&A]O&XBS00\R3';&Z!3@>GQU:-D
MT^RB,GOI Z(=]/OKK[^ )%V:T"/2SY]EG")_!9X$J4O1*=]AGS4DI-&*GK]4
M?6_I)Y8=2.__LW;!Z;&W5<ONI'F^2OD\0'0>:O[I(4AN^VE\F;(.%C@"[2=.
MT7:T5,\I2616?5V5^PN0?S<YOZ!ME]!-0_&ALE6PL2"T:6"I+7+;,+'Y]P $
M3PPU@.8#,Y6,$Y<6WN8QC'_>,@3=);7W;0N2_$W7?7J)J6_B5;)3MS-L+9 E
M:;5'"/62[. N#3N'RE.P;H(A;2U?S_*S$X58A_MX\$6*PU(;5+30TH[$]8!_
MZFHE\*B@7-U#4FI+%/RK7G$-"]C1"=I(E\;D*@1P>ZRMP$$_@@V7<B ;+,U:
M/.ML+WGA .)"9/RKE :S%;?&^H:VAG1RYX_5)9GEB:AOT JEJ >7?QM4SU9M
M\"PD2!VSO.CX3#(T<=:("3' 7$@)),E2Z*%QW=U"V.79WWW^=1U?]O7PS^\1
M7?%Y.B\]E1C(B_;94B=B7.=JIE@+^$@75IYG52B*^ 4!9WXH1V^6QE*!50YK
M(46 3?IFK0!1:U+YU0KA4)U<O(\VZ1I]<+'"B]YLL/PBR7=<"@M!3+8J!<TE
MENN\)7]WD8+#SBX&$W.>;5]["%P7]EG.ZW.?<>?2A=+/-5^*>,@]3IW@)&$V
MP38:WPS_^G[GCH>A07='+1QV+WJ_Q^A6PU/+'F-(:J>0D1I D^18WET +_&R
M)"@Y_).DZ]V "LU<MT];X!58+FS+S=)I3/CZ(_JXGLTH<J8%7*[=.H8[-F5X
MB7]BU(JHZOGQY_RV#FGJY#&/-U''#ET10,<C3SEZP#Z=@ 3J4_QFR7JISC5=
MW5A8XY*<5M&99J8S5VX3-<@I,'%J<'';8+59#@NJ?SD1/TSC^2.+^9L1K4TE
M(>E7,6U3.F\'$A&%?/9Q-M8B#>7-\$1/H7$U'YO_H*6(&-+_.Y70_VMCX2'-
MIA1#X*T)F<?Q18L^1D9XQM+-#IVST+@CU,(E,"L,NG^4;B+4(; @M,U)\3_;
M'MV"V:=(B5EUCSI3%;<],7T-."!;5GO\XLW-Z:0(VJ]&4EC6#*Q'/F9/#*?Z
M_43S)0.JUW*ELA3U\G9'=(\/<]9@*>AMG7]/=*GA\,@ZYC1QDY0)"18@D3CJ
M5)TBFGI#A\;Y('E]FG1I_"[4*#7JNN KN_AQE/;HODA,H\[%5I;+'DU8H; @
M(;<$$(I3500IQO%^Y@7G^0.7]J"J"'\2T(1I?%_L^YO\_4[TH-6@>[8M81\Y
M L0)(J*[<U#.[OHE[HVR'V2[8?WG[UI<<X*9W$]B]Q3;WA,G9\$-/1-)9;?B
M<V=+I_>(F((9JY?<HG:L=IT)7^>&HP8L)W&3/5_H+__6\I R>X"J"[YFW&!I
M;1S?SOMHFVT9@CW^#>0%5N@QU^75(MC>4,WUR88:VD*W0>4.RF/7FR1O( _^
M:(FT.]9]CG)1%9D-J^UR6QNQY,4*4W2[@]8]1X,FWE2O"OC]M]'D\N%G'1BK
M=D:X#-;,H%;'A^:U+YH/XR+B5^U1V=H,.0=^-A8-]$21*#0PRY09+!P04\$1
MGS=A-,+H,R_;%WR/ /2%F6F"U9D( *<8+8#((^.VP1E?[,P ION ?%Y@ID0F
MNIA^20Z$QPU250R0$6A<&'"2_P_E@ 0 )V[G$70K?=L#O>IBXIWX*^W-][>D
M1TIQV7K&;X-+DC%"VU!B_@*P;I?RXG4>-[6\P>=XKN*,G]!:CZ9^E'5]:W3\
MN*L85\^_&=-VH^/[ALA>D#,&TT-\')"J,"^]@@E>E=LEZ5AY/P"A-FWI7P+0
M0S;9'_4+6WV\LXQ],LN?%;,\6W)\,3C)<-T)J7;TMI4#B7@CO(Y"2C[S)"TQ
MJ1"3^R=I@Y@Y>AJUWAG0->O9_3 A*>OJ[U:O836J2!?C3'QS.?#V:E+F+T R
MW-FXN'E9A*(@N,M6U4X!@R@8:91S<_TM,>C*F#JTV:O:/^%DD_,C.LP@HOE&
M8GL*?)P6\7,^,/1ZQ2^>TT&AO6*%-1WS>G.2$FR1;E-C7G!S \ >1[MJ:%[J
M'+M2O*(YA65"*=\>D_6 =X$"4>' YWOTM&.= N,S1XHLPMJ9#'#MY&&>B,K#
M!QPTM$RVDC%'SPZI<I^?>CS\9KP%$+Y#DJTS>F?.F!<].S@][\8*AO[/'XBH
M8DY'C<&<O(Q/-":*+M+#3,Q(#*ATQQ[QY(/*;_2BP&.:=L\HXV[112?/$R*P
M O>H=4<ZR;OBD"]"X:HNH50#H^_=%MX6NN%I(H+U/9Q<:9UL;RBFQ=T/"B,^
M,$M[JK2S9,7(3CKB8=R$97F0/O76VUNACYO].M4)&](ILDR_\D9^831=D1)6
MPWK]AA9*247W(%/3]*L#<?AIV-Y[4?HC]=3K&-X).A6>0H4QC\%3O8#T!S4/
M?ZIWKQO\:".L5<N_XM)-16<.? UW=_>D#,)96.Z5X8DM<15#*D+AS>JD1-E-
M U)H-Z(!S!!)G/G6J]6:YM:@[[TUAS$LV9AOE6E3RU$WW'X1:$JNGFH1388U
M;@RZH<=;"PNILOB8J+=_0NV40,M8(5B1#2V]UXS['S"O.&FIB6*XA><AU2S"
M!49BJD+TX<B(ECA]8Q -N/\JR:UY"(X_5Q/DUCB)HCK;LC[MGA#>VLK%]RLM
MXN%1)#0R"+_E1WL]"4AD(=:HR )CFQE2S*OZH-<E 2PR5ZO<QDEJ?<X=OM>M
ME.['53T;C)O7PYO^M9KTTE@;4J:WTF$JR"SLI]W0OS3\2V%,V1/3+)/EN?/1
MMQ]^C0__8I<T5)MX&>!K+YN?T#-UIWAL53 >S<O;J ]JMSHI=$@4!J8VQGC<
M-T<4\F-JC;5!VL2"^+DA20T_XJTHI(R:B@'N>>&3KS(5O/9Z@H)Z\KR;NW/.
M1V)?Y_&3B5Y(-SW_V/],YO3M7<+U9AZ/\?;FB/1D_HNT18%"!3D^2&F&YPFV
MDHNN&X'I _^#0<>_"E!'GHH'[)AT58@7?3$QY_5+VZW8?&,KWFJE 2&^1X0L
M[ZA(Q"+%X[@!S ,RD@/U[7\#J8?!( _F>M:I;>R*N!&YD+YUO\-0/4RT$FGX
MB)]QOO%&FQBQ&=?K:\F 4,/P Q<J*CDQ&:]E840ZR2';HG#/K+ J[R5#3P#!
MMTP+]HOM>O6FXP6  %@DH]AL\ZOCML_&&_Y"0Z3%P(-)]?BA\2K!_4H[)$*)
M5(=26XD4A6Q$>QYWF/,B68E]^@1KD.PC6\Q998>_?>&%C0"E]0W+9#R!($7*
MG0H;6\)ZKQOODOV-/D_U^ PD?ESW9R/&W='SL%IGLM'%TA&8W#N3[VVSIH+)
M1*+F]WD9 !HFHI:C+SXK9U6]&'CW_/8Q\W>)*?#U$JOVIP/BF%NZ&]5@Z21O
MV!O=E1=#8U:"\2^YN^8(IY/[5W.X#:#D\,9)F1Y0D,N'9U;!33>=?>9OQY?)
M;>>6;KS!^M %X-)(AZQEO-M!!PIL7XY--\%1$"S"]N-/WS"%F$'<)66R?;)I
MI0^=V([/P35_0!UNA7'%:L,0HTI'3$G\^UT] O'QW^CZG"-K?H^9?;.WLZ7K
MXQ3IS%V63:23:<FAH9ZR+BE9%2(-^T4CW?K3IY.676WI?AQ^G,#_XJ)KPF0+
M%Y@EM^ZJS7T1W@;K$&@=?S'8F>+E29NNM9ON7VI*(+K"UAO[>+=M=/=0AUNM
MC^ 7YW3.;5IU\WY2[H7N.<?TO%3"F3KLF&OA5Z(Z[GSUV[.\I66%QJBOW;>G
M%ZP7\3:I5H, ^VTSHI>V,*!J"GZFT1AWRMH4&X0$U^!2N4;%S87U\GN=+E6K
M[R:)^MFEV5K-<A$?$<]$DTM['RK+<-(Y'3U^-5LL:S$7FGEY&5\I4+=K@)Y/
MNW]L<N,DF6<B":H.259V/IS)($\6Q8M0UK(L)!"?5V/*6_=T."U>=-V]01A=
M\+(4RG&4YPRZYO\N UAX.M(H=HCZ0H^!BS3"V.B+_70 RM/D_49E+AS2M"SM
MEBY7983#>?0I57\ X&DX<(K&%_NDBDY2NXIYVK48 0KP9^IK%YIE[$[M;7EA
M_DG"I?H@GX..P^@>MW'LC)HLLW=AKE09RG1F^I55V1V-_%8<M49A%U]R?NH)
M#Z8?RYJ9.LRPHZI@.2'MSB]EU=3XN=VA/?O\C/<H5THJIZ-,]+*-:2S1FJV+
MBN'E7."*:'?2'*P&F0>"\#94!,$,GY$LG0AJ:9LJ:9O$5[KORW@3LUA6Z0K@
MF707V1U"FR;B^OHW,!360]>!;Y0GF$XU?+$-MBCE73W.*2(L3Z#4@/#&UXG[
M +Q"@>TRN#XX#'^8**#82QH+R4N7CY&F0&_YD*([:^6LX6-?IU2Q86*JCC:/
M1NJ\01;A^O"&5=TBG$ PT$--P,T.+!DG[%_6E1S0R,M;D2A8TFDK]<9:&H#I
M%/XK<-9]0=W+E:DU#2CH:FL@8?M=>?,F>:N.2]\Y3X:)3@)_JV'U8/PH,J#Q
M0$D[?3".)YG4>V#RMLK(7"Z.]VRO*S?((2DE=U&)>6B6W>IS.I9;%EK*7:PC
M\#PHX=1:*5C($>]4I&!V*P\K6F4R+=0"6_H",[]9XK[NFV;T-M),2O4&.;+(
M)7#2 ).X?U#R3/M3^V3BP-/(MK*3,"<(I+@&H_IULMT'"^P0#GTV7>?[S2(9
M D/PP3D:[ *8P0_AW)7\A-OW<B8+RV3W8F&MKB-K+;^?+LETS/.:T/$"W9T*
M8!]<=T4'+RXNK-HE8CFVU#APV]Q)[0&%[6F8=U4(OGK['B^"S)>"4RUT]S0K
M_R&PFU_96>W9>NT@36,W!'I>]2-]5S96?]DU, T0!*%Y>1PKY1CPRGVH1QQ?
ME*;O;?MES)"\WG%E>9V/1QQ):I]<FMU/W0:RRD4<72#>)Y7QD4;QXD)86@A
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MN1I]Y2UJ9N#X@M<Y$"P[A%#,'"8:V]?<\D+2Y72.4GSW-[6UY%FL+/K;)3(
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MXFX/SB)]";<DCI(CMG@A4QOZE.TRL[*2BB<QWY/H\CTN@!J:U,@D2O%R0GA
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MFP._?OZ/V<PY\W'@?75.J#L[)POZDW.%5OBK\R=,,$,193\YOZ @YC^A9WZ
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M<906 \B3^%=M20\RS2@,*!9E"MBDF8-[6L9(?[7W@S^.F8LC,#%7E,Q<CEK
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M8B_F%Z2<,D;9,64,)\$@D'K#?,J2O-+V=J,P1;*6W*-J\)!.P(VRF,(IS.'
M)(Z8Q4FF<0KSY.RPF GM2:6C:B R $<FO\2RB4-29:A$)$72 ?<*^29$GN95
M=[*I4KJJ@4>!+I$/Y.M:_*$ LD"<L7I3E=!Y= S&9@/!D;C%3%XF4AANKI8F
M1]V.NI,R_W>2\D7Z;.HDN*0$;Y(VY;.8>.K:U#K0AL)65VDI<L6^NDEN%+>W
M&HK34B+LR>/B2]B@@-WSKLDM;TMG0!>_]%MN,RO;G*+-Y-,Y8K[_=I(9T\AH
M&XMGDSK@)?)I'3&O":\QA_WDS/.#F$=IV^[\Y"(QV+J+EJW5.H[2BP1/$2.
M,*_2B0M!I+RJ;K(*O"K-[&RG=K*Y':[+3F%V$6BD\_.HPA$83,@UI9V^4CA]
M5-FZZ>SY38;7MWR!S^CB(4S6%%]228%V05EBD.:/-([*)]BD:E+9#Q;5))O/
M@0F3-94L*0[5*4SJ(#ZKDT^;?F$X5A%(\.ZK9@]2^,2,[RM+2HYLW;>FXY$*
MVDVOG54_M"@"^04QG^<!%(10\ZGI**--!HW4V22"NQ@P3'I-Z$H2\^U^9[K=
MIHWY]719^-1([F2^HX"WK=XM,;^W/[?Q:<7OGI:7M#Q@JV3HBMXEG<@1,Y7<
M259=C.BN3S$2IYW%$6!_!:K@<H3%JS67/O%7\4H@E?7]/L 4K.'TN)1-E?Q>
M*:X5LSOEZ9UT_M339A@X H6*(\ZQ,.^2(8C #2S*B#B1[?G4(9BQ8TKXW>(5
M\H6R+,Y ["CX/XQ83YH;8)H/$/0DOF,^^[/3)B>GRHPKL%?W+SAXQI>41$O)
M@8KN$,U'+>,KAH25;U$MN%K?O]#^VI #,A\]3:($.XQ[L[*'.0=PC050IH\W
M3BG_(O/>J@:<T;AOG%""9/KDY(3R+[+NS8J_D-+L*7X!R?2)RRG%7\P&VU8S
M*>VDY<GKCY7FB)U]\82)Z<9F>35**DT-DN9Y$^2U--2K$5EI7U!HL#=;9,@.
MG:=GM*29BX_2+H8,DI.!,I&\V9YU$UV&#\2'#6,82_-6'Z6%QBW$I''1$3"=
M=[=W#[RI9C(2*SV7:AJIU7UI4A'YA@T?(Q;0.W^5N:407,NZK6GH8[7"5Y"?
M@.L(P,X6LK,%;4)-:_M/I31**W=-S:A3$28CIT4_*SGC%EHFU,VF0S-JA%6R
MO,V':,PNO+_@S3E9Q_SD:VK"%77RD[1S$\ Z"=R"<S"CGA5OITJ@M!'3$I(>
M0KR(@PO0F?",LM*M@/F5@%(BI2V7"71'@'<6O,4TG< 1,SCY%$:<?9\&B2W)
M]6R1QCK*K1+SEE8)TW%>>S?R)VET) GZS#4<UP6!TB4@[9YJ"@!MB!HVO ,.
MM05(GZ0!4HW#W3@Y7+-T@A/),4F<B91.U2")^Z8MA:F7,DIH=GV4#K72<GN!
MV@RV%23?8I<2%Y0L[7+,#S)]QP0O?+FKDE;.RY#Y3[:'G9P4NNF*>$YM^@A4
MBE9SEJ]Q@+'G!A)TRLQNP'(>G6'89B:G46/ 9K,=#Z&P M7#3&.Z*MXB]>H3
M!</SV*8<> .!XD Q#^%@TJ#FW+^RFC0#,ET%'T01VOCT!D0-&Q7 C)0T]<1?
M+#"/%_UM(*HL\G: IFO?@XA>E6]O0 7@!\<,>[ZXKPP#JI+#6!H@3)>X!Q%S
M,V^&O(VR^1&Q.IS$Y6XA9^/V<&F-Q-(GM-0AF*Y)*PI,FZ[!%Z*>N'8MQ0V&
M>)SP5%!J+ER>^LJV"/S"4QY7\_,O\Q5E47K87$_ 0\UIND[=7R6&Y;[52G0L
MKH@\)V>7OU32JW6/CO7D6LMTIF\DGD9UE'ANM=9<T#"\)CLE]^&UI6$:-2T9
M[X7*:;1$RF.KM4.\OCB\-J1@U:0_WG.5TTB_Q,,WL!_(;-H)!@H8OPGH-3G6
MG2<MYT% 7W@>4WNCH 5;,5DTWAN7@VPA.K!S?)-PMX3@9H&"X'HA*BG\P#E0
M*-!)B6U8]4HC%25G/,^G3-";6;S"V,@WAG)UK0)0%*;EN;HFQEC7DUJXW @T
MD9+L89,=ZR&KSGR6MH-LP2;5J02PJ,VDUW>8N+M+W&K/RV_%C%I9A%*2Y3=U
M9="+A2@^P6ZIRG!1JIX+$#A&/HE]\I1V+Q2N"ZZN:QT89DR7BJP[%ZP& 6ZZ
M3*6O!SM&<$ 6V^3T5,C2+U[U@VJZDC6)KDQ8Z6J(6%6PS$+M9B/!076"9+IH
MU5W*G4E^F\M?IYK5%9[ITM8D2]YHZ4L%P5L<Q8S<4XUZ6'^PIHMDX]L!%;;:
M8>X'K:2-.:'I,MKX2F-[6:T_#5VJ:Z//:KK(9EJQ+"F_=26DMBZ4_#4<WE*U
MSF:Z&&=&FQ2%8*\6R6IT/6&:+M"9T0AK"W8ZV[A>U;O!)S)>RIMDRV1EJ4\I
MO<-K8&==RH&#03=>,AS?UFAP^:U9'?6R8S=HQFN0D]B/-UBCK']02EJIDYYR
M;GY):OJ:I)2V]N.ZGZ7GEML)G?S4[LX#DTJ7*WRNGDG>?7"R^4Z%5'/Y_QY1
MB.$G_P102P,$%     @ F6!?67I:'9XW9P  BR ' !4   !S:'!H+3(P,C0P
M-C,P7V1E9BYX;6SMO5MSW#BR+OI^(O9_J.T5L:,GXKAM^>Y>,V='61>/8LDJ
M+4GNWONI@B)1*DZS"#4OLFM^_0%X*[(*B0L+) "IYJ''D@ P,[\$D$AD)O[^
MOW^NHLDC2M(0Q_]X<?3KZQ<3%/LX"./[?[SX?O-R>G-\?OYBDF9>''@1CM$_
M7L3XQ?_^__['_S,A__O[_WSY<G(6HBCX;7*"_9?G\0+_Y^326Z'?)E]1C!(O
MP\E_3G[WHIS^!I^%$4HFQWCU$*$,D3^4'_YM\O[7-^^\R<N7$N/^CN( )]^O
MSYMQEUGVD/[VZM6/'S]^C?&C]P,G?Z:_^G@E-^!-YF5YVHSV^N?KZG]E][]'
M8?SG;_0_=UZ*)D1><?K;SS3\QPOZW>JS/][^BI/[5V]>OSYZ]7^^7=SX2[3R
M7H8QE9N/7M2]Z"BL?D>?/W]^5?RU;KK3\N==$M7?>/NJ)J<9F?PUR)H.[<;O
M7Y5_;#<-.4.WB$[#W]*"DPOL>UFA(4**)F +^M/+NME+^JN71V]>OCWZ]6<:
MO*AQ*H2=X A=H\6$_C\!NOEJNLRS+$(/2R]9>13@5[3%JV-,%)B06_1=)FCQ
MCQ?I\F%)/O'FW>L/;U_3#_Q'IU&V?B"*G(94#U],7NWS\2]>1*5ULT0H2T5$
M,!L/1<R5EZ X6Z(L]+U(B3)F3XUDTAF'5N03Z6PQ>Z"K!-$MH?#XO08B[WCI
MQ?<H/8]O,NS_N<110):LT[_R,%NKT"LQS/@,*"G(/F,.Q9J7+L\B_$-)<W8Z
M#4U<?RES1]!(]BRY]^+PW\5\FL;!14B0#"047-1/(XG7**TE,UM<)>@QQ'D:
MK<_3-$?!61B3M2OTHHWT1*3W'4^GLN2KE9>L9XN;\#X.%P3;.)OZ/L[CC!A?
M5S@*_1")55MI%(WD7R"RBPO)Z[;2^/E+G"$R,=;>781>)B@B0 5DGHB55MA1
M(Y''."9&1Q:23Q6?)9.D_7FQR2+57>L"IK[)C;"?G: D?"3+S".Z"+V[, HS
MB9G![:1U:=KHT&WBQ:GG2YDSHGX:23PG)[H5NO5^BJ7&:*J1D/_.";<HB=;-
M$GOB9=[WV,O)OH$"HN#5PAR(Z%0?2>O2?9>BOW*R,9P^RNPV4/O1=Q.]N\J
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M#8U7#S@NX_M.T (E";U;^EEZ6]6]T0JC#7,1L%A0%S[1DUJ6U\1>ZPI:_79
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M@8A5PY Z;;%IX):06;3S[I!,A^Q_)8*@>^4LWOR.6T!'V-4MO-2X I'LZV6
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MS>/0JS-79+K'V1)EH;^I5MI]@N9HB"=H)K]TOGQXDJ8/U8<G:49\DJ8/0&7
M#[TFPC'5?W[Q>D$WN^O52_%L47W9+3)%A="!YF8*U<O)&LLP .%BKCR]#F!L
M+E*O#3Q+2],#<>FB$O7<;F,_GR,U9Z3*HH_]CHX"4-NEP44(L=N/_C).#VPX
ME(.H&(-E-UCAI#ICRX75R/6?&WI+=(^8#9 -"$.3]0BW::_]*-?(1^$CWVZ7
MZNXB@  7NE=&P&/!B )J94,#O@M^)WM!D*0=-/^&%KW@HA[NX)K(.W2#UMI8
MXJ9A TU"BK+L.[U=!6*7"=!E:J[,]UVV"=C>9N6L]N8)ZGW+CF$OD/U8 3VT
M0T^RW=PO^>6-T==>7-18@/ P%J@^:!5]:T%3X@#"3/-][:X2B7(-V:K7S>6S
M%@)9XB'I&PM"9Q#=NN,_SI.DY?&2.= PNML+FS(7$'Z:KV!W"9(*91!ULQ<(
M:>IY]T3#(E"?<=6-[)V>KN' 9D#&P6;/?7EU/<V^"'_#NPC/EFCG,GQSW7VX
MWCY<;^_N*#9=;Z=)U@*'_+0!AOPP;SU&#UQB=U^LM_K*FD7J.-<S\E(&[SV[
MQ!NZB.9(D"GCD:^;!Q*SE=?*_: 8\_)8@,:-CV(O"3&QXQY#G*?1^AH]X"1#
M 7@C2;J)>HU]9<S5=ZQ$MB5+T6-8/PK1Q ]NUSO:A/;QH.HUU.CWRI( ]F=&
MQA(>.P)@@#>V62FY5IQ:I*F'@#)VGSS8"]NV8R5#_SBKI4J>:X(78<:OE;9I
M8ST&6Z2"%IP5QWF:M$D35<C_T0"A1R]JQ;JS3_5O>:=Z.M#$BX/R'ZTA6T?[
M#=_#\K9Y4#5-448C^VM/2XC2;\BCY >S^)I6?J;E!.G[,'S6W_%8IY^;%-_[
M?R?E%PM!M+XYJ3\ZP?&D^>RD^.X@K@^!R7(5>=D")ZNR%@A.CI/U0X8+VGD.
M$-)5KN=XQA>''L@IPN?"&A>)M+!W#"]9F5B?'=#,XR_KYI__# E3Q"A97U"3
MA)\F(-M_?.>+"DK 8]%2,K%HLV^HK=;"(LUIEP51%+OB,&;2#A1! A!6$91-
M>0DFD+;2X32Z-EB:Z-"0>QX_Y%E:L'PD"J+G=#*4Y-!O8@)PLKFR=]5NT?NF
M#W1OS"9!#(7=&ZO=5BR*W_9!K^HT9VTJ#J/79@O<1\VC]V5=F(7'U',J;?%N
M=W'4R&5SKB\.7Q]*Y=$?<B]\C_%=BI(BEZ/00/JD3.R'45CXP=N,2AM&VK]H
MW%H&T :T8R")6VE+.Z]=CECH1C704OO]^\UM4K"XWCR6)[(BX#ZF_/B#+QM8
M10 0RN:JCE8EDKQHDT$B,#:@#DZ9&GRN]66@[8W/;>+%Z0(E]#ZC?)R.J&Q3
M-K7-0'I+R$C9?Q(M_WJ_8LB@$&"*!^38/A/"/;VQVE0PIEN6&@=5!IO('N@T
MFW\R8P(,,M6Q@$\(LD^:4\>GOH\BNO>AX QY&;%M0$QH>ZCY_,B0DV=(<,0,
M@\X[<Z^[EW9J8[9NX@^F=S2\Q^?DD0F[SM^R5HR!HP;[W&>K,02A:&QUW"2,
MEAP(,P"!#J[AQ67#NEL.4+MZS##7D!(P8IV_M156U6MIE.OO&HHJ7%EWLMTL
M%BTV%%;*W5ZNP2?F!?07V3D/^\X_UX"3X0:"KF^9%4W;G:P5Z>J2R*(>@L)8
MA966_BAM7:Z" K( (:.YCLKN0KL65"#B]'!&^%)\@'Z*P1'8/9G+8[';UW54
M((X@?%JU4@SFDTSC+'P9A%%.>=G<>)W^]*.<#%H^A;AZR+/JC?JZPNP52HJ7
M5+CI%^]YZ1>=+T\VGY[4WYY0I":MKQ?/,53?IV\O3 H*3->@H'SL(< =-6/L
MY]J^8*C>14?;]N!$5"]#\W?,)Y-H5P#FYCX,/M:GJ>S)[)<U>P#^Y?N@'S57
MC608#<+CB<X^WR:3V$MOA417NN*>9J[WQ\!/1F-V96C3M?]PN-M\/6^?;EAZ
M;;_USJA\8)^@HZ'<'.D9BE69L6Y![Q5P8>A.OR<LN[2#ZZO)DC!9$OI954WS
M.Y%D>GWS7?PV#*>;J=#8GC")>0%O+2PSAZ0WB.D*Y[Q+*2W#&WOR<^#SH4;A
M2 1ZC.\,RU<K+UG/%C?A?5Q4N(JSJ>]3H@D;5S@*?<)NY62ZI$L<%03;X_5A
MQ^-5#DY=5ZWA)YOQ)_4'&C_6I/G&H:IJ'ZH/557M]+?<Y'<I^BNGM<@>*?'D
M4X+G0J$.EE9=%9%MG4G*H%1TR.1T,?14J$#:0FSL=07HA,?FP[\F""T]L6_1
M*SIH,)L;.IV+9PL7&NL*OC[3"M]Z8SX/%;Y'V2<.%;Y%4%A4X9M9,WGKY8T]
M2DD+1AK=_;1/)6D97NQS/Y7O5VU.:+@J@\T]OW [6;JOR) .SCG+T!$9RX)N
M9LXS,I*7PLK><\T0<%FYKPT#J:7G'&[9>8GK%5'G^9&A&G1R\TNA!G^;'_!D
M9*[Z7.&T)SNVSW.B-FWF;UY;7M]]FU:).XBQ/=?8_W.)(T)%2BNP9VMB.9%_
MH^(/-P]1R+FYDNCL $2R3%CG0CW&JQ6."S*OO&26%"P'13Y1??_%B\D0=K8?
M.VDFQG%/*&#7?5=3'3ZY_O8CJ,*'=;9_2_T*,M/S-,TW%\#<2=?N8#],7,+!
M([,UN,SR+,V\. CC>P5P6KT<1&B'>@@F8SFE@[V\9#U84@Q >!E+/*7/])R=
MG!^?QT451%%<$[.Y_=APR(80Z9MPJ@61[W$HC\=68S?08!(-8=$W]71O++YY
MR9\HHW[-39R:L" %IY/]V B)AS#Z;,[[]XA*CW_I6#F/,T2V2@Y 4 _[T>%3
M#AYFS;W#2)BG#^'-XAN/9G-MZ.=<<W ZV8^0D'C806?3(E>S40;ET@)\V1(E
MMTLOOD6K!YQXR?I\]>"%B0#+_<>V'W)=/(*:8<RA42\OY6)3&;*7B+NTLGO8
MCR*?<A ;8WX*EM9=(R\*_XV"(6=OOV_8C[]N7D&-,>9!87'X/4ZV>%33AMW^
M;B(-\0&B:,S!4N:G>BD*:)(,6:2*RT/!S=I.>_M1XM$-HM+7C0+4*&+3 %6(
M EI;+&HAU:"@C9W(BY67>QL.3P5Q7XNQ4N0!1,[8.?TRIQ*8+:X1V3&KY?=>
M8(# ?>Q'2D0[>'UI-'>Q*;QR'=XOLY=X\3TM2S?3U],162;.8UK?K PXNL-Y
M5E8Z(S91\5=N^:Z/O/)=]?<FY(/E\^GEZ^ETU$GKHQ./?G72?+9J,?[K\E^\
MR(M]=+-$*&O1=XTB>M5YB[N"X;\K_XDGF>I#D^)+'5%4WYID>%L>J0&!G.6T
M2-TECE_ZE-Z(JOPW\JE5OBIHNO+6A?I_)Y](NM)IBMYQI?29)Z7RZY/NYR?5
M]RLEJ2F8%"3LZ%!#Q6C"ZZ@&/Q7XW>MM[K> -I[F>X'(K$75,I#Z2?A0R4F4
M\ROL:*@F*Y,L038PMY,UJ<&24&T7;14+Q/JDX8+Z8R(N6G(V]Z);E*SX4?=P
M#V,A]S) ;$/'9]NB"#@6J:)0;EX?,V'W0H&+\;$WX%XO1#:'VFN#<9@@>\!O
M49 QO4\0XJ:'T;:LIJ8>9Y>8!%B"<NTW;("4+]$/!4$#K>>&2ORHR9I'/"3N
MC\9VD*L(!?>TU$Z>/!"+@[^],QL[M+-SF+4I-+I+I6BS )J;V<IY$N9B8>\&
MK@,.F[?M/2&S-"/N F49]2@>)R@(A84_6*WG8S^)(#4QMFTH@&X0$&.K6M>)
MU?BWN'<04!=C[VWV\P4(^("P,GMD.?WY$"9ELJ67H2/!866KM6, P2Q8=^*O
MM><,)]?<R-JMAHXAPJ3>.DNMY*T[O>GA@"S(U6E!Y/SD]74,,EF&P*U)[XF3
MJLWO7A+2X\ UL(+1ACOM7!$[AWA(Q.8>/F3H1HM'M5G2ZN@*5BK<0.#UC:("
MYL<5.6<3[?'NZ?TUK?QT5]W5 _,$;.\*!A),0*+7'"IUFF;ABEY&?R,+XS):
MEZF+TP1YWPC;&:(OM*-CS$S+H -(]W<)&D6F0$^:L5C#,CYR?8+(J8U;-*+;
MT!6,>-1#8&A^!E%UGCR)>=%S'A@+7:L4@^-%KENX@@*3;/!@:#(B[1)G*"5'
M)VH.ODS*@*<K+VE"A011,T?;43/%>)-ZP#J"JAC1GE":$RI#%'Q!,?D'?50T
MWO"P@RE+&Z6Z&]I4FH"Q73+3#9VI]..,4L-8$WJC!"WXL**"Z*P/R;EN3>K;
MA'#B%94\TR_K]E_XMW@J8YBKE-D+ONU"<*K"LLC1UR91=.?$:FOF_J^'R&',
M[+T3W \<FV\#!P#0TAO"-J'B$IG;;0V]"L"9'C ,P[T% !S49HM%Z*,DO7G
M.:?^*&W+:FKJY3VQ<+D4@\N49NFVR:R(X8H8;#]_;[.<^62#7E*#9<K+I'AA
M:MU6P_F1H4"#?:QK)@\0)N9"=Q+L(Q2D])F\:_10W2E2UV_[:'S'NT65',%)
M$-68L\Y"KG7PR@L#J4(;54,GL6+R .XX-MA4+>NQK%M&-*OU.^7S*6L0)Z%4
MY@^TG2V#F=Y *\-*.STE&#?\0+ 9NX4'*#[I ]O)$X/M1 B;L2HF= L^C],L
MR8ML B\K+^ (P5(A%%+=G812@3,(5&.U9-O[N9SEXB1$NPQ 2!B[N.]JT7GL
M)T7VCN\G.0K$!3*ENCN)G0)G$*C&2M_T.^T]N1->_U.=P?B!MM:=>3X2U76&
M>CB)&)\9WBVE#7#5JP(U@LMG+#81=_)+*#S&$X!4S!X(LKF'=B(O)2O('S32
M(\YF25%_J*[9U*I][441D=&Z:I=6#3E7T7L.[*0Z:.$9U!'C]6^K:*&J#OHT
M#BYQ[(O*P$MT=A)K:;Y /%L^GM'#R8YQ_(B2+"24%Y%@!=V;"#.YH+(WVT%E
MK5&K #-:NZP3:F9/<-G-$B=9D>]/%O$=M%D51-GM38>/=>B2CA9C];(F.(P/
M#1@-!DO"^N"O6S+V;#&E^\']SFO=NS@"S2T(Z>)@@&58L.XJJD5AN4K&WN8W
M[3 :4:")\D!FPKSXN.#]6 )OM8P=<DS!:W.@V( J,&K]IXW%?94G_E*Z1I&P
MGZ$(L;[3#2NR9MT:W#UF\[=&5EN7]D685XN" ;I$7GHK8>T<N(>9;8XC9AX>
MNZS:M)GI@\7F[6EOZ$;=A*91AK=.V]S-!VQO*G16. &P+/'@A.F[CH')I/+B
M9E/[V7Y1PX2#]SZ:Q7S[@Q"YKO_;QOU+$@;WI6.)*WR%$>;O/MB/B3(_$%3O
M/F@.+)_F]WF:;=%W17@-TQ0G:S%4\@/,/QB*/5=:J!39@8#ZT#LH706H;6^M
M.E+L$>8?#)5=W1LJ'C\@5KU+L0JPPK=+G*=>')!#64.A/%"B[O./#FQ':LQ
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MQKY0! E 6$50-AD@)I"VV6 93QLLM6@:<HNS:5JP_%:TJ7(ZS=\:.I?WFYH
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MKCEZ@:\!ESB&YP'CV12PN^4@J+,"XF/,(?$-!6&^HJP6Y,-38ZNAY=#PB(9
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M%I_^S,C2EH?ILDQ?XWL%A5W=P%R2#1 Z8SY";LQ9\<=9K8AE]25.+)?Z6&Z
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M%9G)E#C!1B(_Q/RCF8V$G]+7BPL(H8_&?&J.E0K0L'](5@.P-S;6^CSN0S4
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M> ,:I(!C&F[ OTX2='L6^ZF<*, UREB87)=,T84%T-S,=9*<K+$, _9=)^D
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MD_X+=CK5-]]@'T..7)6YAA58L6Z9I?ZS/$-)PZ (*J## +-P8*!XC( P&;V
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M/= 8"H 2=3/E %#!18H'[6=_Z$4OMGH<X_B1G*-"0J)X]BB-82K$3@4A=8;
M%4\S7'74V.9-UHN+8RXXG!ZF'I52@4)$/B3X]YH%#R^FLQCIV6J@@4R%-NK9
M:[A<0>CICFT$"-M[E0/',%6&9]]5CL\0!->GPT,7]F<M&:M-<,A:LO1(>\A:
MD@3/TCMN0N4*QT40I,1]:;>IJ1LYJ7P)+M'VW<(U>E85CRDHEMR =KLXLOE
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M#L3>F(\&X*9X%4T?]/SA'$=>ACD0>&,IDRW7$O_&:*NA*V QR09A,.:-89Y
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M(,PM5Q?TK&;U>_J?.[)YD-_\_U!+ P04    " "98%]9ARZ#J+BK  "N]0D
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MCK$&$)M)_#PHME.( -2;S+E=N:=2#TL^O5%Z]LEU =-/"UC'O^D2:KDIK(&
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M7@4#AR80U\8)-V*%#.;1I'%:S:V(?[E[BL@+O#[4%1U!"3!U%%RKY'E[P<*
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MNRL[)Q78-1ECLM9>J8G/0HQ8<&/R59$_WN-RQP_HYN%?KA5HDJ4S03'+DJF
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M9&Y3XT3GR,Q0I^SJ-+KQ#P"OG@D<ND)L.DD'4&FQ2MPOH_2@QW22RX)Q5 :
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M?'!..8#4NARJA)C6@HYFB=(-%-A-6= E7?+^Y5-%"XU==_?K;N*:+/;HQ-7
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M;>_!.GN3A*B<634X@>?AU5'0/^FNMY\JO#UD='NYNBC*4=Y.GWCC$DJ>TUZ
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MQ5LU5@%G3U5I'*&)C05G]TU9Q!@G%<U%[-*Y!\L4+\>DY/F>7PL#)K?[:C3
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M80(PZ0"('JZ!,[92-FN:UXZW(QG'F#E4@9G1")1IU;$&B*GBM"F4<,P51[K
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MQ16"1NF ]%"&R]6BH*9G1IBJB9EW4M H?I]N[&;*1!4 7:3&6'!GI ?5O^C
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MNG?A\!IERJ'[@MH@$\]%3= <5L*UX^<A=V/HVI'08RYD!59XPX!2*!3/-F_
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MG_OHX/TUC+U'S;4M>O+K&BG@1(;\'DMLEH7G>1(\,J0ZZ+A ; B.>_PU1C$
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MC1VV\'N:F!2">Q(7E%/&M&IHS_1Z-V([ZUYS&&A6 17-2,/R5(6)"+RM915
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M .'0&1T1$">-X)I\#"RNBGV7]$62H$S2'&FF__Q"3C@;\I75A@&'JD^F)_6
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M^?EO?_FWO_[EIV]M_M\/5G[X9U_2ZN.O_;--+0MRJ3X/_JS1GZ -S<A.7&2
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MR^<&,Q$LN:FF1K#LX)!P:@+6%/5MDV:2#@4WKK*20G!^?L$4](PLDJ],5U&
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M!=>8,-@-).L#1<^8CT$; 2& MOJ*RGC89.T<V.&!4DE_$V=4F?3F+E&D.H-
M037FF "@$@TGSQ)<JW-A.6?P<;C;'HJ6,5>%-EIRRM&!N8M2DD!1X3:&0F+,
M/Z$-B81F=#PNHO"%GOE\.C4M:%3]H"@9\V!HHP3C!#I@ER3V7_*GU76V*'DO
M*%C&W!/:8$&X@ Y5^YA83?2@!$O5#PJ7,>^%-EPP3J #IK.BQJPC8]X+;6!
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M-Q9:>BH<ASS\/B6&J&^%&_/YG0H][>?%;='$O2?J0\$3]5SDI?W0$XA/"SZ
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M4$:1'J?P8_[R&5TZ*9''^'6:?1T(=XA&#_^KYZ,*_.LUM ,OKJR)>#Y1<)_
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MP-00\:Z)D])=1H@':R]N#O4N&#OJF 1&3KHE6V1A*]2FP_&."W )I.Z*%8@
M=K)SEQ*8)[,.NCIFS!;T*M,:A1TP Y1'P*Q@@+U+<\"2Q U#-K$6K8&I<<T_
M2(U"^Z-Y!<<!J,<>=#2/2J$Q<0W5R.N%5F5F*OTH9L6L=T"Y: Y=L8B.(),K
MU9H56L9T <U3;?TY?4&:*39 Z_1D0UBTMCAM/*8O-S/9*K'I." XJ?=U^$%1
MWDG: ZW,S$#,E 09=9-POMSW!\!AX/5%<VQ-"XB8+?;ERRS#U'_G^4'&*#A>
M?5R]ND%&!RW>Y-SML^+CJTU5TW=-XOPU&VF<\9]E<<:M+R^.GUY4WUXP?!:-
MK^=O793?9P];+/(9G"..)ZD5T9*($0*A*O8Q\7?LN,/0+Q8R,1OPBXV,I*.G
M8SF+9K(OV"$T9I9<U^">C&GX$=PC:?EXX \@OT0W^M&S($[#1_20=/[D[IP=
M45WIJWO:(20G6'P@B6ER!OOZOO/<*CSP2MD1.U =*L_='$T80]#]/4;C+HQ=
M[P\$Q4@LQ12E;M+8=].RXN?GT$^3^X?/ZO=QI-VPHQ8'0@1B!CID([> Y8Z=
MD8Q96M7PV.4B)CX'36M&M3&PQAV5[79.?%AM'OSG,*_2%:;](W7IYKECZHR1
MS_<Y_:7G<RH&9\ZCQO"+X_B+Z@.U)VE1?^/L4SH7@#T7@+6Y*JED^O@>BX?L
M*2%_9*R*W0LC@'Y*\:ZIJ,.<H!#1@'Y*Y\Q,=3R7=+$$$KF(J;&QY3#=F9KJ
M("!HCGUP5HJ8'! K:LQ^A06L)\X)/1>PQB]@S:T$W'DV8D2I9.5(F'%S@RLE
M _F#[HHHGEDZ&GU16=A9:EQ).\U!@4'H0,^$%,Q.96@INMD!#T#L8%C98G1)
M2VX#?+'JSE"#S%CE%I \ZE0BMTP5YGX]JL)=F8>ET68NU>#[=,TZ/#]W[&^C
M@#(W8?5+TP/=@%E)^OP/#_O E_CV0)W1CSY@9.&L0%]=%]%N%X7YQ-9.O(IS
M(KT\FZ#RJ<NN>0&=L2M;@6'38 4Z;.WG!/61@_;'OA+6J-VOPQ!T_!JRED\L
MN4F2['BI)%UJ[0YHZ6HCEA>/Y%EO?CW:5EE*3ZBAYX?/&IBV>F%?]0\'ED/\
MK-%%?]<&\=EU*"5O &96>?_Z\N;B)LPK<:G".03-T1+EM)>MC%S\#9+.[G/H
MPZ'H-4;+?AL"A(!4=!B*YT28K^X8C*/,KY=VPB[N!(8%0/JLU=U-^$(*WW?A
M0;H)4T*QD. J[@$^FJ.CJJ(:?<7][/@A>X)L%3XX+&7A.&&)YU_:"0H.ON,$
M0#LZ/CRU4,V["%-D-<G2+8D?MT[X2';[*';BP\UN[_BQ L8IQD;W1X]2L,,X
MJ:^'?RKT<$B>F8_@$?WIS$H-%4JIM*KOB%09BWJ@E^G34,9RJF>]O_+$^YXX
M@?]/XIE4&$._ 14;?$_2])RU<E?Y',8=HO0$@=<?"C*^5TF/(^@ %DF 3D(\
MEI] ]5C.4L6-):<]%"!\EY"<XL&J&_\9:[LMO-_>PX4$W\DT#;WXUH"@9A!_
M#8B*-0E;0_%$]%5)YV^)#L[E2!K:(EZ8D+Y0F/!]5W!.H(-VE[%HH]7FGM"E
M7VJ*9X46E?4!AQN@@Z2FW)K\Q;J QKW_O$W?19O/25&&F3W62ZA&N E9;;&"
MR4]1EA95QJANS_\J+:+U5UD1K>I["_K!XK7>XK%>-NJB\=&%P[ZZJ#];MAA7
M.DM4**Z>;/X16>IB7D!-V!Q)2[:@N8AD'E]>6ZSX.CDO^6I02"JZVOO%B7VV
MY $@<)JBA<(- $%(*3H&#QF=5JZ\F/M)<E;KM$.+:!O ?3Z-8QVFN(6@U4M&
M?ZE,[PP= )9LB6B>HJ/4"5!1:NO>M7-0V'2B]FCQ;:/WFR[-Z/HN-Z96M>VV
M>J*V44B\FY">Q.GI^YE<1W&;A+KDJQBW48.BQ;@- '<"[MEGSW]T B=TR<.6
MD+1A3M^3(+\7B]H$)5)#_F\R0[[\T"+_4LMR+[^U2*.N^9Z<[7>E8OV5,+$D
MWO*%_O:9W!.6]5/]\9'$NQ^@*A<RTFQM?SB;T+6T=.*,"2Q [)XNF36)76D<
MEOY(<SI7#.63?4KX.F,UU.^B\)W+=&3 3DN?J'CNLEW+D/A,/R':8J2:^2>9
M9BZ^OFA_?E%^O_2C5#-8Y%/HN5GJ69P5-O>\0NT%(L"MXFRAD1B^FVLZ?R?X
M'^)(4E/'C#DC)3Z>=>CJ'$3"94;NJ YY_$*"%_(I"M.MY*0T?,0YJ?>Q?)L-
M\$Q:'[]$X_&N!YJ3?VH@E^:%+OVF[($R_:'FY=0:R*E987P=96.WZ]9(<W)[
M#>73O !N5&0="7 ^TIQ<7T/Y-!N QP.+F,MI$- W< \A)94>9TM' ?&N7EW:
M5)5J.' XM*S0J85#Q;%9WRQJ7WZ,O=B8/J!OM"/-VDN+U@V$O$CZC]]W'5Z=
M^X2Q!=#?LJ.JC-A*W-C?,_ 4Q<VEG9"KV@U6?@)R\"N>\Z=WJRY_KNQH1P%"
M@ B" +NUJ4IZ&=81YG*7.0&[;Y)7\A3WF"],(HK0JZ;SIJ:JYBGK8PM$<J$#
MX#-1$4_!9IE_<?D<$R*M3\S:\IMB%Y93RTTS>4)&[MASLH##=^2+!I.%K;$+
MJ>CQ64$TNDMB'1#OF3VZDL7[*%$\E\%M;(M^T=T"N,28J4\_' ^5XA<TMP,3
MB6S)L;"E7/,M25-VCWL1$\]7/I'!;XU=$%$J4+U=5TPONJ;B1[-^EF;1B;L@
MEV4&'IQ  ;V?+4J?RR=V];KWXZ+JMY,22<0?OS5V8>5AV,@H1X>E$I7K*+Z7
MQNCU&N);M4/ $-"+C@//E\WL1ZIR2X-2S]7?[8M='WGHTH%RQ=#)A,E(E1=V
M+U!9K"&G'?;VKLEQ 146+X\&57IKH]41NWKQ= N#PP]#JZ(,5':>6:(U_<?R
MJ<PD%ZP.27OLPL(#5HF2>D-<OTI2?\>N'O/XP>!0E+->QL3Y1 WWE(0L*%J0
M;L@&T.B/71MX "K:W$'7:66AF<,EH<<OZ:,CW8;XCJXA.DM KZ'5HKLZQJ\&
M8]54!JP&^Z6_E *)3_'8 KUJ[S"![Y)H2X#"7922A!Z$F)GW+BZR&M=.7.?F
M*&(6?NC&+.3C+:H!JS3)?,33!3(TB6K2! YM4 ^ M$W4Z5>79,,2>3^2D/XC
M70=.F!RGGZC>=M<;QJJ ""BVW0U'CV3\H(G^-!M!(>K0"6!W.ZX !HEU3\&"
M",8/K+AO".UC3 ET\E==DX^'YE_D5VPZ8[P=B'6H1@_0:$Y)=3_':VL';/K"
M*L',E@N[YIS4SZGVVV)?/8A%2\+\DP1OK#8;WR5Q\K"/,LE3M:PMORFV:UK-
M6O'<#3N?CQ,K/R]EKZ0]MIL-QF,EP>BGUNHA &69UEY#Y&ME+=-2\/J!;159
MUW'D$N(EUY38>[(O;_:84[9YI'V276J"1\#6_V/PT^43.K"5P*T=WP.]+5(W
MQ+Z4GF*9=:B>]=LB ENR2,6B(MCXG?;)AS\(MC4Q1@(&< M]K0KFS*Z/M1$M
M.F%?G!M L,D-6Q&['(+8I0YBQN[0#2!V:1-B;'.^"9,TSO(X<2<M[M'H%$$Q
M$,#NV&>$,2AJ<0@=S^9.#S-N\*_DI[)LK &A+3(WH1OGV1BN&V>L6*KJC5%@
M=^RK^ND6E8)#Z'@..P%.<NHS=O,_;F.;P4FO+6+7CDM4=2W$/="C!*9;:WU&
MS/H4V%4DA>9@1G'^!HUWC*B#ZUO9&%!)L-);H\\L]%5\$3@)U3*_LA"/,%W%
M>07RZM6@QJ/D3A!0IAS*=DG94'+G.7I@J"18Z1":B*WHXG$T__((CO)M^F7H
MW46AVWZH7F8%2SI#8;;2ZZ/!'ELBR"ZBD.XKJ4^GF\?FY),]QNC XLC>=^/(
M&J.6,67L":U6=-ED\623[&G'V4NBS!IJG=<>.ZCL81O%:9ZI3B<(CB'C];(C
M>D&.BS!"C$<0?D!8:U8]/<)[K)??W@YH($+7>[N73Q!^2-<C'7NU6;(M]SG/
M_I!';PF:SQ88 3WH(5B-&16[4N@<?].,9E(% 6D/9 >44K'L8*A-HIGZ.D=+
M=IW%[A9<!P;0#_O6?J TMMXRAG('W<QO'USEZI#7UHX%-$ 7\HA!+Q?3GM2=
MLU-6C!'WL ,9L7Q)\6@28D:!+8,TZIR(I(I+TAX_>D$N-4W-I"3;6&8?G-7C
MV&S250SG,P:/'[_0:1VJ_S9A_AC[WG-QZI=R7FL$:,B'P=M-.!X#>&,(I67V
MG"5I9SYK2IN?)%%\4(.D,P T/,!@?("&;M+FS"DAZKK/]#$2C0 %R>!]\TB0
MY+PQC%+TN(VRQ D]:JS7,X)#I.X.#@>P"1\H5R8]@23$_?8Y>OG.(WYA[M)_
M'*U<^L-OM^39":["U!=FSM%6O49VV+(ZIPP>%0T[\!2L+CXM/$#0)NT6R$SF
M<:S'T_:,S9P,/M)UDQ+'.Q[B;V\OI*I$V@,MSK+'KKZR )"*[J'X1!QV*5#<
MJ^^SE#G+Y'X*<8_YZ1$E28W :GOP47DM9'WLP$@E=0!\;,FB[<Z-982Y[/UU
M*G<JASJD+W:0JUH %6")&6*=\EO'ODM^B0+*7/:*CBY\@N[8\:ZC$92RQ3H0
M[_WD]^N8D&:8F"Z2LC&P V!'PZEF$#JF>5@?F_#5'QF5N(MHMX_"_,9(:IHH
MNMFQ]PVY\I?3U;!Q<>#J3$MEGPB:6P(/1/0Z^ @(PC9-BHIW#VGD_JY2@)RF
MT L!8REL4JGJQH6*2$57964(J@J 3C.HT](*YG-)1&?\M>/'OSA!1CX>ZG_^
MIT]B.J7MX9:\D$"^F4#[6Z*V]'<5*(&-)$=D)!N63-*?LFK;T1S&#ESUI%B$
M,(QB[/VJGEENIB8Y=1]4BE/:"1H[8,Q8'R2Z(A3%;$%7ME][-3^PTAU0O.^O
M5E2(.Q?O^QJ+]_W9F%_1@NI]?!"2.&T 0'\Z,I_^\-L]BU45*#+Z]\:?[9!^
M'1W5GG_#+WEB]@H%NIJ@)0'F;7[Q>3E1H/@@9G[R0W^7B:\A:)M.$^BY<_KD
MT"Z_>MSD$H.B CXYKTJVMIM V3I]$*N:K3QBT.W)1LB3O%A%KR%R44EY>EK/
M:\6E$I_[LT]>MP/>R9/5YU?G@LN#JU<2NWY"\HO%^H\UX9)', <.AUT#<[S8
M0%DV:V%I5F4%[P#23MC)(UK  \A'WQK$I5BN-AOBLNH#XTK7<(?!KG^I!>,@
M%ED&[( BBE8](3D",!NK(UZ2V'_)2WO<^LX3B\*A=H,,&&YS[&J6FJ!(2)[U
M+F=IZ2]CGKZ)E*>]I;XZZ3EE71[0F;7= 3M2<.CAE4>VH;2D\K'RZRA>!XY;
ME'-X)N)G=H7-L</X8+R6TV#) J@.(\O0*TXCJRQ-4B?T_/"94:B,>I'T1$]+
MUEH34$[,>O^2$=F--1T&?7\4]/*5DXF!B$/HJ[@.,UAZ_\B2E$WPZ&< Q%_P
MNZ%7F]0"#L2#P8N7VC+8#I:Z_/&US]X_IO+(7D"6P"ON@5Y@4L^WHJ <??EQ
MSSN0:J#*CE"@;/&>@/A@ 5ZMZM1$MTHWT2[2;:.SI$>W9;A\#IT=)<[_)_%8
M!4P=A+A=H5C9XD,!\@(=M3PWG0J39"=J-(&B8(=+HT<;IO4O.%97CA:9'F,-
M.>V@8"![+02SMT3^,1Y]0'9M*.F8O;7=>214?HW);0R^M[8"2@F]EBVP-34R
M(\]WRU/!.O;IB6#O!-#E)NX/1<P.1X4>5RP#$?E]JO=VN"R&OD@U/[]CGMUY
MDR24KLN,RN9S(:\/6\K3Y(Y\R?\DS0Z']8?B;X=C0X\KLQ: 9GQ,?3-(7.*_
M')_JD,<']7M!P;;#.0+A +J6-O]4M1V>D*D?I\8W6)>%?R#G-]Q%+.\%Q=0.
MCPF$ ^@+3'#S?J'R%*OZ0:&RPZT"X\*,5V.^A>?QOA*;IM$&"I\=X2-]ZDY3
M&[TC)W=1*%XWG%+CDNY0_EL04J++$W25]XEX?K9CM.7S%2^(7D-P!+@5JT)
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MT[Q>\&.4RW$AN@+/"Z ?]A-'4SSA#F8/YL(50,N(6X4/A!7ES"\"FJJ'"9\
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M"5\BWR7)3<BG1;"L= ; OFI10ZI+D5W'B^/[3_]%#D5Z;'V  KX#]>?O9>]
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M PD<R.>B2Q+[+[D&J'.26:WS0@AEYZ._R,Y'QU'KQ_4.BWK<\SEINAK(2D]
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M!@!F;W)M<RTQ7S P,BYJ<&=02P$"% ,4    " "98%]9=((P0'6(  ##F
M#P              @ $V< < 9F]R;7,M,5\P,#,N:G!G4$L! A0#%     @
MF6!?685C^0LWV $ S2 "  \              ( !V/@' &9O<FUS+3%?,# T
M+FIP9U!+ 0(4 Q0    ( )E@7UD^H"(^:(X  (V<   /              "
M 3S1"0!F;W)M<RTQ7S P-2YJ<&=02P$"% ,4    " "98%]9-EQ'\(>3  !;
MH   #P              @ '17PH 9F]R;7,M,5\P,#8N:G!G4$L! A0#%
M  @ F6!?60 L_W^@<   ]I$   \              ( !A?,* &9O<FUS+3%?
M,# W+FIP9U!+ 0(4 Q0    ( )E@7UESG.;5%9P  %ZW   /
M  "  5)D"P!F;W)M<RTQ7S P."YJ<&=02P$"% ,4    " "98%]9$F!KN/DG
M  #>+   #P              @ &4  P 9F]R;7,M,5\P,#DN:G!G4$L! A0#
M%     @ F6!?6<(#6R^Y0P  #%4   \              ( !NB@, &9O<FUS
M+3%?,#$P+FIP9U!+ 0(4 Q0    ( )E@7UGMG\/_77H! /V* 0 /
M      "  :!L# !F;W)M<RTQ7S Q,2YJ<&=02P$"% ,4    " "98%]9ZD;8
M!#09  !./ $ $0              @ $JYPT <VAP:"TR,#(T,#8S,"YX<V10
M2P$"% ,4    " "98%]9CVU)[&D8  !&1 $ %0              @ &-  X
M<VAP:"TR,#(T,#8S,%]C86PN>&UL4$L! A0#%     @ F6!?67I:'9XW9P
MBR ' !4              ( !*1D. '-H<&@M,C R-# V,S!?9&5F+GAM;%!+
M 0(4 Q0    ( )E@7UF'+H.HN*L  *[U"0 5              "  9. #@!S
M:'!H+3(P,C0P-C,P7VQA8BYX;6Q02P$"% ,4    " "98%]9-Z8<\3I_   K
MLP@ %0              @ %^+ \ <VAP:"TR,#(T,#8S,%]P<F4N>&UL4$L%
3!@     1 !$ )00  .NK#P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>form424b4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SHPH="http://shuttlepharma.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="shph-20240630.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2016-08-122016-08-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-12</startDate>
            <endDate>2016-08-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2024-08-062024-08-06_us-gaap_InvestorMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-13_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-13</instant>
        </period>
    </context>
    <context id="From2024-08-132024-08-13_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2024-08-13</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember29538078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-02-162023-02-16_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-16</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-16_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="AsOf2023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:LeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-16</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="From2023-02-152023-02-16_custom_NewLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-16_custom_NewLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2023-02-152023-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-01_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-06-212021-06-21_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-11</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember_custom_AltoConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="From2021-03-092021-03-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="From2021-12-282021-12-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-28_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="From2022-04-302022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-09-302022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="From2022-02-082022-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="From2022-03-112022-03-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-12-312022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-01_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="AsOf2022-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwentyTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandAndTwentyTwoNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_AltoConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-02-072024-02-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-07_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="From2024-02-072024-02-07_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember29542531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleNoteDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleNoteDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DecemberTwentyThousandTwentyOneNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwentyThousandTwentyOneNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwentyTwentyTwoConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsOfficersAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsOfficersAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember29544828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_WarrantMember29544843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_WarrantMember29544859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:AyrtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AugustTwoThousandTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:AugustTwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_custom_AltoWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AltoWarrantsMember_custom_MeasurementInputEstimatedFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AcceleratedFeatureMember29546515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AcceleratedFeatureMember29546593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AltoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:AltoAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_NotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:NotesDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember29546843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember29546859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:DecemberTwoThousandTwentyOneNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandTwentyTwoNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandTwentyTwoConvertibleNotesDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TCGGreenChemIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TCGGreenChemIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-08-062024-08-06_custom_AltoConvertibleNoteMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="From2024-07-302024-07-30_us-gaap_SubsequentEventMember_custom_AllianceGlobalPartnersMember_custom_OfferingMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:AllianceGlobalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SHPH:OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="From2024-08-082024-08-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="From2023-08-312023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-13_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-06_us-gaap_SubsequentEventMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="From2024-07-302024-07-30_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingOccurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingOccurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfQualifiedIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfQualifiedIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputProbabilityOfIPOListingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilitySeriesAPreferredStockObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityAugustTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:WarrantLiabilityBousteadPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandAndTwentyTwoPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NotesPayableRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AugustTwoThousandAndTwentyOnePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AugustTwoThousandAndTwentyOnePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NotesPayableRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MeasurementInputIpoDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_IssuanceDatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_IssuanceDatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-03_custom_MeasurementInputSharePriceProbabilityOfIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputSharePriceProbabilityOfIPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-03</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_IssuanceDatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputEstimatedFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:IssuanceDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">SHPH:SettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIpoDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FederalTaxableIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:FederalTaxableIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StateTaxableIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:StateTaxableIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TaxYear2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TaxYear2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="TradingDays">
        <measure>utr:D</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>SHPH:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-06-30" id="Fact000004">Shuttle Pharmaceuticals Holdings, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="From2024-01-01to2024-06-30" id="Fact000005">424B4</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-06-30" id="Fact000006">0001757499</dei:EntityCentralIndexKey>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0040"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0041"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0061"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-06-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0067"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0068"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0082"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-04-012024-06-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0191"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-06-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0193"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FinanceFee
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FinanceFee
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FinanceFee
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForConversionOfAccruedInterest
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForConversionOfAccruedInterest
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:InitialRecognitionOfRightOfUseAssetAndLiability
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      id="xdx2ixbrl0618">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0768"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0781"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0782"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0786"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0787"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0791"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0802"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0803"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0817"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0821"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0822"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0826"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0832"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0910"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0912"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0929"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0930"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0931"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828"
      decimals="INF"
      id="xdx2ixbrl1123"
      unitRef="USDPShares">23.21</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember29544843"
      id="xdx2ixbrl1127"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember29544843"
      id="xdx2ixbrl1129"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1498"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FairValueAdjustmentOfWarrant
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1519"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:GainOnSettlementOfAccountsPayable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1527"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1539"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1542"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1545"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1581"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1607"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1619"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1624"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1625"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1626"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1627"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1628"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1646"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1649"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1650"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1652"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1653"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1656"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1657"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1658"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfPreferredStock
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1659"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1660"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfPreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityClassifiedWrittenCallOptionModificationDividendIncreaseDecreaseInEquityAmount
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1668"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1670"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1671"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1672"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1673"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1674"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividend
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1675"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1680"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1688"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1691"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1692"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1695"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1709"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1720"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1724"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1727"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1728"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1733"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1736"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1737"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1742"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1743"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1744"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1746"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1752"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1758"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1759"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1760"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1761"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1765"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1768"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1772"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl1779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1783"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1802"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1809"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1812"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:AccruedInterestSettledWithCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1815"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1820"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:GainOnSettlementOnAccountsPayable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1823"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1826"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1836"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1854"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1869"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1872"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1878"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1883"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1886"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ProceedsFromNotesPayableAndWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1895"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1902"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1925"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1926"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForConversionOfAccruedInterestAsRestated
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1931"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1937"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1940"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1950"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:InitialRecognitionOfRightOfUseAssetAndLiability
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1954"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FinanceFee
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2066"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2078"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2090"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2094"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2118"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForCash
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2124"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantsExercisedForCash
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2128"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2138"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2158"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2170"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2182"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2186"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:GainOnInterestReliefOnConversionOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2192"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ProceedsFromNotesPayableAndWarrants
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2218"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl2328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl2329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl2333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl2334"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeLiabilityWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl2342"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeLiabilityWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl2343"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeLiabilityAcceleratedFeature
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl2347"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeLiabilityAcceleratedFeature
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl2348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl2352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl2353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="xdx2ixbrl2385"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="xdx2ixbrl2393"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="xdx2ixbrl2397"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="xdx2ixbrl2401"
      unitRef="Pure"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilitiesIssued
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="xdx2ixbrl2471"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilitiesExercised
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="xdx2ixbrl2473"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilities
      contextRef="AsOf2022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="xdx2ixbrl2479"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilities
      contextRef="AsOf2021-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      id="xdx2ixbrl2481"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilities
      contextRef="AsOf2022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      id="xdx2ixbrl2491"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilities
      contextRef="AsOf2021-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      id="xdx2ixbrl2493"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilitiesExercised
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      id="xdx2ixbrl2497"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:WarrantLiabilities
      contextRef="AsOf2022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      id="xdx2ixbrl2503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="xdx2ixbrl2541"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      id="xdx2ixbrl2549"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="xdx2ixbrl2612">P4Y11M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="xdx2ixbrl2616"
      unitRef="Pure">0.1046</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember"
      id="xdx2ixbrl3052">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      id="xdx2ixbrl3064">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <SHPH:DerivativeLiabilityOfCarringValueMeasurementDate
      contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember"
      id="xdx2ixbrl3262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      id="xdx2ixbrl3276"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SettlementMember"
      id="xdx2ixbrl3296"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SettlementMember"
      id="xdx2ixbrl3302"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      id="xdx2ixbrl3308"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember"
      id="xdx2ixbrl3316"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      id="xdx2ixbrl3324"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703"
      id="xdx2ixbrl3356"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_SettlementMember"
      id="xdx2ixbrl3378"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      id="xdx2ixbrl3386"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      id="xdx2ixbrl3398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember"
      id="xdx2ixbrl3400"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      id="xdx2ixbrl3402"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      id="xdx2ixbrl3404"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember"
      id="xdx2ixbrl3406"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeSettlementsOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      id="xdx2ixbrl3408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      id="xdx2ixbrl3410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember"
      id="xdx2ixbrl3412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember"
      id="xdx2ixbrl3428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember"
      id="xdx2ixbrl3430"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_NotesDerivativeMember"
      id="xdx2ixbrl3432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember"
      id="xdx2ixbrl3450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember"
      id="xdx2ixbrl3452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember"
      id="xdx2ixbrl3454"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember"
      id="xdx2ixbrl3456"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember"
      id="xdx2ixbrl3458"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember"
      id="xdx2ixbrl3460"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember"
      id="xdx2ixbrl3462"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember"
      id="xdx2ixbrl3464"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember"
      id="xdx2ixbrl3466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember"
      id="xdx2ixbrl3468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember"
      id="xdx2ixbrl3470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember"
      id="xdx2ixbrl3472"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3509"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ShortfallOfStockCompensationExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl3529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl3537"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeferredTaxLiabilitiesFairMarketValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl3559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl3564"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeferredTaxLiabilitiesFiniteLivedAssets
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl3568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl3579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl3580"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3591"
      unitRef="Pure"
      xsi:nil="true"/>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3603"
      unitRef="Pure"
      xsi:nil="true"/>
    <SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3618"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3621"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl3623"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl3624"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000022"
      unitRef="USD">695594</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000023"
      unitRef="USD">2576416</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000025"
      unitRef="USD">139518</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000026"
      unitRef="USD">114473</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000028"
      unitRef="USD">1642995</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000029"
      unitRef="USD">2887215</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000031"
      unitRef="USD">7226</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000032"
      unitRef="USD">14901</us-gaap:InterestReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000034"
      unitRef="USD">2485333</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000035"
      unitRef="USD">5593005</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000037"
      unitRef="USD">21953</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000038"
      unitRef="USD">24827</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000043"
      unitRef="USD">305712</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000044"
      unitRef="USD">333904</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000046"
      unitRef="USD">2812998</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000047"
      unitRef="USD">5951736</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000055"
      unitRef="USD">364891</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000056"
      unitRef="USD">282860</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000059"
      unitRef="USD">446</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000062"
      unitRef="USD">446</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000064"
      unitRef="USD">130898</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">110453</us-gaap:InterestPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">826235</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">595999</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">504</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">62092</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">52479</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">1384620</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">1042237</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">135089</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">359919</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">414512</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000088"
      unitRef="USD">267025</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">304127</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">2011564</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">1895965</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000100"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000102"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000104"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000106"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000108"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000110"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000112"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000114"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000116"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000118"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000123"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000125"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">2106233</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">2106233</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">2008689</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">2008689</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000120"
      unitRef="USD">21</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">20</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000139"
      unitRef="USD">29996963</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">29489055</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000142"
      unitRef="USD">-29195550</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">-25433304</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000145"
      unitRef="USD">801434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000148"
      unitRef="USD">2812998</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">5951736</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">645719</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">839665</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000163"
      unitRef="USD">1231823</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">1761466</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000166"
      unitRef="USD">310038</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">209279</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">634647</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">464633</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000171"
      unitRef="USD">526877</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">416688</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000173"
      unitRef="USD">1001011</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">784312</us-gaap:LegalFees>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000176"
      unitRef="USD">1482634</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">1465632</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">2867481</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">3010411</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">-1482634</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000182"
      unitRef="USD">-1465632</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">-2867481</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">-3010411</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-04-012023-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000192"
      unitRef="USD">2588</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000194"
      unitRef="USD">6825</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-04-012024-06-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000196"
      unitRef="USD">430685</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-04-012023-06-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000197"
      unitRef="USD">729351</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-06-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000198"
      unitRef="USD">928200</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-06-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000199"
      unitRef="USD">1328682</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">14158</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">19267</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000203"
      unitRef="USD">35611</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">35955</us-gaap:InvestmentIncomeInterest>
    <SHPH:FinanceFee
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">104245</SHPH:FinanceFee>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-143773</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">434275</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000213"
      unitRef="USD">54089</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000214"
      unitRef="USD">1675275</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">39683</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">1744</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000223"
      unitRef="USD">43720</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">1744</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-27964</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-26534</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000228"
      unitRef="USD">-28670</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">11528</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">415553</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000233"
      unitRef="USD">71315</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000234"
      unitRef="USD">433807</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-548581</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-718740</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-894765</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-149057</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-2031215</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000277"
      unitRef="USD">-2184372</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000278"
      unitRef="USD">-3762246</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-3159468</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">2104933</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">2104933</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000285"
      unitRef="Shares">1780171</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000287"
      unitRef="Shares">1780171</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">2090890</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">2090890</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000293"
      unitRef="Shares">1742520</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">1742520</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000297"
      unitRef="USDPShares">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000299"
      unitRef="USDPShares">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000301"
      unitRef="USDPShares">-1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000303"
      unitRef="USDPShares">-1.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000305"
      unitRef="USDPShares">-1.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000307"
      unitRef="USDPShares">-1.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000309"
      unitRef="USDPShares">-1.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000311"
      unitRef="USDPShares">-1.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000318"
      unitRef="Shares">2008689</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">20</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">29489055</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-25433304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">78197</SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">1</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">325297</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">325298</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">15625</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">111449</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">111449</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">-1731031</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-1731031</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">2102511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">21</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">29925801</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-27164335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000347"
      unitRef="USD">2761487</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">3722</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">71162</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000361"
      unitRef="USD">71162</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-2031215</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-2031215</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000373"
      unitRef="Shares">2106233</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">21</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">29996963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">-29195550</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000371"
      unitRef="USD">801434</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000380"
      unitRef="Shares">1700414</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">17</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">26518433</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-18840581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">7677869</us-gaap:StockholdersEquity>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000387"
      unitRef="USD">8727</SHPH:WarrantsIssuanceFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">90816</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000385"
      unitRef="USD">90816</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000394"
      unitRef="Shares">6375</SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">104547</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">104547</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">8333</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">8333</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">-975097</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">-975097</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000411"
      unitRef="Shares">1706789</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">17</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000407"
      unitRef="USD">26722129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000408"
      unitRef="USD">-19815678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000409"
      unitRef="USD">6906468</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000418"
      unitRef="Shares">1706789</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000413"
      unitRef="USD">17</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">26722129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000415"
      unitRef="USD">-19815678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">6906468</us-gaap:StockholdersEquity>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000425"
      unitRef="Shares">228489</SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000420"
      unitRef="USD">2</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000421"
      unitRef="USD">2163990</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000423"
      unitRef="USD">2163992</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000428"
      unitRef="USD">49522</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000430"
      unitRef="USD">49522</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">-2184372</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000435"
      unitRef="USD">-2184372</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000442"
      unitRef="Shares">1935278</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">19</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000438"
      unitRef="USD">28935641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">-22000050</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000440"
      unitRef="USD">6935610</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000449"
      unitRef="Shares">1935278</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">19</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">28935641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">-22000050</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000447"
      unitRef="USD">6935610</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000454"
      unitRef="USD">-3762246</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000455"
      unitRef="USD">-3159468</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000460"
      unitRef="USD">2874</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000461"
      unitRef="USD">2970</us-gaap:Depreciation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000463"
      unitRef="USD">54089</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000464"
      unitRef="USD">1675275</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000469"
      unitRef="USD">832014</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000470"
      unitRef="USD">1116422</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000472"
      unitRef="USD">43720</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000473"
      unitRef="USD">1744</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000475"
      unitRef="USD">-28670</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000476"
      unitRef="USD">11528</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <SHPH:AccruedInterestSettledWithCommonStock
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000478"
      unitRef="USD">18783</SHPH:AccruedInterestSettledWithCommonStock>
    <SHPH:AccruedInterestSettledWithCommonStock
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000479"
      unitRef="USD">240831</SHPH:AccruedInterestSettledWithCommonStock>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000481"
      unitRef="USD">71315</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000482"
      unitRef="USD">433807</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000490"
      unitRef="USD">182611</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000491"
      unitRef="USD">57855</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000496"
      unitRef="USD">-7675</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000497"
      unitRef="USD">6950</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000499"
      unitRef="USD">25045</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000500"
      unitRef="USD">-82199</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000502"
      unitRef="USD">82031</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000503"
      unitRef="USD">-28004</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000505"
      unitRef="USD">-446</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000506"
      unitRef="USD">-12500</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000508"
      unitRef="USD">20445</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000509"
      unitRef="USD">75511</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">-98135</SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000517"
      unitRef="USD">703</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000518"
      unitRef="USD">-30</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000520"
      unitRef="USD">-2638425</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000521"
      unitRef="USD">-2984039</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000526"
      unitRef="USD">35982</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000527"
      unitRef="USD">2970905</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000529"
      unitRef="USD">1295252</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000530"
      unitRef="USD">80000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000535"
      unitRef="USD">1259270</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000536"
      unitRef="USD">-2890905</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000548"
      unitRef="USD">685473</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000551"
      unitRef="USD">3935000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000557"
      unitRef="USD">345000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">501667</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-501667</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000563"
      unitRef="USD">2904527</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000565"
      unitRef="USD">-1880822</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000566"
      unitRef="USD">-2970417</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000568"
      unitRef="USD">2576416</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">8417203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000571"
      unitRef="USD">695594</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000572"
      unitRef="USD">5446786</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000577"
      unitRef="USD">56958</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000578"
      unitRef="USD">102373</us-gaap:InterestPaidNet>
    <SHPH:CommonStockIssuedForSettlementOfDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000589"
      unitRef="USD">325298</SHPH:CommonStockIssuedForSettlementOfDebt>
    <SHPH:CommonStockIssuedForSettlementOfDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000590"
      unitRef="USD">2268539</SHPH:CommonStockIssuedForSettlementOfDebt>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000595"
      unitRef="USD">0</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000597"
      unitRef="USD">8727</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000593"
      unitRef="USD">90816</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:InitialRecognitionOfRightOfUseAssetAndLiability
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000600"
      unitRef="USD">365556</SHPH:InitialRecognitionOfRightOfUseAssetAndLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000602">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLXVKFIsS1ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82D_zXC00uKq6eif"&gt;Organization and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Organization
and Line of Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shuttle
Pharmaceuticals Holdings, Inc. (&#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, the &#x201c;Company&#x201d;) was originally formed
as Shuttle Pharmaceuticals, LLC in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed articles of conversion
with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name to Shuttle Pharmaceuticals,
Inc. (&#x201c;Shuttle&#x201d;). In connection with the conversion the Company issued &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbp3AWOqkUol" title="Number of shares issued"&gt;5,625,000&lt;/span&gt; shares of common stock in exchange for
&lt;span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhgNNlG0A6ck" title="Sale of stock membership percentage"&gt;100&lt;/span&gt;% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed a reverse merger with
Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation, pursuant to which
Shuttle, our operating entity, became a wholly owned subsidiary of the Company. All share numbers referenced herein reflect a 1-for-8 reverse split of our common stock on a post-split basis, which was effective as of August 13, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#x2019;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#x2019;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was initially funded by a Small Business Innovation Research (&#x201c;SBIR&#x201d;) contract
provided by the National Cancer Institute (&#x201c;NCI&#x201d;), a unit of the National Institutes of Health (&#x201c;NIH&#x201d;). Ropidoxuridine
has been further developed though the Company&#x2019;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#x2019;s initial public offering in September
2022, the Company has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation
with metabolite biomarkers and develop prostate cancer cell lines in health disparities research.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
production and marketing of the Company&#x2019;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#x201c;FDA&#x201d;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in its clinical trials that will cause the Company or the FDA
to delay or suspend the clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
unaudited condensed consolidated financial statements are prepared on a going concern basis, which contemplates the realization of
assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since
inception and has a net loss of approximately $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_zs7rQzF5awJ1" title="Net loss"&gt;3.8&lt;/span&gt;
million and &lt;span id="xdx_90A_eus-gaap--Revenues_dxL_c20240101__20240630_zCRK4PZjgxB" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;no&lt;/span&gt;&lt;/span&gt; revenues
for the six months ended June 30, 2024 and has working capital of approximately $&lt;span id="xdx_90A_ecustom--WorkingCapital_pn5n6_c20240101__20240630_z2hYoN0mxKp2" title="Working capital"&gt;1.1&lt;/span&gt;
million as of June 30, 2024. In addition, the convertible note payable outstanding at June 30, 2024 includes covenants and certain
cash payment requirements. On July 12, 2024, the Company informed the investor of its convertible note that the Company&#x2019;s expected restatement
of its financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the convertible
note. On August 6, 2024, the Company paid $&lt;span id="xdx_905_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20240806_zZosElncYMMa" title="Convertible note"&gt;0.6&lt;/span&gt; million to the investor of the convertible note and received a waiver from the investor
related to the default. The funds paid are restricted and will be held as collateral to the balance owed under the convertible note (see
Note 9). These conditions, and the Company&#x2019;s ability to comply with such conditions, raise substantial doubt
about the Company&#x2019;s ability to continue as a going concern within one year after the date that the unaudited condensed
consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2023,
the Company entered into a securities purchase agreement with an institutional investor through which the Company sold a convertible
note with a principal value of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgjKBnoYEK3h" title="Debt instrument, face amount"&gt;4.3&lt;/span&gt; million, along with a &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zirqzGcgOZm6" title="Warrant term::XDX::P4Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0618"&gt;four&lt;/span&gt;&lt;/span&gt;-year warrant to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2U5NvKbcKEd" title="Warrant to purchase common stock"&gt;127,260&lt;/span&gt; shares of common stock, exercisable
at $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDNMyH8Ns1G" title="Exercisable price per share"&gt;18.80&lt;/span&gt; per share, providing the Company with approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhbTYHHvDnTh" title="Net proceeds from warrants"&gt;3.6&lt;/span&gt; million in net proceeds. To date, the warrant has not yet been exercised.
However, the Company&#x2019;s existing cash resources, marketable securities and the cash received from the equity offering and convertible
note are not expected to provide sufficient funds to carry out the Company&#x2019;s operations and clinical trials through the next twelve
months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA approval of the IND
for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the Company agreed
to an expansion of the clinical trial, necessitating additional capital to complete the trial as well as fund ongoing operations. As
a result, management  had initiated a $&lt;span id="xdx_90E_eus-gaap--PartnersCapital_iI_pn5n6_c20230131_zo1XdISLnkXe" title="Initiated a capital offering"&gt;4.5&lt;/span&gt;
million rights offering and submitted an application for a SBIR grant for
non-dilutive funding for pre-clinical project through the NIH. The Company is also
currently pursuing other financing. The ability of the Company to continue as a going concern is dependent upon its ability to
successfully raise additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials and bring a
drug candidate to commercialization to generate revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the future effects on
the recoverability and classification of assets or the amounts and classification of liabilities if the Company is unable to
continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000604"
      unitRef="Shares">5625000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000606"
      unitRef="Pure">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="-5"
      id="Fact000608"
      unitRef="USD">-3800000</us-gaap:NetIncomeLoss>
    <SHPH:WorkingCapital
      contextRef="From2024-01-01to2024-06-30"
      decimals="-5"
      id="Fact000612"
      unitRef="USD">1100000</SHPH:WorkingCapital>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-08-06"
      decimals="-5"
      id="Fact000614"
      unitRef="USD">600000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000616"
      unitRef="USD">4300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000620"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000622"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000624"
      unitRef="USD">3600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PartnersCapital
      contextRef="AsOf2023-01-31"
      decimals="-5"
      id="Fact000626"
      unitRef="USD">4500000</us-gaap:PartnersCapital>
    <us-gaap:ErrorCorrectionTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000628">&lt;p id="xdx_807_eus-gaap--ErrorCorrectionTextBlock_zMuTpislNY6" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Note &lt;span style="font-family: Times New Roman, Times, Serif"&gt;2
&#x2013; &lt;span id="xdx_827_zBsHq7vx4ZIf"&gt;Restatement of Previously Issued Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_ztc1gOR7tjkb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;The impact of the errors described above also impact
the Company&#x2019;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B9_zV3IdsUTWKfl"&gt;Schedule
 of Error Corrections And Prior Period Adjustments&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpAZDsJ2HHgh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zil2vv7D4Zn1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z2miWDOBG6Jf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_iI_z20joSFUHD9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;19,543,363&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,489,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z1MXLFGq7K93" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(15,487,612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(25,433,304&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Adjustments
    include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9htjoTqHbv2" title="Stock compensation"&gt;7,843,052&lt;/span&gt;);
    recognition of Series A Preferred Stock accrued dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zljaKMw5yfJ3" title="Accrued dividends"&gt;402,064&lt;/span&gt;);
    correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9y2rds0NWB" title="Issuance cost"&gt;174,082&lt;/span&gt;);
    corrections to the Company&#x2019;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_znckfEMQmWO5" title="Warrants"&gt;416,266&lt;/span&gt;),
    reclassifications of warrants from liability to equity (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zf8dTIB15zDj" title="Warrants from liability"&gt;881,554&lt;/span&gt;);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zVyoTMoi5uwc" title="Debt instrument"&gt;2,213,498&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Adjustments include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z8gOY06XlUha" title="Stock compensation"&gt;8,009,461&lt;/span&gt;); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zvngUaX6yOKh" title="Fair value of warrants"&gt;240,930&lt;/span&gt;); reversal of accrued Series A Preferred Stock dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zFjHB3SKH1u5" title="Accrued dividends"&gt;402,064&lt;/span&gt;); recognition of bifurcated derivatives and recording of loss at issuance (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zSVO2RCnUXYd" title="Derivatives loss"&gt;296,151&lt;/span&gt;); correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zrUKb6hAliXh" title="Issuance cost"&gt;166,407&lt;/span&gt;); and the aggregate adjustments to 2022 net loss as detailed below (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zGiFL1ScJAR" title="Net income loss"&gt;1,967,621&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zYWPsIODHLee" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ErrorCorrectionTextBlock>
    <SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000630">&lt;p id="xdx_89C_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_ztc1gOR7tjkb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;The impact of the errors described above also impact
the Company&#x2019;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B9_zV3IdsUTWKfl"&gt;Schedule
 of Error Corrections And Prior Period Adjustments&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpAZDsJ2HHgh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zil2vv7D4Zn1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z2miWDOBG6Jf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_iI_z20joSFUHD9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;19,543,363&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,489,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z1MXLFGq7K93" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(15,487,612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(25,433,304&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Adjustments
    include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9htjoTqHbv2" title="Stock compensation"&gt;7,843,052&lt;/span&gt;);
    recognition of Series A Preferred Stock accrued dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zljaKMw5yfJ3" title="Accrued dividends"&gt;402,064&lt;/span&gt;);
    correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9y2rds0NWB" title="Issuance cost"&gt;174,082&lt;/span&gt;);
    corrections to the Company&#x2019;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_znckfEMQmWO5" title="Warrants"&gt;416,266&lt;/span&gt;),
    reclassifications of warrants from liability to equity (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zf8dTIB15zDj" title="Warrants from liability"&gt;881,554&lt;/span&gt;);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zVyoTMoi5uwc" title="Debt instrument"&gt;2,213,498&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Adjustments include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z8gOY06XlUha" title="Stock compensation"&gt;8,009,461&lt;/span&gt;); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zvngUaX6yOKh" title="Fair value of warrants"&gt;240,930&lt;/span&gt;); reversal of accrued Series A Preferred Stock dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zFjHB3SKH1u5" title="Accrued dividends"&gt;402,064&lt;/span&gt;); recognition of bifurcated derivatives and recording of loss at issuance (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zSVO2RCnUXYd" title="Derivatives loss"&gt;296,151&lt;/span&gt;); correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zrUKb6hAliXh" title="Issuance cost"&gt;166,407&lt;/span&gt;); and the aggregate adjustments to 2022 net loss as detailed below (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zGiFL1ScJAR" title="Net income loss"&gt;1,967,621&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">19543363</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000633"
      unitRef="USD">9945692</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000634"
      unitRef="USD">29489055</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">-15487612</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000637"
      unitRef="USD">-9945692</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000638"
      unitRef="USD">-25433304</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">7843052</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDividendsReceivable
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">402064</us-gaap:IncreaseDecreaseInDividendsReceivable>
    <SHPH:IncreaseDecreaseInIssuanceCost
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000644"
      unitRef="USD">174082</SHPH:IncreaseDecreaseInIssuanceCost>
    <SHPH:IncreaseDecreaseInWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">416266</SHPH:IncreaseDecreaseInWarrants>
    <SHPH:IncreaseDecreaseInWarrantsFromLiability
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">881554</SHPH:IncreaseDecreaseInWarrantsFromLiability>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000650"
      unitRef="USD">2213498</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000652"
      unitRef="USD">8009461</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <SHPH:IncreaseDecreaseInFairValueOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000654"
      unitRef="USD">240930</SHPH:IncreaseDecreaseInFairValueOfWarrants>
    <us-gaap:IncreaseDecreaseInDividendsReceivable
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000656"
      unitRef="USD">402064</us-gaap:IncreaseDecreaseInDividendsReceivable>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">296151</us-gaap:DerivativeGainLossOnDerivativeNet>
    <SHPH:IncreaseDecreaseInIssuanceCost
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000660"
      unitRef="USD">166407</SHPH:IncreaseDecreaseInIssuanceCost>
    <SHPH:IncreaseDecreaseInNetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">1967621</SHPH:IncreaseDecreaseInNetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000664">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zwX833PQD2H7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_829_zWAALifadsVe"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbNA1oLSmCg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zCBeclORz1k"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial statements and with the instructions to Form 10-Q
and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not
contain all information and notes required by GAAP for annual financial
statements. A complete discussion of the Company&#x2019;s significant accounting policies is included in the Company&#x2019;s Annual Report
on Form 10-K for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all of
the adjustments necessary to present the financial position of the Company as of June 30, 2024 and the results of operations and
cash flows for the periods presented. The accompanying condensed consolidated financial statements of the Company have not been
audited by the Company&#x2019;s independent registered public accounting firm, except that the year-end consolidated balance sheet
was derived from audited financial statements. The results of operations for the six months ended June 30, 2024 are not necessarily
indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial
statements should be read in conjunction with the restated financial statements and related notes thereto for the year ended
December 31, 2023 included in the Company&#x2019;s Annual Report on Form 10-K/A filed with the SEC on September 3, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--ReverseStockSplitPolicyTextBlock_zUQwwFrvzScl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zMdaqovuKvXk"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 13, 2024, in order to meet Nasdaq&#x2019;s minimum bid price requirement of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdpnAuWG6Lol" title="Minimum bid price"&gt;1.00&lt;/span&gt;
per share (the &#x201c;Minimum Bid Price Requirement&#x201d;), the Company effectuated a &lt;span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1d0psoH6nQc" title="Reverse stock split"&gt;1-for-8 reverse stock split&lt;/span&gt; of its issued and
outstanding common stock, rounding up to account for any fractional shares (the &#x201c;Reverse Stock Split&#x201d;). The Reverse
Stock Split had no effect on the Company&#x2019;s authorized shares of common stock or preferred stock and the par value will remain
unchanged at $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240813_zMXv9hl7eJbj" title="Common stock, par value"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240813_z0BWOOj98It8" title="Preferred stock, par value"&gt;0.00001&lt;/span&gt;&lt;/span&gt;,
respectively. Following the reverse stock split on August 13, 2024, the Company had a total of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zztmaLiD6Qoe" title="Common stock shares issued"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlqhzVPvDeRi" title="Common stock shares outstanding"&gt;2,111,235&lt;/span&gt;&lt;/span&gt;
shares issued and outstanding (or &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240630_z7CZ066K6Nl3" title="Common stock shares issued"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240630_z8BjDAR117Yd" title="Common stock shares outstanding"&gt;2,106,233&lt;/span&gt;&lt;/span&gt;
on a post-split basis as of June 30, 2024).&lt;/span&gt; All common stock share, option, warrant and per share amounts (except our
authorized but unissued shares) have been retroactively adjusted in these financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zVRaxJZ6JGAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zi0eokpZriz4"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned
subsidiaries, Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zty8POBdZ14f"&gt;Correction
of an Immaterial Error in the Prior Period Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards
Codification (&#x201c;ASC&#x201d;) 730. As a result, certain prior year amounts have been corrected for consistency with the current
year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial
statements in accordance with SEC Staff Accounting Bulletin No. 99, &#x201c;Materiality,&#x201d; (ASC Topic 250, Accounting Changes
and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed
consolidated statements of operations are not material to any previously presented financial statements based upon overall
considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated
balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes
in stockholders&#x2019; equity, to these financial statements, or for any previously presented interim or annual financial
statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted
earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was
$&lt;span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zjzxGy9n2Tqg" title="General and administrative expense"&gt;93,708&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zEx5IEd6PiT8" title="General and administrative expense"&gt;182,715&lt;/span&gt;, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and
six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zUEa4AVq93g1" style="display: none"&gt;Schedule of the Error Correction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztXtgIiL0mS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Correction&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Corrected&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Research and development expense&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,944,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(182,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,761,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;281,918&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;182,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;464,633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,226,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,226,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z3JEbn1v7fOi"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the
reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on
current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&#x2019;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed
consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of
bifurcated derivative liabilities and other financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zokUH3G8A7Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zxtJnn7V0F96"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of June 30, 2024 and December 31, 2023, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zkEJLZMnX1Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zFoSdsPsZsdh" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630_zdf2YYEPgH92" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_z0DgJpGOb3c6" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zpVNW72A3ffa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;645,594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zkXzbm1UOUsk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zESWBcrIg25g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;695,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zn4zpQIooYi6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240630_zFoCnqZK8quc" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per institution. The
amount in excess of the FDIC insurance as of June 30, 2024 was approximately $&lt;span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20240630_zjyRhVQqCk7e" title="Cash, uninsured amount"&gt;0.4&lt;/span&gt; million. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zewlyN8EM7Ig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zWYFKpwXUUxb"&gt;Marketable
Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding
balance of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20240630_zOxm6QfMfZeg" title="Marketable securities, outstanding balance"&gt;1.6&lt;/span&gt;
million and $&lt;span id="xdx_907_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20231231_zNyG7iZlRMN7" title="Marketable securities, outstanding balance"&gt;2.9&lt;/span&gt;
million as of June 30, 2024 and December 31, 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company
recognized interest income of $&lt;span id="xdx_90A_eus-gaap--InvestmentIncomeInterest_c20240401__20240630_zcq2CT9LGwf8" title="Interest income"&gt;14,158&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--InvestmentIncomeInterest_c20230401__20230630_z07CBpxiZfPd" title="Interest income"&gt;19,267&lt;/span&gt;,
realized gains of $&lt;span id="xdx_90E_eus-gaap--GainLossOnSaleOfInvestments_c20240401__20240630_zqFcztULftf2" title="Gain on sale of marketable securities"&gt;39,683&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--GainLossOnSaleOfInvestments_c20230401__20230630_zztdgOwkA1Al" title="Gain on sale of marketable securities"&gt;1,744&lt;/span&gt;,
and unrealized loss of $&lt;span id="xdx_90A_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20240401__20240630_zWCIvWQwRsIf" title="Unrealized loss"&gt;27,964&lt;/span&gt;
and unrealized loss of $&lt;span id="xdx_907_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20230401__20230630_zVAgkZCa1xv9" title="Unrealized loss"&gt;26,534&lt;/span&gt;,
respectively. During the six months ended June 30, 2024 and 2023, the Company recognized interest income of $&lt;span id="xdx_903_eus-gaap--InterestIncomeExpenseNet_c20240101__20240630_zyDmZWPkZUo7" title="Interest income"&gt;35,611&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630_zEhr8qDKa026" title="Interest income"&gt;35,955&lt;/span&gt;,
realized gains of $&lt;span id="xdx_902_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20240101__20240630_zq28xeSQy6Xd" title="Marketable securities realized gain loss"&gt;43,720&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20230630_zFgLIQUum3e7" title="Marketable securities realized gain loss"&gt;1,744&lt;/span&gt;,
and unrealized loss of $&lt;span id="xdx_901_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20240101__20240630_zKHoCz44OTX2" title="Marketable securities unrealized gain loss"&gt;28,670&lt;/span&gt;
and unrealized gain of $&lt;span id="xdx_908_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230630_ze93KZfxuNKd" title="Marketable securities unrealized gain loss"&gt;11,528&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvCubePqHs28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zsCyT2nR28g1"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4Fjp8jYHK5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of June 30, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z04BtaXIERfc" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zExD2SVowPH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLJtGezKo55" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmfWKey4sYWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630_zjoqMgNxUsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLGc9i6fzSJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zxYQDrtyDMk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zDwqI7ggcyO2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zr8UHTdpBgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z9RhqCNdYVqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0781"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;359,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;359,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zNRORHgltpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zwgNXMGU1U4b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;360,423&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;360,423&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zb7iOAM75Kdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z76zr6Fa3GUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z01v4lD9OZA8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zwkx62sH2px7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zvkOmL0nCbfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zoumSoH7GBU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zUOt3GVPWwL6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zS2K50xTTHjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zgtC2JqIWhO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zIDEG5nHspT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zm2eBRJ81m98" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0826"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zcF4kM03SRN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zsDUSByWTOL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zU1IAwdJYrok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zc92axd5kqph"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of
our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its
fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed
consolidated statements of operations. For our liability classified derivative financial instruments, the Company used a Monte Carlo
valuation model to value the derivative instruments at inception and on subsequent valuation dates. For our equity classified
derivative financial instruments, we used a Black-Scholes option-pricing model at the grant date to value the derivative instrument.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zlFf6cI9ITB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zBAgigV4CUnf"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in FASB ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;)
and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether
the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a
component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria
for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each
balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the
unaudited condensed consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zK4BilFFxXkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zCKkoNeWM1e4"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Research and development expenses
are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical
and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief
operating officer, chief financial officer and directors&#x2019; compensation. For the three and six months ended June 30,
2024 and 2023, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3sLaUIdASYc" title="Share based compensation"&gt;0.1&lt;/span&gt;
million and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDnOqNRLzbMj" title="Share based compensation"&gt;0.3&lt;/span&gt;
million, respectively, and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLXJrFhnixJ1" title="Share based compensation"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxhtNDbme28j" title="Share based compensation"&gt;0.6&lt;/span&gt;
million, respectively, was included within research and development due to their active involvement in the research and development
activities, materials, supplies, related subcontract expenses, and consulting costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, &lt;i&gt;Government Assistance&lt;/i&gt;, as adopted January 1, 2022, we disclose certain types of government
assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction including the
nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other provisions of
relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable alternative for
the accounting treatment &#x2013; a reduction of costs, a deferred credit to be amortized, revenue or other income. The Company has concluded
that reimbursements received for R&amp;amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements against
incurred research costs. There were no reimbursements received for the six months ended June 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPYN1jBumNz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zXKKuKw3o4M7"&gt;Net
Loss Per Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share of common stock requires presentation of basic earnings per share on the face of the unaudited condensed consolidated
statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and
denominator of the basic earnings per share computation. In the accompanying unaudited condensed consolidated financial statements,
basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and
potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from
common shares issuable through contingent share arrangements, stock options and warrants unless the result would be
antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#x201c;treasury
stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted
method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVkGRAVxSzPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z0Up43jkQn2f" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Convertible notes (Note 5)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zV8FndxIngK" title="Convertible notes (Note 6)"&gt;80,744&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zTo8N3BvlMOd" title="Convertible notes (Note 6)"&gt;155,378&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant (Note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXic79bck0k1" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxRJezezYiRe" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zO4l3p8AWrTc" title="Restricted stock units"&gt;58,839&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG41pxOQnzb2" title="Restricted stock units"&gt;10,382&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_ztFD3kr5Ef39" title="Anti-dilutive securities"&gt;323,583&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zTCgcgQrSTIe" title="Anti-dilutive securities"&gt;349,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zl7y3OUGU5xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zu1RgEyL4q5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zny4h9Jlpx5i"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASC 340-10-S99-1, costs directly attributable to an offering of equity securities are deferred and would be charged against the
gross proceeds of an offering as a reduction of additional paid-in capital. Deferred offering costs may consist of underwriting,
legal, accounting, and other expenses incurred through the balance sheet date that are directly related to a proposed public
offering. Should the proposed public offering prove to be unsuccessful, any deferred costs, as well as additional expenses to be
incurred, will be expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zPaMS221bwti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zoIhNWXVKYPl"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.
2023-07, Segment Reporting Topic 280, &#x201c;Segment Reporting-Improvements to Reportable Segment Disclosures,&#x201d; which allows disclosure
of one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance.
Additionally, the standard requires enhanced disclosures of significant segment expenses and other segment items, as well as incremental
qualitative disclosures on both an annual and interim basis. This guidance is effective for annual reporting periods beginning after
December 15, 2023, and interim reporting periods after December 15, 2024. Early adoption is permitted and retrospective application is
required for all periods presented. The adoption of this new guidance is not expected to have a significant impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, Income Taxes Topic 740, &#x201c;Income Tax-Improvements to Income Tax Disclosures,&#x201d;
which requires enhanced disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation,
disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit,
and income tax expense or benefit from continuing operations. This guidance is effective for annual reporting periods beginning after
December 15, 2024. Early adoption is permitted and should be applied on a prospective basis, however retrospective application is permitted.
The Company is currently evaluating the impact of adopting this guidance on its consolidated and condensed financial statements and disclosures
included within notes to consolidated and condensed financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85B_zXrZEEtLe4f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000666">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbNA1oLSmCg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zCBeclORz1k"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial statements and with the instructions to Form 10-Q
and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not
contain all information and notes required by GAAP for annual financial
statements. A complete discussion of the Company&#x2019;s significant accounting policies is included in the Company&#x2019;s Annual Report
on Form 10-K for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all of
the adjustments necessary to present the financial position of the Company as of June 30, 2024 and the results of operations and
cash flows for the periods presented. The accompanying condensed consolidated financial statements of the Company have not been
audited by the Company&#x2019;s independent registered public accounting firm, except that the year-end consolidated balance sheet
was derived from audited financial statements. The results of operations for the six months ended June 30, 2024 are not necessarily
indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial
statements should be read in conjunction with the restated financial statements and related notes thereto for the year ended
December 31, 2023 included in the Company&#x2019;s Annual Report on Form 10-K/A filed with the SEC on September 3, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <SHPH:ReverseStockSplitPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000668">&lt;p id="xdx_847_ecustom--ReverseStockSplitPolicyTextBlock_zUQwwFrvzScl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zMdaqovuKvXk"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 13, 2024, in order to meet Nasdaq&#x2019;s minimum bid price requirement of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdpnAuWG6Lol" title="Minimum bid price"&gt;1.00&lt;/span&gt;
per share (the &#x201c;Minimum Bid Price Requirement&#x201d;), the Company effectuated a &lt;span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1d0psoH6nQc" title="Reverse stock split"&gt;1-for-8 reverse stock split&lt;/span&gt; of its issued and
outstanding common stock, rounding up to account for any fractional shares (the &#x201c;Reverse Stock Split&#x201d;). The Reverse
Stock Split had no effect on the Company&#x2019;s authorized shares of common stock or preferred stock and the par value will remain
unchanged at $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240813_zMXv9hl7eJbj" title="Common stock, par value"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240813_z0BWOOj98It8" title="Preferred stock, par value"&gt;0.00001&lt;/span&gt;&lt;/span&gt;,
respectively. Following the reverse stock split on August 13, 2024, the Company had a total of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zztmaLiD6Qoe" title="Common stock shares issued"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlqhzVPvDeRi" title="Common stock shares outstanding"&gt;2,111,235&lt;/span&gt;&lt;/span&gt;
shares issued and outstanding (or &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240630_z7CZ066K6Nl3" title="Common stock shares issued"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240630_z8BjDAR117Yd" title="Common stock shares outstanding"&gt;2,106,233&lt;/span&gt;&lt;/span&gt;
on a post-split basis as of June 30, 2024).&lt;/span&gt; All common stock share, option, warrant and per share amounts (except our
authorized but unissued shares) have been retroactively adjusted in these financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</SHPH:ReverseStockSplitPolicyTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000670"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-08-132024-08-13_us-gaap_SubsequentEventMember"
      id="Fact000672">1-for-8 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-13"
      decimals="INF"
      id="Fact000674"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-13"
      decimals="INF"
      id="Fact000676"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000678"
      unitRef="Shares">2111235</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000680"
      unitRef="Shares">2111235</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000682"
      unitRef="Shares">2106233</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000684"
      unitRef="Shares">2106233</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000686">&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zVRaxJZ6JGAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zi0eokpZriz4"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned
subsidiaries, Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2024-01-01to2024-06-30" id="Fact000688">&lt;p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zty8POBdZ14f"&gt;Correction
of an Immaterial Error in the Prior Period Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards
Codification (&#x201c;ASC&#x201d;) 730. As a result, certain prior year amounts have been corrected for consistency with the current
year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial
statements in accordance with SEC Staff Accounting Bulletin No. 99, &#x201c;Materiality,&#x201d; (ASC Topic 250, Accounting Changes
and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed
consolidated statements of operations are not material to any previously presented financial statements based upon overall
considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated
balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes
in stockholders&#x2019; equity, to these financial statements, or for any previously presented interim or annual financial
statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted
earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was
$&lt;span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zjzxGy9n2Tqg" title="General and administrative expense"&gt;93,708&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zEx5IEd6PiT8" title="General and administrative expense"&gt;182,715&lt;/span&gt;, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and
six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zUEa4AVq93g1" style="display: none"&gt;Schedule of the Error Correction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztXtgIiL0mS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Correction&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Corrected&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Research and development expense&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,944,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(182,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,761,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;281,918&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;182,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;464,633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,226,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,226,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">93708</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="0"
      id="Fact000692"
      unitRef="USD">182715</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000694">&lt;p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zUEa4AVq93g1" style="display: none"&gt;Schedule of the Error Correction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztXtgIiL0mS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Correction&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Corrected&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Research and development expense&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,944,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(182,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,761,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;281,918&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;182,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;464,633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,226,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,226,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000696"
      unitRef="USD">1944181</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000697"
      unitRef="USD">-182715</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000698"
      unitRef="USD">1761466</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000700"
      unitRef="USD">281918</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000701"
      unitRef="USD">182715</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">464633</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">2226099</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000706"
      unitRef="USD">2226099</us-gaap:ProfitLoss>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-06-30" id="Fact000708">&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z3JEbn1v7fOi"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the
reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on
current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&#x2019;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed
consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of
bifurcated derivative liabilities and other financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000710">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zokUH3G8A7Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zxtJnn7V0F96"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of June 30, 2024 and December 31, 2023, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zkEJLZMnX1Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zFoSdsPsZsdh" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630_zdf2YYEPgH92" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_z0DgJpGOb3c6" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zpVNW72A3ffa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;645,594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zkXzbm1UOUsk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zESWBcrIg25g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;695,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zn4zpQIooYi6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240630_zFoCnqZK8quc" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per institution. The
amount in excess of the FDIC insurance as of June 30, 2024 was approximately $&lt;span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20240630_zjyRhVQqCk7e" title="Cash, uninsured amount"&gt;0.4&lt;/span&gt; million. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000712">&lt;p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zkEJLZMnX1Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zFoSdsPsZsdh" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630_zdf2YYEPgH92" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_z0DgJpGOb3c6" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zpVNW72A3ffa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;645,594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zkXzbm1UOUsk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zESWBcrIg25g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;695,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000714"
      unitRef="USD">645594</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000715"
      unitRef="USD">1550098</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000717"
      unitRef="USD">50000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000718"
      unitRef="USD">1026318</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000720"
      unitRef="USD">695594</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000721"
      unitRef="USD">2576416</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000723"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000725"
      unitRef="USD">400000</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2024-01-01to2024-06-30" id="Fact000727">&lt;p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zewlyN8EM7Ig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zWYFKpwXUUxb"&gt;Marketable
Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding
balance of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20240630_zOxm6QfMfZeg" title="Marketable securities, outstanding balance"&gt;1.6&lt;/span&gt;
million and $&lt;span id="xdx_907_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20231231_zNyG7iZlRMN7" title="Marketable securities, outstanding balance"&gt;2.9&lt;/span&gt;
million as of June 30, 2024 and December 31, 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company
recognized interest income of $&lt;span id="xdx_90A_eus-gaap--InvestmentIncomeInterest_c20240401__20240630_zcq2CT9LGwf8" title="Interest income"&gt;14,158&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--InvestmentIncomeInterest_c20230401__20230630_z07CBpxiZfPd" title="Interest income"&gt;19,267&lt;/span&gt;,
realized gains of $&lt;span id="xdx_90E_eus-gaap--GainLossOnSaleOfInvestments_c20240401__20240630_zqFcztULftf2" title="Gain on sale of marketable securities"&gt;39,683&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--GainLossOnSaleOfInvestments_c20230401__20230630_zztdgOwkA1Al" title="Gain on sale of marketable securities"&gt;1,744&lt;/span&gt;,
and unrealized loss of $&lt;span id="xdx_90A_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20240401__20240630_zWCIvWQwRsIf" title="Unrealized loss"&gt;27,964&lt;/span&gt;
and unrealized loss of $&lt;span id="xdx_907_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_iN_di_c20230401__20230630_zVAgkZCa1xv9" title="Unrealized loss"&gt;26,534&lt;/span&gt;,
respectively. During the six months ended June 30, 2024 and 2023, the Company recognized interest income of $&lt;span id="xdx_903_eus-gaap--InterestIncomeExpenseNet_c20240101__20240630_zyDmZWPkZUo7" title="Interest income"&gt;35,611&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630_zEhr8qDKa026" title="Interest income"&gt;35,955&lt;/span&gt;,
realized gains of $&lt;span id="xdx_902_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20240101__20240630_zq28xeSQy6Xd" title="Marketable securities realized gain loss"&gt;43,720&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20230630_zFgLIQUum3e7" title="Marketable securities realized gain loss"&gt;1,744&lt;/span&gt;,
and unrealized loss of $&lt;span id="xdx_901_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20240101__20240630_zKHoCz44OTX2" title="Marketable securities unrealized gain loss"&gt;28,670&lt;/span&gt;
and unrealized gain of $&lt;span id="xdx_908_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230630_ze93KZfxuNKd" title="Marketable securities unrealized gain loss"&gt;11,528&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000729"
      unitRef="USD">1600000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000731"
      unitRef="USD">2900000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000733"
      unitRef="USD">14158</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000735"
      unitRef="USD">19267</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000737"
      unitRef="USD">39683</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000739"
      unitRef="USD">1744</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000741"
      unitRef="USD">-27964</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000743"
      unitRef="USD">-26534</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000745"
      unitRef="USD">35611</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000747"
      unitRef="USD">35955</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000749"
      unitRef="USD">43720</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000751"
      unitRef="USD">1744</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000753"
      unitRef="USD">28670</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000755"
      unitRef="USD">11528</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-06-30" id="Fact000757">&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvCubePqHs28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zsCyT2nR28g1"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4Fjp8jYHK5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of June 30, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z04BtaXIERfc" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zExD2SVowPH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLJtGezKo55" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmfWKey4sYWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630_zjoqMgNxUsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLGc9i6fzSJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zxYQDrtyDMk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zDwqI7ggcyO2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zr8UHTdpBgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z9RhqCNdYVqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0781"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;359,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;359,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zNRORHgltpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zwgNXMGU1U4b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;360,423&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;360,423&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zb7iOAM75Kdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z76zr6Fa3GUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z01v4lD9OZA8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zwkx62sH2px7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zvkOmL0nCbfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zoumSoH7GBU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zUOt3GVPWwL6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zS2K50xTTHjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zgtC2JqIWhO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zIDEG5nHspT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zm2eBRJ81m98" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0826"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zcF4kM03SRN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zsDUSByWTOL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000759">&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4Fjp8jYHK5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of June 30, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z04BtaXIERfc" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zExD2SVowPH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLJtGezKo55" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmfWKey4sYWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630_zjoqMgNxUsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLGc9i6fzSJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zxYQDrtyDMk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zDwqI7ggcyO2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,642,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zr8UHTdpBgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z9RhqCNdYVqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0781"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;359,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;359,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zNRORHgltpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zwgNXMGU1U4b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;360,423&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;360,423&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zb7iOAM75Kdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z76zr6Fa3GUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z01v4lD9OZA8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zwkx62sH2px7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zvkOmL0nCbfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zoumSoH7GBU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zUOt3GVPWwL6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zS2K50xTTHjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zgtC2JqIWhO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zIDEG5nHspT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zm2eBRJ81m98" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative Liability &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0826"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zcF4kM03SRN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000766"
      unitRef="USD">1642995</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2024-06-30_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000769"
      unitRef="USD">1642995</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000771"
      unitRef="USD">1642995</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000774"
      unitRef="USD">1642995</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000783"
      unitRef="USD">359919</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">359919</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000788"
      unitRef="USD">504</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000789"
      unitRef="USD">504</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000793"
      unitRef="USD">360423</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000794"
      unitRef="USD">360423</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">2887215</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000804"
      unitRef="USD">2887215</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000806"
      unitRef="USD">2887215</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000809"
      unitRef="USD">2887215</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">410660</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000819"
      unitRef="USD">410660</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000823"
      unitRef="USD">3852</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">3852</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000828"
      unitRef="USD">3852</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">3852</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000833"
      unitRef="USD">414512</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000834"
      unitRef="USD">414512</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000836">&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zU1IAwdJYrok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zc92axd5kqph"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of
our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its
fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed
consolidated statements of operations. For our liability classified derivative financial instruments, the Company used a Monte Carlo
valuation model to value the derivative instruments at inception and on subsequent valuation dates. For our equity classified
derivative financial instruments, we used a Black-Scholes option-pricing model at the grant date to value the derivative instrument.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <SHPH:WarrantsPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000838">&lt;p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zlFf6cI9ITB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zBAgigV4CUnf"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in FASB ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;)
and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether
the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a
component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria
for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each
balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the
unaudited condensed consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</SHPH:WarrantsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-06-30" id="Fact000840">&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zK4BilFFxXkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zCKkoNeWM1e4"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Research and development expenses
are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical
and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief
operating officer, chief financial officer and directors&#x2019; compensation. For the three and six months ended June 30,
2024 and 2023, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3sLaUIdASYc" title="Share based compensation"&gt;0.1&lt;/span&gt;
million and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDnOqNRLzbMj" title="Share based compensation"&gt;0.3&lt;/span&gt;
million, respectively, and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLXJrFhnixJ1" title="Share based compensation"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxhtNDbme28j" title="Share based compensation"&gt;0.6&lt;/span&gt;
million, respectively, was included within research and development due to their active involvement in the research and development
activities, materials, supplies, related subcontract expenses, and consulting costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, &lt;i&gt;Government Assistance&lt;/i&gt;, as adopted January 1, 2022, we disclose certain types of government
assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction including the
nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other provisions of
relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable alternative for
the accounting treatment &#x2013; a reduction of costs, a deferred credit to be amortized, revenue or other income. The Company has concluded
that reimbursements received for R&amp;amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements against
incurred research costs. There were no reimbursements received for the six months ended June 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact000842"
      unitRef="USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact000844"
      unitRef="USD">300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact000846"
      unitRef="USD">200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact000848"
      unitRef="USD">600000</us-gaap:ShareBasedCompensation>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000850">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPYN1jBumNz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zXKKuKw3o4M7"&gt;Net
Loss Per Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share of common stock requires presentation of basic earnings per share on the face of the unaudited condensed consolidated
statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and
denominator of the basic earnings per share computation. In the accompanying unaudited condensed consolidated financial statements,
basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and
potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from
common shares issuable through contingent share arrangements, stock options and warrants unless the result would be
antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#x201c;treasury
stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted
method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVkGRAVxSzPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z0Up43jkQn2f" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Convertible notes (Note 5)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zV8FndxIngK" title="Convertible notes (Note 6)"&gt;80,744&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zTo8N3BvlMOd" title="Convertible notes (Note 6)"&gt;155,378&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant (Note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXic79bck0k1" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxRJezezYiRe" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zO4l3p8AWrTc" title="Restricted stock units"&gt;58,839&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG41pxOQnzb2" title="Restricted stock units"&gt;10,382&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_ztFD3kr5Ef39" title="Anti-dilutive securities"&gt;323,583&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zTCgcgQrSTIe" title="Anti-dilutive securities"&gt;349,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zl7y3OUGU5xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000852">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVkGRAVxSzPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the six months ended June 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z0Up43jkQn2f" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Convertible notes (Note 5)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zV8FndxIngK" title="Convertible notes (Note 6)"&gt;80,744&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zTo8N3BvlMOd" title="Convertible notes (Note 6)"&gt;155,378&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant (Note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXic79bck0k1" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxRJezezYiRe" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zO4l3p8AWrTc" title="Restricted stock units"&gt;58,839&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG41pxOQnzb2" title="Restricted stock units"&gt;10,382&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_ztFD3kr5Ef39" title="Anti-dilutive securities"&gt;323,583&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zTCgcgQrSTIe" title="Anti-dilutive securities"&gt;349,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000854"
      unitRef="Shares">80744</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Shares">155378</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">184000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">184000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">58839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">10382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">323583</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000868"
      unitRef="Shares">349760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <SHPH:DeferredOfferingCostsPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000870">&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zu1RgEyL4q5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zny4h9Jlpx5i"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASC 340-10-S99-1, costs directly attributable to an offering of equity securities are deferred and would be charged against the
gross proceeds of an offering as a reduction of additional paid-in capital. Deferred offering costs may consist of underwriting,
legal, accounting, and other expenses incurred through the balance sheet date that are directly related to a proposed public
offering. Should the proposed public offering prove to be unsuccessful, any deferred costs, as well as additional expenses to be
incurred, will be expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</SHPH:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000872">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zPaMS221bwti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zoIhNWXVKYPl"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.
2023-07, Segment Reporting Topic 280, &#x201c;Segment Reporting-Improvements to Reportable Segment Disclosures,&#x201d; which allows disclosure
of one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance.
Additionally, the standard requires enhanced disclosures of significant segment expenses and other segment items, as well as incremental
qualitative disclosures on both an annual and interim basis. This guidance is effective for annual reporting periods beginning after
December 15, 2023, and interim reporting periods after December 15, 2024. Early adoption is permitted and retrospective application is
required for all periods presented. The adoption of this new guidance is not expected to have a significant impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, Income Taxes Topic 740, &#x201c;Income Tax-Improvements to Income Tax Disclosures,&#x201d;
which requires enhanced disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation,
disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit,
and income tax expense or benefit from continuing operations. This guidance is effective for annual reporting periods beginning after
December 15, 2024. Early adoption is permitted and should be applied on a prospective basis, however retrospective application is permitted.
The Company is currently evaluating the impact of adopting this guidance on its consolidated and condensed financial statements and disclosures
included within notes to consolidated and condensed financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000874">&lt;p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_zkftMnGKRIX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82E_zpNBimatGMvg"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease right-of-use (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the present value of the future lease payments as of
the lease commencement date. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company had a lease agreement which allowed for the use of a laboratory facility for a monthly
payment of $&lt;span id="xdx_90F_eus-gaap--OperatingLeasePaymentsUse_c20230101__20230630_zHUYfXFcZhfl" title="Lease payment"&gt;6,480&lt;/span&gt;. The laboratory lease commenced on October 1, 2018 and expired on &lt;span id="xdx_905_eus-gaap--LeaseExpirationDate1_c20230101__20230630_zA0ZrFrtE0Gh" title="Lease expiration term"&gt;October 31, 2023&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently has a lease agreement which allows for the use of a laboratory facility, entered into on February 16, 2023, with base
rent of $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zoZsDXC0givj" title="Payments for rent"&gt;7,206&lt;/span&gt; per month for a period of &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_z90MMRHe9x1k" title="Lease term"&gt;64&lt;/span&gt; months, which increases at the rate of &lt;span id="xdx_901_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zXU3xXYu5Qa1" title="Rent variable rate"&gt;3&lt;/span&gt;% per year, that &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_ze8OT5LVf6N6" title="Lease commencement"&gt;commenced June 1, 2023&lt;/span&gt;. The lease
included a six-month &lt;span id="xdx_905_ecustom--PercentageOfRentAbatement_pid_dp_uPure_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zvUYrqolu84i" title="Percentage of rent abatement"&gt;50%&lt;/span&gt; rent abatement upon commencement. Additional common area maintenance (&#x201c;CAM&#x201d;) fees are charged monthly
and revised annually. The estimated monthly CAM fees are $&lt;span id="xdx_90C_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember_zcYoJffu1Op3" title="Estimated monthly common area maintenance cost"&gt;3,300&lt;/span&gt; per month for the first year of the lease, which are being expensed as
incurred. An irrevocable letter of credit (&#x201c;LOC&#x201d;) for the security deposit of $&lt;span id="xdx_90E_eus-gaap--SecurityDeposit_iI_c20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zeAKOZIE73Qh" title="Security deposit"&gt;43,234&lt;/span&gt; and base rent of $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zZQMAJ2qUPfd" title="Payments for rent"&gt;3,891&lt;/span&gt;, including
&lt;span id="xdx_904_ecustom--PercentageOfRentAbatement_pid_dp_uPure_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zL3jVRGhrh83" title="Percentage of rent abatement"&gt;50%&lt;/span&gt; abatement, and $&lt;span id="xdx_90B_ecustom--CommonAreaMaintenanceCost_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zylt0HN5Fgu8" title="Common area maintenance cost"&gt;3,315&lt;/span&gt; of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is
the beneficiary of the LOC, and the expiry date of the LOC is &lt;span id="xdx_901_eus-gaap--LeaseExpirationDate1_dd_c20230216__20230216__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_ztDTesw2ekc9" title="Expiry date"&gt;March 1, 2025&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zK422Uc0lu5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the ROU lease expense components and cash flow information for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zuH7q1lj8SJd" style="display: none"&gt;Schedule of Right-of Use Asset and Lease Information about Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240401__20240630_zo4SVVRAslZ4" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230401__20230630_zbeeaqAgEQqg" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20240630_zhRuAhvewrL8" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630_zxL68u1cciD4" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Six
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseCost_maLCzBxV_z9q8sduJrjNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,947&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,193&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45,894&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--VariableLeaseCost_maLCzBxV_zcBgOYmHf708" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Variable
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,937&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,377&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--SubleaseIncome_iN_di_msLCzBxV_z3kL2k1B3bb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sublease
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,163&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,121&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,326&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,242&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LeaseCost_iT_mtLCzBxV_zt70iWUKYVJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,721&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,072&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61,945&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;38,495&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zDvzNXhAEmD8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    paid for operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,707&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,331&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45,189&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42,771&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zDgjUOaa64wi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    assets obtained in exchange for new operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;365,556&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_ztNUTeUGd3ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zKOOShJEE5dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
balance sheet information related to operating leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zmYseQ6pdvtj" style="display: none"&gt;Schedule of Balance Sheet Information Related to Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin: 0"&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 60%"&gt;&lt;p style="margin: 0"&gt;Weighted-average remaining lease term (year)&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zJlgJo77R5Ga" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)"&gt;4.18&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zXbHD3zsmgMd" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)"&gt;4.98&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20240630_zqJYJPwpJeXi" title="Weighted-average discount rate - operating leases"&gt;10.48&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z2wnmDWx5pXc" title="Weighted-average discount rate - operating leases"&gt;10.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zP9XtOBsNn76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmlHgFzUal7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
non-cancelable minimum lease payments under the operating lease liability as of June 30, 2024, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zsVIUUnQJvr1" style="display: none"&gt;Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240630_zNDWEz2YNUT9" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzRbr_zHHdpQpnj0cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 80%"&gt;2024 (excluding the six months ended June 30, 2024)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzRbr_z0YgUsRG8Qv6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94,246&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzRbr_ztHycVa7y8O1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzRbr_zUATw95C4R95" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzRbr_zpEa8QZPruM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;68,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzRbr_zvIAUmy9odxl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzRbr_z8Voh6apDace" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zHDliea95yo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(76,737&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zRffpWzzHwPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;329,117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z4tEeYU5Ws8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000876"
      unitRef="USD">6480</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:LeaseExpirationDate1 contextRef="From2023-01-012023-06-30" id="Fact000878">2023-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember"
      decimals="0"
      id="Fact000880"
      unitRef="USD">7206</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2023-02-16_custom_LeaseAgreementMember"
      id="Fact000882">P64M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <SHPH:RentVariableRate1
      contextRef="AsOf2023-02-16_custom_LeaseAgreementMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Pure">0.03</SHPH:RentVariableRate1>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember"
      id="Fact000886">commenced June 1, 2023</us-gaap:LesseeOperatingLeaseDescription>
    <SHPH:PercentageOfRentAbatement
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Pure">0.50</SHPH:PercentageOfRentAbatement>
    <SHPH:EstimatedMonthlyCommonAreaMaintenanceCost
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember"
      decimals="0"
      id="Fact000890"
      unitRef="USD">3300</SHPH:EstimatedMonthlyCommonAreaMaintenanceCost>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">43234</us-gaap:SecurityDeposit>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember"
      decimals="0"
      id="Fact000894"
      unitRef="USD">3891</us-gaap:PaymentsForRent>
    <SHPH:PercentageOfRentAbatement
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Pure">0.50</SHPH:PercentageOfRentAbatement>
    <SHPH:CommonAreaMaintenanceCost
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">3315</SHPH:CommonAreaMaintenanceCost>
    <us-gaap:LeaseExpirationDate1
      contextRef="From2023-02-162023-02-16_custom_LeaseAgreementMember_us-gaap_LetterOfCreditMember"
      id="Fact000900">2025-03-01</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000902">&lt;p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zK422Uc0lu5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the ROU lease expense components and cash flow information for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zuH7q1lj8SJd" style="display: none"&gt;Schedule of Right-of Use Asset and Lease Information about Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240401__20240630_zo4SVVRAslZ4" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230401__20230630_zbeeaqAgEQqg" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20240630_zhRuAhvewrL8" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630_zxL68u1cciD4" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Six
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseCost_maLCzBxV_z9q8sduJrjNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,947&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,193&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45,894&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--VariableLeaseCost_maLCzBxV_zcBgOYmHf708" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Variable
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,937&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,377&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--SubleaseIncome_iN_di_msLCzBxV_z3kL2k1B3bb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sublease
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,163&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,121&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,326&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,242&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LeaseCost_iT_mtLCzBxV_zt70iWUKYVJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,721&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,072&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61,945&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;38,495&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zDvzNXhAEmD8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    paid for operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,707&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,331&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45,189&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42,771&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zDgjUOaa64wi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    assets obtained in exchange for new operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;365,556&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000904"
      unitRef="USD">22947</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000905"
      unitRef="USD">25193</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000906"
      unitRef="USD">45894</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000907"
      unitRef="USD">42737</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000909"
      unitRef="USD">9937</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000911"
      unitRef="USD">20377</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000914"
      unitRef="USD">2163</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000915"
      unitRef="USD">2121</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000916"
      unitRef="USD">4326</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000917"
      unitRef="USD">4242</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000919"
      unitRef="USD">30721</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000920"
      unitRef="USD">23072</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000921"
      unitRef="USD">61945</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000922"
      unitRef="USD">38495</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000924"
      unitRef="USD">22707</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000925"
      unitRef="USD">23331</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000926"
      unitRef="USD">45189</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000927"
      unitRef="USD">42771</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000932"
      unitRef="USD">365556</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <SHPH:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000934">&lt;p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zKOOShJEE5dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
balance sheet information related to operating leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zmYseQ6pdvtj" style="display: none"&gt;Schedule of Balance Sheet Information Related to Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin: 0"&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 60%"&gt;&lt;p style="margin: 0"&gt;Weighted-average remaining lease term (year)&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zJlgJo77R5Ga" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)"&gt;4.18&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zXbHD3zsmgMd" style="text-align: right; width: 16%" title="Weighted-average remaining lease term (year)"&gt;4.98&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20240630_zqJYJPwpJeXi" title="Weighted-average discount rate - operating leases"&gt;10.48&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z2wnmDWx5pXc" title="Weighted-average discount rate - operating leases"&gt;10.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-06-30" id="Fact000936">P4Y2M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact000938">P4Y11M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000940"
      unitRef="Pure">0.1048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000942"
      unitRef="Pure">0.1046</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000944">&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmlHgFzUal7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
non-cancelable minimum lease payments under the operating lease liability as of June 30, 2024, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zsVIUUnQJvr1" style="display: none"&gt;Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240630_zNDWEz2YNUT9" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzRbr_zHHdpQpnj0cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 80%"&gt;2024 (excluding the six months ended June 30, 2024)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzRbr_z0YgUsRG8Qv6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94,246&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzRbr_ztHycVa7y8O1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzRbr_zUATw95C4R95" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzRbr_zpEa8QZPruM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;68,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzRbr_zvIAUmy9odxl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzRbr_z8Voh6apDace" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zHDliea95yo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(76,737&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zRffpWzzHwPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;329,117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000946"
      unitRef="USD">46313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000948"
      unitRef="USD">94246</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000950"
      unitRef="USD">97074</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000952"
      unitRef="USD">99986</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000954"
      unitRef="USD">68235</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000958"
      unitRef="USD">405854</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000960"
      unitRef="USD">76737</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000962"
      unitRef="USD">329117</us-gaap:OperatingLeaseLiability>
    <SHPH:NotesPayableRelatedPartyDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000964">&lt;p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zP7btAoQNmwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_826_zsfoxsulziO5"&gt;Notes Payable-Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2023 the Company incurred $&lt;span id="xdx_905_eus-gaap--InterestExpense_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSa2G3pqRPfl" title="Interest expense"&gt;2,588&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--InterestExpense_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zNbppl22HDG3" title="Interest expense"&gt;6,825&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, in interest expense. During the three and six months ended June 30, 2023 principal payments of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zwMgXRNbcgZ5" title="Proceeds from related party"&gt;139,229
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z8SnsyEB7An" title="Proceeds from related party"&gt;685,473&lt;/span&gt;,
respectively,&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and accrued interest of $&lt;span id="xdx_90F_eus-gaap--InterestPaidNet_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zYlR3qXv9cy2" title="Accrued interest"&gt;25,917
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90B_eus-gaap--InterestPaidNet_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z9j5fEuesSf2" title="Accrued interest"&gt;102,373
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were paid, respectively, on notes to related
parties. The principal and accrued interest for these notes were fully paid by December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SHPH:NotesPayableRelatedPartyDisclosureTextBlock>
    <us-gaap:InterestExpense
      contextRef="From2023-04-012023-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000966"
      unitRef="USD">2588</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000968"
      unitRef="USD">6825</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2023-04-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">139229</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">685473</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:InterestPaidNet
      contextRef="From2023-04-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">25917</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000976"
      unitRef="USD">102373</us-gaap:InterestPaidNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000978">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zvYU5YvLJ2vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_82D_zulWBaOMF4J6"&gt;Convertible Notes and Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Alto
Opportunity Master Fund, SPC&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 11, 2023, the Company entered into a securities purchase agreement (the &#x201c;SPA&#x201d;) with Alto Opportunity Master
Fund, SPC &#x2013; Segregated Master Portfolio B, a Cayman entity (the &#x201c;Investor&#x201d;), pursuant to which the Company sold to
the Investor a $&lt;span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNtDRaoZtrl9" title="Convertible debt"&gt;4,300,000&lt;/span&gt;
convertible note (the &#x201c;Alto Convertible Note&#x201d;) and warrant (the &#x201c;Warrant&#x201d;) to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWVFzsFu6Yqc" title="Warrants to purchase common stock"&gt;127,260&lt;/span&gt;
shares of common stock, exercisable at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWcGwhV8OVC" title="Warrants exerciable shares"&gt;18.80&lt;/span&gt;
per share, in exchange for gross proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znRi0JXEEfif" title="Proceeds from convertible note payable"&gt;3,935,000&lt;/span&gt; (the &#x201c;Investment Amount&#x201d;) (See Note 7). The Company determined that the Warrant contains a net cash settlement
feature at inception and categorized the Warrant as a liability in the accompanying unaudited condensed consolidated financial
statements. The Alto Convertible Note matures on March 11, 2025, but may be extended at the option of the noteholder. The Alto
Convertible Note amortizes on a monthly basis and the Company can make such monthly amortization payments in cash or, subject to
certain equity conditions, in registered shares of common stock or a combination thereof. Installments may be deferred by the
noteholder, resulting in a variable interest rate. However, the effective interest rate is approximately &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zHGXkMmAHFEa" title="Effective interest rate"&gt;218&lt;/span&gt;%
based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment, &lt;span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgbKfszLE1Pk" title="Debt description"&gt;the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $18.80
per share.&lt;/span&gt; The noteholder has an acceleration
of installment amount conversion option (the &#x201c;Acceleration Option&#x201d;), whereby the noteholder, with certain share
percentage limitations, can convert to common stock any outstanding installment amount at an amount equal to the installment amount
plus five times (5x) the installment amount at any time. The Company has determined the Acceleration Option is an embedded
derivative within the host instrument and has bifurcated it from the host instrument and recorded it as a derivative liability
valued at $&lt;span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztla3FvLtVm7" title="Derivative liability"&gt;1,442,000&lt;/span&gt;
at inception, using a Monte Carlo simulation model (Note 7). The Convertible Note is repayable over 26 months and bears interest at
the rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGSX9sVhQJVc" title="Debt interest rate"&gt;5&lt;/span&gt;%
per annum. Additionally, the note contains certain redemption options and &#x201c;Make Whole&#x201d; provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the &#x201c;Security
Agreement&#x201d;), an intellectual property security agreement (the &#x201c;IP Security Agreement&#x201d;) and a subsidiary guaranty (the
&#x201c;Subsidiary Guaranty&#x201d;). The security agreements and guaranty allow, among other things, for the Investor to have a security
interest in and place a lien on all of the Company&#x2019;s assets and intellectual property until such time as the Alto Convertible Note
is paid off. In addition, the SPA called for the Company to enter into a springing deposit account control agreement (the &#x201c;Springing
DACA&#x201d;), which, in the event the Company defaults on its repayment of the Alto Convertible Note, would allow the Investor to assume
control of the Company&#x2019;s bank account only with regard to any funds remaining outstanding under the Alto Convertible Note. As such,
in conjunction with entry into the SPA, the Company established a separate bank account in which it deposited the Investment Amount and
pursuant to which the Company, the Investor and the bank holding the Investment Amount, First Republic Bank, entered into the Springing
DACA agreement. As the Investment Amount had been held at First Republic Bank, in light of certain banking crises then affecting smaller
banks, on March 12, 2023, the Company and the Investor moved the Investment Amount from First Republic Bank, after which time the Springing
DACA was no longer in effect. Further, pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor
agreed that all of the Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing
DACA would no longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $&lt;span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20240630_zmlZe7B5LWFg" title="Convertible notes payable"&gt;10.0&lt;/span&gt;
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Warrant, excluding the Springing
DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an opportunity to participate
in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company expects that such subsequent convertible
notes and warrants would be issued on substantially similar terms as the January 11, 2023 initial agreement, as amended, thus providing
the Company the opportunity to negotiate certain aspects of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Boustead
Securities, LLC (&#x201c;Boustead&#x201d;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$&lt;span id="xdx_90A_ecustom--PaymentForPlacementAgent_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zfcJ9GxVRehj" title="Payment for placement agent"&gt;345,000&lt;/span&gt; cash compensation and a warrant to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zNlaNCWlQFEk" title="Warrants to purchase common stock"&gt;8,909&lt;/span&gt; shares of common stock, exercisable at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zciP5gmwiOl2" title="Warrants exerciable shares"&gt;18.80&lt;/span&gt; per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfzgohzrdu27" title="Expected years"&gt;five years&lt;/span&gt;, volatility of &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zWL0h0g74kDi" title="Warrants and rights outstanding measurement input"&gt;110&lt;/span&gt;%, a risk-free rate of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zGw4xw7rEyWk"&gt;3.53&lt;/span&gt;% for a value of $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zZTfzl6Rfn1c" title="Fair value of warrants"&gt;99,543&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocated the finance costs related to the Boustead placement agent fee of $&lt;span id="xdx_90A_ecustom--PaymentForPlacementAgent_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z4JyrnAVvbLg" title="Payment for placement agent"&gt;345,000&lt;/span&gt;, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $&lt;span id="xdx_90D_eus-gaap--PaymentsOfFinancingCosts_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zrWgAvpXqS2c" title="Allocation of financing costs"&gt;232,027&lt;/span&gt; to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zRgZBhK3xSf5" title="Warrant derivative liability"&gt;104,245&lt;/span&gt; to the warrant derivative liability component,
expensed as a finance fee, and $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFeeAmount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zuCQAQYPFkPg" title="Equity warrant as reduction in additional paid in capital"&gt;8,727&lt;/span&gt; to the equity warrant as a reduction in additional paid in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocated to the debt component of the note an original discount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zbmjpy9sD1Kc" title="Debt discount"&gt;300,000&lt;/span&gt;, legal fees of $&lt;span id="xdx_908_eus-gaap--LegalFees_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zftX1FdSi2m" title="Legal fees"&gt;65,000&lt;/span&gt;, $&lt;span id="xdx_908_ecustom--InterestFeeAmount_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zRdflibszHe9" title="Interest fee"&gt;215,000&lt;/span&gt; for additional
interest fees on day one added to note principal, $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zzl1hJdfMbC5" title="Debt principal amount"&gt;1,442,000&lt;/span&gt; for the accelerated conversion feature, and $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zd6OUJitGPy" title="Fair value of warrants"&gt;1,288,543&lt;/span&gt; for the fair value
of warrants, resulting in an additional $&lt;span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zIa7wH7wgpSf" title="Interest expense debt"&gt;3,310,543&lt;/span&gt; debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2024, the Company recorded interest expense of $&lt;span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zLmWmanlrPug"&gt;430,685&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zbQvQuOPoK54"&gt;928,200&lt;/span&gt;,
respectively, which included amortization of debt discount as interest expense of $&lt;span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20240401__20240630_zbRxsjT5yFma"&gt;386,505&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_c20240101__20240630_zchKazdBMQ49"&gt;832,014&lt;/span&gt;, respectively. During the
three and six months ended June 30, 2024, the Company settled $&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zeAglM2UxOf9" title="Debt, principal"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zRhgO3GIB9xj" title="Debt, principal"&gt;235,200&lt;/span&gt;
of principal, and settled $&lt;span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240401__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zvJq2u0LTtu1" title="Accrued interest"&gt;0&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20240630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zvAQzKj5FWUi" title="Accrued interest"&gt;18,783&lt;/span&gt;
of accrued interest, which settlements were made in the form of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3RJm6JzvED5" title="Stock issuance"&gt;0&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFQtuxbx6yr7" title="Stock issuance"&gt;78,197&lt;/span&gt;
shares of common stock. The Company also settled for cash during the six months ended June 30, 2024 $&lt;span id="xdx_90A_eus-gaap--ProceedsFromInterestReceived_c20240101__20240630_zaXDOH3wagz" title="Settled for cash"&gt;501,667&lt;/span&gt;
of principal and $&lt;span id="xdx_90D_eus-gaap--InterestPaidNet_c20240101__20240630_zYSujkvbVNdg" title="Interest paid"&gt;56,958&lt;/span&gt;
of accrued interest for a total of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630_zGBqCyl7UCjk" title="Debt, principal"&gt;558,628&lt;/span&gt;
of principal and interest paid in cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2023, the Company recorded interest expense of $&lt;span id="xdx_904_eus-gaap--InterestExpenseDebt_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGT7GdaEWCni"&gt;729,351 &lt;/span&gt;and $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zFPXgYg7KKgb"&gt;1,328,682&lt;/span&gt; respectively, which included
amortization of debt discount as interest expense of $&lt;span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20230401__20230630_zMxxM1CXMpc"&gt;549,125&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20230630_zoY2rXLAEqt4"&gt;1,012,177 &lt;/span&gt;respectively. During the three and six months ended June
30, 2023, the Company paid $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zUW43QIDHUXd" title="Debt, principal"&gt;1,527,750 &lt;/span&gt;and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z9x2WOo2cGAl" title="Debt, principal"&gt;1,593,900&lt;/span&gt; of principal, respectively, and paid $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230401__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zUe5fHa2cxdk" title="Accrued interest settled with common stock"&gt;220,689&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20230630__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmqCQLosGhb4" title="Accrued interest settled with common stock"&gt;240,831&lt;/span&gt;, respectively, of accrued
interest, which payments were made in the form of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCyPHYOAPai" title="Stock issuance"&gt;228,489&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyBirkFQ3xBi" title="Stock issuance"&gt;234,864&lt;/span&gt; shares of common stock, respectively, during the three and
six months ended June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2024, the outstanding principal for the convertible note was $&lt;span id="xdx_901_eus-gaap--ConvertibleDebt_iI_c20240630_z8EL5KiE4e8h"&gt;1,517,989&lt;/span&gt; and the debt discount remaining was $&lt;span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20240101__20240630_z2iz59NMbfka"&gt;691,754&lt;/span&gt;, with
a net convertible note carrying value of $&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20240630_zlqpdcBCfOu7" title="Convertible note payable"&gt;826,235&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">4300000</us-gaap:ConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000984"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000986"
      unitRef="USD">3935000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember_custom_AltoConvertibleNoteMember"
      decimals="INF"
      id="Fact000988"
      unitRef="Pure">2.18</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember"
      id="Fact000990">the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $18.80
per share.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000992"
      unitRef="USD">1442000</us-gaap:DerivativeLiabilities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000994"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-06-30"
      decimals="-6"
      id="Fact000996"
      unitRef="USD">10000000.0</us-gaap:ConvertibleNotesPayable>
    <SHPH:PaymentForPlacementAgent
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000998"
      unitRef="USD">345000</SHPH:PaymentForPlacementAgent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact001000"
      unitRef="Shares">8909</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact001002"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001004">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Pure">110</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001007"
      unitRef="Pure">3.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">99543</us-gaap:FairValueAdjustmentOfWarrants>
    <SHPH:PaymentForPlacementAgent
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">345000</SHPH:PaymentForPlacementAgent>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001013"
      unitRef="USD">232027</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">104245</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001017"
      unitRef="USD">8727</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact001019"
      unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact001021"
      unitRef="USD">65000</us-gaap:LegalFees>
    <SHPH:InterestFeeAmount
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact001023"
      unitRef="USD">215000</SHPH:InterestFeeAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact001025"
      unitRef="USD">1442000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact001027"
      unitRef="USD">1288543</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact001029"
      unitRef="USD">3310543</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">430685</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001031"
      unitRef="USD">928200</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001032"
      unitRef="USD">386505</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001033"
      unitRef="USD">832014</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001035"
      unitRef="USD">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001037"
      unitRef="USD">235200</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-04-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001039"
      unitRef="USD">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001041"
      unitRef="USD">18783</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001043"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001045"
      unitRef="Shares">78197</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001047"
      unitRef="USD">501667</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001049"
      unitRef="USD">56958</us-gaap:InterestPaidNet>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001051"
      unitRef="USD">558628</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">729351</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001053"
      unitRef="USD">1328682</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact001054"
      unitRef="USD">549125</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact001055"
      unitRef="USD">1012177</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">1527750</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001059"
      unitRef="USD">1593900</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-04-012023-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001061"
      unitRef="USD">220689</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-01-012023-06-30_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact001063"
      unitRef="USD">240831</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001065"
      unitRef="Shares">228489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001067"
      unitRef="Shares">234864</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001068"
      unitRef="USD">1517989</us-gaap:ConvertibleDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001069"
      unitRef="USD">691754</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001071"
      unitRef="USD">826235</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001073">&lt;p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zubp9uVS5blb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_82A_zYlPRc9g3vDd"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2024, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdsDLxcAnab7" title="Common stock issued for conversion of convertible debt, shares"&gt;0&lt;/span&gt;
    and &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAT6Im2P4UUj" title="Common stock issued for conversion of convertible debt, shares"&gt;78,197&lt;/span&gt; shares of common stock to settle $&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzNUw4GTFV29" title="Debt, principal"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjQZ0pRzzXnh" title="Debt, principal"&gt;235,200&lt;/span&gt; of principal and $&lt;span id="xdx_907_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNgAcatAe9y8" title="Accrued interest settled with common stock"&gt;0&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvDezBijxjF5" title="Accrued interest settled with common stock"&gt;18,783&lt;/span&gt; of interest on a convertible note and
    incurred $&lt;span id="xdx_903_ecustom--LossOnSettlementOfConvertibleDebt_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVJTkLAL3qeg" title="Loss on settlement of convertible debt"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--LossOnSettlementOfConvertibleDebt_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQlD6AmYN1Xf" title="Loss on settlement of convertible debt"&gt;71,315&lt;/span&gt; of loss on settlement, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZOJdp03Nw5k" title="Restricted stock award granted shares"&gt;3,722&lt;/span&gt;
    and &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAJzMnDlVHLd" title="Restricted stock award granted shares"&gt;19,347&lt;/span&gt; shares of common stock issued for vesting of restricted stock units, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2023, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg5iQH2Al9ld" title="Common stock issued for conversion of convertible debt, shares"&gt;228,489&lt;/span&gt;
    and &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV8etwoNF2Wj" title="Common stock issued for conversion of convertible debt, shares"&gt;234,864&lt;/span&gt; shares of common stock to settle $&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxu4slUQep81" title="Debt, principal"&gt;1,527,750&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCjBOb1u081" title="Debt, principal"&gt;1,593,900&lt;/span&gt; of principal and $&lt;span id="xdx_906_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuXR7cKEL242" title="Accrued interest settled with common stock"&gt;220,689&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zna8nfAjTQLa" title="Accrued interest settled with common stock"&gt;240,831&lt;/span&gt; of interest, respectively,
    on a Convertible Note and incurred $&lt;span id="xdx_905_ecustom--LossOnSettlementOfConvertibleDebt_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5adwDj3Cn27" title="Loss on settlement of convertible debt"&gt;415,553&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOmdqL20ei81" title="Loss on settlement of convertible debt"&gt;433,807&lt;/span&gt; of loss on settlement, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zPif5ycVXr3b" title="Number of warrants to purchase"&gt;8,909&lt;/span&gt; shares of common stock, at an
exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_z7gEP7R4EiKj" title="Exercisable price per share"&gt;18.80&lt;/span&gt; per share (Note 5). In addition, Alto was granted warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zrQ8PLWNTO9f" title="Number of warrants to purchase"&gt;127,260&lt;/span&gt; shares of common stock, at an
exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zZgg2BUMc7Xk" title="Exercise price per share"&gt;18.80&lt;/span&gt; per share (Note 5, 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpt1jpLKTnHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding all warrants issued for the six months ended June 30, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zPuNzHLoPhTh" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Warrants Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGmmy2OE5gHk" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;184,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_dxL_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcGkCjRORBv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance::XDX::23.21"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;23.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOaykqGoQ2hl" title="Weighted Average Life (Years)"&gt;2.77&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmNPQtO3uEl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1127"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znf668NBwEk5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1129"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzfCOsHPgAd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;184,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJRjwVBNdTqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;23.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuurucvHOak" title="Weighted Average Life (Years)"&gt;2.29&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zQyMJQPWbiZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
intrinsic value of the warrants as of June 30, 2024 is $&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_c20240630_zrLHD6yyDvj7" title="Aggregate intrinsic value of warrants"&gt;0&lt;/span&gt;. All of the outstanding warrants are exercisable as of June 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#x2019;s
compensation committee. We have reserved &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKKCH4Els9Bl" title="Common stock reserved for future issuance"&gt;3,000,000&lt;/span&gt; shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
June 30, 2024, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zXHPCQPnyPv1" title="Share granted under equity incentive plan"&gt;138,234&lt;/span&gt; shares have been granted under the 2018 Equity Incentive Plan, of which &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zEPMg6K0JHpj" title="Number of shares vested under plan"&gt;79,395&lt;/span&gt; shares have vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
may grant restricted stock units (&#x201c;RSU&#x201d;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2024 and 2023, pursuant to agreements with officers and consultants, &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zVRudqb7T8d8" title="Restricted stock award granted shares"&gt;28,455&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zycSAg4ekbQj" title="Restricted stock award granted shares"&gt;53,455&lt;/span&gt;,
respectively and &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zi8Vr62kbj4h" title="Restricted stock award granted shares"&gt;4,291&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zcc9v726PQEi" title="Restricted stock award granted shares"&gt;7,416&lt;/span&gt;
RSUs, respectively with a value of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zVLqaWWaF1Jf" title="Restricted stock award granted value"&gt;100,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zahRoVeuXWG1" title="Restricted stock award granted value"&gt;141,840&lt;/span&gt;,
respectively, and $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zSVjDqdcDh89" title="Restricted stock award granted value"&gt;47,400&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zR3yQfkAExvf" title="Restricted stock award granted value"&gt;95,400&lt;/span&gt;,
respectively, were granted and compensation expense for RSUs of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBfWRddBcxxl" title="Share based compensation"&gt;182,611&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGHgu9ZQqXGj" title="Share based compensation"&gt;57,855&lt;/span&gt;,
respectively, was incurred. During the three and six months ended June 30, 2024 and 2023, $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQouVId4nEB4" title="Compensation under research and development"&gt;13,033&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3hX2VAYfkDf" title="Compensation under research and development"&gt;46,986&lt;/span&gt;,
respectively, and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvDFsIQLsC4d" title="Compensation under research and development"&gt;41,190&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9XvLM6eXVtg" title="Compensation under research and development"&gt;41,190&lt;/span&gt;, respectively was included in compensation under Research and Development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2024, there was $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zV8lrdvvbUV9" title="Unrecognized compensation cost"&gt;190,779&lt;/span&gt; of unrecognized RSU compensation cost related to non-vested stock-based compensation arrangements
which is expected to be recognized over a weighted-average period of &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrbVlRGnz8t6" title="Weighted average term"&gt;1.97&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zuu6KI1jjRoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding the Restricted Stock Units issued follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zFcZXEx7rJsb" style="display: none"&gt;Schedule of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Fair Value Per RSU&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVRgs3QKydz5" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;24,731&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaBR0c6rk6W" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;11.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGKXMKubzvhh" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;53,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5h9v578mi67" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXBbyqQ5zQ7i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Vested"&gt;(19,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpWt13yUHaGb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;7.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Outstanding, June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqeDXbv4Uwll" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Outstanding, Ending Balance"&gt;58,839&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYvZB97qXPK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance"&gt;4.87&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zwD6B45yNhl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Rights
Offering and Financing Commitment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase agreement
(the &#x201c;Purchase Agreement&#x201d;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed to commit
to purchasing from the Company $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207_zIZlzOJYfMOb" title="Sale of stock consideration received per transaction"&gt;2,250,000&lt;/span&gt; of units from the Company, with each Unit consisting of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207_zy6wBKPtpeih" title="Share based compensation arrangement by share based payment award description"&gt;(i) one share of the Company&#x2019;s
common stock, (ii) a warrant to purchase one share of the Company&#x2019;s common stock exercisable at a purchase price of $18.80 per share,
and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a
22% interest in Diagnostics.&lt;/span&gt; Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90%
of the VWAP of the Company&#x2019;s common stock for the five trading days immediately preceding closing. The parties entered into the
Purchase Agreement in anticipation of the Company commencing a rights offering (the &#x201c;Rights Offering&#x201d;) pursuant to which
the Company intends to offer a total of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207_zsS8UX9UTZ91" title="Proceeds from issuance of common stock"&gt;4,500,000&lt;/span&gt; of Units to existing stockholders, which includes the $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207_zvqqAGepJnKe" title="Sale of stock consideration received per transaction"&gt;2,250,000&lt;/span&gt; of Units being sold
to SRO LLC, an entity which is controlled by Keith Moore, Executive Chairman of Boustead &amp;amp; Company Limited, an affiliate of Boustead.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company filed an initial registration statement on Form S-1 (the &#x201c;Form S-1&#x201d;) with the SEC in April 2024 related to the
registration of subscription rights to purchase the Units to be sold in the Rights Offering. The Form S-1 has not been declared
effective as of the date these unaudited condensed consolidated financial statements were issued. Upon the Form S-1 being declared
effective, the Purchase Agreement allows SRO LLC up to 60 days to raise the initial $&lt;span id="xdx_90D_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zJpaFIvFceI3" title="Escrow deposit"&gt;2,250,000&lt;/span&gt;,
which funds will be placed in escrow with Sutter Securities, Inc. (&#x201c;SSI&#x201d;), an affiliate of BSL, pursuant to the terms of
an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI on February 7, 2024 (the &#x201c;Escrow
Agreement&#x201d;). The funds will remain in escrow up until closing on the Rights Offering. In addition, in the event the Company
fails to raise the full $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBuFf9clofx7" title="Right offering"&gt;4,500,000&lt;/span&gt;
in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant to which it would have the right to purchase any remaining
Units not purchased by existing Company stockholders in the Rights Offering, up to an additional $&lt;span id="xdx_900_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaqSR8vowk6j" title="Escrow deposit"&gt;2,250,000&lt;/span&gt;
(the &#x201c;Back-up Contingency&#x201d;). &lt;span id="xdx_90C_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlfeowy1ptsb" title="Initial public offering description"&gt;Unless
the parties waive the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the
Company&#x2019;s existing stockholders, the Company will not close on the offering and any funds raised and held in escrow will be
returned to investors&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with its entry into the Purchase Agreement, on February 7, 2024, the Company entered into a placement agent and advisory
services agreement (the &#x201c;Placement Agent Agreement&#x201d;) with BSL, pursuant to which BSL and BSL&#x2019;s affiliates will provide
the Company with regular and customary financial consulting advice and will act as placement agent, on a best efforts basis, for the
Rights Offering. In exchange for its services, BSL will receive a commitment fee equal to $&lt;span id="xdx_90D_eus-gaap--PaymentsForFees_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zamAQiHKQ0Z" title="Commitment fee"&gt;112,500&lt;/span&gt; upon the earlier of the Company filing
the registration statement on Form S-1 registering the Rights Offering or upon such date as the Company terminates the Rights Offering,
a commission equal 8% of the gross proceeds disbursed to the Company upon closing the Rights Offering, and $&lt;span id="xdx_906_eus-gaap--OtherGeneralExpense_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zX9SmJTVysWe" title="Related expense"&gt;40,000&lt;/span&gt; in diligence and related
expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2024, the Company has incurred $&lt;span id="xdx_90C_eus-gaap--DirectOperatingCosts_c20240101__20240630_zMx62q2PKDIl" title="Direct cost"&gt;142,000&lt;/span&gt;
in costs directly related to the planned Rights Offering and initially deferred these costs as other current assets in the unaudited
condensed consolidated balance sheet. However, since that date, the Rights Offering has not been consummated and, therefore, the
deferred costs have been expensed. As of June 30, 2024, there were no deferred costs recorded on the Company&#x2019;s unaudited condensed consolidated
balance sheet. Subsequent to June 30, 2024, the Company is pursuing other financing options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001077"
      unitRef="Shares">78197</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001079"
      unitRef="USD">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001081"
      unitRef="USD">235200</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001083"
      unitRef="USD">0</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001085"
      unitRef="USD">18783</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001087"
      unitRef="USD">0</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001089"
      unitRef="USD">71315</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001091"
      unitRef="Shares">3722</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Shares">19347</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Shares">228489</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">234864</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001099"
      unitRef="USD">1527750</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001101"
      unitRef="USD">1593900</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001103"
      unitRef="USD">220689</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001105"
      unitRef="USD">240831</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001107"
      unitRef="USD">415553</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001109"
      unitRef="USD">433807</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember"
      decimals="INF"
      id="Fact001111"
      unitRef="Shares">8909</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember"
      decimals="INF"
      id="Fact001113"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001115"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001117"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001119">&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpt1jpLKTnHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding all warrants issued for the six months ended June 30, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zPuNzHLoPhTh" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Warrants Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGmmy2OE5gHk" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;184,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_dxL_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcGkCjRORBv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance::XDX::23.21"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;23.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOaykqGoQ2hl" title="Weighted Average Life (Years)"&gt;2.77&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmNPQtO3uEl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1127"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znf668NBwEk5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1129"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzfCOsHPgAd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;184,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJRjwVBNdTqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;23.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuurucvHOak" title="Weighted Average Life (Years)"&gt;2.29&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828"
      decimals="INF"
      id="Fact001121"
      unitRef="Shares">184000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact001125">P2Y9M7D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember29544859"
      decimals="INF"
      id="Fact001131"
      unitRef="Shares">184000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember29544859"
      decimals="INF"
      id="Fact001133"
      unitRef="USDPShares">23.20</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember29544843"
      id="Fact001135">P2Y3M14D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001137"
      unitRef="USD">0</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001139"
      unitRef="Shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">138234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-06-30_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001143"
      unitRef="Shares">79395</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">28455</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="INF"
      id="Fact001147"
      unitRef="Shares">53455</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="INF"
      id="Fact001149"
      unitRef="Shares">4291</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="INF"
      id="Fact001151"
      unitRef="Shares">7416</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="0"
      id="Fact001153"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="0"
      id="Fact001155"
      unitRef="USD">141840</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="0"
      id="Fact001157"
      unitRef="USD">47400</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="0"
      id="Fact001159"
      unitRef="USD">95400</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171"
      decimals="0"
      id="Fact001161"
      unitRef="USD">182611</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171"
      decimals="0"
      id="Fact001163"
      unitRef="USD">57855</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001165"
      unitRef="USD">13033</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001167"
      unitRef="USD">46986</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001169"
      unitRef="USD">41190</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001171"
      unitRef="USD">41190</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001173"
      unitRef="USD">190779</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171"
      id="Fact001175">P1Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001177">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zuu6KI1jjRoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding the Restricted Stock Units issued follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zFcZXEx7rJsb" style="display: none"&gt;Schedule of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Fair Value Per RSU&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVRgs3QKydz5" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;24,731&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaBR0c6rk6W" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;11.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGKXMKubzvhh" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;53,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5h9v578mi67" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXBbyqQ5zQ7i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Vested"&gt;(19,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpWt13yUHaGb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;7.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Outstanding, June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqeDXbv4Uwll" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, Outstanding, Ending Balance"&gt;58,839&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYvZB97qXPK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance"&gt;4.87&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001179"
      unitRef="Shares">24731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001181"
      unitRef="USDPShares">11.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171"
      decimals="INF"
      id="Fact001183"
      unitRef="Shares">53455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171"
      decimals="INF"
      id="Fact001185"
      unitRef="USDPShares">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171"
      decimals="INF"
      id="Fact001187"
      unitRef="Shares">19347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember29542171"
      decimals="INF"
      id="Fact001189"
      unitRef="USDPShares">7.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001191"
      unitRef="Shares">58839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001193"
      unitRef="USDPShares">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-02-072024-02-07"
      decimals="0"
      id="Fact001195"
      unitRef="USD">2250000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2024-02-072024-02-07" id="Fact001197">(i) one share of the Company&#x2019;s
common stock, (ii) a warrant to purchase one share of the Company&#x2019;s common stock exercisable at a purchase price of $18.80 per share,
and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a
22% interest in Diagnostics.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-072024-02-07"
      decimals="0"
      id="Fact001199"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-02-072024-02-07"
      decimals="0"
      id="Fact001201"
      unitRef="USD">2250000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2024-02-07_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001203"
      unitRef="USD">2250000</us-gaap:EscrowDeposit>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001205"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <SHPH:AdditionalEscrowDeposit
      contextRef="AsOf2024-02-07_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001207"
      unitRef="USD">2250000</SHPH:AdditionalEscrowDeposit>
    <SHPH:InitialPublicOfferingDescription
      contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember"
      id="Fact001209">Unless
the parties waive the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the
Company&#x2019;s existing stockholders, the Company will not close on the offering and any funds raised and held in escrow will be
returned to investors</SHPH:InitialPublicOfferingDescription>
    <us-gaap:PaymentsForFees
      contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001211"
      unitRef="USD">112500</us-gaap:PaymentsForFees>
    <us-gaap:OtherGeneralExpense
      contextRef="From2024-02-072024-02-07_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">40000</us-gaap:OtherGeneralExpense>
    <us-gaap:DirectOperatingCosts
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001215"
      unitRef="USD">142000</us-gaap:DirectOperatingCosts>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001217">&lt;p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zJNmEEvXSAl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_82B_zIhS88dXVUbl"&gt;Derivative Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Assumptions Used in Accounting for Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_zPAPiNLbogbc" title="Number of shares warrant to purchase"&gt;127,260&lt;/span&gt; shares of common stock,
with an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_z7M6EgL6C2Ca" title="Exercise price per share"&gt;18.80&lt;/span&gt; per share, valued at inception at $&lt;span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230131_zJRXsooKvA1g" title="Derivative liability non-current"&gt;1,189,000&lt;/span&gt; and as of June 30, 2024, at $&lt;span id="xdx_90F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240630_zDBchRfCnQid" title="Derivative liability non-current"&gt;359,919&lt;/span&gt;. The Company determined
our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy the classification as equity
instruments due to the existence of a certain net cash settlement provision that is not within the sole control of the Company. In addition,
there are certain down round provisions that could reduce the exercise price if the Company issues securities at lower prices in the
future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has determined the Acceleration Option is an embedded derivative within the host instrument and has bifurcated it from the host
instrument and recorded it as a derivative liability valued at $&lt;span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNk3tCUzaOMe" title="Derivative liability"&gt;1,442,000&lt;/span&gt;, using a Monte Carlo simulation model. The Company determined
our derivative liability from the noteholder&#x2019;s Acceleration Option for the Alto Convertible Note is not clearly and closely related
to the host and should be thus accounted for as a bifurcated derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023 ($&lt;span id="xdx_90B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230111_z4UdVj7UHyj8"&gt;2,631,000&lt;/span&gt; included in debt discount) and June 30, 2024 ($&lt;span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20240630_zkjXlLQevCbe" title="Derivative fair value"&gt;360,423&lt;/span&gt;). Key inputs for the simulation are summarized
below. The Monte Carlo simulation uses an implied VWAP for the January 11, 2023 valuation date. The implied VWAP was backsolved by setting
the summation of the parts (e.g., derivatives and debt without derivatives) equal to the cash proceeds. The simulation was then iterated
and manipulated to solve for the implied share price, which was approximately $&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr8rjPrxTp0k" title="Share price"&gt;12.64 &lt;/span&gt;per share (or an approximate &lt;span id="xdx_904_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWDGDkUud5W8" title="Derivative discount percentage"&gt;14&lt;/span&gt;% discount to the
quoted market VWAP on January 11, 2023).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zddhrcXyuLig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs for the Monte Carlo simulation as of June 30, 2024, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z7WE6Sm8yWM4" style="display: none"&gt;Schedule of Monte Carlo Simulation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Net cash settlement and down round key valuation inputs &#x2013; warrants*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z7lnS5s2jUN9"&gt;89.76&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmZc9bAYLWi3"&gt;99.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zENOS2CF7rv2"&gt;4.61&lt;/span&gt;%
- &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zyedZGpSQBvj"&gt;5.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Quoted VWAP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zxmx6iG5WaC8"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zRmUEyhycePc"&gt;18.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Probability assessment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zw0Gt6uGAQW"&gt;2.5&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zdiXmuzlTMof"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zvnG2xSED8Zd"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z3NcjrfcqcJh" title="Time period (years)"&gt;0.11&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zpUW5ldGkXt6" title="Time period (years)"&gt;2.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Based on a Monte
Carlo simulation analysis of 250,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Acceleration option key valuation inputs*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z33q7ziTcqyb"&gt;64.76&lt;/span&gt;% - &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zvHaxuOUsMaa"&gt;74.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zWe5o0ZipMb8"&gt;5.23&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zqss6ZSDbcra"&gt;5.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Quoted VWAP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z9VW6iGSTos3"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zmppDXxJVuna"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zTfh1HZ0FQ8e" title="Time period (years)"&gt;0&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zFH5tWpTdkS" title="Time period (years)"&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0A_zqQfP1wZvzHb" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i id="xdx_F15_z5AQlH6MsWM9"&gt;Based on a Monte Carlo simulation analysis of 250,000 iterations&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p id="xdx_8A2_zqtwNN3nAG7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zB2cIqfiiimd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes in the derivative liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8BD_z0zcJjty7khd" style="display: none"&gt;Schedule of Derivative Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="9" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accelerated Feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwRqyS7RiOpe" style="width: 16%; text-align: right" title="Beginning balance"&gt;410,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zMg9AP4dwfr" style="width: 16%; text-align: right" title="Beginning balance"&gt;3,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcrO6JJ4haVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(196,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zbHPKQPIrEPl" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(1,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance - March 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpyk9HeHJchg" style="text-align: right" title="Beginning balance"&gt;214,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zkDLUMuDhQN1" style="text-align: right" title="Beginning balance"&gt;2,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;(Gain) loss on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkYuPFzcXtak" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;145,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zAQS817134U3" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(1,531&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance - June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCSwKsfFnXg5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;359,919&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zGNmvRYrn13g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zf5oWZxa1N16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001219"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001221"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-01-31"
      decimals="0"
      id="Fact001223"
      unitRef="USD">1189000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001225"
      unitRef="USD">359919</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001227"
      unitRef="USD">1442000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2023-01-11"
      decimals="0"
      id="Fact001228"
      unitRef="USD">2631000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001230"
      unitRef="USD">360423</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001232"
      unitRef="USDPShares">12.64</us-gaap:DebtInstrumentMeasurementInput>
    <SHPH:DerivativeDiscountPercentage
      contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001234"
      unitRef="Pure">0.14</SHPH:DerivativeDiscountPercentage>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001236">&lt;p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zddhrcXyuLig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs for the Monte Carlo simulation as of June 30, 2024, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z7WE6Sm8yWM4" style="display: none"&gt;Schedule of Monte Carlo Simulation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Net cash settlement and down round key valuation inputs &#x2013; warrants*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z7lnS5s2jUN9"&gt;89.76&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmZc9bAYLWi3"&gt;99.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zENOS2CF7rv2"&gt;4.61&lt;/span&gt;%
- &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zyedZGpSQBvj"&gt;5.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Quoted VWAP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zxmx6iG5WaC8"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zRmUEyhycePc"&gt;18.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Probability assessment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zw0Gt6uGAQW"&gt;2.5&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zdiXmuzlTMof"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zvnG2xSED8Zd"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z3NcjrfcqcJh" title="Time period (years)"&gt;0.11&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zpUW5ldGkXt6" title="Time period (years)"&gt;2.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Based on a Monte
Carlo simulation analysis of 250,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Acceleration option key valuation inputs*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z33q7ziTcqyb"&gt;64.76&lt;/span&gt;% - &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zvHaxuOUsMaa"&gt;74.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zWe5o0ZipMb8"&gt;5.23&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zqss6ZSDbcra"&gt;5.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Quoted VWAP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uUSDPShares_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____z9VW6iGSTos3"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zmppDXxJVuna"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zTfh1HZ0FQ8e" title="Time period (years)"&gt;0&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zFH5tWpTdkS" title="Time period (years)"&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0A_zqQfP1wZvzHb" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i id="xdx_F15_z5AQlH6MsWM9"&gt;Based on a Monte Carlo simulation analysis of 250,000 iterations&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001237"
      unitRef="Pure">89.76</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001238"
      unitRef="Pure">99.20</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Pure">4.61</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001240"
      unitRef="Pure">5.48</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">3.12</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001242"
      unitRef="USDPShares">18.80</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001243"
      unitRef="Pure">2.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Pure">30</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001245"
      unitRef="Pure">15</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember"
      id="Fact001247">P0Y1M9D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember"
      id="Fact001249">P2Y6M10D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001250"
      unitRef="Pure">64.76</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Pure">74.98</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Pure">5.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001253"
      unitRef="Pure">5.48</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001254"
      unitRef="USDPShares">3.12</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-06-30_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001255"
      unitRef="Pure">15</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember"
      id="Fact001257">P0Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember"
      id="Fact001259">P0Y8M12D</us-gaap:DebtInstrumentTerm>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001262">&lt;p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zB2cIqfiiimd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes in the derivative liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8BD_z0zcJjty7khd" style="display: none"&gt;Schedule of Derivative Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="9" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accelerated Feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwRqyS7RiOpe" style="width: 16%; text-align: right" title="Beginning balance"&gt;410,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zMg9AP4dwfr" style="width: 16%; text-align: right" title="Beginning balance"&gt;3,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcrO6JJ4haVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(196,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240101__20240331__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zbHPKQPIrEPl" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(1,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance - March 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpyk9HeHJchg" style="text-align: right" title="Beginning balance"&gt;214,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zkDLUMuDhQN1" style="text-align: right" title="Beginning balance"&gt;2,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;(Gain) loss on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkYuPFzcXtak" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;145,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zAQS817134U3" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(1,531&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance - June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCSwKsfFnXg5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;359,919&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240401__20240630__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zGNmvRYrn13g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;504&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001264"
      unitRef="USD">410660</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember29546515"
      decimals="0"
      id="Fact001266"
      unitRef="USD">3852</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001268"
      unitRef="USD">196045</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2024-01-012024-03-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact001270"
      unitRef="USD">1817</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001272"
      unitRef="USD">214615</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-03-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact001274"
      unitRef="USD">2035</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2024-04-012024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001276"
      unitRef="USD">-145304</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2024-04-012024-06-30_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact001278"
      unitRef="USD">1531</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001280"
      unitRef="USD">359919</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-06-30_custom_AcceleratedFeatureMember29546593"
      decimals="0"
      id="Fact001282"
      unitRef="USD">504</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001284">&lt;p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z6Ygdi2uTzK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_82C_zuRgz1jdtTz5"&gt;Related Party transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#x201c;TCG GreenChem&#x201d;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. During the six months ended June 30, 2024 and 2023, the Company expensed
$&lt;span id="xdx_90F_eus-gaap--OtherResearchAndDevelopmentExpense_c20240101__20240630_zFANokcYPHQe" title="Research, development expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20230630_zJVwkXP4auU2" title="Research, development expense"&gt;608,000&lt;/span&gt;, respectively, related to these services.&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001286"
      unitRef="USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact001288"
      unitRef="USD">608000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001290">&lt;p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zhRykpIpCk17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_82A_z9UOamJIec8j"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zuia5MsmHcik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zJ13jlUAhpRd" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNnudPW8ZBD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_z4DEPqCtDR89" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zGX2v3cjwAYj" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001292">&lt;p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_zuia5MsmHcik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zJ13jlUAhpRd" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNnudPW8ZBD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_z4DEPqCtDR89" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zGX2v3cjwAYj" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001294">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNnudPW8ZBD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_z4DEPqCtDR89" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zGX2v3cjwAYj" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001296">&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3vH6xpYk5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zGX2v3cjwAYj" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <SHPH:QuarterlyFinancialDataTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001298">&lt;p id="xdx_807_ecustom--QuarterlyFinancialDataTextBlock_zAj1b1gYgbM9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; &lt;span id="xdx_82D_zMMrfyxDrHZd"&gt;Quarterly Financial Data (Unaudited and Restated)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zWSfLbAcpoNc" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zaVdbSJYZaUe"&gt;Schedule
of Quarterly Financial Data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SHPH:QuarterlyFinancialDataTextBlock>
    <SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001300">&lt;p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zWSfLbAcpoNc" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zaVdbSJYZaUe"&gt;Schedule
of Quarterly Financial Data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001302">&lt;p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zUQoX5990Tac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_827_z2gPZJ4Q7DBh"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 2, Summary of Significant Accounting Policies, Reverse Stock Split, above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Alto
                                            Opportunity Master Fund, SPC&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 12, 2024, the Company informed the Investor in the Alto Convertible Note that the Company&#x2019;s expected restatement of its consolidated
financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the Alto Convertible
Note. On August 6, 2024, the Company paid $&lt;span id="xdx_90B_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20240806__20240806__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2ZNykpWEqLf"&gt;600,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to the Investor, which funds will be held as
collateral to the balance owed under the Alto Convertible Note, and received a waiver from the Investor related to the default.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Alliance Global Partners&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 30, 2024, the Company engaged A.G.P./Alliance Global Partners (&#x201c;AGP&#x201d;) to serve as exclusive underwriter, placement
agent or advisor in any public or private offering or financing (as defined, the &#x201c;Offering&#x201d;) of up to $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240730__20240730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember__srt--RangeAxis__srt--MaximumMember_zUhRrUXZO3C2"&gt;10.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Phase
II study of Ropidoxuridine&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 8, 2024, the Company entered into a work order (the &#x201c;Work Order&#x201d;) with Theradex Systems, Inc., a New Jersey contract
research organization (&#x201c;CRO&#x201d;) for purposes of supporting the Company&#x2019;s Phase II Study of Ropidoxuridine as a Radiation
Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promotor.&#x201d;
As such, Shuttle Pharma is now in the process of signing up six clinical sites where the clinical studies will be performed &#x2013; two
of which have completed initial site initiation visits and one of which is ready to enroll patients &#x2013; and where the CRO will oversee
such studies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the Work Order, the CRO will oversee the studies for a period of 53 months (the &#x201c;Term&#x201d;), including overseeing
and monitoring the regulatory aspects of the Phase II clinical trial, and managing the documentation surrounding the clinical trial in
exchange for a fee of approximately $&lt;span id="xdx_903_eus-gaap--PaymentsForFees_pn5n6_c20240808__20240808__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCaIeCPJVK59" title="Exchange fee"&gt;2.3&lt;/span&gt; million, payable in stages and based upon services performed during the Term of the study.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2024-08-062024-08-06_custom_AltoConvertibleNoteMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001303"
      unitRef="USD">600000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-07-302024-07-30_us-gaap_SubsequentEventMember_custom_AllianceGlobalPartnersMember_custom_OfferingMember_srt_MaximumMember"
      decimals="-5"
      id="Fact001304"
      unitRef="USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsForFees
      contextRef="From2024-08-082024-08-08_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001306"
      unitRef="USD">2300000</us-gaap:PaymentsForFees>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001314"
      unitRef="USD">2576416</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001315"
      unitRef="USD">8417203</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001317"
      unitRef="USD">114473</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001318"
      unitRef="USD">161148</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001320"
      unitRef="USD">2887215</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001323"
      unitRef="USD">14901</us-gaap:InterestReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001326"
      unitRef="USD">5593005</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001327"
      unitRef="USD">8578351</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001332"
      unitRef="USD">121685</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001334"
      unitRef="USD">114875</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001329"
      unitRef="USD">24827</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001330"
      unitRef="USD">12592</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001336"
      unitRef="USD">24827</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001337"
      unitRef="USD">12592</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001340"
      unitRef="USD">6480</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001342"
      unitRef="USD">333904</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001343"
      unitRef="USD">56122</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001345"
      unitRef="USD">5951736</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001346"
      unitRef="USD">8653545</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001354"
      unitRef="USD">282860</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001355"
      unitRef="USD">116745</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001357"
      unitRef="USD">446</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001358"
      unitRef="USD">12500</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001360"
      unitRef="USD">110453</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001364"
      unitRef="USD">98135</us-gaap:InterestPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001367"
      unitRef="USD">685473</us-gaap:NotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001369"
      unitRef="USD">595999</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001375"
      unitRef="USD">52479</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001376"
      unitRef="USD">62823</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001378"
      unitRef="USD">1042237</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001379"
      unitRef="USD">975676</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001381"
      unitRef="USD">135089</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001384"
      unitRef="USD">414512</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001387"
      unitRef="USD">414512</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001390"
      unitRef="USD">304127</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001393"
      unitRef="USD">1895965</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001394"
      unitRef="USD">975676</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001402"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001404"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001406"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001408"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001410"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001412"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001414"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001416"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001421"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001423"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001425"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001427"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">2008689</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001431"
      unitRef="Shares">2008689</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001433"
      unitRef="Shares">1700414</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001435"
      unitRef="Shares">1700414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001418"
      unitRef="USD">20</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001419"
      unitRef="USD">17</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001437"
      unitRef="USD">29489055</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001438"
      unitRef="USD">26518433</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001440"
      unitRef="USD">-25433304</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001441"
      unitRef="USD">-18840581</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001443"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001444"
      unitRef="USD">7677869</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001446"
      unitRef="USD">5951736</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001447"
      unitRef="USD">8653545</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001455"
      unitRef="USD">3517093</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001456"
      unitRef="USD">1047385</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001458"
      unitRef="USD">3517093</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001459"
      unitRef="USD">1047385</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001461"
      unitRef="USD">1046854</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001462"
      unitRef="USD">473714</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001464"
      unitRef="USD">1046854</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001465"
      unitRef="USD">473714</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001467"
      unitRef="USD">1328435</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001468"
      unitRef="USD">822727</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001470"
      unitRef="USD">1328435</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001471"
      unitRef="USD">822727</us-gaap:LegalFees>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001473"
      unitRef="USD">5892382</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001474"
      unitRef="USD">2343826</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001476"
      unitRef="USD">5892382</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001477"
      unitRef="USD">2343826</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001479"
      unitRef="USD">-5892382</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001480"
      unitRef="USD">-2343826</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001482"
      unitRef="USD">-5892382</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001483"
      unitRef="USD">-2343826</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">6825</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">52010</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001491"
      unitRef="USD">2484193</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001492"
      unitRef="USD">428688</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001494"
      unitRef="USD">2484193</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001495"
      unitRef="USD">428688</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001497"
      unitRef="USD">79117</us-gaap:InvestmentIncomeInterest>
    <SHPH:FinanceFee
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001500"
      unitRef="USD">104245</SHPH:FinanceFee>
    <SHPH:FinanceFee
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001501"
      unitRef="USD">189912</SHPH:FinanceFee>
    <SHPH:FinanceFee
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001503"
      unitRef="USD">104245</SHPH:FinanceFee>
    <SHPH:FinanceFee
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001504"
      unitRef="USD">189912</SHPH:FinanceFee>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001506"
      unitRef="USD">2216488</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001507"
      unitRef="USD">-189000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001509"
      unitRef="USD">2216488</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001510"
      unitRef="USD">-189000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <SHPH:FairValueAdjustmentOfWarrant
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001513"
      unitRef="USD">398675</SHPH:FairValueAdjustmentOfWarrant>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001515"
      unitRef="USD">4970</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001518"
      unitRef="USD">71568</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001521"
      unitRef="USD">477221</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001522"
      unitRef="USD">1795652</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001524"
      unitRef="USD">477221</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001525"
      unitRef="USD">1795652</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:GainOnSettlementOfAccountsPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001528"
      unitRef="USD">328687</SHPH:GainOnSettlementOfAccountsPayable>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001531"
      unitRef="USD">73007</SHPH:GainOnForgivenessOfNotePayable>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001533"
      unitRef="USD">-700341</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001534"
      unitRef="USD">-2652243</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001536"
      unitRef="USD">-6592723</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001537"
      unitRef="USD">-4996069</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001540"
      unitRef="USD">402064</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001543"
      unitRef="USD">439427</SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStockAsRestated>
    <SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001546"
      unitRef="USD">941000</SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001549"
      unitRef="USD">-31423</SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividends>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001551"
      unitRef="USD">-6592723</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001552"
      unitRef="USD">-6747137</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001554"
      unitRef="Shares">1866275</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001556"
      unitRef="Shares">1866275</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001558"
      unitRef="Shares">1337742</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001560"
      unitRef="Shares">1337742</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001562"
      unitRef="USDPShares">-3.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001564"
      unitRef="USDPShares">-3.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001566"
      unitRef="USDPShares">-5.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001568"
      unitRef="USDPShares">-5.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001577"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001579"
      unitRef="Shares">1164039</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">12</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001572"
      unitRef="USD">12063940</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001574"
      unitRef="USD">-13844512</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001575"
      unitRef="USD">-1764220</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001588"
      unitRef="Shares">352443</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001582"
      unitRef="USD">4</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001583"
      unitRef="USD">9951352</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001586"
      unitRef="USD">9951356</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001592"
      unitRef="USD">14662</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001595"
      unitRef="USD">14662</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001604"
      unitRef="Shares">105</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001599"
      unitRef="USD">16340</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact001600"
      unitRef="USD">-16340</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001613"
      unitRef="Shares">36876</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001608"
      unitRef="USD">1199916</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001611"
      unitRef="USD">1199916</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001622"
      unitRef="Shares">66250</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001616"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001617"
      unitRef="USD">2153123</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001620"
      unitRef="USD">2153124</us-gaap:StockIssuedDuringPeriodValueOther>
    <SHPH:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001631"
      unitRef="Shares">22535</SHPH:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001640"
      unitRef="Shares">3500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001644"
      unitRef="USD">237547</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001647"
      unitRef="USD">237547</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001651"
      unitRef="USD">402064</SHPH:DividendsOnSeriesPreferredStock>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001654"
      unitRef="USD">402064</SHPH:DividendsOnSeriesPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001684"
      unitRef="Shares">-1213</us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001686"
      unitRef="Shares">54666</us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001679"
      unitRef="USD">402064</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001682"
      unitRef="USD">402064</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001690"
      unitRef="USD">881553</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001693"
      unitRef="USD">881553</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001699"
      unitRef="USD">-4996069</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001700"
      unitRef="USD">-4996069</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001711"
      unitRef="Shares">1700414</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001703"
      unitRef="USD">17</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001704"
      unitRef="USD">26518433</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001706"
      unitRef="USD">-18840581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001707"
      unitRef="USD">7677869</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001722"
      unitRef="Shares">1700414</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001714"
      unitRef="USD">17</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001715"
      unitRef="USD">26518433</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001717"
      unitRef="USD">-18840581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001718"
      unitRef="USD">7677869</us-gaap:StockholdersEquity>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001731"
      unitRef="USD">8727</SHPH:WarrantsIssuanceFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001726"
      unitRef="USD">90816</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001729"
      unitRef="USD">90816</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001740"
      unitRef="Shares">297625</SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001734"
      unitRef="USD">3</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001735"
      unitRef="USD">2697846</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001738"
      unitRef="USD">2697849</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001749"
      unitRef="Shares">10650</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001753"
      unitRef="USD">181960</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001756"
      unitRef="USD">181960</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001762"
      unitRef="USD">-6592723</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001763"
      unitRef="USD">-6592723</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001774"
      unitRef="Shares">2008689</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001766"
      unitRef="USD">20</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001767"
      unitRef="USD">29489055</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001769"
      unitRef="USD">-25433304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001770"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001785"
      unitRef="Shares">2008689</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001777"
      unitRef="USD">20</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001778"
      unitRef="USD">29489055</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001780"
      unitRef="USD">-25433304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001781"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001790"
      unitRef="USD">-6592723</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001791"
      unitRef="USD">-4996069</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001796"
      unitRef="USD">6811</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001797"
      unitRef="USD">5972</us-gaap:Depreciation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001799"
      unitRef="USD">2216488</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001800"
      unitRef="USD">-189000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001803"
      unitRef="USD">398675</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001805"
      unitRef="USD">2123049</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001806"
      unitRef="USD">377384</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001808"
      unitRef="USD">4970</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001811"
      unitRef="USD">71568</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <SHPH:AccruedInterestSettledWithCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001814"
      unitRef="USD">294927</SHPH:AccruedInterestSettledWithCommonStock>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001817"
      unitRef="USD">477221</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001818"
      unitRef="USD">1795652</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001821"
      unitRef="USD">189912</SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds>
    <SHPH:GainOnSettlementOnAccountsPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001824"
      unitRef="USD">328687</SHPH:GainOnSettlementOnAccountsPayable>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001827"
      unitRef="USD">73007</SHPH:GainOnForgivenessOfNotePayable>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001829"
      unitRef="USD">181960</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001830"
      unitRef="USD">237547</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001835"
      unitRef="USD">14901</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001838"
      unitRef="USD">-46675</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001839"
      unitRef="USD">156282</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001841"
      unitRef="USD">166115</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001842"
      unitRef="USD">-382881</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001844"
      unitRef="USD">-12054</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001845"
      unitRef="USD">12500</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001847"
      unitRef="USD">110453</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001848"
      unitRef="USD">18378</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001850"
      unitRef="USD">-98135</SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties>
    <SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001851"
      unitRef="USD">51188</SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001853"
      unitRef="USD">-6480</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001856"
      unitRef="USD">16001</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001857"
      unitRef="USD">-5693</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001859"
      unitRef="USD">-5581147</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001860"
      unitRef="USD">-2666411</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001865"
      unitRef="USD">2998572</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001868"
      unitRef="USD">187895</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001871"
      unitRef="USD">19046</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001874"
      unitRef="USD">-2829723</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001877"
      unitRef="USD">-2829723</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001884"
      unitRef="USD">9995513</SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001887"
      unitRef="USD">50000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001889"
      unitRef="USD">685473</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001890"
      unitRef="USD">50000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001892"
      unitRef="USD">3935000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001893"
      unitRef="USD">550715</us-gaap:ProceedsFromConvertibleDebt>
    <SHPH:ProceedsFromNotesPayableAndWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001896"
      unitRef="USD">50000</SHPH:ProceedsFromNotesPayableAndWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001898"
      unitRef="USD">345000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001899"
      unitRef="USD">17363</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001901"
      unitRef="USD">334444</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001904"
      unitRef="USD">2570083</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001905"
      unitRef="USD">10578865</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001907"
      unitRef="USD">2570083</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001908"
      unitRef="USD">10578865</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001910"
      unitRef="USD">-5840787</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001911"
      unitRef="USD">7912454</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001913"
      unitRef="USD">8417203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001914"
      unitRef="USD">504749</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001916"
      unitRef="USD">2576416</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001917"
      unitRef="USD">8417203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001922"
      unitRef="USD">164807</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001923"
      unitRef="USD">39201</us-gaap:InterestPaidNet>
    <SHPH:CommonStockIssuedForConversionOfAccruedInterestAsRestated
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001932"
      unitRef="USD">16340</SHPH:CommonStockIssuedForConversionOfAccruedInterestAsRestated>
    <SHPH:CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001934"
      unitRef="USD">2697849</SHPH:CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated>
    <SHPH:CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001935"
      unitRef="USD">1199916</SHPH:CommonStockIssuedUponConversionOfConvertibleDebtAndExerciseOfRelatedWarrantsAsRestated>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001938"
      unitRef="USD">2153124</SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable>
    <SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001941"
      unitRef="Shares">402064</SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001946"
      unitRef="USD">8727</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001948"
      unitRef="USD">0</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001943"
      unitRef="USD">90816</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001944"
      unitRef="USD">14662</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001951"
      unitRef="USD">881553</SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering>
    <SHPH:InitialRecognitionOfRightOfUseAssetAndLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001953"
      unitRef="USD">365556</SHPH:InitialRecognitionOfRightOfUseAssetAndLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact001956">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLSnJOFJjx87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82A_zNQTfjOQsJoh"&gt;Organization and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Organization
and Line of Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#x201c;Shuttle&#x201d;). In connection with the conversion the Company issued &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuWYMCwBa1l" title="Conversion of stock, shares issued"&gt;5,625,000&lt;/span&gt; shares of common
stock in exchange for &lt;span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrFlg9kE6KXj" title="Sale of stock membership percentage"&gt;100&lt;/span&gt;% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#x201c;Company&#x201d;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#x2019;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#x2019;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#x201c;SBIR&#x201d;) contract provided
by the National Cancer Institute (&#x201c;NCI&#x201d;), a unit of the National Institutes of Health (&#x201c;NIH&#x201d;). Ropidoxuridine
has been further developed though the Company&#x2019;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#x2019;s initial public offering, the Company
has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
production and marketing of the Company&#x2019;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#x201c;FDA&#x201d;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay
or suspend clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and
has a net loss of approximately $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zvDIDv0jCj34" title="Net income loss"&gt;6.6&lt;/span&gt;
million and no revenues for the year ended December 31, 2023 and working capital of approximately $&lt;span id="xdx_90D_ecustom--WorkingCapital_iN_pn5n6_di_c20230101__20231231_zpMi8peYTBP7" title="Working capital"&gt;4.6&lt;/span&gt;
million as of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and
certain cash payment requirements. On July 12, 2024, the Company informed the investor of its convertible note that the
Company&#x2019;s expected restatement of its financial statements for the years ended December 31, 2022 and 2023 constituted an event
of default under the terms of the convertible note. On August 6, 2024, the Company paid $&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20240806__20240806__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zXZVY5oJ2dl5" title="Proceeds from convertible debt"&gt;0.6&lt;/span&gt; million to the investor of the
convertible note and received a waiver from the investor related to the default. The funds paid are restricted and will be held as
collateral to the balance owed under the convertible note (see Note 12). These conditions, and the Company&#x2019;s ability to comply
with such conditions, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after
the date that the consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLz2DBKNXBw9"&gt;4.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, along with a four-year warrant to purchase
&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zl355kJKiw01"&gt;127,260
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, exercisable at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUpMqMf0Hl09"&gt;18.80
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, providing the Company with approximately
$&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zObOWFtvk5K9"&gt;3.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in net proceeds. To date, the warrant
has not yet been exercised. However, the Company&#x2019;s existing cash resources, marketable securities and the cash received from the
equity offering and convertible note are not expected to provide sufficient funds to carry out the Company&#x2019;s operations and clinical
trials through the next twelve months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
IPO and subsequent capital raise have supported operations, the manufacture of drug product and FDA
approval of the IND for the Phase II clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and
the company agreed to an expansion of the clinical trial, necessitating additional capital to complete the trial, as well as fund ongoing operations. As a result, management had initiated
a $&lt;span id="xdx_90E_eus-gaap--PartnersCapital_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsiazBOPM4B4" title="Initiated a capital offering"&gt;4.5&lt;/span&gt; million rights offering and submitted an application for a SBIR grant for non-dilutive funding for pre-clinical project through
the NIH. The Company is also currently pursuing other financing. The ability of the Company to continue as a going concern is dependent
upon its ability to successfully raise additional equity or debt financing to allow it to fund ongoing operations, conduct clinical trials
and bring a drug candidate to commercialization to generate revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements do not include any adjustments to reflect the future effects on the recoverability and
classification of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On August 13, 2024, in order to meet
Nasdaq&#x2019;s minimum bid price requirement of $&lt;span title="Share Price"&gt;&lt;span id="xdx_900_eus-gaap--SharePrice_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGJmbQWtYsma" title="Share price"&gt;1.00&lt;/span&gt;&lt;/span&gt;
per share (the &#x201c;Minimum Bid Price Requirement&#x201d;), the Company effectuated a &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20240813__20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjuBpwCxWvQe" title="Reverse stock split"&gt;1-for-8 reverse stock split&lt;/span&gt; of its issued and outstanding common stock, rounding up to account for any fractional shares (the
&#x201c;Reverse Stock Split&#x201d;). The Reverse Stock Split had no effect on the Company&#x2019;s authorized shares of common stock
or preferred stock. Following the reverse stock split on August 13, 2024, the Company had a total of &lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znxZOrhkU0C1" title="Common stock shares issued"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdFH3eQyw6x7" title="Common stock shares outstanding"&gt;2,111,235&lt;/span&gt;&lt;/span&gt;
shares issued and outstanding (or &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20231231_zaV7QAG26O38" title="Common stock, shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zhLIdladDdp" title="Common stock, shares outstanding"&gt;2,008,689&lt;/span&gt;&lt;/span&gt;
on a post-split basis as of December 31, 2023). The Reverse Stock Split also resulted in an adjustment to the consolidated balance
sheets for the years ended December 31, 2023, December 31, 2022 and December 31, 2021 with an increase to additional paid in capital
of $&lt;span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20230101__20231231_z7lwD9NG56F4" title="Adjustments to additional paid in capital stock split"&gt;141&lt;/span&gt;,
$&lt;span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20220101__20221231_zuVy3UoPY47c" title="Adjustments to additional paid in capital stock split"&gt;119&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20210101__20211231_zzaW9Jev2whh" title="Adjustments to additional paid in capital stock split"&gt;81&lt;/span&gt;,
respectively, and an offsetting adjustment to the carrying value of common stock. All share, option, warrant and per share amounts
(except our authorized outstanding) have been retroactively restated in these financial statements and related disclosures. The
effect of the Reverse Stock Split has been included in Note 2 in the &#x201c;As Reported&#x201d; and in Note 11 in the &#x201c;As
Reported&#x201d; amounts for additional paid in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001958"
      unitRef="Shares">5625000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001960"
      unitRef="Pure">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001962"
      unitRef="USD">-6600000</us-gaap:NetIncomeLoss>
    <SHPH:WorkingCapital
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001964"
      unitRef="USD">-4600000</SHPH:WorkingCapital>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-08-062024-08-06_us-gaap_InvestorMember_srt_ScenarioForecastMember"
      decimals="-5"
      id="Fact001966"
      unitRef="USD">600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001967"
      unitRef="USD">4300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001968"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001969"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001970"
      unitRef="USD">3600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PartnersCapital
      contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001972"
      unitRef="USD">4500000</us-gaap:PartnersCapital>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001974"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-08-132024-08-13_us-gaap_SubsequentEventMember"
      id="Fact001976">1-for-8 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001978"
      unitRef="Shares">2111235</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001980"
      unitRef="Shares">2111235</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001982"
      unitRef="Shares">2008689</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001984"
      unitRef="Shares">2008689</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001986"
      unitRef="USD">141</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001988"
      unitRef="USD">119</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact001990"
      unitRef="USD">81</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:ErrorCorrectionTextBlock contextRef="From2023-01-012023-12-31" id="Fact001992">&lt;p id="xdx_80B_eus-gaap--ErrorCorrectionTextBlock_zYnQb5pXRUd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;Note &lt;span style="font-family: Times New Roman, Times, Serif"&gt;2
&#x2013; &lt;span id="xdx_826_zS4IaF9iKHzg"&gt;Restatement of Previously Issued Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As previously disclosed in the Company&#x2019;s
Quarterly Report on Form 10-Q for the period ended March 31, 2024, filed with the Securities and Exchange Commission
(&#x201c;SEC&#x201d;) on May 13, 2024, following the entry of a cease-and-desist order by the SEC against our former auditor, B.F.
Borgers CPA PC (&#x201c;BF Borgers&#x201d;), we commenced the re-audit (the &#x201c;Re-audit&#x201d;) of our consolidated financial
statements for the year ended December 31, 2022, which had been audited by BF Borgers. Since that time and as a result of the
Re-audit, and as initially disclosed on Form 8-K dated July 10, 2024, the Company and the Audit Committee have concluded and
informed our current auditor, Forvis Mazars, LLP, that our audited consolidated financial statements for the year ended December 31,
2022 (the &#x201c;2022 Financial Statements&#x201d;), our audited consolidated financial statements for the year ended December 31,
2023 (the &#x201c;2023 Financial Statements&#x201d;), and the quarterly periods included in the Company&#x2019;s Annual Report
for the year ended December 31, 2023, and the quarterly report for the period ended March 31, 2024 require restatement and are not reliable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The accounting errors impacting our 2022 Financial
Statements include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Stock Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Application of the incorrect grant date fair values in determining the value of certain equity awards
granted during the years ended December 31, 2019 and 2020;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Miscalculation of the pattern of recognition of stock-based compensation over the requisite service periods
for certain equity awards granted during the years ended December 31, 2019 and 2020;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Series A Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Utilization of incorrect inputs to the fair value estimates for the warrant obligation related to
                                                                     the Series A Convertible Preferred Stock; incorrectly recording the reclassification of the warrant obligation upon issuance as a
                                                                     gain and not as a reclassification to stockholders&#x2019; equity;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Recording of accrued dividends on the Series A Convertible Preferred Stock as a liability prior to
                                                                     the dividends being declared;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Failure to recognize the accounting impact for the amendment to the terms of the Series A
                                                                     Convertible Preferred Stock in April 2022, which the Company subsequently concluded should have been recognized as an
                                                                     extinguishment;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Failure to recognize deemed contribution related to the settlement of the
Series A Convertible Preferred Stock and accrued dividends;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                   &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Misidentification of certain debt and equity issuance costs and incorrect association with certain of
the Company&#x2019;s financings during the years ended December 31, 2022 and 2021;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Application of the incorrect amortization period and pattern of recognition for debt discounts recorded
in relation to the Company&#x2019;s debt financings during the years ended December 31, 2022 and 2021;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Incorrect recognition of bifurcated derivative liabilities, as well as incorrect initial and subsequent
fair value measurements, in relation to the December 2021 Notes, 2022 Convertible Notes and August 2022 Notes;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Misclassification of certain warrants issued with debt transactions during the year ended December 31,
2022;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Failure to recognize certain liability-classified warrants issued in exchange for services provided related
to the Company&#x2019;s financing activities during the year ended December 31, 2022; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Incorrect application of extinguishment or conversion models in accounting for certain debt instruments
upon their settlement; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Initial Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Incorrect identification of deferred issuance costs incurred in relation to the initial public offering; Incorrect identification and classification of issuance costs incurred in relation to the initial public offering.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In addition to the restatement of the consolidated
financial statements, the Company has also restated the following notes to reflect the errors described above:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Note 2 - Summary of Significant Accounting Policies (now Note 3)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Note 5 &#x2013; Notes Payable-Related Party&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;b&gt;&#x25cf;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Note 6 &#x2013; Convertible Notes (now labeled Notes Payable)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;b&gt;&#x25cf;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Note 7 &#x2013; Stockholders&#x2019; Equity&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;b&gt;&#x25cf;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Note 8 &#x2013; Derivative Liabilities&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;b&gt;&#x25cf;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Note 10 &#x2013; Income Taxes&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_gL3SOECAPPATT-CTUD_zsjBbHmPqf0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The impact of the errors described above also impact
the Company&#x2019;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z0zZqA0Nnjde" style="display: none"&gt;Schedule
 of Error Corrections And Prior Period Adjustments &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwetAMD0zH8g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJmDSENBI7ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_z4uPlYfsUoR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_iI_z2zeGbBRXc0g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;19,543,363&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,489,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zaoGgdHo6uwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(15,487,612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(25,433,304&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_znh5diDZJD2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Additionally, the Company has provided Note 11 &#x2013; Quarterly Financial
Data (unaudited and restated) to present the impact of the above restatements on the unaudited quarterly financial information for the
period ended September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company&#x2019;s prior and updated accounting for
the errors described above do not have any effect on the Company&#x2019;s previously reported cash or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_C03_gL3SOECAPPATT-CTUD_zjl0AJp8VmS4"&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C0B_gL3SOECAPPATT-CTUD_zZbMdljBzSu" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The following tables summarize the effect of the restatement
on each financial statement line item as of the dates indicated:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_308_134_zg7BX6nomyV7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6IPnX7kMpQd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zqIfqvq3dbla" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_zVBmgAKxgFu2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;16,572,741&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zRFyZ3enDeJ4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;26,518,433&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z7ch26L7ImB3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8,894,889&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zq9la8ZM1J46" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(18,840,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F09_z6tdetXqK1di" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zNZReqJ1vZk4" style="font-size: 10pt"&gt;Adjustments
    include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj" title="Stock compensation"&gt;7,843,052&lt;/span&gt;);
    recognition of Series A Preferred Stock accrued dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8" title="Accrued dividends"&gt;402,064&lt;/span&gt;);
    correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta" title="Issuance cost"&gt;174,082&lt;/span&gt;);
    corrections to the Company&#x2019;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8" title="Warrants"&gt;416,266&lt;/span&gt;),
    reclassifications of warrants from liability to equity (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh" title="Warrants from liability"&gt;881,554&lt;/span&gt;);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l" title="Debt instrument"&gt;2,213,498&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0D_zaNZZatnnmHh" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zzreMJkmsia8" style="font-size: 10pt"&gt;Adjustments include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a" title="Stock compensation"&gt;8,009,461&lt;/span&gt;); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc" title="Fair value of warrants"&gt;240,930&lt;/span&gt;); reversal of accrued Series A Preferred Stock dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a" title="Accrued dividends"&gt;402,064&lt;/span&gt;); recognition of bifurcated derivatives and recording of loss at issuance (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih" title="Derivatives loss"&gt;296,151&lt;/span&gt;); correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e" title="Issuance cost"&gt;166,407&lt;/span&gt;); and the aggregate adjustments to 2022 net loss as detailed below (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf" title="Net income loss"&gt;1,967,621&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zCPDzGSrLKea" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Statement of Operations for the year ended December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zfF7oBBVekwd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zwoKT7aBJHO8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zWrYFaOF7wz2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zj2MSn4b2I9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Research and development, net of contract expense reimbursements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,148,712&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(101,327&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,047,385&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_zfl0BeByAfcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;538,796&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(65,082&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;473,714&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LegalFees_i01_zVxLruGqxV9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Legal and professional&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;866,770&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(44,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;822,727&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_zmOcF5iBAFc8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss from operations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,554,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;210,452&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,343,826&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestExpense_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zdoL3oeTEEUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(917,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;489,191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(428,688&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--FinanceFee_i01N_di_zcGL6QyywMmb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financing fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2066"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zuPH3lpTUpn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of derivative liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zZ7eV5qwPDs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(492,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(398,675&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_ztFvHLdBYq75" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on extinguishment of debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zslkvUkqO935" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,028,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,967,621&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,996,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zRrY7MweYN9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend on Series A Preferred Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(71,009&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(331,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeemedDividendOnExtinguishmentOfSeriesPreferredStock_iN_di_z5JuaOYNMOtj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deemed dividend on extinguishment of Series A Preferred Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2090"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(439,427&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(439,427&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_iN_di_zNL0yHlXVCs9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deemed dividend on modification of equity-classified warrants, as restated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(941,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(941,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_iN_di_zu7usXLwRWu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;31,423&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;31,423&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zMdGKJyjwBM2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,099,457&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,647,680&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(6,747,137&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss per shares - basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMuzbPGlFEhh" title="Net loss per shares - basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zccDRV02xjSf" title="Net loss per shares - basic"&gt;(2.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB4urI05QeH1" title="Net loss per shares - basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKBYOEmr9nYi" title="Net loss per shares - Diluted"&gt;(2.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_z5ihkRTEuiul" title="Net loss per shares - Basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zSznyrVunGh9" title="Net loss per shares - Diluted"&gt;(5.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_309_134_zJX9uMgHKaPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Statement of Stockholders&#x2019; Equity as of December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwS0vTQ9jBnd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcwAjgI1jFjg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zV0UlYwvROeh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zWvWqPGPs5Ya" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,951,356&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,951,356&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CommonStockIssuedForCash_zHDj0uGsfbqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,008,095&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10,008,095&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2124"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--WarrantsExercisedForCash_z2d1h2nIc9ac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants exercised for cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2128"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zhhR4qDxRN8l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Warrants issued for financing costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;412,241&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(397,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;14,662&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zhykxizzqMlh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for conversion of accrued interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;588,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(588,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2136"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zyHZ1nRPI2pe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued upon conversion of convertible debt and exercise of related warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,199,916&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,199,916&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zwf7FzAmToLf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for exercise of warrants with settlement of notes payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;576,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,576,648&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,153,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsDHZesDpxNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;403,956&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(166,409&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DividendsOnSeriesPreferredStock_iN_di_zvqx0AJOOAIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividends on Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(71,009&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(331,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_zABJ06Gj07Ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common shares issued for dividends on and conversion of Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,068&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_z5MiqqZKDCgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Reclassification of fair value of warrant liability to equity upon initial public offering&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2158"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_zxnxLSWBTqm9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,028,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,967,621&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,996,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xdx_C02_gL3SOECAPPATT-CTUD_zbUUVOgV6av4"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_C09_gL3SOECAPPATT-CTUD_zLvKL6q0ueWd"&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C07_gL3SOECAPPATT-CTUD_zhhDmZ3MOnCh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zdfyzfvfDy16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Statement of Cash Flows for the year ended December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zy1sl4WmcFif" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zeDLOhNW3Qh1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_z3HtR4Rnmup1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zCatNeztmy4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(3,028,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(1,967,621&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(4,996,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_zobw7LZjY4ph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of derivative liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2170"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01_zH5N7jyNN6bb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(94,025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;492,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;398,675&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i01_zuFdOtXI1xQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amortization of debt discount and finance fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;885,505&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(508,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;377,384&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LossOnSettlementOfConvertibleDebt_i01_zjcoYliHCWO2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on settlement of convertible debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2182"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FairValueOfFreestandingInstrumentsInExcessOfProceeds_i01_zOCefK4QX4t2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Fair value of freestanding instruments in excess of proceeds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2186"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--GainOnInterestReliefOnConversionOfNotesPayable_i01N_di_zbi2XyEBcw01" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Gain on interest relief on conversion of notes payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(12,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_z9JN5YP8HCA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;403,956&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(166,409&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_zdwCVGgYjudb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued interest payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(13,177&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;31,555&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;18,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zS9xgAWVXgZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,710,454&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;44,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,666,411&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_zPeJwFkUi6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    from issuance of common shares and warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,022,193&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(26,680&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,995,513&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_zX9wJ2hh4D47" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    from convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600,715&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;550,715&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProceedsFromNotesPayableAndWarrants_i01_zB9jBkRcOoei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    from notes payable and warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2214"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PaymentsOfFinancingCosts_i01N_di_zSy4wmzIPBff" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
    for finance costs related to convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2218"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(17,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(17,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_z1cIFFnQqII8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,622,908&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(44,043&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,578,865&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxesPaid_i01_z2AXVU0ATqRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Supplemental non-cash financing activities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--CommonStockIssuedUponConversionOfConvertibleDebt_i01_zqxadejLpiX2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued upon conversion of convertible debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;588,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;611,392&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,199,916&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zl91Hr9vTr9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for exercise of warrants with settlement of notes payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;576,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,576,648&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,153,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_i01_zSvMjywi1h66" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common shares issued for dividends on and conversion of Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,068&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--WarrantsIssuedForFinancingFees_i01_zEdVHlVkRYRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants issued for financing fees, net of issuance fees of $&lt;span id="xdx_901_ecustom--WarrantsIssuanceFees_c20230101__20231231_z3f2JIJxQ6Sg" title="Warranst of issuance fees"&gt;8,727&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--WarrantsIssuanceFees_c20220101__20221231_zdqu9lkBFd4" title="Warranst of issuance fees"&gt;0&lt;/span&gt;, respectively&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;412,241&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(397,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,662&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_i01_zpGNzvsa7kK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Reclassification of fair value of warrant liability to equity upon initial public offering&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30B_134_zABYLOApGVBf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zLsnU6dc6oAc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z4f2SrKUNhEd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_z9hEcTZm93ad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;4,150,948&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AdditionalPaidInCapital_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zSrXYy1elD59" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital"&gt;7,912,992&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;12,063,940&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zqI4Ca10eqGi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated Deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,795,432&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zbPV9duglp2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit"&gt;(8,049,080&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(13,844,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F09_zyx8H6MNpq29" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zVcwwitNryW8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk" title="Increase decrease of notes payable"&gt;7,351&lt;/span&gt;); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh" title="Increase decrease in preferred stock"&gt;89,118&lt;/span&gt;); and stock compensation adjustments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l" title="Stock compensation"&gt;8,009,461&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0A_z8KUvJcM4081" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F11_zlKB34EfShAa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
    include reversal of dividend liability recorded (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1" title="Increase decrease in dividend liability"&gt;331,059&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    identification of deferred IPO costs (decrease of ($&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi"&gt;55,182&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh"&gt;89,118&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    adjustment to the estimated fair value of warrant liability (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63"&gt;240,930&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj"&gt;274,048&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    and stock compensation adjustments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc"&gt;8,009,461&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_C06_gL3SOECAPPATT-CTUD_zXQh9xUmmI5"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ErrorCorrectionTextBlock>
    <SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact002000">&lt;p id="xdx_890_ecustom--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock_gL3SOECAPPATT-CTUD_zsjBbHmPqf0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The impact of the errors described above also impact
the Company&#x2019;s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z0zZqA0Nnjde" style="display: none"&gt;Schedule
 of Error Corrections And Prior Period Adjustments &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwetAMD0zH8g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJmDSENBI7ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_z4uPlYfsUoR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_iI_z2zeGbBRXc0g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;19,543,363&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,489,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zaoGgdHo6uwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(15,487,612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(25,433,304&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The following tables summarize the effect of the restatement
on each financial statement line item as of the dates indicated:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_308_134_zg7BX6nomyV7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6IPnX7kMpQd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zqIfqvq3dbla" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_zVBmgAKxgFu2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;16,572,741&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zRFyZ3enDeJ4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;26,518,433&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z7ch26L7ImB3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8,894,889&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zq9la8ZM1J46" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(18,840,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F09_z6tdetXqK1di" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zNZReqJ1vZk4" style="font-size: 10pt"&gt;Adjustments
    include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj" title="Stock compensation"&gt;7,843,052&lt;/span&gt;);
    recognition of Series A Preferred Stock accrued dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8" title="Accrued dividends"&gt;402,064&lt;/span&gt;);
    correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta" title="Issuance cost"&gt;174,082&lt;/span&gt;);
    corrections to the Company&#x2019;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8" title="Warrants"&gt;416,266&lt;/span&gt;),
    reclassifications of warrants from liability to equity (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh" title="Warrants from liability"&gt;881,554&lt;/span&gt;);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l" title="Debt instrument"&gt;2,213,498&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0D_zaNZZatnnmHh" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zzreMJkmsia8" style="font-size: 10pt"&gt;Adjustments include corrections for stock compensation errors (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a" title="Stock compensation"&gt;8,009,461&lt;/span&gt;); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc" title="Fair value of warrants"&gt;240,930&lt;/span&gt;); reversal of accrued Series A Preferred Stock dividends (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a" title="Accrued dividends"&gt;402,064&lt;/span&gt;); recognition of bifurcated derivatives and recording of loss at issuance (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih" title="Derivatives loss"&gt;296,151&lt;/span&gt;); correction of issuance cost recognition related to financing transactions (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e" title="Issuance cost"&gt;166,407&lt;/span&gt;); and the aggregate adjustments to 2022 net loss as detailed below (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf" title="Net income loss"&gt;1,967,621&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zCPDzGSrLKea" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Statement of Operations for the year ended December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zfF7oBBVekwd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zwoKT7aBJHO8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zWrYFaOF7wz2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zj2MSn4b2I9f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Research and development, net of contract expense reimbursements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,148,712&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(101,327&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,047,385&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_zfl0BeByAfcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;538,796&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(65,082&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;473,714&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LegalFees_i01_zVxLruGqxV9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Legal and professional&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;866,770&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(44,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;822,727&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_zmOcF5iBAFc8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss from operations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,554,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;210,452&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,343,826&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestExpense_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zdoL3oeTEEUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(917,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;489,191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(428,688&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--FinanceFee_i01N_di_zcGL6QyywMmb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financing fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2066"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zuPH3lpTUpn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of derivative liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zZ7eV5qwPDs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(492,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(398,675&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_ztFvHLdBYq75" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on extinguishment of debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zslkvUkqO935" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,028,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,967,621&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,996,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zRrY7MweYN9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend on Series A Preferred Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(71,009&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(331,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeemedDividendOnExtinguishmentOfSeriesPreferredStock_iN_di_z5JuaOYNMOtj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deemed dividend on extinguishment of Series A Preferred Stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2090"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(439,427&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(439,427&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated_iN_di_zNL0yHlXVCs9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deemed dividend on modification of equity-classified warrants, as restated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(941,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(941,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated_iN_di_zu7usXLwRWu3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;31,423&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;31,423&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zMdGKJyjwBM2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,099,457&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,647,680&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(6,747,137&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss per shares - basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMuzbPGlFEhh" title="Net loss per shares - basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zccDRV02xjSf" title="Net loss per shares - basic"&gt;(2.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB4urI05QeH1" title="Net loss per shares - basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKBYOEmr9nYi" title="Net loss per shares - Diluted"&gt;(2.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_z5ihkRTEuiul" title="Net loss per shares - Basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpAA__" id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zSznyrVunGh9" title="Net loss per shares - Diluted"&gt;(5.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_309_134_zJX9uMgHKaPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Statement of Stockholders&#x2019; Equity as of December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwS0vTQ9jBnd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcwAjgI1jFjg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zV0UlYwvROeh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zWvWqPGPs5Ya" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,951,356&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,951,356&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CommonStockIssuedForCash_zHDj0uGsfbqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,008,095&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10,008,095&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2124"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--WarrantsExercisedForCash_z2d1h2nIc9ac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants exercised for cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2128"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zhhR4qDxRN8l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Warrants issued for financing costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;412,241&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(397,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;14,662&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zhykxizzqMlh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for conversion of accrued interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;588,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(588,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2136"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zyHZ1nRPI2pe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued upon conversion of convertible debt and exercise of related warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,199,916&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,199,916&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zwf7FzAmToLf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for exercise of warrants with settlement of notes payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;576,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,576,648&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,153,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsDHZesDpxNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;403,956&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(166,409&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DividendsOnSeriesPreferredStock_iN_di_zvqx0AJOOAIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividends on Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(71,009&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(331,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_zABJ06Gj07Ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common shares issued for dividends on and conversion of Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,068&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_z5MiqqZKDCgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Reclassification of fair value of warrant liability to equity upon initial public offering&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2158"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_zxnxLSWBTqm9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,028,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,967,621&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,996,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zdfyzfvfDy16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Statement of Cash Flows for the year ended December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zy1sl4WmcFif" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zeDLOhNW3Qh1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_z3HtR4Rnmup1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_zCatNeztmy4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(3,028,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(1,967,621&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(4,996,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_zobw7LZjY4ph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of derivative liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2170"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01_zH5N7jyNN6bb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(94,025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;492,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;398,675&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i01_zuFdOtXI1xQf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amortization of debt discount and finance fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;885,505&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(508,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;377,384&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LossOnSettlementOfConvertibleDebt_i01_zjcoYliHCWO2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on settlement of convertible debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2182"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,795,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FairValueOfFreestandingInstrumentsInExcessOfProceeds_i01_zOCefK4QX4t2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Fair value of freestanding instruments in excess of proceeds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2186"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;189,912&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--GainOnInterestReliefOnConversionOfNotesPayable_i01N_di_zbi2XyEBcw01" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Gain on interest relief on conversion of notes payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(12,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_z9JN5YP8HCA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;403,956&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(166,409&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_zdwCVGgYjudb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued interest payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(13,177&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;31,555&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;18,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zS9xgAWVXgZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,710,454&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;44,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,666,411&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_zPeJwFkUi6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    from issuance of common shares and warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,022,193&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(26,680&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,995,513&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_zX9wJ2hh4D47" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    from convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600,715&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;550,715&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProceedsFromNotesPayableAndWarrants_i01_zB9jBkRcOoei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    from notes payable and warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2214"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PaymentsOfFinancingCosts_i01N_di_zSy4wmzIPBff" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
    for finance costs related to convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2218"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(17,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(17,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_z1cIFFnQqII8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,622,908&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(44,043&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,578,865&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxesPaid_i01_z2AXVU0ATqRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Supplemental non-cash financing activities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--CommonStockIssuedUponConversionOfConvertibleDebt_i01_zqxadejLpiX2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued upon conversion of convertible debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;588,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;611,392&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,199,916&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zl91Hr9vTr9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common stock issued for exercise of warrants with settlement of notes payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;576,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,576,648&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,153,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock_i01_zSvMjywi1h66" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Common shares issued for dividends on and conversion of Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,068&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;402,064&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--WarrantsIssuedForFinancingFees_i01_zEdVHlVkRYRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants issued for financing fees, net of issuance fees of $&lt;span id="xdx_901_ecustom--WarrantsIssuanceFees_c20230101__20231231_z3f2JIJxQ6Sg" title="Warranst of issuance fees"&gt;8,727&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--WarrantsIssuanceFees_c20220101__20221231_zdqu9lkBFd4" title="Warranst of issuance fees"&gt;0&lt;/span&gt;, respectively&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;412,241&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(397,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,662&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering_i01_zpGNzvsa7kK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Reclassification of fair value of warrant liability to equity upon initial public offering&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;881,553&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30B_134_zABYLOApGVBf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Error Corrections And Prior Period Adjustments (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Consolidated Balance Sheet as of December 31, 2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zLsnU6dc6oAc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z4f2SrKUNhEd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_z9hEcTZm93ad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;4,150,948&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AdditionalPaidInCapital_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDEp_zSrXYy1elD59" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Additional paid in capital"&gt;7,912,992&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;12,063,940&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zqI4Ca10eqGi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated Deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,795,432&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_fKDIp_zbPV9duglp2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit"&gt;(8,049,080&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(13,844,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F09_zyx8H6MNpq29" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zVcwwitNryW8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk" title="Increase decrease of notes payable"&gt;7,351&lt;/span&gt;); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh" title="Increase decrease in preferred stock"&gt;89,118&lt;/span&gt;); and stock compensation adjustments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l" title="Stock compensation"&gt;8,009,461&lt;/span&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0A_z8KUvJcM4081" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F11_zlKB34EfShAa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
    include reversal of dividend liability recorded (decrease of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1" title="Increase decrease in dividend liability"&gt;331,059&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    identification of deferred IPO costs (decrease of ($&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi"&gt;55,182&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh"&gt;89,118&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    adjustment to the estimated fair value of warrant liability (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63"&gt;240,930&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj"&gt;274,048&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;);
    and stock compensation adjustments (increase of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc"&gt;8,009,461&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;</SHPH:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002002"
      unitRef="USD">19543363</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002003"
      unitRef="USD">9945692</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002004"
      unitRef="USD">29489055</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002006"
      unitRef="USD">-15487612</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002007"
      unitRef="USD">-9945692</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002008"
      unitRef="USD">-25433304</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002010"
      unitRef="USD">16572741</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002013"
      unitRef="USD">9945692</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002011"
      unitRef="USD">26518433</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002015"
      unitRef="USD">-8894889</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002018"
      unitRef="USD">-9945692</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002016"
      unitRef="USD">-18840581</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002021"
      unitRef="USD">7843052</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDividendsReceivable
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002023"
      unitRef="USD">402064</us-gaap:IncreaseDecreaseInDividendsReceivable>
    <SHPH:IncreaseDecreaseInIssuanceCost
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002025"
      unitRef="USD">174082</SHPH:IncreaseDecreaseInIssuanceCost>
    <SHPH:IncreaseDecreaseInWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002027"
      unitRef="USD">416266</SHPH:IncreaseDecreaseInWarrants>
    <SHPH:IncreaseDecreaseInWarrantsFromLiability
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002029"
      unitRef="USD">881554</SHPH:IncreaseDecreaseInWarrantsFromLiability>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002031"
      unitRef="USD">2213498</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002034"
      unitRef="USD">8009461</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <SHPH:IncreaseDecreaseInFairValueOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002036"
      unitRef="USD">240930</SHPH:IncreaseDecreaseInFairValueOfWarrants>
    <us-gaap:IncreaseDecreaseInDividendsReceivable
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002038"
      unitRef="USD">402064</us-gaap:IncreaseDecreaseInDividendsReceivable>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002040"
      unitRef="USD">296151</us-gaap:DerivativeGainLossOnDerivativeNet>
    <SHPH:IncreaseDecreaseInIssuanceCost
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002042"
      unitRef="USD">166407</SHPH:IncreaseDecreaseInIssuanceCost>
    <SHPH:IncreaseDecreaseInNetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002044"
      unitRef="USD">1967621</SHPH:IncreaseDecreaseInNetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002046"
      unitRef="USD">1148712</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002047"
      unitRef="USD">-101327</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002048"
      unitRef="USD">1047385</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002050"
      unitRef="USD">538796</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002051"
      unitRef="USD">-65082</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002052"
      unitRef="USD">473714</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002054"
      unitRef="USD">866770</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002055"
      unitRef="USD">-44043</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002056"
      unitRef="USD">822727</us-gaap:LegalFees>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002058"
      unitRef="USD">-2554278</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002059"
      unitRef="USD">210452</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002060"
      unitRef="USD">-2343826</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact002062"
      unitRef="USD">917879</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact002063"
      unitRef="USD">-489191</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact002064"
      unitRef="USD">428688</us-gaap:InterestExpense>
    <SHPH:FinanceFee
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002067"
      unitRef="USD">189912</SHPH:FinanceFee>
    <SHPH:FinanceFee
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002068"
      unitRef="USD">189912</SHPH:FinanceFee>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002071"
      unitRef="USD">-189000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002072"
      unitRef="USD">-189000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002074"
      unitRef="USD">-94025</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002075"
      unitRef="USD">492700</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002076"
      unitRef="USD">398675</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002079"
      unitRef="USD">-1795652</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002080"
      unitRef="USD">-1795652</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002082"
      unitRef="USD">-3028448</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002083"
      unitRef="USD">-1967621</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002084"
      unitRef="USD">-4996069</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002086"
      unitRef="USD">71009</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002087"
      unitRef="USD">331055</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002088"
      unitRef="USD">402064</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002091"
      unitRef="USD">439427</SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock>
    <SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002092"
      unitRef="USD">439427</SHPH:DeemedDividendOnExtinguishmentOfSeriesPreferredStock>
    <SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002095"
      unitRef="USD">941000</SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated>
    <SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002096"
      unitRef="USD">941000</SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrantsAsRestated>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002099"
      unitRef="USD">-31423</SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated>
    <SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002100"
      unitRef="USD">-31423</SHPH:DeemedContributionOnConversionOfPreferredStockAndSettlementOfPreferredStockDividendsAsRestated>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002102"
      unitRef="USD">-3099457</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002103"
      unitRef="USD">-3647680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002104"
      unitRef="USD">-6747137</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact002106"
      unitRef="USDPShares">-2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact002108"
      unitRef="USDPShares">-2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="Fact002110"
      unitRef="USDPShares">-2.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="Fact002112"
      unitRef="USDPShares">-2.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002114"
      unitRef="USDPShares">-5.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002116"
      unitRef="USDPShares">-5.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002119"
      unitRef="USD">9951356</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002120"
      unitRef="USD">9951356</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SHPH:CommonStockIssuedForCash
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002122"
      unitRef="USD">10008095</SHPH:CommonStockIssuedForCash>
    <SHPH:CommonStockIssuedForCash
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002123"
      unitRef="USD">-10008095</SHPH:CommonStockIssuedForCash>
    <SHPH:WarrantsExercisedForCash
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002126"
      unitRef="USD">14098</SHPH:WarrantsExercisedForCash>
    <SHPH:WarrantsExercisedForCash
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002127"
      unitRef="USD">-14098</SHPH:WarrantsExercisedForCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002130"
      unitRef="USD">412241</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002131"
      unitRef="USD">-397579</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002132"
      unitRef="USD">14662</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002134"
      unitRef="USD">588524</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002135"
      unitRef="USD">-588524</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002139"
      unitRef="USD">1199916</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002140"
      unitRef="USD">1199916</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002142"
      unitRef="USD">576476</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002143"
      unitRef="USD">1576648</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002144"
      unitRef="USD">2153124</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002146"
      unitRef="USD">403956</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002147"
      unitRef="USD">-166409</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002148"
      unitRef="USD">237547</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002150"
      unitRef="USD">71009</SHPH:DividendsOnSeriesPreferredStock>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002151"
      unitRef="USD">331055</SHPH:DividendsOnSeriesPreferredStock>
    <SHPH:DividendsOnSeriesPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002152"
      unitRef="USD">402064</SHPH:DividendsOnSeriesPreferredStock>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002154"
      unitRef="USD">402068</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002155"
      unitRef="USD">-4</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002156"
      unitRef="USD">402064</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002159"
      unitRef="USD">881553</SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002160"
      unitRef="USD">881553</SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002162"
      unitRef="USD">-3028448</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002163"
      unitRef="USD">-1967621</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002164"
      unitRef="USD">-4996069</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002166"
      unitRef="USD">-3028448</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002167"
      unitRef="USD">-1967621</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002168"
      unitRef="USD">-4996069</us-gaap:NetIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002171"
      unitRef="USD">-189000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002172"
      unitRef="USD">-189000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002174"
      unitRef="USD">-94025</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002175"
      unitRef="USD">492700</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002176"
      unitRef="USD">398675</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002178"
      unitRef="USD">885505</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002179"
      unitRef="USD">-508121</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002180"
      unitRef="USD">377384</us-gaap:AmortizationOfDebtDiscountPremium>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002183"
      unitRef="USD">1795652</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002184"
      unitRef="USD">1795652</SHPH:LossOnSettlementOfConvertibleDebt>
    <SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002187"
      unitRef="USD">189912</SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds>
    <SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002188"
      unitRef="USD">189912</SHPH:FairValueOfFreestandingInstrumentsInExcessOfProceeds>
    <SHPH:GainOnInterestReliefOnConversionOfNotesPayable
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002190"
      unitRef="USD">-12625</SHPH:GainOnInterestReliefOnConversionOfNotesPayable>
    <SHPH:GainOnInterestReliefOnConversionOfNotesPayable
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002191"
      unitRef="USD">12625</SHPH:GainOnInterestReliefOnConversionOfNotesPayable>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002194"
      unitRef="USD">403956</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002195"
      unitRef="USD">-166409</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002196"
      unitRef="USD">237547</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002198"
      unitRef="USD">-13177</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002199"
      unitRef="USD">31555</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002200"
      unitRef="USD">18378</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002202"
      unitRef="USD">-2710454</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002203"
      unitRef="USD">44043</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002204"
      unitRef="USD">-2666411</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002206"
      unitRef="USD">10022193</SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002207"
      unitRef="USD">-26680</SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002208"
      unitRef="USD">9995513</SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002210"
      unitRef="USD">600715</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002211"
      unitRef="USD">-50000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002212"
      unitRef="USD">550715</us-gaap:ProceedsFromConvertibleDebt>
    <SHPH:ProceedsFromNotesPayableAndWarrants
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002215"
      unitRef="USD">50000</SHPH:ProceedsFromNotesPayableAndWarrants>
    <SHPH:ProceedsFromNotesPayableAndWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002216"
      unitRef="USD">50000</SHPH:ProceedsFromNotesPayableAndWarrants>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002219"
      unitRef="USD">17363</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002220"
      unitRef="USD">17363</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002222"
      unitRef="USD">10622908</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002223"
      unitRef="USD">-44043</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002224"
      unitRef="USD">10578865</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <SHPH:CommonStockIssuedUponConversionOfConvertibleDebt
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002230"
      unitRef="USD">588524</SHPH:CommonStockIssuedUponConversionOfConvertibleDebt>
    <SHPH:CommonStockIssuedUponConversionOfConvertibleDebt
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002231"
      unitRef="USD">611392</SHPH:CommonStockIssuedUponConversionOfConvertibleDebt>
    <SHPH:CommonStockIssuedUponConversionOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002232"
      unitRef="USD">1199916</SHPH:CommonStockIssuedUponConversionOfConvertibleDebt>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002234"
      unitRef="USD">576476</SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002235"
      unitRef="USD">1576648</SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002236"
      unitRef="USD">2153124</SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable>
    <SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact002238"
      unitRef="Shares">402068</SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock>
    <SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="Fact002239"
      unitRef="Shares">-4</SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock>
    <SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002240"
      unitRef="Shares">402064</SHPH:CommonSharesIssuedForDividendsOnAndConversionOfSeriesPreferredStock>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002246"
      unitRef="USD">8727</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002248"
      unitRef="USD">0</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002242"
      unitRef="USD">412241</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002243"
      unitRef="USD">-397579</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002244"
      unitRef="USD">14662</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002251"
      unitRef="USD">881553</SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering>
    <SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002252"
      unitRef="USD">881553</SHPH:ReclassificationOfFairValueOfWarrantLiabilityToEquityUponInitialPublicOffering>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002254"
      unitRef="USD">4150948</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002257"
      unitRef="USD">7912992</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact002255"
      unitRef="USD">12063940</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002259"
      unitRef="USD">-5795432</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002262"
      unitRef="USD">-8049080</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact002260"
      unitRef="USD">-13844512</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:IncreaseDecreaseInNotesPayableCurrent
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002265"
      unitRef="USD">7351</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
    <SHPH:IncreaseDecreaseInPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002267"
      unitRef="USD">89118</SHPH:IncreaseDecreaseInPreferredStock>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002269"
      unitRef="USD">8009461</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <SHPH:IncreaseDecreaseInDividendLiability
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002272"
      unitRef="USD">331059</SHPH:IncreaseDecreaseInDividendLiability>
    <SHPH:IncreaseDecreaseInIssuanceCost
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002273"
      unitRef="USD">55182</SHPH:IncreaseDecreaseInIssuanceCost>
    <SHPH:IncreaseDecreaseInPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002274"
      unitRef="USD">89118</SHPH:IncreaseDecreaseInPreferredStock>
    <SHPH:IncreaseDecreaseInFairValueOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002275"
      unitRef="USD">240930</SHPH:IncreaseDecreaseInFairValueOfWarrants>
    <us-gaap:IncreaseDecreaseInNotesPayableCurrent
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002276"
      unitRef="USD">274048</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002277"
      unitRef="USD">8009461</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-012023-12-31" id="Fact002279">&lt;p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zAbDMxtvqVkb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Note 3 &#x2013; &lt;span id="xdx_824_zYouvyiEJF0f"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zN9JmHykJAle"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zXzky5zRn35g"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z51lIHBaxIod"&gt;Reclassifications&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_znBsmi9qpX7i"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company
regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical
experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the
Company&#x2019;s estimates. To the extent there are material differences between the estimates and the actual results, future results
of operations will be affected. Significant estimates are contained in the accompanying consolidated financial statements for the
recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other
financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zJkXkj4AZTy2"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zAIRmxIIPtT9" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;5,411,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,005,825&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash
and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,417,203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $&lt;span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount"&gt;1,849,000&lt;/span&gt;. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zcIP2rrvmXK8"&gt;Marketable
Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance"&gt;2,887,215&lt;/span&gt;. During the year ended December 31, 2023, the Company recognized interest income of $&lt;span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income"&gt;52,855&lt;/span&gt;,
realized gains of $&lt;span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss"&gt;4,970&lt;/span&gt;, and unrealized gains of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss"&gt;71,568&lt;/span&gt;. The were &lt;span id="xdx_90F_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zbAdEjByFAZi" title="Marketable securities::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2316"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zqfmU6VxYX7j"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zMDw775NrT6i" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Marketable Securities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2328"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2329"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2334"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DerivativeLiabilityWarrants_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zLHLaG6Wpet4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2342"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DerivativeLiabilityAcceleratedFeature_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_z1GMbV70G7Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2348"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2352"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2353"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company had non-derivative warrant liabilities that were measured at fair value on a recurring
basis. Each of these fair value measurements was considered to be a Level 3 measurement by the Company as they used significant unobservable
inputs, such as the Company&#x2019;s pre-IPO stock price, probability of event occurrence and other management estimates. The key inputs
for each of these warrant liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoMWqw0jB0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zKUJ72QdTXY5" style="display: none"&gt;Schedule
of Key Inputs of Warrant Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; Series A Preferred Stock Obligation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zLyVGKOArAWd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock"&gt;40.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zgBrdL1LrT7c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price (based on estimated IPO or Listing terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_znoxhYjetF0l" title="Exercise price"&gt;40.00&lt;/span&gt; - $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zArhlIcCb06d" title="Exercise price"&gt;166.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zp65fcqYKv7b" title="Exercise price"&gt;32.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Number of warrants (based on estimated Series A Preferred Stock conversion shares upon IPO or Listing at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_ztMXqnmuU9cb" title="Number of warrants"&gt;12,135&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zMp7IKseQgnc" title="Number of warrants"&gt;33,681&lt;/span&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7zVZKsduoz2" title="Number of warrants"&gt;42,101&lt;/span&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdcX1kzMoQCd" title="Warrants and rights outstanding measurement input"&gt;86.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zW1kmGuIywhe" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z78eGWXIszP4" title="Warrants and rights outstanding measurement input"&gt;1.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zbRqcuFc7Kx4" title="Warrants and rights outstanding measurement input"&gt;3.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated IPO date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7abpz07AmNb" title="Estimated IPO date"&gt;9/30/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zreHcuEZR3gi" title="Estimated IPO date"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2385"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated Term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z815JlVntnri" title="Estimated Term"&gt;3.75&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z1GevZdwSlle" title="Estimated Term"&gt;3.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO or Listing Occurring&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zkuIhmucDUIl" title="Warrants and rights outstanding measurement input"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zP3rqfuREZce" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2393"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO as &#x201c;Qualified IPO&#x201d;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKZbZZdwX904" title="Warrants and rights outstanding measurement input"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zAVfbA32ifU9" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2397"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Probability of IPO as &#x201c;Listing&#x201d;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zao8vkaRcnof" title="Warrants and rights outstanding measurement input"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKRwLLcGWTNc" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2401"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdV5UMoJ21Bj" title="Estimated fair value"&gt;334,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z0UVRkniDVEg" title="Estimated fair value"&gt;756,723&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; August 2022 Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification/Settlement Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9nZuNwXlNZ9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9B1oFEU8qSd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zL1GvJpV5Cld" title="Exercise price"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z7OvmG4tIEqi" title="Exercise price"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Number of warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zZ3lsYq0BOS3" title="Number of warrants"&gt;6,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zWW3jeBT6Epe" title="Number of warrants"&gt;6,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zsUhFnC28Jl7" title="Estimated Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zmfGu7F5nHW3" title="Estimated Term"&gt;4.9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zBV3c4wuqEq3" title="Warrants and rights outstanding measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z0zoN4DV2El9" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zkEcXWlx3BOc" title="Warrants and rights outstanding measurement input"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2A0YB3qNMNd" title="Warrants and rights outstanding measurement input"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z1XDBZyN0Kv5" title="Estimated fair value"&gt;146,624&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2TqMctNvqrh" title="Estimated fair value"&gt;151,726&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; Boustead Placement Agent Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zGirhz4ePWDd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsu1obyU1Wfi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price (based on estimated Convertible Note conversion terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z0coh5dRpsxa" title="Exercise price"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoeIDPCXPcQc" title="Exercise price"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Number of warrants (based on estimated Convertible Note conversion terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoXzU7kpwwt5" title="Number of warrants"&gt;3,688&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zgcbWp2u3FLf" title="Number of warrants"&gt;2,581&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zXIPSshDbQ7" title="Estimated Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXzeaxUL0tM4" title="Estimated Term"&gt;4.4&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLzgZeRBaps9" title="Estimated Term"&gt;4.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z1Fa93A6ZRvi" title="Warrants and rights outstanding measurement input"&gt;86.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zNweZGNbvpN3" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhzYuy6xQ1gh" title="Warrants and rights outstanding measurement input"&gt;1.8&lt;/span&gt;% - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPg7CsZ2CbB2" title="Warrants and rights outstanding measurement input"&gt;2.0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsxT4r0C5eu5" title="Warrants and rights outstanding measurement input"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyTizCgvTLpl" title="Estimated fair value"&gt;92,336&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z72Y855ESgJb" title="Estimated fair value"&gt;64,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zecpDhgOgxS8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A rollforward of these warrant liabilities for the year ended December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleofWarrantLiabilitiesTableTextBlock_ztBVEOc64Ov8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zeSONc0gOzva" style="display: none"&gt;Schedule
of Warrant Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
    Liability &#x2013; Series A Preferred Stock Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    December 31, 2021 (as restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zNsPYB7LzPi3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Warrant liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;334,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zF5QjxZXZTJg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised (settled)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_ztUOjfervEfb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2473"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss on change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z5rYb9iCCVZc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;421,768&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassifications to stockholders&#x2019;
    equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7151H6TNz22" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(756,723&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z6PdrHa7bupc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2479"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrant Liability &#x2013; August 2022 Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zlZwC2L7J5Eg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2481"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zIeMYiGkql7i" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued"&gt;146,624&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercised (settled)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zhb4cBwGbSah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;(91,036&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zXN8bvqeOFIl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loss on change in fair value"&gt;5,102&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Reclassifications to stockholders&#x2019; equity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_za8LAb6YMJX" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"&gt;(60,690&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zawcjTzKvje2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrant Liability &#x2013; Boustead Placement Agent Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zol065gJ4hZg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2493"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zHGwX8iZIuNe" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued"&gt;92,336&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercised (settled)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_ziqTyVquujLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2497"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zf7xXRmbzS94" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Gain on change in fair value"&gt;(28,196&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Reclassification to stockholders&#x2019; equity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"&gt;&lt;p id="xdx_983_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zjJcvweR4b02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Reclassifications to stockholders' equity"&gt;(64,140&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyZqV655aYsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2503"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zRZQvVXDUPo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Refer to Note 7 for additional background on
the reclassification of warrant liabilities to equity. See Note 8 for additional disclosures related to the fair value of the Company&#x2019;s
derivative liabilities.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zUfQ5IhZAVZ7"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine if an arrangement is a lease at inception. &lt;span style="background-color: white"&gt;Operating leases are included in operating
lease right-of-use asset (&#x201c;ROU&#x201d;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Leases
with a lease term of 12 months or less at inception are not recorded on our &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;balance &lt;/span&gt;sheets &lt;span style="background-color: white"&gt;and are expensed on a straight-line
basis over the lease term in our statement of operations. &lt;/span&gt;We have lease agreements with lease and non-lease components, which
are generally accounted for separately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#x201c;incremental borrowing rate&#x201d; or &#x201c;IBR&#x201d;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zhMEboul1fnf"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zLo9hjhMywRk" style="display: none"&gt;Schedule of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;Furniture&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Computers and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research Equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zYSObLAWFqrd"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
our derivative financial instruments, the Company utilizes the most appropriate valuation model (such as Monte Carlo simulations or probability-weighted expected
return models, based on the nature of the terms of the instrument) to value the derivative
instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such
instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheet sheets as current or non-current based on whether or not net-cash settlement or
conversion of the instrument could be required within twelve (12) months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zIShPO1DVFMg"&gt;Convertible
Notes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its convertible notes for embedded features and bifurcates these features (such as conversion options and
redemption options) from their host instruments and accounts for them as free standing derivative financial instruments if certain
criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid
instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under
otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)
a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zbFQsfTI6WN7"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity
(&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants
are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the
warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a
circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. Finally, the Company
determines if the warrants meet the definition of a derivative based on their contractual terms. This assessment, which requires the
use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while
the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and at each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;statements of operations. &lt;/span&gt;&lt;/span&gt;The Company also evaluates if changes in contractual terms
or other considerations would result in the reclassification of outstanding warrants from liabilities to stockholders&#x2019; equity (or
vice versa).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="background-color: white"&gt;
The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zMKVdyEG0BI7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z4CSzyso8ih9"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost for stock awards, which include restricted stock units (&#x201c;RSUs&#x201d;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z01OOEEOeht9"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#x2019; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$&lt;span id="xdx_90F_ecustom--ShareBasedCompensations_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhkgxJb4oO55" title="Share based compensation"&gt;0.8&lt;/span&gt; million and $&lt;span id="xdx_900_ecustom--ShareBasedCompensations_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znRCeUIPhCNa" title="Share based compensation"&gt;0.5&lt;/span&gt; million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, &lt;i&gt;Government Assistance&lt;/i&gt;, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#x2013; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $&lt;span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230101__20231231_zY9s230h9slk" title="Research and development, net of contract expense reimbursements"&gt;3.5&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20220101__20221231_zuzMe32hXUdd" title="Research and development, net of contract expense reimbursements"&gt;1.0&lt;/span&gt; million in Research and development, net of contract expense reimbursements, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zjUxdX9ZNGFl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQkEcVy4u6Y6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zDl56YzwE8M1"&gt;Segment
Information&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate and discrete information is available for evaluation by the
chief operating decision-maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and assess performance. The Company and the
Company&#x2019;s CODM, the Company&#x2019;s chief executive officer, evaluates the Company&#x2019;s operations and manages its business
as a &lt;span id="xdx_900_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_z3kfWGafUOSj" title="Number of reportable operating segments::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2541"&gt;single&lt;/span&gt;&lt;/span&gt; operating segment. All of the Company&#x2019;s long-lived assets are held in the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zwbvAlIY1l46"&gt;Net
Loss Per Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share of common stock requires presentation of basic earnings per common share on the face of the statements of operations
for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic
earnings per share computation. In the accompanying consolidated financial statements, basic loss per common share is computed by
dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the weighted average
number of shares of common stock outstanding and potentially dilutive shares of common stock during the period to reflect the
potential dilution that could occur from common shares issuable through convertible securities, contingent share arrangements, stock
options and warrants unless the result would be antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
dilutive effect of restricted stock units and other stock-based payment awards subject to vesting and common stock warrants is
calculated using the &#x201c;treasury stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these
instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible
securities is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be
converted at the beginning of the period, and the resulting shares of common stock are included in the denominator of the diluted
calculation for the entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zz6N2TjW0PMb" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;(as
                                            restated)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Convertible notes (Note 6)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"&gt;119,939&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2549"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants (Note 7)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"&gt;47,831&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 7)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"&gt;24,731&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"&gt;2,966&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"&gt;328,670&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"&gt;50,797&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zSWNCgOEheR1"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#x2019;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;does not expect the adoption of this standard to
have any material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.&lt;/p&gt;

&lt;p id="xdx_85E_zQNfopfWoCN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002281">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zN9JmHykJAle"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002283">&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zXzky5zRn35g"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2023-01-012023-12-31" id="Fact002285">&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z51lIHBaxIod"&gt;Reclassifications&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;


</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="From2023-01-012023-12-31" id="Fact002287">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_znBsmi9qpX7i"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company
regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical
experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the
Company&#x2019;s estimates. To the extent there are material differences between the estimates and the actual results, future results
of operations will be affected. Significant estimates are contained in the accompanying consolidated financial statements for the
recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other
financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002289">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zJkXkj4AZTy2"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zAIRmxIIPtT9" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;5,411,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,005,825&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash
and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,417,203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $&lt;span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount"&gt;1,849,000&lt;/span&gt;. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact002291">&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zAIRmxIIPtT9" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;5,411,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,005,825&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash
and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,417,203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002293"
      unitRef="USD">1550098</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002294"
      unitRef="USD">5411378</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002296"
      unitRef="USD">1026318</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002297"
      unitRef="USD">3005825</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002299"
      unitRef="USD">2576416</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002300"
      unitRef="USD">8417203</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002302"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002304"
      unitRef="USD">1849000</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2023-01-012023-12-31" id="Fact002306">&lt;p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zcIP2rrvmXK8"&gt;Marketable
Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance"&gt;2,887,215&lt;/span&gt;. During the year ended December 31, 2023, the Company recognized interest income of $&lt;span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income"&gt;52,855&lt;/span&gt;,
realized gains of $&lt;span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss"&gt;4,970&lt;/span&gt;, and unrealized gains of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss"&gt;71,568&lt;/span&gt;. The were &lt;span id="xdx_90F_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zbAdEjByFAZi" title="Marketable securities::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2316"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002308"
      unitRef="USD">2887215</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002310"
      unitRef="USD">52855</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002312"
      unitRef="USD">4970</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002314"
      unitRef="USD">71568</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-012023-12-31" id="Fact002318">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zqfmU6VxYX7j"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zMDw775NrT6i" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Marketable Securities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2328"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2329"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2334"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DerivativeLiabilityWarrants_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zLHLaG6Wpet4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2342"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DerivativeLiabilityAcceleratedFeature_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_z1GMbV70G7Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2348"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2352"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2353"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company had non-derivative warrant liabilities that were measured at fair value on a recurring
basis. Each of these fair value measurements was considered to be a Level 3 measurement by the Company as they used significant unobservable
inputs, such as the Company&#x2019;s pre-IPO stock price, probability of event occurrence and other management estimates. The key inputs
for each of these warrant liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoMWqw0jB0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zKUJ72QdTXY5" style="display: none"&gt;Schedule
of Key Inputs of Warrant Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; Series A Preferred Stock Obligation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zLyVGKOArAWd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock"&gt;40.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zgBrdL1LrT7c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price (based on estimated IPO or Listing terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_znoxhYjetF0l" title="Exercise price"&gt;40.00&lt;/span&gt; - $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zArhlIcCb06d" title="Exercise price"&gt;166.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zp65fcqYKv7b" title="Exercise price"&gt;32.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Number of warrants (based on estimated Series A Preferred Stock conversion shares upon IPO or Listing at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_ztMXqnmuU9cb" title="Number of warrants"&gt;12,135&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zMp7IKseQgnc" title="Number of warrants"&gt;33,681&lt;/span&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7zVZKsduoz2" title="Number of warrants"&gt;42,101&lt;/span&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdcX1kzMoQCd" title="Warrants and rights outstanding measurement input"&gt;86.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zW1kmGuIywhe" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z78eGWXIszP4" title="Warrants and rights outstanding measurement input"&gt;1.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zbRqcuFc7Kx4" title="Warrants and rights outstanding measurement input"&gt;3.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated IPO date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7abpz07AmNb" title="Estimated IPO date"&gt;9/30/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zreHcuEZR3gi" title="Estimated IPO date"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2385"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated Term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z815JlVntnri" title="Estimated Term"&gt;3.75&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z1GevZdwSlle" title="Estimated Term"&gt;3.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO or Listing Occurring&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zkuIhmucDUIl" title="Warrants and rights outstanding measurement input"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zP3rqfuREZce" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2393"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO as &#x201c;Qualified IPO&#x201d;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKZbZZdwX904" title="Warrants and rights outstanding measurement input"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zAVfbA32ifU9" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2397"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Probability of IPO as &#x201c;Listing&#x201d;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zao8vkaRcnof" title="Warrants and rights outstanding measurement input"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKRwLLcGWTNc" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2401"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdV5UMoJ21Bj" title="Estimated fair value"&gt;334,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z0UVRkniDVEg" title="Estimated fair value"&gt;756,723&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; August 2022 Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification/Settlement Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9nZuNwXlNZ9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9B1oFEU8qSd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zL1GvJpV5Cld" title="Exercise price"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z7OvmG4tIEqi" title="Exercise price"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Number of warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zZ3lsYq0BOS3" title="Number of warrants"&gt;6,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zWW3jeBT6Epe" title="Number of warrants"&gt;6,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zsUhFnC28Jl7" title="Estimated Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zmfGu7F5nHW3" title="Estimated Term"&gt;4.9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zBV3c4wuqEq3" title="Warrants and rights outstanding measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z0zoN4DV2El9" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zkEcXWlx3BOc" title="Warrants and rights outstanding measurement input"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2A0YB3qNMNd" title="Warrants and rights outstanding measurement input"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z1XDBZyN0Kv5" title="Estimated fair value"&gt;146,624&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2TqMctNvqrh" title="Estimated fair value"&gt;151,726&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; Boustead Placement Agent Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zGirhz4ePWDd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsu1obyU1Wfi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price (based on estimated Convertible Note conversion terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z0coh5dRpsxa" title="Exercise price"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoeIDPCXPcQc" title="Exercise price"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Number of warrants (based on estimated Convertible Note conversion terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoXzU7kpwwt5" title="Number of warrants"&gt;3,688&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zgcbWp2u3FLf" title="Number of warrants"&gt;2,581&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zXIPSshDbQ7" title="Estimated Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXzeaxUL0tM4" title="Estimated Term"&gt;4.4&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLzgZeRBaps9" title="Estimated Term"&gt;4.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z1Fa93A6ZRvi" title="Warrants and rights outstanding measurement input"&gt;86.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zNweZGNbvpN3" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhzYuy6xQ1gh" title="Warrants and rights outstanding measurement input"&gt;1.8&lt;/span&gt;% - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPg7CsZ2CbB2" title="Warrants and rights outstanding measurement input"&gt;2.0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsxT4r0C5eu5" title="Warrants and rights outstanding measurement input"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyTizCgvTLpl" title="Estimated fair value"&gt;92,336&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z72Y855ESgJb" title="Estimated fair value"&gt;64,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zecpDhgOgxS8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A rollforward of these warrant liabilities for the year ended December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleofWarrantLiabilitiesTableTextBlock_ztBVEOc64Ov8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zeSONc0gOzva" style="display: none"&gt;Schedule
of Warrant Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
    Liability &#x2013; Series A Preferred Stock Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    December 31, 2021 (as restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zNsPYB7LzPi3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Warrant liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;334,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zF5QjxZXZTJg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised (settled)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_ztUOjfervEfb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2473"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss on change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z5rYb9iCCVZc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;421,768&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassifications to stockholders&#x2019;
    equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7151H6TNz22" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(756,723&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z6PdrHa7bupc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2479"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrant Liability &#x2013; August 2022 Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zlZwC2L7J5Eg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2481"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zIeMYiGkql7i" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued"&gt;146,624&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercised (settled)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zhb4cBwGbSah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;(91,036&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zXN8bvqeOFIl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loss on change in fair value"&gt;5,102&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Reclassifications to stockholders&#x2019; equity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_za8LAb6YMJX" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"&gt;(60,690&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zawcjTzKvje2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrant Liability &#x2013; Boustead Placement Agent Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zol065gJ4hZg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2493"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zHGwX8iZIuNe" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued"&gt;92,336&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercised (settled)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_ziqTyVquujLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2497"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zf7xXRmbzS94" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Gain on change in fair value"&gt;(28,196&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Reclassification to stockholders&#x2019; equity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"&gt;&lt;p id="xdx_983_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zjJcvweR4b02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Reclassifications to stockholders' equity"&gt;(64,140&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyZqV655aYsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2503"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zRZQvVXDUPo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Refer to Note 7 for additional background on
the reclassification of warrant liabilities to equity. See Note 8 for additional disclosures related to the fair value of the Company&#x2019;s
derivative liabilities.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact002320">&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zMDw775NrT6i" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Marketable Securities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2328"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2329"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2334"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DerivativeLiabilityWarrants_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zLHLaG6Wpet4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2342"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DerivativeLiabilityAcceleratedFeature_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_z1GMbV70G7Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2348"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2352"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2353"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact002327"
      unitRef="USD">2887215</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact002330"
      unitRef="USD">2887215</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact002332"
      unitRef="USD">2887215</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002335"
      unitRef="USD">2887215</us-gaap:AssetsFairValueDisclosure>
    <SHPH:DerivativeLiabilityWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact002344"
      unitRef="USD">410660</SHPH:DerivativeLiabilityWarrants>
    <SHPH:DerivativeLiabilityWarrants
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact002345"
      unitRef="USD">410660</SHPH:DerivativeLiabilityWarrants>
    <SHPH:DerivativeLiabilityAcceleratedFeature
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact002349"
      unitRef="USD">3852</SHPH:DerivativeLiabilityAcceleratedFeature>
    <SHPH:DerivativeLiabilityAcceleratedFeature
      contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact002350"
      unitRef="USD">3852</SHPH:DerivativeLiabilityAcceleratedFeature>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002354"
      unitRef="USD">414512</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002355"
      unitRef="USD">414512</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact002357">&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoMWqw0jB0c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zKUJ72QdTXY5" style="display: none"&gt;Schedule
of Key Inputs of Warrant Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; Series A Preferred Stock Obligation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zLyVGKOArAWd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock"&gt;40.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zgBrdL1LrT7c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price (based on estimated IPO or Listing terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_znoxhYjetF0l" title="Exercise price"&gt;40.00&lt;/span&gt; - $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zArhlIcCb06d" title="Exercise price"&gt;166.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zp65fcqYKv7b" title="Exercise price"&gt;32.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Number of warrants (based on estimated Series A Preferred Stock conversion shares upon IPO or Listing at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MinimumMember_ztMXqnmuU9cb" title="Number of warrants"&gt;12,135&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember__srt--RangeAxis__srt--MaximumMember_zMp7IKseQgnc" title="Number of warrants"&gt;33,681&lt;/span&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7zVZKsduoz2" title="Number of warrants"&gt;42,101&lt;/span&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdcX1kzMoQCd" title="Warrants and rights outstanding measurement input"&gt;86.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zW1kmGuIywhe" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z78eGWXIszP4" title="Warrants and rights outstanding measurement input"&gt;1.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zbRqcuFc7Kx4" title="Warrants and rights outstanding measurement input"&gt;3.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated IPO date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7abpz07AmNb" title="Estimated IPO date"&gt;9/30/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zreHcuEZR3gi" title="Estimated IPO date"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2385"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated Term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z815JlVntnri" title="Estimated Term"&gt;3.75&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z1GevZdwSlle" title="Estimated Term"&gt;3.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO or Listing Occurring&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zkuIhmucDUIl" title="Warrants and rights outstanding measurement input"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingOccurringMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zP3rqfuREZce" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2393"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO as &#x201c;Qualified IPO&#x201d;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKZbZZdwX904" title="Warrants and rights outstanding measurement input"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfQualifiedIPOMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zAVfbA32ifU9" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2397"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Probability of IPO as &#x201c;Listing&#x201d;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zao8vkaRcnof" title="Warrants and rights outstanding measurement input"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfIPOListingMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zKRwLLcGWTNc" title="Warrants and rights outstanding measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2401"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zdV5UMoJ21Bj" title="Estimated fair value"&gt;334,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z0UVRkniDVEg" title="Estimated fair value"&gt;756,723&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; August 2022 Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification/Settlement Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9nZuNwXlNZ9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z9B1oFEU8qSd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zL1GvJpV5Cld" title="Exercise price"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z7OvmG4tIEqi" title="Exercise price"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Number of warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zZ3lsYq0BOS3" title="Number of warrants"&gt;6,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zWW3jeBT6Epe" title="Number of warrants"&gt;6,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zsUhFnC28Jl7" title="Estimated Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zmfGu7F5nHW3" title="Estimated Term"&gt;4.9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zBV3c4wuqEq3" title="Warrants and rights outstanding measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z0zoN4DV2El9" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zkEcXWlx3BOc" title="Warrants and rights outstanding measurement input"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2A0YB3qNMNd" title="Warrants and rights outstanding measurement input"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z1XDBZyN0Kv5" title="Estimated fair value"&gt;146,624&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_z2TqMctNvqrh" title="Estimated fair value"&gt;151,726&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Warrant Liability &#x2013; Boustead Placement Agent Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Reclassification Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Estimated fair value of Company&#x2019;s stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsEstimatedFairValue_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zGirhz4ePWDd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsEstimatedFairValue_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsu1obyU1Wfi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Estimated fair value of company's stock"&gt;32.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price (based on estimated Convertible Note conversion terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z0coh5dRpsxa" title="Exercise price"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoeIDPCXPcQc" title="Exercise price"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Number of warrants (based on estimated Convertible Note conversion terms at issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zoXzU7kpwwt5" title="Number of warrants"&gt;3,688&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zgcbWp2u3FLf" title="Number of warrants"&gt;2,581&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Remaining term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zXIPSshDbQ7" title="Estimated Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXzeaxUL0tM4" title="Estimated Term"&gt;4.4&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLzgZeRBaps9" title="Estimated Term"&gt;4.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z1Fa93A6ZRvi" title="Warrants and rights outstanding measurement input"&gt;86.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zNweZGNbvpN3" title="Warrants and rights outstanding measurement input"&gt;82.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhzYuy6xQ1gh" title="Warrants and rights outstanding measurement input"&gt;1.8&lt;/span&gt;% - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPg7CsZ2CbB2" title="Warrants and rights outstanding measurement input"&gt;2.0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsxT4r0C5eu5" title="Warrants and rights outstanding measurement input"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyTizCgvTLpl" title="Estimated fair value"&gt;92,336&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_z72Y855ESgJb" title="Estimated fair value"&gt;64,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <SHPH:WarrantsEstimatedFairValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002359"
      unitRef="USDPShares">40.00</SHPH:WarrantsEstimatedFairValue>
    <SHPH:WarrantsEstimatedFairValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002361"
      unitRef="USDPShares">32.50</SHPH:WarrantsEstimatedFairValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002363"
      unitRef="USDPShares">40.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002365"
      unitRef="USDPShares">166.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002367"
      unitRef="USDPShares">32.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002369"
      unitRef="Shares">12135</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002371"
      unitRef="Shares">33681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002373"
      unitRef="Shares">42101</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002375"
      unitRef="Pure">0.863</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002377"
      unitRef="Pure">0.825</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002379"
      unitRef="Pure">0.0108</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002381"
      unitRef="Pure">0.0344</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="Fact002383">2022-09-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="Fact002387">P3Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      id="Fact002389">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingOccurringMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002391"
      unitRef="Pure">0.90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfQualifiedIPOMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002395"
      unitRef="Pure">0.33</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MeasurementInputProbabilityOfIPOListingMember_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="INF"
      id="Fact002399"
      unitRef="Pure">0.67</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="0"
      id="Fact002403"
      unitRef="USD">334955</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="0"
      id="Fact002405"
      unitRef="USD">756723</us-gaap:FairValueAdjustmentOfWarrants>
    <SHPH:WarrantsEstimatedFairValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002407"
      unitRef="USDPShares">32.00</SHPH:WarrantsEstimatedFairValue>
    <SHPH:WarrantsEstimatedFairValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002409"
      unitRef="USDPShares">32.50</SHPH:WarrantsEstimatedFairValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002411"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002413"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002415"
      unitRef="Shares">6250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002417"
      unitRef="Shares">6250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      id="Fact002419">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      id="Fact002421">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002423"
      unitRef="Pure">0.800</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002425"
      unitRef="Pure">0.825</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002427"
      unitRef="Pure">0.027</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact002429"
      unitRef="Pure">0.033</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="0"
      id="Fact002431"
      unitRef="USD">146624</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="0"
      id="Fact002433"
      unitRef="USD">151726</us-gaap:FairValueAdjustmentOfWarrants>
    <SHPH:WarrantsEstimatedFairValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002435"
      unitRef="USDPShares">32.00</SHPH:WarrantsEstimatedFairValue>
    <SHPH:WarrantsEstimatedFairValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002437"
      unitRef="USDPShares">32.50</SHPH:WarrantsEstimatedFairValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002439"
      unitRef="USDPShares">16.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002441"
      unitRef="USDPShares">16.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002443"
      unitRef="Shares">3688</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002445"
      unitRef="Shares">2581</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      id="Fact002447">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember"
      id="Fact002449">P4Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember"
      id="Fact002451">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002453"
      unitRef="Pure">0.861</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002455"
      unitRef="Pure">0.825</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002457"
      unitRef="Pure">0.018</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002459"
      unitRef="Pure">0.020</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002461"
      unitRef="Pure">0.034</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact002463"
      unitRef="USD">92336</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact002465"
      unitRef="USD">64140</us-gaap:FairValueAdjustmentOfWarrants>
    <SHPH:ScheduleofWarrantLiabilitiesTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact002467">&lt;p id="xdx_89E_ecustom--ScheduleofWarrantLiabilitiesTableTextBlock_ztBVEOc64Ov8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zeSONc0gOzva" style="display: none"&gt;Schedule
of Warrant Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
    Liability &#x2013; Series A Preferred Stock Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    December 31, 2021 (as restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zNsPYB7LzPi3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Warrant liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;334,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_zF5QjxZXZTJg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised (settled)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_ztUOjfervEfb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2473"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss on change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z5rYb9iCCVZc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;421,768&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassifications to stockholders&#x2019;
    equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z7151H6TNz22" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(756,723&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilitySeriesAPreferredStockObligationMember_z6PdrHa7bupc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2479"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrant Liability &#x2013; August 2022 Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zlZwC2L7J5Eg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2481"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zIeMYiGkql7i" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued"&gt;146,624&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercised (settled)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zhb4cBwGbSah" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;(91,036&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zXN8bvqeOFIl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loss on change in fair value"&gt;5,102&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Reclassifications to stockholders&#x2019; equity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_za8LAb6YMJX" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassifications to stockholders' equity"&gt;(60,690&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityAugustTwentyTwoWarrantsMember_zawcjTzKvje2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrant Liability &#x2013; Boustead Placement Agent Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilities_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zol065gJ4hZg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2493"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilitiesIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zHGwX8iZIuNe" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Issued"&gt;92,336&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercised (settled)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantLiabilitiesExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_ziqTyVquujLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercised (settled)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2497"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--GainOnChangeInFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zf7xXRmbzS94" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Gain on change in fair value"&gt;(28,196&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Reclassification to stockholders&#x2019; equity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on change in fair value"&gt;&lt;p id="xdx_983_ecustom--ReclassificationsToStockholdersEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zjJcvweR4b02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Reclassifications to stockholders' equity"&gt;(64,140&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantLiabilities_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zyZqV655aYsl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2503"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleofWarrantLiabilitiesTableTextBlock>
    <SHPH:WarrantLiabilities
      contextRef="AsOf2021-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="0"
      id="Fact002469"
      unitRef="USD">334955</SHPH:WarrantLiabilities>
    <SHPH:GainOnChangeInFairValue
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="0"
      id="Fact002475"
      unitRef="USD">421768</SHPH:GainOnChangeInFairValue>
    <SHPH:ReclassificationsToStockholdersEquity
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilitySeriesAPreferredStockObligationMember"
      decimals="0"
      id="Fact002477"
      unitRef="USD">-756723</SHPH:ReclassificationsToStockholdersEquity>
    <SHPH:WarrantLiabilitiesIssued
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="0"
      id="Fact002483"
      unitRef="USD">146624</SHPH:WarrantLiabilitiesIssued>
    <SHPH:WarrantLiabilitiesExercised
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="0"
      id="Fact002485"
      unitRef="USD">-91036</SHPH:WarrantLiabilitiesExercised>
    <SHPH:GainOnChangeInFairValue
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="0"
      id="Fact002487"
      unitRef="USD">5102</SHPH:GainOnChangeInFairValue>
    <SHPH:ReclassificationsToStockholdersEquity
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityAugustTwentyTwoWarrantsMember"
      decimals="0"
      id="Fact002489"
      unitRef="USD">-60690</SHPH:ReclassificationsToStockholdersEquity>
    <SHPH:WarrantLiabilitiesIssued
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact002495"
      unitRef="USD">92336</SHPH:WarrantLiabilitiesIssued>
    <SHPH:GainOnChangeInFairValue
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact002499"
      unitRef="USD">-28196</SHPH:GainOnChangeInFairValue>
    <SHPH:ReclassificationsToStockholdersEquity
      contextRef="From2022-01-012022-12-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact002501"
      unitRef="USD">-64140</SHPH:ReclassificationsToStockholdersEquity>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002505">&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zUfQ5IhZAVZ7"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine if an arrangement is a lease at inception. &lt;span style="background-color: white"&gt;Operating leases are included in operating
lease right-of-use asset (&#x201c;ROU&#x201d;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Leases
with a lease term of 12 months or less at inception are not recorded on our &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;balance &lt;/span&gt;sheets &lt;span style="background-color: white"&gt;and are expensed on a straight-line
basis over the lease term in our statement of operations. &lt;/span&gt;We have lease agreements with lease and non-lease components, which
are generally accounted for separately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#x201c;incremental borrowing rate&#x201d; or &#x201c;IBR&#x201d;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002507">&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zhMEboul1fnf"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zLo9hjhMywRk" style="display: none"&gt;Schedule of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;Furniture&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Computers and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research Equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact002509">&lt;p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zLo9hjhMywRk" style="display: none"&gt;Schedule of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;Furniture&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Computers and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research Equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact002511">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact002513">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_EquipmentMember"
      id="Fact002515">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002517">&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zYSObLAWFqrd"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
our derivative financial instruments, the Company utilizes the most appropriate valuation model (such as Monte Carlo simulations or probability-weighted expected
return models, based on the nature of the terms of the instrument) to value the derivative
instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such
instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheet sheets as current or non-current based on whether or not net-cash settlement or
conversion of the instrument could be required within twelve (12) months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <SHPH:ConvertibleNotePolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002519">&lt;p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zIShPO1DVFMg"&gt;Convertible
Notes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its convertible notes for embedded features and bifurcates these features (such as conversion options and
redemption options) from their host instruments and accounts for them as free standing derivative financial instruments if certain
criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid
instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under
otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)
a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</SHPH:ConvertibleNotePolicyTextBlock>
    <SHPH:WarrantsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002521">&lt;p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zbFQsfTI6WN7"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity
(&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants
are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the
warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a
circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. Finally, the Company
determines if the warrants meet the definition of a derivative based on their contractual terms. This assessment, which requires the
use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while
the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and at each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;statements of operations. &lt;/span&gt;&lt;/span&gt;The Company also evaluates if changes in contractual terms
or other considerations would result in the reclassification of outstanding warrants from liabilities to stockholders&#x2019; equity (or
vice versa).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="background-color: white"&gt;
The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SHPH:WarrantsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002523">&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zMKVdyEG0BI7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-012023-12-31" id="Fact002525">&lt;p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z4CSzyso8ih9"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost for stock awards, which include restricted stock units (&#x201c;RSUs&#x201d;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-012023-12-31" id="Fact002527">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z01OOEEOeht9"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#x2019; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$&lt;span id="xdx_90F_ecustom--ShareBasedCompensations_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhkgxJb4oO55" title="Share based compensation"&gt;0.8&lt;/span&gt; million and $&lt;span id="xdx_900_ecustom--ShareBasedCompensations_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znRCeUIPhCNa" title="Share based compensation"&gt;0.5&lt;/span&gt; million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, &lt;i&gt;Government Assistance&lt;/i&gt;, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#x2013; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $&lt;span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230101__20231231_zY9s230h9slk" title="Research and development, net of contract expense reimbursements"&gt;3.5&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20220101__20221231_zuzMe32hXUdd" title="Research and development, net of contract expense reimbursements"&gt;1.0&lt;/span&gt; million in Research and development, net of contract expense reimbursements, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <SHPH:ShareBasedCompensations
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact002529"
      unitRef="USD">800000</SHPH:ShareBasedCompensations>
    <SHPH:ShareBasedCompensations
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact002531"
      unitRef="USD">500000</SHPH:ShareBasedCompensations>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact002533"
      unitRef="USD">3500000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-5"
      id="Fact002535"
      unitRef="USD">1000000.0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002537">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zjUxdX9ZNGFl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002539">&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQkEcVy4u6Y6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zDl56YzwE8M1"&gt;Segment
Information&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate and discrete information is available for evaluation by the
chief operating decision-maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and assess performance. The Company and the
Company&#x2019;s CODM, the Company&#x2019;s chief executive officer, evaluates the Company&#x2019;s operations and manages its business
as a &lt;span id="xdx_900_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_z3kfWGafUOSj" title="Number of reportable operating segments::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2541"&gt;single&lt;/span&gt;&lt;/span&gt; operating segment. All of the Company&#x2019;s long-lived assets are held in the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002543">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zwbvAlIY1l46"&gt;Net
Loss Per Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share of common stock requires presentation of basic earnings per common share on the face of the statements of operations
for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic
earnings per share computation. In the accompanying consolidated financial statements, basic loss per common share is computed by
dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during
the year. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the weighted average
number of shares of common stock outstanding and potentially dilutive shares of common stock during the period to reflect the
potential dilution that could occur from common shares issuable through convertible securities, contingent share arrangements, stock
options and warrants unless the result would be antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
dilutive effect of restricted stock units and other stock-based payment awards subject to vesting and common stock warrants is
calculated using the &#x201c;treasury stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these
instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible
securities is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be
converted at the beginning of the period, and the resulting shares of common stock are included in the denominator of the diluted
calculation for the entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zz6N2TjW0PMb" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;(as
                                            restated)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Convertible notes (Note 6)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"&gt;119,939&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2549"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants (Note 7)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"&gt;47,831&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 7)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"&gt;24,731&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"&gt;2,966&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"&gt;328,670&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"&gt;50,797&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-012023-12-31" id="Fact002545">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zz6N2TjW0PMb" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;(as
                                            restated)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Convertible notes (Note 6)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"&gt;119,939&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2549"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants (Note 7)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"&gt;184,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"&gt;47,831&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 7)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"&gt;24,731&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"&gt;2,966&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"&gt;328,670&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"&gt;50,797&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact002547"
      unitRef="Shares">119939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember29538078"
      decimals="INF"
      id="Fact002551"
      unitRef="Shares">184000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002553"
      unitRef="Shares">47831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002555"
      unitRef="Shares">24731</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002557"
      unitRef="Shares">2966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002559"
      unitRef="Shares">328670</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002561"
      unitRef="Shares">50797</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact002563">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zSWNCgOEheR1"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#x2019;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;does not expect the adoption of this standard to
have any material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-012023-12-31" id="Fact002565">&lt;p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_z08OzEyKAwJ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 - &lt;span id="xdx_82E_zYhGzQEhHDX1"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had two lease agreements during the year which allowed for the use of laboratory facilities. &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zEya2wAH9aKc" title="Lessee, operating lease, description"&gt;The first was for a monthly payment
of $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_c20230101__20231231_z4j16dhXCej9" title="Payments for rent"&gt;6,480&lt;/span&gt;, with a security deposit of $&lt;span id="xdx_90A_eus-gaap--Deposits_iI_c20231231_zO8e4gkFsUJk" title="Deposits"&gt;6,480&lt;/span&gt; held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019&lt;/span&gt; and ended on &lt;span id="xdx_90D_eus-gaap--LeaseExpirationDate1_c20230101__20231231_zI0l5Mds2Am4" title="Lease expiration date"&gt;October 31, 2023&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2023, the Company entered into a new lease agreement for new office and laboratory space, with base rent of $&lt;span id="xdx_90C_eus-gaap--PaymentsForRent_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zzwRNVzOdczf" title="Payments for rent"&gt;7,206&lt;/span&gt; per month
for a period of 64 months, which increases at the rate of &lt;span id="xdx_903_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIt1JZKcThLk" title="Rent variable rate"&gt;3&lt;/span&gt;% per year, that &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIlMHykNlrM1" title="Operating lease description"&gt;commenced June 1, 2023&lt;/span&gt;. The new lease included a six-month
50% rent abatement upon commencement. Additional common area maintenance (&#x201c;CAM&#x201d;) fees are charged monthly and revised annually.
The estimated monthly CAM fees are $&lt;span id="xdx_908_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230215__20230216_zd0rmLCuEgvl" title="Estimated monthly common area maintenance cost"&gt;3,300&lt;/span&gt; per month for the first year of the lease, which are being expensed as incurred. An irrevocable
letter of credit (&#x201c;LOC&#x201d;) for the security deposit of $&lt;span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20230216_zE3n7U3fwQok" title="Security deposit"&gt;43,234&lt;/span&gt; and base rent of $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_c20230215__20230216_zETIouZ8QDv6" title="Payments for rent"&gt;3,891&lt;/span&gt;, including 50% abatement, and $&lt;span id="xdx_909_ecustom--CommonAreaMaintenanceCost_c20230215__20230216_zRiqEIIYf8j8" title="Common area maintenance cost"&gt;3,315&lt;/span&gt;
of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is the beneficiary of the LOC,
and the expiry date of the LOC is February 15, 2024. Subsequent to December 31, 2023, the LOC was renewed with an updated expiry date
of March 1, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the right-of use asset and lease information for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z3chxPAugTvb" style="display: none"&gt;Schedule of Right-of Use Asset and Lease Information About Operating Lease&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;112,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;70,175&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;24,222&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2595"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Sublease income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,819&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,070&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128,425&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,105&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Other information&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;95,641&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;76,248&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;365,556&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average remaining lease term - operating leases (year)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dxL_c20231231_zyA8Do3k9Nfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)::XDX::P4Y11M23D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2612"&gt;4.67&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)"&gt;0.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average discount rate - operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dpxL_uPure_c20231231_zWuyyS7WvFVl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases::XDX::10.46"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2616"&gt;10.48&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_z8NlF0txAYKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases"&gt;10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zAskMv6Jd9Ib" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOSrvaX8p16l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zhh9Zl5mOtfe" style="display: none"&gt;Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz2AR_zxdBtjySLTu6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024 (excluding the six months ended June 30, 2024)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz2AR_z7Q1UTfjXlRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;91,502&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz2AR_zxt7KD3Psq8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,247&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz2AR_zCEFnZuV9lP6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;97,074&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz2AR_zB3e7mhwfEwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;99,986&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz2AR_zjrflcieALdj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;68,235&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz2AR_zKCt4MJzhhad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;451,044&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(94,438&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Present value of payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;356,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zGZjjGq7mVc5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2023-01-012023-12-31" id="Fact002567">The first was for a monthly payment
of $6,480, with a security deposit of $6,480 held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002569"
      unitRef="USD">6480</us-gaap:PaymentsForRent>
    <us-gaap:Deposits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002571"
      unitRef="USD">6480</us-gaap:Deposits>
    <us-gaap:LeaseExpirationDate1 contextRef="From2023-01-012023-12-31" id="Fact002573">2023-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember"
      decimals="0"
      id="Fact002575"
      unitRef="USD">7206</us-gaap:PaymentsForRent>
    <SHPH:RentVariableRate1
      contextRef="AsOf2023-02-16_custom_NewLeaseAgreementMember"
      decimals="INF"
      id="Fact002577"
      unitRef="Pure">0.03</SHPH:RentVariableRate1>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember"
      id="Fact002579">commenced June 1, 2023</us-gaap:LesseeOperatingLeaseDescription>
    <SHPH:EstimatedMonthlyCommonAreaMaintenanceCost
      contextRef="From2023-02-152023-02-16"
      decimals="0"
      id="Fact002581"
      unitRef="USD">3300</SHPH:EstimatedMonthlyCommonAreaMaintenanceCost>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-02-16"
      decimals="0"
      id="Fact002583"
      unitRef="USD">43234</us-gaap:SecurityDeposit>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-152023-02-16"
      decimals="0"
      id="Fact002585"
      unitRef="USD">3891</us-gaap:PaymentsForRent>
    <SHPH:CommonAreaMaintenanceCost
      contextRef="From2023-02-152023-02-16"
      decimals="0"
      id="Fact002587"
      unitRef="USD">3315</SHPH:CommonAreaMaintenanceCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact002589">&lt;p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the right-of use asset and lease information for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z3chxPAugTvb" style="display: none"&gt;Schedule of Right-of Use Asset and Lease Information About Operating Lease&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;112,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;70,175&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;24,222&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2595"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Sublease income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,819&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,070&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128,425&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,105&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Other information&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;95,641&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;76,248&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;365,556&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average remaining lease term - operating leases (year)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dxL_c20231231_zyA8Do3k9Nfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)::XDX::P4Y11M23D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2612"&gt;4.67&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average remaining lease term - operating leases (year)"&gt;0.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average discount rate - operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dpxL_uPure_c20231231_zWuyyS7WvFVl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases::XDX::10.46"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2616"&gt;10.48&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_z8NlF0txAYKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-average discount rate - operating leases"&gt;10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002591"
      unitRef="USD">112022</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002592"
      unitRef="USD">70175</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002594"
      unitRef="USD">24222</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002597"
      unitRef="USD">7819</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002598"
      unitRef="USD">7070</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002600"
      unitRef="USD">128425</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002601"
      unitRef="USD">63105</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002606"
      unitRef="USD">95641</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002607"
      unitRef="USD">76248</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002609"
      unitRef="USD">365556</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31" id="Fact002614">P0Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact002618"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact002620">&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOSrvaX8p16l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zhh9Zl5mOtfe" style="display: none"&gt;Schedule
of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz2AR_zxdBtjySLTu6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024 (excluding the six months ended June 30, 2024)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz2AR_z7Q1UTfjXlRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;91,502&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz2AR_zxt7KD3Psq8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,247&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz2AR_zCEFnZuV9lP6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;97,074&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz2AR_zB3e7mhwfEwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;99,986&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz2AR_zjrflcieALdj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;68,235&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz2AR_zKCt4MJzhhad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;451,044&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(94,438&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Present value of payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;356,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002624"
      unitRef="USD">91502</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002626"
      unitRef="USD">94247</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002628"
      unitRef="USD">97074</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002630"
      unitRef="USD">99986</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002632"
      unitRef="USD">68235</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002634"
      unitRef="USD">451044</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002636"
      unitRef="USD">94438</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002638"
      unitRef="USD">356606</us-gaap:OperatingLeaseLiability>
    <SHPH:NotesPayableRelatedPartyDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact002640">&lt;p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zd061yowJNd3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_825_zH1XaP0tjrW5"&gt;Notes Payable-Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $&lt;span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zamdIkxYJlAj" title="Loan transaction amount"&gt;426,243&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWqcEUtfPTu6"&gt;7.5&lt;/span&gt;% per annum, with a maturity date of &lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zfFRy9Sub3Hc"&gt;December 31, 2021&lt;/span&gt;; and (ii) a single loan
owed to an officer of the Company in the principal amount of $&lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z23uTB9maqmg" title="Principal amount"&gt;139,229&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_90A_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zerWcgbpUGVj"&gt;7.5&lt;/span&gt;% per annum, with a maturity
date of December 31, 2021. &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211231_zT9SOlLu3LFk" title="Debt instrument maturiy date description"&gt;In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zgvqBs3CjI55" title="Loan transaction amount"&gt;120,000&lt;/span&gt; (principal) with
an interest rate of &lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z7JDA19McyJa"&gt;7.5&lt;/span&gt;% per annum due June 21, 2022. In July of 2022, the loan was extended to June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company accounted for these loan extensions during
the year ended December 31, 2022, as a troubled debt restructuring as the Company was experiencing financial difficulties and the extensions
represented a concession by the lenders. As the future undiscounted cash flows of these related party notes exceeded their carrying value,
no gain or loss was recognized upon the extensions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023 principal payments of $&lt;span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zSYaCBxemUD8"&gt;685,473&lt;/span&gt; and interest of $&lt;span id="xdx_905_eus-gaap--InterestPaid_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z83SkWky2Pa" title="Interest paid"&gt;104,968&lt;/span&gt; were paid. As of December 31, 2023, there were &lt;span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_do_c20230101__20231231_z5bCjpTtB4u2" title="Increase accrued interest"&gt;no&lt;/span&gt; outstanding
principal or interest balances for these related party notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;On August 1, 2022, in conjunction with a private placement of notes and
warrants (as detailed in Note 6 below), in exchange for a $&lt;span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zCQ4BFsht1I5" title="Payments upon subscription"&gt;50,000&lt;/span&gt; payment upon subscription, the Company issued a convertible note to
the spouse of an officer of the Company in the amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWcxBHe7uvM8" title="Principal amount"&gt;50,000 &lt;/span&gt;(principal) with an interest rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z6n2o8Hg614f" title="Interest rate"&gt;6&lt;/span&gt;% per annum, and warrants to purchase
&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z40JRGFDyq7c" title="Warrants to purchase of common stock"&gt;2,500&lt;/span&gt; shares of common stock. The loan was fully repaid, including $&lt;span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z6p8z1cYrBy7" title="Repayments of accrued interest"&gt;822&lt;/span&gt; of accrued interest, in September of 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</SHPH:NotesPayableRelatedPartyDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact002642"
      unitRef="USD">426243</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="INF"
      id="Fact002643"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      id="Fact002644">2021-12-31</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember"
      decimals="0"
      id="Fact002646"
      unitRef="USD">139229</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember"
      decimals="INF"
      id="Fact002647"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2021-12-012021-12-31" id="Fact002649">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact002651"
      unitRef="USD">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="INF"
      id="Fact002652"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact002653"
      unitRef="USD">685473</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact002655"
      unitRef="USD">104968</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002657"
      unitRef="USD">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-08-012022-08-01_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact002659"
      unitRef="USD">50000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-08-01_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact002661"
      unitRef="USD">50000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-08-01_custom_OfficersSpouseMember"
      decimals="INF"
      id="Fact002663"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-08-01_custom_OfficersSpouseMember"
      decimals="INF"
      id="Fact002665"
      unitRef="Shares">2500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2022-09-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact002667"
      unitRef="USD">822</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact002669">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zFKpdNkIRYg4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Note 6 -&lt;span&gt; Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_82B_zZ6z698dByx6" style="display: none"&gt;Convertible Notes and Notes Payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Alto
Opportunity Master Fund, SPC&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 11, 2023, the Company entered into a securities purchase agreement (the &#x201c;SPA&#x201d;) with Alto Opportunity Master
Fund, SPC &#x2013; Segregated Master Portfolio B, a Cayman entity (the &#x201c;Investor&#x201d;), pursuant to which the Company sold to
the Investor a $&lt;span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1qYaf3PFxbb" title="Convertible debt"&gt;4,300,000&lt;/span&gt;
convertible note (the &#x201c;Alto Convertible Note&#x201d;) and warrant (the &#x201c;Alto Warrant&#x201d;) to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zI1s666a13S3" title="Warrants to purchase common stock"&gt;127,260&lt;/span&gt;
shares of common stock, exercisable at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDE7HRqOETJb" title="Warrants exerciable shares"&gt;18.80&lt;/span&gt;
per share, in exchange for gross proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqpTwBuXgLIh" title="Proceeds from convertible note payable"&gt;3,935,000&lt;/span&gt;
(the &#x201c;Investment Amount&#x201d;) (See Note 7). The Company determined that the Alto Warrant contains a net cash settlement
feature at inception and categorized the Alto Warrant as a liability in the accompanying consolidated financial statements. The Alto
Convertible Note matures on March 11, 2025, but may be extended at the option of the noteholder. The Alto Convertible Note amortizes
on a monthly basis and the Company can make such monthly amortization payments in cash or, subject to certain equity conditions, in
registered shares of common stock or a combination thereof. Installments may be deferred by the noteholder, resulting in a variable
interest rate. However, the effective interest rate is approximately &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYihioEmX1N1" title="Effective interest rate"&gt;346&lt;/span&gt;%
based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment, &lt;span id="xdx_900_eus-gaap--DebtInstrumentDescription_c20230111__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQZdUUfRm3u2" title="Debt description"&gt;the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_c20230111_zqknXDQiiXwl" title="Share Price"&gt;18.80&lt;/span&gt;
per share.&lt;/span&gt; The noteholder has an acceleration of installment amount conversion option (the &#x201c;Alto Acceleration
Option&#x201d;), whereby the noteholder, with certain share percentage limitations, can convert to common stock any outstanding
installment amount at an amount equal to the installment amount plus five times (5x) the installment amount at any time. The Company
has determined the Alto Acceleration Option is an embedded derivative within the host instrument and has bifurcated it from the host
instrument and recorded it as a derivative liability valued at $&lt;span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zw9FmdP2k1rj" title="Derivative liability"&gt;1,442,000&lt;/span&gt;,
using a Monte Carlo simulation model (Note 8). The Convertible Note is repayable over 26 months and bears interest at the rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIDfdUAlNQL7" title="Debt interest rate"&gt;5&lt;/span&gt;%
per annum. Additionally, the note contains certain redemption options and &#x201c;Make Whole&#x201d; provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the
&#x201c;Security Agreement&#x201d;), an intellectual property security agreement (the &#x201c;IP Security Agreement&#x201d;) and a
subsidiary guaranty (the &#x201c;Subsidiary Guaranty&#x201d;). The security agreements and guaranty allow, among other things, for the
Investor to have a security interest in and place a lien on all of the Company&#x2019;s assets and intellectual property until such
time as the Alto Convertible Note is paid off. In addition, the SPA called for the Company to enter into a springing deposit account
control agreement (the &#x201c;Springing DACA&#x201d;), which, in the event the Company defaults on its repayment of the Alto
Convertible Note, would allow the Investor to assume control of the Company&#x2019;s bank account only with regard to any funds
remaining outstanding under the Alto Convertible Note. As such, in conjunction with entry into the SPA, the Company established a
separate bank account in which it deposited the Investment Amount and pursuant to which the Company, the Investor and the bank
holding the Investment Amount, First Republic Bank, entered into the Springing DACA agreement. As the Investment Amount had been
held at First Republic Bank, in light of certain banking crises then affecting smaller banks, on March 12, 2023, the Company and the
Investor moved the Investment Amount from First Republic Bank, after which time the Springing DACA was no longer in effect. Further,
pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor agreed that all of the
Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing DACA would no
longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $&lt;span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20231231_zhjUClDQimI" title="Convertible notes payable"&gt;10&lt;/span&gt;
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Alto Warrant, excluding
the Springing DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an
opportunity to participate in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company
expects that such subsequent convertible notes and warrants would be issued on substantially similar terms as the January 11, 2023
initial agreement, as amended, thus providing the Company the opportunity to negotiate certain aspects of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Boustead
Securities, LLC (&#x201c;Boustead&#x201d;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$&lt;span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_ziS9eEQtuv1f" title="Payment for placement agent"&gt;345,000&lt;/span&gt; cash compensation and a warrant to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zAqlkvNNaDpd" title="Warrants to purchase common stock"&gt;8,909&lt;/span&gt; shares of common stock, exercisable at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zojy77XppzIe" title="Warrants exerciable shares"&gt;18.80&lt;/span&gt; per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPC674AVJKXc" title="Expected years"&gt;five years&lt;/span&gt;, volatility of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znMOWfqPGjYf" title="Warrants and rights outstanding measurement input"&gt;110&lt;/span&gt;%, a risk-free rate of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zILXwC7DhWBl"&gt;3.53&lt;/span&gt;% for a value of $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zEonjOrQ2ZU" title="Fair value of warrants"&gt;99,543&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocated the finance costs related to the Boustead placement agent fee of $&lt;span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z1qEjzidygn" title="Payment for placement agent"&gt;345,000&lt;/span&gt;, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $&lt;span id="xdx_902_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGBEljeJa0Nb" title="Allocation of financing costs"&gt;232,027&lt;/span&gt; to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmNk8FczQ6Wh" title="Warrant derivative liability"&gt;104,245&lt;/span&gt; to the warrant derivative liability component,
expensed as a finance fee, and $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zSUixncCkJS1" title="Equity warrant as reduction in additional paid in capital"&gt;8,727&lt;/span&gt; to the equity warrant as a reduction in additional paid in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocated to the debt component of the note an original discount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zMx5hPAesnIi" title="Debt discount"&gt;300,000&lt;/span&gt;, legal fees of $&lt;span id="xdx_90D_eus-gaap--LegalFees_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zLBOZ1MJKbi8" title="Legal fees"&gt;65,000&lt;/span&gt;, $&lt;span id="xdx_900_ecustom--InterestFeeAmount_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zqJJyHoHEi83" title="Interest fee"&gt;215,000&lt;/span&gt; for additional
interest fees on day one added to note principal, $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zayR1vJlE2s9" title="Debt principal amount"&gt;1,442,000&lt;/span&gt; for the accelerated conversion feature, and $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zxa2TC77bmFd" title="Fair value of warrants"&gt;1,288,543&lt;/span&gt; for the fair value
of warrants, resulting in an additional $&lt;span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_znnI28Rtm2fb" title="Interest expense debt"&gt;3,310,543&lt;/span&gt; debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company recorded interest expense of $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_znhWETUYiYQb"&gt;2,484,193&lt;/span&gt;, which included amortization of debt discount as
interest expense of $&lt;span id="xdx_900_eus-gaap--InterestExpenseDebt_c20230101__20231231_zpTyEbkt4Xac"&gt;2,123,049&lt;/span&gt;. During the year ended December 31, 2023, the Company settled $&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJLs4MfXiOZ5" title="Debt, principal"&gt;1,925,700&lt;/span&gt; of principal and settled $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIH04jwIMOkl" title="Accrued interest"&gt;294,927&lt;/span&gt;
of accrued interest, which settlements were made in the form of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z61rjBMkQSyb"&gt;297,625&lt;/span&gt; shares of common stock during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the outstanding principal for the convertible note was $&lt;span id="xdx_902_eus-gaap--ConvertibleDebt_iI_c20231231_zSRsEaMmQVQd"&gt;2,254,856&lt;/span&gt; and the debt discount remaining was $&lt;span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20231231_zLkKrYZw6Y46"&gt;1,523,768&lt;/span&gt;,
with a net convertible note carrying value of $&lt;span id="xdx_90C_ecustom--ConvertibleNotesPayableCurrentNonCurrent_iI_c20231231_zuETJj7Bxv4l" title="Convertible note payable"&gt;731,088&lt;/span&gt;, which represents the current and non-current portions of the convertible note
as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to December 31, 2023, the Company and the Investor agreed to certain changes in terms of the Alto Convertible Note as well as the waiver
of certain covenant violations. See Subsequent Events for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Paycheck
Protection Program Term Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 9, 2021, the Company obtained a $&lt;span id="xdx_905_eus-gaap--MediumTermNotes_iI_c20210309_zqzjdB5Jbxke" title="Term notes issued"&gt;73,007&lt;/span&gt; term note issued under the Coronavirus Aid, Relief, and Economic Security Act&#x2019;s Paycheck
Protection Program (the &#x201c;PPP&#x201d;). The note bore an interest rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210309_z99RiodwMrtj" title="Interest rate"&gt;1&lt;/span&gt;% per annum, had a six-month deferral period with payments
due on the seventh month, with all outstanding principal and interest due and payable within two years from the note&#x2019;s inception
date. Under its terms, all or a portion of the note may be forgiven in accordance with PPP requirements, with &lt;span id="xdx_908_eus-gaap--ShortTermDebtDescription_c20210309__20210309_zYoBKdc2rg0k" title="Term note description"&gt;no more than 25% of the
amount forgiven to be attributable to non-payroll costs&lt;/span&gt;. As of December 31, 2021, a &#x201c;Loan Forgiveness Application&#x201d; was submitted
to PNC Bank along with the requested documentation. Thereafter, during the quarter ended March 31, 2022, the note liability was reduced
in its entirety and the Company recognized a gain on forgiveness of $&lt;span id="xdx_90B_eus-gaap--MediumTermNotes_iI_c20221231_zScgzlhv1dok" title="Term notes issued"&gt;73,007&lt;/span&gt; in its statement of operations for the year ended December
31, 2022. (as restated)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;December
2021 Promissory Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 28, 2021, the Company issued promissory note units, consisting of an aggregate $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_c20211228_z8zCyT3ROlM8" title="Notes payable"&gt;500,000&lt;/span&gt;
in &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211228_zTW6LR0Kzba8" title="Interest rate"&gt;10&lt;/span&gt;%
unsecured promissory notes with a maturity date of &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20211228__20211228_z2nwNfHdgjxk" title="Debt maturity date"&gt;December
28, 2022 &lt;/span&gt;(the &#x201c;December 2021 Promissory Notes&#x201d;) and warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211228_zNoT2sbNViB4" title="Warrants to purchase of common stock"&gt;62,500&lt;/span&gt;
shares of common stock exercisable at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211228_z5iMOMfl5y8k" title="Exercise price of warrants"&gt;8.00&lt;/span&gt;
per share with an expiration date of December 28, 2026. The Company received net proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20211228__20211228_zsaZJ1BsY731" title="Promissory note"&gt;494,925&lt;/span&gt;
upon the issuance of these promissory note units and incurred $&lt;span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20211228_zvn3OApisrb5" title="Issuance cost"&gt;21,890&lt;/span&gt; in additional issuance costs which were allocated between the December 2021 Promissory Notes
and the warrants. The Company assessed the embedded features of the December 2021 Promissory Notes
and determined that the accelerated repayment upon an initial public offering represented a derivative feature requiring
bifurcation. The Company estimated the fair value of the derivative to be $&lt;span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20211228__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUD8Ry6bhtO7" title="Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value"&gt;367,000&lt;/span&gt;
at issuance (see Note 8 for fair value considerations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that the warrants issued with the December 2021 Promissory Notes should be classified as equity. The Company
measured the fair value of these warrants using a Black-Scholes model and allocated fair value to these warrants on a relative fair
value basis. The proceeds from the December 2021 Promissory Notes allocated to the warrants at issuance was $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_c20211228__20211228_zqbgjTw8ZEB2" title="Proceeds from issuance of warrants"&gt;418,449&lt;/span&gt;. The inputs to
the Black-Scholes model included an estimated fair value of the Company&#x2019;s common stock of $&lt;span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20211228__20211228_zpY9EgGY1YV5" title="Conversion price per share"&gt;40.00&lt;/span&gt;,
the exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zAR1l1qtI5Kj" title="Exercise price of warrants"&gt;8.00&lt;/span&gt;
per share, a five year term, &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20211228__20211228_zPXD89MZnqYk" title="Volatility"&gt;86.3%&lt;/span&gt;
volatility and a risk free rate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20211228__20211228_zqFIbTWnireh" title="Risk free rate"&gt;1.27%&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
discount on the December 2021 Promissory Notes was being amortized using the straight-line method as the initial proceeds received were
fully allocated to the warrants and bifurcated derivative, through the maturity date of the notes. The Company recognized amortization
expense of $&lt;span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231_zkuIO5Agz0Qb"&gt;331,978&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;related
to the discount on the December 2021 Promissory Notes as interest expense in its statement of operations for the year ended December
31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In April 2022, the warrants were modified by the Company
to nullify the effect of the April 2022 reverse stock split, allowing the warrant to remain outstanding and exercisable for &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220430_zgVPTzfdkwIi" title="Warrants outstanding and exercisable"&gt;62,500&lt;/span&gt; shares
of common stock at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zAmiQlpLmEgj" title="Exercise price of warrants"&gt;8.00&lt;/span&gt; per share. The Company calculated the incremental fair value provided to the holders of
the warrants due to the modification as $&lt;span id="xdx_908_ecustom--DeemedDividendOnModificationOfEquityclassifiedWarrants_c20220101__20221231_zAhnDE9G1f13" title="Deemed dividend on modification of equity classified warrants"&gt;941,000&lt;/span&gt;, which was recorded as a deemed dividend during the year ended December 31, 2022. The
incremental fair value was estimated using a Black-Scholes model, with inputs including the estimated fair value of the Company&#x2019;s
common stock of $&lt;span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220430__20220430_zpBlE4y3tN23" title="Conversion price per share"&gt;32.00&lt;/span&gt;, the exercise price of either $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220429_z2Tjj9vjnFh5" title="Exercise price of warrants"&gt;16.00&lt;/span&gt; (pre-modification) or $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zKAy7DyBmHD6" title="Exercise price of warrants"&gt;8.00&lt;/span&gt; (post-modification), a remaining term of &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220430__20220430_z2Yg4OdIZeW1" title="Expected term"&gt;4.75&lt;/span&gt;
years, volatility of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220430__20220430_ztFZjO6SaNya" title="Volatility"&gt;83.6&lt;/span&gt;% and a risk free rate of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220430__20220430_zCU9XEt1wWb2" title="Risk free rate"&gt;2.55&lt;/span&gt;%.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2022, the warrants were exercised by the lenders in exchange for tendering the outstanding principal balance ($&lt;span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20220930_zNOkFecwyUhg"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930_zzztFeBEnntc"&gt;500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
on the December 2021 Promissory Notes. The Company treated the settlement as a debt extinguishment for accounting purposes. The Company
recognized a loss on extinguishment of $&lt;span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220930__20220930_zmDjf6XXKwjf" title="Gain (loss) on extinguishment of debt"&gt;1,531,852&lt;/span&gt; upon this settlement and issuance of the &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220930__20220930_znW9JkwrD5N3" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"&gt;62,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock upon exercise, based on
the difference between the estimated fair value of the common stock issued ($&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220930__20220930_z7wjBfLimlIb" title="Stock issued during period, value, new issues"&gt;2,031,250&lt;/span&gt;) and the carrying value of the December 2021 Promissory
Notes. The Company paid all accrued interest under the December 2021 Promissory Notes from issuance through settlement to the lenders
in cash during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2022
Convertible Bridge Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2022 and March 11, 2022, the Company sold $&lt;span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zQlxj9Q5Ql6d" title="Convertible notes payable"&gt;365,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zGDLoRiCyxh" title="Convertible notes payable"&gt;225,000&lt;/span&gt;, respectively, in &lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zqwZx4citFg4" title="Interest rate"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zzZ1LFFS3Mg3" title="Interest rate"&gt;6&lt;/span&gt;&lt;/span&gt;% convertible notes (the &#x201c;2022 Convertible
Notes&#x201d;), which bore &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z5SRnogjh75e" title="Interest rate"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zulLgLSgXCz6" title="Interest rate"&gt;6&lt;/span&gt;&lt;/span&gt;% interest (which would be waived upon a conversion event), were repayable on December 31, 2024,
and were convertible upon the completion of the Company&#x2019;s initial public offering or other liquidity event at &lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zIkIVWHdFLo7" title="Debt instrument conversion rate"&gt;&lt;span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zNp9Sn8aTy3d" title="Debt instrument conversion rate"&gt;50&lt;/span&gt;&lt;/span&gt;% of the per share
price paid by investors in such an event. In addition, if the 2022 Convertible Notes were not converted during the period 12 months after
their initial issuance, the outstanding principal amount of the 2022 Convertible Notes would be increased by &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zlYP9u9a0jFd" title="Interest rate"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zTGMOJrwbLzl" title="Interest rate"&gt;10&lt;/span&gt;&lt;/span&gt;%. The Company received
net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zxtsxaAEaMm6" title="Promissory note"&gt;&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zsqVooPhdkD6" title="Promissory note"&gt;525,715&lt;/span&gt;&lt;/span&gt; from the 2022 Convertible Notes, after deducting a total of $&lt;span id="xdx_905_eus-gaap--PaymentsForFees_c20220208__20220208__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zFnz4XMrMQ35" title="Fees paid"&gt;&lt;span id="xdx_90F_eus-gaap--PaymentsForFees_c20220311__20220311__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zOLqo5nrMuP2" title="Fees paid"&gt;64,285&lt;/span&gt;&lt;/span&gt; in fees paid to Boustead Securities LLC
for services provided as placement agent for the offering. Boustead also received warrants in connection with the issuances with a total estimated fair value of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220208__20220208_zfx0Ekvr8o1b" title="Warrants issuance"&gt;&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220311__20220311_zZro2KRDmNX1" title="Warrants issuance"&gt;92,336&lt;/span&gt;&lt;/span&gt; (see
discussion below) and the Company incurred $&lt;span id="xdx_902_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220208__20220208_zA0uTo9mqO9i" title="Debt issuance costs"&gt;&lt;span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220311__20220311_zlztB8r0gx7g" title="Debt issuance costs"&gt;17,363&lt;/span&gt;&lt;/span&gt; in additional costs which were recorded as debt issuance costs upon issuance of the
2022 Convertible Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assessed the embedded features of the 2022 Convertible Notes and determined that the automatic conversion feature with a &lt;span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z5IAgS7IL8j2" title="Debt instrument conversion rate"&gt;50&lt;/span&gt;%
discount to per share price paid (a share-settled redemption feature) and the &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zXVSuxRrisQ7" title="Principal increase decrease rate"&gt;10&lt;/span&gt;%
principal increase feature were not clearly and closely related to the debt host instrument and met the definition of a derivative
and as such, required bifurcation from the 2022 Convertible Notes. The Company estimated the fair value at issuance of these
features to be $&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z6H0bw1GU022" title="Convertible Notes"&gt;221,000&lt;/span&gt;
and recorded as a discount to the 2022 Convertible Notes (see Note 8 for fair value considerations). Of the total $&lt;span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeIKoXaDnoRl" title="Debt issuance costs related party"&gt;173,984&lt;/span&gt; of
issuance costs incurred related to the 2022 Convertible Notes, the Company allocated $&lt;span id="xdx_904_eus-gaap--PaymentOfFinancingAndStockIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zKum10API6K6" title="Debt issuance costs related party"&gt;108,858&lt;/span&gt; of the debt issuance costs to the 2022
Convertible Notes (as a discount) and $&lt;span id="xdx_907_eus-gaap--PaymentsOfDerivativeIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zcmsPGjnjx24" title="Payments of derivative issuance costs"&gt;65,126&lt;/span&gt;
allocated to the derivative liability and expensed as a component of the finance fee (as restated)
in the statement of operations. The discount on the 2022 Convertible Notes was amortized under the effective interest method through
the maturity dates of the notes. The Company recognized amortization expense of $&lt;span id="xdx_909_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zLem4dHIES25" title="Amortization expense"&gt;37,745&lt;/span&gt;
related to the discount on the 2022 Convertible Notes as interest expense in its statement of operations for the year ended December
31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
services provided in the offering, Boustead Securities LLC also received warrants to purchase &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zYRM3ija2OU9" title="Interest rate"&gt;10%&lt;/span&gt; of the shares of common stock
issuable upon conversion of the 2022 Convertible Notes, at the conversion price of the notes. Upon conversion, the warrant became
exercisable for a total of &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zgtdsATR8uhj"&gt;2,582&lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zD1w3meaWV4l"&gt;16.00&lt;/span&gt;
per share. These warrants were accounted for under ASC 718 and classified as liabilities due to the fact that the conversion of the
2022 Convertible Notes would impact their fair value. The fair value at issuance of the warrants was estimated as $&lt;span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zhF1rI2RViwa"&gt;92,336&lt;/span&gt;
using a Black-Scholes model, with inputs that included an estimated fair value of the Company&#x2019;s common
stock of $&lt;span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220101__20221231_zvAeKYk7lF56" title="Conversion price per share"&gt;32.00&lt;/span&gt;, an exercise price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20221231_zphB410M6SZ3" title="Common stock trading price per share"&gt;16.00&lt;/span&gt; per share (based on the estimated conversion terms), a five year term, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20221231__20221231_zsbef1bln51b"&gt;86.1%&lt;/span&gt; volatility and
a risk free rate of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zQP9ACdPtKXh"&gt;1.81%&lt;/span&gt; to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKPFT8LVZdda"&gt;1.96%&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the 2022 Convertible Notes were automatically converted into the securities issued by the Company
to the investors in the initial public offering, at a discounted price of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zaZSeiFu6ENl"&gt;32.00&lt;/span&gt;
per unit. Consistent with the investors in the initial public offering, the 2022 Convertible Note holders received &lt;span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z2KIozp5gaNb" title="Common stock"&gt;18,438&lt;/span&gt;
shares of common stock and warrants to purchase &lt;span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zbCa8RGTqZJg" title="Warrant"&gt;18,438&lt;/span&gt;
shares of common stock with an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zg1CenawUwSc"&gt;0.08 &lt;/span&gt;per
share. The warrants issued to the 2022 Convertible Note holders were immediately exercised. Pursuant to the automatic exercise of
the share-settled redemption feature, the Company accounted for the conversion as an extinguishment of debt. The Company recognized
the issuance of the shares of common stock and warrants at their estimated fair value, and recorded a loss on extinguishment of
$&lt;span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zlQ9GDshnun5"&gt;310,621&lt;/span&gt;
based on the difference between the estimated fair value ($&lt;span id="xdx_907_eus-gaap--GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c20220101__20221231_zNe91AEjzuI8" title="Gain (loss) on sale of assets and asset impairment charges"&gt;1,198,438&lt;/span&gt;) and the net carrying amount of the 2022 Convertible Notes
(including the carrying value of the bifurcated derivative liabilities, which were adjusted to then fair value upon settlement). The
accrued cash interest was waived upon conversion and was included as a component of the loss on extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;August
2022 Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2022, the Company issued promissory note units, consisting of an aggregate $&lt;span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zYMm3h2Z6Jla" title="Convertible notes payable"&gt;50,000&lt;/span&gt;
in &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zdmGRqygbDSh" title="Interest rate"&gt;10&lt;/span&gt;%
promissory notes with a maturity date of July 31, 2023 (the &#x201c;August 2022 Promissory Notes&#x201d;) and warrants to purchase &lt;span id="xdx_904_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zKExtJPYWj6" title="Notes issued"&gt;2,500&lt;/span&gt;
shares of common stock exercisable at a price of the lesser of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zDLw326Qekd8" title="Exercise price"&gt;20.00&lt;/span&gt;
per share or &lt;span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zUJI3EnS6Bf6" title="Debt instrument conversion rate"&gt;50&lt;/span&gt;%
of the per share price paid in the Company&#x2019;s initial public offering. In addition, the Company issued convertible note units,
consisting of an aggregate of $&lt;span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zJG5INTNLW83" title="Convertible notes payable"&gt;75,000&lt;/span&gt;
in &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zneO0eW0aEY" title="Interest rate"&gt;6&lt;/span&gt;%
convertible notes with a maturity date of December 31, 2024 (the &#x201c;August 2022 Convertible Notes&#x201d;, and collectively, the
&#x201c;August 2022 Notes&#x201d;) and warrants to purchase &lt;span id="xdx_90D_eus-gaap--NotesIssued1_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zDCuroyddOQ5" title="Notes issued"&gt;3,750&lt;/span&gt; shares of common stock exercisable at a price of the lesser of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zVaVSQ1CrCl3" title="Exercise price"&gt;20.00&lt;/span&gt; per share or
&lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoConvertibleNotesMember_zQumnPGZM0ch" title="Debt instrument conversion rate"&gt;50&lt;/span&gt;% of the per share price paid in the Company&#x2019;s initial public offering. The Company received net proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfDebt_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zN0SEm1WMah8" title="Promissory note"&gt;50,000&lt;/span&gt;
upon the issuance of the August 2022 Promissory Notes, $&lt;span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z83ZCk3k6UHh" title="Convertible notes payable"&gt;25,000&lt;/span&gt;
upon the issuance of the August 2022 Convertible Notes (non-related party) and $&lt;span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zrWY6Dw0HyQj" title="Proceeds from note payable-related party"&gt;50,000&lt;/span&gt;
upon the issuance of the August 2022 Convertible Notes issued to a related party (as detailed in Note 5 above).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company assessed the embedded features of the August 2022 Promissory Notes and determined that the accelerated repayment upon an initial
public offering represented a derivative feature requiring bifurcation. The Company estimated the fair value of the derivative to be $&lt;span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zR3hLi26HtHd"&gt;45,000&lt;/span&gt;
at issuance (see Note 8 for fair value considerations). The Company assessed the embedded features of the August 2022 Convertible Notes
and determined that the automatic conversion feature with a &lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_z1vMpx7rwZQk" title="Debt instrument conversion rate"&gt;50%&lt;/span&gt; discount to per share price paid (a share-settled redemption feature)
and the &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20220801__20220801_zL3NX9ArYLl9"&gt;10%&lt;/span&gt; principal increase feature were not clearly and closely related to the debt host instrument and met the definition of a derivative
and as such, required bifurcation from the August 2022 Convertible Notes. The Company estimated the fair value at issuance of these features
to be $&lt;span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zbf9S5mk9j5j" title="Convertible Notes"&gt;31,000&lt;/span&gt; and recorded as a discount to the August 2022 Convertible Notes (see Note 8 for fair value considerations).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that the warrants issued with the August 2022 Notes should be classified as liabilities under ASC 815, as the
settlement amount could vary based on the occurrence of the initial public offering. The Company measured the fair value of these
warrants using a Black-Scholes model with inputs that included an estimated fair value of the Company&#x2019;s common stock of
$&lt;span id="xdx_904_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220801_zNQSa6fh5Jyb" title="Conversion price per share"&gt;32.00&lt;/span&gt;, an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801_zhDjOeqYB3Ig" title="Exercise price of warrants"&gt;20.00&lt;/span&gt; per share, a five-year term, &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220801_zTB5zBB5Z3r"&gt;80.0%&lt;/span&gt; volatility and a risk free rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220801_zhDninb2yZ8c"&gt;2.66%&lt;/span&gt;, and recognized them
at their full fair value of $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220801_zglbH34c0Oq4" title="Estimated fair value"&gt;146,624&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of these warrants, the fair value of the bifurcated derivative liabilities and the other debt issuance costs incurred (totaling $&lt;span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zG3VvAvMBPrb" title="Fair value measurement"&gt;27,162&lt;/span&gt;,
including the fair value of the Boustead warrants described below), exceeded the proceeds received and as such, the Company
recorded a loss at issuance of $&lt;span id="xdx_902_ecustom--FinanceFee_c20220801__20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zzVapSNIHQPb" title="Finance fee"&gt;124,786&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
in finance fee (as restated) in the statement of operations. The discount on the August 2022 Notes was being amortized under the
straight-line method, as the initial carrying value was $&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220801__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zm5pd5EFmREa"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
through the maturity date of the respective notes. The Company recognized amortization expense of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z51deQhstPIe"&gt;7,661
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;related to the discount on the August 2022 Notes
as interest expense in its statement of operations for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Boustead
Securities LLC acted as placement agent for the August 2022 Notes and received warrants to purchase &lt;span id="xdx_90B_ecustom--IssuanceOfWarrantsShares_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJ3Zz8ChVC4b" title="Issuance of warrants shares"&gt;625&lt;/span&gt; shares of common stock at an
exercise price of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zMw5BDNiLCTb" title="Share price"&gt;20.00&lt;/span&gt; per share. The fair value of the warrants was estimated as $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zcaazmVLUtQ5"&gt;14,662&lt;/span&gt; using a Black-Scholes model with inputs that included an estimated fair value of the Company&#x2019;s common stock of $&lt;span id="xdx_908_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zsK4QqlvOI64" title="Conversion price per share"&gt;32.00&lt;/span&gt;, an exercise price
of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zFehufcMrrG4" title="Exercise price of warrants"&gt;20.00&lt;/span&gt; per share, a five-year term, &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z62TFWnzUBXf"&gt;80.0%&lt;/span&gt; volatility and a risk free rate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zsGSYYxEm8w6"&gt;2.66%&lt;/span&gt;, and recorded by
the Company in stockholders&#x2019; equity at issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the lender under the August 2022 Promissory Notes and one lender under the August 2022 Convertible
Notes exercised warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zIDoBp88TF2d" title="Number of warrants to purchase"&gt;3,750&lt;/span&gt;
shares of common stock in exchange for tendering their outstanding principal balance ($&lt;span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z3hPJeUx9oIi" title="Principal balance"&gt;75,000&lt;/span&gt;)
on their respective notes. As the warrants being exercised were classified as liabilities, the Company accounted for the settlement
as an extinguishment of debt. The Company recognized the issuance of the &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z3062R9HrRQ1" title="Principal balance"&gt;3,750&lt;/span&gt;
shares of common stock at their estimated fair value ($&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoNotesMember_zAtoWELHHhX5"&gt;121,875&lt;/span&gt;), and recorded a gain on extinguishment of $&lt;span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zAl5sY7U1d37"&gt;44,614&lt;/span&gt;
based on the difference between the estimated fair value and the net carrying amount of the tendered August 2022 Notes. The
remaining $&lt;span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_zCSU5eZDdFdj"&gt;50,000&lt;/span&gt;
outstanding under the August 2022 Convertible Notes (and owed to the related party) was fully repaid in cash during the year ended
December 31, 2022 (see Note 5), resulting in the recognition of a gain on extinguishment of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyTwoPromissoryNotesMember_z4l3Icw5MxTd" title="Unamortized discount"&gt;2,206&lt;/span&gt;
based on the difference between the repayment in cash and the net carrying
amount of the notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact002671"
      unitRef="USD">4300000</us-gaap:ConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact002673"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact002675"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact002677"
      unitRef="USD">3935000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact002679"
      unitRef="Pure">3.46</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2023-01-112023-01-11_custom_SecuritiesPurchaseAgreementMember"
      id="Fact002681">the
Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $18.80, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to
payment date. The noteholder may convert at any time at a fixed price of $18.80
per share.</us-gaap:DebtInstrumentDescription>
    <us-gaap:SharePrice
      contextRef="AsOf2023-01-11"
      decimals="INF"
      id="Fact002683"
      unitRef="USDPShares">18.80</us-gaap:SharePrice>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact002685"
      unitRef="USD">1442000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact002687"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="-6"
      id="Fact002689"
      unitRef="USD">10000000</us-gaap:ConvertibleNotesPayable>
    <SHPH:PaymentForPlacementAgent
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002691"
      unitRef="USD">345000</SHPH:PaymentForPlacementAgent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002693"
      unitRef="Shares">8909</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002695"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact002697">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact002699"
      unitRef="Pure">110</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact002700"
      unitRef="Pure">3.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002702"
      unitRef="USD">99543</us-gaap:FairValueAdjustmentOfWarrants>
    <SHPH:PaymentForPlacementAgent
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002704"
      unitRef="USD">345000</SHPH:PaymentForPlacementAgent>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002706"
      unitRef="USD">232027</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002708"
      unitRef="USD">104245</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002710"
      unitRef="USD">8727</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact002712"
      unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact002714"
      unitRef="USD">65000</us-gaap:LegalFees>
    <SHPH:InterestFeeAmount
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact002716"
      unitRef="USD">215000</SHPH:InterestFeeAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact002718"
      unitRef="USD">1442000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact002720"
      unitRef="USD">1288543</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact002722"
      unitRef="USD">3310543</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002723"
      unitRef="USD">2484193</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002724"
      unitRef="USD">2123049</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002726"
      unitRef="USD">1925700</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002728"
      unitRef="USD">294927</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002729"
      unitRef="Shares">297625</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002730"
      unitRef="USD">2254856</us-gaap:ConvertibleDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002731"
      unitRef="USD">1523768</us-gaap:AmortizationOfFinancingCosts>
    <SHPH:ConvertibleNotesPayableCurrentNonCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002733"
      unitRef="USD">731088</SHPH:ConvertibleNotesPayableCurrentNonCurrent>
    <us-gaap:MediumTermNotes
      contextRef="AsOf2021-03-09"
      decimals="0"
      id="Fact002735"
      unitRef="USD">73007</us-gaap:MediumTermNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-03-09"
      decimals="INF"
      id="Fact002737"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermDebtDescription contextRef="From2021-03-092021-03-09" id="Fact002739">no more than 25% of the
amount forgiven to be attributable to non-payroll costs</us-gaap:ShortTermDebtDescription>
    <us-gaap:MediumTermNotes
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002741"
      unitRef="USD">73007</us-gaap:MediumTermNotes>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-28"
      decimals="0"
      id="Fact002743"
      unitRef="USD">500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-12-28"
      decimals="INF"
      id="Fact002745"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-12-282021-12-28" id="Fact002747">2022-12-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-28"
      decimals="INF"
      id="Fact002749"
      unitRef="Shares">62500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-28"
      decimals="INF"
      id="Fact002751"
      unitRef="USDPShares">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2021-12-282021-12-28"
      decimals="0"
      id="Fact002753"
      unitRef="USD">494925</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2021-12-28"
      decimals="0"
      id="Fact002755"
      unitRef="USD">21890</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-28_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002757"
      unitRef="USD">367000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2021-12-282021-12-28"
      decimals="0"
      id="Fact002759"
      unitRef="USD">418449</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2021-12-282021-12-28"
      decimals="INF"
      id="Fact002761"
      unitRef="USDPShares">40.00</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact002763"
      unitRef="USDPShares">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-12-282021-12-28"
      decimals="INF"
      id="Fact002765"
      unitRef="Pure">0.863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-12-282021-12-28"
      decimals="INF"
      id="Fact002767"
      unitRef="Pure">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002768"
      unitRef="USD">331978</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-04-30"
      decimals="INF"
      id="Fact002770"
      unitRef="Shares">62500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-30"
      decimals="INF"
      id="Fact002772"
      unitRef="USDPShares">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002774"
      unitRef="USD">941000</SHPH:DeemedDividendOnModificationOfEquityclassifiedWarrants>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-04-302022-04-30"
      decimals="INF"
      id="Fact002776"
      unitRef="USDPShares">32.00</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-29"
      decimals="INF"
      id="Fact002778"
      unitRef="USDPShares">16.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-30"
      decimals="INF"
      id="Fact002780"
      unitRef="USDPShares">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-04-302022-04-30" id="Fact002782">P4Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-04-302022-04-30"
      decimals="INF"
      id="Fact002784"
      unitRef="Pure">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-04-302022-04-30"
      decimals="INF"
      id="Fact002786"
      unitRef="Pure">0.0255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="Fact002787"
      unitRef="USD">500000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="Fact002788"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-09-302022-09-30"
      decimals="0"
      id="Fact002790"
      unitRef="USD">1531852</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-09-302022-09-30"
      decimals="INF"
      id="Fact002792"
      unitRef="Shares">62500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-302022-09-30"
      decimals="0"
      id="Fact002794"
      unitRef="USD">2031250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002796"
      unitRef="USD">365000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002798"
      unitRef="USD">225000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002800"
      unitRef="Pure">6</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002802"
      unitRef="Pure">6</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002804"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002806"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002808"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002810"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002812"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002814"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002816"
      unitRef="USD">525715</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002818"
      unitRef="USD">525715</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsForFees
      contextRef="From2022-02-082022-02-08_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002820"
      unitRef="USD">64285</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="From2022-03-112022-03-11_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002822"
      unitRef="USD">64285</us-gaap:PaymentsForFees>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-02-082022-02-08"
      decimals="0"
      id="Fact002824"
      unitRef="USD">92336</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-03-112022-03-11"
      decimals="0"
      id="Fact002826"
      unitRef="USD">92336</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-02-082022-02-08"
      decimals="0"
      id="Fact002828"
      unitRef="USD">17363</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-03-112022-03-11"
      decimals="0"
      id="Fact002830"
      unitRef="USD">17363</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002832"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002834"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002836"
      unitRef="USD">221000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact002838"
      unitRef="USD">173984</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002840"
      unitRef="USD">108858</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentsOfDerivativeIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002842"
      unitRef="USD">65126</us-gaap:PaymentsOfDerivativeIssuanceCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002844"
      unitRef="USD">37745</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002846"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002847"
      unitRef="Shares">2582</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002848"
      unitRef="USDPShares">16.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002849"
      unitRef="USD">92336</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002851"
      unitRef="USDPShares">32.00</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact002853"
      unitRef="USDPShares">16.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-12-312022-12-31"
      decimals="INF"
      id="Fact002854"
      unitRef="Pure">0.861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact002855"
      unitRef="Pure">0.0181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact002856"
      unitRef="Pure">0.0196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002857"
      unitRef="USDPShares">32.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002859"
      unitRef="Shares">18438</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002861"
      unitRef="Shares">18438</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002862"
      unitRef="USDPShares">0.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002863"
      unitRef="USD">310621</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002865"
      unitRef="USD">1198438</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002867"
      unitRef="USD">50000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="INF"
      id="Fact002869"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesIssued1
      contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002871"
      unitRef="USD">2500</us-gaap:NotesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="INF"
      id="Fact002873"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="INF"
      id="Fact002875"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact002877"
      unitRef="USD">75000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact002879"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesIssued1
      contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact002881"
      unitRef="USD">3750</us-gaap:NotesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact002883"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact002885"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002887"
      unitRef="USD">50000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-08-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002889"
      unitRef="USD">25000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002891"
      unitRef="USD">50000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-08-01_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002892"
      unitRef="USD">45000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-08-012022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact002894"
      unitRef="Pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2022-08-012022-08-01"
      decimals="INF"
      id="Fact002895"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-08-01_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="0"
      id="Fact002897"
      unitRef="USD">31000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-08-012022-08-01"
      decimals="INF"
      id="Fact002899"
      unitRef="USDPShares">32.00</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-01"
      decimals="INF"
      id="Fact002901"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-08-012022-08-01"
      decimals="INF"
      id="Fact002902"
      unitRef="Pure">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-08-012022-08-01"
      decimals="INF"
      id="Fact002903"
      unitRef="Pure">0.0266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-08-012022-08-01"
      decimals="0"
      id="Fact002905"
      unitRef="USD">146624</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002907"
      unitRef="USD">27162</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:FinanceFee
      contextRef="From2022-08-012022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002909"
      unitRef="USD">124786</SHPH:FinanceFee>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-08-01_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002910"
      unitRef="USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002911"
      unitRef="USD">7661</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <SHPH:IssuanceOfWarrantsShares
      contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002913"
      unitRef="Shares">625</SHPH:IssuanceOfWarrantsShares>
    <us-gaap:SharePrice
      contextRef="AsOf2022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002915"
      unitRef="USDPShares">20.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact002916"
      unitRef="USD">14662</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002918"
      unitRef="USDPShares">32.00</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002920"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002921"
      unitRef="Pure">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002922"
      unitRef="Pure">0.0266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="INF"
      id="Fact002924"
      unitRef="Shares">3750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002926"
      unitRef="USD">75000</us-gaap:ConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="INF"
      id="Fact002928"
      unitRef="Shares">3750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoNotesMember"
      decimals="0"
      id="Fact002929"
      unitRef="USD">121875</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002930"
      unitRef="USD">44614</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-01-012022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002931"
      unitRef="USD">50000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-12-31_custom_AugustTwentyTwentyTwoPromissoryNotesMember"
      decimals="0"
      id="Fact002933"
      unitRef="USD">2206</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact002935">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRCb1RVFvgkc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 - &lt;span id="xdx_825_zr458jZvyJC5"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231_zZds9nkiSPPl" title="Common stock issued for conversion of convertible debt, shares"&gt;297,625&lt;/span&gt;
    shares of common stock to settle $&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRAn1fkxWHy9" title="Debt, principal"&gt;1,925,700&lt;/span&gt; of principal and $&lt;span id="xdx_90B_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jBXJnIxDLa" title="Accrued interest settled with common stock"&gt;294,927&lt;/span&gt; of interest on a Convertible Note and incurred $&lt;span id="xdx_908_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBMO1eJwiZXi" title="Loss on settlement of convertible debt"&gt;477,221&lt;/span&gt; of
    loss on settlement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z96iryR5Kbn2" title="Common stock issued for conversion of convertible debt, shares"&gt;10,650&lt;/span&gt;
    shares of common stock issued for vesting of restricted stock units.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20220101__20221231_zK4bFGW68v1d"&gt;105&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for conversion of $&lt;span id="xdx_90F_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20220101__20221231_zCR0LvynQrpk"&gt;16,340
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of accrued interest&lt;/span&gt;.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--CommonStockVestingOfRestrictedStockUnit_c20220101__20221231_zTGhXRDb9rbf" title="Common stock vesting of restricted stock unit"&gt;3,500&lt;/span&gt;
    shares of common stock upon vesting of restricted stock units.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--StockIssuedUponCompletionShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm82jSpb10G9" title="Common stock issued for cash, shares"&gt;352,443&lt;/span&gt;
    shares of common stock upon completion of the Company&#x2019;s initial public offering (including the exercise of the underwriter&#x2019;s overallotment option),
and the immediate exercise of warrants issued as part of the IPO Units, for net proceeds of $&lt;span id="xdx_90D_ecustom--StockIssuedUponCompletion_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztBO8w1FCG9i" title="Stock issued upon completion"&gt;9,951,356&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredShares_pp0p0_c20220101__20221231_zMXs1V3yATd" title="Number shares issued for conversion of note, shares"&gt;42,113&lt;/span&gt;
    shares of common stock upon the automatic conversion of preferred shares and &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesConversionOfDividends_pp0p0_c20220101__20221231_zeGN8oiBf77k" title="Number shares issued for conversion dividends payable, shares"&gt;12,553&lt;/span&gt;
    shares of common stock to settle cumulative dividends on the preferred shares totaling  $&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodValueDividendsPayable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxo9SNpEoe9d" title="Common stock issued for dividends payable"&gt;402,064&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;A total of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zxyDKKIWjKuk"&gt;36,876&lt;/span&gt;
                                                                              shares of common stock issued to the lenders upon conversion of the 2022 Convertible Notes, including &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_z1Xao5Bob1b1" title="Number of shares of common stock issued for exercise of warrants"&gt;18,438&lt;/span&gt;
                                                                              shares of common stock issued upon the conversion of the 2022 Convertible Notes into units with an estimated fair value of
                                                                              $&lt;span id="xdx_909_eus-gaap--GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c20220101__20221231_zbf8lmaUR3k9"&gt;1,198,438&lt;/span&gt; at settlement, and &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zrdc6TSg0esi"&gt;18,438&lt;/span&gt;
                                                                              shares of common stock upon the exercise of the common stock warrants, for total proceeds of $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleNoteDerivativeMember_zr3w3mA5VSn5"&gt;1,475&lt;/span&gt;.&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;A total of &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThousandTwentyOneNotesMember_zcDW6A0xy2Ql"&gt;66,250&lt;/span&gt;
                                                                              shares of common stock upon the exercise of warrants and settlement of the December 2021 Notes and certain August 2022 Notes .
                                                                              Includes &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zPGVu9X1DeC1" title="Shares exercised"&gt;62,500&lt;/span&gt; shares of common stock issued upon the exercise and settlement of the December 2021 Notes with an estimated fair
                                                                              value of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231_zjIknkL1dEr" title="Common stock issued for cash upon initial public offering and exercise of warrants"&gt;2,031,249&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231_zQbLTUGQQzi5" title="Principal balance"&gt;3,750&lt;/span&gt; shares of common stock issued upon the exercise and settlement of certain August 2022 Notes with an
                                                                              estimated fair value of $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoNotesMember_zJolIab5z3z"&gt;121,875&lt;/span&gt;.&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zHEE3kox8S48"&gt;22,535&lt;/span&gt; shares of common stock upon the cashless exercise of warrants issued
to Boustead Securities LLC for placement agent and underwriter services provided to the Company&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series
A Preferred Shares&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&#x2019;s
common stock upon the closing of the sale of shares of common stock to the public in a qualified offering (at a 10% discount to the
initial public offering price, as set forth in the Series A certificate of designation) or upon listing of the Company&#x2019;s
common stock on a national securities exchange at a fixed price. The Series A Preferred Stock, while outstanding, accrued cumulative dividends at a
rate of &lt;span id="xdx_908_ecustom--CumulativeDividendsPercentage_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBwB2pdVcS3h" title="Cumulative dividends percentage"&gt;8.5&lt;/span&gt;%
per annum. In addition, the Series A Preferred Stock is callable by the Company, at a price equal to the stated value of the Series
A Preferred Stock ($&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdvc3pjAqQeh" title="Preferred stock value share"&gt;1,000&lt;/span&gt;
per share), plus accrued and unpaid cumulative dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2022, the Company and holders of the Series A Preferred Stock agreed to modifications of the Series A certificate of designation
which changed the definition of a &#x201c;Qualified IPO&#x201d; by lowering the minimum required proceeds to $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220430__srt--RangeAxis__srt--MinimumMember_ze0aX768wD2h"&gt;10,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and removing the minimum per share IPO price,
and changed the conversion price upon the listing of the Company&#x2019;s common stock from $&lt;span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220401__20220430__srt--RangeAxis__srt--MinimumMember_zua3GSvpnDZ5"&gt;99.92
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share to $&lt;span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220401__20220430__srt--RangeAxis__srt--MaximumMember_zgy4dbYdgdv9"&gt;40.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The Company determined that these
changes represented a substantial change in the terms of the Series A Preferred Stock and accounted for the changes as an extinguishment.
The Company recognized the excess of the post-amendment fair value of the Series A Preferred Stock over its carrying value as a deemed
dividend of $&lt;span id="xdx_90E_ecustom--DeemedDividend_c20220101__20221231_zISNNccnJ8b" title="Deemed dividend"&gt;439,427&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which increases net loss attributable to common stockholders during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022 and upon completion of its initial public offering, the Company converted &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXJuvuls14Dg" title="Converted shares"&gt;1,213&lt;/span&gt;
shares of Series A Preferred Stock into &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zezrTqDjoPjc" title="Stock issued for cash, shares"&gt;42,113&lt;/span&gt;
shares of common stock, based on a conversion price of &lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionRatio_iI_uPure_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXiemcZ6GUL2" title="Conversion price percentage"&gt;90&lt;/span&gt;%
of the per share IPO price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXWzm5lHgLsd" title="Share price"&gt;32.00&lt;/span&gt;
per share, resulting in a discounted conversion price of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhe5cDcFIHUi" title="conversion price"&gt;28.80&lt;/span&gt;
per share. Based on the nature of the settlement (as the exercise of a share-settled redemption feature) the Company recognized
a deemed contribution of $&lt;span id="xdx_90D_ecustom--DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends_c20220101__20221231_zCwQGOw28NSl" title="Deemed contribution"&gt;31,423&lt;/span&gt; during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company accrued $&lt;span id="xdx_901_eus-gaap--CumulativeDividends_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2gKCbTpzqQf" title="Cumulative dividends"&gt;71,009&lt;/span&gt; for the &lt;span id="xdx_909_ecustom--CumulativeDividendsPercentage_dp_uPure_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGEXxzV26fXb" title="Cumulative dividends percentage"&gt;8.5&lt;/span&gt;% cumulative dividends on the Series A Preferred stock, and
as of the date of conversion of the Series A Preferred Stock, the total cumulative dividends accrued were equal to $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuSkbBGJR2bd" title="Stock issued for conversion, vallue"&gt;402,064&lt;/span&gt;. Upon the
conversion of the Series A Preferred Stock, the cumulative dividends were also converted into &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGWSrwY7YB0g" title="Cumulative dividends, shares"&gt;12,553&lt;/span&gt; shares of the Company&#x2019;s common
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the Company had no shares of Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--WarrantsDescription_c20220101__20221231_zhMFkvoqAKeg" title="Warrants description"&gt;The
Series A Preferred Stock sold in the Company&#x2019;s 2018 and 2019 private placement offerings included warrants to be issued upon
the earlier of a closing of the sale of shares of common stock to the public or upon a listing of the Company&#x2019;s common stock.
The warrants will be exercisable for a period of three years after the date of issuance at an exercise price contingent on the terms
of the public offering. The initial form of the warrants were expected to include contingent call features based on the terms of the
public offering. As originally drafted, if an initial public offering occurs at a price at or above $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zSPV5KxElvHk" title="Class of warrant or right, exercise price of warrants or rights"&gt;111.04&lt;/span&gt;, then the warrants are
callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise price. In the scenario where the common
stock is listed with a common stock issuance price below $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zKLZSjEWej99" title="Class of warrant or right, exercise price of warrants or rights"&gt;111.04&lt;/span&gt;, then the warrants are callable if the 20-day VWAP of the common
stock is at or above the $&lt;span id="xdx_907_ecustom--WarrantSharePrice_iI_c20221231_zwhTOC8pVm83" title="Warrant share price"&gt;166.56&lt;/span&gt; exercise price. Upon the issuance of the warrants in September 2022, the contingent call features
were not included in the agreements. Given the variability in the number of warrants and exercise price, the detachable warrants
contained terms and features that gave rise to liability classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In April 2022, the Company modified the terms of the Series A Preferred
Stock as discussed above. These modifications impacted the potential terms of these contingently issuable warrants (potential warrant
shares and exercise price). The impact of this modification was reflected in the fair value of the warrant obligation recorded during
the interim periods within the year ended December 31, 2022. Upon
completion of our initial public offering, the Series A Preferred Stock was converted, and warrants were issued in relation to the conversion,
with each warrant then exercisable at the equivalent of the per share initial public offering price. In total, the Company issued warrants
to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhjYBEwkaq45" title="Warrants shares"&gt;42,113&lt;/span&gt; shares of common stock, at an exercise price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z07rLdSPBaXg" title="Share price"&gt;32.00&lt;/span&gt; per share in settlement of this warrant obligation. In addition,
upon the issuance of these warrants, the Company reassessed the classification accounting and concluded that the issued warrants met
the requirements for classification in stockholders&#x2019; equity. The Company reclassified the then fair value of these warrants, totaling
$&lt;span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6rHDj3XOS1j" title="Additional paid in capital"&gt;756,723&lt;/span&gt;, to additional paid in capital in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liability related to the Series A Preferred Stock was $&lt;span id="xdx_90A_ecustom--WarrantLiability_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zijLF2pHWOn7" title="Warrants liability"&gt;0&lt;/span&gt;
as of December 31, 2022. For the period ended December 31, 2022 (prior to reclassification), the change in fair value of warrant
obligation liability was a loss of $&lt;span id="xdx_90C_ecustom--WarrantObligationLiability_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1BslpzMON86" title="Warrants obligation liability"&gt;421,768&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants Issued to Boustead as Placement Agent
or Underwriter&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;For services provided in relation to the 2022 Convertible
Notes and August 2022 Notes offerings, Boustead received warrants to purchase &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220831_zlaXxGjIK6u2" title="Interest rate"&gt;10%&lt;/span&gt; of the shares of common stock issuable upon conversion
of the 2022 Convertible Notes, at the conversion price of the notes. Upon conversion, the warrant became exercisable for a total of &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zzZCbYOypgg5"&gt;2,582&lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoConvertibleBridgeNotesMember_zxYSEOIYeGQ9"&gt;16.00&lt;/span&gt; per share. These warrants were accounted for under ASC 718 and classified as liabilities
due to the fact that the conversion of the 2022 Convertible Notes would impact their fair value. These warrants were exercised on a cashless
basis in September 2022. The Company reclassified the then fair value of the warrants of $&lt;span id="xdx_909_ecustom--WarrantLiabilitiesExercised_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityBousteadPlacementAgentWarrantsMember_zsWthAVovwJ4" title="Warrant liabilities exercised"&gt;64,140&lt;/span&gt; at the initial public offering to equity, with the estimated
fair value based on a Black-Scholes model, with inputs that included an estimated fair value of the Company&#x2019;s common stock of $&lt;span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831_zEX66QT8buA" title="Conversion price per share"&gt;32.50&lt;/span&gt;,
an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831_zoa3je9Yw6Kb" title="Exercise price of warrants"&gt;16.00&lt;/span&gt; per share, a remaining term of &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220831_z7pwhPfE80Ud"&gt;4.5&lt;/span&gt; years, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220801__20220831_zegwdnEEv8cd"&gt;82.5%&lt;/span&gt; volatility and a risk free rate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220801__20220831_ze2LVFKjUYKj"&gt;3.43%&lt;/span&gt;. &#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Boustead acted as placement agent for the August 2022
Notes and received warrants to purchase &lt;span id="xdx_904_ecustom--IssuanceOfWarrantsShares_c20220801__20220801__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zBWMmocLKco4" title="Issuance of warrants shares"&gt;625&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220801_zlLQGpblHuI3" title="Exercise price of warrants"&gt;20.00&lt;/span&gt; per share. These warrants were classified
in equity and exercised on a cashless basis in September 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Boustead additionally received a warrant to purchase
&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zP9zmXLeAhEc" title="Four year warrant to purchase"&gt;21,453&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zo1W4YbGHOAa"&gt;97.52&lt;/span&gt; per share upon the closing of the IPO. These warrants were classified in
equity and exercised on a cashless basis in September 2022. Upon the closing of the overallotment option to the IPO, Boustead received
an additional warrant to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_znYBxCL7ikwl" title="Four year warrant to purchase"&gt;3,218&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIFBmHSGKKoi"&gt;97.52&lt;/span&gt; per share. The Company determined that these warrants should be classified in equity.
The fair value of the warrant issued at the closing of the IPO was estimated to be $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zUZUtgjgxeQ5" title="Fair value adjustment of warrants"&gt;426,752&lt;/span&gt; using a Black-Scholes model, with inputs that
included an estimated fair value of the Company&#x2019;s common stock of $&lt;span id="xdx_90F_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zUEfIv8BIgM3" title="Exercise price"&gt;32.50&lt;/span&gt;, an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zXA1uFVP0yQ6" title="Exercise price of warrant"&gt;97.52&lt;/span&gt; per share, a &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zDGIsWnXriP3" title="Warrant term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3052"&gt;five-year&lt;/span&gt;&lt;/span&gt; term,
&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_zC6zYGIE33ha" title="Volatility rate"&gt;101.8&lt;/span&gt;% volatility and a risk free rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--BlackScholesModelMember_z5q1wYXMoDc3" title="Risk free rate"&gt;3.27&lt;/span&gt;%. The fair value of the warrant issued at the closing of the overallotment option was estimated
to be $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zMEmyrWnrd5h" title="Fair value adjustment of warrants"&gt;111,296&lt;/span&gt; using a Black-Scholes model, with inputs that included an estimated fair value of the Company&#x2019;s common stock of $&lt;span id="xdx_901_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zCkzORPa939j" title="Exercise price"&gt;50.88&lt;/span&gt;,
an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBAJJgavIVIi" title="Exercise price of warrant"&gt;97.52&lt;/span&gt; per share, a &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBlCg0hh75ij" title="Warrant term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3064"&gt;five-year&lt;/span&gt;&lt;/span&gt; term, &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsJZMdsOaRmg" title="Volatility rate"&gt;101.4&lt;/span&gt;% volatility and a risk free rate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220801__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zXxjeYY46rya" title="Risk free rate"&gt;3.74&lt;/span&gt;%. The fair value of these warrants
was recorded to additional paid in capital and represented an issuance cost of the initial public offering (recorded as a deduction to
additional paid in capital). These warrants remain outstanding
as of December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Alto Opportunity Master Fund, SPC&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zam6FgbDoIvd" title="Number of warrants to purchase"&gt;8,909&lt;/span&gt; shares of common stock, at an
exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_ziFSekf5Pqm7" title="Exercisable price per share"&gt;18.80&lt;/span&gt; per share (Note 6). In addition, Alto was granted warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zxfR1IUHlnT6" title="Number of warrants to purchase"&gt;127,260&lt;/span&gt; shares of common stock, at an
exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zCr58QMvgMwh" title="Exercise price per share"&gt;18.80&lt;/span&gt; per share (Note 6, 8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zQPSvyFjdRPc" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance"&gt;62,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;8.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUtrsMLQInh5" title="Weighted average life (years), outstanding balance"&gt;4.99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of warrants outstanding, granted"&gt;270,910&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price, outstanding granted"&gt;14.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted average life (years), granted"&gt;4.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9CkaYjHRKW6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, exercised"&gt;(285,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zcPe5lHTomfb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding exercised"&gt;9.58&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance"&gt;47,831&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;35.77&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted average life (years), outstanding balance"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted - Boustead&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted"&gt;8,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted"&gt;18.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted average life (years), granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Granted - Ayrton&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted"&gt;127,260&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted"&gt;18.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted average life (years), granted"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance"&gt;184,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;23.21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted average life (years), outstanding balance"&gt;2.77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted
    warrants include those granted on the issuance of the August 2022 Promissory Notes&lt;/span&gt; (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoPromissoryNotesMember_z8eerCsA7Vic" title="Granted warrants, shares"&gt;3,750&lt;/span&gt; warrants); Notes Payable &#x2013; Related
    Parties  (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zRpN5cBP0s45" title="Granted warrants, shares"&gt;2,500&lt;/span&gt; warrants); upon conversion of the
    Series A Preferred Shares (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zScqfutTyNe1" title="Converted shares issued"&gt;42,114&lt;/span&gt; warrants);
    automatic conversion of the 2022 Convertible Notes  (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyTwoConvertibleNotesMember_zts6c3ymErAi" title="Granted warrants, shares"&gt;18,447&lt;/span&gt; warrants); issued during the IPO, including overallotment option (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8ldYZ9uZqP4" title="Number of shares issued"&gt;176,222&lt;/span&gt; warrants) and issued to Boustead Securities LLC  (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--BousteadSecuritiesLLCMember_zWH28ubFIhwb" title="Number of shares issued"&gt;27,877&lt;/span&gt; warrants).&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Exercised warrants include the exercise of the warrants
issued with the December 2021 Notes (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyOnePromissoryNotesMember_z3vUeINzv4nc" title="Number of shares issued"&gt;62,500
&lt;/span&gt;warrants); the exercise of the warrants issued with the August 2022 Notes (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zUXECz6R3mD5" title="Number of shares issued"&gt;3,750
&lt;/span&gt;warrants); the exercise of the warrants issued upon conversion of the Convertible Notes (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zV8n48EOlaxg" title="Converted shares issued"&gt;18,447&lt;/span&gt;
warrants); and the exercise of the warrants issued during the IPO, including overallotment option (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiePm976S3i" title="Number of shares issued"&gt;176,222&lt;/span&gt;
warrants), and warrants exercised on a cashless basis (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zBFrdGlEuIid" title="Number of shares issued"&gt;24,660&lt;/span&gt;
warrants).&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_z33AkX1pnRpc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
intrinsic value of the warrants as of December 31, 2023 is $&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20231231_zEluMLI6PNGh" title="Aggregate intrinsic value of warrants"&gt;0&lt;/span&gt;. All of the outstanding warrants are exercisable as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#x2019;s
compensation committee. We have reserved &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zrwC5T6Afeh" title="Common stock reserved for future issuance"&gt;3,000,000&lt;/span&gt; shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
December 31, 2023, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zZqAzrExO8Pf" title="Share granted under equity incentive plan"&gt;84,779&lt;/span&gt; shares have been granted under the 2018 Equity Incentive Plan, of which &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231_zdTmHNQqbfgf" title="Number of shares vested under plan"&gt;60,048&lt;/span&gt; shares have vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
may grant restricted stock units (&#x201c;RSU&#x201d;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, pursuant to agreements with directors, officers and consultants, &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zgXIzzjME8hg" title="Restricted stock award granted shares"&gt;32,415&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zr5k4LAu04y5" title="Restricted stock award granted shares"&gt;4,449&lt;/span&gt; RSUs
with a value of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zOZ0Qy75taC1" title="Restricted stock award granted value"&gt;352,400&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsOfficersAndConsultantsMember_zlWaoMfX80Tl" title="Restricted stock award granted value"&gt;100,000&lt;/span&gt; were granted, respectively. Compensation expense for the vesting RSUs were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zc5RchDtdYW" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;span id="xdx_8BF_zWWEFBZRefcb" style="display: none"&gt;Schedule
of Restricted Stock Units&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20230101__20231231_zO2ONL04juDe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20220101__20221231_zsR9hqKKMoLh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFSDfn5qktl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Recognized in general and administrative expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;115,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;105,582&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zP0z6A5Wtzm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Recognized in research and development expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;66,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;131,965&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zypbbKjXmu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zBje0QYIgd4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, there was $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEzBhMNnlrN8" title="Unrecognized compensation cost"&gt;231,550&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5mtOdUbbZX" title="Unrecognized compensation cost"&gt;61,111&lt;/span&gt;, respectively, of unrecognized stock-based compensation expense
related to unvested RSUs, which is expected to be recognized over a weighted-average period of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXuwnfeYO91d" title="Weighted Average Life (Years), Outstanding Ending"&gt;1.06&lt;/span&gt; years
and &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSrNXYP6sZG7" title="Weighted Average Life (Years), Outstanding Ending"&gt;1.83&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding the Restricted Stock Units issued follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zXV9pKVawChd" style="display: none"&gt;Schedule of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Outstanding, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;2,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;185.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;4,449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;22.48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Vested (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE3XiT4Awrd8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"&gt;(3,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zczNKvkuf77f" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;116.48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Outstanding, December 31, 2022 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;2,966&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;22.48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;32,415&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;10.88&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Vested (as restated)&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"&gt;(10,650&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;12.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Ending Balance"&gt;24,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance"&gt;11.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_zV6HtUCMIcil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002937"
      unitRef="Shares">297625</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002939"
      unitRef="USD">1925700</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002941"
      unitRef="USD">294927</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002943"
      unitRef="USD">477221</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact002945"
      unitRef="Shares">10650</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002946"
      unitRef="Shares">105</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002947"
      unitRef="USD">16340</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:CommonStockVestingOfRestrictedStockUnit
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002949"
      unitRef="Shares">3500</SHPH:CommonStockVestingOfRestrictedStockUnit>
    <SHPH:StockIssuedUponCompletionShares
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531"
      decimals="INF"
      id="Fact002951"
      unitRef="Shares">352443</SHPH:StockIssuedUponCompletionShares>
    <SHPH:StockIssuedUponCompletion
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact002953"
      unitRef="USD">9951356</SHPH:StockIssuedUponCompletion>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfPreferredShares
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002955"
      unitRef="Shares">42113</SHPH:StockIssuedDuringPeriodSharesConversionOfPreferredShares>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfDividends
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002957"
      unitRef="Shares">12553</SHPH:StockIssuedDuringPeriodSharesConversionOfDividends>
    <SHPH:StockIssuedDuringPeriodValueDividendsPayable
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002959"
      unitRef="USD">402064</SHPH:StockIssuedDuringPeriodValueDividendsPayable>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember"
      decimals="INF"
      id="Fact002960"
      unitRef="Shares">36876</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember"
      decimals="INF"
      id="Fact002962"
      unitRef="Shares">18438</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002963"
      unitRef="USD">1198438</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember"
      decimals="INF"
      id="Fact002964"
      unitRef="Shares">18438</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_TwentyTwentyTwoConvertibleNoteDerivativeMember"
      decimals="0"
      id="Fact002965"
      unitRef="USD">1475</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_DecemberTwentyThousandTwentyOneNotesMember"
      decimals="INF"
      id="Fact002966"
      unitRef="Shares">66250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002968"
      unitRef="Shares">62500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact002970"
      unitRef="USD">2031249</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002972"
      unitRef="Shares">3750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoNotesMember"
      decimals="0"
      id="Fact002973"
      unitRef="USD">121875</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact002974"
      unitRef="Shares">22535</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <SHPH:CumulativeDividendsPercentage
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002976"
      unitRef="Pure">0.085</SHPH:CumulativeDividendsPercentage>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002978"
      unitRef="USDPShares">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012022-04-30_srt_MinimumMember"
      decimals="INF"
      id="Fact002979"
      unitRef="Shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-04-012022-04-30_srt_MinimumMember"
      decimals="INF"
      id="Fact002980"
      unitRef="USDPShares">99.92</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-04-012022-04-30_srt_MaximumMember"
      decimals="INF"
      id="Fact002981"
      unitRef="USDPShares">40.00</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <SHPH:DeemedDividend
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002983"
      unitRef="USD">439427</SHPH:DeemedDividend>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact002985"
      unitRef="Shares">1213</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002987"
      unitRef="Shares">42113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002989"
      unitRef="Pure">90</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002991"
      unitRef="USDPShares">32.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002993"
      unitRef="USDPShares">28.80</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <SHPH:DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002995"
      unitRef="USD">31423</SHPH:DeemedContributionOfConversionOfPreferredStockAndSettlementOfPreferredStockDividends>
    <us-gaap:CumulativeDividends
      contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact002997"
      unitRef="USD">71009</us-gaap:CumulativeDividends>
    <SHPH:CumulativeDividendsPercentage
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact002999"
      unitRef="Pure">0.085</SHPH:CumulativeDividendsPercentage>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact003001"
      unitRef="USD">402064</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact003003"
      unitRef="Shares">12553</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <SHPH:WarrantsDescription contextRef="From2022-01-012022-12-31" id="Fact003005">The
Series A Preferred Stock sold in the Company&#x2019;s 2018 and 2019 private placement offerings included warrants to be issued upon
the earlier of a closing of the sale of shares of common stock to the public or upon a listing of the Company&#x2019;s common stock.
The warrants will be exercisable for a period of three years after the date of issuance at an exercise price contingent on the terms
of the public offering. The initial form of the warrants were expected to include contingent call features based on the terms of the
public offering. As originally drafted, if an initial public offering occurs at a price at or above $111.04, then the warrants are
callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise price. In the scenario where the common
stock is listed with a common stock issuance price below $111.04, then the warrants are callable if the 20-day VWAP of the common
stock is at or above the $166.56 exercise price. Upon the issuance of the warrants in September 2022, the contingent call features
were not included in the agreements. Given the variability in the number of warrants and exercise price, the detachable warrants
contained terms and features that gave rise to liability classification.</SHPH:WarrantsDescription>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact003007"
      unitRef="USDPShares">111.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact003009"
      unitRef="USDPShares">111.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SHPH:WarrantSharePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact003011"
      unitRef="USDPShares">166.56</SHPH:WarrantSharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact003013"
      unitRef="Shares">42113</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact003015"
      unitRef="USDPShares">32.00</us-gaap:SharePrice>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact003017"
      unitRef="USD">756723</us-gaap:AdditionalPaidInCapital>
    <SHPH:WarrantLiability
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact003019"
      unitRef="USD">0</SHPH:WarrantLiability>
    <SHPH:WarrantObligationLiability
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact003021"
      unitRef="USD">421768</SHPH:WarrantObligationLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-08-31"
      decimals="INF"
      id="Fact003023"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact003024"
      unitRef="Shares">2582</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember_custom_TwentyTwentyTwoConvertibleBridgeNotesMember"
      decimals="INF"
      id="Fact003025"
      unitRef="USDPShares">16.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SHPH:WarrantLiabilitiesExercised
      contextRef="From2022-08-012022-08-31_custom_WarrantLiabilityBousteadPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact003027"
      unitRef="USD">64140</SHPH:WarrantLiabilitiesExercised>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-08-012022-08-31"
      decimals="INF"
      id="Fact003029"
      unitRef="USDPShares">32.50</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-31"
      decimals="INF"
      id="Fact003031"
      unitRef="USDPShares">16.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-08-31" id="Fact003032">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-08-012022-08-31"
      decimals="INF"
      id="Fact003033"
      unitRef="Pure">0.825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-08-012022-08-31"
      decimals="INF"
      id="Fact003034"
      unitRef="Pure">0.0343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <SHPH:IssuanceOfWarrantsShares
      contextRef="From2022-08-012022-08-01_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact003036"
      unitRef="Shares">625</SHPH:IssuanceOfWarrantsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-01"
      decimals="INF"
      id="Fact003038"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact003040"
      unitRef="Shares">21453</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact003041"
      unitRef="USDPShares">97.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact003043"
      unitRef="Shares">3218</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact003044"
      unitRef="USDPShares">97.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember"
      decimals="0"
      id="Fact003046"
      unitRef="USD">426752</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember"
      decimals="INF"
      id="Fact003048"
      unitRef="USDPShares">32.50</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember"
      decimals="INF"
      id="Fact003050"
      unitRef="USDPShares">97.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember"
      decimals="INF"
      id="Fact003054"
      unitRef="Pure">1.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_custom_BlackScholesModelMember"
      decimals="INF"
      id="Fact003056"
      unitRef="Pure">0.0327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      id="Fact003058"
      unitRef="USD">111296</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact003060"
      unitRef="USDPShares">50.88</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact003062"
      unitRef="USDPShares">97.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact003066"
      unitRef="Pure">1.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-08-012022-08-31_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact003068"
      unitRef="Pure">0.0374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember"
      decimals="INF"
      id="Fact003070"
      unitRef="Shares">8909</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember"
      decimals="INF"
      id="Fact003072"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact003074"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact003076"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-012023-12-31" id="Fact003078">&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zQPSvyFjdRPc" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance"&gt;62,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;8.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUtrsMLQInh5" title="Weighted average life (years), outstanding balance"&gt;4.99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of warrants outstanding, granted"&gt;270,910&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price, outstanding granted"&gt;14.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted average life (years), granted"&gt;4.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9CkaYjHRKW6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, exercised"&gt;(285,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zcPe5lHTomfb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding exercised"&gt;9.58&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance"&gt;47,831&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;35.77&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted average life (years), outstanding balance"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted - Boustead&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted"&gt;8,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted"&gt;18.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted average life (years), granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Granted - Ayrton&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted"&gt;127,260&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding granted"&gt;18.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted average life (years), granted"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, balance"&gt;184,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;23.21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted average life (years), outstanding balance"&gt;2.77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted
    warrants include those granted on the issuance of the August 2022 Promissory Notes&lt;/span&gt; (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyTwoPromissoryNotesMember_z8eerCsA7Vic" title="Granted warrants, shares"&gt;3,750&lt;/span&gt; warrants); Notes Payable &#x2013; Related
    Parties  (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zRpN5cBP0s45" title="Granted warrants, shares"&gt;2,500&lt;/span&gt; warrants); upon conversion of the
    Series A Preferred Shares (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zScqfutTyNe1" title="Converted shares issued"&gt;42,114&lt;/span&gt; warrants);
    automatic conversion of the 2022 Convertible Notes  (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyTwoConvertibleNotesMember_zts6c3ymErAi" title="Granted warrants, shares"&gt;18,447&lt;/span&gt; warrants); issued during the IPO, including overallotment option (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8ldYZ9uZqP4" title="Number of shares issued"&gt;176,222&lt;/span&gt; warrants) and issued to Boustead Securities LLC  (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--BousteadSecuritiesLLCMember_zWH28ubFIhwb" title="Number of shares issued"&gt;27,877&lt;/span&gt; warrants).&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Exercised warrants include the exercise of the warrants
issued with the December 2021 Notes (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandAndTwentyOnePromissoryNotesMember_z3vUeINzv4nc" title="Number of shares issued"&gt;62,500
&lt;/span&gt;warrants); the exercise of the warrants issued with the August 2022 Notes (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zUXECz6R3mD5" title="Number of shares issued"&gt;3,750
&lt;/span&gt;warrants); the exercise of the warrants issued upon conversion of the Convertible Notes (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zV8n48EOlaxg" title="Converted shares issued"&gt;18,447&lt;/span&gt;
warrants); and the exercise of the warrants issued during the IPO, including overallotment option (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiePm976S3i" title="Number of shares issued"&gt;176,222&lt;/span&gt;
warrants), and warrants exercised on a cashless basis (&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zBFrdGlEuIid" title="Number of shares issued"&gt;24,660&lt;/span&gt;
warrants).&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003080"
      unitRef="Shares">62500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003082"
      unitRef="USDPShares">8.00</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531"
      id="Fact003084">P4Y11M26D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact003086"
      unitRef="Shares">270910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact003088"
      unitRef="USDPShares">14.57</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      id="Fact003090">P4Y8M4D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531"
      decimals="INF"
      id="Fact003092"
      unitRef="Shares">-285579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531"
      decimals="INF"
      id="Fact003094"
      unitRef="USDPShares">9.58</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003096"
      unitRef="Shares">47831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003098"
      unitRef="USDPShares">35.77</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember29542531"
      id="Fact003100">P2Y9M10D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact003102"
      unitRef="Shares">8909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact003104"
      unitRef="USDPShares">18.80</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      id="Fact003106">P5Y</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      decimals="INF"
      id="Fact003108"
      unitRef="Shares">127260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      decimals="INF"
      id="Fact003110"
      unitRef="USDPShares">18.80</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      id="Fact003112">P4Y</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828"
      decimals="INF"
      id="Fact003114"
      unitRef="Shares">184000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember29544828"
      decimals="INF"
      id="Fact003116"
      unitRef="USDPShares">23.21</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact003118">P2Y9M7D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_AugustTwoThousandAndTwentyTwoPromissoryNotesMember"
      decimals="INF"
      id="Fact003121"
      unitRef="Shares">3750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_NotesPayableRelatedPartiesMember"
      decimals="INF"
      id="Fact003123"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact003125"
      unitRef="Shares">42114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact003127"
      unitRef="Shares">18447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact003129"
      unitRef="Shares">176222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact003131"
      unitRef="Shares">27877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_custom_AugustTwoThousandAndTwentyOnePromissoryNotesMember"
      decimals="INF"
      id="Fact003133"
      unitRef="Shares">62500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_custom_NotesPayableRelatedPartiesMember"
      decimals="INF"
      id="Fact003135"
      unitRef="Shares">3750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="INF"
      id="Fact003137"
      unitRef="Shares">18447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact003139"
      unitRef="Shares">176222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003141"
      unitRef="Shares">24660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003143"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact003145"
      unitRef="Shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact003147"
      unitRef="Shares">84779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003149"
      unitRef="Shares">60048</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember"
      decimals="INF"
      id="Fact003151"
      unitRef="Shares">32415</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember"
      decimals="INF"
      id="Fact003153"
      unitRef="Shares">4449</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember"
      decimals="0"
      id="Fact003155"
      unitRef="USD">352400</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOfficersAndConsultantsMember"
      decimals="0"
      id="Fact003157"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003159">&lt;p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zc5RchDtdYW" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;span id="xdx_8BF_zWWEFBZRefcb" style="display: none"&gt;Schedule
of Restricted Stock Units&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20230101__20231231_zO2ONL04juDe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20220101__20221231_zsR9hqKKMoLh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;(as restated)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFSDfn5qktl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Recognized in general and administrative expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;115,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;105,582&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zP0z6A5Wtzm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Recognized in research and development expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;66,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;131,965&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zypbbKjXmu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact003161"
      unitRef="USD">115000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact003162"
      unitRef="USD">105582</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact003164"
      unitRef="USD">66960</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact003165"
      unitRef="USD">131965</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003167"
      unitRef="USD">181960</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003168"
      unitRef="USD">237547</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact003170"
      unitRef="USD">231550</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact003172"
      unitRef="USD">61111</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546"
      id="Fact003174">P1Y21D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562"
      id="Fact003176">P1Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003178">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding the Restricted Stock Units issued follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zXV9pKVawChd" style="display: none"&gt;Schedule of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Outstanding, December 31, 2021 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;2,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;185.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;4,449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;22.48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Vested (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE3XiT4Awrd8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"&gt;(3,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zczNKvkuf77f" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;116.48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Outstanding, December 31, 2022 (as restated)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;2,966&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;22.48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;32,415&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;10.88&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Vested (as restated)&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"&gt;(10,650&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;12.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Outstanding, Ending Balance"&gt;24,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance"&gt;11.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003180"
      unitRef="Shares">2017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003182"
      unitRef="USDPShares">185.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562"
      decimals="INF"
      id="Fact003184"
      unitRef="Shares">4449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562"
      decimals="INF"
      id="Fact003186"
      unitRef="USDPShares">22.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562"
      decimals="INF"
      id="Fact003188"
      unitRef="Shares">3500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember29544562"
      decimals="INF"
      id="Fact003190"
      unitRef="USDPShares">116.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003192"
      unitRef="Shares">2966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003194"
      unitRef="USDPShares">22.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546"
      decimals="INF"
      id="Fact003196"
      unitRef="Shares">32415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546"
      decimals="INF"
      id="Fact003198"
      unitRef="USDPShares">10.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546"
      decimals="INF"
      id="Fact003200"
      unitRef="Shares">10650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember29544546"
      decimals="INF"
      id="Fact003202"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003204"
      unitRef="Shares">24731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003206"
      unitRef="USDPShares">11.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-012023-12-31" id="Fact003208">&lt;p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zM0LnaDFnXNf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_82A_z4aTbusRJlK5"&gt;Derivative Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Assumptions Used in Accounting for Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Alto Opportunity Master Fund, SPC&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_z11cwYracUa3" title="Number of shares warrant to purchase"&gt;127,260&lt;/span&gt;
shares of common stock, with an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zIh20NrCUX41" title="Exercise price per share"&gt;18.80&lt;/span&gt;
per share, valued at inception at $&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20230131_zH7frUfNB0S" title="Warrants price"&gt;1,189,000&lt;/span&gt;
and as of December 31, 2023, at $&lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20231231_zg9NwO9znFZi" title="Warrants price"&gt;410,660&lt;/span&gt;. The Company determined our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy
the classification as equity instruments due to the existence of a certain net cash settlement provision that is not within the sole
control of the Company. In addition, there are certain down round provisions that could reduce the exercise price if the Company
issues securities at lower prices in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined our derivative liability from the noteholder&#x2019;s Acceleration Option for the Alto Convertible Note is not clearly
and closely related to the host and should be thus accounted for as a bifurcated derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023, and for each reporting period. Key inputs for the simulation are summarized below. The Monte Carlo simulation
uses an implied VWAP for each valuation date. The implied VWAP was backsolved by setting the summation of the parts (e.g., derivatives
and debt without derivatives) equal to the cash proceeds. The simulation was then iterated and manipulated to solve for the implied share
price, which was approximately $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TLyu8dorpa" title="Share price"&gt;12.64
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (or an approximate &lt;span id="xdx_902_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjE6Jw38fbK2" title="Derivative discount percentage"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
discount to the quoted market VWAP on January 11, 2023). Additionally, the Company estimates probability for various specific scenarios
impacting the warrant valuation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_znb7Uj9EztTl" style="display: none"&gt;Schedule of Monte Carlo Simulation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net cash settlement and down round key valuation inputs &#x2013; Alto Warrants*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 78%"&gt;Annualized volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z4g0dzX4U7zf"&gt;77.51&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z301m69d8Gyi"&gt;92.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZAEk7427avk"&gt;4.01&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zgCPUuxlHzHc"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKg_____zynIkUyUvoc5"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zx3O4OnWlhIe"&gt;18.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability assessment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZhnjkBS7Tu6"&gt;5&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zyEeLFE48kV1"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zUzGci9OyFOe"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zp3kUyM7mCF1" title="Time period (years)"&gt;0.53&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z2QZvDKXSZc8" title="Time period (years)"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_985_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zzfOPZcmFp21" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance"&gt;1,189,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (December 31, 2023)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zoconmEERXL5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value"&gt;410,660&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Alto Acceleration Option key valuation inputs*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsLip3AEalOf"&gt;34.23&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zrecJIDgSDtl"&gt;59.15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zJ1iIi9Tuuh5"&gt;4.68&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zzEjaz9gjDGe"&gt;5.60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zq9lJmRsxA0c"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zHhUsf9wJkQl"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zBDp4x7lFOLe" title="Time period (years)"&gt;0&lt;/span&gt; - &lt;span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zN3n43wPlwJ7" title="Time period (years)"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____z1a2AIcEwJo7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance"&gt;1,442,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (December 31, 2023)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zMZsZdoRik44" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value"&gt;3,852&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F02_zP9EgyZUvD22"&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F10_zpHGdXc8eMz1"&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A5_z9FqO83Hz1gf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;December 2021 Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_zjlCwF4i7uJj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In connection with the issuance of the December 2021
Notes, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative liability
as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value of the
derivative just prior to the settlement of the December 2021 Notes. Key inputs for this valuation model are summarized below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;span id="xdx_8B2_zjG7V0BTJGN6" style="display: none"&gt;Schedule
of Derivative Liability Valuation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;December 2021 Notes derivative key valuation inputs&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zCCUZkonud72" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Date&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231__us-gaap--AwardDateAxis__custom--SettlementDateMember_zi03jzsAnAh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Settlement Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Amount due upon acceleration&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcTc9BXjF7gb" title="Amount due upon acceleration"&gt;533,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zWOG2jS5GJUb" title="Amount due upon acceleration"&gt;533,973&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Carrying value of December 2021 Notes at measurement date&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIEsyqfZYvLg" title="Carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3262"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zcwi7FULk9jc" title="Carrying value"&gt;337,398&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;IPO date&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zVBlR0B9tUP7" title="IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zJw91gnzLS2j" title="IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO acceleration&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_903_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zFuITDP3UXf" title="Probability of IPO acceleration"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zpxKsbtLWcB9" title="Probability of IPO acceleration"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Probability of maturity&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zzFXbd5Og0G4" title="Probability of Maturity"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_z7lRzYZKo0S2" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3276"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Time period to maturity (years)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zX1096vaLn9i" title="Time period to maturity (years)"&gt;1.00&lt;/span&gt; years&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z6tjv8ZW9Ry1" title="Time period to maturity (years)"&gt;0.32&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Discount rate&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcAOY0484Dgi" title="Discount rate"&gt;50.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zUkS1jzZb5c9" title="Discount rate"&gt;50.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z8IXFIyc2pgh" title="Estimated fair value"&gt;367,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z11mi2p3YAV3" title="Estimated fair value"&gt;162,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z3urm4comLn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2022
Convertible Bridge Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the issuance of the 2022 Convertible Notes in February and March 2022, the Company identified certain embedded features
that required bifurcation as a combined derivative liability, including the share-settled redemption of the 2022 Convertible Notes at
a 50% discount and the automatic increase in principal of 10% if conversion does not occur within 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
classified this derivative liability as a Level 3 fair value measurement and used the a with and without probability weighted scenario
model to estimate the fair value as of each issuance date of the 2022 Convertible Notes, as well as just prior to their settlement upon
the initial public offering. Key inputs for this valuation model are summarized below.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_z5brvl3KzAle" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zD9WNYfYXy6"&gt;Schedule
of Derivative Key Valuation Inputs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022
    Convertible Notes derivative key valuation inputs*&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    Dates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Settlement Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zrI7eNI0ycE5" title="Annualized volatility"&gt;75.0&lt;/span&gt;%
    - &lt;span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z0yV9SlEpTnf" title="Annualized volatility"&gt;82.0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zKgfUKZ0UPn4" title="Annualized volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3296"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIJa6GBq3Vu9" title="Risk-free interest rate"&gt;0.6&lt;/span&gt;%
    - &lt;span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7kAtMbqmLOb" title="Risk-free interest rate"&gt;1.2&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMKLBnZnSszd" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3302"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price (implied)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zusIOIenjwY5" title="Exercise price (implied)"&gt;45.52&lt;/span&gt;
    - $&lt;span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zSrzItTHe8Xl" title="Exercise price (implied)"&gt;85.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z59iWMKVRj15" title="Exercise price (implied)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3308"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated
    IPO date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_z48Fv311BmSl" title="Estimated IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zWHulQCfI3ce" title="Estimated IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability
    of default&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember_zq8jLqAQ0tdi" title="Probability of default"&gt;50&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMACi2a6YyD" title="Probability of default"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3316"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability
    of IPO or Alternative Liquidity Event&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_znwcKoeawLJg" title="Probability of IPO or Alternative Liquidity Event"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zT1PeOh2Neth" title="Probability of IPO or Alternative Liquidity Event"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability
    of Maturity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zlGZHJ3XRNug" title="Probability of Maturity"&gt;5&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zjjniTfeAEkc" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3324"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Time
    period (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_ztMKhfW5VVmg" title="Time period (years)"&gt;0.47&lt;/span&gt;
    - &lt;span id="xdx_904_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zwX6ZWWfyt65" title="Time period (years)"&gt;1.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zwYvRAgB6W9h" title="Time period (years)"&gt;0.00&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zc3b3riNCOg1" title="Estimated fair value"&gt;221,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z86312yZwukb" title="Estimated fair value"&gt;571,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zgVopIKtfTcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;August 2022 Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_zgGEkQpbb6be" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In connection with the issuance of the August 2022
Promissory Note, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative
liability as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value
of the derivative just prior to the settlement of the August 2022 Promissory Notes. Key inputs for this valuation model are summarized
below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;span id="xdx_8B3_zXnr1bjxbu8" style="display: none"&gt;Schedule
of Derivative Issuance Valuation Inputs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;August 2022 Promissory Notes derivative key valuation inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Issuance Dates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Settlement Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Amount due upon acceleration (estimated at issuance)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zX5muKr38VWd" title="Amount due upon acceleration"&gt;50,411&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zlLZamz1oBT8" title="Amount due upon acceleration"&gt;50,438&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Carrying value of August 2022 Promissory Notes at measurement date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90C_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zVydJGz543cb" title="Carrying value"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zj9Ng4Pbbdij" title="Carrying value"&gt;4,521&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;IPO date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zbhJNV5W9Fb5" title="IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zAzR2pIn59Hh" title="IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Probability of IPO acceleration&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zQN6XCDs8M2c" title="Probability of IPO acceleration"&gt;90%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zNspkjjAgVO5" title="Probability of IPO acceleration"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Probability of maturity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zRY8a4wqnEzc" title="Probability of Maturity"&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zjb0uw9A2rnf" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3356"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Time period to maturity (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIWJR1XsIxRj" title="Time period to maturity (years)"&gt;1.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z84rwfz9M3L5" title="Time period to maturity (years)"&gt;0.91&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zIO5KOr85SO8" title="Discount rate"&gt;16.03%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zipUF0l5Eyj8" title="Discount rate"&gt;18.81%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zOHFLWCnr45d" title="Estimated fair value"&gt;45,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zbkhZ58Bq7H3" title="Estimated fair value"&gt;45,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zqWwxoGLbSTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_ziGGYyZ5pmTh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In connection with the issuance of the August 2022
Convertible Notes, the Company identified certain embedded features that required bifurcation as a combined derivative liability, including
the share-settled redemption of the 2022 Convertible Notes at a 50% discount and the automatic increase in principal of 10% if conversion
does not occur within 12 months. Key inputs for this valuation model are summarized below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;span id="xdx_8BC_zWO7z0wylKdf" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Derivative Key Valuation Inputs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;2022 Convertible Notes derivative key valuation inputs*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Settlement Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated IPO date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_zYV50vMb4Kpl" title="Estimated IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zK2pnOjpOfEl" title="Estimated IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Probability of default&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z8XT09NZrZS2" title="Probability of default"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zyickfmFFPwk" title="Probability of default"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3378"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO or Alternative Liquidity Event&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zViedUQmqePa" title="Probability of IPO or Alternative Liquidity Event"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221203__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_zeCONxG8il3e" title="Probability of IPO or Alternative Liquidity Event"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Probability of Maturity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z70biHfaABAd" title="Probability of Maturity"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zBayx5yPk7Le" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3386"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Time period (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z57pzvg3q9Nf" title="Time period (years)"&gt;1.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z3l5G2HZZkl6" title="Time period (years)"&gt;0.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zSD24dEZxe4b" title="Estimated fair value"&gt;31,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z78qN4UlNr08" title="Estimated fair value"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_zJDBxpywOaf1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes in the derivative liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zHuN5mIWCcld" style="display: none"&gt;Schedule of Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Alto Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Alto Acceleration Option&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance - December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zWuG16l7lUb4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3398"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_ztFTCUemysu2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3400"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Addition of new derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zdAHyDuWCfwc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition of new derivative"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3402"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance, accelerated feature"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z8RTtBdyQRV1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3404"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zPbLi4vsu6Y5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3406"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Settlements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zvjRWlcR4Oq4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3408"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance, accelerated feature"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance - December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z227U3NgZrsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3410"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zIZ54psJBNEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3412"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Addition of new derivatives&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zi2intGd88Ic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;1,189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zulYRhCn5Bo4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;1,442,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zN2fSOlVe2Hg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;(778,340&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zl9oFisctE59" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;(1,438,148&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zqedp41mnRcc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zfSvJfrVCkJi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 2021 Notes Derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;August 2022 Notes Derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022 Convertible &#160;Notes Derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;Balance - December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zMfR6d3t1ZTc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"&gt;367,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zvQSmx5SZQT9" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3428"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zpfuhLUsv1Kc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Addition of new derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--NotesDerivativeMember_zWqliR34XJic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3432"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zaBmeMoUsWw1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"&gt;76,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zrcnlskbqQTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"&gt;221,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss (gain) on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_znz5bKggSfBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;(205,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zNYi4yyZGiY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;44,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_ztLRWglWKal8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;350,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Settlements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zOwd68kF1fT8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;(162,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zHWin4V5gVni" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;(120,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zqIBjN8wVsyj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;(571,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance - December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zWxsN5hlwSIg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zmOWqAKHdd28" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3452"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_z224mM1Sbfoe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3454"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Addition of new derivatives&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zEiFnJUobl0a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3456"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zMvnSYCrVEHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3458"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zxo25N8sCZEj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3460"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zlxz2dtxaAqi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3462"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zKJxXoIfZ5oi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3464"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zkRrGHyYGnb7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3466"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_z5rEzxpFNtYh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zOIIACleWQL4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zFv0uFQF4CY3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A3_zixrotcpmfIc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact003210"
      unitRef="Shares">127260</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact003212"
      unitRef="USDPShares">18.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact003214"
      unitRef="USD">1189000</SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue>
    <SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact003216"
      unitRef="USD">410660</SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003218"
      unitRef="USDPShares">12.64</us-gaap:DebtInstrumentMeasurementInput>
    <SHPH:DerivativeDiscountPercentage
      contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003220"
      unitRef="Pure">0.14</SHPH:DerivativeDiscountPercentage>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003222">&lt;p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_znb7Uj9EztTl" style="display: none"&gt;Schedule of Monte Carlo Simulation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net cash settlement and down round key valuation inputs &#x2013; Alto Warrants*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 78%"&gt;Annualized volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z4g0dzX4U7zf"&gt;77.51&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z301m69d8Gyi"&gt;92.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZAEk7427avk"&gt;4.01&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zgCPUuxlHzHc"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKg_____zynIkUyUvoc5"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zx3O4OnWlhIe"&gt;18.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability assessment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zZhnjkBS7Tu6"&gt;5&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zyEeLFE48kV1"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zUzGci9OyFOe"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zp3kUyM7mCF1" title="Time period (years)"&gt;0.53&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____z2QZvDKXSZc8" title="Time period (years)"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_985_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zzfOPZcmFp21" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance"&gt;1,189,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (December 31, 2023)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_fKg_____zoconmEERXL5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value"&gt;410,660&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Alto Acceleration Option key valuation inputs*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsLip3AEalOf"&gt;34.23&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zrecJIDgSDtl"&gt;59.15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zJ1iIi9Tuuh5"&gt;4.68&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zzEjaz9gjDGe"&gt;5.60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zq9lJmRsxA0c"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zHhUsf9wJkQl"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zBDp4x7lFOLe" title="Time period (years)"&gt;0&lt;/span&gt; - &lt;span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zN3n43wPlwJ7" title="Time period (years)"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (issuance)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____z1a2AIcEwJo7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value issuance"&gt;1,442,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value (December 31, 2023)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember_fKg_____zMZsZdoRik44" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" title="Estimated fair value"&gt;3,852&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F02_zP9EgyZUvD22"&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F10_zpHGdXc8eMz1"&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003223"
      unitRef="Pure">77.51</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003224"
      unitRef="Pure">92.33</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003225"
      unitRef="Pure">4.01</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003226"
      unitRef="Pure">5.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_custom_AltoWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact003227"
      unitRef="USDPShares">4.72</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003228"
      unitRef="USDPShares">18.80</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003229"
      unitRef="Pure">5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003230"
      unitRef="Pure">25</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_custom_AltoWarrantsMember"
      decimals="INF"
      id="Fact003231"
      unitRef="Pure">17</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_AltoWarrantsMember"
      id="Fact003233">P0Y6M10D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_AltoWarrantsMember"
      id="Fact003235">P3Y10D</us-gaap:DebtInstrumentTerm>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_custom_AltoWarrantsMember_custom_MeasurementInputEstimatedFairValueMember"
      decimals="0"
      id="Fact003237"
      unitRef="USD">1189000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_AltoWarrantsMember"
      decimals="0"
      id="Fact003239"
      unitRef="USD">410660</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact003240"
      unitRef="Pure">34.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact003241"
      unitRef="Pure">59.15</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact003242"
      unitRef="Pure">4.68</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact003243"
      unitRef="Pure">5.60</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact003244"
      unitRef="USDPShares">4.72</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact003245"
      unitRef="Pure">17</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember"
      id="Fact003247">P0Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember"
      id="Fact003249">P1Y2M12D</us-gaap:DebtInstrumentTerm>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember"
      decimals="0"
      id="Fact003251"
      unitRef="USD">1442000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_StockOptionMember_custom_MeasurementInputEstimatedFairValueMember"
      decimals="0"
      id="Fact003253"
      unitRef="USD">3852</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003256">&lt;p id="xdx_892_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_zjlCwF4i7uJj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In connection with the issuance of the December 2021
Notes, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative liability
as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value of the
derivative just prior to the settlement of the December 2021 Notes. Key inputs for this valuation model are summarized below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;span id="xdx_8B2_zjG7V0BTJGN6" style="display: none"&gt;Schedule
of Derivative Liability Valuation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;December 2021 Notes derivative key valuation inputs&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zCCUZkonud72" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Date&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231__us-gaap--AwardDateAxis__custom--SettlementDateMember_zi03jzsAnAh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Settlement Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Amount due upon acceleration&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcTc9BXjF7gb" title="Amount due upon acceleration"&gt;533,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--DerivativeLiabilityOfAcceleration_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zWOG2jS5GJUb" title="Amount due upon acceleration"&gt;533,973&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Carrying value of December 2021 Notes at measurement date&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIEsyqfZYvLg" title="Carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3262"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zcwi7FULk9jc" title="Carrying value"&gt;337,398&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;IPO date&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zVBlR0B9tUP7" title="IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zJw91gnzLS2j" title="IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO acceleration&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_903_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zFuITDP3UXf" title="Probability of IPO acceleration"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zpxKsbtLWcB9" title="Probability of IPO acceleration"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Probability of maturity&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zzFXbd5Og0G4" title="Probability of Maturity"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_z7lRzYZKo0S2" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3276"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Time period to maturity (years)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zX1096vaLn9i" title="Time period to maturity (years)"&gt;1.00&lt;/span&gt; years&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z6tjv8ZW9Ry1" title="Time period to maturity (years)"&gt;0.32&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Discount rate&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zcAOY0484Dgi" title="Discount rate"&gt;50.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--DerivativeLiabilityDiscoutRate_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zUkS1jzZb5c9" title="Discount rate"&gt;50.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated fair value&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z8IXFIyc2pgh" title="Estimated fair value"&gt;367,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z11mi2p3YAV3" title="Estimated fair value"&gt;162,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock>
    <SHPH:DerivativeLiabilityOfAcceleration
      contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember"
      decimals="0"
      id="Fact003258"
      unitRef="USD">533699</SHPH:DerivativeLiabilityOfAcceleration>
    <SHPH:DerivativeLiabilityOfAcceleration
      contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      decimals="0"
      id="Fact003260"
      unitRef="USD">533973</SHPH:DerivativeLiabilityOfAcceleration>
    <SHPH:DerivativeLiabilityOfCarringValueMeasurementDate
      contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      decimals="0"
      id="Fact003264"
      unitRef="USD">337398</SHPH:DerivativeLiabilityOfCarringValueMeasurementDate>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember"
      id="Fact003266">2022-08-31</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember"
      id="Fact003268">2022-09-02</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <SHPH:DerivativeLiabilityOfProbabilityAcceleration
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember"
      decimals="INF"
      id="Fact003270"
      unitRef="Pure">90</SHPH:DerivativeLiabilityOfProbabilityAcceleration>
    <SHPH:DerivativeLiabilityOfProbabilityAcceleration
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      decimals="INF"
      id="Fact003272"
      unitRef="Pure">100</SHPH:DerivativeLiabilityOfProbabilityAcceleration>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember"
      decimals="INF"
      id="Fact003274"
      unitRef="Pure">10</us-gaap:DerivativeLiabilityMeasurementInput>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember"
      id="Fact003278">P1Y</SHPH:DerivativeLiabilityMeasurementDuration>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2021-01-012021-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember"
      id="Fact003280">P0Y3M25D</SHPH:DerivativeLiabilityMeasurementDuration>
    <SHPH:DerivativeLiabilityDiscoutRate
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDateMember"
      decimals="INF"
      id="Fact003282"
      unitRef="Pure">50.0</SHPH:DerivativeLiabilityDiscoutRate>
    <SHPH:DerivativeLiabilityDiscoutRate
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      decimals="INF"
      id="Fact003284"
      unitRef="Pure">50.0</SHPH:DerivativeLiabilityDiscoutRate>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember"
      decimals="0"
      id="Fact003286"
      unitRef="USD">367000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember"
      decimals="0"
      id="Fact003288"
      unitRef="USD">162000</us-gaap:ConvertibleNotesPayable>
    <SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003290">&lt;p id="xdx_896_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_z5brvl3KzAle" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zD9WNYfYXy6"&gt;Schedule
of Derivative Key Valuation Inputs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022
    Convertible Notes derivative key valuation inputs*&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    Dates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Settlement Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zrI7eNI0ycE5" title="Annualized volatility"&gt;75.0&lt;/span&gt;%
    - &lt;span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z0yV9SlEpTnf" title="Annualized volatility"&gt;82.0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zKgfUKZ0UPn4" title="Annualized volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3296"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIJa6GBq3Vu9" title="Risk-free interest rate"&gt;0.6&lt;/span&gt;%
    - &lt;span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7kAtMbqmLOb" title="Risk-free interest rate"&gt;1.2&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMKLBnZnSszd" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3302"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price (implied)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zusIOIenjwY5" title="Exercise price (implied)"&gt;45.52&lt;/span&gt;
    - $&lt;span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zSrzItTHe8Xl" title="Exercise price (implied)"&gt;85.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z59iWMKVRj15" title="Exercise price (implied)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3308"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated
    IPO date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_z48Fv311BmSl" title="Estimated IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zWHulQCfI3ce" title="Estimated IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability
    of default&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember_zq8jLqAQ0tdi" title="Probability of default"&gt;50&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zMACi2a6YyD" title="Probability of default"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3316"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability
    of IPO or Alternative Liquidity Event&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_znwcKoeawLJg" title="Probability of IPO or Alternative Liquidity Event"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zT1PeOh2Neth" title="Probability of IPO or Alternative Liquidity Event"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability
    of Maturity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zlGZHJ3XRNug" title="Probability of Maturity"&gt;5&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zjjniTfeAEkc" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3324"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Time
    period (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_ztMKhfW5VVmg" title="Time period (years)"&gt;0.47&lt;/span&gt;
    - &lt;span id="xdx_904_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zwX6ZWWfyt65" title="Time period (years)"&gt;1.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zwYvRAgB6W9h" title="Time period (years)"&gt;0.00&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zc3b3riNCOg1" title="Estimated fair value"&gt;221,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z86312yZwukb" title="Estimated fair value"&gt;571,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

</SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact003292"
      unitRef="Pure">75.0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact003294"
      unitRef="Pure">82.0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact003298"
      unitRef="Pure">0.6</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact003300"
      unitRef="Pure">1.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MinimumMember"
      decimals="INF"
      id="Fact003304"
      unitRef="Pure">45.52</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember_srt_MaximumMember"
      decimals="INF"
      id="Fact003306"
      unitRef="Pure">85.92</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember"
      id="Fact003310">2022-08-31</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember"
      id="Fact003312">2022-09-02</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputDefaultRateMember"
      decimals="INF"
      id="Fact003314"
      unitRef="Pure">50</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember"
      decimals="INF"
      id="Fact003318"
      unitRef="Pure">45</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_SettlementMember"
      decimals="INF"
      id="Fact003320"
      unitRef="Pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact003322"
      unitRef="Pure">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember"
      id="Fact003326">P0Y5M19D</SHPH:DerivativeLiabilityMeasurementDuration>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember"
      id="Fact003328">P1Y</SHPH:DerivativeLiabilityMeasurementDuration>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember"
      id="Fact003330">P0Y</SHPH:DerivativeLiabilityMeasurementDuration>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDateMember"
      decimals="0"
      id="Fact003332"
      unitRef="USD">221000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember"
      decimals="0"
      id="Fact003334"
      unitRef="USD">571000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_AugustTwoThousandTwentyTwoNotesMember"
      id="Fact003336">&lt;p id="xdx_895_ecustom--ScheduleOfDerivativeOfSettlementValuationTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_zgGEkQpbb6be" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In connection with the issuance of the August 2022
Promissory Note, the Company identified an accelerated repayment upon IPO feature that required bifurcation. We classified this derivative
liability as a Level 3 fair value measurement and used a probability weighted scenario model to estimate the fair value
of the derivative just prior to the settlement of the August 2022 Promissory Notes. Key inputs for this valuation model are summarized
below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;span id="xdx_8B3_zXnr1bjxbu8" style="display: none"&gt;Schedule
of Derivative Issuance Valuation Inputs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;August 2022 Promissory Notes derivative key valuation inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Issuance Dates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Settlement Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Amount due upon acceleration (estimated at issuance)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_904_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zX5muKr38VWd" title="Amount due upon acceleration"&gt;50,411&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--DerivativeLiabilityOfAcceleration_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zlLZamz1oBT8" title="Amount due upon acceleration"&gt;50,438&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Carrying value of August 2022 Promissory Notes at measurement date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90C_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zVydJGz543cb" title="Carrying value"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--DerivativeLiabilityOfCarringValueMeasurementDate_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zj9Ng4Pbbdij" title="Carrying value"&gt;4,521&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;IPO date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zbhJNV5W9Fb5" title="IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_zAzR2pIn59Hh" title="IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Probability of IPO acceleration&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zQN6XCDs8M2c" title="Probability of IPO acceleration"&gt;90%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--DerivativeLiabilityOfProbabilityAcceleration_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zNspkjjAgVO5" title="Probability of IPO acceleration"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Probability of maturity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zRY8a4wqnEzc" title="Probability of Maturity"&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zjb0uw9A2rnf" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3356"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Time period to maturity (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--IssuanceDateMember_zIWJR1XsIxRj" title="Time period to maturity (years)"&gt;1.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardDateAxis__custom--SettlementMember_z84rwfz9M3L5" title="Time period to maturity (years)"&gt;0.91&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--IssuanceDatesMember_zIO5KOr85SO8" title="Discount rate"&gt;16.03%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--DerivativeLiabilityOfDiscountRate_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardDateAxis__custom--SettlementMember_zipUF0l5Eyj8" title="Discount rate"&gt;18.81%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zOHFLWCnr45d" title="Estimated fair value"&gt;45,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zbkhZ58Bq7H3" title="Estimated fair value"&gt;45,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</SHPH:ScheduleOfDerivativeOfSettlementValuationTableTextBlock>
    <SHPH:DerivativeLiabilityOfAcceleration
      contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember"
      decimals="0"
      id="Fact003338"
      unitRef="USD">50411</SHPH:DerivativeLiabilityOfAcceleration>
    <SHPH:DerivativeLiabilityOfAcceleration
      contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      decimals="0"
      id="Fact003340"
      unitRef="USD">50438</SHPH:DerivativeLiabilityOfAcceleration>
    <SHPH:DerivativeLiabilityOfCarringValueMeasurementDate
      contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember"
      decimals="0"
      id="Fact003342"
      unitRef="USD">0</SHPH:DerivativeLiabilityOfCarringValueMeasurementDate>
    <SHPH:DerivativeLiabilityOfCarringValueMeasurementDate
      contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember"
      decimals="0"
      id="Fact003344"
      unitRef="USD">4521</SHPH:DerivativeLiabilityOfCarringValueMeasurementDate>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember"
      id="Fact003346">2022-08-31</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember"
      id="Fact003348">2022-09-02</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <SHPH:DerivativeLiabilityOfProbabilityAcceleration
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703"
      decimals="INF"
      id="Fact003350"
      unitRef="Pure">0.90</SHPH:DerivativeLiabilityOfProbabilityAcceleration>
    <SHPH:DerivativeLiabilityOfProbabilityAcceleration
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703"
      decimals="INF"
      id="Fact003352"
      unitRef="Pure">1</SHPH:DerivativeLiabilityOfProbabilityAcceleration>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703"
      decimals="INF"
      id="Fact003354"
      unitRef="Pure">0.10</us-gaap:DerivativeLiabilityMeasurementInput>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_IssuanceDateMember"
      id="Fact003358">P1Y</SHPH:DerivativeLiabilityMeasurementDuration>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2022-08-012022-08-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember"
      id="Fact003360">P0Y10M28D</SHPH:DerivativeLiabilityMeasurementDuration>
    <SHPH:DerivativeLiabilityOfDiscountRate
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember29551703"
      decimals="INF"
      id="Fact003362"
      unitRef="Pure">16.03</SHPH:DerivativeLiabilityOfDiscountRate>
    <SHPH:DerivativeLiabilityOfDiscountRate
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_SettlementMember29551703"
      decimals="INF"
      id="Fact003364"
      unitRef="Pure">18.81</SHPH:DerivativeLiabilityOfDiscountRate>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDatesMember"
      decimals="0"
      id="Fact003366"
      unitRef="USD">45000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember"
      decimals="0"
      id="Fact003368"
      unitRef="USD">45000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_AugustTwoThousandTwentyTwoNotesMember"
      id="Fact003370">&lt;p id="xdx_897_ecustom--ScheduleofDerivativeKeyValuationInputsTableTextBlock_hus-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyTwoNotesMember_ziGGYyZ5pmTh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In connection with the issuance of the August 2022
Convertible Notes, the Company identified certain embedded features that required bifurcation as a combined derivative liability, including
the share-settled redemption of the 2022 Convertible Notes at a 50% discount and the automatic increase in principal of 10% if conversion
does not occur within 12 months. Key inputs for this valuation model are summarized below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;span id="xdx_8BC_zWO7z0wylKdf" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Derivative Key Valuation Inputs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;2022 Convertible Notes derivative key valuation inputs*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Issuance Dates&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Settlement Date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Estimated IPO date&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember_zYV50vMb4Kpl" title="Estimated IPO date"&gt;8/31/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleMaturityDate_iI_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIpoDateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zK2pnOjpOfEl" title="Estimated IPO date"&gt;9/2/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Probability of default&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z8XT09NZrZS2" title="Probability of default"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zyickfmFFPwk" title="Probability of default"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3378"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Probability of IPO or Alternative Liquidity Event&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zViedUQmqePa" title="Probability of IPO or Alternative Liquidity Event"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20221203__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputSharePriceProbabilityOfIPOMember_zeCONxG8il3e" title="Probability of IPO or Alternative Liquidity Event"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Probability of Maturity&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z70biHfaABAd" title="Probability of Maturity"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--AwardTypeAxis__custom--SettlementMember_zBayx5yPk7Le" title="Probability of Maturity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3386"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Time period (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_z57pzvg3q9Nf" title="Time period (years)"&gt;1.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--DerivativeLiabilityMeasurementDuration_dtY_c20220801__20220831__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z3l5G2HZZkl6" title="Time period (years)"&gt;0.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--IssuanceDatesMember_zSD24dEZxe4b" title="Estimated fair value"&gt;31,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20220831__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEstimatedFairValueMember__us-gaap--AwardTypeAxis__custom--SettlementMember_z78qN4UlNr08" title="Estimated fair value"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</SHPH:ScheduleofDerivativeKeyValuationInputsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember"
      id="Fact003372">2022-08-31</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleMaturityDate
      contextRef="AsOf2022-12-31_custom_MeasurementInputIpoDateMember_custom_SettlementMember"
      id="Fact003374">2022-09-02</us-gaap:DebtSecuritiesAvailableForSaleMaturityDate>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputDefaultRateMember_custom_IssuanceDatesMember"
      decimals="INF"
      id="Fact003376"
      unitRef="Pure">50</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-08-31_custom_MeasurementInputSharePriceProbabilityOfIPOMember_custom_IssuanceDatesMember"
      decimals="INF"
      id="Fact003380"
      unitRef="Pure">45</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-03_custom_MeasurementInputSharePriceProbabilityOfIPOMember"
      decimals="INF"
      id="Fact003382"
      unitRef="Pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-08-31_us-gaap_MeasurementInputSharePriceMember_custom_IssuanceDatesMember"
      decimals="INF"
      id="Fact003384"
      unitRef="Pure">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_IssuanceDatesMember"
      id="Fact003388">P1Y</SHPH:DerivativeLiabilityMeasurementDuration>
    <SHPH:DerivativeLiabilityMeasurementDuration
      contextRef="From2022-08-012022-08-31_us-gaap_MeasurementInputExpectedTermMember_custom_SettlementMember"
      id="Fact003390">P0Y</SHPH:DerivativeLiabilityMeasurementDuration>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_IssuanceDatesMember"
      decimals="0"
      id="Fact003392"
      unitRef="USD">31000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-08-31_custom_MeasurementInputEstimatedFairValueMember_custom_SettlementMember"
      decimals="0"
      id="Fact003394"
      unitRef="USD">75000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-01-012023-12-31" id="Fact003396">&lt;p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes in the derivative liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zHuN5mIWCcld" style="display: none"&gt;Schedule of Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Alto Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Alto Acceleration Option&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance - December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zWuG16l7lUb4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3398"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_ztFTCUemysu2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3400"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Addition of new derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zdAHyDuWCfwc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition of new derivative"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3402"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance, accelerated feature"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z8RTtBdyQRV1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3404"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zPbLi4vsu6Y5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3406"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Settlements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zvjRWlcR4Oq4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3408"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance, accelerated feature"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance - December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_z227U3NgZrsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3410"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zIZ54psJBNEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3412"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Addition of new derivatives&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zi2intGd88Ic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;1,189,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zulYRhCn5Bo4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;1,442,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zN2fSOlVe2Hg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;(778,340&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zl9oFisctE59" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;(1,438,148&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AltoWarrantsMember_zqedp41mnRcc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;410,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--AwardTypeAxis__custom--AltoAccelerationOptionMember_zfSvJfrVCkJi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;3,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 2021 Notes Derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;August 2022 Notes Derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022 Convertible &#160;Notes Derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;Balance - December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zMfR6d3t1ZTc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"&gt;367,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zvQSmx5SZQT9" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3428"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zpfuhLUsv1Kc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Addition of new derivative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--NotesDerivativeMember_zWqliR34XJic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3432"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zaBmeMoUsWw1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"&gt;76,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zrcnlskbqQTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivative"&gt;221,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss (gain) on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_znz5bKggSfBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;(205,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zNYi4yyZGiY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;44,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DerivativeGainLossOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_ztLRWglWKal8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;350,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Settlements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zOwd68kF1fT8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;(162,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zHWin4V5gVni" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;(120,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DerivativeSettlementsOnDerivativeWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zqIBjN8wVsyj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Settlements"&gt;(571,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance - December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zWxsN5hlwSIg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zmOWqAKHdd28" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3452"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_z224mM1Sbfoe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3454"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Addition of new derivatives&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zEiFnJUobl0a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3456"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zMvnSYCrVEHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3458"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zxo25N8sCZEj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Addition of new derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3460"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_zlxz2dtxaAqi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3462"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zKJxXoIfZ5oi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3464"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DerivativeGainLossOnDerivativeWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zkRrGHyYGnb7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain loss on change in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3466"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--DecemberTwoThousandTwentyOneNotesDerivativeMember_z5rEzxpFNtYh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyTwoNotesDerivativeMember_zOIIACleWQL4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesDerivativeMember_zFv0uFQF4CY3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      decimals="0"
      id="Fact003414"
      unitRef="USD">1189000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember"
      decimals="0"
      id="Fact003416"
      unitRef="USD">1442000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      decimals="0"
      id="Fact003418"
      unitRef="USD">-778340</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember"
      decimals="0"
      id="Fact003420"
      unitRef="USD">-1438148</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoWarrantsMember"
      decimals="0"
      id="Fact003422"
      unitRef="USD">410660</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AltoAccelerationOptionMember"
      decimals="0"
      id="Fact003424"
      unitRef="USD">3852</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember"
      decimals="0"
      id="Fact003426"
      unitRef="USD">367000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember"
      decimals="0"
      id="Fact003434"
      unitRef="USD">76000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember"
      decimals="0"
      id="Fact003436"
      unitRef="USD">221000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember"
      decimals="0"
      id="Fact003438"
      unitRef="USD">-205000</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember29546843"
      decimals="0"
      id="Fact003440"
      unitRef="USD">44000</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember29546859"
      decimals="0"
      id="Fact003442"
      unitRef="USD">350000</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:DerivativeSettlementsOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_DecemberTwoThousandTwentyOneNotesDerivativeMember"
      decimals="0"
      id="Fact003444"
      unitRef="USD">-162000</SHPH:DerivativeSettlementsOnDerivativeWarrants>
    <SHPH:DerivativeSettlementsOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_AugustTwoThousandTwentyTwoNotesDerivativeMember29546843"
      decimals="0"
      id="Fact003446"
      unitRef="USD">-120000</SHPH:DerivativeSettlementsOnDerivativeWarrants>
    <SHPH:DerivativeSettlementsOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_TwoThousandTwentyTwoConvertibleNotesDerivativeMember29546859"
      decimals="0"
      id="Fact003448"
      unitRef="USD">-571000</SHPH:DerivativeSettlementsOnDerivativeWarrants>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact003474">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zysAiD3uWv96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_82D_z9InGb4rQSfk" style="display: none"&gt;Related Party transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#x201c;TCG GreenChem&#x201d;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. The Company paid TCG GreenChem $&lt;span id="xdx_909_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20221231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zs0HwiZEVXj3" title="Payments to invoices in research and development"&gt;450,000&lt;/span&gt; during the year ended December
31, 2022 and a total of $&lt;span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20230101__20231231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zEZHhc9Bky7j" title="Payments to invoices in research and development"&gt;1,096,370&lt;/span&gt; during the year ended December 31, 2023, completing the contract.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-01-012022-12-31_custom_TCGGreenChemIncMember"
      decimals="0"
      id="Fact003476"
      unitRef="USD">450000</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_custom_TCGGreenChemIncMember"
      decimals="0"
      id="Fact003478"
      unitRef="USD">1096370</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact003480">&lt;p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zIzNnGyFJnD8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_82A_zYL3mUjUjp33"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has no income tax expense or benefit for the years ended December 31, 2023 and 2022, since the Company has a full valuation allowance
for the net operating loss carryforwards in these periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination
by the taxing authorities based on the technical merits of the position. The tax benefits recognized from such positions are estimated
based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain
tax positions to be reported for the tax years 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) amended IRC Section 174 to require capitalization of all research and development
(&#x201c;R&amp;amp;D&#x201d;) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over
five years if the R&amp;amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. For
tax reporting purposes, the Company capitalized $&lt;span id="xdx_90F_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20231231_zXvHn7wdQpqg" title="Research and development expenses"&gt;3,517,485&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20221231_zCI5g925C8v7" title="Research and development expenses"&gt;1,488,530&lt;/span&gt; of R&amp;amp;D expenses incurred as of December 31, 2023 and
2022, respectively.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income tax benefit at the U.S. statutory rate of &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate"&gt;21&lt;/span&gt;% to the Company&#x2019;s tax expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z2tRzaeOyVg3" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zdjdEVmue1Gk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zfJ37FBIxa2e" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt; 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(as restated)&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(1,384,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(1,049,174&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income taxes, net of federal tax effect&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(452,682&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(351,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Rate change&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,710&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(409&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzspy_zFfwkzSx8Rlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;R &amp;amp; D tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(240,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(69,461&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;286,015&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;201,235&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_iB_zfBXR3fVjSNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_i01_maITEBzspy_zFPKFfQPSv17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Derivative Debt Discount Amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;562,568&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3509"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_i01_maITEBzspy_zWZOWC4F5JIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Change in FMV of Warrant Liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(617,655&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;217,926&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_i01_maITEBzspy_zmAom1OVDsn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Loss on convertible note conversion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,984&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;503,249&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_i01_maITEBzspy_zVvkEdEmZTEh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;126,012&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;169,946&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,535,466&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;377,709&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;40,674&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;16,800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3529"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3530"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zdVsqCFpXlch" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of deferred tax assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zPU61r3hFOe7" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(as restated)&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax asset:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,727,566&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;751,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3537"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;804&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Intangibles (includes Section 174 capitalization)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,197,938&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;405,172&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;423,915&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;200,715&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Equity based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,251&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,626&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest &amp;amp; other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72,140&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,336&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease asset/(liability)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,326&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,889&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,429,136&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,401,386&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;(as restated)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Change in fair market value of securities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(19,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3559"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(30,544&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(46,718&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsDeferredIncome_iNI_di_zxk4s8z19xdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income tax deferred&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3564"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(60,196&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,746&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3568"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(53,233&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(106,914&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total deferred tax asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,375,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,294,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,375,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,294,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3579"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3580"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zrwMVAPp8x91" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zI3yIfzm5n7c" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zaqDxtXO4WE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z1v7OlEmFVIa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3591"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_iB_uPure_zOBXO0OlU256" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_i01_pid_dp_uPure_maDEF_znJQzfgFZxP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Derivative Debt Discount Amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3603"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_i01_pid_dp_uPure_maDEF_zq633uEUFSgc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Change in FMV of Warrant Liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_i01_pid_dp_uPure_maDEF_zC9Kr4APSLOc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Loss on convertible note conversion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10.1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_i01_pid_dp_uPure_maDEF_zRz4rIboyPlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(23.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3618"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3621"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total income tax expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3623"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3624"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_ziTYp8KTsYlh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalTaxableIncomeMember_zrG81Ug3Peyl" title="Net operatiing loss"&gt;6.4&lt;/span&gt;
million and $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--StateTaxableIncomeMember_zXVNaHVK7E06" title="Net operatiing loss"&gt;5.9&lt;/span&gt; million of net operating losses (&#x201c;NOL&#x201d;) carried forward to offset federal and state taxable income, if
any, in the future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making
this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax
asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be
realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;NOLs created prior to
2018 could be carried back two years and carried forward &lt;span id="xdx_90E_ecustom--DeferredTaxAssetsOperatingLossCarriedForward_dtY_c20230101__20231231_ztKkx6mJrK2h" title="Carried forward"&gt;20&lt;/span&gt;
years. As amended by the Tax Cuts and Jobs Act of 2017 (TCJA), NOLs created after 2017 can no longer be carried back and are instead
carried forward indefinitely. The Company has $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2016Member_zzagpmkbLOni" title="Operating loss carryforwards"&gt;139,813&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2017Member_zflhOv8qsPn8" title="Operating loss carryforwards"&gt;238,380&lt;/span&gt;
of federal NOL carryforwards from 2016 and 2017, respectively, which begin to expire in 2036. The Company has an additional $&lt;span id="xdx_907_eus-gaap--CurrentFederalTaxExpenseBenefit_pn5n6_c20230101__20231231_zmwr2NmmCXT6" title="Federal income tax"&gt;6.0&lt;/span&gt;
million and $&lt;span id="xdx_90B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn5n6_c20230101__20231231_zwfL0wOfQM5e" title="State income tax"&gt;5.9&lt;/span&gt;
million of federal and state NOLs created after 2017, respectively, which can be carried forward indefinitely. The NOLs can be used
to offset future income limited to the lesser of the NOL or &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_pid_dp_uPure_c20230101__20231231_zA745rNSZcVk" title="Future taxable income"&gt;80&lt;/span&gt;%
of the year&#x2019;s taxable income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As of December 31, 2023, the Company has $&lt;span id="xdx_904_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_zyM9U2Dualt9" title="Federal Research and Development"&gt;360,715&lt;/span&gt;
of federal Research and Development (R&amp;amp;D) tax credits. These can be carried forward &lt;span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_dtY_c20230101__20231231_zE0Rx6zu1dBh" title="Carried forward"&gt;20&lt;/span&gt; years to offset future federal income tax.
These begin to expire in 2037. Additionally, the Company has $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zgHvq6C4B1f" title="R&amp;amp;D tax credits"&gt;80,000&lt;/span&gt; of state R&amp;amp;D tax credits which can be carried forward seven years.
These begin to expire in 2030.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003482"
      unitRef="USD">3517485</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003484"
      unitRef="USD">1488530</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003486">&lt;p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income tax benefit at the U.S. statutory rate of &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate"&gt;21&lt;/span&gt;% to the Company&#x2019;s tax expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z2tRzaeOyVg3" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zdjdEVmue1Gk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zfJ37FBIxa2e" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt; 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(as restated)&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(1,384,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(1,049,174&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income taxes, net of federal tax effect&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(452,682&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(351,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Rate change&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,710&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(409&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzspy_zFfwkzSx8Rlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;R &amp;amp; D tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(240,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(69,461&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;286,015&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;201,235&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesAbstract_iB_zfBXR3fVjSNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization_i01_maITEBzspy_zFPKFfQPSv17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Derivative Debt Discount Amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;562,568&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3509"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability_i01_maITEBzspy_zWZOWC4F5JIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Change in FMV of Warrant Liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(617,655&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;217,926&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote_i01_maITEBzspy_zmAom1OVDsn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Loss on convertible note conversion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,984&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;503,249&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther_i01_maITEBzspy_zVvkEdEmZTEh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;126,012&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;169,946&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,535,466&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;377,709&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;40,674&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;16,800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3529"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3530"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003488"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003490"
      unitRef="USD">-1384472</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003491"
      unitRef="USD">-1049174</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003493"
      unitRef="USD">-452682</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003494"
      unitRef="USD">-351022</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003496"
      unitRef="USD">-5710</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003497"
      unitRef="USD">-409</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003499"
      unitRef="USD">240000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003500"
      unitRef="USD">69461</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <SHPH:IncomeTaxReconciliationProvisionAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003502"
      unitRef="USD">286015</SHPH:IncomeTaxReconciliationProvisionAdjustments>
    <SHPH:IncomeTaxReconciliationProvisionAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003503"
      unitRef="USD">201235</SHPH:IncomeTaxReconciliationProvisionAdjustments>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003508"
      unitRef="USD">562568</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesDerivativeDebtDiscountAmortization>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003511"
      unitRef="USD">-617655</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003512"
      unitRef="USD">217926</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesChangeInFMVOfWarrantLiability>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003514"
      unitRef="USD">132984</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003515"
      unitRef="USD">503249</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesLossOnConvertibleNote>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003517"
      unitRef="USD">126012</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003518"
      unitRef="USD">169946</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferencesOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003520"
      unitRef="USD">1535466</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003521"
      unitRef="USD">377709</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <SHPH:ShortfallOfStockCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003523"
      unitRef="USD">40674</SHPH:ShortfallOfStockCompensationExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003526"
      unitRef="USD">16800</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact003527"
      unitRef="USD">1</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003532">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of deferred tax assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zPU61r3hFOe7" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(as restated)&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax asset:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,727,566&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;751,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3537"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;804&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Intangibles (includes Section 174 capitalization)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,197,938&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;405,172&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;423,915&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;200,715&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Equity based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,251&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,626&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest &amp;amp; other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72,140&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,336&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease asset/(liability)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,326&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,889&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,429,136&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,401,386&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;(as restated)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Change in fair market value of securities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;(19,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3559"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(30,544&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(46,718&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsDeferredIncome_iNI_di_zxk4s8z19xdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income tax deferred&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3564"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(60,196&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,746&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3568"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(53,233&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(106,914&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total deferred tax asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,375,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,294,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,375,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,294,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3579"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3580"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003534"
      unitRef="USD">1727566</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003535"
      unitRef="USD">751844</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003538"
      unitRef="USD">804</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003540"
      unitRef="USD">1197938</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003541"
      unitRef="USD">405172</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003543"
      unitRef="USD">423915</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003544"
      unitRef="USD">200715</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <SHPH:DeferredTaxAssetsbasedCompensation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003546"
      unitRef="USD">1251</SHPH:DeferredTaxAssetsbasedCompensation>
    <SHPH:DeferredTaxAssetsbasedCompensation
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003547"
      unitRef="USD">11626</SHPH:DeferredTaxAssetsbasedCompensation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003549"
      unitRef="USD">72140</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003550"
      unitRef="USD">29336</us-gaap:DeferredTaxAssetsOther>
    <SHPH:DeferredTaxAssetsLeaseLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003552"
      unitRef="USD">6326</SHPH:DeferredTaxAssetsLeaseLiabilities>
    <SHPH:DeferredTaxAssetsLeaseLiabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003553"
      unitRef="USD">1889</SHPH:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003555"
      unitRef="USD">3429136</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003556"
      unitRef="USD">1401386</us-gaap:DeferredTaxAssetsGross>
    <SHPH:DeferredTaxLiabilitiesFairMarketValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003558"
      unitRef="USD">19943</SHPH:DeferredTaxLiabilitiesFairMarketValue>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003561"
      unitRef="USD">30544</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003562"
      unitRef="USD">46718</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003565"
      unitRef="USD">60196</us-gaap:DeferredTaxAssetsDeferredIncome>
    <SHPH:DeferredTaxLiabilitiesFiniteLivedAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003567"
      unitRef="USD">-2746</SHPH:DeferredTaxLiabilitiesFiniteLivedAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003570"
      unitRef="USD">53233</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003571"
      unitRef="USD">106914</us-gaap:DeferredIncomeTaxLiabilities>
    <SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003573"
      unitRef="USD">3375903</SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003574"
      unitRef="USD">1294472</SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003576"
      unitRef="USD">3375903</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact003577"
      unitRef="USD">1294472</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003582">&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zI3yIfzm5n7c" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zaqDxtXO4WE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z1v7OlEmFVIa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3591"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAbstract_iB_uPure_zOBXO0OlU256" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization_i01_pid_dp_uPure_maDEF_znJQzfgFZxP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Derivative Debt Discount Amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3603"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability_i01_pid_dp_uPure_maDEF_zq633uEUFSgc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Change in FMV of Warrant Liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion_i01_pid_dp_uPure_maDEF_zC9Kr4APSLOc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Loss on convertible note conversion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10.1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther_i01_pid_dp_uPure_maDEF_zRz4rIboyPlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(23.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3618"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3621"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total income tax expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3623"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3624"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003584"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003585"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003587"
      unitRef="Pure">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003588"
      unitRef="Pure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003590"
      unitRef="Pure">0.001</SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003593"
      unitRef="Pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003594"
      unitRef="Pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003596"
      unitRef="Pure">-0.043</SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003597"
      unitRef="Pure">-0.040</SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003602"
      unitRef="Pure">-0.086</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeDebtDiscountAmortization>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003605"
      unitRef="Pure">0.094</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003606"
      unitRef="Pure">-0.043</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesDerivativeChangeInFMVOfWarrantLiability>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003608"
      unitRef="Pure">-0.020</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003609"
      unitRef="Pure">-0.101</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesLossOnConvertibleNoteConversion>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003611"
      unitRef="Pure">-0.019</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003612"
      unitRef="Pure">-0.034</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferencesOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003614"
      unitRef="Pure">-0.232</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact003615"
      unitRef="Pure">-0.076</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003617"
      unitRef="Pure">-0.006</SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003620"
      unitRef="Pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_custom_FederalTaxableIncomeMember"
      decimals="-5"
      id="Fact003626"
      unitRef="USD">6400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_custom_StateTaxableIncomeMember"
      decimals="-5"
      id="Fact003628"
      unitRef="USD">5900000</us-gaap:OperatingLossCarryforwards>
    <SHPH:DeferredTaxAssetsOperatingLossCarriedForward contextRef="From2023-01-012023-12-31" id="Fact003630">P20Y</SHPH:DeferredTaxAssetsOperatingLossCarriedForward>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_TaxYear2016Member"
      decimals="0"
      id="Fact003632"
      unitRef="USD">139813</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_TaxYear2017Member"
      decimals="0"
      id="Fact003634"
      unitRef="USD">238380</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact003636"
      unitRef="USD">6000000.0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact003638"
      unitRef="USD">5900000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact003640"
      unitRef="Pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact003642"
      unitRef="USD">360715</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <SHPH:DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome contextRef="From2023-01-012023-12-31" id="Fact003644">P20Y</SHPH:DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003646"
      unitRef="USD">80000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <SHPH:QuarterlyFinancialDataTextBlock contextRef="From2023-01-012023-12-31" id="Fact003648">&lt;p id="xdx_804_ecustom--QuarterlyFinancialDataTextBlock_zAR4xkS5UMZb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; &lt;span id="xdx_822_zXYsPgZKlPo1"&gt;Quarterly Financial Data (Unaudited and Restated)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is providing restated quarterly unaudited consolidated financial information as of
September 30, 2023 in the table below. See Note 2, Restatement of Previously Issued Consolidated Financial Statements, for further background
concerning the events preceding the restatement of financial information in this Comprehensive Form 10-K/A.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zCJ5d5NxEJJe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
restated consolidated balance sheet line items for the third fiscal quarter of 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zpA95ya3gad8"&gt;Schedule
of Quarterly Financial Data&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8jkE4tUBFO6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z81uuwNEseHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230930_z4FaFFsGclHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Restated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_zTeRcSTsNBP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;Additional paid in capital &lt;span id="xdx_F42_zJDO1gumiNob"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;19,456,841&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;29,402,533&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z9CGSTF3pEoc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(13,847,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(23,792,804&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0D_zBq7OWkLDr08" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zuvLr0XRWxrh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital"&gt;140&lt;/span&gt; and an offsetting adjustment to the carrying value of common stock.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p id="xdx_8A9_zwjvQAsnkhR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The adjustments did not have an effect on the consolidated
statement of operations or cash flows for the three fiscal quarters of 2023.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company has included its restated quarterly unaudited
consolidated financial information for the interim periods ended March 31, 2023 and June 30, 2023 within Form 10-Q/A for the period ended
March 31, 2024 and Form 10-Q for the period ended June 30, 2024, respectively, filed concurrent with this Form 10-K/A.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

</SHPH:QuarterlyFinancialDataTextBlock>
    <SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact003650">&lt;p id="xdx_895_ecustom--ScheduleofQuarterlyFinancialDataTableTextBlock_zCJ5d5NxEJJe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
restated consolidated balance sheet line items for the third fiscal quarter of 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zpA95ya3gad8"&gt;Schedule
of Quarterly Financial Data&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8jkE4tUBFO6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z81uuwNEseHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230930_z4FaFFsGclHi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Restated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_iI_zTeRcSTsNBP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;Additional paid in capital &lt;span id="xdx_F42_zJDO1gumiNob"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;19,456,841&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;29,402,533&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_z9CGSTF3pEoc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(13,847,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(9,945,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(23,792,804&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0D_zBq7OWkLDr08" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zuvLr0XRWxrh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb" title="Increase decrease in additional paid in capital"&gt;140&lt;/span&gt; and an offsetting adjustment to the carrying value of common stock.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


</SHPH:ScheduleofQuarterlyFinancialDataTableTextBlock>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact003652"
      unitRef="USD">19456841</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact003653"
      unitRef="USD">9945692</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact003654"
      unitRef="USD">29402533</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact003656"
      unitRef="USD">-13847112</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact003657"
      unitRef="USD">-9945692</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact003658"
      unitRef="USD">-23792804</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact003661"
      unitRef="USD">140</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-012023-12-31" id="Fact003663">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zgVbCW0iKpTk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12 &#x2013; &lt;span id="xdx_824_zs2tFHK7qGtg"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluated all additional events subsequent to the balance sheet date through the date the consolidated financial statements were issued
and determined that the following items are required to be disclosed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restatement
of Previously Issued Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 2.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nasdaq
Bid Price Requirement Extension Granted until August 26, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 7.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 31, 2023, after the Company&#x2019;s common stock had traded below $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20230831_zMaOM7ZhXbF7"&gt;1.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share for &lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uTradingDays_c20230831__20230831_zz8MxLwLRTY8" title="Consecutive trading days"&gt;30
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consecutive trading days, the Company received
notice from the Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the
&#x201c;Bid Price Requirement&#x201d;). In accordance with Nasdaq Rules, the Company was provided with an initial period of 180 calendar
days, or until February 27, 2024, to regain compliance with the Bid Price Requirement. On February 19, 2024, the Company submitted a
plan of compliance to Nasdaq seeking an additional 180-day grace period to regain compliance with the Bid Price Requirement. On February
29, 2024, the Company received formal approval from Nasdaq granting it an additional 180 days, or until August 26, 2024, to regain compliance
&#x2013; whether organically through market forces or by effectuating a reverse stock split, should such action be required. On August
6, 2024, the Company filed a certificate of amendment to its certificate of incorporation, effective August 13, 2024, to effectuate a
one-for-eight reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the &#x201c;Reverse
Stock Split&#x201d;). The Reverse Stock Split had no effect on the Company&#x2019;s authorized shares of common stock or preferred stock.
Following the reverse stock split on August 13, 2024, the Company had a total of &lt;span id="xdx_903_ecustom--ReverseCommonStockSharesOutstanding_iI_c20240813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBur87NIR7jg" title="Reverse common stock shares outstanding"&gt;2,111,235
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares issued and outstanding (or &lt;span id="xdx_907_ecustom--ReverseCommonStockSharesOutstanding_iI_c20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd7cI2lLYPFc" title="Reverse common stock shares outstanding"&gt;2,008,689
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on a post-split basis as of December 31, 2024)
and trades under the new CUSIP number 925693302. All common stock share, option, warrant and per share amounts (except our authorized
but unissued shares) have been retroactively restated in these consolidated financial statements and related disclosures. Following the
Reverse Stock Split, on August 27, 2024, the Company received a written notice from Nasdaq informing the Company that it has regained
compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;FDA
Approval to Proceed with Phase II study of Ropidoxuridine (IPdR)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 8, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), issued a press release announcing
that the Company had received the &#x201c;Safe to Proceed&#x201d; letter from the U.S. Food and Drug Administration for the Company&#x2019;s
investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence
the Phase II study and, as a result, the Company is currently finalizing site enrollment with &#x201c;first patient, first dose&#x201d;
expected in the coming months. &lt;/span&gt;The Phase II clinical trial was also approved by the Institutional Review Board &#x201c;IRB&#x201d;
on June 21, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On August 8, 2024, the Company
entered into a work order (the &#x201c;Work Order&#x201d;) with Theradex Systems, Inc., a New Jersey contract research organization (&#x201c;CRO&#x201d;)
for purposes of supporting the Company&#x2019;s Phase II Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in
Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promotor.&#x201d; As such, Shuttle Pharma is now in the
process of signing up six clinical sites where the clinical studies will be performed &#x2013; two of which have completed initial site
initiation visits and one of which is ready to enroll patients &#x2013; and where the CRO will oversee such studies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Under the terms of the Work
Order, the CRO will oversee the studies for a period of 53 months (the &#x201c;Term&#x201d;), including overseeing and monitoring the regulatory
aspects of the Phase II clinical trial, and managing the documentation surrounding the clinical trial in exchange for a fee of approximately
$2.3 million, payable in stages and based upon services performed during the Term of the study.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Rights
Offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase
agreement (the &#x201c;Purchase Agreement&#x201d;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed
to commit to purchasing from the Company $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJDnbJVClHRk" title="Sale of stock consideration received per transaction"&gt;2,250,000&lt;/span&gt;
of units from the Company, with each Unit consisting of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUwwlJvcREg6" title="Share based payment award description"&gt;(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $18.80
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.&lt;/span&gt; Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90% of the VWAP of SHPH common
stock for the five trading days immediately preceding closing. The parties entered into the Purchase Agreement in anticipation of
the Company commencing a rights offering (the &#x201c;Rights Offering&#x201d;) pursuant to which the Company intends to offer a total
of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlQLd9zaTDXg" title="Proceeds from issuance of common stock"&gt;4,500,000&lt;/span&gt;
Units to existing stockholders, which includes the $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEVUQW1Y2LFg" title="Sale of stock consideration received per transaction"&gt;2,250,000&lt;/span&gt;
Units being sold to SRO LLC, an entity which is owned by Keith Moore, CEO of Boustead Securities, LLC
(&#x201c;BSL&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Purchase Agreement allows SRO LLC up to 60 days to raise the initial $&lt;span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zeJXcEGJ6F95" title="Escrow deposit"&gt;2,250,000&lt;/span&gt;, which funds will be placed in escrow with Sutter Securities,
Inc. (&#x201c;SSI&#x201d;), an affiliate of BSL, pursuant to the terms of an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI
on February 7, 2024 (the &#x201c;Escrow Agreement&#x201d;). The funds will remain in escrow up until closing on the Rights Offering. In
addition, in the event the Company fails to raise a full $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zAbw8U4vQqh" title="Right offering"&gt;4,500,000&lt;/span&gt; in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant
to which it would have the right to purchase any remaining Units not purchased by existing SHPH stockholders in the Rights Offering,
up to an additional $&lt;span id="xdx_905_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLidexbeXPOd" title="Escrow deposit"&gt;2,250,000&lt;/span&gt; (the &#x201c;Back-up Contingency&#x201d;). &lt;span id="xdx_901_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjbhaGD0F2h6" title="Initial public offering description"&gt;Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#x2019;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;Restricted Stock Awarded to Chief Financial Officer&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On March 8, 2024, the Company&#x2019;s then CFO
was awarded &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zrFoglyhoPx1" title="Restricted stock units"&gt;12,500&lt;/span&gt;
restricted stock units (&#x201c;RSUs&#x201d;), with a value of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zz0X64iPXAvj" title="Restricted stock value"&gt;41,840&lt;/span&gt;,
with such RSUs vesting in full as of the date of issuance. Each RSU represents the right to receive one share of SHPH common
stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 13, 2024, the Company&#x2019;s newly appointed CFO was awarded &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240613__20240613__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRJIfmRYFdT5" title="Restricted stock units"&gt;28,455&lt;/span&gt;
restricted stock units (&#x201c;RSUs&#x201d;), with a value of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240613__20240613__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zn7ip2Rkozz3" title="Restricted stock value"&gt;100,000&lt;/span&gt;,
with such RSUs vesting annually in three equal installments following the date of issuance. Each RSU
represents the right to receive one share of SHPH common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;Alto Opportunity Master Fund, SPC&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 12, 2024, the Company informed the Investor in the Alto Convertible Note that the Company&#x2019;s expected restatement of its
consolidated financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of
the Alto Convertible Note. On August 6, 2024, the Company paid $&lt;span id="xdx_905_eus-gaap--ConvertibleDebt_iI_c20240806__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWhRE3Lfrsz7" title="Convertible debt"&gt;600,000&lt;/span&gt;
to the Investor, which funds will be held as collateral to the balance owed under the Alto Convertible Note, and received a waiver
from the Investor related to the default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;Alliance Global Partners &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On July 30, 2024, the Company
engaged A.G.P./Alliance Global Partners (&#x201c;AGP&#x201d;) to serve as exclusive underwriter, placement agent or advisor in
any public or private offering or financing (as defined, the &#x201c;Offering&#x201d;) of up to $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20240730__20240730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSfHFktjdED8"&gt;10
&lt;/span&gt;million.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2023-08-31"
      decimals="INF"
      id="Fact003664"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="From2023-08-312023-08-31"
      decimals="INF"
      id="Fact003666"
      unitRef="TradingDays">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <SHPH:ReverseCommonStockSharesOutstanding
      contextRef="AsOf2024-08-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact003668"
      unitRef="Shares">2111235</SHPH:ReverseCommonStockSharesOutstanding>
    <SHPH:ReverseCommonStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact003670"
      unitRef="Shares">2008689</SHPH:ReverseCommonStockSharesOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact003672"
      unitRef="USD">2250000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      id="Fact003674">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $18.80
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact003676"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact003678"
      unitRef="USD">2250000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact003680"
      unitRef="USD">2250000</us-gaap:EscrowDeposit>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact003682"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <SHPH:AdditionalEscrowDeposit
      contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact003684"
      unitRef="USD">2250000</SHPH:AdditionalEscrowDeposit>
    <SHPH:InitialPublicOfferingDescription
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      id="Fact003686">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#x2019;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.</SHPH:InitialPublicOfferingDescription>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact003688"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact003690"
      unitRef="USD">41840</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-132024-06-13_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact003692"
      unitRef="Shares">28455</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-06-132024-06-13_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact003694"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-08-06_us-gaap_SubsequentEventMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact003696"
      unitRef="USD">600000</us-gaap:ConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-07-302024-07-30_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="Fact003697"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001237"
          xlink:label="Fact001237"
          xlink:type="locator"/>
        <link:footnote id="Footnote001260" xlink:label="Footnote001260" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 250,000 iterations</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001237"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001238"
          xlink:label="Fact001238"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001238"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001239"
          xlink:label="Fact001239"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001239"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001240"
          xlink:label="Fact001240"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001240"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001241"
          xlink:label="Fact001241"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001241"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001242"
          xlink:label="Fact001242"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001242"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001243"
          xlink:label="Fact001243"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001243"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001244"
          xlink:label="Fact001244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001244"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001245"
          xlink:label="Fact001245"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001245"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001247"
          xlink:label="Fact001247"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001247"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001249"
          xlink:label="Fact001249"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001249"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001250"
          xlink:label="Fact001250"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001250"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001251"
          xlink:label="Fact001251"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001251"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001252"
          xlink:label="Fact001252"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001252"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001253"
          xlink:label="Fact001253"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001253"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001254"
          xlink:label="Fact001254"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001254"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001255"
          xlink:label="Fact001255"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001255"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001257"
          xlink:label="Fact001257"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001257"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001259"
          xlink:label="Fact001259"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001259"
          xlink:to="Footnote001260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002013"
          xlink:label="Fact002013"
          xlink:type="locator"/>
        <link:footnote id="Footnote002019" xlink:label="Footnote002019" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjustments
    include corrections for stock compensation errors (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrnatiiGYqAj"
  title="Stock compensation">7,843,052</xhtml:span>);
    recognition of Series A Preferred Stock accrued dividends (decrease of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_900_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbDEqb7CBhm8"
  title="Accrued dividends">402,064</xhtml:span>);
    correction of issuance cost recognition related to financing transactions (decrease of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_905_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zitiKyxDQta"
  title="Issuance cost">174,082</xhtml:span>);
    corrections to the Company&#x2019;s initial classification and recognition of warrants issued in financing transactions (decrease of
    $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_ecustom--IncreaseDecreaseInWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z4WTuHUEYTV8"
  title="Warrants">416,266</xhtml:span>),
    reclassifications of warrants from liability to equity (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_904_ecustom--IncreaseDecreaseInWarrantsFromLiability_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zor6OyzZQjoh"
  title="Warrants from liability">881,554</xhtml:span>);
    correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zU6B5O7aL68l"
  title="Debt instrument">2,213,498</xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002013"
          xlink:to="Footnote002019"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002018"
          xlink:label="Fact002018"
          xlink:type="locator"/>
        <link:footnote id="Footnote002032" xlink:label="Footnote002032" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjustments include corrections for stock compensation errors (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_902_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zd2VlHHbtd9a"
  title="Stock compensation">8,009,461</xhtml:span>); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_902_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRLAtmA54Yxc"
  title="Fair value of warrants">240,930</xhtml:span>); reversal of accrued Series A Preferred Stock dividends (decrease of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--IncreaseDecreaseInDividendsReceivable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zy6neIXuyb4a"
  title="Accrued dividends">402,064</xhtml:span>); recognition of bifurcated derivatives and recording of loss at issuance (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_907_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z3ChwofPyOih"
  title="Derivatives loss">296,151</xhtml:span>); correction of issuance cost recognition related to financing transactions (decrease of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_903_ecustom--IncreaseDecreaseInIssuanceCost_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zRqr6Yrcet9e"
  title="Issuance cost">166,407</xhtml:span>); and the aggregate adjustments to 2022 net loss as detailed below (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90E_ecustom--IncreaseDecreaseInNetIncomeLoss_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zjfEI9W0Jbhf"
  title="Net income loss">1,967,621</xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002018"
          xlink:to="Footnote002032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002257"
          xlink:label="Fact002257"
          xlink:type="locator"/>
        <link:footnote id="Footnote002263" xlink:label="Footnote002263" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjustments include adjustment
    to the carrying value of notes payable, including recognition of day 1 loss (decrease of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_909_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zrVTszjRgvfk"
  title="Increase decrease of notes payable">7,351</xhtml:span>); identification of costs to be
    recorded against Series A Preferred Stock carrying value (decrease of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_902_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z9D7ZPSm7tvh"
  title="Increase decrease in preferred stock">89,118</xhtml:span>); and stock compensation adjustments (increase of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_905_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zC6A1A5rc68l"
  title="Stock compensation">8,009,461</xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002257"
          xlink:to="Footnote002263"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002262"
          xlink:label="Fact002262"
          xlink:type="locator"/>
        <link:footnote id="Footnote002270" xlink:label="Footnote002270" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    include reversal of dividend liability recorded (decrease of $<xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_903_ecustom--IncreaseDecreaseInDividendLiability_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zOEhXcORUos1"
      title="Increase decrease in dividend liability">331,059</xhtml:span></xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of deferred IPO costs (decrease of ($<xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_90C_ecustom--IncreaseDecreaseInIssuanceCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0GxIljb7SUi">55,182</xhtml:span></xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of <xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_901_ecustom--IncreaseDecreaseInPreferredStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zEh9jrsYbyoh">89,118</xhtml:span></xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the estimated fair value of warrant liability (increase of $<xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_90B_ecustom--IncreaseDecreaseInFairValueOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zgMoO6wP2z63">240,930</xhtml:span></xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $<xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_90E_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBqHgefKGYzj">274,048</xhtml:span></xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">);
    and stock compensation adjustments (increase of $<xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVycm9yIENvcnJlY3Rpb25zIEFuZCBQcmlvciBQZXJpb2QgQWRqdXN0bWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_904_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z54Q3IbfAMQc">8,009,461</xhtml:span></xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002262"
          xlink:to="Footnote002270"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003086"
          xlink:label="Fact003086"
          xlink:type="locator"/>
        <link:footnote id="Footnote003119" xlink:label="Footnote003119" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Granted
    warrants include those granted on the issuance of the August 2022 Promissory Notes</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003086"
          xlink:to="Footnote003119"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003088"
          xlink:label="Fact003088"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003088"
          xlink:to="Footnote003119"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003090"
          xlink:label="Fact003090"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003090"
          xlink:to="Footnote003119"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003223"
          xlink:label="Fact003223"
          xlink:type="locator"/>
        <link:footnote id="Footnote003254" xlink:label="Footnote003254" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 50,000 iterations</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003223"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003224"
          xlink:label="Fact003224"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003224"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003225"
          xlink:label="Fact003225"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003225"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003226"
          xlink:label="Fact003226"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003226"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003227"
          xlink:label="Fact003227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003227"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003228"
          xlink:label="Fact003228"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003228"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003229"
          xlink:label="Fact003229"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003229"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003230"
          xlink:label="Fact003230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003230"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003231"
          xlink:label="Fact003231"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003231"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003233"
          xlink:label="Fact003233"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003233"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003235"
          xlink:label="Fact003235"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003235"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003237"
          xlink:label="Fact003237"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003237"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003239"
          xlink:label="Fact003239"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003239"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003240"
          xlink:label="Fact003240"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003240"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003241"
          xlink:label="Fact003241"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003241"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003242"
          xlink:label="Fact003242"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003242"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003243"
          xlink:label="Fact003243"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003243"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003244"
          xlink:label="Fact003244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003244"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003245"
          xlink:label="Fact003245"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003245"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003247"
          xlink:label="Fact003247"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003247"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003249"
          xlink:label="Fact003249"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003249"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003251"
          xlink:label="Fact003251"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003251"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003253"
          xlink:label="Fact003253"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003253"
          xlink:to="Footnote003254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003652"
          xlink:label="Fact003652"
          xlink:type="locator"/>
        <link:footnote id="Footnote003659" xlink:label="Footnote003659" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
                                            Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated
                                            balance sheet for the period ended September 30, 2023 with an increase to additional paid
                                            in capital of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YXJ0ZXJseSBGaW5hbmNpYWwgRGF0YSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230930_znJr9ekugxrb"
  title="Increase decrease in additional paid in capital">140</xhtml:span> and an offsetting adjustment to the carrying value of common stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003652"
          xlink:to="Footnote003659"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003653"
          xlink:label="Fact003653"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003653"
          xlink:to="Footnote003659"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003654"
          xlink:label="Fact003654"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003654"
          xlink:to="Footnote003659"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
